



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 126032

TO: Terra Gibbs
Location: rem/2d10/2c18
Art Unit : 1635
Wednesday, June 30, 2004

Case Serial Number: 10/024369

From: Toby Port
Location: Biotech-Chem Library
REM-1A59
Phone: (571) 272-2523
toby.port@uspto.gov

Search Notes

THIS PAGE BLANK (USPTO)

SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 75%.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.

THIS PAGE BLANK (USPIC,

Schreiber, David

126032

From: Gibbs, Terra
Sent: Thursday, June 24, 2004 4:48 PM
To: Schreiber, David
Subject: Sequence search request...

Hi David,

I have another request for a score over length search:

I need a length limited nucleotide sequence search of SEQ ID NO:3 in USSN 10/024,369, where the returns are rank ordered based on the score over length/ratio as we've discussed. I need the lengths limited to hits between 8 and 50 nucleotides, and I'll take as many hits as you can import into excel (64,000?), and alignments for anything above .75 on the above ratio. Hope this is clear, please call me if it's not. I also need the interference databases searched if possible.

*Terra Cotta Gibbs, Ph.D.
Art Unit 1635
Remsen Building 2D10
571-272-0758*

THIS PAGE BLANK (USPTO)

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: _____ Examiner #: _____ Date: _____
 Art Unit: _____ Phone Number 30 _____ Serial Number: 10 024 369
 Mail Box and Bldg/Room Location: _____ Results Format Preferred (check): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

STAFF USE ONLY

Searcher: <u>P. Schreder</u>	Type of Search	Vendors and cost where applicable
Searcher Phone #: <u>272-2526</u>	NA Sequence (#) <u>15</u>	STN _____
Searcher Location: <u>Kingsen E01/PC4</u>	AA Sequence (#) _____	Dialog _____
Date Searcher Picked Up: _____	Structure (#) _____	Questel/Orbit _____
Rate Completed: <u>6130</u>	Bibliographic _____	Dr.Link _____
Searcher Prep & Review Time: <u>15</u>	Litigation _____	Lexis/Nexis _____
Technical Prep Time: _____	Fulltext _____	Sequence Systems <u>CompuGen</u>
Online Time: <u>94</u>	Patent Family _____	WWW/Internet _____
	Other _____	Other (specify) _____

(THIS PAGE BLANK (USPTO))

C 107	20	0.9	20	1	AAI62411	Human ABC transpor
C 108	20	0.9	20	1	AAI62420	Human ABC transpor
C 109	20	0.9	20	1	AAI62430	Human ABC transpor
C 110	20	0.9	20	1	AAI62404	Human ABC transpor
C 111	19	0.8	19	1	AAI62408	Primer ON-TAP1-F2
C 112	19	0.8	19	1	ABK82324	Human ATP-binding
C 113	19	0.8	19	1	ABT03523	Human pol kappa 76
C 114	19	0.8	19	1	ACD13526	Human bi-direction
C 115	19	0.8	19	1	ADA97827	Human tumour necro
C 116	18	0.8	18	1	AAZ32694	Human MHC Class II
C 117	18	0.8	18	1	AAI76193	Human TAP-1 PCR pr
C 118	18	0.8	18	1	ACC42628	HIV Class II regio
C 119	17.2	0.8	22	1	AAV28200	Antisense oligonuc
C 120	17.2	0.8	22	1	AAI18712	Target MMR antisen
C 121	17.2	0.8	22	1	AAI23703	Deletion sequence
C 122	16.8	0.7	20	1	AAI56534	Human PARP-1 antis
C 123	16.8	0.7	20	1	AAI97378	Human NOV-associat
C 124	16.8	0.7	21	1	AAI96716	Human gene single
C 125	16.4	0.7	20	1	AAI60854	CDK4 specific anti
C 126	16.4	0.7	20	1	AAI60835	CDK4 specific anti
C 127	16.4	0.7	21	1	AAI64762	RRV interleukin 6
C 128	16.2	0.7	21	1	AAI73042	Tyrosine-kinase sy
C 129	16.2	0.7	21	1	AAI26604	Human polymorphic
C 130	16.2	0.7	21	1	AAI55721	PCR primer P13. p
C 131	16.2	0.7	21	1	AAI14466	Human src biomarke
C 132	16	0.7	21	1	AAI95793	Capture oligonuclo
C 133	16	0.7	21	1	ABD84244	Chicken glyceralde
C 134	16	0.7	21	1	ADD35649	Chicken glyceralde
C 135	15.8	0.7	19	1	AAI31954	Oligonucleotide PG
C 136	15.8	0.7	19	1	AAI58592	Oligonucleotide PG
C 137	15.8	0.7	19	1	AAI83147	PCR primer used fo
C 138	15.8	0.7	19	1	ABK47527	Matrix metalloprot
C 139	15.8	0.7	20	1	AAI43607	Chlamydia trachoma
C 140	15.8	0.7	20	1	AAV28201	Antisense oligonuc
C 141	15.8	0.7	20	1	AAI18713	Target MMR antisen
C 142	15.8	0.7	20	1	AAI23704	Deletion sequence
C 143	15.8	0.7	20	1	AAI85332	CDNA primer for PA
C 144	15.8	0.7	20	1	AAI85331	CDNA primer for PA
C 145	15.8	0.7	20	1	AAI63984	Human tankyrase2 e
C 146	15.8	0.7	20	1	AAI63985	Human tankyrase2 e
C 147	15.8	0.7	20	1	AAI40440	Mouse caspase 6 an
C 148	15.8	0.7	21	1	ABK59425	Human phosphorilas
C 149	15.8	0.7	21	1	ABK70040	Mycobacterium mari
C 150	15.8	0.7	21	1	ABK81857	M marinum P34 gene
C 151	15.8	0.7	21	1	ABX10097	M. marinum upstrea
C 152	15.4	0.7	17	1	ABN00900	Human GDMLP-1 17-m
C 153	15.4	0.7	17	1	ABN00899	Human GDMLP-1 17-m
C 154	15.4	0.7	17	1	ABN00901	Human GDMLP-1 17-m
C 155	15.4	0.7	17	1	ACI64870	Murine oligonucleo
C 156	15.4	0.7	18	1	AAI62734	Granule bound star
C 157	15.4	0.7	18	1	AAI89104	p53 binding PG-mot
C 158	15.4	0.7	19	1	AAI84556	Cyclin E ribozyme
C 159	15.4	0.7	19	1	AAI84554	Cyclin E ribozyme
C 160	15.4	0.7	19	1	AAI84555	Cyclin E ribozyme
C 161	15.4	0.7	19	1	AAI859718	Cyclin E ribozyme
C 162	15.4	0.7	19	1	AAI859716	Cyclin E ribozyme
C 163	15.4	0.7	19	1	AAI859717	Cyclin E ribozyme
C 164	15.4	0.7	20	1	ABZ93303	Human oligonucleot
C 165	15.2	0.7	20	1	AAI08666	Primer p53-3X7P fo
C 166	15.2	0.7	20	1	AAI99867	Primer for exon 7
C 167	15.2	0.7	20	1	AAI99837	Primer for exon 7
C 168	15.2	0.7	20	1	AAV28203	Antisense oligonuc
C 169	15.2	0.7	20	1	AAV28202	Antisense oligonuc
C 170	15.2	0.7	20	1	AAI237478	Human mdm2 phospho
C 171	15.2	0.7	20	1	AAI205545	PCR primer used to
C 172	15.2	0.7	20	1	AAI18715	Target MMR antisen
C 173	15.2	0.7	20	1	AAI18714	Target MMR antisen
C 174	15.2	0.7	20	1	AAI23705	Deletion sequence
C 175	15.2	0.7	20	1	AAI23706	Deletion sequence
C 176	15.2	0.7	20	1	AAI95547	PCR primer used to
C 177	15.2	0.7	20	1	AAI93890	PCR primer used to
C 178	15.2	0.7	20	1	AAI94024	PCR primer used to
C 179	15.2	0.7	20	1	AAI29357	JNK3-specific prob
C 180	15.2	0.7	20	1	AAI97546	Streptomyces albuli
C 181	15.2	0.7	20	1	AAI55792	Human histone deac
C 182	15.2	0.7	20	1	AAI74434	Human histone deac
C 183	15.2	0.7	20	1	AAI74482	Human histone deac
C 184	15.2	0.7	20	1	AAI62900	Human histone deac
C 185	15.2	0.7	20	1	AAI43102	JNK antisense olig
C 186	15.2	0.7	20	1	AAI80632	Antisense oligo, t
C 187	15.2	0.7	20	1	AAI80632	Human mdm2 phospho
C 188	15.2	0.7	20	1	AAI07537	Human mdm2 phospho
C 189	15.2	0.7	20	1	AAI83925	ER gene PCR primer
C 190	15.2	0.7	20	1	AAI10981	Murine PAI-1 genot
C 191	15.2	0.7	20	1	AAI54600	Human HLA Class I
C 192	15.2	0.7	20	1	AAI92247	Human mdm2 antisen
C 193	15.2	0.7	20	1	AAI93207	Human oestrogen re
C 194	15.2	0.7	20	1	AAI92551	Adenovirus 5 relat
C 195	15.2	0.7	20	1	AAI39601	Human SR-CYP antis
C 196	15.2	0.7	20	1	ABZ93174	Human oestrogen re
C 197	15.2	0.7	20	1	ABZ88194	Human oligonucleot
C 198	15.2	0.7	20	1	ABZ93288	Human oligonucleot
C 199	15.2	0.7	20	1	ABX33969	Human interleukin
C 200	15.2	0.7	20	1	ABZ84008	Toxicologically re
C 201	15.2	0.7	20	1	ADA26604	Human Jun N-termi
C 202	15.2	0.7	20	1	ACI99727	Rat edgl lysophosp
C 203	15.2	0.7	20	1	ADB25679	Beta-tubulin PCR p
C 204	15.2	0.7	20	1	ADB85885	Human connective t
C 205	15.2	0.7	20	1	ADB85885	Antisense oligonu
C 206	15.2	0.7	20	1	ADD21443	Microsomal triglyc
C 207	15.2	0.7	20	1	ADD21443	Human mdm2 antis
C 208	15	0.7	15	1	AAI48868	IGFBP3 oligonucleo
C 209	15	0.7	19	1	AAV70949	PCR primer used to
C 210	15	0.7	19	1	AAI16176	Listeria sp. ident
C 211	15	0.7	19	1	AAI89335	Sample member clus
C 212	15	0.7	20	1	AAI62952	Mouse PEPCK-cyoso
C 213	15	0.7	20	1	AAI05948	Human diacylglycer
C 214	14.8	0.7	18	1	AAV44610	Human uncoupling p
C 215	14.8	0.7	18	1	AAI93370	KT3 epitope DNA, S
C 216	14.8	0.7	18	1	AAI27570	DNA encoding KT3 e
C 217	14.8	0.7	18	1	ABK71488	DNA encoding prote
C 218	14.8	0.7	18	1	ADCI8351	KT3 epitope nucleo
C 219	14.8	0.7	19	1	AAV17327	KT3 epitope DNA.
C 220	14.8	0.7	19	1	AAV41791	Primer used in con
C 221	14.8	0.7	19	1	ABZ72149	Human pancreatic c
C 222	14.8	0.7	19	1	ABK75002	Human gene 216 pol
C 223	14.8	0.7	19	1	ADA25739	Human REL-A short
C 224	14.8	0.7	19	1	ADA26088	Human REL-A short
C 225	14.8	0.7	19	1	ADA25493	Human PKC-alpha sh
C 226	14.8	0.7	19	1	ADA25368	Human PKC-alpha sh
C 227	14.8	0.7	19	1	ADK30297	Mitogen activated
C 228	14.8	0.7	19	1	ADK30297	Mitogen activated
C 229	14.6	0.6	15	1	ABK16959	Pyridoxal (pyridox
C 230	14.4	0.6	17	1	AAI42677	PCR primer Clamut-
C 231	14.4	0.6	17	1	AAI21561	PCR primer Clamut-
C 232	14.4	0.6	17	1	AAI21733	PCR primer Clamut-
C 233	14.4	0.6	17	1	AAI41301	PCR primer Clamut-
C 234	14.4	0.6	17	1	AAI66674	Primer Clamut-Kan
C 235	14.4	0.6	17	1	AAI62264	Granule bound star
C 236	14.4	0.6	17	1	AAI24820	Oestrogen receptor
C 237	14.4	0.6	17	1	AAI77757	Retinoblastoma mut
C 238	14.4	0.6	17	1	ABK77758	Retinoblastoma mut
C 239	14.4	0.6	17	1	ABN00902	Human GDMLP-1 17-m
C 240	14.4	0.6	17	1	ABN08014	Human GDMLP-1 17-m
C 241	14.4	0.6	17	1	ABN08013	Human GDMLP-1 17-m
C 242	14.4	0.6	17	1	ABN00898	Human GDMLP-1 17-m
C 243	14.4	0.6	17	1	ABV65489	Human pp-GaNTase 1
C 244	14.4	0.6	17	1	ABV65490	Human pp-GaNTase 1
C 245	14.4	0.6	17	1	ABT39140	Tumour suppresson
C 246	14.4	0.6	17	1	ABV57647	Human HGPRTMY2-ass
C 247	14.4	0.6	17	1	ACD61070	HCV DNAzyme subst
C 248	14.4	0.6	18	1	ABK51004	Human genotyping p
C 249	14.4	0.6	18	1	AAI53970	Human KIR2Bbeta mu
C 250	14.4	0.6	18	1	ADA24424	PCR primer #1 for
C 251	14.4	0.6	19	1	AAV72326	Human steroid horm
C 252	14.4	0.6	19	1	ABV58297	Human GLUT 10 SSCP

253	14.4	0.6	19	1	AAD55156	Goat beta-lac exon
C 254	14.4	0.6	19	1	ADA50311	Human PCR primer r
C 255	14.4	0.6	19	1	ADE29675	Mtogen activated
C 256	14.4	0.6	19	1	ADE29512	Mtogen activated
C 257	14	0.6	14	1	AAQ45287	Sequence of minima
C 258	14	0.6	15	1	AAFA4867	IGFBP3 oligonucleo
C 259	14	0.6	15	1	AAFA4869	IGFBP3 oligonucleo
C 260	14	0.6	16	1	ABA89702	Serial analysis of
C 261	14	0.6	17	1	AAQ92210	p53 detection prob
C 262	14	0.6	17	1	AAT81544	Human c-myc hamer
C 263	14	0.6	17	1	AAT65652	Primer for studyn
C 264	14	0.6	17	1	ABN00903	Human GDMWP-1 17-m
C 265	14	0.6	17	1	ABN00904	Human GDMWP-1 17-m
C 266	14	0.6	17	1	ABT39797	Tumour suppression
C 267	14	0.6	17	1	ACD61599	HCV minus strand D
C 268	14	0.6	18	1	AAZ20330	Antisense modulat
C 269	14	0.6	18	1	AAAF76101	CCR5/CCR2b PCR pr1
C 270	14	0.6	18	1	AAAF76102	CCR5/CCR2b PCR pr1
C 271	14	0.6	18	1	AAAF94632	Rho A antisense ph
C 272	14	0.6	18	1	ABL44589	Human chromosome 1
C 273	13.8	0.6	17	1	AAA24819	Oestrogen receptor
C 274	13.8	0.6	17	1	AAAF02145	Hammerhead ribozym
C 275	13.8	0.6	17	1	AAAF02081	Hammerhead ribozym
C 276	13.8	0.6	17	1	AAAF01721	Hammerhead ribozym
C 277	13.8	0.6	17	1	ABK02015	Human NOGO zinzyme
C 278	13.8	0.6	17	1	ABK00106	Human NOGO Hammer
C 279	13.8	0.6	17	1	ABK01837	Human NOGO zinzyme
C 280	13.8	0.6	17	1	ABN08065	Human GDMWP-1 17-m
C 281	13.8	0.6	17	1	ABN09591	Human GDMWP-1 17-m
C 282	13.8	0.6	17	1	ABN08064	Human GDMWP-1 17-m
C 283	13.8	0.6	17	1	ABN01968	Human GDMWP-1 17-m
C 284	13.8	0.6	17	1	ABN06530	Human GDMWP-1 17-m
C 285	13.8	0.6	17	1	ABN06533	Human GDMWP-1 17-m
C 286	13.8	0.6	17	1	ABN01538	Human GDMWP-1 17-m
C 287	13.8	0.6	17	1	ABN00673	Human GDMWP-1 17-m
C 288	13.8	0.6	17	1	ABN01580	Human GDMWP-1 17-m
C 289	13.8	0.6	17	1	ABN02747	Human GDMWP-1 17-m
C 290	13.8	0.6	17	1	ABN06534	Human GDMWP-1 17-m
C 291	13.8	0.6	17	1	ABN00523	Human GDMWP-1 17-m
C 292	13.8	0.6	17	1	ABN06766	Human GDMWP-1 17-m
C 293	13.8	0.6	17	1	ABN06529	Human GDMWP-1 17-m
C 294	13.8	0.6	17	1	ABO64238	Human GDMWP-1 17-m
C 295	13.8	0.6	17	1	ABV85488	Human pp-GaNTase 1
C 296	13.8	0.6	17	1	ABV85444	Human pp-GaNTase 1
C 297	13.8	0.6	17	1	ABV85800	Human pp-GaNTase 1
C 298	13.8	0.6	17	1	ABV79273	Human pp-GaNTase 1
C 299	13.8	0.6	17	1	ABK19231	Human ERG scannin
C 300	13.8	0.6	17	1	ABK19230	Human ERG Amberzym
C 301	13.8	0.6	17	1	ABV89725	Human POSHL1 scann
C 302	13.8	0.6	17	1	ABV90613	Human POSHL1 scann
C 303	13.8	0.6	17	1	ABV89726	Human POSHL1 scann
C 304	13.8	0.6	17	1	ABV89724	Human POSHL1 scann
C 305	13.8	0.6	17	1	ABV89723	Human POSHL1 scann
C 306	13.8	0.6	17	1	ABL31770	Human HLA genocyp1
C 307	13.8	0.6	17	1	ABL31552	Human HLA genocyp1
C 308	13.8	0.6	17	1	ABK54592	Human C1CA1 gene e
C 309	13.8	0.6	17	1	ABST1929	Human GTP-Rho bind
C 310	13.8	0.6	17	1	ACD00799	G-protein coupled
C 311	13.8	0.6	17	1	ABT36908	Tumour suppression
C 312	13.8	0.6	17	1	ACA09052	NFKB sub-unit modu
C 313	13.8	0.6	17	1	ACA08871	NFKB sub-unit modu
C 314	13.8	0.6	17	1	ACA09051	NFKB sub-unit modu
C 315	13.8	0.6	17	1	ACA06758	NFKB sub-unit modu
C 316	13.8	0.6	17	1	ADA9387	Human MDZ3 scannin
C 317	13.8	0.6	17	1	ADA9387	Human MDZ3 scannin
C 318	13.8	0.6	17	1	ADB00407	Human MDZ3 scannin
C 319	13.8	0.6	17	1	ADB02397	Human MDZ4 scannin
C 320	13.8	0.6	17	1	ABZ61560	Human H-Ras DNazyme
C 321	13.8	0.6	17	1	ABZ64771	Human HER2 DNazyme
C 322	13.8	0.6	17	1	ABZ65040	Human HER2 DNazyme
C 323	13.8	0.6	17	1	ABZ62176	Human H-Ras DNazyme
C 324	13.8	0.6	17	1	ABZ62177	Human H-Ras DNazyme
C 325	13.8	0.6	17	1	ABZ61559	Human H-Ras DNazyme
C 326	13.8	0.6	17	1	ACD53120	HBV inozyme subctr
C 327	13.8	0.6	17	1	ACD60172	HBV DNazyme subctr
C 328	13.8	0.6	17	1	ACD63300	HCV minus strand D
C 329	13.8	0.6	17	1	ACD51659	HBV hammerhead rib
C 330	13.8	0.6	17	1	ACD61635	HCV minus strand D
C 331	13.8	0.6	17	1	ACD65283	HCV DNAzyme subctr
C 332	13.8	0.6	17	1	ACD57472	Murine oligonucleo
C 333	13.8	0.6	17	1	ACD68479	Murine oligonucleo
C 334	13.8	0.6	17	1	ACC66564	Murine oligonucleo
C 335	13.8	0.6	17	1	ACC66635	Murine oligonucleo
C 336	13.8	0.6	17	1	ADB42925	Tumour suppression
C 337	13.8	0.6	17	1	ADB44878	Tumour suppression
C 338	13.8	0.6	17	1	AAQ56855	PCR primer P-74 fo
C 339	13.8	0.6	18	1	AAQ91475	Human cyclooxygena
C 340	13.8	0.6	18	1	AAT27721	Fibroblast growth
C 341	13.8	0.6	18	1	AAV25472	Primer for 307 bp
C 342	13.8	0.6	18	1	AAV25936	Fibroblast growth
C 343	13.8	0.6	18	1	AAV25935	Fibroblast growth
C 344	13.8	0.6	18	1	AAV16023	PCR primer used to
C 345	13.8	0.6	18	1	AAV15991	NBCS (PTC) gene e
C 346	13.8	0.6	18	1	AAV70503	Truncated tpob amp
C 347	13.8	0.6	18	1	AAV81444	Sense oligonucleo
C 348	13.8	0.6	18	1	AAV81445	Antisense oligonuc
C 349	13.8	0.6	18	1	AAAS6803	FGF sense oligodeo
C 350	13.8	0.6	18	1	AAAS6804	FGF antisense olig
C 351	13.8	0.6	18	1	AAZ44157	Human EGR-1 DNA an
C 352	13.8	0.6	18	1	AAZ43496	Clone vp3.1 hybrid
C 353	13.8	0.6	18	1	AAZ74103	Human biallelic ma
C 354	13.8	0.6	18	1	AAZ43282	Murine Sox2 gene P
C 355	13.8	0.6	18	1	AAAO5267	PCR primer C-F use
C 356	13.8	0.6	18	1	AAAS2031	Antisense oligonuc
C 357	13.8	0.6	18	1	AAAS6588	Alzheimer's diseas
C 358	13.8	0.6	18	1	AAF83007	Human MBS2 amplif
C 359	13.8	0.6	18	1	AAF83006	Human MBS2 amplif
C 360	13.8	0.6	18	1	AAAS1809	Human surfactant p
C 361	13.8	0.6	18	1	AAAS1811	Human surfactant p
C 362	13.8	0.6	18	1	AAF79676	Human Akt-3 antise
C 363	13.8	0.6	18	1	AAFI7452	Primer JB1133. Sy
C 364	13.8	0.6	18	1	AAH39762	SNP specific lower
C 365	13.8	0.6	18	1	AAAD20900	Fibroblast growth
C 366	13.8	0.6	18	1	AAH76247	Human macrophage 1
C 367	13.8	0.6	18	1	AAH76247	Oat Beta-amylin sy
C 368	13.8	0.6	18	1	ABL89316	HIV-1 related bind
C 369	13.8	0.6	18	1	ABL89316	HIV-1 related bind
C 370	13.8	0.6	18	1	ABL40470	Endothelial differ
C 371	13.8	0.6	18	1	ABL40468	Endothelial differ
C 372	13.8	0.6	18	1	AAAD40986	Human PI3K p85 ant
C 373	13.8	0.6	18	1	AAK98275	Rat Con-218 R2A ge
C 374	13.8	0.6	18	1	ABK94431	Human MLH1 DNA mis
C 375	13.8	0.6	18	1	ABL46114	Mycobacterium tube
C 376	13.8	0.6	18	1	AAAD41843	Fibroblast growth
C 377	13.8	0.6	18	1	ABT06050	Human Igm heavy ch
C 378	13.8	0.6	18	1	ACC46880	Human GCPD related
C 379	13.8	0.6	18	1	ABZ98168	Human GCPD + A1261
C 380	13.8	0.6	18	1	ABT34032	Human pigmentation
C 381	13.8	0.6	18	1	ABT34033	Human pigmentation
C 382	13.8	0.6	18	1	ABX95733	Oligonucleotide #2
C 383	13.8	0.6	18	1	ABX95732	Oligonucleotide #1
C 384	13.8	0.6	18	1	ACD27923	Fibroblast growth
C 385	13.8	0.6	18	1	ACD27922	Fibroblast growth
C 386	13.8	0.6	18	1	ACFS7054	TM2P cloning forw
C 387	13.8	0.6	18	1	ADC03333	FGF antisense olig
C 388	13.8	0.6	18	1	ADC03332	FGF sense oligonuc
C 389	13.8	0.6	18	1	ADC98362	FGF sense oligonuc
C 390	13.8	0.6	18	1	ADD43511	fosB01 polymorphis
C 391	13.8	0.6	15	1	AAAS98700	Human mitochondria
C 392	13.6	0.6	15	1	ABSG4329	Colony stimulating
C 393	13.6	0.6	15	1	ABZ48393	Tachykinin recepto
C 394	13.6	0.6	15	1	ABZ50856	Human ATP-binding
C 395	13.6	0.6	15	1	ABZ43222	Human ATP-binding
C 396	13.4	0.6	15	1	AAQ11153	3'-terminal noncod
C 397	13.4	0.6	15	1	AAT52346	Mouse ICAM hamerh
C 398	13.4	0.6	15	1	AAT52187	Mouse ICAM hamerh

C 399	13.4	0.6	15	1	AAx64669	Human B7-1 hamme
C 400	13.4	0.6	15	1	AAV97119	Murine p27 wild-ty
C 401	13.4	0.6	15	1	AAV41112	3'-noncoding flank
C 402	13.4	0.6	15	1	AA623879	Substrate for ham
C 403	13.4	0.6	15	1	AA56243	V-55' point mutati
C 404	13.4	0.6	15	1	AA52432	TdtR-expressing Ram
C 405	13.4	0.6	15	1	AA95130	Allele specific pr
C 406	13.4	0.6	15	1	AA48041	IGFBP3 oligonucleo
C 407	13.4	0.6	15	1	AA48044	IGFBP3 oligonucleo
C 408	13.4	0.6	15	1	AA48436	IGFBP3 oligonucleo
C 409	13.4	0.6	15	1	AA48045	IGFBP3 oligonucleo
C 410	13.4	0.6	15	1	AA48043	IGFBP3 oligonucleo
C 411	13.4	0.6	15	1	AA50836	IGF-I oligonucleot
C 412	13.4	0.6	15	1	AA48568	IGFBP2 oligonucleo
C 413	13.4	0.6	15	1	AA45301	IGFBP2 oligonucleo
C 414	13.4	0.6	15	1	AA48042	IGFBP3 oligonucleo
C 415	13.4	0.6	15	1	AA49257	IGF-I oligonucleot
C 416	13.4	0.6	15	1	AA50837	IGF-I oligonucleot
C 417	13.4	0.6	15	1	AA50835	IGF-I oligonucleot
C 418	13.4	0.6	15	1	AA470395	Human DRD2 allele
C 419	13.4	0.6	15	1	ABR96650	Interleukin-3 (Il-
C 420	13.4	0.6	15	1	AB9A1622	Primer used in iso
C 421	13.4	0.6	15	1	ABX00932	Hepatitis C virus
C 422	13.4	0.6	16	1	AA15073	5' PCR primer with
C 423	13.4	0.6	16	1	AB8A9678	Serial analysis of
C 424	13.4	0.6	16	1	ABA89770	Serial analysis of
C 425	13.4	0.6	16	1	ABA89672	Serial analysis of
C 426	13.4	0.6	17	1	AA53630	Rat ICM hammerhea
C 427	13.4	0.6	17	1	AA53449	Rat ICM hammerhea
C 428	13.4	0.6	17	1	AA53480	Rat ICM hammerhea
C 429	13.4	0.6	17	1	AA53565	Rat ICM hammerhea
C 430	13.4	0.6	17	1	AA53574	Rat ICM hammerhea
C 431	13.4	0.6	17	1	AA53751	Rat ICM hammerhea
C 432	13.4	0.6	17	1	AA53494	Rat ICM hammerhea
C 433	13.4	0.6	17	1	AAV20574	Human BRCA1 probe
C 434	13.4	0.6	17	1	AA18459	Human TIF-2 subscr
C 435	13.4	0.6	17	1	AAA20642	Integrin alpha 6 s
C 436	13.4	0.6	17	1	AA18460	Human TIF-2 subscr
C 437	13.4	0.6	17	1	AA5185	Multiple antisense
C 438	13.4	0.6	17	1	AAA34632	Human adenosine re
C 439	13.4	0.6	17	1	AA21457	Human multiple tar
C 440	13.4	0.6	17	1	AA20754	Human multiple tar
C 441	13.4	0.6	17	1	AA70633	Single nucleotide
C 442	13.4	0.6	17	1	AA70630	Single nucleotide
C 443	13.4	0.6	17	1	AA502107	Hammerhead ribozym
C 444	13.4	0.6	17	1	AA507421	Hammerhead ribozym
C 445	13.4	0.6	17	1	AA502109	Hammerhead ribozym
C 446	13.4	0.6	17	1	AA502108	Hammerhead ribozym
C 447	13.4	0.6	17	1	AA502208	Hammerhead ribozym
C 448	13.4	0.6	17	1	ABK02411	Human NOGO Amberzy
C 449	13.4	0.6	17	1	ABK00912	Human NOGO Inozyme
C 450	13.4	0.6	17	1	AA526892	Beet necrotic yell
C 451	13.4	0.6	17	1	AA662173	Oligomer antiparal
C 452	13.4	0.6	17	1	AB272318	Gene 216 polymorph
C 453	13.4	0.6	17	1	ABN06958	Human GDMLP-1 17-m
C 454	13.4	0.6	17	1	ABN06764	Human GDMLP-1 17-m
C 455	13.4	0.6	17	1	ABN08015	Human GDMLP-1 17-m
C 456	13.4	0.6	17	1	ABN00897	Human GDMLP-1 17-m
C 457	13.4	0.6	17	1	ABN06765	Human GDMLP-1 17-m
C 458	13.4	0.6	17	1	ABN08062	Human GDMLP-1 17-m
C 459	13.4	0.6	17	1	ABN06960	Human GDMLP-1 17-m
C 460	13.4	0.6	17	1	ABN06959	Human GDMLP-1 17-m
C 461	13.4	0.6	17	1	ABN08012	Human GDMLP-1 17-m
C 462	13.4	0.6	17	1	ABO63624	Human KTOM1a porti
C 463	13.4	0.6	17	1	ABO63623	Human KTOM1a porti
C 464	13.4	0.6	17	1	ABO63625	Human KTOM1a porti
C 465	13.4	0.6	17	1	ABO63625	Human pp-ga
C 466	13.4	0.6	17	1	ABY85491	Human ERG Amberzym
C 467	13.4	0.6	17	1	ABK19232	Human ERG Amberzym
C 468	13.4	0.6	17	1	AB574945	Human PAP-P-Ea asso
C 469	13.4	0.6	17	1	AB574947	Human PAP-P-Ea asso
C 470	13.4	0.6	17	1	AB574946	Human PAP-P-Ea asso
C 471	13.4	0.6	17	1	ABY90560	Human POSH11 scan

	472	13.4	0.6	17	1	ABV90561	Human POSH1 scan
XX	473	13.4	0.6	17	1	ABV90559	Human POSH1 scan
XX	c 474	13.4	0.6	17	1	ABK57194	Human CLCA1 gene e
C	475	13.4	0.6	17	1	ABK56649	Human CLCA1 gene e
c	476	13.4	0.6	17	1	ABK56493	Human CLCA1 gene e
c	477	13.4	0.6	17	1	ABZ97151	Human MTA oligonuc
c	478	13.4	0.6	17	1	ABZ66448	Human nucleic acid
c	479	13.4	0.6	17	1	ACD00797	G-protein coupled
c	480	13.4	0.6	17	1	ACD00798	Tumour suppression
c	481	13.4	0.6	17	1	ABT38416	NFKB sub-unit modu
c	482	13.4	0.6	17	1	ACA07802	NFKB sub-unit modu
c	484	13.4	0.6	17	1	ACA06237	NFKB sub-unit modu
c	485	13.4	0.6	17	1	ACA09009	NFKB sub-unit modu
c	486	13.4	0.6	17	1	ACA06236	NFKB sub-unit modu
c	487	13.4	0.6	17	1	ABZ61828	Human H-Rae DNazym
c	488	13.4	0.6	17	1	ABZ64627	Human HRR2 DNazyme
c	489	13.4	0.6	17	1	ACDS3016	HBV inozyme subutr
c	490	13.4	0.6	17	1	ACDS7386	HBV inozyme subutr
c	491	13.4	0.6	17	1	ACDS3015	HBV inozyme subutr
c	492	13.4	0.6	17	1	ABX75171	Human 216 gene all
c	493	13.4	0.6	17	1	ACC62886	Murine oligonucleo
c	494	13.4	0.6	17	1	ACC66050	Murine oligonucleo
c	495	13.4	0.6	17	1	ADB43052	Tumour suppression

ALIGNMENTS

RESULT 1	
ABZ48393	
ID	ABZ48393 standard; DNA; 41 BP.
XX AC	ABZ48393;
XX DT	26-JUN-2003 (first entry)
DE	
XX	Human ATP-binding cassette ABCB3/TAP1 gene polymorphic site, #5176.
KW	Human; drug metabolizing enzyme; gene; drug metabolism; chromosome 6;
KM	polymorphic site; drug evaluation; drug screening; genotyping;
KS	genetic profiling; therapeutic customisation; adverse reaction;
XX	clinical trial; drug approval; single nucleotide polymorphism; SNP; ds.
OS	Homo sapiens.
XX	
FH	Key
FT	Variation
FT	Location/Qualifiers replace(21,G) /*tag= a /standard_name= "Single nucleotide polymorphism (SNP) "
XX PM	WO200252044-A2.
XX PD	04-JUL-2002.
XX PF	27-DEC-2001; 2001WO-JP011592.
XX PR	27-DEC-2000; 2000JP-00399443.
PR	02-MAY-2001; 2001JP-00135256.
PR	27-AUG-2001; 2001JP-00256862.
XX PA	(RIKE) RIKEN KK.
XX PI	Nakamura Y, Sekine A, Iida A, Saito S;
DR	WPJ; 2002-583571/62.
PT	Identifying individuals having a polymorphism, useful for determining the
PT	effectiveness or side effect of a drug or treatment protocol, comprises
PT	detecting at least one polymorphism in the drug metabolizing enzyme
PT	nucleic acid.
SS	Claim 23; Page 165; 2785pp; English.

```

XX Sequences AB243217-AB250887 represent polymorphic sites within genes
CC encoding enzymes associated with drug metabolism. The invention relates
CC to methods and compositions for identifying individuals who have at least
CC one polymorphism in such drug metabolizing enzyme-encoding genes. The
CC polymorphisms may be identified in a nucleic acid sample using probes or
CC primers specific for a sequence selected from AB243217-AB250887 using a
CC variety of detection assays, including hybridisation assays, nucleic acid
CC arrays and PCR-based methods. The invention also encompasses methods of
CC evaluating and screening drugs using genetic polymorphism data. Genetic
CC polymorphism data, particularly that relating to single nucleotide
CC polymorphisms (SNPs), may be used in studying the relationship between
CC DNA sequence variations and human diseases, conditions, and responses to
CC drugs. SNPs are also useful as polymorphism markers for discovering genes
CC that cause or exacerbate certain diseases. SNPs are particularly useful
CC in the above respects as they are stable in populations, occur
CC frequently, and have lower mutation rates than other genome variations
CC such as repeating sequences. The detection and analysis of polymorphisms
CC in genes encoding drug metabolising enzymes allows the customisation of
CC drug therapies based upon the genetic profile of individual patients.
CC This would not only take the guesswork out of selecting the drug with the
CC greatest therapeutic effect for a particular patient, but would also
CC reduce the likelihood of adverse reactions, thereby increasing safety.
CC Methods of the invention are also useful in the drug discovery and
CC approval processes. For example, individuals could be selected for
CC clinical trials only if their genetic profiles indicate that they are
CC capable of responding to a particular drug or drug class, and previously
CC failed drug candidates could be revived if they were matched with more
CC appropriate patient populations. The methods, data and compositions of
CC the invention may therefore lead to an increase in the range of
CC possible drug targets and decreases in the number of adverse drug
CC reactions, failed drug trials, the time taken for a drug to be approved,
CC the length of time patients are on medication and the number of different
CC medications a patient needs to take before finding an effective therapy
XX
XX Sequence 41 BP; 5 A; 19 C; 5 G; 12 T; 0 U; 0 Other;
SQ
Query Match 1.8%; Score 41; DB 1; Length 41;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 41; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 977 CCTCACCATTGTCACCCCTGATCACCCCTGCTGCTTTTC 1017
Db 1 CCTCACCATTGTCACCCCTGATCACCCCTGCTGCTTTTC 41
RESULT 2
AB250856
ID AB250856 standard; DNA; 41 BP.
AC
XX AB250856;
XX
XX 26-JUN-2003 (first entry)
XX
DE Human ATP-binding cassette ABCB2/TAP2 gene polymorphic site, #7638.
XX
KM Human: drug metabolising enzyme; gene: drug metabolism; chromosome 6;
KM polymorphic site; drug evaluation; drug screening; genotyping;
KM genetic profiling; therapeutic customisation; adverse reaction;
KM clinical trial; drug approval; single nucleotide polymorphism; SNP; ds.
XX
XX Homo sapiens.
XX
OS
XX
FH Key Location/Qualifiers
FT variation /*tag= a
FT replace(21,G)
FT /standard_name= "Single nucleotide polymorphism (SNP)"
XX
XX W0300252044-A2.
XX
XX 04-JUL-2002.
XX
XX 27-DEC-2001; 2001WO-JP011592.
XX

```

```

XX
XX 27-DEC-2000; 2000JP-00399443.
PR 02-MAY-2001; 2000JP-00135256.
PR 27-AUG-2001; 2001JP-00256862.
XX
XX (RIKE ) RIKEN KK.
XX
XX Nakamura Y, Sekine A, Iida A, Saito S;
XX WPI; 2002-583571/62.
XX
XX Identifying individuals having a polymorphism, useful for determining the
XX effectiveness or side effect of a drug or treatment protocol, comprises
XX detecting at least one polymorphism in the drug metabolizing enzyme
XX nucleic acid.
XX
XX Claim 23; Page 223; 2785pp; English.
XX
XX Sequences AB243217-AB250887 represent polymorphic sites within genes
CC encoding enzymes associated with drug metabolism. The invention relates
CC to methods and compositions for identifying individuals who have at least
CC one polymorphism in such drug metabolizing enzyme-encoding genes. The
CC polymorphisms may be identified in a nucleic acid sample using probes or
CC primers specific for a sequence selected from AB243217-AB250887 using a
CC variety of detection assays, including hybridisation assays, nucleic acid
CC arrays and PCR-based methods. The invention also encompasses methods of
CC evaluating and screening drugs using genetic polymorphism data. Genetic
CC polymorphism data, particularly that relating to single nucleotide
CC polymorphisms (SNPs), may be used in studying the relationship between
CC DNA sequence variations and human diseases, conditions, and responses to
CC drugs. SNPs are also useful as polymorphism markers for discovering genes
CC that cause or exacerbate certain diseases. SNPs are particularly useful
CC in the above respects as they are stable in populations, occur
CC frequently, and have lower mutation rates than other genome variations
CC such as repeating sequences. The detection and analysis of polymorphisms
CC in genes encoding drug metabolising enzymes allows the customisation of
CC drug therapies based upon the genetic profile of individual patients.
CC This would not only take the guesswork out of selecting the drug with the
CC greatest therapeutic effect for a particular patient, but would also
CC reduce the likelihood of adverse reactions, thereby increasing safety.
CC Methods of the invention are also useful in the drug discovery and
CC approval processes. For example, individuals could be selected for
CC clinical trials only if their genetic profiles indicate that they are
CC capable of responding to a particular drug or drug class, and previously
CC failed drug candidates could be revived if they were matched with more
CC appropriate patient populations. The methods, data and compositions of
CC the invention may therefore lead to an increase in the range of
CC possible drug targets and decreases in the number of adverse drug
CC reactions, failed drug trials, the time taken for a drug to be approved,
CC the length of time patients are on medication and the number of different
CC medications a patient needs to take before finding an effective therapy
XX
XX Sequence 41 BP; 5 A; 19 C; 5 G; 12 T; 0 U; 0 Other;
SQ
Query Match 1.8%; Score 41; DB 1; Length 41;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 41; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 977 CCTCACCATTGTCACCCCTGATCACCCCTGCTGCTTTTC 1017
Db 1 CCTCACCATTGTCACCCCTGATCACCCCTGCTGCTTTTC 41
RESULT 3
AB243222
ID AB243222 standard; DNA; 41 BP.
AC
XX AB243222;
XX
XX 26-JUN-2003 (first entry)
XX
XX Human ATP-binding cassette ABCB2/TAP2 gene polymorphic site, #6.
XX
XX

```

KW Human; drug metabolising enzyme; gene; drug metabolism; chromosome 6;
KW polymorphic site; drug evaluation; drug screening; genotyping;
KW genetic profiling; therapeutic customisation; adverse reaction;
KW clinical trial; drug approval; single nucleotide polymorphism; SNP; ds.
OS Homo sapiens.
FH Key Location/Qualifiers
FT replacement(21,G)
FT /*tag= a
FT /standard_name= "Single nucleotide polymorphism (SNP)"
XX MO200252044-A2.
XX 04-JUL-2002.
XX 27-DEC-2001; 2001WO-JP011592.
XX 27-DEC-2000; 2000JP-00399443.
XX 02-MAY-2001; 2001JP-00135256.
XX 27-AUG-2001; 2001JP-00256862.
XX (RIKE) RIKEN KK.
XX Nakamura Y, Sekine A, Iida A, Saito S;
XX WPI; 2002-583571/62.
XX Identifying individuals having a polymorphism, useful for determining the
PT effectiveness or side effect of a drug or treatment protocol, comprises
PT detecting at least one polymorphism in the drug metabolizing enzyme
PT nucleic acid.
XX Claim 23; Page 64; 27855pp; English.
XX Sequences AB243217-AB250887 represent polymorphic sites within genes
CC encoding enzymes associated with drug metabolism. The invention relates
CC to methods and compositions for identifying individuals who have at least
CC one polymorphism in such drug metabolizing enzyme-encoding genes. The
CC polymorphisms may be identified in a nucleic acid sample using probes or
CC primers specific for a sequence selected from AB243217-AB250887 using a
CC variety of detection assays, including hybridisation assays, nucleic acid
CC arrays and PCR-based methods. The invention also encompasses methods of
CC evaluating and screening drugs using genetic polymorphism data. Genetic
CC polymorphisms (SNPs), may be used in studying the relationship between
CC DNA sequence variations and human diseases, conditions, and responses to
CC drugs. SNPs are also useful as polymorphism markers for discovering genes
CC that cause or exacerbate certain diseases. SNPs are particularly useful
CC in the above respects as they are stable in populations, occur
CC frequently, and have lower mutation rates than other genome variations
CC such as repeating sequences. The detection and analysis of polymorphisms
CC in genes encoding drug metabolising enzymes allows the customisation of
CC drug therapies based upon the genetic profile of individual patients.
CC This would not only take the guesswork out of selecting the drug with the
CC greatest therapeutic effect for a particular patient, but would also
CC reduce the likelihood of adverse reactions, thereby increasing safety.
CC Methods of the invention are also useful in the drug discovery and
CC approval processes. For example, individuals could be selected for
CC clinical trials only if their genetic profiles indicate that they are
CC capable of responding to a particular drug or drug class, and previously
CC failed drug candidates could be revived if they were matched with more
CC appropriate patient populations. The methods, data and compositions of
CC the invention may therefore lead to an increase in the range of
CC possible drug targets and decreases in the number of adverse drug
CC reactions, failed drug trials, the time taken for a drug to be approved,
CC the length of time patients are on medication and the number of different
CC medications a patient needs to take before finding an effective therapy
XX
XX Sequence 41 BP; 5 A; 19 C; 5 G; 12 T; 0 U; 0 Other;

Query Match 1.8%; Score 41; DB 1; Length 41;
Best Local Similarity 100.0%; Pred. No. 0.011;

Matches 41; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 977 CCTTCACCATGTCACCCCTGATACCCCTGCTTTTC 1017
Db 1 CCTTCACCATGTCACCCCTGATACCCCTGCTTTTC 41

RESULT 4
AAI30848
ID AAI30848 standard; DNA; 31 BP.
XX AAI30848;
XX AC
XX AA130848;
XX 18-OCT-2001 (first entry)
XX Human single nucleotide polymorphism (SNP) TAP1 1.
XX DE
XX Human; resequencing; genotype; disease; forensic; paternity testing;
KW single nucleotide polymorphism; SNP; ss.
XX OS
XX Homo sapiens.
XX FH Key Location/Qualifiers
FT Variation replacement(16,C)
FT /*tag= a
FT /standard_name= "single nucleotide polymorphism"
XX MO200166800-A2.
XX 13-SEP-2001.
XX 07-MAR-2001; 2001WO-US007268.
XX 07-MAR-2000; 2000US-0187510P.
XX 22-MAY-2000; 2000US-0206129P.
XX (WHEB) WHITEHEAD INST BIOMEDICAL RES.
XX Cargill M, Ireland JS, Lander ES;
XX WPI; 2001-522952/57.
XX Nucleic acid molecules from the human genome which include polymorphic
PT sites, useful in methods for predicting the presence, absence or severity
PT of a particular phenotype or disorder (e.g. diabetes) associated with a
PT particular genotype.
XX PS Claim 1; Page 112; 145pp; English.
XX The invention relates to the identification of nucleic acid molecules
CC (AAI29513-AAI31314) from the human genome which include polymorphic sites
CC which can predispose individuals to disease. Various genes from a number
CC of individuals were resequenced and single nucleotide polymorphisms
CC (SNPs) in these genes discovered. The method is useful for predicting the
CC presence, absence or severity of a particular phenotype or disorder (e.g.
CC diabetes) associated with a particular genotype. The nucleic acids
CC containing the polymorphic sites may be useful in forensics and paternity
CC testing
XX
XX Sequence 31 BP; 4 A; 11 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 1.4%; Score 31; DB 1; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.44;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 408 CCTTACCGCTTCTGTGTGACGTTATGACGC 438
Db 1 CCTTACCGCTTCTGTGTGACGTTATGACGC 31
RESULT 5
ABK82176
ID ABK82176 standard; DNA; 28 BP.

```

XX ABK82176;
AC
XX 27-AUG-2002 (first entry)
DT
XX
XX Human ATP-binding cassette (ABC) transporter probe #14.
DE
XX Human; ATP-binding cassette transporter; ABC transporter;
KM expression rate; drug development; biochemical kinetic; anthelmintic;
KW probe; ss.
XX
XX Homo sapiens.
OS
XX JF2002112775-A.
PN
XX 16-APR-2002.
PD
XX
XX 03-OCT-2000; 2000JP-00303404.
PF
XX 03-OCT-2000; 2000JP-00303404.
PR
XX
XX (SAKA ) OTSUKA SEIYAKU KOGYO KK.
PA
XX WPI; 2002-458864/49.
DR
XX
XX Probe for determination of human ATP-binding cassette (ABC) transporters
PT capable of hybridization with 33 regions of genes.
PT
XX
XX Claim 4; Page 20; 36pp; Japanese.
PS
XX
XX The invention describes new probes for identification of human ATP-
CC binding cassette (ABC) transporters capable of hybridisation with 33
CC regions of genes. Elucidation of expression rate of ABC transporters is
CC useful for development of drugs and their biochemical kinetics. This
CC sequence represents a probe used to detect human ATP-binding cassette
CC (ABC) transporters
CC
XX Sequence 28 BP; 8 A; 9 C; 5 G; 6 T; 0 U; 0 Other;
SQ
Query Match 1.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 653 ATGGCTCAGCCGATACCTTCACTCGAAA 680
DB 1 ATGGCTCAGCCGATACCTTCACTCGAAA 28

```

```

XX Simultaneous determination of a number of different molecular species of
PT protein mRNAs and a kit for the determination composed of primers and
PT probes.
PT
XX
XX Example 1; Page 14; 23pp; Japanese.
XX
XX The invention relates to a method for the simultaneous determination of a
CC number of different molecular species of protein mRNAs by the polymerase
CC chain reaction (PCR). The kits of the invention comprise of holes each
CC containing one primer and probe. The invention particularly comprises a
CC combination of a kit of reporter and quencher pigments, for the
CC determination of different molecular species. This polynucleotide
CC sequence represents a human ABC gene region relating to the invention
XX
XX Sequence 28 BP; 8 A; 9 C; 5 G; 6 T; 0 U; 0 Other;
SQ
Query Match 1.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 653 ATGGCTCAGCCGATACCTTCACTCGAAA 680
DB 1 ATGGCTCAGCCGATACCTTCACTCGAAA 28

```

RESULT 7

AAT59824/c

ID AAT59824 standard; DNA; 27 BP.

XX AAT59824;

AC AAT59824;

XX 15-NOV-1997 (first entry)

DT

XX TAP-1 antisense oligonucleotide.

DE

XX Major histocompatibility complex; MHC class I; antisense; TAP-1;

KM tumour specific antigen; cancer; infection; vaccine;

KW cytotoxic T lymphocyte; CTL; ss.

XX

OS Synthetic.

XX

XX MO9707128-A1.

PN

XX 27-FEB-1997.

PD

XX 20-AUG-1996; 96WO-US013457.

PF

XX 21-AUG-1995; 95US-00517373.

PR

XX (UYDU-) UNIV DUKE.

PA

XX Nair SK, Gilboa E;

PI

XX WPI; 1997-165238/15.

DR

XX High density presentation of antigens on cells - used in vaccines and to

PT generate cytotoxic T cells for treatment of infection and cancer.

PT

XX Disclosure; Page 3; 53pp; English.

PS

XX An antisense oligonucleotide (AAT59823) is complementary to nucleotides

CC 2214-2188 of the human TAP-1 mRNA. It can be used in a novel method of

CC altering the presentation of a peptide on a cell. This involves

CC inhibiting the activity of an MHC Class I pathway-- associated component

CC (e.g. TAP, IMP, heat shock protein or proteasome) in a cell using e.g. an

CC antisense oligonucleotide, and then contacting the cell with an antigenic

CC peptide to produce a potent antigen-presenting cell. Cells loaded with

CC the peptides are useful in vaccines for treatment or prevention of

CC bacterial or viral infections and, if the peptide is a tumour-specific

CC antigen, cancer. The cells can also stimulate proliferation of T cells in

CC vitro, generating CTL for treatment of infection and cancer. Inhibition

CC of MHC Class I pathway-associated components leads to cells that are

CC deficient in endogenous peptide loading, and thus are able to be loaded
 CC at high density with the peptides, which are presented in the form of a
 CC MHC-binding epitope, providing powerful APC for stimulation of the immune
 CC response in vivo or in vitro
 XX
 SQ Sequence 27 BP; 9 A; 6 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 1.2%; Score 27; DB 1; Length 27;
 Best Local Similarity 100.0%; Pred. No. 1.9;
 Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1978 AAACCGTGTACTTATCTCGATGAT 2004
 ||||||||||||||||||||||||||||
 Db 27 AAACCGTGTACTTATCTCGATGAT 1

RESULT 8

AAT59823/C
 ID AAT59823 standard; DNA; 27 BP.

AC AAT59823;

DT 15-NOV-1997 (first entry)

DE TAP-1 antisense oligonucleotide.

XX Major histocompatibility complex; MHC class I; antisense; TAP-1;

KW tumour specific antigen; cancer; infection; vaccine;

KW cytotoxic T lymphocyte; CTL; ss.

OS Synthetic.

PN W09707128-A1.

PD 27-FEB-1997.

PF 20-AUG-1996; 96WO-US013457.

PR 21-AUG-1995; 95US-00517373.

PA (UYDU-) UNIV DUKE.

PI Nair SK, Gilboa E;

DR WPI; 1997-165238/15.

XX High density presentation of antigens on cells - used in vaccines and to

PT generate cytotoxic T cells for treatment of infection and cancer.

XX Disclosure; Page 3; 53pp; English.

PS An antisense oligonucleotide (AAT59823) is complementary to nucleotides

CC 1428-1402 of the human TAP-1 mRNA. It can be used in a novel method of

CC altering the presentation of a peptide on a cell. This involves

CC inhibiting the activity of an MHC Class I pathway- associated component

CC (e.g. TAP, IMP, heat shock protein or proteasome) in a cell using e.g.

CC an antisense oligonucleotide, and then contacting the cell with an

CC antigenic peptide to produce a potent antigen-presenting cell. Cells

CC loaded with the peptides are useful in vaccines for treatment or

CC prevention of bacterial or viral infections and, if the peptide is a

CC tumour-specific antigen, cancer. The cells can also stimulate

CC proliferation of T cells in vitro, generating CTL for treatment of

CC infection and cancer. Inhibition of MHC Class I pathway-associated

CC components leads to cells that are deficient in endogenous peptide

CC loading, and thus are able to be loaded at high density with the

CC peptides, which are presented in the form of a MHC-binding epitope,

CC providing powerful APC for stimulation of the immune response in vivo or

CC in vitro

Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1192 AAGACTCAACAGAGAGGCTGTG 1218
 ||||||||||||||||||||||||||||
 Db 27 AAGACTCAACAGAGAGGCTGTG 1

RESULT 9
 AAV6541/C
 ID AAV6541 standard; DNA; 27 BP.

AC AAV6541;

DT 08-JAN-1999 (first entry)

DE Antisense oligonucleotide for nucleotides 2214-2188 of human TAP-1.

XX Antisense oligonucleotide; antigen processing protein; TAP; transporter;

KW proteasome; antigen-presenting cell; cancer; infection; cytotoxic T cell;

KW phosphorothioate; ss.

OS Synthetic.

XX Homo sapiens.

EN US5831068-A.

PD 03-NOV-1998.

PF 20-AUG-1996; 96US-00700035.

PR 21-AUG-1995; 95US-00517373.

PA (UYDU-) UNIV DUKE.

PI Gilboa E, Nair SK;

DR WPI; 1998-609331/51.

XX Increasing the presentation of a peptide on a mammalian cell for

PT production of antigen-presenting cells and stimulation of immune response

PT - by contacting cells with antigen after inactivating the protein

PT transporter associated with antigen processing or proteasome.

XX Example 3; Col 7; 27pp; English.

PS AAV6537-44 represent antisense oligonucleotides directed against nucleic

CC acid encoding antigen processing (TAP) proteins. The oligonucleotides are

CC synthesised as phosphorothioate derivatives, and are used in the course

CC of the invention. The specification describes a method for increasing the

CC presentation of a peptide (antigen) on a mammalian cell. The method

CC comprises inhibiting the activity of a transporter associated with TAP or

CC proteasome in the cell in vitro before contacting the cell with the

CC peptide. Antigen-presenting cells produced as above can be used to

CC stimulate an immune response in vitro or in vivo e.g. to treat or prevent

CC cancer or infection with a pathogen, e.g. a bacterium or virus. Cytotoxic

CC T cells produced as above can also be used for therapy

XX Sequence 27 BP; 9 A; 6 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 1.2%; Score 27; DB 1; Length 27;

Best Local Similarity 100.0%; Pred. No. 1.9;

Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1978 AAACCGTGTACTTATCTCGATGAT 2004
 ||||||||||||||||||||||||||||
 Db 27 AAACCGTGTACTTATCTCGATGAT 1

RESULT 10
 AAV6540/C
 ID AAV6540 standard; DNA; 27 BP.

XX AAV6540;

AC AAV6540;

```

XX 08-JAN-1999 (first entry)
XX
XX Antisense oligonucleotide for nucleotides 1426-1402 of human TAP-1.
DE
XX Antisense oligonucleotide; antigen processing protein; TAP; transporter;
KW proteasome; antigen-presenting cell; cancer; infection; cytotoxic T cell;
KM phosphorothioate; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX US5831068-A.
XX
XX 03-NOV-1998.
XX
XX 20-AUG-1996; 96US-00700035.
XX
XX 21-AUG-1995; 95US-00517373.
XX
XX (UYDU-) UNIV DUKE.
XX
XX Gilboa E, Nair SK;
XX
XX WPI; 1998-609331/51.
XX
XX Increasing the presentation of a peptide on a mammalian cell for
PT production of antigen-presenting cells and stimulation of immune response
PT - by contacting cells with antigen after inactivating the protein
PT transporter associated with antigen processing or proteasome.
XX
XX Example 3; Col 7; 27pp; English.
XX
XX AA66537-44 represent antisense oligonucleotides directed against nucleic
CC acid encoding antigen processing (TAP) proteins. The oligonucleotides are
CC synthesized as phosphorothioate derivatives, and are used in the course
CC of the invention. The specification describes a method for increasing the
CC presentation of a peptide (antigen) on a mammalian cell. The method
CC comprises inhibiting the activity of a transporter associated with TAP or
CC proteasome in the cell in vitro before contacting the cell with the
CC peptide. Antigen-presenting cells produced as above can be used to
CC stimulate an immune response in vitro or in vivo e.g. to treat or prevent
CC cancer or infection with a pathogen, e.g. a bacterium or virus. Cytotoxic
CC T cells produced as above can also be used for therapy
XX
XX Sequence 27 BP; 3 A; 8 C; 6 G; 10 T; 0 U; 0 Other;
SQ
Query Match 1.2%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1192 AAGACTCAACCGAAGAGGCTGTG 1218
DB 27 AAGACTCAACCGAAGAGGCTGTG 1

```

```

XX 16-APR-2002.
XX
XX 03-OCT-2000; 2000JP-00303404.
XX
XX 03-OCT-2000; 2000JP-00303404.
XX
XX (SAKA ) OTSUKA SEIYAKU KOGYO KK.
XX
XX WPI; 2002-458864/49.
XX
XX Probes for determination of human ATP-binding cassette (ABC) transporters
PT capable of hybridization with 33 regions of genes.
XX
XX Claim 4; Page 20; 36pp; Japanese.
XX
XX The invention describes new probes for identification of human ATP-
CC binding cassette (ABC) transporters capable of hybridisation with 33
CC regions of genes. elucidation of expression rate of ABC transporters is
CC useful for development of drugs and their biochemical kinetics. This
CC sequence represents a probe used to detect human ATP-binding cassette
CC (ABC) transporters
XX
XX Sequence 26 BP; 4 A; 7 C; 6 G; 9 T; 0 U; 0 Other;
SQ
Query Match 1.2%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 2.7;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 330 TGCTTGTTCCGAGAGCTGATCTCAT 355
DB 1 TGCTTGTTCCGAGAGCTGATCTCAT 26

```

RESULT 12
AA234534
ID AA234534 standard; DNA; 24 BP.
XX
AC AA234534;
XX
DT 01-FEB-2000 (first entry)
XX
DE Transporter protein TAP1 exon 9 PCR primer.
XX
KW TAP1; transporter associated with antigen protein; TAP; splice variant;
KW vaccine; diagnosis; therapy; autoimmune disease; diabetes; cancer; PCR;
KW primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
FN W09952928-A1.
XX
PD 21-OCT-1999.
XX
PF 15-APR-1999; 99WO-US008205.
XX
PR 16-APR-1998; 98US-00061764.
XX
PA (GENO) GEN HOSPITAL CORP.
XX
PI Faustman DL;
XX
DR WPI; 1999-633819/54.
XX
PT Nucleic acid encoding splice variants of transporter associated with
PT antigen processing proteins, useful for improving the immune responses.
XX
PS Example 2; Page 71; 77pp; English.
XX
XX This oligonucleotide is based on exon 9 of the human TAP1 (transporter
CC associated with antigen processing 1) gene. It was used as the forward
CC primer in the PCR amplification of multiple samples of cDNA from various

CC cell lines in order to determine the pattern of expression of TAP1 and
 CC its splice variant TAP1iso. The discovery of splice variant TAP subunits
 CC (see AY3133-34) introduces a cellular mechanism for diversification of
 CC antigen display to the CD8-positive T cells of the immune system. Methods
 CC for diagnosis and treatment of diseases or conditions associated with
 CC abnormal TAP isoform expression, or of expanding the repertoire of
 CC antigen peptides to which an individual's immune system is capable of
 CC responding, are also disclosed

XX Sequence 24 BP; 4 A; 8 C; 3 G; 9 T; 0 U; 0 Other;

SO Query Match 1.1%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 5.5;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1866 TAGTTTCATCTCTGGACTCCCTCA 1889
 1 TAGTTTCATCTCTGGACTCCCTCA 24

Db

RESULT 13
 AAL62374
 ID AAL62374 standard; DNA; 23 BP.
 XX
 AC AAL62374;
 XX
 DT 06-OCT-2003 (first entry)
 XX
 DE Human ABC transporter MHC I DNA specific forward PCR primer.
 XX
 KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
 KW hyperproliferative; autoimmune disorder; antisense gene therapy;
 KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
 KW PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO2003051309-A2.
 XX
 PD 26-JUN-2003.
 XX
 PF 12-DEC-2002; 2002WO-US040101.
 XX
 PR 17-DEC-2001; 2001US-00024369.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Borchers AH, Ward DT, Freier SM;
 XX
 DR WPI; 2003-577305/54.
 XX
 PT New antisense compound that hybridizes and inhibits the nucleic acid
 PT encoding ABC transporter major histocompatibility complex 1, for treating
 PT diseases or conditions such as a hyperproliferative or autoimmune
 PT disorder.
 XX
 PS Example 13; Page 78; 112pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
 CC where the compound specifically hybridizes with the nucleic acid molecule
 CC and inhibits expression of ATM or specifically hybridizes with at least a
 CC portion of an active site on the nucleic acid molecule. The invention is
 CC useful for inhibiting the expression of ATM in cells or tissues. The
 CC invention is useful for treating an animal with hyperproliferative or
 CC autoimmune disorder. The invention is useful for diagnostics,
 CC therapeutics, prophylaxis, as research reagents and kits, for
 CC distinguishing functions of various members of a biological pathway and
 CC in antisense gene therapy. The invention is also useful prophylactically
 CC e.g., to prevent or delay infection, inflammation or tumour formation.
 CC The present sequence is human ABC transporter major histocompatibility
 CC complex 1 DNA specific PCR primer. This sequence is used to illustrate
 CC the method of the invention

XX Sequence 23 BP; 7 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

SO Query Match 1.0%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 7.8;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 731 TGGGTGACGGGATCTATACAC 753
 1 TGGGTGACGGGATCTATACAC 23

Db

RESULT 14
 ABR82236
 ID ABR82236 standard; DNA; 22 BP.
 XX
 AC ABR82236;
 XX
 DT 27-AUG-2002 (first entry)
 XX
 DE Human ATP-binding cassette (ABC) transporter probe #74.
 XX
 KW Human; ATP-binding cassette transporter; ABC transporter;
 KW expression rate; drug development; biochemical kinetic; antehelminthic;
 KW probe; ss.
 XX
 OS Homo sapiens.
 XX
 PN JP2002112775-A.
 XX
 PD 16-APR-2002.
 XX
 PF 03-OCT-2000; 2000JP-00303404.
 XX
 PR 03-OCT-2000; 2000JP-00303404.
 XX
 PA (SAKA) OTSUKA SEIYAKU KOGYO KK.
 XX
 DR WPI; 2002-458864/49.
 XX
 PT Probes for determination of human ATP-binding cassette (ABC) transporters
 PT capable of hybridization with 33 regions of genes.
 XX
 PS Claim 8; Page 27; 36pp; Japanese.
 XX
 CC The invention describes new probes for identification of human ATP-
 CC binding cassette (ABC) transporters capable of hybridisation with 33
 CC regions of genes. Elucidation of expression rate of ABC transporters is
 CC useful for development of drugs and their biochemical kinetics. This
 CC sequence represents a probe used to detect human ATP-binding cassette
 CC (ABC) transporters
 XX
 SO Sequence 22 BP; 4 A; 8 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 1.0%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 11;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 628 CGCCTCACTGACGTGATTCTAC 649
 1 CGCCTCACTGACGTGATTCTAC 22

Db

RESULT 15
 ABR82237/C
 ID ABR82237 standard; DNA; 22 BP.
 XX
 AC ABR82237;
 XX
 DT 27-AUG-2002 (first entry)
 XX
 DE Human ATP-binding cassette (ABC) transporter probe #75.
 XX

KM Human; ATP-binding cassette transporter; ABC transporter;
 KM expression rate; drug development; biochemical kinetic; anthelmintic;
 KM probe; ss.
 XX Homo sapiens.
 OS
 PN JP2002112775-A.
 XX
 PD 16-APR-2002.
 XX
 PF 03-OCT-2000; 2000JP-00303404.
 XX
 PR 03-OCT-2000; 2000JP-00303404.
 XX
 PA (SAKA) OTSUKA SEIYAKU KOGYO KK.
 DR WPI; 2002-458864/49.
 XX
 PT Probes for determination of human ATP-binding cassette (ABC) transporters
 PT capable of hybridization with 33 regions of genes.
 XX
 PS Claim 8; Page 27; 36pp; Japanese.
 XX
 CC The invention describes new probes for identification of human ATP-
 CC binding cassette (ABC) transporters capable of hybridisation with 33
 CC regions of genes. elucidation of expression rate of ABC transporters is
 CC useful for development of drugs and their biochemical kinetics. This
 CC sequence represents a probe used to detect human ATP-binding cassette
 CC (ABC) transporters
 XX
 SQ Sequence 22 BP; 5 A; 7 C; 3 G; 7 T; 0 U; 0 Other;
 XX
 QY Query Match 1.0%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 11;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 Db 731 TGGGTGACGGGATCTATACAA 752
 22 TGGGTGACGGGATCTATACAA 1
 XX
 RESULT 16
 AAL40543/C
 ID AAL40543 standard; DNA; 22 BP.
 XX
 AC AAL40543;
 XX
 DT 25-SEP-2002 (first entry)
 XX
 DE Human ABCB2 gene region SEQ ID No 20.
 KM Plural mRNA; kit; reporter; quencher pigment; human; ABC gene; ds.
 XX
 OS Homo sapiens.
 PN JP2002181818-A.
 XX
 PD 26-JUN-2002.
 XX
 PF 15-DEC-2000; 2000JP-00381621.
 XX
 PR 15-DEC-2000; 2000JP-00381621.
 XX
 PA (SAKA) OTSUKA SEIYAKU KOGYO KK.
 DR WPI; 2002-543426/58.
 XX
 PT Simultaneous determination of a number of different molecular species of
 PT protein mRNAs and a kit for the determination composed of primers and
 PT probes.
 XX
 PS Example 1; Page 14; 23pp; Japanese.
 XX

CC The invention relates to a method for the simultaneous determination of a
 CC number of different molecular species of protein mRNAs by the polymerase
 CC chain reaction (PCR). The kits of the invention comprise of holes each
 CC containing one primer and probe. The invention particularly comprises a
 CC combination of a kit of reporter and quencher pigments, for the
 CC determination of different molecular species. This polynucleotide
 CC sequence represents a human ABC gene region relating to the invention
 XX
 SQ Sequence 22 BP; 5 A; 7 C; 3 G; 7 T; 0 U; 0 Other;
 XX
 QY Query Match 1.0%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 11;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 Db 731 TGGGTGACGGGATCTATACAA 752
 22 TGGGTGACGGGATCTATACAA 1
 XX
 RESULT 17
 AAL40542
 ID AAL40542 standard; DNA; 22 BP.
 XX
 AC AAL40542;
 XX
 DT 25-SEP-2002 (first entry)
 XX
 DE Human ABCB2 gene region SEQ ID No 19.
 KM Plural mRNA; kit; reporter; quencher pigment; human; ABC gene; ds.
 XX
 OS Homo sapiens.
 PN JP2002181818-A.
 XX
 PD 26-JUN-2002.
 XX
 PF 15-DEC-2000; 2000JP-00381621.
 XX
 PR 15-DEC-2000; 2000JP-00381621.
 XX
 PA (SAKA) OTSUKA SEIYAKU KOGYO KK.
 DR WPI; 2002-543426/58.
 XX
 PT Simultaneous determination of a number of different molecular species of
 PT protein mRNAs and a kit for the determination composed of primers and
 PT probes.
 XX
 PS Example 1; Page 14; 23pp; Japanese.
 XX
 CC The invention relates to a method for the simultaneous determination of a
 CC number of different molecular species of protein mRNAs by the polymerase
 CC chain reaction (PCR). The kits of the invention comprise of holes each
 CC containing one primer and probe. The invention particularly comprises a
 CC combination of a kit of reporter and quencher pigments, for the
 CC determination of different molecular species. This polynucleotide
 CC sequence represents a human ABC gene region relating to the invention
 XX
 SQ Sequence 22 BP; 4 A; 8 C; 4 G; 6 T; 0 U; 0 Other;
 XX
 QY Query Match 1.0%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 11;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 Db 628 CGCCTCACTAGTGGATTCTAC 649
 1 CGCCTCACTAGTGGATTCTAC 22
 XX
 RESULT 18
 AAP96003
 ID AAP96003 standard; DNA; 21 BP.
 XX

```

XX AAF96003;
AC
XX
XX 06-JUN-2001 (first entry)
DT
XX
XX Human gene single nucleotide polymorphism #764.
DE
XX
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KM polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
XX pulmonary embolism; paternity test; ds.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH replace(11,G)
FT /*tag= a
FT /standard_name= "single nucleotide polymorphism"
FT
FT
XX MO200118250-A2.
XX
XX 15-MAR-2001.
XX
XX 07-SEP-2000; 2000WO-US024503.
XX
XX 10-SEP-1999; 99US-01S3357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILLENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
PI WPI; 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX
XX
XX Example; Page 101; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
XX
XX Sequence 21 BP; 5 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 706 ATAGCCAGTGCAGTGTGGAG 726
Db 1 ATAGCCAGTGCAGTGTGGAG 21
RESULT 19
AAF96004
ID AAF96004 standard; DNA; 21 BP.
XX
XX AAF96004;
XX
XX 06-JUN-2001 (first entry)
DT

```

```

XX
DE Human gene single nucleotide polymorphism #765.
XX
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KM polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
XX pulmonary embolism; paternity test; ds.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH replace(11,T)
FT /*tag= a
FT /standard_name= "single nucleotide polymorphism"
FT
FT
XX MO200118250-A2.
XX
XX 15-MAR-2001.
XX
XX 07-SEP-2000; 2000WO-US024503.
XX
XX 10-SEP-1999; 99US-01S3357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILLENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
PI WPI; 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX
XX
XX Example; Page 101; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
XX
XX Sequence 21 BP; 3 A; 9 C; 3 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 407 ACCCTACCGCCTTGTTGTC 427
Db 1 ACCCTACCGCCTTGTTGTC 21
RESULT 20
AAF96011
ID AAF96011 standard; DNA; 21 BP.
XX
XX AAF96011;
XX
XX 06-JUN-2001 (first entry)
DT
XX
XX Human gene single nucleotide polymorphism #772.
XX
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW

```

KM polymorphism; vascular disease; coronary artery disease; forensics;
 KM myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
 KM pulmonary embolism; paternity test; de.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Variation replace(11,T)
 FT /*tag= a
 FT /standard_name= "single nucleotide polymorphism"
 XX
 PN WO200118250-A2.
 XX
 PD 15-MAR-2001.
 XX
 PF 07-SEP-2000; 2000WO-US024503.
 XX
 PR 10-SEP-1999; 99US-0153357P.
 PR 26-JUL-2000; 2000US-0220947P.
 PR 16-AUG-2000; 2000US-0225724P.
 XX
 PA (WHEED) WHITEHEAD INST BIOMEDICAL RES.
 PA (MILL-) MILENNIUM PHARM INC.
 PI Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
 PI WPI; 2001-226749/23.
 DR
 XX
 PT Nucleic acids comprising single nucleotide polymorphisms, useful in
 PT applications such as forensics, paternity testing, medicine, genetic
 PT analysis and phenotype correlations to diseases such as diabetes and
 PT atherosclerosis.
 XX
 PS Example; Page 102; 242pp; English.
 XX
 CC The present invention provides a method of diagnosing a vascular disease
 CC in an individual, involving determining the sequence at various
 CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
 CC genes. The sequences at a number of polymorphic sites are also provided
 CC in the specification. In particular, the method can be used in the
 CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
 CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
 CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
 CC useful in forensics, paternity testing, genetic analysis and phenotype
 CC correlations to diseases. The present sequence is an example of one of
 CC the human gene SNPs shown in the specification
 CC
 XX
 SQ Sequence 21 BP; 6 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
 XX
 QY Query Match 0.9%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 15;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 Db 1537 CCAAAACGCCGAGATGCTTA 1557
 1 CCAAAACGCCGAGATGCTTA 21
 XX
 RESULT 21
 AAF96007 standard; DNA; 21 BP.
 XX
 AC AAF96007;
 XX
 DT 06-JUN-2001 (first entry)
 DE Human gene single nucleotide polymorphism #768.
 XX
 KM Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
 KM polymorphism; vascular disease; coronary artery disease; forensics;
 KM myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
 KM pulmonary embolism; paternity test; ds.
 XX

OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Variation replace(11,T)
 FT /*tag= a
 FT /standard_name= "single nucleotide polymorphism"
 XX
 PN WO200118250-A2.
 XX
 PD 15-MAR-2001.
 XX
 PF 07-SEP-2000; 2000WO-US024503.
 XX
 PR 10-SEP-1999; 99US-0153357P.
 PR 26-JUL-2000; 2000US-0220947P.
 PR 16-AUG-2000; 2000US-0225724P.
 XX
 PA (WHEED) WHITEHEAD INST BIOMEDICAL RES.
 PA (MILL-) MILENNIUM PHARM INC.
 PI Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
 PI WPI; 2001-226749/23.
 DR
 XX
 PT Nucleic acids comprising single nucleotide polymorphisms, useful in
 PT applications such as forensics, paternity testing, medicine, genetic
 PT analysis and phenotype correlations to diseases such as diabetes and
 PT atherosclerosis.
 XX
 PS Example; Page 101; 242pp; English.
 XX
 CC The present invention provides a method of diagnosing a vascular disease
 CC in an individual, involving determining the sequence at various
 CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
 CC genes. The sequences at a number of polymorphic sites are also provided
 CC in the specification. In particular, the method can be used in the
 CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
 CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
 CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
 CC useful in forensics, paternity testing, genetic analysis and phenotype
 CC correlations to diseases. The present sequence is an example of one of
 CC the human gene SNPs shown in the specification
 CC
 XX
 SQ Sequence 21 BP; 4 A; 3 C; 5 G; 9 T; 0 U; 0 Other;
 XX
 QY Query Match 0.9%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 15;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 Db 1245 TAGATTTCAGTATGCTGCT 1265
 1 TAGATTTCAGTATGCTGCT 21
 XX
 RESULT 22
 AAF96006 standard; DNA; 21 BP.
 XX
 AC AAF96006;
 XX
 DT 06-JUN-2001 (first entry)
 DE Human gene single nucleotide polymorphism #767.
 XX
 KM Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
 KM polymorphism; vascular disease; coronary artery disease; forensics;
 KM myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
 KM pulmonary embolism; paternity test; ds.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Variation replace(11,G)
 XX

```

FT      /*tag= a
FT      /standard_name= "single nucleotide polymorphism"
PN      WO200118250-A2.
XX
XX      15-MAR-2001.
XX
XX      07-SEP-2000; 2000WO-US024503.
XX
XX      10-SEP-1999; 99US-0153357P.
XX      26-JUL-2000; 2000US-0220947P.
XX      16-AUG-2000; 2000US-0225724P.
XX
XX      (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
XX      (MILL-) MILLENNIUM PHARM INC.
PI      Lander ES, Gargill M, Ireland JS, Bolk S, Daley GO, McCarthy JF;
XX      WPI; 2001-226749/23.
XX
XX      Nucleic acids comprising single nucleotide polymorphisms, useful in
XX      applications such as forensics, paternity testing, medicine, genetic
XX      analysis and phenotype correlations to diseases such as diabetes and
XX      atherosclerosis.
XX
XX      Example; Page 101; 242pp; English.
XX
XX      The present invention provides a method of diagnosing a vascular disease
XX      in an individual, involving determining the sequence at various
XX      polymorphic sites within the human thrombospondin 1 and thrombospondin 4
XX      genes. The sequences at a number of polymorphic sites are also provided
XX      in the specification. In particular, the method can be used in the
XX      diagnosis of atherosclerosis, myocardial infarction, coronary heart
XX      disease, stroke, peripheral vascular diseases, venous thromboembolism and
XX      pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
XX      useful in forensics, paternity testing, genetic analysis and phenotype
XX      correlations to diseases. The present sequence is an example of one of
XX      the human gene SNPs shown in the specification
XX
XX      Sequence 21 BP; 0 A; 7 C; 5 G; 9 T; 0 U; 0 Other;
XX
XX      Query Match      0.9%; Score 21; DB 1; Length 21;
XX      Best Local Similarity 100.0%; Pred. No. 15;
XX      Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX      QY      578 TGTGTCCTCTCTCTCTTG 598
XX      Db      1 TGTGTCCTCTCTCTCTTG 21
XX
XX      RESULT 23
XX      AAF96009
XX      ID AAF96009 standard; DNA; 21 BP.
XX
XX      AC AAF96009;
XX
XX      06-JUN-2001 (first entry)
XX
XX      Human gene single nucleotide polymorphism #770.
XX
XX      Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
XX      polymorphism; vascular disease; coronary artery disease; forensics;
XX      myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
XX      pulmonary embolism; paternity test; ds.
XX
XX      Homo sapiens.
XX
XX      Key      Location/Qualifiers
XX      Variation      replace(11,T)
XX      /*tag= a
XX      /standard_name= "single nucleotide polymorphism"
XX
XX      WO200118250-A2.

```

```

XX      15-MAR-2001.
XX
XX      07-SEP-2000; 2000WO-US024503.
XX
XX      10-SEP-1999; 99US-0153357P.
XX      26-JUL-2000; 2000US-0220947P.
XX      16-AUG-2000; 2000US-0225724P.
XX
XX      (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
XX      (MILL-) MILLENNIUM PHARM INC.
PI      Lander ES, Gargill M, Ireland JS, Bolk S, Daley GO, McCarthy JF;
XX      WPI; 2001-226749/23.
XX
XX      Nucleic acids comprising single nucleotide polymorphisms, useful in
XX      applications such as forensics, paternity testing, medicine, genetic
XX      analysis and phenotype correlations to diseases such as diabetes and
XX      atherosclerosis.
XX
XX      Example; Page 102; 242pp; English.
XX
XX      The present invention provides a method of diagnosing a vascular disease
XX      in an individual, involving determining the sequence at various
XX      polymorphic sites within the human thrombospondin 1 and thrombospondin 4
XX      genes. The sequences at a number of polymorphic sites are also provided
XX      in the specification. In particular, the method can be used in the
XX      diagnosis of atherosclerosis, myocardial infarction, coronary heart
XX      disease, stroke, peripheral vascular diseases, venous thromboembolism and
XX      pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
XX      useful in forensics, paternity testing, genetic analysis and phenotype
XX      correlations to diseases. The present sequence is an example of one of
XX      the human gene SNPs shown in the specification
XX
XX      Sequence 21 BP; 7 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX      Query Match      0.9%; Score 21; DB 1; Length 21;
XX      Best Local Similarity 100.0%; Pred. No. 15;
XX      Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX      QY      847 AACATCATGTCTCGGTAACA 867
XX      Db      1 AACATCATGTCTCGGTAACA 21
XX
XX      RESULT 24
XX      AAF96010
XX      ID AAF96010 standard; DNA; 21 BP.
XX
XX      AC AAF96010;
XX
XX      06-JUN-2001 (first entry)
XX
XX      Human gene single nucleotide polymorphism #771.
XX
XX      Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
XX      polymorphism; vascular disease; coronary artery disease; forensics;
XX      myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
XX      pulmonary embolism; paternity test; ds.
XX
XX      Homo sapiens.
XX
XX      Key      Location/Qualifiers
XX      Variation      replace(11,G)
XX      /*tag= a
XX      /standard_name= "single nucleotide polymorphism"
XX
XX      WO200118250-A2.
XX
XX      15-MAR-2001.
XX
XX      07-SEP-2000; 2000WO-US024503.

```

```
XX 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX
XX (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
XX (MILL-) MILLENNIUM PHARM INC.
XX
PI Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
XX WPI; 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX
XX Example; Page 102; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
XX
SQ Sequence 21 BP; 3 A; 10 C; 4 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 15;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 987 GGTCAACCTGATCACCCTGCC 1007
Db 1 GGTCAACCTGATCACCCTGCC 21
XX
RESULT 25
AAF96005
ID AAF96005 standard; DNA; 21 BP.
XX
AC AAF96005;
XX
XX 06-JUN-2001 (first entry)
XX
DE Human gene single nucleotide polymorphism #766.
XX
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
XX polymorphism; vascular disease; coronary artery disease; forensics;
XX myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
XX pulmonary embolism; paternity test; ds.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX PT replace (11,G)
XX FT /*tag= a
XX FT /standard_name= "single nucleotide polymorphism"
XX
XX WO200118250-A2.
XX
XX 15-MAR-2001.
XX
XX 07-SEP-2000; 2000WO-US024503.
XX
XX 10-SEP-1999; 99US-0153357P.
XX 26-JUL-2000; 2000US-0220947P.
XX 16-AUG-2000; 2000US-0225724P.
XX
```

```
XX (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
XX (MILL-) MILLENNIUM PHARM INC.
XX
PI Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
XX WPI; 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX
XX Example; Page 101; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
XX
SQ Sequence 21 BP; 1 A; 7 C; 6 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 15;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 318 CTTGCCGCGACTTGCTTTT 338
Db 1 CTTGCCGCGACTTGCTTTT 21
XX
RESULT 26
AAD41089/C
ID AAD41089 standard; DNA; 21 BP.
XX
AC AAD41089;
XX
XX 30-OCT-2002 (first entry)
XX
DE Primer ON-TAP1-R2 used for DNA sequencing.
XX
XX Tumour necrosis-factor; TNF; promoter; autoimmune disorder; cancer;
XX therapy; primer; ss.
XX
XX Unidentified.
XX
XX WO200246433-A2.
XX
XX 13-JUN-2002.
XX
XX 07-DEC-2001; 2001WO-EP014412.
XX
XX 08-DEC-2000; 2000US-0254649P.
XX
XX (SAUS/) SAUS J.
XX
XX Saus J;
XX
XX WPI; 2002-519670/55.
XX
XX Novel tumor necrosis-factor inducible promoter useful for identifying
PT candidate compounds for treating/preventing autoimmune disorders/cancer,
PT or for identifying promoters that are regulated by tumor necrosis factor.
XX
XX Example; Page 18; 95pp; English.
XX
```

CC The invention relates to a tumour necrosis-factor TNF inducible promoter.
 CC The invention is useful for identifying candidate TNF inducible promoters
 CC by aligning a test sequence consisting of a nucleic acid sequence with a
 CC comparison sequence selected from the invention, using a gap opening
 CC penalty of 50 and a gap extension penalty of 3 to define a test
 CC alignment, shuffling the nucleic sequence of the test sequence at least
 CC one hundred times, while maintaining its length and composition, to
 CC produce a series of randomised sequences, aligning the randomised
 CC sequences with the comparison sequence using a gap opening penalty of 50
 CC and a gap extension penalty of 3, to produce a series of randomised
 CC alignments, determining an average alignment quality of the randomised
 CC alignments, where the average alignment quality of the randomised
 CC alignments represent an alignment expected by chance, comparing the test
 CC alignment with the average alignment quality of the randomised alignments
 CC and identifying a test alignment with a probability value of less than
 CC 0.05 that the alignment is obtained by chance as a candidate TNF
 CC inducible promoter. The invention is useful for identifying candidate
 CC compounds for treating or preventing autoimmune disorders or cancer. The
 CC present sequence is a primer used in the exemplification of the invention
 XX
 SQ Sequence 21 BP; 5 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 15;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 658 TCAGCCGATACCTTCACTCGA 678
 |||||
 Db 21 TCAGCCGATACCTTCACTCGA 1

RESULT 27
 ABR03924/C
 ID ABR03924 standard; DNA; 21 BP.

AC ABR03924;

DT 18-SEP-2002 (first entry)

XX Human pol kappa 76 DNA polymerase sequencing primer #30.

DE Human; pol kappa 76; Goodpasture antigen binding protein; GBBP;

KW chromosome 5q12-13; apoptosis; autoimmune disorder; cancer; cytosstatic;

KM immunosuppressive; PCR; primer; sequencing; ss.

XX Homo sapiens.

OS WO200246378-A2.

PN 13-JUN-2002.

PF 07-DEC-2001; 2001WO-EP014409.

XX 08-DEC-2000; 2000US-0254649P.

PA (SAUS/) SAUS J.

PI Saus J;

XX WPI; 2002-537563/57.

DR Novel isolated pol kappa76 polypeptide, a 76 kDa alternatively spliced

PT variant of DNA polymerase kappa, useful as target for treating a patient

PT with autoimmune disorder or cancer.

XX Example; Page 16; 90pp; English.

CC The present invention provides the protein and coding sequences of human
 CC DNA polymerase pol kappa 76. The gene is found on human chromosome 5q12-
 CC 13, in a head-to-head arrangement with the Goodpasture antigen binding
 CC protein (GPBP). The detection of the coding sequence can be used for
 CC diagnosing an autoimmune condition and identifying cells undergoing
 CC apoptosis, and the sequences can be used in the treatment of autoimmune

CC diseases and cancer. The present sequence is a sequencing primer
 CC described in the invention
 XX
 SQ Sequence 21 BP; 5 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 15;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 658 TCAGCCGATACCTTCACTCGA 678
 |||||
 Db 21 TCAGCCGATACCTTCACTCGA 1

RESULT 28
 ACD13527/C
 ID ACD13527 standard; DNA; 21 BP.

AC ACD13527;

DT 14-AUG-2003 (first entry)

XX Human bi-directional promoter PCR/sequencing primer ON-TAP1-R2.

DE Human; ss; Goodpasture antigen binding protein; GBBP; COL4A3BP;

KW collagen 4 alpha 3 binding protein; DNA polymerase kappa; Pol kappa;

KM Goodpasture disease; cutaneous lupus; polK76; bi-directional promoter;

XX autoimmune disease; cancer; antisense therapy; PCR; primer.

OS Homo sapiens.

PN US2003027165-A1.

PD 06-FEB-2003.

PF 07-DEC-2001; 2001US-00010920.

XX 08-DEC-2000; 2000US-0254649P.

PA (SAUS/) SAUS J.

PI Saus J;

XX WPI; 2003-479531/45.

PT New isolated DNA polymerase, pol kappa 76, useful in identifying

PT autoimmune disorders and in treating cancer and autoimmune disorders by

PT modifying its expression.

XX Example; Page 7; 54pp; English.

XX The invention relates to an isolated pol kappa (K) 76 polypeptide (an

CC alternatively spliced form of DNA polymerase kappa), appearing as

CC ABO07927 (encoded by the cDNA appearing as ACD13492). The gene for

CC POLKappa is located on chromosome 5q12-13 in a head-head arrangement with

CC the gene encoding Goodpasture antigen binding protein (GPBP or collagen 4

CC alpha 3 binding protein (COL4A3BP), associated with autoimmune diseases

CC such as Goodpasture's disease and cutaneous lupus) i.e. has a bi-

CC directional promoter. Also included are a recombinant expression vector

CC comprising the polK76 cDNA, a host cell transfected with the vector,

CC detecting (M1) polK76 (comprising providing a protein sample to be

CC screened, contacting the protein sample to be screened with an anti-

CC polK76 antibody and detecting the formation of an antibody- polypeptide

CC complexes, where the presence of the antibody-polypeptide complexes

CC indicates the presence of polK76), detecting (M2) the polK76 nucleic acid

CC in a sample (comprising contacting the sample with one or more polK76 PCR

CC primer, carrying out PCR to generate PCR products, and identifying the

CC polK76-specific PCR), detecting an autoimmune condition in a patient

CC (comprising providing a tissue or body fluid sample from the patient,

CC providing a control tissue or body fluid sample in which no autoimmune

CC condition is present, and detecting an increase in pol K76 RNA expression

CC in the tissue of body fluid samples compared to the control sample, where

CC the increase indicates the presence of an autoimmune condition) and

CC treating (M3) a patient with an autoimmune disorder or cancer by
 CC modifying the expression or activity of pol k76 in the patient. Modifying
 CC the expression or activity of polK76 or polK76 nucleic acid, such as by
 CC increasing or decreasing their expression or activity using antibodies or
 CC antisense therapy, is useful for treating an autoimmune disorder or
 CC cancer. The present sequence is a PCR and/or sequencing primer used in
 CC the analysis of bi-directional promoters of other genes (and/or of
 CC polkappa/SPBP), whose structure and sequence were compared to the
 CC polkappa/SPBP bi-directional promoter
 XX
 SQ Sequence 21 BP; 5 A; 3 C; 8 G; 5 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 15;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 658 TCAGCCGATACCTTCACTCGA 678
 Db 21 TCAGCCGATACCTTCACTCGA 1
 RESULT 29
 ADA97828/C
 ID ADA97828 standard; DNA; 21 BP.
 XX
 AC ADA97828;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human tumour necrosis factor (TNF) inducible promoter PCR primer #30.
 XX
 KM Human; tumour necrosis factor inducible promoter; TNF;
 KM autoimmune disorder; cancer; PCR; immunosuppressive; cytostatic; ss;
 KM primer.
 XX
 OS Homo sapiens.
 XX
 PN US2003082745-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 07-DEC-2001; 2001US-00008721.
 XX
 PR 08-DEC-2000; 2000US-0254649P.
 XX
 PA (SAUS/) SAUS J.
 XX
 PI Saus J;
 XX
 WPI; 2003-606062/57.
 XX
 DR
 XX
 PT New tumor necrosis factor inducible promoters, useful for identifying
 PT promoters that are regulated by tumor necrosis factor, or for identifying
 PT candidate compounds for treating or preventing autoimmune disorders or
 PT cancer.
 XX
 PS Example; Page 7; 57bp; English.
 XX
 CC The invention relates to a tumour necrosis factor (TNF) inducible
 CC promoter. Also disclosed are an expression vector comprising one or more
 CC tumour necrosis factor inducible promoters and a recombinant host cell
 CC transfected with one or more expression vectors. The TNF inducible
 CC promoter, expression vectors and host cells are useful for identifying
 CC promoters that are regulated by tumour necrosis factor or for identifying
 CC candidate compounds for treating or preventing autoimmune disorders or
 CC cancer. This sequence represents a PCR primer used for isolating a tumour
 CC necrosis factor inducible promoter of the invention.
 XX
 SQ Sequence 21 BP; 5 A; 3 C; 8 G; 5 T; 0 U; 0 Other;
 Query Match 0.9%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 15;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 658 TCAGCCGATACCTTCACTCGA 678
 Db 21 TCAGCCGATACCTTCACTCGA 1
 RESULT 30
 ABK82235/C
 ID ABK82235 standard; DNA; 20 BP.
 XX
 AC ABK82235;
 XX
 DT 27-AUG-2002 (first entry)
 XX
 DE Human ATP-binding cassette (ABC) transporter probe #73.
 XX
 KM Human; ATP-binding cassette transporter; ABC transporter;
 KM expression rate; drug development; biochemical kinetic; anthelmintic;
 KM probe; ss.
 XX
 OS Homo sapiens.
 XX
 PN JP2002112775-A.
 XX
 PD 16-APR-2002.
 XX
 PF 03-OCT-2000; 2000JP-00303404.
 XX
 PR 03-OCT-2000; 2000JP-00303404.
 XX
 PA (SAKA) OTSUKA SEIYAKU KOGYO KK.
 XX
 DR WPI; 2002-458864/49.
 XX
 PT Probes for determination of human ATP-binding cassette (ABC) transporters
 PT capable of hybridization with 33 regions of genes.
 XX
 PS Claim 8; Page 27; 36pp; Japanese.
 XX
 CC The invention describes new probes for identification of human ATP-
 CC binding cassette (ABC) transporters capable of hybridisation with 33
 CC regions of genes. Elucidation of expression rate of ABC transporters is
 CC useful for development of drugs and their biochemical kinetics. This
 CC sequence represents a probe used to detect human ATP-binding cassette
 CC (ABC) transporters
 XX
 SQ Sequence 20 BP; 7 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.9%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 22;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 412 ACCGCTTCGTTGCTGACTTA 431
 Db 20 ACCGCTTCGTTGCTGACTTA 1
 RESULT 31
 AAL62402/C
 ID AAL62402 standard; DNA; 20 BP.
 XX
 AC AAL62402;
 XX
 DT 06-OCT-2003 (first entry)
 XX
 DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206583.
 XX
 KM ABC transporter; ABC; major histocompatibility complex; MHC; cytostatic;
 KM hyperproliferative; autoimmune disorder; antisense gene therapy;
 KM inflammation; tumour formation; immunosuppressive; antitubercular; human;
 KM phosphorothioate backbone; antisense; ss.
 XX
 OS Homo sapiens.

```
OS Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002WO-US040101.
XX PF 17-DEC-2001; 2001US-00024369.
XX PR 17-DEC-2001; 2001US-00024369.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX DR 12-DEC-2002; 2002WO-US040101.
XX XX
XX FT New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX PS Claim 3; Page 80; 112pp; English.
XX XX
XX CC The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridises with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridises with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX SQ Sequence 20 BP; 4 A; 3 C; 5 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 740 GGATCTATACACACCATG 759
Db 20 GGATCTATACACACCATG 1
```

```
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206594.
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
OS Homo sapiens.
XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002WO-US040101.
XX PF 17-DEC-2001; 2001US-00024369.
XX PR 17-DEC-2001; 2001US-00024369.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX DR 12-DEC-2002; 2002WO-US040101.
XX XX
XX FT New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX PS Example 15; Page 80; 112pp; English.
XX XX
XX CC The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridises with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridises with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX SQ Sequence 20 BP; 6 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 962 TCTGGGATCAGTGTCCCTC 981
Db 20 TCTGGGATCAGTGTCCCTC 1
```


RESULT 33
AAL62423/C
ID AAL62423 standard; DNA; 20 BP.
XX
XX
AC AAL62423;
DT 06-OCT-2003 (first entry)
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206604.
XX
KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
OS Homo sapiens.
XX Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'phosphorothioate backbone; All cytidines are 5-
FT methy/cytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
PN WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
PF 12-DEC-2002; 2002WO-US040101.
XX
PR 17-DEC-2001; 2001US-00024369.
XX
PA (ISIS-) ISIS PHARM INC.
PI Borchers AH, Ward DT, Freier SM;
DR WPI; 2003-577305/54.
PS
Claim 3; Page 81; 112pp; English.
XX
The invention relates to a compound targeted to a nucleic acid molecule
encoding ABC transporter (ABCT) major histocompatibility complex (MHC) I
where the compound specifically hybridises with the nucleic acid molecule
and inhibits expression of ATM or specifically hybridises with at least a
portion of an active site on the nucleic acid molecule. The invention is
useful for inhibiting the expression of ATM in cells or tissues. The
invention is useful for treating an animal with hyperproliferative or
autoimmune disorder. The invention is useful for diagnostics,
therapeutics, prophylaxis, as research reagents and kits, for
distinguishing functions of various members of a biological pathway and
antisense gene therapy. The invention is also useful prophylactically
e.g., to prevent or delay infection, inflammation or tumour formation.
The present sequence is an antisense oligo targeted to human ABC
transporter MHC I DNA. This sequence is used to illustrate the method of
the invention
Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;

[illegible]

CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 6 A; 2 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1378 GTACTGCTCTCCATCTACCC 1397
|||
Db 20 GTACTGCTCTCCATCTACCC 1

RESULT 35
AAL62445/c
ID AAL62445 standard; DNA; 20 BP.
XX
AC AAL62445;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206626.
XX
KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
FN WO2003051309-A2.
XX
PD 26-JUN-2003.
XX
PD 12-DEC-2002; 2002WO-US040101.
XX
PR 17-DEC-2001; 2001US-00024369.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Borchers AH, Ward DT, Freier SM;
XX
DR WPI; 2003-577305/54.
XX
PT New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
PS Claim 3; Page 81; 112pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridises with the nucleic acid molecule

CC and inhibits expression of ATM or specifically hybridises with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissue. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1842 TGCTGACGTAAAGTCTGGGG 1861
|||
Db 20 TGCTGACGTAAAGTCTGGGG 1

RESULT 36
AAL62449/c
ID AAL62449 standard; DNA; 20 BP.
XX
AC AAL62449;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206630.
XX
KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
FN WO2003051309-A2.
XX
PD 26-JUN-2003.
XX
PD 12-DEC-2002; 2002WO-US040101.
XX
PR 17-DEC-2001; 2001US-00024369.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Borchers AH, Ward DT, Freier SM;
XX
DR WPI; 2003-577305/54.
XX
PT New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating

PT diseases or conditions such as a hyperproliferative or autoimmune
 PT disorder.
 XX
 PS Claim 3; Page 81, 112pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
 CC where the compound specifically hybridizes with the nucleic acid molecule
 CC and inhibits expression of ATM or specifically hybridizes with at least a
 CC portion of an active site on the nucleic acid molecule. The invention is
 CC useful for inhibiting the expression of ATM in cells or tissues. The
 CC invention is useful for treating an animal with hyperproliferative or
 CC autoimmune disorder. The invention is useful for diagnostics,
 CC therapeutics, prophylaxis, as research reagents and kits, for
 CC distinguishing functions of various members of a biological pathway and
 CC in antisense gene therapy. The invention is also useful prophylactically
 CC e.g., to prevent or delay infection, inflammation or tumour formation.
 CC The present sequence is an antisense oligo targeted to human ABC
 CC transporter MHC I DNA. This sequence is used to illustrate the method of
 CC the invention
 XX
 SQ Sequence 20 BP; 7 A; 3 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.9%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 22;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1978 AAACCGTGTACTTATCCT 1997
 DB 20 AAACCGTGTACTTATCCT 1
 XX
 RESULT 37
 AAL62380/C
 ID AAL62380 standard; DNA; 20 BP.
 XX
 AC AAL62380;
 XX
 DT 06-OCT-2003 (first entry)
 XX
 DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206561.
 XX
 KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
 KW hyperproliferative; autoimmune disorder; antisense gene therapy;
 KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
 KW phosphorothioate backbone; antisense; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidines are 5-
 FT modified_base 1
 FT 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"
 FT
 FT
 XX WO2003051309-A2.
 PN 26-JUN-2003.
 XX
 PD 12-DEC-2002; 2002WO-US040101.
 XX
 PR 17-DEC-2001; 2001US-00024369.
 XX

PA (ISIS-) ISIS PHARM INC.
 XX
 PI Borchers AH, Ward DT, Freier SM;
 XX
 DR WPI; 2003-577305/54.
 XX
 XX
 PT New antisense compound that hybridizes and inhibits the nucleic acid
 PT encoding ABC transporter major histocompatibility complex 1, for treating
 PT diseases or conditions such as a hyperproliferative or autoimmune
 PT disorder.
 XX
 PS Claim 3; Page 80, 112pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
 CC where the compound specifically hybridizes with the nucleic acid molecule
 CC and inhibits expression of ATM or specifically hybridizes with at least a
 CC portion of an active site on the nucleic acid molecule. The invention is
 CC useful for inhibiting the expression of ATM in cells or tissues. The
 CC invention is useful for treating an animal with hyperproliferative or
 CC autoimmune disorder. The invention is useful for diagnostics,
 CC therapeutics, prophylaxis, as research reagents and kits, for
 CC distinguishing functions of various members of a biological pathway and
 CC in antisense gene therapy. The invention is also useful prophylactically
 CC e.g., to prevent or delay infection, inflammation or tumour formation.
 CC The present sequence is an antisense oligo targeted to human ABC
 CC transporter MHC I DNA. This sequence is used to illustrate the method of
 CC the invention
 XX
 SQ Sequence 20 BP; 6 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.9%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 22;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 ATGGCTAGCTCTAGTGTC 20
 DB 20 ATGGCTAGCTCTAGTGTC 1
 XX
 RESULT 38
 AAL62384/C
 ID AAL62384 standard; DNA; 20 BP.
 XX
 AC AAL62384;
 XX
 DT 06-OCT-2003 (first entry)
 XX
 DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206565.
 XX
 KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
 KW hyperproliferative; autoimmune disorder; antisense gene therapy;
 KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
 KW phosphorothioate backbone; antisense; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidines are 5-
 FT modified_base 1
 FT 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"
 FT
 FT
 XX

```

PN WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridises with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridises with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
XX Sequence 20 BP; 2 A; 9 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 219 CGGGGTCTCAGGGCAACGG 238
DB 20 CGGGGTCTCAGGGCAACGG 1
RESULT 39
AAL62385/c
ID AAL62385 standard; DNA; 20 BP.
XX
XX AAL62385;
AC
XX
XX 06-OCT-2003 (first entry)
DT
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206566.
DE
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH 1. .20
FT /mod_base= OTHER
FT /tag= a
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1. .5

```

```

FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16. .20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridises with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridises with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
XX Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 225 CCTCAGGGCAACGGTTGGCT 244
DB 20 CCTCAGGGCAACGGTTGGCT 1
RESULT 40
AAL62398/c
ID AAL62398 standard; DNA; 20 BP.
XX
XX AAL62398;
AC
XX
XX 06-OCT-2003 (first entry)
DT
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206579.
DE
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.

```

```

XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; all cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
PN WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002MO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 644 TTCTACAAGATGGCTCAGCC 663
XX ||||||||||||||||
XX 20 TTCTACAAGATGGCTCAGCC 1
XX
XX RESULT 41
XX AAL62405/c
XX ID AAL62405 standard; DNA; 20 BP.
XX
XX AC AAL62405;
XX
XX DT 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206586.
DE

```

```

XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; all cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
PN WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002MO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 847 AACATCATGTCGGGTAAC 866
XX ||||||||||||||||
XX 20 AACATCATGTCGGGTAAC 1
XX
XX RESULT 42

```

AAL62426/C
 ID AAL62426 standard; DNA; 20 BP.
 XX
 AC AAL62426;
 XX
 DT 06-OCT-2003 (first entry)
 XX
 DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206607.
 XX
 KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
 KW hyperproliferative; autoimmune disorder; antisense gene therapy;
 KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
 KW phosphorothioate backbone; antisense; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidines are 5-
 FT methylcytidines"
 FT modified_base 1
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"
 FT
 XX WO2003051309-A2.
 XX
 PN 26-JUN-2003.
 PD
 XX 12-DEC-2002; 2002WO-US040101.
 XX
 PR 17-DEC-2001; 2001US-00024369.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Borchers AH, Ward DT, Freier SM;
 XX
 DR WPI; 2003-577305/54.
 XX
 PT New antisense compound that hybridizes and inhibits the nucleic acid
 PT encoding ABC transporter major histocompatibility complex 1, for treating
 PT diseases or conditions such as a hyperproliferative or autoimmune
 PT disorder.
 XX
 PS Claim 3; Page 81; 112pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
 CC where the compound specifically hybridises with the nucleic acid molecule
 CC and inhibits expression of ATM or specifically hybridises with at least a
 CC portion of an active site on the nucleic acid molecule. The invention is
 CC useful for inhibiting the expression of ATM in cells or tissues. The
 CC invention is useful for treating an animal with hyperproliferative or
 CC autoimmune disorder. The invention is useful for diagnostics,
 CC therapeutics, prophylaxis, as research reagents and kits, for
 CC distinguishing functions of various members of a biological pathway and
 CC in antisense gene therapy. The invention is also useful prophylactically
 CC e.g., to prevent or delay infection, inflammation or tumour formation.
 CC The present sequence is an antisense oligo targeted to human ABC
 CC transporter MHC I DNA. This sequence is used to illustrate the method of
 CC the invention
 XX
 SQ Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 Query March 0.9%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 22;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1123 CCTACAGTTCGAAGCTTTGC 1142
 |||||||
 Db 20 CCTACAGTTCGAAGCTTTGC 1
 RESULT 43
 AAL62448/C
 ID AAL62448 standard; DNA; 20 BP.
 XX
 AC AAL62448;
 XX
 DT 06-OCT-2003 (first entry)
 XX
 DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206629.
 XX
 KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
 KW hyperproliferative; autoimmune disorder; antisense gene therapy;
 KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
 KW phosphorothioate backbone; antisense; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidines are 5-
 FT methylcytidines"
 FT modified_base 1..5
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"
 FT
 XX WO2003051309-A2.
 XX
 PN 26-JUN-2003.
 PD
 XX 12-DEC-2002; 2002WO-US040101.
 XX
 PR 17-DEC-2001; 2001US-00024369.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Borchers AH, Ward DT, Freier SM;
 XX
 DR WPI; 2003-577305/54.
 XX
 PT New antisense compound that hybridizes and inhibits the nucleic acid
 PT encoding ABC transporter major histocompatibility complex 1, for treating
 PT diseases or conditions such as a hyperproliferative or autoimmune
 PT disorder.
 XX
 PS Claim 3; Page 81; 112pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
 CC where the compound specifically hybridises with the nucleic acid molecule
 CC and inhibits expression of ATM or specifically hybridises with at least a
 CC portion of an active site on the nucleic acid molecule. The invention is
 CC useful for inhibiting the expression of ATM in cells or tissues. The
 CC invention is useful for treating an animal with hyperproliferative or
 CC autoimmune disorder. The invention is useful for diagnostics,
 CC therapeutics, prophylaxis, as research reagents and kits, for
 CC distinguishing functions of various members of a biological pathway and
 CC in antisense gene therapy. The invention is also useful prophylactically
 CC e.g., to prevent or delay infection, inflammation or tumour formation.

CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX

Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1885 CCTCAGGCGCTATGCACACGA 1904
DB 20 CCTCAGGCGCTATGCACACGA 1

RESULT 44
AAL62451/C
ID AAL62451 standard; DNA; 20 BP.
XX
AC AAL62451;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206632.
XX
KM ABC transporter; ABC; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX

Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
methylecytidines"
FT 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT WO2003051309-A2.
XX
PD 26-JUN-2003.
XX
PF 12-DEC-2002; 2002WO-US040101.
XX
PR 17-DEC-2001; 2001US-00024369.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Borchers AH, Ward DT, Freier SM;
XX
DR WPI; 2003-577305/54.
XX

New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
PS Claim 3; Page 81; 112pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABC) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridises with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridises with at least a

CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX

Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2003 ATGCCACCACTGCGCTCGAT 2022
DB 20 ATGCCACCACTGCGCTCGAT 1

RESULT 45
AAL62401/C
ID AAL62401 standard; DNA; 20 BP.
XX
AC AAL62401;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206582.
XX
KM ABC transporter; ABC; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX

Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
methylecytidines"
FT 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT WO2003051309-A2.
XX
PD 26-JUN-2003.
XX
PF 12-DEC-2002; 2002WO-US040101.
XX
PR 17-DEC-2001; 2001US-00024369.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Borchers AH, Ward DT, Freier SM;
XX
DR WPI; 2003-577305/54.
XX

New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune

```
PT disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics.
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 6 A; 9 C; 3 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 714 TGCAGTCTGCGAGTTCGTGG 733
Db 20 TGCAGTCTGCGAGTTCGTGG 1
XX
RESULT 46
AAL62406/c
ID AAL62406 standard; DNA; 20 BP.
XX
XX AAL62406;
AC
XX
XX 06-OCT-2003 (first entry)
DT
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206587.
DE
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
PA
```

```
XX
XX Borchers AH, Ward DT, Freier SM;
PT
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics.
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 866 CAGAGACACGTCACCCCTG 885
Db 20 CAGAGACACGTCACCCCTG 1
XX
XX
XX AAL62414/c
ID AAL62414 standard; DNA; 20 BP.
XX
XX AAL62414;
AC
XX
XX 06-OCT-2003 (first entry)
DT
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206595.
DE
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
```



```

XX 26-JUN-2003.
PD 12-DEC-2002; 2002MO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Example 15; Page 80; 112pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 969 ATCAGTGTCCCTCACCATGG 988
Db 20 ATCAGTGTCCCTCACCATGG 1
XX
RESULT 48
AAL62437/c
ID AAL62437 standard; DNA; 20 BP.
XX
AC AAL62437;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206618.
XX
KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*cag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT modified_base 1..5
FT /*cag= b
FT

```

```

FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
FT modified_base 15..20
FT /*cag= c
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002MO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX
XX Claim 3; Page 81; 112pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 1506 TGTCAGTTCACAGATGCT 1525
Db 20 TGTCAGTTCACAGATGCT 1
XX
RESULT 49
AAL62388/c
ID AAL62388 standard; DNA; 20 BP.
XX
AC AAL62388;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206569.
XX
KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX

```

FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002WO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX Claim 3; Page 80; 112pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 294 ATTAGTCGGGCACTGGGCT 313
DB 20 ATTAGTCGGGCACTGGGCT 1
RESULT 50
ID AAL62392 standard; DNA; 20 BP.
XX AAL62392;
XX 06-OCT-2003 (first entry)
DT Human ABC transporter MHC I antisense oligonucleotide, ISIS 206573.
XX

KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX Homo sapiens.
OS Synthetic.
OS
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002WO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX Claim 3; Page 80; 112pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 391 CTGCACTGGGGAGTCAACC 410
DB 20 CTGCACTGGGGAGTCAACC 1
RESULT 51
ID AAL62397/c

ID AAL62397 standard; DNA; 20 BP.
 XX
 AC AAL62397;
 XX
 DT 06-OCT-2003 (first entry)
 XX
 DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206578.
 XX
 KM ABC transporter; ABC; major histocompatibility complex; MHC; cytostatic;
 KM hyperproliferative; autoimmune disorder; antisense gene therapy;
 KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
 KM phosphorothioate backbone; antisense; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"
 XX
 PN WO2003051309-A2.
 XX
 PD 26-JUN-2003.
 XX
 PF 12-DEC-2002; 2002WO-US040101.
 XX
 PR 17-DEC-2001; 2001US-00024369.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Borchers AH, Ward DT, Freier SM;
 XX
 DR WPI; 2003-577305/54.
 XX
 PT New antisense compound that hybridizes and inhibits the nucleic acid
 PT encoding ABC transporter major histocompatibility complex 1, for treating
 PT diseases or conditions such as a hyperproliferative or autoimmune
 PT disorder.
 XX
 PS Claim 3; Page 80; 112pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
 CC where the compound specifically hybridizes with the nucleic acid molecule
 CC and inhibits expression of ATM or specifically hybridizes with at least a
 CC portion of an active site on the nucleic acid molecule. The invention is
 CC useful for inhibiting the expression of ATM in cells or tissues. The
 CC invention is useful for treating an animal with hyperproliferative or
 CC autoimmune disorder. The invention is useful for diagnostics,
 CC therapeutics, prophylaxis, as research reagents and kits, for
 CC distinguishing functions of various members of a biological pathway and
 CC in antisense gene therapy. The invention is also useful prophylactically
 CC e.g., to prevent or delay infection, inflammation or tumour formation.
 CC The present sequence is an antisense oligo targeted to human ABC
 CC transporter MHC I DNA. This sequence is used to illustrate the method of
 CC the invention
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 0.94; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 22;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 620 TTACGGCGCGCTCAGTAC 639
 |||||
 DB 20 TTACGGCGCGCTCAGTAC 1
 |||||
 RESULT 52
 AAL62422/c
 ID AAL62422 standard; DNA; 20 BP.
 XX
 AC AAL62422;
 XX
 DT 06-OCT-2003 (first entry)
 XX
 DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206603.
 XX
 KM ABC transporter; ABC; major histocompatibility complex; MHC; cytostatic;
 KM hyperproliferative; autoimmune disorder; antisense gene therapy;
 KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
 KM phosphorothioate backbone; antisense; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"
 XX
 PN WO2003051309-A2.
 XX
 PD 26-JUN-2003.
 XX
 PF 12-DEC-2002; 2002WO-US040101.
 XX
 PR 17-DEC-2001; 2001US-00024369.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Borchers AH, Ward DT, Freier SM;
 XX
 DR WPI; 2003-577305/54.
 XX
 CC New antisense compound that hybridizes and inhibits the nucleic acid
 CC encoding ABC transporter major histocompatibility complex 1, for treating
 CC diseases or conditions such as a hyperproliferative or autoimmune
 CC disorder.
 XX
 PS Claim 3; Page 81; 112pp; English.
 XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
 CC where the compound specifically hybridizes with the nucleic acid molecule
 CC and inhibits expression of ATM or specifically hybridizes with at least a
 CC portion of an active site on the nucleic acid molecule. The invention is
 CC useful for inhibiting the expression of ATM in cells or tissues. The
 CC invention is useful for treating an animal with hyperproliferative or
 CC autoimmune disorder. The invention is useful for diagnostics,
 CC therapeutics, prophylaxis, as research reagents and kits, for
 CC distinguishing functions of various members of a biological pathway and
 CC in antisense gene therapy. The invention is also useful prophylactically
 CC e.g., to prevent or delay infection, inflammation or tumour formation.
 CC The present sequence is an antisense oligo targeted to human ABC

CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1078 CTGGCAAGTCCAGCCAGGT 1097
Db 20 CTGGCAAGTCCAGCCAGGT 1
RESULT 53
AAL62440/C
ID AAL62440 standard; DNA; 20 BP.
XX
AC AAL62440;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206621.
XX
KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
PN WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
PD 12-DEC-2002; 2002WO-US040101.
XX
PP 17-DEC-2001; 2001US-00024369.
XX
PR 17-DEC-2001; 2001US-00024369.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Borchers AH, Ward DT, Freier SM;
XX
DR WPI; 2003-577305/54.
XX
XX
PT New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridises with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridises with at least a
CC portion of an active site on the nucleic acid molecule. The invention is

CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 2 A; 9 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1743 GGCTGCAGTGGGACAGAGC 1762
Db 20 GGCTGCAGTGGGACAGAGC 1
RESULT 54
AAL62442/C
ID AAL62442 standard; DNA; 20 BP.
XX
AC AAL62442;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206623.
XX
KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
PN WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
PD 12-DEC-2002; 2002WO-US040101.
XX
PP 17-DEC-2001; 2001US-00024369.
XX
PR 17-DEC-2001; 2001US-00024369.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Borchers AH, Ward DT, Freier SM;
XX
DR WPI; 2003-577305/54.
XX
XX
PT New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.

XX Claim 3; Page 81; 112pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule

CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1

CC where the compound specifically hybridizes with the nucleic acid molecule

CC and inhibits expression of ATM or specifically hybridizes with at least a

CC portion of an active site on the nucleic acid molecule. The invention is

CC useful for inhibiting the expression of ATM in cells or tissues. The

CC invention is useful for treating an animal with hyperproliferative or

CC autoimmune disorder. The invention is useful for diagnostics,

CC therapeutics, prophylaxis, as research reagents and kits, for

CC distinguishing functions of various members of a biological pathway and

CC in antisense gene therapy. The invention is also useful prophylactically

CC e.g., to prevent or delay infection, inflammation or tumour formation.

CC The present sequence is an antisense oligo targeted to human ABC

CC transporter MHC I DNA. This sequence is used to illustrate the method of

CC the invention

XX

SQ Sequence 20 BP; 4 A; 5 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 22;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1773 TGGAGAGGCTTCAGAAA 1792

DB 20 TGGAGAGGCTTCAGAAA 1

RESULT 55

AA162456/c

ID AA162456 standard; DNA; 20 BP.

XX

XX AA162456;

DT 06-OCT-2003 (first entry)

XX

DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206637;

XX

KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;

KM hyperproliferative; autoimmune disorder; antisense gene therapy;

KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;

KM phosphorothioate backbone; antisense; ss.

XX

XX Homo sapiens.

OS Synthetic.

XX

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate backbone; All cytidines are 5-

FT methylcytidines"

FT modified_base 1..5

FT /*tag= b

FT /mod_base= OTHER

FT /note= "2-methoxyethyl nucleotides"

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2-methoxyethyl nucleotides"

XX

XX WO2003051309-A2.

XX

XX 26-JUN-2003.

XX

XX 12-DEC-2002; 2002WO-US040101.

XX

XX 17-DEC-2001; 2001US-00024369.

XX

XX (ISIS-) ISIS PHARM INC.

XX

PI Borchers AH, Ward DT, Freter SM;

XX WPI; 2003-577305/54.

XX

XX New antisense compound that hybridizes and inhibits the nucleic acid

PT encoding ABC transporter major histocompatibility complex 1, for treating

PT diseases or conditions such as a hyperproliferative or autoimmune

PT disorder.

XX

XX Claim 3; Page 81; 112pp; English.

XX

XX The invention relates to a compound targeted to a nucleic acid molecule

CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1

CC where the compound specifically hybridizes with the nucleic acid molecule

CC and inhibits expression of ATM or specifically hybridizes with at least a

CC portion of an active site on the nucleic acid molecule. The invention is

CC useful for inhibiting the expression of ATM in cells or tissues. The

CC invention is useful for treating an animal with hyperproliferative or

CC autoimmune disorder. The invention is useful for diagnostics,

CC therapeutics, prophylaxis, as research reagents and kits, for

CC distinguishing functions of various members of a biological pathway and

CC in antisense gene therapy. The invention is also useful prophylactically

CC e.g., to prevent or delay infection, inflammation or tumour formation.

CC The present sequence is an antisense oligo targeted to human ABC

CC transporter MHC I DNA. This sequence is used to illustrate the method of

CC the invention

XX

SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 22;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2106 CCTCAGCCTGTGTGAGCAGG 2125

DB 20 CCTCAGCCTGTGTGAGCAGG 1

RESULT 56

AA162387/c

ID AA162387 standard; DNA; 20 BP.

XX

XX AA162387;

DT 06-OCT-2003 (first entry)

XX

DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206568.

XX

KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;

KM hyperproliferative; autoimmune disorder; antisense gene therapy;

KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;

KM phosphorothioate backbone; antisense; ss.

XX

XX Homo sapiens.

OS Synthetic.

XX

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate backbone; All cytidines are 5-

FT methylcytidines"

FT modified_base 1..5

FT /*tag= b

FT /mod_base= OTHER

FT /note= "2-methoxyethyl nucleotides"

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2-methoxyethyl nucleotides"

XX

XX WO2003051309-A2.

XX

```

PD 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 6 A; 9 C; 4 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 270 GGGCTGCTGCTGCTTTGA 289
XX |||||
XX 20 GGGCTGGCTGGCTCTTTGA 1
XX
XX RESULT 57
XX AAL62395/C
XX ID AAL62395 standard; DNA; 20 BP.
XX
XX AAL62395;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206576.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX Key location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "phosphorothioate backbone; All cytidines are 5-
XX methylcytidines"
XX 1..5
XX /tag= b
XX /mod_base= OTHER
XX

```

```

FT modified_base /note= "2'methoxyethyl nucleotides"
FT 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 459 GTGGCACAACTCGGAGCC 478
XX |||||
XX 20 GTGGCACAACTCGGAGCC 1
XX
XX RESULT 58
XX AAL62416/C
XX ID AAL62416 standard; DNA; 20 BP.
XX
XX AAL62416;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206597.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX Key location/Qualifiers
XX

```

```

FT modified_base 1. .20
FT /+tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1. .5
FT /+tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16. .20
FT /+tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002WO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM,
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX CC therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX CC e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX SQ Sequence 20 BP; 7 A; 3 C; 8 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 995 TGATCACCCTGCTCTGCTT 1014
Db 20 TGATCACCCTGCTCTGCTT 1

```

```

KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antidiicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX Homo sapiens.
XX OS Synthetic.
XX
XX Key
XX modified_base 1. .20
XX /+tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone; All cytidines are 5-
XX methylcytidines"
XX modified_base 1. .5
XX /+tag= b
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
XX modified_base 16. .20
XX /+tag= c
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002WO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM,
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX CC therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX CC e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1131 TCGAGCTTGCCACGAGG 1150
Db 20 TCGAGCTTGCCACGAGG 1

```

RESULT 59
AAL62427/c
ID AAL62427 standard; DNA; 20 BP.
XX
AC AAL62427;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206608.
XX
KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;

```

XX AAL62441;
AC
XX
XX 06-OCT-2003 (first entry)
DT
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206622.
DE
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX Key
FH Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2' methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2' methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
PI
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridises with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridises with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

```

```

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1756 CAAGAGCCACAGGTATTGG 1775
DB |||||||
DB 20 CAAGAGCCACAGGTATTGG 1
ID AAL62375/c
ID AAL62375 standard; DNA; 20 BP.
XX
XX AAL62375;
XX
XX 06-OCT-2003 (first entry)
DT
XX
XX Human ABC transporter MHC I DNA specific reverse PCR primer.
DE
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX PCR; primer; ss.
XX
XX Homo sapiens.
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
PI
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Example 13; Page 78; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridises with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridises with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is human ABC transporter major histocompatibility
CC complex I DNA specific PCR primer. This sequence is used to illustrate
CC the method of the invention
XX
SQ Sequence 20 BP; 6 A; 10 C; 1 G; 3 T; 0 U; 0 Other;

```

```

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 778 TTGCAGGAGAGGCTTTGG 797
DB |||||||
DB 20 TTGCAGGAGAGGCTTTGG 1
ID AAL62376
ID AAL62376 standard; DNA; 20 BP.

```



```

XX AC AAL62376;
XX DT 06-OCT-2003 (first entry)
XX DE Human ABC transporter MHC I DNA specific PCR probe.
XX KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX KM hyperproliferative; autoimmune disorder; antinease gene therapy;
XX KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX KM PCR; probe; ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX FT modified_base 1 /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "FAM labelled"
XX FT modified_base 20
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "TAMRA labelled"
XX PN WO2003051309-A2.
XX PD 26-JUN-2003.
XX PF 12-DEC-2002; 2002WO-US040101.
XX PR 17-DEC-2001; 2001US-00024369.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Borchers AH, Ward DT, Freier SM;
XX DR WPI; 2003-577305/54.
XX PT New antinease compound that hybridizes and inhibits the nucleic acid
XX PT encoding ABC transporter major histocompatibility complex 1, for treating
XX PT diseases or conditions such as a hyperproliferative or autoimmune
XX PT disorder.
XX PS Example 13; Page 78; 112pp; English.
XX CC The invention relates to a compound targeted to a nucleic acid molecule
XX CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX CC where the compound specifically hybridizes with the nucleic acid molecule
XX CC and inhibits expression of ATM or specifically hybridizes with at least a
XX CC portion of an active site on the nucleic acid molecule. The invention is
XX CC useful for inhibiting the expression of ATM in cells or tissues. The
XX CC invention is useful for treating an animal with hyperproliferative or
XX CC autoimmune disorder. The invention is useful for diagnostics,
XX CC therapeutics, prophylaxis, as research reagents and kits, for
XX CC distinguishing functions of various members of a biological pathway and
XX CC in antisense gene therapy. The invention is also useful prophylactically
XX CC e.g., to prevent or delay infection, inflammation or tumour formation.
XX CC The present sequence is human ABC transporter MHC I DNA specific PCR
XX CC probe. This sequence is used to illustrate the method of the invention
XX SQ Sequence 20 BP; 4 A; 8 C; 6 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 756 CATGGCCACGTCACAGCC 775
XX 1 CATGGCCACGTCACAGCC 20

```

RESULT 63
AAL62389/c

```

ID AC AAL62389 standard; DNA; 20 BP.
XX AC AAL62389;
XX DT 06-OCT-2003 (first entry)
XX DE Human ABC transporter MHC I antinease oligonucleotide, ISIS 206570.
XX KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX KM hyperproliferative; autoimmune disorder; antinease gene therapy;
XX KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX KM phosphorothioate backbone; antinease; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 1. .20 /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "Phosphorothioate backbone; All cytidines are 5-
XX FT modified_base 1. .5 methylecylidines"
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "2-methoxyethyl nucleotides"
XX FT modified_base 16. .20 /*tag= c
XX FT /mod_base= OTHER
XX FT /note= "2-methoxyethyl nucleotides"
XX PN WO2003051309-A2.
XX PD 26-JUN-2003.
XX PF 12-DEC-2002; 2002WO-US040101.
XX PR 17-DEC-2001; 2001US-00024369.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Borchers AH, Ward DT, Freier SM;
XX DR WPI; 2003-577305/54.
XX PT New antinease compound that hybridizes and inhibits the nucleic acid
XX PT encoding ABC transporter major histocompatibility complex 1, for treating
XX PT diseases or conditions such as a hyperproliferative or autoimmune
XX PT disorder.
XX PS Claim 3; Page 80; 112pp; English.
XX CC The invention relates to a compound targeted to a nucleic acid molecule
XX CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX CC where the compound specifically hybridizes with the nucleic acid molecule
XX CC and inhibits expression of ATM or specifically hybridizes with at least a
XX CC portion of an active site on the nucleic acid molecule. The invention is
XX CC useful for inhibiting the expression of ATM in cells or tissues. The
XX CC invention is useful for treating an animal with hyperproliferative or
XX CC autoimmune disorder. The invention is useful for diagnostics,
XX CC therapeutics, prophylaxis, as research reagents and kits, for
XX CC distinguishing functions of various members of a biological pathway and
XX CC in antisense gene therapy. The invention is also useful prophylactically
XX CC e.g., to prevent or delay infection, inflammation or tumour formation.
XX CC The present sequence is an antinease oligo targeted to human ABC
XX CC transporter MHC I DNA. This sequence is used to illustrate the method of
XX CC the invention
XX SQ Sequence 20 BP; 4 A; 8 C; 7 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

0y	300	GGGGCACTGGGGCTTGAGCCC	319
Db	20	TCGGGCACTGGGGCTTGAGCCC	1
RESULT 64			
ID	AA162391/C		
XX	AA162391	standard, DNA; 20 BP.	
XX	AA162391;		
XX	06-OCT-2003	(first entry)	
XX	Human ABC transporter MHC I antisense oligonucleotide, ISIS 206572.		
XX	ABCT		
XX	ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;		
XX	hyperproliferative; autoimmune disorder; antisense gene therapy;		
XX	inflammation; tumour formation; immunosuppressive; antimicrobial; human;		
XX	phosphorothioate backbone; antisense; ss.		
OS	Homo sapiens.		
XX	Synthetic.		
FH	Key	Location/Qualifiers	
FT	modified_base	1..20	
FT		/tag= a	
FT		/mod_base= OTHER	
FT		/note= "phosphorothioate backbone; All cytidines are 5-	
FT		methylcytidines"	
FT	modified_base	1..5	
FT		/tag= b	
FT		/mod_base= OTHER	
FT		/note= "2'methoxyethyl nucleotides"	
FT	modified_base	16..20	
FT		/tag= c	
FT		/mod_base= OTHER	
FT		/note= "2'methoxyethyl nucleotides"	
XX	WO2003051309-A2.		
XX	26-JUN-2003.		
XX	12-DEC-2002; 2002W0-US040101.		
XX	17-DEC-2001; 2001US-00024369.		
XX	(ISIS-) ISIS PHARM INC.		
XX	Borchers AH, Ward DF, Freier SM;		
XX	WPI; 2003-577305/54.		
XX	New antisense compound that hybridizes and inhibits the nucleic acid		
XX	encoding ABC transporter major histocompatibility complex 1, for treating		
XX	diseases or conditions such as a hyperproliferative or autoimmune		
XX	disorder.		
XX	Claim 3; Page 80; 112pp; English.		
XX	The invention relates to a compound targeted to a nucleic acid molecule		
XX	encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1		
XX	where the compound specifically hybridizes with the nucleic acid molecule		
XX	and inhibits expression of ATM or specifically hybridizes with at least a		
XX	portion of an active site on the nucleic acid molecule. The invention is		
XX	useful for inhibiting the expression of ATM in cells or tissues. The		
XX	invention is useful for treating an animal with hyperproliferative or		
XX	autoimmune disorder. The invention is useful for diagnostics,		
XX	therapeutics, prophylaxis, as research reagents and kits, for		
XX	distinguishing functions of various members of a biological pathway and		
XX	in antisense gene therapy. The invention is also useful prophylactically		
XX	e.g., to prevent or delay infection, inflammation or tumour formation.		
XX	The present sequence is an antisense oligo targeted to human ABC		

[illegible]

CC useful for inhibiting the expression of ATM in cells or tissues. The
 CC invention is useful for treating an animal with hyperproliferative or
 CC autoimmune disorder. The invention is useful for diagnostics,
 CC therapeutics, prophylaxis, as research reagents and kits, for
 CC distinguishing functions of various members of a biological pathway and
 CC in antisense gene therapy. The invention is also useful prophylactically
 CC e.g., to prevent or delay infection, inflammation or tumour formation.
 CC The present sequence is an antisense oligo targeted to human ABC
 CC transporter MHC I DNA. This sequence is used to illustrate the method of
 CC the invention

XX
 SQ Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 22;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 953 GGATCATGCTCTGGGATCA 972
 |||||
 Db 20 GGATCATGCTCTGGGATCA 1

RESULT 66
 AAL62434/c
 ID AAL62434 standard; DNA; 20 BP.

XX
 AC AAL62434;

XX
 DT 06-OCT-2003 (first entry)

XX
 DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206615.

XX
 KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
 KW hyperproliferative; autoimmune disorder; antisense gene therapy;
 KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
 XX phosphorothioate backbone; antisense; ss.

OS Homo sapiens.
 OS Synthetic.

XX
 FT Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone; All cytidines are 5-
 FT methylcytidines"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"

XX
 PN WO2003051309-A2.

XX
 PD 26-JUN-2003.

XX
 PF 12-DEC-2002; 2002WO-US040101.

XX
 PR 17-DEC-2001; 2001US-00024369.

XX
 PA (ISIS-) ISIS PHARM INC.

XX
 PI Borchers AH, Ward DT, Freier SM,

XX
 DR WPI; 2003-577305/54.

XX
 PT New antisense compound that hybridizes and inhibits the nucleic acid
 PT encoding ABC transporter major histocompatibility complex 1, for treating
 PT diseases or conditions such as a hyperproliferative or autoimmune
 PT disorder.

XX
 PS Example 15; Page 81; 112pp; English.

XX
 CC The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
 CC where the compound specifically hybridizes with the nucleic acid molecule
 CC and inhibits expression of ATM or specifically hybridizes with at least a
 CC portion of an active site on the nucleic acid molecule. The invention is
 CC useful for inhibiting the expression of ATM in cells or tissues. The
 CC invention is useful for treating an animal with hyperproliferative or
 CC autoimmune disorder. The invention is useful for diagnostics,
 CC therapeutics, prophylaxis, as research reagents and kits, for
 CC distinguishing functions of various members of a biological pathway and
 CC in antisense gene therapy. The invention is also useful prophylactically
 CC e.g., to prevent or delay infection, inflammation or tumour formation.
 CC The present sequence is an antisense oligo targeted to human ABC
 CC transporter MHC I DNA. This sequence is used to illustrate the method of
 CC the invention

XX
 SQ Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 22;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1431 AATATTGAGTACCTGACC 1450
 |||||
 Db 20 AATATTGAGTACCTGACC 1

RESULT 67
 AAL62407/c
 ID AAL62407 standard; DNA; 20 BP.

XX
 AC AAL62407;

XX
 DT 06-OCT-2003 (first entry)

XX
 DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206588.

XX
 KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
 KW hyperproliferative; autoimmune disorder; antisense gene therapy;
 KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
 XX phosphorothioate backbone; antisense; ss.

OS Homo sapiens.
 OS Synthetic.

XX
 FT Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidines are 5-
 FT methylcytidines"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'methoxyethyl nucleotides"

XX
 PN WO2003051309-A2.

XX
 PD 26-JUN-2003.

XX
 PF 12-DEC-2002; 2002WO-US040101.

XX
 PR 17-DEC-2001; 2001US-00024369.

XX
 PA (ISIS-) ISIS PHARM INC.

PD	26-JUN-2003.
XX	
PF	12-DEC-2002; 2002WO-US040101.
XX	
PR	17-DEC-2001; 2001US-00024369.
XX	
PA	(ISIS-) ISIS PHARM INC.
PI	Borchers AH, Ward DT, Freier SM;
XX	
DR	WPI, 2003-577305/54.
XX	
PT	New antisense compound that hybridizes and inhibits the nucleic acid
PT	encoding ABC transporter major histocompatibility complex 1, for treating
PT	diseases or conditions such as a hyperproliferative or autoimmune
PT	disorder.
XX	
PS	Claim 3; Page 81; 112pp; English.
XX	
CC	The invention relates to a compound targeted to a nucleic acid molecule
CC	encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC	where the compound specifically hybridises with the nucleic acid molecule
CC	and inhibits expression of ATM or specifically hybridises with at least a
CC	portion of an active site on the nucleic acid molecule. The invention is
CC	useful for inhibiting the expression of ATM in cells or tissues. The
CC	invention is useful for treating an animal with hyperproliferative or
CC	autoimmune disorder. The invention is useful for diagnostics,
CC	therapeutics, prophylaxis, as research reagents and kits, for
CC	distinguishing functions of various members of a biological pathway and
CC	in antisense gene therapy. The invention is also useful prophylactically
CC	e.g., to prevent or delay infection, inflammation or tumour formation.
CC	The present sequence is an antisense oligo targeted to human ABC
CC	transporter MHC 1 DNA. This sequence is used to illustrate the method of
CC	the invention
XX	
SQ	Sequence 20 BP; 5 A; 7 C; 2 G; 6 T; 0 U; 0 Other;
	Query Match 0.9%; Score 20; DB 1; Length 20;
	Best Local Similarity 100.0%; Pred. No. 22;
	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	1033 GTGGGAAATGTGTACCACTT 1052
DB	20 GTGGGAAATGTGTACCACTT 1
	RESULT 69
	AAI62431/c
ID	AAI62431 standard; DNA; 20 BP.
XX	
AC	AAI62431;
XX	
DT	06-OCT-2003 (first entry)
XX	
DE	Human ABC transporter MHC I antisense oligonucleotide, ISIS 206612.
XX	
KW	ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW	hyperproliferative; autoimmune disorder; antisense gene therapy;
KW	inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW	phosphorothioate backbone; antisense; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
FM	Key
FT	modified_base
FT	Location/Qualifiers
FT	1..20
FT	/*tag= a
FT	/mod base= OTHER
FT	/note= "phosphorothioate backbone; All cytidines are 5-
FT	methylcytidines"
FT	1..5
FT	modified_base
FT	1..5
FT	/*tag= b
FT	/mod base= OTHER

```
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Example 15; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 5 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1345 CTCACCAAGTGCAGTTCAC 1364
DB 20 CTCACCAAGTGCAGTTCAC 1
XX
XX RESULT 70
XX AAL62452/c
XX ID AAL62452 standard; DNA; 20 BP.
XX
XX AAL62452;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206633.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX Key Location/Qualifiers
```

```
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
XX
XX modified_base 1..5
XX /*tag= b
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 3 A; 4 C; 5 G; 8 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2020 GATGCAAAACGCCAGTTACA 2039
DB 20 GATGCAAAACGCCAGTTACA 1
XX
XX RESULT 71
XX AAL62446/c
XX ID AAL62446 standard; DNA; 20 BP.
XX
XX AAL62446;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206627.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
```

```
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Example 15; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 6 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1871 TCATCTCGAGCTCCCTCAG 1890
DB 20 TCATCTCGAGCTCCCTCAG 1
```

```
RESULT 72
AAL62447/c
ID AAL62447 standard; DNA; 20 BP.
```

```
XX
XX AAL62447;
AC 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206628.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
OS
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1879 GGACTCCCTCAGGCGCTATGA 1898
 |||||
 DB 20 GGACTCCCTCAGGCGCTATGA 1

RESULT 73
 AAL62453/c
 ID AAL62453 standard; DNA; 20 BP.

XX AAL62453;

XX 06-OCT-2003 (first entry)

XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206634.

XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
 KM hyperproliferative; autoimmune disorder; antisense gene therapy;
 KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
 KM phosphorothioate backbone; antisense; ss.

XX Homo sapiens.
 OS Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"

FT modified_base 1..5

FT /*tag= b

FT /mod_base= OTHER

FT /note= "2'methoxyethyl nucleotides"

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2'methoxyethyl nucleotides"

XX WO2003051309-A2.

XX 26-JUN-2003.

XX 12-DEC-2002; 2002WO-US040101.

XX 17-DEC-2001; 2001US-00024369.

XX (ISIS-) ISIS PHARM INC.

XX Borchers AH, Ward DT, Freier SM;

XX WPI; 2003-577305/54.

XX New antisense compound that hybridizes and inhibits the nucleic acid
 PT encoding ABC transporter major histocompatibility complex 1, for treating
 PT diseases or conditions such as a hyperproliferative or autoimmune
 PT disorder.

XX Claim 3; Page 81; 112pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
 CC where the compound specifically hybridizes with the nucleic acid molecule
 CC and inhibits expression of ATM or specifically hybridizes with at least a
 CC portion of an active site on the nucleic acid molecule. The invention is
 CC useful for inhibiting the expression of ATM in cells or tissues. The
 CC invention is useful for treating an animal with hyperproliferative or
 CC autoimmune disorder. The invention is useful for diagnostics,
 CC immunotherapy, prophylaxis, as research reagents and kits, for
 CC distinguishing functions of various members of a biological pathway and
 CC in antisense gene therapy. The invention is also useful prophylactically
 CC e.g., to prevent or delay infection, inflammation or tumour formation.
 CC The present sequence is an antisense oligo targeted to human ABC
 CC transporter MHC I DNA. This sequence is used to illustrate the method of

CC the invention
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 22;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2041 GTGAGCAGCTCCTGTACGA 2060
 |||||
 DB 20 GTGAGCAGCTCCTGTACGA 1

RESULT 74
 AAL62454/c
 ID AAL62454 standard; DNA; 20 BP.

XX AAL62454;

XX 06-OCT-2003 (first entry)

XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206635.

XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
 KM hyperproliferative; autoimmune disorder; antisense gene therapy;
 KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
 KM phosphorothioate backbone; antisense; ss.

XX Homo sapiens.
 OS Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"

FT modified_base 1..5

FT /*tag= b

FT /mod_base= OTHER

FT /note= "2'methoxyethyl nucleotides"

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2'methoxyethyl nucleotides"

XX WO2003051309-A2.

XX 26-JUN-2003.

XX 12-DEC-2002; 2002WO-US040101.

XX 17-DEC-2001; 2001US-00024369.

XX (ISIS-) ISIS PHARM INC.

XX Borchers AH, Ward DT, Freier SM;

XX WPI; 2003-577305/54.

XX New antisense compound that hybridizes and inhibits the nucleic acid
 PT encoding ABC transporter major histocompatibility complex 1, for treating
 PT diseases or conditions such as a hyperproliferative or autoimmune
 PT disorder.

XX Claim 3; Page 81; 112pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
 CC where the compound specifically hybridizes with the nucleic acid molecule
 CC and inhibits expression of ATM or specifically hybridizes with at least a
 CC portion of an active site on the nucleic acid molecule. The invention is
 CC useful for inhibiting the expression of ATM in cells or tissues. The

CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 2059 GAAAGCCTGAGCGGTACTC 2078
Db 20 GAAAGCCTGAGCGGTACTC 1

RESULT 75
AAL62409/c
ID AAL62409 standard; DNA; 20 BP.
XX
XX AAL62409;
XX
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206590.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "Phosphorothioate backbone; All cytidines are 5-
XX FT methylcytidines"
XX modified_base 1..5
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "2' methoxyethyl nucleotides"
XX modified_base 16..20
XX FT /*tag= c
XX FT /mod_base= OTHER
XX FT /note= "2' methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX

PS Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridises with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridises with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
SQ Sequence 20 BP; 8 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 915 ATTTCGTGTGTAAGCTGCTGC 934
Db 20 ATTTCGTGTGTAAGCTGCTGC 1

RESULT 76
AAL62417/c
ID AAL62417 standard; DNA; 20 BP.
XX
XX AAL62417;
XX
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206598.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "Phosphorothioate backbone; All cytidines are 5-
XX FT methylcytidines"
XX modified_base 1..5
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "2' methoxyethyl nucleotides"
XX modified_base 16..20
XX FT /*tag= c
XX FT /mod_base= OTHER
XX FT /note= "2' methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX


```

XX DR 12-DEC-2002; 2002MO-US040101.
XX PF 17-DEC-2001; 2001US-00024369.
XX PR (ISIS-) ISIS PHARM INC.
XX PA Borchers AH, Ward DT, Freier SM;
XX PI WPI; 2003-577305/54.
XX PS Claim 3; Page 81; 112pp; English.
XX PT New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX PS Claim 3; Page 81; 112pp; English.
XX PT The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention.
XX SQ Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1018 CTTCTGCCCAAGAGTGGG 1037
XX DB 20 CTTCTGCCCAAGAGTGGG 1
XX
XX RESULT 77
XX AAL62418/c
XX ID AAL62418 standard; DNA; 20 BP.
XX AC AAL62418;
XX DT 06-OCT-2003 (first entry)
XX DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206599.
XX XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX XX
XX Key Location/Qualifiers
XX FT 1..20 /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "Phosphorothioate backbone; All cytidines are 5-
XX FT methylcytidines"
XX FT 1..5
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "2-methoxyethyl nucleotides"
XX FT 16..20
XX FT /*tag= c
XX FT /mod_base= OTHER
XX FT /note= "2-methoxyethyl nucleotides"
XX PN WO2003051309-A2.
XX PD 26-JUN-2003.

```

```

XX XX
XX 12-DEC-2002; 2002MO-US040101.
XX PF 17-DEC-2001; 2001US-00024369.
XX PR (ISIS-) ISIS PHARM INC.
XX PA Borchers AH, Ward DT, Freier SM;
XX PI WPI; 2003-577305/54.
XX PS Claim 3; Page 81; 112pp; English.
XX PT The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention.
XX SQ Sequence 20 BP; 3 A; 8 C; 1 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1028 AGAAGGTGGGAAATGCTAC 1047
XX DB 20 AGAAGGTGGGAAATGCTAC 1
XX
XX RESULT 78
XX AAL62421/c
XX ID AAL62421 standard; DNA; 20 BP.
XX AC AAL62421;
XX DT 06-OCT-2003 (first entry)
XX DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206602.
XX XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX XX
XX Key Location/Qualifiers
XX FT 1..20 /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "Phosphorothioate backbone; All cytidines are 5-
XX FT methylcytidines"
XX FT 1..5
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "2-methoxyethyl nucleotides"
XX PN WO2003051309-A2.
XX PD 26-JUN-2003.

```

FT	modified_base	16..20
FT		/*tag= C
FT		/mod_base= OTHER
FT		/note= "2'methoxyethyl nucleotides"
XX		
PN	MO2003051309-A2.	
XX		
PD	26-JUN-2003.	
XX		
XX	12-DEC-2002; 2002WO-US040101.	
XX		
PR	17-DEC-2001; 2001US-00024369.	
XX		
PA	(ISIS-) ISIS PHARM INC.	
XX		
P1	Borchers AH, Ward DT, Freier SM;	
XX		
DR	WPI; 2003-577305/54.	
XX		
PT	New antisense compound that hybridizes and inhibits the nucleic acid	
PT	encoding ABC transporter major histocompatibility complex 1, for treating	
PT	diseases or conditions such as a hyperproliferative or autoimmune	
PT	disorder.	
XX		
PS	Claim 3; Page 81, 112pp; English.	
XX		
CC	The invention relates to a compound targeted to a nucleic acid molecule	
CC	encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1	
CC	where the compound specifically hybridises with the nucleic acid molecule	
CC	and inhibits expression of ATM or specifically hybridises with at least a	
CC	portion of an active site on the nucleic acid molecule. The invention is	
CC	useful for inhibiting the expression of ATM in cells or tissues. The	
CC	invention is useful for treating an animal with hyperproliferative or	
CC	autoimmune disorder. The invention is useful for diagnostics,	
CC	therapeutics, prophylaxis, as research reagents and kits, for	
CC	distinguishing functions of various members of a biological pathway and	
CC	in antisense gene therapy. The invention is also useful prophylactically	
CC	e.g., to prevent or delay infection, inflammation or tumour formation.	
CC	The present sequence is an antisense oligo targeted to human ABC	
CC	transporter MHC I DNA. This sequence is used to illustrate the method of	
CC	the invention	
XX		
SO	Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;	
XX		
Query Match	0.9%; Score 20; DB 1; Length 20;	
Best Local Similarity	100.0%; Pred. No. 22;	
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1045 TACCAGTTGCTGGAAGTCA 1064	
DB	20 TACCAGTTGCTGGAAGTCA 1	
RESULT 79		
ID	AAL62433/C	
AC	AAL62433 standard; DNA; 20 BP.	
XX		
XX	AAL62433;	
DT		
DT	06-OCT-2003 (first entry)	
DE		
XX	Human ABC transporter MHC I antisense oligonucleotide, ISIS 206614.	
KW	ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;	
KW	hyperproliferative; autoimmune disorder; antisense gene therapy;	
KW	inflammation; tumour formation; immunosuppressive; antimicrobial; human;	
XX	phosphorochiolate backbone; antisense; ss.	
OS	Homo sapiens.	
OS	Synthetic.	
XX		
Key	Location/Qualifiers	
TH	modified_base 1..20	
FT		

FT		/tag= a	New antisease compound that hybridizes and inhibits the nucleic acid encoding ABC transporter major histocompatibility complex 1, for treating diseases or conditions such as a hyperproliferative or autoimmune disorder.
FT		/mod_base= OTHER	
FT		/note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"	
FT		1..5	
modified_base		/tag= b	
FT		/mod_base= OTHER	
FT		/note= "2' methoxyethyl nucleotides"	
FT		16..20	
FT		/tag= c	
FT		/mod base= OTHER	
FT		/note= "2'methoxyethyl nucleotides"	
FN			
MW		WO2003051309-A2.	
PD			
PD		26-JUN-2003.	
PF			
PR		12-DEC-2002; 2002MO-US040101.	
XX			
PA		17-DEC-2001; 2001US-00024369.	
PI		(ISIS-) ISIS PHARM INC.	
BH		Borchers AH, Ward DT, Freier SM,	
DJ		WP1; 2003-577305/54.	
PT			
PT			
PT			
PS			
Claim 3;		Page 81; 112pp; English.	
The invention relates to a compound targetted to a nucleic acid molecule encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1 where the compound specifically hybridises with the nucleic acid molecule and inhibits expression of ATM or specifically hybridises with at least a portion of an active site on the nucleic acid molecule. The invention is useful for inhibiting the expression of ATM in cells or tissues. The invention is useful for treating an animal with hyperproliferative or autoimmune disorder. The invention is useful for diagnostics, therapeutics, prophylaxis, as research reagents and kits, for distinguishing functions of various members of a biological pathway and in antisense gene therapy. The invention is also useful prophylactically e.g., to prevent or delay infection, inflammation or tumour formation. The present sequence is an antisense oligo targeted to human ABC transporter MHC I DNA. This sequence is used to illustrate the method of the invention			
SQ		Sequence 20 BP; 5 A; 4 C; 2 G; 9 T; 0 U; 0 Other;	
Query Match	0.9%; Score 20; DB 1; Length 20;		
Best Local Similarity	100.0%; Pred. No. 22;		
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
OY	1424 CAGAGAAAATATTGACTAC 1443 		
Db	20 CAGAGAAAAATTTTGACTAC 1		
RESULT 80			
AAL62435/c			
ID	AAL62435 standard; DNA; 20 BP.		
AX			
AAI62435;			
DT	06-OCT-2003 (first entry)		
HUMAN ABC TRANSPORTER MHC I ANTISENSE OLIGONUCLEOTIDE, ISIS 206616.			
ABC TRANSPORTER; ABCT; MAJOR HISTOCOMPATIBILITY COMPLEX; MHC; CYTOSTATIC; HYPERPROLIFERATIVE; AUTOIMMUNE DISORDER; ANTISENSE GENE THERAPY;			
KW			

KM		inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XW		phosphorochioate backbone; antisense; ss.
OS	Homo sapiens.	
XX	Synthetic.	
FH	Key	Location/Qualifiers
FT	modified_base	1..20
FT	/tag= a	
FT	/mod_base= OTHER	
FT	/note= "Phosphorochioate backbone; All cytidines are 5-methylcytidines"	
FT	modified_base	1..5
FT	/tag= b	
FT	/mod_base= OTHER	
FT	/note= "2'methoxyethyl nucleotides"	
FT	modified_base	16..20
FT	/tag= c	
FT	/mod_base= OTHER	
FT	/note= "2'methoxyethyl nucleotides"	
PN	WO2003051309-A2.	
XX		
PD	26-JUN-2003.	
XX		
PE	12-DEC-2002; 2002WO-US040101.	
XX		
PR	17-DEC-2001; 2001US-00024369.	
XX		
PA	(ISIS-) ISIS PHARM INC.	
P1	Borchers AH, Ward DT, Freiler SM;	
DR	WPI; 2003-577305/54.	
XX		
PT	New antisense compound that hybridizes and inhibits the nucleic acid encoding ABC transporter major histocompatibility complex 1, for treating diseases or conditions such as a hyperproliferative or autoimmune disorder.	
PS	Claim 3; Page 81; 112pp; English.	
XX		
CC	The invention relates to a compound targeted to a nucleic acid molecule encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1 where the compound specifically hybridises with the nucleic acid molecule and inhibits expression of ATM or specifically hybridises with at least a portion of an active site on the nucleic acid molecule. The invention is useful for inhibiting the expression of ATM in cells or tissues. The invention is useful for treating an animal with hyperproliferative or autoimmune disorder. The invention is useful for diagnostics, therapeutics, prophylaxis, as research reagents and kits, for distinguishing functions of various members of a biological pathway and in antisense gene therapy. The invention is also useful prophylactically e.g., to prevent or delay infection, inflammation or tumour formation. The present sequence is an antisense oligo targeted to human ABC transporter MHC I DNA. This sequence is used to illustrate the method of the invention	
SO	Sequence 20 BP; 8 A; 4 C; 6 G; 2 T; 0 U; 0 Other;	
OY	Query Match	0.9%; Score 20; DB 1; Length 20;
DB	Best Local Similarity	100.0%; Pred. No. 22;
XX	Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX	1473 TGGTCTGTTGACTCCCTTAC 1492	
XX		
XX	20 TGGTCTGTTGACTCCCTTAC 1	
XX		
XX	AAL62450/C	
XX	AAL62450 standard; DNA; 20 BP.	

AC	AA162450;	
XX		
DT	06-OCT-2003	(first entry)
XX		
DE	Human ABC transporter MHC I antisense oligonucleotide, ISIS 206631.	
XX		
KW	ABC transporter; ABC1; major histocompatibility complex; MHC; cytostatic;	
KW	hyperproliferative; autoimmune disorder; antisense gene therapy;	
KW	inflammation; tumour formation; immunosuppressive; antimicrobial; human;	
KW	phosphorothioate backbone; antisense; ss.	
XX		
OS	Homo sapiens.	
OS	Synthetic.	
XX		
FH	Key	Location/Qualifiers
FT	modified_base	1..20
FT		/*tag= a
FT		/mod_base= OTHER
FT		/note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"
FT	modified_base	1..5
FT		/*tag= b
FT		/mod_base= OTHER
FT	modified_base	16..20
FT		/*tag= c
FT		/mod_base= OTHER
FT		/note= "2'-methoxyethyl nucleotides"
XX		
PN	WO2003051309-A2.	
XX		
PD	26-JUN-2003.	
XX		
PE	12-DEC-2002; 2002WO-US040101.	
XX		
XX	17-DEC-2001; 2001US-00024369.	
PR		
XX		
PA	(ISIS-) ISIS PHARM INC.	
XX		
PI	Borchers AH, Ward DT, Freier SM;	
XX		
DR	WPI; 2003-577305/54.	
XX		
PT	New antisense compound that hybridizes and inhibits the nucleic acid	
PT	encoding ABC transporter major histocompatibility complex 1, for treating	
PT	diseases or conditions such as a hyperproliferative or autoimmune	
PT	disorder.	
XX		
PS	Claim 3; Page 81; 112p; English.	
XX		
CC	The invention relates to a compound targetted to a nucleic acid molecule	
CC	encoding ABC transporter (ABC1) major histocompatibility complex (MHC) 1	
CC	where the compound specifically hybridizes with the nucleic acid molecule	
CC	and inhibits expression of ATM or specifically hybridizes with at least a	
CC	portion of an active site on the nucleic acid molecule. The invention is	
CC	useful for inhibiting the expression of ATM in cells or tissues. The	
CC	invention is useful for treating an animal with hyperproliferative or	
CC	autoimmune disorder. The invention is useful for diagnostic,	
CC	therapeutic, prophylaxis, as research reagents and kits, for	
CC	distinguishing functions of various members of a biological pathway and	
CC	in antisense gene therapy. The invention is also useful prophylactically	
CC	e.g., to prevent or delay infection, inflammation or tumour formation.	
CC	The present sequence is an antisense oligo targetted to human ABC	
CC	transporter MHC I DNA. This sequence is used to illustrate the method of	
CC	the invention	
XX		
SQ	Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;	
XX		
Query March	0.9%; Score 20; DB 1; Length 20;	
Best Local Similarity	100.0%; Prid. No. 22;	
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	

1988 TACTTATCTCGATGATGCC 2007

```

Db          20 TACTTATCCTGGATGATGCC 1
|||||
RESULT 82
AAL62382/C
ID AAL62382 standard; DNA; 20 BP.
XX
XX AAL62382;
AC
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206563.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridises with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridises with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention

```

```

XX
SQ Sequence 20 BP; 4 A; 7 C; 8 G; 1 T; 0 U; 0 Other;
      Query Match 0.9%; Score 20; DB 1; Length 20;
      Best Local Similarity 100.0%; Pred. No. 22;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 90 CGCCGACTGGGTGCTCTCC 109
Db 20 CGCCGACTGGGTGCTCTCC 1
|||||
RESULT 83
AAL62386/C
ID AAL62386 standard; DNA; 20 BP.
XX
XX AAL62386;
AC
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206567.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridises with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridises with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or

```

CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 255 AAACGCGGTGCCCGAGGCT 274
Db 20 AAACGCGGTGCCCGAGGCT 1
RESULT 84
AAL62436/c
ID AAL62436 standard; DNA; 20 BP.
XX AAL62436;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206617.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*cag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone; All cytidines are 5-
XX methyletylidines"
XX modified_base 1..5
XX /*cag= b
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
XX modified_base 16..20
XX /*cag= c
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM,
XX
XX WPI; 2003-577305/54.
XX
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 81; 112pp; English.

XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
SQ Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1481 TGACTCCCTTACACTTGAG 1500
Db 20 TGACTCCCTTACACTTGAG 1
RESULT 85
AAL62444/c
ID AAL62444 standard; DNA; 20 BP.
XX AAL62444;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206625.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*cag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone; All cytidines are 5-
XX methyletylidines"
XX modified_base 1..5
XX /*cag= b
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
XX modified_base 16..20
XX /*cag= c
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM,
XX
XX

```
DR WPI: 2003-577305/54.
XX
PT New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
PS Claim 3; Page 81; 112pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 4 A; 6 C; 3 G; 7 T; 0 U; 0 Other;
Query March 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1824 TATGAGGAATCACACGCTG 1843
Db 20 TATGAGGAATCACACGCTG 1
RESULT 86
AAL62415/c
ID AAL62415 standard; DNA; 20 BP.
XX
AC AAL62415;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206596.
XX
KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methyleytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
PN WO2003051309-A2.
XX
PD 26-JUN-2003.
XX
```

```
PF 12-DEC-2002; 2002WO-US040101.
XX
PR 17-DEC-2001; 2001US-00024369.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Borchers AH, Ward DT, Freier SM;
XX
DR WPI: 2003-577305/54.
XX
PT New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
PS Example 15; Page 81; 112pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
Query March 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 979 CTCACATGTCACCCCTGAT 998
Db 20 CTCACATGTCACCCCTGAT 1
RESULT 87
AAL62439/c
ID AAL62439 standard; DNA; 20 BP.
XX
AC AAL62439;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206620.
XX
KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methyleytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT
```

```

FT      /*tag= c
PT      /mod_base= OTHER
FT      /note= "2'methoxyethyl nucleotides"
XX
XX
XX      WO2003051309-A2.
XX
XX      26-JUN-2003.
XX
XX      12-DEC-2002; 2002WO-US040101.
XX
XX      17-DEC-2001; 2001US-00024369.
XX
XX      (ISIS-) ISIS PHARM INC.
XX
XX      Borchers AH, Ward DT, Freier SM;
XX
XX      WPI; 2003-577305/54.
XX
XX      New antinease compound that hybridizes and inhibits the nucleic acid
PT      encoding ABC transporter major histocompatibility complex 1, for treating
PT      diseases or conditions such as a hyperproliferative or autoimmune
PT      disorder.
XX
XX      Claim 3; Page 81; 112pp; English.
XX
XX      The invention relates to a compound targeted to a nucleic acid molecule
CC      encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC      where the compound specifically hybridizes with the nucleic acid molecule
CC      and inhibits expression of ATM or specifically hybridizes with at least a
CC      portion of an active site on the nucleic acid molecule. The invention is
CC      useful for inhibiting the expression of ATM in cells or tissues. The
CC      invention is useful for treating an animal with hyperproliferative or
CC      autoimmune disorder. The invention is useful for diagnostic,
CC      therapeutic, prophylaxis, as research reagents and kits, for
CC      distinguishing functions of various members of a biological pathway and
CC      in antinease gene therapy. The invention is also useful prophylactically
CC      e.g., to prevent or delay infection, inflammation or tumour formation.
CC      The present sequence is an antinease oligo targeted to human ABC
CC      transporter MHC I DNA. This sequence is used to illustrate the method of
CC      the invention
XX
XX      Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;
SQ
Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1537 CCAAACCGCCGATGCTT 1556
DB      20 CCAAACCGCCGATGCTT 1

```

```

FT      /mod_base= OTHER
FT      /note= "Phosphorothioate backbone; All cytidines are 5-
FT      methylcytidines"
XX
XX      modified_base
XX      /*tag= b
XX      /mod_base= OTHER
XX      /note= "2'methoxyethyl nucleotides"
XX
XX      modified_base
XX      /*tag= c
XX      /mod_base= OTHER
XX      /note= "2'methoxyethyl nucleotides"
XX
XX      WO2003051309-A2.
XX
XX      26-JUN-2003.
XX
XX      12-DEC-2002; 2002WO-US040101.
XX
XX      17-DEC-2001; 2001US-00024369.
XX
XX      (ISIS-) ISIS PHARM INC.
XX
XX      Borchers AH, Ward DT, Freier SM;
XX
XX      WPI; 2003-577305/54.
XX
XX      New antinease compound that hybridizes and inhibits the nucleic acid
PT      encoding ABC transporter major histocompatibility complex 1, for treating
PT      diseases or conditions such as a hyperproliferative or autoimmune
PT      disorder.
XX
XX      Claim 3; Page 81; 112pp; English.
XX
XX      The invention relates to a compound targeted to a nucleic acid molecule
CC      encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC      where the compound specifically hybridizes with the nucleic acid molecule
CC      and inhibits expression of ATM or specifically hybridizes with at least a
CC      portion of an active site on the nucleic acid molecule. The invention is
CC      useful for inhibiting the expression of ATM in cells or tissues. The
CC      invention is useful for treating an animal with hyperproliferative or
CC      autoimmune disorder. The invention is useful for diagnostic,
CC      therapeutic, prophylaxis, as research reagents and kits, for
CC      distinguishing functions of various members of a biological pathway and
CC      in antinease gene therapy. The invention is also useful prophylactically
CC      e.g., to prevent or delay infection, inflammation or tumour formation.
CC      The present sequence is an antinease oligo targeted to human ABC
CC      transporter MHC I DNA. This sequence is used to illustrate the method of
CC      the invention
XX
XX      Sequence 20 BP; 2 A; 4 C; 6 G; 8 T; 0 U; 0 Other;
SQ
Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1810 ACCGAGAGCCACTATGGA 1829
DB      20 ACCGAGAGCCACTATGGA 1

```

```

RESULT 88
AAL62443/c
ID      AAL62443 standard; DNA; 20 BP.
XX
XX      AAL62443;
XX
XX      06-OCT-2003 (first entry)
XX
XX      Human ABC transporter MHC I antinease oligonucleotide, ISIS 206624.
XX
XX      ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX      hyperproliferative; autoimmune disorder; antinease gene therapy;
XX      inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX      phosphorothioate backbone; antinease; 88.
XX
XX      Homo sapiens.
XX      Synthetic.
XX
XX      Key      Location/Qualifiers
XX      modified_base 1..20
XX      /*tag= a

```

```

RESULT 89
AAL62381/c
ID      AAL62381 standard; DNA; 20 BP.
XX
XX      AAL62381;
XX
XX      06-OCT-2003 (first entry)
XX
XX      Human ABC transporter MHC I antinease oligonucleotide, ISIS 206562.
XX
XX      ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX      hyperproliferative; autoimmune disorder; antinease gene therapy;
XX      inflammation; tumour formation; immunosuppressive; antimicrobial; human;

```

```
KM phosphorothioate backbone; antisense; ss.
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridises with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridises with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC 1 DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 6 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 49 GGAGCTTCTTCGCATGGCT 68
Db 20 GGAGCTTCTTCGCATGGCT 1
```

```
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC 1 antisense oligonucleotide, ISIS 206575.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "phosphorothioate backbone; All cytidines are 5-
XX methylcytidines"
XX modified_base 1..5
XX /tag= b
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
XX modified_base 16..20
XX /tag= c
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridises with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridises with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC 1 DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 1 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 436 GCGGCACTGCCCGACGACG 455
XXXXXXXXXXXXXXXXXXXX
```


Db 20 GCGGACTGCGCGAGCAGC 1

RESULT 91
AAL62424/C
ID AAL62424 standard; DNA; 20 BP.
XX
XX AAL62424;
XX
DT 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206605.
XX
XX ABC transporter; ABCT, major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002MO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
PI
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutic, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention

SQL Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1101 CATTGAGGCTCTGTGCGCCA 1120
DB 20 CATTGAGGCTCTGTGCGCCA 1

RESULT 92
AAL62425/C
ID AAL62425 standard; DNA; 20 BP.
XX
XX AAL62425;
XX
DT 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206606.
XX
XX ABC transporter; ABCT, major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002MO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
PI
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,

```
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1109 CTCTGTCGGCCATGCTTACA 1128
Db 20 CTCTGTCGGCCATGCTTACA 1

RESULT 93
AAL62429/C
ID AAL62429 standard; DNA; 20 BP.
XX
AC AAL62429;
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206610.
XX
KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= C
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
PN WO2003051309-A2.
XX
PD 26-JUN-2003.
XX
PF 12-DEC-2002; 2002WO-US040101.
XX
PR 17-DEC-2001; 2001US-00024369.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Borchers AH, Ward DT, Freier SM;
XX
DR WPI; 2003-577305/54.
XX
PT New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
PS Claim 3; Page 81; 112pp; English.
XX
```

```
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridises with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridises with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1218 GGCTATGCACTCACTCCT 1237
Db 20 GGCTATGCACTCACTCCT 1

RESULT 94
AAL62455/C
ID AAL62455 standard; DNA; 20 BP.
XX
AC AAL62455;
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206636.
XX
KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= C
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
PN WO2003051309-A2.
XX
PD 26-JUN-2003.
XX
PF 12-DEC-2002; 2002WO-US040101.
XX
PR 17-DEC-2001; 2001US-00024369.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Borchers AH, Ward DT, Freier SM;
XX
DR WPI; 2003-577305/54.
XX
```

```

XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Example 15; Page 81, 112pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostic,
CC therapeutic, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2073 GTACTCCGCTCAGTGCCTTC 2092
    |||||
Db 20 GTACTCCGCTCAGTGCCTTC 1

RESULT 95
AAL62457/c
ID AAL62457 standard; DNA; 20 BP.
XX
AC AAL62457;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206638.
XX
KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "phosphorothioate backbone; All cytidines are 5-
XX methylcytidines"
XX modified_base 1..5
XX /tag= b
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
XX modified_base 16..20
XX /tag= c
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002WO-US040101.
XX

```

```

XX 17-DEC-2001; 2001US-00024369.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Claim 3; Page 81, 112pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostic,
CC therapeutic, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2228 CTGCAGATGCTCCGAGATGA 2247
    |||||
Db 20 CTGCAGATGCTCCGAGATGA 1

RESULT 96
AAL62396/c
ID AAL62396 standard; DNA; 20 BP.
XX
AC AAL62396;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206577.
XX
KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone; All cytidines are 5-
XX methylcytidines"
XX modified_base 1..5
XX /tag= b
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
XX modified_base 16..20
XX /tag= c
XX

```

```

FT FT /mod_base= OTHER
FT FT /note= "2'methoxyethyl nucleotides"
XX XX WO2003051309-A2.
XX XX
XX XX 26-JUN-2003.
XX XX
XX XX 12-DEC-2002; 2002WO-US040101.
XX XX
XX XX 17-DEC-2001; 2001US-00024369.
XX XX
XX XX (ISIS-) ISIS PHARM INC.
XX XX
XX XX Borchers AH, Ward DT, Freier SM;
XX XX
XX XX WPI; 2003-577305/54.
XX XX
XX XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX XX
XX XX Claim 3; Page 80; 112pp; English.
XX XX
XX XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridises with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridises with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX XX
XX XX Sequence 20 BP; 3 A; 9 C; 7 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 475 AGCCTGGGTCGCCGCGG 494
Db 20 AGCCTGGGTCGCCGCGG 1

```

```

FT FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT FT methylcytidines"
XX XX modified_base
XX XX 1..5
XX XX /*tag= b
FT FT /mod_base= OTHER
FT FT /note= "2'methoxyethyl nucleotides"
XX XX 16..20
XX XX /*tag= c
FT FT /mod_base= OTHER
FT FT /note= "2'methoxyethyl nucleotides"
XX XX
XX XX WO2003051309-A2.
XX XX
XX XX 26-JUN-2003.
XX XX
XX XX 12-DEC-2002; 2002WO-US040101.
XX XX
XX XX 17-DEC-2001; 2001US-00024369.
XX XX
XX XX (ISIS-) ISIS PHARM INC.
XX XX
XX XX Borchers AH, Ward DT, Freier SM;
XX XX
XX XX WPI; 2003-577305/54.
XX XX
XX XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX XX
XX XX Claim 3; Page 80; 112pp; English.
XX XX
XX XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridises with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridises with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX XX
XX XX Sequence 20 BP; 5 A; 1 C; 7 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 672 CACTCGAACTTAACCTCA 691
Db 20 CACTCGAACTTAACCTCA 1

```

```

XX Homo sapiens.
OS Synthetic.
XX Key
FH modified_base
FT 1. .20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT 1. .5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base
FT 16. .20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002WO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 920 TGTGTGTTCTGTGTGCGAGGC 939
DB 20 TGTGTGTTCTGTGTGCGAGGC 1

```

```

DT 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206564.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX Key
FH modified_base
FT 1. .20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT 1. .5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base
FT 16. .20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002WO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Example 15; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 4 A; 7 C; 8 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 137 TGTGTGTGCTGACCGGCGCTG 156
DB 20 TGTGTGTGCTGACCGGCGCTG 1

```

```
RESULT 100
AAL62390/c
ID AAL62390 standard; DNA; 20 BP.
XX
XX AAL62390;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206571.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX W02003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Example 15; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridises with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridises with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 4 A; 7 C; 8 G; 1 T; 0 U; 0 Other;
```

```
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 304 GCACTGGGCTTGGCCCTGCC 323
Db 20 GCACTGGGCTTGGCCCTGCC 1
RESULT 101
AAL62393/c
ID AAL62393 standard; DNA; 20 BP.
XX
XX AAL62393;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206574.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX W02003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridises with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridises with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
```

CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 425 TCAGTTATGCAGCGCACTG 444
20 TCAGTTATGCAGCGCACTG 1
Db
RESULT 102
AAL62399/c
ID AAL62399 standard; DNA; 20 BP.
AC AAL62399;
DT 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206580.
DE
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methyleytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
XX
FN WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule

CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 649 CAAGATGCTCAGCCGATAC 668
20 CAAGATGCTCAGCCGATAC 1
Db
RESULT 103
AAL62403/c
ID AAL62403 standard; DNA; 20 BP.
AC AAL62403;
DT 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206584.
DE
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methyleytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
XX
FN WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX

```

PT New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
PS Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 6 A; 8 C; 2 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 776 ACTTGACGAGGAGGAGTGT 795
Db 20 ACTTGACGAGGAGGAGTGT 1
RESULT 104
AAL62408/c
ID AAL62408 standard; DNA; 20 BP.
XX
XX AAL62408;
AC
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206589.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
FH Key location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX

```

```

PR 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Borchers AH, Ward DT, Freier SM;
PI WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Example 15; Page 80; 112pp; English.
PS
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 8 A; 5 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 899 GTGAGAACTGAGCTTATT 918
Db 20 GTGAGAACTGAGCTTATT 1
RESULT 105
AAL62428/c
ID AAL62428 standard; DNA; 20 BP.
XX
XX AAL62428;
AC
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206609.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
FH Key location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT

```



```

FT      /note= "2'methoxyethyl nucleotides"
XX
XX      WO2003051309-A2.
XX
XX      26-JUN-2003.
XX
XX      12-DEC-2002; 2002WO-US040101.
XX
XX      17-DEC-2001; 2001US-00024369.
XX
XX      (ISIS-) ISIS PHARM INC.
XX
XX      Borchers AH, Ward DT, Freier SM,
XX
XX      WPI; 2003-577305/54.
XX
XX      New antisense compound that hybridizes and inhibits the nucleic acid
XX      encoding ABC transporter major histocompatibility complex 1, for treating
XX      diseases or conditions such as a hyperproliferative or autoimmune
XX      disorder.
XX
XX      Claim 3; Page 81; 112pp; English.
XX
XX      The invention relates to a compound targeted to a nucleic acid molecule
XX      encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX      where the compound specifically hybridizes with the nucleic acid molecule
XX      and inhibits expression of ATM or specifically hybridizes with at least a
XX      portion of an active site on the nucleic acid molecule. The invention is
XX      useful for inhibiting the expression of ATM in cells or tissues. The
XX      invention is useful for treating an animal with hyperproliferative or
XX      autoimmune disorder. The invention is useful for diagnostics,
XX      therapeutics, prophylaxis, as research reagents and kits, for
XX      distinguishing functions of various members of a biological pathway and
XX      in antisense gene therapy. The invention is also useful prophylactically
XX      e.g., to prevent or delay infection, inflammation or tumour formation.
XX      The present sequence is an antisense oligo targeted to human ABC
XX      transporter MHC I DNA. This sequence is used to illustrate the method of
XX      the invention
XX
XX      Sequence 20 BP; 3 A; 6 C; 3 G; 8 T; 0 U; 0 Other;
XX
XX      Query Match      0.9%; Score 20; DB 1; Length 20;
XX      Best Local Similarity 100.0%; Pred. No. 22;
XX      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX      QY      1157 AAGCCAGAGTTAGGAA 1176
XX      |||||||
XX      20 AAGCCAGAGTTAGGAA 1
XX
XX      Db
XX
XX      RESULT 106
XX      AAL62438/c
XX      ID      AAL62438 standard; DNA; 20 BP.
XX
XX      AC      AAL62438;
XX
XX      DT      06-OCT-2003 (first entry)
XX
XX      DE      Human ABC transporter MHC I antisense oligonucleotide, ISIS 206619.
XX
XX      KM      ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX      hyperproliferative; autoimmune disorder; antisense gene therapy;
XX      inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX      phosphorothioate backbone; antisense; ss.
XX
XX      OS      Homo sapiens.
XX      OS      Synthetic.
XX
XX      FH      Key      Location/Qualifiers
XX      FT      modified_base 1..20
XX      FT      /*tag= a
XX      FT      /mod_base= OTHER
XX      FT      /note= "Phosphorothioate backbone; All cytidines are 5-

```

```

FT      methylcytidines"
XX
XX      modified_base 1..5
XX      FT      /*tag= b
XX      FT      /mod_base= OTHER
XX      FT      /note= "2'methoxyethyl nucleotides"
XX
XX      modified_base 16..20
XX      FT      /*tag= c
XX      FT      /mod_base= OTHER
XX      FT      /note= "2'methoxyethyl nucleotides"
XX
XX      WO2003051309-A2.
XX
XX      26-JUN-2003.
XX
XX      12-DEC-2002; 2002WO-US040101.
XX
XX      17-DEC-2001; 2001US-00024369.
XX
XX      (ISIS-) ISIS PHARM INC.
XX
XX      Borchers AH, Ward DT, Freier SM,
XX
XX      WPI; 2003-577305/54.
XX
XX      New antisense compound that hybridizes and inhibits the nucleic acid
XX      encoding ABC transporter major histocompatibility complex 1, for treating
XX      diseases or conditions such as a hyperproliferative or autoimmune
XX      disorder.
XX
XX      Claim 3; Page 81; 112pp; English.
XX
XX      The invention relates to a compound targeted to a nucleic acid molecule
XX      encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX      where the compound specifically hybridizes with the nucleic acid molecule
XX      and inhibits expression of ATM or specifically hybridizes with at least a
XX      portion of an active site on the nucleic acid molecule. The invention is
XX      useful for inhibiting the expression of ATM in cells or tissues. The
XX      invention is useful for treating an animal with hyperproliferative or
XX      autoimmune disorder. The invention is useful for diagnostics,
XX      therapeutics, prophylaxis, as research reagents and kits, for
XX      distinguishing functions of various members of a biological pathway and
XX      in antisense gene therapy. The invention is also useful prophylactically
XX      e.g., to prevent or delay infection, inflammation or tumour formation.
XX      The present sequence is an antisense oligo targeted to human ABC
XX      transporter MHC I DNA. This sequence is used to illustrate the method of
XX      the invention
XX
XX      Sequence 20 BP; 7 A; 2 C; 8 G; 3 T; 0 U; 0 Other;
XX
XX      Query Match      0.9%; Score 20; DB 1; Length 20;
XX      Best Local Similarity 100.0%; Pred. No. 22;
XX      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX      QY      1521 TGTCCTTGCTACCCAA 1540
XX      |||||||
XX      20 TGTCCTTGCTACCCAA 1
XX
XX      Db
XX
XX      RESULT 107
XX      AAL62411/c
XX      ID      AAL62411 standard; DNA; 20 BP.
XX
XX      AC      AAL62411;
XX
XX      DT      06-OCT-2003 (first entry)
XX
XX      DE      Human ABC transporter MHC I antisense oligonucleotide, ISIS 206592.
XX
XX      KM      ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX      hyperproliferative; autoimmune disorder; antisense gene therapy;
XX      inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX      phosphorothioate backbone; antisense; ss.
XX
XX      OS      Homo sapiens.
XX      OS      Synthetic.
XX
XX      FH      Key      Location/Qualifiers
XX      FT      modified_base 1..20
XX      FT      /*tag= a
XX      FT      /mod_base= OTHER
XX      FT      /note= "Phosphorothioate backbone; All cytidines are 5-

```

OS Homo sapiens.
OS Synthetic.
XX Key
FH modified_base 1..20
FT location/Qualifiers
FT 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"
FT 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid encoding ABC transporter major histocompatibility complex 1, for treating diseases or conditions such as a hyperproliferative or autoimmune disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1 where the compound specifically hybridizes with the nucleic acid molecule and inhibits expression of ATM or specifically hybridizes with at least a portion of an active site on the nucleic acid molecule. The invention is useful for inhibiting the expression of ATM in cells or tissues. The invention is useful for treating an animal with hyperproliferative or autoimmune disorder. The invention is useful for diagnostics, for example, prophylaxis, as research reagents and kits, for distinguishing functions of various members of a biological pathway and in antisense gene therapy. The invention is also useful prophylactically e.g., to prevent or delay infection, inflammation or tumour formation. The present sequence is an antisense oligo targeted to human ABC transporter MHC I DNA. This sequence is used to illustrate the method of the invention
XX
SQ Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 936 AGGCTATGTCCTTGGGA 955
DB 20 AGGCTATGTCCTTGGGA 1
RESULT 108
AAL62420/C
ID AAL62420 standard; DNA; 20 BP.
XX
XX AAL62420;
AC
XX
DT 06-OCT-2003 (first entry)

XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206601.
DE
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic; hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX Key
FH modified_base 1..20
FT location/Qualifiers
FT 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"
FT 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid encoding ABC transporter major histocompatibility complex 1, for treating diseases or conditions such as a hyperproliferative or autoimmune disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1 where the compound specifically hybridizes with the nucleic acid molecule and inhibits expression of ATM or specifically hybridizes with at least a portion of an active site on the nucleic acid molecule. The invention is useful for inhibiting the expression of ATM in cells or tissues. The invention is useful for treating an animal with hyperproliferative or autoimmune disorder. The invention is useful for diagnostics, for example, prophylaxis, as research reagents and kits, for distinguishing functions of various members of a biological pathway and in antisense gene therapy. The invention is also useful prophylactically e.g., to prevent or delay infection, inflammation or tumour formation. The present sequence is an antisense oligo targeted to human ABC transporter MHC I DNA. This sequence is used to illustrate the method of the invention
XX
SQ Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1041 ATGGTACCAAGTTGCTGAAG 1060
DB 20 ATGGTACCAAGTTGCTGAAG 1

```

RESULT 109
AAL62404/c
ID AAL62404 standard; DNA; 20 BP.
XX
XX AAL62404;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206585.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methyleytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 5 A; 4 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX

```

```

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 839 AGACAGGTAACATCATGTCT 858
Db 20 AGACAGGTAACATCATGTCT 1
XX
XX RESULT 110
XX AAL62430/c
XX ID AAL62430 standard; DNA; 20 BP.
XX
XX AAL62430;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206611.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methyleytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX
XX

```

CC in antisense gene therapy. The invention is also useful prophylactically
 CC e.g., to prevent or delay infection, inflammation or tumour formation.
 CC The present sequence is an antisense oligo targeted to human ABC
 CC transporter MHC I DNA. This sequence is used to illustrate the method of
 CC the invention
 XX
 SQ Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.9%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 22;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1274 GAATCCTCTACATTGCTGGG 1293
 DB 20 GAATCCTCTACATTGCTGGG 1
 RESULT 111
 AAD41088
 ID AAD41088 standard; DNA; 19 BP.
 AC AAD41088;
 XX
 XX 30-OCT-2002 (first entry)
 DT
 XX
 DE Primer ON-TAP1-F2 used for DNA sequencing.
 XX
 KM Tumour necrosis-factor; TNF; promoter; autoimmune disorder; cancer;
 KW therapy; primer; ss.
 XX
 OS Unidentified.
 XX
 PN WO200246433-A2.
 XX
 PD 13-JUN-2002.
 XX
 PF 07-DEC-2001; 2001WO-EP014412.
 XX
 PR 08-DEC-2000; 2000US-0254649P.
 XX
 PA (SAUS/) SAUS J.
 XX
 PI Saus J;
 XX
 XX WPI; 2002-519670/55.
 DR
 XX
 PT Novel tumor necrosis-factor inducible promoter useful for identifying
 PT candidate compounds for treating/preventing autoimmune disorders/cancer,
 PT or for identifying promoters that are regulated by tumor necrosis factor.
 XX
 PS Example; Page 18; 95bp; English.
 XX
 CC The invention relates to a tumour necrosis-factor TNF inducible promoter.
 CC The invention is useful for identifying candidate TNF inducible promoters
 CC by aligning a test sequence consisting of a nucleic acid sequence with a
 CC comparison sequence selected from the invention, using a gap opening
 CC penalty of 50 and a gap extension penalty of 3 to define a test
 CC alignment, shuffling the nucleic sequence of the test sequence at least
 CC one hundred times, while maintaining its length and composition, to
 CC produce a series of randomised sequences, aligning the randomised
 CC sequences with the comparison sequence using a gap opening penalty of 50
 CC and a gap extension penalty of 3, to produce a series of randomised
 CC alignments, determining an average alignment quality of the randomised
 CC alignments, where the average alignment quality of the randomised
 CC alignments represent an alignment expected by chance, comparing the test
 CC alignment with the average alignment quality of the randomised alignments
 CC and identifying a test alignment with a probability value of less than
 CC 0.05 that the alignment is obtained by chance as a candidate TNF
 CC inducible promoter. The invention is useful for identifying candidate
 CC compounds for treating or preventing autoimmune disorders or cancer. The
 CC present sequence is a primer used in the exemplification of the invention
 XX
 SQ Sequence 19 BP; 3 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 30;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 626 GCCGCTCTACTGACTGGAT 644
 DB 1 GCCGCTCTACTGACTGGAT 19
 RESULT 112
 ABR82234
 ID ABR82234 standard; DNA; 19 BP.
 AC ABR82234;
 XX
 XX 27-AUG-2002 (first entry)
 DT
 XX
 DE Human ATP-binding cassette (ABC) transporter probe #72.
 DE
 XX Human ATP-binding cassette transporter; ABC transporter;
 KW Human; ATP-binding cassette transporter; ABC transporter;
 KW expression rate; drug development; biochemical kinetic; anthelmintic;
 KW probe; ss.
 XX
 OS Homo sapiens.
 XX
 PN JP2002112775-A.
 XX
 PD 16-APR-2002.
 XX
 PF 03-OCT-2000; 2000JP-00303404.
 XX
 PR 03-OCT-2000; 2000JP-00303404.
 XX
 PR 03-OCT-2000; 2000JP-00303404.
 XX
 PA (SAKA) OTSUKA SEIYAKU KOGYO KK.
 XX
 DR WPI; 2002-458864/49.
 XX
 XX
 PT Probes for determination of human ATP-binding cassette (ABC) transporters
 PT capable of hybridization with 33 regions of genes.
 XX
 PS Claim 8; Page 27; 36pp; Japanese.
 XX
 CC The invention describes new probes for identification of human ATP-
 CC binding cassette (ABC) transporters capable of hybridisation with 33
 CC regions of genes. Blucadation of expression rate of ABC transporters is
 CC useful for development of drugs and their biochemical kinetics. This
 CC sequence represents a probe used to detect human ATP-binding cassette
 CC (ABC) transporters
 XX
 SQ Sequence 19 BP; 4 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.8%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 30;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 286 TTGAAGCCATTAGCTGCGG 304
 DB 1 TTGAAGCCATTAGCTGCGG 19
 RESULT 113
 ABR03923
 ID ABR03923 standard; DNA; 19 BP.
 AC ABR03923;
 XX
 XX 18-SEP-2002 (first entry)
 DT
 XX Human pol kappa 76 DNA polymerase sequencing primer #29.
 DE Human pol kappa 76; Goodpasture antigen binding protein; GPBP;
 KW Human; pol kappa 76; Goodpasture antigen binding protein; GPBP;
 KW chromosome Sq12-13; apoptosis; autoimmune disorder; cancer; cytostatic;

```

KM Immunosuppressive; PCR; primer; sequencing; ss.
XX
XX Homo sapiens.
XX
XX WO200246378-A2.
XX
XX 13-JUN-2002.
XX
XX 07-DEC-2001; 2001MO-EP014409.
XX
XX 08-DEC-2000; 2000US-0254649P.
XX
XX (SAUS/) SAUS J.
XX
XX Saus J;
XX
XX WPI; 2002-537563/57.
XX
XX Novel isolated pol kappa76 polypeptide, a 76 kDa alternatively spliced
XX variant of DNA polymerase kappa, useful as target for treating a patient
XX with autoimmune disorder or cancer.
XX
XX Example; Page 16; 90pp; English.
XX
XX The present invention provides the protein and coding sequences of human
XX DNA polymerase pol kappa 76. The gene is found on human chromosome 5q12-
XX 13, in a head-to-head arrangement with the Goodpasture antigen binding
XX protein (GPBP). The detection of the coding sequence can be used for
XX diagnosing an autoimmune condition and identifying cells undergoing
XX apoptosis, and the sequences can be used in the treatment of autoimmune
XX diseases and cancer. The present sequence is a sequencing primer
XX described in the invention
XX
XX Sequence 19 BP; 3 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 30;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 626 GCCGCTCACTGACTGAT 644
XX |||||
XX 1 GCCGCTCACTGACTGAT 19
XX
XX RESULT 114
XX ACD13526
XX ID ACD13526 standard; DNA; 19 BP.
XX
XX AC ACD13526;
XX
XX 14-AUG-2003 (first entry)
XX
XX Human bi-directional promoter PCR/sequencing primer ON-TAP1-F2.
XX
XX Human; ss; Goodpasture antigen binding protein; GPBP; COL4A3BP;
XX collagen 4 alpha 3 binding protein; DNA polymerase kappa; pol kappa;
XX Goodpasture disease; cutaneous lupus; polK76; bi-directional promoter;
XX autoimmune disease; cancer; antisense therapy; PCR; primer.
XX
XX Homo sapiens.
XX
XX US2003027165-A1.
XX
XX 06-FEB-2003.
XX
XX 07-DEC-2001; 2001US-00010920.
XX
XX 08-DEC-2000; 2000US-0254649P.
XX
XX (SAUS/) SAUS J.
XX
XX Saus J;
XX
XX

```

```

DR WPI; 2003-479531/45.
XX
XX New isolated DNA polymerase, pol kappa 76, useful in identifying
XX autoimmune disorders and in treating cancer and autoimmune disorders by
XX modifying its expression.
XX
XX Example; Page 7; 54pp; English.
XX
XX The invention relates to an isolated pol kappa (k) 76 polypeptide (an
XX alternatively spliced form of DNA polymerase kappa), appearing as
XX AB007327 (encoded by the cDNA appearing as ACD13492). The gene for
XX polkappa is located on chromosome 5q12-13 in a head-head arrangement with
XX the gene encoding Goodpasture antigen binding protein (GPBP or collagen 4
XX alpha 3 binding protein (COL4A3BP)), associated with autoimmune diseases
XX such as Goodpasture's disease and cutaneous lupus) i.e. has a bi-
XX directional promoter. Also included are a recombinant expression vector
XX comprising the polK76 cDNA, a host cell transfected with the vector,
XX detecting (M1) polK76 (comprising providing a protein sample to be
XX screened, contacting the protein sample to be screened with an anti-
XX polK76 antibody and detecting the formation of an antibody-polypeptide
XX complexes, where the presence of the antibody-polypeptide complexes
XX indicates the presence of polK76), detecting (M2) the polK76 nucleic acid
XX in a sample (comprising contacting the sample with one or more polK76 PCR
XX primer, carrying out PCR to generate PCR products, and identifying the
XX polK76-specific PCR), detecting an autoimmune condition in a patient,
XX (comprising providing a tissue or body fluid sample from the patient,
XX providing a control tissue or body fluid sample in which no autoimmune
XX condition is present, and detecting an increase in pol K76 RNA expression
XX in the tissue of body fluid samples compared to the control sample, where
XX the increase indicates the presence of an autoimmune condition) and
XX treating (M3) a patient with an autoimmune disorder or cancer by
XX modifying the expression or activity of pol K76 in the patient. Modifying
XX the expression or activity of polK76 or polK76 nucleic acid, such as by
XX increasing or decreasing their expression or activity using antibodies or
XX antisense therapy, is useful for treating an autoimmune disorder or
XX cancer. The present sequence is a PCR and/or sequencing primer used in
XX the analysis of bi-directional promoters of other genes (and/or of
XX polkappa/GPBP), whose structure and sequence were compared to the
XX polkappa/GPBP bi-directional promoter
XX
XX Sequence 19 BP; 3 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 30;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 626 GCCGCTCACTGACTGAT 644
XX |||||
XX 1 GCCGCTCACTGACTGAT 19
XX
XX RESULT 115
XX ADA97827
XX ID ADA97827 standard; DNA; 19 BP.
XX
XX AC ADA97827;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human tumour necrosis factor (TNF) inducible promoter PCR primer #29.
XX
XX Human; tumour necrosis factor inducible promoter; TNF;
XX autoimmune disorder; cancer; PCR; immunosuppressive; cytostatic; ss;
XX primer.
XX
XX Homo sapiens.
XX
XX US2003082745-A1.
XX
XX 01-MAY-2003.
XX
XX 07-DEC-2001; 2001US-00008721.
XX
XX

```

```
PR 08-DEC-2000; 2000US-0254649P.
XX
XX (SAUS/) SAUS J.
XX
XX Saus J;
XX
XX WPI; 2003-606062/57.
DR
XX
XX New tumor necrosis factor inducible promoters, useful for identifying
PT promoters that are regulated by tumor necrosis factor, or for identifying
PT candidate compounds for treating or preventing autoimmune disorders or
PT cancer.
XX
XX Example; Page 7; 57pp; English.
XX
XX The invention relates to a tumor necrosis factor (TNF) inducible
CC promoter. Also disclosed are an expression vector comprising one or more
CC tumor necrosis factor inducible promoters and a recombinant host cell
CC transfected with one or more expression vectors. The TNF inducible
CC promoters, expression vectors and host cells are useful for identifying
CC promoters that are regulated by tumor necrosis factor or for identifying
CC candidate compounds for treating or preventing autoimmune disorders or
CC cancer. This sequence represents a PCR primer used for isolating a tumour
CC necrosis factor inducible promoter of the invention.
XX
XX Sequence 19 BP; 3 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 626 GCCGCTCAGTACTGGAT 644
Db 1 GCCGCTCAGTACTGGAT 19
RESULT 116
AAZ32694
ID AAZ32694 standard; DNA; 18 BP.
XX
XX AAZ32694;
AC
XX
XX 21-JAN-2000 (first entry)
DT
XX
XX Human MHC Class II locus TAP1 gene-specific PCR primer TAP1A.
XX
XX Major histocompatibility complex; MHC; Class II; autoimmune disorder;
KM transfection; transgenic animal; animal model; disease; transgene;
KM co-lipofection; yeast artificial chromosome; YAC; lipid; cationic;
KM selectable; TAP1; PCR; primer; ss.
XX
XX Synthetic.
OS
XX Homo sapiens.
XX
XX US981175-A.
PN
XX
XX 09-NOV-1999.
PD
XX
XX 25-JAN-1994; 94US-00187161.
PF
XX
XX 07-JAN-1993; 93US-00001493.
PR 18-JUN-1993; 93US-00079444.
XX
XX (GENP-) GENPHARM INT INC.
PA
XX
XX Kay RM, Choi T, Loring JF;
PI
XX WPI; 1999-633306/54.
XX
XX Production of transfected mammalian cells by co-lipofection with multiple
PT DNA species, useful for the production of transgenic animals for use as
PT disease models.
XX
```

```
PS Example 4; Col 31; 29pp; English.
XX
XX This sequence represents human TAP1 PCR primer TAP1A, used with primer
CC TAP1B (AAZ32695), to amplify the TAP1 gene in murine embryonic stem cells
CC transfected via a novel method with a YAC (yeast artificial chromosome)
CC containing the human MHC (major histocompatibility complex) Class II
CC locus which contains the TAP1 gene. The novel method of transfection
CC produces a selectable co-lipofected mammalian cell incorporating multiple
CC heterologous DNA species. It comprises forming a co-lipofection complex
CC comprising a cationic lipid, a first polynucleotide larger than 50 kb,
CC and an unlinked second polynucleotide comprising a selectable marker gene
CC expression cassette, and transfecting mammalian cells with it. Both
CC heterologous nucleotides are integrated into the genome, forming
CC selectable co-lipofected mammalian cells which contain incorporated
CC multiple heterologous DNA species. The method can be used for
CC transferring large segments of DNA, such as large YAC clones, into
CC mammalian cells such as embryonic stem cells. The methods can be used to
CC producing mammalian cells which express human TAP1 which can be used to
CC produce transgenic animals as models for autoimmune disorders. The
CC methods can also be used for producing transgenic animals as models for
CC Alzheimer's disease
XX
XX Sequence 18 BP; 3 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 42;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 879 CACCCGTGATGATTCCT 896
Db 1 CACCCGTGATGATTCCT 18
RESULT 117
AAF76193
ID AAF76193 standard; DNA; 18 BP.
XX
XX AAF76193;
AC
XX
XX 05-JUN-2001 (first entry)
DT
XX
XX Human TAP-1 PCR primer, SEQ ID NO:59.
XX
XX Transgenic mouse; immunodeficient; tissue recipient;
KM lymphocyte deficient; human cytokine; interleukin; IL-7; IL-6; SCF; LIF;
KM stem cell factor; leukemia inhibitory factor; GM-CSF; M-CSF;
KM granulocyte macrophage-colony stimulating factor;
KM macrophage-colony stimulating factor; human MHC Class II; DR3;
KM major histocompatibility complex; allergenicity determination;
KM human monoclonal antibody generation; haematopoietic cell development;
KM human immune system animal model; PCR primer; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200115521-A1.
PN
XX
XX 08-MAR-2001.
PD
XX
XX 30-AUG-2000; 2000WO-US023971.
PF
XX
XX 31-AUG-1999; 99US-0151688P.
PR
XX
XX (GENV ) GENENCOR INT INC.
PA
XX
XX Huang MA, Harding FA;
PI
XX WPI; 2001-169001/17.
XX
XX New transgenic mice, useful as non-human mammalian models of human
PT disease, comprise recombination activation gene mutations and donor
PT specific transgenes encoding cytokines.
XX
XX Example 4; Page 47; 68pp; English.
PS
```

XX The invention relates to a transgenic immunodeficient recipient mouse
CC which is capable of supporting the growth of donor cells. In the mouse,
CC both alleles of a gene activated in early lymphocyte development are
CC disrupted, causing it to lack mature B and T cells. In particular, both
CC alleles of the recombination activation gene-2 (RAG-2) gene are
CC disrupted, which in turn prevents VDJ recombination. The mouse also
CC comprises donor (e.g., human) specific transgenes encoding the cytokines
CC interleukin-7 (IL-7), stem cell factor (SCF), leukemia inhibitory factor
CC (LIF), granulocyte macrophage-colony stimulating factor (GM-CSF),
CC macrophage-colony stimulating factor (M-CSF), and IL-6, which enable it
CC to support the growth of transplanted donor cells. In another embodiment
CC of the invention, the mouse comprises DNA encoding the human major
CC histocompatibility complex (MHC) class II DR3 molecule, where the
CC transgene has naturally linked Drab and Ddab alleles. The transgenic
CC mouse may be used as a model for determining the allergenicity of non-
CC donor, e.g., non-human, macromolecules; to determine the effect compounds
CC have on a human immune system; to generate fully human polyclonal or
CC monoclonal antibodies to specific antigens; to determine whether
CC humanised or other monoclonal antibodies will raise a response in a human
CC immune system; to investigate the human cell mediated response to
CC pathogens and other immunomodulatory compounds; and to determine the
CC factors involved in regulating the development and function of human
CC haematopoietic cells. The transgenic mouse supports the functional
CC properties of human haematopoietic cells, unlike previous animal models
CC which produce functionally impaired haematopoietic cells or are
CC immunologically dysfunctional. In addition the transgenic mouse provides
CC a unique model system which supports T cell development in a manner which
CC more closely resembles normal ontogeny, as they possess CD4+ T cells in
CC the periphery that exhibit MHC-restricted antigen-specific responses.
CC Sequences AAT76193-AAT76204 represent PCR primers used to determine the
CC presence of a VNC containing a 550kb segment of the human MHC class II
CC region in murine embryonic stem (ES) cells
XX
SQ Sequence 18 BP, 3 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 42;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 879 CACCTGAGTGATTCTCT 896
DB 1 CACCTGAGTGATTCTCT 18
RESULT 118
ACCA2628 ID ACCA2628 standard; DNA, 18 BP.
XX ACAC2628;
AC ACCA2628;
XX 26-AUG-2003 (first entry)
DT
DE HLA Class II region Tap 1 gene PCR primer 1069 F.
XX
XX Human: PCR: transgenic mouse; lymphocyte maturation; IL-3; IL-7;
KW cytokine; interleukin-3; interleukin-6; IL-6; interleukin-7; M-CSF; SCF;
KW macrophage-colony stimulating factor; stem cell factor; oncostatin M; OM;
KW granulocyte-colony stimulating factor; GM-CSF; LIF;
KW leukaemia inhibitory factor; HLA Class II region; Tap 1; ss.
XX
XX Homo sapiens.
OS
XX W02003018744-A2.
PN
XX
XX 06-MAR-2003.
PD
XX 05-AUG-2002; 2002WO-US024807.
PF
XX 23-AUG-2001; 2001US-00938689.
PR
XX (GEMV) GENENCOR INT INC.
PA
XX

PI Harding FA, Huang M;
XX
XX WPI; 2003-278650/27.
DR
XX
XX New recipient mammal, preferably a mouse, useful as a model of human
PT disease to assess efficacy of therapeutic or prophylactic treatments, or
PT for facilitating production of donor-specific functional immunity.
XX
PS Example; Page 46; 70pp; English.
XX
XX The present invention relates to a new transgenic mouse, which comprises
CC a disruption in both alleles of a gene such that lymphocyte maturation
CC does not occur and exogenous cytokines. The cytokines are selected from:
CC interleukin-3 (IL-3), interleukin-6 (IL-6), interleukin-7 (IL-7),
CC macrophage-colony stimulating factor (M-CSF), granulocyte-colony
CC stimulating factor (GM-CSF), stem cell factor (SCF), leukemia inhibitory
CC factor (LIF) and oncostatin M (OM). The gene disruption is in a gene that
CC modulated VDJ recombination e.g. a RAG gene. The gene is disrupted by
CC insertion of a transgene comprising major histocompatibility complex
CC (MHC, HLA) Class II DR3 and DQ2 genes. The transgenic mouse is useful as
CC a model of human disease to assess efficacy of therapeutic or
CC prophylactic treatments, or to assess the antigenic potential of
CC compounds. The transgenic mouse is also useful for supporting donor
CC haematopoietic stem cells or facilitating production of donor-specific
CC functional immunity. PCR primers ACC42571-ACC42639 were used to generate
CC the transgenic mouse
XX
SQ Sequence 18 BP, 3 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 42;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 879 CACCTGAGTGATTCTCT 896
DB 1 CACCTGAGTGATTCTCT 18
RESULT 119
AAV28200/C ID AAV28200 standard; DNA, 22 BP.
XX
XX AAV28200;
AC
XX 08-OCT-1998 (first entry)
DT
XX Antisense oligonucleotide to multi-drug resistance-1 gene (MDR-1).
DE
XX Purification; oligonucleotide; matrix; affinity unit;
KW affinity purification; antisense; multi-drug resistance-1 gene; MDR-1;
KW ss.
XX
XX Synthetic.
OS
XX W09827425-A1.
PN
XX 25-JUN-1998.
PD
XX 18-DEC-1997; 97WO-US023284.
PF
XX 19-DEC-1996; 96US-00769951.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Chen D, Srivatsa GS, Cole DL;
XX WPI; 1998-362922/31.
DR
XX
XX Matrix for selective separation of oligo:nucleotide - useful for, e.g.
PT large scale purification of anti-sense agents from their deletion
PT derivatives formed during synthesis.
XX
XX Disclosure; Page 101; 183pp; English.
PS

XX AAV28155-268 represent oligonucleotides which can be purified using the
CC method of the invention. The specification describes a matrix that
CC comprises a support and an affinity unit that specifically and reversibly
CC binds a target oligonucleotide, and comprises a sequence of bases having
CC the reverse complement of a hybridising portion of the target of
CC oligonucleotide. The matrix is used for affinity purification of
CC synthetic oligonucleotides, specifically antisense agents, for treatment
CC of hyperproliferative diseases, for treating a non-pathogen, non-
CC hyperproliferative disease, e.g. Alzheimer's, for modulating expression
CC of cell surface proteins, and to inhibit a eukaryotic pathogen,
CC retrovirus or other viruses
XX
SQ Sequence 22 BP; 3 A; 9 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 76;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1617 CAATGGCTCTGGGAAGACACA 1638
DB 22 CAGTGGCTGTGGGAAGACACA 1
RESULT 120
AA18712/c
ID AA18712 standard; DNA; 22 BP.
XX
AC AA18712;
XX
DT 10-MAY-1999 (first entry)
XX
DE Target MDR antisense oligonucleotide #44.
XX
DE Cellular adhesion protein; proliferation; antisense oligonucleotide;
KM alimentary canal; transport; gastrointestinal mucosa; cancer;
KM Alzheimer's disease; beta-thalassemia; malaria; viral infection; HIV;
KM inflammation; ss.
XX
XX Synthetic.
OS
PN WO9901579-A1.
XX
PD 14-JAN-1999.
XX
PF 01-JUL-1998; 98WO-US013574.
XX
PR 01-JUL-1997; 97US-00886829.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Teng C, Hardee G;
XX
DR WPI; 1999-106077/09.
XX
PT Composition comprising nucleic acid and penetration enhancer - used
PT particularly for delivering therapeutic antisense oligonucleotides across
PT the gastrointestinal mucosa, provides high bioavailability.
XX
PS Example 2; Page 89; 115pp; English.
XX
CC A pharmaceutical composition has been developed which comprises a nucleic
CC acid and at least one penetration enhancer. The compositions are used:
CC (i) to treat or prevent any disease or disorder that can be treated with
CC the nucleic acid, e.g. cancer, Alzheimer's disease, beta-thalassemia,
CC malaria, viral infections (including human immune deficiency virus
CC (HIV)), inflammation, in human or animal medicine; (ii) to investigate
CC the role of a gene or gene product in non-human animals; and (iii) to
CC modulate gene expression in cells, tissues or organs. The compositions
CC provide bioavailability of at least 15, preferably 17-35%. The
CC penetration enhancer improves: (i) transport of the nucleic acid across
CC the mucosa of the alimentary canal and into cells; and (ii) increases
CC stability of the nucleic acid. Oral administration avoids the

CC complications and expense of intravenous or other methods of
CC administration. AA18669 to AA18799 and AA18801 represent antisense
CC oligonucleotides which can be used as the nucleic acid in the method of
CC the invention
XX
SQ Sequence 22 BP; 3 A; 9 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 76;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1617 CAATGGCTCTGGGAAGACACA 1638
DB 22 CAGTGGCTGTGGGAAGACACA 1
RESULT 121
AA23703/c
ID AA23703 standard; DNA; 22 BP.
XX
AC AA23703;
XX
DT 18-JUN-1999 (first entry)
XX
DE Deletion sequence oligonucleotide 156.
XX
DE Deletion sequence oligonucleotide; sensor array; eukaryotic pathogen;
KM probe; cellular adhesion modulator; cellular proliferation modulator;
KM human retrovirus; human immunodeficiency virus; non-human retrovirus;
KM HIV; primer; ss.
XX
XX Synthetic.
OS
PN WO9911820-A1.
XX
PD 11-MAR-1999.
XX
PF 01-SEP-1998; 98WO-US018084.
XX
PR 02-SEP-1997; 97US-00923771.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Chen D, Srivatsa GS;
XX
DR WPI; 1999-205198/17.
XX
PT New compositions comprising sensor arrays made up of unique probe
PT oligonucleotides - useful for characterizing a sample of target deletion
PT oligonucleotides.
XX
PS Example 9; Page 157; 163pp; English.
XX
CC This invention describes a novel composition comprising a number of
CC sensor arrays, where each array comprises a unique probe oligonucleotide,
CC which is the reverse complement of part of a unique target
CC oligonucleotide present in a mixture of target deletion sequence
CC oligonucleotides. The compositions form a method for characterizing a
CC sample of target deletion oligonucleotides which are labelled and
CC hybridize with the probe oligonucleotides of the sensor arrays. Such
CC oligonucleotides and their targets are represented in AA23548-X23709.
CC Oligonucleotides characterized by the method form pharmaceutical
CC compositions that are useful for modulating cellular adhesion or
CC proliferation, and being active against a eukaryotic pathogen, a human
CC retrovirus, a human immunodeficiency virus (HIV), or a non-human
CC retrovirus, including influenza virus, Epstein-Barr virus, Respiratory
CC Syncytial Virus or cytomegalovirus (CMV). The compositions enable
CC characterization of deletion sequence oligonucleotides having related,
CC but different nucleobase sequences, and quantification of different
CC species of deletion sequence ("target") oligonucleotides in a mixture.
CC Also, if the specificity of the oligonucleotide's nucleobase sequence for
CC its reverse complement is not modified, the method may be performed using
CC oligodeoxynucleotides

XX Sequence 22 BP; 3 A; 9 C; 4 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 76;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 1617 CAATGGGCTGGGAGAGACACA 1638
Db 22 CAGTGGCTGGGAGAGACACA 1
RESULT 122
ID AAS45634 standard; DNA; 20 BP.
XX AAS45634;
XX 18-DEC-2001 (first entry)
XX
DE Human PARP-1 antisense inhibitor ISIS #125995.
XX
XX Human; ss; PARP; Poly (ADP-ribose) polymerase; antisense oligonucleotide;
XX cytoskeletal; neurotrophic; neuroprotective; antiinflammatory; antidiabetic;
XX immunosuppressant; hyperproliferative disorder; cancer; cellular injury;
XX oxidative stress; neurological disorder; parkinsonism; apoptosis;
XX meningitis-associated intracranial complication; ischaemia; probe;
XX inflammatory disorder; autoimmune disorder; arthritis; diabetes.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "All cytidine residues are 5-methyl cytidine"
FT modified_base 1..5
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= d
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
XX
PN WO200164955-A1.
XX
PD 07-SEP-2001.
XX
PF 01-MAR-2001; 2001WO-US006572.
XX
PR 02-MAR-2000; 2000US-00517467.
XX
XX (ISIS-) ISIS PHARM INC.
XX
PI Popoff I, Cowsett LM;
XX
DR WPI; 2001-602570/68.
XX
XX Antisense compound useful for treating hyperproliferative, neurological,
PT inflammatory and autoimmune disorders and diabetes inhibits human PARP.
XX
XX Claim 3; Page 83; 168pp; English.
XX
CC The invention relates to antisense oligonucleotides targeted to human
CC PARP nucleic acid and inhibiting expression of human PARP. PARP (Poly
CC (ADP-ribose) polymerase plays an important role in chromatin
CC decondensation, DNA replication, DNA repair, gene expression, malignant
CC transformation, cellular differentiation and apoptosis. The antisense

CC oligonucleotide inhibitors are useful for inhibiting the expression of
CC PARP in human cells or tissues. They are also useful for treating a human
CC with a disease associated with PARP especially hyperproliferative
CC disorders (e.g. cancer), cellular injury resulting from oxidative stress,
CC neurological (e.g. parkinsonism, meningitis-associated intracranial
CC complications and ischaemia), inflammatory and autoimmune disorders (e.g
CC arthritis) and diabetes. The present sequence is an antisense
CC oligonucleotide of the invention
XX
SQ Sequence 20 BP; 0 A; 6 C; 6 G; 8 T; 0 U; 0 Other;
Query Match 0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 78;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1193 AGACACTCAACCGAGAGAG 1212
Db 20 AGACACCCCAACCGAGAGAG 1
RESULT 123
ID ABX97378 standard; DNA; 20 BP.
XX ABX97378;
XX
AC ABX97378;
XX
DT 20-MAY-2003 (first entry)
XX
XX Human NOV-associated forward primer from primer-probe set Ag3437.
DE
XX
XX NOVA; cytoskeletal; cardiant; antiarteriosclerotic; antiasthmatic; cancer;
XX hypotensive; cardiomyopathy; bronchial asthma; gene therapy; vaccine;
XX human; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200272757-A2.
XX
PD 19-SEP-2002.
XX
XX 08-MAR-2002; 2002WO-US006908.
XX
PF 08-MAR-2001; 2001US-0274101P.
PR 08-MAR-2001; 2001US-0274194P.
PR 08-MAR-2001; 2001US-0274281P.
PR 08-MAR-2001; 2001US-0274322P.
PR 09-MAR-2001; 2001US-0274849P.
PR 12-MAR-2001; 2001US-0275235P.
PR 13-MAR-2001; 2001US-0275578P.
PR 13-MAR-2001; 2001US-0275579P.
PR 13-MAR-2001; 2001US-0275601P.
PR 14-MAR-2001; 2001US-0276000P.
PR 16-MAR-2001; 2001US-0276776P.
PR 19-MAR-2001; 2001US-0276994P.
PR 20-MAR-2001; 2001US-0277239P.
PR 20-MAR-2001; 2001US-0277321P.
PR 20-MAR-2001; 2001US-0277327P.
PR 21-MAR-2001; 2001US-0277791P.
PR 22-MAR-2001; 2001US-0277833P.
PR 23-MAR-2001; 2001US-0278152P.
PR 26-MAR-2001; 2001US-0278894P.
PR 27-MAR-2001; 2001US-0278999P.
PR 27-MAR-2001; 2001US-0279036P.
PR 28-MAR-2001; 2001US-0279344P.
PR 30-MAR-2001; 2001US-0277338P.
PR 30-MAR-2001; 2001US-0279955P.
PR 30-MAR-2001; 2001US-0280233P.
PR 02-APR-2001; 2001US-0280802P.
PR 02-APR-2001; 2001US-0280832P.
PR 02-APR-2001; 2001US-0280900P.
PR 04-APR-2001; 2001US-0281194P.
PR 13-APR-2001; 2001US-0283675P.
PR 30-APR-2001; 2001US-0287424P.

PR 02-MAY-2001; 2001US-0288066P.
 PR 03-MAY-2001; 2001US-0288342P.
 PR 03-MAY-2001; 2001US-0288528P.
 PR 15-MAY-2001; 2001US-0291190P.
 PR 16-MAY-2001; 2001US-0291099P.
 PR 16-MAY-2001; 2001US-0291240P.
 PR 30-MAY-2001; 2001US-0294485P.
 PR 31-MAY-2001; 2001US-0294899P.
 PR 18-JUN-2001; 2001US-0299027P.
 PR 19-JUN-2001; 2001US-0299303P.
 PR 19-JUN-2001; 2001US-0299310P.
 PR 10-JUL-2001; 2001US-0304354P.
 PR 31-JUL-2001; 2001US-0309198P.
 PR 16-AUG-2001; 2001US-0312903P.
 PR 10-SEP-2001; 2001US-0318462P.
 PR 12-SEP-2001; 2001US-0318770P.
 PR 27-SEP-2001; 2001US-0325681P.
 PR 18-OCT-2001; 2001US-0330380P.
 PR 31-OCT-2001; 2001US-0335301P.
 PR 14-NOV-2001; 2001US-0332172P.
 PR 14-NOV-2001; 2001US-0332271P.
 PR 14-NOV-2001; 2001US-0332272P.
 PR 14-NOV-2001; 2001US-0333184P.
 PR 14-NOV-2001; 2001US-0333272P.
 PR 21-NOV-2001; 2001US-0332094P.
 PR 03-DEC-2001; 2001US-0337426P.
 PR 03-DEC-2001; 2001US-0338092P.
 PR 04-DEC-2001; 2001US-0337185P.
 PR 03-JAN-2002; 2002US-0345705P.
 PR 07-MAR-2002; 2002US-00092900.
 XX
 PA (CURAGEN CORP.

XX Padigaru M, Spytek KA, Shenoy SG, Taupier RJ, Pena CE, Li L;
 PI Zehnusen BD, Gasev V, Ji W, Gorman L, Miller CE, Kekuda R;
 PI Patunrajan M, Gangoli E, Vernet CM, Guo X, Tchernev V;
 PI Fernandes ER, Casman SJ, Malyankar UM, Gerlach V, Liu Y, Anderson D;
 PI Spedena SK, Catterton E, Burgess C, Leite M, Zhong H, Alsbrook JP;
 PI Lepley DM, Rieger DK;
 XX
 DR WPI; 2002-723332/78.

PT NOVA polypeptides and polynucleotides, useful for preventing or treating
 PT a disorder associated with aberrant NOVA expression or activity e.g.,
 PT cancer, hypertension, atherosclerosis, cardiomyopathy or bronchial
 PT asthma.

XX Example C; Page 762; 1103pp; English.

CC This invention describes novel human NOVA polypeptides which have
 CC cytosolic, cardiant, antiarteriosclerotic, antiasthmatic and hypotensive
 CC activity. Pharmaceutical compositions comprising the NOVA proteins or
 CC nucleic acid molecules or NOVA antibodies are useful for preventing or
 CC treating a disorder associated with aberrant NOVA expression or activity
 CC e.g. cancer, hypertension, atherosclerosis, cardiomyopathy or bronchial
 CC asthma. The products of the invention can be used for gene therapy or in
 CC a vaccine. ABX13460-ABX13462 and ABX97186-ABX97593 represent PCR primers
 CC polynucleotides represented in ABX97008-ABX97185 which encode the
 CC polypeptides represented in ABU65041-ABU65218
 CC
 XX

SQ Sequence 20 BP; 6 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 78;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1259 TGCTGCTGAAGTGGGAATC 1278
 ||||||||||||
 Db 1 TGCTGCTGAAGTGGGAATC 20

RESULT 124

AAF96716
 ID AAF96716 standard; DNA; 21 BP.

XX AAF96716;

DT 06-JUN-2001 (first entry)

XX Human gene single nucleotide polymorphism #1477.

DE Human; variant thrombospondin 1; variant thrombospondin 4; SNP;

KW polymorphism; vascular disease; coronary artery disease; forensics;
 KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
 KW pulmonary embolism; paternity test; ds.

XX Homo sapiens.

OS

XX Key Location/Qualifiers

FT Variation replace(11,T)
 FT /*tag= a
 FT /standard_name= "single nucleotide polymorphism"

XX W0200118250-A2.

XX 15-MAR-2001.

PF 07-SEP-2000; 2000WO-US024503.

XX 10-SEP-1999; 99US-0153357P.

PR 26-JUL-2000; 2000US-0220947P.

PR 16-AUG-2000; 2000US-0225724P.

XX (MHED) WHITEHEAD INST BIOMEDICAL RES.

PA (MILL-) MILLENNIUM PHARM INC.

PI Lander ES, Garrill M, Ireland JS, Bolk S, Daley GQ, McCarthy JJ;
 DR WPI; 2001-226749/23.

PT Nucleic acids comprising single nucleotide polymorphisms, useful in
 PT applications such as forensics, paternity testing, medicine, genetic
 PT analysis and phenotype correlations to diseases such as diabetes and
 PT atherosclerosis.

PS Example; Page 148; 242pp; English.

CC The present invention provides a method of diagnosing a vascular disease
 CC in an individual, involving determining the sequence at various
 CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
 CC genes. The sequences at a number of polymorphic sites are also provided
 CC in the specification. In particular, the method can be used in the
 CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
 CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
 CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
 CC useful in forensics, paternity testing, genetic analysis and phenotype
 CC correlations to diseases. The present sequence is an example of one of
 CC the human gene SNPs shown in the specification
 CC
 XX

SQ Sequence 21 BP; 5 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 84;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1565 AGGGGCTGACATTACCCCTA 1584
 |||||||||
 Db 2 AGGGGCTGACGTTTACCCCTA 21

RESULT 125
 AAX60854/C
 ID AAX60854 standard; DNA; 20 BP.

```

XX AAX60854;
XX 09-AUG-1999 (first entry)
XX CDK4 specific antisense oligo HYB102932.
XX Cyclin-dependent kinase 4; CDK4; antisense; G1/S phase transition;
XX cancerous cell; cyclin D1; p16; tumour growth; ss.
XX Synthetic.
XX WO9927087-A1.
XX 03-JUN-1999.
XX 21-NOV-1997; 97WO-US022234.
XX 21-NOV-1997; 97WO-US022234.
XX (HYBR-) HYBRIDON INC.
XX Morrissey D, Von Hofe E;
XX WPI; 1999-357832/30.
XX Antisense oligonucleotide targeted to cyclin-dependent kinase 4 gene,
XX useful for regulating G1 to S phase transition in a cell.
XX Claim 3; Page 17; 60pp; English.
XX Sequences AAX60831-864 represent synthetic oligonucleotides complementary
XX to a cyclin-dependent kinase 4 (CDK4) nucleic acid. The antisense
XX oligonucleotides are used to regulate G1/S phase transition, especially
XX to inhibit growth of cancerous cells. The oligonucleotides can be
XX administered in the form of a therapeutic composition to treat a mammal
XX afflicted with a tumour associated with aberrant expression of CDK4,
XX cyclin D1, or p16, to reduce tumour growth
XX
SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 92;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 102 GCTGCTCCGACCGCGCT 119
Db 18 GCTGCTCCGACCGAGCT 1

RESULT 126
AAX60835/C
ID AAX60835 standard; DNA; 20 BP.
XX
XX AAX60835;
XX
XX 09-AUG-1999 (first entry)
XX
XX CDK4 specific antisense oligo HYB102135.
XX
XX Cyclin-dependent kinase 4; CDK4; antisense; G1/S phase transition;
XX cancerous cell; cyclin D1; p16; tumour growth; ss.
XX Synthetic.
XX WO9927087-A1.
XX 03-JUN-1999.
XX 21-NOV-1997; 97WO-US022234.
XX 21-NOV-1997; 97WO-US022234.
XX

```

```

PA (HYBR-) HYBRIDON INC.
XX Morrissey D, Von Hofe E;
XX WPI; 1999-357832/30.
XX Antisense oligonucleotide targeted to cyclin-dependent kinase 4 gene,
XX useful for regulating G1 to S phase transition in a cell.
XX Claim 3; Page 16; 60pp; English.
XX Sequences AAX60831-864 represent synthetic oligonucleotides complementary
XX to a cyclin-dependent kinase 4 (CDK4) nucleic acid. The antisense
XX oligonucleotides are used to regulate G1/S phase transition, especially
XX to inhibit growth of cancerous cells. The oligonucleotides can be
XX administered in the form of a therapeutic composition to treat a mammal
XX afflicted with a tumour associated with aberrant expression of CDK4,
XX cyclin D1, or p16, to reduce tumour growth
XX
SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 92;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 102 GCTGCTCCGACCGCGCT 119
Db 19 GCTGCTCCGACCGAGCT 2

RESULT 127
AAC64762/C
ID AAC64762 standard; DNA; 21 BP.
XX
XX AAC64762;
XX
XX 28-FEB-2001 (first entry)
XX
XX RRV Interleukin 6 (IL-6) PCR primer SEQ ID NO:171.
XX
XX Macaca mulatta rhadinovirus 17577; RRV; rhesus macaque rhadinovirus;
XX genome; Kaposi's sarcoma-associated herpesvirus; KSHV; Interleukin 6;
XX IL-6; macrophage inflammatory protein; MIP; diagnosis; vaccine;
XX cytostatic; anti-HIV; gene therapy; infection; Kaposi's sarcoma;
XX lymphoproliferative disorder; B-cell hyperplasia; lymphadenopathy;
XX splenomegaly; hypergammaglobulinemia; autoimmune haemolytic anaemia;
XX PCR primer; ss.
XX
XX Macaca mulatta rhadinovirus 17577.
XX
XX WO200028040-A2.
XX
XX 18-MAY-2000.
XX
XX 05-NOV-1999; 99WO-US026260.
XX
XX 06-NOV-1998; 98US-0107507P.
XX 20-NOV-1998; 98US-0109409P.
XX
XX (UYOR-) UNIV OREGON HEALTH SCI.
XX
XX Wong SW, Axthelm MK, Searles RP;
XX WPI; 2000-376552/32.
XX
XX New rhesus rhadino virus for producing non-human primate model useful for
XX testing potential treatments and efficacy of the candidate vaccine for
XX conditions associated with RRV infection.
XX Example 14; Page 37; 141pp; English.
XX
XX The present invention describes a novel rhesus macaque rhadinovirus
XX called macaca mulatta rhadinovirus 17577 (RRV). AAC64754 represents the

```

CC RRV genome sequence, and AAB53123 to AAB53204 represent the proteins
 CC encoded by the genome sequence. The present invention also specifically
 CC claims the individual open reading frame (ORF) nucleotide sequences from
 CC the genome which encode the individual proteins, but these sequences are
 CC not given. A non-human animal infected with RRV can be used for testing
 CC the efficacy of drug in the treatment of condition associated with
 CC infection with RRV such as Kaposi's sarcoma, lymphoproliferative
 CC disorders, B-cell hyperplasia, lymphadenopathy, splenomegaly,
 CC hypergammaglobulinemia or autoimmune haemolytic anaemia, by
 CC administering the drug to a immuno-compromised non-human primate
 CC preferably Rhesus macaque monkey obtained by as a result of infection by
 CC Simian Immunodeficiency Virus (SIV). RRV is useful for producing non-
 CC human primate model for testing potential treatments for conditions
 CC associated with RRV infection. It is also useful for testing the efficacy
 CC of the candidate vaccine against RRV infection or conditions associated
 CC with its infection by administering the vaccine to the subject capable of
 CC infection with RRV, inoculating the subject with RRV and observing the
 CC effect of vaccine. AAC64755 to AAC64765 and AAB53205 to AAB53213
 CC represent sequence used in the exemplification of the present invention
 XX

SQ Sequence 21 BP; 1 A; 6 C; 5 G; 9 T; 0 U; 0 Other;

Query March 0.7%; Score 16.4; DB 1; Length 21;
 Best Local Similarity 94.4%; Pred. No. 98;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 834 GAACGACAGTAAACAT 851
 |||||
 Db 18 GAACGACAGCGAACAAT 1

RESULT 128
 AAQ73042
 ID AAQ73042 standard; DNA; 21 BP.

AC AAQ73042;

DT 25-MAR-2003 (revised)
 DT 10-MAR-2003 (revised)
 DT 17-JUN-1995 (first entry)

XX Tyrosine-kinase syk DNA probe Z.

XX Tyrosine-kinase; DNA probe Z; ss.

OS Homo sapiens.

XX MO9425565-A1.

XX 10-NOV-1994.

XX 25-APR-1994; 94WO-US004540.

XX 23-APR-1993; 93US-00052560.

XX (ARIA-) ARIAD PHARM INC.

PI Brugge J, Morganstern J, Shiu L, Zydowsky L, Zoller M, Pawson A;

XX WPI; 1994-358247/44.

XX Novel DNA encoding human syk tyrosine kinase - its recombinant prod.
 PT useful to develop tyrosine activation motif mimics, useful for treating
 PT allergies.

XX Disclosure; Fig 1; 63pp; English.

XX The DNA probe is used in the isolation and cloning of human tyrosine-
 CC kinase (Syk) cDNA. The protein, SH2 domains or fusion proteins can be
 CC used in the development of tyrosine activation motif mimics or other
 CC phosphopeptides which can interfere with the signal transduction cascade
 CC of events leading to allergic responses. These can be used as
 CC antiinflammatory agents. (Updated on 10-MAR-2003 to add missing OS

CC field.) (Updated on 25-MAR-2003 to correct PN field.)
 XX

SQ Sequence 21 BP; 8 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

Query March 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 821 AGTTTCCACAGACACAG 841
 |||||
 Db 1 AGTTTCCACAGACACAG 21

RESULT 129
 AAZ26604/C
 ID AAZ26604 standard; DNA; 21 BP.

XX AAZ26604;

XX 30-NOV-1999 (first entry)

XX Human polymorphic region 793.

XX Polymorphism; human; inhibitor; cancer; treatment; cell growth; LOH;
 KM cell viability; loss of heterozygosity; precancerous condition; ASI;
 KM allele specific inhibitor; somatic cell; diagnosis; prevention;
 KM atherosclerotic plaque; premalignant metaplastic lesion; endometriosis;
 KM dysplastic lesion; benign tumour; polycystic kidney disease; transplant;
 KM graft versus host disease; malignant cell removal; bone marrow; ss.

XX Homo sapiens.

XX MO9841648-A2.

XX 24-SEP-1998.

XX 19-MAR-1998; 98WO-US005419.

XX 20-MAR-1997; 97US-0041057P.

XX (VARI-) VARIGENICS INC.

XX Housman D, ledley PD, Stanton VP;

XX WPI; 1998-521232/44.

XX Identifying target genes for allele-specific drugs - used for diagnosis,
 PT prevention and treatment of, e.g. cancers, atherosclerotic plaque,
 PT dysplastic lesions, endometriosis or graft versus host disease.

XX Disclosure; Fig 7; 605pp; English.

XX This invention describes a novel method for identifying an inhibitor
 CC potentially useful for treatment of cancer, where the inhibitor is active
 CC on a gene vital for cell growth or viability, and where the gene is
 CC subject to loss of heterozygosity (LOH) in a cancer. The inhibitor is
 CC used for preventing the development of cancer in a patient having a
 CC precancerous condition, by administering to the patient a first allele
 CC specific inhibitor (ASI) targeted to an allele of a first essential gene
 CC present in cells of the precancerous condition, where the normal somatic
 CC cells of the patient are heterozygous for the first gene, the inhibitor
 CC is active on at least one but less than all allelic forms of the gene
 CC present in a population and targets only one allelic form present in the
 CC normal somatic cells, and the first gene. The products and methods can be
 CC used in the diagnosis, prevention and treatment of LOH disorders, e.g.
 CC cancers, atherosclerotic plaques, premalignant metaplastic or dysplastic
 CC lesions, benign tumours, endometriosis, polycystic kidney disease, and
 CC graft versus host disease. The method can also be used to remove
 CC malignant cells from bone marrow transplants. AAZ25812-226825 represent
 CC human polymorphic sites described in the method of the invention
 XX

SQ Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1389 CATCTACCCGAGCTACAGAA 1409
 |||||
 DB 21 CTCTCTCCCGAGCTGCAGAA 1

RESULT 130

AAFS5721
 ID AAF55721 standard; DNA; 21 BP.

AC AAF55721;

DT 12-APR-2001 (first entry)

XX PCR primer F13.

XX Insecticide; transgenic plant; insect-resistance; PCR primer; probe; ss.

XX Paecilomyces sp.

XX WO200100841-A1.

PD 04-JAN-2001.

PF 23-JUN-2000; 2000WO-GB002457.

PR 29-JUN-1999; 99GB-00015215.

PR 23-DEC-1999; 99GB-00030536.

XX (ZENE) ZENECA LTD.

PI Griffin J, Carlile AJ, Cayley PJ, Mackay EA, Warner SAJ;

PI Vincent JL, Lee MD;

DR WPI; 2001-123015/13.

XX Novel insecticidal protein obtained from species of Paecilomyces for
 PT controlling insects, and for insect-resistant transgenic plant
 production.

XX Example 6; Page 21; 72pp; English.

XX The present invention relates to novel insecticidal proteins obtained
 CC from Paecilomyces sp. (see AAB66899 to AAB66901 and AAB66913). The
 CC insecticidal proteins can be used to produce transgenic plants, which are
 CC insect-resistant. Also, the insecticidal proteins are useful for
 CC controlling insects by providing them at a locus where insects feed. The
 CC present sequence is a PCR primer used in the present invention

XX Sequence 21 BP; 1 A; 9 C; 6 G; 5 T; 0 U; 0 Other;

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 101 TGCTGCTCCGAGCGCGCTGC 121
 |||||
 DB 1 TGCTGCTCCGAGCTGCCTGC 21

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 101 TGCTGCTCCGAGCGCGCTGC 121
 |||||
 DB 1 TGCTGCTCCGAGCTGCCTGC 21

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 101 TGCTGCTCCGAGCGCGCTGC 121
 |||||
 DB 1 TGCTGCTCCGAGCTGCCTGC 21

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 101 TGCTGCTCCGAGCGCGCTGC 121
 |||||
 DB 1 TGCTGCTCCGAGCTGCCTGC 21

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 101 TGCTGCTCCGAGCGCGCTGC 121
 |||||
 DB 1 TGCTGCTCCGAGCTGCCTGC 21

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 101 TGCTGCTCCGAGCGCGCTGC 121
 |||||
 DB 1 TGCTGCTCCGAGCTGCCTGC 21

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

KM predictor set; protein tyrosine kinase activity modulator;
 KM protein tyrosine kinase pathway; protein tyrosine kinase; cytostatic;
 KM gene therapy; drug sensitivity; genetic profile; cancer; human;
 KM PCR primer; ss.

XX Synthetic.

XX Homo sapiens.

XX WO2003062395-A2.

XX 31-JUL-2003.

XX 17-JAN-2003; 2003WO-US001981.

XX 18-JAN-2002; 2002US-0350061P.

XX (BRIM) BRISTOL-MYERS SQUIBB CO.

XX Huang F, Fairchild CR, Lee FY, Shaw P;

XX WPI; 2003-636735/60.

XX New polynucleotides and polypeptides for predicting the activity of
 PT compounds that interact with protein tyrosine kinases and/or protein
 PT tyrosine kinase pathways.

XX Example 2; SEQ ID NO 655; 139pp; English.

XX The present invention describes a predictor set comprising a plurality of
 CC polynucleotides or polypeptides whose expression pattern is predictive of
 CC the response of cells to treatment with a compound that modulates protein
 CC tyrosine kinase activity or members of the protein tyrosine kinase
 CC pathway. Also described: (1) predicting whether a compound is capable of
 CC modulating the activity of cells, comprising obtaining a sample of cells,
 CC determining whether the cells express a plurality of markers, and
 CC correlating the expression of the markers to the compound's ability to
 CC modulate the activity of the cells; (2) a plurality of cell lines for
 CC identifying polynucleotides and polypeptides whose expression levels
 CC correlate with compound sensitivity or resistance of cells associated
 CC with a disease state; and (3) identifying polynucleotides and
 CC polypeptides that predict compound sensitivity or resistance of cells
 CC associated with a disease state, comprising subjecting the plurality of
 CC cell lines to one or more compounds, analysing the expression pattern of
 CC a microarray of polynucleotides or polypeptides, and selecting
 CC polynucleotides or polypeptides that predict the sensitivity or
 CC resistance of cells associated with a disease state by using the
 CC expression pattern of the microarray. The polynucleotides and
 CC polypeptides have cytostatic activities, and can be used in gene therapy.
 CC The polynucleotides and polypeptides are useful in predicting the
 CC activity of compounds that interact with protein tyrosine kinases and/or
 CC protein tyrosine kinase pathways. These may be used in determining drug
 CC sensitivity in patients to allow the development of individualized
 CC genetic profiles which aid in treating diseases and disorders (e.g.
 CC cancer) based on patient response at a molecular level. The present
 CC sequence is used in the exemplification of the present invention.

XX Sequence 21 BP; 0 A; 5 C; 4 G; 12 T; 0 U; 0 Other;

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1003 CTGCTCTGCTTCTTCTTCTG 1023
 |||||
 DB 1 CTGCTCTGCTTCTTCTTCTG 21

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1003 CTGCTCTGCTTCTTCTTCTG 1023
 |||||
 DB 1 CTGCTCTGCTTCTTCTTCTG 21

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1003 CTGCTCTGCTTCTTCTTCTG 1023
 |||||
 DB 1 CTGCTCTGCTTCTTCTTCTG 21

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1003 CTGCTCTGCTTCTTCTTCTG 1023
 |||||
 DB 1 CTGCTCTGCTTCTTCTTCTG 21

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1003 CTGCTCTGCTTCTTCTTCTG 1023
 |||||
 DB 1 CTGCTCTGCTTCTTCTTCTG 21

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1003 CTGCTCTGCTTCTTCTTCTG 1023
 |||||
 DB 1 CTGCTCTGCTTCTTCTTCTG 21

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1003 CTGCTCTGCTTCTTCTTCTG 1023
 |||||
 DB 1 CTGCTCTGCTTCTTCTTCTG 21

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1003 CTGCTCTGCTTCTTCTTCTG 1023
 |||||
 DB 1 CTGCTCTGCTTCTTCTTCTG 21

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1003 CTGCTCTGCTTCTTCTTCTG 1023
 |||||
 DB 1 CTGCTCTGCTTCTTCTTCTG 21

XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1003 CTGCTCTGCTTCTTCTTCTG 1023
 |||||
 DB 1 CTGCTCTGCTTCTTCTTCTG 21

DT	04-DEC-2003	(first entry)
DE	Chicken glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primer #2.	
XX	nucleated red blood cell; nucleic acid isolation;	
XX	high throughput screening assay; genetic analysis;	
KW	avian genetic analysis; fish genetic analysis; reptile genetic analysis;	
KM	amphibian genetic analysis; transgene; chicken;	
KX	glyceraldehyde-3-phosphate dehydrogenase; GAPDH; PCR; primer; ss.	
XX	Gallus gallus.	
OS	US2003049656-A1.	
PN	13-MAR-2003.	
PD	02-MAY-2002; 2002US-00136942.	
PF	15-JAN-2000; 2000US-0176255P.	
XX	PR 13-JAN-2001; 2001US-00760048.	
XX	(HARV/) HARVEY A J.	
PA	Harvey AJ;	
P1	WI; 2003-677928/64.	
DR	Isolation of nucleic acid from nucleated red blood cells involves lysing	
XX	the cells, centrifuging, removing the supernatant, lysing the pellet to	
PT	release nucleic acid, precipitating and washing and drying of the nucleic	
PT	acid.	
XX		
PS	Example 3; Page 6; 18pp; English.	
XX	The invention describes a method of isolating nucleic acid (I) from	
CC	nucleated red blood cells. The method comprises adding a biological	
CC	sample containing the cells to lysis buffer that is confined in a	
CC	container that binds a precipitated nucleic acid, centrifuging, removing	
CC	the supernatant, adding a second lysis buffer to the obtained pellet that	
CC	is incubated in the buffer to release (I), precipitating and washing and	
CC	drying of (I), and dissolving in a solvent. The method is useful for	
CC	extracting DNA from nucleated red blood cells, for a high throughput	
CC	screening assay (e.g. a polymerase chain reaction, ligase chain reaction	
CC	or other conventional DNA detection assay), for detecting a genetic	
CC	sequence in multiple samples and for application towards genetic analysis	
CC	of avians, fish, reptiles and amphibians. The extracted DNA can be used	
CC	for a variety of genetic assays including a high throughput-screening	
CC	assay to identify insertion of a transgene. This sequence represents a	
CC	primer used to isolate DNA encoding chicken glyceraldehyde-3-phosphate	
CC	dehydrogenase (GAPDH) for use as a control in assays for detecting the	
CC	presence of a transgene.	
SQ	Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;	
QY	Query Match 0.7%; Score 16; DB 1; Length 21;	
D6	Best Local Similarity 100.0%; Pred. No. 1,le+02;	
1D	Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
AC	1075 TCCTCGCAAAAGTCCA 1090	
XX		
XX		
XX	TTCTCTGGCAAAAGTCCA 6	
XX		
XX	RESULT 134	
XX	ADD35649/C	
XX	ID ADD35649 standard; DNA; 21 BP.	
XX	AC ADD35649;	
XX	DT 15-JAN-2004 (first entry)	
XX	DE Chicken glyceraldehyde 3-phosphate dehydrogenase (GAPDH) PCR primer #2.	

KM Chicken; glyceraldehyde 3-phosphate dehydrogenase; GAPDH; PCR; primer;
 KM ss; nucleated red blood cell.
 XX
 OS Gallus gallus.
 XX
 PN US6423488-B1.
 XX
 PD 23-JUL-2002.
 XX
 PF 13-JAN-2001; 2001US-00760048.
 XX
 PR 15-JAN-2000; 2000US-0176255P.
 XX
 PA (AVIG-) AVIGENICS INC.
 XX
 PI Harvey AJ;
 XX
 DR WPI; 2003-799767/75.
 XX
 PT Isolating nucleic acid such as red blood cells from avian samples, by
 PT adding to the sample in multi-well plates, lysis buffers which lyse
 PT plasma membrane and release nucleic acid and precipitating the nucleic
 PT acid.
 XX
 PS Example 3; SEQ ID NO 2; 18pp; English.
 XX
 CC The invention relates to a method for isolating a nucleic acid from
 CC nucleated red blood cells. The method comprises adding a biological
 CC sample containing the nucleated red blood cells to a first lysis buffer
 CC to lyse the plasma membranes, where the first lysis buffer is confined in
 CC a container that binds a precipitated nucleic acid, centrifuging the
 CC container, removing the supernatant from the pellet in the container,
 CC adding a second lysis buffer to the pellet in the container, after which
 CC the pellet is incubated in the second lysis buffer for two hours to
 CC release a nucleic acid, precipitating the nucleic acid in the container
 CC with a nucleic acid precipitating solution, washing and drying the
 CC nucleic acid in the container and dissolving the nucleic acid in the
 CC container in a solvent. The method is useful for isolating nucleic acids
 CC from a biological sample, preferably blood, in particular nucleated red
 CC blood cells obtained from a mammal, bird, reptile, fish or amphibian,
 CC especially from a bird. The method is useful for extracting DNA from
 CC avian blood for use in high throughput screening assays, e.g. in an assay
 CC to detect the insertion of foreign DNA in the genome of a recipient. The
 CC method facilitates genetic analysis of avians, fish, reptiles and
 CC amphibians and allows DNA to be extracted rapidly from multiple avian
 CC samples. This sequence represents a PCR primer used in the method of the
 CC invention.
 CC
 SQ Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
 XX
 XX
 Query Match 0.7%; Score 16; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1075 TCTCTGGCAAGTCCA 1090
 |||||||||
 DB 21 TCTCTGGCAAGTCCA 6
 RESULT 135
 AAQ31954
 ID AAQ31954 standard; DNA; 19 BP.
 XX
 AC AAQ31954;
 XX
 DT 25-MAR-2003 (revised)
 DT 27-APR-1993 (first entry)
 XX
 DE Oligonucleotide PG cong. binding region of plasmid CBE.
 KM P53; DNA-binding; cancer; neoplasia; tumour; concatemer; ss.
 XX
 OS Synthetic.

XX
 PN EP518650-A2.
 XX
 PD 16-DEC-1992.
 XX
 PF 10-JUN-1992; 92EP-00305333.
 XX
 PR 14-JUN-1991; 91US-00715182.
 PR 31-MAR-1992; 92US-00860758.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 PA (PEAR-) PHARMAGENICS INC.
 XX
 PI Vogelstein B, Kinzler KW, Sherman MI;
 XX
 DR WPI; 1992-417505/51.
 XX
 PT Detection and expression of wild type P53 protein - useful for diagnosing
 PT and treating cancers, and for screening potential chemotherapeutic
 PT agents.
 XX
 PS Example 12; Page 18; 51pp; English.
 XX
 CC Wild-type p53 protein binds specific fragments of human chromosomal DNA.
 CC To demonstrate that intact p53 can activate expression in human cells
 CC reporter plasmids were constructed. These comprised part of the
 CC polyomavirus early promoter and the CAT gene located downstream of DNA
 CC sequences which could bind p53 in vitro. The p53 binding sequences were
 CC obd. using a series of concatemers of PG, which contains the binding
 CC region of plasmid CBE, previously shown to bind p53 in vitro. The
 CC reporter and an expression vector coding for the intact human wild type
 CC protein p53 were transfected together into the human colorectal cancer
 CC cell line HCT 116. The intact p53 protein was indeed able to activate
 CC transcription. The level of trans-activation of the CAT gene depended on
 CC the strength of binding to p53 of the upstream sequences. Thus, the
 CC longer the number of PG repeats, the greater the binding to p53 in vitro
 CC and the higher the CAT expression in vivo. See also AAQ31948-84. (updated
 CC on 25-MAR-2003 to correct PN field.)
 CC
 SQ Sequence 19 BP; 1 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
 XX
 XX
 Query Match 0.7%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 318 CCTGCCGCGACTTGCTTG 336
 |||||||
 DB 1 CCTGCCGCGACTTGCTTG 19
 RESULT 136
 AAX58592
 ID AAX58592 standard; DNA; 19 BP.
 XX
 AC AAX58592;
 XX
 DT 16-AUG-1999 (first entry)
 XX
 DE Oligonucleotide PG used in p53 cell regulator protein EMSA.
 KM Cell regulatory protein; p53; mouse; cancer; tumour suppressor;
 KM cell cycle control; apoptosis; cell proliferation; therapy;
 KM cell differentiation; electrophoretic mobility shift assay; EMSA; ds.
 XX
 OS Synthetic.
 XX
 PN WO9919357-A2.
 XX
 PD 22-APR-1999.
 XX
 PF 02-OCT-1998; 98WO-US021992.
 XX
 PR 15-OCT-1997; 97US-0062076P.

PR 29-MAY-1998; 98US-0087216P.
 XX (HARD) HARVARD COLLEGE.
 PA Yang A, Mckeon F;
 XX WPI; 1999-277595/23.
 DR
 XX New isolated p63 cell regulatory protein for, e.g. treatment of tumors.
 PT
 XX Example 14; Page 114; 161pp; English.
 PS
 XX This double-stranded oligonucleotide, termed PG, was used in
 CC electrophoretic mobility shift assays designed to determine the location
 CC of the DNA binding portion of novel p63 cell regulator proteins of the
 CC invention. At least 6 different isoforms of p63 exist. These demonstrate
 CC divergent activities, such as transactivation of p53 reporter genes and
 CC induction of apoptosis. p63 is also implicated in haematopoiesis, muscle
 CC wasting (e.g. cachexia) and neuronal differentiation and related
 CC degenerative disorders. Human and murine p63 polypeptides (see AY05953-
 CC 64), polynucleotides (see AAX58572-83) and anti-p63 antibodies of the
 CC invention can be used to identify compounds useful for treating disorders
 CC involving such processes, in detection and diagnosis, and in the
 CC production of transgenic animals
 CC
 XX Sequence 19 BP; 1 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 318 CCTGCCGGGACTTGCCTTG 336
 Db 1 CCTGCTGACTGCTGCTGG 19
 AC83147
 ID AAC83147 standard; DNA; 19 BP.
 XX AAC83147;
 AC
 XX
 DT 01-MAR-2001 (first entry)
 DE PCR primer used for matrix metalloproteinase DNA amplification SEQ ID 4.
 XX
 XX Human; membrane-bound matrix metalloproteinase; progelatinase activation;
 KM atherosclerosis; Alzheimer's disease; emphysema; rheumatic arthritis;
 KM myodystrophy; osteoporosis; neurodegenerative disease; metastasis;
 KM cancer infiltration; PCR primer; ss.
 XX
 XX Synthetic.
 OS
 XX JP2000270874-A.
 PN
 XX 03-OCT-2000.
 PD
 XX 25-MAR-1999; 99JP-00082516.
 PF
 XX 25-MAR-1999; 99JP-00082516.
 PR
 XX (FUJY) FUJY PHARM IND CO LTD.
 PA
 XX WPI; 2001-011049/02.
 DR
 XX A new membrane-bound metalloproteinase for treating diseases such as
 PT atherosclerosis, Alzheimer's disease, emphysema and rheumatic arthritis.
 XX
 XX Example 1; Page 33; 57pp; Japanese.
 PS
 XX This invention relates to a human membrane-bound matrix metalloproteinase
 CC protein. The protein has progelatinase activating ability. The matrix
 CC metalloproteinase can be used for the treatment of various diseases such as

CC atherosclerosis, Alzheimer's disease, emphysema, rheumatic arthritis,
 CC myodystrophy, osteoporosis, neurodegenerative diseases and cancer
 CC infiltration and metastasis. The present sequence represents a PCR primer
 CC specific for DNA encoding human matrix metalloproteinase
 XX
 SQ Sequence 19 BP; 2 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
 Qy 1362 CACCCAGGCTGTGGAGTA 1380
 Db 1 CCCCAGGCTGTGGAGTA 19
 AC83147
 ID AAC83147 standard; DNA; 19 BP.
 XX AAC83147;
 AC
 XX
 DT 18-JUN-2002 (first entry)
 DE Matrix metalloproteinase 19 (MMP-19) associated primer #7.
 XX
 XX Transgenic animal; matrix metalloproteinase 19; MMP-19;
 KM extracellular matrix disorder; chondrogenic failure;
 KM osteogenic failure; osteoporosis; arthritis; synovitis; eye disease;
 KM malignant tumour; joint disease; bone disease; bone deformation;
 KM limb shortening; cranial deformation; defective bite; tooth elongation;
 KM primer; ss.
 XX
 XX Synthetic.
 OS
 XX WO200211530-A1.
 PN
 XX 14-FEB-2002.
 PD
 XX 08-AUG-2001; 2001WO-JP006826.
 PF
 XX 09-AUG-2000; 2000JP-00241748.
 PR
 XX (TAKE) TAKEDA CHEM IND LTD.
 PA
 XX Yoshimura K, Nishimura A, Nishida M, Hosono K;
 PI WPI; 2002-227106/28.
 DR
 XX Transgenic mammal containing foreign MMP-19 gene for use as a model for
 XX bone and cartilage diseases.
 XX
 XX Example 6; Page 21; 46pp; Japanese.
 PS
 XX The invention describes a non-human transgenic mammal containing a
 CC recombinant DNA encoding a foreign matrix metalloproteinase 19 (MMP-19)
 CC gene or its modified form. Identification of agents for the treatment and
 CC prevention of extracellular matrix disorders including chondrogenic
 CC failure, osteogenic failure, osteoporosis, arthritis deformans,
 CC rheumatoid arthritis, synovitis, metabolic arthritis, eye disease,
 CC malignant tumours, and associated complications. The transgenic mammals
 CC are a model for joint and bone diseases including deformation and
 CC shortening of limbs, cranial deformation, defective bite, tooth
 CC elongation, and defects of lumbar and tail vertebrae. This sequence
 CC represents a primer associated with the creation of the transgenic animal
 CC expressing the recombinant MMP-19 protein
 XX
 SQ Sequence 19 BP; 5 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
 Qy 0.7%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

PA (ISIS-) ISIS PHARM INC.
XX
PI Teng C, Hardee G;
XX
DR WPI, 1999-106077/09.
XX
PT Composition comprising nucleic acid and penetration enhancer - used
PT particularly for delivering therapeutic antisense oligonucleotides across
PT the gastrointestinal mucosa, provides high bioavailability.
XX
PS Example 2; Page 89; 115pp; English.
XX
CC A pharmaceutical composition has been developed which comprises a nucleic
CC acid and at least one penetration enhancer. The compositions are used:
CC (i) to treat or prevent any disease or disorder that can be treated with
CC the nucleic acid, e.g. cancer, Alzheimer's disease, beta-thalassemia,
CC malaria, viral infections (including human immune deficiency virus
CC (HIV)), inflammation, in human or animal medicine; (ii) to investigate
CC the role of a gene or gene product in non-human animals; and (iii) to
CC modulate gene expression in cells, tissues or organs. The compositions
CC provide bioavailability of at least 15, preferably 17-35,%. The
CC penetration enhancer improves: (i) transport of the nucleic acid across
CC the mucosa of the alimentary canal and into cells; and (ii) increases
CC stability of the nucleic acid. Oral administration avoids the
CC complications and expense of intravenous or other methods of
CC administration. AAX1869 to AAX1879 and AAX1801 represent antisense
CC oligonucleotides which can be used as the nucleic acid in the method of
CC the invention
XX
SQ Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1620 TGGCTGTGGAGAGACACA 1638
Db ||| ||||| ||||| |||||
19 TGGCTGTGGAGAGACACA 1

RESULT 142
AAX23704/c
ID AAX23704 standard; DNA; 20 BP.
XX
AC AAX23704;
XX
DT 18-JUN-1999 (first entry)
XX
DE Deletion sequence oligonucleotide 157.
XX
XX Deletion sequence oligonucleotide; sensor array; eukaryotic pathogen;
KM probe; cellular adhesion modulator; cellular proliferation modulator;
KM human retrovirus; human immunodeficiency virus; non-human retrovirus;
KM HIV; primer; ss.
XX
OS Synthetic.
XX
PN WO9911820-A1.
XX
PD 11-MAR-1999.
XX
XX 01-SEP-1998; 98WO-US018084.
PF
PR 02-SEP-1997; 97US-00923771.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Chen D, Sivatsa GS;
XX
DR WPI, 1999-205198/17.
XX
PT New compositions comprising sensor arrays made up of unique probe
PT oligonucleotides - useful for characterizing a sample of target deletion

PT oligonucleotides.
XX
PS Example 9; Page 158; 163pp; English.
XX
CC This invention describes a novel composition comprising a number of
CC sensor arrays, where each array comprises a unique probe oligonucleotide,
CC which is the reverse complement of part of a unique target
CC oligonucleotide present in a mixture of target deletion sequence
CC oligonucleotides. The compositions form a method for characterizing a
CC sample of target deletion oligonucleotides which are labelled and
CC hybridize with the probe oligonucleotides of the sensor arrays. Such
CC oligonucleotides and their targets are represented in AAX23548-X23709.
CC
CC Oligonucleotides characterized by the method form pharmaceutical
CC compositions that are useful for modulating cellular adhesion or
CC proliferation, and being active against a eukaryotic pathogen, a human
CC retrovirus, a human immunodeficiency virus (HIV), or a non-human
CC retrovirus, including influenza virus, Epstein-Barr virus, Respiratory
CC Syncytial Virus or cytomegalovirus (CMV). The compositions enable
CC characterization of deletion sequence oligonucleotides having related,
CC but different nucleobase sequences, and quantification of different
CC species of deletion sequence ("target") oligonucleotides in a mixture.
CC Also, if the specificity of the oligonucleotide's nucleobase sequence for
CC its reverse complement is not modified, the method may be performed using
CC oligodeoxynucleotides
XX
SQ Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1620 TGGCTGTGGAGAGACACA 1638
Db ||| ||||| ||||| |||||
19 TGGCTGTGGAGAGACACA 1

RESULT 143
AAC85332/c
ID AAC85332 standard; cDNA; 20 BP.
XX
AC AAC85332;
XX
DT 29-MAR-2001 (first entry)
XX
DE cDNA primer for PARP1A/PARP2B, p6.
XX
XX Human; poly(ADP-ribose) polymerase; hPARP2; oxidative stress; ARDS;
KM inflammation; ischemic stroke; hemorrhagic shock; myocardial ischemia;
KM infection; cerebral vasospasm; rheumatoid arthritis; osteoarthritis;
KM gouty arthritis; spondylitis; Behcet's disease; sepsis; septic shock;
KM endotoxic shock; gram negative sepsis; gram positive sepsis; trauma;
KM toxic shock syndrome; multiple organ injury syndrome; vasculitis;
KM hemorrhage; conjunctivitis; uveitis; thyroid-associated ophthalmopathy;
KM eosinophilic granuloma; asthma; chronic bronchitis; allergic rhinitis;
KM chronic obstructive pulmonary disease; silicosis; reperfusion injury;
KM pulmonary sarcoidosis; pleurisy; alveolitis; pneumonia; myocardium;
KM bronchiectasis; pulmonary oxygen toxicity; keloid formation; brain;
KM scar tissue formation; atherosclerosis; systemic lupus erythematosus;
KM autoimmune thyroiditis; multiple sclerosis; Reynaud's syndrome;
KM graft versus host disease; allograft rejection; cystic fibrosis;
KM chronic glomerulonephritis; inflammatory bowel disease; Crohn's disease;
KM ulcerative colitis; necrotizing enterocolitis; inflammatory dermatosis;
KM contact dermatitis; atopic dermatitis; psoriasis; urticaria; fever;
KM myalgia; meningitis; encephalitis; Sjogren's syndrome;
KM alcoholic hepatitis; bacterial pneumonia; hypovolemic shock;
KM Type 1 diabetes mellitus; hypersensitivity; leukocyte dyscrasia;
KM thermal injury; cytokine-induced toxicity; expressed sequence tag; EST;
KM RACE; PCR; amplification; primer; polymerase chain reaction; ss.
XX
OS Synthetic.
XX
PN WO200077179-A2.
XX

PD 21-DEC-2000.
 XX 16-JUN-2000; 2000WO-US016629.
 PF 16-JUN-1999; 99US-0139543P.
 XX (ICOS-) ICOS CORP.
 PA Christenson E, Demaggio AJ, Goldman PS, Mcelligott DL,
 XX WPI; 2001-025335/03.
 DR
 XX New human poly(ADP-ribose) polymerase for treating inflammatory,
 PT neurological, cardiovascular, or neoplastic tissue growth disorders, such
 PT as, arthritis, encephalitis, myocardial ischemia, and leukocyte
 PT metastasis.
 XX
 XX Example 3; Page 78; 129pp; English.
 XX
 CC The sequences given in AAC85321-40 and AAC85342-51 are primers which were
 CC used in the construction of baculovirus expression vectors for the
 CC expression of the fusion protein PAPR1A/PAPR2B. This protein contains
 CC amino acids 1-662 of hPAPR1 fused upstream of amino acids 230-583 of
 CC hPAPR2. The fusion protein coding sequence is given in AAC85341. The
 CC protein of the invention, hPAPR2, causes the covalent addition of
 CC polymers of ADP-ribose to protein targets. hPAPR2 activity is induced in
 CC many instances of oxidative stress or during inflammation where there is
 CC direct damage to the DNA. hPAPR2 may be used to identify antagonists
 CC which may be used to treat a human having a disorder mediated by PAPR2
 CC activity, such as, inflammatory, neurological, cardiovascular, or
 CC neoplastic tissue growth disorders. hPAPR2 and antibodies to it, can also
 CC be used to diagnose these conditions
 XX
 SQ Sequence 20 BP; 0 A; 5 C; 7 G; 8 T; 0 U; 0 Other;
 Query Match 0.7%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1193 AGACACTCAACCGAAGGA 1211
 DB 19 AGACACCCCAACCGAAGGA 1
 AC AAC85331;
 XX
 XX 29-MAR-2001 (first entry)
 DT
 XX
 DE cDNA primer for PAPR1A/PAPR2B. P5.
 XX
 XX Human, poly(ADP-ribose) polymerase; hPAPR2; oxidative stress; ARDS;
 KM inflammation; ischemic stroke; hemorrhagic shock; myocardial ischemia;
 KM infarction; cerebral vasospasm; rheumatoid arthritis; osteoarthritis;
 KM gouty arthritis; spondylitis; Behcet's disease; sepsis; septic shock;
 KM endotoxic shock; gram negative sepsis; gram positive sepsis; trauma;
 KM toxic shock syndrome; multiple organ injury syndrome; vasculitis;
 KM hemorrhage; conjunctivitis; uveitis; thyroid-associated ophthalmopathy;
 KM eosinophilic granuloma; asthma; chronic bronchitis; allergic rhinitis;
 KM chronic obstructive pulmonary disease; silicosis; reperfusion injury;
 KM pulmonary sarcoidosis; pleurisy; alveolitis; pneumonia; myocardium;
 KM bronchiectasis; pulmonary oxygen toxicity; keloid formation; brain;
 KM scar tissue formation; atherosclerosis; systemic lupus erythematosus;
 KM autoimmune thyroiditis; multiple sclerosis; Raynaud's syndrome;
 KM graft versus host disease; allograft rejection; cystic fibrosis;
 KM chronic glomerulonephritis; inflammatory bowel disease; Crohn's disease;
 KM ulcerative colitis; necrotizing enterocolitis; inflammatory dermatosis;
 KM contact dermatitis; atopic dermatitis; psoriasis; urticaria; fever;
 KM myalgia; meningitis; encephalitis; Sjogren's syndrome;
 KM alcoholic hepatitis; bacterial pneumonia; hypovolemic shock;

KM Type 1 diabetes mellitus; hypersensitivity; leukocyte dyscrasia;
 KM thermal injury; cytokine-induced toxicity; expressed sequence tag; EST;
 KM RACE; PCR; amplify; primer; polymerase chain reaction; ss.
 XX
 XX Synthetic.
 OS
 XX WO200077179-A2.
 PN
 XX 21-DEC-2000.
 PD
 XX 16-JUN-2000; 2000WO-US016629.
 PF 16-JUN-1999; 99US-0139543P.
 XX (ICOS-) ICOS CORP.
 PA Christenson E, Demaggio AJ, Goldman PS, Mcelligott DL,
 XX WPI; 2001-025335/03.
 DR
 XX New human poly(ADP-ribose) polymerase for treating inflammatory,
 PT neurological, cardiovascular, or neoplastic tissue growth disorders, such
 PT as, arthritis, encephalitis, myocardial ischemia, and leukocyte
 PT metastasis.
 XX
 XX Example 3; Page 78; 129pp; English.
 XX
 CC The sequences given in AAC85321-40 and AAC85342-51 are primers which were
 CC used in the construction of baculovirus expression vectors for the
 CC expression of the fusion protein PAPR1A/PAPR2B. This protein contains
 CC amino acids 1-662 of hPAPR1 fused upstream of amino acids 230-583 of
 CC hPAPR2. The fusion protein coding sequence is given in AAC85341. The
 CC protein of the invention, hPAPR2, causes the covalent addition of
 CC polymers of ADP-ribose to protein targets. hPAPR2 activity is induced in
 CC many instances of oxidative stress or during inflammation where there is
 CC direct damage to the DNA. hPAPR2 may be used to identify antagonists
 CC which may be used to treat a human having a disorder mediated by PAPR2
 CC activity, such as, inflammatory, neurological, cardiovascular, or
 CC neoplastic tissue growth disorders. hPAPR2 and antibodies to it, can also
 CC be used to diagnose these conditions
 XX
 SQ Sequence 20 BP; 8 A; 7 C; 5 G; 0 T; 0 U; 0 Other;
 Query Match 0.7%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1193 AGACACTCAACCGAAGGA 1211
 DB 2 AGACACCCCAACCGAAGGA 20
 AC AAF63984;
 XX
 XX 05-APR-2001 (first entry)
 DT
 XX Human tankyrase2 expression plasmid PCR primer SEQ ID NO: 171.
 DE
 KM Human, tankyrase2; TANK2; TRF1; telomere; cancer; neoplasia; aging;
 KM inflammatory disorder; PCR primer; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200100849-A1.
 PN
 XX 04-JAN-2001.
 PD 28-JUN-2000; 2000WO-US017827.
 PF
 XX

```

PR 29-JUN-1999; 99US-0141582P.
XX
XX (ICOS-) ICOS CORP.
XX
PI Christenson E, Demaggio AJ, Goldman PS, Mcelligott DL;
XX WPI; 2001-102896/11.
XX
XX New tankyrase2 polypeptides, useful for treating conditions mediated by
PT poly(denoposine diphosphate-ribose) polymerase activity e.g. cancers,
PT inflammatory and autoimmune disorders.
XX
XX Example 7; Page 231; 242pp; English.
XX
XX The present invention provides the protein and coding sequence for the
CC human tankyrase2 protein. This is found in two different versions,
CC designated TANK2-LONG and TANK2-SHORT. Tankyrase2 has polyADP-
CC ribosylation activity and is involved in the modification of TRF1, which
CC is a telomere-specific binding protein. The regulation of telomere
CC length, in which TRF1 has a role, is linked to ageing and cancer. The
CC sequences are useful in the treatment of cancers and inflammatory
CC disorders
XX
SQ Sequence 20 BP; 8 A; 7 C; 5 G; 0 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1193 AGACACTCAACCGAGAAGA 1211
Db 2 AGACACCCCAACCGAGAAGA 20
RESULT 146
AAF63985/c
ID AAF63985 standard; DNA; 20 BP.
XX
XX AAF63985;
XX
DT 05-APR-2001 (first entry)
XX
XX Human tankyrase2 expression plasmid PCR primer SEQ ID NO. 172.
DE
XX Human; tankyrase2; TANK2; TRF1; telomere; cancer; neoplasm; aging;
KM inflammatory disorder; PCR primer; ss.
XX
XX Homo sapiens.
OS
XX WO200100849-A1.
XX
XX 04-JAN-2001.
XX
XX 28-JUN-2000; 2000WO-US017827.
XX
XX 29-JUN-1999; 99US-0141582P.
XX
XX (ICOS-) ICOS CORP.
XX
PI Christenson E, Demaggio AJ, Goldman PS, Mcelligott DL;
XX WPI; 2001-102896/11.
XX
XX New tankyrase2 polypeptides, useful for treating conditions mediated by
PT poly(denoposine diphosphate-ribose) polymerase activity e.g. cancers,
PT inflammatory and autoimmune disorders.
XX
XX Example 7; Page 231; 242pp; English.
XX
XX The present invention provides the protein and coding sequence for the
CC human tankyrase2 protein. This is found in two different versions,
CC designated TANK2-LONG and TANK2-SHORT. Tankyrase2 has polyADP-
CC ribosylation activity and is involved in the modification of TRF1, which

```

```

CC is a telomere-specific binding protein. The regulation of telomere
CC length, in which TRF1 has a role, is linked to ageing and cancer. The
CC sequences are useful in the treatment of cancers and inflammatory
CC disorders
XX
SQ Sequence 20 BP; 0 A; 5 C; 7 G; 8 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1193 AGACACTCAACCGAGAAGA 1211
Db 19 AGACACCCCAACCGAGAAGA 1
RESULT 147
AAL40440/c
ID AAL40440 standard; DNA; 20 BP.
XX
XX AAL40440;
XX
DT 19-SEP-2002 (first entry)
XX
XX Mouse caspase 6 antisense inhibition related oligo SEQ ID No 159.
DE
XX Muscular; cytosstatic; nootropic; neuroprotective; ophthalmological;
XX anti-lipemic; osteopathic; caspase 6; Rieger's syndrome; bone metabolism;
XX ataxia telangiectasia; hyperproliferative disorder; cholesterol disorder;
KM haematopoietic disorder; cancer; neurological; Alzheimer's disease;
KM apoptotic; mouse; murine; ds.
XX
XX Mus musculus.
OS
XX WO200229066-A1.
XX
XX 11-APR-2002.
XX
XX 03-OCT-2001; 2001WO-US030871.
XX
XX 04-OCT-2000; 2000US-00679299.
XX
XX (ISIS-) ISIS PHARM INC.
XX
PI Brown-Driver VL, Zhang H, Watt AT;
XX WPI; 2002-471315/50.
XX
XX An antisense oligonucleotide of 8 to 50 nucleotides in length that
PT inhibits caspase 6, is useful for treating Rieger's syndrome.
XX
XX Claim 3; Page 93; 141pp; English.
XX
XX The invention relates to an antisense oligonucleotide compound of 8 to 50
CC nucleotides in length that is targeted to a nucleic acid molecule
CC encoding caspase 6, where the oligonucleotide specifically hybridises
CC with and inhibits the expression of caspase 6. The oligonucleotide of the
CC invention specifically hybridises to and inhibits expression of caspase 6
CC in cells or tissues. The oligonucleotides can be administered
CC therapeutically or prophylactically to treat an animal having a disease
CC or condition associated with caspase 6, such as Rieger's syndrome or
CC ataxia telangiectasia, hyperproliferative disorder, a haematopoietic
CC disorder, a bone metabolism or cholesterol disorder, various types of
CC cancer, neurological conditions such as Alzheimer's disease and other de-
CC regulated apoptotic pathological conditions. This polynucleotide sequence
CC represents a mouse caspase 6 oligonucleotide relating to the invention.
CC NOTE: This phosphorothioate oligonucleotide sequence has 2'-MOB wings and
CC a deoxy gap
XX
SQ Sequence 20 BP; 2 A; 7 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;

```

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1885 CCTCAGGCGCTATGACAG 1903
 |||||
 Db 20 CCTCAGGCGCTATGACACCG 2

RESULT 148
 ABK69425/c
 ID ABK69425 standard; DNA, 20 BP.
 XX
 AC ABK69425;
 XX
 DT 15-JUL-2002 (first entry)
 XX
 DE Human phosphorylase kinase alpha-1 antisense oligonucleotide #9.
 XX
 KW Human; rat; antisense; phosphorylase kinase alpha 1; ss;
 KM antiinflammatory; cytostatic; antimicrobial; antidiabetic;
 KM metabolic disorder; diabetes; infection; inflammation; tumour; probe.
 XX
 OS Homo sapiens.
 OS Mus sp.
 OS Synthetic.
 OS Chimeric.
 XX

Key Location/Qualifiers
 modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER = phosphorothioate backbone, all cytidine
 residues are 5-methyl cytidine"
 modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER = 2'-O-methoxyethyl"
 modified_base 5..15
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER = 2' deoxynucleotide"
 modified_base 15..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER = 2'-O-methoxyethyl"
 XX
 EN WO200220546-A1.
 XX
 PD 14-MAR-2002.
 XX
 PF 24-AUG-2001; 2001WC-US026608.
 XX
 PR 07-SEP-2000; 2000US-00657452.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Monica BP, Wyatt JR;
 XX
 DR WPI; 2002-351759/38.
 XX
 PT New antisense compound which is targeted to nucleic acid encoding
 PT phosphorylase kinase alpha 1 and inhibits expression of kinase protein,
 PT useful for treating a condition associated with kinase, e.g. diabetes.
 XX
 PS Claim 3; Page 85; 140pp; English.
 XX
 XX This invention relates to a novel antisense nucleic acid compound
 CC targeted to a nucleic acid molecule encoding phosphorylase kinase alpha-1
 CC which specifically hybridises with and inhibits expression of
 CC phosphorylase kinase alpha-1. The compound of the invention is useful for
 CC inhibiting the expression of phosphorylase kinase alpha-1 in cells or
 CC tissues, and for treating an animal having a disease condition associated
 CC with phosphorylase kinase alpha-1, e.g. a metabolic disorder such as
 CC diabetes. The compounds are also useful prophylactically, e.g. to prevent

CC or delay infection, inflammation or tumour formation. The antisense
 CC compounds are also useful as therapeutic, diagnostic and research
 CC reagent, for distinguishing functions of various members of a biological
 CC pathway, and in antisense gene therapy. The present sequence represents
 CC an antisense oligonucleotide probe used to create the phosphorylase
 CC kinase alpha-1 inhibiting compound of the invention
 XX

SO Sequence 20 BP; 4 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1676 GGGGACAGCTGCTTGA 1694
 |||||
 Db 19 GGGGACAGCTGCTTGA 1

RESULT 149
 ABS70040
 ID ABS70040 standard; DNA, 21 BP.
 XX
 AC ABS70040;
 XX
 DT 22-NOV-2002 (first entry)
 XX
 DE Mycobacterium marinum capture probe #1.
 XX
 KW Mycobacterium differentiation; Mycobacterium detection; us-p34;
 KM Mycobacterium species-specific; upstream p34 gene region; biochip;
 KM micro-array; Mycobacterium avium-complex; MAC-complex; TUB; MOTT;
 KM Mycobacterium tuberculosis-complex; mycobacterial species;
 KM non-tuberculous mycobacteria; NTM; probe; ss.
 XX
 OS Mycobacterium marinum.
 OS
 PN EP1233076-A2.
 XX
 PD 21-AUG-2002.
 XX
 PF 15-FEB-2002; 2002EP-00447026.
 XX
 PR 19-FEB-2001; 2001EP-00870030.
 PR 21-FEB-2001; 2001US-0269848P.
 PR 23-MAY-2001; 2001US-0292509P.
 XX
 PA (UYLO-) UNIV CATHOLIQUE LOUVAIN.
 XX
 PI Gala J, Vannuffel P;
 XX
 DR WPI; 2002-637887/69.
 XX
 PT Detecting/differentially detecting Mycobacterium strain in sample, by
 PT reacting non-tuberculosis Mycobacterium species-specific upstream p34
 PT gene region probe with sample and detecting duplexes having the probe.
 XX
 PS Claim 17; Page 22; 92pp; English.
 XX
 XX The present invention relates to methods for differentiating and
 CC detecting between Mycobacterium strains in a sample based on species-
 CC specific upstream p34 gene region (us-p34) sequences. Also provided are
 CC new us-p34 sequences, primers and probes. The invention also relates to
 CC methods for detecting and differentiating between Pseudomonas strains. A
 CC Mycobacterium species-specific us-p34 nucleotide probe or primer is
 CC useful for producing a biochip or a micro-array for detecting M. avium-
 CC complex (MAC-complex) Mycobacterium species in a sample, and detecting
 CC Mycobacterium other than M. tuberculosis-complex (TUB) (MOTT)
 CC Mycobacterium in a sample. A Mycobacterium us-p34 nucleotide primer is
 CC useful for detecting new us-p34 sequences in a sample. The method of the
 CC invention identifies in a single assay, a wide range of mycobacterial
 CC species that include members of the TUB and non-tuberculous mycobacteria
 CC (NTM). ABS70027-ABS70068 represent capture probes for Mycobacterium
 CC strains

```

XX      Sequence 21 BP; 2 A; 4 C; 11 G; 4 T; 0 U; 0 Other;
SQ
Query Match
  Best Local Similarity 89.5%; Score 15.8; DB 1; Length 21;
  Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      1594 GAGGTGACGGCGCTGTCG 1612
      |||||
      3 GAGGTGATGGCGCTGTCG 21

RESULT 150
ABA81857
ID      ABA81857 standard; DNA; 21 BP.
XX
XX      ABA81857;
AC
XX      25-JAN-2002 (first entry)
DT
XX      M marinum P34 gene capture oligonucleotide.
DE
XX      Microorganism detection; capture oligonucleotide; probe; cancer; biochip;
KM      polymorphism detection; genetic disease diagnosis; microarray; ss.
XX
OS      Mycobacterium marinum.
XX      WO20017372-A2.
XX      18-OCT-2001.
PD
XX      26-MAR-2001; 2001WO-BE000053.
PF
XX      24-MAR-2000; 2000EP-00870055.
PR      15-SEP-2000; 2000EP-00870204.
XX
XX      (UTNO-) UNIV NOTRE-DAME DE LA PAIX.
PA
XX      Remacle J, Hamels S, Zammateo N, Lockman L, Dufour S;
PI      Alexandre I, De Longueville F;
XX
XX      WPI; 2002-010921/01.
DR
XX      Identifying or quantifying organisms or genes, useful e.g. for diagnosis,
PT      by detecting specific nucleotide sequences present among several
XX      homologous sequences.
PS      Example 8; Page 33; 56pp; English.
XX
XX      The present invention provides a method of identifying or quantitating a
CC      microorganism in a sample by detecting its nucleotide sequence from
CC      amongst homologous sequences. The method can be used to detect
CC      microorganisms and polymorphisms, and to diagnosis genetic diseases
CC      including cancer. The present sequence is a capture oligonucleotide used
CC      in the exemplification of the invention
XX
XX      Sequence 21 BP; 2 A; 4 C; 11 G; 4 T; 0 U; 0 Other;
SQ
Query Match
  Best Local Similarity 89.5%; Score 15.8; DB 1; Length 21;
  Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      1594 GAGGTGACGGCGCTGTCG 1612
      |||||
      3 GAGGTGATGGCGCTGTCG 21

RESULT 151
ABX10097
ID      ABX10097 standard; DNA; 21 BP.
XX
XX      ABX10097;
AC
XX

```

```

DT      23-JAN-2003 (first entry)
XX
XX      M. marinum upstream p34 gene oligonucleotide probe.
DE
XX      Mycobacterial disease; tuberculosis; leprosy; AIDS; us-p34;
XX      acquired immunodeficiency syndrome; upstream p34 gene; NTM;
XX      systemic bacterial opportunistic infection; ss; probe;
XX      non-tuberculosis Mycobacterium strain.
XX
XX      Mycobacterium marinum.
XX      Jp2002238563-A.
XX
XX      27-AUG-2002.
PD
XX      31-JAN-2001; 2001JP-00024023.
PF
XX      31-JAN-2001; 2001JP-00024023.
PR
XX      (UYLO-) UNIV CATHOLIQUE LOUVAIN.
PA
XX
XX      WPI; 2003-003950/01.
DR
XX
XX      Identification of nucleotide sequences specific for mycobacteria and
PT      development of differential diagnosis strategies for mycobacteria
XX      species.
XX      Claim 17; Page 12; 65pp; Japanese.
PS
XX
XX      The invention relates to detection of non-tuberculosis Mycobacterium
CC      (NTM) strains in a sample comprising: i) providing a NTM species-specific
CC      upstream p-34 gene region (us-p34) nucleotide probe, (ii) reacting said
CC      us-p34 nucleotide probe with said sample under conditions that allow for
CC      the selective formation of nucleotide duplexes between said us-p34
CC      nucleotide probe and a corresponding NTM nucleic acid target present in
CC      said sample, and (iii) detecting any nucleotide duplexes containing said
CC      us-p34 nucleotide probe. Also included is a NTM species-specific us-p34
CC      nucleotide probe or primer comprising at least 8 continuous nucleotides
CC      from one of the nucleotide sequences shown in Fig. 3 or its complement or
CC      the corresponding sequences wherein T has been replaced by U. The method
CC      is used for the detection of NTM strains in a sample. NTM strains are
CC      responsible for mycobacterial disease e.g. systemic bacterial
CC      opportunistic infection (particularly in individuals with AIDS, acquired
CC      immunodeficiency syndrome), whereas pathogenic strains are responsible
CC      for leprosy and tuberculosis. The present sequence is a strain specific
CC      oligonucleotide probe used to detect us-p34 sequences from different
CC      Mycobacterium strains
XX
XX      Sequence 21 BP; 2 A; 4 C; 11 G; 4 T; 0 U; 0 Other;
SQ
Query Match
  Best Local Similarity 89.5%; Score 15.8; DB 1; Length 21;
  Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      1594 GAGGTGACGGCGCTGTCG 1612
      |||||
      3 GAGGTGATGGCGCTGTCG 21

RESULT 152
ABN00900/c
ID      ABN00900 standard; DNA; 17 BP.
XX
XX      ABN00900;
AC
XX
XX      29-MAY-2002 (first entry)
DT
XX
XX      Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:892.
DE
XX      Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX      muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX      skeletal muscle disorder; amplicon; screening; ss.
XX

```

OS Homo sapiens.
XX
XX MO200192524-A2.
PN
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PT Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMMP-1.
XX
XX Disclosure; SEQ ID NO 892; 214pp; English.

CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMMP-1). The protein and polynucleotide sequences of hGDMMP-
CC 1 can be used in gene therapy and vaccine production. The hGDMMP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMMP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMMP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMMP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMMP-
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMMP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMMP-1-
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMMP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMMP-1, in particular heart
CC and skeletal muscle disorders. hGDMMP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMMP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pot_sequence

SO Sequence 17 BP; 4 A; 1 C; 9 G; 3 T; 0 U; 0 Other;

QY Query Match 0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0

DB 17 AGCCCCCTTCCCACATAT 1716
|||||
|||||

RESULT 153
ABN00899/C
ID ABN00899 standard; DNA; 17 BP.

XX	AC	AEN00899;
XX	DT	29-MAY-2002 (first entry)
XX	DE	Human GDMLP-1 17-mex scanning SEQ ID NO:4 sequence SEQ ID NO:891.
KW	KW	Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart; muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease; skeletal muscle disorder; amplicon; screening; ss.
XX	OS	Homo sapiens.
XX	PN	WO200192524-A2.
XX	PD	06-DEC-2001.
XX	PF	25-MAY-2001; 2001WO-US016981.
XX	PR	26-MAY-2000; 2000US-0207456P.
XX	PR	21-SEP-2000; 2000US-0234687P.
XX	PR	27-SEP-2000; 2000US-0236359P.
XX	PR	04-OCT-2000; 2000GB-00024263.
XX	PR	30-JAN-2001; 2001WO-US000661.
XX	PR	30-JAN-2001; 2001WO-US000662.
XX	PR	30-JAN-2001; 2001WO-US000663.
XX	PR	30-JAN-2001; 2001WO-US000664.
XX	PR	30-JAN-2001; 2001WO-US000665.
XX	PR	30-JAN-2001; 2001WO-US000666.
XX	PR	30-JAN-2001; 2001WO-US000667.
XX	PR	30-JAN-2001; 2001WO-US000668.
XX	PR	30-JAN-2001; 2001WO-US000669.
XX	PR	30-JAN-2001; 2001WO-US000670.
XX	PR	05-FEB-2001; 2001US-0266860P.
PA	(AEOB-) AEOMICA INC.	
XX	PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME,
XX	DR	WPI; 2002-179446/23.
PT	PT	New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins, or as specific biomolecule capture probes for surface-enhanced laser desorption ionization, comprises human myosin-like protein hGDMLP-1.
PS	PS	Disclosure; SEQ ID NO 891; 214pp; English.
XX	CC	The present invention describes a human genome-derived myosin-like protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP- 1 can be used in gene therapy and vaccine production. The hGDMLP-1 nucleic acids can be used as probes to detect, characterise and quantify hGDMLP-1 nucleic acids in samples, as amplification substrates, to provide initial substrates for the recombinant engineering of hGDMLP-1 protein variants having desired phenotypic improvements, and for expressing the proteins. The hGDMLP-1 proteins or polypeptides may be used as immunogens to raise antibodies that specifically recognise hGDMLP- 1 proteins, as standards in assays used to determine the concentration and/or amount specifically of hGDMLP proteins, as specific biomolecule capture probes for surface-enhanced laser desorption ionisation, as therapeutic supplement in patients having specific deficiency in hGDMLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a disorder associated with the expression of hGDMLP-1, in particular heart and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMLP-1 sequence in the exemplification of the present invention. N.B. The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequence
XX	SEQ	Sequence 17 BP; 4 A; 2 C; 9 G; 2 T; 0 U; 0 Other;
Query Match	0.7%; Score 15.4; DB 1; Length 17;	

Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1701 GCCCCTTCCCATATG 1717
|||
17 GCCCCTTCCCATATG 1

Db

RESULT 154
ABN00901/c
ID ABN00901 standard; DNA; 17 BP.
XX
AC ABN00901;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:893.
XX
KM Human, genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN W0200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-026860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 893; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present invention represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at fcp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 1 C; 9 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1699 AAGCCCTTCCCATAT 1715
|||
17 AAGCCCTTCCCATAT 1

Db

RESULT 155
ACC64870
ID ACC64870 standard; DNA; 17 BP.
XX
AC ACC64870;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 2117.
XX
KM Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KM tumour suppression; tumour reversion; apoptosis; virus resistance;
KM viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KM schizophrenia; ss.
XX
OS Mus musculus.
XX
PN W02003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 278; 738pp; French.
XX
XX The present invention relates to murine oligonucleotides (ACC62754-
XX ACC68806), which are associated with tumour suppression, tumour
XX reversion, apoptosis and virus resistance. The oligonucleotides are
XX useful as (1) as probes and primers for detecting, identifying,
XX quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX recombinant polypeptides. The oligonucleotides are useful for preparation
XX of pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 1 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 996 GATCACCCTGCTCTGC 1012
 |||||
 DB 1 GATCTCCCTGCTCTGC 17

RESULT 156
 ID AAX62734
 AAX62734 standard; RNA; 18 BP.

XX AAX62734;

XX 16-JUL-1999 (first entry)

XX Granule bound starch synthase hairpin substrate SEQ ID NO:609.

XX Matze; corn; Zea mays; delta-9 desaturase; GBSS; target; substrate;
 KW granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;
 KW modulation; gene expression; transgenic plant; cleavage; canola plant;
 KW caffeine synthesis; coffee plant; nicotine production; tobacco;
 KW fruit ripening; flower pigmentation; lignin production; ss.

XX Zea mays.

XX MO9710328-A2.

XX 20-MAR-1997.

XX PF 12-JUL-1996; 96WO-US011689.

XX PR 13-JUL-1995; 95US-0001135P.

XX PA (RIBO-) RIBOZYME PHARM INC.
 (DOMC) DOWELANCO.

XX PI Zwick MG, Edington BE, Mcswigen JA, Merlo PAO, Guo L, Skokut TA;
 PI Young SA, Folkerts O, Merlo DJ;

XX WPI; 1997-202224/18.

PT Ribozyme which modulates plant gene expression - preferably modulates
 PT expression of DELTA-9 desaturase or granule bound starch synthase in
 PT maize or canola.

PS Claim 42; Page 84; 155pp; English.

XX The present invention describes an enzymatic nucleic acid molecule (I)
 CC with RNA cleaving activity, which modulates the expression of a plant
 CC gene. Also described is a gene comprising a cDNA sequence encoding maize
 CC delta-9 desaturase. (I) can be used to modulate expression of a gene,
 CC preferably delta-9 desaturase or a granule bound starch synthase (GBSS)
 CC gene, in a plant (preferably a maize or canola plant). (I) can be used to
 CC modulate caffeine synthesis in a coffee plant, nicotine production in a
 CC tobacco plant, fruit ripening processes in an apple, tomato, pear, plum
 CC or peach plant, flower pigmentation in a rose, petunia, chrysanthemum or
 CC marigold plant or lignin production in a tobacco, aspen, poplar or pine
 CC plant

XX Sequence 18 BP; 4 A; 6 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 0.7%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 82.4%; Pred. No. 1.2e+02;
 Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2178 CCAGCAGCTCATGGAGA 2194
 |||||
 DB 2 CCCGACGACUAGGAGA 18

RESULT 157

ID AA289104
 AA289104 standard; DNA; 18 BP.
 XX AA289104;

XX 01-JUN-2000 (first entry)
 DT
 XX
 DE p53 binding PG-motif consensus DNA.

XX p53; recombinase; promoter; transcription factor; suicide gene;
 KW tumor cell; treatment; ss.

XX Unidentified.

XX DE19834430-A1.

XX 03-FEB-2000.

XX 30-JUL-1998; 98DE-01034430.

XX 30-JUL-1998; 98DE-01034430.

XX (VWEL/) VON MELCHNER H.
 PA (HOEL/) HOELZER D.

PI Von Melchner H, Ebensperger C, Andreu T;

XX WPI; 2000-225128/20.

PT New self-deleting vector, for treatment of tumors, contains a suicide
 PT gene deleted from normal cells but retained in tumor cells that lack
 PT functional transcription factor.

XX Disclosure; Page 4; 16pp; German.

XX This invention describes a novel recombinant vector (A) which comprises
 CC (1) a first transcription cassette containing a recombinase-encoding
 CC sequence (I), a minimal promoter (MP) that requires a transcription
 CC factor (TF) for activation, a TF-binding site and optionally a
 CC polyadenylation sequence; (2) a second transcription cassette containing
 CC suicide gene (SG), linked to promoter (P) and optionally a
 CC polyadenylation sequence; and (3) 5' and/or 3'-flanking sequences that
 CC contain a target sequence for recombinase. Normal cells express
 CC functional TF, so activate MP, resulting in expression of recombinase and
 CC deletion of the suicide gene cassette. Tumor cells that are defective in
 CC functional TF can not do this, so the suicide gene cassette is retained
 CC and the tumor cell is killed. (A) are used for the treatment of tumors.
 CC (A) provide targeted and selective killing of tumor cells. This sequence
 CC represents a PG DNA motif found in p53 binding consensus sequences, and
 CC which is used in the construction of the vector described in the method
 CC of the invention

XX Sequence 18 BP; 1 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 1.2e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 318 CCGGCGGAGCTTGCT 334
 |||||
 DB 1 CCGGCGGAGCTTGCT 17

RESULT 158
 ID AA84556/C
 AA84556 standard; DNA; 19 BP.

XX AAA84556;

XX 04-DEC-2000 (first entry)

XX Cyclin B ribozyme binding site #89.

XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; reestenosis; ss.
 KW Mammalia.

PN WO200032765-A2.
XX
XX 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JW;
XX
XX WPI; 2000-412314/35.
XX
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
XX Disclosure; Page 78; 109pp; English.
XX
XX The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AA82415 to AA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 19 BP; 4 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1179 GCTGCAAGAAATAAGA 1195
DB 17 GCTGCAATTAATAAGA 1

RESULT 159
AA84554/C
ID AA84554 standard; DNA; 19 BP.
XX
XX AA84554;
AC
XX
DT 04-DEC-2000 (first entry)
XX
DE Cyclin E ribozyme binding site #87.
XX
KM Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JW;
XX
XX WPI; 2000-412314/35.
XX
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
XX Disclosure; Page 78; 109pp; English.

XX
XX The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AA82415 to AA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 19 BP; 4 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1179 GCTGCAAGAAATAAGA 1195
DB 19 GCTGCAATTAATAAGA 3

RESULT 160
AA84555/C
ID AA84555 standard; DNA; 19 BP.
XX
XX AA84555;
AC
XX
DT 04-DEC-2000 (first entry)
XX
DE Cyclin E ribozyme binding site #88.
XX
KM Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JW;
XX
XX WPI; 2000-412314/35.
XX
DE New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
PS Disclosure; Page 78; 109pp; English.
XX
XX The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AA82415 to AA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 19 BP; 4 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1179 GCTGCAAGAAATAAGA 1195
DB 18 GCTGCAATTAATAAGA 2

RESULT 161
AAH59718/c
ID AAH59718 standard; DNA; 19 BP.
XX
AC AAH59718;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cyclic E ribozyme binding site SEQ ID NO:2142.
XX
XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
XX recognition site; target; ribozyme binding site; eye disease; vulnery;
XX proliferative disease; skin disease; psoriasis; diabetic retinopathy;
XX cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
XX matrix metalloproteinase; growth factor; reductase; scarring; cytosolic;
XX antiproliferative; dermatological; anti-seborrheic; antidiabetic; virucide;
XX antisticking; ophthalmological; keratolytic; gene therapy; viral wart;
XX acopic dermatitis; actinic keratosis; squamous cell carcinoma;
XX basal cell carcinoma; seboreic wart; vitreoretinopathy; scar;
XX sickle cell retinopathy; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO200130362-A2.
XX
XX 03-MAY-2001.
XX
XX 26-OCT-2000; 2000WO-US029500.
XX
XX 26-OCT-1999; 99US-0161532P.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Robbins JM, Tritz R;
XX
XX WPI; 2001-300427/31.
XX
XX Treating proliferative skin or eye diseases and scarring, using ribozymes
XX that cleave RNA encoding cytokines involved in inflammation, matrix
XX metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX Example 1; Page 227; 408pp; English.
XX
XX The present invention describes a method for treating a proliferative
XX skin or eye disease and scarring. The method involves administering a
XX ribozyme (I) which cleaves RNA encoding a cytokine involved in
XX inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
XX dependent kinase, growth factor or a reductase, or administering a
XX nucleic acid molecule (II) comprising a promoter operably linked to a
XX nucleic acid segment encoding (I). (I) can have antipsoriatic,
XX dermatological, cytosolic, anti-seborrheic, antidiabetic, antisticking,
XX ophthalmological, vulnery, keratolytic and virucide activities, and
XX cleaves RNA encoding cytokine involved in inflammation. (I) can be used
XX in gene therapy. (I) and (II) are useful for treating proliferative skin
XX diseases such as psoriasis, acopic dermatitis, actinic keratosis,
XX squamous or basal cell carcinoma and viral or seboreic wart. They can
XX also be used for treating proliferative eye diseases such as diabetic
XX retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
XX prematurity and retinal detachment, and for treating and preventing
XX bearing such as keloid, adhesion and hypertrophic or hypertrophic burn
XX scar. AAH57577 to AAH62099 represent sequences used in the
XX exemplification of the present invention
XX
XX Sequence 19 BP; 4 A; 4 C; 2 G; 9 T; 0 U; 0 Other;
SQ

Query Match 0.7%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1179 GCTGCAAGAAATAAGA 1195

Db 17 GCTGCAAGAAATAAGA 1
|||||
RESULT 162
AAH59716/c
ID AAH59716 standard; DNA; 19 BP.
XX
AC AAH59716;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cyclic E ribozyme binding site SEQ ID NO:2140.
XX
XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
XX recognition site; target; ribozyme binding site; eye disease; vulnery;
XX proliferative disease; skin disease; psoriasis; diabetic retinopathy;
XX cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
XX matrix metalloproteinase; growth factor; reductase; scarring; cytosolic;
XX antiproliferative; dermatological; anti-seborrheic; antidiabetic; virucide;
XX antisticking; ophthalmological; keratolytic; gene therapy; viral wart;
XX acopic dermatitis; actinic keratosis; squamous cell carcinoma;
XX basal cell carcinoma; seboreic wart; vitreoretinopathy; scar;
XX sickle cell retinopathy; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO200130362-A2.
XX
XX 03-MAY-2001.
XX
XX 26-OCT-2000; 2000WO-US029500.
XX
XX 26-OCT-1999; 99US-0161532P.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Robbins JM, Tritz R;
XX
XX WPI; 2001-300427/31.
XX
XX Treating proliferative skin or eye diseases and scarring, using ribozymes
XX that cleave RNA encoding cytokines involved in inflammation, matrix
XX metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX Example 1; Page 227; 408pp; English.
XX
XX The present invention describes a method for treating a proliferative
XX skin or eye disease and scarring. The method involves administering a
XX ribozyme (I) which cleaves RNA encoding a cytokine involved in
XX inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
XX dependent kinase, growth factor or a reductase, or administering a
XX nucleic acid molecule (II) comprising a promoter operably linked to a
XX nucleic acid segment encoding (I). (I) can have antipsoriatic,
XX dermatological, cytosolic, anti-seborrheic, antidiabetic, antisticking,
XX ophthalmological, vulnery, keratolytic and virucide activities, and
XX cleaves RNA encoding cytokine involved in inflammation. (I) can be used
XX in gene therapy. (I) and (II) are useful for treating proliferative skin
XX diseases such as psoriasis, acopic dermatitis, actinic keratosis,
XX squamous or basal cell carcinoma and viral or seboreic wart. They can
XX also be used for treating proliferative eye diseases such as diabetic
XX retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
XX prematurity and retinal detachment, and for treating and preventing
XX bearing such as keloid, adhesion and hypertrophic or hypertrophic burn
XX scar. AAH57577 to AAH62099 represent sequences used in the
XX exemplification of the present invention
XX
XX Sequence 19 BP; 4 A; 4 C; 2 G; 9 T; 0 U; 0 Other;
SQ

Query Match 0.7%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1179 GCTGCAAGAAATTAAGA 1195
|||
19 GCTGCAATTAATTAAGA 3

RESULT 163

AAH59717/c
ID AAH59717 standard; DNA; 19 BP.

AC AAH59717;

DT 10-SEP-2001 (first entry)

DE Cyclin E ribozyme binding site SEQ ID NO:2141.

Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme; recognition site; target; ribozyme binding site; eye disease; vulnery; proliferative disease; skin disease; psoriasis; diabetic retinopathy; cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP; matrix metalloproteinase; growth factor; reductase; scarring; cytosolic; antiproliferative; dermatological; antiseborrheic; antidiabetic; vitruide; antisticking; ophthalmological; keratolytic; gene therapy; viral wart; atopic dermatitis; actinic keratosis; squamous cell carcinoma; basal cell carcinoma; seboreic wart; vitreoretinopathy; scar; sickle cell retinopathy; ss.

OS Homo sapiens.
OS Synthetic.

PN W0200130362-A2.

PD 03-MAY-2001.

PF 26-OCT-2000; 2000WO-US029500.

PR 26-OCT-1999; 99US-0161532P.

PA (IMMU-) IMMUSOL INC.

PI Robbins JM, Tritz R;

DR WPI; 2001-300427/31.

PT Treating proliferative skin or eye diseases and scarring, using ribozymes that cleave RNA encoding cytokines involved in inflammation, matrix metalloproteinases, growth factors and cell-cycle dependent kinases.

PS Example 1; Page 227; 408pp; English.

CC The present invention describes a method for treating a proliferative skin or eye disease and scarring. The method involves administering a ribozyme (I) which cleaves RNA encoding a cytokine involved in inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle dependent kinase, growth factor or a reductase, or administering a nucleic acid molecule (II) comprising a promoter operably linked to a nucleic acid segment encoding (I). (I) can have antiproliferative, dermatological, cytosolic, antiseborrheic, antidiabetic, antisticking, ophthalmological, vulnery, keratolytic and vitruide activities, and cleaves RNA encoding cytokine involved in inflammation. (I) can be used in gene therapy. (I) and (II) are useful for treating proliferative skin diseases such as psoriasis, atopic dermatitis, actinic keratosis, squamous or basal cell carcinoma and viral or seboreic wart. They can also be used for treating proliferative eye diseases such as diabetic retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of prematurity and retinal detachment, and for treating and preventing scarring such as keloid, adhesion and hypertrophic or hypertrophic burn scar. AAH57577 to AAH62099 represent sequences used in the exemplification of the present invention

Sequence 19 BP; 4 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1179 GCTGCAAGAAATTAAGA 1195
|||
18 GCTGCAATTAATTAAGA 2

RESULT 164

ABZ93303
ID ABZ93303 standard; DNA; 20 BP.

AC ABZ93303;

DT 17-OCT-2003 (first entry)

DE Human oligonucleotide sequence.

Human; antisense; lung dysfunction; nasal airway dysfunction; antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic; antiasthmatic; hypotensive; immunosuppressive; cytosolic; gene therapy; antisense gene therapy; respiratory; lung; adenosine sensitivity; adenosine receptor; bronchodilation; bronchoconstriction; lung allergy; lung inflammation; respiratory disease; ds.

OS Homo sapiens.

PN W0200285308-A2.

PD 31-OCT-2002.

PF 23-APR-2002; 2002WO-US013135.

PR 24-APR-2001; 2001US-0286137P.

PA (EPIC-) EPIGENESIS PHARM INC.

PI Myce JM, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

DR WPI; 2003-229219/22.

PT Pharmaceutical composition for treating ailments associated with impaired respiration, has oligo(s) antisense to specific gene(s) or its corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or ubiquinone.

PS Disclosure; SEQ ID NO 8545; 872pp; English.

CC The invention relates to a novel pharmaceutical composition, which has a first active agent comprising an oligonucleotide antisense to the initiation codon, coding region, 5' or 3' end genomic flanking regions, 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of junctions of genes encoding a polypeptide associated with lung and/or nasal airway dysfunction and a second active agent comprising an antiinflammatory steroid and ubiquinone. A composition of the invention has antiinflammatory, antiallergic, antiasthmatic, hypotensive, immunosuppressive, and cytosolic activity. The composition may have a use in antisense gene therapy. The composition is useful for treating or preventing a respiratory, lung or malignant disease or condition, also for enhancing the prophylactic or therapeutic respiratory effect of an antiinflammatory steroid in a subject, for reducing or depleting levels of, or reducing sensitivity to adenosine, reducing levels of ubiquinone or receptor, producing bronchodilation, increasing levels of ubiquinone or lung surfactant in a subject's tissue, or treating bronchoconstriction, lung inflammation, lung allergies, or a respiratory disease or condition. Note: The sequence data for this patent is not represented in the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 20 BP; 7 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2036 TACAGTCGAGCAGCTC 2052
|||||
DB 2 TACAGATGAGCAGCTC 18

RESULT 165

AAT08666
ID AAT08666 standard; DNA; 20 BP.

XX AAT08666;

XX 05-SEP-1996 (first entry)

DE Primer p53-3X7P for p53 gene exon 7 amplification.

KM primer; PCR; polymerase chain reaction; hierarchy; immunoassay;

KM quantitative assay; fragment length; DNA sequencing; p53; mutation; ss.

XX Synthetic.

XX WO9601909-A1.

XX 25-JAN-1996.

XX 07-JUL-1995; 95WO-US006605.

XX 08-JUL-1994; 94US-00271946.

XX 14-FEB-1995; 95US-00388381.

XX (VIST-) VISIBLE GENETICS INC.

XX Diamandis E, Dunn JM, Stevens JK;

PI WPI; 1996-097638/10.

PT Testing for disease-associated p53 gene mutation(s) using a hierarchy of
PT assay techniques - e.g. immunoassay, DNA amplification and DNA
PT sequencing.

XX Claim 22; Page 22; 44pp; English.

CC Rapid and cost effective diagnosis of disease-associated mutations in the
CC p53 gene is achieved by employing a selected number of diagnostic tools,
CC in a hierarchy of increasing accuracy and cost per tool, in which each
CC tool detects essentially no false positives. Tests that may be employed,
CC in order of increasing accuracy and cost are: (a) immunoassays; (b) DNA
CC fragment length/quantity analysis; and (c) DNA sequencing of regions
CC most likely to harbour point mutations. AAT08645-66 are primers used in
CC DNA fragment length/quantity analysis. The amplification of the eleven
CC exons is advantageously carried out in 3 multiplex pools, the members of
CC a pool selected because they all use the same hybridisation temperature
CC and none of the expected fragment lengths will overlap in an
CC electrophoresis gel. One of each pair of primers is labeled at the 5' end
CC with an identifiable marker such as fluorescein, rhodamine or cyanine.
CC The present sequence is used with AAT08665 to amplify a 286 bp fragment
CC of exon 7

XX Sequence 20 BP; 5 A; 4 C; 10 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1935 GGGTCAGCGCAGCAGTGG 1954
|||||
DB 1 GGGTCAGCGCAGCAGTGG 20

RESULT 166

AAT99867

ID AAT99867 standard; DNA; 20 BP.

XX AAT99867;

XX 07-MAY-1998 (first entry)

DE Primer for exon 7 of p53 gene.

KM PCR primer; amplify; pathogen identification; mutation detection;

KM nucleic acid analysis; microorganism characterisation; human;

KM HLA type determination; p53 gene exon 7; ss.

XX Synthetic.

XX Homo sapiens.

XX WO9741259-A1.

XX 06-NOV-1997.

XX 29-APR-1997; 97WO-US007135.

XX 01-MAY-1996; 96US-00640672.

XX 19-JUL-1996; 96US-00684498.

XX 27-FEB-1997; 97US-00807138.

XX (VIST-) VISIBLE GENETICS INC.

XX Leushner J, Hui M, Dunn JM, Larson MT, Lacroix J, Shipman R;

PI WPI; 1997-549755/50.

PT Nucleic acid sequence determination - comprising synthesising chain
PT extension products, which are indicative of positions of selected species
PT of nucleotide in nucleotide sequence.

XX Example 4; Page 20; 69pp; English.

CC This sequence represents a primer for exon 7 of the p53 gene. This
CC position can be used in the method of the invention for determining the
CC position of at least one selected species of nucleotide, in a region of
CC interest, in a target nucleic acid polymer, in a sample. The method
CC comprises combining the sample with a reaction mixture to synthesise
CC chain extension products indicative of the positions of the species of
CC nucleotide in the region of interest and evaluating the products
CC produced, characterised in that the sample, which is combined with the
CC reaction mixture, and contains target and non-target nucleic acid
CC polymers in natural abundance. The method can be used to detect
CC mutations, particularly mutations of medical significance, in samples
CC derived from a human patient, animal, plant or microorganism, determine
CC HLA type ancillary to transplant procedures, detect and identify
CC microorganisms, particularly pathogenic microorganisms, in a sample and
CC in situ sequencing reactions to produce sequencing fragments in a
CC histological specimen

XX Sequence 20 BP; 5 A; 4 C; 10 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1935 GGGTCAGCGCAGCAGTGG 1954
|||||
DB 1 GGGTCAGCGCAGCAGTGG 20

RESULT 167

AAT99837

ID AAT99837 standard; DNA; 20 BP.

XX AAT99837;

XX 07-MAY-1998 (first entry)

DE Primer for exon 7 of p53 gene.
 XX PCR primer; amplify; p53 gene exon 7; multiplex amplification reaction;
 KM nucleic acid analysis; microorganism characterisation; human;
 KM mutation detection; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 PN WO9741258-A1.
 XX
 PD 06-NOV-1997.
 XX
 PF 29-APR-1997; 97WO-US007134.
 XX
 PR 01-MAY-1996; 96US-00640672.
 PR 19-JUL-1996; 96US-00684498.
 XX
 PA (VIST-) VISIBLE GENETICS INC.
 XX
 PI Leushner J, Hui M, Dunn JM, Larson MT, Lacroix J;
 DR WPI; 1997-549754/50.
 XX
 PT Analysing nucleic acid containing sample - comprises performing multiplex
 PT amplification reaction and reacting amplified fragments in sequencing
 PT reaction mixture.
 XX
 PS Example 4; Page 18; 37pp; English.
 XX
 CC This sequence represents a primer for exon 7 of the p53 gene. This
 CC sequence can be used in the method of the invention for analysing a
 CC nucleic acid containing sample. The method comprises performing a
 CC multiplex amplification reaction on the nucleic acids in the sample using
 CC amplification primer pairs, one pair for each region to be analysed, to
 CC produce a mixture of amplified fragments, and determining the sequence of
 CC at least one species of amplified fragment, characterised in that the
 CC sequence is determined by combining the mixture of amplification
 CC fragments with a sequencing reaction mixture for the production of
 CC sequencing fragments, and evaluating the sequencing fragments produced.
 CC The method can be used to analyse regions in the nucleic acids in the
 CC sample for the presence of mutations, or detect and type microorganisms.
 CC The method directly performs sequencing reactions on complex DNA mixtures
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 10 G; 1 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1935 GGGTCAGCGACAGCAGCTGG 1954
 Db 1 GGGTCAGCGCGCAACAGAGG 20
 XX
 RESULT 168
 AAV28203/c
 ID AAV28203 standard; DNA; 20 BP.
 XX
 AC AAV28203;
 XX
 DT 08-OCT-1998 (first entry)
 XX
 DE Antisense oligonucleotide to multi-drug resistance-1 gene (MDR-1).
 XX
 KM Purification; oligonucleotide; matrix; affinity unit;
 KM affinity purification; antisense; multi-drug resistance-1 gene; MDR-1;
 KM ss.
 XX
 OS Synthetic.
 OS
 PN WO9827425-A1.

PD 25-JUN-1998.
 XX
 PF 18-DEC-1997; 97WO-US023284.
 XX
 PR 19-DEC-1996; 96US-00769951.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Chen D, Srivatsa GS, Cole DL;
 DR WPI; 1998-362922/31.
 XX
 PT Matrix for selective separation of oligo:nucleotide - useful for, e.g.
 PT large scale purification of anti-sense agents from their deletion
 PT derivatives formed during synthesis.
 XX
 PS Disclosure; Page 104; 183pp; English.
 XX
 CC AAV28155-268 represent oligonucleotides which can be purified using the
 CC method of the invention. The specification describes a matrix that
 CC comprises a support and an affinity unit that specifically and reversibly
 CC binds a target oligonucleotide, and comprises a sequence of bases having
 CC the reverse complement of a hybridising portion of the target
 CC oligonucleotide. The matrix is used for affinity purification of
 CC synthetic oligonucleotides, specifically antisense agents, for treatment
 CC of hyperproliferative diseases, for treating a non-pathogen, non-
 CC hyperproliferative disease, e.g. Alzheimer's, for modulating expression
 CC of cell surface proteins, and to inhibit a eukaryotic pathogen,
 CC retrovirus or other viruses
 XX
 SQ Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1617 CAATGGCTCGGGAAGCA 1636
 Db 20 CAGTGGCTGTGGGAAGGCA 1
 XX
 RESULT 169
 AAV28202/c
 ID AAV28202 standard; DNA; 20 BP.
 XX
 AC AAV28202;
 XX
 DT 08-OCT-1998 (first entry)
 XX
 DE Antisense oligonucleotide to multi-drug resistance-1 gene (MDR-1).
 XX
 KM Purification; oligonucleotide; matrix; affinity unit;
 KM affinity purification; antisense; multi-drug resistance-1 gene; MDR-1;
 KM ss.
 XX
 OS Synthetic.
 OS
 PN WO9827425-A1.
 XX
 PD 25-JUN-1998.
 XX
 PF 18-DEC-1997; 97WO-US023284.
 XX
 PR 19-DEC-1996; 96US-00769951.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Chen D, Srivatsa GS, Cole DL;
 DR WPI; 1998-362922/31.
 XX
 PT Matrix for selective separation of oligo:nucleotide - useful for, e.g.
 PT large scale purification of anti-sense agents from their deletion

PT derivatives formed during synthesis.
 XX
 PS Disclosure; Page 103; 183pp; English.
 CC
 XX AAV28155-268 represent oligonucleotides which can be purified using the
 CC method of the invention. The specification describes a matrix that
 CC comprises a support and an affinity unit that specifically and reversibly
 CC binds a target oligonucleotide, and comprises a sequence of bases having
 CC the reverse complement of a hybridizing portion of the target
 CC oligonucleotide. The matrix is used for affinity purification of
 CC synthetic oligonucleotides, specifically antisense agents, for treatment
 CC of hyperproliferative diseases, for treating a non-pathogen, non-
 CC hyperproliferative disease, e.g. Alzheimer's, for modulating expression
 CC of cell surface proteins, and to inhibit a eukaryotic pathogen.
 CC retrovirus or other viruses
 XX
 SQ Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1618 AATGGCTCTGGAGAGCAGC 1637
 DB 20 AGTGGCTGTGGAGAGCAGC 1
 RESULT 170
 AA237478/c
 ID AA237478 standard; DNA; 20 BP.
 XX
 AC AA237478;
 XX
 DT 07-JAN-2000 (first entry)
 XX
 DE Human mdm2 phosphorothioate oligodeoxynucleotide #8.
 XX
 KM Human mdm2 gene; proliferation; tumour; phosphorothioate; p53; cancer;
 KM antisense; modulation; oligonucleotide; expression; inhibition;
 KM hyperproliferation; blood cancer; brain cancer; breast cancer;
 KM lung cancer; soft tissue cancer; psoriasis; fibrosis; atherosclerosis;
 KM restenosis; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 OS
 PN WO9949065-A1.
 XX
 PD 30-SEP-1999.
 XX
 PF 26-MAR-1999; 99WO-US006702.
 XX
 PR 26-MAR-1998; 98US-00048810.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Mireglia LJ, Nero P, Graham MJ, Monia BP, Cowse LM;
 DR WPI; 1999-610754/52.
 XX
 PT New antisense compounds used to treat eg. hyperproliferative conditions.
 XX
 PS Example 2; Page 37; 157pp; English.
 XX
 CC AA237473-237738 represent human mdm2 phosphorothioate oligonucleotides.
 CC AA237471, AA237472, AA237739, AA237740 and AA237741 are used in the
 CC exemplification of the present invention. The present invention describes
 CC novel nucleotide antisense compounds, targeted to the 5' untranslated,
 CC translation termination codon, or 3' untranslated region of a nucleic
 CC acid encoding human mdm2, that modulates expression of human mdm2. The
 CC oligonucleotides mediate their effect by antisense inhibition of
 CC hyperproliferative gene expression. The antisense compound is used to
 CC treat an animal having a disease or condition associated with mdm2,

CC particularly a hyperproliferative condition, more particularly cancer,
 CC especially of the blood, brain, breast, lung or soft tissue, or
 CC psoriasis, fibrosis, atherosclerosis or restenosis
 XX
 SQ Sequence 20 BP; 1 A; 4 C; 9 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 243 CTCGAGCGGAAACCGCAG 262
 DB 20 CTCGAGCGGAAACCGCAG 1
 RESULT 171
 AA205545
 ID AA205545 standard; DNA; 20 BP.
 XX
 AC AA205545;
 XX
 DT 07-OCT-1999 (first entry)
 XX
 DE PCR primer used to amplify an ORF of Chlamydia trachomatis.
 XX
 KM Vaccine; eye disease; conventional trachoma; nongonococcal trachoma;
 KM paratrachoma; inclusion conjunctivitis; genital disease; perithenitis;
 KM nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
 KM Bartholinitis; pneumonia; venereal lymphogranulomatosis; ss.
 XX
 OS Synthetic.
 OS Chlamydia trachomatis.
 OS
 PN WO9928475-A2.
 XX
 PD 10-JUN-1999.
 XX
 PF 27-NOV-1998; 98WO-IB001939.
 XX
 PR 28-NOV-1997; 97FR-00015041.
 PR 17-DEC-1997; 97FR-00016034.
 PR 04-NOV-1998; 98US-0107077P.
 XX
 PA (GEST) GENSET.
 XX
 PI Griffois R;
 XX
 DR WPI; 1999-371125/31.
 XX
 PT Genome sequence of Chlamydia trachomatis.
 XX
 PS Disclosure; Page 1779; 1755pp; English.
 XX
 CC PCR primers AA201426-206209 were used to amplify open reading frames
 CC (ORFs) of the genome of Chlamydia trachomatis (see AA201425). These ORFs
 CC encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
 CC against Chlamydia trachomatis. Antisense and ribozyme sequences can also
 CC be used to control growth of the microorganism. Chlamydia trachomatis is
 CC responsible for a large number of diseases, e.g. eye diseases such as
 CC conventional trachoma, nongonococcal trachoma, paratrachoma, and inclusion
 CC conjunctivitis; genital diseases such as nongonococcal urethritis,
 CC epididymitis, cervicitis, salpingitis, perithenitis, Bartholinitis;
 CC pneumonia; in breast feeding infants; and venereal lymphogranulomatosis.
 CC The polypeptides of the invention may be of use in treating these
 CC diseases
 XX
 SQ Sequence 20 BP; 5 A; 1 C; 9 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 780 GCAGGAGAGGTGTGGCG 799

```
Db      1 GCATGAGAGATGTTGGAG 20
|||||
RESULT 172
AA18715/c
ID      AA18715 standard; DNA; 20 BP.
XX
AC      AA18715;
XX
XX      10-MAY-1999 (first entry)
DT
DE      Target MDR antisense oligonucleotide #47.
XX
XX      Cellular adhesion protein; proliferation; antisense oligonucleotide;
KM      alimentary canal; transport; gastrointestinal mucosa; cancer;
KM      Alzheimer's disease; beta-thalassemia; malaria; viral infection; HIV;
KM      inflammation; ss.
XX
OS      Synthetic.
XX      WO9901579-A1.
XX      14-JAN-1999.
PD
XX      01-JUL-1998; 98WO-US013574.
XX      01-JUL-1997; 97US-00886829.
XX      01-JUL-1997; 97US-00886829.
XX      (ISIS-) ISIS PHARM INC.
PA      (ISIS-) ISIS PHARM INC.
XX
PI      Teng C, Hardee G;
XX
XX      WPI; 1999-106077/09.
DR
XX      Composition comprising nucleic acid and penetration enhancer - used
PT      particularly for delivering therapeutic antisense oligonucleotides across
PT      the gastrointestinal mucosa, provides high bioavailability.
XX
XX      Example 2; Page 90; 115pp; English.
PS
XX      A pharmaceutical composition has been developed which comprises a nucleic
CC      acid and at least one penetration enhancer. The compositions are used:
CC      (i) to treat or prevent any disease or disorder that can be treated with
CC      the nucleic acid, e.g. cancer, Alzheimer's disease, beta-thalassemia,
CC      malaria, viral infections (including human immune deficiency virus
CC      (HIV)), inflammation, in human or animal medicine; (ii) to investigate
CC      the role of a gene or gene product in non-human animals; and (iii) to
CC      modulate gene expression in cells, tissues or organs. The compositions
CC      provide bioavailability of at least 15, preferably 17-35,%. The
CC      penetration enhancer improves: (i) transport of the nucleic acid across
CC      the mucosa of the alimentary canal and into cells; and (ii) increases
CC      stability of the nucleic acid. Oral administration avoids the
CC      complications and expense of intravenous or other methods of
CC      administration. AA18669 to AA18799 and AA18801 represent antisense
CC      oligonucleotides which can be used as the nucleic acid in the method of
CC      the invention
XX
XX      Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
SQ
Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY      1617 CAATGGCTCTGGGAAGACA 1636
Db      20 CAGTGGCTGTGGGAAGACA 1
|||||
RESULT 173
AA18714/c
ID      AA18714 standard; DNA; 20 BP.
XX
```

```
AC      AA18714;
XX
XX      10-MAY-1999 (first entry)
DT
DE      Target MDR antisense oligonucleotide #46.
XX
XX      Cellular adhesion protein; proliferation; antisense oligonucleotide;
KM      alimentary canal; transport; gastrointestinal mucosa; cancer;
KM      Alzheimer's disease; beta-thalassemia; malaria; viral infection; HIV;
KM      inflammation; ss.
XX
OS      Synthetic.
XX      WO9901579-A1.
XX      14-JAN-1999.
PD
XX      01-JUL-1998; 98WO-US013574.
XX      01-JUL-1997; 97US-00886829.
XX      01-JUL-1997; 97US-00886829.
XX      (ISIS-) ISIS PHARM INC.
PA      (ISIS-) ISIS PHARM INC.
XX
PI      Teng C, Hardee G;
XX
XX      WPI; 1999-106077/09.
DR
XX      Composition comprising nucleic acid and penetration enhancer - used
PT      particularly for delivering therapeutic antisense oligonucleotides across
PT      the gastrointestinal mucosa, provides high bioavailability.
XX
XX      Example 2; Page 90; 115pp; English.
PS
XX      A pharmaceutical composition has been developed which comprises a nucleic
CC      acid and at least one penetration enhancer. The compositions are used:
CC      (i) to treat or prevent any disease or disorder that can be treated with
CC      the nucleic acid, e.g. cancer, Alzheimer's disease, beta-thalassemia,
CC      malaria, viral infections (including human immune deficiency virus
CC      (HIV)), inflammation, in human or animal medicine; (ii) to investigate
CC      the role of a gene or gene product in non-human animals; and (iii) to
CC      modulate gene expression in cells, tissues or organs. The compositions
CC      provide bioavailability of at least 15, preferably 17-35,%. The
CC      penetration enhancer improves: (i) transport of the nucleic acid across
CC      the mucosa of the alimentary canal and into cells; and (ii) increases
CC      stability of the nucleic acid. Oral administration avoids the
CC      complications and expense of intravenous or other methods of
CC      administration. AA18669 to AA18799 and AA18801 represent antisense
CC      oligonucleotides which can be used as the nucleic acid in the method of
CC      the invention
XX
XX      Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
SQ
Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY      1618 AATGGCTCTGGGAAGACAC 1637
Db      20 AGTGGCTGTGGGAAGACAC 1
|||||
RESULT 174
AA18715/c
ID      AA18715 standard; DNA; 20 BP.
XX
AC      AA18715;
XX
XX      10-MAY-1999 (first entry)
DT
DE      Deletion sequence oligonucleotide 158.
XX
XX      Deletion sequence oligonucleotide; sensor array; eukaryotic pathogen;
KM      probe; cellular adhesion modulator; cellular proliferation modulator;
KM
```



```

KM human retrovirus; human immunodeficiency virus; non-human retrovirus;
KM HIV; primer; ss.
XX
XX Synthetic.
XX MO9911820-A1.
XX
XX 11-MAR-1999.
XX
XX 01-SEP-1998; 98WO-US018084.
XX
XX 02-SEP-1997; 97US-00923771.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Chen D, Srivatsa GS;
XX
XX WPI; 1999-205198/17.
XX
XX New compositions comprising sensor arrays made up of unique probe
PT oligonucleotides - useful for characterizing a sample of target deletion
PT oligonucleotides.
XX
XX Example 9; Page 158; 163pp; English.
XX
XX This invention describes a novel composition comprising a number of
CC sensor arrays, where each array comprises a unique probe oligonucleotide,
CC which is the reverse complement of part of a unique target
CC oligonucleotide present in a mixture of target deletion sequence
CC oligonucleotides. The compositions form a method for characterizing a
CC sample of target deletion oligonucleotides which are labelled and
CC hybridize with the probe oligonucleotides of the sensor arrays. Such
CC oligonucleotides and their targets are represented in AAX23548-X23709.
CC Oligonucleotides characterized by the method form pharmaceutical
CC compositions that are useful for modulating cellular adhesion or
CC proliferation, and being active against a eukaryotic pathogen, a human
CC retrovirus, a human immunodeficiency virus (HIV), or a non-human
CC retrovirus, including influenza virus, Epstein-Barr virus, Respiratory
CC syncytial virus or cytomegalovirus (CMV). The compositions enable
CC characterization of deletion sequence oligonucleotides having related,
CC but different nucleobase sequences, and quantification of different
CC species of deletion sequence ("target") oligonucleotides in a mixture.
CC Also, if the specificity of the oligonucleotide's nucleobase sequence for
CC its reverse complement is not modified, the method may be performed using
CC oligodeoxynucleotides
XX
XX Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1618 AATGGCTGTGGAGAGCAC 1637
DB 20 AGTGGCTGTGGAGAGCAC 1
XX
XX RESULT 175
XX AAX23706/c
XX ID AAX23706 standard; DNA; 20 BP.
XX
XX AAX23706;
XX
XX 18-JUN-1999 (first entry)
XX
XX Deletion sequence oligonucleotide 159.
XX
XX Deletion sequence oligonucleotide; sensor array; eukaryotic pathogen;
KM probe; cellular adhesion modulator; cellular proliferation modulator;
KM human retrovirus; human immunodeficiency virus; non-human retrovirus;
KM HIV; primer; ss.
XX
XX Synthetic.

```

```

XX
XX MO9911820-A1.
XX
XX 11-MAR-1999.
XX
XX 01-SEP-1998; 98WO-US018084.
XX
XX 02-SEP-1997; 97US-00923771.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Chen D, Srivatsa GS;
XX
XX WPI; 1999-205198/17.
XX
XX New compositions comprising sensor arrays made up of unique probe
PT oligonucleotides - useful for characterizing a sample of target deletion
PT oligonucleotides.
XX
XX Example 9; Page 159; 163pp; English.
XX
XX This invention describes a novel composition comprising a number of
CC sensor arrays, where each array comprises a unique probe oligonucleotide,
CC which is the reverse complement of part of a unique target
CC oligonucleotide present in a mixture of target deletion sequence
CC oligonucleotides. The compositions form a method for characterizing a
CC sample of target deletion oligonucleotides which are labelled and
CC hybridize with the probe oligonucleotides of the sensor arrays. Such
CC oligonucleotides and their targets are represented in AAX23548-X23709.
CC Oligonucleotides characterized by the method form pharmaceutical
CC compositions that are useful for modulating cellular adhesion or
CC proliferation, and being active against a eukaryotic pathogen, a human
CC retrovirus, a human immunodeficiency virus (HIV), or a non-human
CC retrovirus, including influenza virus, Epstein-Barr virus, Respiratory
CC syncytial virus or cytomegalovirus (CMV). The compositions enable
CC characterization of deletion sequence oligonucleotides having related,
CC but different nucleobase sequences, and quantification of different
CC species of deletion sequence ("target") oligonucleotides in a mixture.
CC Also, if the specificity of the oligonucleotide's nucleobase sequence for
CC its reverse complement is not modified, the method may be performed using
CC oligodeoxynucleotides
XX
XX Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1617 CAATGGCTGTGGAGAGCA 1636
DB 20 CAGTGGCTGTGGAGAGCA 1
XX
XX RESULT 176
XX AAX95547
XX ID AAX95547 standard; DNA; 20 BP.
XX
XX AAX95547;
XX
XX 13-SEP-1999 (first entry)
XX
XX PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KM sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KM neutralising epitope; PCR primer; ss.
XX
XX Synthetic.
XX Chlamydia pneumoniae.
OS
XX
XX MO9927105-A2.
XX
XX 03-JUN-1999.

```

```

XX 20-NOV-1998; 98WO-IB001890.
PF
XX
XX 21-NOV-1997; 97FR-00014673.
PR
XX 04-NOV-1998; 98US-0107078P.
XX
XX (GEST ) GENSET.
PA
XX
XX Griffais R;
XX
XX WPI; 1999-357842/30.
XX
XX Genome sequence of Chlamydia pneumoniae.
PT
XX
XX Page 1756; Disclosure; 1912pp; English.
XX
XX AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC (see AAX91990). C. pneumoniae causes respiratory disease such as
CC pneumonia and bronchitis and is thought to be a contributing factor in
CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC nodosum or pharyngitis. The polypeptides encoded by the open reading
CC frames of the C. pneumoniae genome (see AAY34584 - AAY35879) can be used
CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC nucleotides sequences can also be used as immunogenic compositions,
CC especially where the vector directs the expression of a neutralising
CC epitope of C. pneumoniae
XX
XX Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.7%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 1.5e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY
XX 1696 GGGAGGCCCTTCCCAATA 1715
XX |||||
XX 1 GGAAAGCCCTTCCCTAATA 20
Db
XX
XX RESULT 177
XX AAX93890
XX ID AAX93890 standard; DNA; 20 BP.
XX
XX AAX93890;
XX
XX 13-SEP-1999 (first entry)
XX
XX PCR primer used to amplify an ORF of Chlamydia pneumoniae.
DE
XX
XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KM sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KM neutralising epitope; PCR primer; ss.
XX
XX Synthetic.
OS Chlamydia pneumoniae.
XX
XX WO9927105-A2.
XX
XX 03-JUN-1999.
XX
XX 20-NOV-1998; 98WO-IB001890.
XX
XX 21-NOV-1997; 97FR-00014673.
XX
XX 04-NOV-1998; 98US-0107078P.
XX
XX (GEST ) GENSET.
XX
XX Griffais R;
XX
XX WPI; 1999-357842/30.
XX
XX Genome sequence of Chlamydia pneumoniae.
XX
XX

```

```

PS Page 1627; Disclosure; 1912pp; English.
XX
XX AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC (see AAX91990). C. pneumoniae causes respiratory disease such as
CC pneumonia and bronchitis and is thought to be a contributing factor in
CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC nodosum or pharyngitis. The polypeptides encoded by the open reading
CC frames of the C. pneumoniae genome (see AAY34584 - AAY35879) can be used
CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC nucleotides sequences can also be used as immunogenic compositions,
CC especially where the vector directs the expression of a neutralising
CC epitope of C. pneumoniae
XX
XX Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.7%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 1.5e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY
XX 1762 CCACAGGTATTGGAGAG 1781
XX |||||
XX 1 CCACAGGTCTTTGAGGAG 20
Db
XX
XX RESULT 178
XX AAX94024
XX ID AAX94024 standard; DNA; 20 BP.
XX
XX AAX94024;
XX
XX 13-SEP-1999 (first entry)
XX
XX PCR primer used to amplify an ORF of Chlamydia pneumoniae.
DE
XX
XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KM sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KM neutralising epitope; PCR primer; ss.
XX
XX Synthetic.
OS Chlamydia pneumoniae.
XX
XX WO9927105-A2.
XX
XX 03-JUN-1999.
XX
XX 20-NOV-1998; 98WO-IB001890.
XX
XX 21-NOV-1997; 97FR-00014673.
XX
XX 04-NOV-1998; 98US-0107078P.
XX
XX (GEST ) GENSET.
XX
XX Griffais R;
XX
XX WPI; 1999-357842/30.
XX
XX Genome sequence of Chlamydia pneumoniae.
XX
XX Page 1637; Disclosure; 1912pp; English.
XX
XX AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC (see AAX91990). C. pneumoniae causes respiratory disease such as
CC pneumonia and bronchitis and is thought to be a contributing factor in
CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC nodosum or pharyngitis. The polypeptides encoded by the open reading
CC frames of the C. pneumoniae genome (see AAY34584 - AAY35879) can be used
CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC nucleotides sequences can also be used as immunogenic compositions,
CC especially where the vector directs the expression of a neutralising
CC epitope of C. pneumoniae
XX
XX

```

Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 939 CCTATGCTCTTGGGATCA 958
|||
1 CCTATGATCTTGGGACCA 20

RESULT 179

AA29357
ID AAX29357 standard; DNA; 20 BP.

AC AAX29357;

XX 10-JUN-1999 (first entry)

XX JNK3-specific probe ISIS No: 16704.

XX Antisense oligonucleotide; Jun N-terminal kinase; JNK; hybridase; JNK1;

XX JNK2; JNK3; cell cycle progression; phosphorylation; tumour; probe;

XX hyperproliferative disease; human; ss.

XX Synthetic.

XX Homo sapiens.

XX MO9909214-A1.

XX 25-FEB-1999.

XX 07-AUG-1998; 98WO-US016488.

XX 13-AUG-1997; 97US-00910629.

XX (ISIS-) ISIS PHARM INC.

XX McKay R, Dean N, Monia BP, Nero PS, Gaarde WA;

XX WPI; 1999-181060/15.

XX New antisense oligonucleotides that detect and modulate the expression of

PT Jun N-terminal kinase proteins - useful for treating hyperproliferative

PT diseases and inhibiting tumor growth in animals, and for modulating

PT protein phosphorylation by these proteins.

XX Example 5; Page 102; 190pp; English.

XX The invention relates to antisense oligonucleotides that detect and

CC modulate the expression of Jun N-terminal kinase (JNK) proteins. The

CC oligonucleotides specifically hybridize to a nucleic acid encoding a

CC JNK1, JNK2 or JNK3 protein, and which modulate expression of these

CC proteins. The oligonucleotides are useful for modulating JNK protein

CC expression and cell cycle progression in cultured cells or animal cells.

CC The oligonucleotides are also useful for modulating the phosphorylation

CC of a protein that has been phosphorylated by a JNK protein, and the

CC expression of a cellular protein that promotes one or more metastatic

CC events. The oligonucleotides also form pharmaceutical compositions for

CC treating animals with a hyperproliferative disease, and for inhibiting

CC tumor growth in an animal

RESULT 180
AAA97546
ID AAA97546 standard; DNA; 20 BP.

XX AAA97546;

XX 29-JAN-2001 (first entry)

XX Streptomyces albulus strain IF014147 plasmid pNO33 insert PCR primer #4.

DE Plasmid pNO33; Streptomyces albulus strain IF014147;

XX epsilon-polylysine production; detection; PCR primer; ss.

XX Streptomyces albulus.

XX MO200056892-A1.

XX 28-SEP-2000.

XX 21-MAR-2000; 2000MO-JP001698.

XX 23-MAR-1999; 99JP-00077445.

XX (CHCC) CHISSO CORP.

XX Inoue S, Takagi H, Nakamori S;

XX WPI; 2000-602222/57.

XX Detection of epsilon-polylysine-producing bacteria strain with base

PT sequence originating in plasmid pNO33 by gene amplification or

PT hybridization, for highly-efficient production of epsilon-polylysine.

XX Example 1; Page 12; 25pp; Japanese.

XX The invention relates to a novel method for detecting an epsilon-

CC polylysine-producing bacterium. The method of the invention comprises the

CC detection of a bacterial strain having a base sequence originating in

CC plasmid pNO33. The invention also relates to a process for producing

CC epsilon-polylysine by using the epsilon-polylysine-producing bacterium

CC detected by the method of the invention, and an epsilon-polylysine-

CC producing bacterium comprising a Streptomyces albulus strain IF014147

CC plasmid pNO33 insert sequence. Bacterial strains identified as containing

CC the pNO33 insert sequence using the method of the invention can be used

CC for the efficient production of epsilon-polylysine. Sequences AAA97543-

CC AAA97549 represent PCR primers used in an exemplification of the

CC invention to amplify portions of the Streptomyces albulus strain IF014147

CC plasmid pNO33 insert sequence

XX Sequence 20 BP; 4 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1795 ATTCCTAGGCTTACCA 1814
|||
1 ATTCCTAGGCTTACCA 20

RESULT 181
AAA5792/c
ID AAA5792 standard; DNA; 20 BP.

XX AAA5792;

XX 01-SEP-2000 (first entry)

DE Human histone deacetylase HD1 antisense oligonucleotide SEQ ID NO:35.

XX Human, DNA methyltransferase; DNA Metase; antisense oligonucleotide;

XX modulation; inhibition; gene expression; combination therapy; p16;

XX histone deacetylase; HDAC; thymidylate synthase; tumour suppressor;

XX

KW methylation; gene therapy; tumour; cytostatic; antiaesthetic;
 KW antiinflammatory; inflammation; asthma; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200023112-A1.
 XX
 PD 27-APR-2000.
 XX
 PF 19-OCT-1999; 99WO-US024278.
 XX
 PR 19-OCT-1998; 98US-0104804P.
 XX
 PA (METH-) METHYLENE INC.
 XX
 PI Besterman JM, Macleod AR, Siders WM;
 XX
 DR WPI; 2000-339532/29.
 XX
 PT Inhibiting gene expression e.g. DNA methyltransferase, by treating cells
 PT with a synergistic amount of antisense oligonucleotide and protein
 PT effectors e.g. 5-aza-cytidine of gene products, useful for gene therapy
 PT of e.g. tumors.
 XX
 PS Disclosure; Page 29; 99pp; English.
 XX
 CC The present invention describes a method for inhibiting the expression of
 CC a gene in a cell comprising contacting the cell with an effective
 CC synergistic amount of an antisense oligonucleotide which inhibits
 CC expression of the gene, and an effective synergistic amount of a protein
 CC effector of a product of the gene. Also described are: (1) a method for
 CC treating a disease responsive to inhibition of a gene in a mammal; (2) a
 CC method for inhibiting tumour growth in mammal; (3) an inhibitor of a gene
 CC comprising an antisense oligonucleotide which inhibits expression of the
 CC gene in operable association with a protein effector of a gene product;
 CC and (4) a pharmaceutical composition comprising the inhibitor of (3). The
 CC methods and compositions are useful as analytical tools for transgenic
 CC studies and as therapeutic tools, e.g. as gene therapy tools for human
 CC diseases including benign and malignant tumours, inflammation or asthma.
 CC The methods, inhibitors and compositions of the invention that inhibit
 CC expression or activity of a gene or gene product may be used to treat
 CC patients having, or predisposed to developing, a disease responsive to
 CC inhibition of the gene. These may also be used to activate silenced genes
 CC to provide missing gene functions and improve a given condition.
 CC Furthermore, the methods and compositions are useful as probes of the
 CC physiological function of a gene product in an experimental cell culture
 CC or animal system, and to evaluate the effect of inhibiting gene activity
 CC or expression. AA65758 to AA65842 represent oligonucleotide sequences
 CC which are used in the exemplification of the present invention
 XX
 SQ Sequence 20 BP; 6 A; 6 C; 8 G; 0 T; 0 U; 0 Other;
 XX
 QY Query Match 0.7%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 XX
 Db 26 CCGCGGAGTCCGCTGCCTC 45
 |||||
 20 CCGCGTGTGCTGCTGTCTC 1
 |||||
 RESULT 182
 AA274434
 ID AA274434 standard; DNA; 20 BP.
 XX
 AC AA274434;
 XX
 DT 10-SEP-2001 (first entry)
 XX
 DE Human biallelic marker downstream amplification primer SEQ ID NO:8790.
 XX
 KW Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;

KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9954500-A2.
 XX
 PD 28-OCT-1999.
 XX
 PF 21-APR-1999; 99WO-IB000822.
 XX
 PR 21-APR-1998; 98US-0082614P.
 XX
 PR 23-NOV-1998; 98US-0109732P.
 XX
 PA (GEST) GENSET.
 XX
 PI Cohen D, Blumenfeld M, Chumakov I;
 XX
 DR WPI; 2000-013267/01.
 XX
 PT Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome.
 XX
 PS Claim 8; Page 2104; 2745pp; English.
 XX
 CC AA26564 to AA26978 represent human biallelic markers from the present
 CC invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AA26979 to AA27740 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the invention
 CC have a variety of uses: they can be used for high density mapping of the
 CC human genome, and in complex association studies and haplotyping studies
 CC which are useful in determining the genetic basis for disease states.
 CC Compositions and methods of the invention can also be useful for the
 CC identification of the targets for the development of pharmaceutical
 CC agents and diagnostic methods, as well as the characterisation of the
 CC differential efficacious responses to and side effects from
 CC pharmaceutical agents acting on a disease as well as other treatment.
 CC N.B. The SEQ ID Nos 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
 CC 3367, are not actually given a sequence in the Sequence Listing from the
 CC present invention
 XX
 SQ Sequence 20 BP; 9 A; 1 C; 7 G; 3 T; 0 U; 0 Other;
 XX
 QY Query Match 0.7%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 XX
 Db 1025 CCAAGAGGTGGGAAATGG 1044
 |||||
 1 CAAAGTAGTGGAAATGG 20
 |||||
 RESULT 183
 AA274482/C
 ID AA274482 standard; DNA; 20 BP.
 XX
 AC AA274482;
 XX
 DT 10-SEP-2001 (first entry)
 XX
 DE Human biallelic marker downstream amplification primer SEQ ID NO:8838.
 XX
 KW Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9954500-A2.
 XX

```

PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
XX
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GENSET ) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Claim 8; Page 2115; 2745pp; English.
XX
CC AA265654 to AA269578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AA269579 to AA277440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterization of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID Nos 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 20 BP; 6 A; 0 C; 11 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 688 CTCATGTCATTCACCAT 707
DB 20 CTCCTCTCATTCACCAT 1

RESULT 184
AAC62900
ID AAC62900 standard; DNA; 20 BP.
XX
AC AAC62900;
XX
DT 06-FEB-2001 (first entry)
XX
DE JNK antisense oligonucleotide ISIS #16704.
XX
XX Antisense; gene therapy; JNK2 protein; apoptosis; cancer;
XX cellular hyperproliferation; Alzheimer's; Parkinson's disease;
XX amyotrophic lateral sclerosis; retinitis; pigmentosa; epilepsy;
XX myocardial infarction; stroke; obstructive jaundice; polycystic kidney;
XX diabetes; Jun N-terminal kinase; ss.
XX
OS Homo sapiens.
XX
PN WO200059549-A1.
XX
PD 12-OCT-2000.
XX
PF 04-APR-2000; 2000WO-US008880.
XX
PR 07-APR-1999; 99US-00287796.
XX
PA (ISIS-) ISIS PHARM INC.
XX

```

```

PI McKay R, Dean NM, Monia BP, Nero PS, Garde WA;
XX
DR WPI; 2000-638427/61.
XX
PT Novel methods for reducing apoptosis comprising contacting cells with
PT antisense oligonucleotides, useful for treating apoptotic disorders, e.g.
PT cancer.
XX
XX Example 5; Page 138; 160pp; English.
XX
XX The present invention relates to antisense oligonucleotides (AAC62844-
XX C63000, AA96093-A96099 and AA607993) that hybridise specifically to a
XX nucleotide encoding a Jun N-terminal kinase (JNK2) protein, resulting in
XX decrease of JNK2 expression and leading to induction of apoptosis. The
XX present sequence is one such antisense oligonucleotide. The
XX oligonucleotides of the present invention are useful for treating
XX diseases or conditions with reduced apoptosis, e.g. cancer and cellular
XX hyperproliferation. The oligonucleotides may also be used to increase the
XX stimulation of apoptotic proteins, e.g. for treating Alzheimer's or
XX Parkinson's disease, amyotrophic lateral sclerosis, retinitis,
XX pigmentosa, epilepsy, myocardial infarction, stroke, obstructive
XX jaundice, polycystic kidney and diabetes. The present sequence may have a
XX phosphorothioate backbone
XX
SQ Sequence 20 BP; 2 A; 3 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 167 GGGTCTGGCGGCGGCTG 186
DB 1 GGGTCTGGTGGTGGACATG 20

RESULT 185
AAH43102/c
ID AAH43102 standard; DNA; 20 BP.
XX
AC AAH43102;
XX
DT 19-SEP-2001 (first entry)
XX
DE Antisense oligo, target HDAC-1 17-36.
XX
XX Antisense; histone deacetylase; HDAC-1; HDAC-2; HDAC-4; inhibitor;
XX cell proliferation; cancer; restenosis; poriasis; protozoal infection;
XX fungal infections; ss.
XX
OS Synthetic.
XX
PN WO200138322-A1.
XX
PD 31-MAY-2001.
XX
PF 22-NOV-2000; 2000WO-IB001881.
XX
PR 23-NOV-1999; 99US-0167035P.
XX
PA (METH-) METHYLENE INC.
XX
XX Delorme D, Ruel R, Lavoie R, Thibault C, Abou-Khalil E;
XX
DR WPI; 2001-432601/46.
XX
XX New inhibitors of histone deacetylase e.g. N-hydroxy-5-(4-
XX (benzenesulfonylamino)-phenyl)-4-yn-2-pentanamide for treating cancer,
XX restenosis or fungal infections.
XX
XX Disclosure; Page 40; 147pp; English.
XX
XX The sequences given in AAH43102-14 are oligonucleotides which are
XX antisense to the histone deacetylase gene, HDAC-1. These oligonucleotides
XX

```

```

CC may be used in combination with an inhibitor of histone deacetylase
CC enzyme function, to given an improved inhibitory effect, thereby reducing
CC the amount of inhibitor required to obtain a given inhibitory effect.
CC Compounds containing these oligonucleotides may be used to treat cell
CC proliferation conditions such as cancer, restenosis or psoriasis. They
CC can also be used to treat protozoal and fungal infections
XX
SQ Sequence 20 BP; 6 A; 6 C; 8 G; 0 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 26 CCGCGGGGTGCGCTGCCTC 45
Db 20 CCGCGGTGTGCTGCTCTC 1
RESULT 186
AAAF80632/c
ID AAF80632 standard; DNA; 20 BP.
XX
AC AAF80632;
XX
DT 02-MAY-2001 (first entry)
XX
DE Human mdm2 phosphorothioate oligonucleotide #6.
XX
KM Antisense; mdm2; hyperproliferation; cancer; psoriasis; ss.
XX
OS Homo sapiens.
XX
PN US6184212-B1.
XX
PD 06-FEB-2001.
XX
PF 26-MAR-1999; 99US-00280805.
XX
PR 26-MAR-1998; 98US-00048810.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowseert LM;
XX
DR WPI; 2001-190948/19.
XX
PT Novel antisense compound 8-30 nucleobases in length targeted to a nucleic
PT acid molecule encoding human mdm-2 useful for modulating the expression
PT of human mdm-2 and reducing hyperproliferation of human cells.
XX
PS Example 2; Col 20; 77pp; English.
XX
CC The present invention relates to an antisense compound 8-30 nucleobases
CC in length targeted to nucleobases 1-308 of the 5' untranslated region
CC 1776-1806 of the translation termination codon region or 1818-2370 of the
CC 3' untranslated region of a nucleic acid molecule encoding human mdm-2.
CC The invention is useful for reducing hyperproliferation of human cells,
CC modulating the expression of mdm2 in human cells or tissues or in vitro.
CC The hyperproliferative disorder includes cancer or psoriasis
XX
SQ Sequence 20 BP; 1 A; 4 C; 9 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 243 CTCGAAGCGGAAGACGCAG 262
Db 20 CTCGAAGCGGAAGACCCCG 1
RESULT 187
AAD07537/c

```

```

ID AAD07537 standard; DNA; 20 BP.
XX
XX AAD07537;
AC
XX 10-AUG-2001 (first entry)
DT
XX
XX Human mdm2 antisense oligonucleotide (ISIS #16511).
DE
XX Human; mdm2 inhibitor; gene therapy; cell proliferation; therapeutic;
XX tumour; prophylaxis; antisense; ss.
XX
XX Homo sapiens.
XX
FH Key Location/Qualifiers
FH modified_base 1..20
FH /tag= a
FH /mod_base= OTHER
FH /note= "Phosphorothioate backbone"
FH modified_base 1..6
FH /tag= b
FH /mod_base= OTHER
FH /note= "2'-methoxyethoxy residues"
FH modified_base 1
FH /tag= c
FH /mod_base= m5c
FH modified_base 15..20
FH /tag= d
FH /mod_base= OTHER
FH /note= "2'-methoxyethoxy residues"
XX
XX US6238921-B1.
XX
XX 29-MAY-2001.
XX
XX 26-MAR-1998; 98US-00048810.
XX
XX 26-MAR-1998; 98US-00048810.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Miraglia LJ, Nero P, Graham MJ, Monia BP;
XX
XX WPI; 2001-366477/38.
XX
XX New oligonucleotides 16506, 16507, 16518, 16520, 16521, 16522 and 16524,
XX which inhibits human mdm2 expression, useful for inhibiting, diagnosing
XX or treating abnormal proliferative conditions associated with mdm2.
XX
XX Example 2; Col 16; 19pp; English.
XX
XX The present invention relates to compositions and methods for modulating
XX the expression of human mdm2 gene, a naturally present cellular gene
XX implicated in abnormal cell proliferation and tumour formation. The
XX invention also provides antisense oligonucleotides which are targeted to
XX the mdm2 gene and are capable of inhibiting the expression of mdm2 gene.
XX The oligonucleotides are useful in diagnostics, therapeutics, prophylaxis
XX and as research reagents. They are especially useful for inhibiting,
XX diagnosing and treating abnormal proliferative conditions associated with
XX mdm2. The method is useful for detecting and determining the role of mdm2
XX expression in various cell functions and physiological processes and
XX conditions, and for diagnosing conditions associated with mdm2
XX expression. The present sequence is human mdm2 antisense oligonucleotide
XX (ISIS #16511) with a phosphorothioate backbone. This sequence is
XX targeted to the 5'-UTR (untranslated region) of the mdm-2 gene
XX
SQ Sequence 20 BP; 1 A; 4 C; 9 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 243 CTCGAAGCGGAAGACGCAG 262

```

Db 20 CTCGACGCGGAAAAACCCCG 1

RESULT 188

AAAC83925 standard; DNA; 20 BP.

AC AAC83925;

XX

XX 02-MAR-2001 (first entry)

XX

DE ER gene PCR primer #2.

XX

KM Osteoporosis; human; polymorphism; vitamin D receptor; VDR;

KM oestrogen receptor; apolipoprotein E; ApoE; PCR primer; detection probe;

KM 88.

XX Homo sapiens.

OS

XX EPI054066-A2.

PN

XX 22-NOV-2000.

PD

XX 18-MAY-2000; 2000EP-00110219.

XX

PF 18-MAY-1999; 99JP-00136653.

PR

XX 11-JUN-1999; 99JP-00165642.

XX

PA (NISS-) NISSHO CORP.

XX

PI Shiraki M, Ouchi Y, Hosoi T, Kusaba N, Baba T, Yoshida H;

XX

DR WPI; 2001-018132/03.

XX

PT Diagnosing sensitivity to a medicine for osteoporosis involves analyzing

PT genetic polymorphisms of vitamin D receptor gene, estrogen receptor gene

PT and apolipoprotein E gene.

XX

PS Claim 18; Page 42; 51pp; English.

XX

CC The present invention relates to a method for anticipating the

CC sensitivity to a medicine for osteoporosis. The method involves analysing

CC combinations of genetic polymorphisms of a vitamin D receptor gene (VDR),

CC an estrogen receptor (ER) gene, and an apolipoprotein E (ApoE) gene from

CC a human genome DNA sample. PCR primers AAC83918-C83926 and AAC83937-

CC C83942 were used in the method of the present invention to amplify the

CC VDR, ER and ApoE genes, and detection probes AAC83927-C83936 were used

CC for detecting VDR, ER and ApoE genetic polymorphism. By relating a

CC combination of the genetic polymorphisms detected using the detection

CC probes described in AAC83927-C83936, a remedy for a bone-associated

CC disease can be selected

CC

XX

SQ Sequence 20 BP; 6 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

XX

Query Match 0.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1647 CTTGCTGCAGAACTGTACC 1666

Db 1 CTTGCACCAAGAAATGTACC 20

XX

RESULT 189

AAD10981

XX AAD10981 standard; DNA; 20 BP.

XX

XX AAD10981;

XX

XX 24-SEP-2001 (first entry)

XX

DE Murine PAI-1 genotype determining common reverse PCR primer.

XX

KM Murine; plasminogen activator inhibitor type-1; PAI-1; antithrombotic;

KM angiotensin II receptor; antagonist; AIIra; enalapril; captopril; asthma;

KM spirinolactone; imidapril; angiotensin converting enzyme inhibitor; ACEI;

KM chronic obstructive pulmonary disease; COPD; delfibrotide; PCR primer;

KM therapy; 88.

XX

XX Mus BP.

OS

XX WO200151085-A1.

PN

XX 19-JUL-2001.

XX

PD 12-JAN-2001; 2001WO-US001158.

XX

PF 14-JAN-2000; 2000US-0176211P.

XX

PR (TANO-) TANOX INC.

XX

PA Oh CK, Cho SH, Demisseie-Sanders S, Thomas DW, Tan SW;

XX

PI WPI; 2001-451817/48.

XX

DR

XX

XX

PT Treating chronic obstructive pulmonary disease or asthma in a mammal

PT comprises administering a plasminogen activator inhibitor-1 antagonist.

XX

PS Example 10; Page 18; 40pp; English.

XX

CC The invention relates to plasminogen activator inhibitor type-1 (PAI-1)

CC antagonists. PAI-1 antagonists are used in the treatment of asthma and

CC chronic obstructive pulmonary disease (COPD). PAI-1 is highly expressed

CC in the airways of murine asthma model. PAI-1 antagonist can be an

CC antibody, a peptide, a protein, a polynucleotide, a small organic

CC molecule or a polymer. Examples of PAI-1 antagonist are spirinolactone,

CC imidapril, angiotensin converting enzyme inhibitor (ACEI), captopril,

CC enalapril, an angiotensin II receptor antagonist (AIIra) and delfibrotide

CC (a polydeoxyribonucleotide). The present DNA sequence is a common reverse

CC PCR primer which is used for determining murine plasminogen activator

CC inhibitor type-1 (PAI-1) 4G/5G allele genotype. This PCR primer is

CC designed to minimise the dimer-primer formation

CC

XX

SQ Sequence 20 BP; 1 A; 8 C; 6 G; 5 T; 0 U; 0 Other;

XX

Query Match 0.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1460 GCTGCCACCCAGTGTCTG 1479

Db 1 GCTGTCCACCCGGTGTCTG 20

XX

RESULT 190

AAF54600

XX AAF54600 standard; DNA; 20 BP.

XX

XX AAF54600;

XX

XX 03-APR-2001 (first entry)

XX

DE Human HLA Class I oligonucleotide probe SEQ ID NO: 45.

XX

KM Human; HLA typing; oligonucleotide array; Class I; gene discovery;

KM expression; polymorphism detection; mapping; probe; PCR primer; 88.

XX

OS Homo sapiens.

XX

XX WO200079006-A1.

PN

XX 28-DEC-2000.

XX

PD 16-JUN-2000; 2000WO-US016722.

XX

PF 17-JUN-1999; 99US-0139843P.

XX

```

XX (HUTC-) HUTCHINSON CANCER RES CENT FRED.
PA (UNIW ) UNIV WASHINGTON.
XX
PI Petersdorf EW, Guo Z, Hansen JA, Hood L;
XX
XX WPI; 2001-102734/11.
XX
XX Oligonucleotide arrays useful for human leukocyte antigen (HLA) tissue
PT typing, comprises HLA class I oligonucleotide probes representing all
PT known polymorphisms in HLA class I locus, on a solid support.
XX
XX
PS Disclosure; Page 56; 83pp; English.
XX
XX The present invention provides a microarray of oligonucleotides
CC comprising probes for the human HLA Class I genes attached to a solid
CC support. These can be used in HLA typing. Oligonucleotide arrays are also
CC useful in large scale gene discovery, monitoring gene expression,
CC polymorphism detection and gene mapping
XX
SQ Sequence 20 BP; 2 A; 8 C; 9 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 487 CCGCGCGATCAGCGCGCTC 506
Db 1 CCGCGCGACACGCGGCTC 20
XX
RESULT 191
AAS29247/C
ID AAS29247 standard; DNA; 20 BP.
XX
AC AAS29247;
XX
DT 21-NOV-2001 (first entry)
XX
DE Human mdm2 antisense oligonucleotide 16511.
XX
KW Human; mdm2; hyperproliferative disorder; cancer; psoriasis;
KW atherosclerosis; tumour; cytostatic; anti psoriatic;
KW anti arteriosclerotic; vasotropic; antisense; phosphorothioate; ss.
XX
OS Homo sapiens.
XX
XX Key location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= All phosphorothioate linkages,
FT additionally bases 1-6 and bases 15-20 are 2'-o-
FT methoxyethyl bases, and bases 7-14 are deoxynucleotides"
XX
XX US2001016575-A1.
XX
XX 23-AUG-2001.
XX
XX 02-JAN-2001; 2001US-00752983.
XX
XX 26-MAR-1998; 98US-00048810.
XX 26-MAR-1999; 99US-00280805.
XX
XX (MIRA/) MIRAGLIA L J.
PA (NERO/) NERO P.
PA (GRAH/) GRAHAM M J.
PA (MONI/) MONIA B P.
PA (COWS/) COWSERT L M.
XX
PI Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowsert LM;
XX WPI; 2001-53565/59.

```

```

XX An antisense compound, useful for treating e.g. cancer, comprises
PT nucleobases targeted a region (e.g. translation termination codon region)
PT of a nucleic acid encoding human mdm2.
XX
XX Example 2; Page 11; 81pp; English.
XX
XX The present invention relates to antisense compounds, 8-30 nucleobases in
CC length targeted to the 5' untranslated region, translation termination
CC codon region, 3' untranslated region, coding region or translation start
CC site of a nucleic acid encoding human mdm2, where the antisense compound
CC modulates the expression of human mdm2. The antisense oligonucleotides of
CC the invention are useful for encoding human mdm2 and for inhibiting the
CC expression of human mdm2. They may be used for treating an animal having
CC a disease or condition associated with amplification of mdm2 gene or
CC overexpression of mdm2 e.g. a hyperproliferative disorder such as cancer
CC (blood, brain, breast, lung, or a soft tissue cancer) and psoriasis,
CC fibrosis, atherosclerosis or restenosis, tumours, colorectal carcinoma
CC and chronic myelogenous leukemia. The antisense compound may be
CC administered with a chemotherapeutic agent to overcome drug resistance.
CC The antisense compound reduces hyperproliferation of human cells. The
CC method, which involves the use of the antisense compound, is also useful
CC for detecting the role of mdm2 expression in various cell functions and
CC physiological processes and useful in both clinical research and
CC diagnostic tools. AAS29242-AAS29507 represent the human mdm2 antisense
CC oligonucleotides of the present invention
XX
SQ Sequence 20 BP; 1 A; 4 C; 9 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 243 CTCGAGAGCGAAGAACGACG 262
Db 20 CTCGAGCGGAGAAACCCCG 1
XX
RESULT 192
ABA93207
ID ABA93207 standard; DNA; 20 BP.
XX
AC ABA93207;
XX
DT 17-APR-2002 (first entry)
XX
DE Human oestrogen receptor gene PCR primer SEQ ID NO:16.
XX
XX Human; vitamin D receptor; apolipoprotein E; oestrogen receptor; VDR;
KW ApoE; bone-related disease; polymorphism; detection; PCR primer; ss.
XX
OS Homo sapiens.
XX
XX JP2001333798-A.
XX
XX 04-DEC-2001.
XX
XX 26-MAY-2000; 2000JP-00155871.
XX
XX 26-MAY-2000; 2000JP-00155871.
XX
XX (NISS-) NISSHO KK.
XX
XX WPI; 2002-135948/18.
XX
XX A reagent for detecting simultaneously a gene polymorphism of the vitamin
PT D receptor gene, apolipoprotein E gene and estrogen receptor gene.
PT
XX Claim 3; Page 2; 13pp; Japanese.
XX
XX The present invention describes a reagent for detecting simultaneously
CC the gene polymorphism of the vitamin D receptor (VDR) gene,
CC apolipoprotein E (ApoE) gene and oestrogen receptor (ER) gene. Also

```


CC described is a method for detecting simultaneously the gene polymorphism
CC of VDR gene, ApoE gene and ER gene in which the reagent is used to detect
CC the gene polymorphism of VDR, ApoE and ER in a sample. The reagent can be
CC used for selecting a creating agent for bone-related diseases. The
CC present sequence represents a specifically claimed PCR primer for the
CC human ER gene, for use in a reagent of the present invention
XX
SQ Sequence 20 BP; 6 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1647 CCTGCTGAGATCTGTACC 1666
DB 1 CCTGCACGAGATGTATGACC 20

RESULT 193
ABA92551
ID ABA92551 standard; DNA; 20 BP.

AC ABA92551;
XX
XX 20-MAR-2002 (first entry)

XX Adenovirus 5 related 5' PCR primer E4.

KW Adenovirus 5; adenovirus vector; inflammatory; gene therapy; PCR primer;
KM 88.

XX Mastadenovirus.

XX WO200190392-A1.

XX 29-NOV-2001.

XX 24-MAY-2001; 2001WO-JP004360.

XX 26-MAY-2000; 2000JP-00155603.

XX 08-DEC-2000; 2000JP-00373850.

XX (SUMU) SUMITOMO PHARM CO LTD.

XX Nakai M, Komiya K, Murata M, Tohdoh N, Saito I;

XX WPI; 2002-097660/13.

XX Adenovirus vector with reduced inflammatory side effects for use in gene
XX therapy.

XX Example 6; Page 58; 108bp; Japanese.

XX The present invention describes a recombinant adenovirus vector having
XX reduced inflammatory activity when administered in vivo. The adenovirus
XX vector has the adenovirus E1a and E2B genes deleted; a foreign gene is
XX inserted under the control of a foreign promoter. The expression of an
XX adenovirus gene is suppressed by insertion of the foreign promoter. The
XX recombinant virus produces viral particles similar to those of wild-type
XX adenovirus. Also described are: (1) mammalian cells expressing adenoviral
XX E1 and E2 genes, and able to proliferate the recombinant adenovirus
XX vector; (2) a method for the preparation of the viral vector using these
XX cells; (3) drug compositions containing the recombinant adenovirus vector
XX; and (4) a method for gene therapy using these drug compositions. The
XX adenovirus vectors can be used for effective gene therapy of a wide range
XX of human diseases. The present sequence represents a PCR primer for
XX adenovirus 5 which is used in an example from the present invention
XX

SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1410 GGCTGTGGCTCCTCAGAGA 1429
DB 1 GGCAGTGCTCTCTCAGCGA 20

RESULT 194
AAD39601/c
ID AAD39601 standard; DNA; 20 BP.

AC AAD39601;

XX 04-OCT-2002 (first entry)

XX Human SR-cyp antisense oligonucleotide, ISIS #123865.

KW Human; antisense; SR-cyp; CLK-associated RS cyclophilin; inflammation;
KM hyperproliferative disorder; cancer; prophylaxis; infection; therapy;
XX tumour; CARS-cyp; phosphorothioate backbone; ss.

XX Homo sapiens.
OS Synthetic.

XX Key Location/Qualifiers

XX modified_base 1..20

XX /+tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone"

XX modified_base 1..5

XX /+tag= b
XX /mod_base= OTHER
XX /note= "2-methoxyethyl nucleotides"

XX modified_base 1

XX /+tag= d
XX /mod_base= m5c

XX modified_base 15

XX /+tag= e
XX /mod_base= m5c

XX modified_base 16..20

XX /+tag= c
XX /mod_base= OTHER

XX /note= "2-methoxyethyl nucleotides"

XX modified_base 17

XX /+tag= f
XX /mod_base= m5c

XX modified_base 19

XX /+tag= g
XX /mod_base= m5c

XX WO200236809-A2.

XX 10-MAY-2002.

XX 30-OCT-2001; 2001WO-US047335.

XX 03-NOV-2000; 2000US-00706197.

XX (ISIS-) ISIS PHARM INC.

XX (COLD-) COLD SPRING HARBOR LAB.

XX Bennett CF, Spector DL, Wyatt JR;

XX WPI; 2002-479763/51.

XX Novel antisense compounds targeted to nucleic acids encoding SR-cyp, CLK-

XX associated RS cyclophilin for modulating the gene expression and treating

XX hyperproliferative disorders such as cancer.

XX Claim 3; Page 89; 117pp; English.

XX The invention relates to antisense compounds targeted to a nucleic acid

XX molecule encoding human SR-cyp (CLK-associated RS cyclophilin) to inhibit

XX its expression. SR-cyp is also referred to as CARS-cyp. Antisense

CC compounds of the invention are used for treating diseases or conditions
CC associated with SR-cyp. The diseases treated include hyperproliferative
CC disorders e.g. cancer or hyperproliferative disorders resulting from an
CC alternative splicing event. They are useful for diagnostics, therapeutics
CC and as research reagents, e.g. prophylactically to prevent or delay
CC infection, inflammation or tumour formation. They are also used in
CC antisense therapy. The present sequence is an antisense oligonucleotide
CC targeted to human SR-cyp
XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1269 AGTGGATCCTCTACATTG 1288
Db 20 AGTGAGACTCTCCACATTG 1
|||||
RESULT 195
ABAG3174
ID ABAG3174 standard; DNA; 20 BP.
XX
AC ABAG3174;
XX
DT 17-APR-2002 (first entry)
XX
DE Human oestrogen receptor gene PCR primer SEQ ID NO:8.
XX
KM Human; vitamin D receptor; apolipoprotein E; oestrogen receptor; VDR;
KM ApoE; osteoporosis; polymorphism; allele; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN JP2001333799-A.
XX
PD 04-DEC-2001.
XX
PF 26-MAY-2000; 2000JP-00155993.
XX
PR 26-MAY-2000; 2000JP-00155993.
XX
PA (NISS-) NISSHO KK.
XX
DR WPI; 2002-135949/18.
XX
PT Estimate of sensitivity to drugs for osteoporosis and a reagent kit.
XX
PS Example 1; Page 7; 13pp; Japanese.
XX
CC The present invention describes a method for the estimation of
CC sensitivity to drugs for osteoporosis in which each gene polymorphism of
CC vitamin D receptor (VDR) gene, oestrogen receptor (ER) gene and
CC apolipoprotein E3 (ApoE3) allele (2/2, 2/3, 2/4, 3/3, 3/4 or 4/4) are
CC analysed from the genomic DNA contained in a sample collected from a
CC human and, based on these combinations of gene polymorphisms, it is
CC estimated that the sample is derived from an individual showing a
CC specific priority on the sensitivity against a plural of treating agents
CC for osteoporosis. Also described is a reagent kit for analysing gene
CC polymorphisms of VDR, ApoE and ER genes containing primers specific to
CC each of the genes and detecting probes for detecting each gene
CC polymorphisms. The reagent can be used for selecting an effective drug
CC for osteoporosis. The present sequence represents a PCR primer for human
CC ER which is used in the exemplification of the present invention
XX
SQ Sequence 20 BP; 6 A; 7 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1647 CCTGCTGCAGATCTGTACC 1666

Db 1 CCTGCACCAAGATATGTACC 20
|||||
RESULT 196
ABZ88194
ID ABZ88194 standard; DNA; 20 BP.
XX
AC ABZ88194;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KM Human; antisense; lung dysfunction; nasal airway dysfunction;
KM antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KM antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KM antisense gene therapy; respiratory; lung; adenosine sensitivity;
KM adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KM lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahbuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX ubiquinone.
XX
PS Disclosure; SEQ ID NO 3436; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1726 TACCTGCACAGGAGGTGGC 1745

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1633 AGCACAGTGGCTGCTGCT 1652
 |||||
 Db 20 AGGACAGTGGCTGCTGCT 1

RESULT 199
 AB284008
 ID AB284008 standard; DNA; 20 BP.
 XX
 AC AB284008;
 XX
 DT 14-MAY-2003 (first entry)
 XX
 DE Toxicologically relevant rat PCR primer #1167.
 XX
 KM Toxicologically relevant gene; toxicological response; PCR primer; ss.
 XX
 OS Rattus sp.
 OS Synthetic.
 XX
 PN W02003016500-A2.
 PD 27-FEB-2003.
 XX
 PF 16-AUG-2002; 2002WO-US026514.
 XX
 PR 16-AUG-2001; 2001US-0313080P.
 XX
 PA (PHAS-) PHASE-1 MOLECULAR TOXICOLOGY INC.
 XX
 PI Neft RE, Dunn RT, Adkins K, Pickett GJ, Klier LD, Schweiser K;
 PI Alen P;
 XX
 DR WPI; 2003-268322/26.
 XX
 PT Determining a toxicological response to an agent, useful for screening of
 PT drugs, comprises comparing the expression profile of one or more human
 PT toxic response genes to a reference gene expression profile indicative of
 PT toxicity.
 XX
 PS Claim 1; Page 327; 455pp; English.

CC The present invention describes a method (M1) for determining a
 CC toxicological response to an agent, which comprises comparing the
 CC expression profile of one or more human toxic response genes to a
 CC reference gene expression profile indicative of toxicity, and so
 CC determining the presence of a toxic response to the agent. Also
 CC described: (1) an array comprising one or more polynucleotides selected
 CC from the genes corresponding to the partial sequences given in AB282842
 CC to AB284764, or their fragments of at least 20 nucleotides, or homologues
 CC ; and (2) determining if a gene putatively identified to be a toxic
 CC response gene plays a role on toxic response pathways by determining the
 CC expression profile of the gene after exposure of cells or a human subject
 CC to a known toxic pharmaceutical or industrial agent, comprising: (a)
 CC exposing cells to an agent or isolating cells from a human subject who
 CC was exposed to an agent; (b) obtaining the test gene expression profile
 CC for a putatively identified toxic response gene after exposure to a known
 CC toxic pharmaceutical or industrial agent; and (c) comparing the test
 CC profile to the expression profile of a gene with a similar function or
 CC comparing the test profile to the expression profile of that gene after
 CC exposure to other known toxic compounds. The methods are useful for
 CC predicting and determining toxicological responses on a cellular, organ
 CC or system level. The arrays comprising the human genes are useful for
 CC toxicological screening of drugs, pharmaceutical compounds and chemicals

XX
 SQ Sequence 20 BP; 0 A; 6 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1004 TGCTTGTGCTTTTCCTTCTG 1023
 |||||
 Db 1 TGCTTGTGCTGTTCTCTG 20

RESULT 200
 ADA26604
 ID ADA26604 standard; DNA; 20 BP.
 XX
 AC ADA26604;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human Jun N-terminal kinase, JNK3, antisense oligonucleotide ISIS16704.
 XX
 KM ss; human; Jun N-terminal kinase; JNK1; JNK2; JNK3; antisense;
 KM cytosolic; antiinflammatory; apoptosis; prostate cancer;
 KM prostate tumour; inflammation; fibrosis; fibrotic disease;
 KM fibrotic scarring; peritoneal adhesion; lung fibrosis;
 KM conjunctival scarring; hyperproliferative disease; cancer; probe.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FH modified_base 1..6
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'methoxyethoxy-modified"
 FT modified_base 15..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'methoxyethoxy-modified"
 XX
 XX US2003004120-A1.
 XX
 PD 02-JAN-2003.
 XX
 PF 31-JAN-2001; 2001US-00774809.
 XX
 PR 13-AUG-1997; 97US-00910629.
 PR 07-AUG-1998; 98US-00130616.
 PR 07-APR-1999; 99US-00282796.
 PR 15-SEP-1999; 99US-00396902.
 XX
 PA (MCKA/) MCKAY R.
 PA (DEAN/) DEAN N M.
 PA (MONI/) MONIA B P.
 PA (NERO/) NERO P. P.
 PA (GAAR/) GAARDE W A.
 XX
 PI Mckay R, Dean NM, Monia BP, Nero P, Gaarde WA;
 PI WPI; 2003-311908/30.
 XX
 DR WPI; 2003-311908/30.
 XX
 PT New oligonucleotides which hybridizes to, and modulates the expression of
 PT Jun N-terminal kinase, useful for treating a disease or condition
 PT characterized by a reduction in apoptosis, e.g. prostate cancer,
 PT inflammation or fibrosis.
 XX
 PS Example 5; Page 30; 69pp; English.

XX The invention relates to an oligonucleotide (antisense, AS) comprising 8-
 XX 30 nucleotides connected by covalent linkages, where the oligonucleotide
 XX has a sequence specifically hybridisable with a nucleic acid encoding a
 XX Jun N-terminal kinase (JNK) protein and modulates the expression of the
 XX JNK protein. Also included are a pharmaceutical composition comprising
 XX the AS oligonucleotide (or its bioequivalent, and a pharmaceutical
 XX carrier), treating an animal having/suspected of having/prone to having a
 XX hyperproliferative disease (by administering to a prophylactic or
 XX therapeutic amount of the composition of the AS oligonucleotide),
 XX modulating the expression of a JNK protein in cells or tissues by
 XX contacting the cells or tissues with the AS oligonucleotide, modulating
 XX the cell cycle progression (or the phosphorylation of a protein

phosphorylated by a JNK protein, or expression of a cellular protein that promotes one or more metastatic events in cultured cells or the cells of an animal) by administering the oligonucleotide to the cells, inhibiting the growth of a tumour in an animal by administering the oligonucleotide, inducing apoptosis in a cell by contacting a cell with an AS oligonucleotide for JNK2 and treating a human having a disease or condition associated with a JNK protein or characterised by a reduction in apoptosis by administering a prophylactic or therapeutic amount of the AS oligonucleotide. The antisense oligonucleotide is useful for treating a disease or condition characterised by a reduction in apoptosis, such as prostate cancer or prostate tumour, inflammation, fibrosis or fibrotic disease or conjunctival scarring), hyperproliferative disease or fibrosis or conjunctival scarring), hyperproliferative disease or condition, such as cancer. The antisense oligonucleotides may also be used as research agents and diagnostic aids, to detect the presence of JNK protein-specific nucleic acids in a cell, or tissue sample, and to study the function of one or more genes in the animal. The present sequence is an antisense oligonucleotide targeting human JNK3.

SO Sequence 20 BP; 2 A; 3 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 167 GGGCTGGGGGGGGGGCTG 166
DB 1 GGGCTGGCTGGTGACATG 20

RESULT 201

ACF05303 standard; DNA; 20 BP.

AC ACF05303;

DT 06-NOV-2003 (first entry)

DE Rat edg1 lysophospholipid antisense PCR primer.

KW Rat; edg1; lysophospholipid; receptor; hypotensive; cardiant; PCR; primer; ss.

OS Rattus sp.

PN MO2003051395-A2.

PD 26-JUN-2003.

PF 28-NOV-2002; 2002MO-EP013429.

PR 30-NOV-2001; 2001US-0334106P.

PA (SOLV) SOLVAY PHARM GMBH.

PI Molderings Gf, Bruesse M;

DR WPI; 2003-569116/53.

PT Treatment and/or prophylaxis of hypertension, comprises administering an edg-receptor agonist or its pharmaceutically acceptable salt to a mammal.

PS Example; Page 14; 38pp; English.

XX The present sequence is that of an antisense PCR primer for rat
XX lysophospholipid receptor type edg1. The sense primer is given in
XX ACF05302. PCR was performed to obtain evidence for receptor expression,
XX using cDNA from undifferentiated PC12 cells and genomic DNA prepared from
XX rat whole blood. Edg1 PCR products were obtained from the genomic DNA but
XX not from the cDNA. The invention relates to the treatment and/or
XX prophylaxis of hypertension using an edg-receptor agonist, preferably a
XX highly selective 1/1-receptor agonist that is essentially devoid of
XX alpha2-receptor agonist activity, and having an imidazoline structure.

CC Screening tools for identifying such compounds are also provided, where
CC the compound is effective with regard to dysfunctions, disorders or
CC diseases of the cardiovascular system including the heart, blood pressure
CC control e.g. hypertension or vasodilation, myocardial ischemia,
CC ischemic preconditioning, cardioprotective activity and other heart
CC related diseases, nervous system including central nervous system (CNS),
CC and also of glucose and insulin metabolism or with regard to
CC dysfunctions, disorders or diseases related to increased sympathetic
CC tonicity (claimed)

SO Sequence 20 BP; 8 A; 5 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1182 GCAGGAATGATGACACTCA 1201
DB 1 GCAGGCAATGATGACACTCA 20

RESULT 202

ACC99727/c standard; DNA; 20 BP.

AC ACC99727;

DT 02-SEP-2003 (first entry)

DE Beta-tubulin PCR primer SEQ ID NO:108.

KW Multiplex real-time quantitative PCR; PCR primer; copy number;
KW Alzheimer's disease; ss.

OS Synthetic.

PN MO2003048377-A2.

PD 12-JUN-2003.

PF 02-DEC-2002; 2002MO-US038806.

PR 30-NOV-2001; 2001US-0336095P.

PA 19-JUL-2002; 2002US-0397475P.

PI (YRRP) UNIV ROCHESTER.
(THER/) THERIANOS S.

PA Zhu M, Coleman P;

DR WPI; 2003-532841/50.

PT Determining the relative copy number of a group of target nucleic acid
PT molecules present in a sample by performing a first or second PCR in a
PT PCR mixture and quantifying the number of copies of the second target
PT nucleic acid product.

PS Disclosure; Fig 6; 118pp; English.

XX The present invention describes a multiplex real-time quantitative PCR
XX method for determining the relative copy number of a group of target
XX nucleic acid molecules present in a sample. The method comprises: (1)
XX performing a first PCR in a PCR mixture; (2) performing a second PCR in a
XX PCR mixture; and (3) quantifying the number of copies of the second
XX target nucleic acid product present in the sample containing the target
XX nucleic acid molecule. Also described: (1) quantifying the copy number of
XX a group of target nucleic acids in a sample; and (2) determining whether
XX a subject is at risk of acquiring Alzheimer's disease. The method is
XX useful for determining the relative copy number of a group of target
XX nucleic acid molecules present in a sample for determining whether a
XX subject is at risk of acquiring Alzheimer's disease. ACC99620 to ACC99730
XX represent PCR primer used in the exemplification of the present invention

SQ Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1349 ACCGATGCACTTCACCGAG 1368
|||
20 ACGAGATGAGTTCACCGAG 1
Db
RESULT 203
ADB5679
ID ADB5679 standard; DNA; 20 BP.
AC ADB5679;
XX
DT 20-NOV-2003 (first entry)
DE Human connective tissue growth factor antisense oligo DNA (SeqID 72).
XX
XX antisense; human; ss; connective tissue growth factor; CTGF;
KM chromosome 6q23.1; ctgofact; fibroblast inducible secreted protein;
KM fisp-12; NOV2;
KM insulin-like growth factor binding protein-2; IGFBP-rp2;
KM IGFBP-8; Hc624; ecogenin; acute lymphoblastic leukaemia; gene therapy;
KM hyperproliferative disorder; cancer; pulmonary fibrosis; renal fibrosis;
KM scleroderma; atherosclerosis; cystostatic; dermatological;
KM antiarteriosclerotic.
XX
XX Homo sapiens.
OS
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone, where 1-5 and
16-20 are 2' methoxyethyl nucleotides. All cytidines are
5-methylcytidines"
XX
XX W02003053340-A2.
XX
XX 03-JUL-2003.
XX
XX 09-DEC-2002; 2002WO-US038618.
XX
XX 10-DEC-2001; 2001US-00006191.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Gaarde WA, Watt AT;
PI
DR WPI; 2003-559091/52.
XX
XX
PT New antisense oligonucleotides for modulating connective tissue growth
PT factor expression, particularly useful for treating cancers (e.g. breast
PT or prostate cancer), pulmonary or renal fibrosis, scleroderma or
PT atherosclerosis.
XX
XX
PS Claim 3; Page 86; 139pp; English.
XX
XX This invention relates to novel methods for modulating the expression of
XX connective tissue growth factor (CTGF) by antisense oligonucleotides.
XX CTGF has been mapped to human chromosome region 6q23.1, and is also known
XX as ctgofact, fibroblast inducible secreted protein, fisp-12, NOV2.
XX Insulin-like growth factor binding protein-related protein 2, IGFBP-rp2,
XX IGFBP-8, Hc624 and ecogenin. It is known to stimulate DNA synthesis and
XX promote chemotaxis of fibroblasts, however, it is also upregulated in
XX acute lymphoblastic leukaemia and in tumour or endothelial cells
XX associated with the vasculature. Accordingly, antisense oligonucleotides
XX that inhibit the expression of CTGF in cells or tissues can be used in
XX gene therapy to treat various conditions including hyperproliferative
XX disorders (particularly cancer, e.g. breast, prostate or renal cancer),

CC pulmonary fibrosis, renal fibrosis, scleroderma and atherosclerosis. As
CC such, the present invention describes these antisense oligos as having
CC cytosatic, dermatological and antiarteriosclerotic activities. This
CC oligonucleotide sequence is a chimeric phosphorothioate antisense oligo
CC with 2' MOE wings and a deoxy gap, which is used to inhibit expression of
CC human CTGF of the invention.
XX
SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 763 CACGTGCACAGCCACTTGA 782
|||
1 CACGTGCACGTGACTTGA 20
Db
RESULT 204
ADB8985/C
ID ADB8985 standard; DNA; 20 BP.
AC ADB8985;
XX
DT 04-DEC-2003 (first entry)
DE Antisense oligonucleotide targeting human C3 component, ISIS139987.
XX
XX Human; ss; antisense; complement component C3; inflammation;
KM septic shock; multiple organ failure; hyperacute organ failure;
KM autoimmune disorder; CNS inflammation; multiple sclerosis;
KM atherosclerosis; tumour.
XX
XX Homo sapiens.
OS
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone and all cytosines are 5
-methyl cytosines"
XX
XX modified_base 1..5
XX /*tag= a
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
XX
XX US2003096775-A1.
XX
XX 22-MAY-2003.
XX
XX 23-OCT-2001; 2001US-00001076.
XX
XX 23-OCT-2001; 2001US-00001076.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Graham MJ, Watt AT;
PI
DR WPI; 2003-606441/57.
XX
XX
PT New antisense oligonucleotides targeted to a nucleic acid molecule
PT encoding complement component C3, useful for treating a disease or
PT condition associated with complement component C3, e.g. autoimmune
PT disorder or infection.
XX
XX
PS Claim 3; Page 25; 72pp; English.
XX
XX The invention relates to a compound 8-50 nucleobases in length targeted
XX to a nucleic acid molecule encoding complement component C3. The compound

```

CC specifically hybridises with the nucleic acid molecule encoding
CC complement component C3 and inhibits the expression of complement
CC component C3, or specifically hybridises with at least an 8-nucleobase
CC portion of an active site on a nucleic acid molecule encoding complement
CC component C3. Also included are a composition comprising the compound and
CC a pharmaceutical carrier or diluent, inhibiting the expression of
CC complement component C3 in cells or tissues (comprising contacting the
CC cells or tissues with the compound cited above) and treating an animal
CC having a disease or condition associated with complement component C3
CC comprising administering to the animal the compound cited above so that
CC expression of complement component C3 is inhibited. The antisense
CC compound are useful for inhibiting the expression of complement
CC component C3 in cells or tissues, or for treating an animal having a
CC autoimmune disorder (e.g. multiple sclerosis), an infection, or
CC atherosclerosis, inflammation, septic shock, multiple organ failure,
CC hyperacute organ failure and CNS inflammation. The compounds are also
CC useful as research reagents and diagnostics, in distinguishing functions
CC of various members of a biological pathway, or for preventing or delaying
CC infection, inflammation or tumour formation. The present sequence is an
CC antisense oligonucleotide targeting human C3.
XX
SQ Sequence 20 BP; 4 A; 1 C; 8 G; 7 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1348 TACCAATGCACTTCACCCA 1367
DB 20 TACCAATGCACTTCACCCA 1
RESULT 205
ADB68620/C
ID ADB68620 standard; DNA; 20 BP.
XX
AC ADB68620;
XX
DT 04-DEC-2003 (first entry)
XX
DE Microsomal triglyceride transfer protein antisense oligonucleotide #36.
XX
KM microsomal triglyceride transfer protein; antisense oligonucleotide;
KM hybridisation; microsomal triglyceride transfer protein inhibitor;
KM cardiant; antiarteriosclerotic; antilipemic; antisense gene therapy;
KM abnormal lipid metabolism; abnormal cholesterol metabolism;
KM atherosclerosis; cardiovascular disease; human; phosphorothioate; ss;
KM 2'-O-methoxyethyl.
XX
XX Synthetic.
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages, and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
XX WO2003018600-A2.
XX
XX 06-MAR-2003.
XX
XX 17-JUL-2002; 2002WO-US022799.

```

```

XX
XX 30-JUL-2001; 2001US-00917963.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Crooke RM, Graham MJ;
XX
XX WPI; 2003-300705/29.
XX
PT New antisense oligonucleotide compounds, useful for diagnosing,
PT preventing and/or treating conditions with aberrant activity of the
PT microsomal triglyceride transfer protein, such as atherosclerosis and
PT heart disease.
XX
PS Example 15; Page 95; 135pp; English.
XX
CC The present invention describes compounds (I) comprising 8-50 nucleobases
CC in length targeted to a nucleic acid molecule encoding a microsomal
CC triglyceride transfer protein, where the compounds specifically hybridise
CC with and inhibit the expression of the microsomal triglyceride transfer
CC protein. Also described: (1) a compound 8-50 nucleobases in length which
CC specifically hybridises with at least an 8-nucleobase portion of an
CC active site on a nucleic acid molecule encoding microsomal triglyceride
CC transfer protein; (2) a composition comprising (1) and a carrier or
CC diluent; (3) inhibiting the expression of microsomal triglyceride
CC transfer protein in cells or tissues, comprising contacting the cells or
CC tissues with (1) so that expression of microsomal triglyceride transfer
CC protein is inhibited; and (4) treating an animal having a disease or
CC condition associated with microsomal triglyceride transfer protein.
CC comprising administering (1) to the animal so that expression of
CC microsomal triglyceride transfer protein is inhibited. (1) have cardiant,
CC antiarteriosclerotic and antilipemic activities, and can be used in
CC antisense gene therapy. The methods and compositions of the present
CC invention are useful for the diagnosis, prevention and/or treatment of
CC diseases or conditions associated with aberrant expression or activity of
CC microsomal triglyceride transfer protein, such as an abnormal lipid or
CC cholesterol metabolism condition like atherosclerosis and cardiovascular
CC disease. The present sequence represents a human microsomal triglyceride
CC transfer protein chimeric phosphorothioate antisense oligonucleotide,
CC which is used in an example from the present invention.
XX
SQ Sequence 20 BP; 4 A; 3 C; 10 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 146 CCACCGGCTGCCACTGCTC 165
DB 20 CCACCGGCTGCCACTGCTC 1
RESULT 206
ADD21443/C
ID ADD21443 standard; DNA; 20 BP.
XX
AC ADD21443;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human mdm2 antisense oligonucleotide #6.
XX
KM antisense oligonucleotide; human; mdm2; hyperproliferation;
KM hyperproliferative disorder; cancer; postrasls; fibrosis;
KM atherosclerosis; testosls; apoptosis modulation; p21; ss;
KM 2'-methoxyethoxy-residue; phosphorothioate backbone.
XX
XX Homo sapiens.
XX
XX WO2003048315-A2.
XX
XX 12-JUN-2003.
XX

```

```
PF 02-DEC-2002; 2002WO-US038281.
XX
XX 04-DEC-2001; 2001US-00005344.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Miraglia LJ, Nero PS, Graham MJ, Monia BP, Koller E, Chiang MY;
PI Manoharan M;
PS WPI; 2003-577263/54.
XX
XX Novel antisense compound targeted to 5' untranslated region, coding
PT region, or intron:exon junction of nucleic acid molecule encoding mdm2,
PT useful for treating e.g. cancer, psoriasis or restenosis by inhibiting
PT mdm2 expression.
XX
XX Example 2; SEQ ID NO 8; 289pp; English.
XX
XX The invention comprises antisense oligonucleotides which are targeted to
CC the human mdm2 gene. The antisense oligonucleotides of the invention are
CC useful for reducing hyperproliferation of human cells. The antisense
CC oligonucleotides are also useful for treating: hyperproliferative
CC disorders (e.g. cancer), psoriasis, fibrosis, atherosclerosis, or
CC restenosis. The antisense oligonucleotides are also useful for modulating
CC apoptosis, and for increasing expression of p21. The present DNA sequence
CC represents a human mdm2 gene antisense oligonucleotide of the invention.
CC The present sequence contains 2'-methoxyethoxy-residues and has a
CC phosphorothioate backbone.
XX
XX Sequence 20 BP; 1 A; 4 C; 9 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 243 CTCGACGCGGAAACGCG 262
Db 20 CTCGACGCGGAAACCGG 1
RESULT 207
AAF48868
ID AAF48868 standard; DNA; 15 BP.
XX
XX AAF48868;
AC
XX
XX 30-MAR-2001 (first entry)
DT
XX
XX IGFBP3 oligonucleotide #2288.
DE
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiac; virologic; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200078341-A1.
PN
XX
XX 28-DEC-2000.
PD
XX
XX 21-JUN-2000; 2000WO-AU000693.
PF
XX
XX 21-JUN-1999; 99US-0140345P.
PR
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
XX
XX Wraight CJ, Werther GA, Edmondson SR;
```

```
DR WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 7; Page 59; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
XX Sequence 15 BP; 2 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1643 CTGCGCTGCTGCAGA 1657
Db 1 CTGCGCTGCTGCAGA 15
RESULT 208
AAV70949/c
ID AAV70949 standard; DNA; 19 BP.
XX
XX AAV70949;
AC
XX
XX 04-FEB-1999 (first entry)
DT
XX
XX PCR primer used to amplify the p53 gene.
DE
XX
XX MGE tumour-specific antigen gene; disseminated tumour cell;
XX prostate cancer; non-small or small lung cancer; sarcoma;
XX malignant melanoma; breast cancer; colorectal cancer;
XX tumour adjuvant vaccine; p53; PCR primer; ss.
XX
XX Synthetic.
OS
XX
XX Homo sapiens.
XX
XX WO9846788-A2.
PN
XX
XX 22-OCT-1998.
PD
XX
XX 09-APR-1998; 98WO-EP002081.
PF
XX
XX 11-APR-1997; 97EP-00106026.
PR
XX (MICR-) MICROMET GMBH.
PA
XX
XX Kufer P, Zippelius A;
PI
XX
XX WPI; 1998-594590/50.
DR
XX
XX New MAGE-derived primers detecting disseminated tumour cells - hybridise
PT to nucleic acid complementary to the mRNA of a gene encoding a MAGE
PT tumour-specific antigen, used for tumour adjuvant vaccines.
XX
XX Example 3; Page 26; 65pp; English.
PS
```



```

XX PCR primers AAV70948-49 are used to amplify the p53 gene in a RT-PCR
CC reaction. The specification describes primers specific for MAGE genes
CC which are used for detecting disseminated tumour cells which indicate a
CC cancerous condition, such as a condition related to prostate cancer, non-
CC small or small lung cancer, sarcoma, malignant melanoma, breast cancer or
CC colorectal cancer. The PCR products of this detection can be used to
CC prepare a tumour adjuvant vaccine
XX
SQ Sequence 19 BP; 4 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

Query Match      0.7%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      335 TGTTCGAGAGCTGA 349
Db      15 TGTTCGAGAGCTGA 1

RESULT 209
AADI6176
ID AADI6176 standard; DNA; 19 BP.
XX
AC AADI6176;
XX
DT 19-NOV-2001 (first entry)
XX
DE Listeria sp. Identifying PCR upper primer.
XX
XX Cell isolation; bacterial cell; non-specific ligand; eukaryotic parasite;
KM PCR primer; ss.
XX
OS Listeria sp.
XX
PN MO200153525-A2.
XX
PD 26-JUL-2001.
XX
PF 22-JAN-2001; 2001MO-GB000240.
XX
PR 21-JAN-2000; 2000GB-00001450.
XX
PA (GENP-) GENPOINT AS.
XX (GARD/) GARDNER R.
XX
PI Refseth UH, Kolpus T;
XX
DR WPI; 2001-541431/60.
XX
PT Isolating cells from a sample, particularly bacterial cell, comprises
PT binding the cells to a solid support by means of a non-specific ligand
PT immobilized on the solid support.
XX
PS Example 2; Page 29; 77pp; English.
XX
XX The present invention relates to a method for isolating cells from a
CC sample comprising binding the cells to a solid support using a non-
CC specific ligand immobilised on the solid support. The method is useful
CC for isolating a wide variety of microorganisms, specifically bacteria, in
CC a sample. The method may also be used in the isolation of eukaryotic
CC parasites, particularly those which are able to bind the complex
CC polyaccharides found on human cell, to isolate simultaneously bacteria
CC and other types of microorganism, such as algae, protozoa, fungi or
CC viruses, or to capture all types of white blood cells from a blood or
CC blood derived sample, from bone marrow or any tissue or fluid containing
CC white blood cells. The present sequence is a PCR primer which is used for
CC identification of isolated bacteria
XX
SQ Sequence 19 BP; 3 A; 6 C; 5 G; 4 T; 0 U; 1 Other;

Query Match      0.7%; Score 15; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;

```

```

Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy      1971 GATCCGAAACCGTNG 1987
Db      1 GWTCTGAAACCGTGTG 17

RESULT 210
AAF89335
ID AAF89335 standard; DNA; 19 BP.
XX
AC AAF89335;
XX
DT 10-DEC-2001 (first entry)
XX
DE Sample member clustering method related human DNA PCR primer #72.
XX
XX Cluster; hierarchical clustering algorithm; population based study;
KM clinical trial; DNA fingerprint; genetic profile analysis; PCR primer;
KM SNP; single nucleotide polymorphism; ss.
XX
OS Homo sapiens.
XX
PN MO200129257-A2.
XX
PD 26-APR-2001.
XX
PF 20-OCT-2000; 2000MO-IB001632.
XX
PR 22-OCT-1999; 99US-0161231P.
PR 07-JUL-2000; 2000US-0216897P.
XX
PA (GEST ) GENSET.
XX
PI Schork N, Skierczynski B;
XX
DR WPI; 2001-316248/33.
XX
XX Genetic clustering by distributing members into optimal numbers of
PT clusters determined by a hierarchical clustering algorithm or by paired-
PT pair analysis of homozygous pairs in clusters got from non-hierarchical
PT clustering.
XX
PS Claim 61; Page 89; 100pp; English.
XX
XX The present invention describes methods of clustering members of a
CC sample, involving applying a hierarchical clustering algorithm to the
CC sample members, determining the optimal number of clusters based on this
CC and distributing the sample members into clusters using non-hierarchical
CC clustering. The methods are useful in population based studies such as
CC clinical trials, DNA fingerprinting and genetic profile analyses. The
CC present sequence was used to demonstrate the method of the invention
XX
SQ Sequence 19 BP; 10 A; 3 C; 4 G; 2 T; 0 U; 0 Other;

Query Match      0.7%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2185 CTCATGAGAAAAAG 2199
Db      1 CTCATGAGAAAAAG 15

RESULT 211
AAF62952
ID AAF62952 standard; DNA; 20 BP.
XX
AC AAF62952;
XX
DT 08-MAY-2001 (first entry)
XX
DE Mouse PEPCK-cytosolic antisense oligonucleotide ISIS 113352.

```

```

XX KM Mouse; antiinflammatory; cytostatic; antisense gene therapy;
XX KM phosphoenol pyruvate carboxykinase-cytosolic; PEPCK-cytosolic; infection;
XX KM inflammation; tumour formation; phosphorothioate; ss.
XX OS Mus musculus.
XX PN US6187545-B1.
XX PD 13-FEB-2001.
XX PD 21-JAN-2000; 2000US-00488671.
XX PR 21-JAN-2000; 2000US-00488671.
XX PA (ISIS-) ISIS PHARM INC.
XX PI McKay R, Butler MM, Wyatt J, Cowseert LM;
XX DR WPI; 2001-190979/19.
XX PT Antisense compound capable of modulating the expression of phosphoenol
XX PT pyruvate carboxykinase-cytosolic, useful for preventing or delaying
XX PT infection, inflammation or tumor formation.
XX PS Claim 1; Col 44; 64pp; English.
XX CC The present sequence is one of a number of antisense compounds of up to
XX CC 30 nucleobases in length that are capable of inhibiting the expression of
XX CC phosphoenol pyruvate carboxykinase-cytosolic (PEPCK-cytosolic). The
XX CC antisense compounds are useful for inhibiting the expression of PEPCK-
XX CC cytosolic in cells or tissues. They are commonly used as research
XX CC reagents and in diagnostics, e.g. to elucidate the function of particular
XX CC genes. They are also useful for distinguishing between functions of
XX CC various members of a biological pathway and for research use. The
XX CC antisense compounds are also useful prophylactically, e.g. to prevent or
XX CC delay infection, inflammation or tumour formation. The present sequence
XX CC is a chimeric phosphorothioate oligonucleotide with 2'-MOE wings and a
XX CC deoxy gap
XX SQ Sequence 20 BP; 9 A; 5 C; 5 G; 1 T; 0 U; 0 Other;

Query Match      0.7%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      830 AACGAGACGACGAG 844
Db      3 AACGAGACGACGAG 17

RESULT 212
AA05948/c
ID AAD05948 standard; DNA; 20 BP.
XX AC AAD05948;
XX DT 31-JUL-2001 (first entry)
XX DE Human diacylglycerol kinase-zeta intron 13/exon 14 junction sequence.
XX KM Human; catalyst; diacylglycerol; DAG; phosphatidic acid; DAG modulator;
XX KM diacylglycerol kinase zeta; DGK; ds.
XX OS Homo sapiens.
XX FH Key
XX FH Intron      Location/Qualifiers
FT      1..10      /*tag= a
FT      /*number= 13
FT      /*partial
FT      11..20     /*tag= b
FT      exon

```

```

FT      /number= 14
FT      /*partial
XX PN US6221658-B1.
XX PD 24-APR-2001.
XX PD 25-AUG-1999; 99US-00382911.
XX PR 22-APR-1996; 96US-0016210P.
XX PR 22-APR-1997; 97US-00841483.
XX PA (UTAH ) UNIV UTAH RES FOUND.
XX PI Prescott SM, Bunting M, Tang W, Topham M;
XX DR WPI; 2001-327248/34.
XX DR New DNAs of the human diacylglycerol kinase, useful for modulating the
XX PT levels of diacylglycerol kinase in cells to catalyze the conversion of
XX PT diacylglycerol to phosphatidic acid, therefore increasing phosphatidic
XX PT acid levels.
XX PS Disclosure; Col 17-18; 74pp; English.
XX CC The patent discloses novel human diacylglycerol kinase (DGK) isoforms
XX CC namely diacylglycerol kinase epsilon, diacylglycerol kinase zeta,
XX CC diacylglycerol kinase kinase zeta-2 and their corresponding cDNAs. Human
XX CC diacylglycerol kinase DNA is useful for coding human diacylglycerol
XX CC kinase, which is useful for catalyzing the conversion of diacylglycerol
XX CC to phosphatidic acid. In particular, the human diacylglycerol kinase and
XX CC its DNA are useful for increasing intracellular levels of diacyl-
XX CC glycerol (DAG) and for increasing intracellular levels of phosphatidic
XX CC acid in cells. The present DNA sequence is the exon/intron junction
XX CC sequence of human diacylglycerol kinase (DGK) zeta gene
XX SQ Sequence 20 BP; 1 A; 9 C; 7 G; 3 T; 0 U; 0 Other;

Query Match      0.7%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1665 CCAGCCACCGGGG 1679
Db      19 CCAGCCACCGGGG 5

RESULT 213
AAV44610/c
ID AAV44610 standard; DNA; 18 BP.
XX AC AAV44610;
XX DT 24-NOV-1998 (first entry)
XX DE Human uncoupling protein-2 UCP2 gene reverse primer hUCP2g_e6r2.
XX KM Uncoupling protein-2; UCP2 gene; human; respiration; thermogenesis;
XX KM obesity; hyperinsulinemia; glucose intolerance; diabetes; syndrome X;
XX KM hypothermia; wasting; cachexia; anorexia; inflammation; fever;
XX KM hyperthermia; gene therapy; diagnosis; PCR; primer; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN W09831396-A1.
XX PD 23-JUL-1998.
XX PD 22-APR-1997; 97MO-US006864.
XX PR 15-JAN-1997; 97US-0034960P.
XX

```



```

XX PF 29-OCT-1999; 99WO-US025431.
XX PR 30-OCT-1998; 98US-0106308P.
XX PR 26-MAY-1999; 99US-0136078P.
XX PA (CELL-) CELLOMICS INC.
XX PI Giuliano KA, Bright G, Olson K, Burroughs-Tencza S,
XX DR WPI; 2000-365644/31.
XX DR P-PSDB; AAY79581.
XX PT Recombinant nucleic acid encoding a protease biosensor useful for
XX PT fluorescence based cell and molecular biochemical assays for drug
XX PT discovery comprising three operably linked nucleic acid sequences.
XX PS Claim 5; Fig 29A; 218pp; English.
XX XX
XX CC The present sequence is that of DNA encoding the K73 epitope (see
XX CC AAY79581). The DNA can be used in a claimed recombinant nucleic acid
XX CC encoding a protease biosensor. The nucleic acid (see AAZ27627-43)
XX CC comprises: (1) a sequence (see AAA27568-76) encoding at least 1
XX CC detectable polypeptide signal, such as K73; (2) a sequence (see AAA27577-
XX CC 611) that encodes at least 1 protease recognition site; and (3) a
XX CC sequence (see AAA27611-26) that encodes at least 1 reactant target
XX CC sequence. An expression vector, a genetically engineered host cell and a
XX CC recombinant protease biosensor are also claimed. A claimed method for
XX CC identifying compounds that modify protease activity in a cell involves
XX CC contacting a host cell that possesses the recombinant protease biosensor
XX CC with a test compound, and determining the protease biosensor distribution
XX CC in the host cell, where changes in the distribution of the protease
XX CC biosensor are correlated with modification of protease activity by the
XX CC test compound. Claimed kits for identifying compounds that modify
XX CC the protease activity in a host cell include the recombinant nucleic acid, or
XX CC the recombinant protease biosensor, or the vector, or the host cell. The
XX CC protease biosensor is useful in high content screens to detect in vivo
XX CC activation of enzymatic activity, and to identify specific activity based
XX CC on cleavage of a known recognition motif
XX SQ Sequence 18 BP; 9 A; 7 C; 2 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 566 TGTTCCTGTCCTGCTGG 583
Db 18 TGTTCCTGTCCTGCTGG 1
RESULT 216
ABS71488/c
ID ABS71488 standard; DNA; 18 BP.
XX AC ABS71488;
XX DT 27-NOV-2002 (first entry)
XX DE DNA encoding protease biosensor signal sequence #3.
XX KM Detection; classification; identification; toxin detection; protease;
XX KM ADP-ribosylating toxin; cytotoxic phospholipase; exfoliative toxin;
XX KM toxic threat agent; ds.
XX OS Synthetic.
XX PN US6416959-B1.
XX PD 09-JUL-2002.
XX PF 25-FEB-2000; 2000US-00513783.
XX XX

```

```

PR 27-FEB-1997; 97US-00810983.
PR 27-FEB-1998; 98US-00031271.
PR 26-FEB-1999; 99US-0122152P.
PR 08-MAR-1999; 99US-0123339P.
PR 12-JUL-1999; 99US-00352171.
PR 31-AUG-1999; 99US-0151797P.
PR 17-SEP-1999; 99US-00398965.
PR 29-OCT-1999; 99US-00430656.
PR 01-DEC-1999; 99US-0168408P.
XX PA (GIUL/) GIULIANO K.
XX PA (KAPU/) KAPUR R.
XX PI Giuliano K, Kapur R;
XX DR WPI; 2002-634730/68.
XX DR P-PSDB; ABG94441.
XX XX
XX PT Automated cell-based toxin detection, classification, and/or
XX PT identification by treating cells involves use of three classes of
XX PT luminescent reporter molecules such as detectors, classifiers or
XX PT identifiers.
XX PS Example 10; Fig 29A-1; 214pp; English.
XX XX
XX CC The invention describes methods of automated detection, classification
XX CC and identification comprising treating cells containing luminescent
XX CC reporter molecules (I) in array of locations with a test substance, where
XX CC (I) are detectors, classifiers or identifiers, imaging cells in each
XX CC location to obtain luminescent signals and converting optical information
XX CC into digital data to interpret presence of toxins in the test substance.
XX CC The method are useful for detection of toxins chosen from proteases, ADP-
XX CC ribosylating toxins, cytotoxic phospholipases, and exfoliative toxins.
XX CC Three classes of cell-based luminescent reporter molecules such as
XX CC detectors, classifiers and identifiers are described and serve as
XX CC reporters of toxic threat agents. The first two levels of
XX CC characterisation ensure a rapid readout of toxin class without
XX CC sacrificing the ability to detect many new mutant toxins or dissect
XX CC several complex mixtures of known toxins. This sequence encodes a
XX CC protease biosensor related signal sequence used in the cell-based
XX CC screening system
XX SQ Sequence 18 BP; 9 A; 7 C; 2 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 566 TGTTCCTGTCCTGCTGG 583
Db 18 TGTTCCTGTCCTGCTGG 1
RESULT 217
ADC2244/c
ID ADC22444 standard; DNA; 18 BP.
XX AC ADC22444;
XX DT 18-DEC-2003 (first entry)
XX DE K73 epitope nucleotide sequence SEQ ID NO:293.
XX KM recombinant fusion protein; fusion protein; binding; detection;
XX KM localisation domain; binding domain;
XX KM subcellular compartment localisation; gene; ds.
XX OS Synthetic.
XX PN WO2003012068-A2.
XX PD 13-FEB-2003.
XX XX

```



```

DT 02-JUN-1998 (first entry)
XX
DE Primer used in construction of antibody of the invention.
XX
KM Anti-CEA antibody; carcinoembryonic antigen; 806.077 Ab; cancer therapy;
KM cancer diagnosis; complementarity determining region; PCR primer; ss.
XX
OS Synthetic.
XX
PN WO9742329-A1.
XX
PD 13-NOV-1997.
XX
PF 29-APR-1997; 97WO-GB001165.
XX
PR 04-MAY-1996; 96GB-00009405.
PR 14-FEB-1997; 97GB-00003103.
XX
PA (ZENE ) ZENECA LTD.
XX
PI Copley CG, Edge MD, Emery SC;
PI WPI; 1997-558987/51.
XX
PT Anti-carcinoembryonic antigen antibody 806.077 Ab - used for diagnosis
PT and therapy of cancer.
XX
PS Example 48; Page 170; 208pp; English.
XX
CC This sequence is a primer that was used to construct the antibody of the
CC invention. The antibody is an anti-CEA (carcinoembryonic antigen)
CC antibody (806.077 Ab). Host cells or transgenic organisms transformed
CC with DNA encoding the antibody, are used to make the antibody or
CC conjugate. The conjugate is used in a medicament suitable for intravenous
CC administration. The conjugate can be used for cancer therapy, selectively
CC killing tumour cells. The antibody can be used for in vivo or in vitro
CC diagnosis of cancer
XX
SQ Sequence 19 BP; 3 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1645 GCCCTGCTGCAGACTCTG 1662
Db 2 GACCTGCTGCAGACTCTG 19
RESULT 220
AAV41791
ID AAV41791 standard; DNA; 19 BP.
XX
AC AAV41791;
XX
DT 20-NOV-1998 (first entry)
XX
DE Human pancreatic carboxypeptidase B primer 677.
XX
KM ss; primer; PCR; amplification; human; pancreatic carboxypeptidase B;
KM insulin; protein sequencing; prodrug therapy.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9835988-A1.
XX
PD 20-AUG-1998.
XX
PF 10-FEB-1998; 98WO-GB000415.
XX
PR 14-FEB-1997; 97GB-00003104.
PR 18-OCT-1997; 97GB-00022003.

```

```

PR 29-OCT-1997; 97GB-00022727.
XX
XX (ZENE ) ZENECA LTD.
XX
PI Edge MD;
XX
DR WPI; 1998-467168/40.
XX
XX New modified pro-domain of carboxy-peptidase B - enhances expression of
PT co-expressed proteins for production of recombinant carboxy-peptidase or
PT its fusions with antibodies, used, e.g. in enzyme prodrug therapy.
XX
PS Example 1; Page 51; 83pp; English.
XX
XX The primers AAV41785-V41794 were used in the cloning of human pancreatic
CC carboxypeptidase B (CPB). The co-expression of a modified pro-domain of
CC CPB from a separate gene enhances recombinant expression. This process
CC can be used to produce recombinant CPB in eukaryotic cells, or fusions of
CC CPB with antibody chains. CPB is used in insulin production and protein
CC sequencing, while its fusions with antibody are useful in antibody-
CC directed enzyme prodrug therapy. The Modified pro-domain provide
CC increased yields of recombinant CPB, possibly by protecting the C-
CC terminus against enzymatic degradation or by increasing intracellular
CC trafficking
XX
SQ Sequence 19 BP; 3 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1645 GCCCTGCTGCAGACTCTG 1662
Db 2 GACCTGCTGCAGACTCTG 19
RESULT 221
AB272149/c
ID AB272149 standard; DNA; 19 BP.
XX
AC AB272149;
XX
DT 03-APR-2003 (first entry)
XX
DE Gene 216 SSCP detection primer SEQ ID NO 121.
XX
XX Human; Gene 216; chromosome 20p13-p12; anasthetic; anorectic;
KM antiinflammatory; gastrointestinal, gene therapy; vaccine; asthma;
KM obesity; inflammatory bowel disease; primer; ss.
XX
OS Synthetic.
XX
PN WO200178894-A2.
XX
PD 25-OCT-2001.
XX
PF 13-APR-2001; 2001WO-US012245.
XX
PR 13-APR-2000; 2000US-00548797.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
XX
PI Keith T;
XX
DR WPI; 2001-639428/73.
XX
XX Isolated genes (Gene 216) from human chromosome 20p13-p12 and the
PT proteins they encode, useful for the prevention, diagnosis and treatment
PT of asthma, obesity and inflammatory bowel disease.
XX
PS Example 10; Page 148; 520pp; English.
XX
CC The invention relates to isolated genes (Gene 216) from human chromosome

```

CC 20p13-p12 and the proteins they encode. The nucleic acids and proteins
 CC may be used in the prevention, diagnosis and treatment of diseases
 CC associated with inappropriate Gene 216 expression. For example, the
 CC nucleic acids (or vectors) and proteins may be used to treat disorders
 CC associated with decreased expression by rectifying mutations or deletions
 CC in a patient's genome that affect the activity of gene 216 by expressing
 CC inactive proteins or to supplement the patients own production of Gene
 CC 216 proteins. Additionally, the nucleic acids may be used to produce the
 CC secreted Gene 216 protein, by inserting the nucleic acids into a host
 CC cell and culturing the cell to express the protein. The nucleic acids and
 CC complementary sequences may also be used as DNA probes in diagnostic
 CC assays to detect and quantitate the presence of similar nucleic acid
 CC sequences in samples and therefore which patients may be in need of
 CC restorative therapy. The Gene 216 protein may also be used as antigens in
 CC the production of antibodies against Gene 216 and in assays to identify
 CC modulators of Gene 216 expression and activity. The anti-Gene 216
 CC antibodies and antagonists may also be used to down regulate expression
 CC and activity. The anti-Gene 216 antibodies may also be used as diagnostic
 CC agents for detecting the presence of Gene 216 proteins in samples (e.g.
 CC by enzyme linked immunosorbant assay or ELISA). Disorders that may be
 CC prevented, diagnosed and/or treated by the above methods include, for
 CC example asthma, obesity and inflammatory bowel disease. The present
 CC sequence is that of a Gene 216 related primer used in examples of the
 CC invention. The primers are used in the physical mapping of the gene
 CC (ABZ72067-ABZ72088), polymorphism identification using single strand
 CC conformational polymorphism (SSCP) analysis (ABZ72091-ABZ72184),
 CC sequencing (ABZ72185-ABZ72268) and genotyping (ABZ72317-ABZ72362)

XX SQ Sequence 19 BP; 2 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 1.6e+02; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 867 AGAGGACACGTCACCT 884

Db 19 AGAGGACACGACGACCT 2

RESULT 222
 ABX75002/c

ID ABX75002 standard; DNA; 19 BP.

AC ABX75002;

DT 25-MAR-2003 (first entry)

DE Human gene 216 polymorphism detection PCR primer #59.

XX Human; mouse; ss; primer; gene 216; antiasthmatic; antiinflammatory;
 KM anorectic; chromosome 20p13-p12; single nucleotide polymorphism; SNP;
 KM gene therapy; respiratory disease; asthma; obesity; PCR;
 KM bronchial hyper-responsiveness; chronic obstructive pulmonary disease;
 KM adult respiratory distress syndrome; inflammatory bowel syndrome.

OS Homo sapiens.

XX WO200283077-A2.

PD 24-OCT-2002.

PF 15-APR-2002; 2002WO-US012063.

PR 13-APR-2001; 2001US-00834597.

PR 13-APR-2001; 2001WO-US012245.

PA (SCHE) SCHERING CORP.

PI Keith T, Little RD, Van Eerdewegh P, Dupuis J, Del Mastro RG,

PI Simon J, Allen K, Pandit S,

XX WPI; 2003-092960/08.

XX New isolated gene 216 nucleic acids, useful for diagnosing, preventing or
 PT treating a disorder, such as asthma, bronchial hyper-responsiveness,
 PT chronic obstructive pulmonary disease, obesity or inflammatory bowel
 PT syndrome.

PS Example 10; Page 154; 650pp; English.

XX This invention relates to a novel isolated nucleic acid, gene 216,
 CC identified from human chromosome 20p13-p12. The invention also discloses
 CC regions of the 216 gene that contain single nucleotide polymorphisms
 CC (SNPs) which may be used as markers for disease susceptibility or
 CC severity. The nucleotides of the invention may have antiasthmatic,
 CC antiinflammatory or anorectic activities and may be used in gene therapy.
 CC The nucleic acids, antibodies or its fragments are useful for diagnosing,
 CC preventing or treating a disorder, such as respiratory diseases (e.g.
 CC asthma, bronchial hyper-responsiveness, chronic obstructive pulmonary
 CC disease or adult respiratory distress syndrome), obesity, or inflammatory
 CC bowel syndrome. The nucleic acids are also useful for identifying
 CC increased susceptibility of a subject to the disorders mentioned. The
 CC nucleic acids can also be used as primers and templates for the
 CC recombinant production of disorder-associated peptides or polypeptides,
 CC for chromosome and gene mapping, or for tissue distribution studies. The
 CC present sequence represents a gene 216 specific PCR primer used in the
 CC scope of the invention

XX SQ Sequence 19 BP; 2 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 1.6e+02; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 867 AGAGGACACGTCACCT 884

Db 19 AGAGGACACGACGACCT 2

RESULT 223
 ADA25739/c

ID ADA25739 standard; RNA; 19 BP.

AC ADA25739;

DT 20-NOV-2003 (first entry)

DE Human REL-A short interfering nucleic acid SEQ ID NO:87.

XX short interfering nucleic acid; siNA; nuclear factor kappa B; NF-kappaB;
 KM RNA interference; vasotropic; nocotropic; antiparkinsonian;
 KM neuroprotective; cytostatic; antiinflammatory; antiallergic; virostatic;
 KM anti-HIV; immunosuppressive; anticonvulsant; nephroprotectic; gene therapy;
 KM modulation; inhibition; restenosis; central nervous system lesion;
 KM Alzheimer's disease; Parkinson's disease; Huntington's disease; epilepsy;
 KM dementia; amyotrophic lateral sclerosis; cancer;
 KM polycystic kidney disease; inflammatory disease; allergic disease;
 KM viral infection; HIV; autoimmune disease; transplant rejection; ribozyme;
 KM human; V-rel reticuloendotheliosis viral oncogene homologue A; REL-A;
 KM nuclear factor; ss.

OS Synthetic.

XX Homo sapiens.

PN WO2003070970-A2.

PD 28-AUG-2003.

PF 20-FEB-2003; 2003WO-US004951.

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

```

PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L;
XX
XX WPI; 2003-689788/65.
XX
PT New short interfering nucleic acid downregulates expression of the NF-
PT kappaB gene useful e.g. for treatment and diagnosis of cancer and
PT inflammation.
XX
PS Example 3; Page 129; 149pp; English.
XX
XX The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a nuclear factor kappa B (NF-kappaB)
CC gene by RNA interference. Also described: (1) kits for in vitro or in
CC vivo delivery of siNA; (2) conjugates and/or complexes of siNA; and (3)
CC vectors that express siNA. The siNAs have vasotropic, neurotropic,
CC antiparkinsonian, neuroprotective, cytoskeletal, antiinflammatory,
CC antiallergic, virucide, anti-HIV, immunosuppressive, anticonvulsant and
CC nephrotropic activities, and can be used in gene therapy, and for the
CC modulation (inhibition) of expression or activity of NF-kappaB by RNA
CC interference (siNA target mRNA, RNA splice variants, post-
CC transcriptionally modified RNA, pre-RNA and/or RNA templates). The siNA
CC sequences can be used to modulate expression of NF-kappaB genes, in
CC cells, tissue explants or organisms, e.g. by ex vivo gene therapy, in
CC grafts and transplants for treating restenosis and central nervous system
CC lesions and injuries (Alzheimer's, Parkinson's or Huntington's diseases,
CC epilepsy, dementia or amyotrophic lateral sclerosis) or for treating many
CC cancers, other proliferative diseases (restenosis and polycystic kidney
CC disease), inflammatory and/or allergic diseases, viral infections
CC (including HIV), autoimmune diseases and transplant rejection, and also
CC for drug screening; diagnosis; target identification and validation;
CC genetic engineering; pharmacogenomics; studying gene function and gene
CC mapping (e.g. of single-nucleotide polymorphisms). The present sequence
CC represents human v-rel reticuloendotheliosis viral oncogene homologue A
CC (REL-A) siNA, which is used in the exemplification of the present
CC invention. REL-A is a nuclear factor of the kappa light polypeptide gene
CC enhancer in B-cells.
XX
SQ Sequence 19 BP; 1 A; 9 C; 8 G; 0 T; 1 U; 0 Other;
Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 355 TGGGGAGACCCCGGGTCC 372
Db 19 TGGGGAGACCCCGGGGCC 2

```

```

KW nuclear factor; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO2003070970-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US004951.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Beigelman L;
XX
XX WPI; 2003-689788/65.
XX
XX New short interfering nucleic acid downregulates expression of the NF-
PT kappaB gene useful e.g. for treatment and diagnosis of cancer and
PT inflammation.
XX
PS Example 3; Page 129; 149pp; English.
XX
XX The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a nuclear factor kappa B (NF-kappaB)
CC gene by RNA interference. Also described: (1) kits for in vitro or in
CC vivo delivery of siNA; (2) conjugates and/or complexes of siNA; and (3)
CC vectors that express siNA. The siNAs have vasotropic, neurotropic,
CC antiparkinsonian, neuroprotective, cytoskeletal, antiinflammatory,
CC antiallergic, virucide, anti-HIV, immunosuppressive, anticonvulsant and
CC nephrotropic activities, and can be used in gene therapy, and for the
CC modulation (inhibition) of expression or activity of NF-kappaB by RNA
CC interference (siNA target mRNA, RNA splice variants, post-
CC transcriptionally modified RNA, pre-RNA and/or RNA templates). The siNA
CC sequences can be used to modulate expression of NF-kappaB genes, in
CC cells, tissue explants or organisms, e.g. by ex vivo gene therapy, in
CC grafts and transplants for treating restenosis and central nervous system
CC lesions and injuries (Alzheimer's, Parkinson's or Huntington's diseases,
CC epilepsy, dementia or amyotrophic lateral sclerosis) and for treating many
CC cancers, other proliferative diseases (restenosis and polycystic kidney
CC disease), inflammatory and/or allergic diseases, viral infections
CC (including HIV), autoimmune diseases and transplant rejection, and also
CC for drug screening; diagnosis; target identification and validation;
CC genetic engineering; pharmacogenomics; studying gene function and gene
CC mapping (e.g. of single-nucleotide polymorphisms). The present sequence
CC represents human v-rel reticuloendotheliosis viral oncogene homologue A
CC (REL-A) siNA, which is used in the exemplification of the present
CC invention. REL-A is a nuclear factor of the kappa light polypeptide gene
CC enhancer in B-cells.
XX
SQ Sequence 19 BP; 1 A; 8 C; 9 G; 0 T; 1 U; 0 Other;
Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 355 TGGGGAGACCCCGGGTCC 372
Db 1 UGGGGAGACCCCGGGGCC 18

```

```

RESULT 224
ADA26088
ID ADA26088 standard; RNA; 19 BP.
XX
AC ADA26088;
XX
XX 20-NOV-2003 (first entry)
XX
DE Human REL-A short interfering nucleic acid SEQ ID NO:223.
XX
XX short interfering nucleic acid; siNA; nuclear factor kappa B; NF-kappaB;
KM RNA interference; vasotropic; neurotropic; antiparkinsonian;
KM neuroprotective; cytoskeletal; antiinflammatory; antiallergic; virucide;
KM anti-HIV; immunosuppressive; anticonvulsant; nephrotropic; gene therapy;
KM modulation; inhibition; restenosis; central nervous system lesion;
KM Alzheimer's disease; Parkinson's disease; Huntington's disease; epilepsy;
KM dementia; amyotrophic lateral sclerosis; cancer;
KM polycystic kidney disease; inflammatory disease; transplant rejection; ribozyme;
KM viral infection; HIV; autoimmune disease; cancer; allergic disease;
KM human; v-rel reticuloendotheliosis viral oncogene homologue A; REL-A;
KM

```

```

RESULT 225
ADA25493/c
ID ADA25493 standard; RNA; 19 BP.
XX

```


AC ADA25493;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PKC-alpha short interfering nucleic acid SEQ ID NO:224.
 XX
 KM short interfering nucleic acid; siNA; protein kinase C alpha; PKC-alpha;
 KM RNA interference; cytostatic; vasotropic; nephrotropic; modulation;
 KM inhibition; cancer; breast cancer; ovarian cancer; lung cancer;
 KM prostate cancer; glioblastoma; proliferative disease; restenosis;
 KM polycystic kidney disease; human; ribozyme; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO2003070983-A1.
 XX
 PD 28-AUG-2003.
 XX
 PF 11-FEB-2003; 2003WO-US004034.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 18-SEP-2002; 2002US-0411707P.
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 PI Mcswiggen J, Beigelman L;
 DR WPI; 2003-679891/64.
 XX
 PT New short interfering nucleic acid, useful e.g. for treatment and
 PT diagnosis of cancer and restenosis, downregulates expression of the
 PT protein kinase C-alpha gene.
 XX
 PS Example 3; Page 120; 143pp; English.
 XX
 CC The present invention describes a short interfering nucleic acid (siNA)
 CC that downregulates expression of a protein kinase C-alpha (PKC-alpha)
 CC gene by RNA interference. Also described: (1) a siNA that modulates
 CC expression and/or activity of genes for other isoforms of PKC or genes
 CC involved in the PKC pathway; (2) kits for in vitro or in vivo delivery of
 CC siNA; (3) conjugates and/or complexes of siNA; and (4) vectors that
 CC express siNA. The siNA sequences have cytostatic, vasotropic and
 CC nephrotropic activities, and can be used in the modulation (inhibition)
 CC of expression of the PKC-alpha gene by RNA interference. The siNA can be
 CC used to modulate expression of PKC-alpha genes. They are potentially
 CC useful in treating a variety of cancers including e.g. breast cancer,
 CC cancer of the head and neck, ovarian cancer, lung cancer, prostate
 CC cancer, and glioblastoma and for treating other proliferative diseases
 CC and conditions, such as restenosis and polycystic kidney disease. The
 CC siNA may also be useful for diagnosis, drug screening, target
 CC identification, and for gene mapping (e.g. of single-nucleotide polymorphisms).
 CC The present sequence represents a human PKC-alpha siNA, which is used in
 CC the exemplification of the present invention.
 XX
 SO Sequence 19 BP; 4 A; 10 C; 5 G; 0 T; 0 U; 0 Other;
 Query Match 0.7%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 226
 ADA25368
 ID ADA25368 standard; RNA; 19 BP.
 XX
 AC ADA25368;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PKC-alpha short interfering nucleic acid target SEQ ID NO:99.
 XX
 KM short interfering nucleic acid; siNA; protein kinase C alpha; PKC-alpha;
 KM RNA interference; cytostatic; vasotropic; nephrotropic; modulation;
 KM inhibition; cancer; breast cancer; ovarian cancer; lung cancer;
 KM prostate cancer; glioblastoma; proliferative disease; restenosis;
 KM polycystic kidney disease; human; ribozyme; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO2003070983-A1.
 XX
 PD 28-AUG-2003.
 XX
 PF 11-FEB-2003; 2003WO-US004034.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 18-SEP-2002; 2002US-0411707P.
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 PI Mcswiggen J, Beigelman L;
 DR WPI; 2003-679891/64.
 XX
 PT New short interfering nucleic acid, useful e.g. for treatment and
 PT diagnosis of cancer and restenosis, downregulates expression of the
 PT protein kinase C-alpha gene.
 XX
 PS Example 3; Page 120; 143pp; English.
 XX
 CC The present invention describes a short interfering nucleic acid (siNA)
 CC that downregulates expression of a protein kinase C-alpha (PKC-alpha)
 CC gene by RNA interference. Also described: (1) a siNA that modulates
 CC expression and/or activity of genes for other isoforms of PKC or genes
 CC involved in the PKC pathway; (2) kits for in vitro or in vivo delivery of
 CC siNA; (3) conjugates and/or complexes of siNA; and (4) vectors that
 CC express siNA. The siNA sequences have cytostatic, vasotropic and
 CC nephrotropic activities, and can be used in the modulation (inhibition)
 CC of expression of the PKC-alpha gene by RNA interference. The siNA can be
 CC used to modulate expression of PKC-alpha genes. They are potentially
 CC useful in treating a variety of cancers including e.g. breast cancer,
 CC cancer of the head and neck, ovarian cancer, lung cancer, prostate
 CC cancer, and glioblastoma and for treating other proliferative diseases
 CC and conditions, such as restenosis and polycystic kidney disease. The
 CC siNA may also be useful for diagnosis, drug screening, target
 CC identification, and for gene mapping (e.g. of single-nucleotide polymorphisms).
 CC The present sequence represents a human PKC-alpha siNA target, which is
 CC used in the exemplification of the present invention.
 XX
 SO Sequence 19 BP; 0 A; 5 C; 10 G; 0 T; 4 U; 0 Other;
 Query Match 0.7%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 72.2%; Pred. No. 1.6e+02;
 Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```

Db      2 GGCUGGCGUGUGGCGCUG 19
      ||:|||||:|||||:|
RESULT 227
ADE30297
ID      ADE30297 standard; RNA, 19 BP.
XX
AC      ADE30297;
XX
DT      29-JAN-2004 (first entry)
XX
DE      Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:919.
XX
KM      short interfering nucleic acid; siNA; downregulation; inhibition;
KM      mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KM      cytostatic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KM      immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KM      antipruritic; gastrointestinal; obesity; diabetes; tumour;
KM      inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KM      psoriasis; inflammatory bowel disease; drug screening;
KM      genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS      Synthetic.
XX
PN      WO2003072590-A1.
XX
PD      04-SEP-2003.
XX
PF      28-JAN-2003; 2003WO-US002510.
XX
PR      20-FEB-2002; 2002US-0358580P.
PR      11-MAR-2002; 2002US-0363124P.
PR      06-JUN-2002; 2002US-036782P.
PR      29-AUG-2002; 2002US-0406784P.
PR      05-SEP-2002; 2002US-0408378P.
PR      09-SEP-2002; 2002US-0409293P.
PR      15-JAN-2003; 2003US-0440129P.
XX
PA      (SIRN-) SIRNA THERAPEUTICS INC.
PI      Mcswigen J, Belgelman L, Usman N, Haeblerl P, Chowrira B;
DR      WPI; 2003-689980/65.
XX
PT      New short interfering nucleic acid, useful e.g. for treatment and
PT      diagnosis of cancer, downregulates expression of mitogen-activated
PT      protein kinase genes.
XX
PS      Example 3; SEQ ID NO 919; 164pp; English.
XX
CC      The present invention describes a short interfering nucleic acid (siNA)
CC      that downregulates expression of a mitogen-activated protein kinase
CC      (MAPK) genes by RNA interference. Also described: (1) a method for
CC      modulating expression of MAPK genes in cells, tissue explants or
CC      organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC      delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC      vectors that express siNA and cells containing these vectors. MAPK siNAs
CC      have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC      antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC      antiarthritic, antipruritic and gastrointestinal activities. The MAPK
CC      siNAs can be used to modulate the expression of MAPK genes, in cells,
CC      tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC      and II; a wide range of tumours, and inflammatory diseases (asthma,
CC      septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC      disease). They can also be used for drug screening; diagnosis; target
CC      identification and validation; genetic engineering; pharmacogenomics;
CC      studying gene function and gene mapping (e.g. of single-nucleotide
CC      polymorphisms). The present sequence represents a MAPK siNA which is used
CC      in the exemplification of the present invention.
XX
SQ      Sequence 19 BP; 1 A; 10 C; 5 G; 0 T; 3 U; 0 Other;

```

```

Query Match      0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 1.6e+02;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Gy      1455 CCCGCGCGCCGCCACCG 1472
      ||:|||||:|||||
Db      2 CCCUGGCGUGCGCCCG 19
RESULT 228
ADE30088/c
ID      ADE30088 standard; RNA, 19 BP.
XX
AC      ADE30088;
XX
DT      29-JAN-2004 (first entry)
XX
DE      Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:710.
XX
KM      short interfering nucleic acid; siNA; downregulation; inhibition;
KM      mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KM      cytostatic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KM      immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KM      antipruritic; gastrointestinal; obesity; diabetes; tumour;
KM      inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KM      psoriasis; inflammatory bowel disease; drug screening;
KM      genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS      Synthetic.
XX
PN      WO2003072590-A1.
XX
PD      04-SEP-2003.
XX
PF      28-JAN-2003; 2003WO-US002510.
XX
PR      20-FEB-2002; 2002US-0358580P.
PR      11-MAR-2002; 2002US-0363124P.
PR      06-JUN-2002; 2002US-036782P.
PR      29-AUG-2002; 2002US-0406784P.
PR      05-SEP-2002; 2002US-0408378P.
PR      09-SEP-2002; 2002US-0409293P.
PR      15-JAN-2003; 2003US-0440129P.
XX
PA      (SIRN-) SIRNA THERAPEUTICS INC.
PI      Mcswigen J, Belgelman L, Usman N, Haeblerl P, Chowrira B;
DR      WPI; 2003-689980/65.
XX
PT      New short interfering nucleic acid, useful e.g. for treatment and
PT      diagnosis of cancer, downregulates expression of mitogen-activated
PT      protein kinase genes.
XX
PS      Example 3; SEQ ID NO 710; 164pp; English.
XX
CC      The present invention describes a short interfering nucleic acid (siNA)
CC      that downregulates expression of a mitogen-activated protein kinase
CC      (MAPK) genes by RNA interference. Also described: (1) a method for
CC      modulating expression of MAPK genes in cells, tissue explants or
CC      organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC      delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC      vectors that express siNA and cells containing these vectors. MAPK siNAs
CC      have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC      antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC      antiarthritic, antipruritic and gastrointestinal activities. The MAPK
CC      siNAs can be used to modulate the expression of MAPK genes, in cells,
CC      tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC      and II; a wide range of tumours, and inflammatory diseases (asthma,
CC      septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC      disease). They can also be used for drug screening; diagnosis; target
CC      identification and validation; genetic engineering; pharmacogenomics;
CC      studying gene function and gene mapping (e.g. of single-nucleotide

```

CC polymorphisms). The present sequence represents a MAPK siNA which is used
 CC in the exemplification of the present invention.
 XX
 SO Sequence 19 BP; 3 A; 5 C; 10 G; 0 T; 1 U; 0 Other;

Query Match 0.7%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1455 CCTGCTGCCCCACCAG 1472
 DB 18 CCTGCTGCCCCACCAG 1

RESULT 229
 ABRK16959
 ID ABRK16959 standard; DNA, 15 BP.
 AC ABRK16959;
 XX
 DT 26-MAR-2002 (first entry)
 XX
 DE Pyridoxal (Pyridoxine, vitamin B6) kinase (PDXK) PCR primer #20.
 XX
 KM Pyridoxal kinase; pyridoxine; vitamin B6;
 KM PDXK autoimmune polyglanular disease type 1; transgenic animal;
 KM gene therapy; allele specific oligonucleotide; ASO; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200190125-A2.
 PD 29-NOV-2001.
 XX
 PF 24-MAY-2001; 2001WO-US016909.
 XX
 PR 24-MAY-2000; 2000US-0206664P.
 XX
 PA (GENA-) GENA155ANCE PHARM INC.
 XX
 PI Chew A, Duda A, Koshy B;
 PT WPI; 2002-106169/14.
 XX
 DR Isolated human pyridoxal (pyridoxine, vitamin B6) kinase, polyNTs, useful
 PT for therapeutic purposes, for studying the expression and function of the
 PT polyNT, and for expressing pyridoxal protein.
 XX
 PS Claim 17; Page 13; 135pp; English.
 XX
 CC The invention describes an isolated human pyridoxal (pyridoxine, vitamin
 CC B6) kinase, (PDXK) polynucleotide. The polynucleotide is useful in
 CC studying the expression and function of PDXK, and in expressing PDXK
 CC protein for use in screening for candidate drugs to treat PDXK related
 CC diseases and for therapeutic purposes. A transgenic animal is useful for
 CC studying expression of the PDXK isogenes in vivo, for in vivo screening
 CC and testing of drugs targeted against PDXK protein, and for testing the
 CC efficacy of therapeutic agents and compounds for autoimmune polyglanular
 CC disease type 1. The polypeptide is useful for studying the effect of the
 CC variation on the biological activity of PDXK and the binding affinity of
 CC candidate drugs targeting PDXK for the treatment of autoimmune
 CC polyglanular disease type 1. Genotyping and haplotyping is useful for
 CC improving the efficacy and reliability of several steps in the discovery
 CC and development of drugs for treating diseases associated with PDXK
 CC activity, e.g., autoimmune polyglanular disease type 1, to validate PDXK
 CC as a candidate agent for treating a specific condition or disease
 CC predicted to be associated with PDXK activity, and in the design of
 CC clinical trials of candidate drugs. This sequence is one of 37 (see
 CC ABRK16941-ABRK16977) allele specific oligonucleotide (ASO) PCR primers used
 CC for detecting PDXK gene polymorphisms, described in the method of the
 CC invention
 CC
 SO Sequence 15 BP; 3 A; 4 C; 5 G; 2 T; 0 U; 1 Other;

*Query Match 0.6%; Score 14.6; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.3e+02;
 Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 500 GCGGCTCTGGAACCC 514
 DB 1 GCGGCTCTGGAACCC 15

RESULT 230
 AAQ42677
 ID AAQ42677 standard; DNA, 17 BP.
 AC AAQ42677;
 XX
 DT 25-MAR-2003 (revised)
 DT 18-FEB-1999 (first entry)
 XX
 DE PCR primer Clamut-Kan for constructing mycobact'1 integrating plasmid.
 XX
 KM cytotoxic T-lymphocyte response; transformed Mycobacteria; BCG;
 KM Mycobacterium emegnat's; vaccine; cell mediated immunity; HIV; pertussis;
 KM malaria; influenza virus; CTL; herpes virus; ss.
 XX
 OS Mycobacterium.
 XX
 PN WO9221374-A1.
 PD 10-DEC-1992.
 XX
 PF 01-JUN-1992; 92WO-US005023.
 XX
 PR 06-JUN-1991; 91US-00711084.
 XX
 PA (MEDI-) MEDIMUNE INC.
 XX
 PI Stover CK, Dela Cruz V;
 PT WPI; 1992-43378/52.
 XX
 DR Tetanus vaccination - by provoking an immune response using transformed
 PT Mycobacteria.
 XX
 PS Example 3; Page 13; 86pp; English.
 XX
 CC This PCR primer was used with AAQ42678 in order to construct an
 CC integrating plasmid including mycobacterial promoter expression cassette,
 CC and the HIV-1 gp120 gene. Plasmid pMV101 was used as template. (updated
 CC on 25-MAR-2003 to correct PN field.)
 XX
 SO Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1690 TTGATGGAAGCCCC 1705
 DB 2 TTGATGGAAGCCCC 17

RESULT 231
 AAQ21561
 ID AAQ21561 standard; DNA, 17 BP.
 AC AAQ21561;
 XX
 DT 03-JUN-1992 (first entry)
 XX
 DE PCR primer Clamut-Kan for mutagenesis of plasmid pMV101.
 XX
 KM Polymerase chain reaction; mycobacterial promoter; kanamycin; resistance;

KM BCG; Bacille Calmette-Guerin; site-specific integration; ss.
 XX Synthetic.
 XX
 PN WO9201783-A.
 XX
 PD 06-FEB-1992.
 XX
 PF 16-JUL-1990; 90US-00553907.
 XX
 PR 16-JUL-1990; 90US-00553907.
 XX
 PA (YESH) EINSTEIN A COLLEGE.
 PA (UPLI-) UNIV OF PITTSBURGH.
 XX
 PI Jacobs WR, Hatfull G;
 XX
 DR WPI; 1992-064943/08.
 XX
 PT DNA site-specific integration into mycobacteria - useful as adjuvant in
 PT vaccines and as therapeutic agent for malaria, influenza, herpes and
 PT human immunodeficiency virus.
 XX
 PS Example 3; Page 19; 82pp; English.
 XX
 CC PCR mutagenesis was performed on plasmid pMV101 (see AAR20991-3) to
 CC remove the ClaI and HindIII sites in the aph gene. Primer ClaMut-Kan was
 CC used with primer HindRmut-Kan (see AAQ21562) and the primer pair HindRmut
 CC -Kan and Bam-Kan (see AAQ21563-4) was used in a separate reaction. The
 CC amplified products were mixed and a single PCR reaction without primers
 CC was performed (94 deg.C for 1 min, 72 deg.C for 1 min, 10 cycles).
 CC Primers ClaMut-Kan and Bam-Kan were added and PCR was resumed. The
 CC resulting PCR product was ligated to ClaI-digested, end-filled pMV101 and
 CC the ligation mixture was transformed into E.coli HB101. Kanamycin-
 CC resistant colonies were screened for plasmids resistant to ClaI and
 CC HindIII digestion. Such plasmids were designated pMV110
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1690 TTGGATGGGAAGCCCC 1705
 Db 2 TTGTATGGGAAGCCCC 17
 RESULT 232
 AAQ31733
 ID AAQ31733 standard; DNA; 17 BP.
 XX
 AC AAQ31733;
 XX
 DT 25-MAR-2003 (revised)
 DT 18-FEB-1999 (first entry)
 XX
 DE PCR primer ClaMut-Kan for constructing mycobact'l integrating plasmid.
 XX
 KM cytotoxic T-lymphocyte response; transformed Mycobacteriia; BCG;
 KM Mycobacterium smegmatis; vaccine; cell mediated immunity; HIV; pertussis;
 KM malaria; influenza virus; CTL; herpes virus; ss.
 XX
 OS Mycobacterium.
 XX
 PN WO9221376-A1.
 XX
 PD 10-DEC-1992.
 XX
 PF 01-JUN-1992; 92WO-US004538.
 XX
 PR 06-JUN-1991; 91US-00711643.
 XX

PA (MEDI-) MEDIMMUNE INC.
 XX
 PI Stover CK, Dela Cruz V;
 XX
 DR WPI; 1992-433380/52.
 XX
 XX Method of inducing cytotoxic T-lymphocyte response - esp. expression
 PT products of transformed Mycobacterium are useful as vaccines against HIV,
 PT pertussis, malaria, influenza virus, herpes virus, etc.
 XX
 PS Example 3; Page 14; 86pp; English.
 XX
 CC This PCR primer was used with AAQ31734 in order to construct an
 CC integrating plasmid including mycobacterial promoter expression cassette,
 CC and the HIV-1 gp120 gene. Plasmid pMV101 was used as template. (updated
 CC on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1690 TTGGATGGGAAGCCCC 1705
 Db 2 TTGTATGGGAAGCCCC 17
 RESULT 233
 AAQ41301
 ID AAQ41301 standard; DNA; 17 BP.
 XX
 AC AAQ41301;
 XX
 DT 25-MAR-2003 (revised)
 DT 04-JUN-1993 (first entry)
 XX
 DE PCR primer ClaMut-Kan for eliminating undesirable restriction sites.
 XX
 KM cytotoxic T-lymphocyte response; transformed Mycobacteriia; BCG;
 KM Mycobacterium smegmatis; vaccine; cell mediated immunity; HIV; pertussis;
 KM malaria; influenza virus; CTL; herpes virus.
 XX
 OS Mycobacterium.
 XX
 PN WO9307897-A1.
 XX
 PD 29-APR-1993.
 XX
 PF 21-OCT-1992; 92WO-US009075.
 XX
 PR 21-OCT-1991; 91US-00780261.
 XX
 PA (MEDI-) MEDIMMUNE INC.
 XX
 PI Stover CK;
 XX
 DR WPI; 1993-152187/18.
 XX
 PT Expression vector for expressing protein or polypeptide in mycobacterium
 PT - conig DNA sequences encoding lipoprotein secretion signal and peptide
 PT heterologous to bacteria expressing fusion protein of lipoprotein
 PT heterologous to bacteria.
 XX
 PS Example 1; Page 16; 86pp; English.
 XX
 CC This PCR primer was used with AAQ41302 in order to eliminate undesirable
 CC restriction sites in the aph (kanR) gene. Plasmid pMV101 was used as
 CC template. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1690 TTGGATGGGAAGCCCC 1705
||| ||||| ||||| |||||
DB 2 TTGTATGGGAAGCCCC 17

RESULT 234

AA068674
ID AA068674 standard; DNA; 17 BP.

XX AA068674;

XX 25-MAR-2003 (revised)

DT 20-JAN-1995 (first entry)

XX Primer Clamut-Kan for plasmid pMW110 construction.

XX Primer; Clamut-Kan; pMW110; vaccine; ss.

XX Streptococcus pneumoniae.

XX MO9414318-A1.

PD 07-JUL-1994.

XX 20-DEC-1993; 93MO-US012504.

PR 24-DEC-1992; 92US-00996689.

XX (MEDI-) MEDIMUNE INC.

PA (UABR-) UAB RES FOUND.

PI Brilee D, Stover CK;

XX WPI; 1994-234231/28.

XX Protecting an animal against Streptococcus pneumoniae - by administering

PT mycobacteria transformed with DNA which includes a sequence which encodes

PS protein or polypeptide which elicits antibodies against S. pneumoniae.

XX Disclosure; Page 10; 53pp; English.

CC The primer is used in the construction of the mycobacterial expression

CC vector pMW110, specifically for elimination of undesirable restriction

CC sites in the kanamycin-resistance gene of pMW101. pMW10 encodes a

CC protein eliciting antibodies against S. pneumoniae, and transformed

CC Mycobacterium spp. are used in a recombinant vaccine. (Updated on 25-MAR-

CC 2003 to correct PN field.)

XX Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

QY 1690 TTGGATGGGAAGCCCC 1705
||| ||||| ||||| |||||
DB 2 TTGTATGGGAAGCCCC 17

RESULT 235

AA062264
ID AA062264 standard; RNA; 17 BP.

XX AA062264;

XX 16-JUL-1999 (first entry)

XX Granule bound starch synthase hammerhead substrate SEQ ID NO:139.

XX Maize; corn; Zea mays; delta-9 desaturase; GBSS; target; substrate;

KM granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;
KM modulation; gene expression; transgenic plant; cleavage; canola plant;
KM caffeine synthesis; coffee plant; nicotine production; tobacco;
KM fruit ripening; flower pigmentation; lignin production; ss.

XX Zea mays.

XX MO9710328-A2.

XX 20-MAR-1997.

XX 12-JUL-1996; 96MO-US011689.

XX 13-JUL-1995; 95US-0001135P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (DOWC) DOWELANCO.

PI Zwick MG, Edington BE, Mcswiggen JA, Merlo PAO, Guo L, Skokut TA;

XX Young SA, Folkerts O, Merlo DJ;

XX WPI; 1997-202224/18.

XX Ribozyme which modulates plant gene expression - preferably modulates

PT expression of DELTA-9 desaturase or granule bound starch synthase in

PT maize or canola.

PS Claim 41; Page 74; 155pp; English.

XX The present invention describes an enzymatic nucleic acid molecule (1)

CC with RNA cleaving activity, which modulates the expression of a plant

CC gene. Also described is a gene comprising a cDNA sequence encoding maize

CC Delta-9 desaturase. (1) can be used to modulate expression of a gene

CC preferably Delta-9 desaturase or a granule bound starch synthase (GBSS)

CC gene, in a plant (preferably a maize or canola plant). (1) can be used to

CC modulate caffeine synthesis in a coffee plant, nicotine production in a

CC tobacco plant, fruit ripening processes in an apple, tomato, pear, plum

CC or peach plant, flower pigmentation in a rose, petunia, chrysanthemum or

CC marigold plant or lignin production in a tobacco, aspen, poplar or pine

CC plant

XX Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;

QY 2179 CAGCAGCTCATGAGAGA 2194
||| ||||| ||||| |||||
DB 1 CCGCAGCTCATGAGAGA 16

RESULT 236
AAA24820/c
ID AAA24820 standard; DNA; 17 BP.

XX AAA24820;

XX 19-JUL-2000 (first entry)

XX Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1318.

XX Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;

XX hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;

XX gene expression modification; cancer; phosphorothioate; endonuclease;

XX anticancer; breast cancer; endometrium cancer; ss.

XX Homo sapiens.

XX MO9954459-A2.

XX 28-OCT-1999.

```

PF 19-APR-1999; 99WU-US008547.
XX
XX 20-APR-1998; 98US-0082404P.
PR 23-JUN-1998; 98US-00103636.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Thompson JD, Beigelman L, Meswiggen JA, Karpelesky A, Bellon L,
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerl P,
PI Matulic-Adamic J;
XX
XX WPI; 2000-013248/01.
XX
XX New nucleic acids that interact, and optionally cleave, target sequences,
PT used to treat cancer.
XX
XX Claim 77; Page 59; 148pp; English.
XX
XX The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphor(di)thioate
CC link, having endonuclease activity. (A), and more generally any catalytic
CC nucleic acid (A) that modulates expression of the oestrogen receptor
CC gene, are used to treat cancer (particularly of breast or endometrium),
CC in vivo or by transforming cells ex vivo and implanting treated cells, or
CC for other conditions associated with levels of oestrogen receptor.
CC Because of the high selectivity for targeted RNA, (A) can also be used to
CC correlate inhibition of gene expression with alterations in phenotype,
CC particularly for identification of therapeutic targets, and as research
CC reagents (for RNA, in the same way that restriction endonucleases are
CC used with DNA). The combination of modifications in (A) improves
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
CC AAA24748 to AAA25992 represent their corresponding target sequences.
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
CC sequences. AAA26107 to AAA26218 represent their corresponding target
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC antisense oligonucleotides used in the exemplification of the present
CC invention
XX
XX SQ Sequence 17 BP; 1 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 1.6e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 540 GGGCTCGAGACGCGC 555
XX |||||
XX 16 GGGCTCGAGACGCGC 1
XX
XX Db
XX
XX RESULT 237
XX ABA77757
XX ID ABA77757 standard; DNA; 17 BP.
XX
XX ABA77757;
XX
XX 24-JAN-2002 (first entry)
XX
XX DE Retinoblastoma mutation correcting oligonucleotide SEQ ID NO: 603.
XX
XX Human, gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MHL1; APOB;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytoskeletal; antistickling; antianaemic; haemostatic;
XX antilipemic; ss.
XX
XX OS Homo sapiens.
XX

```

```

EN W0200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX
XX 27-MAR-2000; 2000US-0192179P.
XX
XX 01-JUN-2000; 2000US-0208538P.
XX
XX 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE ) UNIV DELAWARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
XX
XX WPI; 2001-639230/73.
XX
XX DR
XX
XX PT Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX
XX Claim 7; Page 80; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MHL1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX
XX SQ Sequence 17 BP; 6 A; 7 C; 3 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 1.6e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1806 CCGAGCCGAGAGCA 1821
XX |||||
XX 2 CCGAGCCGAGAGCA 17
XX
XX Db
XX
XX RESULT 238
XX ABA77758/C
XX ID ABA77758 standard; DNA; 17 BP.
XX
XX ABA77758;
XX
XX 24-JAN-2002 (first entry)
XX
XX DE Retinoblastoma mutation correcting oligonucleotide SEQ ID NO: 604.
XX
XX Human, gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MHL1; APOB;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytoskeletal; antistickling; antianaemic; haemostatic;
XX antilipemic; ss.
XX
XX OS Homo sapiens.
XX

```

```

XX XX WO200173002-A2.
XX PN
XX PD
XX 04-OCT-2001.
XX PF
XX 27-MAR-2001; 2001WO-US009761.
XX PR
XX 27-MAR-2000; 2000US-0192176P.
XX PR 27-MAR-2000; 2000US-0192176P.
XX PR 01-JUN-2000; 2000US-0208538P.
XX PR 30-OCT-2000; 2000US-0244989P.
XX PA
XX (UYDE ) UNIV DELAWARE.
XX PI
XX Kmlec EB, Gamper HB, Rice MC;
XX DR
XX WPI, 2001-639230/73.
XX PT
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification.
XX PT
XX Claim 7, Page 80; 294p; English.
XX PS
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CPT, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention
XX SQ
XX Sequence 17 BP; 1 A; 3 C; 7 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 1.6e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX QY
XX 1806 CCTGACCCGAGGCCA 1821
XX |||||||||
XX DB 16 CCAGACCCGAGGCCA 1
XX
XX RESULT 239
XX ABBN00902/c
XX ID ABBN00902 standard; DNA, 17 BP.
XX XX
XX ABBN00902;
XX XX
XX 29-MAY-2002 (first entry)
XX DT
XX Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:894.
XX DE
XX XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; 88.
XX XX
XX Homo sapiens.
XX OS
XX WO200192524-A2.
XX PN
XX 06-DEC-2001.
XX XX
XX 25-MAY-2001; 2001WO-US016981.
XX PF

```

XX	PR	26-MAY-2000;	2000US-0207456P.
XX	FR	21-SEP-2000;	2000US-0234687P.
XX	FR	27-SEP-2000;	2000US-0236359P.
XX	PR	04-OCT-2000;	2000GB-00024263.
XX	PR	30-JAN-2001;	2001WO-US000661.
XX	PR	30-JAN-2001;	2001WO-US000662.
XX	PR	30-JAN-2001;	2001WO-US000663.
XX	PR	30-JAN-2001;	2001WO-US000664.
XX	PR	30-JAN-2001;	2001WO-US000665.
XX	PR	30-JAN-2001;	2001WO-US000666.
XX	PR	30-JAN-2001;	2001WO-US000667.
XX	PR	30-JAN-2001;	2001WO-US000668.
XX	PR	30-JAN-2001;	2001WO-US000669.
XX	PR	30-JAN-2001;	2001WO-US000670.
XX	PR	05-FEB-2001;	2001US-0268660P.
XX	PA	(AEOM-) AEOMICA INC.	
XX	PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;	
XX	DR	WPI; 2002-179446/23.	
XX	PT	New polypeptide, for raising antibodies that recognise hGDMLP-1 proteins,	
XX	PT	or as specific biomolecule capture probes for surface-enhanced laser	
XX	PS	desorption ionization, comprises human myosin-like protein hGDMLP-1.	
XX	PS	Disclosure; SEQ ID NO 894; 214pp; English.	
XX	CC	The present invention describes a human genome-derived myosin-like	
XX	CC	protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-	
XX	CC	1 can be used in gene therapy and vaccine production. The hGDMLP-1	
XX	CC	nucleic acids can be used as probes to detect, characterise and quantify	
XX	CC	hGDMLP-1 nucleic acids in samples, as amplification substrates, to	
XX	CC	provide initial substrates for the recombinant engineering of hGDMLP-1	
XX	CC	protein variants having desired phenotypic improvements, and for	
XX	CC	expressing the proteins. The hGDMLP-1 proteins or polypeptides may be	
XX	CC	used as immunogens to raise antibodies that specifically recognise hGDMLP	
XX	CC	-1 proteins, as standards in assays used to determine the concentration	
XX	CC	and/or amount specifically of hGDMLP proteins, as specific biomolecule	
XX	CC	capture probes for surface-enhanced laser desorption/ionisation, as	
XX	CC	therapeutic supplement in patients having specific deficiency in hGDMLP-1	
XX	CC	production, and in vaccines or for replacement therapy. The	
XX	CC	polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a	
XX	CC	disorder associated with the expression of hGDMLP-1, in particular heart	
XX	CC	and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.	
XX	CC	The present sequence represents an oligomer used in the screening of the	
XX	CC	hGDMLP-1 sequence in the exemplification of the present invention. N.B.	
XX	CC	The sequence data for this patent did not form part of the printed	
XX	CC	specification, but was obtained in electronic format directly from WIPO	
XX	CC	at ftp.wipo.int/pub/published_pct_sequence	
XX	XX	Sequence 17 BP; 3 A; 1 C; 10 G; 3 T; 0 U; 0 Other:	
QY	Query Match	0.6%; Score 14.4; DB 1; Length 17;	
Db	Best Local Similarity	93.8%; Pred. No. 1.6e+02;	
	Matches 15; Conservative	0; Mismatches 1; Indels 0; Gaps 0;	
OY	1699 AAGCCTTCCCCCAAT 1714		
	16 AAGCCTTCCCCCACT 1		
RESULT 240			
ABN08014	1D	ABN08014 standard; DNA; 17 BP.	
XX	AC	ABN08014;	
XX	DT	29-MAY-2002 (first entry)	
XX	DB	Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8006.	

KW		Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;
KM		skeletal muscle; chromosome 22; gene therapy; vaccine; heart disease;
KX		skeletal muscle disorder; amplicon; screening; ss.
OS		Homo sapiens.
XX		
PV	WO200192524-A2.	
PD	06-DEC-2001.	
XX		
PF	25-MAY-2001; 2001WO-US016981.	
XX		
PR	26-MAY-2000; 2000US--0207456P.	
PR	21-SEP-2000; 2000US-0234687P.	
PR	27-SEP-2000; 2000US-0236359P.	
PR	04-OCT-2000; 2000GB-00024263.	
PR	30-JAN-2001; 2001WO-US000661.	
PR	30-JAN-2001; 2001WO-US000662.	
PR	30-JAN-2001; 2001WO-US000663.	
PR	30-JAN-2001; 2001WO-US000664.	
PR	30-JAN-2001; 2001WO-US000665.	
PR	30-JAN-2001; 2001WO-US000666.	
PR	30-JAN-2001; 2001WO-US000667.	
PR	30-JAN-2001; 2001WO-US000668.	
PR	30-JAN-2001; 2001WO-US000669.	
PR	30-JAN-2001; 2001WO-US000670.	
PR	05-FEB-2001; 2001US-0266860P.	
XX		
PA	(AECOM-) AECOMICA INC.	
PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;	
XX		
DR	WPI; 2002-179446/23.	
XX		
PT	New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,	
PT	or as specific biomolecule capture probes for surface-enhanced laser	
PT	desorption ionization, comprises human myosin-like protein hGDMLP-1.	
XX		
PB	Disclosure; SEQ ID NO 8006; 214pp; English.	
XX		
CC	The present invention describes a human genome-derived myosin-like	
CC	protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-	
CC	1 can be used in gene therapy and vaccine production. The hGDMLP-1	
CC	nucleic acids can be used as probes to detect, characterise and quantify	
CC	hGDMLP-1 nucleic acids in samples, as amplification substrates, to	
CC	provide initial substrates for the recombinant engineering of hGDMLP-1	
CC	protein variants having desired phenotypic improvements, and for	
CC	expressing the proteins. The hGDMLP-1 proteins or polypeptides may be	
CC	used as immunogens to raise antibodies that specifically recognise hGDMLP	
CC	-1 proteins, as standards in assays used to determine the concentration	
CC	and/or amount specifically of hGDMLP proteins, as specific biomolecule	
CC	capture probes for surface-enhanced laser desorption/ionisation, as	
CC	therapeutic supplement in patients having specific deficiency in hGDMLP-1	
CC	production, and in vaccines or for replacement therapy. The	
CC	polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a	
CC	disorder associated with the expression of hGDMLP-1, in particular heart	
CC	and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.	
CC	The present sequence represents an oligomer used in the screening of the	
CC	hGDMLP-1 sequence in the exemplification of the present invention. N.B.	
CC	The sequence data for this patent did not form part of the printed	
CC	specification, but was obtained in electronic format directly from WIPO	
CC	at ftp.wipo.int/pub/published_pct_sequence	
XX		
SQ	Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;	
XX		
Query Match:	0.6%; Score 14.4; DB 1; Length 17;	
Best Local Similarity	93.8%; Pred. No. 1.6e+02;	
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;		
OY	2038 CAGGTGACGACGCTTC 2053	
db	1 CAGCTGGAGCAGCTTC 16	

RESULT 241	
ABN08013	
ID	ABN08013 standard; DNA; 17 BP.
XX	
AC	
XX	ABN08013;
DT	29-MAY-2002 (first entry)
XX	
DE	Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8005.
XX	
KW	Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW	skeletal muscle disorder; amplicon; screening; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO200192524-A2.
XX	
PD	06-DEC-2001.
XX	
PF	25-MAY-2001; 2001WO-US016981.
XX	
PR	26-MAY-2000; 2000US-0207456P.
PR	21-SEP-2000; 2000US-0234687P.
PR	27-SEP-2000; 2000US-0236359P.
PR	04-OCT-2000; 2000GB-00024263.
PR	30-JAN-2001; 2001WO-US000661.
PR	30-JAN-2001; 2001WO-US000662.
PR	30-JAN-2001; 2001WO-US000663.
PR	30-JAN-2001; 2001WO-US000664.
PR	30-JAN-2001; 2001WO-US000665.
PR	30-JAN-2001; 2001WO-US000667.
PR	30-JAN-2001; 2001WO-US000668.
PR	30-JAN-2001; 2001WO-US000669.
PR	30-JAN-2001; 2001WO-US000670.
PR	05-FEB-2001; 2001US-0266860P.
XX	
PA	(ABOM-) ABOMICA INC.
PI	
XX	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME,
PI	WPI; 2002-179446/23.
DR	
XX	
XX	New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT	or as specific biomolecule capture probes for surface-enhanced laser
PT	desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX	
PS	Disclosure; SEQ ID NO 8005; 214pp; English.
XX	
CC	The present invention describes a human genome-derived myosin-like
CC	protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-1
CC	1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC	nucleic acids can be used as probes to detect, characterize, and quantify
CC	hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC	provide initial substructures for the recombinant engineering of hGDMLP-1
CC	protein variants having desired phenotypic improvements, and for
CC	expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC	used as immunogens to raise antibodies that specifically recognise hGDMLP
CC	-1 proteins, as standards in assays used to determine the concentration
CC	and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC	capture probes for surface-enhanced laser desorption ionisation, as
CC	therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC	production, and in vaccines or for replacement therapy. The
CC	polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC	disorder associated with the expression of hGDMLP-1, in particular heart
CC	and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC	The present sequence represents an oligomer used in the screening of the
CC	hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC	The sequence data for this patent did not form part of the printed
CC	specification, but was obtained in electronic format directly from WIPO
CC	at ftp.wipo.int/pub/published_pct sequence

XX Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2038 CAGCTGAGCAGCTCC 2053
|||
Db 2 CAGCTGAGCAGCTCC 17
RESULT 242
ABN00898/c
ID ABN00898 standard; DNA; 17 BP.
AC ABN00898;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:890.
DE
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 30-JAN-2001; 2001WO-US000670.
XX
XX 05-FEB-2001; 2001US-0266860P.
XX
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
XX Disclosure; SEQ ID NO 890; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the protein. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule

CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 4 A; 1 C; 10 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1702 CCCCTCCCAATATG 1717
|||
Db 17 CCCCTCCCACTATG 2
RESULT 243
ABV85489/c
ID ABV85489 standard; DNA; 17 BP.
AC ABV85489;
XX
XX 11-DEC-2002 (first entry)
XX
XX Human pp-GaNTase 10 scanning 17-mer SEQ ID NO:482.
DE
XX Human; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10;
KM pp-GaNTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
KW ss.
XX
XX Homo sapiens.
XX
XX Synthetic.
XX
XX EP1243660-A2.
XX
XX 25-SEP-2002.
XX
XX 25-JAN-2002; 2002EP-00001161.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 30-JAN-2001; 2001WO-US000670.
XX
XX 23-MAY-2001; 2001US-00864761.
XX
XX 30-AUG-2001; 2001US-0315984P.
XX
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhang J, Gu Y, Nguyen C;
XX
XX WPI; 2002-724954/79.
XX
XX
XX Nucleic acid encoding human UDP-GalNAc:polypeptide N-
PT cetyl-galactosaminyltransferase 10 protein is useful to diagnose, prevent
PT and treat disorders associated with reduced or over expression of the
PT encoded protein.
XX
XX Example 2; SEQ ID NO 482; 59pp; English.
XX
XX The present invention describes an isolated nucleic acid (1) encoding a
CC human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10 (pp-
CC GaNTase 10, EC 2.4.1.41) protein. Human pp-GaNTase 10 is located to

CC chromosome 7q11.2. (I) can be used in gene therapy. Molecules of the
 CC present invention can be used in therapy, particularly to prevent or
 CC treat a disorder associated with decreased expression or activity of pp-
 CC GANTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to
 CC ABP53504 are given in the exemplification of the present invention. N.B.
 CC The sequence data for this patent is not represented in the printed
 CC specification but is based on sequence information supplied by the
 CC European Patent Office
 CC
 XX
 SQ Sequence 17 BP; 5 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1487 CCTTACACTTGAGCG 1502
 |||||
 DB 17 CCTTACACTTGAGCG 2
 RESULT 244
 ABV85490/c
 ID ABV85490 standard; DNA; 17 BP.
 XX
 AC ABV85490;
 XX
 DT 11-DEC-2002 (first entry)
 XX
 DE Human pp-GANTase 10 scanning 17-mer SEQ ID NO:483.
 XX
 KW Human, UDP-GalNAc:polypeptide N-acetylglactosaminyltransferase 10;
 KW pp-GANTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
 KW 85.
 XX
 OS Homo sapiens.
 OS Synthetic.
 OS
 XX
 PN EPI243660-A2.
 XX
 PD 25-SEP-2002.
 XX
 PF 25-JAN-2002; 2002EP-00001161.
 XX
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 30-AUG-2001; 2001US-0315964P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Zhang J, Gu Y, Nguyen C;
 XX
 DR WPI; 2002-724954/79.
 XX
 PT Nucleic acid encoding human UDP-GalNAc:polypeptide N-
 PT cetylglactosaminyltransferase 10 protein is useful to diagnose, prevent
 PT and treat disorders associated with reduced or over expression of the
 PT encoded protein.
 XX
 PS Example 2; SEQ ID NO 483; 59pp; English.
 XX
 CC The present invention describes an isolated nucleic acid (I) encoding a
 CC human UDP-GalNAc:polypeptide N-acetylglactosaminyltransferase 10 (pp-
 CC GANTase 10, EC 2.4.1.41) protein. Human pp-GANTase 10 is located to
 CC chromosome 7q11.2. (I) can be used in gene therapy. Molecules of the
 CC present invention can be used in therapy, particularly to prevent or
 CC treat a disorder associated with decreased expression or activity of pp-

CC GANTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to
 CC ABP53504 are given in the exemplification of the present invention. N.B.
 CC The sequence data for this patent is not represented in the printed
 CC specification but is based on sequence information supplied by the
 CC European Patent Office
 CC
 XX
 SQ Sequence 17 BP; 6 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1487 CCTTACACTTGAGCG 1502
 |||||
 DB 16 CCTTACACTTGAGCG 1
 RESULT 245
 ABT39140
 ID ABT39140 standard; DNA; 17 BP.
 XX
 AC ABT39140;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID NO 4777.
 XX
 DE
 XX
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX
 OS Homo sapiens.
 OS
 XX
 PN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004208.
 XX
 PR 17-SEP-2001; 2001FR-00011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Teلمان A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 592; 720pp; French.
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein

CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human faktin oligonucleotide of the invention
XX

Sequence 17 BP; 4 A; 4 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2081 GCTCAGTCTTCAT 2096

DB 1 GATCAGTCTTCAT 16

RESULT 246

ABBS7647/C

ID ABBS7647 standard; DNA, 17 BP.

AC ABBS7647;

DT 14-FEB-2003 (first entry)

DE Human HGPBMY2-associated oligonucleotide SEQ ID 33.

XX Human; G-protein coupled receptor; HGPBMY1; HGPBMY2; immunosuppressive;

XX Human; neuroprotective; antiinflammatory; cytostatic; vulnerary;

XX vaccine; gene therapy; autoimmune; cardiovascular; neural; reproductive;

XX hematopoietic; pulmonary; gastrointestinal; proliferation; cell cycle;

XX birth defect; aberrant phosphorylation; acute phase response; primer;

XX signal transduction; hyperimmune activity; inflammatory; hypercongenital;

XX necrotic lesion; wound; organ transplant rejection; disorder; PCR; ss.

OS Homo sapiens.

PN WO200268591-A2.

PD 06-SEP-2002.

PF 22-FEB-2002; 2002MO-US005281.

PR 23-FEB-2001; 2001US-0270792P.

PR 23-FEB-2001; 2001US-0270793P.

PR 06-JUN-2001; 2001US-0296427P.

XX (BRIM) BRISTOL-MYERS SQUIBB CO.

PI Feder J, Ramanathan C, Nelson T, Mintier G, Cacace A, Barber L;

PI Kornacker M, Bol D;

DR WPI; 2003-058304/05.

PS New human HGPBMY1 or HGPBMY2 polynucleotide and polypeptide, useful

XX preventing, treating or ameliorating a disorder e.g., wound,

XX cardiovascular disorder or transplant rejection.

XX Disclosure; Page 135; 316pp; English.

XX This invention describes the novel human G-protein coupled receptors

XX (GPCR/s), HGPBMY1 or HGPBMY2 which have immunosuppressive, cardiant,

XX neuroprotective, antiinflammatory, cytostatic and vulnerary activity and

XX can be used in vaccines or for gene therapy. Pharmaceutical compositions

XX comprising HGPBMY1 or HGPBMY2 polypeptides or their agonists or

XX antagonists or modulators, or a HGPBMY1- or HGPBMY2-specific antibody

XX are useful for preventing, treating or ameliorating a medical condition

XX comprising autoimmune, cardiovascular, neural, reproductive,

XX hematopoietic, pulmonary, gastrointestinal or proliferating disorder, a

XX cell cycle or birth defect, a disorder related to aberrant

XX phosphorylation, acute phase responses or signal transduction or to

XX hyperimmune activity, an inflammatory or hypercongenital condition, a

XX necrotic lesion, a wound, organ transplant rejection or a condition

XX related to organ transplant rejection. This sequence represents a PCR

XX primer used in the amplification of the genes encoding the HGPBMY

CC proteins described in the disclosure of the invention
XX
XX Sequence 17 BP; 3 A; 4 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 113 CCGGCTGCCCCGCAT 128

DB 17 CCGGCTGCCCCGCAT 2

RESULT 247

ACD61070

ID ACD61070 standard; RNA, 17 BP.

AC ACD61070;

DT 24-SEP-2003 (first entry)

DE HCV DNAzyme substrate sequence #2144.

XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;

XX RNA stability; RNA expression; RNA synthesis; antisense;

XX enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;

XX amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;

XX HBV reverse transcriptase; Enhancer 1 region; viral replication;

XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;

XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;

XX virucide; antiinflammatory; substrate; ss.

OS Hepatitis C virus.

PN WO200281494-A1.

PD 17-OCT-2002.

PF 26-MAR-2002; 2002MO-US009187.

PR 26-MAR-2001; 2001US-00817879.

PR 08-JUN-2001; 2001US-00877478.

PR 08-JUN-2001; 2001US-0296876P.

PR 24-OCT-2001; 2001US-0335059P.

PR 05-DEC-2001; 2001US-0337055P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BIAT/) BIATT L.

PA (MACE/) MACEJAK D.

PA (MCSW/) MCSWIGGEN J.

PA (MORR/) MORRISSEY D.

PA (PAVC/) PAVCO P.

PA (LEEP/) LEE P.

PA (DRAP/) DRAPER K.

PA (ROBE/) ROBERTS E.

XX Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;

XX Draper K, Roberts E;

XX WPI; 2003-229207/22.

PS Novel compound useful for treating cirrhosis, liver failure,

XX hepatocellular carcinoma, or condition associated with hepatitis C virus

XX infection.

XX Claim 1; Page 272; 387pp; English.

XX The present invention relates to nucleic acid molecules which modulate

XX the synthesis, expression and/or stability of Hepatitis C virus (HCV) or

XX Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense

XX and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,

XX inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed

XX are nucleic acid decoy molecules and aptamers that bind to HBV reverse

CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNazyme or minus strand DNazyme sequences disclosed in the present
 CC invention
 XX
 SQ Sequence 17 BP, 3 A, 7 C, 3 G, 0 T, 4 U, 0 Other;
 Query Match 0.6%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 1.6e+02;
 Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
 QY 1224 TGCACTCACTCTGCG 1239
 : |||:||||:|:|
 Db 1 UCCAGUCAACUCUCUG 16
 RESULT 248
 ABS61004
 ID ABS61004 standard; DNA, 18 BP.
 XX
 AC ABS61004;
 XX
 DT 05-NOV-2002 (first entry)
 XX
 DE Human genotyping PCR primer #157.
 XX
 KW Human; ss; aminopeptidase P; XPNP2; bradykinin receptor B1; primer;
 KW BDKRB1; tachykinin receptor B1; TACR1; Cl esterase inhibitor; C1NH;
 KW kallikrein 1; KUK1; bradykinin receptor B2; BDKRB2; gene therapy;
 KW angiotensin converting enzyme 2; ACE2; protease inhibitor 4; P14;
 KW polymorphisms; haemangioma; tumour; sarcoma; Crohn's disease; trachoma;
 KW cardiovascular disease; angina pectoris; hypertension; heart failure;
 KW myocardial infarction; ventricular hypertrophy; vascular disease;
 KW aneurysm; embolism; thrombosis; coronary artery disease; angiodaema;
 KW arteriosclerosis; atherosclerosis; hypersensitivity; sepsis; PCR;
 KW autoimmune disease; inflammatory arthritis; cancer; wound; genotyping;
 KW viral infection; bacterial infection; fungal infection; COPD;
 KW Chronic obstructive pulmonary disease; enterocolitis.
 KM
 XX
 OS Homo sapiens.
 XX
 PN WO200261131-A2.
 XX
 PD 08-AUG-2002.
 XX
 PE 03-DEC-2001; 2001WO-US047235.
 XX
 PR 04-DEC-2000; 2000US-0251015P.
 PR 23-JAN-2001; 2001US-0263678P.
 PR 02-MAR-2001; 2001US-0273037P.
 XX
 PA (BRIM) BRISTOL-MYERS SQUIBB CO.
 PA (TSUC/) TSUCHIHASHI Z.
 PA (HUI/) HUI L.
 PI Teuchihashi Z, Hui L, Zerba KE, Ma-Edmonds M, Perrone MH;
 PI Swanson BN, Powell JR;
 XX
 DR WPI; 2002-619265/66.
 XX
 PT New isolated nucleic acid with at least one polymorphic position, useful
 PT for detecting, diagnosing and treating disorders such as angiodema,
 PT cancer, viral, bacterial or fungal infection, cardiovascular and
 PT autoimmune diseases.
 XX

PS Example 3; Page 914; 977pp; English.
 XX
 CC The invention relates to an isolated nucleic acid from a human gene
 CC encoding aminopeptidase P (XPNP2), bradykinin receptor B1 (BDKRB1),
 CC tachykinin receptor B1 (TACR1), Cl esterase inhibitor (C1NH), Kallikrein
 CC 1 (KUK1), bradykinin receptor B2 (BDKRB2), angiotensin converting enzyme
 CC 2 (ACE2) or protease inhibitor 4 (P14), comprising at least one
 CC polymorphic position. Also included are (1) a probe that hybridises to a
 CC polymorphic position as provided in the detailed summary of single
 CC nucleotide polymorphisms comprising additional 5' and 3' flanking genomic
 CC sequence; (2) analysing (M1) at least one nucleic acid sample comprising
 CC obtaining the sample from one or more individuals and determining the
 CC nucleic acid sequence at one or more polymorphic positions in a gene
 CC encoding a protein selected from the group above; (3) constructing (M2)
 CC haplotypes using the genes comprising grouping at least two nucleic acids
 CC (4) identifying (M3) an individual at risk of developing a disorder
 CC upon administration of an ACE inhibitor and/or vasopressinase inhibitor
 CC using the polymorphic data; (5) a library of nucleic acids, each of which
 CC comprises one or more polymorphic positions within a gene encoding a
 CC human protein selected from the group above; and (6) genotyping (M4) an
 CC individual comprising obtaining a nucleic acid sample, determining the
 CC nucleotide present in at least one polymorphic position, and comparing at
 CC least one position with a known data set. The genes, (M1, M2, M3 and M4)
 CC and compositions are useful for detecting, diagnosing, treating,
 CC preventing various disorders such as angiodaema and diseases which
 CC involve angiogenesis like haemangiomas, tumours, sarcomas, Crohn's
 CC disease, trachomas, and cardiovascular diseases like angina pectoris,
 CC hypertension, heart failure, myocardial infarction, ventricular
 CC hypertrophy, vascular diseases, aneurysm, embolism, thrombosis, coronary
 CC artery disease, arteriosclerosis and/or atherosclerosis, and
 CC hypersensitivity reactions, sepsis, autoimmune diseases, inflammatory
 CC arthritis, cancer, wounds, viral, bacterial or fungal infection, Chronic
 CC obstructive pulmonary disease (COPD) and enterocolitis (many other
 CC diseases and disorders are listed in the specification). The
 CC polymucleotides are also useful for chromosome identification. Antibodies
 CC against the proteins may be utilised for immunophenotyping of cell lines
 CC and biological samples. The present sequence is a genotyping PCR primer
 CC for the gene encoding one of the proteins listed above
 XX
 SQ Sequence 18 BP, 7 A, 2 C, 8 G, 1 T, 0 U, 0 Other;
 Query Match 0.6%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2190 GGAGAAAAGGCGTGC 2205
 : ||||| ||||| |||
 Db 2 GGAGAAAAGGCGTGC 17
 RESULT 249
 AAD53970
 ID AAD53970 standard; DNA, 18 BP.
 XX
 AC AAD53970;
 XX
 DT 17-JUN-2003 (first entry)
 XX
 DE Human KIF1Bbeta mutant DNA fragment.
 XX
 KW KIF1B protein; gene therapy; molecular motor protein; kinesin; human;
 KW Kif1Bbeta gene-associated disease; Charcot-Marie-Tooth disease type 2A;
 KW muscular; transgenic; mutant; gene; ds.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT 1. 18
 FT CDS /*tag= a
 FT /product= "Human KIF1Bbeta mutant peptide"
 FT /note= "CDS does not include start and stop codon"
 FT /partial

```

FT mutation replace(14,A)
PT /*tag= b
XX
PN WO200297079-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-JP005226.
XX
PR 29-MAY-2001; 2001US-0293513P.
XX
PA (UYTY ) UNIV TOKYO.
XX
PI Hirokawa N, Hayashi Y;
XX
DR WPI; 2003-167270/16.
DR P-PsDB; AAE35320.
XX
PT New KIF11b polypeptide having motor activity that transports synaptic
PT vesicle precursor, is useful for developing therapeutic or preventive
PT agent for kif11b gene-associated diseases e.g. Charcot-Marie-Tooth
PT disease type 2A.
XX
PS Example 6; Fig 7; 44pp; English.
XX
CC The invention relates to KIF11b protein which belongs to kinesin
CC superfamily of molecular motor proteins (KIFs). KIF11b is useful for
CC screening for a compound binding to it. Composition comprising the
CC selected compound is useful for treating, alleviating, or preventing a
CC KIF11b gene-associated disease, in particular Charcot-Marie-Tooth
CC disease type 2A. Transgenic non-human vertebrate, are useful for
CC screening for a candidate compound for treating, alleviating, or
CC preventing a KIF11b gene-associated disease. KIF11b DNA is useful for
CC gene therapy and for recombinant production of polypeptides. KIF11b
CC antibody is useful for affinity purification of KIF11b and for detecting
CC expression of KIF11b gene at the protein level. The present sequence
CC is human KIF11b gene mutant DNA fragment
XX
SQ Sequence 18 BP; 2 A; 4 C; 5 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.64; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.84; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1796 TTGGCTATGGCCGAC 1811
DB 2 TTGGCTATGGCGTAC 17
XX
RESULT 250
ADA24424/C
ID ADA24424 standard; DNA; 18 BP.
XX
AC ADA24424;
XX
DT 20-NOV-2003 (first entry)
XX
DE PCR primer #1 for generating human TSL1 probe.
XX
KW Human tumour suppressor gene; TSL1; hTSL1; cancer; carcinoma;
KW pre-critical stage; cancer therapy; chemical therapy; radiotherapy;
KW TSLC1; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN US2003109016-A1.
XX
PD 12-JUN-2003.
XX
PF 29-AUG-2002; 2002US-00230335.
XX
PR 11-OCT-2001; 2001JP-00313966.
XX

```

```

PA (PRES-) PRESIDENT NAT CANCER CENT.
PA (BMLB-) EML INC.
XX
PI Murakami Y, Nomura S;
XX
DR WPI; 2003-626209/59.
XX
PT New protein encoded by tumor suppressor gene, designated as TSL1 gene,
PT useful for preventing or treating cancers, predicting of prognosis of
PT cancer therapy, or diagnosing carcinoma in pre-clinical stages.
XX
PS Example; Page 6; 20pp; English.
XX
CC The present invention relates to the isolation of a human tumour
CC suppressor gene, TSL1 (hTSL1), and the encoding protein. The TSL1 gene
CC and protein are useful for preventing and treating cancers. The gene is
CC useful for diagnosing carcinoma in pre-clinical stages, qualitative
CC diagnosis of carcinoma, predicting the prognosis of cancer therapy, and
CC forecasting the sensitivity of a carcinoma to chemical therapy,
CC radiotherapy and gene therapy. The TSL1 protein is homologous the TSLC1
CC protein. The present sequence represents a PCR primer used to generate a
CC probe for human TSL1 cDNA.
XX
SQ Sequence 18 BP; 5 A; 7 C; 4 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.64; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.84; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 264 TGCCAGGCGCTGCTG 279
DB 17 TGTCAGGCGCTGCTG 2
XX
RESULT 251
AAV72326/C
ID AAV72326 standard; DNA; 19 BP.
XX
AC AAV72326;
XX
DT 28-JUL-1999 (first entry)
XX
DE Human steroid hormone binding protein primer 13.
XX
KW Steroid hormone binding protein; membrane bound; hSMBP1; hSMBP2;
KW anti-allergenic; drug screening; treatment; immune disorder; allergy;
KW autoimmune disease; hormone-dependent tumour; primer; ss.
XX
OS Synthetic.
XX
OS Homo sapiens.
XX
PN WO9924568-A1.
XX
PD 20-MAY-1999.
XX
PF 06-NOV-1998; 98WO-JP005010.
XX
PR 07-NOV-1997; 97JP-00322376.
XX
PA (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX
PI Hirata Y;
XX
DR WPI; 1999-327400/27.
XX
PT New membrane bound steroid binding protein useful in treatment of immune
PT disorders.
XX
PS Example 1; Page 42; 46pp; Japanese.
XX
CC This invention describes a membrane bound steroid binding proteins
CC (hSMBP1 and hSMBP2) of human origin which have anti-allergenic activity.
CC hSMBP1 is used to screen candidate drugs for their ability to bind to it.

```

CC The drugs identified may be used in the treatment of immune disorders
 CC such as allergy and autoimmune disease, and of hormone-dependent tumours
 XX
 SQ Sequence 19 BP; 4 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 19;
 Best Local Similarity 93.8%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1258 ATGCTGCTGAAAGTGG 1273
 |||||
 DB 16 ATGCTGCTGAAAGTGG 1

RESULT 252
 ABL58297
 ID ABL58297 standard; DNA; 19 BP.
 XX

AC ABL58297;
 XX
 DT 15-JUN-2002 (first entry)
 XX

DE Human GLUT 10 SSCP analysis primer GLUT10 ex2aR.

KM Glucose transporter; GLUT10; insulin; chromosome 20Q12-13.3; human;
 KM glucose metabolism; single strand conformational polymorphism; PCR;
 KM type 2 diabetes; SSCP; primer; ss.
 XX

OS Homo sapiens.

PN WO200218621-A2.

PD 07-MAR-2002.

PF 22-AUG-2001; 2001WO-US026184.

PR 31-AUG-2000; 2000US-00652292.

PA (UYWA-) UNIV WAKE FOREST.

PI Bowden DW, Dawson PA, Fossey SC;

DR WPI; 2002-371828/40.

XX New glucose transporter gene and protein, designated GLUT10, useful for
 PT studying and analyzing biological processes of glucose metabolism and
 PT Type 2 diabetes, as well as for screening modulators of glucose
 PT transporter activity.

PS Example 4; Page 52; 85pp; English.

XX The invention relates to a novel glucose transporter gene and protein,
 CC designated GLUT10. GLUT 10 is an insulin-responsive glucose transporter
 CC gene located in the type 2 diabetes linked region of chromosome 20Q12-
 CC 13.3. The GLUT 10 polypeptide can be expressed by standard recombinant
 CC methodology. The GLUT 10 glucose transporter gene and protein are useful
 CC for studying and analyzing biological processes of both glucose
 CC metabolism and type 2 diabetes. These are also useful in drug screening
 CC techniques, especially for screening modulators of glucose transporter
 CC activity or compounds having the ability to be transported across the
 CC cell membranes. Sequences ABL58290-315 represent primers specific for the
 CC various regions of the human GLUT 10 glucose transporter gene, used in
 CC single strand conformational polymorphism (SSCP) analysis of the gene
 XX
 SQ Sequence 19 BP; 5 A; 7 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 19;
 Best Local Similarity 93.8%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2118 GGAGCAGGCTGACAC 2133
 |||||
 DB 2 GGAGCAGGCTGACAC 17

RESULT 253
 AAD5156
 ID AAD5156 standard; DNA; 19 BP.
 XX

AC AAD5156;

DT 07-AUG-2003 (first entry)

DE Goat beta-lac exon 1 amplifying primer, C.

KM Transgenic; nucleoprotein; recombinase; beta-lac; goat; PCR; primer; ss.

OS Capra hircus.

PN WO2003022220-A2.

PD 20-MAR-2003.

PF 06-SEP-2002; 2002WO-US028763.

PR 07-SEP-2001; 2001US-0317915P.

PA (REGC) UNIV CALIFORNIA.

PI Mega EA, Anderson GB, Murray JD, Oppenheim SM;

DR WPI; 2003-313182/30.

XX Producing transgenic livestock animal e.g. pig, by introducing
 PT nucleoprotein made of nucleic acid and recombinase into totipotent or
 PT pluripotent cell, and growing the resulting recombinant totipotent or
 PT pluripotent cell.

PS Disclosure; Page 30; 25pp; English.

XX The invention relates to a method for producing transgenic livestock
 CC animal e.g. pig, by introducing nucleoprotein made of nucleic acid and
 CC recombinase into totipotent or pluripotent cell, and growing the
 CC resulting recombinant totipotent or pluripotent cell. The method is
 CC useful for producing transgenic livestock animal such as pigs, goats,
 CC sheep, cows or horses, preferably goats and pigs. The present sequence is
 CC a primer used for amplifying goat beta-lac exon 1. This sequence is used
 CC to illustrate the method of the invention

SQ Sequence 19 BP; 1 A; 6 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 19;
 Best Local Similarity 93.8%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 268 CAGGCGTGGCTGGCTG 283
 |||||
 DB 1 CCGGCGTGGCTGGCTG 16

RESULT 254

ID ADA50311/c

AC ADA50311;

DT 20-NOV-2003 (first entry)

DE Human PCR primer rs1061581r related to abacavir hypersensitivity.

XX hypersensitivity reaction; abacavir; 57.1 ancestral haplotype;
 KM Major Histocompatibility Complex; MHC; human leukocyte antigen; HLA;
 KM HLA-B*5701; C4A6; HLA-DR7; HLA-DQ3; Human immunodeficiency virus; HIV;
 KM immune system; acquired immune deficiency syndrome; AIDS;
 KM peripheral nervous system; antiviral compound; HIV replication inhibitor;
 KM antiviral; nucleoside reverse transcriptase inhibitor; NRTI;

KM antiretroviral drug; abacavir; human; sequencing primer; primer; PCR; ss;
 KM SNP detection; pyrosequence; rs1061581.
 XX
 OS Homo sapiens.
 XX
 PN WO2003068985-A1.
 XX
 PD 21-AUG-2003.
 XX
 PF 12-FEB-2003; 2003WO-AU000183.
 XX
 PR 12-FEB-2002; 2002AU-00000464.
 XX
 PA (EPiP-) EPIPOP PTY LTD.
 XX
 PI Mallal S;
 XX
 DR WPI; 2003-697530/66.
 XX
 PT Method for the identification of subjects hypersensitive to abacavir,
 PT useful for excluding patients from treatment, comprises detecting the
 PT presence of the 57.1 ancestral haplotype.
 XX
 PS Example 2; Page 23; 43pp; English.
 XX
 CC This invention relates to a method for determining whether a patient will
 CC show a hypersensitivity, or similar, reaction to abacavir by typing the
 CC patient for presence of the 57.1 ancestral haplotype of the Major
 CC Histocompatibility Complex (MHC). The ancestral haplotype is defined by
 CC presence of the human leukocyte antigen (HLA) subtypes HLA-B*5701, C4A6,
 CC HLA-D7 and HLA-DQ3. Human immunodeficiency virus (HIV) is the
 CC aetiological agent of a complex disease that includes progressive
 CC destruction of the immune system (acquired immune deficiency syndrome,
 CC AIDS) and degeneration of the peripheral nervous system. It is known that
 CC some antiviral compounds which act as inhibitors of HIV replication are
 CC effective agents in the treatment of AIDS. Treatment with an antiviral to
 CC a person with hypersensitivity may lead to a range of ailments and
 CC occasionally death. Patients who have the 57.1 ancestral haplotype are at
 CC a high risk of developing a hypersensitive reaction to abacavir, a
 CC nucleoside reverse transcriptase inhibitor (NRTI) antiretroviral drug
 CC often used to treat HIV and AIDS. The identification method of the
 CC invention may be useful for identifying patients who need to be excluded
 CC from treatment with abacavir. The present sequence is that of a human
 CC sequencing and PCR amplification primer which was used for SNP detection
 CC on the pyrosequencer for identifying the presence or absence of the 57.1
 CC ancestral haplotype of the MHC of the invention.
 XX
 SQ Sequence 19 BP; 3 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.64; Score 14.4; DB 1; Length 19;
 Best Local Similarity 93.84; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1208 AGGAGCTGTGGCCTA 1223
 Db 17 ACGAGCTGTGGCCTA 2
 RESULT 255
 ADE29675
 ID ADE29675 standard; RNA; 19 BP.
 XX
 AC ADE29675;
 XX
 XX 29-JAN-2004 (first entry)
 XX
 DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:297.
 KM short interfering nucleic acid; siNA; downregulation; inhibition;
 KM mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
 KM cytosolic; anorectic; antidiabetic; antiinflammatory; antitumour;
 KM immunosuppressive; antibacterial; antineumatic; antiarthritic;
 KM antiporiatic; gastrointestinal; obesity; diabetes; tumour;

KM inflammatory disease; asthma; septic shock; rheumatoid arthritis;
 KM psoriasis; inflammatory bowel disease; drug screening;
 KM genetic engineering; pharmacogenomic; gene mapping; ss.
 XX
 OS Synthetic.
 XX
 PN WO2003072590-A1.
 XX
 PD 04-SEP-2003.
 XX
 PF 28-JAN-2003; 2003WO-US002510.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 06-JUN-2002; 2002US-036782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Mcswiggen J, Beigelman L, Usman N, Haerberli P, Chowrira B;
 XX
 DR WPI; 2003-689980/65.
 XX
 PT New short interfering nucleic acid, useful e.g. for treatment and
 PT diagnosis of cancer, downregulates expression of mitogen-activated
 PT protein kinase genes.
 XX
 PS Example 3; SEQ ID NO 297; 164pp; English.
 XX
 CC The present invention describes a short interfering nucleic acid (siNA)
 CC that downregulates expression of a mitogen-activated protein kinase
 CC (MAPK) genes by RNA interference. Also described: (1) a method for
 CC modulating expression of MAPK genes in cells, tissue explants or
 CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
 CC vectors that express siNA and cells containing these vectors. MAPK siNAs
 CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
 CC antiaesthetic, immunosuppressive, antibacterial, antirheumatic,
 CC antitumour, antiporiatic and gastrointestinal activities. The MAPK
 CC siNAs can be used to modulate the expression of MAPK genes, in cells,
 CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
 CC and II; a wide range of tumours; and inflammatory diseases (asthma,
 CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
 CC disease). They can also be used for drug screening; diagnosis; target
 CC identification and validation; genetic engineering; pharmacogenomics;
 CC studying gene function and gene mapping (e.g. of single-nucleotide
 CC polymorphisms). The present sequence represents a MAPK siNA which is used
 CC in the exemplification of the present invention.
 XX
 SQ Sequence 19 BP; 6 A; 1 C; 5 G; 0 T; 7 U; 0 Other;
 Query Match 0.64; Score 14.4; DB 1; Length 19;
 Best Local Similarity 56.24; Pred. No. 1.8e+02;
 Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
 QY 1431 AATATTGAGTACTGCTG 1446
 Db 1 AAUAAUUGAGUACUUG 16
 RESULT 256
 ADE29512/C
 ID ADE29512 standard; RNA; 19 BP.
 XX
 AC ADE29512;
 XX
 XX 29-JAN-2004 (first entry)
 XX
 DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:134.
 KM

KM short interfering nucleic acid; siNA, downregulation; inhibition;
 KM mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
 KM cytosolic; anorectic; antidiabetic; antiinflammatory; antisthmatic;
 KM immunosuppressive; antibacterial; antirheumatic; antiarthritic;
 KM antiproliferative; gastrointestinal; obesity; diabetes; tumour;
 KM inflammatory disease; asthma; septic shock; rheumatoid arthritis;
 KM psoriasis; inflammatory bowel disease; drug screening;
 KM genetic engineering; pharmacogenomics; gene mapping; ss.
 XX Synthetic.
 OS
 XX WO2003072590-A1.
 PN
 XX
 XX 04-SEP-2003.
 PD
 XX 28-JAN-2003; 2003WO-US002510.
 PF
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 06-JUN-2002; 2002US-036782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR
 XX (SIRN-) SIRNA THERAPEUTICS INC.
 PA
 XX Mcswigen J, Beigelman L, Usman N, Haeblerli P, Chowitra B;
 PI
 XX WPI; 2003-689980/65.
 DR
 XX
 XX New short interfering nucleic acid, useful e.g. for treatment and
 PT diagnosis of cancer, downregulates expression of mitogen-activated
 PT protein kinase genes.
 XX
 XX Example 3; SEQ ID NO 134; 164pp; English.
 PS
 XX The present invention describes a short interfering nucleic acid (siNA)
 CC that downregulates expression of a mitogen-activated protein kinase
 CC (MAPK) genes by RNA interference. Also described: (1) a method for
 CC modulating expression of MAPK genes in cells, tissue explants or
 CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
 CC vectors that express siNA and cells containing these vectors. MAPK siNAs
 CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
 CC antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
 CC antiarthritic, antiproliferative and gastrointestinal activities. The MAPK
 CC siNAs can be used to modulate the expression of MAPK genes, in cells,
 CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
 CC and II; a wide range of tumours, and inflammatory diseases (asthma,
 CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
 CC disease). They can also be used for drug screening; diagnosis; target
 CC identification and validation; genetic engineering; pharmacogenomics;
 CC studying gene function and gene mapping (e.g. of single-nucleotide
 CC polymorphisms). The present sequence represents a MAPK siNA which is used
 CC in the exemplification of the present invention.
 CC
 XX Sequence 19 BP; 7 A; 5 C; 1 G; 0 T; 6 U; 0 Other;
 SO
 Query Match 0.64; Score 14.4; DB 1; Length 19;
 Best Local Similarity 93.8%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1431 AATATTGAGTACCTG 1446
 |||||
 Db 19 AATATTGAGTACTTG 4

RESULT 257
 AAQ45287
 ID AAQ45287 standard; rRNA; 14 BP.
 XX
 AC AAQ45287;

XX 25-MAR-2003 (revised)
 DT 09-OCT-1994 (first entry)
 XX
 XX Sequence of minimal sequence required for anti-g10 antibody recognition.
 KM D10 epitope; g10 antibody; control RNA; loop sequence; ss.
 KM
 KM Synthetic.
 OS
 XX WO9406934-A1.
 PN
 XX 31-MAR-1994.
 PD
 XX 31-AUG-1993; 93WO-US008210.
 PF
 XX 11-SEP-1992; 92US-00944208.
 PR 30-SEP-1992; 92US-00956693.
 PR
 XX (UYDU-) UNIV DUKE.
 PA
 XX
 XX Keene JD, Kenan DJ, Tsai DE;
 PI
 XX WPI; 1994-118482/14.
 DR
 XX
 XX Generating nucleic acid epitopes cross-reactive with non-nucleic acid
 PT immunogens, pref. viruses and allergens - used to generate immune
 PT responses in humans and animals.
 XX
 PS Example; Page 34; 56pp; English.
 PS
 XX Anti-g10 antibody is specific for proteins contg. a g10 fusion peptide
 CC (see AAB51052). However, whereas the g10 peptide is a useful epitope tag
 CC for analysing complexes contg. protein, an RNA epitope tag would be
 CC equally useful for studying complexes contg. RNA. The anti-g10 serum was
 CC presented with a degenerate pool of RNA contg. 1,048,576 species
 CC representing all possible RNA species. The transcripts were
 CC immunoprecipitated with the anti-g10 serum. A single RNA species, D10,
 CC was obt. The minimal sequence required for antibody recognition is
 CC AAQ45287, in the context of a stem. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 CC
 XX Sequence 14 BP; 2 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
 SO
 Query Match 0.64; Score 14; DB 1; Length 14;
 Best Local Similarity 85.7%; Pred. No. 1.5e+02;
 Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Oy 2112 CCTGCTGAGCAGG 2125
 |||||
 Db 1 CUGUGUGAGCAGG 14

RESULT 258
 AAF48867
 ID AAF48867 standard; DNA; 15 BP.
 XX
 AC AAF48867;
 DT 30-MAR-2001 (first entry)
 DE
 DE IGFBP3 oligonucleotide #2287.
 DE
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KM cytosolic; dermatological; cardiac; virocidic; ophthalmological; keloid;
 KM skin disorder; insulin-like Growth Factor I receptor; IGF-1; psoriasis;
 KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KM growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KM hyperovascular condition; hyperplasia; kidney disease;
 KM neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.


```

XX XX MO200078341-A1.
XX PN
XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000MO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURDOCH CHILDRENS RES INST.
XX PI Wraight CJ, Werther GA, Edmondson SR;
XX DR WPI; 2001-041421/05.
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX PT UV (ultra-violet) treatment (optional) and an antisease nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX PS Example 7; Page 59; 201pp; English.
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisease oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisease
XX CC oligonucleotide of the present invention (see AAF45151 and AAF45153-
XX CC F45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SQ Sequence 15 BP; 1 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1643 CTGCCCTGCTGCAG 1656
Db 2 CTGCCCTGCTGCAG 15
RESULT 259
AAFA8869
ID AAF48869 standard; DNA; 15 BP.
XX AC AAF48869;
XX DT 30-MAR-2001 (first entry)
XX DE IGFBP3 oligonucleotide #2289.
XX
XX Antisease therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiac; virologic; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX OS Homo sapiens.
XX PN MO200078341-A1.
XX PD 28-DEC-2000.

```

```

XX XX 21-JUN-2000; 2000MO-AU000693.
XX PF
XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURDOCH CHILDRENS RES INST.
XX PI Wraight CJ, Werther GA, Edmondson SR;
XX DR WPI; 2001-041421/05.
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX PT UV (ultra-violet) treatment (optional) and an antisease nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX PS Example 7; Page 59; 201pp; English.
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisease oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisease
XX CC oligonucleotide of the present invention (see AAF45151 and AAF45153-
XX CC F45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SQ Sequence 15 BP; 2 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1644 TGCCCTGCTGCAGA 1657
Db 1 TGCCCTGCTGCAGA 14
RESULT 260
ABA89702/c
ID ABA89702 standard; DNA; 16 BP.
XX AC ABA89702;
XX DT 12-FEB-2002 (first entry)
XX DE Serial analysis of ribosomal DNA tag #61.
XX
XX Serial analysis of ribosomal DNA; SARD; genetic diversity;
XX geochemical exploration; agriculture; biotrematation; forensic science;
XX environmental analysis; parasite detection; virus detection; ss.
XX OS Unidentified.
XX PN MO2000177392-A2.
XX PD 18-OCT-2001.
XX PF 10-APR-2001; 2001MO-US011609.
XX PR 10-APR-2000; 2000US-0196063P.
XX PR 11-APR-2000; 2000US-0196258P.
XX PA (ASHB/) ASHBY M.
XX PI Ashby M;

```

XX WP1; 2002-010926/01.

XX

PT Determining genetic diversity of population by analyzing a specific polymorphic region characteristic of particular genome in population of interest, useful for locating mineral deposits or petroleum reserves.

PS Example 3, Fig 16; 83pp; English.

XX

CC The present invention relates to a method of determining the genetic diversity of a population, involving amplifying a genome subregion with a polymorphic site, cleaving amplified fragment close to the polymorphic site, immobilising the amplified fragment, splitting into two pools, adding a linker to each pool, digesting the immobilised product to form tags that are ligated to form digests, and amplifying, cleaving and ligating to form concatemers and sequencing. The method is known as serial analysis of ribosomal DNA (SARD). This can be used to determine the genetic diversity of a population including microbial, viral or immune cell populations. The microbial population whose genetic diversity can be determined is from a sample associated with a site for petroleum or natural gas exploration, i.e., at a site of oil or gas reserves, associated with a site of mineral exploration, associated with a agricultural field, of patient sample suspected to have bacterial or fungal infection, associated with bioremediation site, or of an insect or parasite. The methods have application in fields of geochemical exploration, agriculture, bioremediation, environmental analysis, clinical microbiology, forensic science and medicine. The present sequence is an oligonucleotide described in the exemplification of the invention

XX

SQ Sequence 16 BP; 2 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 297 AGCTGGCGCACTGG 310
|||
Db 16 AGCTGCGGCACACTGG 3

RESULT 261
AA092210/c
ID AA092210 standard; DNA; 17 BP.
XX
AC AA092210;
XX
DT 12-JAN-1996 (first entry)
XX
DE p53 detection probe, (codon 142 del 1 C).
XX
KW Primer: polymerase chain reaction; amplify; mutant; K-ras; PCR; flanking region; amplification; probe; detection; sputum; diagnosis; benign; malignant; neoplasm; lung; lung cancer; head; neck; ss.
XX
OS Synthetic.
XX
PN WO951397-A1.
XX
PD 18-MAY-1995.
XX
PF 10-NOV-1994; 94WO-US012947.
XX
PR 12-NOV-1993; 93US-00152313.
XX
PA (UYJO) UNIV JOHNS HOPKINS SCHOOL MED.
XX
PI Sidransky D;
XX
DR WP1; 1995-194114/25.
XX
PT Detecting target nucleic acid in mammalian sputum - particularly for diagnosis of lung neoplasia involving mutation(s) in the K-ras oncogene

or p53 tumour suppressor.

Example 1; Page 36; 122pp; English.

The sequences given in AA092112-211 are probes which were used in the detection of a mutant p53 gene sequence. The DNA to be detected is amplified using PCR and then these probes which are pref. labeled using 32-P gamma-ATP are used to detect the mutant sequences. The primers and probes given in AA092098-219 are used in the method of the invention for detecting mammalian target DNA in sputum samples. Analysis of the target DNA is used to diagnose benign or malignant neoplasms of the lung. It is also useful for screening people at high risk or for monitoring progress of treatment of lung neoplasms. The method is based on the discovery that mutant target DNA associated with lung cancer is present at detectable levels in sputum. Cells shed into sputum from head and neck cancers may also be detected

Sequence 17 BP; 3 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0

1729 CTGCACAGCAGGT 1742
|||
16 CTGCACAGCAGGT 3

RESULT 262
AA081544
ID AA081544 standard; RNA; 17 BP.
XX
XX AA081544;
AC
XX
DT 14-DEC-1997 (first entry)
XX
XX Human c-myb hammerhead ribozyme target sequence (nt. position 2872).
DE
XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
XX smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW coronary angioplasty; ss.
XX
OS Homo sapiens.
OS
FN WO9531541-A2.
XX
PD 23-NOV-1995.
XX
PF 18-MAY-1995; 95WO-US006368.
XX
XX 18-MAY-1994; 94US-00245466.
PR 13-JAN-1995; 95US-00373124.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
PI WPI; 1996-010927/01.
XX
XX New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT for treating restenosis or cancer.
XX
XX Claim 1; Page 78; 128pp; English.

The present sequence represents the preferred target sequence for an enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves the human c-myb sequence at the base position indicated in the descriptor line. The c-myb sequence was screened for optimal ribozyme target sites using a computer folding algorithm, and regions of the mRNA which did not form secondary folding structures and contained potential ribozyme cleavage sites were identified. Ribozymes were synthesised and their activities optimised by either varying the length of the binding arms or by modification to prevent degradation by nucleases. The ribozymes cleave

CC the c-myb sequence and can be used to prevent smooth muscle cell
CC hyperproliferation in restenosis, especially after coronary angioplasty,
CC and in cancers

XX Sequence 17 BP; 5 A; 4 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 0.6%; Score 14; DB 1; Length 17;

Best Local Similarity 64.3%; Pred. No. 1.9e+02;
Matches 9; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1242 CACTAGTATTTCAG 1255

DB 2 CACUAGUUVUCAG 15

RESULT 263

AA165652/C
ID AA165652 standard; DNA; 17 BP.

AC AA165652;

XX 03-JAN-2002 (first entry)

DE Primer for studying biallelic polymorphic markers in the IBD1 region.

XX Human; inflammatory bowel disease 1 protein; IBD1, IBD1prox;

KM intestinal inflammatory disease; apoptosis; NF-kappa B; cancer;

KM inflammatory disease; immune disease; cryptogenetic inflammation;
KM hemorrhagic rectocolitis; Crohn's disease; Blau syndrome; PCR primer; ss.

XX Homo sapiens.

OS

PN FR2806739-A1.

XX 28-SEP-2001.

PF 27-MAR-2000; 2000FR-00003832.

PR 27-MAR-2000; 2000FR-00003832.

XX (DAUS-) FOND DAUSSET-CEPH JEAN.

PI Hugot JP, Thomas G, Zouali M, Leesage S, Chamailard M;

DR WPI; 2001-608364/70.

XX New human nucleic acids associated with intestinal inflammatory disease,
PT useful for diagnosis, prognosis and control of these diseases, also
PT related proteins.

XX Example 4; Page 85; 97pp; French.

XX Primers AA156647-78 were used to characterise biallelic polymorphic
CC markers in the IBD1 gene region. The IBD1 gene encodes an inflammatory
CC bowel disease 1 (IBD1) polypeptide, which is associated with intestinal
CC inflammatory disease. The specification also describes a polypeptide
CC which is in proximity to IBD1, and is designated IBD1prox. The IBD1 gene
CC is probably involved in regulation of apoptosis and activation of NF-
CC kappa B. The IBD1 and IBD1prox polynucleotides are useful as source of
CC probes and primers, as source of (anti)sense oligonucleotides, for
CC recombinant production of polypeptides, and in screening for interactive
CC compounds. The polypeptides are used to raise specific antibodies which
CC useful for diagnostic detection or purification of IBD1 and IBD1prox, to
CC screen for specific binding agents, potential therapeutic agents. The
CC IBD1 and IBD1prox polynucleotides and polypeptides are useful for
CC treatment and prevention of inflammatory and/or immune diseases or
CC cancer, where associated with mutations in genes corresponding to IBD1
CC and IBD1prox, especially cryptogenetic inflammation of the intestines
CC (hemorrhagic rectocolitis, Crohn's disease and Blau syndrome)

XX Sequence 17 BP; 3 A; 10 C; 2 G; 2 T; 0 U; 0 Other;

QY Query Match 0.6%; Score 14; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 595 CTTGGGAGATGCG 608

DB 14 CTTGGGAGATGCG 1

RESULT 264

ABN00903/C
ID ABN00903 standard; DNA; 17 BP.

AC ABN00903;

XX 29-MAY-2002 (first entry)

DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:895.

XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

OS

PN W0200192524-A2.

XX 06-DEC-2001.

PF 25-MAY-2001; 2001WO-US016981.

PR 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.

XX (AEOM-) AEOMICA INC.

PA Gu Y, Yi Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

PI WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.

XX Disclosure; SEQ ID NO 895; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and vaccine production. The hGDMLP-1
CC can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 2 A; 1 C; 11 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02; Mismatches 0; Indels 0; Gaps 0;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1699 AAGCCCTTCCCCA 1712
 DB 15 AAGCCCTTCCCCA 2
 RESULT 265
 ABN0904/C
 ID ABN0904 standard; DNA; 17 BP.
 XX
 AC ABN0904;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:896.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX
 DR WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
 XX
 PS Disclosure; SEQ ID NO 896; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify

CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 2 A; 1 C; 11 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02; Mismatches 0; Indels 0; Gaps 0;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1699 AAGCCCTTCCCCA 1712
 DB 14 AAGCCCTTCCCCA 1
 RESULT 266
 ABR39797
 ID ABR39797 standard; DNA; 17 BP.
 XX
 AC ABR39797;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID NO 5434.
 XX
 KW Cytostratic; vinicide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004208.
 XX
 PR 17-SEP-2001; 2001FR-00011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 669; 720pp; French.
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic

CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analyses of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human htkutin oligonucleotide of the invention
 CC
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 2 G; 7 T; 0 U; 0 Other;
 Query Match 0.6%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1334 TCACATTGTTCTC 1347
 Db 3 TCACATTGTTCTC 16
 RESULT 267
 ACD61599/c
 ID ACD61599 standard; RNA; 17 BP.
 XX
 AC ACD61599;
 XX
 DT 23-SEP-2003 (first entry)
 DE HCV minus strand DNAzyme substrate sequence #134.
 XX
 KM Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KM RNA stability; RNA expression; RNA synthesis; antisense;
 KM enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; zinczyme;
 KM amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
 KM HBV reverse transcriptase; Enhancer I region; viral replication;
 KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KM virucide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN WO200281494-A1.
 PD 17-OCT-2002.
 XX
 PF 26-MAR-2002; 2002MO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWISGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswisgen J, Morrissey D, Pavco P, Lee P;
 Draper K, Roberts E,

XX
 DR WPI; 2003-229207/22.
 XX
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 XX
 PS Claim 1; Page 277; 387pp; English.
 XX
 CC The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
 CC zinczymes, zinczymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNAzyme or minus strand DNAzyme sequences disclosed in the present
 CC invention
 CC
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 0.6%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1226 CAGTCAACTCTCG 1239
 Db 16 CAGTCAACTCTCG 3
 RESULT 268
 AAZ20330/c
 ID AAZ20330 standard; DNA; 18 BP.
 XX
 AC AAZ20330;
 XX
 DT 15-NOV-1999 (first entry)
 DE Antisense modulator of RhoA, ISIS# 25578.
 XX
 KM RhoA; antisense modulator; antisense inhibitor; human; GTPase; cancer;
 KM Alzheimer's disease; wound repair; clotting disorder; diagnosis; therapy;
 KM infection; inflammation; tumour formation; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..18
 FT /*tag= a
 FT /note= "phosphorothioate nucleotides"
 FT modified_base 1..4
 FT /*tag= b
 FT /note= "optionally 2'-methoxyethyl nucleotides"
 FT modified_base 15..18
 FT /*tag= c
 FT /note= "optionally 2'-methoxyethyl nucleotides"
 PN US5945290-A.
 XX
 PD 31-AUG-1999.
 XX
 PF 18-SEP-1998; 98US-00156424.
 XX
 PR 18-SEP-1998; 98US-00156424.

```
XX (ISIS-) ISIS PHARM INC.
PA
XX Cowsert IM;
PI
XX WPI; 1999-526254/44.
DR
XX New agent for specific modulation of a GTPase especially useful for
PT prevention of tumor formation.
XX
XX Claim 3; Col 28; 24pp; English.
PS
XX This sequence represents an antisense inhibitor of human RhoA expression
CC of the invention. RhoA is a member of the Rho subfamily of small GTPases,
CC and is thought to be involved in both injury and disease states,
CC including Alzheimer's disease, wound repair, clotting disorders, and the
CC development of cancer. The antisense inhibitors are useful for inhibiting
CC expression of RhoA in human cells or tissues by contacting the cells or
CC tissues with the compound in vitro. They are useful for diagnosis,
CC treatment and prevention of reoccurrence of diseases or disorders caused
CC by aberrant expression of RhoA, and is useful prophylactically e.g. to
CC prevent or delay infection, inflammation or tumour formation. Unlike the
CC antisense sequences, prior art therapeutic agents which inhibit RhoA
CC synthesis are not specific to RhoA
XX
XX Sequence 18 BP; 5 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1814 AGAAGCCACTATG 1827
Db |||||
15 AGAAGCCACTATG 2
RESULT 269
AAf76101
ID AAF76101 standard; DNA; 18 BP.
XX
XX AAF76101;
AC
XX 22-MAY-2001 (first entry)
DT
XX
XX CCR5/CCR2b PCR primer, SEQ ID:5, used to genotype HIV susceptibility.
DE
XX
XX CC chemokine receptor; beta chemokine receptor; CCR; human; CCR5; CCR2;
KW polymorphism; genotyping; HIV-1 transmission; infection susceptibility;
KW AIDS; acquired immunodeficiency syndrome; disease progression;
KW chromosome 3p21-22; PCR primer; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200112857-A2.
PN
XX
XX 22-FEB-2001.
PD
XX
XX 11-AUG-2000; 2000WO-US022255.
PF
XX
XX 12-AUG-1999; 99US-0148530P.
PR
XX (UABR-) UAB RES FOUND.
PA
XX Tang J, Kaslow RA;
PI
XX
XX WPI; 2001-211235/21.
DR
XX
XX Surveying CC beta chemokine receptor (CCR) genotypes in population,
PT involves amplifying genomic DNA of individuals with experimental and
PT control primer combinations, size-separating amplicons and determining
PT CCR genotype.
XX
XX Claim 1; Page 42; 118pp; English.
PS
```

```
XX The invention relates to a method of surveying the CC (beta) chemokine
CC receptor (CCR) genotypes in a population. The method is particularly
CC applied to the human CCR5 and CCR2 genes located on chromosome 3p21-22,
CC which encode co-receptors for HIV-1. The method involves obtaining
CC genomic DNA samples from a representative number of individuals within a
CC population; combining each sample with experimental and control primer
CC combinations to produce primer-annealed DNA; amplifying the DNA to
CC produce amplicons; separating the amplicons by size; determining the CCR
CC genotype based upon the presence of CCR alleles; and compiling the
CC genotypes determined. The method is particularly applied to the human
CC CCR5 and CCR2 genes, which encode co-receptors for HIV-1. Polymorphisms
CC in these genes are associated with a variation in the susceptibility of
CC an individual to infection by HIV-1, or with a variation in the disease
CC progression of AIDS after infection. The invention specifically claims
CC the experimental PCR primers AAF76098-AAF76112, and the control PCR
CC primers AAF76113-AAF76114 for surveying CCR5 and CCR2b genotypes. The
CC method of the invention fulfills a longstanding need for the development
CC of a rapid and informative genotyping strategy that can be readily
CC applied to analyse CCR5, CCR2 and related genetic variants, and to
CC evaluate the relationship of each genotype to HIV transmission and
CC disease progression. The present sequence represents a human CCR5/CCR2b
CC experimental PCR primer for use in the method of the invention
XX
XX Sequence 18 BP; 7 A; 0 C; 10 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2189 TGGAGAAAAGGGG 2202
Db |||||
4 TGGAGAAAAGGGG 17
RESULT 270
AAf76102
ID AAF76102 standard; DNA; 18 BP.
XX
XX AAF76102;
AC
XX 22-MAY-2001 (first entry)
DT
XX
XX CCR5/CCR2b PCR primer, SEQ ID:6, used to genotype HIV susceptibility.
DE
XX
XX CC chemokine receptor; beta chemokine receptor; CCR; human; CCR5; CCR2;
KW polymorphism; genotyping; HIV-1 transmission; infection susceptibility;
KW AIDS; acquired immunodeficiency syndrome; disease progression;
KW chromosome 3p21-22; PCR primer; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200112857-A2.
PN
XX
XX 22-FEB-2001.
PD
XX
XX 11-AUG-2000; 2000WO-US022255.
PF
XX
XX 12-AUG-1999; 99US-0148530P.
PR
XX (UABR-) UAB RES FOUND.
PA
XX Tang J, Kaslow RA;
PI
XX
XX WPI; 2001-211235/21.
DR
XX
XX Surveying CC beta chemokine receptor (CCR) genotypes in population,
PT involves amplifying genomic DNA of individuals with experimental and
PT control primer combinations, size-separating amplicons and determining
PT CCR genotype.
XX
XX Claim 1; Page 42; 118pp; English.
PS
```

CC The invention relates to a method of surveying the CC (beta) chemokine
 CC receptor (CCR) genotypes in a population. The method is particularly
 CC applied to the human CCR5 and CCR2 genes located on chromosome 3p21-22,
 CC which encode co-receptors for HIV-1. The method involves obtaining
 CC genomic DNA samples from a representative number of individuals within a
 CC population; combining each sample with experimental and control primer
 CC combinations to produce primer-annealed DNA; amplifying the DNA to
 CC produce amplicons; separating the amplicons by size; determining the CCR
 CC genotype based upon the presence of CCR alleles; and compiling the
 CC genotypes determined. The method is particularly applied to the human
 CC CCR5 and CCR2 genes, which encode co-receptors for HIV-1. Polymorphisms
 CC in these genes are associated with a variation in the susceptibility of
 CC an individual to infection by HIV-1, or with a variation in the disease
 CC progression of AIDS after infection. The invention specifically claims
 CC the experimental PCR primers AAF76038-AAF76112, and the control PCR
 CC primers AAF76113-AAF76114 for surveying CCR5 and CCR2b genotypes. The
 CC method of the invention fulfills a longstanding need for the development
 CC of a rapid and informative genotyping strategy that can be readily
 CC applied to analyse CCR5, CCR2 and related genetic variants, and to
 CC evaluate the relationship of each genotype to HIV transmission and
 CC disease progression. The present sequence represents a human CCR5/CCR2b
 CC experimental PCR primer for use in the method of the invention

SQ Sequence 18 BP; 8 A; 0 C; 9 G; 1 T; 0 U; 0 Other;
 Query Match 0.6%; Score 14; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2189 TCGAGAAAAAGCGG 2202
 |||||
 4 TCGAGAAAAAGCGG 17

RESULT 271
 AAF94632/C
 ID AAF94632 standard; DNA; 18 BP.

AC AAF94632;

DT 23-MAY-2001 (first entry)

DE Rho A antisense phosphorothioate oligonucleotide SEQ ID 56.

KM Rho; GTP binding protein; phosphorothioate antisense oligonucleotide;
 KM RhoA; RhoB; RhoC; RhoG; Rac 1; cdc42; Hyperproliferative condition;
 KM cancer; wound healing; clotting; ischaemia; reperfusion; reoxygenation;
 KM ss.

OS Homo sapiens.

PN W0200115739-A1.

PD 08-MAR-2001.

PF 18-AUG-2000; 2000WO-US022808.

PR 31-AUG-1999; 99US-00387341.

PA (ISIS-) ISIS PHARM INC.

PI Roberts ML, Cowse LM;

DR WPI; 2001-191677/19.

PT An antisense compound targeted to a nucleic acid molecule encoding a
 PT member of the human Rho family of small GTP binding proteins useful for
 PT treating e.g. cancer and ischemia.

PS Example 8; Page 53; 156pp; English.

CC This invention relates to an antisense compound targeted to a nucleic
 CC acid molecule encoding a member of the human Rho family of small GTP

CC binding proteins, where the antisense compound inhibits the expression of
 CC the member of the human Rho family. The invention includes antisense
 CC oligonucleotides AAF94580 - AAF94637 which target a RhoA nucleotide
 CC sequence, AAF94645 - AAF94684 which target a RhoB nucleotide sequence,
 CC AAF94686 - AAF94725 which target a RhoC nucleotide sequence, AAF94727 -
 CC AAF94766 which target RhoG nucleotide sequence, AAF94769 - AAF94790 which
 CC target a Rac 1 nucleotide sequence and AAF94795 - AAF94809 which target
 CC cdc42 nucleotide sequence. The antisense compound is useful for treating
 CC hyperproliferative conditions, especially cancer, abnormal wound healing
 CC or clotting conditions and ischaemia/reperfusion or reoxygenation injury.
 CC The compound may also be used to diagnose the above conditions

SQ Sequence 18 BP; 5 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 0.6%; Score 14; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1814 AGAAGCCAACTATG 1827
 |||||
 15 AGAAGCCAACTATG 2

RESULT 272
 ABL44589
 ID ABL44589 standard; DNA; 18 BP.

AC ABL44589;

DT 11-APR-2002 (first entry)

DE Human chromosome 1p36-35 PCR primer SEQ ID NO:1633.

KM Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
 KM PCR primer; ss.

OS Homo sapiens.

PN JP2001321190-A.

PD 20-NOV-2001.

PF 12-MAR-2001; 2001JP-00068285.

PR 10-MAR-2000; 2000JP-00066716.

PA (RIKA) RIKAGAKU KENKYUSHO.

XX (GENO-) GENOTEX YG.

DR WPI; 2002-144136/19.

PT Arraying genome clones.

PS Claim 4; Page 37; 528pp; Japanese.

CC The present invention describes a method of arraying genome clones. The
 CC method comprises: (a) clones of the genomic libraries contained in
 CC multiwell plates numbered for discrimination are mixed in each of the
 CC multiwell plates; (b) a primer designed based on the chromosome marker
 CC sequence is added to the mixture to carry out an amplification reaction;
 CC (c) a signal corresponding to the marker is detected from the resultant
 CC amplified product to specify the discrimination Nos. of the multiwell
 CC plates containing the clones having said marker sequence; (d) the order
 CC of the markers is changed so that the same discrimination Nos. succeed to
 CC the maximum in the specified discrimination Nos. to array the multiwell
 CC plates; (e) the clones in the multiwell plates of the specified
 CC discrimination Nos. are mixed respectively in each wells of longitudinal
 CC and lateral directions; (f) the mixed clones are cultured and the
 CC resultant cultures are amplified by using the above primer; (g) signals
 CC are detected from the amplified products; (h) the clones in the multiwell
 CC plates are specified from the detected result; and (i) the clones are
 CC reconstituted as the positions on the chromosome and arrayed. The
 CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent

CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC represent PCR primers for human chromosome 21q22.1, which are
CC specifically claimed for use in the present invention
XX
SQ Sequence 18 BP; 3 A; 1 C; 10 G; 4 T; 0 U; 0 Other;
Query Match 0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 594 TCTTGGGAGATGG 607
DB 4 TCTTGGGAGATGG 17
RESULT 273
AAA24819/c
ID AAA24819 standard; DNA; 17 BP.
XX
AC AAA24819;
XX
DT 19-JUL-2000 (first entry)
XX
DE Oestrogen receptor hammerhead ribozyme target sequence SRQ ID NO:1317.
XX
KM Oestrogen receptor; c-rai; k-raa; bcl-2; ribozyme; cleavage;
KM hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KM gene expression modification; cancer; phosphorothioate; endonuclease;
KM anticancer; breast cancer; endometrium cancer; ss.
XX
OS Homo sapiens.
XX
PN MO9954459-A2.
XX
PD 28-OCT-1999.
XX
PF 19-APR-1999; 99WO-US008547.
XX
PR 20-APR-1998; 98US-0082404P.
PR 23-JUN-1998; 98US-00103636.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Thompson JD, Beigelman L, Mowsiggen UA, Karpelsky A, Bellon L,
PI Reynolds M, Zwick M, Jarvis T, Wolf T, Haeblerl P,
PI Matulic-Adamic J;
XX
DR WPI; 2000-013246/01.
XX
PT New nucleic acids that interact, and optionally cleave, target sequences,
PT used to treat cancer.
XX
PS Claim 77; Page 59; 148pp; English.
XX
CC The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphoro(di)thioate
CC link, having endonuclease activity. (A), and more generally any catalytic
CC nucleic acid (A') that modulates expression of the oestrogen receptor
CC gene, are used to treat cancer (particularly of breast or endometrium),
CC in vivo or by transforming cells ex vivo and implanting treated cells, or
CC for other conditions associated with levels of oestrogen receptor.
CC Because of the high selectivity for targeted RNA, (A) can also be used to
CC correlate inhibition of gene expression with alterations in phenotype,
CC particularly for identification of therapeutic targets, and as research
CC reagents (for RNA, in the same way that restriction endonucleases are
CC used with DNA). The combination of modifications in (A) improves
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
CC AAA24748 to AAA25992 represent their corresponding target sequences.
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
CC sequences, and AAA26107 to AAA26218 represent their corresponding target
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC antisense oligonucleotides used in the exemplification of the present

CC invention
XX
SQ Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 541 GGCTCGAGACGCCCG 557
DB 17 GGCTCGAGACACGCTG 1
RESULT 274
AAF02145/c
ID AAF02145 standard; DNA; 17 BP.
XX
AC AAF02145;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #440.
XX
KM Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KM interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mowsiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 37; Page 66; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COP-1P-1, the GATA transcription
CC factor gene, IRF-2 and/or the C/EBP displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
SQ Sequence 17 BP; 3 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1843 GCTGCACTAAAGCTGG 1859
DB 17 GCCACAGTAAAGTCTGG 1
RESULT 275
AAF02081/c
ID AAF02081 standard; DNA; 17 BP.
XX
AC AAF02081;

XX 16-FEB-2001 (first entry)
XX Hammerhead ribozyme substrate #376.
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX Interferon alpha; ss.
XX Homo sapiens.
XX WO200061729-A2.
XX 19-OCT-2000.
XX 11-APR-2000; 2000WO-US009721.
XX 12-APR-1999; 99US-0129390P.
XX (RIBO-) RIBOZYME PHARM INC.
XX Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX WPI; 2000-647423/62.
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
XX useful for producing e.g. granulocyte colony stimulating factor protein,
XX Interferon alpha and erythropoietin.
XX Claim 37; Page 64; 164pp; English.
XX The present invention relates to enzymatic and antisense nucleic acid
XX molecules that act as inhibitors of the expression of repressor genes
XX encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
XX factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
XX Inhibition of the repressors removes prevents inhibition (and
XX consequently increases expression of) genes involved in the production of
XX erythropoietin, granulocyte colony stimulating factor protein and
XX Interferon alpha
XX Sequence 17 BP; 2 A; 5 C; 8 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2004 TGCCACCAAGTGCCTCG 2020
DB 17 TGCCCCCAGAGCCCTG 1
RESULT 276
AAFO1721
ID AAFO1721 standard; DNA; 17 BP.
XX AAFO1721;
XX 16-FEB-2001 (first entry)
XX Hammerhead ribozyme substrate #16.
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX Interferon alpha; ss.
XX Homo sapiens.
XX WO200061729-A2.
XX 19-OCT-2000.
XX 11-APR-2000; 2000WO-US009721.
XX 12-APR-1999; 99US-0129390P.
XX

PA (RIBO-) RIBOZYME PHARM INC.
XX Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX WPI; 2000-647423/62.
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
XX useful for producing e.g. granulocyte colony stimulating factor protein,
XX Interferon alpha and erythropoietin.
XX Claim 37; Page 56; 164pp; English.
XX The present invention relates to enzymatic and antisense nucleic acid
XX molecules that act as inhibitors of the expression of repressor genes
XX encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
XX factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
XX Inhibition of the repressors removes prevents inhibition (and
XX consequently increases expression of) genes involved in the production of
XX erythropoietin, granulocyte colony stimulating factor protein and
XX Interferon alpha
XX Sequence 17 BP; 1 A; 4 C; 5 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 949 TTGGGATCATGCTCTG 965
DB 1 TTGTGATCCTGCTCTG 17
RESULT 277
ABK02015
ID ABK02015 standard; RNA; 17 BP.
XX ABK02015;
XX 12-MAR-2002 (first entry)
XX Human NCOG zinczyme #337.
XX Human; ss; antisense therapy; cytoskeletal; antiinflammatory; haemostatic;
XX cerebroprotective; neuroprotective; antiparkinsonian;
XX muscular; C/EBP; neurite growth inhibitor gene; NCOG; hammerhead ribozyme;
XX DNase; inozyme; G-cleaver; amberyzyme; zinczyme; lymphoma; leukaemia;
XX B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
XX human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
XX MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
XX inflammatory arthropathy; central nervous system injury;
XX cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
XX chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
XX Parkinson's disease; ataxia; Huntington's disease;
XX Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX Homo sapiens.
XX Synthetic.
XX WO200159103-A2.
XX 16-AUG-2001.
XX 09-FEB-2001; 2001WO-US004273.
XX 11-FEB-2000; 2000US-0181797P.
XX 28-FEB-2000; 2000US-0185516P.
XX 06-MAR-2000; 2000US-0187128P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (CHOW/) CHOWRIRA B M.
XX

PI Blatt L, Mcswigen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 88; Page 101; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOCO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving a NYN motif) pr
 CC possessing an NGH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
 CC an amberzyme (cleaving RNA with an NGN triplet), a zynzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOCO-
 CC targeting nucleic acid is used to cleave RNA of the NOCO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a zynzyme molecule of the invention
 CC
 XX
 SQ Sequence 17 BP; 1 A; 1 C; 9 G; 0 T; 6 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 64.7%; Pred. No. 2e+02;
 Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 OY 784 GGAGAGGTGTTGGGCG 800
 |||||:::||||
 Db 1 GGAGUGGUGUUGGUGC 17
 RESULT 278
 ABR00106
 ID ABR00106 standard; RNA; 17 BP.
 XX
 AC ABR00106;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human NOGO Hammerhead Ribozyme #106.
 XX
 KW Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberzyme; zynzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;

KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN MO200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PR 09-FEB-2001; 2001MO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswigen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 DR
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 88; Page 67; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOCO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving a NYN motif) pr
 CC possessing an NGH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
 CC an amberzyme (cleaving RNA with an NGN triplet), a zynzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOCO-
 CC targeting nucleic acid is used to cleave RNA of the NOCO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a hammerhead ribozyme of the invention
 CC
 XX
 SQ Sequence 17 BP; 9 A; 3 C; 2 G; 0 T; 3 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2e+02;
 Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
 OY 1778 GAAGCTTCAGAAAT 1794
 |||||:::|||||||:

Db 1 GAACACUCUCAAAGAAAU 17
 RESULT 279
 ID ABK01837/c
 ID ABK01837 standard; RNA; 17 BP.
 XX
 AC ABK01837;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human NOGO zinzyme #159.
 XX
 KM Human; ss; antitense therapy; cyostatic; antiinflammatory; haemostatic;
 KM cerebroprotective; neuroprotective; antiparkinsonian; antiparkinsonian;
 KM muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KM DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukemia;
 KM B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukemia;
 KM human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KM MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KM inflammatory arthropathy; central nervous system injury;
 KM cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KM chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KM Parkinson's disease; ataxia; Huntington's disease;
 KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 OS
 PN WO200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PR 09-FEB-2001; 2001WO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, McSwiggen J, Chowrira BM;
 XX
 DR WPI; 2001-607195/69.
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 88; Page 98; 200P; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberzyme (cleaving RNA with an NGN tripler), a zinzyme (cleaving RNA
 CC with a YXY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-

CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a zinzyme molecule of the invention
 XX
 SQ Sequence 17 BP; 3 A; 9 C; 5 G; 0 T; 0 U; 0 Other;
 XX
 QY Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 199 GTGCTCGGCTGGGGC 215
 Db 17 GGAGCTCGCTGGGGC 1
 XX
 RESULT 280
 AEN08065
 ID AEN08065 standard; DNA; 17 BP.
 XX
 AC AEN08065;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8057.
 XX
 KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KM skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 OS
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PR 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 PA
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX
 DR WPI; 2002-179446/23.
 XX
 CC New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 CC or as specific biomolecule capture probes for surface-enhanced laser
 CC desorption ionization, comprises human myosin-like protein hGDMLP-1.
 XX

PS Disclosure; SEQ ID NO 8057; 214pp; English.

XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the protein. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence

XX
SQ Sequence 17 BP; 7 A; 4 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
Matches 15; Conservative 0; Indels 2

Qy 2231 CAGATGCTCCAGAAATGA 2247
Db 1 CAGATGACCCAGAGA 17
|||||

RESULT 281
ABN09591
ID ABN09591 standard; DNA; 17 BP.

XX
AC ABN09591;
XX
XX 29-MAY-2002 (first entry)

DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9583.
XX
XX Human: genome-derived myosin-like protein 1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 03-FEB-2001; 2001US-026860P.

XX
PA (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI WPI; 2002-179446/23.
XX
XX
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
PS Disclosure; SEQ ID NO 9583; 214pp; English.

XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence

XX
SQ Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
Matches 15; Conservative 0; Indels 2

Qy 1167 GTTAGGGAAGCTGC 1183
Db 1 GTCGAGGGAAGCTGC 17
|||||

RESULT 282
ABN08064
ID ABN08064 standard; DNA; 17 BP.

XX
AC ABN08064;
XX
XX 29-MAY-2002 (first entry)

DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8056.
XX
XX Human: genome-derived myosin-like protein 1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PA (AEOM-) AEOMICA INC.
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 DR
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT description ionization, comprises human myosin-like protein hGDMLP-1.
 XX
 PS Disclosure; SEQ ID NO 8056; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP-
 CC 1-proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser description ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 CC
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 6 G; 1 T; 0 U; 0 Other;
 Query Match 0.64; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 2;
 QY 2230 GCAGATGCTCCAGATG 2246
 Db 1 GCAGATGCTCCAGATG 17
 RESULT 283
 ABN01968
 ID ABN01968 standard; DNA; 17 BP.
 XX
 AC ABN01968;
 XX
 XX 29-MAY-2002 (first entry)
 DT
 XX
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1960.
 XX
 KM Human, genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KM skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.

XX
 PN- WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 DR
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT description ionization, comprises human myosin-like protein hGDMLP-1.
 XX
 PS Disclosure; SEQ ID NO 1960; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP-
 CC 1-proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser description ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 CC
 XX
 SQ Sequence 17 BP; 5 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 0.64; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 2;
 QY 1832 AAATCAGCTGCTGCA 1848
 Db 1 AAATCAGCTGCTGCA 17
 RESULT 284
 ABN06530
 ID ABN06530 standard; DNA; 17 BP.
 XX

AC ABN06530;
XX
XX 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6522.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEWOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
PS Disclosure; SEQ ID NO 6522; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 8 C; 4 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 2101 CAGCAGCTCAGCCTGT 2117
|||
Db 1 CACGACCGCAGCCTGT 17
RESULT 285
ID ABN06533
ID ABN06533 standard; DNA; 17 BP.
XX
XX ABN06533;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6525.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEWOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
PS Disclosure; SEQ ID NO 6525; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart

CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 4 A; 6 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 2104 CACCTGAGCTGTGTA 2120
1 CACCTGAGCTGTGTA 17
Db
RESULT 286
ABN01538
ID ABN01538 standard; DNA; 17 BP.
XX
AC ABN01538;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1530.
XX
KW Human, genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN M0200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0268660P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 1530; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 2 A; 1 C; 10 G; 4 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1595 AGGTGACGGCGCTGTG 1611
1 AGGTGATGGGCTGTG 17
Db
RESULT 287
ABN00673/c
ID ABN00673 standard; DNA; 17 BP.
XX
AC ABN00673;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:665.
XX
KW Human, genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN M0200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0268660P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX

PR	30-JAN-2001; 2001WO-US000668.
PR	30-JAN-2001; 2001WO-US000669.
PR	30-JAN-2001; 2001WO-US000670.
PR	05-FEB-2001; 2001US-026860P.
PA	(AEOM-) AEOMICA INC.
XX	
PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
DR	WPI; 2002-179446/23.
XX	
PT	New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT	or as specific biomolecule capture probes for surface-enhanced laser
PT	desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX	
PS	Disclosure; SEQ ID NO 1572; 214pp; English.
XX	
CC	The present invention describes a human genome-derived myosin-like
CC	protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC	1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC	nucleic acids can be used as probes to detect, characterize and quantify
CC	hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC	provide initial substrates for the recombinant engineering of hGDMLP-1
CC	protein variants having desired phenotypic improvements, and for
CC	expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC	used as immunogens to raise antibodies that specifically recognise hGDMLP
CC	-1 proteins, as standards in assays used to determine the concentration
CC	and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC	capture probes for surface-enhanced laser desorption ionisation, as
CC	therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC	production, and in vaccines or for replacement therapy. The
CC	polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC	disorder associated with the expression of hGDMLP-1, in particular heart
CC	and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC	The present sequence represents an oligomer used in the screening of the
CC	hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC	The sequence data for this patent did not form part of the printed
CC	specification, but was obtained in electronic format directly from WIPO
CC	at ftp.wipo.int/pub/published_pct_sequence
XX	
SQ	Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
XX	
Query Match	0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 2e+02;
Matches 15; Conservative	0; Mismatches 2; Indels 0; Gaps 0;
OY	267 CCAGGGCTGGCTGGCTG 283
DB	17 CCAGAGCAAGCTGGCTG 1
RESULT 289	
ABN02747	
ID	ABN02747 standard; DNA, 17 BP.
XX	
AC	ABN02747;
XX	
DT	29-MAY-2002 (first entry)
XX	
DE	Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2739.
XX	
KW	Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW	skeletal muscle disorder; amplicon; screening; ss.
OS	Homo sapiens.
XX	
PV	WO200192524-A2.
XX	
PD	06-DEC-2001.
XX	
PF	25-MAY-2001; 2001WO-US016981.
XX	

RESULT 291
ABN00523/c
ID ABN00523 standard; DNA; 17 BP.
XX
AC ABN00523;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:515.
XX
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0268660P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 515; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence

SEQ Sequence 17 BP; 3 A; 8 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 160 CTGCTCCGGGCTGGGC 176
DB 17 CTGCTCAGGGTCGGGCGC 1
RESULT 292
ABN06766
ID ABN06766 standard; DNA; 17 BP.
XX
AC ABN06766;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6758.
XX
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0268660P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 6758; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as

CC	protein_1 (hgdmLP-1). The protein and polynucleotide sequences of hgdmLP-
CC	1 can be used in gene therapy and vaccine production. The hgdmLP-1
CC	nucleic acids can be used as probes to detect, characterise and quantify
CC	hgdmLP-1 nucleic acids in samples, as amplification substrates, to
CC	provide initial substrates for the recombinant engineering of hgdmLP-1
CC	protein variants having desired phenotypic improvements, and for
CC	expressing the protein. The hgdmLP-1 proteins or polypeptides may be
CC	used as immunogens to raise antibodies that specifically recognise hgdmLP
CC	-1 proteins, as standards in assays used to determine the concentration
CC	and/or amount specifically of hgdmLP proteins, as specific biomolecule
CC	capture probes for surface-enhanced laser desorption/ionisation, as
CC	therapeutic supplement in patients having specific deficiency in hgdmLP-1
CC	production, and in vaccines or for replacement therapy. The
CC	polynucleotide sequences encoding hgdmLP-1 may be used for diagnosing a
CC	disorder associated with the expression of hgdmLP-1, in particular heart
CC	and skeletal muscle disorders. hgdmLP-1 is localised to chromosome 22.
CC	The present sequence represents an oligomer used in the screening of the
CC	hgdmLP-1 sequence in the exemplification of the present invention. N.B.
CC	the sequence data for this patent does not form part of the printed
CC	specification, but was obtained in electronic format directly from WIPO
CC	at ftp.wipo.int/pub/published_pct_sequence
SQ	Sequence 17 BP; 3 A; 9 C; 4 G; 1 T; 0 U; 0 Other;
OY	Query Match 0.6%; Score 13.8; DB 1; Length 17;
Db	Best Local Similarity 88.2%; Pred. No. 2e+02;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
	2100 CCAGCACTCAGCGCTGG 2116
	1 CCACCACCGCAGCGCTGG 17
RESULT 294	
ABQ64238	
ID	ABQ64238 standard; DNA; 17 BP.
XX	
XX	ABQ64238;
XX	
DT	20-AUG-2002 (first entry)
DE	Human KTM1a portion (ABQ63232) probe # 951.
XX	
KW	Human; KTM1a; KTM1; kidney tumour overexpressed membrane; cytosolic;
KM	gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
XX	kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
OS	Homo sapiens.
XX	
PN	WO200224750-A2.
PD	
XX	28-MAR-2002.
PF	
XX	21-SEP-2001; 2001WO-US029656.
XX	
PR	21-SEP-2000; 2000US-0234687P.
PR	27-SEP-2000; 2000US-0236359P.
PR	04-OCT-2000; 2000GB-00024263.
PR	30-JAN-2001; 2001WO-US000661.
PR	30-JAN-2001; 2001WO-US000662.
PR	30-JAN-2001; 2001WO-US000663.
PR	30-JAN-2001; 2001WO-US000664.
PR	30-JAN-2001; 2001WO-US000665.
PR	30-JAN-2001; 2001WO-US000666.
PR	30-JAN-2001; 2001WO-US000667.
PR	30-JAN-2001; 2001WO-US000668.
PR	30-JAN-2001; 2001WO-US000670.
PR	23-MAY-2001; 2001US-00864761.
PR	28-AUG-2001; 2001US-0315676P.
XX	
PA	(AEOM-) AEOMICA INC.
XX	

```
PI Zhang J;
XX
XX WPI; 2002-479509/51.
XX
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
XX Example 2; Page 282; 418bp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding human
CC KTOM1 (Kidney tumour overexpressed membrane) protein. The protein of the
CC invention has cytostatic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (AB063232)
XX
SQ Sequence 17 BP; 4 A; 8 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 147 CACCGCGCTGCCACTGC 163
Db 1 CACCGAGCAGCCACTGC 17
RESULT 295
ABV85488/c
ID ABV85488 standard; DNA; 17 BP.
XX
AC ABV85488;
XX
DT 11-DEC-2002 (first entry)
XX
DE Human pp-GaNTase 10 scanning 17-mer SEQ ID NO:481.
XX
KM Human; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10;
KM pp-GaNTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
KM ss.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX EPI243660-A2.
XX
XX 25-SEP-2002.
XX
XX 25-JAN-2002; 2002EP-00001161.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 30-JAN-2001; 2001US-00864761.
XX 23-MAY-2001; 2001US-00864761.
XX 30-AUG-2001; 2001US-0315984P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhang J, Gu Y, Nguyen C;
XX
XX WPI; 2002-724954/79.
XX
DR
```

```
XX
XX Nucleic acid encoding human UDP-GalNAc:polypeptide N-
XX PT cetylalactosaminyltransferase 10 protein is useful to diagnose, prevent
XX PT and treat disorders associated with reduced or over expression of the
XX PT encoded protein.
XX
XX Example 2; SEQ ID NO 481; 59pp; English.
XX
XX
XX The present invention describes an isolated nucleic acid (1) encoding a
XX human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10 (pp-
XX GaNTase 10, EC 2.4.1.41) protein. Human pp-GaNTase 10 is located to
XX chromosome 7q11.2. (1) can be used in gene therapy. Molecules of the
XX present invention can be used in therapy, particularly to prevent or
XX treat a disorder associated with decreased expression or activity of pp-
XX GaNTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to
XX ABP53504 are given in the exemplification of the present invention. N.B.
XX The sequence data for this patent is not represented in the printed
XX specification but is based on sequence information supplied by the
XX European Patent Office
XX
SQ Sequence 17 BP; 5 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 148 CTTACTTGAGAGGCC 1504
Db 17 CTTACTTGAGAGGCC 1
RESULT 296
ABV85444
ID ABV85444 standard; DNA; 17 BP.
XX
AC ABV85444;
XX
DT 11-DEC-2002 (first entry)
XX
DE Human pp-GaNTase 10 scanning 17-mer SEQ ID NO:437.
XX
XX
XX Human; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10;
XX KM pp-GaNTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
XX KM ss.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX EPI243660-A2.
XX
XX 25-SEP-2002.
XX
XX 25-JAN-2002; 2002EP-00001161.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 30-JAN-2001; 2001US-00864761.
XX 30-AUG-2001; 2001US-0315984P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhang J, Gu Y, Nguyen C;
XX
XX WPI; 2002-724954/79.
XX
XX
XX Nucleic acid encoding human UDP-GalNAc:polypeptide N-
XX PT cetylalactosaminyltransferase 10 protein is useful to diagnose, prevent
XX PT
```

PT and treat disorders associated with reduced or over expression of the
PT encoded protein.
XX
PS Example 2; SEQ ID NO 437; 59pp; English.
XX
CC The present invention describes an isolated nucleic acid (1) encoding a
CC human UDP-GalNAc:polypeptide N-acetylglucosaminyltransferase 10 (pp-
CC GANTase 10, EC 2.4.1.41) protein. Human pp-GANTase 10 is located to
CC chromosome 7q11.2. (1) can be used in gene therapy. Molecules of the
CC present invention can be used in therapy, particularly to prevent or
CC treat a disorder associated with decreased expression or activity of pp-
CC GANTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to
CC ABP53504 are given in the exemplification of the present invention. N.B.
CC The sequence data for this patent is not represented in the printed
CC specification but is based on sequence information supplied by the
CC European Patent Office
XX
SQ Sequence 17 BP; 7 A; 3 C; 2 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;
QY 1421 CCTCAGAGAAAATTT 1437
Db 1 CCTCAGTGAATAATTT 17
XX
RESULT 297
ABV85800
ID ABV85800 standard; DNA; 17 BP.
XX
AC ABV85800;
XX
DT 11-DEC-2002 (first entry)
XX
DE Human pp-GANTase 10 scanning 17-mer SEQ ID NO:793.
XX
KW Human; UDP-GalNAc:polypeptide N-acetylglucosaminyltransferase 10;
KW pp-GANTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
KW ss.
XX
XX Homo sapiens.
OS Synthetic.
OS
XX
PN EP1243660-A2.
XX
PD 25-SEP-2002.
XX
PF 25-JAN-2002; 2002EP-00001161.
XX
PR 30-JAN-2001; 2001WO-US000663.
XX
PR 30-JAN-2001; 2001WO-US000664.
XX
PR 30-JAN-2001; 2001WO-US000665.
XX
PR 30-JAN-2001; 2001WO-US000666.
XX
PR 30-JAN-2001; 2001WO-US000667.
XX
PR 30-JAN-2001; 2001WO-US000668.
XX
PR 30-JAN-2001; 2001WO-US000669.
XX
PR 30-JAN-2001; 2001WO-US000670.
XX
PR 23-MAY-2001; 2001US-00864761.
XX
PR 30-AUG-2001; 2001US-0315984P.
XX
PA (ABOM-) ABOmica INC.
XX
PI Zhang J, Gu Y, Nguyen C;
XX
DR WPI; 2002-724954/79.
XX
PT Nucleic acid encoding human UDP-GalNAc:polypeptide N-
PT acetylglucosaminyltransferase 10 protein is useful to diagnose, prevent
PT and treat disorders associated with reduced or over expression of the
PT encoded protein.
XX

PS Example 2; SEQ ID NO 793; 59pp; English.
XX
CC The present invention describes an isolated nucleic acid (1) encoding a
CC human UDP-GalNAc:polypeptide N-acetylglucosaminyltransferase 10 (pp-
CC GANTase 10, EC 2.4.1.41) protein. Human pp-GANTase 10 is located to
CC chromosome 7q11.2. (1) can be used in gene therapy. Molecules of the
CC present invention can be used in therapy, particularly to prevent or
CC treat a disorder associated with decreased expression or activity of pp-
CC GANTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to
CC ABP53504 are given in the exemplification of the present invention. N.B.
CC The sequence data for this patent is not represented in the printed
CC specification but is based on sequence information supplied by the
CC European Patent Office
XX
SQ Sequence 17 BP; 1 A; 5 C; 4 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;
QY 277 CTGGCTGCTTTGAAGCC 293
Db 1 CTGGCTTCTTTGATGCC 17
XX
RESULT 298
ABV79273
ID ABV79273 standard; DNA; 17 BP.
XX
AC ABV79273;
XX
DT 03-JAN-2003 (first entry)
XX
DE Human HTPPL scanning oligonucleotide SEQ ID 519.
XX
XX
KW Human; gene therapy; tumour suppressor; HTPPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
XX Homo sapiens.
OS
OS
XX
PN EP1229046-A2.
XX
PD 07-AUG-2002.
XX
PF 28-JAN-2002; 2002EP-00001167.
XX
PR 30-JAN-2001; 2001WO-US000663.
XX
PR 30-JAN-2001; 2001WO-US000664.
XX
PR 30-JAN-2001; 2001WO-US000665.
XX
PR 30-JAN-2001; 2001WO-US000666.
XX
PR 30-JAN-2001; 2001WO-US000667.
XX
PR 30-JAN-2001; 2001WO-US000668.
XX
PR 23-MAY-2001; 2001US-00864761.
XX
PR 09-OCT-2001; 2001US-0327989P.
XX
PA (ABOM-) ABOmica INC.
XX
PI Zhan J;
XX
DR WPI; 2002-676582/73.
XX
XX
PT Novel isolated human testis expressed Patched like protein (HTPPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPPL.
XX
PS Example 2; Page 131; 718pp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPPL, see ABV78759 to ABV78762 and ABP98519 to ABP98520). HTPPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop

CC codon in HTP-L-S (S for short) compared to HTP-L-L (L for long). HTP-L
 CC shares an overall structure organisation with the Patched protein. The
 CC shared structural features strongly imply that HTP-L plays a role similar
 CC to that of Patched, and is a potential tumour suppressor. HTP-L is
 CC important in regulating male germ cell development, and the HTP-L gene was
 CC mapped to human chromosome 10p12.1. HTP-L and its coding sequence are
 CC useful for diagnosing a disorder caused by mutation in HTP-L, and in
 CC therapy and manufacture of a medicament for treatment or prevention of
 CC such disorder associated with decreased expression or activity of human
 CC HTP-L. Such disorders include disorders of testis, or adrenal, adult and
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate.
 CC skeletal muscle or colon function. HTP-L proteins and nucleic acids are
 CC clinically useful diagnostic markers and potential therapeutic agents for
 CC male infertility and cancer. The present oligonucleotide was used in an
 CC example from the invention

SO Sequence 17 BP; 0 A; 8 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 131 TCTCCCTGCTGGGCCC 147
 1 TCTTCTGCTGGGCCC 17

Db

RESULT 299
 ABRK19231/c
 ID ABRK19231 standard; RNA; 17 BP.
 XX
 AC ABRK19231;
 XX
 DT 09-APR-2002 (first entry)
 XX

Human ERG Amberzyme target sequence Seq ID No 1878.

XX Human; hammerhead ribozyme; cytosstatic; antitumour; antidiabetic;
 KM ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KM vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KM tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KM neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KM angioliobroma of tuberosus sclerosis; port-wine stain; wound healing;
 KM Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KM Oster-Weber-rendu syndrome; leukaemia; osteoporosis; DNazyme; inozyme;
 KM amberzyme.

XX Homo sapiens.
 OS
 XX WO200188124-A2.
 PN
 XX 22-NOV-2001.
 PD
 XX 16-MAY-2001; 2001WO-US015866.
 PF
 XX 16-MAY-2000; 2000US-00572021.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 PA
 XX Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
 PI WPI; 2002-082995/11.
 DR
 XX Novel polynucleotide which down regulates expression of Ets-related gene,
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,
 PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
 XX
 XX Claim 4; Page 123; 149pp; English.
 PS
 CC The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,

CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angioliobroma of tuberosus sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Oster-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABRK17354-ABRK2719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention

SO Sequence 17 BP; 4 A; 8 C; 4 G; 0 T; 1 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 345 GCTGATCTCATGGGGAG 361
 17 GCTGATCTCCTGGGGG 1

Db

RESULT 300
 ABRK19230/c
 ID ABRK19230 standard; RNA; 17 BP.
 XX
 AC ABRK19230;
 XX
 DT 09-APR-2002 (first entry)
 XX

Human ERG Amberzyme target sequence Seq ID No 1877.

XX Human; hammerhead ribozyme; cytosstatic; antitumour; antidiabetic;
 KM ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KM vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KM tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KM neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KM angioliobroma of tuberosus sclerosis; port-wine stain; wound healing;
 KM Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KM Oster-Weber-rendu syndrome; leukaemia; osteoporosis; DNazyme; inozyme;
 KM amberzyme.

XX Homo sapiens.
 OS
 XX WO200188124-A2.
 PN
 XX 22-NOV-2001.
 PD
 XX 16-MAY-2001; 2001WO-US015866.
 PF
 XX 16-MAY-2000; 2000US-00572021.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 PA
 XX Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
 PI WPI; 2002-082995/11.
 DR
 XX Novel polynucleotide which down regulates expression of Ets-related gene,
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,

PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
 XX
 PS Claim 4; Page 123; 149pp; English.
 XX
 CC The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration, osteo-
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiodioma of tuberous sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu
 CC syndrome, leukamaia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg²⁺. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention
 CC
 SQ Sequence 17 BP; 4 A; 7 C; 5 G; 0 T; 1 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
 Matches 15; Conservative 0; Indels 2; Indels 0;
 Oy 346 CTGATCTCATGGGAGC 362
 Db 17 CTGATCTCTGGGGGC 1
 RESULT 301
 ID ABV89725 standard; DNA; 17 BP.
 XX
 AC ABV89725;
 XX
 DT 23-DEC-2002 (first entry)
 XX
 DE Human POSHL1 scanning oligonucleotide SEQ ID NO 438.
 XX
 KM Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KM Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 XX gene therapy; transgenic; ss.
 XX
 OS Homo sapiens.
 XX
 PN EPI239051-A2.
 XX
 PD 11-SEP-2002.
 XX
 PF 28-JAN-2002; 2002EP-00001165.
 XX
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 10-OCT-2001; 2001US-0328205P.

XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Shannon M;
 XX
 DR WPI; 2002-664061/74.
 XX
 PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
 PT -1, useful for treating disorders associated with decreased expression or
 PT activity of human POSHL1.
 XX
 PS Example 2; SEQ ID NO 438; 60pp + Sequence Listing; English.
 XX
 CC The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (SI, ABB83999), a sequence having 65% sequence identity to (SI),
 CC (S1) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they are useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention. Note: The present sequence did not form part of the
 CC printed specification, but is based on sequence information supplied to
 CC Derwent by the European Patent Office
 CC
 SQ Sequence 17 BP; 1 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
 Matches 15; Conservative 0; Indels 2; Indels 0;
 Oy 1103 TTGAGGCTCTGTGGCC 1119
 Db 1 TTGAGGCGCTGTGGCC 17
 RESULT 302
 ID ABV90613 standard; DNA; 17 BP.
 XX
 AC ABV90613;
 XX
 DT 23-DEC-2002 (first entry)
 XX
 DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1326.
 XX
 KM Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KM Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 XX gene therapy; transgenic; ss.
 XX
 OS Homo sapiens.
 XX
 PN EPI239051-A2.
 XX
 PD 11-SEP-2002.
 XX
 PF 28-JAN-2002; 2002EP-00001165.
 XX
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.

PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
DR WPI; 2002-684061/74.
XX
PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 1326; 60pp + Sequence Listing; English.
XX
CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 3 A; 9 C; 1 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2092 CTCATCACCAGCACCT 2108
1 CTTATCACCCCGCACCT 17
Db
RESULT 303
ABV89726
ID ABV89726 standard; DNA; 17 BP.
XX
AC ABV89726;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 439.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EPI239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
DR WPI; 2002-684061/74.
XX
PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 439; 60pp + Sequence Listing; English.
XX
CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 2 A; 6 C; 7 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1104 TGAGGCTGTGCGCCA 1120
1 TGAAGCGCTCGCGCCA 17
Db
RESULT 304
ABV89724
ID ABV89724 standard; DNA; 17 BP.
XX
AC ABV89724;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 437.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EPI239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX (AEOM-) AEOMICA INC.
XX Shannon M;
XX WPI; 2002-684061/74.
XX
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
XX Example 2; SEQ ID NO 437; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
XX Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Gy 1102 ATTGAGGCTCTGCGC 1118
Db 1 ATTGAGGCTCTGCGC 17
RESULT 305
ABV89723
ID ABEV89723 standard; DNA; 17 BP.
XX
XX ABEV89723;
XX
XX 23-DEC-2002 (first entry)
XX
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 436.
XX
XX Human, POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KM Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
XX Homo sapiens.
XX
XX BPI239051-A2.
XX
XX 11-SEP-2002.
XX

PF 28-JAN-2002; 2002EP-00001165.
XX
XX 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
XX (AEOM-) AEOMICA INC.
XX Shannon M;
XX WPI; 2002-684061/74.
XX
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
XX Example 2; SEQ ID NO 436; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
XX Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Gy 1101 CATTGAGGCTCTGCGG 1117
Db 1 CATTGAGGCTCTGCGG 17
RESULT 306
ABL31770
ID ABL31770 standard; DNA; 17 BP.
XX
XX ABL31770;
XX
XX 21-MAR-2002 (first entry)
XX
XX Human HLA genotyping oligonucleotide SEQ ID NO 1259.
XX
XX Human, human leukocyte antigen; HLA; genotype; polymorphism;
KM immunogenetic; transplantation; genetic disease; ss.
XX
XX Homo sapiens.
XX
XX WO200192572-A1.
XX

```

PD      06-DEC-2001.
XX      XX
EF      01-JUN-2001; 2001WO-JP004662.
XX      XX
PR      01-JUN-2000; 2000JP-00164798.
XX      XX
PA      (NISHIN ) NISSHINBO IND INC.
PA      (SYST-) SYSTEM RES INC.
XX      XX
P1      Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX      XX
DR      WPI; 2002-122074/16.
XX      XX
PT      Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
PT      individuals e.g. by determining immunogenetic differences when
PT      transplanting between them.
XX      XX
PS      Claim 10; Page 332; 345pp; Japanese.
XX      XX
CC      The invention relates to a typing kit for judging human leukocyte antigen
CC      (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC      oligonucleotides (ABJ30512-ABJ31809) originating in the sequences of
CC      genes e.g. belonging to HLA class I antigens on human genome and
CC      containing gene polymorphisms as allantoins have been immobilised as
CC      primers for amplification of cleaved nucleic acids relating to gene
CC      polymorphisms. The method is useful for judging HLA genotypes of
CC      individuals by determining immunogenetic differences before transplanting
CC      between them, providing genetic information to decide compatibility of
CC      organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC      pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC      diagnosis of genetic diseases and identifying individuals
XX      XX
SQ      Sequence 17 BP; 3 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
XX      XX
Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No.2e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;
QY      370 TCCGCGATAGCACCAG 386
        ||||| | |||||
Db       1 TCCGGGGTACCAACCAG 17
RESULT 307
ABLJ31552
ID      ABLJ31552 standard; DNA; 17 BP.
XX      XX
AC      ABLJ31552;
XX      XX
DT      21-MAR-2002 (first entry)
XX      XX
DE      Human HLA genotyping oligonucleotide SEQ ID NO 1041.
XX      XX
KW      Human; human leukocyte antigen; HLA; genotype; polymorphism;
KW      immunogenetic; transplantation; genetic disease; ss.
XX      XX
OS      Homo sapiens.
XX      XX
PN      WO200192572-A1.
XX      XX
PD      06-DEC-2001.
XX      XX
PF      01-JUN-2001; 2001WO-JP004662.
XX      XX
PR      01-JUN-2000; 2000JP-00164798.
XX      XX
PA      (NISHIN ) NISSHINBO IND INC.
PA      (SYST-) SYSTEM RES INC.
XX      XX
P1      Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX      XX
DR      WPI; 2002-122074/16.
XX      XX

```

PT	Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of individuals e.g. by determining immunogenetic differences when transplanting between them.
PT	
XX	
PS	Claim 10; Page 290; 345pp; Japanese.
XX	
CC	The invention relates to a typing kit for judging human leukocyte antigen (HLA) genotype of a sample by hybridising a substrate on which 10-24 base oligonucleotides (ABJ30512-ABJ31809) originating in the sequences of CC genes e.g. belonging to HLA class I antigens on human genome and CC containing gene polymorphisms as alloantigens have been immobilised as primers for amplification of cleaved nucleic acids relating to gene CC polymorphisms. The method is useful for judging HLA genotypes of CC individuals by determining immunogenetic differences before transplanting CC between them, providing genetic information to decide compatibility of CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver, CC pancreas, Langerhans islet in pancreas and cornea, susceptibility CC diagnosis of genetic diseases and identifying individuals
XX	
SQ	Sequence 17 BP; 3 A; 5 C; 8 G; 1 T; 0 U; 0 Other;
	Query Match 0.6%; Score 13.8; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 2e+02;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0
OY	490 GCGCGTCAGGCGGCTC 506 1 GCGCGACAGCGGCTC 17
DB	
RESULT 308	
ABK56492/c	
ID	ABK56492 standard; RNA; 17 BP.
XX	
AC	ABK56492;
XX	
DT	02-JUL-2002 (first entry)
XX	
DE	Human CLCA1 gene enzymatic nucleic acid #863.
XX	
KW	Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic; antinflammatory; chronic obstructive pulmonary disease; COPD; asthma; chronic bronchitis; cystic fibrosis; obstructive bowel syndrome; oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic; acetylcholine.
XX	
OS	Homo sapiens.
XX	
PN	WO200211674-A2.
PD	14-FEB-2002.
XX	
PF	09-AUG-2001; 2001WO-US024970.
XX	
PR	09-AUG-2000; 2000US-0224383P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(SYNT) SYNTX USA LLC.
PA	(THOM/) THOMPSON J.
XX	
PI	Thompson J, McSwiggen J, McKenzie T, Ayers D, Szymkowski DE, Grube A;
XX	
DR	WPI, 2002-217145/27.
XX	
PT	Enzymatic polynucleotide that down regulates expression of chloride channel calcium activated gene, useful for treating Chronic obstructive pulmonary disease (COPD), chronic bronchitis and asthma.
XX	
PS	Claim 4; Page 72; 152pp; English.
XX	
CC	The invention relates to enzymatic nucleic acid molecules that down regulate expression of chloride channel calcium activated 1 (CLCA1) genes

CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that related to or will respond to the levels of CLCA1 in a cell or
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
 CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of CLCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibiotics, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of CLCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 4 G; 0 T; 4 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1997 TGGATGATGCCACCACT 2013
 Db 17 TGGATGATGCCACCACT 1
 RESULT 309
 ABS71929/c
 ID ABS71929 standard; DNA; 17 BP.
 XX
 AC ABS71929;
 XX
 DT 02-DEC-2002 (first entry)
 XX
 DE Human GRP-Rho binding protein 2 17mer probe #39.
 XX
 KM Human; 88; GRP-Rho binding protein 2; GRBP2; chromosome 19q12; oncogene;
 KM tumour; liposarcoma; ichthyosis congenita III; probe;
 KM benign familial infantile convulsion; gene therapy.
 KM
 OS Homo sapiens.
 XX
 PN BP1231216-A2.
 XX
 PD 14-AUG-2002.
 XX
 PF 17-JAN-2002; 2002EP-00001026.
 XX
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 29-JUN-2001; 2001US-00895040.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Shannon ME, JI Y;
 XX
 DR WPI; 2002-684026/74.
 XX
 XX Novel GRP-Rho binding protein 2 and nucleic acids encoding the protein,
 PT useful for the manufacture of a medicament for treating a disease
 PT associated with altered expression or activity of human GRBP2 protein.
 XX
 PS Example 4; Page 72; 101pp; English.
 XX
 CC The invention relates to an isolated GRP-Rho binding protein 2 (GRBP2)
 CC polypeptide or a fragment of at least 6 amino acids or a sequence in

CC which at least 95% of deviations from GRBP2 sequences are conservative
 CC substitutions. Also included are an isolated nucleic acid (GRBP2 NA)
 CC encoding GRBP2 comprising the full length cDNA or CDS, fragments or
 CC variants, GRBP2 vectors, host cells, antibodies, transgenic non-human
 CC animals modified to contain GRBP2 NA (or unable to express the endogenous
 CC orthologue of GRBP2), diagnosing a disease caused by a mutation in human
 CC GRBP2 or altered expression of GRBP2, anti-agonists of GRBP2, GRBP2
 CC microarrays, fusion proteins and screening for agents that modulate the
 CC expression of GRBP2 NA. GRBP2 is useful for identifying binding partners
 CC of GRBP2. GRBP2 NA and Ab are useful in therapy and in the
 CC manufacture of a medicament for the treatment or prevention of a disorder
 CC associated with increased or decreased expression or activity of human
 CC GRBP2 (e.g. tumour, liposarcoma, ichthyosis congenita III and benign
 CC familial infantile convulsion, all associated with the chromosome 1
 CC location of GRBP2, 19q12). GRBP2 is useful as a standard in immunoassay
 CC specific for the proteins, to be used in a therapeutic agent, as
 CC vaccines, to be and as antigens (e.g. for epitope mapping) or immunogens
 CC (e.g. for raising antibodies). GRBP2 NA is useful as hybridisation probes,
 CC to prime synthesis of nucleic acids, to prime first strand cDNA sequence
 CC on an mRNA template, and to drive in vivo expression of the proteins. The
 CC vector is useful for shuttling GRBP2 NA between host cells derived from
 CC disparate organisms, for inserting GRBP2 NA into host cell chromosome,
 CC for expressing sense or antisense RNA transcripts of GRBP2 NA in vitro or
 CC within a host cell, and for expressing GRBP2 alone or as fusions to
 CC heterologous polypeptides. The antibody is useful as an analytical
 CC reagent for detection and quantification of GRBP2 and as an immuno
 CC therapeutic agent and is useful for flow cytometric detection, for
 CC scanning laser cytometric detection, or for fluorescent immunosassay. The
 CC present sequence is a probe for GRBP2
 XX
 SQ Sequence 17 BP; 1 A; 12 C; 4 G; 0 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 206 GGCTGGGGGCGCTGGCGG 222
 Db 17 GGCTGGGGGCGCGCGG 1
 RESULT 310
 ACD00799/c
 ID ACD00799 standard; DNA; 17 BP.
 XX
 AC ACD00799;
 XX
 DT 28-JUL-2003 (first entry)
 XX
 DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #1272.
 XX
 KM Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
 KM G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003031621-A2.
 XX
 PD 17-APR-2003.
 XX
 PF 11-OCT-2002; 2002WO-US032599.
 XX
 PR 12-OCT-2001; 2001US-0329000P.
 XX
 PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
 XX
 PI Zhang J;
 XX
 DR WPI; 2003-381720/36.
 XX
 XX New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
 PT investigating and/or treating disorders associated with aberrant
 PT expression or activity of GPCR-A-1, such as tumors and cancers.

XX Example 2; SEQ ID NO 1296; 156bp; English.
 XX
 CC The invention describes an isolated nucleic acid encoding a G protein
 CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
 CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
 CC 409 residue amino acid sequence, all given in the specification, with or
 CC without conservative amino acid substitutions, or complements of the
 CC sequence of them. The encoding nucleic acid is not more than 100 base in
 CC length. The methods and compositions of the present invention are useful
 CC for diagnosing, investigating and/or treating disorders associated with
 CC aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
 CC This sequence represents an oligonucleotide used to analyse the gene
 CC encoding human G-protein coupled receptor GPCR-A-1
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Oy 859 CCGGTACAGAGACAC 875
 | | | | | | | | | | | | | | | | | |
 Db 17 CAGGTACAGAGAAC 1
 RESULT 311
 ABT36908
 ID ABT36908 standard; DNA; 17 BP.
 XX
 AC ABT36908;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID NO 2545.
 XX
 KM Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KM schizophrenia; protein chip; gene therapy; tumour suppression;
 KM human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002MO-IB004208.
 XX
 PR 17-SEP-2001; 2001FR-00011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 330; 720pp; French.
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,

CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 1 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Oy 996 GATCACCCCTGCCTGTC 1012
 | | | | | | | | | | | | | | | | | |
 Db 1 GATCTGCCTGCCTCTGC 17
 RESULT 312
 ACA09052/C
 ID ACA09052 standard; RNA; 17 BP.
 XX
 AC ACA09052;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFKB sub-unit modulating amberzyme substrate #215.
 XX
 KM Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KM G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KM lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KM oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KM cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KM lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KM chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KM cyclophosphamide; doxorubicin; fluorouracil carboxylate; edatrexate;
 KM gemcitabine; radiation therapy; inflammatory disease; achma; diabetes;
 KM rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KM transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KM allergic airway inflammation; inflammatory bowel disease; infection; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002177568-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 23-MAY-2001; 2001US-00864785.
 XX
 PR 07-DEC-1992; 92US-00987132.
 PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00291932.
 PR 23-DEC-1996; 96US-00777916.
 XX
 PA (STIN/) STINCHCOMB D T.
 PA (MCSW/) MCSWIGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 PI Stinchcomb DT, Mcswigen J, Draper KG;
 DR WPI; 2003-340953/32.
 XX
 PT Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 XX

PS Claim 3; Page 55; 72pp; English.

XX The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule

XX Sequence 17 BP; 1 A; 9 C; 6 G; 0 T; 1 U; 0 Other;

SO Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 355 TGGGAGACCCCGGCTC 371
 17 TGGGAGACCCCGGCTC 1

DB

RESULT 313
 ACA08871/c
 ID ACA08871 standard; RNA; 17 BP.

XX ACA08871;
 AC

XX 03-JUN-2003 (first entry)

DE NFkB sub-unit modulating amberzyme substrate #34.

XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
 KM G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KM lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KM oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KM cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KM lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KM chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KM cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KM gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KM rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KM transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KM allergic airway inflammation; inflammatory bowel disease; infection; ss.

XX Homo sapiens.

XX US2002177568-A1.
 PN 28-NOV-2002.
 PD 23-MAY-2001; 2001US-00864785.
 PF 07-DEC-1992; 92US-00987132.
 PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00291932.

PR 23-DEC-1996; 96US-00777916.

XX (STIN/) STINGHOMB D T.
 PA (MCSM/) MCSMIGSEN J.
 PA (DRAE/) DRAPER K G.
 XX Stinchcomb DT, Mcawigsen J, Draper KG;
 DR WPI; 2003-340953/32.

XX Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.

XX Claim 3; Page 50; 72pp; English.

PS The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule

XX Sequence 17 BP; 5 A; 4 C; 7 G; 0 T; 1 U; 0 Other;

SO Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTCCTGCTCTG 579
 17 CACTGTCCTGCTCTG 1

DB

RESULT 314
 ACA09051/c
 ID ACA09051 standard; RNA; 17 BP.

XX ACA09051;
 AC

XX 03-JUN-2003 (first entry)

DE NFkB sub-unit modulating amberzyme substrate #214.

XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
 KM G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KM lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KM oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KM cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KM lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KM chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KM cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KM gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KM rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2162 GGGAGGGGGAGCCAC 2178
DB 17 GGGATGGGGAGCCAC 1

RESULT 316
ADA99387/c
ID ADA99387 standard; DNA, 17 BP.

AC ADA99387;
XX
XX 20-NOV-2003 (first entry)

DE Human MD23 scanning oligonucleotide SEQ ID 376.

XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KM zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KM chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KM developmental disorder; ss.

XX Homo sapiens.

XX EP1281758-A2.

XX 05-FEB-2003.

XX 30-JUL-2002; 2002EP-00016874.

XX 02-AUG-2001; 2001US-00922181.

XX (AEOM-) AEOMICA INC.

XX Shannon M, Gu Y, Nguyen C;

XX WPI; 2003-423107/40.

XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.

PS Example 8; SEQ ID NO 376; 103pp; English.

XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder,
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.

XX Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2176 CACGACGAGCTCAGGA 2192
DB 17 CACGACGAGCTCAGGA 1

RESULT 317

ADA99540
ID ADA99540 standard; DNA, 17 BP.

XX ADA99540;

XX 20-NOV-2003 (first entry)

DE Human MD23 scanning oligonucleotide SEQ ID 529.

XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KM zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KM chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KM developmental disorder; ss.

XX Homo sapiens.

XX EP1281758-A2.

XX 05-FEB-2003.

XX 30-JUL-2002; 2002EP-00016874.

XX 02-AUG-2001; 2001US-00922181.

XX (AEOM-) AEOMICA INC.

XX Shannon M, Gu Y, Nguyen C;

XX WPI; 2003-423107/40.

XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.

PS Example 8; SEQ ID NO 529; 103pp; English.

XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder,
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.

XX Sequence 17 BP; 5 A; 4 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 773 GCCACTTGGAGGAGAG 789
DB 1 GCCACAGGAGGAGAG 17

RESULT 318
ADB00407/c
ID ADB00407 standard; DNA, 17 BP.

XX ADB00407;

XX 20-NOV-2003 (first entry)

DE Human MD23 scanning oligonucleotide SEQ ID 1393.

```

XX  Cytostatic; immunostimulant; gene therapy; vaccine; human;
KM  zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KM  chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KM  developmental disorder; ss.
XX
OS  Homo sapiens.
XX  EPI281758-A2.
XX  EPI281758-A2.
XX  05-FEB-2003.
XX  05-FEB-2003.
XX  30-JUL-2002; 2002EP-00016874.
XX  02-AUG-2001; 2001US-00922181.
XX  02-AUG-2001; 2001US-00922181.
PA  (AEOM-) AEOMICA INC.
XX  Shannon M, Gu Y, Nguyen C;
PI  Shannon M, Gu Y, Nguyen C;
XX  WPI; 2003-423107/40.
XX
XX  New zinc finger-containing proteins and nucleic acids, useful in
PT  manufacturing a medicament for treating or preventing a disorder
PT  associated with decreased or increased expression or activity of MD23,
PT  MD24, MD27 or MD212, e.g. cancer.
XX
XX  Example 8; SEQ ID NO 1393; 103bp; English.
XX
XX  The present invention relates to novel human zinc finger-containing
CC  proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC  encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC  MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC  15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC  or in manufacturing a medicament for treating or preventing a disorder
CC  associated with decreased or increased expression or activity of MD23,
CC  MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC  acids and proteins are also useful for diagnosing or monitoring a disease
CC  caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC  acids can also be used as probes to detect and characterize gross
CC  alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC  useful in constructing microarrays for measuring gene expression. The
CC  proteins are useful as therapeutic agents for gene therapy or as
CC  vaccines. The present sequence was used to illustrate the invention.
XX
XX  Sequence 17 BP; 4 A; 8 C; 4 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.64; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.24; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1639 GTGGCTGCCCTGCTGCA 1655
Db 17 GTGGCTGCCCTGCTGCA 1

```

```

PN  EPI281758-A2.
XX  05-FEB-2003.
XX  05-FEB-2003.
XX  30-JUL-2002; 2002EP-00016874.
XX  02-AUG-2001; 2001US-00922181.
XX  02-AUG-2001; 2001US-00922181.
PA  (AEOM-) AEOMICA INC.
XX  Shannon M, Gu Y, Nguyen C;
PI  Shannon M, Gu Y, Nguyen C;
XX  WPI; 2003-423107/40.
XX
XX  New zinc finger-containing proteins and nucleic acids, useful in
PT  manufacturing a medicament for treating or preventing a disorder
PT  associated with decreased or increased expression or activity of MD23,
PT  MD24, MD27 or MD212, e.g. cancer.
XX
XX  Example 8; SEQ ID NO 3383; 103bp; English.
XX
XX  The present invention relates to novel human zinc finger-containing
CC  proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC  encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC  MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC  15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC  or in manufacturing a medicament for treating or preventing a disorder
CC  associated with decreased or increased expression or activity of MD23,
CC  MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC  acids and proteins are also useful for diagnosing or monitoring a disease
CC  caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC  acids can also be used as probes to detect and characterize gross
CC  alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC  useful in constructing microarrays for measuring gene expression. The
CC  proteins are useful as therapeutic agents for gene therapy or as
CC  vaccines. The present sequence was used to illustrate the invention.
XX
XX  Sequence 17 BP; 2 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.64; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.24; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2176 CACCAGCAGCTCATGGA 2192
Db 17 CACCAGCAGCTCATGGA 1

```

```

RESULT 319
ADB02397/c
ID  ADB02397 standard; DNA; 17 BP.
XX
AC  ADB02397;
XX
XX  20-NOV-2003 (first entry)
XX
XX  Human MD24 scanning oligonucleotide SEQ ID 3383.
XX
XX  Cytostatic; immunostimulant; gene therapy; vaccine; human;
KM  zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KM  chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KM  developmental disorder; ss.
XX
XX  Homo sapiens.
XX

```

```

RESULT 320
ABZ61560
ID  ABZ61560 standard; RNA; 17 BP.
XX
XX  ABZ61560;
XX
XX  21-MAR-2003 (first entry)
XX
XX  Human H-Ras DNAzyme target #351.
XX
XX  Human; ribozyme; short interfering RNA; siRNA; HRR2; K-Ras;
KM  enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
KM  anti-rheumatic; cancer; AIDS; ss.
XX
XX  Homo sapiens.
XX
XX  W0200297114-A2.
XX
XX  05-DEC-2002.
XX
XX  29-MAY-2002; 2002WO-US016840.
XX
XX  29-MAY-2001; 2001US-0294140P.
XX  06-JUN-2001; 2001US-0296249P.
XX  10-SEP-2001; 2001US-0318471P.
XX

```


XX (RIBO-) RIBOZYME PHARM INC.
 XX Mcswiggen J;
 XX WPI; 2003-140484/13.
 XX Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
 XX Claim 58; Page 117; 185pp; English.
 XX The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
 CC rheumatic activity. The nucleic acid molecules are useful for reducing
 CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
 CC also useful for treating breast, ovarian, colorectal, lung, prostate,
 CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
 CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ65520 - ABZ65524,
 CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
 CC ribozymes of the invention
 XX
 SO Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 2e+02;
 Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 QY 446 CGCGACGAGCCCTGTG 462
 | ||||| ||||| : |||||
 1 CAGCAGCUCGCCUCUGG 17
 DB
 RESULT 321
 ABZ64771/C
 ID ABZ64771 standard; RNA; 17 BP.
 XX
 AC ABZ64771;
 XX
 DT 21-MAR-2003 (first entry)
 XX
 DE Human HER2 DNAzyme substrate #228.
 XX
 KM Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
 KM anti-rheumatic; cancer; AIDS; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200297114-A2.
 XX
 PD 05-DEC-2002.
 XX
 PF 29-MAY-2002; 2002WO-US016840.
 XX
 PR 29-MAY-2001; 2001US-0294140P.
 PR 06-JUN-2001; 2001US-0296249P.
 PR 10-SEP-2001; 2001US-0318471P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswiggen J;
 XX
 DR WPI; 2003-140484/13.
 XX
 PT Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
 XX

PS Claim 4; Page 137; 185pp; English.
 XX The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
 CC rheumatic activity. The nucleic acid molecules are useful for reducing
 CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
 CC also useful for treating breast, ovarian, colorectal, lung, prostate,
 CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
 CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ65520 - ABZ65524,
 CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
 CC ribozymes of the invention
 XX
 SO Sequence 17 BP; 3 A; 8 C; 3 G; 0 T; 3 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 259 GCAGTGCCGAGGCTG 275
 | ||||| ||||| |||||
 17 GTAGGTGACCGAGGCTG 1
 DB
 RESULT 322
 ABZ65040/C
 ID ABZ65040 standard; RNA; 17 BP.
 XX
 AC ABZ65040;
 XX
 DT 21-MAR-2003 (first entry)
 XX
 DE Human HER2 DNAzyme substrate #497.
 XX
 KM Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
 KM anti-rheumatic; cancer; AIDS; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200297114-A2.
 XX
 PD 05-DEC-2002.
 XX
 PF 29-MAY-2002; 2002WO-US016840.
 XX
 PR 29-MAY-2001; 2001US-0294140P.
 PR 06-JUN-2001; 2001US-0296249P.
 PR 10-SEP-2001; 2001US-0318471P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswiggen J;
 XX
 DR WPI; 2003-140484/13.
 XX
 PT Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
 XX
 PS Claim 4; Page 142; 185pp; English.
 XX The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
 CC rheumatic activity. The nucleic acid molecules are useful for reducing
 CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
 CC also useful for treating breast, ovarian, colorectal, lung, prostate,
 CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences

CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
XX ribozymes of the invention
SQ Sequence 17 BP; 5 A; 6 C; 5 G; 0 T; 1 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 269 AGGCGTGGCTGCT 285
17 AGGCGTGGCTGCTCT 1
Db 17 TGACACATCTCTTTC 1
RESULT 323
ABZ62176/c
ID ABZ62176 standard; RNA; 17 BP.
XX
AC ABZ62176;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human H-Ras DNAzyme target #967.
XX
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
KM anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
XX 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
XX WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 131; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosolic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 6 A; 2 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2127 TGACACATCTCTTTC 2143

Db 17 TGACACATCTCTTTC 1
RESULT 324
ABZ62177/c
ID ABZ62177 standard; RNA; 17 BP.
XX
AC ABZ62177;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human H-Ras DNAzyme target #968.
XX
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
KM anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
XX 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
XX WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 131; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosolic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2125 GGTGACCATCTCTT 2141
17 GGTGACCATCTGCTT 1
Db 17 GGTGACCATCTGCTT 1
RESULT 325
ABZ61559
ID ABZ61559 standard; RNA; 17 BP.
XX
AC ABZ61559;
XX
DT 21-MAR-2003 (first entry)

```

XX Human H-Ras DNzyme target #350.
DE
XX
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
XX anti-rheumatic; cancer; AIDS; ss.
OS
XX Homo sapiens.
XX
XX NO200297114-A2.
PN
XX
XX 05-DEC-2002.
PD
XX
XX 29-MAY-2002; 2002MO-US016840.
PF
XX
XX 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Mcswiggen J;
PI
XX
XX WPI; 2003-140484/13.
DR
XX
XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer; modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
XX Claim 58; Page 117; 185pp; English.
PS
XX
XX The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in AB259889 - AB262216, AB264544 - AB265531, AB265520 - AB265524,
CC AB265530 - AB265585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
XX
SQ Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 443 TGGCCGAGCAGCCCTG 459
DB 1 UGCCAGCAGCUGCCUG 17

```

```

XX
XX Hepatitis B virus.
OS
XX
XX NO200281494-A1.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 26-MAR-2002; 2002MO-US009187.
PF
XX
XX 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX (BLAT/) BLATT L.
PA
XX
XX (MACE/) MACEJAK D.
PA
XX
XX (MCSW/) MCSWIGGEN J.
PA
XX
XX (MORR/) MORRISSEY D.
PA
XX
XX (PAVC/) PAVCO P.
PA
XX
XX (LEEP/) LEE P.
PA
XX
XX (DRAP/) DRAPER K.
PA
XX
XX (ROBE/) ROBERTS E.
XX
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
DR
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Example 1; Page 164; 387pp; English.
PS
XX
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNzyme or amberzyme sequences
CC disclosed in the present invention
XX
XX
SQ Sequence 17 BP; 5 A; 6 C; 3 G; 0 T; 3 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 964 TGGGAGTCACTGCCCT 980
DB 17 TGAGATGAGTGTCCCT 1

```

DE HCV DNAzyme substrate sequence #1694.

XX
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW ambzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer 1 region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.

XX
OS Hepatitis C virus.

XX
PN WO200281494-A1.

XX
PD 17-OCT-2002.

XX
PE 26-MAR-2002; 2002WO-US009187.

XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.

XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MORRISGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEBP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.

XX
PI Blatt L, Macejak D, Newswigen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
PI WPI; 2003-229207/22.

XX
DR Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.

XX
PS Claim 1; Page 264; 387pp; English.

XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, ambzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer 1 region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC invention

XX
SQ Sequence 17 BP; 3 A; 8 C; 2 G; 0 T; 4 U; 0 Other;

XX
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

09 689 TCATGTCATTCTCACC 705

Db 1 UCACGUCACUGCUCAC 17

RESULT 328
ACD63300
ID ACD63300 standard; RNA; 17 BP.
XX ACD63300;
XX
XX 30-SEP-2003 (first entry)
XX
DE HCV minus strand DNAzyme substrate sequence #995.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX RNA stability; RNA expression; RNA synthesis; antisense;
XX enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
XX amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
XX HBV reverse transcriptase; Enhancer I region; viral replication;
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
XX virucide; antiinflammatory; substrate; ss.
XX
XX Hepatitis C virus.
XX
XX WO200281494-A1.
XX
XX 17-OCT-2002.
XX
XX 26-MAR-2002; 2002MO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
XX 08-JUN-2001; 2001US-00877478.
XX 08-JUN-2001; 2001US-0296876P.
XX 24-OCT-2001; 2001US-0335059P.
XX 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX (BIAT-) BIATT L.
XX (MACEJ-) MACEJAK D.
XX (MCSW-) MCSWIGGEN J.
XX (MORR-) MORRISSEY D.
XX (PACV-) PAVCO P.
XX (LEBP-) LEE P.
XX (DRAV-) DRAPER K.
XX (ROBB-) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
XX Draper K, Roberes E;
XX
XX WPI, 2003-229207/22.
XX
XX
XX Novel compound useful for treating cirrhosis, liver failure,
XX hepatocellular carcinoma, or condition associated with hepatitis C virus
XX infection.
XX
XX
XX Claim 1; Page 292; 387pp; English.

The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of Hepatitis C virus (HCV) or Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes, inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed are nucleic acid decoy molecules and aptamers that bind to HBV reverse transcriptase and/or HBV reverse transcriptase primer sequences, as well as oligonucleotides that specifically bind the Enhancer I region of HBV DNA. The nucleic acids may be used to modulate the expression of HBV genes and HBV viral replication. Also disclosed is a method for screening compounds and/or potential therapies directed against HBV, and compounds that modulate the expression and/or replication of HCV. The compounds and methods of the invention are useful for the treatment of degenerative and disease states related to HBV and HCV infection, replication and gene expression such as cirrhosis, liver failure, and hepatocellular

CC	carcinoma. The present sequence represents a substrate for one of the HCV
CC	DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC	invention
XX	
XX	Sequence 17 BP, 1 A; 4 C; 9 G; 0 T; 3 U; 0 Other;
XX	
XX	Query Match 0.6%; Score 13.8; DB 1; Length 17;
XX	Best Local Similarity 76.5%; Fred. No. 2e+02;
XX	Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0
OY	1948 GCAGTGGCGTTGACCCG 1964
DB	1 GCAGGAGGUGUGACCCG 17
XX	
XX	RESULT 329
XX	ACD51659/C
ID	ACD51659 standard; RNA; 17 BP.
XX	
XX	ACD51659;
XX	
DT	24-SEP-2003 (first entry)
XX	
DE	HBV hammerhead ribozyme substrate sequence #666.
XX	
KW	Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW	RNA stability; RNA expression; RNA synthesis; antisense;
KW	enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW	amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW	HBV reverse transcriptase; enhancer I region; viral replication;
KW	degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW	liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW	virucide; antiinflammatory; substrate; ss.
XX	
OS	Hepatitis B virus.
XX	
XX	WO200281494-A1.
XX	
PD	17-OCT-2002.
XX	
XX	26-MAR-2002; 2002W0-US009187.
XX	
XX	26-MAR-2001; 2001US-00817879.
PR	08-JUN-2001; 2001US-00877478.
PR	08-JUN-2001; 2001US-0296876P.
PR	24-OCT-2001; 2001US-0335059P.
PR	05-DEC-2001; 2001US-0337055P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(BLAT/) BLATT L.
PA	(MACE/) MACEJAK D.
PA	(MCSW/) MCSWIGEN J.
PA	(MORR/) MORRISSEY D.
PA	(PANC/) PAVCO P.
PA	(LEBP/) LEE P.
PA	(DRAP/) DRAPER K.
PA	(ROBE/) ROBERTS E.
XX	
P1	Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P,
P1	Draper K, Roberts E;
XX	
XX	WPI; 2003-229207/22.
XX	
PT	Novel compound useful for treating cirrhosis, liver failure,
PT	hepatocellular carcinoma, or condition associated with hepatitis C virus
PT	infection.
XX	
XX	Example 1; Page 149; 387bp; English.
XX	
CC	The present invention relates to nucleic acid molecules which modulate
CC	the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC	Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC	and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,

CC	inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC	are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC	transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC	as oligonucleotides that specifically bind the Enhancer I region of HBV
CC	DNA. The nucleic acids may be used to modulate the expression of HBV
CC	genes and HBV viral replication. Also disclosed is a method for screening
CC	compounds and/or potential therapies directed against HBV, and compounds
CC	that modulate the expression and/or replication of HCV. The compounds and
CC	methods of the invention are useful for the treatment of degenerative and
CC	disease states related to HBV and HCV infection, replication and gene
CC	expression such as cirrhosis, liver failure, and hepatocellular
CC	carcinoma. The present sequence represents a substrate for one of the HBV
CC	ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC	disclosed in the present invention
SQ	Sequence 17 BP; 4 A; 6 C; 4 G; 0 T; 3 U; 0 Other;
Query Match	0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 2e+02; Mismatches 2; Indels 0; Gaps 0.
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0.	
Oy	963 CTGGGATCATGTGCC 979 Db 17 CTGAGATGACTGTCCC 1
RESULT 330	
ACD63635	
ID	ACD63635 standard; RNA; 17 BP.
XX	ACD63635;
XX	
DT	30-SEP-2003 (first entry)
XX	
DE	HCV minus strand DNAzyme substrate sequence #1162.
XX	
KM	Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KM	RNA stability; RNA expression; RNA synthesis; antisense;
KM	enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KM	amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KM	HBV reverse transcriptase; Enhancer I region; viral replication;
KM	degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KM	liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KM	virocidic; antiinflammatory; substrate; ss.
OS	
XX	Hepatitis C virus.
XX	
FN	WO200281494-A1.
XX	
PD	17-OCT-2002.
XX	
PF	26-MAR-2002; 2002WO-US009187.
XX	
PR	26-MAR-2001; 2001US-00817879.
PR	08-JUN-2001; 2001US-00877478.
PR	08-JUN-2001; 2001US-0296876P.
PR	24-OCT-2001; 2001US-0335059P.
PR	05-DEC-2001; 2001US-0337055P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(BLAT) BLATT L.
PA	(MACEJ) MACEJAK D.
PA	(MCSW) MCSWIGEN J.
PA	(MORR/) MORRISSEY D.
PA	(PAYC) PAYCO P.
PA	(LEEP/) LEE P.
PA	(DRAP/) DRAPER K.
PA	(ROBE/) ROBERTS E.
XX	
Pt	Blatt L., Macejak D., Mcswigen J., Morrissey D., Payco P., Lee P;
PI	Draper K., Roberts E;
XX	
DR	WPI; 2003-229207/22.

[illegible]

PA	(MOSW/)	MOSWITGEN J.	
PA	(MORR/)	MORRISSEY D.	
PA	(PAVC/)	PAVCO P.	
PA	(LEBP/)	LEE P.	
PA	(DRAP/)	DRAPER K.	
PA	(ROBE/)	ROBERTS E.	
XX			
PI	Blatt L,	Moswigen J,	Morrissey D,
PI	Draper K,	Roberts E,	Pavco P,
DR			Lee P;
XX			
PT	Novel compound useful for treating cirrhosis, liver failure,		
PT	hepatocellular carcinoma, or condition associated with hepatitis C virus		
XX			
DR	WPI, 2003-229207/22.		
XX			
PS	Claim 1, Page 310; 387pp; English.		
XX			
CC	The present invention relates to nucleic acid molecules which modulate		
CC	the synthesis, expression and/or stability of Hepatitis C virus (HCV) or		
CC	Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense		
CC	and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,		
CC	ribozymes, zincymes, amberyzymes, and G-cleaver ribozymes. Also disclosed		
CC	are nucleic acid decoy molecules and aptamers that bind to HBV reverse		
CC	transcriptase and/or HBV reverse transcriptase primer sequences, as well		
CC	as oligonucleotides that specifically bind the Enhancer I region of HBV		
CC	DNA. The nucleic acids may be used to modulate the expression of HBV		
CC	genes and HBV viral replication. Also disclosed is a method for screening		
CC	compounds and/or potential therapies directed against HBV, and compounds		
CC	that modulate the expression and/or replication of HCV. The compounds and		
CC	methods of the invention are useful for the treatment of degenerative and		
CC	disease states related to HBV and HCV infection, replication and gene		
CC	expression such as cirrhosis, liver failure, and hepatocellular		
CC	carcinoma. The present sequence represents a substrate for one of the HCV		
CC	DNAzyme or minus strand DNAzyme sequences disclosed in the present		
XX	invention		
XX			
SQ	Sequence 17 BP; 5 A; 6 C; 3 G; 0 T; 3 U; 0 Other;		
XX			
Query Match	0.6%; Score 13.8; DB 1; Length 17;		
Best Local Similarity	88.2%; Pred. No. 2e+02;		
Matches 15; Conservative	0; Mismatches 2; Indels 0; Gaps 0;		
OY	59 TCGCATGGCTGGGAGACA 75		
DB	17 TCGCATGGCTGGGAGATA 1		
RESULT 332			
ACDS7472	ACDS7472 standard; RNA; 17 BP.		
XX			
AC	ACDS7472;		
XX			
DT	23-SEP-2003 (first entry)		
XX			
DE	HCV DNAzyme substrate sequence #338.		
XX			
KM	Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;		
KM	RNA stability; RNA expression; RNA synthesis; antisense;		
KM	enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; ribozyme; zinczyme;		
KM	amberyzyme; G-cleaver ribozyme; decoy molecule; aptamer;		
KM	HBV reverse transcriptase; Enhancer I region; viral replication;		
KM	degenerative; disease state; HBV infection; HCV infection; cirrhosis;		
KM	liver failure; hepatocellular carcinoma; hepatocytropic; cytostatic;		
KM	virucide; antiinflammatory; substrate; ss.		
XX			
OS	Hepatitis C virus.		
XX			
PN	WO200281494-A1.		
XX			
PD	17-OCT-2002.		
XX			

XX WPI; 2003-333167/31.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
PS
XX Disclosure; Page 476; 738bp; French.
XX
XX The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 1 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;

QY 996 GATCACCCTGCCTCTGC 1012
Db 1 GATCGGCTGCTCTGC 17
|||||
|

RESULT 335
ACC64635
ID ACC64635 standard; DNA; 17 BP.
XX
AC ACC64635;
XX
DT 01-JUL-2003 (first entry)
XX
XX Murine oligonucleotide associated with tumour suppression, SEQ ID 1882.
XX
XX Cyrostatic; vincristine; neuroprotective; neurotropic; neuroleptic; murine;
KM tumour suppression; tumour reversion; apoptosis; virus resistance;
KM viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KM schizophrenia; ss.
XX
XX Mus musculus.
OS
XX WO2003025176-A2.
PN
XX 27-MAR-2003.
PD
XX 17-SEP-2002; 2002WO-IB004210.
PF
XX 17-SEP-2001; 2001FR-00011979.
PR
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
PA Teleman A, Amson R, Tuijnder M;
PI
XX WPI; 2003-333167/31.
XX
DR New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
PT
XX
PS Disclosure; Page 251; 738bp; French.
XX
XX The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a

CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 2 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;

QY 1359 GTTACCCAGGCTGTGG 1375
Db 1 GATCTCCAGGCTGTGG 17
|||||
|

RESULT 336
ADB42925
ID ADB42925 standard; DNA; 17 BP.
XX
AC ADB42925;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
XX Tumour suppression/reversion associated nucleotide #3248.
XX
XX Cyrostatic; antiviral; neuroprotective; neurotropic; neuroleptic; ss;
KM primer; probe; tumour suppression; tumour reversion; apoptosis;
KM virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KM diagnosis.
XX
XX Homo sapiens.
OS
XX WO2003040369-A2.
PN
XX 15-MAY-2003.
PD
XX 17-SEP-2002; 2002WO-IB004219.
PF
XX 17-SEP-2001; 2001FR-00011981.
PR
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
PA Teleman A, Amson R, Tuijnder M;
PI
XX WPI; 2003-441574/41.
XX
DR New nucleic acid encoding human prostate membrane-specific antigen,
XX useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
PT
XX
PS Disclosure; Page 411; 771bp; French.
XX
XX The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and/or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,

CC potentially useful for treating diseases associated with abnormal
 CC expression of the nucleotides.

XX Sequence 17 BP; 1 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

XX Sequence 17 BP; 1 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 996 GATCACCCTGCTCTGC 1012

Db 1 GATCCTCTGCTCTGC 17

RESULT 337

ADB44878

ID ADB44878 standard; DNA; 17 BP.

AC ADB44878;

DT 18-DEC-2003 (first entry)

DE Tumour suppression/reversion associated nucleotide #5201.

KM cytosarctic; antiviral; neuroprotective; nootropic; neuroleptic; ss;

KM primer; probe; tumour suppression; tumour reversion; apoptosis;

KM virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;

OS Homo sapiens.

PN WO2003040369-A2.

PD 15-MAY-2003.

PF 17-SEP-2002; 2002WO-IB04219.

PR 17-SEP-2001; 2001PR-00011981.

(MOLE-) MOLECULAR ENGINES LAB.

PI Telerman A, Amson R, Tuijnder M;

DR WPI; 2003-441574/41.

PT New nucleic acid encoding human prostate membrane-specific antigen,

PT useful e.g. for treatment of tumors and viral infection, also related

PS polypeptide and antibodies.

PS Disclosure; Page 640; 771pp; French.

CC The invention relates to the isolation of 6327 nucleotide sequences,

CC fragments of at least 15 consecutive nucleotides of these nucleotides, a

CC sequence having at least 80% identity, after optimal alignment, with the

CC nucleotides, a sequence that hybridizes under stringent conditions with

CC the nucleotides, or the complement, or corresponding RNA, of the

CC nucleotides. The nucleotides are used as probes or primers for detecting,

CC identifying, quantifying and/or amplifying nucleic acids, as in vitro

CC sense and antisense sequences, of nucleotides involved in tumour

CC recombinant polypeptides, and to prepare transgenic animals, as

CC experimental models. The nucleotides (also vectors containing them and

CC cells containing the vectors) are useful for prevention and/or treatment

CC (ab) against the polypeptide are useful for prevention and/or treatment

CC of viral infections or diseases characterized by development of tumours

CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).

CC Analysis of the expression of the nucleotides can be used for diagnosis

CC and/or prognosis of these diseases. The nucleotides and polypeptides can

CC also be used to screen for their specific interactive molecules,

CC potentially useful for treating diseases associated with abnormal

CC expression of the nucleotides.

CC Sequence 17 BP; 1 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

XX Sequence 17 BP; 1 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 996 GATCACCCTGCTCTGC 1012

Db 1 GATCCTCTGCTCTGC 17

RESULT 338

AAQ56855

ID AAQ56855 standard; DNA; 18 BP.

AC AAQ56855;

DT 25-MAR-2003 (revised)

DT 05-OCT-1994 (first entry)

DE PCR primer P-74 for detection of Norwalk-related virus.

KM Norwalk virus; HucV; Sapporo; pathogen; acute gastroenteritis;

KM food poisoning; seafood contamination; diagnostic assay; PCR primer;

KM human calcivirus; small round virus; polymerase chain reaction; ss.

OS Synthetic.

PN WO9405700-A2.

PD 17-MAR-1994.

PF 07-SEP-1993; 93WO-US008447.

PR 07-SEP-1992; 92US-00941365.

(BAYU) BAYLOR COLLEGE MEDICINE.

PI Matson DO, Estes MK, Jiang X, Graham DY;

DR WPI; 1994-101125/12.

PT DNA from Norwalk and related viruses - used for preparing probe. for use

PT in diagnostic assays, detection and vaccines for Norwalk and related

PS viruses.

PS Claim 49; Page 104; 156pp; English.

CC Sets of PCR primers (see AAQ56835-Q56857) are used as probes to detect

CC Norwalk-related viruses, e.g. SREV/KY/89, HucV Sapporo, HucV Houston and

CC primate calcivirus. Detection of viral RNA is by RT-PCR. (Updated on 25-

CC MAR-2003 to correct PN field.)

XX Sequence 18 BP; 2 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Qy 1639 GTGGCTGCTCTGCA 1655

Db 2 GAGGCTGCTCTGCTCA 18

RESULT 339

AAQ91475/C

ID AAQ91475 standard; DNA; 18 BP.

AC AAQ91475;

DT 08-FEB-1996 (first entry)

DE Human cyclooxygenase-2 antisense oligonucleotide hCOX-1.1.

XX Human cyclooxygenase-2 antisense oligonucleotide hCOX-1.1.

KW human; cyclooxygenase-2; COX-2; prostaglandin; thromboxane; inhibition;
 KW antisense therapy; premature labour; preclampsia; endometriosis;
 KW rheumatoid arthritis; glomerulitis; ARDS;
 KW adult respiratory distress syndrome; ss.
 XX
 OS Synthetic.
 XX
 PN W09516466-A1.
 XX
 PD 22-JUN-1995.
 XX
 PF 16-DEC-1994; 94WO-US014508.
 XX
 PR 17-DEC-1993; 93US-00170089.
 XX
 PA (OHIS) UNIV OHIO STATE.
 XX
 PI Kniss DA;
 XX
 DR WPI; 1995-231361/30.
 XX
 PT Anti:sense oligo:nucleotide(s) binding cyclo:oxygenase and thromboxane A2
 PT synthase mRNA - used in treatment of diseases involving prostaglandin(s)
 PT and thromboxane metabolism.
 XX
 PS Claim 2; Page 36; 50pp; English.
 XX
 CC Antisense oligonucleotides were designed based on the 5'-UTR and 3'-UTR
 CC sequences of mouse and human cyclooxygenase cDNAs. The phosphorothioate
 CC derivative ("S-oligonucleotides") of the different antisense sequences were
 CC found to be effective for inhibiting translation of cyclooxygenase and
 CC subsequent production of prostaglandins and thromboxanes. The S-
 CC oligonucleotide derivs of AAQ1475- AAQ1484 are based on the human
 CC cyclooxygenase-2 cDNA and are useful for antisense therapy of ARDS,
 CC glomerulitis, rheumatoid arthritis, premature labour, preclampsia,
 CC endometriosis, etc
 XX
 SQ Sequence 18 BP; 2 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 XX
 QY Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Db Best Local Similarity 88.2%; Pred.No.2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 807 GCGCCAGACGACGAGT 823
 Db 18 GCGCCATGAGCCGCGAGT 2
 XX
 RESULT 340
 AAT27721/C
 ID AAT27721 standard; DNA; 18 BP.
 XX
 AC AAT27721;
 XX
 DT 10-JAN-1997 (first entry)
 XX
 DE Fibroblast growth factor fragment.
 XX
 KW Epidermal growth factor; BGF; receptor; proliferation factor; astrocyte;
 KW multipotent neural stem cell; mammary; neuron; oligodendrocyte; therapy;
 KW fibroblast growth factor; transforming growth factor alpha; brain injury;
 KW regulatory factor; neurological disorder; central nervous system;
 KW scar prevention; spinal cord injury; neural scar tissue; axonal element;
 KW ds.
 XX
 OS Mus cookii.
 XX
 PN W09615226-A1.
 XX
 PD 23-MAY-1996.
 XX
 PF 14-NOV-1995; 95WO-CA000637.
 XX

PR 14-NOV-1994; 94US-00338730.
 XX
 XX (NEUR-) NEUROSPHERES HOLDINGS LTD.
 XX
 PI Weiss S, Reynolds BA;
 XX
 DR WPI; 1996-259834/26.
 XX
 PT Regulation of in vitro proliferation of multi-potent neural stem cell(s)
 PT and their progeny - using compsns. concg. biological factors, which can
 PT prevent scar tissue formn. in patients with brain or spinal cord injury.
 XX
 PS Example 3; Page 23; 39pp; English.
 XX
 CC This sequence represents a fibroblast growth factor (FGF) fragment. FGF
 CC can be used as the proliferative factor in the method of the invention
 CC for regulating in vitro proliferation of multipotent neural stem (MNS)
 CC cells, and their progeny. The method of the invention comprises
 CC dissociating mammalian neural tissue containing at least one MNS cell
 CC which produces progeny which differentiate into neurons, astrocytes and
 CC oligodendrocytes. The cells are then proliferated in a medium containing
 CC at least one proliferative factor (e.g. FGF, epidermal growth factor, or
 CC transforming growth factor alpha) inducing stem cell proliferation and a
 CC regulatory factor which regulates proliferation of the stem cell. The
 CC precursor cells can be used for transplantation to treat neurological
 CC disorders. The method can also be used to test the proliferative or
 CC regulatory effects of biological factors on mammalian MNS cell
 CC proliferation in vitro prior to using the factors for the in vivo
 CC regulation of the proliferation of a patients normally quiescent stem
 CC cells. A therapeutic composition can also be produced for regulating the
 CC proliferation of neural stem cells in a patients central nervous system,
 CC containing a neural stem cell regulatory factor. The composition can be
 CC used to prevent scar tissue formation, in patients with brain or spinal
 CC cord injury. This composition reduces neural scar tissue formation at the
 CC site of injury, and enhances conditions allowing for the reconnection of
 CC axonal elements
 XX
 SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
 XX
 QY Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Db Best Local Similarity 88.2%; Pred.No.2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1593 CGAGGTACGCGCGCTGG 1609
 Db 18 CGAGGTGATGCGCGCTGG 2
 XX
 RESULT 341
 AAV25472/C
 ID AAV25472 standard; DNA; 18 BP.
 XX
 AC AAV25472;
 XX
 DT 07-JUL-1998 (first entry)
 XX
 DE Primer for 307 bp collagen type II gene sequence.
 XX
 KW PCR primer; 307 bp collagen type II gene sequence;
 KW human chondrocyte cDNA library; ss.
 XX
 OS Synthetic.
 XX
 PN W09804681-A2.
 XX
 PD 05-FEB-1998.
 XX
 PF 25-JUL-1997; 97WO-US013140.
 XX
 PR 25-JUL-1996; 96US-0022801P.
 PR 25-JUL-1996; 96US-0022810P.
 PR 26-JUL-1996; 96US-0022711P.
 XX

```

XX (GENZ ) GENZYME CORP.
PA Mcpherson JM, Yaeger PC, Brown ME, Hanlon JG, Binette F;
PI WPI; 1998-159151/14.
XX Defined cell culture medium - comprises supplement mixture, component
PT mixture, vitamin mixture, inorganic salt mixture and amino acid mixture.
XX Example 7; Page 47; 59pp; English.
XX The present sequence is a primer for a 307 bp collagen type II gene
CC sequence, amplified from a human chondrocyte cDNA library
XX Sequence 18 BP; 5 A; 8 C; 3 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 717 AGTGTGAGTCTGCTGG 733
DB 17 AGTGTGAGTCTGCTGG 1
RESULT 342
AAV25936
ID AAV25936 standard; DNA; 18 BP.
XX AAV25936;
AC AAV25935;
XX 25-MAR-2003 (revised)
DT 15-JUL-1998 (first entry)
XX Fibroblast growth factor antisense primer.
DE Epidermal growth factor; receptor; fibroblast growth factor; EGF; FGF;
XX neural cell; genetically modified; neurodegenerative disorder;
KW neurotransmitter; primer; ss.
XX Synthetic.
OS US5750376-A.
XX 12-MAY-1998.
PD 07-JUN-1995; 95US-00483122.
XX 08-JUL-1991; 91US-00726812.
PR 16-OCT-1992; 92US-00961813.
PR 28-OCT-1992; 92US-00967622.
PR 29-JAN-1993; 93US-00010829.
PR 09-NOV-1993; 93US-00149508.
PR 01-APR-1994; 94US-00221655.
PR 05-JUL-1994; 94US-00270412.
PR 23-SEP-1994; 94US-00311099.
PR 14-NOV-1994; 94US-00338730.
PR 20-DEC-1994; 94US-00359945.
PR 20-JAN-1995; 95US-00376062.
PR 07-FEB-1995; 95US-00385404.
XX (NEUR-) NEUROSPHERES HOLDINGS LTD.
PA Hamman JP, Reynolds B, Baetge EE, Weiss S;
PI WPI; 1998-296768/26.
XX Production of genetically modified neural cells for production of e.g.
PT growth factors - comprises combining mammalian neural tissue cells with
PT serum-free culture medium containing at least one growth factor and
PT inducing proliferation.
XX

```

```

PS Example 43; Col 59; 43pp; English.
XX The present sequence represents a primer used to carry out sense and
CC antisense experiments on fibroblast growth factor (FGF), in an example of
CC the present invention. The present invention describes a method for the
CC production of genetically modified neural cells. The cells can be
CC genetically modified (i) to produce a growth factor product; (ii) to
CC produce a neurotrophic factor; (iii) to express a growth factor receptor; (iii)
CC to contain a neurotrophic factor synthesizing gene; (iv) to express a
CC neurotrophic factor receptor; or (v) to express chromaffin granule amine
CC transporter. The cells may be used in the treatment of neurodegenerative
CC disorders. (Updated on 25-MAR-2003 to correct PR field.) (Updated on 25-
CC MAR-2003 to correct PA field.)
XX Sequence 18 BP; 2 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1593 CGAGTGTAGCGGCTGG 1609
DB 1 CGAGTGTAGCGGCTGG 17
RESULT 343
AAV25935/C
ID AAV25935 standard; DNA; 18 BP.
XX AAV25935;
AC AAV25935;
XX 25-MAR-2003 (revised)
DT 15-JUL-1998 (first entry)
XX Fibroblast growth factor sense primer.
DE Epidermal growth factor; receptor; fibroblast growth factor; EGF; FGF;
XX neural cell; genetically modified; neurodegenerative disorder;
KW neurotransmitter; primer; ss.
XX Synthetic.
OS US5750376-A.
XX 12-MAY-1998.
PD 07-JUN-1995; 95US-00483122.
XX 08-JUL-1991; 91US-00726812.
PR 16-OCT-1992; 92US-00961813.
PR 28-OCT-1992; 92US-00967622.
PR 29-JAN-1993; 93US-00010829.
PR 09-NOV-1993; 93US-00149508.
PR 01-APR-1994; 94US-00221655.
PR 05-JUL-1994; 94US-00270412.
PR 23-SEP-1994; 94US-00311099.
PR 14-NOV-1994; 94US-00338730.
PR 20-DEC-1994; 94US-00359945.
PR 20-JAN-1995; 95US-00376062.
PR 07-FEB-1995; 95US-00385404.
XX (NEUR-) NEUROSPHERES HOLDINGS LTD.
PA Hamman JP, Reynolds B, Baetge EE, Weiss S;
PI WPI; 1998-296768/26.
XX Production of genetically modified neural cells for production of e.g.
PT growth factors - comprises combining mammalian neural tissue cells with
PT serum-free culture medium containing at least one growth factor and
PT inducing proliferation.
XX Example 43; Col 59; 43pp; English.

```

XX The present sequence represents a primer used to carry out sense and
 CC antisense experiments on fibroblast growth factor (FGF), in an example of
 CC the present invention. The present invention describes a method for the
 CC production of genetically modified neural cells. The cells can be
 CC genetically modified (i) to produce a growth factor product; (ii) to
 CC produce a neuropeptide; (iii) to express a growth factor receptor; (iii)
 CC to contain a neurotransmitter synthesizing gene; (iv) to express a
 CC neurotransmitter receptor; or (v) to express chromaffin granule amine
 CC transporter. The cells may be used in the treatment of neurodegenerative
 CC disorders. (Updated on 25-MAR-2003 to correct PR field.) (Updated on 25-
 CC MAR-2003 to correct PA field.)

XX SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGGTGACGGCGCTGG 1609
 |||||
 DB 18 CGAGGTGATGCCGCTGG 2

RESULT 344
 AAV16023/C
 ID AAV16023 standard; DNA; 18 BP.
 XX
 AC AAV16023;
 XX
 DT 21-MAY-1998 (first entry)
 XX
 DE PCR primer used to identify Sox-2 gene mutations in mice.
 XX
 KM Mutation; Sox-2; mutational screening; recessive; phenotypic alteration;
 KM mouse model; FGF-4; PCR primer; amplify; ss.
 XX
 OS Synthetic.
 OS Mus sp.
 XX
 PN WO9744485-A1.
 XX
 PD 27-NOV-1997.
 XX
 PF 16-MAY-1997; 97WO-GB001354.
 XX
 PR 17-MAY-1996; 96GB-00010355.
 XX
 PA (HEXA-) HEXAGEN TECHNOLOGY LTD.
 XX
 PI Goodfellow PN;
 XX
 DR WPI; 1998-018536/02.
 XX
 PT Identification of mutation(s) in genes of interest - without prior
 PT observation of phenotypic alteration in the mutated organism or cell.
 XX
 PS Example 6, Page 43; 66pp; English.
 XX
 CC PCR primers AAV16019-36 were used to identify mutations in Sox-2 using
 CC the method of the invention. The method comprises testing a nucleic acid
 CC sample from a mutated organism for a mutation in a gene of interest
 CC without the prior observation of a phenotypic alteration in the mutated
 CC organism resulting from the mutation. Sox-2 is a member of the Sox gene
 CC family, and is involved in transcriptional regulation of the FGF-4 gene.
 CC FGF-4 codes for a signalling protein whose expression is essential for
 CC postimplantation mouse development, and, at later embryonic stages, for
 CC limb patterning and growth. Mutagenised mice in which a Sox-2 mutation is
 CC identified can be studied and provide a mouse model for a mutant human
 CC Sox-2 gene. The method provides mutational screening based on genomic and
 CC genetic techniques rather than on phenotypic observation. The method
 CC identifies and characterises genes via mutagenesis to identify genes
 CC encoding products which may have therapeutic benefit. The method also

CC identifies the presence of mutations in a gene which do not rely solely
 CC upon prior matching of a gene with a disease. Heterozygotic organisms can
 CC also be screened to identify those carrying a mutation in a copy of a
 CC gene of interest even though the gene may be recessive and therefore
 CC causes no phenotypic alteration

XX SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2200 GGGTCTACTGGCCAT 2216
 |||||
 DB 18 GGGTCTCTGGCCAT 2

RESULT 345
 AAV15991/C
 ID AAV15991 standard; DNA; 18 BP.
 XX
 AC AAV15991;
 XX
 DT 27-MAY-1998 (first entry)
 XX
 DE NBCCS (PTC) gene exon 20 amplifying primer PTCR25.
 XX
 KM Nevroid basal cell carcinoma syndrome; NBCCS; PTC; PATCHED; detection;
 KM tumour suppressor; human; mutation; Gorlin's syndrome; PCR primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9743414-A2.
 XX
 PD 20-NOV-1997.
 XX
 PF 16-MAY-1997; 97WO-US008433.
 XX
 PR 17-MAY-1996; 96US-0017906P.
 PR 21-MAY-1996; 96AU-00000011.
 PR 07-JUN-1996; 96AU-000000363.
 PR 14-JUN-1996; 96US-0019765P.
 PR 16-MAY-1997; 97US-00857636.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PI Dean MF, Hahn H, Wicking C, Christiansen J, Zaphiropoulos PG;
 PI Galliani MR, Shanley S, Chidambaram A, Vorechovsky I, Holmberg E;
 PI Unden AB, Gillies S, Negus K, Smyth I, Pressman C, Loeffel D;
 PI Gerrard B, Goldstein A, Mainwright B, Toftegard R, Chevenix-Trench G;
 XX
 DR WPI; 1998-008883/01.
 XX
 PT Nevroid basal cell carcinoma syndrome tumour suppressor gene - useful for
 PT detection of pre:disposition to basal cell carcinoma(s).
 XX
 PS Claim 3; Page 79; 148pp; English.
 XX
 CC This primer is used for the PCR amplification of exon 20 of a nevroid
 CC basal cell carcinoma syndrome (NBCCS) (PTC) protein encoding cDNA. The
 CC NBCCS nucleic acid specifically hybridises, under stringent conditions,
 CC to a second nucleic acid consisting of a 6568 (full-length sequence),
 CC 1732 (exon 1a, b) (AAV15998) or 659 (exon 2a) (AAV15999) base pair
 CC sequence, in the presence of a human genomic library. The PTC polypeptide
 CC when presented as an antigen elicits the production of an antibody which
 CC specifically binds to a polypeptide encoded by the above three sequences.
 CC The NBCCS gene and its protein product, is a tumour suppressor, and is a
 CC homologue of the Drosophila PATCHED (PTC) gene. Detection of the NBCCS
 CC nucleic acid, in particular abnormal sequences, by hybridisation assays
 CC is useful for detecting a predisposition to NBCCS or to a basal cell
 CC carcinoma (also known as Gorlin syndrome). Alternatively, detection is of
 CC the polypeptide and is carried out by immunoassay. Vectors comprising

CC this nucleic acid can be used to treat NBCCS. The PTC polypeptide can
 CC mitigate symptoms of NBCCS in an organism. The NBCCS nucleic acid
 CC includes one or more nucleotides, chosen from Exon-5 693nsc, Exon-17
 CC 2988delBP, Exon-21 3538delG, Exon-22 G4302T, Exon-12
 CC 1639insA, Exon-16 2707delC, and Intron-17 3157-2A to G. The mutation may
 CC be a nonsense or frameshift mutation. Frameshift mutations are chosen
 CC from 244delCT, 271insA, 464insAC, 693nsc, 804del137, 877delG, 929delC,
 CC 1370del176, 1393insnsc, 144del6, 1497dup8, 1639insA, 1711nsc,
 CC 2183delCT, 2320insAA, 2392delA, 2574delA, 2583delC, 2596complex,
 CC 2707delC, 2748insC, 2749dup7, 2988delBP, 301insA, 3352delAT and
 CC 3338delG. The mutation may be missense, chosen from G391T, G1148A,
 CC G1368T, G1555T, C2050T, C2065T, C3015A, G3193C AND G4302T. Alternatively,
 CC the mutation alters mRNA splicing and is chosen from A1055-2C, 3157-2A to
 CC G and 1493-8ins21. All these mutations are claimed but their sequences
 CC are not provided in the specification

XX Sequence 18 BP; 3 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1461 CTGCCACCCAGTCGTC 1477
 Db 17 CTGCCACCAAGTCATC 1

RESULT 346
 AAV70503/c
 XX AAV70503 standard; DNA; 18 BP.
 AC AAV70503;
 XX
 DT 08-APR-1999 (first entry)
 XX
 DE Truncated rpoB amplicon generating primer 57-119(mismatch).
 XX
 KM Nucleic acid detection; nucleic acid characterisation; hybridisation;
 KM infection; disease; cancer; forensic; paternity; multiplexing; rpoB;
 KM PCR primer; truncated; mutated; ss.
 XX
 OS Synthetic.
 OS Mycobacterium tuberculosis.
 XX
 PN WO9850403-A1.
 PD 12-NOV-1998.
 XX
 PF 05-MAY-1998; 98MO-US003194.
 XX
 PR 05-MAY-1997; 97US-00851588.
 PR 19-SEP-1997; 97US-00934097.
 PR 03-MAR-1998; 98US-00034205.
 XX
 PA (THIR-) THIRD WAVE TECHNOLOGIES INC.
 PI Dong F, Lyamichiev VI, Prudent JR, Fors L, Neri BP, Brow MAD;
 PI Anderson TA, Dahlberg JE;
 XX
 DR WPI; 1998-610317/51.
 XX
 PT Detection and characterisation of nucleic acid sequences - by mixing a
 PT folded target and one or more probes to form a probe/folded target
 PT complex and detecting and characterising the complexes.
 XX
 PS Example 13; Page 149; 279pp; English.
 XX
 CC The invention relates to methods and compositions of detection and
 CC characterisation of nucleic acid sequences and sequence changes. One
 CC method of detection and characterisation comprises: (a) providing: (1) a
 CC folded target having a DNA sequence comprising at least 1 double stranded
 CC region and at least 1 single stranded region; and (1i) at least 1 probe
 CC complementary to at least a portion of the folded target; and (b) mixing

CC the target and probes so that the probe hybridises to form a probe
 CC /folded target complex. Also provided are methods for determination of
 CC structure formation in nucleic acid targets; for analysing folded nucleic
 CC acids targets; and for analysis of nucleic acid structures. The methods
 CC can be used for the detection and characterisation of nucleic acid
 CC sequences to detect the presence of pathogenic nucleic acid sequences
 CC indicative of an infection, the presence of variants or alleles of
 CC mammalian genes associated with disease and cancers, and the
 CC identification of the source of nucleic acids found in forensic samples,
 CC as well as in paternity determinations. The methods allow simultaneous
 CC analysis of both strands (e.g. the sense and antisense strands) and are
 CC ideal for high-level multiplexing. The products produced are amenable to
 CC qualitative, quantitative and positional analysis. The methods may be
 CC performed in solution or in the solid phase (e.g. on a solid support).
 CC The methods are powerful in that they allow for analysis of longer
 CC fragments of nucleic acid than current methodologies. The present
 CC sequence represents a PCR primer used for generating a truncated or
 CC mutated rpoB amplicon. This is used in exemplifying the method of
 CC structural analysis of nucleic acid targets

XX Sequence 18 BP; 3 A; 10 C; 5 G; 0 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 483 GGTGCCCGGGCGTCAGC 499
 Db 17 GGAGCCCGCGGCTCTGG 1

RESULT 347
 AAV81444/c
 ID AAV81444 standard; cDNA; 18 BP.
 XX
 AC AAV81444;
 XX
 DT 16-MAR-1999 (first entry)
 XX
 DE Sense oligonucleotide targeted to RGF sequence.
 XX
 KM Proliferation; differentiation; stem cell; growth factor; drug screening;
 KM differentiation factor; transplantation; antisense; receptor; ss.
 XX
 OS Synthetic.
 OS
 XX
 PN US5851832-A.
 PD 22-DEC-1998.
 XX
 PF 07-JUN-1995; 95US-00486648.
 XX
 PR 08-JUL-1991; 91US-00726812.
 PR 16-OCT-1992; 92US-00961813.
 PR 28-OCT-1992; 92US-00967622.
 PR 29-JAN-1993; 93US-00010829.
 PR 09-NOV-1993; 93US-00149508.
 PR 01-APR-1994; 94US-00221655.
 PR 05-JUL-1994; 94US-00270412.
 PR 23-SEP-1994; 94US-00311039.
 PR 14-NOV-1994; 94US-00338730.
 PR 20-DEC-1994; 94US-00359945.
 PR 20-JAN-1995; 95US-00376062.
 PR 07-FEB-1995; 95US-00385404.
 XX
 PA (NEUR-) NEUROSPHERES LTD.
 PI Baetge EE, Hammang JP, Weiss S, Reynolds B;
 DR WPI; 1999-080415/07.
 XX
 PT Culture of neural stem cells in vitro - for production of differentiated
 PT neural cells.

```
XX Example 43; Col 59; 44pp; English.
PS
XX The invention relates to methods for proliferating and differentiating
CC neural stem cells and their progeny by culturing the cells in media
CC containing growth factors and/or differentiation factors. The
CC differentiating neural cells can be used for transplantation or drug
CC screening. Growth factors used to induce proliferation include the
CC proteins activin, bone morphogenetic protein (BMP) 2, transforming growth
CC factor (TGF)-beta, interleukin-2, -6 or -8, macrophage inflammatory
CC protein (MIP)-delta, -1beta or 2, tumour necrosis factor (TNF)-alpha,
CC nerve growth factor (NGF), platelet-derived growth factor (PDGF),
CC epidermal growth factor (EGF) or fibroblast growth factor (FGF).
CC Oligonucleotides AAV81442-V81445 are used in antisense and sense
CC experiments for cell growth induced by FGF. This sequence represents a
CC sense oligonucleotide targeted to the FGF sequence
XX
SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1593 CGAGGTGACGCGCTGG 1609
Db 18 CGAGGTGATGCCGCTGG 2
RESULT 348
AAV81445
ID AAV81445 standard; cDNA; 18 BP.
AC AAV81445;
XX
XX 16-MAR-1999 (first entry)
DT
XX Antisense oligonucleotide targeted to FGF receptor sequence.
DE
XX Proliferation; differentiation; stem cell; growth factor; drug screening;
KM differentiation factor; transplantation; antisense; receptor; ss.
XX
XX Synthetic.
OS
XX
XX US5851832-A.
PN
XX 22-DEC-1998.
PD
XX
XX 07-JUN-1995; 95US-00486648.
PF
XX
XX 08-JUL-1991; 91US-00726812.
PR
XX 16-OCT-1992; 92US-00961813.
PR
XX 28-OCT-1992; 92US-00967622.
PR
XX 29-JAN-1993; 93US-00010829.
PR
XX 09-NOV-1993; 93US-00149508.
PR
XX 01-APR-1994; 94US-00221655.
PR
XX 05-JUL-1994; 94US-00270412.
PR
XX 23-SEP-1994; 94US-00311099.
PR
XX 14-NOV-1994; 94US-00338730.
PR
XX 20-DEC-1994; 94US-00359945.
PR
XX 20-JAN-1995; 95US-00376062.
PR
XX 07-FEB-1995; 95US-00385404.
PA
XX (NEUR-) NEUROSPHERES LTD.
XX
XX Baetge EE, Hamman JP, Weiss S, Reynolds B;
PI WPI; 1999-080415/07.
XX
XX Culture of neural stem cells in vitro - for production of differentiated
PT neural cells.
XX
XX Example 43; Col 59; 44pp; English.
XX
```

```
CC The invention relates to methods for proliferating and differentiating
CC neural stem cells and their progeny by culturing the cells in media
CC containing growth factors and/or differentiation factors. The
CC differentiating neural cells can be used for transplantation or drug
CC screening. Growth factors used to induce proliferation include the
CC proteins activin, bone morphogenetic protein (BMP) 2, transforming growth
CC factor (TGF)-beta, interleukin-2, -6 or -8, macrophage inflammatory
CC protein (MIP)-delta, -1beta or 2, tumour necrosis factor (TNF)-alpha,
CC nerve growth factor (NGF), platelet-derived growth factor (PDGF),
CC epidermal growth factor (EGF) or fibroblast growth factor (FGF).
CC Oligonucleotides AAV81442-V81445 are used in antisense and sense
CC experiments for cell growth induced by FGF. This sequence represents an
CC antisense oligonucleotide targeted to the FGF sequence
XX
SQ Sequence 18 BP; 2 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1593 CGAGGTGACGCGCTGG 1609
Db 1 CGAGGTGATGCCGCTGG 17
RESULT 349
AAA56803/C
ID AAA56803 standard; cDNA; 18 BP.
AC AAA56803;
XX
XX 17-OCT-2000 (first entry)
DT
XX FGF sense oligodeoxynucleotide.
DE
XX Fibroblast growth factor; FGF; nootropic; anticonvulsant;
KM neuroprotective; antiparkinsonian; gene therapy; Alzheimer's disease;
KM neurodegenerative disease; Huntington's disease; Alzheimer's disease;
KM Parkinson's disease; neurological trauma; tissue graft;
KM neural cell proliferation; ss.
XX
XX Unidentified.
OS
XX
XX US6071889-A.
PN
XX 06-JUN-2000.
PD
XX
XX 07-JUN-1995; 95US-00479795.
PF
XX
XX 08-JUL-1991; 91US-00726812.
PR
XX 16-OCT-1992; 92US-00961813.
PR
XX 28-OCT-1992; 92US-00967622.
PR
XX 29-JAN-1993; 93US-00010829.
PR
XX 09-NOV-1993; 93US-00149508.
PR
XX 01-APR-1994; 94US-00221655.
PR
XX 05-JUL-1994; 94US-00270412.
PR
XX 23-SEP-1994; 94US-00311099.
PR
XX 14-NOV-1994; 94US-00338730.
PR
XX 20-DEC-1994; 94US-00359945.
PR
XX 20-JAN-1995; 95US-00376062.
PR
XX 07-FEB-1995; 95US-00385404.
PA
XX (NEUR-) NEUROSPHERES HOLDINGS LTD.
XX
XX Baetge EE, Hamman JP, Reynolds B, Weiss S;
PI WPI; 2000-411199/35.
XX
XX In vivo transfer of nucleic acid sequence to proliferating neural cells
PT in central nervous system for treating neurodegenerative disorders,
PT involves administering exogenous nucleic acid sequence and growth
PT factor (B).
XX
```

PS Example 43; Col 59; 42pp; English.
XX
CC The present sequence is a fibroblast growth factor (FGF) sense
CC oligodeoxynucleotide. The oligonucleotide was applied to wells containing
CC primary striatal cells grown in EGF. Sense and antisense experiments were
CC used to assay striatum-derived neurosphere proliferation in response to
CC various combinations of proliferative and regulator factors. Growth
CC factors which induce neural cell proliferation may be administered to the
CC brain with useful genetic material, e.g. genes for neurotransmitters,
CC growth factors or growth factor receptors. The growth factors induce
CC proliferation of neural precursor cells, thereby facilitating the
CC incorporation of the genetic material into the cell progeny. This method
CC of in vivo gene transfer may be used for treating neurodegenerative
CC diseases such as Huntington's disease, Alzheimer's disease, Parkinson's
CC disease and neurological trauma. The neural cells and their progeny are
CC useful as tissue grafts and are also useful for screening potential
CC neurologically therapeutic pharmaceuticals
XX
SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1593 CGAGGTGACGCGCTGG 1609
Db 18 CGAGGTGATGCCCTGG 2
|||||
AA56804 standard; cDNA; 18 BP.
XX
AC AAA56804;
XX
DT 17-OCT-2000 (first entry)
XX
DE FGF antisense oligodeoxynucleotide.
XX
KM Fibroblast growth factor; FGF; nootropic; anticonvulsant;
KM neuroprotective; antiparkinsonian; gene therapy; Alzheimer's disease;
KM neurodegenerative disease; Huntington's disease; Parkinson's disease;
KM Parkinson's disease; neurological trauma; tissue graft;
KM neural cell proliferation; ss.
XX
OS Undefined.
XX
PN US6071889-A.
XX
PD 06-JUN-2000.
XX
PF 07-JUN-1995; 95US-00479795.
XX
PR 08-JUL-1991; 91US-00726812.
PR 16-OCT-1992; 92US-00961813.
PR 26-OCT-1992; 92US-00967622.
PR 29-JAN-1993; 93US-00010829.
PR 09-NOV-1993; 93US-00149508.
PR 01-APR-1994; 94US-00221655.
PR 05-JUL-1994; 94US-00270412.
PR 23-SEP-1994; 94US-00311099.
PR 14-NOV-1994; 94US-00338730.
PR 20-DEC-1994; 94US-00359945.
PR 20-JAN-1995; 95US-00376062.
PR 07-FEB-1995; 95US-00385404.
XX
PA (NEUR-) NEUROSPHERES HOLDINGS LTD.
XX
PI Baetge EE, Hammang JP, Reynolds B, Weiss S;
XX WPI; 2000-411199/35.
XX
PT In vivo transfer of nucleic acid sequence to proliferating neural cells

PT in central nervous system for treating neurodegenerative disorders,
PT involves administering exogenous nucleic acid sequence and growth
PT factor (s).
XX
PS Example 43; Col 59; 42pp; English.
XX
XX The present sequence is a fibroblast growth factor (FGF) antisense
CC oligodeoxynucleotide. The oligonucleotide was applied to wells containing
CC primary striatal cells grown in EGF. Sense and antisense experiments were
CC used to assay striatum-derived neurosphere proliferation in response to
CC various combinations of proliferative and regulator factors. Growth
CC factors which induce neural cell proliferation may be administered to the
CC brain with useful genetic material, e.g. genes for neurotransmitters,
CC growth factors or growth factor receptors. The growth factors induce
CC proliferation of neural precursor cells, thereby facilitating the
CC incorporation of the genetic material into the cell progeny. This method
CC of in vivo gene transfer may be used for treating neurodegenerative
CC diseases such as Huntington's disease, Alzheimer's disease, Parkinson's
CC disease and neurological trauma. The neural cells and their progeny are
CC useful as tissue grafts and are also useful for screening potential
CC neurologically therapeutic pharmaceuticals
XX
SQ Sequence 18 BP; 2 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.9; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1593 CGAGGTGACGCGCTGG 1609
Db 1 CGAGGTGATGCCCTGG 17
|||||
AA244157 standard; DNA; 18 BP.
XX
ID AA244157
XX
AC AA244157;
XX
DT 24-MAR-2000 (first entry)
XX
DE Human EGR-1 DNA antisense primer #24179.
XX
KM EGR-1; early growth response 1; antisense; inhibition; human; primer;
KM anti-inflammatory; cytoskeletal; antiviral; detection; diagnosis;
KM viral infection; inflammation; tumor; ss.
XX
OS Homo sapiens.
XX
PN US6008048-A.
XX
PD 28-DEC-1999.
XX
PF 04-DEC-1998; 98US-00205921.
XX
PR 04-DEC-1998; 98US-00205921.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Cowseert LM;
XX WPI; 2000-096375/08.
XX
DR
XX
PT Antisense oligonucleotides that inhibit expression of human early growth
PT response-1, useful for diagnosis, treatment and prevention of tumors,
PT inflammation and infection.
XX
PS Claim 1; Col 39-40; 31pp; English.
XX
XX This invention describes novel antisense oligonucleotides (I) capable of
CC inhibiting expression of human EGR-1 (early growth response-1). The
CC products of the invention have anti-inflammatory, cytoskeletal and
CC antiviral activity. (I) was tested for its effects on EGR-1 mRNA levels

CC by real-time polymerase chain reaction (PCR), results indicated that 60%
 CC inhibition was achieved. When (I) was modified by 2'-O-methoxyethyl
 CC substitution of the first 4 and last 4 residues, and by replacing any C
 CC in these flanking regions with 5-methyl-C, the degree of inhibition was
 CC increased to 71%. (I) is used to inhibit expression of EGR-1 in cells and
 CC tissues in vitro, for research or diagnosis, e.g. detecting EGR-1
 CC encoding nucleic acid. (I) may also be used to treat or prevent EGR-1-
 CC associated diseases, particularly viral infections, inflammation and
 CC tumor. AA244124-244169 represent antisense primers used to inhibit the
 CC human EGR-1 protein

XX
 SQ Sequence 18 BP; 4 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2054 TGTACGAAAGCCCTGAG 2070
 Db 2 TGTCCGAAAGCCCTGTG 18
 |||||
 |||||

RESULT 352
 AAA23496/C
 ID AAA23496 standard; DNA; 18 BP.
 XX
 AC AAA23496;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Clone vp3_1 hybridisation probe, SEQ ID NO:114.
 XX
 KW Human; secreted protein; cancer; tumour; cardiovascular disorder;
 KW blood disorder; haemophilia; autoimmune disease; diabetes; inflammation;
 KW infection; fungal; bacterial; viral; HIV; allergy; arthritis;
 KW neurodegenerative disease; asthma; contraceptive; hybridisation probe;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200011015-A1.
 XX
 PD 02-MAR-2000.
 XX
 PF 24-AUG-1999; 99WO-US019351.
 XX
 PR 24-AUG-1998; 98US-0097638P.
 PR 24-AUG-1998; 98US-0087659P.
 PR 09-SEP-1998; 98US-0099618P.
 PR 28-SEP-1998; 98US-0102092P.
 PR 25-NOV-1998; 98US-0109978P.
 PR 23-DEC-1998; 98US-0113645P.
 PR 23-DEC-1998; 98US-0113646P.
 PR 23-AUG-1999; 99US-00379246.
 XX
 PA (ALPH-) ALPHAGEN INC.
 XX
 PI Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P;
 XX
 DR WPI; 2000-224657/19.
 XX
 PT New secreted or transmembrane proteins and polynucleotides encoding them,
 PT useful for treating neurodegenerative disorders, autoimmune diseases and
 PT cancer.
 XX
 PS Disclosure; Page 344; 357pp; English.
 XX
 CC The invention relates to 40 human secreted proteins (AA94981-Y95020),
 CC and cDNA sequences encoding them (AAA23423-A23462). The secreted proteins
 CC of the invention include those that are thought to be only partially
 CC secreted, i.e., transmembrane proteins. The proteins of the invention may
 CC exhibit one or more activities selected from the following: cytokine
 CC activity; cell proliferation; differentiation; immune modulation;

CC haematopoiesis regulation; tissue growth activity; activin/inhibin
 CC activity; chemotactic/chemokinetic activity; haemostatic and thrombolytic
 CC activity; anti-inflammatory activity; and tumour inhibition activity. The
 CC proteins may be administered to patients as vaccines, and the nucleotides
 CC may be used as part of a gene therapy regime. Diseases or conditions that
 CC may be treated using the proteins or nucleotides of the invention include
 CC autoimmune diseases; genetic disorders; haemophilia; cardiovascular
 CC diseases; cancer; bacterial, fungal and viral infections, especially HIV;
 CC multiple sclerosis; rheumatoid arthritis; pulmonary inflammation;
 CC Guillain-Barre syndrome; insulin dependent diabetes mellitus; and
 CC allergic reactions such as asthma and anaemia. They may also be used for
 CC treating wounds, burns, ulcers, osteoporosis, osteoarthritis, periodontal
 CC diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease
 CC and amyotrophic lateral sclerosis (ALS). Proteins with activin/inhibin
 CC activity may additionally be useful as contraceptives. Nucleic acid
 CC sequences of the invention may be used in chromosome mapping, and as a
 CC source of diagnostic primers and probes. Sequences AA234463-A23502
 CC represent hybridisation probes which may be used to isolate the cDNA
 CC clones of the invention

XX
 SQ Sequence 18 BP; 3 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1919 GGAGCCAGCTGTCAAGG 1935
 Db 18 GGAGCCAGGTGTCAAGG 2
 |||||
 |||||

RESULT 353
 AA274103
 ID AA274103 standard; DNA; 18 BP.
 XX
 AC AA274103;
 XX
 DT 10-SEP-2001 (first entry)
 XX
 DE Human biallelic marker downstream amplification primer SEQ ID NO:8459.
 XX
 KW Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9954500-A2.
 XX
 PD 28-OCT-1999.
 XX
 PF 21-APR-1999; 99WO-IB000822.
 XX
 PR 21-APR-1998; 98US-0082614P.
 PR 23-NOV-1998; 98US-0109732P.
 XX
 PA (GEST) GENSET.
 XX
 PI Cohen D, Blumenfeld M, Chumakov I;
 XX
 DR WPI; 2000-013267/01.
 XX
 PT Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome.
 XX
 PS Claim 8; Page 2034; 2745pp; English.
 XX
 CC AA265654 to AA269578 represent human biallelic markers from the present
 CC invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AA269579 to AA277440 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the invention

CC have a variety of uses: they can be used for high density mapping of the
 CC human genome, and in complex association studies and haplotyping studies
 CC which are useful in determining the genetic basis for disease states.
 CC Compositions and methods of the invention can also be useful for the
 CC identification of the targets for the development of pharmaceutical
 CC agents and diagnostic methods, as well as the characterization of the
 CC differential efficacious responses to and side effects from
 CC pharmaceutical agents acting on a disease as well as other treatment.
 CC N.B. The SEQ ID Nos 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
 CC 3367, are not actually given a sequence in the Sequence Listing from the
 CC present invention
 XX
 SQ Sequence 18 BP; 3 A; 8 C; 1 G; 6 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 77 TACTGCTACTTCTCGCC 93
 Db 2 TACTGCTACTACTCTCC 18
 RESULT 354
 AA243282/C
 ID AA243282 standard; DNA; 18 BP.
 XX
 AC AA243282;
 XX
 DT 11-FEB-2000 (first entry)
 XX
 DE Murine Sox2 gene PCR primer 5.
 XX
 KM Screening; mutation; treatment; disease; drug discovery; PCR primer; ss.
 XX
 OS Mus musculus.
 XX
 PN US5994075-A.
 XX
 PD 30-NOV-1999.
 XX
 PF 16-MAY-1997; 97US-00857946.
 XX
 PR 17-MAY-1996; 96US-0017824P.
 XX
 PA (HEXA-) HEXAGEN TECHNOLOGY LTD.
 XX
 PI Goodfellow PN;
 XX
 DR WPI; 2000-038255/03.
 XX
 PT Identifying a mutation in a gene of interest in an organism useful for
 PT identifying genes encoding products which may have therapeutic benefits.
 XX
 PS Example 7; Col 69-70; 70pp; English.
 XX
 CC This invention describes a novel mutational screening method based on
 CC genomic and genetic techniques to identify and characterize a mutation in
 CC a gene of interest without first selecting a phenotypic characteristic.
 CC The screening methods are useful for identifying genes encoding products
 CC which may have therapeutic benefit for treating human or animal diseases.
 CC The method can be used for the DNA mutation screening of a class or a
 CC family of genes providing a rapid assay for identifying mutant genes. The
 CC methods produce organisms which can be used for drug discovery e.g.
 CC providing a model for the study and treatment of a disease state, allow
 CC in vitro assessment of drug activity and interbreeding of mutants which
 CC allow investigation of gene interactions in the overall phenotype. A
 CC range of phenotypes associated with different mutations, and specified
 CC mutations in a gene of interest can be determined. The method can be
 CC adapted to screen for a mutation in two or more genes of interest in an
 CC organism. The methods allow mutations in a gene of interest to be
 CC identified without having to rely on matching a gene with a disease.
 CC AA243260-243421 represent PCR primers used in the method of the invention

XX
 SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2200 GGGTGTCTCTGGGCCAT 2216
 Db 18 GGGTCTCTCTGGGCCAT 2
 RESULT 355
 AAA05267/C
 ID AAA05267 standard; DNA; 18 BP.
 XX
 AC AAA05267;
 XX
 DT 19-MAY-2000 (first entry)
 XX
 DE PCR primer C-F used in Sox-2 ampilmer generation.
 XX
 KM PCR primer; Sox-2; Sox-3; T gene; Tyrosinase; MGF; Sry; C-Kit; Trp-1;
 KM Pax-6; mutation detection; therapeutic target identification; mouse;
 KM mast cell growth factor; ss.
 XX
 OS Mus sp.
 XX
 PN US6015670-A.
 XX
 PD 18-JAN-2000.
 XX
 PF 14-NOV-1997; 97US-00970740.
 XX
 PR 17-MAY-1996; 96US-0017824P.
 PR 16-MAY-1997; 97US-00857946.
 XX
 PA (HEXA-) HEXAGEN TECHNOLOGY LTD.
 XX
 PI Goodfellow PN;
 XX
 DR WPI; 2000-181139/16.
 XX
 PT Detecting mutations in selected genes, useful e.g. for identifying
 PT therapeutic targets or products, by analyzing DNA in mutated embryonic
 PT stem cells without phenotypic characterization.
 XX
 PS Example 6; Col 32; 66pp; English.
 XX
 CC PCR primers AAA05245-A05406 are used to generate ampilmers from the mouse
 CC Sox-3 gene, Sox-2 gene, T gene, Tyrosinase gene, Trp-1 gene, Sry gene,
 CC MGF (mast cell growth factor) gene, C-Kit gene, and the Pax-6 gene. The
 CC primers are used in a method for the identification of a mutation in a
 CC selected gene in a tissue without the prior observation of a phenotypic
 CC alteration in the mutated organism or cell. The method is used to
 CC identify mutations in a selected gene that encode products of potential
 CC therapeutic activity or that are potential targets, particularly where
 CC the gene of interest has been identified as a candidate gene by
 CC positional cloning. Other applications are determining functions of genes
 CC ; detecting the range of phenotypes associated with different mutations
 CC in a particular gene and identification of particular mutations. Animals
 CC containing an identified mutation are used as models for studying
 CC diseases or their treatment, and cells from them for in vitro assessment
 CC of drug action. Interbreeding of mutant mice is used to investigate
 CC genetic interaction in the overall phenotype
 XX
 SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2200 GGGTGTCTCTGGGCCAT 2216

Db 18 GGGTTCCTGGCCAT 2

RESULT 356
AAAS2031/C
ID AAAS2031 standard; cDNA; 18 BP.

XX AAAS2031;

DT 19-DEC-2000 (first entry)

DE Antisense oligonucleotide directed against PI3K p85 subunit.

XX Phosphatidylinositol 3-kinase; PI3K; p85; p110; heterodimer; hormone;
KW growth factor; receptor; antisense; inhibitor; expression; diagnosis;
KW modulation; growth factor mediated cell transformation; mitogenesis;
KW protein trafficking; cell survival; cell proliferation; DNA synthesis;
KW apoptosis; neurite outgrowth; insulin-stimulated glucose transport; ss.

XX Synthetic.

OS US6100090-A.

PN 08-AUG-2000.

XX 25-JUN-1999; 99US-00344521.

XX 25-JUN-1999; 99US-00344521.

XX (ISIS-) ISIS PHARM INC.

PA Monia BP, Cowsett LM;

PI WPI; 2000-542426/49.

XX Antisense compounds targeted to the coding region of human

PT phosphatidylinositol 3-kinase (PI3K) p85 and inhibiting PI3K p85

PT expression, useful for treating disorders associated with PI3K p85

PT expression.

XX Example 15; Col 39; 32pp; English.

XX The phosphatidylinositol 3-kinases (PI3Ks) represent a ubiquitous family
CC of heterodimeric lipid kinases that are found in association with the
CC cytoplasmic domain of hormone and growth factor receptors and oncogene
CC products. PI3Ks act as downstream effectors of these receptors, are
CC recruited upon receptor stimulation and mediate the activation of second
CC messenger signaling pathways. The PI3 Kinase enzyme consists of a 110KD
CC catalytic subunit (p110) associated with an 85KD regulatory subunit (p85)
CC and it is through the SH2 domains of the p85 subunit that the enzyme
CC associates with the membrane bound receptors. PI3Ks have been implicated
CC in many cellular activities including growth factor mediated cell
CC transformation, mitogenesis, protein trafficking, cell survival and
CC proliferation, DNA synthesis, apoptosis, neurite outgrowth and insulin-
CC stimulated glucose transport. Antisense compounds directed against PI3K
CC p85 and which inhibit its expression are useful as diagnostics and
CC research reagents, and as a component of kits, which can be used for
CC detecting the level of PI3K p85 in a sample. The compounds may be
CC administered to an animal or human suspected of having a disease or
CC disorder which can be treated by modulating the expression of PI3K p85.
CC The compounds may further be useful prophylactically, e.g., to prevent or
CC delay infection, inflammation or tumour formation. The target site of
CC this antisense molecule is nucleotide 1674 of the coding region of the
CC PI3K p85 subunit (See GENSEQ record AAAS2007)

XX Sequence 18 BP; 4 A; 5 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

YY 1772 TTGAGAGAGCTTCAA 1788

Db 17 TTGAGAGAGCTTCAA 1

RESULT 357
AAC67588/C
ID AAC67588 standard; DNA; 18 BP.

XX AAC67588;

DT 14-FEB-2001 (first entry)

DE Alzheimer's disease-linked mitochondrial SNP PCR primer #288.

XX Human; mitochondrial genome; single nucleotide polymorphism; SNP;
KW Alzheimer's disease; mtDNA; PCR primer; ss.

XX Homo sapiens.

PN M0200063441-A2.

PN 26-OCT-2000.

XX 19-APR-2000; 2000WO-US010906.

XX 20-APR-1999; 99US-0130447P.

XX 22-OCT-1999; 99US-0160901P.

XX (MITO-) MITOKOR.

PA Herrnstadt C, Davis RE;

PI WPI; 2000-672748/65.

XX Diagnosing a subject at the risk for or having Alzheimer's disease

PT comprises determining at least one single nucleotide polymorphism in

PT mitochondrial DNA associated with the disease in the sample from the

PT subject.

XX Example 9; Page 57; 89pp; English.

XX The present invention describes a novel method for determining the risk

CC of or diagnosing Alzheimer's disease using single nucleotide

CC polymorphisms (SNPs) present in an individual's mitochondrial DNA

CC (mtDNA). In addition, the SNPs identified can be used to identify agents

CC suitable for use in treating Alzheimer's disease. Sequences AAC67301-

CC C67610 are PCR primers used to demonstrate the method of the invention

XX Sequence 18 BP; 5 A; 2 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

YY 658 TCAGCCGATACCTTCAC 674

Db 18 TCATCCCGCTACCTTCAC 2

RESULT 358
AAF83007/C
ID AAF83007 standard; DNA; 18 BP.

XX AAF83007;

DT 29-JUN-2001 (first entry)

DE Human MBSBP2 amplifying gene-specific primer 10354784 S2.

XX MBSBP2; cancer; preclampsia; immune system; neurological; cytostatic;

XX gynecological; antiinflammatory; neuroprotective; inotropic; relaxant;

XX cardiant; dermatological; gene therapy; human; MBSBP2; PCR primer; ss.

```

OS Homo sapiens.
XX
XX WO200127277-A2.
XX
XX 19-APR-2001.
XX
XX PF 13-OCT-2000; 2000WO-US028480.
XX
XX PR 13-OCT-1999; 99US-0159231P.
XX 12-JAN-2000; 2000US-0175670P.
XX 12-OCT-2000; 2000US-00159231.
XX
XX (CURA-) CURAGEN CORP.
XX
XX Shimkels RA, Lichenstein H, Boldog FL;
XX WPI; 2001-282030/29.
XX
XX Novel human polynucleotide sequences and the membrane bound or secreted
XX polypeptides encoded by these sequences, designated MBSPX.
XX
XX Example 1; Page 132; 157pp; English.
XX
XX The invention relates to novel polypeptides, termed MBSPX and
XX polynucleotides encoding the MBSPX polypeptides. The MBSPX polypeptide,
XX nucleic acid and an MBSPX antibody are useful for treating or preventing
XX a pathology associated with the protein especially in humans. The MBSPX
XX nucleic acid can be used to express MBSPX protein (e.g. via a recombinant
XX expression vector in a host cell in gene therapy applications), an to
XX detect MBSPX mRNA in a biological sample or a genetic lesion in a MBSPX
XX gene. Disorders associated with insufficient or excessive production of
XX MBSPX protein include cancer, preclampsia, immune system disorders and
XX inflammation, neurological disorders, cardiovascular disorders, and skin
XX and muscle abnormalities. The anti-MBSPX antibodies can be used to detect
XX and isolate MBSPX proteins and modulate MBSPX activity. Sequences
XX AAF83006-013 represent gene specific PCR primers for amplifying the MBSPX
XX cDNA
XX
XX Sequence 18 BP; 5 A; 8 C; 4 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.64; Score 13.8; DB 1; Length 18;
XX Best Local Similarity 88.24; Pred. No. 2.2e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 197 CCGTCTCTGCTGGG 213
XX 17 CCGTCTGCTGCTGAGG 1
XX
XX RESULT 359
XX AAF83006
XX ID AAF83006 standard; DNA, 18 BP.
XX
XX AAF83006;
XX
XX 29-JUN-2001 (first entry)
XX
XX Human MBSPX2 amplifying gene-specific primer 10354784 S1.
XX
XX MBSPX; cancer; preclampsia; immune system; neurological; cytostratic;
XX synecological; antiinflammatory; neuroprotective; inotropic; relaxant;
XX cardant; dermatological; gene therapy; human; MBSPX2; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX WO200127277-A2.
XX
XX 19-APR-2001.
XX
XX 13-OCT-2000; 2000WO-US028480.
XX
XX 13-OCT-1999; 99US-0159231P.
XX 12-JAN-2000; 2000US-0175670P.
XX

```

```

PR 12-OCT-2000; 2000US-00159231.
XX
XX (CURA-) CURAGEN CORP.
XX
XX Shimkels RA, Lichenstein H, Boldog FL;
XX WPI; 2001-282030/29.
XX
XX Novel human polynucleotide sequences and the membrane bound or secreted
XX polypeptides encoded by these sequences, designated MBSPX.
XX
XX Example 1; Page 132; 157pp; English.
XX
XX The invention relates to novel polypeptides, termed MBSPX and
XX polynucleotides encoding the MBSPX polypeptides. The MBSPX polypeptide,
XX nucleic acid and an MBSPX antibody are useful for treating or preventing
XX a pathology associated with the protein especially in humans. The MBSPX
XX nucleic acid can be used to express MBSPX protein (e.g. via a recombinant
XX expression vector in a host cell in gene therapy applications), an to
XX detect MBSPX mRNA in a biological sample or a genetic lesion in a MBSPX
XX gene. Disorders associated with insufficient or excessive production of
XX MBSPX protein include cancer, preclampsia, immune system disorders and
XX inflammation, neurological disorders, cardiovascular disorders, and skin
XX and muscle abnormalities. The anti-MBSPX antibodies can be used to detect
XX and isolate MBSPX proteins and modulate MBSPX activity. Sequences
XX AAF83006-013 represent gene specific PCR primers for amplifying the MBSPX
XX cDNA
XX
XX Sequence 18 BP; 1 A; 4 C; 8 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.64; Score 13.8; DB 1; Length 18;
XX Best Local Similarity 88.24; Pred. No. 2.2e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 197 CCGTCTCTGCTGGG 213
XX 2 CCGTCTGCTGCTGAGG 18
XX
XX RESULT 360
XX AAS11809
XX ID AAS11809 standard; DNA, 18 BP.
XX
XX AAS11809;
XX
XX 24-OCT-2001 (first entry)
XX
XX Human surfactant protein B, SPB, probe 3'fl.
XX
XX Human; surfactant protein B; SPB; Thyroid transcription factor; TTF-1;
XX lung cancer; thyroid cancer; 3'fl; ds; probe; HNF-3; EMSA;
XX electrophoretic mobility shift assay.
XX
XX Homo sapiens.
XX
XX US2001016352-A1.
XX
XX 23-AUG-2001.
XX
XX 26-MAY-1999; 99US-00320337.
XX
XX 18-MAY-1994; 94US-00245356.
XX 17-MAY-1995; 95US-00442809.
XX
XX (BOHL/) BOHINSKI R J.
XX (WHIT/) WHITSETT J A.
XX
XX Bohinski RJ, Whitsett JA;
XX WPI; 2001-513959/56.
XX
XX Oligonucleotide sequences which bind nuclear proteins and surfactants
XX found in lung cells, useful for detecting cancers that originate in the
XX

```

```
PT lung.
XX
XX Example 2; Fig 9a; 76pp; English.
XX
CC The invention relates to an oligonucleotide which includes at least 1
CC nucleic acid sequence which binds to at least 1 nuclear protein found in
CC lung cells (e.g. the thyroid transcription factor 1, TTF-1, protein). The
CC oligonucleotide can be expressed in lung cells via a vector and can be
CC used to target therapeutic agents to kill lung or thyroid cancer cells.
CC The oligonucleotide can be used to detect or diagnose lung or thyroid
CC cancer. The oligonucleotides may be designed from the sequences of, for
CC example, the promoters of lung-specific genes such as those encoding
CC surfactant proteins. The present sequence is a Human surfactant protein
CC B, SPB, probe 3' fl based on the SPB-fl probe and is used to identify TTF-
CC 1 and HNF-3 binding sites in the SPB promoter using EMSA, electrophoretic
CC mobility shift assay
XX
SQ Sequence 18 BP; 5 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1416 GGGCTCCTCAGAGAAA 1432
Db      1 GGGCTTTCAGAGCAA 17

RESULT 361
AAS1811
ID AAS1811 standard; DNA; 18 BP.
XX
XX AAS1811;
AC
XX
XX 24-OCT-2001 (first entry)
DT
XX
DE Human surfactant protein B, SPB, probe 3'SPB-fl.
XX
XX Human; surfactant protein B; SPB; Thyroid transcription factor; TTF-1;
XX lung cancer; thyroid cancer; 3'SPB-fl; ss; probe; HNF-3; EMSA;
XX electrophoretic mobility shift assay.
XX
XX Homo sapiens.
OS
XX
XX US2001016352-A1.
XX
XX 23-AUG-2001.
PD
XX
XX 26-MAY-1999; 99US-00320337.
PF
XX
XX 18-MAY-1994; 94US-00245356.
PR
XX 17-MAY-1995; 95US-00442809.
PR
XX
PA (BOHI/) BOHINSKI R J.
PA (WHIT/) WHITSETT J A.
XX
XX Bohinski RJ, Whitesett JA;
XX
XX WPI; 2001-513959/56.
XX
XX Oligonucleotide sequences which bind nuclear proteins and surfactants
XX found in lung cells, useful for detecting cancers that originate in the
XX lung.
XX
XX Example 2; Fig 10a; 76pp; English.
XX
XX The invention relates to an oligonucleotide which includes at least 1
XX nucleic acid sequence which binds to at least 1 nuclear protein found in
XX lung cells (e.g. the thyroid transcription factor 1, TTF-1, protein). The
XX oligonucleotide can be expressed in lung cells via a vector and can be
XX used to target therapeutic agents to kill lung or thyroid cancer cells.
XX The oligonucleotide can be used to detect or diagnose lung or thyroid
XX cancer. The oligonucleotides may be designed from the sequences of, for
```

```
CC example, the promoters of lung-specific genes such as those encoding
CC surfactant proteins. The present sequence is a Human surfactant protein
CC B, SPB, probe 3'SPB-fl and is used to identify TTF-1 and HNF-3 binding
CC sites in the SPB promoter using EMSA, electrophoretic mobility shift
CC assay
XX
SQ Sequence 18 BP; 5 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1416 GGGCTCCTCAGAGAAA 1432
Db      1 GGGCTTTCAGAGCAA 17

RESULT 362
AAE79676/C
ID AAE79676 standard; DNA; 18 BP.
XX
XX AAE79676;
AC
XX
XX 29-MAY-2001 (first entry)
DT
XX
XX Human Akt-3 antisense oligonucleotide, SEQ ID NO: 84.
DE
XX
XX Human; Akt-3; protein kinase; cytosolic; antiinflammatory; infection;
XX antisense therapy; inflammation; tumour; ss.
XX
XX Homo sapiens.
OS
XX
XX US6187586-B1.
XX
XX 13-FEB-2001.
PD
XX
XX 29-DEC-1999; 99US-00474922.
PF
XX
XX 29-DEC-1999; 99US-00474922.
PR
XX
XX 29-DEC-1999; 99US-00474922.
PR
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Cowseert LM, Roth RA;
XX
XX WPI; 2001-264979/27.
XX
XX New antisense compounds targeting nucleic acids encoding human Akt-3
XX useful for treating a disease or condition associated with Akt-3
XX expression, or in preventing or delaying inflammation or tumor formation.
XX
XX Claim 1; Col 40; 37pp; English.
XX
XX The present sequence is one of a number of antisense compounds of up to
XX 30 nucleobases in length targeted to a nucleic acid encoding human Akt-3.
XX The antisense compounds are useful for inhibiting the expression of human
XX Akt-3 in human cells or tissues. They are also useful for modulating the
XX expression of Akt-3, and for treating a human or an animal suspected of
XX having, or being prone to, a disease or condition associated with Akt-3
XX expression. The antisense compounds may also be used as research
XX reagents, in kits and in diagnostics, e.g. to elucidate the function of a
XX particular gene or to distinguish between functions of various members of
XX a biological pathway; and as a prophylactic, e.g. to prevent or delay
XX infection, inflammation or tumour formation
XX
SQ Sequence 18 BP; 8 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1867 AGTTTCATCTGTGACT 1883
Db      18 AGTTCTTCTGTGAGT 2
```

RESULT 363
AAFI7452
ID AAFI7452 standard; DNA; 18 BP.
XX
AC AAFI7452;
XX
DT 09-MAR-2001 (first entry)
XX
DE Primer UB1133.
XX
KM Retrotransposon; genetic defect; cystic fibrosis; ss.
XX
OS Synthetic.
XX
PN US6150160-A.
XX
PD 21-NOV-2000.
XX
PF 28-APR-1997; 97US-00847844.
XX
PR 16-NOV-1995; 95US-0006831P.
XX
PR 15-NOV-1996; 96US-00749805.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Moran JV, Dombroski BA, Kazazian HH, Boeke JD;
XX
DR WPI; 2001-060015/07.
XX
PT DNAC comprising a promoter P and an L1 cassette sequence having a core
PT retrotransposon element, useful for random insertion of a heterologous or
PT homologous DNA sequence into a cell genome and for correcting genetic
PT defects.
XX
XX
PS Example 2; Col 34; 87pp; English.
XX
CC The present invention relates to DNA for a promoter and an L1 cassette
CC sequence having a core retrotransposon element. The invention is useful
CC for random insertion of a heterologous or homologous DNA sequence into a
CC cell genome, and for correction of a genetic defect in the cell into
CC which the insertion is made. Genetic defects which may be corrected
CC includes cystic fibrosis, mutations in the dystrophin gene, genetic
CC defects associated with blood clotting and other genetic defects
XX
SQ Sequence 18 BP; 7 A; 3 C; 5 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.24; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1817 AGCCACTATGAGGAA 1833
Db 2 AGGCACTATGAGTAA 18
XX
RESULT 364
AAH39762/c
ID AAH39762 standard; DNA; 18 BP.
XX
AC AAH39762;
XX
DT 14-AUG-2001 (first entry)
XX
DE SNP specific lower PCR primer SEQ ID 2558.
XX
KM Single nucleotide polymorphism; SNP; single nucleotide primer extension;
KM SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
KM Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
KM polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
KM acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;

KM inflammation; forensic investigation; paternity analysis; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX WO200129262-A2.
XX
XX 26-APR-2001.
XX
PD 13-OCT-2000; 2000MO-US028436.
XX
PF 15-OCT-1999; 99US-0160096P.
XX
PR (ORCH-) ORCHID BIOSCIENCES INC.
XX
PA Picoult-Newburg L, Pohl M;
XX
PI WPI; 2001-290930/30.
XX
DR New genotyping oligonucleotide, useful for detecting the presence,
XX
PT absence or identity of single polynucleotide polymorphism in a nucleic
PT acid sample.
XX
XX
PS Claim 1; Page 63; 83pp; English.
XX
XX
CC Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
CC primer extension (SNPE) primers, and the sequences of regions flanking
CC sites of single nucleotide polymorphisms SNPs. The present invention
CC includes kits for determining the presence or absence of a SNP, using the
CC oligonucleotides of the invention. The PCR primers are used to amplify a
CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.
CC The oligonucleotides are useful for genotyping a nucleic acid sample by
CC performing a single-nucleotide primer extension reaction. The
CC oligonucleotides are useful for determining the presence, absence or
CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to
CC assess by association analysis the genotype of an individual or group of
CC individuals, having a pathological phenotypic trait suspected of being
CC caused by one or more SNPs. Phenotypic traits include diseases e.g.
CC agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
CC traits also include symptoms of or susceptibility to multifactorial
CC disease of which a component is or may be genetic such as autoimmune
CC inflammation, cancer, nervous system diseases and infection by pathogenic
CC microorganism. The method is also useful in forensic investigations and
CC paternity analysis. The present sequence represents a PCR primer specific
CC for a human SNP containing DNA sequence
XX
SQ Sequence 18 BP; 3 A; 8 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.24; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1925 AGCTGTCAGGGGCTCAG 1941
Db 18 AGCTGTCATGGGCGCCAG 2
XX
RESULT 365
AAD20900/c
ID AAD20900 standard; DNA; 18 BP.
XX
AC AAD20900;
XX
DT 15-JAN-2002 (first entry)
XX
DE Fibroblast growth factor (FGF) oligonucleotide.
XX
KM Proliferation; differentiation; central nervous system; neurosphere;
KM multipotent neural stem cell; neurotransplantation; therapy;
KM neurodegenerative disease; neurological trauma; drug screening;
KM fibroblast growth factor; FGF; regulatory factor; neuroprotective; ss.

```

XX OS Unidentified.
XX OS US6294346-B1.
XX PN 25-SEP-2001.
XX PD
XX PF 07-JUN-1995; 95US-00484406.
XX XX
XX PR 08-JUL-1991; 91US-00726812.
XX PR 28-OCT-1992; 92US-00967632.
XX PR 09-NOV-1993; 93US-00149508.
XX PR 03-JUL-1994; 94US-00270412.
XX PR 23-SEP-1994; 94US-00311099.
XX PR 14-NOV-1994; 94US-00338730.
XX PR 20-DEC-1994; 94US-00359945.
XX PR 20-JAN-1995; 95US-00376062.
XX PR 07-FEB-1995; 95US-00385404.
XX PA (NEUR-) NEUROSHERES HOLDINGS LTD.
XX PI Weiss S, Reynolds B, Hammang JP, Baetge EE;
XX XX
XX DR WPI; 2001-647262/74.
XX XX
XX PT Screening biological agents affecting proliferation, differentiation or
XX PT survival of central nervous system cells, useful for drug screening,
XX PT comprises contacting a cell culture of a neural cell population with a
XX PT growth factor.
XX XX
XX PS Example 43; Col 61; 42pp; English.
XX XX
XX CC The present invention relates to a method for screening biological agents
XX CC which affect proliferation, differentiation or survival of central
XX CC nervous system cells, comprises contacting a cell culture of a neural
XX CC cell population with a biological agent, where the neurospheres comprise
XX CC a cluster of multipotent neural stem cells, each capable of producing
XX CC progeny which can differentiate into neurons and glia, including
XX CC astrocytes. The method is useful for generating large numbers of
XX CC (un)differentiated neural cells for neurotransplantation into a host to
XX CC treat neurodegenerative disease and neurological trauma, for non-surgical
XX CC methods and for drug screening applications. The present sequence is a
XX CC fibroblast growth factor (FGF) oligonucleotide which is used for assaying
XX CC striatum-derived neurosphere proliferation in response to various
XX CC combinations of proliferative and regulatory factors
XX CC
XX SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGGTGACGGCGCTGG 1609
Db 18 CGAGGTGATGCGCTGG 2

RESULT 366
AAH76247
ID AAH76247 standard; DNA; 18 BP.
XX AC
XX AC AAH76247;
XX XX
XX DT 29-OCT-2001 (first entry)
XX XX
XX DE Human macrophage inflammatory protein-2-alpha primer MIP2alpha-F.
XX XX
XX OS Pyrone; gene therapy; antiinflammatory; gene expression; interleukin;
XX OS hemoxygenase-1; prostaglandin G/H synthase-2; RANTES; TNF alpha; p78;
XX OS macrophage inflammatory protein; chemokine; growth regulated protein-1;
XX OS matrix metalloproteinase-9; migration inhibitory factor-related protein;
XX OS lysozyme; GABA(A) receptor-associated protein; interferon; SCO homolog-2;
XX OS transketolase; adenosine A2a receptor; CD37 antigen properdin P factor;

```

```

KW KM G-protein, Nef-associated factor-1, signal peptidase; PCR primer; ss.
XX OS
XX OS Homo sapiens.
XX XX
XX PN WO200151480-A1.
XX PD
XX PD 19-JUL-2001.
XX XX
XX PF 11-JAN-2001; 2001WO-JP000082.
XX XX
XX PR 13-JAN-2000; 2000JP-00004989.
XX PR 03-OCT-2000; 2000JP-00303711.
XX XX
XX PA (TAKI ) TAKARA SHUZO CO LTD.
XX PI Enoki T, Yamashita S, Nishimura K, Sagawa H, Kato I;
XX XX
XX DR WPI; 2001-514436/56.
XX XX
XX PT Agent for correcting gene expression regulation error comprises pyrone
XX PT compound or dihydroxy compound.
XX XX
XX PS Example 6; Page 72; 93pp; Japanese.
XX XX
XX CC The invention provides an agent comprising a pyrone compound or dihydroxy
XX CC compound of specified formulae given in the specification. The agent is
XX CC used for correcting gene expression regulation errors. Errors in the
XX CC following genes may be corrected: IL-6, IL-10, hemoxygenase-1,
XX CC prostaglandin G/H synthase-2, macrophage inflammatory protein-1-alpha,
XX CC RANTES, IL-1alpha, IL-1beta, TNF alpha, IL-7 receptor, macrophage
XX CC inflammatory protein-1beta, liver and activation-regulated chemokine,
XX CC macrophage-derived chemokine, macrophage inflammatory protein-2-beta,
XX CC macrophage inflammatory protein-2-alpha, growth regulated protein-1,
XX CC matrix metalloproteinase-9, migration inhibitory factor-related protein -
XX CC 8, lysozyme, GABA(A) receptor-associated protein, interferon-induced 17 -
XX CC kDa/15-kDa protein, interferon-inducible protein p78, SCO homolog-2,
XX CC transketolase, adenosine A2a receptor, CD37 antigen properdin P factor,
XX CC regulator of G-protein signaling-2, Nef-associated factor-1, myeloid
XX CC leukemia cell differentiation protein-1, signal peptidase complex, and
XX CC also side-effects caused by them such as inflammation. Sequences AAH76220
XX CC -76280 represent PCR primers used in the course of the invention
XX XX
XX SQ Sequence 18 BP; 0 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 564 GCTGTTCTGCTCCTGG 580
Db 2 GCTGCTCTGCTCCTGG 18

RESULT 367
AAS09811
ID AAS09811 standard; DNA; 18 BP.
XX AC
XX AC AAS09811;
XX XX
XX DT 24-OCT-2001 (first entry)
XX XX
XX DE Oat Beta-amylin synthase sequencing primer 53.
XX XX
XX OS Oat; Beta-amylin synthase; triterpenoid; palatability;
XX OS oxidosqualene cyclase; pathogen resistance; transgenic plant;
XX OS fungal disease; sequencing primer; ss.
XX OS
XX OS Avena strigosa.
XX OS
XX PN WO200146391-A2.
XX PD
XX PD 28-JUN-2001.
XX XX

```

PF 20-DEC-2000; 2000WO-GB004908.
 XX
 PR 22-DEC-1999; 99GB-00030394.
 PR 16-AUG-2000; 2000GB-00020217.
 XX
 PA (PLAN-) PLANT BIOSCIENCE LTD.
 XX
 PI Ooboun AE, Haralampidis K, Bryan GT;
 XX WPI; 2001-418055/44.
 DR
 XX Novel beta-amyrin synthase encoding nucleic acids useful for influencing
 PT or affecting triterpene synthetase, and hence resistance to fungal
 PT pathogen, taste, palatability or nutritional value of plants.
 XX
 PS Example 4; Page 59; 69pp; English.
 XX
 CC The sequence represents a primer used to sequence nucleic acids encoding
 CC Oat Beta-amyrin synthase (an oxidoglucanase cyclase). Beta-amyrin is a
 CC triterpenoid responsible for palatability to animals and resistance to
 CC pathogens and predators. The beta-amyrin synthase encoding nucleic acid
 CC is useful for producing a transgenic plant, by introducing a vector
 CC containing it into a host cell, optionally causing or allowing
 CC recombination between the vector and the host cell genome so as to
 CC transform the host cell, and regenerating a plant from the transformed
 CC plant cell. The DNA is also useful for identifying, cloning or
 CC determining the presence of a nucleic acid in a sample and for
 CC influencing or affecting the quantity or quality of triterpenoid
 CC synthetase, preferably an oleanane-type triterpene saponin synthetase, in a
 CC plant, such as altering resistance to a fungal pathogen e.g., an
 CC ascomycete having a sterol-containing membrane, optionally selected from
 CC Geunamomyces graminis varis tritici and avenae, Fusarium culmorum, F.
 CC avenaceum, Stagonopora nodorum or S. avenae, taste, palatability and/or
 CC nutritional value, of the plant, by causing or allowing expression of the
 CC DNA within the cells of the plant, following an earlier step of
 CC introducing the DNA into a cell or its ancestor. The DNA is also useful
 CC for reducing the level of triterpenoids in the plant, by causing or
 CC allowing transcription from an antisense molecule in the plant, allowing
 CC transcription from the DNA, or its part such as to reduce beta-amyrin
 CC synthase expression by co-suppression, use of a nucleic acid encoding a
 CC ribozyme specific for the DNA
 CC
 SQ Sequence 18 BP; 3 A; 3 C; 6 G; 6 T; 0 U; 0 Other;
 XX
 XX
 QY 941 TATGCTCTTGGGATC 957
 Db 1 TATGGCTCTTGGGGAAC 17
 XX
 RESULT 368
 ABL89316 0.6%; Score 13.8; DB 1; Length 18;
 ID ABL89316 standard; DNA; 18 BP.
 XX
 AC ABL89316;
 XX
 DT 22-MAY-2002 (first entry)
 XX
 DE HIV-1 related binding molecule oligonucleotide sequence SEQ ID NO:538.
 XX
 KW Binding molecule; HIV-1; human immunodeficiency virus type 1;
 XX reverse transcriptase; binding group; ss.
 XX
 OS Human immunodeficiency virus 1.
 OS Synthetic.
 XX
 PN EP1174518-A1.
 XX
 PD 23-JAN-2002.
 XX

PF 20-JUL-2000; 2000EP-00202611.
 XX
 PR 20-JUL-2000; 2000EP-00202611.
 XX
 PA (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
 XX
 PI Loukachov VV, Van Gemen B, Goudsmat J;
 XX WPI; 2002-156696/21.
 DR
 XX Collection of binding groups for determining or typing samples,
 PT especially clinical samples, has groups capable to identify essentially
 PT all members of the family of nucleic acids of relatively high
 PT significance.
 XX
 PS Disclosure; Page 137; 166pp; English.
 XX
 CC The present invention describes a collection of binding groups for a
 CC family of nucleic acids comprising members of relative high and relative
 CC low significance, where the binding groups are selected to be capable to
 CC identify, alone or in combination, essentially all members of the family
 CC of nucleic acids of relatively high significance. The collection of
 CC binding groups is useful for typing of nucleic acid in a clinical sample,
 CC by contacting the nucleic acid with the collection and determining
 CC whether one or more binding groups bound to the nucleic acid of the
 CC sample. This method is useful for determining whether the sample
 CC comprises at least a part of a member of relatively high significance of
 CC a family of nucleic acids. The collection of binding groups is useful for
 CC diagnosing the severity of a disease caused by a pathogen containing a
 CC member of a family of nucleic acids. ABL88779 to ABL89321 represent
 CC oligonucleotide sequences used in the exemplification of the present
 CC invention
 CC
 SQ Sequence 18 BP; 9 A; 6 C; 2 G; 1 T; 0 U; 0 Other;
 XX
 XX
 QY 836 ACCGACAGCTAACATC 852
 Db 2 ACCGACAGCAAAACATC 18
 XX
 RESULT 369
 ABL89307 0.6%; Score 13.8; DB 1; Length 18;
 ID ABL89307 standard; DNA; 18 BP.
 XX
 AC ABL89307;
 XX
 DT 22-MAY-2002 (first entry)
 XX
 DE HIV-1 related binding molecule oligonucleotide sequence SEQ ID NO:529.
 XX
 KW Binding molecule; HIV-1; human immunodeficiency virus type 1;
 XX reverse transcriptase; binding group; ss.
 XX
 OS Human immunodeficiency virus 1.
 OS Synthetic.
 XX
 PN EP1174518-A1.
 XX
 PD 23-JAN-2002.
 XX
 DE 20-JUL-2000; 2000EP-00202611.
 XX
 PR 20-JUL-2000; 2000EP-00202611.
 XX
 PA (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
 XX
 PI Loukachov VV, Van Gemen B, Goudsmat J;
 XX WPI; 2002-156696/21.
 DR

XX Collection of binding groups for determining or typing samples,
PT especially clinical samples, has groups capable to identify essentially
PT all members of the family of nucleic acids of relatively high
PT significance.
XX
PS Disclosure; Page 135; 166pp; English.
XX
CC The present invention describes a collection of binding groups for a
CC family of nucleic acids comprising members of relative high and relative
CC low significance, where the binding groups are selected to be capable to
CC identify, alone or in combination, essentially all members of the family
CC of nucleic acids of relatively high significance. The collection of
CC binding groups is useful for typing of nucleic acid in a clinical sample,
CC by contacting the nucleic acid with the collection and determining
CC whether one or more binding groups bound to the nucleic acid of the
CC sample. This method is useful for determining whether the sample
CC comprises at least a part of a member of relatively high significance of
CC a family of nucleic acids. The collection of binding groups is useful for
CC diagnosing the severity of a disease caused by a pathogen containing a
CC member of a family of nucleic acids. ABL8779 to ABL9321 represent
CC oligonucleotide sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 18 BP; 9 A; 6 C; 2 G; 1 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 836 ACCGACAGGTACATC 852
Db 2 ACCGACAGGAACATC 18

RESULT 370
ABL40470/c
ID ABL40470 standard; DNA; 18 BP.
XX
AC ABL40470;
XX
DT 10-JUN-2002 (first entry)
XX
DE Endothelial differentiation gene-1 (EDG-1) sense oligo.
XX
XX Angiogenesis; sphingosine-1-phosphate; SPP; EDG-1; EDG-3; antidiabetic;
XX endothelial differentiation gene; antineumatic; antichratic; cardiant;
XX antiporiatic; antulcer; vasotropic; vulnerary; cyostatic;
XX gene therapy; ss.
XX
OS Synthetic.
XX
OS Homo sapiens.
XX
PN WO200217899-A2.
XX
PD 07-MAR-2002.
XX
PF 31-AUG-2001; 2001WO-US027064.
XX
PR 31-AUG-2000; 2000US-00651846.
XX
XX (UYCO-) UNIV CONNECTICUT.
XX
XX Hla T, Lee M, Claffey KP, Ancellin N, Thangada S;
XX
XX WPI; 2002-269443/31.
XX
XX
XX Regulating angiogenesis for treating cancer and diseases and disorders
XX PT associated with angiogenesis, comprises affecting endothelial
XX PT differentiation gene-1 receptor-mediated signal transduction.
XX
XX Example 12; Fig 12; 79pp; English.
XX
XX

CC The invention relates to methods for regulating angiogenesis in vivo. The
CC method for inducing angiogenesis involves administering a composition
CC comprising sphingosine-1-phosphate (SPP), its analogue, (salts or
CC derivatives of SPP or its analogues), or their combination. The method
CC for inhibiting angiogenesis in vivo, involves administering an antisense
CC oligonucleotide of an mRNA encoding an endothelial differentiation gene
CC (EDG-1 or EDG-3) protein receptor. The methods are useful for regulating
CC (inducing or inhibiting) angiogenesis in vivo. Inducing angiogenesis is
CC useful for protecting endothelial cells from apoptotic cell death,
CC increasing at least one of the VE-cadherin, alpha-catenin, beta-catenin
CC or gamma-catenin at endothelial cell-cell junctions, and modulating
CC vessel maturation. Inhibiting angiogenesis by administering antagonist of
CC signal transduction of EDG-1 or EDG-3 or their combination is useful for
CC treating tumours, rheumatoid arthritis, diabetic retinopathy, Kaposi's
CC sarcoma, haemangioma or psoriasis, where an additional anti-angiogenic
CC factor is also administered, and also for treating unwanted angiogenesis
CC in a human or animal, where a chicken-anti-human-EDG-1 antibody or its
CC biologically active fragment is also administered with the antagonist of
CC EDG-1 signal transduction. The methods are useful for promoting vascular
CC or cardiac endothelial cell growth and morphogenesis. Inducing
CC angiogenesis is useful to accelerate wound healing in a diabetic ulcers,
CC stomach and other gastrointestinal ulcers, and to induce new vessels
CC growth in myocardium of heart suffering from reduced blood supply due to
CC ischaemic heart disease. The present sequence represents a sense oligo
CC used in experiments for determining the inhibition of angiogenesis by
CC phosphothioate oligonucleotides
XX
SQ Sequence 18 BP; 3 A; 7 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1602 GCGCGTGTGGACCCA 1618
Db 18 GACGCTGTGACCCCA 2

RESULT 371
ABL40468
ID ABL40468 standard; DNA; 18 BP.
XX
AC ABL40468;
XX
DT 10-JUN-2002 (first entry)
XX
DE Endothelial differentiation gene-1 (EDG-1) antisense oligo #1.
XX
XX Angiogenesis; sphingosine-1-phosphate; SPP; EDG-1; EDG-3; antidiabetic;
XX endothelial differentiation gene; antineumatic; antichratic; cardiant;
XX antiporiatic; antulcer; vasotropic; vulnerary; cyostatic;
XX gene therapy; antisense; ss.
XX
OS Synthetic.
XX
OS Homo sapiens.
XX
PN WO200217899-A2.
XX
PD 07-MAR-2002.
XX
PF 31-AUG-2001; 2001WO-US027064.
XX
PR 31-AUG-2000; 2000US-00651846.
XX
XX (UYCO-) UNIV CONNECTICUT.
XX
XX Hla T, Lee M, Claffey KP, Ancellin N, Thangada S;
XX
XX WPI; 2002-269443/31.
XX
XX
XX Regulating angiogenesis for treating cancer and diseases and disorders
XX PT associated with angiogenesis, comprises affecting endothelial
XX PT differentiation gene-1 receptor-mediated signal transduction.
XX
XX

XX Claim 8; Page 44; 79pp; English.

PS

XX The invention relates to methods for regulating angiogenesis in vivo. The

CC method for inducing angiogenesis involves administering a composition

CC comprising sphingosine-1-phosphate (S1P), its analogue, (salts or

CC derivatives of S1P or its analogues), or their combination. The method

CC for inhibiting angiogenesis in vivo, involves administering an antisense

CC oligonucleotide of an mRNA encoding an endothelial differentiation gene

CC (EDG-1 or EDG-3) protein receptor. The methods are useful for regulating

CC (inducing or inhibiting) angiogenesis in vivo. Inducing angiogenesis is

CC useful for protecting endothelial cells from apoptotic cell death,

CC increasing at least one of the VE-cadherin, alpha-catenin, beta-catenin

CC or gamma-catenin at endothelial cell-cell junctions, and modulating

CC vessel maturation. Inhibiting angiogenesis by administering antagonist of

CC signal transduction of EDG-1 or EDG-3 or their combination is useful for

CC treating tumours, rheumatoid arthritis, diabetic retinopathy, Kaposi's

CC sarcoma, haemangioma or psoriasis, where an additional anti-angiogenic

CC factor is also administered, and also for treating unwanted angiogenesis

CC in a human or animal, where a chicken-anti-human-EDG-1 antibody or its

CC biologically active fragment is also administered with the antagonist of

CC EDG-1 signal transduction. The methods are useful for promoting vascular

CC or cardiac endothelial cell growth and morphogenesis. Inducing

CC angiogenesis is useful to accelerate wound healing in a diabetic ulcers,

CC stomach and other gastrointestinal ulcers, and to induce new vessel

CC growth in myocardium of heart suffering from reduced blood supply due to

CC ischemic heart disease. The present sequence represents a specific

CC example of an antisense oligo specific for the EDG-1 mRNA, used in the

CC method of the invention

XX

SQ Sequence 18 BP; 2 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

QY

Query Match 0.64; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.24; Pred. No. 2.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 1602 GGGCGTGTGGACCCA 1618

1 GACGCTGTGGCCCCA 17

RESULT 372

AA040986/c

ID AAD40986 standard; DNA; 18 BP.

XX

XX AAD40986;

XX

XX 30-OCT-2002 (first entry)

XX

XX Human PI3K p85 antisense oligonucleotide ISIS #28034.

XX

XX Human; antisense; PI3K p85; obesity; type 2 diabetes; cancer; tumour;

XX prophylaxis; hyperproliferative condition; infection; inflammation;

XX therapy; phosphorothioate; ss.

XX

XX Homo sapiens.

OS Synthetic.

OS

XX

XX Key Location/Qualifiers

XX modified_base 1..18

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate backbone"

FT modified_base 1..4

FT /*tag= b

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl nucleotides"

FT modified_base 3

FT /*tag= d

FT /mod_base= m5c

FT modified_base 15..18

FT /*tag= c

FT /mod_base= OTHER

FT modified_base 15

FT /*tag= e

FT /mod_base= m5c

PN WO200240637-A2.

XX

XX 23-MAY-2002.

PD

XX

XX 19-NOV-2001; 2001MO-US045006.

PF

XX

XX 20-NOV-2000; 2000US-00715983.

PR

XX

PA (ISIS-) ISIS PHARM INC.

XX

PI Monia BP, Cowseert LM, Murray SF, Butler MM, Dean NM;

XX

XX WPI; 2002-519374/55.

DR

XX

XX Antisense compounds targeted against polynucleotides encoding PI3K p85

PT useful for treating e.g. cancer, Type 2 diabetes, obesity.

PS

XX Example 16; Page 79; 121pp; English.

XX

XX The invention relates to antisense compounds targeted to a nucleic acid

XX molecule encoding PI3K p85 to inhibit its expression. Antisense

XX compounds of the invention are used for treating obesity, Type 2 diabetes

XX and hyperproliferative condition e.g. cancer. They may also be useful

XX prophylactically, e.g. to prevent or delay infection, inflammation or

XX tumour formation. Antisense compounds either alone or in combination with

XX other antisense compounds or therapeutics can be used as tools in

XX differential and/or combinatorial analyses to elucidate expression

XX patterns of a portion or the entire complement of genes expressed within

XX cells and tissues. They are commonly used as research reagents and

XX diagnostics. The present sequence is an antisense oligonucleotide

XX targeted to human PI3K p85 DNA

SQ Sequence 18 BP; 4 A; 5 C; 1 G; 8 T; 0 U; 0 Other;

QY

Query Match 0.64; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.24; Pred. No. 2.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 1772 TTGGAAGAGCTTCAA 1788

17 TTGGAAGAGACTTGA 1

RESULT 373

AAK98275

ID AAK98275 standard; DNA; 18 BP.

XX

XX AAK98275;

XX

XX 28-FEB-2002 (first entry)

XX

XX Rat Con-218 R2A sense PCR primer.

DE

XX

XX Con-218; G protein-coupled receptor; GPCR; anti-HIV; antiparkinsonian;

XX neuroprotective; cytoskeletal; tranquilliser; neuroleptic; antianemic;

XX antidepressant; immunosuppressive; antimigraine; nociceptive; cardiac;

XX antidiabetic; antidiabetic; thrombolytic; antiparkinsonian;

XX vasotropic; anticonvulsant; antithyroid; antiinflammatory; nephrotoxic;

XX hypotensive; antineumatic; antiarthritic; cerebroprotective; virucide;

XX antileptileity; gene therapy; thyroid disorder; renal failure;

XX inflammatory conditions; cell differentiation; homeostasis; CNS disorder;

XX rheumatoid arthritis; autoimmune disorder; movement disorder; stroke;

XX psychotic disorder; neurological disorder; dyskinesia; infection;

XX attention disorder; degenerative disorder; metabolic; cardiovascular;

XX cancer; hyperproliferative disorder; psoriasis; hormonal disorder;

XX sexual dysfunction; schizophrenia; rat; PCR primer; ss.

OS Rattus norvegicus.

XX (THIR-) THIRD WAVE TECHNOLOGIES INC.
 PA Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;
 PI WPI; 2002-049698/06.
 XX
 XX Identifying oligonucleotides hybridizing to nucleic acids containing
 PT secondary structure, useful in clinical diagnosis, comprises identifying
 PT primers that interact with the target to form an extension product under
 PT amplification conditions.
 XX
 XX Example 13; Page 178; 409pp; English.
 XX
 XX The present invention describes a method for identifying oligonucleotides
 CC with desired hybridization properties to nucleic acid targets containing
 CC secondary structure. The method comprises amplifying a target nucleic
 CC acid having at least one accessible and one inaccessible site. Primers
 CC that form an extension product are identified as the oligonucleotides
 CC which can interact with the folded target nucleic acid. Oligonucleotides
 CC from the present invention can be used in novel detection methods for
 CC clinical diagnostic purposes, including the detection and identification
 CC of pathogenic organisms (e.g. HIV). The method allows the ability to
 CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent
 CC sequences used in the exemplification of the present invention
 XX
 SQ Sequence 18 BP; 3 A; 10 C; 5 G; 0 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 483 GGTGCGCGCGCTGAG 499
 Db 17 GGGGCGCGCGCTGG 1
 RESULT 376
 AAD41843/c
 ID AAD41843 standard; DNA; 18 BP.
 XX
 AC AAD41843;
 XX
 DT 04-NOV-2002 (first entry)
 XX
 DE Fibroblast growth factor (FGF) sense oligonucleotide.
 XX
 KM cDNA library; multipotent neural stem cell; neural tissue; neurosphere;
 KM neurological disorder; neurodegenerative disease; neurological trauma;
 KM drug-screening; therapy; fibroblast growth factor; FGF; ss.
 XX
 OS Unidentified.
 XX
 PN US6399369-B1.
 XX
 PD 04-JUN-2002.
 XX
 PF 07-JUN-1995; 95US-00484203.
 XX
 PR 08-JUL-1991; 91US-00726812.
 PR 16-OCT-1992; 92US-00961813.
 PR 28-OCT-1992; 92US-00967622.
 PR 29-JAN-1993; 93US-00010829.
 PR 09-NOV-1993; 93US-00149508.
 PR 01-APR-1994; 94US-00221655.
 PR 05-JUL-1994; 94US-00270412.
 PR 23-SEP-1994; 94US-00311099.
 PR 14-NOV-1994; 94US-00338730.
 PR 20-DEC-1994; 94US-00359945.
 PR 20-JAN-1995; 95US-00376062.
 PR 07-FEB-1995; 95US-00385404.
 XX
 PA (NEUR-) NEUROSPHERES HOLDINGS LTD.

XX
 PI Weiss S, Reynolds B;
 XX
 DR WPI; 2002-546286/58.
 XX
 XX Obtaining cDNA library comprises proliferating multipotent neural stem
 PT cells in medium containing growth factor to form neurospheres;
 PT proliferating neurospheres into neural cells and obtaining cDNA library
 PT from the neural cells.
 XX
 XX Example 43; Col 67; 39pp; English.
 XX
 XX The invention relates to a method for obtaining a cDNA library, which
 CC involves proliferating at least one multipotent neural stem cell derived
 CC from mammalian neural tissue in culture medium containing one or more
 CC growth factor(s) that induce multipotent neural stem cell proliferation
 CC into one or more neurospheres, proliferating neurospheres into population
 CC of neural cells and obtaining cDNA library from the neural cells. The
 CC method is useful for obtaining a cDNA library from neural cells that can
 CC be either normal or dysfunctional, allowing for the identification of a
 CC sequence of gene expression during neural development and can be used in
 CC the design of therapies to treat the neurological disorder. It can also
 CC be used to reveal the effects of biological agents on gene expression in
 CC neural cells. The method is useful for generating large numbers of
 CC undifferentiated and differentiated neural cells for neurotransplantation
 CC into a host in order to treat neurodegenerative disease and neurological
 CC trauma, for non-surgical methods of treating neurodegenerative disease
 CC and neurological trauma and for drug-screening applications. The present
 CC sequence is a fibroblast growth factor (FGF) oligonucleotide used in the
 CC exemplification of the invention
 XX
 SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1593 CGAGTGACGCGCTGG 1609
 Db 18 CGAGTGATGCCCTGG 2
 RESULT 377
 ABT06050/c
 ID ABT06050 standard; DNA; 18 BP.
 XX
 AC ABT06050;
 XX
 DT 28-OCT-2002 (first entry)
 XX
 DE Human Igm heavy chain gene related PCR primer SEQ ID No 64.
 XX
 KM Single Primer Amplification; nested oligonucleotide extension reaction;
 KM hairpin; SPA; library; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200248401-A2.
 XX
 PD 20-JUN-2002.
 XX
 PF 10-DEC-2001; 2001WO-US047727.
 XX
 PR 11-DEC-2000; 2000US-0254669P.
 PR 19-SEP-2001; 2001US-0323400P.
 XX
 PA (ALEX-) ALEXION PHARM INC.
 XX
 PI Bowditch KS, Barbas-Frederickson S, Lin Y, McWhirter J, Maryama T;
 XX WPI; 2002-500537/53.
 DR
 XX Amplifying nucleic acid by synthesizing template nucleic acid containing

PT a predetermined sequence and hairpin structure and using the template for
PT target amplification by Single Primer Amplification.
XX
XX Example 3; Page 22; 54pp; English.
XX
CC The invention relates to a method for amplifying a nucleic acid using
CC Single Primer Amplification (SPA). The method comprises synthesising a
CC template nucleic acid containing a predetermined sequence and hairpin
CC structure with the nested oligonucleotide extension reaction. The method
CC is useful for amplifying a nucleic acid, preferably for amplifying a
CC family of related nucleic acid sequences to build a complex library of
CC polypeptides encoded by the sequences. The engineered nucleic acid strand
CC is useful for amplifying a nucleic acid strand by providing a nucleic
CC acid with a predetermined sequence engineered onto its first end, a
CC structure complementary to the predetermined sequence and a hairpin
CC structure between them and contacting the engineered nucleic acid strand
CC with a primer containing at least a portion of the predetermined
CC sequence. This process is done in the presence of a polymerase and
CC nucleotides under conditions suitable for polymerisation to produce a
CC complementary nucleic acid strand. The method of the invention is useful
CC for producing large amounts of a target nucleic acid sequence and for
CC amplifying simultaneously more than one different target nucleic acid
CC sequence located on the same or different nucleic acid molecules. This
CC polynucleotide sequence represents a PCR primer of the invention
XX
SQ Sequence 18 BP; 4 A; 5 C; 3 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1757 AAGAGCCACAGGTATTT 1773
Db 17 AAGAACCAACAGGTCTTT 1
XX
RESULT 378
ACC46880
ID ACC46880 standard; DNA; 18 BP.
XX
AC ACC46880;
XX
DT 05-JUN-2003 (first entry)
XX
DE Human COPD related gene forward PCR primer SEQ ID NO:159.
XX
KM Human; chronic obstructive pulmonary disease; COPD; chronic lung disease;
KM PCR primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200297127-A2.
XX
PD 05-DEC-2002.
XX
PF 28-MAY-2002; 2002WO-EP005835.
XX
PR 31-MAY-2001; 2001GB-00013266.
XX
PA (FARB) BAYER AG.
XX
PI Oellers N, Gehrmann W, Kallabis H, Hall R, Schulze T, Kroegel C;
XX
DR WPI; 2003-140492/13.
XX
PT Predicting, diagnosing or prognosing chronic lung disease, by detecting a
PT chronic obstructive pulmonary disease (COPD) gene in a biological sample.
XX
PS Example 1; Page 213; 214pp; English.
XX
CC The present invention describes a method for predicting, diagnosing or
CC prognosing chronic lung disease by detecting a chronic obstructive

CC pulmonary disease (COPD) gene related polynucleotide (see ACC46750 to
CC ACC46777, which encode the COPD related proteins in ABP6779 to
CC ABP6806). The method is useful for predicting, diagnosing or prognosing
CC chronic lung disease in a biological sample. The COPD genes and proteins
CC encoded by them from the present invention (I) can be used for treating
CC or preventing chronic lung disease in a mammal. (II) can be used in an
CC animal model for determining the efficacy, toxicity, or side effects of
CC treatment with (I), and determining the mechanism of action of (I).
CC ACC46778 to ACC46903 represent COPD related PCR primers and probes used
CC in an example from the present invention
XX
SQ Sequence 18 BP; 0 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 564 GCTGCTCTGCTCTG 580
Db 2 GCTGCTCTGCTCTG 18
XX
RESULT 379
AB298168/C
ID AB298168 standard; DNA; 18 BP.
XX
AC AB298168;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human CD23 + A1261 oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KM antinflammatory steroid; ubiquinone; antinflammatory; antiallergic;
KM antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KM antisense gene therapy; respiratory; lung; adenosine sensitivity;
KM adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KM lung inflammation; respiratory disease; de.
XX
OS Homo sapiens.
OS
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX
PT Miller S, Tang L, Shahbuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13410; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antinflammatory steroid and ubiquinone. A composition of the invention
CC has antinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or

CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC anti-inflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 18 BP; 7 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

QY Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 1003 CTGCTCTGCTTTTCTT 1019
18 CTGACTCTGCTTCTCT 2

RESULT 380
ABT34032/c
ID ABT34032 standard; DNA; 18 BP.
XX
AC ABT34032;
XX
DT 29-MAY-2003 (first entry)
XX
DE Human pigmentation trait-related PCR primer - SEQ ID No 131.
XX
KM Human; single nucleotide polymorphism; SNP; ss; melanocortin-1 receptor;
KM genetic pigmentation trait; MC1R; agouti signaling protein; ASIP; race;
KM hair colour; eye colour; forensic tool; PCR; primer.
XX
OS Homo sapiens.
XX
PN WO200297047-A2.
XX
PD 05-DEC-2002.
XX
PF 28-MAY-2002; 2002WO-US016789.
XX
PR 25-MAY-2001; 2001US-0293560P.
PR 21-JUN-2001; 2001US-0300187P.
PR 07-AUG-2001; 2001US-0310781P.
PR 17-SEP-2001; 2001US-0323662P.
PR 26-OCT-2001; 2001US-0344418P.
PR 15-NOV-2001; 2001US-0334674P.
PR 02-JAN-2002; 2002US-0346303P.
XX
PA (DNAP-) DNAPRINT GENOMICS INC.
XX
PI Fridakis T;
XX
DR WPI; 2003-239091/23.
XX
PT Inferring genetic pigmentation trait such as hair/eye color or shade from
PT nucleic acid sample of human subject, by identifying a pigmentation-
PT related haplotype allele of a pigmentation gene in the sample.
XX
PS Example 17; Page 245; 396pp; English.
XX
CC The invention comprises a method for inferring a genetic pigmentation
CC trait of a human. The method involves identifying a single nucleotide
CC polymorphism (SNP) in a pigmentation gene - where the pigmentation gene
CC is not melanocortin-1 receptor (MC1R) and agouti signaling protein
CC (ASIP). The method of the invention is useful for inferring a genetic
CC pigmentation trait of a human, especially for inferring the race of a
CC human subject. The method is useful for inferring a genetic pigmentation
CC trait such as hair shade or colour, or eye shade or colour of a human
CC subject. The method may be used as a forensic tool for obtaining

CC information relating to physical characteristics of a potential crime
CC victim or a perpetrator of a crime from a nucleic acid sample present at
CC a crime scene. The present PCR primer is used in the exemplification of
CC the invention

XX
SQ Sequence 18 BP; 2 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

QY Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 1077 TCTGCAAGTCCAGCC 1093
17 TCCGCAAGTCCAGGC 1

RESULT 381
ABT34033/c
ID ABT34033 standard; DNA; 18 BP.
XX
AC ABT34033;
XX
DT 29-MAY-2003 (first entry)
XX
DE Human pigmentation trait-related PCR primer - SEQ ID No 132.
XX
KM Human; single nucleotide polymorphism; SNP; ss; melanocortin-1 receptor;
KM genetic pigmentation trait; MC1R; agouti signaling protein; ASIP; race;
KM hair colour; eye colour; forensic tool; PCR; primer.
XX
OS Homo sapiens.
XX
PN WO200297047-A2.
XX
PD 05-DEC-2002.
XX
PF 28-MAY-2002; 2002WO-US016789.
XX
PR 25-MAY-2001; 2001US-0293560P.
PR 21-JUN-2001; 2001US-0300187P.
PR 07-AUG-2001; 2001US-0310781P.
PR 17-SEP-2001; 2001US-0323662P.
PR 26-OCT-2001; 2001US-0344418P.
PR 15-NOV-2001; 2001US-0334674P.
PR 02-JAN-2002; 2002US-0346303P.
XX
PA (DNAP-) DNAPRINT GENOMICS INC.
XX
PI Fridakis T;
XX
DR WPI; 2003-239091/23.
XX
PT Inferring genetic pigmentation trait such as hair/eye color or shade from
PT nucleic acid sample of human subject, by identifying a pigmentation-
PT related haplotype allele of a pigmentation gene in the sample.
XX
PS Example 17; Page 245; 396pp; English.
XX
CC The invention comprises a method for inferring a genetic pigmentation
CC trait of a human. The method involves identifying a single nucleotide
CC polymorphism (SNP) in a pigmentation gene - where the pigmentation gene
CC is not melanocortin-1 receptor (MC1R) and agouti signaling protein
CC (ASIP). The method of the invention is useful for inferring a genetic
CC pigmentation trait of a human, especially for inferring the race of a
CC human subject. The method is useful for inferring a genetic pigmentation
CC trait such as hair shade or colour, or eye shade or colour of a human
CC subject. The method may be used as a forensic tool for obtaining
CC information relating to physical characteristics of a potential crime
CC victim or a perpetrator of a crime from a nucleic acid sample present at
CC a crime scene. The present PCR primer is used in the exemplification of
CC the invention

XX
SQ Sequence 18 BP; 2 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1077 TCTGCAAGTCAGCC 1093
 |||||||
 Db 17 TCCGGCAAGTCAGGC 1

RESULT 382
 ABX95733
 ID ABX95733 standard; DNA; 18 BP.
 XX
 AC ABX95733;
 XX
 DT 03-JUL-2003 (first entry)
 XX
 DE Oligonucleotide #2 for DNA encoding human FGF.
 XX
 KW Multipotent neural stem cell progeny; neural tissue; neural stem cell;
 KW multipotent central nervous system; CNS; cell proliferation; CNS trauma;
 KW autologous transplantation; neurological disease; neurodegeneration;
 KW cell differentiation; progenitor cell; fibroblast growth factor; human;
 KW FGF; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6497872-B1.
 XX
 PD 24-DEC-2002.
 XX
 PF 07-JUN-1995; 95US-00486313.
 XX
 PR 08-JUL-1991; 91US-00726812.
 PR 16-OCT-1992; 92US-00961813.
 PR 28-OCT-1992; 92US-00967622.
 PR 29-JAN-1993; 93US-00010829.
 PR 09-NOV-1993; 93US-00149508.
 PR 01-APR-1994; 94US-00221655.
 PR 05-JUL-1994; 94US-00270412.
 PR 23-SEP-1994; 94US-00311099.
 PR 14-NOV-1994; 94US-00338730.
 PR 20-DEC-1994; 94US-00359945.
 PR 20-JAN-1995; 95US-00376062.
 PR 07-FEB-1995; 95US-00385404.
 XX
 PA (NEUR-) NEUROSPHERES HOLDINGS LTD.
 XX
 PI Weiss S, Reynolds B, Hammang JP, Baetge EE;
 PI
 DR WPI; 2003-401068/38.
 XX
 PT Transplanting of multipotent neural stem cell progeny to a host
 PT comprising obtaining a population of cells derived from mammalian neural
 PT tissue containing multipotent central nervous system neural stem cells.
 XX
 PS Example 43; Col 60; 43pp; English.
 XX
 CC The present invention relates to a method of transplanting a multipotent
 CC neural stem cell progeny to a host by obtaining a population of cells
 CC derived from mammalian neural tissue containing at least one multipotent
 CC central nervous system (CNS) neural stem cell, culturing the neural stem
 CC cell in a culture medium containing growth factor(s) which under culture
 CC conditions induces multipotent neural stem cell proliferation, inducing
 CC proliferation of the multipotent neural stem cell to produce neural stem
 CC cell progeny which includes multipotent neural stem cell progeny cells,
 CC and transplanting the multipotent neural stem cell progeny to the host.
 CC The method is useful for transplanting multipotent neural stem cell
 CC progeny to a host. The method of the invention can be used in autologous
 CC transplantation to in neurological disease, neurodegeneration, and CNS
 CC trauma. The method of the invention allows proliferation and
 CC differentiation of the progenitor cell directly in the host without the

CC need for transplantation. ABX95726-ABX95733 represent oligonucleotides
 CC used in the examples of the present invention
 CC
 SQ Sequence 18 BP; 2 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGTGACGCGCTGG 1609
 |||||||
 Db 1 CGAGTGATGCGCTGG 17

RESULT 383
 ABX95732/c
 ID ABX95732 standard; DNA; 18 BP.
 XX
 AC ABX95732;
 XX
 DT 03-JUL-2003 (first entry)
 XX
 DE Oligonucleotide #1 for DNA encoding human FGF.
 XX
 KW Multipotent neural stem cell progeny; neural tissue; neural stem cell;
 KW multipotent central nervous system; CNS; cell proliferation; CNS trauma;
 KW autologous transplantation; neurological disease; neurodegeneration;
 KW cell differentiation; progenitor cell; fibroblast growth factor; human;
 KW FGF; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6497872-B1.
 XX
 PD 24-DEC-2002.
 XX
 PF 07-JUN-1995; 95US-00486313.
 XX
 PR 08-JUL-1991; 91US-00726812.
 PR 16-OCT-1992; 92US-00961813.
 PR 28-OCT-1992; 92US-00967622.
 PR 29-JAN-1993; 93US-00010829.
 PR 09-NOV-1993; 93US-00149508.
 PR 01-APR-1994; 94US-00221655.
 PR 05-JUL-1994; 94US-00270412.
 PR 23-SEP-1994; 94US-00311099.
 PR 14-NOV-1994; 94US-00338730.
 PR 20-DEC-1994; 94US-00359945.
 PR 20-JAN-1995; 95US-00376062.
 PR 07-FEB-1995; 95US-00385404.
 XX
 PA (NEUR-) NEUROSPHERES HOLDINGS LTD.
 XX
 PI Weiss S, Reynolds B, Hammang JP, Baetge EE;
 PI
 DR WPI; 2003-401068/38.
 XX
 PT Transplanting of multipotent neural stem cell progeny to a host
 PT comprising obtaining a population of cells derived from mammalian neural
 PT tissue containing multipotent central nervous system neural stem cells.
 XX
 PS Example 43; Col 60; 43pp; English.
 XX
 CC The present invention relates to a method of transplanting a multipotent
 CC neural stem cell progeny to a host by obtaining a population of cells
 CC derived from mammalian neural tissue containing at least one multipotent
 CC central nervous system (CNS) neural stem cell, culturing the neural stem
 CC cell in a culture medium containing growth factor(s) which under culture
 CC conditions induces multipotent neural stem cell proliferation, inducing
 CC proliferation of the multipotent neural stem cell to produce neural stem
 CC cell progeny which includes multipotent neural stem cell progeny cells,
 CC and transplanting the multipotent neural stem cell progeny to the host.
 CC The method is useful for transplanting multipotent neural stem cell

CC progeny to a host. The method of the invention can be used in autologous
CC transplantation to in neurological disease, neurodegeneration, and CNS
CC trauma. The method of the invention allows proliferation and
CC differentiation of the progenitor cell directly in the host without the
CC need for transplantation. ABX95726-ABX95733 represent oligonucleotides
CC used in the examples of the present invention
XX
SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1593 CGAGGTGACGCGCTGG 1609
DB 18 CGAGGTGATCCCTGG 2
RESULT 384
ACD27923
ID ACD27923 standard; DNA, 18 BP.
AC ACD27923;
XX 24-SEP-2003 (first entry)
DT
XX Fibroblast growth factor GGF antisense oligonucleotide.
DE
XX Fibroblast growth factor; FGF; ss; CNS cell proliferation; antisense;
KM CNS cell differentiation; CNS cell survival; CNS cell phenotype;
KM CNS cell function; central nervous system; neurological condition;
KM Alzheimer's disease; Parkinson's disease; Down's syndrome.
XX
OS Unidentified.
XX
XX US2003082515-A1.
PN
XX
PD 01-MAY-2003.
PF
XX 19-JUL-2002; 2002US-00199189.
PR
XX 08-JUL-1991; 91US-00726812.
PR 16-OCT-1992; 92US-00961813.
PR 28-OCT-1992; 92US-00967622.
PR 28-JAN-1993; 93US-00010829.
PR 09-NOV-1993; 93US-00149508.
PR 01-APR-1994; 94US-00221655.
PR 05-JUL-1994; 94US-00270412.
PR 23-SEP-1994; 94US-00311099.
PR 14-NOV-1994; 94US-00338730.
PR 20-DEC-1994; 94US-00359945.
PR 20-JAN-1995; 95US-00376062.
PR 07-FEB-1995; 95US-00385404.
PR 07-JUN-1995; 95US-00486313.
XX
PA (WEIS/) WEISS S.
PA (REYN/) REYNOLDS B.
PA (HAMM/) HAMMANG J P.
PA (BAET/) BAETGE E E.
PI Weiss S, Reynolds B, Hammang JP, Baetge EE;
XX WPI; 2003-567461/53.
DR
XX
XX
XX Screening for biological agents affecting proliferation, differentiation,
PT survival, phenotype or function of central nervous system cells,
PT comprises contacting a neural stem cell population with at least one
PT biological agent.
XX
XX Example 43; Page 33; 40pp; English.
XX
XX The invention relates to a method of screening for biological agents
CC affecting proliferation, differentiation, survival, phenotype or function

CC of central nervous system (CNS) cells comprising contacting a neural stem
CC cell population with at least one biological agent and determining if the
CC agent has an effect on any of the listed cell properties. The method is
CC useful for screening for biological agents which affect proliferation,
CC differentiation, survival, phenotype, or function of CNS cells which may
CC have a therapeutic use in treating neurological conditions (e.g.
CC Alzheimer's disease, Parkinson's disease or Down's syndrome). The method
CC allows drug screening to be performed on a cell population consisting
CC essentially of the progeny of a single multipotent neural stem cell grown
CC in vitro. The present sequence represents a fibroblast growth factor GGF
CC receptor antisense oligonucleotide used in a striatum derived neurosphere
XX assay
XX
SQ Sequence 18 BP; 2 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1593 CGAGGTGACGCGCTGG 1609
DB 1 CGAGGTGATCCCTGG 17
RESULT 385
ACD27922/c
ID ACD27922 standard; DNA, 18 BP.
AC ACD27922;
XX 24-SEP-2003 (first entry)
DT
XX Fibroblast growth factor GGF sense oligonucleotide.
DE
XX Fibroblast growth factor; FGF; ss; CNS cell proliferation;
KM CNS cell differentiation; CNS cell survival; CNS cell phenotype;
KM CNS cell function; central nervous system; neurological condition;
KM Alzheimer's disease; Parkinson's disease; Down's syndrome.
XX
OS Unidentified.
XX
XX US2003082515-A1.
PN
XX
PD 01-MAY-2003.
PF
XX 19-JUL-2002; 2002US-00199189.
PR
XX 08-JUL-1991; 91US-00726812.
PR 16-OCT-1992; 92US-00961813.
PR 28-OCT-1992; 92US-00967622.
PR 28-JAN-1993; 93US-00010829.
PR 09-NOV-1993; 93US-00149508.
PR 01-APR-1994; 94US-00221655.
PR 05-JUL-1994; 94US-00270412.
PR 23-SEP-1994; 94US-00311099.
PR 14-NOV-1994; 94US-00338730.
PR 20-DEC-1994; 94US-00359945.
PR 20-JAN-1995; 95US-00376062.
PR 07-FEB-1995; 95US-00385404.
PR 07-JUN-1995; 95US-00486313.
XX
PA (WEIS/) WEISS S.
PA (REYN/) REYNOLDS B.
PA (HAMM/) HAMMANG J P.
PA (BAET/) BAETGE E E.
PI Weiss S, Reynolds B, Hammang JP, Baetge EE;
XX WPI; 2003-567461/53.
DR
XX
XX
XX Screening for biological agents affecting proliferation, differentiation,
PT survival, phenotype or function of central nervous system cells,
PT comprises contacting a neural stem cell population with at least one

PT biological agent.
 XX
 XX Example 43; Page 33; 40pp; English.
 CC The invention relates to a method of screening for biological agents
 CC affecting proliferation, differentiation, survival, phenotype or function
 CC of central nervous system (CNS) cells comprising contacting a neural stem
 CC cell population with at least one biological agent and determining if the
 CC agent has an effect on any of the listed cell properties. The method is
 CC useful for screening for biological agents which affect proliferation,
 CC differentiation, survival, phenotype, or function of CNS cells which may
 CC have a therapeutic use in treating neurological conditions (e.g. which may
 CC Alzheimer's disease, Parkinson's disease or Down's syndrome). The method
 CC allows drug screening to be performed on a cell population consisting
 CC essentially of the progeny of a single multipotent neural stem cell grown
 CC in vitro. The present sequence represents a fibroblast growth factor FGF
 CC sense oligonucleotide used in a striatum derived neurosphere assay
 XX
 SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1593 CGAGCTGACGGCGCTGG 1609
 DB 18 CGAGGTGATGCCGCTGG 2
 RESULT 386
 ACF57054/C
 ID ACF57054 standard; DNA; 18 BP.
 XX
 AC ACF57054;
 XX
 DT 13-Oct-2003 (first entry)
 XX
 DE TIMP2 cloning forward PCR primer SEQ ID NO:7.
 XX
 XX Human; human serum albumin; TIMP2; fusion protein; antiinflammatory;
 KW tissue inhibitors of metalloproteinase; cytosolic; antiarthritic;
 KW antiproliferative; ophthalmological; protein therapy; angiogenesis;
 KW arthritis; psoriasis; retinopathy; metastasis; cancer; PCR primer; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO2003057884-A1.
 PD 17-JUL-2003.
 XX
 PF 06-JAN-2003; 2003WO-KR000015.
 XX
 PR 08-JAN-2002; 2002KR-00001057.
 XX
 PA (LEAD-) LEADBIO INC.
 PA (ANGI-) ANGIOLAB INC.
 XX
 PI Kim J, Kim M, Park E, Chang J, Kang H;
 XX
 DR WPI; 2003-569550/53.
 XX
 PT New human serum albumin-tissue inhibitors of metalloproteinase 2 (TIMP2)
 PT fusion protein, useful for treating diseases related to angiogenesis
 PT (e.g. arthritis, psoriasis or retinopathy) and/or metastasis of cancer
 PT cells.
 XX
 PS Example 1; Page 30; 36pp; English.
 XX
 CC The present invention describes a human serum albumin (HSA)-tissue
 CC inhibitors of metalloproteinase 2 (TIMP2) fusion protein (I). Also
 CC described: (1) a polynucleotide encoding (I); (2) a vector comprising the
 CC polynucleotide; (3) a host cell transformed with the vector; (4) a method

CC of producing (I) by cultivating the transformed host cell in a medium to
 CC produce the fusion protein, and recovering (I); and (5) a pharmaceutical
 CC composition comprising (I), and a pharmaceutical carrier or diluent. (I)
 CC has cytostatic, antiproliferative, antiinflammatory, antipsoriatic and
 CC ophthalmological activities, and can be used in protein therapy. The
 CC fusion protein (I) or polynucleotide encoding it can be used for treating
 CC diseases related to angiogenesis (e.g. arthritis, psoriasis or
 CC retinopathy) and/or metastasis of cancer cells. The present sequence
 CC represents a TIMP2 cloning PCR primer, which is used in an example from
 CC the present invention
 XX
 SQ Sequence 18 BP; 1 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1671 CACCGGGGACAGCTGC 1687
 DB 18 CACCGGGGACAGCTGC 2
 RESULT 387
 ADC03333
 ID ADC03333 standard; DNA; 18 BP.
 XX
 AC ADC03333;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE FGF antisense oligonucleotide.
 XX
 XX ss; FGF; multipotent neural stem cell proliferation;
 KW neurological disorder; neurotransplantation; neurodegeneration;
 KW CNS trauma; Alzheimer's disease; Parkinson's disease; stroke;
 KW head injury; depression; epilepsy; schizophrenia.
 XX
 OS Synthetic.
 XX
 PN US2003049837-A1.
 PD 13-MAR-2003.
 XX
 PF 09-AUG-2001; 2001US-00925911.
 XX
 XX 08-JUL-1991; 91US-00726812.
 PR 16-OCT-1992; 92US-00961813.
 PR 28-OCT-1992; 92US-00967622.
 PR 29-JAN-1993; 93US-00010829.
 PR 09-NOV-1993; 93US-00149508.
 PR 01-APR-1994; 94US-00221655.
 PR 05-JUL-1994; 94US-00270412.
 PR 23-SEP-1994; 94US-00311099.
 PR 14-NOV-1994; 94US-00338730.
 PR 20-DEC-1994; 94US-00359945.
 PR 20-JAN-1995; 95US-00376062.
 PR 07-FEB-1995; 95US-00385404.
 PR 07-JUN-1995; 95US-00484203.
 XX
 PA (WEIS/) WEISS S.
 PA (REYN/) REYNOLDS B.
 PA (HAMM/) HAMMANG J P.
 PA (BAET/) BAETGE E E.
 XX
 PI Weiss S, Reynolds B, Hammang JP, Baetge EE;
 XX
 DR WPI; 2003-605757/57.
 XX
 XX In vitro proliferation of a multipotent neural stem cell, useful for
 XX treating neurological disorders, comprises the use of growth factors to
 XX induce proliferation of the neural stem cell and produce a neural stem
 XX cell progeny.

PS Example 43; Page 33; 42pp; English.

XX The invention relates to a method of in vitro proliferation of a
 CC multipotent neural stem cell comprising the use of growth factors to
 CC induce proliferation of the neural stem cell and produce a progeny that
 CC may be passaged repeatedly to produce a sufficient number of cells to
 CC obtain representative nucleic acid samples. The method is useful in
 CC proliferating multipotent neural stem cells to produce a progeny that may
 CC be used to treat neurological disorders or diagnose genetic disorders.
 CC The progeny is used for neurotransplantation in the undifferentiated or
 CC differentiated state to alleviate the symptoms of neurologic disease,
 CC neurodegeneration and CNS trauma (e.g. Alzheimer's disease, Parkinson's
 CC disease, stroke, head injury, depression, epilepsy or schizophrenia).
 CC These cells may also be used for drug screening of putative therapeutic
 CC agents targeted at the nervous system. The present sequence represents
 CC the RFL antisense oligonucleotide.

SQ Sequence 18 BP; 2 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

QY Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

DB 1 CGAGGTGATGCCGCTGG 17

QY 1593 CGAGGTGACGCGCTGG 1609

RESULT 388
 ADC03332/C
 ID ADC03332 standard; DNA; 18 BP.

XX ADC03332;
 AC
 XX 18-DEC-2003 (first entry)
 DT
 XX
 XX FGF sense oligonucleotide.
 DE
 XX
 XX ss; FGF; multipotent neural stem cell proliferation;
 KM neurological disorder; neurotransplantation; neurodegeneration;
 KM CNS trauma; Alzheimer's disease; Parkinson's disease; stroke;
 KM head injury; depression; epilepsy; schizophrenia.
 XX
 OS Synthetic.
 XX
 XX US2003049837-A1.
 PN
 XX
 XX 13-MAR-2003.
 PD
 XX
 XX 09-AUG-2001; 2001US-00925911.
 PF
 XX
 XX 08-JUL-1991; 91US-00726812.
 PR
 XX 16-OCT-1992; 92US-00961813.
 PR
 XX 28-OCT-1992; 92US-00967622.
 PR
 XX 29-JAN-1993; 93US-00010829.
 PR
 XX 09-NOV-1993; 93US-00149508.
 PR
 XX 01-APR-1994; 94US-00221555.
 PR
 XX 05-JUL-1994; 94US-00270412.
 PR
 XX 23-SEP-1994; 94US-00311099.
 PR
 XX 14-NOV-1994; 94US-00338730.
 PR
 XX 20-DEC-1994; 94US-00359945.
 PR
 XX 20-JAN-1995; 95US-00376062.
 PR
 XX 07-FEB-1995; 95US-00385404.
 PR
 XX 07-JUN-1995; 95US-00484203.
 PR
 XX
 XX (WEIS/) WEISS S.
 PA (REYN/) REYNOLDS B.
 PA (HAMM/) HAMMANG J P.
 PA (BAET/) BAETGE E E.
 PI Weiss S, Reynolds B, Hammang JP, Baetge EE;
 XX WPI; 2003-605757/57.

XX In vitro proliferation of a multipotent neural stem cell, useful for
 PT treating neurological disorders, comprises the use of growth factors to
 PT induce proliferation of the neural stem cell and produce a neural stem
 PT cell progeny.

PS Example 43; Page 33; 42pp; English.

XX The invention relates to a method of in vitro proliferation of a
 CC multipotent neural stem cell comprising the use of growth factors to
 CC induce proliferation of the neural stem cell and produce a progeny that
 CC may be passaged repeatedly to produce a sufficient number of cells to
 CC obtain representative nucleic acid samples. The method is useful in
 CC proliferating multipotent neural stem cells to produce a progeny that may
 CC be used to treat neurological disorders or diagnose genetic disorders.
 CC The progeny is used for neurotransplantation in the undifferentiated or
 CC differentiated state to alleviate the symptoms of neurologic disease,
 CC neurodegeneration and CNS trauma (e.g. Alzheimer's disease, Parkinson's
 CC disease, stroke, head injury, depression, epilepsy or schizophrenia).
 CC These cells may also be used for drug screening of putative therapeutic
 CC agents targeted at the nervous system. The present sequence represents
 CC the RFL sense oligonucleotide.

SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

QY Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

DB 18 CGAGGTGATGCCGCTGG 2

QY 1593 CGAGGTGACGCGCTGG 1609

RESULT 389
 ADC98362
 ID ADC98362 standard; DNA; 18 BP.

XX ADC98362;
 AC
 XX 01-JAN-2004 (first entry)
 DT
 XX
 XX FOSB01 polymorphism marker PCR primer B primer seq.
 DE
 XX
 XX low bone mineral density; BMD; bone damage; polymorphism; osteoporosis;
 KM single nucleotide polymorphism; SNP; PCR primer; ss; human.
 KM
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX WO2003054218-A2.
 PN
 XX
 XX 03-JUL-2003.
 PD
 XX
 XX 19-DEC-2002; 2002WO-US040948.
 PF
 XX
 XX 20-DEC-2001; 2001US-0342711P.
 PR
 XX 04-NOV-2002; 2002US-0423559P.
 PR
 XX
 XX (INCY-) INCYTE GENOMICS INC.
 PA
 PI Jones KA, Valdes A, Townley DJ, Mangion J, Galwey N, Bennett S;
 PI McKay I, Schafer A;
 XX WPI; 2003-559156/52.
 DR
 XX
 XX Determining whether an individual is predisposed to susceptibility to low
 PT bone mineral density (BMD) and/or bone damage, involves identifying
 PT polymorphisms in associated genes.
 XX
 XX Example 8; Page 237; 246pp; English.
 PS
 CC The present invention describes a method of determining whether an

CC individual is predisposed to susceptibility to low bone mineral density
 CC (BMD) and/or bone damage comprising identifying whether the individual
 CC has at least one polymorphism in a polynucleotide encoding a protein,
 CC where the polynucleotide is one of at 200-500 nucleotide sequences (S1),
 CC see AOC9835 to AOC9835). An agent identified in a method from the of a
 CC present invention which can be used for the prevention or treatment of a
 CC disease resulting in susceptibility to low BMD and/or bone damage is
 CC useful in the manufacture of a medicament for use in modulating the
 CC susceptibility to low BMD and/or bone damage. The disease associated with
 CC low BMD and/or bone damage is osteoporosis. The present PCR primer
 CC sequence is used in the exemplification of the present invention.

XX Sequence 18 BP; 5 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1614 ACCCAATGGTCTGCGA 1630
 Db 1 ACCCAATGATCTGCGA 17

RESULT 390
 ADD43511/c
 ID ADD43511 standard; DNA; 18 BP.

XX AC ADD43511;

XX DT 15-JAN-2004 (first entry)

XX DE Human mitochondrial DNA (mtDNA) PCR primer SEQ ID NO:685.

XX KM mitochondrial haplogroup; mitochondrial DNA; mtDNA;

KW single nucleotide polymorphism; SNP; genetic relationship; antidiabetic;

KM neurotrophic; neuroprotective; cytosstatic; gene therapy; genealogy;

KM forensic; Alzheimer's disease; cancer; type 2 diabetes mellitus; human;

XX KM PCR primer; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN WO2003046225-A1.

XX PD 05-JUN-2003.

XX PF 25-NOV-2002; 2002WO-US038276.

XX PR 26-NOV-2001; 2001US-0333622P.

XX PR 28-MAR-2002; 2002US-0369131P.

XX PR 01-APR-2002; 2002US-0369539P.

XX PA (MITO-) MITOKOR.

XX PI Hermetad C;

XX DR WPI; 2003-505214/47.

XX PT Determining single nucleotide polymorphisms in mtDNA or homoplasmic mtDNA

XX PT mutations, useful for diagnosing and treating diseases, such as

XX PT Alzheimer's disease, cancer and type 2 diabetes mellitus.

XX PS Example 2; SEQ ID NO 685; 193bp; English.

XX XX The present invention describes a method (M1) for determining the

XX CC mitochondrial haplogroup of a subject, comprising determining in a

XX CC biological sample with mitochondrial DNA (mtDNA) from a subject, the

XX CC presence or absence of at least one mitochondrial single nucleotide

XX CC polymorphism (SNP) that is associated with a mitochondrial haplogroup.

XX CC Also described: (1) determining a genetic relationship between two

XX CC subjects; (2) determining a genetic relationship between an unknown

XX CC source or biological subject from which an unidentified sample is

XX CC obtained, and a known source or biological subject from an identified

CC sample is obtained; and (3) determining the presence of or the risk of
 CC having a disease associated with a mtDNA SNP. Mitochondrial DNA can have
 CC antidiabetic, neurotrophic, neuroprotective and cytosstatic activities, and
 CC can be used in gene therapy. M1 and compositions of the present invention
 CC are useful for detecting the presence or risk of diseases, treating such
 CC diseases, determining the haplogroup of an individual, and establishing
 CC genetic relationships between individuals for genealogical and forensic
 CC purposes. The diseases include Alzheimer's disease, cancer and type 2
 CC diabetes mellitus. The present sequence represents a PCR primer used in
 CC the amplification of human mtDNA in an example from the present
 CC invention.

XX Sequence 18 BP; 5 A; 2 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 658 TCAGCCGATACCTTCAC 674
 Db 18 TCATCCGCTACCTTCAC 2

RESULT 391
 AAS98700
 ID AAS98700 standard; DNA; 15 BP.

XX AC AAS98700;

XX DT 26-MAR-2002 (first entry)

XX DE Colony stimulating factor 1 receptor (CSF1R) oligonucleotide #66.

XX KM Colony stimulating factor 1 receptor; CSF1R; polymorphic variant;

KW cytosstatic; gene therapy; malignant histiocytosis; isogene;

KM myeloid malignancy; inflammatory disorder; transgenic animal; haplotype;

KM genotype; human; allele specific oligonucleotide; ASO; primer; ss.

XX KM Homo sapiens.

XX OS WO200179225-A2.

XX PD 25-OCT-2001.

XX PF 12-APR-2001; 2001WO-US012044.

XX PR 12-APR-2000; 2000US-0196411P.

XX PA (GENA-) GENAISSANCE PHARM INC.

XX PI Chew A, Choi JY, Koshy B;

XX DR WPI; 2002-075058/10.

XX PT Novel polymorphic variants of colony stimulating factor 1 receptor useful

XX PT in studying expression and function of the protein, useful for screening

XX PT candidate drugs to treat diseases e.g. inflammatory disorders.

XX PS Claim 15; Page 16; 164pp; English.

XX XX The invention describes a novel isolated polynucleotide (I) comprising a

XX CC sequence which is a polymorphic variant (PV) of a reference sequence for

XX CC colony stimulating factor 1 receptor (CSF1R) gene, found on the

XX CC polypeptide are useful for improving the discovery and development of

XX CC drugs for treating diseases associated with CSF1R activity, e.g.,

XX CC malignant histiocytosis, myeloid malignancies, and inflammatory disorders

XX CC and the haplotypes can be used to validate CSF1R as a candidate target

XX CC for treating a specific condition or disease predicted to be associated

XX CC with CSF1R activity. Genotyping the CSF1R gene of an individual can also

XX CC be used in developing diagnostic tests and therapeutic treatments. (I) is

XX CC useful in studying the expression and function of CSF1R, and in

XX CC expressing CSF1R protein for use in screening for candidate drugs to

XX CC treat diseases related to CSF1R activity and in studying the effect of

CC the variation on the biological activity of CSF1R as well as on the
 CC binding affinity of candidate drugs targeting CSF1R. Antibodies are
 CC useful in a variety of diagnostic and prognostic formats and therapeutic
 CC methods. A transgenic animal is useful in studying expression of the
 CC CSF1R isogenes *in vivo*, for *in vivo* screening and testing of drugs
 CC targeted against CSF1R protein, and for testing the efficacy of
 CC therapeutic agents and compounds. Allele specific oligonucleotides (ASO)
 CC are useful as probes and primers, and for assaying a polymorphism in the
 CC target region. Without requiring any a priori knowledge of the phenotypic
 CC effect of any particular CSF1R or haplotype the invention provides a
 CC method for identifying lead compounds that are more likely to show
 CC efficacy in clinical trials. This sequence is an allele specific
 CC oligonucleotide primer used for detecting CSF1R gene polymorphisms,
 CC described in the method of the invention

XX
 SQ Sequence 15 BP; 3 A; 3 C; 3 G; 5 T; 0 U; 1 Other;

Query Match 0.6%; Score 13.6; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.9e+02;
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1648 CTGCTGCAGATCT 1661
 Db 2 CTGCTGCAGATST 15

RESULT 392
 ABS64229
 ID ABS64229 standard; DNA, 15 BP.
 AC ABS64229;
 XX
 DT 15-NOV-2002 (first entry)

DE Tachykinin receptor gene TACR2, allele-specific primer #39.
 XX
 KM Human; single nucleotide polymorphism; SNP; TACR2; primer; probe; ss;
 KM tachykinin receptor.
 XX
 OS Homo sapiens.
 XX
 PN WO20263046-A1.
 XX
 PD 15-AUG-2002.
 XX
 PF 09-NOV-2001; 2001WO-US047394.
 XX
 PR 09-NOV-2000; 2000US-0247649P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 PI Cappola G, Chew A, Gilson CR, Koshy B;
 XX
 DR WPI; 2002-636600/68.
 XX
 PT New genetic variants having polymorphisms in the Tachykinin receptor
 PT (TACR2) protein, useful for studying the function of TACR2, and for
 PT treating disorders associated with abnormal expression or function of
 PT TACR2 isogene.
 PT
 PS Claim 14; Page 15; 139pp; English.
 XX

CC The invention relates to an isolated polypeptide comprising a polymeric
 CC variant of a reference sequence for the Tachykinin receptor (TACR2)
 CC protein. Also described is a method for: (1) haplotyping or genotyping
 CC the TACR2 gene of an individual; (2) predicting a haplotype pair for the
 CC TACR2 gene of an individual; (3) identifying an association between a
 CC trait and at least one haplotype or haplotype pair of the TACR2 gene; and
 CC (4) isolated oligonucleotide for detecting a single nucleotide
 CC polymorphism in the TACR2 gene. Polymorphic variants of the TACR2 gene
 CC are useful in studying the expression and biological function of TACR2,
 CC and in identifying drugs targeting TACR2 protein for treating disorders
 CC associated with abnormal expression or function of TACR2, e.g. asthma or

CC breast cancer. Polynucleotides comprising a polymorphic gene variant or
 CC fragment may be used for therapeutic purposes, where a patient could
 CC benefit from expression or increased expression of a particular TACR2
 CC protein isoform, or an expression vector encoding the isoform may be
 CC administered to the patient. Haplotype information is useful in improving
 CC the efficiency and output of several steps in drug discovery and
 CC development process, including target validation, identifying lead
 CC compounds, and early phase clinical trials. Information on polymorphisms
 CC may be applied in studying biological functions of TACR2 as well as in
 CC identifying drugs targeting this protein for the treatment of disorders
 CC related to its abnormal expression or function. ABS64163-ABS64302
 CC represent human TACR2 gene allele-specific oligonucleotide probes and
 CC primers used to detect haplotypes of the TACR2 gene of the invention

XX
 SQ Sequence 15 BP; 2 A; 4 C; 6 G; 2 T; 0 U; 1 Other;

Query Match 0.6%; Score 13.6; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.9e+02;
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 62 CATGGCTGGGACA 75
 Db 1 CATGGCTGGGACR 14

RESULT 393
 ABZ48393/C
 ID ABZ48393 standard; DNA, 41 BP.
 AC ABZ48393;
 XX
 DT 26-JUN-2003 (first entry)

DE Human ATP-binding cassette ABCB3/ABCB1 gene polymorphic site, #5176.
 XX
 KM Human; drug metabolizing enzyme; gene; drug metabolism; chromosome 6;
 KM polymorphic site; drug evaluation; drug screening; genotyping;
 KM genetic profiling; therapeutic customisation; adverse reaction;
 KM clinical trial; drug approval; single nucleotide polymorphism; SNP; de.
 XX
 OS Homo sapiens.
 XX
 PN WO200252044-A2.
 XX
 PD 04-JUL-2002.
 XX
 PF 27-DEC-2001; 2001WO-JP011592.
 XX
 PR 27-DEC-2000; 2000JP-00399443.
 PR 02-MAY-2001; 2001JP-0035256.
 PR 27-AUG-2001; 2001JP-00256862.
 XX
 PA (RIKE) RIKEN KK.
 PI Nakamura Y, Sekine A, Iida A, Saito S;
 XX
 DR WPI; 2002-583571/62.
 XX
 PT Identifying individuals having a polymorphism, useful for determining the
 PT effectiveness or side effect of a drug or treatment protocol, comprises
 PT detecting at least one polymorphism in the drug metabolizing enzyme
 PT nucleic acid.
 XX
 PS Claim 23; Page 165; 2785pp; English.
 XX
 CC Sequences ABZ43217-ABZ50887 represent polymorphic sites within genes
 CC encoding enzymes associated with drug metabolism. The invention relates
 CC to methods and compositions for identifying individuals who have at least

CC one polymorphism in such drug metabolising enzyme-encoding genes. The
CC polymorphisms may be identified in a nucleic acid sample using probes or
CC primers specific for a sequence selected from ABZ43217-ABZ50887 using a
CC variety of detection assays, including hybridisation assays, nucleic acid
CC arrays and PCR-based methods. The invention also encompasses methods of
CC evaluating and screening drugs using genetic polymorphism data. Genetic
CC polymorphism data, particularly that relating to single nucleotide
CC polymorphisms (SNPs), may be used in studying the relationship between
CC DNA sequence variations and human diseases, conditions, and responses to
CC drugs. SNPs are also useful as polymorphism markers for discovering genes
CC that cause or exacerbate certain diseases. SNPs are particularly useful
CC in the above respects as they are stable in populations, occur
CC frequently, and have lower mutation rates than other genome variations
CC such as repeating sequences. The detection and analysis of polymorphisms
CC in genes encoding drug metabolising enzymes allows the customisation of
CC drug therapies based upon the genetic profile of individual patients.
CC This would not only take the guesswork out of selecting the drug with the
CC greatest therapeutic effect for a particular patient, but would also
CC reduce the likelihood of adverse reactions, thereby increasing safety.
CC Methods of the invention are also useful in the drug discovery and
CC approval processes. For example, individuals could be selected for
CC clinical trials only if their genetic profiles indicate that they are
CC capable of responding to a particular drug or drug class, and previously
CC failed drug candidates could be revived if they were matched with more
CC appropriate patient populations. The methods, data and compositions of
CC the invention may therefore lead to an increase in the range of
CC possible drug targets and decreases in the number of adverse drug
CC reactions, failed drug trials, the time taken for a drug to be approved,
CC the length of time patients are on medication and the number of different
CC medications a patient needs to take before finding an effective therapy

XX
SQ Sequence 41 BP; 5 A; 19 C; 5 G; 12 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.6; DB 1; Length 41;
Best Local Similarity 67.9%; Pred. No. 3.8e+02;
Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 2105 ACCTCAGCCTGGTGAGCAGGCTGACCA 2132
Db 37 AGCAGAGGCAGGGTGATCAGGCTGACCA 10

RESULT 394
ABZ50856/c
ID ABZ50856 standard; DNA; 41 BP.

XX AC ABZ50856;

XX DT 26-JUN-2003 (first entry)

XX Human ATP-binding cassette ABCB2/TAP2 gene polymorphic site, #7638.

XX Human; drug metabolising enzyme; gene; drug metabolism; chromosome 6;

KW polymorphic site; drug evaluation; drug screening; genotyping;

KW genetic profiling; therapeutic customisation; adverse reaction;

KW clinical trial; drug approval; single nucleotide polymorphism; SNP; ds.

XX Homo sapiens.

XX Key Location/Qualifiers

XX FT variation

XX PF 27-DEC-2001; 2001WO-JP011592.

XX PR 27-DEC-2000; 2000JP-00399443.

XX PR 02-MAY-2001; 2001JP-00135256.

XX PR 27-AUG-2001; 2001JP-00256862.

XX (RIKE) RIKEN KK.
XX PA Nakamura Y, Sekine A, Iida A, Saito S;
XX PI WPI; 2002-583571/62.
XX DR
XX PT Identifying individuals having a polymorphism, useful for determining the
XX PT effectiveness or side effect of a drug or treatment protocol, comprises
XX PT detecting at least one polymorphism in the drug metabolizing enzyme
XX PT nucleic acid.

PS Claim 23; Page 223; 2785pp; English.

XX Sequences ABZ43217-ABZ50887 represent polymorphic sites within genes
XX encoding enzymes associated with drug metabolism. The invention relates
XX to methods and compositions for identifying individuals who have at least
XX one polymorphism in such drug metabolising enzyme-encoding genes. The
XX polymorphisms may be identified in a nucleic acid sample using probes or
XX primers specific for a sequence selected from ABZ43217-ABZ50887 using a
XX variety of detection assays, including hybridisation assays, nucleic acid
XX arrays and PCR-based methods. The invention also encompasses methods of
XX evaluating and screening drugs using genetic polymorphism data. Genetic
XX polymorphism data, particularly that relating to single nucleotide
XX polymorphisms (SNPs), may be used in studying the relationship between
XX DNA sequence variations and human diseases, conditions, and responses to
XX drugs. SNPs are also useful as polymorphism markers for discovering genes
XX that cause or exacerbate certain diseases. SNPs are particularly useful
XX in the above respects as they are stable in populations, occur
XX frequently, and have lower mutation rates than other genome variations
XX such as repeating sequences. The detection and analysis of polymorphisms
XX in genes encoding drug metabolising enzymes allows the customisation of
XX drug therapies based upon the genetic profile of individual patients.
XX This would not only take the guesswork out of selecting the drug with the
XX greatest therapeutic effect for a particular patient, but would also
XX reduce the likelihood of adverse reactions, thereby increasing safety.
XX Methods of the invention are also useful in the drug discovery and
XX approval processes. For example, individuals could be selected for
XX clinical trials only if their genetic profiles indicate that they are
XX capable of responding to a particular drug or drug class, and previously
XX failed drug candidates could be revived if they were matched with more
XX appropriate patient populations. The methods, data and compositions of
XX the invention may therefore lead to an increase in the range of
XX possible drug targets and decreases in the number of adverse drug
XX reactions, failed drug trials, the time taken for a drug to be approved,
XX the length of time patients are on medication and the number of different
XX medications a patient needs to take before finding an effective therapy

XX
SQ Sequence 41 BP; 5 A; 19 C; 5 G; 12 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.6; DB 1; Length 41;
Best Local Similarity 67.9%; Pred. No. 3.8e+02;
Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 2105 ACCTCAGCCTGGTGAGCAGGCTGACCA 2132
Db 37 AGCAGAGGCAGGGTGATCAGGCTGACCA 10

RESULT 395
ABZ43222/c
ID ABZ43222 standard; DNA; 41 BP.

XX AC ABZ43222;

XX DT 26-JUN-2003 (first entry)

XX Human ATP-binding cassette ABCB2/TAP2 gene polymorphic site, #6.

XX Human; drug metabolising enzyme; gene; drug metabolism; chromosome 6;

KW polymorphic site; drug evaluation; drug screening; genotyping;

KW genetic profiling; therapeutic customisation; adverse reaction;

KW clinical trial; drug approval; single nucleotide polymorphism; SNP; ds.

XX	Homo sapiens.
OS	
XX	
FH	Key Location/Qualifiers
FT	variation replace(21,G)
FT	/tag= a
TT	/standard_name= "single nucleotide polymorphism (SNP) "
XX	
NM	MO200252044-A2.
XX	
PD	04-JUL-2002.
PF	27-DEC-2001; 2001WO-JP011592.
PR	27-DEC-2000; 2000JP-00399443.
PR	02-MAY-2001; 2001JP-00135256.
PR	27-AUG-2001; 2001JP-00256862.
XX	
PA	(RIKE) RIKEN KK.
XX	
P1	Nakamura Y, Sekine A, Iida A, Saito S;
XX	
DR	WPI; 2002-583571/62.
XX	
PT	Identifying individuals having a polymorphism, useful for determining the effectiveness or side effect of a drug or treatment protocol, comprises detecting at least one polymorphism in the drug metabolizing enzyme nucleic acid.
PT	
PS	Claim 23; Page 64; 2785pp; English.
XX	
CC	Sequences ABZ43217-ABZ50887 represent polymorphic sites within genes encoding enzymes associated with drug metabolism. The invention relates to methods and compositions for identifying individuals who have at least one polymorphism in such drug metabolizing enzyme-encoding genes. The polymorphisms may be identified in a nucleic acid sample using probes or primers specific for a sequence selected from ABZ43217-ABZ50887 using a variety of detection assays, including hybridisation assays, nucleic acid arrays and PCR-based methods. The invention also encompasses methods of evaluating and screening drugs using genetic polymorphism data. Genetic polymorphism data, particularly that relating to single nucleotide polymorphisms (SNPs), may be used in studying the relationship between DNA sequence variations and human diseases, conditions, and responses to drugs. SNPs are also useful as polymorphism markers for discovering genes that cause or exacerbate certain diseases. SNPs are particularly useful in the above respects as they are stable in populations, occur frequently, and have lower mutation rates than other genome variations such as repeating sequences. The detection and analysis of polymorphisms in genes encoding drug metabolising enzymes allows the customisation of drug therapies based upon the genetic profile of individual patients. CC This would not only take the guesswork out of selecting the drug with the greatest therapeutic effect for a particular patient, but would also reduce the likelihood of adverse reactions, thereby increasing safety. CC Methods of the invention are also useful in the drug discovery and approval processes. For example, individuals could be selected for clinical trials only if their genetic profiles indicate that they are capable of responding to a particular drug or drug class, and previously failed drug candidates could be revived if they were matched with more appropriate patient populations. The methods, data and compositions of the invention may therefore lead to a an increase in the range of possible drug targets and decreases in the number of adverse drug reactions, failed drug trials, the time taken for a drug to be approved, the length of time patients are on medication and the number of different medications a patient needs to take before finding an effective therapy
SO	Sequence 41 BP; 5 A; 19 C; 5 G; 12 T; 0 U; 0 Other;
	Query Match 0.6%; Score 13.6; DB 1; Length 41;
	Best Local Similarity 67.9%; Pred. No. 3.8e+02;
	Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0
Y	ACCTGAGCCTGTGGAGCGACTGAACA 2132

```

Db          37 AGCAGAGCGAGGTGATCAGGTGACCA 10
?+
RESULT 396
AA01153
ID AA01153 standard; DNA; 15 BP.
XX
AC AA01153;
XX
DT 25-MAR-2003 (revised)
DT 31-MAY-1991 (first entry)
XX
DE 3'-terminal noncoding sequence of an influenza virus genome.
XX
KW Influenza virus; ribonucleoprotein complex; RNA polymerase; vaccine;
KW negative strand RNA template; chimeric virus; ss.
XX
OS Synthetic.
XX
PN WO9103552-A.
PD
PD 21-MAR-1991.
XX
PF 28-AUG-1989; 89US-00399728.
XX
PR 28-AUG-1989; 89US-00399728.
PR 21-NOV-1989; 89US-00440053.
PR 22-MAY-1990; 90US-00527237.
XX
PA (MOUN ) MOUNT SINAI SCHOOL MEDICINE.
XX
PI Palese P, Parvin UD, Krystal M;
XX
DR WPI; 1991-102072/14.
XX
PT Recombinant negative strand RNA template - for RNA polymerase binding
PT site used to produce expression prods. and chimeric viruses for influenza
PT vaccines.
XX
PS Claim 5; Page 87; 114p; English.
XX
CC This sequence comprises the terminal 15 residues of the 3' non-coding
CC viral sense flanking region of an influenza genomic segment. It is a
CC component of a recombinant negative strand RNA template and is used as an
CC RNA polymerase binding site, in the prepn. of a ribonucleoprotein complex
CC (RNP). The template also contains a heterologous RNA sequence and opt.
CC also a 5'-noncoding viral sense flanking sequence of influenza. The
CC heterologous sequences is selected from e.g. epitopes of HIV, HBsAg or
CC herpes viruses. A vast repertoire of vaccine formulations can be produced
CC using the chimeric viruses. This alleviates the problem of host
CC resistance. See also AA01152, AA01154-56 and AA01192-93. (Updated on
CC 25-MAR-2003 to correct PA field.)
XX
SQ Sequence 15 BP; 1 A; 7 C; 2 G; 0 T; 5 U; 0 Other;
Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0.
QY 999 CACCTGCGCTGCT 1013
DB 1 CACCTGCGCTGCT 15
AC AAT52346;
XX
DT 25-MAR-2003 (revised)
DT 02-APR-1997 (first entry)
XX

```

DE Mouse ICM hammerhead ribozyme target sequence (nt. position 1678).
XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
XX gene expression; downregulation; interleukin-5; IL-5; ICM-1;
KM intercellular adhesion molecule; rel A; tumour necrosis factor;
KM TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KM translocation; chronic myelogenous leukaemia; CML; cancer;
KM Philadelphia chromosome; inflammation; autoimmune disease;
KM atherosclerosis; myocardial infarction; stroke; restenosis;
KM transplant rejection; rheumatoid arthritis; psoriasis;
KM myocardial ischemia; Kawasaki disease; septic shock; HIV;
KM human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KM ss.
XX Mus musculus.
XX WO9523225-A2.
XX 31-AUG-1995.
XX 23-FEB-1995; 95WO-IB000156.
XX 23-FEB-1994; 94US-00201109.
XX 29-MAR-1994; 94US-00218934.
XX 04-APR-1994; 94US-00222795.
XX 07-APR-1994; 94US-00224483.
XX 15-APR-1994; 94US-00227958.
XX 15-APR-1994; 94US-00228041.
XX 18-MAY-1994; 94US-00245736.
XX 06-JUL-1994; 94US-00271280.
XX 15-AUG-1994; 94US-00291932.
XX 16-AUG-1994; 94US-00291433.
XX 17-AUG-1994; 94US-00292620.
XX 19-AUG-1994; 94US-00293520.
XX 02-SEP-1994; 94US-00300000.
XX 08-SEP-1994; 94US-00303039.
XX 23-SEP-1994; 94US-00311486.
XX 23-SEP-1994; 94US-00311749.
XX 28-SEP-1994; 94US-00314397.
XX 03-OCT-1994; 94US-00316771.
XX 07-OCT-1994; 94US-00319492.
XX 11-OCT-1994; 94US-00321993.
XX 04-NOV-1994; 94US-00334847.
XX 10-NOV-1994; 94US-00337608.
XX 28-NOV-1994; 94US-00345516.
XX 16-DEC-1994; 94US-00357577.
XX 23-DEC-1994; 94US-00363233.
XX 30-JAN-1995; 95US-00380734.
XX (RIBO-) RIBOZYME PHARM INC.
XX Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpelsky A, Kisich K, Matulic-Adamic J, Mcswigen JA;
PI Modak A, Pavco P, Belgelman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Usman N, Wincott FE, Woolf T;
XX WPI; 1995-351090/45.
XX Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX Claim 2, Page 178; 407bp; English.
XX The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICM-1 mRNA at the
CC nucleotide base position indicated in the DE line. Regions of the mRNA
CC that do not form secondary folding structures and that contain potential
CC hammerhead and hairpin ribozyme cleavage sites were identified by
CC computer analysis. Ribozymes directed against these mRNA sequences were
CC designed and synthesised with modifications that improve their nuclease
CC resistance. The ribozymes cleave the ICM-1 target sequences and thereby
CC inhibit ICM-1 expression, making them useful for reducing transplant
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,

CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC correct PI field.)
XX SQ Sequence 15 BP; 3 A; 5 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 12; Conservative 2; Mismatches 1;
DY 2102 AGCACCTCAGCCTCG 2116
DB 1 AGCACCTCAGCCTCG 15
RESULT 398
AAT52187
ID AAT52187 standard; RNA; 15 BP.
XX AAT52187;
AC AAT52187;
DT 25-MAR-2003 (revised)
DT 01-APR-1997 (first entry)
XX Mouse ICM hammerhead ribozyme target sequence (nt. position 48).
XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KM gene expression; downregulation; interleukin-5; IL-5; ICM-1;
KM intercellular adhesion molecule; rel A; tumour necrosis factor;
KM TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KM translocation; chronic myelogenous leukaemia; CML; cancer;
KM Philadelphia chromosome; inflammation; autoimmune disease;
KM atherosclerosis; myocardial infarction; stroke; restenosis;
KM transplant rejection; rheumatoid arthritis; psoriasis;
KM myocardial ischemia; Kawasaki disease; septic shock; HIV;
KM human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KM ss.
XX Mus musculus.
XX WO9523225-A2.
XX 31-AUG-1995.
XX 23-FEB-1995; 95WO-IB000156.
XX 23-FEB-1994; 94US-00201109.
XX 29-MAR-1994; 94US-00218934.
XX 04-APR-1994; 94US-00222795.
XX 07-APR-1994; 94US-00224483.
XX 15-APR-1994; 94US-00227958.
XX 15-APR-1994; 94US-00228041.
XX 18-MAY-1994; 94US-00245736.
XX 06-JUL-1994; 94US-00271280.
XX 15-AUG-1994; 94US-00291932.
XX 16-AUG-1994; 94US-00291433.
XX 17-AUG-1994; 94US-00292620.
XX 19-AUG-1994; 94US-00293520.
XX 02-SEP-1994; 94US-00300000.
XX 08-SEP-1994; 94US-00303039.
XX 23-SEP-1994; 94US-00311486.
XX 23-SEP-1994; 94US-00311749.
XX 28-SEP-1994; 94US-00314397.
XX 03-OCT-1994; 94US-00316771.
XX 07-OCT-1994; 94US-00319492.
XX 11-OCT-1994; 94US-00321993.
XX 04-NOV-1994; 94US-00334847.
XX 10-NOV-1994; 94US-00337608.
XX 28-NOV-1994; 94US-00345516.
XX 16-DEC-1994; 94US-00357577.
XX 23-DEC-1994; 94US-00363233.
XX 30-JAN-1995; 95US-00380734.
XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LM;
 PI Grifm S, Karpelsky A, Kisch K, Matulic-Adamic J, McWiggen JA;
 PI Modak A, Pavco P, Belgelman L, Sullivan SM, Svedler D, Thompson JD;
 PI Ttacz D, Uman N, Wincott FB, Woolf T;
 XX WPI: 1995-351090/45.
 DR
 XX
 PT Ribozymes having modified bases and methods for producing them - for use
 PT in inhibiting disease related genes.
 XX
 PS Claim 2; Page 177; 407pp; English.
 XX
 CC The present sequence represents a preferred target sequence for an
 CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
 CC nucleotide base position indicated in the DE line. Regions of the mRNA
 CC that do not form secondary folding structures and that contain potential
 CC hammerhead and hairpin ribozyme cleavage sites were identified by
 CC computer analysis. Ribozymes directed against these mRNA sequences were
 CC designed and synthesized with modifications that improve their nuclease
 CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
 CC inhibit ICAM-1 expression, making them useful for reducing transplant
 CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
 CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
 CC correct PI field.)
 CC
 XX
 SQ Sequence 15 BP; 3 A; 5 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 2e+02;
 Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 2102 AGCACCCTGAGCTGG 2116
 DB 1 AGGACCCUAGCCUGG 15
 ID AAX64669 standard; RNA; 15 BP.
 XX
 AC AAX64669;
 XX
 DT 20-JUL-1999 (first entry)
 XX
 DE Human B7-1 hammerhead ribozyme target SEQ ID NO:1301.
 XX
 XX Arthritis condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW streptolysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9618736-A2.
 XX
 PD 20-JUN-1996.
 XX
 PF 22-NOV-1995; 95WO-US015516.
 XX
 XX 13-DEC-1994; 94US-00354920.
 PR 23-DEC-1994; 94US-00363253.
 PR 23-DEC-1994; 94US-00363254.
 PR 17-FEB-1995; 95US-00390850.
 PR 20-APR-1995; 95US-00426124.
 PR 02-MAY-1995; 95US-00432874.
 PR 04-MAY-1995; 95US-00434509.
 PR 07-JUL-1995; 95US-0000951P.
 PR 07-JUL-1995; 95US-0000974P.
 PR 07-AUG-1995; 95US-00512861.
 PR 05-OCT-1995; 95US-00541365.
 XX

PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Belgelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
 PI McWiggen J, Gustofson J, Uman N, Wincott F, Matulic-Adamic J;
 PI Karpelsky A, Thompson JD, Modak A, Burgin A;
 XX WPI: 1996-300653/30.
 DR
 XX
 PT Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.
 XX
 PS Claim 10; Page 167; 307pp; English.
 XX
 CC The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an allograft or for treating autoimmune disease, and for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC streptolysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention
 CC
 XX
 SQ Sequence 15 BP; 3 A; 4 C; 4 G; 0 T; 4 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 502 GGCTCTGGAAACCT 516
 DB 15 GGCTCTGGAAACCT 1
 ID AAT97119 standard; DNA; 15 BP.
 XX
 AC AAT97119;
 XX
 DT 05-MAR-1998 (first entry)
 XX
 DE Murine p27 wild-type fragment.
 XX
 KW Hyperproliferic variant organism; p27; cyclin; inhibitor; hyperplasia;
 KW proliferation; AIDS; antisense; ss.
 XX
 OS Mus musculus.
 XX
 PN WO9726327-A1.
 XX
 PD 24-JUL-1997.
 XX
 PF 17-JAN-1997; 97WO-US000831.
 XX
 PR 18-JAN-1996; 96US-00588595.
 PR 31-MAY-1996; 96US-00656562.
 XX
 PA (HUTC-) HUTCHINSON CANCER RES CENT FRED.
 XX
 PI Robertes JM, Coats SR, Fero ML;
 XX WPI: 1997-385332/35.
 DR

XX Hypertrophic variant organism with inactivated cyclin inhibitor gene -
PT useful as models for therapy of abnormal cell proliferation diseases,
PT e.g. hyperplasia.
XX
PS Example 3; Page 72; 9pp; English.
XX
CC A novel method has been developed for producing a hypertrophic variant
CC organism. The method comprises functionally inactivating expression of a
CC cyclin inhibitor gene in an organism where a hypertrophic variant is
CC produced, the hypertrophy being relative to an organism having the
CC functional cyclin inhibitor gene. Also produced are: (1) a polynucleotide
CC targeting a construct, comprising a sequence that is homologous to a
CC sequence present in a cyclin inhibitor gene and which when integrated at
CC the corresponding cyclin inhibitor gene locus, functionally inactivates
CC cyclin inhibitor protein expression; (2) a hypertrophic non-human
CC organism having a functionally inactivated cyclin inhibitor gene, the
CC hypertrophy being relative to an organism having the functional cyclin
CC inhibitor gene; (3) a method for increasing the proportion of dividing
CC cells in a vertebrate cell population, comprising exposing the cells to a
CC p27 inhibitor in an amount sufficient to increase the proportion of
CC dividing cells to non-dividing cells relative to an untreated cell
CC population; and (4) a p27 inhibitor that comprises an oligonucleotide
CC that specifically binds to DNA encoding p27, or RNA transcribed from
CC this, and inhibits expression of the p27 protein. The present sequence
CC represents a wild-type fragment of murine p27 used in example 3 of the
CC present specification to show how protein expression inhibited by
CC antisense oligonucleotides can be overcome
XX
SQ Sequence 15 BP; 3 A; 4 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 799 GCTGTCTCGCGCCAG 813
Db 15 GCTCTCTCGCGCCAG 1

RESULT 401
AAV41112
ID AAV41112 standard; RNA; 15 BP.
XX
AC AAV41112;
XX
DT 17-OCT-2003 (revised)
DT 01-OCT-1998 (first entry)
XX
DE 3'-noncoding flanking region of RNA polymerase binding site.
XX
KM RNA-directed RNA polymerase; binding site; negative-strand RNA virus;
KM HIV; chimeric virus; humoral immune response induction; AIDS;
KM cell-mediated immune response; ss.
XX
OS Human immunodeficiency virus 1.
XX
PN US5786199-A.
XX
PD 28-JUL-1998.
XX
PE 14-OCT-1994; 94US-00323192.
XX
PR 28-AUG-1989; 89US-00399728.
PR 21-NOV-1989; 89US-00440053.
PR 22-MAY-1990; 90US-00527237.
PR 04-AUG-1992; 92US-00925061.
PR 01-FEB-1994; 94US-00190698.
PR 01-JUN-1994; 94US-00252508.
XX
PA (MOUN) MOUNT SINAI SCHOOL MEDICINE.
XX
PI Palasee P;

XX WPI; 1998-436533/37.
DR
XX Chimeric RNA virus containing HIV sequences - contains multi-epitopic
PT sequences, useful for vaccination against HIV infection.
XX
XX Claim 4; Col 94; 83pp; English.
PS
CC This sequence represents a 3'-noncoding flanking region that can be used
CC in the RNA molecule of the invention. The RNA molecule comprises a
CC binding site specific for an RNA-directed RNA polymerase of a negative-
CC strand RNA virus, operatively linked to a heterologous RNA sequence
CC comprising the reverse complement of an HIV coding sequence. A chimeric
CC virus containing the RNA molecule can be used to induce humoral and cell-
CC mediated immune responses to HIV (human immunodeficiency virus), the
CC causative agent of acquired immunodeficiency syndrome (AIDS) e.g.
CC vaccination against HIV. The RNA molecules are based on sequences which
CC express heterologous gene products of HIV in the attempt that expression
CC of the products will induce an immune response in a vaccinated host.
CC Using a range of different sequences, different epitopes can be produced
CC in immune responses. Previous attempts at similar procedures have not had
CC epitopic variety due to lack of availability of negative-strand RNA
CC molecules that are also infectious. (Updated on 17-OCT-2003 to
CC standardise OS field)
XX
SQ Sequence 15 BP; 1 A; 7 C; 2 G; 0 T; 5 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 999 CACCCGCTCTGCT 1013
Db 1 CACCCGCTCTGCT 15

RESULT 402
AAZ63879
ID AAZ63879 standard; RNA; 15 BP.
XX
AC AAZ63879;
XX
DT 28-MAR-2000 (first entry)
XX
DE Substrate for hammerhead ribozyme which cleaves HCV RNA at nt. 2510.
XX
KM Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
KM cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
KM autoimmune disease; ss.
XX
OS Hepatitis C virus.
XX
PN W09955847-A2.
XX
PD 04-NOV-1999.
XX
PE 26-APR-1999; 99WO-US009027.
XX
PR 27-APR-1998; 98US-0083217P.
PR 18-SEP-1998; 98US-0100842P.
PR 25-FEB-1999; 99US-00257608.
PR 23-MAR-1999; 99US-00274553.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Mcswiggen JA, Roberts E, Pavco PA, Macejak D;
XX WPI; 2000-062023/05.
DR
XX Novel ribozymes for the treatment of diseases and conditions related to
PT hepatitis C infection.
XX
PS Claim 1; Page 73; 123pp; English.

XX The present sequence represents the preferred target sequence of an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the Hepatitis C virus (HCV) RNA sequence at the base position given in
CC the descriptor line. The HCV sequence was screened for optimal ribozyme
CC target sites using a computer folding algorithm and regions of the mRNA
CC which did not form secondary folding structures and contained potential
CC ribozyme cleavage sites were identified. Ribozymes were synthesised to
CC target these sites and their activities optimised by either varying the
CC length of the binding arms or by modification to prevent degradation by
CC nucleases. The ribozymes of the invention inhibit gene expression and/or
CC viral replication, and are used to treat diseases associated with
CC Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and
CC hepatocellular carcinoma. The ribozymes may be used in combination with
CC interferon to treat HCV infection, other infectious diseases, autoimmune
CC diseases, and cancer

SQ Sequence 15 BP; 0 A; 6 C; 1 G; 0 T; 8 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 40.0%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
Matches 6; Conservative 8; Indels 1;

OY 1010 TCGTTTCCTTCGTC 1024
:||||:|:|:|:
1 UGCUUUUCCUUCUCC 15

Db

RESULT 403
AAZ56243
ID AAZ56243 standard; RNA; 15 BP.
XX
AC AAZ56243;
XX
DT 15-MAR-2000 (first entry)
XX
DE V-d5' point mutation 3' promoter sequence V-CS SEQ ID NO:12.
XX
KM Recombinant negative strand viral RNA template; virus particle;
KM RNA directed RNA polymerase complex; expression; chimeric virus; vaccine;
KM packaging; ss.
XX
OS Influenza virus.
OS Synthetic.
XX
PN US6001634-A.
XX
PD 14-DEC-1999.
XX
PF 29-JUN-1998; 98US-00106377.
XX
PR 28-AUG-1989; 89US-0039728.
PR 21-NOV-1989; 89US-00440053.
PR 22-MAY-1990; 90US-00527237.
PR 04-AUG-1992; 92US-00925061.
PR 01-FEB-1994; 94US-00190698.
PR 01-JUN-1994; 94US-00252508.
XX
PA (PALE/) PALESE P.
PA (GARC/) GARCIA-SASTRE A.
XX
PI Palese P, Garcia-Sastre A;
XX
DR WPI; 2000-071660/06.
XX
PT Chimeric virus containing influenza virus RNA segments, useful for
PT expressing heterologous gene products in appropriate host cell systems.
XX
PS Example; Col 61; 67bp; English.
XX
CC The present invention describes a chimeric virus comprising influenza
CC virus containing a heterologous RNA segment from another strain of
CC influenza virus or 8 genomic segments from different strains of influenza

CC virus, with each segment comprising the reverse complement of a mRNA
CC coding sequence operatively linked to a binding site specific for an RNA-
CC directed RNA polymerase of a negative strand RNA virus. The recombinant
CC negative strand virus RNA templates may be used to express heterologous
CC gene products in appropriate host cell systems and/or to construct
CC recombinant viruses that express, package and/or present the heterologous
CC gene product. The expression products and chimeric viruses may be used in
CC vaccine formulations. AAY57746 to AAY57748, and AAZ56234 to AAZ56290,
CC represent sequences used in the exemplification of the present invention

SQ Sequence 15 BP; 1 A; 7 C; 2 G; 0 T; 5 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
Matches 10; Conservative 4; Indels 1;

OY 999 CACCCGCTTCCTGCT 1013
:||||:|:|:|:
1 CACCCUCUUCUUCU 15

Db

RESULT 404
AAA52432/C
ID AAA52432 standard; DNA; 15 BP.
XX
AC AAA52432;
XX
DT 18-SEP-2000 (first entry)
XX
DE TdR-expressing Ramos cell VH insertion+deletion mutation, F242.
XX
KM Lymphoid cell; antibody producing cell; Ramos cell; immunoglobulin M;
KM IGM; V gene diversity; directed constitutive hypermutation;
KM target sequence diversification; terminal deoxynucleotidyl transferase;
KM TdR; Clonal expansion; selection; heavy chain variable region; VH;
KM mutant; ds.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN W0200022111-A1.
XX
PD 20-APR-2000.
XX
PF 08-OCT-1999; 99WO-GB003358.
XX
PR 09-OCT-1998; 98GB-00022104.
PR 19-JAN-1999; 99GB-00001141.
PR 09-JUN-1999; 99GB-00013435.
XX
PA (MEDI-) MEDICAL RES COUNCIL.
XX
PI Sale JE, Neuberger MS, Cumbers SJ;
XX
DR WPI; 2000-317971/27.
XX
PT Lymphoid cell line preparation useful for producing gene products having
PT desired activity, involves screening and selecting cells having ongoing
PT target sequence diversification and higher mutation rates.
XX
PS Example 4; Fig 6; 69bp; English.
XX
CC The invention relates to a method of preparing a lymphoid cell line
CC capable of capable of directed constitutive hypermutation of a target
CC nucleic acid region. The method comprises screening a cell population for
CC ongoing target sequence diversification and selecting a cell in which the
CC rate of target nucleic acid mutation exceeds that of other nucleic acid
CC mutation by a factor of 100 or more. The invention also relates to a
CC method for preparing a gene product with a desired activity, comprising
CC expressing a nucleic acid encoding the target gene operably linked to a
CC sequence which directs hypermutation e.g., terminal deoxynucleotidyl
CC transferase (TdR), in the lymphoid cell line, and identifying a cell or
CC cells which express a mutated gene product with the desired activity. One

CC or more clonal populations of the identified cells is established, and
 CC cells with an improved activity of interest are selected. These steps may
 CC be iteratively repeated until a gene product with a desired of activity
 CC is obtained. The cell lines prepared according to the method of the
 CC invention are used for directed constitutive hypermutation of a nucleic
 CC acid region in the preparation of a gene product, preferably an enzyme or
 CC an immunoglobulin (Ig) with a desired activity. In the exemplifications
 CC of the invention, IgM-secreting Ramos cells were selected for use as they
 CC undergo hypermutation during clonal expansion. This was determined on the
 CC basis of the amount of diversity in the heavy chain variable region (VH).
 CC Sequences AA52366-A52434 represent fragments of Ramos cell VH region DNA
 CC containing mutations other than single nucleotide substitutions. The
 CC number assigned to the mutation represents the position in the wild-type
 CC VH DNA (AA52364) to which the first nucleotide in the mutant fragment
 CC corresponds. Sequences AA52368-A52434 represent mutations that occur in
 CC Ramos cells which express Tdt, and sequences AA52366-A52487 represent
 CC mutations that occur in non-Tdt- expressing control Ramos cells
 CC
 SQ Sequence 15 BP; 3 A; 4 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 18 TCCCGCTCCCGCGG 32
 |||
 DB 15 TCTGCTCCCGCGG 1

RESULT 405
 ID AA95130 standard; DNA; 15 BP.
 AC AA95130;
 XX
 DT 12-JAN-2001 (first entry)
 XX
 DE Allele specific primer #1 for detection of TNFR1 gene polymorphism.
 XX
 KW TNFR1; tumour necrosis factor receptor; polymorphism; human; tumour;
 KW cancer; apoptosis; bacterial infection; primer;
 KW allele specific oligonucleotide; ASO; ss.
 XX
 OS Homo sapiens.
 XX
 PN W0200050436-A1.
 PD 31-AUG-2000.
 XX
 PF 23-FEB-2000; 2000WO-US004606.
 XX
 PR 23-FEB-1999; 99US-0121314P.
 XX
 PA (GENA-) GENASSANCE PHARM INC.
 PA (SCHU/) NANDABALAN K.
 PA (STEP/) SCHULZ V P.
 PA (CHEW/) STEPHENS J C.
 XX
 PI Nandabalan K, Schulz VP, Stephens JC, Chew A;
 XX
 DR WPI; 2000-543909/49.
 XX
 PT Polynucleotides comprising polymorphic variants of a reference sequence
 PT for tumor necrosis factor receptor 1 (TNFR1), useful for studying the
 PT biological function of TNFR1 and identifying drugs targeting the protein
 PT for treating disorders.
 XX
 PS Claim 14; Page 20; 79pp; English.
 XX
 CC The present invention relates to polymorphic variants of the tumour
 CC necrosis factor receptor 1 (TNFR1) gene. The sequence of the gene is
 CC given in AA95102, AA95103 and AA95104. The polymorphisms were

CC identified by amplifying and sequencing regions of the gene. Twelve
 CC polymorphic loci were discovered. Of these twelve polymorphisms, four can
 CC cause a change in the TNFR1 protein. The present sequence is an allele
 CC specific oligonucleotide (ASO) primer that may be used to detect a TNFR1
 CC gene polymorphism. The TNFR1 polymorphisms may be useful for studying the
 CC biological function of TNFR1 as well as for identifying drugs targeting
 CC the protein for treatment of disorders related to its abnormal expression
 CC or function such as tumours, apoptosis related disorders and bacterial
 CC infection
 CC
 SQ Sequence 15 BP; 5 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 832 CAGAACGACAGAGT 846
 |||
 DB 1 CAGATCCAGACAGGT 15

RESULT 406
 ID AAF48041/C
 AC AAF48041 standard; DNA; 15 BP.
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGFBP3 oligonucleotide #1461.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antiposietic;
 KW cystostatic; dermatological; cardiac; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN W0200078341-A1.
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 PA Wraight CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 7; Page 53; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation, and
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,

CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

XX Sequence 15 BP; 3 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

Qy Query Match 0.6%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db 1408 AAGGCTGTGGCTCC 1422

15 AAGGCTGTGAGCTCC 1

RESULT 407
 AAF48044/c
 ID AAF48044 standard; DNA; 15 BP.

XX AAF48044;

XX 30-MAR-2001 (first entry)

XX IGFBP3 oligonucleotide #1464.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 XX growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
 XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 XX hyperneovascular condition; hyperplasia; kidney disease;
 XX neovascular condition of the retina; ss.

XX Homo sapiens.

XX WO200078341-A1.

XX 28-DEC-2000.

XX 21-JUN-2000; 2000MO-AU000693.

XX 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wright CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 XX inhibits or reduces growth factor mediated cell proliferation and/or
 XX inflammation.

XX Example 7; Page 53; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
 XX skin disorders. The method comprises contacting the skin with an
 XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 XX inhibiting or reducing growth factor mediated cell proliferation,
 XX inflammation and/or other disorders. The present sequence is an
 XX oligonucleotide which can be used to design the antisense
 XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
 XX P4516). The method is useful for ameliorating the effects of psoriasis,
 XX ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
 XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 XX hyperneovascular condition such as a neovascular condition of the retina,
 XX brain or skin, growth factor-mediated malignancies, other sclerotic
 XX disease, kidney disease, hyperproliferation of the inside of blood

CC vessels or any other hyperplasia

XX Sequence 15 BP; 2 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

Qy Query Match 0.6%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db 1405 CAGAGGCTGTGGC 1419

15 CAGAGGCTGTGAGC 1

RESULT 408
 AAF48436
 ID AAF48436 standard; DNA; 15 BP.

XX AAF48436;

XX 30-MAR-2001 (first entry)

XX IGFBP3 oligonucleotide #1856.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 XX growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
 XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 XX hyperneovascular condition; hyperplasia; kidney disease;
 XX neovascular condition of the retina; ss.

XX Homo sapiens.

XX WO200078341-A1.

XX 28-DEC-2000.

XX 21-JUN-2000; 2000MO-AU000693.

XX 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wright CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 XX inhibits or reduces growth factor mediated cell proliferation and/or
 XX inflammation.

XX Example 7; Page 56; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
 XX skin disorders. The method comprises contacting the skin with an
 XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 XX inhibiting or reducing growth factor mediated cell proliferation,
 XX inflammation and/or other disorders. The present sequence is an
 XX oligonucleotide which can be used to design the antisense
 XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
 XX P4516). The method is useful for ameliorating the effects of psoriasis,
 XX ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
 XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 XX hyperneovascular condition such as a neovascular condition of the retina,
 XX brain or skin, growth factor-mediated malignancies, other sclerotic
 XX disease, kidney disease, hyperproliferation of the inside of blood
 XX vessels or any other hyperplasia

XX Sequence 15 BP; 3 A; 2 C; 4 G; 6 T; 0 U; 0 Other;

```

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy          910 AGCTATTCTGTGG 924
Db          1 AGCTATTCTGTAG 15

RESULT 409
AAF48045/c
ID AAF48045 standard; DNA; 15 BP.
XX
AC AAF48045;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP3 oligonucleotide #1465.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytosolic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN MO200078341-A1.
XX
PD 28-DEC-2000.
XX
PE 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 7; Page 53; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 2 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Oy          1404 ACAGAGGCTGTGG 1418
Db          15 ACAGAGGCTGTGAG 1

RESULT 410
AAF48043/c
ID AAF48043 standard; DNA; 15 BP.
XX
AC AAF48043;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP3 oligonucleotide #1463.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytosolic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN MO200078341-A1.
XX
PD 28-DEC-2000.
XX
PE 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 7; Page 53; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 3 A; 6 C; 2 G; 4 T; 0 U; 0 Other;

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy          1406 AGAAGGCTGTGGCT 1420
Db          15 AGAAGGCTGTGAGCT 1

```

RESULT 411
 AAF50836
 ID AAF50836 standard; DNA, 15 BP.
 XX
 AC AAF50836;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGF-1 oligonucleotide #1796.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 KM
 XX Homo sapiens.
 OS
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wright CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 PT
 PS Example 8; Page 72; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 CC
 XX
 SQ Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;
 XX
 QY Query Match 0.6%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 2e+02; Indels 0; Gaps 0;
 Matches 14; Conservative 0; Mismatches 1;
 DB 974 TGTCCTCACCATGG 988
 1 TGACCTCACCATGG 15
 RESULT 412
 AAF48568/c
 ID AAF48568 standard; DNA, 15 BP.

XX
 AC AAF48568;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGFBP3 oligonucleotide #1988.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 KM
 XX Homo sapiens.
 OS
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wright CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 PT
 PS Example 7; Page 57; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 CC
 XX
 SQ Sequence 15 BP; 4 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
 XX
 QY Query Match 0.6%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 2e+02; Indels 0; Gaps 0;
 Matches 14; Conservative 0; Mismatches 1;
 DB 2009 CCAAGTCCCTGGATG 2023
 15 CCAAGTCCCTGGATG 1
 RESULT 413
 AAF45301
 ID AAF45301 standard; DNA, 15 BP.
 XX
 AC AAF45301;
 XX
 DT 30-MAR-2001 (first entry)

```

XX XX IGFBP2 oligonucleotide #140.
DE XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KM skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM hyperneovascular condition; hyperplasia; kidney disease;
KM neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX WO200078341-A1.
XX
XX 26-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
PI
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 6; Page 35; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
CC
XX
SQ Sequence 15 BP; 0 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

```

```

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 149 CCGGCTGCGCACTGC 163
Db 1 CCGGCTGCGGCTGC 15

```

```

RESULT 414
AAF48042/c
ID AAF48042 standard; DNA; 15 BP.
XX
XX AAF48042;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGFBP3 oligonucleotide #1462.
DE
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM

```

```

KM Cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KM skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM hyperneovascular condition; hyperplasia; kidney disease;
KM neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX WO200078341-A1.
XX
XX 26-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
PI
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 7; Page 53; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
CC
XX
SQ Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

```

```

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 1407 GAAGCTGCGGCTC 1421
Db 15 GAAGCTGCGGCTC 1

```

```

RESULT 415
AAF49257/c
ID AAF49257 standard; DNA; 15 BP.
XX
XX AAF49257;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGF-1 oligonucleotide #217.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KM skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KM

```

KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
OS Homo sapiens.
XX
XX WO200078341-A1.
XX
XX 28-DEC-2000.
PD
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX WPI: 2001-041421/05.
DR
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisease nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
PS
XX Example 8; Page 62; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisease oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisease
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
CC neoplasmias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia

XX
SQ Sequence 15 BP; 3 A; 7 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2e+02; Indels 0;
Matches 14; Conservative 0; Mismatches 1; Gaps 0.

QY 1366 CAGGCTGTGAGGTA 1380
 |||||
DB 15 CAGGATGTGAGGTA 1

RESULT 416
AAF50837
ID AAF50837 standard; DNA; 15 BP.
XX
AC AAF50837;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #1797.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM cyostatic; dermatological; cardant; virucide; ophthalmological; keloid;
KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KM growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM hyperneovascular condition; hyperplasia; kidney disease;
KM neovascular condition of the retina; ss.

OS Homo sapiens.
 XX WO200078341-A1.
 EN
 XX 28-DEC-2000.
 PP
 XX 21-JUN-2000; 2000WO-AU000693.
 PE
 XX 21-JUN-1999; 99US-0140345P.
 PR
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 PA
 XX Wraight CJ, Werther GA, Edmondson SR;
 PI
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 PT
 XX
 PS Example 8; Page 72; 201pp; English.
 CC
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F4161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrheoa, keloids, keratosis,
 CC neviplasia, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 CC
 SQ Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0
 QY 975 GTCCCTCACCATTGGT 989
 DB 1 GACCCCTCACATGGT 15
 RESULT 417
 AAF50835
 ID AAF50835 standard; DNA; 15 BP.
 AC
 XX AAF50835;
 AC
 DT 30-MAR-2001 (first entry)
 XX
 DE IGF-I oligonucleotide #1795.
 XX
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 XX cytoskeletal; dermatological; cardiac; virucide; ophthalmological; keloid;
 XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 XX growth factor mediated cell proliferation; ichthyosis; seborrheoa; ruba;
 XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 XX hyperneovascular condition; hyperplasia; kidney disease;
 XX neovascular condition of the retina; ss.
 OS Homo sapiens.
 XX
 XX WO200078341-A1.
 EN
 XX 28-DEC-2000.
 PP
 XX 21-JUN-2000; 2000WO-AU000693.
 PE
 XX 21-JUN-1999; 99US-0140345P.
 PR
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 PA
 XX Wraight CJ, Werther GA, Edmondson SR;
 PI
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 PT
 XX
 PS Example 8; Page 72; 201pp; English.
 CC
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F4161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, seborrheoa, keloids, keratosis,
 CC neviplasia, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 CC
 SQ Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0
 QY 975 GTCCCTCACCATTGGT 989
 DB 1 GACCCCTCACATGGT 15

PD 28-DEC-2000.
 XX
 XX 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wraight CJ, Werther GA, Edmondson SR;
 XX WPI; 2001-041421/05.
 DR
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 8; Page 72; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F5161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, rubra, pilaris, seborrheoa, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;
 QY
 Query Match 0.6%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Db 973 GTGTCCTCCACCATG 987
 1 GTGACCTCACCATG 15
 RESULT 418
 AAF70395
 ID AAF70395 standard; DNA; 15 BP.
 XX
 AC AAF70395;
 XX
 DT 20-APR-2001 (first entry)
 XX
 DE Human DRD2 allele specific oligonucleotide primer SEQ ID NO:138.
 XX
 KW Human; dopamine receptor D2; DRD2; polymorphism; allele specific;
 KW drug target isogene; detection; single nucleotide polymorphism; SNP;
 KW genotype; schizophrenia; Parkinson's disease; myoclonus dystonia; MD;
 KW probe; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200105832-A1.
 XX
 PD 25-JAN-2001.
 XX
 PF 19-JUL-2000; 2000WO-US019644.
 XX
 PR 19-JUL-1999; 99US-014493P.
 XX
 PA (GENA-) GENAISANCE PHARM INC.
 XX

PI Chew A, Denton RR, Duda A, Nandabalan K, Stephens JC;
 XX WPI; 2001-091967/10.
 DR
 XX
 PT Polynucleotides comprising single nucleotide polymorphisms in the human
 PT dopamine receptor D2, useful for detecting mutations associated with,
 PT e.g. schizophrenia, Parkinson's and myoclonus dystonia.
 XX
 PS Claim 15; Page 24; 135pp; English.
 XX
 CC The present invention describes polynucleotides comprising single
 CC nucleotide polymorphisms (SNPs) in the human dopamine receptor D2 (DRD2).
 CC The polynucleotides may be used in assays to detect and characterise
 CC polymorphisms in DRD2 that affect its expression and activity and are
 CC involved in disorders such as schizophrenia, Parkinson's and myoclonus
 CC dystonia (MD). This information would be useful for studying the
 CC biological function of DRD2 as well as in identifying drugs targeting
 CC this protein for the treatment of disorders related to its abnormal
 CC expression or function. Polymorphisms in the DRD2 gene affect the
 CC expression of active and functional polypeptides. Therefore it is
 CC advantageous to detect polymorphisms in the DRD2 gene and how those
 CC polymorphisms are combined in different copies of the gene. AAF70261 to
 CC AAF70308 represent human DRD2 allele specific oligonucleotide probes, and
 CC AAF70309 to AAF70404 represent human DRD2 allele specific oligonucleotide
 CC primers which are used in the detection of DRD2 polymorphisms. AAF70405
 CC to AAF70452 represent oligonucleotide primers for the detection of human
 CC DRD2 polymorphisms which are given in the exemplification of the present
 CC invention. AAF70453 to AAF70538 represent PCR primers for the human DRD2
 CC gene which are used in examples from the present invention
 XX
 SQ Sequence 15 BP; 3 A; 8 C; 4 G; 0 T; 0 U; 0 Other;
 QY
 Query Match 0.6%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Db 1662 GTACCAAGCCACCGG 1676
 1 GCACCAAGCCACCGG 15
 RESULT 419
 ABR96650/C
 ID ABR96650 standard; DNA; 15 BP.
 XX
 AC ABR96650;
 XX
 DT 24-SEP-2002 (first entry)
 XX
 DE Interleukin-3 (IL-3) allele specific oligonucleotide primer #1.
 XX
 KW Interleukin 3; colony-stimulating factor; IL3; transgenic animal;
 KW IL3 isogene; central nervous system disorder; multiple sclerosis;
 KW Alzheimer's disease; Parkinson's disease; CNS injury; immune disorder;
 KW inflammatory disorder; allele specific oligonucleotide; ASO; PCR; primer;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200244410-A1.
 XX
 PD 06-JUN-2002.
 XX
 PF 28-NOV-2000; 2000WO-US032381.
 XX
 PR 28-NOV-2000; 2000WO-US032381.
 XX
 PA (GENA-) GENAISANCE PHARM INC.
 XX
 PI Chew A, Denton RR, Nandabalan K, Stephens JC;
 XX WPI; 2002-519590/55.
 DR
 XX

PT Novel isolated polynucleotide comprising a sequence which is a
PT polymorphic variant for a reference sequence for interleukin 3 gene
PT useful for studying the expression and biological function of the
PT protein.
PS Claim 11, Page 16, 62pp; English.
XX
CC The invention describes an isolated polynucleotide (1) comprising a
CC sequence which is a polymorphic variant for a reference sequence for
CC interleukin 3 (colony-stimulating factor) (IL3) gene or its fragment. (1)
CC is useful for studying the expression and biological function of IL3, as
CC well as in developing drugs targeting the IL3 protein. A transgenic
CC animal is useful for studying expression of IL3 isogenes in vivo, for in
CC vivo screening and testing of drugs targeted against IL3 protein, and for
CC testing the efficacy of therapeutic agents and compounds for diseases of
CC the central nervous system e.g. multiple sclerosis, Alzheimer's disease,
CC Parkinson's disease and CNS injury, and immune or inflammatory disorders.
CC The method described in the invention is useful in developing diagnostic
CC tests and therapeutic treatments for diseases of the central nervous
CC system and immune or inflammatory disorders. This sequence represents an
CC allele specific oligonucleotide primer for detecting polymorphisms in the
CC IL-3 gene
XX
SQ Sequence 15 BP; 2 A; 5 C; 5 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 339 CCGAGAGCTGATCTC 353
Db 15 CCGAGAGCTGATCTC 1
XX
RESULT 420
ABA91622
ID ABA91622 standard; DNA; 15 BP.
XX
AC ABA91622;
XX
DT 23-APR-2002 (first entry)
XX
DE Primer used in isometric primer extension reaction.
XX
KM Isometric primer extension; nucleic acid detection; rat; primer; ss.
XX
OS Ratus SP.
XX
PN EP1162278-A2.
XX
PD 12-DEC-2001.
XX
PF 06-JUN-2001; 2001EP-00304958.
XX
PR 08-JUN-2000; 2000US-020987P.
PR 23-MAY-2001; 2001US-00862417.
XX
PA (WANG/) WANG X B.
PA (MORI/) MORISAWA S.
PI Wang XB;
XX
DR WPI; 2002-149491/20.
XX
PT Detecting or quantifying a specific nucleic acid in a sample by
XX hybridizing primers to the target nucleic acid, extending the primers and
XX detecting extended primer by label detection or mass spectrometry.
XX
PS Example 1; Page 6; 10pp; English.
XX
CC The present sequence is that of a primer that corresponds to a rat brain
CC specific cDNA. It was used in an example to demonstrate an isometric
CC primer extension method of the invention. The method involves carrying

CC out a primer extension reaction in the absence of a free nucleotide so
CC that the primer extension reaction is stopped where the absent nucleotide
CC would have been inserted. As the amount of incorporation of a labelled
CC nucleotide on the primer extended product is detected, the amount of
CC target RNA or DNA in the sample is measured. The method provides a
CC faster, cheaper, more sensitive assay which produces less biohazard or
CC radioisotope waste than northern analysis and RNase protection assays
XX
SQ Sequence 15 BP; 3 A; 3 C; 6 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1322 GTGGAAACCTTGCA 1336
Db 1 GTGGAAACCTTGCA 15
XX
RESULT 421
ABX00932
ID ABX00932 standard; RNA; 15 BP.
XX
AC ABX00932;
XX
DT 23-DEC-2002 (first entry)
XX
DE Hepatitis C virus substrate #714 for HCV hammerhead ribozyme #714.
XX
KM Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
KM HCV ribozyme; HCV expression; HCV replication; cirrhosis; virologic;
KM liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
KM type I interferon; interferon alpha; interferon beta; cytostatic;
KM interferon gamma; consensus interferon; hepatocytic; antiinflammatory;
KM substrate; hammerhead ribozyme; HH ribozyme; ss.
XX
OS Hepatitis C virus.
XX
PN US2002082225-A1.
XX
PD 27-JUN-2002.
XX
PF 23-MAR-1999; 99US-00274553.
XX
PR 23-MAR-1999; 99US-00274553.
XX
PA (BLATT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (ROBE/) ROBERTS B.
PA (PAVCO/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswiggen JA, Roberts B, Pavco PA, Macejack D;
XX
DR WPI; 2002-617759/66.
XX
PT New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
PT replication and are useful to treat hepatitis C virus infections and
PT cirrhosis, liver failure or hepatocellular carcinoma.
XX
PS Claim 1; Page 42; 80pp; English.
XX
CC The present invention relates to enzymatic nucleic acids which
CC specifically cleave RNA derived from Hepatitis C virus (HCV). The
CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
CC (HP) motif where the binding arms comprise sequences complementary to one
CC of the substrate sequences defined in the specification. The HCV
CC ribozymes are useful for modulating the expression and/or replication of
CC HCV. They can be used to treat cirrhosis, liver failure and/or
CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating
CC a condition associated with HCV infection in conjunction with one or more
CC other drug therapies, particularly type I interferon, especially
CC interferon alpha, beta or gamma or consensus interferon. The present

CC sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:
 CC Some of the sequence data for this patent did not form part of the
 CC printed specification. The complete sequence data for this patent was
 CC obtained in electronic format directly from the USPTO web site at
 CC seqdata.uspto.gov/patseq/IDEntry.html
 XX
 SQ Sequence 15 BP; 0 A; 6 C; 1 G; 0 T; 8 U; 0 Other;
 QY Query Match 0.6%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 40.0%; Pred. No. 2e+02;
 Matches 6; Conservative 8; Mismatches 1; Indels 0; Gaps 0;
 Db 1010 TGCTTTTCCTTCG 1024
 :||::||::|
 1 UGCUUUUCUUCUCC 15
 RESULT 422
 AAD15073/C
 ID AAD15073 standard; DNA; 16 BP.
 XX
 AC AAD15073;
 XX
 DT 01-NOV-2001 (first entry)
 DE 5' PCR primer with parsing bases CTGA.
 XX
 XX Fatty lesion development; atherosclerosis; Alzheimer's disease;
 KM nervous system disorder; Parkinson's disease; immune system disorder;
 KM ischaemia; lymphopaenia; leukocyte adhesion deficiency syndrome;
 KM haemoglobinuria; anaemia; hyperproliferative disorder; Gaucher's disease;
 KM coagulation disorder; blood platelet disorder; autoimmune disorder;
 KM dermatitis; herpes simplex; Addison's disease; rheumatoid arthritis;
 KM Grave's disease; gene therapy; arteriosclerotic; immunostimulant;
 KM cardiovascular; antiviral; PCR primer; ss.
 XX
 OS Unidentified.
 XX
 PN WO200154651-A2.
 XX
 PD 02-AUG-2001.
 XX
 PF 25-JAN-2001; 2001WO-US002439.
 XX
 PR 25-JAN-2000; 2000US-0177963P.
 XX
 PA (DIGI-) DIGITAL GENE TECHNOLOGIES INC.
 XX
 PI Leonardi A, Sartani A, Glaes JR, Sutcliffe JG, Hasel KM;
 DR WPI; 2001-514526/56.
 XX
 XX New polynucleotides regulated by fatty lesion development and their
 PT encoded polypeptides, useful for preventing, treating or ameliorating
 PT atherosclerosis, as well as for immune or hyperproliferative disorders.
 XX
 XX Disclosure; Page 162; 18bp; English.
 PS
 XX The present invention relates to an isolated nucleic acid regulated by
 CC fatty lesion development, which comprises any of 55 polynucleotide
 CC sequences from *Oryzotilus cuniculus*. The polynucleotide, polypeptide or
 CC antibody is useful for preventing, treating, modulating or ameliorating a
 CC medical condition, particularly atherosclerosis. The invention is used as
 CC a marker or detector of nervous system disorder or disease (e.g.
 CC Parkinson's disease, Alzheimer's disease, ischaemia, dementia). The
 CC invention may also be useful for treating deficiencies or disorders of
 CC the immune system (e.g. lymphopaenia, leukocyte adhesion deficiency
 CC syndrome or haemoglobinuria, anaemia), hyperproliferative disorders
 CC (e.g. Gaucher's disease), infectious disease (e.g. herpes simplex),
 CC coagulation disorders, blood platelet disorders and autoimmune disorders
 CC (Addison's disease, rheumatoid arthritis, dermatitis, Grave's disease).
 CC The polynucleotide sequence is also used in gene therapy. The present
 CC sequence is a 5' PCR primer with parsing bases CTGA. This primer is used

CC in the invention
 XX
 SQ Sequence 16 BP; 3 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
 QY Query Match 0.6%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 93.3%; Pred. No. 2.2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Db 658 TCAGCCGATACCTTC 672
 |||||
 16 TCAGCCGATACCTTC 2
 RESULT 423
 ABA89678/C
 ID ABA89678 standard; DNA; 16 BP.
 XX
 AC ABA89678;
 XX
 DT 12-FEB-2002 (first entry)
 DE Serial analysis of ribosomal DNA tag #37.
 XX
 XX Serial analysis of ribosomal DNA; SARD; genetic diversity;
 KM geochemical exploration; agriculture; bioremediation; forensic science;
 KM environmental analysis; parasite detection; virus detection; ss.
 XX
 OS Unidentified.
 XX
 PN WO200177392-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 10-APR-2001; 2001WO-US011609.
 XX
 PR 10-APR-2000; 2000US-0196063P.
 PR 11-APR-2000; 2000US-0196258P.
 XX
 PA (ASHB/) ASHBY M.
 XX
 PI Ashby M;
 DR WPI; 2002-010926/01.
 XX
 XX Determining genetic diversity of population by analyzing a specific
 PT polymorphic region characteristic of particular genome in population of
 PT interest, useful for locating mineral deposits or petroleum reserves.
 XX
 XX Example 3; Fig 15; 83bp; English.
 PS
 XX The present invention relates to a method of determining the genetic
 CC diversity of a population, involving amplifying a genome subregion with a
 CC polymorphic site, cleaving amplified fragment close to the polymorphic
 CC site, immobilising the amplified fragment, splitting into two pools,
 CC adding a linker to each pool, digesting the immobilised product to form
 CC tags that are ligated to form concatemers and sequencing. The method is known as
 CC serial analysis of ribosomal DNA (SARD). This can be used to determine the
 CC genetic diversity of a population including microbial, viral or immune
 CC cell populations. The microbial population whose genetic diversity can be
 CC determined is from a sample associated with a site for petroleum or
 CC natural gas exploration, i.e., at a site of oil or gas reserves,
 CC associated with a site of mineral exploration, associated with a
 CC agricultural field, of patient sample suspected to have bacterial or
 CC fungal infection, associated with bioremediation site, or of an insect or
 CC parasite. The methods have application in fields of geochemical
 CC exploration, agriculture, bioremediation, environmental analysis,
 CC clinical microbiology, forensic science and medicine. The present
 CC sequence is an oligonucleotide described in the exemplification of the
 CC invention
 XX
 SQ Sequence 16 BP; 1 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 93.3%; Pred. No. 2.2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTGCGGCACTGGG 311
 |||||
 DB 16 AGCTGCGGCACTGGG 2

RESULT 424
 ABA89770/c
 ID ABA89770 standard; DNA; 16 BP.
 XX
 AC ABA89770;
 XX
 DT 12-FEB-2002 (first entry)
 DE Serial analysis of ribosomal DNA tag #129.
 XX
 KM Serial analysis of ribosomal DNA; SARD; genetic diversity;
 KM geochemical exploration; agriculture; bioremediation; forensic science;
 KM environmental analysis; parasite detection; virus detection; ss.
 XX
 OS Unidentified.
 XX
 PN WO200177392-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 10-APR-2001; 2001WO-US011609.
 XX
 PR 10-APR-2000; 2000US-0196063P.
 PR 11-APR-2000; 2000US-0196258P.
 XX
 PA (ASHB/) ASHBY M.
 XX
 PI Ashby M;
 XX
 DR WPI; 2002-010926/01.
 XX
 PT Determining genetic diversity of population by analyzing a specific
 PT polymorphic region characteristic of particular genome in population of
 PT interest, useful for locating mineral deposits or petroleum reserves.
 XX
 PS Example 3; Fig 16; 83bp; English.
 XX
 CC The present invention relates to a method of determining the genetic
 CC diversity of a population, involving amplifying a genome subregion with a
 CC polymorphic site, cleaving amplified fragment close to the polymorphic
 CC site, immobilising the amplified fragment, splitting into two pools,
 CC adding a linker to each pool, digesting the immobilised product to form
 CC tags that are ligated to form ditags, and amplifying, cleaving and
 CC ligating to form concatemers and sequencing. The method is known as
 CC serial analysis of ribosomal DNA (SARD). This can be used to determine the
 CC genetic diversity of a population including microbial, viral or immune
 CC cell populations. The microbial population whose genetic diversity can be
 CC determined is from a sample associated with a site for petroleum or
 CC natural gas exploration, i.e., at a site of oil or gas reserves,
 CC associated with a site of mineral exploration, associated with a
 CC agricultural field, of patient sample suspected to have bacterial or
 CC fungal infection, associated with bioremediation site, or of an insect or
 CC parasite. The methods have application in fields of geochemical
 CC exploration, agriculture, bioremediation, environmental analysis,
 CC clinical microbiology, forensic science and medicine. The present
 CC sequence is an oligonucleotide described in the exemplification of the
 CC invention
 XX
 SQ Sequence 16 BP; 1 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 93.3%; Pred. No. 2.2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTGCGGCACTGGG 311
 |||||
 DB 16 AGCTGCGGCACTGGG 2

RESULT 425
 ABA89672/c
 ID ABA89672 standard; DNA; 16 BP.
 XX
 AC ABA89672;
 XX
 DT 12-FEB-2002 (first entry)
 DE Serial analysis of ribosomal DNA tag #31.
 XX
 KM Serial analysis of ribosomal DNA; SARD; genetic diversity;
 KM geochemical exploration; agriculture; bioremediation; forensic science;
 KM environmental analysis; parasite detection; virus detection; ss.
 XX
 OS Unidentified.
 XX
 PN WO200177392-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 10-APR-2001; 2001WO-US011609.
 XX
 PR 10-APR-2000; 2000US-0196063P.
 PR 11-APR-2000; 2000US-0196258P.
 XX
 PA (ASHB/) ASHBY M.
 XX
 PI Ashby M;
 XX
 DR WPI; 2002-010926/01.
 XX
 PT Determining genetic diversity of population by analyzing a specific
 PT polymorphic region characteristic of particular genome in population of
 PT interest, useful for locating mineral deposits or petroleum reserves.
 XX
 PS Example 3; Fig 15; 83bp; English.
 XX
 CC The present invention relates to a method of determining the genetic
 CC diversity of a population, involving amplifying a genome subregion with a
 CC polymorphic site, cleaving amplified fragment close to the polymorphic
 CC site, immobilising the amplified fragment, splitting into two pools,
 CC adding a linker to each pool, digesting the immobilised product to form
 CC tags that are ligated to form ditags, and amplifying, cleaving and
 CC ligating to form concatemers and sequencing. The method is known as
 CC serial analysis of ribosomal DNA (SARD). This can be used to determine the
 CC genetic diversity of a population including microbial, viral or immune
 CC cell populations. The microbial population whose genetic diversity can be
 CC determined is from a sample associated with a site for petroleum or
 CC natural gas exploration, i.e., at a site of oil or gas reserves,
 CC associated with a site of mineral exploration, associated with a
 CC agricultural field, of patient sample suspected to have bacterial or
 CC fungal infection, associated with bioremediation site, or of an insect or
 CC parasite. The methods have application in fields of geochemical
 CC exploration, agriculture, bioremediation, environmental analysis,
 CC clinical microbiology, forensic science and medicine. The present
 CC sequence is an oligonucleotide described in the exemplification of the
 CC invention
 XX
 SQ Sequence 16 BP; 1 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 93.3%; Pred. No. 2.2e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTGCGGCACTGGG 311
 |||||
 DB 16 AGCTGCGGCACTGGG 2

OS	Rattus rattus.
XX	
PN	W09523225-A2.
XX	
PD	31-AUG-1995.
XX	
PE	23-FEB-1995; 95MO-IB000156.
XX	
XX	23-FEB-1994; 94US-00201109.
PR	29-MAR-1994; 94US-00218934.
PR	04-APR-1994; 94US-00222795.
PR	07-APR-1994; 94US-00224483.
PR	15-APR-1994; 94US-00227958.
PR	15-APR-1994; 94US-00228041.
PR	18-MAY-1994; 94US-00245736.
PR	06-JUL-1994; 94US-00271280.
PR	15-AUG-1994; 94US-00291932.
PR	16-AUG-1994; 94US-00292143.
PR	17-AUG-1994; 94US-00292620.
PR	19-AUG-1994; 94US-00293520.
PR	02-SEP-1994; 94US-00300000.
PR	08-SEP-1994; 94US-00303039.
PR	23-SEP-1994; 94US-00311486.
PR	23-SEP-1994; 94US-00311749.
PR	28-SEP-1994; 94US-00314597.
PR	03-OCT-1994; 94US-00316771.
PR	07-OCT-1994; 94US-00319492.
PR	11-OCT-1994; 94US-00321993.
PR	04-NOV-1994; 94US-00334847.
PR	10-NOV-1994; 94US-00337608.
PR	28-NOV-1994; 94US-00345516.
PR	16-DEC-1994; 94US-00357577.
PR	23-DEC-1994; 94US-00363233.
PR	30-JAN-1995; 95US-00380734.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
XX	
PI	Strincomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LW;
PI	Grimm S, Karajewsky A, Kisch K, Matulic-Adamic J, McSwiggen JA;
PI	Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD
PI	Tiecz D, Uman N, Wincott FE, Woolf T;
XX	
DR	WPI; 1995-351090/45.
XX	
PT	Ribozymes having modified bases and methods for producing them - for use
PT	in inhibiting disease related genes.
XX	
XX	Claim 2; Page 203; 407bp; English.
XX	

PR 03-OCT-1994; 94US-00316771.

	CC	The present sequence represents a preferred target sequence for an
	CC	nucleotide base position indicated in the DE line. Regions of the mRNA
	CC	that do not form secondary folding structures and that contain potential
	CC	hammerhead and hairpin ribozyme cleavage sites were identified by
	CC	computer analysis. Ribozymes directed against these mRNA sequences were
	CC	designed and synthesised with modifications that improve their nuclease
	CC	resistance. The ribozymes making the ICAM-1 target sequences and thereby
	CC	inhibit ICAM-1 expression, making them useful for reducing transplant
	CC	rejection and alleviating symptoms in patients with rheumatoid arthritis,
	CC	asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
	CC	correct PI field.)
SQ	Sequence 17 BP; 0 A; 7 C; 5 G; 0 T; 5 U; 0 Other;	
Oy	TTCGTGATCGTGATG 583 :: :: :: :: :: 2 UCUGGUCUUGUGUCA 16	
Dn		
RESULT 427		
ID	AATS3449	
XX AC	AATS3449 standard; RNA; 17 BP.	
DT	AATS3449;	
DT	25-MAR-2003 (revised)	
XX DT	27-MAR-1997 (first entry)	
DE	Rat ICAM hammerhead ribozyme target sequence (nt. position 102).	
XX		
KW	Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition; gene expression; downregulation; interleukin-5; IL-5; ICAM-1; intercellular adhesion molecule; rel A; tumour necrosis factor; TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene; translocation; chronic myelogenous leukaemia; CML; cancer; Philadelphia chromosome; inflammation; autoimmune disease; atherosclerosis; myocardial infarction; stroke; restenosis; transplant rejection; rheumatoid arthritis; psoriasis; myocardial ischemia; Kawasaki disease; septic shock; HIV; human immunodeficiency virus; acquired immune deficiency syndrome; AIDS; ss.	
XX OS	Rattus rattus.	
XX PN	WO9523225-A2.	
Pd	31-AUG-1995.	
PF	23-FEB-1995; 95WO-IB000156.	
PR	23-FEB-1994; 94US-00201109. 29-MAR-1994; 94US-00218934. 04-APR-1994; 94US-00222795. 07-APR-1994; 94US-00224483. 15-APR-1994; 94US-00227958. 15-APR-1994; 94US-00228041. 18-MAY-1994; 94US-00245776. 06-JUL-1994; 94US-00271280. 15-AUG-1994; 94US-00281932. 16-AUG-1994; 94US-00291433. 19-AUG-1994; 94US-00292620. 02-SEP-1994; 94US-00293520. 08-SEP-1994; 94US-00300000. 23-SEP-1994; 94US-00303039. 23-SEP-1994; 94US-00311486. 28-SEP-1994; 94US-00311749. 03-OCT-1994; 94US-00314397. 94US-00316771.	

```

PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpelesky A, Kisch K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Belgelman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Ueman N, Wincott FE, Woolf T;
XX
XX WPI; 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX
XX Claim 2; Page 201; 407bp; English.
XX
XX The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
CC nucleotide base position indicated in the DE line. Regions of the mRNA
CC that do not form secondary folding structures and that contain potential
CC hammerhead and hairpin ribozyme cleavage sites were identified by
CC computer analysis. Ribozymes directed against these mRNA sequences were
CC designed and synthesized with modifications that improve their nuclease
CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC inhibit ICAM-1 expression, making them useful for reducing transplant
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC correct PI field.)
XX
XX Sequence 17 BP; 0 A; 7 C; 5 G; 0 T; 5 U; 0 Other;
XX
XX
XX Query Match 0.6%; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 60.0%; Pred. No. 2.3e+02;
XX Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
XX
XX 569 TCCTGTCCTGCTGCG 583
XX 2 UCCUGGUCGUGCG 16
XX
XX
XX RESULT 428
XX AAT53480
XX ID AAT53480 standard; RNA; 17 BP.
XX
XX AC AAT53480;
XX
XX 25-MAR-2003 (revised)
XX 27-MAR-1997 (first entry)
XX
XX DE Rat ICAM hammerhead ribozyme target sequence (nt. position 735).
XX
XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
XX gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
XX intercellular adhesion molecule; rel A; tumour necrosis factor;
XX TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
XX translocation; chronic myelogenous leukaemia; CML; cancer;
XX Philadelphia chromosome; inflammation; autoimmune disease;
XX atherosclerosis; myocardial infarction; stroke; restenosis;
XX transplant rejection; rheumatoid arthritis; psoriasis;
XX myocardial ischemia; Kawasaki disease; septic shock; HIV;
XX human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
XX 86.
XX
XX Ratius ratius.
XX
XX OS
XX
XX MO9523225-A2.

```

```

XX
XX 31-AUG-1995.
XX
XX 23-FEB-1995; 95MO-IB000156.
XX
XX 23-FEB-1994; 94US-00201109.
XX 29-MAR-1994; 94US-00218934.
XX 04-APR-1994; 94US-00222795.
XX 07-APR-1994; 94US-00224483.
XX 15-APR-1994; 94US-00227958.
XX 15-APR-1994; 94US-00228041.
XX 18-MAY-1994; 94US-00245736.
XX 06-JUL-1994; 94US-00271280.
XX 15-AUG-1994; 94US-00291932.
XX 16-AUG-1994; 94US-00291433.
XX 17-AUG-1994; 94US-00292620.
XX 19-AUG-1994; 94US-00293520.
XX 02-SEP-1994; 94US-00300000.
XX 08-SEP-1994; 94US-00303039.
XX 23-SEP-1994; 94US-00311749.
XX 28-SEP-1994; 94US-00314397.
XX 03-OCT-1994; 94US-00316771.
XX 07-OCT-1994; 94US-00319492.
XX 11-OCT-1994; 94US-00321993.
XX 04-NOV-1994; 94US-00334847.
XX 10-NOV-1994; 94US-00337608.
XX 28-NOV-1994; 94US-00345516.
XX 16-DEC-1994; 94US-00357577.
XX 23-DEC-1994; 94US-00363233.
XX 30-JAN-1995; 95US-00380734.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LW;
XX Grimm S, Karpelesky A, Kisch K, Matulic-Adamic J, Mcswiggen JA;
XX Modak A, Pavco P, Belgelman L, Sullivan SM, Sweedler D, Thompson JD;
XX Tracz D, Ueman N, Wincott FE, Woolf T;
XX
XX WPI; 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX
XX Claim 2; Page 201; 407bp; English.
XX
XX The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
CC nucleotide base position indicated in the DE line. Regions of the mRNA
CC that do not form secondary folding structures and that contain potential
CC hammerhead and hairpin ribozyme cleavage sites were identified by
CC computer analysis. Ribozymes directed against these mRNA sequences were
CC designed and synthesized with modifications that improve their nuclease
CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC inhibit ICAM-1 expression, making them useful for reducing transplant
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC correct PI field.)
XX
XX Sequence 17 BP; 0 A; 7 C; 5 G; 0 T; 5 U; 0 Other;
XX
XX
XX Query Match 0.6%; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 60.0%; Pred. No. 2.3e+02;
XX Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
XX
XX 569 TCCTGTCCTGCTGCG 583
XX 2 UCCUGGUCGUGCG 16
XX
XX
XX RESULT 429
XX AAT53565
XX ID AAT53565 standard; RNA; 17 BP.

```

XX		AAT53565;	
AC			
XX			
DT	25-MAR-2003	(revised)	
DT	27-MAR-1997	(first entry)	
XX			
DE	Rat ICAM hammerhead ribozyme target sequence (nt. position 1233).		
XX			
KM	Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;		
KM	gene expression; downregulation; interleukin-5; IL-5; ICAM-1;		
KM	intercellular adhesion molecule; rel A; tumour necrosis factor;		
KW	TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;		
KW	translocation; chronic myelogenous leukaemia; CML; cancer;		
KW	Philadelphia chromosome; inflammation; autoimmune disease;		
KW	atherosclerosis; myocardial infarction; stroke; restenosis;		
KW	transplant rejection; rheumatoid arthritis; psoriasis;		
KM	myocardial ischaemia; Kawasaki disease; septic shock; HIV;		
KW	human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;		
SW	hs.		
XX			
OS	Rattus rattus.		
XX			
PN	WO9523225-A2.		
XX			
PD	31-AUG-1995.		
XX			
PF	23-FEB-1995;	95WO-IB000156.	
XX			
PR	23-FEB-1994;	94US-00201109.	
PR	29-MAR-1994;	94US-00218934.	
PR	04-APR-1994;	94US-00222795.	
PR	07-APR-1994;	94US-00224483.	
PR	15-APR-1994;	94US-00227958.	
PR	15-APR-1994;	94US-00228041.	
PR	18-MAY-1994;	94US-00245736.	
PR	06-JUL-1994;	94US-00271280.	
PR	15-AUG-1994;	94US-00291932.	
PR	16-AUG-1994;	94US-00291433.	
PR	17-AUG-1994;	94US-00293620.	
PR	19-AUG-1994;	94US-00293520.	
PR	02-SEP-1994;	94US-00300000.	
PR	08-SEP-1994;	94US-00303039.	
PR	23-SEP-1994;	94US-00311486.	
PR	23-SEP-1994;	94US-00311749.	
PR	28-SEP-1994;	94US-00314397.	
PR	03-OCT-1994;	94US-00316771.	
PR	07-OCT-1994;	94US-00319492.	
PR	11-OCT-1994;	94US-00321993.	
PR	04-NOV-1994;	94US-00334847.	
PR	10-NOV-1994;	94US-00337608.	
PR	28-NOV-1994;	94US-00345516.	
PR	16-DEC-1994;	94US-00351577.	
PR	23-DEC-1994;	94US-00363233.	
PR	30-JAN-1995;	95US-00380734.	
XX			
PA	(RIBO-) RIBOZYME PHARM INC.		
P1	Stinchcomb DT, Chowrira B, Direnzo A, Draper KG, Dudycz LW,		
P1	Grimm S, Karpelesky A, Kisch K, Matulich-Adamic J, Mcswiggen JA,		
P1	Molak A, Pavco P, Belgien L, Sullivan SM, Sweedler D, Thompson JD,		
P1	Tracz D, Usman N, Wincott FE, Wolff T;		
XX			
DR	WPI, 1995-351090/45.		
XX			
PT	Ribozymes having modified bases and methods for producing them - for use		
PT	in inhibiting disease related genes.		
XX			
PS	Claim 2; Page 202; 407pp; English.		
CC	The present sequence represents a preferred target sequence for an		
CC	enzymatic nucleic acid (i.e., a ribozyme) which cleaves ICAM-1 mRNA at the		
CC	nucleotide base position indicated in the DE line. Regions of the mRNA		
CC	that do not form secondary folding structures and that contain potential		

Query	Match	Similarity	Score	DB 1	Length	17
Db	2	UCCUGGUCUGGUCG 16	60.0%;	Pred. No. 2.3e+02;	Mismatches 1;	Indels 0; Gaps 0;
QY	569	TCCGCTCTCTGCG 583				
RESULT 430 AAT53574 ID AAT53574 standard; RNA, 17 BP. XX AC AAT53574; XX DT 25-MAR-2003 (revised) DT 27-MAR-1997 (first entry) XX DE Rat ICM hammerhead ribozyme target sequence (nt. position 1696). XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition; KM gene expression; downregulation; interleukin-5; IL-5; ICM-1; KM intercellular adhesion molecule; rel A; tumour necrosis factor; KM TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene; KM translocation; chronic myelogenous leukemia; CML; cancer; KM Philadelphia chromosome; inflammation; autoimmune disease; KM atherosclerosis; myocardial infarction; stroke; restenosis; KM transplant rejection; rheumatoid arthritis; psoriasis; KM myocardial ischemia; Kawasaki disease; septic shock; HIV; KM human immunodeficiency virus; acquired immune deficiency syndrome; AIDS; BS.						
OS	Rattus rattus.					
XX						
XX	W09523225-A2.					
XX						
XX	31-AUG-1995.					
XX						
PF	23-FEB-1995;	95WO-IB000156.				
XX						
XX	23-FEB-1994;	94US-00201109.				
PR	29-MAR-1994;	94US-00218934.				
PR	04-APR-1994;	94US-00222795.				
PR	07-APR-1994;	94US-00224483.				
PR	15-APR-1994;	94US-00227958.				
PR	15-APR-1994;	94US-00228041.				
PR	18-MAY-1994;	94US-00245736.				
PR	06-JUL-1994;	94US-00271280.				
PR	15-AUG-1994;	94US-00291932.				
PR	16-AUG-1994;	94US-00291433.				
PR	17-AUG-1994;	94US-00292620.				
PR	19-AUG-1994;	94US-00293520.				
PR	02-SEP-1994;	94US-00300000.				
PR	08-SEP-1994;	94US-00303039.				
PR	23-SEP-1994;	94US-00311486.				
PR	23-SEP-1994;	94US-00311749.				
PR	28-SEP-1994;	94US-00314397.				
PR	03-OCT-1994;	94US-00316771.				
PR	07-OCT-1994;	94US-00319492.				
PR	11-OCT-1994;	94US-00321993.				
PR	04-NOV-1994;	94US-00334847.				
PR	10-NOV-1994;	94US-00337608.				

```

PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Chowitra B, Dizenzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpetsky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Belgelman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Ueman N, Wincott FE, Woolf T;
XX
DR WPI; 1995-351090/45.
XX
PT Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX
PS Claim 2; Page 202; 407pp; English.
XX
CC The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
CC nucleotide base position indicated in the DE line. Regions of the mRNA
CC that do not form secondary folding structures and that contain potential
CC hammerhead and hairpin ribozyme cleavage sites were identified by
CC computer analysis. Ribozymes directed against these mRNA sequences were
CC designed and synthesised with modifications that improve their nuclease
CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC inhibit ICAM-1 expression, making them useful for reducing transplant
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC correct PI field.)
XX
SQ Sequence 17 BP; 0 A; 7 C; 5 G; 0 T; 5 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 2.3e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
QY 569 TCCTGCGCTCGGCGG 583
DB 2 UCCUGGUCUGGUCG 16
XX
RESULT 431
AAT53751
ID AAT53751 standard; RNA; 17 BP.
XX
AC AAT53751;
XX
DT 25-MAR-2003 (revised)
DT 03-APR-1997 (first entry)
XX
DE Rat ICAM hammerhead ribozyme target sequence (nt. position 2596).
XX
KM Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KM gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KM intercellular adhesion molecule; rel A; tumour necrosis factor;
KM TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KM translocation; chronic myelogenous leukaemia; CML; cancer;
KM Philadelphia chromosome; inflammation; autoimmune disease;
KM atherosclerosis; myocardial infarction; stroke; restenosis;
KM transplant rejection; rheumatoid arthritis; psoriasis;
KM myocardial ischemia; Kawasaki disease; septic shock; HIV;
KM human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KM BB.
XX
OS Rattus rattus.
XX
PN MO9523225-A2.
XX
PD 31-AUG-1995.
XX
PF 23-FEB-1995; 95WO-IB000156.

```

```

XX
XX 23-FEB-1994; 94US-00201109.
PR 29-MAR-1994; 94US-00218934.
PR 04-APR-1994; 94US-00222795.
PR 07-APR-1994; 94US-00224483.
PR 15-APR-1994; 94US-00227958.
PR 15-APR-1994; 94US-00228041.
PR 18-MAY-1994; 94US-00245736.
PR 06-JUL-1994; 94US-00271280.
PR 15-AUG-1994; 94US-00291932.
PR 16-AUG-1994; 94US-00291933.
PR 17-AUG-1994; 94US-00292620.
PR 19-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
PR 23-SEP-1994; 94US-00311486.
PR 23-SEP-1994; 94US-00311749.
PR 28-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Chowitra B, Dizenzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpetsky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Belgelman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Ueman N, Wincott FE, Woolf T;
XX
DR WPI; 1995-351090/45.
XX
PT Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX
PS Claim 2; Page 204; 407pp; English.
XX
CC The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
CC nucleotide base position indicated in the DE line. Regions of the mRNA
CC that do not form secondary folding structures and that contain potential
CC hammerhead and hairpin ribozyme cleavage sites were identified by
CC computer analysis. Ribozymes directed against these mRNA sequences were
CC designed and synthesised with modifications that improve their nuclease
CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC inhibit ICAM-1 expression, making them useful for reducing transplant
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC correct PI field.)
XX
SQ Sequence 17 BP; 0 A; 7 C; 5 G; 0 T; 5 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 2.3e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
QY 569 TCCTGCGCTCGGCGG 583
DB 2 UCCUGGUCUGGUCG 16
XX
RESULT 432
AAT53494
ID AAT53494 standard; RNA; 17 BP.
XX
AC AAT53494;
XX
DT 25-MAR-2003 (revised)

```

DT 27-MAR-1997 (first entry)

XX Rat ICAM hammerhead ribozyme target sequence (nt. position 792).

XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;

KM gene expression; downregulation; interleukin-5; IL-5; ICAM-1;

KM intercellular adhesion molecule; rel A; tumour necrosis factor;

KM TNF- α ph; respiratory syncytial virus; RSV; bcr-abl; oncogene;

KM translocation; chronic myelogenous leukaemia; CML; cancer;

KM Philadelphia chromosome; inflammation; autoimmune disease;

KM atherosclerosis; myocardial infarction; stroke; restenosis;

KM transplant rejection; rheumatoid arthritis; psoriasis;

KM myocardial ischemia; Kawasaki disease; septic shock; HIV;

KM human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;

KM ss.

XX Rattus rattus.

OS

XX MO9523225-A2.

PN

XX 31-AUG-1995.

PD

XX 23-FEB-1995; 95WO-IB000156.

PF

XX 23-FEB-1994; 94US-00201109.

PR 29-MAR-1994; 94US-00218934.

PR 04-APR-1994; 94US-00222795.

PR 07-APR-1994; 94US-00224483.

PR 15-APR-1994; 94US-00227958.

PR 15-APR-1994; 94US-00228041.

PR 18-MAY-1994; 94US-00245736.

PR 06-JUL-1994; 94US-00271280.

PR 15-AUG-1994; 94US-00291932.

PR 16-AUG-1994; 94US-00291433.

PR 17-AUG-1994; 94US-00292620.

PR 19-AUG-1994; 94US-00293520.

PR 02-SEP-1994; 94US-00300000.

PR 08-SEP-1994; 94US-00303039.

PR 23-SEP-1994; 94US-00311486.

PR 28-SEP-1994; 94US-00311749.

PR 03-OCT-1994; 94US-00316771.

PR 07-OCT-1994; 94US-00319492.

PR 11-OCT-1994; 94US-00321993.

PR 04-NOV-1994; 94US-00334847.

PR 10-NOV-1994; 94US-00337608.

PR 28-NOV-1994; 94US-00345516.

PR 16-DEC-1994; 94US-00357577.

PR 23-DEC-1994; 94US-00363233.

PR 30-JAN-1995; 95US-00380734.

XX

PA (RIBO-) RIBOZYME PHARM INC.

XX

PI Stinchcomb DF, Chowrira B, DiRenzo A, Draper KG, Dudycz LM;

PI Gittim S, Karpelesky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;

PI Modak A, Parco P, Belgelman L, Sullivan N, Sweedler D, Thompson JD;

PI Tracz D, Usman N, Wincott FE, Woolf T;

XX

DR WPI; 1995-351090/45.

XX

PT Ribozymes having modified bases and methods for producing them - for use

PT in inhibiting disease related genes.

XX

PS Claim 2; Page 201; 407bp; English.

XX

CC The present sequence represents a preferred target sequence for an

CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the

CC nucleotide base position indicated in the DB line. Regions of the mRNA

CC that do not form secondary folding structures and that contain potential

CC hammerhead and hairpin ribozyme cleavage sites were identified by

CC computer analysis. Ribozymes directed against these mRNA sequences were

CC designed and synthesised with modifications that improve their nuclease

CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby

CC inhibit ICAM-1 expression, making them useful for reducing transplant

CC rejection and alleviating symptoms in patients with rheumatoid arthritis,

CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to

CC correct PI field.)

XX

SO Sequence 17 BP; 0 A; 7 C; 5 G; 0 T; 5 U; 0 Other;

Qy Query Match 0.6%; Score 13.4; DB 1; Length 17;

Db Best Local Similarity 60.0%; Pred. No. 2.3e+02;

Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCCGCTGCG 583

Db 2 UCCUGGUCUGGUCG 16

RESULT 433

AAV20574

ID AAV20574 standard; DNA, 17 BP.

XX

AC AAV20574;

XX

DT 02-JUL-1998 (first entry)

DE

XX Human BRCA1 probe #8.

XX

KM Breast cancer; ovarian cancer; mutation; classification; detection;

KM tumour; diagnostic; prognostic; probe; ss.

XX

OS Synthetic.

OS Homo sapiens.

XX

PN W09805677-A1.

PN

PD 12-FEB-1998.

XX

PF 04-AUG-1997; 97MO-US013654.

PR

XX 05-AUG-1996; 96US-00233184P.

PR 05-AUG-1996; 96US-0023187P.

PR 05-AUG-1996; 96US-0023223P.

PR 06-AUG-1996; 96US-0022421P.

XX

PA (ONCO-) ONCOMED INC.

XX

PI Murphy PD, Allen AC, White MB, Olson SJ, Zeng B;

PI

XX WPI; 1998-159166/14.

XX

DR

PT Detection of mutation(s) in the BRCA1 gene - by hybridisation with an

PT allele-specific oligo:nucleotide or by amplification, useful particularly

PT for breast or ovarian cancers.

XX

XX Example 10; Page 41; 62pp; English.

XX

CC AAV20567-V20574 are probes used in a method to detect mutations in the

CC human BRCA1 gene. Such mutations are used for classifying a tumour for

CC diagnostic and prognostic purposes or detecting a predisposition of

CC higher susceptibility to breast and ovarian cancer in an individual. The

CC methods can be used for reducing the high incidence and mortality

CC associated with breast and ovarian cancer through the early detection of

CC women at high risk. These women, once identified, can be targeted for

CC more aggressive prevention programmes

CC

XX Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

SO

Qy Query Match 0.6%; Score 13.4; DB 1; Length 17;

Db Best Local Similarity 93.3%; Pred. No. 2.3e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 454 GCCCTGGGCAAAA 468

Db 1 GCCATGTGGCAAAA 15

RESULT 434
 AAA18459
 ID AAA18459 standard; RNA, 17 BP.
 XX
 AC AAA18459;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Human TIE-2 substrate sequence SEQ ID NO:1685.
 XX
 KM Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KM integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KM hammerhead ribozyme; angiogenic factor; cytoskeletal; antidiabetic;
 KM ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KM dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KM age related macular degeneration; inflammation; neovascular glaucoma;
 KM myopic degeneration; psoriasis; verruca vulgaris; angiodiroma;
 KM tubercous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KM Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9950403-A2.
 XX
 PD 07-OCT-1999.
 XX
 XX 24-MAR-1999; 99WO-US006507.
 XX
 PR 27-MAR-1998; 98US-0079678P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mewlissen JA;
 XX
 DR WPI; 1999-591315/50.
 XX
 PT Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 XX
 PS Claim 56; Page 96; 305pp; English.
 XX
 CC The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiodiroma of tubercous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX
 SQ Sequence 17 BP; 1 A; 2 C; 5 G; 0 T; 9 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 46.7%; Pred. No. 2.3e+02;

Matches 7; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
 Cy 909 GAGCTTATTCGTGG 923
 Db 3 GGGCUCUADUUCUGUG 17
 RESULT 435
 AAA20642/c
 ID AAA20642 standard; RNA, 17 BP.
 XX
 AC AAA20642;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:3868.
 XX
 KM Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KM integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KM hammerhead ribozyme; angiogenic factor; cytoskeletal; antidiabetic;
 KM ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KM dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KM age related macular degeneration; inflammation; neovascular glaucoma;
 KM myopic degeneration; psoriasis; verruca vulgaris; angiodiroma;
 KM tubercous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KM Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9950403-A2.
 XX
 PD 07-OCT-1999.
 XX
 XX 24-MAR-1999; 99WO-US006507.
 XX
 PR 27-MAR-1998; 98US-0079678P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mewlissen JA;
 XX
 DR WPI; 1999-591315/50.
 XX
 PT Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 XX
 PS Claim 55; Page 158; 305pp; English.
 XX
 CC The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiodiroma of tubercous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3

XX Sequence 17 BP; 5 A; 3 C; 4 G; 0 T; 5 U; 0 Other;
 SQ Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 675 TCGAACTTACTCT 689
 Db 17 TCGAACTGAACTCT 3

RESULT 436
 AAA18460
 ID AAA18460 standard; RNA; 17 BP.
 XX
 AC AAA18460;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Human TIE-2 substrate sequence SEQ ID NO:1686.
 XX
 KW Human: aryl hydrotocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tubercous scleriosis; poc-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 KW
 XX
 OS Homo sapiens.
 OS
 PN WO9950403-A2.
 XX
 PD 07-OCT-1999.
 XX
 PF 24-MAR-1999; 99WO-US006507.
 XX
 PR 27-MAR-1998; 98US-0079678P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
 XX WPI; 1999-591315/50.
 XX
 DR Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 XX
 PS Claim 56; Page 96; 305pp; English.
 XX
 CC The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as

CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tubercous scleriosis, poc-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX
 SQ Sequence 17 BP; 3 A; 2 C; 4 G; 0 T; 8 U; 0 Other;
 QY Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 46.7%; Pred. No. 2.3e+02;
 Matches 7; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
 QY 909 GAGCTATTCTGTG 923
 Db 1 GUCCUAAUUCUGUG 15

RESULT 437
 AAX5185
 ID AAX5185 standard; DNA; 17 BP.
 XX
 AC AAX5185;
 XX
 DT 05-JUL-1999 (first entry)
 XX
 DE Multiple antisense oligonucleotide 6.
 XX
 KW Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; impeded respiration;
 KW respiratory distress syndrome; pain; cystic fibrosis;
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.
 KW
 XX
 OS Synthetic.
 OS
 PN WO9913886-A1.
 XX
 PD 25-MAR-1999.
 XX
 PF 17-SEP-1998; 98WO-US019419.
 XX
 PR 17-SEP-1997; 97US-0059160P.
 XX PR 09-JUN-1998; 98US-00093972.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 XX
 PI Nyce JW;
 XX WPI; 1999-229400/19.
 XX
 DR New antisense oligonucleotides used in treatment of, e.g. pulmonary
 PT vasoconstriction.
 XX
 PS Disclosure; Page 73; 120pp; English.
 XX
 CC The specification describes antisense oligonucleotides (AAX52869-X55271)
 CC directed against at least 2 mRNAs selected from target gene, coding and
 CC non-coding regions of RNAs corresponding to target gene, gene initiation
 CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-
 CC end and the juxta-section between coding and non-coding regions and all
 CC segments of RNAs encoding proteins associated with one or more diseases,
 CC conditions or mixtures. The antisense oligonucleotides may be derived
 CC from sequences AAX55272-74. These multiple target oligonucleotides
 CC (specifically AAX55180-271) can be used for the antisense treatment of
 CC diseases and conditions. Typical diseases and conditions are those
 CC associated with impaired respiration and inflammation, including lung
 CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
 CC acute asthma, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
 CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
 CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
 CC colon cancer, breast cancer, lung cancer, pancreatic cancer,
 CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
 CC well as all types of cancers which may metastasize or have metastasized
 CC to the lungs, including breast and prostate cancer
 XX
 SQ Sequence 17 BP; 0 A; 6 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 565 CTGTTCTGTCGTCG 579
 Db 1 CTGTCCTGTCGTCG 15
 RESULT 438
 AAA34632
 ID AAA34632 standard; DNA; 17 BP.
 XX
 AC AAA34632;
 XX
 DT 26-JUL-2000 (first entry)
 XX
 DE Human adenosine receptor related polynucleotide SEQ ID NO:221.
 XX
 KM Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KM phosphorothioate; impaired respiration; inflammation; allergy;
 KM allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KM antiallergic; antiasthmatic; cytosolic; analgesic; impaired airway;
 KM lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KM respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KM pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KM cancer; leukemia; lymphoma; carcinoma; metastasis; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200009525-A2.
 XX
 PD 24-FEB-2000.
 XX
 PF 03-AUG-1999; 99WO-US017712.
 XX
 PR 03-AUG-1998; 98US-0095212P.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 XX
 PI NYCE JW;
 XX
 WPI; 2000-205971/18.
 XX
 DR
 XX
 PT New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischaemic or
 PT cancers.
 XX
 PS Disclosure; Page 555; 1343pp; English.
 XX
 CC The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cytosolic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impaired respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,

CC carcinomas, and cancers which may metastasize to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ON reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
 CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
 CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
 CC AAA33992) are specifically claimed ONs from the present invention. N.B.
 CC Sequences given in the disclosure of the present invention do not match
 CC up with their corresponding SEQ ID NO: sequences given in the sequence
 CC listing
 XX
 SQ Sequence 17 BP; 0 A; 6 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 565 CTGTTCTGTCGTCG 579
 Db 1 CTGTCCTGTCGTCG 15
 RESULT 439
 AAF21457
 ID AAF21457 standard; DNA; 17 BP.
 XX
 AC AAF21457;
 XX
 DT 14-MAR-2001 (first entry)
 XX
 DE Human multiple target antisense (MTA) oligonucleotide #3024.
 XX
 KM Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KM human; airway disorder; bronchoconstriction; lung inflammation;
 KM surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KM immunosuppressive; antiasthmatic; analgesic; hypotensive; cytosolic;
 KM respiratory obstruction; pulmonary obstruction; impaired respiration;
 KM surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KM respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KM pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KM chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KM cancer; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200062736-A2.
 XX
 PD 26-OCT-2000.
 XX
 PF 24-MAR-2000; 2000WO-US008020.
 XX
 PR 06-APR-1999; 99US-0127958P.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 XX
 PI (NYCE/) NYCE J W.
 XX
 WPI; 2000-679539/66.
 XX
 DR
 XX
 PT Low adenosine (A) content antisense oligonucleotides which do not trigger
 PT adenosine receptors during metabolism, useful e.g. for treating cancers
 PT and respiratory obstructions.
 XX
 PS Disclosure; Page 296; 1592pp; English.
 XX
 CC The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,

CC immunosuppressive, antiasthmatic, hypotensive and cyostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and/or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
 CC surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hyperextension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
 CC fragments and antisense oligonucleotides used in the exemplification of
 CC the present invention
 CC
 SQ Sequence 17 BP; 0 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 565 CTGTTCTCGTCTCG 579
 |||||
 1 CTGTCCTCGTCTCG 15

RESULT 440
 AAF20754
 ID AAF20754 standard; DNA; 17 BP.

AC AAF20754;
 DT 14-MAR-2001 (first entry)
 XX

DE Human multiple target antisense (MTA) oligonucleotide #2321.

XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KM human; airway disorder; bronchoconstriction; lung inflammation;
 KM surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KM immunosuppressive; antiasthmatic; analgesic; hypotensive; cyostatic;
 KM respiratory obstruction; pulmonary obstruction; impeded respiration;
 KM surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KM respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KM pulmonary hyperextension; emphysema; pulmonary transplantation rejection;
 KM chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KM cancer; ss.

OS Homo sapiens.
 XX
 PN WO200062736-A2.

XX 26-OCT-2000.

PF 24-MAR-2000; 2000WO-US008020.

XX 06-APR-1999; 99US-0127958P.

XX (UYEC-) UNIV EAST CAROLINA.

PA (NYCE/) NYCE J W.

XX NYCE JW;
 XX

DR WPI; 2000-679539/66.

XX Low adenosine (A) content antisense oligonucleotides which do not trigger
 PT adenosine receptors during metabolism, useful e.g. for treating cancers
 PT and respiratory obstructions.

XX Claim 14; Page 623; 1592pp; English.

PS The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cyostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and/or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
 CC surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hyperextension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
 CC fragments and antisense oligonucleotides used in the exemplification of
 CC the present invention
 CC
 SQ Sequence 17 BP; 0 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 565 CTGTTCTCGTCTCG 579
 |||||
 1 CTGTCCTCGTCTCG 15

RESULT 441
 AAC70633/C
 ID AAC70633 standard; DNA; 17 BP.

AC AAC70633;
 XX

DT 09-FEB-2001 (first entry)
 XX

DE Single nucleotide polymorphism PCR primer #309.

XX Single nucleotide polymorphism; SNP; human; genetic disease;
 KM disease susceptibility; cardiovascular system; endocrine system;
 KM neurological system; forensic testing; paternity testing; PCR primer; ss.

OS Homo sapiens.

XX WO200058519-A2.

XX 05-OCT-2000.

PF 30-MAR-2000; 2000WO-US008440.

XX 31-MAR-1999; 99US-0127248P.
 XX

PA (WHEED) WHITEHEAD INST BIOMEDICAL RES.
PA (AFFY-) AFFYMETRIX INC.
XX
XX PI Altschuler D, Cargill M, Daley GO, Ireland JS, Lander ES;
PI Lipshutz RJ, Pacil N, Sklar P;
XX WPI; 2000-611722/58.
XX
PT Nucleic acid selected from one of 106 genes comprising single nucleotide
PT polymorphisms, allele-specific oligonucleotides to the genes are useful
PT for phenotypic correlations, forensics, paternity testing, medicine and
PT genetic analysis.
XX
PS Claim 8; Fig 5; 214pp; English.
XX
CC The present invention is concerned with a number of human single
CC nucleotide polymorphisms (SNPs) which the inventors identified in human
CC genes. These SNPs can be used in disease diagnosis and prediction of an
CC individual's susceptibility to disease, in forensic and paternity testing
CC and in genetic mapping. In particular, the SNPs of the invention can be
CC used to diagnose susceptibility to diseases of the cardiovascular,
CC endocrine and neurological systems, such as coronary artery disease,
CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
CC diseases
XX
SQ Sequence 17 BP; 3 A; 10 C; 3 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 174 GGGCGTGGCCTGAG 188
DB 15 GGGGCTGGCCTGAG 1
XX
RESULT 442
AAC70630/c
ID AAC70630 standard; DNA; 17 BP.
XX
AC AAC70630;
XX
DT 09-FEB-2001 (first entry)
XX
DE Single nucleotide polymorphism PCR primer #307.
XX
XX Single nucleotide polymorphism; SNP; human; genetic disease;
XX disease susceptibility; cardiovascular system; endocrine system;
XX neurological system; forensic testing; paternity testing; PCR primer; ss.
OS Homo sapiens.
XX
XX WO200058519-A2.
XX
XX 05-OCT-2000.
XX
XX 30-MAR-2000; 2000WO-US008440.
XX
XX 31-MAR-1999; 99US-0127248P.
XX
XX (WHEED) WHITEHEAD INST BIOMEDICAL RES.
XX (AFFY-) AFFYMETRIX INC.
XX
XX Altschuler D, Cargill M, Daley GO, Ireland JS, Lander ES;
XX Lipshutz RJ, Pacil N, Sklar P;
XX WPI; 2000-611722/58.
XX
XX Nucleic acid selected from one of 106 genes comprising single nucleotide
XX polymorphisms, allele-specific oligonucleotides to the genes are useful
XX for phenotypic correlations, forensics, paternity testing, medicine and
XX genetic analysis.
XX

PS Claim 8; Fig 5; 214pp; English.
XX
XX The present invention is concerned with a number of human single
XX nucleotide polymorphisms (SNPs) which the inventors identified in human
XX genes. These SNPs can be used in disease diagnosis and prediction of an
XX individual's susceptibility to disease, in forensic and paternity testing
XX and in genetic mapping. In particular, the SNPs of the invention can be
XX used to diagnose susceptibility to diseases of the cardiovascular,
XX endocrine and neurological systems, such as coronary artery disease,
XX schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
XX diseases
XX
SQ Sequence 17 BP; 3 A; 10 C; 3 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 174 GGGCGTGGCCTGAG 188
DB 15 GGGGCTGGCCTGAG 1
XX
RESULT 443
AAF02107/c
ID AAF02107 standard; DNA; 17 BP.
XX
XX AAF02107;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #402.
XX
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX interferon alpha; ss.
XX
OS Homo sapiens.
XX
XX WO200061729-A2.
XX
XX 19-OCT-2000.
XX
XX 11-APR-2000; 2000WO-US009721.
XX
XX 12-APR-1999; 99US-0129390P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX WPI; 2000-647423/62.
XX
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
XX useful for producing e.g. granulocyte colony stimulating factor protein,
XX interferon alpha and erythropoietin.
XX
XX Claim 37; Page 65; 164pp; English.
XX
XX The present invention relates to enzymatic and antisense nucleic acid
XX molecules that act as inhibitors of the expression of repressor genes
XX encoding the TR2 Orphan receptor, EAR3/COUP-TE-1, the GATA transcription
XX factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
XX Inhibition of the repressors removes prevents inhibition (and
XX consequently increases expression of) genes involved in the production of
XX erythropoietin, granulocyte colony stimulating factor protein and
XX interferon alpha
XX
SQ Sequence 17 BP; 7 A; 3 C; 1 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
QY      1784 TTCAGAGAAATATTG 1798
      |||||
      17  TTCAGAGAAATGTTG 3

RESULT 444
AAFO7421/c
ID  AAF07421 standard; DNA; 17 BP.
XX
XX  AAF07421;
XX
XX  16-FEB-2001 (first entry)
XX
XX  Hammerhead ribozyme substrate #3678.
XX
XX  Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KM  interferon alpha; ss.
XX
XX  Homo sapiens.
OS
XX  WO200061729-A2.
XX
XX  19-OCT-2000.
XX
XX  11-APR-2000; 2000WO-US009721.
XX
XX  12-APR-1999; 99US-0129390P.
XX
XX  (RIBO-) RIBOZYME PHARM INC.
XX
XX  Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX  WPI; 2000-647423/62.
XX
XX  Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT  useful for producing e.g. granulocyte colony stimulating factor protein,
PT  interferon alpha and erythropoietin.
XX
XX  Claim 54; Page 140; 164pp; English.
XX
XX  The present invention relates to enzymatic and antisense nucleic acid
CC  molecules that act as inhibitors of the expression of repressor genes
CC  encoding the TR2 Orphan receptor, EAR3/COUP-TR-1, the GATA transcription
CC  factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
CC  Inhibition of the repressors removes prevents inhibition (and
CC  consequently increases expression of) genes involved in the production of
CC  erythropoietin, granulocyte colony stimulating factor protein and
CC  interferon alpha
XX
XX  Sequence 17 BP; 5 A; 3 C; 5 G; 4 T; 0 U; 0 Other;
SQ

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      283 GCTTTGAAGCCATT 297
      |||||
      15  GCTCTGAAGCCATT 1

RESULT 445
AAFO2109/c
ID  AAF02109 standard; DNA; 17 BP.
XX
XX  AAF02109;
XX
XX  16-FEB-2001 (first entry)
XX
XX  Hammerhead ribozyme substrate #404.
XX
XX  Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KM  interferon alpha; ss.
XX
```

```
OS  Homo sapiens.
XX
XX  WO200061729-A2.
XX
XX  19-OCT-2000.
XX
XX  11-APR-2000; 2000WO-US009721.
XX
XX  12-APR-1999; 99US-0129390P.
XX
XX  (RIBO-) RIBOZYME PHARM INC.
XX
XX  Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX  WPI; 2000-647423/62.
XX
XX  Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT  useful for producing e.g. granulocyte colony stimulating factor protein,
PT  interferon alpha and erythropoietin.
XX
XX  Claim 37; Page 65; 164pp; English.
XX
XX  The present invention relates to enzymatic and antisense nucleic acid
CC  molecules that act as inhibitors of the expression of repressor genes
CC  encoding the TR2 Orphan receptor, EAR3/COUP-TR-1, the GATA transcription
CC  factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
CC  Inhibition of the repressors removes prevents inhibition (and
CC  consequently increases expression of) genes involved in the production of
CC  erythropoietin, granulocyte colony stimulating factor protein and
CC  interferon alpha
XX
XX  Sequence 17 BP; 6 A; 3 C; 2 G; 6 T; 0 U; 0 Other;
SQ

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1784 TTCAGAGAAATATTG 1798
      |||||
      15  TTCAGAGAAATGTTG 1

RESULT 446
AAFO2108/c
ID  AAF02108 standard; DNA; 17 BP.
XX
XX  AAF02108;
XX
XX  16-FEB-2001 (first entry)
XX
XX  Hammerhead ribozyme substrate #403.
XX
XX  Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KM  interferon alpha; ss.
XX
XX  Homo sapiens.
OS
XX  WO200061729-A2.
XX
XX  19-OCT-2000.
XX
XX  11-APR-2000; 2000WO-US009721.
XX
XX  12-APR-1999; 99US-0129390P.
XX
XX  (RIBO-) RIBOZYME PHARM INC.
XX
XX  Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX  WPI; 2000-647423/62.
XX
XX  Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT  useful for producing e.g. granulocyte colony stimulating factor protein,
PT
```

PT Interferon alpha and erythropoietin.
 XX
 PS Claim 37; Page 65; 164pp; English.
 CC The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC Interferon alpha
 CC
 SQ Sequence 17 BP; 7 A; 3 C; 1 G; 6 T; 0 U; 0 Other;
 XX
 XX
 Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 1784 TTCAGAGAAATATG 1798
 Db 16 TTCAGAGAAATGTTG 2
 RESULT 447
 ID AAF02208
 AC AAF02208 standard; DNA; 17 BP.
 XX
 AC AAF02208;
 XX
 DT 16-FEB-2001 (first entry)
 XX
 DE Hammerhead ribozyme substrate #503.
 XX
 KM Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KM Interferon alpha; ss.
 XX
 OS Homo sapiens.
 XX
 PN W0200061729-A2.
 XX
 PD 19-OCT-2000.
 XX
 PF 11-APR-2000; 2000WO-US009721.
 XX
 PR 12-APR-1999; 99US-0129390P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
 XX
 DR WPI; 2000-647423/62.
 XX
 PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor protein,
 PT Interferon alpha and erythropoietin.
 XX
 PS Claim 37; Page 67; 164pp; English.
 XX
 CC The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC Interferon alpha
 CC
 SQ Sequence 17 BP; 1 A; 11 C; 1 G; 4 T; 0 U; 0 Other;
 XX
 XX
 Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1384 CTCCTCATCTACCC 1398
 Db 1 CTCCTCATCTACCC 15
 RESULT 448
 ID ABR02411/c
 AC ABR02411 standard; RNA; 17 BP.
 XX
 AC ABR02411;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human NOGO Ambertzyme #93.
 XX
 KM Human; ss; antisense therapy; cyostatic; antiinflammatory; haemostatic;
 KM cerebroprotective; neuroprotective; antiparkinsonian;
 KM musclar; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KM DNazyme; Inozyme; G-cleaver; ambertzyme; zinzyme; lymphoma; leukaemia;
 KM B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KM human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KM MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KM inflammatory arthropathy; central nervous system injury;
 KM cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KM chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KM Parkinson's disease; ataxia; Huntington's disease;
 KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W0200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PF 09-FEB-2001; 2001WO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswiggen J, Chowrira BM;
 XX
 DR WPI; 2001-607195/69.
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 88; Page 132; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acid may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNazyme) an Inozyme (an endolytic nucleic acid cleaving a RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an ambertzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic

CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is an amberzyme molecule of the invention
 XX
 SQ Sequence 17 BP; 4 A; 8 C; 5 G; 0 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 201 GCTCTGGCTGGGGGC 215
 Db 16 GCTCTGGCTGGGGGC 2
 RESULT 449
 ID ABRK0912 standard; RNA; 17 BP.
 XX ABRK0912;
 AC ABRK0912;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human NOGO Inozyme #182.
 XX
 KW Human; ss; antisense therapy; cytosstatic; antiinflammatory; haemostatic;
 KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNAzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 KW
 XX Homo sapiens.
 OS Synthetic.
 XX
 PN WO200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PD 09-FEB-2001; 2001WO-US004273.
 PF
 XX 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSM/) MCSMIGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswigen J, Chowrira BM;
 XX WPI, 2001-607195/69.
 XX

PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 88; Page 80; 200pp; English.
 XX
 XX The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acid may be enzymatic nucleic acids (e.g., a ribozyme or a
 CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving a RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is an inozyme of the invention
 XX
 SQ Sequence 17 BP; 4 A; 7 C; 6 G; 0 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 201 GCTCTGGCTGGGGGC 215
 Db 17 GCTCTGGCTGGGGGC 3
 RESULT 450
 ID AAF26892 standard; DNA; 17 BP.
 XX AAF26892;
 AC AAF26892;
 XX
 DT 11-SEP-2003 (revised)
 DT 09-APR-2001 (first entry)
 XX
 DE Beet necrotic yellow vein virus RNA-2 PCR primer SEQ ID NO:5.
 XX
 KW Beet necrotic yellow vein virus; BNYVV; transformed plant;
 KW Rhizomania disease-resistant plant; PCR primer; ss.
 XX
 OS Beet necrotic yellow vein virus.
 XX
 PN JP2000312540-A.
 XX
 PD 14-NOV-2000.
 PD
 XX 28-APR-1999; 99JP-00122628.
 PF 28-APR-1999; 99JP-00122628.
 XX
 PR 28-APR-1999; 99JP-00122628.
 XX

XX (HOKK-) HOKKAIDO PREFECTURE.
PA (HOKK-) HOKKAIDO TENSAN SH.
XX WPI; 2001-054202/07.
DR WPI; 2001-054202/07.
PT A transformed plant having resistance to beet necrotic yellow vein virus
XX (BNYVV) comprises a gene derived from BNYVV genome.
XX
PS Example 1; Page 5; 11pp; Japanese.
XX
CC The present invention describes a method for producing a transformed
CC plant in which resistance against beet necrotic yellow vein virus (BNYVV)
CC is given by transforming expressably a gene derived from BNYVV genome or
CC a DNA corresponding to its part or a DNA substantially same as it in a
CC plant genome. The vector structure can be used for transforming a plant
CC or a plant cell having BNYVV resistance. The present sequence represents
CC a PCR primer for a BNYVV nucleotide sequence which is used in an example
CC from the present invention. (Updated on 11-SEP-2003 to standardise OS
CC field)
XX
SQ Sequence 17 BP; 4 A; 7 C; 1 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 666 TACCTTCACTCGAAA 680
DB 2 TACCTTCACTCGACA 16
XX
RESULT 451
AAC62173/C
ID AAC62173 standard; DNA; 17 BP.
XX
AC AAC62173;
XX
DT 06-MAR-2001 (first entry)
XX
DE Oligomer antiparallel to human plasmidogen antigen activator mRNA.
XX
KM Biologically active compound; cellular metabolism; DNA replication;
KM RNA transcription; RNA translation; RNA elongation; RNA processing;
KM protein synthesis; protein processing; cellular differentiation;
KM cell division; ion channel transmission; cellular protein; toxin;
KM RNA transportation; cellular oxidation; tumour suppressor p53;
KM plasmidogen antigen activator; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX WO200061775-A1.
XX
XX 19-OCT-2000.
XX
XX 08-APR-1999; 99WO-IB000616.
XX
XX 08-APR-1999; 99WO-IB000616.
XX
PA (SERG/) SERGEEV P.
XX
PI Sergeev P;
XX
DR WPI; 2001-006911/01.
XX
PT Novel method for the synthesis of biologically active compounds from
PT inactive precursors in the cells of living organisms, useful for
PT producing proteins or polynucleotides.
XX
PS Example 8; Page 30; 65pp; English.
XX
CC The specification describes a method of synthesis of biologically active

CC substances of determined structure directly in the cells of living
CC organisms containing specific RNA or DNA sequence. The method is based on
CC the hybridisation of two or more oligomers bound with biologically
CC inactive substances to specific RNA or DNA in vivo in the cells of living
CC organisms. After hybridisation of the oligomers, the biologically
CC inactive precursors bound to the oligomers can interact with each other
CC to make the active form of the substances. This changing of properties is
CC due to chemical reactions which bind the biologically inactive precursors
CC through a chemical bond into a biologically active form of the whole
CC compound. The methods are useful for producing biologically active
CC compounds from inactive precursors. These compounds may be inhibitors or
CC stimulants of cellular metabolism, DNA replication, RNA transcription,
CC RNA translation, RNA elongation RNA processing, protein synthesis,
CC protein processing, cellular differentiation, cell division, ion channel
CC transmission, cellular protein and RNA transportation, processes of
CC cellular oxidation, toxins, proteins or RNAs. Oligomers AAC62167-80 are
CC used to bind peptides AAB30523-36. The peptides are fragments of the
CC tumour suppressor p53, and the oligomers are antiparallel to human
CC plasmidogen antigen activator mRNA. The method of the invention is used
CC to produce the tumour suppressor protein p53 from the bound peptides and
CC oligomers
XX
SQ Sequence 17 BP; 3 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 101 TGCTGCTCCGACCG 115
DB 17 TGCTGCTCCGACCG 3
XX
RESULT 452
AB272318
ID AB272318 standard; DNA; 17 BP.
XX
AC AB272318;
XX
DT 03-APR-2003 (first entry)
XX
DE Gene 216 polymorphism genotyping ASO primer SEQ ID NO 290.
XX
KM Human; Gene 216; chromosome 20p13-p12; antiasthmatic; anorectic;
KM antiinflammatory; gastrointestinal, gene therapy; vaccine; asthma;
KM obesity; inflammatory bowel disease; primer; ss.
XX
OS Synthetic.
XX
XX WO200178894-A2.
XX
XX 25-OCT-2001.
XX
XX 13-APR-2001; 2001WO-US012245.
XX
XX 13-APR-2000; 2000US-00548797.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
XX
PI Keith T;
XX
DR WPI; 2001-639428/73.
XX
XX Isolated genes (Gene 216) from human chromosome 20p13-p12 and the
XX proteins they encode, useful for the prevention, diagnosis and treatment
XX of asthma, obesity and inflammatory bowel disease.
XX
XX Example 11; Page 156; 520pp; English.
XX
XX The invention relates to isolated genes (Gene 216) from human chromosome
XX 20p13-p12 and the proteins they encode. The nucleic acids and proteins
XX may be used in the prevention, diagnosis and treatment of diseases
XX associated with inappropriate Gene 216 expression. For example, the

CC nucleic acids (or vectors) and proteins may be used to treat disorders
 CC associated with decreased expression by rectifying mutations or deletions
 CC in a patient's genome that affect the activity of gene 216 by expressing
 CC inactive proteins or to supplement the patients own production of gene
 CC 216 proteins. Additionally, the nucleic acids may be used to produce the
 CC secreted Gene 216 protein, by inserting the nucleic acids into a host
 CC cell and culturing the cell to express the protein. The nucleic acids and
 CC complementary sequences may also be used as DNA probes in diagnostic
 CC assays to detect and quantitate the presence of similar nucleic acid
 CC sequences in samples and therefore which patients may be in need of
 CC restorative therapy. The Gene 216 protein may also be used as antigens in
 CC the production of antibodies against Gene 216 and in assays to identify
 CC modulators of Gene 216 expression and activity. The anti-Gene 216
 CC antibodies and antagonists may also be used to down regulate expression
 CC and activity. The anti-Gene 216 antibodies may also be used as diagnostic
 CC agents for detecting the presence of Gene 216 proteins in samples (e.g.,
 CC by enzyme linked immunosorbant assay or ELISA). Disorders that may be
 CC prevented, diagnosed and/or treated by the above methods include, for
 CC example asthma, obesity and inflammatory bowel disease. The present
 CC sequence is that of a Gene 216 related primer used in examples of the
 CC invention. The primers are used in the physical mapping of the gene
 CC (AB272067-AB272088), polymorphism identification using single strand
 CC conformational polymorphism (SSCP) analysis (AB272091-AB272184).
 CC sequencing (AB272185-AB272268) and genotyping (AB272317-AB272362)
 CC
 XX Sequence 17 BP; 1 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 588 CTCCTCTCTTGGGGA 602
 Db 2 CTCCTCTCTTGGCGA 16

RESULT 453
 ABN06958
 ID ABN06958 standard; DNA; 17 BP.
 AC ABN06958;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6950.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-026860P.

XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI
 XX WPI; 2002-179446/23.
 DR
 XX
 XX New polypeptide, for raising antibodies that recognise hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.
 XX
 BS Disclosure; SEQ ID NO 6950; 214pp; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 89 TCGCCGACTGGGTGC 103
 Db 3 TCGCCGACTGGGTGC 17

RESULT 454
 ABN06764
 ID ABN06764 standard; DNA; 17 BP.
 AC ABN06764;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6756.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.

```
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-026860P.
PA (AEOM-) AEOMICA INC.
PI Gu Y, J1 Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 6756; 214bp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.66; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 93.3%; Pred. No. 2.3e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2041 GTGAGAGAGCTCTG 2055
XX |||||
Db 3 GTGAGAGAGCTCTG 17
XX
XX RESULT 455
XX ABN08015
XX ID ABN08015 standard; DNA; 17 BP.
XX AC ABN08015;
XX
XX 29-MAY-2002 (first entry)
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8007.
XX
XX Human, genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
```

```
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-026860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, J1 Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 8007; 214bp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.66; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 93.3%; Pred. No. 2.3e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2039 AGGTGAGAGAGCTCC 2053
XX |||||
Db 1 AGCTGAGAGAGCTCC 15
XX
XX RESULT 456
XX ABN0897/c
XX ID ABN0897 standard; DNA; 17 BP.
XX
```

AC AEN00897;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:889.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-026860P.
XX
PA (AEOM-) AEOMICA INC.
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
DR
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT description ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
PS Disclosure; SEQ ID NO 889; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser description ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 5 A; 1 C; 9 G; 2 T; 0 U; 0 Other;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1703 CCCTTCCCAATATG 1717
|||
Db 17 CCCTTCCCACTATG 3
RESULT 457
ABN06765
ID ABN06765 standard; DNA; 17 BP.
XX
AC ABN06765;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6757.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-026860P.
XX
PA (AEOM-) AEOMICA INC.
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
DR
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT description ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
PS Disclosure; SEQ ID NO 6757; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser description ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart

CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 2 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2041 GTGGAGCAGCTCTCG 2055
Db 2 GTGGAGCAGCTCTCG 16
RESULT 458
ABN08062
ID ABN08062 standard; DNA; 17 BP.
AC ABN08062;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8054.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-026860P.
XX
PA (ABOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 8054; 214P; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 8 A; 4 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2230 GCAGATGCTCCAGAA 2244
Db 3 GCAGATGCTCCAGAA 17
RESULT 459
ABN08063
ID ABN08063 standard; DNA; 17 BP.
AC ABN08063;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8055.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-026860P.
XX
PA (ABOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
DR WPI; 2002-179446/23.
XX

PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
PS Disclosure; SEQ ID NO 8055; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 7 A; 4 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2230 GCAGATGCTCCAGAA 2244
|||
Db 2 GCAGATGCACCGAA 16

RESULT 460
ABN06960
ID ABR06960 standard; DNA; 17 BP.
XX
AC ABR06960;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6952.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
PS Disclosure; SEQ ID NO 6952; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 89 TCGCCGACTGGCTGC 103
|||
Db 1 TCGCCGACTGGCTGC 15

RESULT 461
ABN06959
ID ABR06959 standard; DNA; 17 BP.
XX
AC ABR06959;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6951.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX

PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-000242423.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 DR
 XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
 XX
 PS Disclosure; SEQ ID NO 6951; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 89 TCGCCGACTGGCTGC 103
 |||||
 Db 2 TCGCCGACTGGCTGC 16
 |||||
 RESULT 462
 ABRN08012
 ID ABRN08012 standard; DNA; 17 BP.
 XX
 AC ABRN08012;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8004.
 XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;

KW muscle; myosin; chromosome 22; Gene therapy; vaccine; heart disease;
 XX skeletal muscle disorder; amplicon; screening; ss.
 KM
 OS Homo sapiens.
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PP 25-MAY-2001; 2001WO-US016981.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-000242423.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 XX (AEOM-) AEOMICA INC.
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 DR
 XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
 XX
 PS Disclosure; SEQ ID NO 8004; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2038 CAGCTGAGCAGCTC 2052
 |||||
 Db 3 CAGCTGAGCAGCTC 17
 |||||

```
RESULT 463
AB063624
ID AB063624 standard; DNA; 17 BP.
XX
AC AB063624;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (AB063232) probe # 337.
XX
KW Human; KTOM1a; KTOM1; kidney tumor overexpressed membrane; cytosolic;
KM gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KN kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J;
XX
DR WPI; 2002-479509/51.
XX
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
PS Example 2; Page 201; 418pp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding human
CC KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the
CC invention has cytosolic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (AB063232)
XX
SQ Sequence 17 BP; 1 A; 4 C; 6 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 566 TGTTCCTGTCCTCG 580
DB 2 TGTTCCTGTCCTCG 16
```

```
RESULT 464
AB063623
ID AB063623 standard; DNA; 17 BP.
XX
AC AB063623;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (AB063232) probe # 336.
XX
KW Human; KTOM1a; KTOM1; kidney tumor overexpressed membrane; cytosolic;
KM gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KN kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J;
XX
DR WPI; 2002-479509/51.
XX
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
PS Example 2; Page 201; 418pp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding human
CC KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the
CC invention has cytosolic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (AB063232)
XX
SQ Sequence 17 BP; 1 A; 4 C; 6 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 566 TGTTCCTGTCCTCG 580
DB 3 TGTTCCTGTCCTCG 17
```



```
RESULT 465
AB063625
ID AB063625 standard; DNA; 17 BP.
XX
AC AB063625;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (AB063232) probe # 338.
XX
KM Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostratic;
KM Gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KM Kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
XX
PR 27-SEP-2000; 2000US-0236359P.
XX
PR 04-OCT-2000; 2000GB-00024263.
XX
PR 30-JAN-2001; 2001WO-US000661.
XX
PR 30-JAN-2001; 2001WO-US000661.
XX
PR 30-JAN-2001; 2001WO-US000663.
XX
PR 30-JAN-2001; 2001WO-US000663.
XX
PR 30-JAN-2001; 2001WO-US000665.
XX
PR 30-JAN-2001; 2001WO-US000665.
XX
PR 30-JAN-2001; 2001WO-US000666.
XX
PR 30-JAN-2001; 2001WO-US000667.
XX
PR 30-JAN-2001; 2001WO-US000668.
XX
PR 30-JAN-2001; 2001WO-US000669.
XX
PR 30-JAN-2001; 2001WO-US000670.
XX
PR 23-MAY-2001; 2001US-00864761.
XX
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J;
XX
DR WPI; 2002-479509/51.
XX
XX
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acid encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
PS Example 2; Page 202; 418pp; English.
XX
XX
CC The invention relates to a novel isolated nucleic acid encoding human
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC invention has cytostratic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (AB063232)
XX
SQ Sequence 17 BP; 0 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 566 TGTTCGTGTCCTGG 580
|||||
```

```
DB 1 TGTTCGTGTCCTGG 15
RESULT 466
ABV85491/c
ID ABV85491 standard; DNA; 17 BP.
XX
AC ABV85491;
XX
DT 11-DEC-2002 (first entry)
XX
DE Human pp-GaNTase 10 scanning 17-mex SEQ ID NO:484.
XX
KM Human; UDP-Ga[NAC:polypeptide N-acetylglactosaminyltransferase 10;
KM pp-GaNTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
KM ss.
XX
OS Homo sapiens.
XX
OS Synthetic.
XX
PN EP1243660-A2.
XX
PD 25-SEP-2002.
XX
PF 25-JAN-2002; 2002EP-00001161.
XX
PR 30-JAN-2001; 2001WO-US000663.
XX
PR 30-JAN-2001; 2001WO-US000664.
XX
PR 30-JAN-2001; 2001WO-US000665.
XX
PR 30-JAN-2001; 2001WO-US000666.
XX
PR 30-JAN-2001; 2001WO-US000667.
XX
PR 30-JAN-2001; 2001WO-US000668.
XX
PR 30-JAN-2001; 2001WO-US000669.
XX
PR 30-JAN-2001; 2001WO-US000670.
XX
PR 23-MAY-2001; 2001US-00864761.
XX
PR 30-AUG-2001; 2001US-0315984P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J, Gu Y, Nguyen C;
XX
DR WPI; 2002-724954/79.
XX
XX
PT Nucleic acid encoding human UDP-Ga[NAC:polypeptide N-
PT cetylglactosaminyltransferase 10 protein is useful to diagnose, prevent
PT and treat disorders associated with reduced or over expression of the
PT encoded protein.
XX
PS Example 2; SEQ ID NO 484; 59pp; English.
XX
XX
CC The present invention describes an isolated nucleic acid (I) encoding a
CC human UDP-Ga[NAC:polypeptide N-acetylglactosaminyltransferase 10 (pp-
CC GaNTase 10, EC 2.4.1.41) protein. Human pp-GaNTase 10 is located to
CC chromosome 7q11.2. (I) can be used in gene therapy. Molecules of the
CC present invention can be used in therapy, particularly to prevent or
CC treat a disorder associated with decreased expression or activity of pp-
CC GaNTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to
CC ABP53504 are given in the exemplification of the present invention. N.B.
CC The sequence data for this patent is not represented in the printed
CC specification but is based on sequence information supplied by the
CC European Patent Office
XX
SQ Sequence 17 BP; 6 A; 4 C; 5 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1487 CCTTACCTTGAGG 1501
|||||
DB 15 CCTTACCTTGAGG 1
```

RESULT 467
ABK19232/c
ID ABK19232 standard; RNA; 17 BP.
XX
XX
AC ABK19232;
XX
DT 09-APR-2002 (first entry)
XX
XX
DE Human ERG Amberzyme target sequence Seq ID No 1879.
XX
XX
KM Human; hammerhead ribozyme; cytosolic; antitumor; antidiabetic;
KM ophthalmological; antiarthritic; antipsoriatic; vitruide; osteopathic;
KM vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KM tumour angiogenesis; diabetic retinopathy; macular degeneration;
KM neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KM angiocibroma of tuberosus sclerosis; port-wine stain; wound healing;
KM Sturge Weber syndrome; Kippel-Trennauay-Weber syndrome; leukaemia; ss;
KM Oslter-Weber-rendu syndrome; leukaemia; osteoporosis; DNazyme; inozyme;
KM amberzyme.
XX
XX
OS Homo sapiens.
XX
XX
PN W0200188124-A2.
XX
XX
PD 22-NOV-2001.
XX
XX
PF 16-MAY-2001; 2001WO-US015866.
XX
XX
PR 16-MAY-2000; 2000US-00572021.
XX
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PA (GLAXO) GLAXO GROUP LTD.
XX
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
XX
XX
DR WPI; 2002-082995/11.
XX
XX
PT Novel polynucleotide which down regulates expression of Ets-related gene,
PT useful for treating cancer, diabetic retinopathy, macular degeneration,
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
XX
PS Claim 4; Page 123; 149pp; English.
XX
XX
CC The invention relates to a nucleic acid molecule (I) which down regulates
CC expression of an Ets-related gene (ERG). (I) is useful for treating
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC vulgaris, angiocibroma of tuberosus sclerosis, port-wine stains, Sturge
CC Weber syndrome, Kippel-Trennauay-Weber syndrome, Oslter-Weber-rendu
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
CC treating a patient having a condition associated with the level of ERG,
CC by contacting cells of the patient with (I) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (I) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17354-ABK22719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention
XX
XX
SQ Sequence 17 BP; 4 A; 7 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 345 GCTGATCTCATGGGG 359
|||
Db 15 GCTGATCTCCTGGGG 1
|||
RESULT 468
ABS74945
ID ABS74945 standard; DNA; 17 BP.
XX
XX
AC ABS74945;
XX
XX
DT 24-DEC-2002 (first entry)
XX
XX
DE Human PAPP-Ea associated 17-mer SEQ ID 471.
XX
XX
KM PAPP-E; human; pregnancy associated plasma protein E; abortive;
KM contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
KM dysgenetic pregnancy; primer; ss.
XX
XX
OS Homo sapiens.
XX
XX
PN US2002102252-A1.
XX
XX
PD 01-AUG-2002.
XX
XX
PF 06-APR-2001; 2001US-00827998.
XX
XX
PR 26-MAY-2000; 2000US-0207456P.
XX
XX
PA (GUY/) GU Y.
XX
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Shannon ME;
XX
XX
DR WPI; 2002-697817/75.
XX
XX
PT New isolated nucleic acid encoding an isoform of human pregnancy
PT associated plasma protein E, for preventing or aborting pregnancy.
XX
XX
PS Example 2; Page 137; 353pp; English.
XX
XX
CC This invention describes a novel isolated nucleic acid that encodes one
CC of three new isoforms of human pregnancy associated plasma protein E,
CC hPAPP-E. The products of the invention have abortive and contraceptive
CC activity and can be used for gene therapy or in a vaccine. The nucleic
CC acid, polypeptide encoded by it, or antibody to the polypeptide can be
CC used in pharmaceutical compositions or vaccines for preventing or
CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of
CC dysgenetic pregnancies. The nucleic acids are used as probes to assess
CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the
CC antibodies can be used to assess the expression levels of PAPP-E isoform
CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
CC antenatally. This sequence represents an oligomer used in scanning the
CC human PAPP-E genes described in the disclosure of the invention
XX
XX
SQ Sequence 17 BP; 9 A; 0 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1027 AAGAAAGTGGGAAA 1041
|||
Db 3 AAGAAAGGCGGAAA 17
|||
RESULT 469
ABS74947
ID ABS74947 standard; DNA; 17 BP.
XX
XX
AC ABS74947;

```
XX 24-DEC-2002 (first entry)
DT
XX
DE Human PAPP-Ea associated 17-mer SEQ ID 473.
XX
XX PAPP-E; human; pregnancy associated plasma protein E; abortive;
KM contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
XX dysgenetic pregnancy; primer; ss.
XX
XX Homo sapiens.
XX
XX US2002102252-A1.
XX
XX 01-AUG-2002.
XX
XX 06-APR-2001; 2001US-00827998.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX (GUY/) GU Y.
XX (SHAN/) SHANNON M E.
XX
XX Gu Y, Shannon ME;
XX
XX WPI; 2002-697817/75.
XX
XX New isolated nucleic acid encoding an isoform of human pregnancy
PT associated plasma protein E, for preventing or aborting pregnancy.
XX
XX Example 2; Page 137; 353pp; English.
XX
XX This invention describes a novel isolated nucleic acid that encodes one
CC of three new isoforms of human pregnancy associated plasma protein E,
CC hPAPP-E. The products of the invention have abortive and contraceptive
CC activity and can be used for gene therapy or in a vaccine. The nucleic
CC acid, polypeptide encoded by it, or antibody to the polypeptide can be
CC used in pharmaceutical compositions or vaccines for preventing or
CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of
CC dysgenetic pregnancies. The nucleic acids are used as probes to assess
CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the
CC antibodies can be used to assess the expression levels of PAPP-E isoform
CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
CC antenatally. This sequence represents an oligomer used in scanning the
CC human PAPP-E genes described in the disclosure of the invention
XX
XX
SQ Sequence 17 BP; 10 A; 0 C; 7 G; 0 T; 0 U; 0 Other;

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1027 AAGAGGTGGGAAA 1041
DB 1 AAGAGGGGGGAAA 15

RESULT 470
ABST4946
ID ABST4946 standard; DNA; 17 BP.
XX
XX ABST4946;
XX
XX 24-DEC-2002 (first entry)
XX
XX Human PAPP-Ea associated 17-mer SEQ ID 472.
XX
XX PAPP-E; human; pregnancy associated plasma protein E; abortive;
KM contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
XX dysgenetic pregnancy; primer; ss.
XX
XX Homo sapiens.
XX
XX US2002102252-A1.
```

```
XX 01-AUG-2002.
PD
XX
XX 06-APR-2001; 2001US-00827998.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX (GUY/) GU Y.
XX (SHAN/) SHANNON M E.
XX
XX Gu Y, Shannon ME;
XX
XX WPI; 2002-697817/75.
XX
XX New isolated nucleic acid encoding an isoform of human pregnancy
PT associated plasma protein E, for preventing or aborting pregnancy.
XX
XX Example 2; Page 137; 353pp; English.
XX
XX This invention describes a novel isolated nucleic acid that encodes one
CC of three new isoforms of human pregnancy associated plasma protein E,
CC hPAPP-E. The products of the invention have abortive and contraceptive
CC activity and can be used for gene therapy or in a vaccine. The nucleic
CC acid, polypeptide encoded by it, or antibody to the polypeptide can be
CC used in pharmaceutical compositions or vaccines for preventing or
CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of
CC dysgenetic pregnancies. The nucleic acids are used as probes to assess
CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the
CC antibodies can be used to assess the expression levels of PAPP-E isoform
CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
CC antenatally. This sequence represents an oligomer used in scanning the
CC human PAPP-E genes described in the disclosure of the invention
XX
XX
SQ Sequence 17 BP; 9 A; 0 C; 8 G; 0 T; 0 U; 0 Other;

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1027 AAGAGGTGGGAAA 1041
DB 2 AAGAGGGGGGAAA 16

RESULT 471
ABV90560
ID ABV90560 standard; DNA; 17 BP.
XX
XX ABV90560;
XX
XX 23-DEC-2002 (first entry)
XX
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 1273.
XX
XX Human; POSHL 1; SH domain; POSH-like signalling protein 1; oncogene;
KM Rho GTPase; signal transduction; gene expression; cancer; vaccine;
XX gene therapy; transgenic; ss.
XX
XX Homo sapiens.
XX
XX EP1239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-00001165.
XX
XX 30-JAN-2001; 2001WO-US0000663.
XX 30-JAN-2001; 2001WO-US0000664.
XX 30-JAN-2001; 2001WO-US0000665.
XX 30-JAN-2001; 2001WO-US0000666.
XX 30-JAN-2001; 2001WO-US0000667.
XX 30-JAN-2001; 2001WO-US0000668.
XX 30-JAN-2001; 2001WO-US0000669.
```

```
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
PA (AEOM-) AEOMICA INC.
XX Shannon M;
PI WPI; 2002-684061/74.
DR WPI; 2002-684061/74.
PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
XX Example 2; SEQ ID NO 1273; 60pp + Sequence Listing; English.
PS
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 6 A; 5 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2182 CAGCTCATGGAGAA 2196
DB 2 CAGCCCATGGAGAA 16
RESULT 472
ABV90561
ID ABV90561 standard; DNA; 17 BP.
XX
AC ABV90561;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1274.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EPI239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
```

```
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
PA (AEOM-) AEOMICA INC.
XX Shannon M;
PI WPI; 2002-684061/74.
DR WPI; 2002-684061/74.
PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
XX Example 2; SEQ ID NO 1274; 60pp + Sequence Listing; English.
PS
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 6 A; 5 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2182 CAGCTCATGGAGAA 2196
DB 1 CAGCCCATGGAGAA 15
RESULT 473
ABV90559
ID ABV90559 standard; DNA; 17 BP.
XX
AC ABV90559;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1272.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EPI239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
```

PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 10-OCT-2001; 2001US-0328205P.
 (AEOM-) AEOMICA INC.
 Shannon M;
 WPI; 2002-684061/74.
 DR WPI; 2002-684061/74.
 XX
 PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
 PT -1, useful for treating disorders associated with decreased expression or
 PT activity of human POSHL1.
 XX
 PS Example 2; SEQ ID NO 1272; 60pp + Sequence Listing; English.
 XX
 CC The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
 CC (S1) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention. Note: The present sequence did not form part of the
 CC printed specification, but is based on sequence information supplied to
 CC Derwent by the European Patent Office
 CC
 SQ Sequence 17 BP; 6 A; 6 C; 4 G; 1 T; 0 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2182 CAGCTCATGGAGAA 2196
 Db 3 CAGCCCATGGAGAA 17
 |||||
 RESULT 474
 ABK57194/c
 ID ABK57194 standard; RNA; 17 BP.
 XX
 AC ABK57194;
 XX
 DT 02-JUL-2002 (first entry)
 XX
 DE Human CLCA1 gene enzymatic nucleic acid #1565.
 XX
 KW Human; chloride channel calcium activated 1; CLCA1; ss; antiaesthetic;
 KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
 KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
 KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
 KW acetylcytosteine.
 KM
 XX
 OS Homo sapiens.
 XX
 PN WO200211674-A2.
 XX

PD 14-FEB-2002.
 XX
 PR 09-AUG-2001; 2001WO-US024970.
 XX
 PR 09-AUG-2000; 2000US-0224383P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (SYNTE) SYNTEK USA LLC.
 PA (THOM/) THOMPSON J.
 XX
 XX Thompson J, Mcawiggen J, McKenzie T, Ayers D, Szymkowski DE;
 PI Grube A;
 PI WPI; 2002-217145/27.
 DR WPI; 2002-217145/27.
 XX
 PT Enzymatic polynucleotide that down regulates expression of chloride
 PT channel calcium activated gene, useful for treating Chronic obstructive
 PT pulmonary disease (COPD), chronic bronchitis and asthma.
 XX
 PS Claim 4; Page 98; 152pp; English.
 XX
 CC The invention relates to enzymatic nucleic acid molecules that down
 CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
 CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of CLCA1 in a cell or
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
 CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of CLCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibiotics, vaccinations, acetylcytosteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of CLCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention
 CC
 SQ Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1887 TCAGGCGCTATGACAC 1901
 Db 15 TCAGGCGCTGACAC 1
 |||||
 RESULT 475
 ABK56649/c
 ID ABK56649 standard; RNA; 17 BP.
 XX
 AC ABK56649;
 XX
 DT 02-JUL-2002 (first entry)
 XX
 DE Human CLCA1 gene enzymatic nucleic acid #1020.
 XX
 KW Human; chloride channel calcium activated 1; CLCA1; ss; antiaesthetic;
 KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
 KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
 KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
 KW acetylcytosteine.
 KM
 XX
 OS Homo sapiens.
 XX
 PN WO200211674-A2.
 XX
 PD 14-FEB-2002.
 XX
 PF 09-AUG-2001; 2001WO-US024970.
 XX

```
XX 09-AUG-2000; 2000US-0224383P.
PR (RIBO-) RIBOZYME PHARM INC.
XX (SYNT ) SYNTAX USA LLC.
PA (THOM/) THOMPSON J.
PI Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE;
XX Grupe A;
XX WPI; 2002-217145/27.
DR
XX Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PR pulmonary disease (COPD), chronic bronchitis and asthma.
XX
XX Claim 4; Page 77; 152pp; English.
XX
XX The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibiotics, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention
XX
XX Sequence 17 BP; 4 A; 5 C; 4 G; 0 T; 4 U; 0 Other;
SQ
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1887 TCAGGCGCTATGACAC 1901
Db 16 TCAGGCGCTGACAC 2
RESULT 476
ABK56493/C
ID ABK56493 standard; RNA; 17 BP.
XX
XX ABK56493;
AC
XX
XX 02-JUL-2002 (first entry)
DT
XX Human CLCA1 gene enzymatic nucleic acid #864.
XX
XX Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KM antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KM chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KM oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KM acetylcysteine.
XX
XX Homo sapiens.
OS
XX
XX WO200211674-A2.
PN
XX
XX 14-FEB-2002.
PD
XX
XX 09-AUG-2001; 2001WO-US024970.
PF
XX
XX 09-AUG-2000; 2000US-0224383P.
PR
XX
```

```
PA (RIBO-) RIBOZYME PHARM INC.
PA (SYNT ) SYNTAX USA LLC.
XX (THOM/) THOMPSON J.
PI Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE;
XX Grupe A;
XX WPI; 2002-217145/27.
DR
XX Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PR pulmonary disease (COPD), chronic bronchitis and asthma.
XX
XX Claim 4; Page 72; 152pp; English.
XX
XX The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibiotics, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention
XX
XX Sequence 17 BP; 3 A; 6 C; 4 G; 0 T; 4 U; 0 Other;
SQ
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1997 TGGATGATGACCA 2011
Db 16 TGGATGATGACCA 2
RESULT 477
ABZ97151
ID ABZ97151 standard; DNA; 17 BP.
XX
XX ABZ97151;
AC
XX
XX 17-OCT-2003 (first entry)
DT
XX Human MTA oligonucleotide.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KM antiinflammatory steroid; ubiquitinome; antiinflammatory; antiasthmatic;
KM antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KM antisense gene therapy; respiratory; lung; adenosine sensitivity;
KM adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KM lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
OS
XX
XX WO200285308-A2.
PN
XX
XX 31-OCT-2002.
PD
XX
XX 23-APR-2002; 2002WO-US013135.
PF
XX
XX 24-APR-2001; 2001US-0286137P.
PR
XX (EPIG-) EPIGENESIS PHARM INC.
XX
```

PI NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahbuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 12393; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end, genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 17 BP; 0 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 565 CTGTTCTGTCCTCG 579
Db 1 CTGTCCTGTCCTCG 15
|||||

RESULT 478

AB296448 standard; DNA; 17 BP.

XX
AC AB296448;

XX
DT 17-OCT-2003 (first entry)

XX
DE Human nucleic acid sequence.

XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX
OS Homo sapiens.

XX
PN W0200285308-A2.

XX
PD 31-OCT-2002.

XX
PF 23-APR-2002; 2002WO-US013135.

XX
PR 24-APR-2001; 2001US-0286137P.

XX
PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahbuddin S;
XX
DR WPI; 2003-229219/22.

XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX
PS Disclosure; SEQ ID NO 11690; 872pp; English.

XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end, genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 17 BP; 0 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 565 CTGTTCTGTCCTCG 579
Db 1 CTGTCCTGTCCTCG 15
|||||

RESULT 479

ACD00797/C standard; DNA; 17 BP.

XX
AC ACD00797;

XX
DT 28-JUL-2003 (first entry)

XX
DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #1270.

XX
KW Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.

XX
OS Homo sapiens.

XX
PN W02003031621-A2.

XX
PD 17-APR-2003.

XX
PF 11-OCT-2002; 2002WO-US032599.

XX
PR 12-OCT-2001; 2001US-0329000P.

XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.

XX
PI Zhang J;

XX
DR WPI; 2003-381720/36.

XX

PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT investigating and/or treating disorders associated with aberrant
PT expression or activity of GPCR-A-1, such as tumors and cancers.
XX
PS Example 2; SEQ ID NO 1294; 156bp; English.
XX
CC The invention describes an isolated nucleic acid encoding a G protein
CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumors and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1
XX
SQ Sequence 17 BP, 1 A; 5 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 861 GGTACACAGAGCACC 875
Db 17 GGTACACAGAGCAAC 3

RESULT 480
ACD00798/c
ID ACD00798 standard; DNA; 17 BP.
XX
AC ACD00798;
XX
DT 28-JUN-2003 (first entry)
XX
DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #1271.
XX
KM Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KM G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS Homo sapiens.
XX
PN MO2003031621-A2.
XX
PD 17-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032559.
XX
PR 12-OCT-2001; 2001US-0329000P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Zhang J;
XX
DR WPI; 2003-381720/36.
XX
PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT investigating and/or treating disorders associated with aberrant
PT expression or activity of GPCR-A-1, such as tumors and cancers.
XX
PS Example 2; SEQ ID NO 1295; 156bp; English.
XX
CC The invention describes an isolated nucleic acid encoding a G protein
CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumors and cancers.

CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1
XX
SQ Sequence 17 BP, 1 A; 5 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 861 GGTACACAGAGCACC 875
Db 16 GGTACACAGAGCAAC 2

RESULT 481
ABT38416
ID ABT38416 standard; DNA; 17 BP.
XX
AC ABT38416;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 4053.
XX
KM Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KM schizophrenia; protein chip; gene therapy; tumour suppression;
KM human fukutin; ds.
XX
OS Homo sapiens.
XX
PN MO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Teلمان A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 507; 720bp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, or the complement
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention

XX Sequence 17 BP; 2 A; 8 C; 2 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 1523 TCCTCTGCTACC 1537
 |||||
 3 TCCTCTGCTACC 17
 Db
 RESULT 482
 ACA07766
 ID ACA07766 standard; RNA; 17 BP.
 AC ACA07766;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFkB sub-unit modulating zinzyme substrate #165.
 KM Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
 KM G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;
 KM lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KM oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KM cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KM lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KM chemotheraphy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KM cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
 KM gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KM rheumatoid arthritis; resenosis; Crohn's disease; obesity; ischaemia;
 KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KM transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KM allergic airway inflammation; inflammatory bowel disease; infection; ss.
 KM
 XX
 OS Homo sapiens.
 XX
 PN US2002177568-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 23-MAY-2001; 2001US-00864785.
 XX
 PR 07-DEC-1992; 92US-00987132.
 PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00291932.
 PR 23-DEC-1996; 96US-00777916.
 XX
 PA (STIN/) STINGCOMB D T.
 PA (MCSW/) MCSWIGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 PI Stinchcomb DT, Mcswigen J, Draper KG;
 XX
 DR WPI; 2003-340953/32.
 XX
 PT Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 PS Claim 3; Page 40; 72pp; English.
 XX
 CC The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberyne
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,

CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate;
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, resenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 CC
 SQ Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
 Oy Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 86.7%; Pred. No. 2.3e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Db 1362 CACCCAGCGTGTGCA 1376
 |||||
 2 CACCCAGCGTGTGCA 16
 Db
 RESULT 483
 ACA07802/C
 ID ACA07802 standard; RNA; 17 BP.
 AC ACA07802;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFkB sub-unit modulating zinzyme substrate #201.
 KM Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
 KM G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;
 KM lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KM oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KM cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KM lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KM chemotheraphy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KM cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
 KM gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KM rheumatoid arthritis; resenosis; Crohn's disease; obesity; ischaemia;
 KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KM transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KM allergic airway inflammation; inflammatory bowel disease; infection; ss.
 KM
 XX
 OS Homo sapiens.
 XX
 PN US2002177568-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 23-MAY-2001; 2001US-00864785.
 XX
 PR 07-DEC-1992; 92US-00987132.
 PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00291932.
 PR 23-DEC-1996; 96US-00777916.
 XX
 PA (STIN/) STINGCOMB D T.
 PA (MCSW/) MCSWIGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 PI Stinchcomb DT, Mcswigen J, Draper KG;
 XX
 DR WPI; 2003-340953/32.
 XX
 PT Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for

PT treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 PS Claim 3; Page 40; 72pp; English.
 XX
 CC The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 XX
 SQ Sequence 17 BP; 2 A; 9 C; 5 G; 0 T; 1 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 355 TGGGAGCCCCCGGG 369
 |||||
 16 TGGGAGCCCCCGGG 2
 RESULT 484
 ID ACA06237 standard; RNA; 17 BP.
 XX
 AC ACA06237;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFKB sub-unit modulating inozyme substrate #56.
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
 XX
 OS Homo sapiens.
 XX
 XX US2002177568-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 23-MAY-2001; 2001US-00864785.
 XX
 PR 07-DEC-1992; 92US-00987132.

PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00291932.
 PR 23-DEC-1996; 96US-00777916.
 XX
 PA (STIN/) STRINGCOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 PI Stinchcomb DT, Mcswiggen J, Draper KG;
 DR WPI; 2003-340953/32.
 XX
 DR WPI; 2003-340953/32.
 XX
 PT Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 PS Claim 3; Page 28; 72pp; English.
 XX
 CC The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;
 Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Oy 565 CTGTCTCTGTCTCTG 579
 |||||
 16 CTGTCTCTGTCTCTG 2
 RESULT 485
 ID ACA09009 standard; RNA; 17 BP.
 XX
 AC ACA09009;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFKB sub-unit modulating amberzyme substrate #172.
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;

KM	rheumatoid arthritis; reestenosis; Crohn's disease; obesity; ischaemia;
KW	gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KX	transplant/graft rejection; reperfusion injury; glomerulonephritis;
KY	allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX	
OS	Homo sapiens.
PN	US2002177568-A1.
PD	28-NOV-2002.
PP	23-MAY-2001; 2001US-00864785.
PR	07-DEC-1992; 92US-00987132.
PT	18-MAY-1994; 94US-00245466.
PR	15-AUG-1994; 94US-00291933.
PR	23-DEC-1996; 96US-00777916.
XX	(STIN/) STINCHEOMB D T.
PA	(MCWS/) MCWSIGGEN J.
PA	(DRAP/) DRAPER K G.
PI	Stinchcomb DT, Mcswigen J, Draper KG;
XX	
WP:	WPI; 2003-340953/32.
XX	
PT	Novel enzymatic nucleic acid molecules which down regulates expression of
PT	a sequence encoding a subunit of nuclear factor kappa B useful for
PT	treating cancer, inflammatory disorders and autoimmune diseases.
XX	
PS	Claim 3, Page 54; 72pp; English.
XX	
CC	The invention describes an enzymatic nucleic acid molecule (I) which down
CC	regulates expression of a sequence encoding a subunit of nuclear factor
CC	kappa B (NRKB), where (I) is an incyzyme, zinczyme, G-cleaver or amberzyme
CC	configuration. The enzymatic nucleic acid molecule is adapted to treat
CC	cancer and is useful for down-regulating REL-A activity in a cell, for
CC	treating a patient having a condition associated with the level of REL-A.
CC	(I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC	the presence of a divalent cation, especially Mg ⁺²⁺ . The enzymatic and
CC	antisense nucleic acid molecules are useful for treating breast, lung,
CC	prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC	cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC	mucinous resistant cancer. The method involves use of other drug
CC	therapies such as monoclonal antibodies, RET-A-specific inhibitors or
CC	chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC	cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
CC	gemtadibine or radiation therapy. The enzymatic and antisense nucleic
CC	acid molecules are also useful for treating inflammatory disease such as
CC	rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC	obesity, autoimmune disease, lupus, multiple sclerosis, transplant/grft
CC	rejection, gene therapy applications, ischaemia/reperfusion injury
CC	(central nervous system (CNS) and myocardial), glomerulonephritis,
CC	sepsis, allergic airway inflammation, inflammatory bowel disease or
CC	infection. This sequence represents the substrate of a novel enzymatic
CC	nucleic acid molecule
XX	
SQ	Sequence 17 BP; 3 A; 7 C; 6 G; 0 T; 1 U; 0 Other;
XX	
Query Match	0.6%; Score 13.4; DB 1; Length 17;
Beat Local Similarity	86.7%; Pred. No. 2, 3e+02;
Matches 13; Conservative	1; Mismatches 1; Indels 0; Gaps 0
Oy	1362 CACCAAGGCTGTGGA 1376 ::
Dd	3 CACCAGCGUCGGGA 17 ::
RESULT 486	
ACA06236/C	
ID ACA06236 standard; RNA; 17 BP.	
XX ACA06236;	

XX	03-JUN-2003	(first entry)
DT	NFKB sub-unit modulating inozyme substrate #55.	
DE		
XX		
XX	Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;	
KM	G-cleaver; amberyze; cancer; RBL-A activity; breast cancer; human;	
KM	lung cancer; prostate cancer; colorectal cancer; brain cancer;	
KM	oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;	
KM	cervical cancer; head and neck cancer; ovarian cancer; melanoma;	
KM	lymphoma; glioma; multidrug resistant cancer; RBL-A-specific inhibitor;	
KM	chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;	
KM	cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;	
KM	gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;	
KM	rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischemia;	
KW	gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;	
KV	transplant/graft rejection; reperfusion injury; glomerulonephritis;	
XX	allergic airway inflammation; inflammatory bowel disease; infection; ss.	
XX		
OS	Homo sapiens.	
PX		
PN	US2002177568-A1.	
PD		
PP	28-NOV-2002.	
PF		
PI	23-MAY-2001; 2001US-00864785.	
PR		
PR	07-DEC-1992; 92US-00987132.	
PR	18-MAY-1994; 94US-00245466.	
PR	15-AUG-1994; 94US-00291932.	
PR	23-DEC-1996; 96US-00777916.	
XX		
PA	(STIN/) STINCCHOMB D T.	
PA	(MCSM/) MCSMIGEN J.	
PA	(DRAP/) DRAPER K G.	
XX		
PI	Stinchcomb DT, Mcswiggen J, Draper KG;	
XX		
XX	WPI; 2003-340953/32.	
PT		
PT	Novel enzymatic nucleic acid molecules which down regulates expression of	
PT	a sequence encoding a subunit of nuclear factor kappa B useful for	
PT	treating cancer, inflammatory disorders and autoimmune diseases.	
XX		
XX	Claim 3; Page 28; 72pp; English.	
XX		
CC	The invention describes an enzymatic nucleic acid molecule (I) which down	
CC	regulates expression of a sequence encoding a subunit of nuclear factor	
CC	kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberyze	
CC	configuration. The enzymatic nucleic acid molecule is adapted to treat	
CC	cancer and is useful for down-regulating RBL-A activity in a cell, for	
CC	treating a patient having a condition associated with the level of RBL-A.	
CC	(I) is useful for cleaving RNA comprising a sequence of RBL-A gene, in	
CC	the presence of a divalent cation, especially Mg ⁺² . The enzymatic and	
CC	antisenase nucleic acid molecules are useful for treating breast, lung,	
CC	prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,	
CC	cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or	
CC	multidrug resistant cancer. The method involves use of other drug	
CC	therapies such as monoclonal antibodies, RBL-A-specific inhibitors or	
CC	chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate, or	
CC	cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,	
CC	gemcitabine or radiation therapy. The enzymatic and antisenase nucleic	
CC	acid molecules are also useful for treating inflammatory disease such as	
CC	rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,	
CC	obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft	
CC	rejection, gene therapy applications, ischaemia/reperfusion injury,	
CC	(central nervous system (CNS) and myocardial), glomerulonephritis,	
CC	sepsis, allergic airway inflammation, inflammatory bowel disease or	
CC	infection. This sequence represents the substrate of a novel enzymatic	
CC	nucleic acid molecule	
XX		
Sequence 17 BP; 6 A; 5 C; 6 G; 0 T; 0 U; 0 Other;		

```

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      565 CTGTTCTGTCGTCG 579
      17 CTGTCCTGTCCTG 3

Db

RESULT 487
ABZ61828
ID ABZ61828 standard; RNA; 17 BP.
XX
AC ABZ61828;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human H-Ras DNAzyme target #619.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer; modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 122; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosolic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ65520 - ABZ65524,
CC ABZ65530 - ABZ65585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 0 A; 2 C; 10 G; 0 T; 5 U; 0 Other;

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 2.3e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      167 GGGTCTGGGCGGTGG 181
      1 GGGUCUGGGCUGUGG 15

Db

RESULT 488
ABZ64627/c

```

```

ID ABZ64627 standard; RNA; 17 BP.
XX
AC ABZ64627;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human HER2 DNAzyme substrate #84.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer; modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 4; Page 134; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosolic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ65520 - ABZ65524,
CC ABZ65530 - ABZ65585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 4 A; 9 C; 2 G; 0 T; 2 U; 0 Other;

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1284 CATTGCTGGCGACGT 1298
      15 CATTGCTGGCGACGT 1

Db

RESULT 489
ACD53016/c
ID ACD53016 standard; RNA; 17 BP.
XX
AC ACD53016;
XX
DT 24-SEP-2003 (first entry)
XX
DE HBV inozyme substrate sequence #687.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinczyme;

```

KM amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 KM HBV reverse transcriptase; Enhancer I region; viral replication;
 KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KM virucide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis B virus.
 PN WO00281494-A1.
 PD 17-OCT-2002.
 XX
 PF 26-MAR-2002; 2002WO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 PI Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX WPI; 2003-229207/22.
 DR
 XX
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 PT
 PS
 PS Example 1; Page 163; 387pp; English.
 XX
 XX The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinczymes, amberyne, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HBV
 CC ribozyme, inozyme, G-cleaver, zinczyme, DNzyme or amberyne sequences
 CC disclosed in the present invention
 XX
 SQ Sequence 17 BP; 2 A; 9 C; 3 G; 0 T; 3 U; 0 Other;
 QY Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2162 GGGAGGGGGAACCC 2176
 DB 15 GGGAGGGGGAACCC 1
 ACDS7386
 ACDS7386

ID ACD57386 standard; RNA; 17 BP.
 XX
 AC ACD57386;
 XX
 DT 23-SEP-2003 (first entry)
 XX
 DE HCV DNzyme substrate sequence #308.
 XX
 KM Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KM RNA stability; RNA expression; RNA synthesis; antisense;
 KM enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinczyme;
 KM amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 KM HBV reverse transcriptase; Enhancer I region; viral replication;
 KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KM virucide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis C virus.
 PN WO00281494-A1.
 PD 17-OCT-2002.
 XX
 PF 26-MAR-2002; 2002WO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 PI Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX WPI; 2003-229207/22.
 DR
 XX
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 PT
 PS
 PS Claim 1; Page 239; 387pp; English.
 XX
 XX The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinczymes, amberyne, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNzyme or minus strand DNzyme sequences disclosed in the present
 CC invention
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;

```

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 2.3e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
Oy      59 TCGCATGGCTGGGGA 73
      11:|||||:|||||
Db      2 UCGCATGGCTGGGGA 16

RESULT 491
ACDS3015/c
ID ACDS3015 standard; RNA; 17 BP.
XX
AC ACDS3015;
XX
XX
DT 24-SEP-2003 (first entry)
XX
DE HBV inozyme substrate sequence #686.
XX
KM Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KM RNA stability; RNA expression; RNA synthesis; antisense;
KM enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KM amberyyme; G-cleaver ribozyme; decoy molecule; aptamer;
KM HBV reverse transcriptase; Enhancer I region; viral replication;
KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KM vitucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis B virus.
XX
PN W0200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEF/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Example 1; Page 163; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberyymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening

```

```

CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberyyme sequences
CC disclosed in the present invention
XX
SQ Sequence 17 BP; 2 A; 9 C; 3 G; 0 T; 3 U; 0 Other;
XX

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy      2162 GCGAGGGGGGAACC 2176
      17 GCGAGGGGTGAACCC 3
Db

RESULT 492
ABX75171
ID ABX75171 standard; DNA; 17 BP.
XX
AC ABX75171;
XX
DT 25-MAR-2003 (first entry)
XX
DE Human 216 gene allele specific oligonucleotide probe #2.
XX
XX
KM Human; mouse; ss; probe; gene 216; antiasthmatic; antiinflammatory;
KM anorectic; chromosome 20p13-p12; single nucleotide polymorphism; SNP;
KM gene therapy; respiratory disease; asthma; obesity;
KM bronchial hyper-responsiveness; chronic obstructive pulmonary disease;
KM adult respiratory distress syndrome; inflammatory bowel syndrome.
XX
OS Homo sapiens.
XX
PN W0200283077-A2.
XX
PD 24-OCT-2002.
XX
PF 15-APR-2002; 2002WO-US012063.
XX
PR 13-APR-2001; 2001US-00834597.
PR 13-APR-2001; 2001WO-US012245.
XX
PA (SCHE ) SCHERING CORP.
PA (GENO-) GENOME THERAPEUTICS CORP.
XX
PI Keith T, Little RD, Van Berdewegh P, Dupuis J, Del Mastro RG;
PI Simon J, Allen K, Pandit S;
XX
DR WPI; 2003-092960/08.
XX
PT New isolated gene 216 nucleic acids, useful for diagnosing, preventing or
PT treating a disorder, such as asthma, bronchial hyper-responsiveness,
PT chronic obstructive pulmonary disease, obesity or inflammatory bowel
PT syndrome.
XX
PS Example 10; Page 166; 650pp; English.
XX
XX
CC This invention relates to a novel isolated nucleic acid, gene 216,
CC identified from human chromosome 20p13-p12. The invention also discloses
CC regions of the 216 gene that contain single nucleotide polymorphisms
CC (SNP's) which may be used as markers for disease susceptibility or
CC severity. The nucleotides of the invention may have antiasthmatic,
CC antiinflammatory or anorectic activities and may be used in gene therapy.
CC The nucleic acids, antibodies or its fragments are useful for diagnosing,
CC preventing or treating a disorder, such as respiratory diseases (e.g.
CC asthma, bronchial hyper-responsiveness, chronic obstructive pulmonary
CC disease or adult respiratory distress syndrome), obesity, or inflammatory
CC bowel syndrome. The nucleic acids are also useful for identifying

```

CC increased susceptibility of a subject to the disorders mentioned. The
CC nucleic acids can also be used as primers and templates for the
CC recombinant production of disorder-associated peptides or polypeptides,
CC for chromosome and gene mapping, or for tissue distribution studies. The
CC present sequence represents a gene 216 specific oligonucleotide probe
CC used in the scope of the invention

XX Sequence 17 BP; 1 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 2.3e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 588 CTCCTCTCTGGGA 602

Db 2 CTCCTCTCTGGCA 16

RESULT 493

ACC62886/c

ID ACC62886 standard; DNA; 17 BP.

AC ACC62886;

DT 01-JUL-2003 (first entry)

DE Murine oligonucleotide associated with tumour suppression, SEQ ID 133.

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;

XX tumour suppression; tumour reversion; apoptosis; virus resistance;

XX viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;

XX schizophrentia; ss.

XX Mus musculus.

XX WO2003025176-A2.

XX 17-SEP-2001; 2001FR-00011979.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX PI Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-333167/31.

XX New isolated nucleic acid, useful for treating viral diseases associated

XX with tumors and cell degeneration, also related polypeptides, antibodies

XX and transfected cells.

XX Disclosure; Page 46; 738pp; French.

XX The present invention relates to murine oligonucleotides (ACC62754-

XX ACC68806), which are associated with tumour suppression, tumour

XX reversion, apoptosis and virus resistance. The oligonucleotides are

XX useful as (1) as probes and primers for detecting, identifying,

XX quantifying and/or amplifying nucleic acid, e.g. as one component of a

XX gene chip; in vitro as (anti)sense reagents; and (2) for production of a

XX recombinant polypeptides. The oligonucleotides are useful for preparation

XX of pharmaceuticals for prevention and/or treatment of viral diseases that

XX are characterised by development of tumours or cell degeneration,

XX specifically cancer but also Alzheimer's disease and schizophrentia

Db 15 TTCTAGAGCTGATC 1

RESULT 494

ACC66050

ID ACC66050 standard; DNA; 17 BP.

AC ACC66050;

DT 01-JUL-2003 (first entry)

DE Murine oligonucleotide associated with tumour suppression, SEQ ID 3297.

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;

XX tumour suppression; tumour reversion; apoptosis; virus resistance;

XX viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;

XX schizophrentia; ss.

XX Mus musculus.

XX WO2003025176-A2.

XX 17-SEP-2002; 2002MO-IB004210.

XX 17-SEP-2001; 2001FR-00011979.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX PI Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-333167/31.

XX New isolated nucleic acid, useful for treating viral diseases associated

XX with tumors and cell degeneration, also related polypeptides, antibodies

XX and transfected cells.

XX Disclosure; Page 416; 738pp; French.

XX The present invention relates to murine oligonucleotides (ACC62754-

XX ACC68806), which are associated with tumour suppression, tumour

XX reversion, apoptosis and virus resistance. The oligonucleotides are

XX useful as (1) as probes and primers for detecting, identifying,

XX quantifying and/or amplifying nucleic acid, e.g. as one component of a

XX gene chip; in vitro as (anti)sense reagents; and (2) for production of a

XX recombinant polypeptides. The oligonucleotides are useful for preparation

XX of pharmaceuticals for prevention and/or treatment of viral diseases that

XX are characterised by development of tumours or cell degeneration,

XX specifically cancer but also Alzheimer's disease and schizophrentia

XX Sequence 17 BP; 2 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 2.3e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 976 TTCCCTACACCTGATC 990

Db 3 TTCCCTACACCTGATC 17

RESULT 495

ADB43052/c

ID ADB43052 standard; DNA; 17 BP.

AC ADB43052;

DT 18-DEC-2003 (revised)

DE Tumour suppression/reversion associated nucleotide #3375.

```

XX  cytosstatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KM  primer; probe; tumour suppression; tumour reversion; apoptosis;
KM  virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KM  diagnosis.
XX
OS  Homo sapiens.
XX  WO2003040369-A2.
XX  15-MAY-2003.
XX  17-SEP-2002; 2002WO-IB004219.
XX  17-SEP-2001; 2001FR-00011981.
XX  (MOLE-) MOLECULAR ENGINES LAB.
XX  Teierman A, Amson R, Tuijnder M;
XX  WPI; 2003-441574/41.
XX  DR  WPI; 2003-441574/41.
XX  PT  New nucleic acid encoding human prostate membrane-specific antigen.
XX  PT  useful e.g. for treatment of tumors and viral infection, also related
XX  PT  polypeptide and antibodies.
XX  PS  Disclosure; Page 426; 771pp; French.
XX
CC  The invention relates to the isolation of 6327 nucleotide sequences,
CC  fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC  sequence having at least 80% identity, after optimal alignment, with the
CC  nucleotides, a sequence that hybridizes under stringent conditions with
CC  the nucleotides, or the complement, or corresponding RNA, of the
CC  nucleotides. The nucleotides are used as probes or primers for detecting,
CC  identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC  sense and antisense sequences, of nucleotides involved in tumour
CC  suppression or reversion, apoptosis and or viral resistance, to produce
CC  recombinant polypeptides, and to prepare transgenic animals, as
CC  experimental models. The nucleotides (also vectors containing them and
CC  cells containing the vectors), the encoded polypeptides and antibodies
CC  (Ab) against the polypeptide are useful for prevention and/or treatment
CC  of viral infections or diseases characterized by development of tumours
CC  or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC  Analysis of the expression of the nucleotides can be used for diagnosis
CC  and/or prognosis of these diseases. The nucleotides and polypeptides can
CC  also be used to screen for their specific interactive molecules,
CC  potentially useful for treating diseases associated with abnormal
CC  expression of the nucleotides.
XX
SQ  Sequence 17 BP; 3 A; 3 C; 1 G; 10 T; 0 U; 0 Other;

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1181 TGCAGAAATTAAGA 1195
Db      17  TGAAGAATAATAAG 3

```

Search completed: June 30, 2004, 08:34:31
 Job time : 15 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 30, 2004, 08:30:23 ; Search time 13 Seconds
(without alignments)
3.554 Million cell updates/sec

Title: US-10-024-369-3
Perfect score: 2247
Sequence: 1 atgcagctcctcagtcgtcc.....ctgcagatgctccagatga 2247

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 583 seqs, 10281 residues

Total number of hits satisfying chosen parameters: 1166

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 589 summaries

Database : rge3.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																										
------------	-------	-------------	--------	----	-------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

C 107	14.8	0.7	19	1	AX326925	ACCESSION:AX326925	C 180	13.8	0.6	18	1	AR084251	ACCESSION:AR084251
C 108	14.4	0.6	16	1	AR362307	ACCESSION:AR362307	181	13.8	0.6	18	1	AR084252	ACCESSION:AR084252
C 109	14.4	0.6	17	1	AR072089	ACCESSION:AR072089	182	13.8	0.6	18	1	AR089741	ACCESSION:AR089741
C 110	14.4	0.6	17	1	131849	ACCESSION:131849	183	13.8	0.6	18	1	AR096651	ACCESSION:AR096651
C 111	14.4	0.6	17	1	147697	ACCESSION:147697	184	13.8	0.6	18	1	AR097623	ACCESSION:AR097623
C 112	14.4	0.6	17	1	173119	ACCESSION:173119	185	13.8	0.6	18	1	AR097624	ACCESSION:AR097624
C 113	14.4	0.6	17	1	AR195674	ACCESSION:AR195674	186	13.8	0.6	18	1	AR130092	ACCESSION:AR130092
C 114	14.4	0.6	17	1	AX263212	ACCESSION:AX263212	187	13.8	0.6	18	1	BD270112	ACCESSION:BD270112
C 115	14.4	0.6	17	1	AX263213	ACCESSION:AX263213	188	13.8	0.6	18	1	AR211763	ACCESSION:AR211763
C 116	14.4	0.6	17	1	AX544969	ACCESSION:AX544969	189	13.8	0.6	18	1	AR211764	ACCESSION:AR211764
C 117	14.4	0.6	17	1	AX544970	ACCESSION:AX544970	190	13.8	0.6	18	1	AR267617	ACCESSION:AR267617
C 118	14.4	0.6	17	1	AX733343	ACCESSION:AX733343	191	13.8	0.6	18	1	AR267618	ACCESSION:AR267618
C 119	14.4	0.6	17	1	AX783931	ACCESSION:AX783931	192	13.8	0.6	18	1	AR296724	ACCESSION:AR296724
C 120	14.4	0.6	17	1	AR783934	ACCESSION:AR783934	193	13.8	0.6	18	1	AX039910	ACCESSION:AX039910
C 121	14.4	0.6	14	1	AR344485	ACCESSION:AR344485	194	13.8	0.6	18	1	AX117435	ACCESSION:AX117435
C 122	14.4	0.6	16	1	AR391489	ACCESSION:AR391489	195	13.8	0.6	18	1	AX179324	ACCESSION:AX179324
C 123	14.4	0.6	16	1	AX281969	ACCESSION:AX281969	196	13.8	0.6	18	1	AX179325	ACCESSION:AX179325
C 124	14.4	0.6	17	1	126890	ACCESSION:126890	197	13.8	0.6	18	1	AX180627	ACCESSION:AX180627
C 125	14.4	0.6	17	1	191631	ACCESSION:191631	198	13.8	0.6	18	1	AX338227	ACCESSION:AX338227
C 126	14.4	0.6	17	1	AX259837	ACCESSION:AX259837	199	13.8	0.6	18	1	AX353323	ACCESSION:AX353323
C 127	14.4	0.6	17	1	AX733800	ACCESSION:AX733800	200	13.8	0.6	18	1	AX353332	ACCESSION:AX353332
C 128	14.4	0.6	18	1	AR206689	ACCESSION:AR206689	201	13.8	0.6	18	1	AX363168	ACCESSION:AX363168
C 129	14.4	0.6	18	1	AR206690	ACCESSION:AR206690	202	13.8	0.6	18	1	AX363177	ACCESSION:AX363177
C 130	14.4	0.6	18	1	AR215508	ACCESSION:AR215508	203	13.8	0.6	18	1	AX418744	ACCESSION:AX418744
C 131	14.4	0.6	18	1	BD089389	ACCESSION:BD089389	204	13.8	0.6	18	1	AX428594	ACCESSION:AX428594
C 132	13.8	0.6	17	1	A29720	ACCESSION:A29720	205	13.8	0.6	18	1	AX428596	ACCESSION:AX428596
C 133	13.8	0.6	17	1	BD253919	ACCESSION:BD253919	206	13.8	0.6	18	1	AX428594	ACCESSION:AX428594
C 134	13.8	0.6	17	1	BD254279	ACCESSION:BD254279	207	13.8	0.6	18	1	AX663784	ACCESSION:AX663784
C 135	13.8	0.6	17	1	BD254343	ACCESSION:BD254343	208	13.8	0.6	18	1	BD085006	ACCESSION:BD085006
C 136	13.8	0.6	17	1	AR286658	ACCESSION:AR286658	209	13.8	0.6	18	1	BD097068	ACCESSION:BD097068
C 137	13.8	0.6	17	1	AR286658	ACCESSION:AR286658	210	13.8	0.6	21	1	BD132439	ACCESSION:BD132439
C 138	13.8	0.6	17	1	AR286648	ACCESSION:AR286648	211	13.8	0.6	21	1	AX095593	ACCESSION:AX095593
C 139	13.8	0.6	17	1	AR326796	ACCESSION:AR326796	212	13.6	0.6	41	1	AX518808	ACCESSION:AX518808
C 140	13.8	0.6	17	1	AR398248	ACCESSION:AR398248	213	13.6	0.6	41	1	AX518978	ACCESSION:AX518978
C 141	13.8	0.6	17	1	AR398338	ACCESSION:AR398338	214	13.4	0.6	15	1	AX521440	ACCESSION:AX521440
C 142	13.8	0.6	17	1	AX214664	ACCESSION:AX214664	215	13.4	0.6	15	1	AR048008	ACCESSION:AR048008
C 143	13.8	0.6	17	1	AX216395	ACCESSION:AX216395	216	13.4	0.6	15	1	AR056189	ACCESSION:AR056189
C 144	13.8	0.6	17	1	AX216573	ACCESSION:AX216573	217	13.4	0.6	15	1	AR056452	ACCESSION:AR056452
C 145	13.8	0.6	17	1	AX423541	ACCESSION:AX423541	218	13.4	0.6	15	1	AR059760	ACCESSION:AR059760
C 146	13.8	0.6	17	1	AX475793	ACCESSION:AX475793	219	13.4	0.6	15	1	AR068636	ACCESSION:AR068636
C 147	13.8	0.6	17	1	AX499212	ACCESSION:AX499212	220	13.4	0.6	15	1	AR076280	ACCESSION:AR076280
C 148	13.8	0.6	17	1	AX530927	ACCESSION:AX530927	221	13.4	0.6	15	1	AR094244	ACCESSION:AR094244
C 149	13.8	0.6	17	1	AX530928	ACCESSION:AX530928	222	13.4	0.6	15	1	AR113947	ACCESSION:AR113947
C 150	13.8	0.6	17	1	AX530929	ACCESSION:AX530929	223	13.4	0.6	15	1	AR114210	ACCESSION:AR114210
C 151	13.8	0.6	17	1	AX530930	ACCESSION:AX530930	224	13.4	0.6	15	1	AR131738	ACCESSION:AR131738
C 152	13.8	0.6	17	1	AX531817	ACCESSION:AX531817	225	13.4	0.6	15	1	AX322707	ACCESSION:AX322707
C 153	13.8	0.6	17	1	AX544924	ACCESSION:AX544924	226	13.4	0.6	15	1	AX633248	ACCESSION:AX633248
C 154	13.8	0.6	17	1	AX544968	ACCESSION:AX544968	227	13.4	0.6	15	1	AX633407	ACCESSION:AX633407
C 155	13.8	0.6	17	1	AX545280	ACCESSION:AX545280	228	13.4	0.6	15	1	BD133298	ACCESSION:BD133298
C 156	13.8	0.6	17	1	AX579025	ACCESSION:AX579025	229	13.4	0.6	16	1	BD208457	ACCESSION:BD208457
C 157	13.8	0.6	17	1	AX615974	ACCESSION:AX615974	230	13.4	0.6	16	1	AR329677	ACCESSION:AR329677
C 158	13.8	0.6	17	1	AX687644	ACCESSION:AX687644	231	13.4	0.6	16	1	AR391399	ACCESSION:AR391399
C 159	13.8	0.6	17	1	AX687797	ACCESSION:AX687797	232	13.4	0.6	16	1	AR391401	ACCESSION:AR391401
C 160	13.8	0.6	17	1	AX688661	ACCESSION:AX688661	233	13.4	0.6	16	1	AR391465	ACCESSION:AR391465
C 161	13.8	0.6	17	1	AX690651	ACCESSION:AX690651	234	13.4	0.6	16	1	AX281879	ACCESSION:AX281879
C 162	13.8	0.6	17	1	AX724195	ACCESSION:AX724195	235	13.4	0.6	16	1	AX281881	ACCESSION:AX281881
C 163	13.8	0.6	17	1	AX726124	ACCESSION:AX726124	236	13.4	0.6	17	1	AX281945	ACCESSION:AX281945
C 164	13.8	0.6	17	1	AX728039	ACCESSION:AX728039	237	13.4	0.6	17	1	AR057440	ACCESSION:AR057440
C 165	13.8	0.6	17	1	AX730911	ACCESSION:AX730911	238	13.4	0.6	17	1	AR057496	ACCESSION:AR057496
C 166	13.8	0.6	17	1	AX745531	ACCESSION:AX745531	239	13.4	0.6	17	1	AR057503	ACCESSION:AR057503
C 167	13.8	0.6	17	1	AX759927	ACCESSION:AX759927	240	13.4	0.6	17	1	AR057539	ACCESSION:AR057539
C 168	13.8	0.6	17	1	AX761880	ACCESSION:AX761880	241	13.4	0.6	17	1	AR057592	ACCESSION:AR057592
C 169	13.8	0.6	17	1	AX783935	ACCESSION:AX783935	242	13.4	0.6	17	1	AR057669	ACCESSION:AR057669
C 170	13.8	0.6	17	1	BD104937	ACCESSION:BD104937	243	13.4	0.6	17	1	AR057730	ACCESSION:AR057730
C 171	13.8	0.6	17	1	BD105155	ACCESSION:BD105155	244	13.4	0.6	17	1	AR151598	ACCESSION:AR151598
C 172	13.8	0.6	18	1	AR67603	ACCESSION:AR67603	245	13.4	0.6	17	1	AR15254	ACCESSION:AR15254
C 173	13.8	0.6	18	1	AR007264	ACCESSION:AR007264	246	13.4	0.6	17	1	AR15261	ACCESSION:AR15261
C 174	13.8	0.6	18	1	AR007265	ACCESSION:AR007265	247	13.4	0.6	17	1	AR15297	ACCESSION:AR15297
C 175	13.8	0.6	18	1	AR029258	ACCESSION:AR029258	248	13.4	0.6	17	1	AR15350	ACCESSION:AR15350
C 176	13.8	0.6	18	1	AR067989	ACCESSION:AR067989	249	13.4	0.6	17	1	AR15427	ACCESSION:AR15427
C 177	13.8	0.6	18	1	AR067990	ACCESSION:AR067990	250	13.4	0.6	17	1	AR15488	ACCESSION:AR15488
C 178	13.8	0.6	18	1	AR083518	ACCESSION:AR083518	251	13.4	0.6	17	1	BD254305	ACCESSION:BD254305
C 179	13.8	0.6	18	1	AR083520	ACCESSION:AR083520	252	13.4	0.6	17	1	BD254306	ACCESSION:BD254306

C 253	13.4	0.6	17	1	BD254307	ACCESSION:BD254307	C 326	13	0.6	17	1	AR327352	ACCESSION:AR327352
C 254	13.4	0.6	17	1	BD254406	ACCESSION:BD254406	C 327	13	0.6	17	1	AR327387	ACCESSION:AR327387
C 255	13.4	0.6	17	1	BD259619	ACCESSION:BD259619	C 328	13	0.6	17	1	AR327651	ACCESSION:AR327651
C 256	13.4	0.6	17	1	ES9892	ACCESSION:ES9892	C 329	13	0.6	17	1	AR327652	ACCESSION:AR327652
C 257	13.4	0.6	17	1	AR326795	ACCESSION:AR326795	C 330	13	0.6	17	1	AR327792	ACCESSION:AR327792
C 258	13.4	0.6	17	1	AR327103	ACCESSION:AR327103	C 331	13	0.6	17	1	AR327793	ACCESSION:AR327793
C 259	13.4	0.6	17	1	AR327353	ACCESSION:AR327353	C 332	13	0.6	17	1	AX672226	ACCESSION:AX672226
C 260	13.4	0.6	17	1	AR329223	ACCESSION:AR329223	C 333	13	0.6	17	1	AX722951	ACCESSION:AX722951
C 261	13.4	0.6	17	1	AR434048	ACCESSION:AR434048	C 334	13	0.6	17	1	AX730455	ACCESSION:AX730455
C 262	13.4	0.6	17	1	AR434049	ACCESSION:AR434049	C 335	13	0.6	17	1	AX732634	ACCESSION:AX732634
C 263	13.4	0.6	17	1	AR434050	ACCESSION:AR434050	C 336	13	0.6	17	1	AX735420	ACCESSION:AX735420
C 264	13.4	0.6	17	1	AX215470	ACCESSION:AX215470	C 337	13	0.6	17	1	AX735658	ACCESSION:AX735658
C 265	13.4	0.6	17	1	AX216969	ACCESSION:AX216969	C 338	13	0.6	17	1	AX802040	ACCESSION:AX802040
C 266	13.4	0.6	17	1	AX327094	ACCESSION:AX327094	C 339	13	0.6	17	1	AX198661	ACCESSION:AX198661
C 267	13.4	0.6	17	1	AX423543	ACCESSION:AX423543	C 340	13	0.6	17	1	BD198662	ACCESSION:BD198662
C 268	13.4	0.6	17	1	AX475178	ACCESSION:AX475178	C 341	12.8	0.6	16	1	A31053	ACCESSION:A31053
C 269	13.4	0.6	17	1	AX475179	ACCESSION:AX475179	C 342	12.8	0.6	16	1	AR028650	ACCESSION:AR028650
C 270	13.4	0.6	17	1	AX475180	ACCESSION:AX475180	C 343	12.8	0.6	16	1	AR053743	ACCESSION:AR053743
C 271	13.4	0.6	17	1	AX531763	ACCESSION:AX531763	C 344	12.8	0.6	16	1	AR069284	ACCESSION:AR069284
C 272	13.4	0.6	17	1	AX531764	ACCESSION:AX531764	C 345	12.8	0.6	16	1	AR126826	ACCESSION:AR126826
C 273	13.4	0.6	17	1	AX531765	ACCESSION:AX531765	C 346	12.8	0.6	16	1	AR137189	ACCESSION:AR137189
C 274	13.4	0.6	17	1	AX544971	ACCESSION:AX544971	C 347	12.8	0.6	16	1	AR146243	ACCESSION:AR146243
C 275	13.4	0.6	17	1	AX579026	ACCESSION:AX579026	C 348	12.8	0.6	16	1	AR156010	ACCESSION:AR156010
C 276	13.4	0.6	17	1	AX579182	ACCESSION:AX579182	C 349	12.8	0.6	16	1	AR178197	ACCESSION:AR178197
C 277	13.4	0.6	17	1	AX579727	ACCESSION:AX579727	C 350	12.8	0.6	16	1	118842	ACCESSION:118842
C 278	13.4	0.6	17	1	AX615975	ACCESSION:AX615975	C 351	12.8	0.6	16	1	122296	ACCESSION:122296
C 279	13.4	0.6	17	1	AX615976	ACCESSION:AX615976	C 352	12.8	0.6	16	1	173322	ACCESSION:173322
C 280	13.4	0.6	17	1	AX634510	ACCESSION:AX634510	C 353	12.8	0.6	16	1	AR214479	ACCESSION:AR214479
C 281	13.4	0.6	17	1	AX634541	ACCESSION:AX634541	C 354	12.8	0.6	16	1	AR217686	ACCESSION:AR217686
C 282	13.4	0.6	17	1	AX634555	ACCESSION:AX634555	C 355	12.8	0.6	16	1	AR229701	ACCESSION:AR229701
C 283	13.4	0.6	17	1	AX634626	ACCESSION:AX634626	C 356	12.8	0.6	16	1	AR234410	ACCESSION:AR234410
C 284	13.4	0.6	17	1	AX634635	ACCESSION:AX634635	C 357	12.8	0.6	16	1	AR255710	ACCESSION:AR255710
C 285	13.4	0.6	17	1	AX634691	ACCESSION:AX634691	C 358	12.8	0.6	16	1	AR274833	ACCESSION:AR274833
C 286	13.4	0.6	17	1	AX634812	ACCESSION:AX634812	C 359	12.8	0.6	16	1	AR328355	ACCESSION:AR328355
C 287	13.4	0.6	17	1	AX722446	ACCESSION:AX722446	C 360	12.8	0.6	16	1	AR328357	ACCESSION:AR328357
C 288	13.4	0.6	17	1	AX725610	ACCESSION:AX725610	C 361	12.8	0.6	16	1	AR329600	ACCESSION:AR329600
C 289	13.4	0.6	17	1	AX732419	ACCESSION:AX732419	C 362	12.8	0.6	16	1	AR364124	ACCESSION:AR364124
C 290	13.4	0.6	17	1	AX734744	ACCESSION:AX734744	C 363	12.8	0.6	16	1	AR364150	ACCESSION:AR364150
C 291	13.4	0.6	17	1	AX737134	ACCESSION:AX737134	C 364	12.8	0.6	16	1	AR382044	ACCESSION:AR382044
C 292	13.4	0.6	17	1	AX745329	ACCESSION:AX745329	C 365	12.8	0.6	16	1	AR391495	ACCESSION:AR391495
C 293	13.4	0.6	17	1	AX745330	ACCESSION:AX745330	C 366	12.8	0.6	16	1	AR399532	ACCESSION:AR399532
C 294	13.4	0.6	17	1	AX760054	ACCESSION:AX760054	C 367	12.8	0.6	16	1	AR436078	ACCESSION:AR436078
C 295	13.4	0.6	17	1	AX783930	ACCESSION:AX783930	C 368	12.8	0.6	16	1	AX281975	ACCESSION:AX281975
C 296	13.4	0.6	17	1	BD198659	ACCESSION:BD198659	C 369	12.8	0.6	16	1	AX708805	ACCESSION:AX708805
C 297	13.4	0.6	17	1	BD198660	ACCESSION:BD198660	C 370	12.8	0.6	16	1	AX802065	ACCESSION:AX802065
C 298	13.4	0.6	17	1	BD200842	ACCESSION:BD200842	C 371	12.8	0.6	16	1	BD166014	ACCESSION:BD166014
C 299	13	0.6	15	1	AR092454	ACCESSION:AR092454	C 372	12.8	0.6	16	1	BD167992	ACCESSION:BD167992
C 300	13	0.6	15	1	AR092463	ACCESSION:AR092463	C 373	12.8	0.6	16	1	BD181119	ACCESSION:BD181119
C 301	13	0.6	15	1	BD266376	ACCESSION:BD266376	C 374	12.8	0.6	17	1	AR028970	ACCESSION:AR028970
C 302	13	0.6	15	1	AR226464	ACCESSION:AR226464	C 375	12.8	0.6	17	1	AR046049	ACCESSION:AR046049
C 303	13	0.6	15	1	AR226473	ACCESSION:AR226473	C 376	12.8	0.6	17	1	AR057432	ACCESSION:AR057432
C 304	13	0.6	15	1	AX362574	ACCESSION:AX362574	C 377	12.8	0.6	17	1	AR057439	ACCESSION:AR057439
C 305	13	0.6	15	1	AX377251	ACCESSION:AX377251	C 378	12.8	0.6	17	1	AR057596	ACCESSION:AR057596
C 306	13	0.6	15	1	BD005833	ACCESSION:BD005833	C 379	12.8	0.6	17	1	AR104994	ACCESSION:AR104994
C 307	13	0.6	15	1	BD208455	ACCESSION:BD208455	C 380	12.8	0.6	17	1	AR115190	ACCESSION:AR115190
C 308	13	0.6	15	1	BD208456	ACCESSION:BD208456	C 381	12.8	0.6	17	1	AR115197	ACCESSION:AR115197
C 309	13	0.6	16	1	AR328425	ACCESSION:AR328425	C 382	12.8	0.6	17	1	AR115354	ACCESSION:AR115354
C 310	13	0.6	17	1	AR046237	ACCESSION:AR046237	C 383	12.8	0.6	17	1	AR145857	ACCESSION:AR145857
C 311	13	0.6	17	1	AR046239	ACCESSION:AR046239	C 384	12.8	0.6	17	1	AR156852	ACCESSION:AR156852
C 312	13	0.6	17	1	AR046724	ACCESSION:AR046724	C 385	12.8	0.6	17	1	BD241028	ACCESSION:BD241028
C 313	13	0.6	17	1	AR046726	ACCESSION:AR046726	C 386	12.8	0.6	17	1	BD241330	ACCESSION:BD241330
C 314	13	0.6	17	1	AR075049	ACCESSION:AR075049	C 387	12.8	0.6	17	1	BD254112	ACCESSION:BD254112
C 315	13	0.6	17	1	AR141867	ACCESSION:AR141867	C 388	12.8	0.6	17	1	BD254113	ACCESSION:BD254113
C 316	13	0.6	17	1	BD254342	ACCESSION:BD254342	C 389	12.8	0.6	17	1	BD254344	ACCESSION:BD254344
C 317	13	0.6	17	1	BD25947	ACCESSION:BD25947	C 390	12.8	0.6	17	1	BD254396	ACCESSION:BD254396
C 318	13	0.6	17	1	153289	ACCESSION:153289	C 391	12.8	0.6	17	1	BD254399	ACCESSION:BD254399
C 319	13	0.6	17	1	153291	ACCESSION:153291	C 392	12.8	0.6	17	1	BD254560	ACCESSION:BD254560
C 320	13	0.6	17	1	153776	ACCESSION:153776	C 393	12.8	0.6	17	1	BD254561	ACCESSION:BD254561
C 321	13	0.6	17	1	153778	ACCESSION:153778	C 394	12.8	0.6	17	1	BD254562	ACCESSION:BD254562
C 322	13	0.6	17	1	AR186780	ACCESSION:AR186780	C 395	12.8	0.6	17	1	BD255504	ACCESSION:BD255504
C 323	13	0.6	17	1	AR186781	ACCESSION:AR186781	C 396	12.8	0.6	17	1	BD259177	ACCESSION:BD259177
C 324	13	0.6	17	1	AR323411	ACCESSION:AR323411	C 397	12.8	0.6	17	1	BD259430	ACCESSION:BD259430
C 325	13	0.6	17	1	AR323412	ACCESSION:AR323412	C 398	12.8	0.6	17	1	BD259431	ACCESSION:BD259431

399	12.8	0.6	17	1	BD270691	ACCESSION:BD270691	472	12.8	0.6	17	1	AX494762	ACCESSION:AX494762
C 400	12.8	0.6	17	1	BD270691	ACCESSION:BD270691	473	12.8	0.6	17	1	AX498756	ACCESSION:AX498756
401	12.8	0.6	17	1	E35301	ACCESSION:E35301	474	12.8	0.6	17	1	AX498757	ACCESSION:AX498757
402	12.8	0.6	17	1	I46652	ACCESSION:I46652	475	12.8	0.6	17	1	AX499211	ACCESSION:AX499211
C 403	12.8	0.6	17	1	I53101	ACCESSION:I53101	476	12.8	0.6	17	1	AX499213	ACCESSION:AX499213
C 404	12.8	0.6	17	1	I84477	ACCESSION:I84477	C 477	12.8	0.6	17	1	AX499242	ACCESSION:AX499242
C 405	12.8	0.6	17	1	I84484	ACCESSION:I84484	C 478	12.8	0.6	17	1	AX499243	ACCESSION:AX499243
C 406	12.8	0.6	17	1	AR186248	ACCESSION:AR186248	C 479	12.8	0.6	17	1	AX499259	ACCESSION:AX499259
407	12.8	0.6	17	1	AR186747	ACCESSION:AR186747	480	12.8	0.6	17	1	AX499260	ACCESSION:AX499260
C 409	12.8	0.6	17	1	AR188407	ACCESSION:AR188407	481	12.8	0.6	17	1	AX530926	ACCESSION:AX530926
C 410	12.8	0.6	17	1	AR188415	ACCESSION:AR188415	482	12.8	0.6	17	1	AX530931	ACCESSION:AX530931
C 411	12.8	0.6	17	1	AR190412	ACCESSION:AR190412	C 483	12.8	0.6	17	1	AX531054	ACCESSION:AX531054
412	12.8	0.6	17	1	AR190474	ACCESSION:AR190474	C 484	12.8	0.6	17	1	AX531055	ACCESSION:AX531055
413	12.8	0.6	17	1	AR190475	ACCESSION:AR190475	C 485	12.8	0.6	17	1	AX531704	ACCESSION:AX531704
C 414	12.8	0.6	17	1	AR286467	ACCESSION:AR286467	C 486	12.8	0.6	17	1	AX531705	ACCESSION:AX531705
C 415	12.8	0.6	17	1	AR322879	ACCESSION:AR322879	487	12.8	0.6	17	1	AX531816	ACCESSION:AX531816
416	12.8	0.6	17	1	AR323378	ACCESSION:AR323378	488	12.8	0.6	17	1	AX531818	ACCESSION:AX531818
417	12.8	0.6	17	1	AR324260	ACCESSION:AR324260	489	12.8	0.6	17	1	AX544923	ACCESSION:AX544923
C 418	12.8	0.6	17	1	AR324268	ACCESSION:AR324268	490	12.8	0.6	17	1	AX544925	ACCESSION:AX544925
C 419	12.8	0.6	17	1	AR324520	ACCESSION:AR324520	C 491	12.8	0.6	17	1	AX544967	ACCESSION:AX544967
420	12.8	0.6	17	1	AR325337	ACCESSION:AR325337	492	12.8	0.6	17	1	AX545279	ACCESSION:AX545279
421	12.8	0.6	17	1	AR325397	ACCESSION:AR325397	493	12.8	0.6	17	1	AX545281	ACCESSION:AX545281
C 422	12.8	0.6	17	1	AR325398	ACCESSION:AR325398	494	12.8	0.6	17	1	AX578253	ACCESSION:AX578253
C 423	12.8	0.6	17	1	AR326829	ACCESSION:AR326829	495	12.8	0.6	17	1	AX578400	ACCESSION:AX578400
C 424	12.8	0.6	17	1	AR326830	ACCESSION:AR326830	C 496	12.8	0.6	17	1	AX578401	ACCESSION:AX578401
C 425	12.8	0.6	17	1	AR327109	ACCESSION:AR327109	C 497	12.8	0.6	17	1	AX578890	ACCESSION:AX578890
C 426	12.8	0.6	17	1	AR327110	ACCESSION:AR327110	C 498	12.8	0.6	17	1	AX579181	ACCESSION:AX579181
427	12.8	0.6	17	1	AR327761	ACCESSION:AR327761	499	12.8	0.6	17	1	AX579898	ACCESSION:AX579898
C 428	12.8	0.6	17	1	AR328681	ACCESSION:AR328681	C 500	12.8	0.6	17	1	AX580127	ACCESSION:AX580127
C 429	12.8	0.6	17	1	AR329248	ACCESSION:AR329248	C 501	12.8	0.6	17	1	AX615494	ACCESSION:AX615494
C 430	12.8	0.6	17	1	AR398457	ACCESSION:AR398457	C 502	12.8	0.6	17	1	AX615495	ACCESSION:AX615495
C 431	12.8	0.6	17	1	AR400294	ACCESSION:AR400294	C 503	12.8	0.6	17	1	AX615973	ACCESSION:AX615973
432	12.8	0.6	17	1	AR402393	ACCESSION:AR402393	504	12.8	0.6	17	1	AX634494	ACCESSION:AX634494
433	12.8	0.6	17	1	AR412050	ACCESSION:AR412050	505	12.8	0.6	17	1	AX634508	ACCESSION:AX634508
C 434	12.8	0.6	17	1	AR434370	ACCESSION:AR434370	506	12.8	0.6	17	1	AX634643	ACCESSION:AX634643
C 435	12.8	0.6	17	1	AR434371	ACCESSION:AR434371	C 507	12.8	0.6	17	1	AX671610	ACCESSION:AX671610
C 436	12.8	0.6	17	1	AR434378	ACCESSION:AR434378	C 508	12.8	0.6	17	1	AX672330	ACCESSION:AX672330
C 437	12.8	0.6	17	1	AR434379	ACCESSION:AR434379	C 509	12.8	0.6	17	1	AX673085	ACCESSION:AX673085
C 438	12.8	0.6	17	1	AX010677	ACCESSION:AX010677	C 510	12.8	0.6	17	1	AX674220	ACCESSION:AX674220
C 439	12.8	0.6	17	1	AX010677	ACCESSION:AX010677	C 511	12.8	0.6	17	1	AX687554	ACCESSION:AX687554
C 440	12.8	0.6	17	1	AX056664	ACCESSION:AX056664	C 512	12.8	0.6	17	1	AX687555	ACCESSION:AX687555
C 441	12.8	0.6	17	1	AX167488	ACCESSION:AX167488	C 513	12.8	0.6	17	1	AX687643	ACCESSION:AX687643
C 442	12.8	0.6	17	1	AX214663	ACCESSION:AX214663	C 514	12.8	0.6	17	1	AX687645	ACCESSION:AX687645
C 443	12.8	0.6	17	1	AX215471	ACCESSION:AX215471	515	12.8	0.6	17	1	AX687796	ACCESSION:AX687796
C 444	12.8	0.6	17	1	AX215569	ACCESSION:AX215569	516	12.8	0.6	17	1	AX687798	ACCESSION:AX687798
445	12.8	0.6	17	1	AX216147	ACCESSION:AX216147	C 517	12.8	0.6	17	1	AX687801	ACCESSION:AX687801
C 446	12.8	0.6	17	1	AX216502	ACCESSION:AX216502	C 518	12.8	0.6	17	1	AX687802	ACCESSION:AX687802
C 447	12.8	0.6	17	1	AX216640	ACCESSION:AX216640	C 519	12.8	0.6	17	1	AX688332	ACCESSION:AX688332
448	12.8	0.6	17	1	AX216891	ACCESSION:AX216891	C 520	12.8	0.6	17	1	AX688333	ACCESSION:AX688333
C 449	12.8	0.6	17	1	AX217378	ACCESSION:AX217378	C 521	12.8	0.6	17	1	AX688366	ACCESSION:AX688366
C 450	12.8	0.6	17	1	AX217540	ACCESSION:AX217540	C 522	12.8	0.6	17	1	AX688367	ACCESSION:AX688367
C 451	12.8	0.6	17	1	AX217882	ACCESSION:AX217882	C 523	12.8	0.6	17	1	AX688660	ACCESSION:AX688660
C 452	12.8	0.6	17	1	AX218127	ACCESSION:AX218127	C 524	12.8	0.6	17	1	AX688662	ACCESSION:AX688662
C 453	12.8	0.6	17	1	AX218281	ACCESSION:AX218281	C 525	12.8	0.6	17	1	AX690650	ACCESSION:AX690650
454	12.8	0.6	17	1	AX226997	ACCESSION:AX226997	C 526	12.8	0.6	17	1	AX690652	ACCESSION:AX690652
C 455	12.8	0.6	17	1	AX227311	ACCESSION:AX227311	527	12.8	0.6	17	1	AX690666	ACCESSION:AX690666
456	12.8	0.6	17	1	AX263388	ACCESSION:AX263388	528	12.8	0.6	17	1	AX690667	ACCESSION:AX690667
C 457	12.8	0.6	17	1	AX263389	ACCESSION:AX263389	529	12.8	0.6	17	1	AX691878	ACCESSION:AX691878
C 458	12.8	0.6	17	1	AX265515	ACCESSION:AX265515	530	12.8	0.6	17	1	AX691879	ACCESSION:AX691879
C 459	12.8	0.6	17	1	AX265516	ACCESSION:AX265516	C 531	12.8	0.6	17	1	AX691881	ACCESSION:AX691881
C 460	12.8	0.6	17	1	AX265711	ACCESSION:AX265711	C 532	12.8	0.6	17	1	AX691882	ACCESSION:AX691882
C 461	12.8	0.6	17	1	AX265712	ACCESSION:AX265712	C 533	12.8	0.6	17	1	AX701413	ACCESSION:AX701413
C 462	12.8	0.6	17	1	AX272955	ACCESSION:AX272955	534	12.8	0.6	17	1	AX710060	ACCESSION:AX710060
C 463	12.8	0.6	17	1	AX421665	ACCESSION:AX421665	535	12.8	0.6	17	1	AX723750	ACCESSION:AX723750
C 464	12.8	0.6	17	1	AX422048	ACCESSION:AX422048	536	12.8	0.6	17	1	AX723821	ACCESSION:AX723821
C 465	12.8	0.6	17	1	AX422379	ACCESSION:AX422379	537	12.8	0.6	17	1	AX724325	ACCESSION:AX724325
466	12.8	0.6	17	1	AX422704	ACCESSION:AX422704	C 538	12.8	0.6	17	1	AX724370	ACCESSION:AX724370
467	12.8	0.6	17	1	AX423493	ACCESSION:AX423493	C 539	12.8	0.6	17	1	AX724543	ACCESSION:AX724543
468	12.8	0.6	17	1	AX423710	ACCESSION:AX423710	540	12.8	0.6	17	1	AX724787	ACCESSION:AX724787
C 469	12.8	0.6	17	1	AX423761	ACCESSION:AX423761	C 541	12.8	0.6	17	1	AX725087	ACCESSION:AX725087
470	12.8	0.6	17	1	AX475792	ACCESSION:AX475792	C 542	12.8	0.6	17	1	AX725274	ACCESSION:AX725274
471	12.8	0.6	17	1	AX475794	ACCESSION:AX475794	C 543	12.8	0.6	17	1	AX725956	ACCESSION:AX725956
							544	12.8	0.6	17	1	AX727191	ACCESSION:AX727191

545	12.8	0.6	17	1	AX727575	ACCESSION:AX727575
546	12.8	0.6	17	1	AX728137	ACCESSION:AX728137
547	12.8	0.6	17	1	AX728606	ACCESSION:AX728606
548	12.8	0.6	17	1	AX728864	ACCESSION:AX728864
549	12.8	0.6	17	1	AX728907	ACCESSION:AX728907
550	12.8	0.6	17	1	AX731757	ACCESSION:AX731757
551	12.8	0.6	17	1	AX732158	ACCESSION:AX732158
552	12.8	0.6	17	1	AX732941	ACCESSION:AX732941
553	12.8	0.6	17	1	AX733047	ACCESSION:AX733047
554	12.8	0.6	17	1	AX733291	ACCESSION:AX733291
555	12.8	0.6	17	1	AX733627	ACCESSION:AX733627
556	12.8	0.6	17	1	AX734653	ACCESSION:AX734653
557	12.8	0.6	17	1	AX734659	ACCESSION:AX734659
558	12.8	0.6	17	1	AX736797	ACCESSION:AX736797
559	12.8	0.6	17	1	AX739468	ACCESSION:AX739468
560	12.8	0.6	17	1	AX739703	ACCESSION:AX739703
561	12.8	0.6	17	1	AX744302	ACCESSION:AX744302
562	12.8	0.6	17	1	AX744303	ACCESSION:AX744303
563	12.8	0.6	17	1	AX745332	ACCESSION:AX745332
564	12.8	0.6	17	1	AX753782	ACCESSION:AX753782
565	12.8	0.6	17	1	AX753783	ACCESSION:AX753783
566	12.8	0.6	17	1	AX756714	ACCESSION:AX756714
567	12.8	0.6	17	1	AX757942	ACCESSION:AX757942
568	12.8	0.6	17	1	AX758903	ACCESSION:AX758903
569	12.8	0.6	17	1	AX759607	ACCESSION:AX759607
570	12.8	0.6	17	1	AX760088	ACCESSION:AX760088
571	12.8	0.6	17	1	AX761127	ACCESSION:AX761127
572	12.8	0.6	17	1	AX761670	ACCESSION:AX761670
573	12.8	0.6	17	1	AX761804	ACCESSION:AX761804
574	12.8	0.6	17	1	AX761929	ACCESSION:AX761929
575	12.8	0.6	17	1	AX781766	ACCESSION:AX781766
576	12.8	0.6	17	1	AX781767	ACCESSION:AX781767
577	12.8	0.6	17	1	AX782300	ACCESSION:AX782300
578	12.8	0.6	17	1	AX782301	ACCESSION:AX782301
579	12.8	0.6	17	1	AX783936	ACCESSION:AX783936
580	12.8	0.6	17	1	AX816806	ACCESSION:AX816806
581	12.8	0.6	17	1	BD067894	ACCESSION:BD067894
582	12.8	0.6	17	1	BD104823	ACCESSION:BD104823
583	12.8	0.6	17	1	BD105166	ACCESSION:BD105166
584	12.8	0.6	17	1	BD202752	ACCESSION:BD202752
585	12.8	0.6	17	1	BD202753	ACCESSION:BD202753
586	12.8	0.6	17	1	BD202918	ACCESSION:BD202918
587	12.8	0.6	17	1	BD203057	ACCESSION:BD203057
588	12.8	0.6	17	1	BD226467	ACCESSION:BD226467
589	12.8	0.6	17	1	AJ587490	ACCESSION:AJ587490

ALIGNMENTS

RESULT 1
AX513808 41 bp DNA linear PAT 05-OCT-2002
DEFINITION Sequence 6 from Patent WO02052044.
ACCESSION AX513808
VERSION AX513808.1 GI:23559990
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Nakamura, Y., Sekine, A., Iida, A. and Saito, S.
TITLE Detection of genetic polymorphisms
JOURNAL Patent: WO 02052044-A 6 04-JUL-2002;
Riken (JP)
FEATURES
source 1. .41
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 40.6; DB 1; Length 41;

Best Local Similarity 97.6%; Pred. No. 0.065;
Matches 40; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 977 CCCTCACCATGTCACCCCTGATCACCCTGCTGCTTTTC 1017
1 CCCTCACCATGTCACCCCTGATCACCCTGCTGCTTTTC 41

RESULT 2
AX518978 41 bp DNA linear PAT 05-OCT-2002
DEFINITION Sequence 5176 from Patent WO02052044.
ACCESSION AX518978
VERSION AX518978.1 GI:23568986
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Nakamura, Y., Sekine, A., Iida, A. and Saito, S.
TITLE Detection of genetic polymorphisms
JOURNAL Patent: WO 02052044-A 5176 04-JUL-2002;
Riken (JP)
FEATURES
source 1. .41
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 40.6; DB 1; Length 41;
Best Local Similarity 97.6%; Pred. No. 0.065;
Matches 40; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 977 CCCTCACCATGTCACCCCTGATCACCCTGCTGCTTTTC 1017
1 CCCTCACCATGTCACCCCTGATCACCCTGCTGCTTTTC 41

RESULT 3
AX521440 41 bp DNA linear PAT 05-OCT-2002
DEFINITION Sequence 7638 from Patent WO02052044.
ACCESSION AX521440
VERSION AX521440.1 GI:23572410
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Nakamura, Y., Sekine, A., Iida, A. and Saito, S.
TITLE Detection of genetic polymorphisms
JOURNAL Patent: WO 02052044-A 7638 04-JUL-2002;
Riken (JP)
FEATURES
source 1. .41
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 40.6; DB 1; Length 41;
Best Local Similarity 97.6%; Pred. No. 0.065;
Matches 40; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 977 CCCTCACCATGTCACCCCTGATCACCCTGCTGCTTTTC 1017
1 CCCTCACCATGTCACCCCTGATCACCCTGCTGCTTTTC 41

RESULT 4
AX249257 31 bp DNA linear PAT 28-SEP-2001
LOCUS AX249257

	DEFINITION	Sequence 1336 from Patent WO0166800.
	ACCESSION	AJ249257
	VERSION	AJ249257.1 GI:15863880
	KEYWORDS	.
	SOURCE	Homo sapiens (human)
	ORGANISM	Homo sapiens
	REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
	AUTHORS	1 Cargill,M., Ireland,J.S. and Lander,E.S.
	TITLE	Human single nucleotide polymorphisms
	JOURNAL	Patent: WO 0166800-A 1336 13-SEP-2001;
		WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)
	FEATURES	Location/Qualifiers
	source	1..31 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
Oy	Query Match	1.4%; Score 30.6; DB 1; Length 31;
	Best Local Similarity	96.8%; Pred. No. 1.6;
Db	Matches	30; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Oy	408 CCTTACCGCCCTTCGTGCTAGTAGCAGCG 438	
Db	1 CCTTACCGCCCTTCGTGCTAGTAGCAGCG 31	
RESULT 5	BD142943	
LOCUS	BD142943	28 bp DNA linear PAT 17-JAN-2003
DEFINITION	BD142943	Method of assaying human ABC transporter and probe and kit therefor.
ACCESSION	BD142943	
VERSION	BD142943.1 GI:27848701	
KEYWORDS	JP 2002112775-A/14.	
SOURCE	JP 2002112775-A/14.	
ORGANISM	unidentified	
	unclassified	
	unclassified.	
REFERENCE	1 (bases 1 to 28)	
AUTHORS	Nishimura,M., Yaguchi,H., Naito,S. and Hiraoaka,I.	
TITLE	Method of assaying human ABC transporter and probe and kit therefor	
JOURNAL	Patent: JP 2002112775-A 14 16-APR-2002;	
	OTSUKA PHARMACEUTICAL FACTORY INC	
COMMENT	OS human ABCB2 gene	
	PN JP 2002112775-A/14	
	PD 16-APR-2002	
	PF 03-OCT-2000 JP 2000303404	
	PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIROAKA	
	PC C12N15/09,C12Q1/68,C12N15/00	
	CC Method of assaying human ABC transporter and probe and kit CC	
	therefor	
	FH Location/Qualifiers	
	FT source	1..28
	FT	/organism='human ABCB2 gene'.
FEATURES	Location/Qualifiers	
source	1..28	
	/organism="unidentified"	
	/mol_type="genomic DNA"	
	/db_xref="taxon:32644"	
Query Match	1.2%; Score 28; DB 1; Length 28;	
Best Local Similarity	100.0%; Pred. No. 3.6;	
Matches	28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Oy	653 ATGGCTACGCCGATACCTTCACTCGAA 680	
Db	1 ATGGCTACGCCGATACCTTCACTCGAA 28	
RESULT 6	BD161970	
LOCUS	BD161970	28 bp DNA linear PAT 17-JAN-2003

DEFINITION	Simultaneous assay method of a plurality of different molecular species proteins mRNA and kit container used therefor.
ACCESSION	BD161970
VERSION	BD161970.1 GI:27867728
KEYWORDS	JP 2002181818-A/21.
SOURCE	unidentified
ORGANISM	unclassified.
REFERENCE	1 (bases 1 to 28)
AUTHORS	Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.
TITLE	Simultaneous assay method of a plurality of different molecular species proteins mRNA and kit container used therefor
JOURNAL	Patent: JP 2002181818-A 21-26-JUN-2002;
COMMENT	OTSUKA PHARMACEUTICAL FACTORY INC
	OS Human ABCB2 gene
	PN JP 2002181818-A/21
	PD 26-JUN-2002
	PF 15-DEC-2000 JP 2000381621
	PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIRAKAWA
	PC G01N33/53,C12N15/09,C12Q1/48,C12Q1/68,G01N33/566,C12N15/00 CC
	Simultaneous assay method of a plurality of different CC
	molecular species
	CC proteins mRNA and kit container used therefor FH Key
	Location/Qualifiers
FT	1..28
FT	source
FEATURES	Location/Qualifiers
source	1..28
	/organism="Human ABCB2 gene"
	/organism="unidentified"
	/mol_type="genomic DNA"
	/db_xref="taxon:32644"
Query Match	1..2%; Score 28; DB 1; Length 28;
Best Local Similarity	100.0%; Pred. No. 3.6;
Matches	28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	653 ATGGCTCAGCCGATACCTTCACTCGAA 660
Db	1 ATGGCTCAGCCGATACCTTCACTCGAA 28
RESULT 7	
LOCUS	AR052638 27 bp DNA linear PAT 29-SEP-1999
DEFINITION	Sequence 4 from patent US 5831068.
ACCESSION	AR052638
VERSION	AR052638.1 GI:5976002
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	unclassified.
AUTHORS	1 (bases 1 to 27)
TITLE	Nair,S.K. and Gilboa,E.
JOURNAL	Method to increase the density of antigen on antigen presenting
FEATURES	cells
source	Patent: US 5831068-A 4 03-NOV-1998;
	Location/Qualifiers
	1..27
	/organism="unknown"
	/mol_type="unassigned DNA"
Query Match	1..2%; Score 27; DB 1; Length 27;
Best Local Similarity	100.0%; Pred. No. 5;
Matches	27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1192 AAGACACTCAACCGAAGAGGCTGTG 1218
Db	27 AAGACACTCAACCGAAGAGGCTGTG 1
RESULT 8	
LOCUS	AR052639 27 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 5 from patent US 5831068.
ACCESSION AR052639
VERSION AR052639.1 GI:5976003
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS Nair,S.K. and Gilla,E.
TITLE Method to increase the density of antigen on antigen presenting cells
JOURNAL Patent: US 5831068-A 5 03-NOV-1998;
FEATURES
source
1. .27
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.2%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 5;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1978 AACCGGTGACTTATCTGGATGAT 2004
Db 27 AACCGGTGACTTATCTGGATGAT 1
RESULT 9
BD142942
LOCUS BD142942 26 bp DNA linear PAT 17-JAN-2003
DEFINITION Method of assaying human ABC transporter and probe and kit therefor.
ACCESSION BD142942
VERSION BD142942.1 GI:27848700
KEYWORDS JP 2002112775-A/13.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.
TITLE Method of assaying human ABC transporter and probe and kit therefor
JOURNAL Patent: JP 2002112775-A 13 16-APR-2002;
COMMENT
OS human ABCB2 gene
PN JP 2002112775-A/13
PD 16-APR-2002
PF 03-OCT-2000 JP 2000303404
PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIRAOKA
PC C12N15/09,C12Q1/68,C12N15/00
CC Method of assaying human ABC transporter and probe and kit CC therefor
FH Key Location/Qualifiers
FT source 1. .26
/organism="human ABCB2 gene".
FEATURES
source
1. .26
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 1.2%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 6.8;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 330 TGCCTTGTTCGAGAGCTGATCTCAT 355
Db 1 TGCCTTGTTCGAGAGCTGATCTCAT 26
RESULT 10
BD143003
LOCUS BD143003 22 bp DNA linear PAT 17-JAN-2003
DEFINITION Method of assaying human ABC transporter and probe and kit therefor.

ACCESSION BD143003
VERSION BD143003.1 GI:27848761
KEYWORDS JP 2002112775-A/74.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.
TITLE Method of assaying human ABC transporter and probe and kit therefor
JOURNAL Patent: JP 2002112775-A 74 16-APR-2002;
COMMENT
OS human ABCB2 gene
PN JP 2002112775-A/74
PD 16-APR-2002
PF 03-OCT-2000 JP 2000303404
PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIRAOKA
PC C12N15/09,C12Q1/68,C12N15/00
CC Method of assaying human ABC transporter and probe and kit CC therefor
FH Key Location/Qualifiers
FT source 1. .22
/organism="human ABCB2 gene".
FEATURES
source
1. .22
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 1.0%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 628 CGCCTCAGCTGAGTCTTAC 649
Db 1 CGCCTCAGCTGAGTCTTAC 22
RESULT 11
BD143004
LOCUS BD143004 22 bp DNA linear PAT 17-JAN-2003
DEFINITION Method of assaying human ABC transporter and probe and kit therefor.
ACCESSION BD143004
VERSION BD143004.1 GI:27848762
KEYWORDS JP 2002112775-A/75.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.
TITLE Method of assaying human ABC transporter and probe and kit therefor
JOURNAL Patent: JP 2002112775-A 75 16-APR-2002;
COMMENT
OS human ABCB2 gene
PN JP 2002112775-A/75
PD 16-APR-2002
PF 03-OCT-2000 JP 2000303404
PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIRAOKA
PC C12N15/09,C12Q1/68,C12N15/00
CC Method of assaying human ABC transporter and probe and kit CC therefor
FH Key Location/Qualifiers
FT source 1. .22
/organism="human ABCB2 gene".
FEATURES
source
1. .22
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 1.0%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	731	TGGGTGACGGATCTATACAA	752	
Db	22	TGGGTGACGGATCTATACAA	1	
RESULT 12				
LOCUS	BD161968			
DEFINITION	BD161968	Simultaneous assay method of a plurality of different molecular species proteins mRNA and kit container used therefor.		
ACCESSION	BD161968			
VERSION	BD161968.1	GI:27867726		
KEYWORDS	JP 2002181818-A/19.			
SOURCE	unidentified			
ORGANISM	unidentified			
REFERENCE	1 (bases 1 to 22)			
AUTHORS	Nishimura,M., Yaguchi,H., Naito,S. and Hirooka,I.			
TITLE	Simultaneous assay method of a plurality of different molecular species proteins mRNA and kit container used therefor			
JOURNAL	Patent: JP 2002181818-A 19 26-JUN-2002;			
COMMENT	OTSUKA PHARMACEUTICAL FACTORY INC			
	OS Human ABCB2 gene			
	PN JP 2002181818-A/19			
	PD 26-JUN-2002			
	PF 15-DEC-2000 JP 2000381621			
	PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIRAOKA			
	PC GO1N33/53,C12N15/09,C12Q1/48,C12Q1/68,GO1N33/566,C12N15/00 CC			
	Simultaneous assay method of a plurality of different molecular species			
	CC proteins mRNA and kit container used therefor FH Key			
FEATURES				
source	FT	1..22		
	location/Qualifiers	/organism='Human ABCB2 gene'.		
	1..22			
	/organism='unidentified'			
	/mol_type='genomic DNA'			
	/db_xref='taxon:32644'			
Query Match	1.0%; Score 22; DB 1; Length 22;			
Best Local Similarity	100.0%; Pred. No. 23;			
Matches	22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	628	CGCTCACTGACTGGATTCTAC	649	
Db	1	CGCTCACTGACTGGATTCTAC	22	
RESULT 13				
LOCUS	BD161969			
DEFINITION	BD161969	Simultaneous assay method of a plurality of different molecular species proteins mRNA and kit container used therefor.		
ACCESSION	BD161969			
VERSION	BD161969.1	GI:27867727		
KEYWORDS	JP 2002181818-A/20.			
SOURCE	unidentified			
ORGANISM	unidentified			
REFERENCE	1 (bases 1 to 22)			
AUTHORS	Nishimura,M., Yaguchi,H., Naito,S. and Hirooka,I.			
TITLE	Simultaneous assay method of a plurality of different molecular species proteins mRNA and kit container used therefor			
JOURNAL	Patent: JP 2002181818-A 20 26-JUN-2002;			
COMMENT	OTSUKA PHARMACEUTICAL FACTORY INC			
	OS Human ABCB2 gene			
	PN JP 2002181818-A/20			
	PD 26-JUN-2002			
	PF 15-DEC-2000 JP 2000381621			
	PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIRAOKA			
	PC GO1N33/53,C12N15/09,C12Q1/48,C12Q1/68,GO1N33/566,C12N15/00 CC			

				Simultaneous assay method of a plurality of different CC			
				molecular species			
				CC proteins mRNA and kit container used therefor FH			
				Location/Qualifiers			
				1. .22			
				FT source			
				/organism='Human ABCB2 gene'.			
				1. .22			
				/organism="unidentified"			
				/mol_type="genomic DNA"			
				/db_xref="taxon:32644"			
Query Match				1.0%; Score 22; DB 1; Length 22;			
Best Local Similarity 100.0%; Pred. No. 23;							
Matches 22; Conservative 0; Mismatches 0; Gaps 0;							
QY				731 TGGGTGACGGGATCTATACAA 752			
Db				22 TGGGTGACGGGATCTATACAA 1			
RESULT 14							
AX477614/c				21 bp DNA linear PAT 12-AUG-2002			
DEFINITION				AX477614			
SEQUENCE				Sequence 66 from Patent WO0246433.			
ACCESSION				AX477614			
VERSION				AX477614.1 GI:22216794			
KEYWORDS							
SOURCE				synthetic construct			
ORGANISM				synthetic construct			
				artificial sequences.			
REFERENCE				1			
AUTHORS				Saus,J.			
TITLE				Tnf-inducible promoters and methods for using			
JOURNAL				Patent: WO 0246433-A 66 13-JUN-2002;			
				Saus, Juan (ES)			
FEATURES				Location/Qualifiers			
source				1. .21			
				/organism="synthetic construct"			
				/mol_type="unassigned DNA"			
				/db_xref="taxon:32630"			
				/note="Primer ON-TAP1-R2"			
Query Match				0.9%; Score 21; DB 1; Length 21;			
Best Local Similarity 100.0%; Pred. No. 31;							
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;							
QY				658 TCAGCCGATACCTTCACCTCGA 678			
Db				21 TCAGCCGATACCTTCACCTCGA 1			
RESULT 15							
AX505034/c				21 bp DNA linear PAT 27-SEP-2002			
DEFINITION				AX505034			
SEQUENCE				Sequence 66 from Patent WO0246378.			
ACCESSION				AX505034			
VERSION				AX505034.1 GI:23386356			
KEYWORDS							
SOURCE				synthetic construct			
ORGANISM				synthetic construct			
				artificial sequences.			
REFERENCE				1			
AUTHORS				Saus,J.			
TITLE				Alternative pol k nucleotide and amino acid sequence and methods			
JOURNAL				Patent: WO 0246378-A 66 13-JUN-2002;			
				Saus, Juan (ES)			
FEATURES				Location/Qualifiers			
source				1. .21			
				/organism="synthetic construct"			
				/mol_type="unassigned DNA"			
				/db_xref="taxon:32630"			

/note="Primer ON-TAP1-R2"

Query Match 0.9%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 658 TCAGCCGATACCTTCACTCGA 678
|||||
21 TCAGCCGATACCTTCACTCGA 1

RESULT 16
AX095590 21 bp DNA linear PAT 30-MAR-2001
LOCUS Sequence 768 from Patent WO0118250.
DEFINITION AX095590
ACCESSION AX095590.1 GI:13511793
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Lander, E.S., Gargill, M., Ireland, J.S., Bolk, S., Daley, G.Q. and
McCarthy, J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patient: WO 0118250-A 768 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium
Pharmaceuticals, Inc. (US)
FEATURES
source Location/Qualifiers
1. 21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 36;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 706 ATAGCCAGTGCAGCTGAG 726
|||||
1 ATAGCCAGTGCAGCTGAG 21

RESULT 17
AX095591 21 bp DNA linear PAT 30-MAR-2001
LOCUS Sequence 769 from Patent WO0118250.
DEFINITION AX095591
ACCESSION AX095591.1 GI:13511794
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Lander, E.S., Gargill, M., Ireland, J.S., Bolk, S., Daley, G.Q. and
McCarthy, J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patient: WO 0118250-A 769 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium
Pharmaceuticals, Inc. (US)
FEATURES
source Location/Qualifiers
1. 21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 36;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 407 ACCCTACCGCTTGTGTCA 427

Db 1 ACCCTACCGCTTGTGTCA 21
|||||

RESULT 18
AX095592 21 bp DNA linear PAT 30-MAR-2001
LOCUS Sequence 770 from Patent WO0118250.
DEFINITION AX095592
ACCESSION AX095592.1 GI:13511795
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Lander, E.S., Gargill, M., Ireland, J.S., Bolk, S., Daley, G.Q. and
McCarthy, J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patient: WO 0118250-A 770 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium
Pharmaceuticals, Inc. (US)
FEATURES
source Location/Qualifiers
1. 21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 36;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 318 CTTGCCGGAGTGCCTTGT 338
|||||
1 CTTGCCGGAGTGCCTTGT 21

RESULT 19
AX095593 21 bp DNA linear PAT 30-MAR-2001
LOCUS Sequence 771 from Patent WO0118250.
DEFINITION AX095593
ACCESSION AX095593.1 GI:13511796
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Lander, E.S., Gargill, M., Ireland, J.S., Bolk, S., Daley, G.Q. and
McCarthy, J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patient: WO 0118250-A 771 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium
Pharmaceuticals, Inc. (US)
FEATURES
source Location/Qualifiers
1. 21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 36;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 578 TGGTGTCTCTCTCTCTTG 598
|||||
1 TGGTGTCTCTCTCTCTTG 21

RESULT 20
AX095594 21 bp DNA linear PAT 30-MAR-2001
LOCUS

DEFINITION Sequence 772 from Patent WO0118250.
ACCESSION AX095594
VERSION AX095594.1 GI:13511797
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 772 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)
FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 36;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1245 TAGTATTTCAGGATGCTGCT 1265
Db 1 TAGTATTTCAGGATGCTGCT 21
RESULT 21
AX095596 21 bp DNA linear PAT 30-MAR-2001
LOCUS Sequence 774 from Patent WO0118250.
ACCESSION AX095596
VERSION AX095596.1 GI:13511799
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 774 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)
FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 36;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 847 AACATCATGCTCGGGTACA 867
Db 1 AACATCATGCTCGGGTACA 21
RESULT 22
AX095597 21 bp DNA linear PAT 30-MAR-2001
LOCUS Sequence 775 from Patent WO0118250.
ACCESSION AX095597
VERSION AX095597.1 GI:13511800
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 775 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)
FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 36;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1537 CCAACCGCCGATGCTTCA 1557
Db 1 CCAACCGCCGATGCTTCA 21
RESULT 24
BD143002/c 20 bp DNA linear PAT 17-JAN-2003
LOCUS Method of assaying human ABC transporter and probe and kit therefor.
ACCESSION BD143002
VERSION BD143002.1 GI:27848760
KEYWORDS JP 2002112775-A/73.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 20)
AUTHORS Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.
TITLE Method of assaying human ABC transporter and probe and kit therefor
JOURNAL Patent: JP 2002112775-A 73 16-APR-2002;
OS OTSUKA PHARMACEUTICAL FACTORY INC
COMMENT human ABCB2 gene

DEFINITION Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
ACCESSION 1
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 775 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)
FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 36;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 987 GGTACCCCTGATCACCTGCC 1007
Db 1 GGTACCCCTGATCACCTGCC 21
RESULT 23
AX095598 21 bp DNA linear PAT 30-MAR-2001
LOCUS Sequence 776 from Patent WO0118250.
ACCESSION AX095598
VERSION AX095598.1 GI:13511801
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 776 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)
FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 36;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1537 CCAACCGCCGATGCTTCA 1557
Db 1 CCAACCGCCGATGCTTCA 21
RESULT 24
BD143002/c 20 bp DNA linear PAT 17-JAN-2003
LOCUS Method of assaying human ABC transporter and probe and kit therefor.
ACCESSION BD143002
VERSION BD143002.1 GI:27848760
KEYWORDS JP 2002112775-A/73.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 20)
AUTHORS Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.
TITLE Method of assaying human ABC transporter and probe and kit therefor
JOURNAL Patent: JP 2002112775-A 73 16-APR-2002;
OS OTSUKA PHARMACEUTICAL FACTORY INC
COMMENT human ABCB2 gene

```

source
  1. .19
  /organism="synthetic construct"
  /mol_type="unassigned DNA"
  /db_xref="taxon:32630"
  /note="Primer ON-TAP1-F2"

Query Match
  0.8%; Score 19; DB 1; Length 19;
  Best Local Similarity 100.0%; Pred. No. 57;
  Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 626 GCCGCTTCTGCTGAGTGA 431
  |||||
  1 GCCGCTTCTGCTGAGTGA 1

RESULT 25
AX477613 19 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 65 from Patent WO246433.
ACCESSION AX477613
VERSION AX477613.1 GI:22216793
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
          artificial sequences.
REFERENCE
  1
  Saus, J.
  Title: Inducible promoters and methods for using
  JOURNAL Patent: WO 0246433-A 65 13-JUN-2002;
  Saus, Juan (ES)
  Location/Qualifiers
    source
      1. .19
      /organism="synthetic construct"
      /mol_type="unassigned DNA"
      /db_xref="taxon:32630"
      /note="Primer ON-TAP1-F2"

Query Match
  0.8%; Score 19; DB 1; Length 19;
  Best Local Similarity 100.0%; Pred. No. 57;
  Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 626 GCCGCTTCTGCTGAGTGA 444
  |||||
  1 GCCGCTTCTGCTGAGTGA 19

RESULT 26
AX505033 19 bp DNA linear PAT 27-SEP-2002
LOCUS AX505033
DEFINITION Sequence 65 from Patent WO246378.
ACCESSION AX505033
VERSION AX505033.1 GI:23386355
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
          artificial sequences.
REFERENCE
  1
  Saus, J.
  Title: Alternative pol k nucleotide and amino acid sequence and methods
  JOURNAL for using
  Patent: WO 0246378-A 65 13-JUN-2002;
  Saus, Juan (ES)
  Location/Qualifiers
    source
      1. .19
      /organism="synthetic construct"
      /mol_type="unassigned DNA"
      /db_xref="taxon:32630"
      /note="Primer ON-TAP1-F2"

Query Match
  0.8%; Score 19; DB 1; Length 19;
  Best Local Similarity 100.0%; Pred. No. 57;
  Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 626 GCCGCTTCTGCTGAGTGA 444
  |||||
  1 GCCGCTTCTGCTGAGTGA 19

RESULT 27
BD143001 19 bp DNA linear PAT 17-JAN-2003
LOCUS BD143001
DEFINITION Method of assaying human ABC transporter and probe and kit
          therefor.
ACCESSION BD143001
VERSION BD143001.1 GI:27848759
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
          unclassified.
REFERENCE
  1 (bases 1 to 19)
  Nishimura, M., Yaguchi, H., Naito, S. and Hiraoka, I.
  Title: Method of assaying human ABC transporter and probe and kit therefor
  JOURNAL Patent: JP 2002112775-A 72 16-APR-2002;
  OTSUKA PHARMACEUTICAL FACTORY INC
  OS human ABCB2 gene
  PN JP 2002112775-A/72
  PD 16-APR-2002
  PF 03-OCT-2000 JP 2000303404
  PI MASUHIRO NISHIMURA, HIROSHI YAGUCHI, SHINSAKU NAITO, ISAO HIRAOKA
  PC C12N15/09, C12Q1/68, C12N15/00
  CC Method of assaying human ABC transporter and probe and kit CC
  therefor
  FH Key Location/Qualifiers
  FT source
    1. .19
    /organism="human ABCB2 gene".

Query Match
  0.8%; Score 19; DB 1; Length 19;
  Best Local Similarity 100.0%; Pred. No. 57;
  Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 626 GCCGCTTCTGCTGAGTGA 644
  |||||
  1 GCCGCTTCTGCTGAGTGA 19

RESULT 28
AX057826 24 bp DNA linear PAT 17-JAN-2001
LOCUS AX057826
DEFINITION Sequence 4 from Patent WO0075334.
ACCESSION AX057826
VERSION AX057826.1 GI:12310468
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
          artificial sequences.
REFERENCE
  1
  Moise, A.R., Jefferies, W.A. and Vitalis, T.Z.
  Title: Apoptosis inhibition by adenovirus e3/6.7k
  JOURNAL Patent: WO 0075334-A 4 14-DEC-2000;
  UNIVERSITY OF BRITISH COLUMBIA (CA)
  Location/Qualifiers
    source
      1. .19
      /organism="synthetic construct"
      /mol_type="genomic DNA"
      /db_xref="taxon:32644"

```

```

source
  1. .19
  /organism="synthetic construct"
  /mol_type="unassigned DNA"
  /db_xref="taxon:32630"
  /note="Primer ON-TAP1-F2"

Query Match
  0.8%; Score 19; DB 1; Length 19;
  Best Local Similarity 100.0%; Pred. No. 57;
  Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 626 GCCGCTTCTGCTGAGTGA 644
  |||||
  1 GCCGCTTCTGCTGAGTGA 19

RESULT 27
BD143001 19 bp DNA linear PAT 17-JAN-2003
LOCUS BD143001
DEFINITION Method of assaying human ABC transporter and probe and kit
          therefor.
ACCESSION BD143001
VERSION BD143001.1 GI:27848759
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
          unclassified.
REFERENCE
  1 (bases 1 to 19)
  Nishimura, M., Yaguchi, H., Naito, S. and Hiraoka, I.
  Title: Method of assaying human ABC transporter and probe and kit therefor
  JOURNAL Patent: JP 2002112775-A 72 16-APR-2002;
  OTSUKA PHARMACEUTICAL FACTORY INC
  OS human ABCB2 gene
  PN JP 2002112775-A/72
  PD 16-APR-2002
  PF 03-OCT-2000 JP 2000303404
  PI MASUHIRO NISHIMURA, HIROSHI YAGUCHI, SHINSAKU NAITO, ISAO HIRAOKA
  PC C12N15/09, C12Q1/68, C12N15/00
  CC Method of assaying human ABC transporter and probe and kit CC
  therefor
  FH Key Location/Qualifiers
  FT source
    1. .19
    /organism="human ABCB2 gene".

Query Match
  0.8%; Score 19; DB 1; Length 19;
  Best Local Similarity 100.0%; Pred. No. 57;
  Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 626 GCCGCTTCTGCTGAGTGA 644
  |||||
  1 GCCGCTTCTGCTGAGTGA 19

RESULT 28
AX057826 24 bp DNA linear PAT 17-JAN-2001
LOCUS AX057826
DEFINITION Sequence 4 from Patent WO0075334.
ACCESSION AX057826
VERSION AX057826.1 GI:12310468
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
          artificial sequences.
REFERENCE
  1
  Moise, A.R., Jefferies, W.A. and Vitalis, T.Z.
  Title: Apoptosis inhibition by adenovirus e3/6.7k
  JOURNAL Patent: WO 0075334-A 4 14-DEC-2000;
  UNIVERSITY OF BRITISH COLUMBIA (CA)
  Location/Qualifiers
    source
      1. .19
      /organism="synthetic construct"
      /mol_type="genomic DNA"
      /db_xref="taxon:32644"

```

```
source
1..24
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Reverse Primer"

Query Match
Best Local Similarity 0.8%; Score 18.2; DB 1; Length 24;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy
1990 CTTATCCTGATGATGCCACG 2012
|||||
2 CTTATCTTGATGTTGCCCCAG 24

Db
2 CTTATCTTGATGTTGCCCCAG 24

RESULT 29
LOCUS AX457168 24 bp DNA linear PAT 08-JUL-2002
DEFINITION Sequence 23 from Patent WO0246231.
ACCESSION AX457168
VERSION AX457168.1 GI:21724825
KEYWORDS
SOURCE
ORGANISM
synthetic construct
artificial sequences.
REFERENCE
1
AUTHORS
Moise,A.R., Jefferies,W.A., Vitalis,T.Z. and Grant,J.R.
TITLE
CamI-binding peptides
JOURNAL
Patent: WO 0246231-A 23 13-JUN-2002;
The University of British Columbia (CA)
FEATURES
location/Qualifiers
1..24
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Reverse Primer"

Query Match
Best Local Similarity 0.8%; Score 18.2; DB 1; Length 24;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy
1990 CTTATCCTGATGATGCCACG 2012
|||||
2 CTTATCTTGATGTTGCCCCAG 24

Db
2 CTTATCTTGATGTTGCCCCAG 24

RESULT 30
LOCUS AR032131/c 22 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5866699.
ACCESSION AR032131
VERSION AR032131.1 GI:5946420
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE
1
AUTHORS
Smyth,A.P.
TITLE
Oligonucleotides with anti-MDR-1 gene activity
JOURNAL
Patent: US 5866699-A 1 02-FEB-1999;
FEATURES
location/Qualifiers
1..22
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 17.2; DB 1; Length 22;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy
1617 CAATGGCTCTGGGAAGACACA 1638
|||||
22 CAGTGGCTGTGGGAAGACACA 1

Db
22 CAGTGGCTGTGGGAAGACACA 1
```

```
RESULT 31
LOCUS BD192479/c 22 bp DNA linear PAT 17-JUL-2003
DEFINITION Compositions and methods for the delivery of oligonucleotides via
the alimentary canal.
ACCESSION BD192479
VERSION BD192479.1 GI:33002218
KEYWORDS
JP 2002510319-A/44.
SOURCE
synthetic construct
artificial sequences.
ORGANISM
1 (bases 1 to 22)
REFERENCE
1
AUTHORS
Teng,C.L. and Hardee,G.
TITLE
Compositions and methods for the delivery of oligonucleotides via
the alimentary canal
JOURNAL
Patent: JP 2002510319-A 44 02-APR-2002;
COMMENT
ISIS PHARMACEUTICALS INC
OS Artificial Sequence
PN JP 2002510319-A/44
PD 02-APR-2002
PF 01-JUL-1998 JP 1999507295
PR 01-JUL-1997 US 08/886829
PI CHING LEOU TENG,GREG HARDEE
PC C1201/68, A61K9/127, A61K48/00, C07H21/04
CC Description of Artificial Sequence: Novel Sequence FH Key

FEATURES
location/Qualifiers
1..22
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 0.8%; Score 17.2; DB 1; Length 22;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy
1617 CAATGGCTCTGGGAAGACACA 1638
|||||
22 CAGTGGCTGTGGGAAGACACA 1

Db
22 CAGTGGCTGTGGGAAGACACA 1

RESULT 32
LOCUS AR230795/c 20 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 55 from Patent US 6451602.
ACCESSION AR230795
VERSION AR230795.1 GI:27271582
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE
1
AUTHORS
Popoff,I. and Cowse,R.L.M.
TITLE
Antisense modulation of PARP expression
JOURNAL
Patent: US 6451602-A 55 17-SEP-2002;
FEATURES
location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.7%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy
1193 AGACATCAACCAAGAG 1212
|||||
20 AGACATCAACCAAGAG 1

Db
20 AGACATCAACCAAGAG 1

RESULT 33
LOCUS AX096303 21 bp DNA linear PAT 30-MAR-2001
```

```

DEFINITION   Sequence 1481 from Patent WO0118250.
ACCESSION    AX096303
VERSION      AX096303.1 GI:13512530
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
REFERENCE    1 Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
AUTHORS      Lander, E.S., Gargall, M., Ireland, J.S., Bolk, S., Daley, G.Q. and
              McCarty, J.U.
TITLE        Single nucleotide polymorphisms in genes
JOURNAL      Patent: WO 0118250-A 1481 15-MAR-2001;
              WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium
              Pharmaceuticals, Inc. (US)
FEATURES     location/Qualifiers
              1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match   0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY            1565 AGGGGCTGACATTCACCCCTA 1584
              |||||
Db            2 AGGGGCTGAGYTTTACCCCTA 21

RESULT 34
LOCUS        AX097152 21 bp DNA linear PAT 30-MAR-2001
DEFINITION   Sequence 2330 from Patent WO0118250.
ACCESSION    AX097152
VERSION      AX097152.1 GI:13513456
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
REFERENCE    1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
              Lander, E.S., Gargall, M., Ireland, J.S., Bolk, S., Daley, G.Q. and
              McCarty, J.U.
TITLE        Single nucleotide polymorphisms in genes
JOURNAL      Patent: WO 0118250-A 2330 15-MAR-2001;
              WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium
              Pharmaceuticals, Inc. (US)
FEATURES     location/Qualifiers
              1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match   0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY            259 GCAGGTGCCGAGGCGCTGCT 278
              |||||
Db            20 GCAGGTGCCMAAGTCGGGCT 1

RESULT 35
LOCUS        AR085050 21 bp DNA linear PAT 01-SEP-2000
DEFINITION   Sequence 12 from patent US 5981262.
ACCESSION    AR085050
VERSION      AR085050.1 GI:10011821
KEYWORDS
SOURCE       Unknown.
ORGANISM     Unknown.
FEATURES     Unclassified.

```

```

REFERENCE    1 (bases 1 to 21)
AUTHORS      Brugge, J., Morganstern, J., Shive, L., Zydowsky, L., Zoller, M. and
              Pawson, A.
TITLE        Human syx
JOURNAL      Patent: US 5981262-A 12 09-NOV-1999;
FEATURES     location/Qualifiers
              1..21
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match   0.7%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY            821 AGTTTCCACAGAACCA 841
              |||||
Db            1 AGTATTTCACAGAACCA 21

RESULT 36
LOCUS        AX060422 21 bp DNA linear PAT 22-JAN-2001
DEFINITION   Sequence 42 from Patent WO0100841.
ACCESSION    AX060422
VERSION      AX060422.1 GI:12405899
KEYWORDS
SOURCE       synthetic construct
ORGANISM     synthetic construct
REFERENCE    1 artificial sequences.
AUTHORS      Griffin, J., Carlile, A.J., Cayley, P.J., Mackay, E.A., Warner, S.A.,
              Vincent, J.L. and Lee, M.D.
TITLE        Insecticidal proteins from psocidomyces and synergistic
              combinations thereof
JOURNAL      Patent: WO 0100841-A 42 04-JAN-2001;
              ZENBECA LIMITED (GB)
FEATURES     location/Qualifiers
              1..21
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"
              /note="Primers"

Query Match   0.7%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY            101 TGCTGCTCCGACCGCGCTGC 121
              |||||
Db            1 TGCTGCCCCGACCTGCGCTGC 21

RESULT 37
LOCUS        AX295751 20 bp DNA linear PAT 21-NOV-2001
DEFINITION   Sequence 7513 from Patent WO0179548.
ACCESSION    AX295751
VERSION      AX295751.1 GI:17057440
KEYWORDS
SOURCE       synthetic construct
ORGANISM     synthetic construct
REFERENCE    1 artificial sequences.
AUTHORS      Barany, F., Zivvi, M., Gerry, N.P., Favis, R. and Kilman, R.
TITLE        Method of designing addressable array for detection of nucleic acid
              sequence differences using ligase detection reaction
JOURNAL      Patent: WO 0179548-A 7513 25-OCT-2001;
              CORNELL RESEARCH FOUNDATION, INC. (US)
FEATURES     location/Qualifiers
              1..20
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"

```

```
/note="Hypothetical Probe Sequence"
Query Match          0.7%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      269 AGGCTGCTGCTGCTGC 284
      |||||
Db      19 AGGCTGCTGCTGCTGC 4

RESULT 38
AR074584      19 bp      DNA      linear      PAT 28-AUG-2000
DEFINITION    Sequence 40 from patent US 5955263.
ACCESSION     AR074584
VERSION       AR074584.1 GI:10001337
KEYWORDS
SOURCE        unknown.
ORGANISM      Unclassified.
REFERENCE     1 (bases 1 to 19)
AUTHORS       Vogelstein,B., Kinzler,K.W. and Sherman,M.I.
TITLE         Sequence specific DNA binding by p53
JOURNAL       Patent: US 5955263-A 40 21-SEP-1999;
FEATURES
source        1..19
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match          0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      318 CCGCGCGGACTTGCTTG 336
      |||||
Db      1 CCGCTGCTGACTTGCTGC 19

RESULT 39
AR157464      19 bp      DNA      linear      PAT 17-OCT-2001
DEFINITION    Sequence 40 from patent US 6245515.
ACCESSION     AR157464
VERSION       AR157464.1 GI:16218405
KEYWORDS
SOURCE        unknown.
ORGANISM      Unclassified.
REFERENCE     1 (bases 1 to 19)
AUTHORS       Vogelstein,B., Kinzler,K.W. and Sherman,M.I.
TITLE         Sequence specific DNA binding p53
JOURNAL       Patent: US 6245515-A 40 12-JUN-2001;
FEATURES
source        1..19
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match          0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      318 CCGCGCGGACTTGCTTG 336
      |||||
Db      1 CCGCTGCTGACTTGCTGC 19

RESULT 40
E39425      19 bp      DNA      linear      PAT 31-JAN-2002
LOCUS        E39425
DEFINITION    Novel membrane-bound metalloprotease.
ACCESSION     E39425
VERSION       E39425.1 GI:18621534
```

```
KEYWORDS      JP 2000270874-A/3.
SOURCE        synthetic construct
ORGANISM      synthetic construct
REFERENCE     1 (bases 1 to 19)
AUTHORS       Ropesumotin,C., Kuadora,E.J., Pendaau,A.M., Fureihe,J.B., Noki,T.,
              Shinagawa,A. and Iwata,K.
TITLE         Novel membrane-bound metalloprotease
JOURNAL       Patent: JP 2000270874-A 3 03-OCT-2000;
COMMENT       FUJI CHEMICAL INDUSTRIES LTD
              OS Artificial Sequence
              PN JP 2000270874-A/3
              PD 03-OCT-2000
              PF 25-MAR-1999 JP 1999082516
              PR
              PI CARLOS ROPESU-OTIN,ELENA JANO KUADORA,ALBERT M PENDASU, PI
              JOSE B FUREIHE,
              PI TAKANORI AOKI,AKIRA SHINAGAWA,KAZUSHI IWATA
              PC C12N15/09,A61K31/00,A61K31/00,A61K31/00,A61K31/00,A61K31/00,
              PC A61K31/00,A61K31/00,A61K31/00,A61K31/70,A61K38/46,
              PC A61K39/395,
              PC A61K39/395,A61K45/00,A61K48/00,C07K16/40,C12N1/19,C12N1/21, PC
              C12N5/10,
              PC C12N9/50,C12Q1/68,G01N33/53,G01N33/573//C12P21/08,C12N15/00,
              PC A61K37/54,
              PC C12N5/00
              CC
              FH Key
              FT source
              FT Location/Qualifiers
              1..19
              /organism="synthetic construct"
              /mol_type="genomic DNA"
              /db_xref="taxon:32630"

FEATURES
source        Location/Qualifiers

Query Match          0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1362 CAGCCAGCTGTGAGGTA 1380
      |||||
Db      1 CCCCAGGCTGTGGGGTA 19

RESULT 41
AX339215      19 bp      DNA      linear      PAT 10-JAN-2002
LOCUS        AX339215
DEFINITION    Sequence 9 from Patent WO0196602.
ACCESSION     AX339215
VERSION       AX339215.1 GI:18135476
KEYWORDS
SOURCE        Homo sapiens (human)
ORGANISM      Homo sapiens
REFERENCE     1
AUTHORS       Yang A.L. and Festing,M.
TITLE         Methods and materials to determine the p53 status of a sample by
              determining the binding of p53 to a vector
JOURNAL       Patent: WO 0196602-A 9 20-DEC-2001;
MEDICAL RESEARCH COUNCIL (GB)
FEATURES
source        1..19
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match          0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 318 CCTGCCGGGACTTGCCTTG 336
Db 1 CCTGCCCTGGACTTGCCTTG 19

RESULT 42

BD141673 19 bp DNA linear PAT 18-SEP-2002
LOCUS Transgenic animal.
DEFINITION BD141673
ACCESSION BD141673.1 GI:23236618
VERSION WO 0211530-A/7.
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 19)
AUTHORS Yoshimura, K., Nishimura, A., Nishida, M. and Hosono, K.
TITLE Transgenic animal
JOURNAL Patent: WO 0211530-A 7 14-FEB-2002;
TAKEDA CHEMICAL INDUSTRIES LTD, KOJI YOSHIMURA, ATSUSHI NISHIMURA,
MAYUMI NISHIDA, KAZUHIRO HOSONO
OS Artificial Sequence
PN WO 0211530-A/7
PD 14-FEB-2002
PF 08-AUG-2001 WO 2001JP06826
PR 09-AUG-2000 JP 00P 241748
PI KOJI YOSHIMURA, ATSUSHI NISHIMURA, MAYUMI NISHIDA, KAZUHIRO PI
HOSONO
PC A01K67/027, A61K45/00, A61P19/00, A61P19/10, A61P19/02, A61P29/00,
PC A61P27/02,
PC A61P35/00, C12N5/16, C12N5/18, C12N15/09, G01N33/15, G01N33/50 CC
Primer
FH Key Location/Qualifiers
FT source 1..19 /organism='Artificial Sequence'.

FEATURES

source
1..19
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1996 CTGGATGATGCCACCACTG 2014
Db 1 CTGGATGATGCCACCAAGG 19

RESULT 43

AR032132/c 20 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 2 from patent US 5866699.
DEFINITION AR032132
ACCESSION AR032132
VERSION AR032132.1 GI:5946421
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Smyth, A.P.
TITLE Oligonucleotides with anti-MDR-1 gene activity
JOURNAL Patent: US 5866699-A 2 02-FEB-1999;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1620 TGGGCTGGGAGAGACACA 1638
Db 19 TGGGCTGGGAGAGACACA 1

RESULT 44

AR220980 20 bp DNA linear PAT 26-SEP-2002
LOCUS Sequence 33 from patent US 6426188.
DEFINITION AR220980
ACCESSION AR220980
VERSION AR220980.1 GI:23327865
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Wyatt, J.
TITLE Antisense modulation of phosphorylase kinase alpha 1 expression
JOURNAL Patent: US 6426188-A 33 30-JUL-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1676 GGGGACAGCTGCTGTGGA 1694
Db 19 GGGGACAGCTGCAATTGGA 1

RESULT 45

AR37234/c 20 bp DNA linear PAT 17-AUG-2003
LOCUS Sequence 159 from patent US 6566135.
DEFINITION AR37234
ACCESSION AR37234
VERSION AR37234.1 GI:33723088
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Watt, A.T.
TITLE Antisense modulation of caspase 6 expression
JOURNAL Patent: US 6566135-A 159 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1885 CCTCAGGGCTATGACACAG 1903
Db 20 CCTCAGGGCTAGGACACCG 2

RESULT 46

AR361456 20 bp DNA linear PAT 17-AUG-2003
LOCUS Sequence 36 from patent US 6599727.
DEFINITION AR361456
ACCESSION AR361456
VERSION AR361456.1 GI:33769294
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Christenson, E., Demaggio, A.J., Goldman, P.S. and McElligott, D.L.

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

TITLE Human poly (ADP-ribose) polymerase 2 materials and methods
JOURNAL Patent: US 6599727-A 36 29-JUL-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1193 AGACACTCAACCGAGAAGA 1211
|||||
2 AGACACCCCAACCGAGAAGA 20

RESULT 47
AR361457/c AR361457 20 bp DNA linear PAT 17-AUG-2003
LOCUS Sequence 37 from patent US 6599727.
DEFINITION AR361457
ACCESSION AR361457.1 GI:33769295
VERSION
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 20)
AUTHORS Christenson,E., Demaggio,A.J., Goldman,P.S. and McElligott,D.L.
JOURNAL Human poly (ADP-ribose) polymerase 2 materials and methods
PATENT: US 6599727-A 37 29-JUL-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1193 AGACACTCAACCGAGAAGA 1211
|||||
19 AGACACCCCAACCGAGAAGA 1

RESULT 48
AX058352 AX058352 20 bp DNA linear PAT 17-JAN-2001
LOCUS Sequence 36 from Patent WO0077179.
DEFINITION AX058352
ACCESSION AX058352
VERSION AX058352.1 GI:12310812
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE artificial sequences.
1
AUTHORS Christenson,E., Demaggio,A.J., Goldman,P.S. and McElligott,D.L.
JOURNAL Human poly (ADP-ribose) polymerase 2 materials and methods
PATENT: WO 0077179-A 36 21-DEC-2000;
FEATURES ICOS CORPORATION (US)
Location/Qualifiers
source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1193 AGACACTCAACCGAGAAGA 1211
|||||
2 AGACACCCCAACCGAGAAGA 20

RESULT 49
AX058353/c AX058353 20 bp DNA linear PAT 17-JAN-2001
LOCUS Sequence 37 from Patent WO0077179.
DEFINITION AX058353
ACCESSION AX058353
VERSION AX058353.1 GI:12310813
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE artificial sequences.
1
AUTHORS Christenson,E., Demaggio,A.J., Goldman,P.S. and McElligott,D.L.
JOURNAL Human poly (ADP-ribose) polymerase 2 materials and methods
PATENT: WO 0077179-A 37 21-DEC-2000;
FEATURES ICOS CORPORATION (US)
Location/Qualifiers
source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1193 AGACACTCAACCGAGAAGA 1211
|||||
19 AGACACCCCAACCGAGAAGA 1

RESULT 50
AX062312 AX062312 20 bp DNA linear PAT 24-JAN-2001
LOCUS Sequence 171 from Patent WO0100849.
DEFINITION AX062312
ACCESSION AX062312
VERSION AX062312.1 GI:12540213
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE artificial sequences.
1
AUTHORS Christenson,E., Demaggio,A.J., Goldman,P.S. and McElligott,D.L.
JOURNAL Tankyrase2 materials and methods
PATENT: WO 0100849-A 171 04-JAN-2001;
FEATURES ICOS CORPORATION (US)
Location/Qualifiers
source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1193 AGACACTCAACCGAGAAGA 1211
|||||
2 AGACACCCCAACCGAGAAGA 20

RESULT 51
AX062313/c AX062313 20 bp DNA linear PAT 24-JAN-2001
LOCUS Sequence 172 from Patent WO0100849.
DEFINITION AX062313
ACCESSION AX062313
VERSION AX062313.1 GI:12540214
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

REFERENCE
AUTHORS 1
TITLE Christenson, E., Demaggio, A.J., Goldman, P.S. and Mcelligott, D.L.
JOURNAL Tenkysrae2 materials and methods
ICOS CORPORATION (US)
Patent: WO 0100849-A 172 04-JAN-2001;
FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1193 AGACACTCAACGAGAGGA 1211
DB 19 AGACACCCCAACCGAGAGGA 1

RESULT 52
BD192480/c 20 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION the alimentary canal.
ACCESSION BD192480.1 GI:33002219
VERSION JP 2002510319-A/45.
KEYWORDS
SOURCE synthetic construct
ORGANISM
REFERENCE
AUTHORS 1 (bases 1 to 20)
TITLE Teng, C.L. and Hardee, G.
JOURNAL Compositions and methods for the delivery of oligonucleotides via
the alimentary canal
Patent: JP 2002510319-A 45 02-APR-2002;
COMMENT
JOURNAL ISIS PHARMACEUTICALS INC
OS Artificial Sequence
PN JP 2002510319-A/45
PD 02-APR-2002
PR 01-JUL-1998 JP 1999507295
PR 01-JUL-1997 US 08/866829
PI CHING LEOU TENG, GREG HARDEE
PC C1201/68, A61K9/12, A61K48/00, C07H21/04
CC Description of Artificial Sequence: Novel Sequence FH Key
FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1620 TGGGCTGGGAGAGACACA 1638
DB 19 TGGCTGTGGAGAGACACA 1

RESULT 53
AX278535 21 bp DNA linear PAT 02-NOV-2001
LOCUS
DEFINITION Sequence 72 from Patent WO0177372.
ACCESSION AX278535
VERSION AX278535.1 GI:16605989
KEYWORDS
SOURCE synthetic construct
ORGANISM
REFERENCE
AUTHORS 1
TITLE artificial sequences.
JOURNAL

REFERENCE
AUTHORS 1
TITLE Remacle, J., Hamels, S., Zammattéo, N., Lockman, L., Dufour, S.,
Alexandre, I. and de Longueville, P.
JOURNAL Identification of biological (micro) organisms by detection of the
ir homologous nucleotide sequences on arrays
Patent: WO 0177372-A 72 18-OCT-2001;
Facultes Universitaires Notre-Dame de la Paix (BE)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="capture probe"

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1594 GAGGTGACGGCGCTGTCG 1612
DB 3 GAGGTGATGCGCGCTGTCG 21

RESULT 54
AX513092 21 bp DNA linear PAT 03-OCT-2002
LOCUS
DEFINITION Sequence 21 from Patent EP1233076.
ACCESSION AX513092
VERSION AX513092.1 GI:23504171
KEYWORDS
SOURCE Mycobacterium marinum
ORGANISM
REFERENCE
AUTHORS 1
TITLE Mycobacterium marinum
JOURNAL Bacteria: Actinobacteria; Actinobacteridae; Actinomycetales;
Corynebacterineae; Mycobacteriaceae; Mycobacterium.
Gala, J.L. and Vannuffel, P.
Differential diagnosis for mycobacterial and pseudomonas species
using species-specific upstream p34 gene region probes
Patent: EP 1233076-A 21 21-AUG-2002;
UNIVERSITE CATHOLIQUE DE LOUVAIN (BE)
FEATURES
source
1. .21
/organism="Mycobacterium marinum"
/mol_type="unassigned DNA"
/db_xref="taxon:1781"

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1594 GAGGTGACGGCGCTGTCG 1612
DB 3 GAGGTGATGCGCGCTGTCG 21

RESULT 55
BD171659 21 bp DNA linear PAT 18-FEB-2003
LOCUS
DEFINITION Identification of nucleotide sequence specific to mycobacteria and
development of discrimination and diagnosis of mycobacteria
species.
ACCESSION BD171659
VERSION BD171659.1 GI:28412951
KEYWORDS JP 2002238563-A/20.
SOURCE synthetic construct
ORGANISM
REFERENCE
AUTHORS 1 (bases 1 to 21)
TITLE Gara, J.L. and Vannuffel, P.
JOURNAL Identification of nucleotide sequence specific to mycobacteria and
development of discrimination and diagnosis of mycobacteria species
Patent: JP 2002238563-A 20 27-AUG-2002;
UNIVERSITE CATHOLIQUE DE LOUVAIN

COMMENT OS Artificial Sequence
PN JP 2002238563-A/20
PD 27-AUG-2002
PF 31-JAN-2001 JP 2001024023
PI JEAN LUC GARA, PASCAL VANNUPPEL,
PC C12N15/09, C12N15/09, C12M1/00, C12Q1/68, G01N33/53, G01N33/566, PC
G01N33/569//
PC (C12N15/09, C12R1:32), (C12Q1/68, C12R1:32), C12N15/00, C12N15/00,
PC (C12N15/00, C12R1:32)
CC Description of Artificial Sequence: oligonucleotide primer FH
Key Location/Qualifiers
FT source 1..21
Location/Qualifiers
1..21
/organism='Artificial Sequence'.
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'

FEATURES
source

Query Match 0.7%; Score 15.4; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1594 GAGGTGACGGCGCTGTGG 1612
|||||
3 GAGGTGATGGCGCTGTGG 21

Db

RESULT 56
AX724430 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2117 from Patent WO03025176.
AX724430
VERSION AX724430.1 GI:30503773
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025176-A 2117 27-MAR-2003;
JOURNAL Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism='Mus musculus'
/mol_type='unassigned DNA'
/db_xref='taxon:10090'

QY 996 GATCACCTGCTCTGC 1012
|||||
1 GATCTCCCTGCTCTGC 17

Db

Query Match 0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2263 from Patent WO03050284.
AX783932
VERSION AX783932
KEYWORDS AX783932.1 GI:32951781
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1

AUTHORS Guo, J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2263 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
/organism='Homo sapiens'
/mol_type='unassigned DNA'
/db_xref='taxon:9606'

Query Match 0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1631 AGACACAGTGTCTGCC 1647
|||||
1 AGACACAGTGTCTGCC 17

Db

RESULT 58
AX783933 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2264 from Patent WO03050284.
AX783933
VERSION AX783933.1 GI:32951782
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
Guo, J.
Human prostate cancer candidate protein 1
Patent: WO 03050284-A 2264 19-JUN-2003;
JOURNAL Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
/organism='Homo sapiens'
/mol_type='unassigned DNA'
/db_xref='taxon:9606'

QY 1632 GAGCACAGTGTCTGCC 1648
|||||
1 GAGCACAGTGTCTGCC 17

Db

RESULT 59
AR039057/c 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 23 from patent US 5807730.
AR039057
VERSION AR039057.1 GI:5958420
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Ito, K., Yamaki, T., Arai, T., Tsuruoka, M. and Nakamura, T.
TITLE Nitrite hydratase
JOURNAL Patent: US 5807730-A 23 15-SEP-1998;
FEATURES
source
1..18
/organism='unknown'
/mol_type='unassigned DNA'

Query Match 0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2068 GAGCGGTACTCCGCTC 2084
 Db 17 GAGCGGTACTCCGCTC 1

RESULT 60
 AR071237/c 18 bp DNA linear PAT 18-FEB-2000
 LOCUS AR071237
 DEFINITION Sequence 23 from patent US 5910432.
 ACCESSION AR071237
 VERSION AR071237.1 GI:7222125
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Ito,K., Yamaki,T., Arai,T., Tsuruoka,M. and Nakamura,T.
 TITLE Nitrite hydratase
 JOURNAL Patent: US 5910432-A 23 08-JUN-1999;
 FEATURES Location/Qualifiers
 source 1..18
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.7%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 1.8e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2068 GAGCGGTACTCCGCTC 2084
 Db 17 GAGCGGTACTCCGCTC 1

RESULT 61
 E14107/c 18 bp DNA linear PAT 28-JUN-1999
 LOCUS E14107
 DEFINITION PCR primer for producing mutated Pseudonocardia nitritelenhydratase.
 ACCESSION E14107
 VERSION E14107.1 GI:5708790
 KEYWORDS JP 1997275978-A/21.
 SOURCE unidentified
 ORGANISM unidentified
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Ito,K., Yamaki,T., Arai,T., Tsuruoka,M. and Nakamura,T.
 TITLE NEW NITRITE-HYDRATASE
 JOURNAL Patent: JP 1997275978-A 21 28-OCT-1997;
 COMMENTS MITSUI TOATSU CHEM INC
 OS None
 CC Artificial sequences.
 PN JP 1997275978-A/21
 PD 28-OCT-1997
 PR 29-JAN-1997 JP 1997015295
 PI 14-FEB-1996 JP 96P 27004
 PI ITO KIYOSHI, YAMAKI TOSHIBUMI, ARAI TERUO, TSURUOKA MIYUKI, PI
 NAKAMURA TAKESHI
 PC C12N9/88, C12N1/21, C12N15/09, (C12N9/88, C12R1.19), (C12N1/21, PC
 C12R1.19),
 CC (C12N15/09, C12R1.01);
 CC strandedness: Single;
 CC topology: Linear;
 CC hypothetical: No;
 CC anti-sense: No;
 FH Key
 FT source 1..18
 /organism="Artificial sequences".
 FT Location/Qualifiers
 1..18
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

Query Match 0.7%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 1.8e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2068 GAGCGGTACTCCGCTC 2084
 Db 17 GAGCGGTACTCCGCTC 1

RESULT 62
 AR196144 18 bp DNA linear PAT 20-APR-2002
 LOCUS AR196144
 DEFINITION Sequence 609 from patent US 6350934.
 ACCESSION AR196144
 VERSION AR196144.1 GI:20245581
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P Ann Owens.,
 TITLE Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.
 JOURNAL Nucleic acid encoding delta-9 desaturase
 Patent: US 6350934-A 609 26-FEB-2002;
 FEATURES Location/Qualifiers
 source 1..18
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.7%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 1.8e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2178 CCAGCAGCTCATGAGA 2194
 Db 2 CCAGCAGCTCATGAGA 18

RESULT 63
 AR300594 18 bp DNA linear PAT 12-JUN-2003
 LOCUS AR300594
 DEFINITION Sequence 1 from patent US 6537805.
 ACCESSION AR300594
 VERSION AR300594.1 GI:31688126
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Melchner,H.V., Andreu,T. and Ebensperger,C.
 TITLE Self-deleting vectors
 JOURNAL Patent: US 6537805-A 1 25-MAR-2003;
 FEATURES Location/Qualifiers
 source 1..18
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.7%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 1.8e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 318 CTTGCGGAGACTGGCT 334
 Db 1 CTTGCGGAGACTGGCT 17

RESULT 64
 AX130922/c 19 bp DNA linear PAT 15-MAY-2001
 LOCUS AX130922
 DEFINITION Sequence 2140 from Patent WO0130362.
 ACCESSION AX130922
 VERSION AX130922.1 GI:14137227
 KEYWORDS

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 2140 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES location/Qualifiers
SOURCE 1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cyclin E ribozyme binding site"

Query Match 0.7%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1179 GCTGCAGAAATAAGA 1195
| | | | | | | | | | | | | | | | | | | | | |
19 GCTGCATAATAATAAGA 3

RESULT 65
AX130923/c 19 bp DNA linear PAT 15-MAY-2001
LOCUS Sequence 2141 from Patent WO0130362.
DEFINITION AX130923
ACCESSION AX130923
VERSION AX130923.1 GI:14137228
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 2141 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES location/Qualifiers
SOURCE 1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cyclin E ribozyme binding site"

Query Match 0.7%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1179 GCTGCAGAAATAAGA 1195
| | | | | | | | | | | | | | | | | | | | | |
18 GCTGCATAATAATAAGA 2

RESULT 66
AX130924/c 19 bp DNA linear PAT 15-MAY-2001
LOCUS Sequence 2142 from Patent WO0130362.
DEFINITION AX130924
ACCESSION AX130924
VERSION AX130924.1 GI:14137229
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye

JOURNAL diseases
Patent: WO 0130362-A 2142 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES location/Qualifiers
SOURCE 1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cyclin E ribozyme binding site"

Query Match 0.7%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1179 GCTGCAGAAATAAGA 1195
| | | | | | | | | | | | | | | | | | | | | |
17 GCTGCATAATAATAAGA 1

RESULT 67
A62106 20 bp DNA linear PAT 09-MAR-1998
LOCUS Sequence 6 from Patent WO9712970.
DEFINITION A62106
ACCESSION A62106
VERSION A62106.1 GI:3716151
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Balmain,A. and Zhu,J.
TITLE ANTITUMOUR VECTOR CONSTRUCTS AND METHODS
JOURNAL Patent: WO 9712970-A 6 10-APR-1997;
CANCER RES CAMPAIGN TECH (GB)
COMMENT Other publication AU 7136696 970428
Other publication GB 2305920 970423.
FEATURES location/Qualifiers
SOURCE 1..20
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 315 GGCCCTGCGGACTTGCT 334
| | | | | | | | | | | | | | | | | | | | | |
1 GGACTTGCTGACTTGCT 20

RESULT 68
AR032133/c 20 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 3 from patent US 5866699.
DEFINITION AR032133
ACCESSION AR032133
VERSION AR032133.1 GI:5946422
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1
AUTHORS Smyth,A.P.
TITLE Oligonucleotides with anti-MDR-1 gene activity
JOURNAL Patent: US 5866699-A 3 02-FEB-1999;
FEATURES location/Qualifiers
SOURCE 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1618 AATGGCTGGAGAGACAC 1637
Db 20 AGTGGCTGTGGAGAGACAC 1

RESULT 69
LOCUS AR032134 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 4 from patent US 5866699.
ACCESSION AR032134
VERSION AR032134.1 GI:5946423
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Smyth,A.P.
TITLE Oligonucleotides with anti-MDR-1 gene activity
JOURNAL Patent: US 5866699-A 4 02-FEB-1999;
FEATURES Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1617 CAATGGCTGGAGAGCA 1636
Db 20 CAGTGGCTGTGGAGAGCA 1

RESULT 70
LOCUS AR084441 20 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 17 from patent US 5981178.
ACCESSION AR084441
VERSION AR084441.1 GI:10011212
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Tsui,L.-C., Rommens,J.M. and Kerem,B.-S.
TITLE Methods for screening for mutations at various positions in the
introns and exons of the cystic fibrosis gene
JOURNAL Patent: US 5981178-A 17 09-NOV-1999;
FEATURES Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1988 TACTTATCTGGATGATGCC 2007
Db 20 TAGTTTCTGTGATGATGCC 1

RESULT 71
LOCUS AR093883 20 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 17 from patent US 6001588.
ACCESSION AR093883
VERSION AR093883.1 GI:10020629
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Tsui,L.-C., Rommens,J.M. and Kerem,B.-S.
TITLE Introns and exons of the cystic fibrosis gene and mutations thereof
JOURNAL Patent: US 6001588-A 17 14-DEC-1999;
FEATURES Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1988 TACTTATCTGGATGATGCC 2007
Db 20 TAGTTTCTGTGATGATGCC 1

RESULT 72
LOCUS AR097398 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 22 from patent US 6071726.
ACCESSION AR097398
VERSION AR097398.1 GI:12806128
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Diamandis,E., Dunn,J.M. and Stevens,J.K.
TITLE Method, reagents and kit for diagnosis and targeted screening for
p53 mutations
JOURNAL Patent: US 6071726-A 22 06-JUN-2000;
FEATURES Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1935 GGGTCAGCGACAGCAGTGG 1954
Db 1 CGGTACGCGCGACAGCAGG 20

RESULT 73
LOCUS AR116476 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 57 from patent US 6133246.
ACCESSION AR116476
VERSION AR116476.1 GI:14096798
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS McKay,R., Dean,N., Monia,B.P., Nero,P.S. and Gaarde,W.A.
TITLE Antisense oligonucleotide compositions and methods for the
modulation of JNK proteins
JOURNAL Patent: US 6133246-A 57 17-OCT-2000;
FEATURES Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 167 GGGTCTGGCGGTGGGCTG 186
Db 1 GGGTCTGGCGGTGGGCTG 186

Db 1 GGGTCTGCTCGGTGACATG 20

RESULT 74
LOCUS AR154591/c 20 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 8 from patent US 6238921.
ACCESSION AR154591
VERSION AR154591.1 GI:15122644
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 20)
AUTHORS Miraglia, L.J., Nero, P., Graham, M.J. and Montia, B.P.
TITLE Antisense oligonucleotide modulation of human mdm2 expression
JOURNAL Patent: US 6238921-A 8 29-MAY-2001;
FEATURES
LOCATION/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 243 CTCACAGAGCGAAAAAGCAG 262
|||
20 CTCACAGCGGAAAAAAGCCCG 1

Db 20 CTCACAGCGGAAAAAAGCCCG 1

RESULT 75
LOCUS BD244905/c 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Modulation of gene expression by combination therapy.
ACCESSION BD244905
VERSION BD244905.1 GI:33054675
KEYWORDS JP 2002528391-A/33.
SOURCE JP 2002528391-A/33.
ORGANISM
artificial construct
artificial sequences.
1 (bases 1 to 20)
REFERENCE
1 Besteman, J.M., MacLeod, A.R. and Siders, W.M.
TITLE Modulation of gene expression by combination therapy
JOURNAL Patent: JP 2002528391-A 33 03-SEP-2002;
METHYLENE INC
COMMENT OS Artificial Sequence
PN JP 2002528391-A/33
PD 03-SEP-2002
PF 19-OCT-1999 JP 2000576885
PR 19-OCT-1998 US 60/104804
PI JEFFREY M BESTERMAN, ALAN ROBERT MACLEOD, WILLIAM M SIDERS PC
AG1K48/00, AG1K31/165, AG1K31/19, AG1K31/513, AG1K31/517, AG1K31/706,
PC,
AG1K31/7068, AG1K31/7088, AG1K31/7125, AG1K45/00, AG1P35/00, C12N15/09//
PC C12N5/10, C12N15/00, C12N5/00
CC antisense
FH Key Location/Qualifiers
FT source 1..20
FT Location/Qualifiers
1..20
/organism="Artificial Sequence".
FEATURES
source
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 26 CCGCGGGGTGCGCTGCCTC 45

Db 20 CCGCGGTGCTGCTGCTC 1

RESULT 76
LOCUS 125703 20 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 22 from patent US 5552283.
ACCESSION 125703
VERSION 125703.1 GI:1605573
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 20)
AUTHORS Diamond, E., Dunn, J.M. and Stevens, J.K.
TITLE Method, reagents and kit for diagnosis and targeted screening for
p53 mutations
JOURNAL Patent: US 5552283-A 22 03-SEP-1996;
FEATURES
LOCATION/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1935 GGGTCAGCGACAGCGAGTG 1954
|||
1 GGGTCAGCGGCGACAGCAGG 20

Db 1 GGGTCAGCGGCGACAGCAGG 20

RESULT 77
LOCUS AR229022/c 20 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 32 from patent US 6448081.
ACCESSION AR229022
VERSION AR229022.1 GI:27268164
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 20)
AUTHORS Baker, B.F. and Freiler, S.M.
TITLE Antisense modulation of interleukin 12 p40 subunit expression
JOURNAL Patent: US 6448081-A 32 10-SEP-2002;
FEATURES
LOCATION/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1633 AGCAGGTGCTGCTGCT 1652
|||
20 AGCAGGTGCTGCTGCT 1

Db 20 AGCAGGTGCTGCTGCT 1

RESULT 78
LOCUS AR243597/c 20 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 47 from patent US 6475797.
ACCESSION AR243597
VERSION AR243597.1 GI:27290962
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 20)
AUTHORS Wyatt, J.

TITLE Antisense modulation of SR-CYP expression
JOURNAL Patent: US 6475797-A 47 05-NOV-2002;
FEATURES Location/Qualifiers
SOURCE 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1269 AGTGGGAATCCTTACATTG 1288
DB 20 AGTGAGACTCCTCCACATTG 1

RESULT 79
AR297055 20 bp DNA linear PAT 12-JUN-2003
LOCUS AR297055
DEFINITION Sequence 8790 from patent US 6537751.
ACCESSION AR297055
VERSION AR297055.1 GI:31684339
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 8790 25-MAR-2003;
FEATURES Location/Qualifiers
SOURCE 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1025 CCAAGAGGTGGGAAATGG 1044
DB 1 CAAAGTAGGTGGGAAATGG 20

RESULT 80
AR297103 20 bp DNA linear PAT 12-JUN-2003
LOCUS AR297103
DEFINITION Sequence 8838 from patent US 6537751.
ACCESSION AR297103
VERSION AR297103.1 GI:31684387
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 8838 25-MAR-2003;
FEATURES Location/Qualifiers
SOURCE 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 688 CTCATGCCATTCACCAT 707
DB 20 CTCCTCCATTCACCAT 1

RESULT 81
AR312679 20 bp DNA linear PAT 12-JUN-2003
LOCUS AR312679
DEFINITION Sequence 3216 from patent US 6559294.
ACCESSION AR312679
VERSION AR312679.1 GI:31706105
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Griffiths,R., Holsech,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
Sankaran,B. and Fletcher,L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559294-A 3216 06-MAY-2003;
FEATURES Location/Qualifiers
SOURCE 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1762 CCACAGGTATTGGAGAG 1781
DB 1 CCACAGGTCTTTGGAGAG 20

RESULT 82
AR312813 20 bp DNA linear PAT 12-JUN-2003
LOCUS AR312813
DEFINITION Sequence 3350 from patent US 6559294.
ACCESSION AR312813
VERSION AR312813.1 GI:31706239
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Griffiths,R., Holsech,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
Sankaran,B. and Fletcher,L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559294-A 3350 06-MAY-2003;
FEATURES Location/Qualifiers
SOURCE 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 939 CCTATGTCCTGGGATCA 958
DB 1 CCTATGTCCTGGGATCA 20

RESULT 83
AR314336 20 bp DNA linear PAT 12-JUN-2003
LOCUS AR314336
DEFINITION Sequence 4873 from patent US 6559294.
ACCESSION AR314336
VERSION AR314336.1 GI:31707762
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Griffiths,R., Holsech,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
Sankaran,B. and Fletcher,L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof

JOURNAL Patent: US 6559294-A 4873 06-MAY-2003;
FEATURES
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1696 GGGAAGCCCTTCCCAATA 1715
Db 1 GGAAAGCCCTTCCCAATA 20

RESULT 84
LOCUS AR322199 20 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 8 from patent US 6566064.
ACCESSION AR322199
VERSION AR322199.1 GI:33707763
KEYWORDS
SOURCE
ORGANISM unknown.
REFERENCE
1 (bases 1 to 20)
AUTHORS Shiraki,M., Ouchi,Y., Hosoi,T., Kusaba,N., Baba,T. and Yoshida,H.
TITLE Method for antipicating sensitivity to medicine for osteoporosis
JOURNAL Patent: US 6566064-A 8 20-MAY-2003;
FEATURES
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1647 CCTGCTGCAGATCTGTACC 1666
Db 1 CCTGCACCAAGATATGTACC 20

RESULT 85
LOCUS AX197430 20 bp DNA linear PAT 29-AUG-2001
DEFINITION Sequence 7 from Patent W00151085.
ACCESSION AX197430
VERSION AX197430.1 GI:15387821
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Oh,C.K., Cho,S.H., Demissie-Sanders,S., Thomas,D.W. and Tan,S.W.
TITLE Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease
JOURNAL Patent: WO 0151085-A 7 19-JUL-2001;
Tanox, Inc. (US)
FEATURES
source
1. .20
location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1460 GCTGCCACCCAGTGTCTG 1479
Db 1 GCTGTCCACCCGGTCTCTG 20

RESULT 86
LOCUS AX546286/c 20 bp DNA linear PAT 26-NOV-2002
DEFINITION Sequence 35 from Patent EP1243290.
ACCESSION AX546286
VERSION AX546286.1 GI:25811477
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Besterman,J.M., Macleod,A.R. and Siders,W.M.
TITLE Modulation of gene expression by combination therapy
JOURNAL Patent: EP 1243290-A 35 25-SEP-2002;
Methylgene, Inc. (CA)
FEATURES
source
1. .20
location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 26 CCCGCGGTGCGCTGCCTC 45
Db 20 CCCGCTGTGCTGCTGTCTC 1

RESULT 87
LOCUS AX546376/c 20 bp DNA linear PAT 26-NOV-2002
DEFINITION Sequence 35 from Patent EP1243289.
ACCESSION AX546376
VERSION AX546376.1 GI:25811567
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Besterman,J.M., Macleod,A.R. and Siders,W.M.
TITLE Modulation of gene expression by combination therapy
JOURNAL Patent: EP 1243289-A 35 25-SEP-2002;
Methylgene, Inc. (CA)
FEATURES
source
1. .20
location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 26 CCCGCGGTGCGCTGCCTC 45
Db 20 CCCGCTGTGCTGCTGTCTC 1

RESULT 88
LOCUS AX794385 20 bp DNA linear PAT 04-OCT-2003
DEFINITION Sequence 6 from Patent W003051395.
ACCESSION AX794385
VERSION AX794385.1 GI:37515463
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .20
location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"

REFERENCE 1
AUTHORS Molderings,G.J. and Brueses,M.
TITLE Edg-receptor agonists for the treatment of hypertension
JOURNAL Patent: WO 03051395-A 6-26-JUN-2003;
Solvay Pharmaceuticals GmbH (DE)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="antisense primer sequence"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2,1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1182 GCAGAAATTAAGACTCA 1201
|||||
1 GCAGGCAATGAAGACTCA 20

RESULT 89
BD004726 20 bp DNA linear PAT 31-JAN-2002
LOCUS
DEFINITION Vitamin D receptor gene, apolipoprotein E gene and reagent for
simultaneously detecting gene polymorphism of estrogen receptor
gene, and method for simultaneously detecting the gene
polymorphism.
BD004726
BD004726.1 GI:18632687
JP 2001029088-A/6.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 20)
Kusaba,N., Baba,T. and Yoshida,H.
Vitamin D receptor gene, apolipoprotein E gene and reagent for
simultaneously detecting gene polymorphism of estrogen receptor
gene, and method for simultaneously detecting the gene polymorphism
Patent: JP 2001029088-A 6-06-FEB-2001;
NISHIO CORP
COMMENT OS Homo sapiens (human)
PN JP 2001029088-A/6
PD 06-FEB-2001
PF 16-MAY-2000 JP 2000142951
PI NORINOBU KUSABA,TOSHIKAKI BABA,HIROSHI YOSHIDA PC
C12N15/09,C12Q1/68,C12N15/00
CC
FH Key Location/Qualifiers
FT source 1..20
location/Qualifiers
1..20
/organism="Homo sapiens (human)".
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2,1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1647 CCGTCTCGAAGATGTACC 1666
|||||
1 CCGTCACCAAGATGTACC 20

RESULT 90
BD074633 20 bp DNA linear PAT 27-AUG-2002
LOCUS
DEFINITION Antisense oligonucleotide composition and modulation method of JNK

ACCESSION protein.
BD074633
VERSION BD074633.1 GI:22620236
KEYWORDS JP 2001514905-A/57.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 20)
AUTHORS McKay,R., Dean,N., Monia,B.P., Scott,P., Nero and Gaarde,W.A.
TITLE Antisense oligonucleotide composition and modulation method of JNK
JOURNAL Protein
Patent: JP 2001514905-A 57 18-SEP-2001;
ISIS PHARMACEUTICALS INC
COMMENT OS Artificial Sequence
PN JP 2001514905-A/57
PD 18-SEP-2001
PF 07-AUG-1998 JP 2000509875
PI 13-AUG-1997 US 08/910629
PI ROBERT MCKAY,NICHOLAS DEAN,BRETT P MONIA,PAMELA SCOTT PI
NERO,WILLIAM A GAARDE
PC C12Q1/68,A61K31/7086,A61K46/00,A61P35/00,C12N15/09,C12P19/34,
PC C12N15/00
CC antisense sequence
CC Location/Qualifiers
FH Key 1..20
FT source 1..20
location/Qualifiers
1..20
/organism="Artificial Sequence".
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2,1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 167 GGGTCTGGCGGCGGCGCTG 186
|||||
1 GGGTCTGTGGTGGGACATG 20

RESULT 91
BD083842 20 bp DNA linear PAT 27-AUG-2002
LOCUS
DEFINITION Method for predicting sensitivity to osteoporosis drug and reagent
kit therefor.
BD083842
BD083842.1 GI:22629452
JP 2001333799-A/8.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 20)
Shiraki,M., Ouchi,Y. and Hosoi,T.
Method for predicting sensitivity to osteoporosis drug and reagent
kit therefor
Patent: JP 2001333799-A 8 04-DEC-2001;
NISHIO CORP
COMMENT OS Homo sapiens (human)
PN JP 2001333799-A/8
PD 04-DEC-2001
PF 26-MAY-2000 JP 2000155993
PI MASATAKA SHIRAKI,YASUYOSHI OUCHI,TAKAYUKI HOSOI PC
C12Q1/68,C12N15/09,G01N33/53,G01N33/566,C12N15/00 CC
the base sequence of estrogen receptor gene FH Key
Location/Qualifiers
FT source 1..20
location/Qualifiers
1..20
/organism="Homo sapiens (human)".
/mol_type="genomic DNA"

Query Match	0.7%;	Score 15.2;	DB 1;	Length 20;
Best Local Similarity	85.0%;	Pred. No. 2.1e+02;		
Matches 17;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;
Oy	1647	CCTGCTGCAGAAATCTGTACC	1666	
Db	1	CCTGCACCAGATATGTACC	20	
RESULT 92				
BD083881				
LOCUS				
DEFINITION	BD083881	20 bp	DNA	linear
	Regent and method for the simultaneous detection of gene			
	polymorphisms in vitamin D receptor gene, apolipoprotein E gene and			
	estrogen receptor gene.			
ACCESSION	BD083881			
VERSION	BD083881.1	GI:22629491		
KEYWORDS	JP 2001333798-A/16.			
SOURCE	Homo sapiens (human)			
ORGANISM	Homo sapiens			
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.			
REFERENCE	1 (bases 1 to 20)			
AUTHORS	Kusaba,N., Baba,T. and Yoshida,H.			
TITLE	Regent and method for the simultaneous detection of gene			
	polymorphisms in vitamin D receptor gene, apolipoprotein E gene and			
	estrogen receptor gene			
JOURNAL	Patent: JP 2001333798-A 16 04-DEC-2001;			
	NISSHO CORP			
COMMENT	OS Homo sapiens (human)			
	PN JP 2001333798-A/16			
	PD 04-DEC-2001			
	PF 26-MAY-2000 JP 2000155871			
	PI MORINOBU KUSABA, TOSHIAKI BABA, HIROSHI YOSHIDA PC			
	C14Q1/68,A61K45/00,A61P19/08,C12N15/09,G01N33/15,G01N33/50, PC			
	G01N33/53;			
	PC G01N33/566,C12N15/00			
	CC Part of base sequence of estrogen receptor gene FH Key			
	Location/Qualifiers			
FT	source	1..20		
	Location/Qualifiers			
	1..20			
	/organism="Homo sapiens (human)".			
	/organism="Homo sapiens"			
	/mol_type="genomic DNA"			
	/db_xref="taxon:9606"			
FEATURES				
source				
Query Match	0.7%;	Score 15.2;	DB 1;	Length 20;
Best Local Similarity	85.0%;	Pred. No. 2.1e+02;		
Matches 17;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;
Oy	1647	CCTGCTGCAGAAATCTGTACC	1666	
Db	1	CCTGCACCAGATATGTACC	20	
RESULT 93				
BD103497				
LOCUS	BD103497	20 bp	DNA	linear
DEFINITION	New recombinant adenovirus vectors with reduced side effects.			
ACCESSION	BD103497.1	GI:22649071		
VERSION	WO 0190392-A/15.			
KEYWORDS	synthetic construct			
SOURCE	synthetic construct			
ORGANISM	artificial sequences.			
	1 (bases 1 to 20)			
REFERENCE	Nakai,M., Komiya,K., Murata,M., Todo,N. and Saito,I.			
AUTHORS	New recombinant adenovirus vectors with reduced side effects			
TITLE	Patent: WO 0190392-A 15 29-NOV-2001;			
JOURNAL	SUNITOMO PHARMACEUTICALS CO LTD,MICHIYO NAKAI,KAZUO KOMIYA, MASASHI			

COMMENT	MURATA, NAOKI TODO, IZUMU SAITO
PN	Artificial Sequence
OS	WO 0190392-A/15
PD	29-NOV-2001
PF	24-MAY-2001 WO 2001JP004360
PI	26-MAY-2000 JP 00P 155603, 08-DEC-2000 JP 00P 373850 PI
MICRO	NAKAI, KAZUO KOMIYA, MASASHI MURATA, NAOKI TODO, IZUMU PI
SAITO	
PC	C12N15/861, C12N5/10, A61K48/00
CC	PCR primer
FH	Key
FT	source
FT	Location/Qualifiers
FT	Location/Qualifiers
FT	1. .20
FT	/organism="Artificial Sequence".
FT	Location/Qualifiers
FT	1. .20
FT	/organism="synthetic construct"
FT	/mol_type="genomic DNA"
FT	/db_xref="taxon:32630"
FEATURES	
source	
Query Match	0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity	85.0%; Pred. No. 2.1e+02;
Matches 17, Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
OY	1410 GGCTGTGGCTCCTCAGAGA 1429
DB	1 GGAGTGGTCTCTCAGCGA 20
RESULT 94	
BD138082/c	
LOCUS	BD138082 20 bp DNA linear PAT 18-SEP-2002
DEFINITION	Antisense modulation of human MDM2 expression.
ACCESSION	BD138082
VERSION	BD138082.1 GI:23233027
KEYWORDS	JP 2002508944-A/8.
SOURCE	unidentified
ORGANISM	unidentified
REFERENCE	unclassified
AUTHORS	1 (bases 1 to 20)
TITLE	Miraglia, L.J., Nero, P., Graham, M.J., Monia, B.P. and Cowse, L.M.
JOURNAL	Antisense modulation of human MDM2 expression
COMMENT	Patent: JP 2002508944-A 8 26-MAR-2002;
OS	ISIS PHARMACEUTICALS INC
PN	JP 2002508944-A/8
PD	26-MAR-2002
PF	26-MAR-1999 JP 2000538025
PI	26-MAR-1998 US 09/048810
PI	LOREN J MIRAGLIA, PAMELA NERO, MARK J GRAHAM, BRETT P MONIA, LEX M
PI	CONSERT
PC	C12N15/09, A61K48/00, A61P9/10, A61P17/06, A61P35/00, C07H21/04//
PC	C12N1/68,
PC	C12N15/00
CC	Strandedness: Single;
CC	Topology: Linear;
CC	Antisense modulation of human MDM2 expression FH Key
FT	Location/Qualifiers
FT	source
FT	1. .20
FT	/organism="Unidentified".
FEATURES	
source	
Query Match	0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity	85.0%; Pred. No. 2.1e+02;
Matches 17, Conservative 0; Mismatches 3; Indels 0; Gaps 0;	
OY	243 CTCGAAGAGCGAAAGCGAG 262
DB	20 CTCGAAGCGGAAAGCCCG 1

```

RESULT 95
BD192481/c
LOCUS
DEFINITION
  BD192481
  Compositions and methods for the delivery of oligonucleotides via
  the alimentary canal.
ACCESSION
  BD192481
VERSION
  JP 2002510319-A/46.
KEYWORDS
  JP 2002510319-A/46.
SOURCE
  synthetic construct
ORGANISM
  artificial sequences.
REFERENCE
  1 (bases 1 to 20)
  Teng,C.L. and Hardee,G.
  Compositions and methods for the delivery of oligonucleotides via
  the alimentary canal.
  Patent: JP 2002510319-A 46 02-APR-2002;
JOURNAL
  ISIS PHARMACEUTICALS INC
COMMENT
  OS Artificial Sequence
  PN JP 2002510319-A/46
  PD 02-APR-2002
  PF 01-JUL-1998 JP 1999507295
  PR 01-JUL-1997 US 08/886829
  PI CHING LEOU TENG,GREG HARDEE
  PC C1201/68,A61K9/127,A61K48/00,C07H21/04
  CC Description of Artificial Sequence: Novel Sequence FH key
  Location/Qualifiers
  1..20
  /organism="synthetic construct"
  /mol_type="genomic DNA"
  /db_xref="taxon:32630"

Query Match
  0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1618 AATGGCTCTGGAGAGACAC 1637
Db 20 AGTGGCTGTGGAGAGACAC 1

RESULT 96
BD192482/c
LOCUS
DEFINITION
  BD192482
  Compositions and methods for the delivery of oligonucleotides via
  the alimentary canal.
ACCESSION
  BD192482
VERSION
  JP 2002510319-A/47.
KEYWORDS
  JP 2002510319-A/47.
SOURCE
  synthetic construct
ORGANISM
  artificial sequences.
REFERENCE
  1 (bases 1 to 20)
  Teng,C.L. and Hardee,G.
  Compositions and methods for the delivery of oligonucleotides via
  the alimentary canal.
  Patent: JP 2002510319-A 47 02-APR-2002;
JOURNAL
  ISIS PHARMACEUTICALS INC
COMMENT
  OS Artificial Sequence
  PN JP 2002510319-A/47
  PD 02-APR-2002
  PF 01-JUL-1998 JP 1999507295
  PR 01-JUL-1997 US 08/886829
  PI CHING LEOU TENG,GREG HARDEE
  PC C1201/68,A61K9/127,A61K48/00,C07H21/04
  CC Description of Artificial Sequence: Novel Sequence FH key
  Location/Qualifiers
  1..20
  /organism="synthetic construct"
  /mol_type="genomic DNA"
  /db_xref="taxon:32630"

FEATURES
  source
  1..20
  /organism="synthetic construct"
  /mol_type="genomic DNA"

```

```

Query Match
  0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1617 CAATGCGCTGTGGAGAGCA 1636
Db 20 CAGTGGCTGTGGAGAGCA 1

RESULT 97
AX114466
LOCUS
DEFINITION
  AX114466
  Sequence 135 from Patent WO0129257.
ACCESSION
  AX114466
VERSION
  AX114466.1 GI:14031430
KEYWORDS
  Homo sapiens (human)
SOURCE
  Homo sapiens
ORGANISM
  Homo sapiens (human)
REFERENCE
  1
  Schork,N. and Skierczynski,B.
  Methods of genetic cluster analysis and use thereof
  Patent: WO 0129257-A 135 26-APR-2001;
JOURNAL
  GENSER (FR)
  Location/Qualifiers
  1..19
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"
  primer_bind
  1..19
  /note="downstream amplification primer 4-32 for SEQ 9, in
  complement"

Query Match
  0.7%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2185 CTCATGGAGAAAAG 2199
Db 1 CTCATGGAGAAAAG 15

RESULT 98
AX202054
LOCUS
DEFINITION
  AX202054
  Sequence 7 from Patent WO0153525.
ACCESSION
  AX202054
VERSION
  AX202054.1 GI:15391837
KEYWORDS
  AX202054.1 GI:15391837
SOURCE
  synthetic construct
ORGANISM
  synthetic construct
  artificial sequences.
REFERENCE
  1
  Refseth,U.H. and Kolpus,T.G.
  Cell Isolation method
  Patent: WO 0153525-A 7 26-JUL-2001;
JOURNAL
  Genpoint AS (NO)
  Location/Qualifiers
  1..19
  /organism="synthetic construct"
  /mol_type="unassigned DNA"
  /db_xref="taxon:32630"
  /note="primer"

FEATURES
  source
  1..19
  /organism="synthetic construct"
  /mol_type="unassigned DNA"
  /db_xref="taxon:32630"

Query Match
  0.7%; Score 15; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2.1e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1971 GATCCGAAACCGTGTG 1987
  ||||| ||||| |||||

```

Db 1 GMTCTGAACCGTGTG 17

RESULT 99
LOCUS AR129704 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 108 from patent US 6187545.
ACCESSION AR129704
VERSION AR129704.1 GI:14117601
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 20)
AUTHORS McKay, R., Butler, M.M., Myatt, J. and Cowse, L.M.
TITLE Antisense modulation of pepck-cytosolic expression
JOURNAL Patent: US 6187545-A 108 13-FEB-2001;
FEATURES
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 830 AACGAAACGACAG 844
|||||
3 AACGAAACGACAG 17

Db

RESULT 100
LOCUS BD242514/c 18 bp DNA linear PAT 17-JUL-2003
DEFINITION A system for cell based screening.
ACCESSION BD242514
VERSION BD242514.1 GI:33052284
KEYWORDS JP 2002528136-A/20.
SOURCE
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 18)
AUTHORS Giuliano, K.A., Bright, G., Olson, K. and Tencza, S.B.
TITLE A system for cell based screening
JOURNAL Patent: JP 2002528136-A 20 03-SEP-2002;
COMMENT OS Artificial Sequence
PN JP 2002528136-A/20
PD 03-SEP-2002
PF 29-OCT-1999 JP 2000579780
PR 30-OCT-1998 US 60/106308, 26-MAY-1999 US 60/136078 PI
KENNETH A. GIULIANO, GARY BRIGHT, KEITH OLSON, SARAH BURROUGHS PI
TENCZA
PC C12N15/09, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12Q1/02, C12Q1/00
PC 37, G01N33/15,
PC G01N33/50, C12N15/00, C12N5/00
CC Description of Artificial Sequence: KT3 epitope FH Key
Location/Qualifiers
FT source 1..18
/organism="Artificial Sequence".
FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.7%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 566 TGTTCCTGCTCGTGTG 583
|||||
18 TGTTCCTGCTCGTGTG 1

Db

RESULT 101
LOCUS AR217439 18 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 39 from patent US 6416959.
ACCESSION AR217439
VERSION AR217439.1 GI:23317132
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 18)
AUTHORS Giuliano, K. and Kapur, R.
TITLE System for cell-based screening
JOURNAL Patent: US 6416959-A 39 09-JUL-2002;
FEATURES
source
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 566 TGTTCCTGCTCGTGTG 583
|||||
18 TGTTCCTGCTCGTGTG 1

Db

RESULT 102
LOCUS AX766750 18 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 39 from Patent EP1314980.
ACCESSION AX766750
VERSION AX766750.1 GI:32260514
KEYWORDS
SOURCE
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Giuliano, K.A. and Kapur, R.
TITLE A system for cell-based screening
JOURNAL Patent: EP 1314980-A 39 28-MAY-2003;
CELLCOMICS, Inc. (US)
FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="KT3 epitope"

Query Match 0.7%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 566 TGTTCCTGCTCGTGTG 583
|||||
18 TGTTCCTGCTCGTGTG 1

Db

RESULT 103
LOCUS A51892 19 bp DNA linear PAT 10-MAR-1997
DEFINITION Sequence 56 from Patent WO9620011.
ACCESSION A51892
VERSION A51892.1 GI:2304640
KEYWORDS
SOURCE
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Blakey, D.C., Davies, D.H., Dowell, R.I., Henman, J.F., Marsham, P.R.,

TITLE Slater, Anthony, M. and Hennequin, L.F.
JOURNAL CHEMICAL COMPOUNDS CHEMICAL COMPOUNDS
Patent: WO 9620011-A 56 04-JUL-1996;

COMMENT ZENECA LTD (GB)
Other publication AU 4269796 960719.

FEATURES
Source
1. .19
Location/Qualifiers

/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCCCTGCTGCAGATCTG 1662
DB 2 GACCTGCTGCAGAGTCTG 19

RESULT 104

LOCUS A67354 19 bp DNA linear PAT 05-MAY-1999
DEFINITION Sequence 110 from Patent WO9742329.
ACCESSION A67354
VERSION A67354.1 GI:4756298

KEYWORDS
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 19)
Copley, C.G., Edge, M.D. and Emery, S.C.

TITLE MONOCLONAL ANTIBODY TO CEA, CONJUGATES COMPRISING SAID ANTIBODY,
AND THEIR THERAPEUTIC USE IN AN ADEPT SYSTEM

JOURNAL Patent: WO 9742329-A 110 13-NOV-1997;
ZENECA LTD (GB)

FEATURES
Source
1. .19
Location/Qualifiers

/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCCCTGCTGCAGATCTG 1662
DB 2 GACCTGCTGCAGAGTCTG 19

RESULT 105
LOCUS A87526 19 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 7 from Patent WO9835988.
ACCESSION A87526
VERSION A87526.1 GI:6736175

KEYWORDS
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 19)
Edge, M.D.

TITLE Proteins
JOURNAL Patent: WO 9835988-A 7 20-AUG-1998;

COMMENT ZENECA LTD (GB); EDGE MICHAEL DEREK (GB)

FEATURES
Source
1. .19
Location/Qualifiers

/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCCCTGCTGCAGATCTG 1662
DB 2 GACCTGCTGCAGAGTCTG 19

RESULT 106

LOCUS AR085857 19 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 52 from patent US 5985281.
ACCESSION AR085857
VERSION AR085857.1 GI:10012623

KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
Unidentified.

REFERENCE 1 (bases 1 to 19)
Taylorson, C. John., Eggelte, H. Johannes., Tarragona-Piol, A.,

TITLE Rabin, B. Robert., Boyle, F. Thomas., Henman, J. Frederick.,
Blakey, D. Charles., Marsham, P. Robert., Heaton, D. William.,
Davies, D. Huw., Slater, A. Michael. and Hennequin, L. Francois. Andre.

JOURNAL Chemical compounds
Patent: US 5985281-A 52 16-NOV-1999;
Location/Qualifiers

1. .19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCCCTGCTGCAGATCTG 1662
DB 2 GACCTGCTGCAGAGTCTG 19

RESULT 107
LOCUS AX326925/c 19 bp DNA linear PAT 07-JAN-2002
DEFINITION Sequence 121 from Patent WO0178894.
ACCESSION AX326925
VERSION AX326925.1 GI:18097636

KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

REFERENCE 1
artificial sequences.

TITLE Novel human gene relating to respiratory diseases, obesity, and
JOURNAL Inflammatory bowel disease

COMMENT Patent: WO 0178894-A 121 25-OCT-2001;
Genome Therapeutics Corp. (US)

FEATURES
Source
1. .19
Location/Qualifiers

/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 867 AGAGGACACGTCACCT 884
DB 19 AGAGGACACGACACCT 2

RESULT 108
AR362307/c

LOCUS AR362307 16 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 15 from patent US 5164485.
ACCESSION AR362307
VERSION AR362307.1 GI:34422223
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Yukio, F., Yasuaki, I., Osamu, N. and Tomoko, F.
TITLE Modified hepatitis B virus surface antigen p31 and production thereof
JOURNAL Patent: US 5164485-A 15 17-NOV-1992;
FEATURES
source Location/Qualifiers
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 85 CTTCTCGCCGACTGGG 100
Db 16 CTTCTCGCAGACTGGG 1

RESULT 109
AR072089/c 17 bp DNA linear PAT 18-FEB-2000
LOCUS AR072089
DEFINITION Sequence 10 from patent US 5912337.
ACCESSION AR072089
VERSION AR072089.1 GI:7222977
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Tripp, C. Ann., Frank, G. Robert. and Griewe, R. B.
TITLE Parasitic helminth p22u proteins
JOURNAL Patent: US 5912337-A 10 15-JUN-1999;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2217 GGTGAGGCTCTGCA 2232
Db 16 GGTGAGGATCTGCA 1

RESULT 110
I31849 17 bp DNA linear PAT 06-FEB-1997
LOCUS I31849
DEFINITION Sequence 6 from patent US 5583038.
ACCESSION I31849
VERSION I31849.1 GI:1822640
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stever, C. K.
TITLE Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins
JOURNAL Patent: US 5583038-A 6 10-DEC-1996;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1690 TTGATGGGAAGCCCC 1705
Db 2 TTGTATGGGAAGCCCC 17

RESULT 111
I47697/c 17 bp DNA linear PAT 07-OCT-1997
LOCUS I47697
DEFINITION Sequence 10 from patent US 5639876.
ACCESSION I47697
VERSION I47697.1 GI:2471662
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Tripp, C. Ann., Frank, G. Robert. and Griewe, R. B.
TITLE Nucleic acid molecules encoding novel parasitic helminth proteins
JOURNAL Patent: US 5639876-A 10 17-JUN-1997;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2217 GGTGAGGCTCTGCA 2232
Db 16 GGTGAGGATCTGCA 1

RESULT 112
I73119/c 17 bp DNA linear PAT 03-APR-1998
LOCUS I73119
DEFINITION Sequence 10 from patent US 5686080.
ACCESSION I73119
VERSION I73119.1 GI:3009258
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Tripp, C. Ann., Frank, G. Robert. and Griewe, R. B.
TITLE Parasitic helminth p4 proteins
JOURNAL Patent: US 5686080-A 10 11-NOV-1997;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2217 GGTGAGGCTCTGCA 2232
Db 16 GGTGAGGATCTGCA 1

RESULT 113
AR195674 17 bp DNA linear PAT 20-APR-2002
LOCUS AR195674
DEFINITION Sequence 139 from patent US 6350934.
ACCESSION AR195674
VERSION AR195674.1 GI:20245111

KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 17)
TITLE Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P.Ann.Owens,
JOURNAL Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.
Nucleic acid encoding delta-9 desaturase
Patent: US 6350934-A 139 26-FEB-2002;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.64; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2179 CAGCAGCTCATGAGA 2194
1 CCGCAGCTCATGAGA 16

RESULT 114
AX263212 17 bp DNA linear PAT 26-OCT-2001
LOCUS
DEFINITION Sequence 603 from Patent WO0173002.
ACCESSION AX263212
VERSION AX263212.1 GI:16512011
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Kntec,B.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
Patent: WO 0173002-A 603 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.64; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1806 CCGAGCCGAGAGCCA 1821
2 CCAGACCCGAGAGCCA 17

RESULT 115
AX263213/c 17 bp DNA linear PAT 26-OCT-2001
LOCUS
DEFINITION Sequence 604 from Patent WO0173002.
ACCESSION AX263213
VERSION AX263213.1 GI:16512012
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Kntec,B.B., Gamper,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
Patent: WO 0173002-A 604 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers

source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.64; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1806 CCGAGCCGAGAGCCA 1821
16 CCAGACCCGAGAGCCA 1

RESULT 116
AX544969/c 17 bp DNA linear PAT 26-NOV-2002
LOCUS
DEFINITION Sequence 482 from Patent EP1243660.
ACCESSION AX544969
VERSION AX544969.1 GI:25810180
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Zhang,J., Gu,Y. and Nguyen,C.T.
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10
JOURNAL Patent: EP 1243660-A 482 25-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.64; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1487 CCTTACCTTGAGGG 1502
17 CCTTACCTTGAGGG 2

RESULT 117
AX544970/c 17 bp DNA linear PAT 26-NOV-2002
LOCUS
DEFINITION Sequence 483 from Patent EP1243660.
ACCESSION AX544970
VERSION AX544970.1 GI:25810181
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Zhang,J., Gu,Y. and Nguyen,C.T.
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10
JOURNAL Patent: EP 1243660-A 483 25-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.64; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1487 CCTTACCTTGAGGG 1502
|||||||

Db 16 CCTTAACTGTGTGGG 1

RESULT 118
LOCUS AX733143 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4777 from Patent WO03025175.
ACCESSION AX733143
VERSION AX733143.1 GI:30512486
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
AUTHORS 1
TITLE Tejerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025175-A 4777 27-MAR-2003;
JOURNAL Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2081 GCTCAGTCTTCTCAT 2096
Db 1 GATCAGTCTTCTCAT 16
|||||
|

RESULT 119
LOCUS AX783931 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2262 from Patent WO03050284.
ACCESSION AX783931
VERSION AX783931.1 GI:32951780
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
AUTHORS 1
TITLE Guo, J.
Human prostate cancer candidate protein 1
Patent: WO 03050284-A 2262 19-JUN-2003;
JOURNAL Amerisham Biosciences (SV) Corp. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1631 AGACACAGTGTCTGC 1646
Db 2 AGACACAGTGTCTGC 17
|||||
|

RESULT 120
LOCUS AX783934 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2265 from Patent WO03050284.
ACCESSION AX783934
VERSION AX783934.1 GI:32951783

KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
AUTHORS 1
TITLE Guo, J.
Human prostate cancer candidate protein 1
Patent: WO 03050284-A 2265 19-JUN-2003;
JOURNAL Amerisham Biosciences (SV) Corp. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1633 AGCACAGTGTGCCC 1648
Db 1 AGCACAGTGTGCCC 16
|||||
|

RESULT 121
LOCUS AR344485 14 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 12 from patent US 6582902.
ACCESSION AR344485
VERSION AR344485.1 GI:33740543
KEYWORDS
SOURCE
ORGANISM Unknown.
Unclassified.

REFERENCE
AUTHORS 1 (bases 1 to 14)
TITLE Keene, J.D., Kenan, D.J. and Tsai, D.E.
Method for deriving epitopes
Patent: US 6582902-A 12 24-JUN-2003;
JOURNAL
FEATURES
source Location/Qualifiers
1..14
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2112 CCTGTGTGAGCAGG 2125
Db 1 CCTGTGTGAGCAGG 14
|||||
|

RESULT 122
LOCUS AR391489 16 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 101 from patent US 6613520.
ACCESSION AR391489
VERSION AR391489.1 GI:40114986
KEYWORDS
SOURCE
ORGANISM Unknown.
Unclassified.

REFERENCE
AUTHORS 1 (bases 1 to 16)
TITLE Aebly, M.
Methods for the survey and genetic analysis of populations
Patent: US 6613520-A 101 02-SEP-2003;
JOURNAL
FEATURES
source Location/Qualifiers
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 14; DB 1; Length 16;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 297 AGCTGGCGGCACTGG 310
|||||
Db 16 AGCTGGCGGCACTGG 3

RESULT 123
LOCUS AX281969/c 16 bp DNA linear PAT 02-NOV-2001
DEFINITION Sequence 101 from Patent WO0177392.
ACCESSION AX281969
VERSION AX281969.1 GI:16609220
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Ashby, M.
TITLE Methods for the survey and genetic analysis of populations
JOURNAL Patent: WO 0177392-A 101 18-OCT-2001;
Ashby, Matthew (US)
FEATURES
source Location/Qualifiers
1.16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/note="unidentified soil organism"

Query Match 0.6%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 297 AGCTGGCGGCACTGG 310
|||||
Db 16 AGCTGGCGGCACTGG 3

RESULT 124
LOCUS 126890/c 17 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 113 from patent US 5561041.
ACCESSION 126890
VERSION 126890.1 GI:1606760
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Sidransky, D.
TITLE Nucleic acid mutation detection by analysis of sputum
JOURNAL Patent: US 5561041-A 113 01-OCT-1996;
FEATURES
source Location/Qualifiers
1.17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1729 CTGCACAGCGAGT 1742
|||||
Db 16 CTGCACAGCGAGT 3

RESULT 125
LOCUS 191631/c 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 113 from patent US 5726019.
ACCESSION 191631
VERSION 191631.1 GI:3936101

KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)
AUTHORS Sidransky, D.
TITLE Analysis of sputum by amplification and detection of mutant nucleic acid sequences
JOURNAL Patent: US 5726019-A 113 10-MAR-1998;
FEATURES
source Location/Qualifiers
1.17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1729 CTGCACAGCGAGT 1742
|||||
Db 16 CTGCACAGCGAGT 3

RESULT 126
LOCUS AX259837/c 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 64 from Patent WO0172822.
ACCESSION AX259837
VERSION AX259837.1 GI:16508911
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Hugot, J.P., Thomas, G., Zouali, M., Lesage, S. and Chamailard, M.
TITLE Genes involved in intestinal inflammatory diseases and use thereof
JOURNAL Patent: WO 0172822-A 64 04-OCT-2001;
Fondation Jean Dausset-Ceph (FR)
FEATURES
source Location/Qualifiers
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 595 CTTGGGGAGATGGC 608
|||||
Db 14 CTTGGGGAGATGGC 1

RESULT 127
LOCUS AX733800 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5434 from Patent WO03025175.
ACCESSION AX733800
VERSION AX733800.1 GI:30513143
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 5434 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers

```
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1334 TCACATTGTCTC 1347
| | | | | | | |
| | | | | | | |
Db 3 TCACATTGTCTC 16

RESULT 128
AR206689 18 bp DNA linear PAT 20-JUN-2002
LOCUS AR206689
DEFINITION Sequence 5 from patent US 6372435.
ACCESSION AR206689
VERSION AR206689.1 GI:21505368
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 18)
AUTHORS Kaslow,R.A. and Tang,J.
TITLE Methods of surveying for CC (Beta) chemokine receptor variants and
their association with HIV-1 transmission and/or disease
progression
JOURNAL Patent: US 6372435-A 5 16-APR-2002;
FEATURES
Location/Qualifiers
1. .18
/mol_type="unassigned DNA"

Query Match
0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2189 TGGAGAAAAGGG 2202
| | | | | | | |
| | | | | | | |
Db 4 TGGAGAAAAGGG 17

RESULT 129
AR206690 18 bp DNA linear PAT 20-JUN-2002
LOCUS AR206690
DEFINITION Sequence 6 from patent US 6372435.
ACCESSION AR206690
VERSION AR206690.1 GI:21505369
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 18)
AUTHORS Kaslow,R.A. and Tang,J.
TITLE Methods of surveying for CC (Beta) chemokine receptor variants and
their association with HIV-1 transmission and/or disease
progression
JOURNAL Patent: US 6372435-A 6 16-APR-2002;
FEATURES
Location/Qualifiers
1. .18
/mol_type="unassigned DNA"

Query Match
0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2189 TGGAGAAAAGGG 2202
| | | | | | | |
| | | | | | | |
Db 4 TGGAGAAAAGGG 17
```

```
RESULT 130
AR215508/c 18 bp DNA linear PAT 25-SEP-2002
LOCUS AR215508
DEFINITION Sequence 56 from patent US 6410323.
ACCESSION AR215508
VERSION AR215508.1 GI:23313764
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 18)
AUTHORS Roberts,M.L. and Cowseert,L.M.
TITLE Antisense modulation of human Rho family gene expression
JOURNAL Patent: US 6410323-A 56 25-JUN-2002;
FEATURES
Location/Qualifiers
1. .18
/mol_type="genomic DNA"

Query Match
0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1814 AGAGCCACTATG 1827
| | | | | | | |
| | | | | | | |
Db 15 AGAGCCACTATG 2

RESULT 131
BD089389 18 bp DNA linear PAT 27-AUG-2002
LOCUS BD089389
DEFINITION A method of arraying genome clone.
ACCESSION BD089389
VERSION BD089389.1 GI:22634999
KEYWORDS JP 2001321190-A/1633.
SOURCE JP 2001321190-A/1633.
ORGANISM synthetic construct
artificial sequences.
REFERENCE
1 (bases 1 to 18)
AUTHORS Soeda,E.
TITLE A method of arraying genome clone
JOURNAL Patent: JP 2001321190-A 1633 20-NOV-2001;
THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
GENOTECHS
OS Artificial Sequence
PN JP 2001321190-A/1633
PD 20-NOV-2001
PF 12-MAR-2001 JP 2001068285
PI EIICHI SOEDA
PC C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
C12N15/00
PC Description of Artificial Sequence:Synthetic DNA FH Key
CC Description of Artificial Sequence:Synthetic DNA FH Key
FT source
FT Location/Qualifiers
1. .18
/mol_type="Artificial Sequence".
FEATURES
Location/Qualifiers
1. .18
/mol_type="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match
0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 594 TCTTGGGAGATGG 607
| | | | | | | |
| | | | | | | |
Db 4 TCTTGGGAGATGG 17

RESULT 132
```

```

A29720      A29720      17 bp      DNA      linear      PAT 29-JUN-1995
LOCUS      Oligonucleotide probe no.3.
DEFINITION
ACCESSION  A29720
VERSION     A29720.1 GI:1248989
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   synthetic construct
REFERENCE  1 (bases 1 to 17)
AUTHORS
TITLE      RECOMBINANT 21 KD COCA PROTEIN AND PRECURSOR
JOURNAL    Patent: WO 9119800-A 5 26-DEC-1991;
FEATURES   Location/Qualifiers
source     1..17
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1897 GACACAGAGGTAGACA 1913
Db      1 GACACAGACGAGACGA 17

RESULT 133
BD253919      17 bp      DNA      linear      PAT 17-JUL-2003
LOCUS      Regulation of repressor gene using nucleic acid molecules.
DEFINITION
ACCESSION  BD253919
VERSION     BD253919.1 GI:33063689
KEYWORDS   UP 2002541795-A/1712.
SOURCE     unidentified
ORGANISM   unidentified
REFERENCE  1 (bases 1 to 17)
AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
TITLE      Regulation of repressor genes using nucleic acid molecules
JOURNAL    Patent: JP 2002541795-A 1712 10-DEC-2002;
COMMENT    RIBOZYME PHARMACEUTICALS INC
OS      Eukaryote
PN      JP 2002541795-A/1712
PD      10-DEC-2002
PR      11-APR-2000 JP 2000611654
PI      LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC      C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC      (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC      A61K37/02,
PC      (C12N5/00,C12R1:91)
CC      Regulation of repressor genes using nucleic acid molecules FH
Key      Location/Qualifiers
FT      source     1..17
            /organism="Eukaryote".

FEATURES
source     1..17
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2004 TGGCACCAGTGCTCTG 2020
Db      17 TGGCCCCAGAGCCCTG 1

RESULT 135
BD254343      17 bp      DNA      linear      PAT 17-JUL-2003
LOCUS      Regulation of repressor gene using nucleic acid molecules.
DEFINITION
ACCESSION  BD254343
VERSION     BD254343.1 GI:33064113
KEYWORDS   UP 2002541795-A/2136.
SOURCE     unidentified
ORGANISM   unidentified
REFERENCE  1 (bases 1 to 17)
AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
TITLE      Regulation of repressor genes using nucleic acid molecules
JOURNAL    Patent: JP 2002541795-A 2136 10-DEC-2002;
COMMENT    RIBOZYME PHARMACEUTICALS INC
OS      Eukaryote
PN      JP 2002541795-A/2136
PD      10-DEC-2002
PR      11-APR-2000 JP 2000611654
PI      LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC

FEATURES
source     1..17
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      949 TTGGGATCATGCTCTG 965
Db      1 TTGTGATCCTGCTCTG 17

RESULT 134
BD254279/c      17 bp      DNA      linear      PAT 17-JUL-2003
LOCUS      Regulation of repressor gene using nucleic acid molecules.
DEFINITION
ACCESSION  BD254279
VERSION     BD254279.1 GI:33064049
KEYWORDS   UP 2002541795-A/2072.
SOURCE     unidentified
ORGANISM   unidentified
REFERENCE  1 (bases 1 to 17)
AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
TITLE      Regulation of repressor genes using nucleic acid molecules
JOURNAL    Patent: JP 2002541795-A 2072 10-DEC-2002;
COMMENT    RIBOZYME PHARMACEUTICALS INC
OS      Eukaryote
PN      JP 2002541795-A/2072
PD      10-DEC-2002
PR      11-APR-2000 JP 2000611654
PI      LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC      C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC      (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC      A61K37/02,
PC      (C12N5/00,C12R1:91)
CC      Regulation of repressor genes using nucleic acid molecules FH
Key      Location/Qualifiers
FT      source     1..17
            /organism="Eukaryote".

FEATURES
source     1..17
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

```

```

C12P21/02,
PC
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02,PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N5/00,C12N5/00,
PC A61K37/02',C12R1:91)
CC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key
Location/Qualifiers
FT
1..17
source
/organism='Eukaryote'.
FEATURES
source
location/Qualifiers
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No.2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1843 GCTGCAGTAAAGTCTGG 1859
DB 17 GCCACAGTAAAGTCTGG 1

RESULT 136
AR286258/c 17 bp RNA linear PAT 10-APR-2003
LOCUS
DEFINITION Sequence 630 from patent US 6528640.
ACCESSION AR286258
VERSION AR286258.1 GI:29723854
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 630 04-MAR-2003;
FEATURES
source
location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No.2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 259 GCAGGTGCCAGGCGCTG 275
DB 17 GTAGGTGACCGAGGCTG 1

RESULT 137
AR286348/c 17 bp RNA linear PAT 10-APR-2003
LOCUS
DEFINITION Sequence 720 from patent US 6528640.
ACCESSION AR286348
VERSION AR286348.1 GI:29723944
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 720 04-MAR-2003;
FEATURES
source
location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No.2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 259 GCAGGTGCCAGGCGCTG 275
DB 17 GTAGGTGACCGAGGCTG 1

RESULT 137
AR286348/c 17 bp RNA linear PAT 10-APR-2003
LOCUS
DEFINITION Sequence 720 from patent US 6528640.
ACCESSION AR286348
VERSION AR286348.1 GI:29723944
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 720 04-MAR-2003;
FEATURES
source
location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

```

```

/mol_type="unassigned RNA"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No.2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 269 AGGGCTGGCTGGCTGCT 285
DB 17 AGGGCTGGCTGGCTGCT 1

RESULT 138
AR326796/c 17 bp RNA linear PAT 17-AUG-2003
LOCUS
DEFINITION Sequence 4198 from patent US 6566127.
ACCESSION AR326796
VERSION AR326796.1 GI:33712604
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4198 20-MAY-2003;
FEATURES
source
location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No.2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 977 CCCTCACCATGTCACC 993
DB 1 CGCTCACCATGTCACC 17

RESULT 139
AR398248/c 17 bp RNA linear PAT 18-DEC-2003
LOCUS
DEFINITION Sequence 629 from patent US 6617438.
ACCESSION AR398248
VERSION AR398248.1 GI:40135903
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 629 09-SEP-2003;
FEATURES
source
location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No.2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 259 GCAGGTGCCAGGCGCTG 275
DB 17 GTAGGTGACCGAGGCTG 1

RESULT 140
AR398338/c 17 bp RNA linear PAT 18-DEC-2003
LOCUS
DEFINITION Sequence 719 from patent US 6617438.

```

```

ACCESSION AR398338
VERSION AR398338.1 GI:40136070
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 17)
Beigelman,L., Burgin,A.B., Beaudry,A., Karpelsky,A.,
Metulic-Adamc,J., Sweedler,D. and Zinnen,S.
Oligoribonucleotides with enzymatic activity
Patent: US 6617438-A 719 09-SEP-2003;
LOCATION/Qualifiers
1..17
/mol_type="unknown"
/mol_type="unassigned RNA"

FEATURES
SOURCE
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 269 AGGCGTGGCTGGCTGCT 265
Db 17 AGGCGTGGCTGCTGCT 1

RESULT 141
AX214664 17 bp RNA linear PAT 07-SEP-2001
LOCUS
DEFINITION Sequence 106 from Patent WO0159103.
ACCESSION AX214664
VERSION AX214664.1 GI:15524707
KEYWORDS
SOURCE
ORGANISM synthetic construct
REFERENCE
AUTHORS 1
Blatt,L., McSwiggen,J. and Chowitra,B.M.
Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
Patent: WO 0159103-A 106 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowitra, Bharat M. (US)
LOCATION/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

FEATURES
source
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1778 GAAGCTTCAAGAAAT 1794
Db 1 GAACACTTCAAGAAAT 17

RESULT 142
AX216395 17 bp RNA linear PAT 07-SEP-2001
LOCUS
DEFINITION Sequence 1837 from Patent WO0159103.
ACCESSION AX216395
VERSION AX216395.1 GI:15526456
KEYWORDS
SOURCE
ORGANISM synthetic construct
REFERENCE
AUTHORS 1
Blatt,L., McSwiggen,J. and Chowitra,B.M.
Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
Patent: WO 0159103-A 1837 16-AUG-2001;
JOURNAL

```

```

RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowitra, Bharat M. (US)
LOCATION/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

FEATURES
SOURCE
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 199 GTGCTGTGGCTGGGCGC 215
Db 17 GGGCTTGCTGCTGGGCGC 1

RESULT 143
AX216573 17 bp RNA linear PAT 07-SEP-2001
LOCUS
DEFINITION Sequence 2015 from Patent WO0159103.
ACCESSION AX216573
VERSION AX216573.1 GI:15526634
KEYWORDS
SOURCE
ORGANISM synthetic construct
REFERENCE
AUTHORS 1
Blatt,L., McSwiggen,J. and Chowitra,B.M.
Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
Patent: WO 0159103-A 2015 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowitra, Bharat M. (US)
LOCATION/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

FEATURES
source
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 784 GGAGAGGTGTTGGGCGC 800
Db 1 GGAGGTGTTGGTGC 17

RESULT 144
AX423541 17 bp RNA linear PAT 18-JUN-2002
LOCUS
DEFINITION Sequence 1877 from Patent WO0188124.
ACCESSION AX423541
VERSION AX423541.1 GI:21526923
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS 1
Garvis,T., von Carlowitz,I., McSwiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
Method and reagent for the inhibition of erg
Patent: WO 0188124-A 1877 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
LOCATION/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

FEATURES
SOURCE

```

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 346 CTGATCTCATGGGAGC 362
|||||
17 CTGATCTCTGGGGGC 1

RESULT 145
AX423542/c 17 bp RNA linear PAT 18-JUN-2002
LOCUS Sequence 1878 from Patent WO0188124.
ACCESSION AX423542
VERSION AX423542.1 GI:21526924
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
1 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Jarvis,T., von Carlwiltz,I., Mcswigen,J.A., McLaughlin,F.G. and
TITLE Randi,A.M.
JOURNAL Method and reagent for the inhibition of erg
PATENT: WO 0188124-A 1878 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 345 GCTGATCTCATGGGAG 361
|||||
17 GCTGATCTCTGGGGGC 1

RESULT 146
AX475793 17 bp DNA linear PAT 12-AUG-2002
LOCUS Sequence 1014 from Patent WO0224750.
ACCESSION AX475793
VERSION AX475793.1 GI:22215078
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
1 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Zhang,J.
JOURNAL Human kidney tumor overexpressed membrane protein 1
PATENT: WO 0224750-A 1014 28-MAR-2002;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 147 CACCGCGCTGCCTACTGC 163
|||||
1 CACCGAGCAGCCACTGC 17

RESULT 147
AX499212 17 bp DNA linear PAT 27-SEP-2002
LOCUS Sequence 519 from Patent EP1229046.
DEFINITION AX499212
ACCESSION AX499212
VERSION AX499212.1 GI:23381505
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
1 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Zhan,J.
JOURNAL Human testis expressed patched like protein
PATENT: EP 1229046-A 519 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 131 TCTCCTGCTGTGCGCC 147
|||||
1 TCTTCTGCTGTGCGCCC 17

RESULT 148
AX530927 17 bp DNA linear PAT 22-NOV-2002
LOCUS Sequence 436 from Patent EP1239051.
DEFINITION AX530927
ACCESSION AX530927
VERSION AX530927.1 GI:25253645
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
1 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Shannon,M.
JOURNAL Human posh-1ike protein 1
PATENT: EP 1239051-A 436 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1101 CATTGAGGCTGTGCGG 1117
|||||
1 CATTGAGGCGCTGCCGG 17

RESULT 149
AX530928 17 bp DNA linear PAT 22-NOV-2002
LOCUS Sequence 437 from Patent EP1239051.
DEFINITION AX530928
ACCESSION AX530928
VERSION AX530928.1 GI:25253647
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
1 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

```
REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-1like protein 1
JOURNAL Patent: EP 1239051-A 437 11-SEP-2002;
FEATURES
SOURCE
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1102 ATTGAGGCTCTGTCGCC 1118
Db 1 ATTGAGGCGCTGCGCGC 17

RESULT 150
LOCUS AX530929 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 438 from Patent EP1239051.
ACCESSION AX530929
VERSION AX530929.1 GI:25253649
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-1like protein 1
JOURNAL Patent: EP 1239051-A 438 11-SEP-2002;
FEATURES
SOURCE
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1103 TTGAGGCTCTGTCGCC 1119
Db 1 TTGAGGCGCTGCGCGC 17

RESULT 151
LOCUS AX530930 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 439 from Patent EP1239051.
ACCESSION AX530930
VERSION AX530930.1 GI:25253651
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-1like protein 1
JOURNAL Patent: EP 1239051-A 439 11-SEP-2002;
FEATURES
SOURCE
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
```

```
Query Match
0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1104 TGAGGCTCTGTCGCCA 1120
Db 1 TGAGGCGCTGCGCGCA 17

RESULT 152
LOCUS AX531817 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 1326 from Patent EP1239051.
ACCESSION AX531817
VERSION AX531817.1 GI:25255410
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-1like protein 1
JOURNAL Patent: EP 1239051-A 1326 11-SEP-2002;
FEATURES
SOURCE
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2092 CTCATCACCAGCACCT 2108
Db 1 CTTATCACCCCGCACCT 17

RESULT 153
LOCUS AX544924 17 bp DNA linear PAT 26-NOV-2002
DEFINITION Sequence 437 from Patent EP1243660.
ACCESSION AX544924
VERSION AX544924.1 GI:25810135
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Zhang,J., Gu,Y. and Nguyen,C.T.
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10
JOURNAL Patent: EP 1243660-A 437 25-SEP-2002;
FEATURES
SOURCE
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1421 CCTCAGAGAAATATTT 1437
Db 1 CCTCAGTGAATAATTT 17

RESULT 154
AX544968/c
```

LOCUS AX544968 17 bp DNA linear PAT 26-NOV-2002
DEFINITION Sequence 481 from Patent EP1243660.
ACCESSION AX544968
VERSION AX544968.1 GI:25810179
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1
AUTHORS Zhang, J., Gu, Y. and Nguyen, C.T.
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10
JOURNALS Patent: EP 1243660-A 481 25-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1488 CTTACACTTGAGGCC 1504
Db 17 CTTACACTTGAGGCC 1

RESULT 155
LOCUS AX545280 17 bp DNA linear PAT 26-NOV-2002
DEFINITION Sequence 793 from Patent EP1243660.
ACCESSION AX545280
VERSION AX545280.1 GI:25810491
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1
AUTHORS Zhang, J., Gu, Y. and Nguyen, C.T.
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10
JOURNALS Patent: EP 1243660-A 793 25-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 277 CTGGCTGCTTGAAGCC 293
Db 1 CTGGCTGCTTGAAGCC 17

RESULT 156
LOCUS AX579025 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 863 from Patent WO0211674.
ACCESSION AX579025
VERSION AX579025.1 GI:27648227
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1
AUTHORS Thompson, J., Mcswigen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.

TITLE and Grube, A.
JOURNALS Method and reagent for the inhibition of calcium activated chloride
channel-1 (Clca-1)
Patent: WO 0211674-A 863 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1997 TGGATGATGCCACGCT 2013
Db 17 TGGATGATGCCACGCT 1

RESULT 157
LOCUS AX615974 17 bp DNA linear PAT 20-FEB-2003
DEFINITION Sequence 781 from Patent EP1262488.
ACCESSION AX615974
VERSION AX615974.1 GI:28447020
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1
AUTHORS Gu, Y. and Nguyen, C.T.
TITLE Human lcll-domain containing protein
JOURNALS Patent: EP 1262488-A 781 04-DEC-2002;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 918 TCTGTGCTACTGCTGC 934
Db 17 TCTGTGCTACTGCTGC 1

RESULT 158
LOCUS AX687644 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 376 from Patent EP1281758.
ACCESSION AX687644
VERSION AX687644.1 GI:29410340
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
Patent: EP 1281758-A 376 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2176 CACCAGCAGCTCATGGA 2192
17 CACCAGCAGCTCCAGGA 1

Db 17 CACCAGCAGCTCCAGGA 1

RESULT 159
LOCUS AX687797 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 529 from Patent EP1281758.
ACCESSION AX687797
VERSION AX687797.1 GI:29410493
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 529 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 773 GCCACTTGCAGGAGAG 789
1 GCCACAGCAGGAGAG 17

Db 1 GCCACAGCAGGAGAG 17

RESULT 160
LOCUS AX688661 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 1393 from Patent EP1281758.
ACCESSION AX688661
VERSION AX688661.1 GI:29411363
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 1393 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1639 GTGGCTGCCCTGCTGCA 1655
17 GTGGCTGCCCTGCTGCA 1

Db 17 GTGGCTGCCCTGCTGCA 1

RESULT 161
LOCUS AX690651 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 3383 from Patent EP1281758.
ACCESSION AX690651
VERSION AX690651.1 GI:29413532
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 3383 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2176 CACCAGCAGCTCATGGA 2192
17 CACCAGCAGCTCATGGA 1

Db 17 CACCAGCAGCTCATGGA 1

RESULT 162
LOCUS AX724195 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1882 from Patent WO03025176.
ACCESSION AX724195
VERSION AX724195.1 GI:30503538
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour regression, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 1882 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1359 GTTCACCCAGGCTGTG 1375
1 GATCTCCAGGCTGTG 17

Db 1 GATCTCCAGGCTGTG 17

RESULT 163
LOCUS AX726124 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3811 from Patent WO03025176.
ACCESSION AX726124
VERSION AX726124.1 GI:30505467

KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
AUTHORS 1
TITLE Teلمان,A., Amson,R. and Tuijnder,M.
Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
Patent: WO 03025176-A 3811 27-MAR-2003;
Molecular Engines Laboratories (FR)

JOURNAL
FEATURES Location/Qualifiers
source 1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 996 GATCACCTGCTCTGC 1012
Db 1 GATCGCTGCTCTGC 17

RESULT 164
AX728039 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 5726 from Patent WO03025176.
AX728039
VERSION AX728039.1 GI:30507382
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
AUTHORS 1
TITLE Teلمان,A., Amson,R. and Tuijnder,M.
Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
Patent: WO 03025176-A 5726 27-MAR-2003;
Molecular Engines Laboratories (FR)

JOURNAL
FEATURES Location/Qualifiers
source 1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 996 GATCACCTGCTCTGC 1012
Db 1 GATCGCTGCTCTGC 17

RESULT 165
AX730911 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 2545 from Patent WO03025175.
AX730911
VERSION AX730911.1 GI:30510254
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Teلمان,A., Amson,R. and Tuijnder,M.

TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL
REFERENCE
AUTHORS 1
TITLE Teلمان,A., Amson,R. and Tuijnder,M.
Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
Patent: WO 03025175-A 2545 27-MAR-2003;
Molecular Engines Laboratories (FR)

JOURNAL
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 996 GATCACCTGCTCTGC 1012
Db 1 GATCGCTGCTCTGC 17

RESULT 166
AX745331/c 17 bp DNA linear PAT 14-MAY-2003
LOCUS Sequence 1296 from Patent WO03031621.
AX745331
VERSION AX745331.1 GI:30723998
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Zhang,J.
A human G protein coupled receptor
Patent: WO 03031621-A 1296 17-APR-2003;
Amer sham Biosciences (SV) Corp. (US)

JOURNAL
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 859 CGGGTAACAGAGAC 875
Db 17 CAGGTAAAGAGAAC 1

RESULT 167
AX759927 17 bp DNA linear PAT 25-JUN-2003
LOCUS Sequence 3248 from Patent WO03040369.
AX759927
VERSION AX759927.1 GI:32254543
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Teلمان,A., Amson,R. and Tuijnder,M.
Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
Patent: WO 03040369-A 3248 15-MAY-2003;
Molecular Engines Laboratories (FR)

JOURNAL
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 996 GATCACCCCTGCTGC 1012
1 GATCCTCTCTGCTCTGC 17

RESULT 168
AX761880 17 bp DNA linear PAT 25-JUN-2003
LOCUS Sequence 5201 from Patent WO03040369.
ACCESSION AX761880
VERSION AX761880.1 GI:32256496
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
Patent: WO 03040369-A 5201 15-MAY-2003;
JOURNAL Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 996 GATCACCCCTGCTGC 1012
1 GATCCTCTCTGCTCTGC 17

RESULT 169
AX783935 17 bp DNA linear PAT 17-JUL-2003
LOCUS AX783935
DEFINITION Sequence 2266 from Patent WO03050284.
ACCESSION AX783935
VERSION AX783935.1 GI:32951784
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
Patent: WO 03050284-A 2266 19-JUN-2003;
JOURNAL Amerisham Biosciences (SV) Corp. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1634 GCACAGTGGCTGCCCTG 1650
1 GCACAGTGTGTGCCCG 17

RESULT 170
BD104937 17 bp DNA linear PAT 27-AUG-2002
LOCUS BD104937
DEFINITION Kit and method for determining HLA type.
ACCESSION BD104937
VERSION BD104937.1 GI:22650511
KEYWORDS WO 0192572-A/1041.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 17)
AUTHORS Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
Nishida,M.
TITLE Kit and method for determining HLA type
Patent: WO 0192572-A 1041 06-DEC-2001;
JOURNAL NISHINO INDUSTRIES INC.,SYSTEM RESEARCH INC.,HIDETOSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO
NISHIDA

COMMENT OS Artificial Sequence
PN WO 0192572-A/1041
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP 00P 164798
PI HIDETOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI
MATSUMURA, SHOGO MORIYA, MICHIO NISHIDA
CC Description of Artificial Sequence:capture
FH Key Location/Qualifiers
FT source 1. .17
/organism="Artificial Sequence".
FEATURES
source 1. .17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 490 GGGCGTCAGGCGGCTC 506
1 GGGCGACAGCGGCTC 17

RESULT 171
BD105155 17 bp DNA linear PAT 27-AUG-2002
LOCUS BD105155
DEFINITION Kit and method for determining HLA type.
ACCESSION BD105155
VERSION BD105155.1 GI:22650729
KEYWORDS WO 0192572-A/1259.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 17)
AUTHORS Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
Nishida,M.
TITLE Kit and method for determining HLA type
Patent: WO 0192572-A 1259 06-DEC-2001;
JOURNAL NISHINO INDUSTRIES INC.,SYSTEM RESEARCH INC.,HIDETOSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO
NISHIDA

COMMENT OS Artificial Sequence
PN WO 0192572-A/1259
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP 00P 164798
PI HIDETOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI
MATSUMURA,

```

PI      SHOGO MORIYA,MICHIIO NISHIDA
PC      C12Q1/68,C12M1/00,C12N15/09,G01N33/53
CC      Description of Artificial Sequence:capture
FH      Key
FT      source
      1..17
      Location/Qualifiers
FEATURES
      source
      1..17
      /organism="synthetic construct"
      /mol_type="genomic DNA"
      /db_xref="taxon:32630"

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      370 TCCGCGGATAGCACCAG 386
Db      1 TCCGCGGATACCACCAG 17

RESULT 172
LOCUS   A67603 18 bp DNA linear PAT 05-MAY-1999
DEFINITION Sequence 23 from Patent W09744485.
ACCESSION A67603
VERSION  A67603.1 GI:4756466
KEYWORDS
SOURCE   unidentified
ORGANISM unidentified
REFERENCE
AUTHORS  Goodfellow,P.N.
TITLE     METHODS FOR IDENTIFYING A MUTATION IN A GENE OF INTEREST
JOURNAL   Patent: WO 9744485-A 23 27-NOV-1997;
          HEXAGEN TECHNOLOGY LIMITED (GB)
FEATURES
      source
      1..18
      /organism="unidentified"
      /mol_type="unassigned DNA"
      /db_xref="taxon:32644"

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      2200 GGGTGCTACTGGGCAT 2216
Db      18 GGGTTCCTCTGGGCAT 2

RESULT 173
LOCUS   AR007264 18 bp DNA linear PAT 04-DEC-1998
DEFINITION Sequence 7 from patent US 5750376.
ACCESSION AR007264
VERSION  AR007264.1 GI:3966748
KEYWORDS
SOURCE   Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS  Weis9,S., Reynolds,B., Hammang,J.P. and Baetge,E.Edward.
TITLE     In vitro growth and proliferation of genetically modified
          multipotent neural stem cells and their progeny
JOURNAL   Patent: US 5750376-A 7 12-MAY-1998;
          Location/Qualifiers
FEATURES
      source
      1..18
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      807 GCGCGATGATGCGGCTGG 823
Db      18 GCGCGATGATGCGGCTGG 2

RESULT 174
LOCUS   AR007265 18 bp DNA linear PAT 04-DEC-1998
DEFINITION Sequence 8 from patent US 5750376.
ACCESSION AR007265
VERSION  AR007265.1 GI:3966749
KEYWORDS
SOURCE   Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS  Weis9,S., Reynolds,B., Hammang,J.P. and Baetge,E.Edward.
TITLE     In vitro growth and proliferation of genetically modified
          multipotent neural stem cells and their progeny
JOURNAL   Patent: US 5750376-A 8 12-MAY-1998;
          Location/Qualifiers
FEATURES
      source
      1..18
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1593 CGAGTGATGATGCGGCTGG 1609
Db      1 CGAGTGATGATGCGGCTGG 17

RESULT 175
LOCUS   AR029258 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 9 from patent US 5859229.
ACCESSION AR029258
VERSION  AR029258.1 GI:5941231
KEYWORDS
SOURCE   Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS  Knise,D.A.
TITLE     Antisense oligonucleotides to suppress eicosanoid formation
JOURNAL   Patent: US 5859229-A 9 12-JAN-1999;
          Location/Qualifiers
FEATURES
      source
      1..18
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      807 GCGCGATGATGCGGCTGG 823
Db      18 GCGCGATGATGCGGCTGG 2

RESULT 176
LOCUS   AR067989 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 7 from patent US 5851832.
ACCESSION AR067989
VERSION  AR067989.1 GI:5999211
KEYWORDS
SOURCE   Unknown.
ORGANISM Unknown.

```

```

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1593 CGAGTGATGATGCGGCTGG 1609
Db      18 CGAGTGATGATGCGGCTGG 2

RESULT 174
LOCUS   AR007265 18 bp DNA linear PAT 04-DEC-1998
DEFINITION Sequence 8 from patent US 5750376.
ACCESSION AR007265
VERSION  AR007265.1 GI:3966749
KEYWORDS
SOURCE   Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS  Weis9,S., Reynolds,B., Hammang,J.P. and Baetge,E.Edward.
TITLE     In vitro growth and proliferation of genetically modified
          multipotent neural stem cells and their progeny
JOURNAL   Patent: US 5750376-A 8 12-MAY-1998;
          Location/Qualifiers
FEATURES
      source
      1..18
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1593 CGAGTGATGATGCGGCTGG 1609
Db      1 CGAGTGATGATGCGGCTGG 17

RESULT 175
LOCUS   AR029258 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 9 from patent US 5859229.
ACCESSION AR029258
VERSION  AR029258.1 GI:5941231
KEYWORDS
SOURCE   Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS  Knise,D.A.
TITLE     Antisense oligonucleotides to suppress eicosanoid formation
JOURNAL   Patent: US 5859229-A 9 12-JAN-1999;
          Location/Qualifiers
FEATURES
      source
      1..18
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      807 GCGCGATGATGCGGCTGG 823
Db      18 GCGCGATGATGCGGCTGG 2

RESULT 176
LOCUS   AR067989 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 7 from patent US 5851832.
ACCESSION AR067989
VERSION  AR067989.1 GI:5999211
KEYWORDS
SOURCE   Unknown.
ORGANISM Unknown.

```

REFERENCE 1 (bases 1 to 18)
AUTHORS Weise,S., Reynolds,B., Hammang,J.P. and Baetge,E. Edward
TITLE In vitro growth and proliferation of multipotent neural stem cells
and their progeny
JOURNAL Patent: US 5851832-A 7 22-DEC-1998;
FEATURES Location/Qualifiers
SOURCE 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGGTACGCGCTGG 1609
Db 18 CGAGGTATGCGCTGG 2

RESULT 177
LOCUS AR067990 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 8 from patent US 5851832.
ACCESSION AR067990
VERSION AR067990.1 GI:5999212
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Weise,S., Reynolds,B., Hammang,J.P. and Baetge,E. Edward.
TITLE In vitro growth and proliferation of multipotent neural stem cells
and their progeny
JOURNAL Patent: US 5851832-A 8 22-DEC-1998;
FEATURES Location/Qualifiers
SOURCE 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGGTACGCGCTGG 1609
Db 1 CGAGGTATGCGCTGG 17

RESULT 178
LOCUS AR083518 18 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 57 from patent US 5976873.
ACCESSION AR083518
VERSION AR083518.1 GI:10010291
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bohinski,R.J. and Whiteett,J.A.
TITLE Nucleic acid sequences controlling lung cell-specific gene
expression
JOURNAL Patent: US 5976873-A 57 02-NOV-1999;
FEATURES Location/Qualifiers
SOURCE 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1416 GGGCTCTCAGAGAAA 1432
Db 1 GGGCTCTCAGAGAAA 17

RESULT 179
LOCUS AR083520 18 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 59 from patent US 5976873.
ACCESSION AR083520
VERSION AR083520.1 GI:10010293
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bohinski,R.J. and Whiteett,J.A.
TITLE Nucleic acid sequences controlling lung cell-specific gene
expression
JOURNAL Patent: US 5976873-A 59 02-NOV-1999;
FEATURES Location/Qualifiers
SOURCE 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1416 GGGCTCTCAGAGAAA 1432
Db 1 GGGCTCTCAGAGAAA 17

RESULT 180
LOCUS AR084251 18 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 7 from patent US 5980885.
ACCESSION AR084251
VERSION AR084251.1 GI:10011022
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Weise,S. and Reynolds,B.
TITLE Growth factor-induced proliferation of neural precursor cells in
vivo
JOURNAL Patent: US 5980885-A 7 09-NOV-1999;
FEATURES Location/Qualifiers
SOURCE 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGGTACGCGCTGG 1609
Db 18 CGAGGTATGCGCTGG 2

RESULT 181
LOCUS AR084252 18 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 8 from patent US 5980885.
ACCESSION AR084252
VERSION AR084252.1 GI:10011023
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Weise,S. and Reynolds,B.
TITLE Growth factor-induced proliferation of neural precursor cells in
vivo
JOURNAL Patent: US 5980885-A 8 09-NOV-1999;
FEATURES Location/Qualifiers
SOURCE 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

REFERENCE 1 (bases 1 to 18)
AUTHORS Weiss,S. and Reynolds,B.
TITLE Growth factor-induced proliferation of neural precursor cells in vivo
JOURNAL Patent: US 5980885-A 8 09-NOV-1999;
FEATURES Location/Qualifiers
SOURCE 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGGTGACGGCGCTGG 1609
Db 1 CGAGGTGATGCCGCTGG 17

RESULT 182
LOCUS AR089741 18 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 23 from patent US 5994075.
ACCESSION AR089741 GI:10016496
VERSION AR089741.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Goodfellow,P.N.
TITLE Methods for identifying a mutation in a gene of interest without a phenocypic guide
JOURNAL Patent: US 5994075-A 23 30-NOV-1999;
FEATURES Location/Qualifiers
SOURCE 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2200 GGGTGCTACTGCGCCAT 2216
Db 18 GGGTCTCTCTGGCCAT 2

RESULT 183
LOCUS AR096651 18 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 35 from patent US 6008048.
ACCESSION AR096651
VERSION AR096651.1 GI:10025638
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Monia,B.P. and Cowser,L.M.
TITLE Antisense inhibition of EGR-1 expression
JOURNAL Patent: US 6008048-A 35 28-DEC-1999;
FEATURES Location/Qualifiers
SOURCE 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2054 TGTACGAAGCCCTGAG 2070
Db 1 TGTACGAAGCCCTGAG 2070

Db 2 TGTCCGAAGCCCTGTG 18

RESULT 184
LOCUS AR097623/c 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 7 from patent US 6071889.
ACCESSION AR097623
VERSION AR097623.1 GI:12806353
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Weiss,S., Reynolds,B., Hammang,U.P. and Baetge,E.Edward.
TITLE In vivo genetic modification of growth factor-responsive neural precursor cells
JOURNAL Patent: US 6071889-A 7 06-JUN-2000;
FEATURES Location/Qualifiers
SOURCE 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGGTGACGGCGCTGG 1609
Db 18 CGAGGTGATGCCGCTGG 2

RESULT 185
LOCUS AR097624 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 8 from patent US 6071889.
ACCESSION AR097624
VERSION AR097624.1 GI:12806354
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Weiss,S., Reynolds,B., Hammang,U.P. and Baetge,E.Edward.
TITLE In vivo genetic modification of growth factor-responsive neural precursor cells
JOURNAL Patent: US 6071889-A 8 06-JUN-2000;
FEATURES Location/Qualifiers
SOURCE 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGGTGACGGCGCTGG 1609
Db 1 CGAGGTGATGCCGCTGG 17

RESULT 186
LOCUS AR130092/c 18 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 84 from patent US 6187586.
ACCESSION AR130092
VERSION AR130092.1 GI:14117989
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Monia,B.P., Cowser,L.M. and Roth,R.A.

TITLE Antisense modulation of AKT-3 expression
JOURNAL Patent: US 6187586-A 84 13-FEB-2001;
FEATURES Location/Qualifiers
source 1. 18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1867 AGTTTCATCTCTGACT 1863
Db 18 AGTTTCATCTCTGAGT 2

RESULT 187
BD270112/c 18 bp DNA linear PAT 17-JUN-2003
LOCUS Secreted proteins and polynucleotides encoding them.
DEFINITION BD270112.1 GI:33079880
ACCESSION BD270112.1 GI:33079880
VERSION JP 2002537757-A/74.
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 18)
AUTHORS Valenzuela, D., Yuan, O., Hoffman, H., Hall, J. and Rapiejko, P.
TITLE Secreted proteins and polynucleotides encoding them
JOURNAL Patent: JP 2002537757-A 74 12-NOV-2002;
ALPHABET INC

OS Artificial Sequence
PN JP 2002537757-A/74
PD 12-NOV-2002
PF 24-AUG-1999 JP 2000566287
PR 24-AUG-1998 US 60/097638, 24-AUG-1998 US 60/097659 PR
09-SEP-1998 US 60/099618, 28-SEP-1998 US 60/102092 PR
25-NOV-1998 US 60/109978, 23-DEC-1998 US 60/113645 PR
23-DEC-1998 US 60/113646, 23-AUG-1999 US 09/379246 PI DARIO
VALENZUELA, OLIVE YUAN, HEIDI HOFFMAN, JEFF HALL, PETER PI RAPIEJKO
PC C12N15/09, A61K38/00, A61K48/00, A61P3/10, A61P11/06, A61P21/00, PC
A61P29/00,

PC A61P31/04, A61P31/10, A61P31/12, A61P31/18, A61P35/00, A61P37/00,
PC C07K14/47,
PC C12N5/10, C12P21/02, G01N33/15, G01N33/50, C12N15/00, A61K37/02, PC
C12N5/00

CC oligonucleotide
FH Key
FT source
Location/Qualifiers
1. 18
/organism="Artificial Sequence".

1. 18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1919 GGAGCCAGCTGTCAGG 1915
Db 18 GGAGCCAGCTGTCAAG 2

RESULT 188
AR211763/c 18 bp DNA linear PAT 20-JUN-2002
LOCUS
DEFINITION Sequence 7 from patent US 6399369.
ACCESSION AR211763
VERSION AR211763.1 GI:21515172
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 18)
AUTHORS Weiss, S. and Reynolds, B.
TITLE Multipotent neural stem cell cDNA libraries
JOURNAL Patent: US 6399369-A 7 04-JUN-2002;
FEATURES Location/Qualifiers
source 1. 18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGTGACCGCGCTGG 1609
Db 18 CGAGTGATGCGCGCTGG 2

RESULT 189
AR211764 18 bp DNA linear PAT 20-JUN-2002
LOCUS AR211764
DEFINITION Sequence 8 from patent US 6399369.
ACCESSION AR211764
VERSION AR211764.1 GI:21515173
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 18)
AUTHORS Weiss, S. and Reynolds, B.
TITLE Multipotent neural stem cell cDNA libraries
JOURNAL Patent: US 6399369-A 8 04-JUN-2002;
FEATURES Location/Qualifiers
source 1. 18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGTGACCGCGCTGG 1609
Db 1 CGAGTGATGCGCGCTGG 17

RESULT 190
AR267617/c 18 bp mRNA linear PAT 10-APR-2003
LOCUS AR267617
DEFINITION Sequence 7 from patent US 6497872.
ACCESSION AR267617
VERSION AR267617.1 GI:29697719
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 18)
AUTHORS Weiss, S., Reynolds, B., Hammang, J.P. and Baetge, E.E.
TITLE Neural transplacental using proliferated multipotent neural stem
cells and their progeny
JOURNAL Patent: US 6497872-A 7 24-DEC-2002;
FEATURES Location/Qualifiers
source 1. 18
/organism="unknown"
/mol_type="mRNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGTGACCGCGCTGG 1609

Db 18 CGAGGTATGCCCTGG 2

RESULT 191
LOCUS AR267618 18 bp mRNA linear PAT 10-APR-2003
DEFINITION Sequence 8 from patent US 6497872.
ACCESSION AR267618
VERSION AR267618.1 GI:29697720
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 18)
AUTHORS Weiss,S., Reynolds,B., Hamman,J.P. and Baetge,E.E.
TITLE Neural transplantation using proliferated multipotent neural stem cells and their progeny
JOURNAL Patent: US 6497872-A 8 24-DEC-2002;
FEATURES
Location/Qualifiers
1..18
/organism="unknown"
/mol_type="mRNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGGTGACGGCGCTGG 1609
Db 1 CGAGGTATGCCCTGG 17

RESULT 192
LOCUS AR296724 18 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 8459 from patent US 6537751.
ACCESSION AR296724
VERSION AR296724.1 GI:31684008
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 18)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 8459 25-MAR-2003;
FEATURES
Location/Qualifiers
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 77 TACTGCTACTTCTGCC 93
Db 2 TACTGCTACTACTCTCC 18

RESULT 193
LOCUS AX039910/c 18 bp DNA linear PAT 18-NOV-2000
DEFINITION Sequence 299 from Patent WO0063441.
ACCESSION AX039910
VERSION AX039910.1 GI:11229939
KEYWORDS
SOURCE
ORGANISM
1. synthetic construct
2. synthetic construct
artificial sequences.

AUTHORS Herrstadt,C. and Davis,R.E.
TITLE Single nucleotide polymorphisms in mitochondrial genes that segregate with Alzheimer's disease
JOURNAL Patent: WO 0063441-A 299 26-OCT-2000;
MITOKOR (US)
FEATURES
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PCR primer"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 658 TCAGCGATACCTTCAC 674
Db 18 TCATCCGCTACCTTCAC 2

RESULT 194
LOCUS AX117435/c 18 bp DNA linear PAT 11-MAY-2001
DEFINITION Sequence 2558 from Patent WO0129262.
ACCESSION AX117435
VERSION AX117435.1 GI:14034386
KEYWORDS
SOURCE
ORGANISM
1. synthetic construct
2. synthetic construct
artificial sequences.

REFERENCE
1
AUTHORS Picoult-Newbury,J. and Pohl,M.
TITLE Genotyping reagents, kits and methods of use thereof
JOURNAL Patent: WO 0129262-A 2558 26-APR-2001;
Orchid Biosciences, Inc. (US)
FEATURES
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No.2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1925 AGCTGTACGGGCTCAG 1941
Db 18 AGCTGTATGGGGCCAG 2

RESULT 195
LOCUS AX179324 18 bp DNA linear PAT 03-JUL-2001
DEFINITION Sequence 25 from Patent WO0127277.
ACCESSION AX179324
VERSION AX179324.1 GI:14598995
KEYWORDS
SOURCE
ORGANISM
1. synthetic construct
2. synthetic construct
artificial sequences.

REFERENCE
1
AUTHORS Shimkets,R.A., Lichenstein,H. and Boldog,F.L.
TITLE Proteins and polynucleotides encoded thereby
JOURNAL Patent: WO 0127277-A 25 19-APR-2001;
Curagen Corporation (US)
FEATURES
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer 10354674 S1"

Query Match	0.6%	Score 13.8;	DB 1;	Length 18;
Beat Local Similarity	88.2%	Pred. No. 2.9e+02;		
Matches 15; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

Qy	197	CCGTGCTCTGGCTGGGG	213
Db	2	CCGTGCTGTGGCTGAGG	18

RESULT 196	18 bp	DNA	linear	PAT 03-JUL-2001
AX179325/c				
LOCUS				
AX179325				
Sequence 26 from Patent WO0127277.				

```

REFERENCE 1
AUTHORS Shimkets, R.A., Lichenstein, H. and Boldog, F.L
TITLE Proteins and polynucleotides encoded thereby
JOURNAL Patent: WO 0127277-A 26 19-APR-2001;
          Curagen Corporation (US)
FEATURES
    source
        1..118
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32650"
            /note="Primer 10354784 S2"

```

Qy	197	CCGTGCTCTGGCTGGGG	213
Db	17	CCGTGCTGTGGCTGAGG	1

RESULT 197	AX180627	LOCUS	AX180627	18 bp	DNA	1 linear	PAT 06-AUG-2001
DEFINITION	Sequence 205 from Patent WO0146391.						
ACCESSION	AX180627						
VERSION	AX180627.1						GI:15132513

```

REFERENCE
AUTHORS      1 Osbourn,A.E., Haralampidis,K. and Bryan,G.T
TITLE         Plant gene
JOURNAL       Patent: WO 0146391-A 205 28-JUN-2001;
              Plant Biocience Limited (GB)
FEATURES
  source
    1..18
      /organism="synthetic construct"
      /mol_type="unassigned DNA"
      /db_xref="taxon:32630"
      /note="Primer"

```

```
Qy      941 TATGTCCTTGGGATC 957
          ||| ||||| |||
Db      1 TATGGCTCTTGGGAAC 17
```

RESULT 198

AX338227	AX338227	18 bp	DNA	linear	PAT 09-JAN-2002
LOCUS	Sequence 9	from Patent WO0181576.			
DEFINITION	AX338227				
ACCESSION	AX338227.1	GI:10128762			
VERSION					

```
REFERENCE
1
AUTHORS Lind, P. and Berthold, M.
TITLE G protein-coupled receptor con-218
JOURNAL Patent: WO 0181576-A 9 01-NOV-2001;
PHARMACIA & UPJOHN COMPANY (US)
FEATURES
source Location/Qualifiers
1.18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"
```

QY 557 GCCTCTCGCTGTTCCTG 573
|||
Db 1 GCCTCTACCTGTTCCTG 17

RESULT	199			
AX353323				
LOCUS	AX353323	18 bp	DNA	linear
DEFINITION	Sequence 529 from Patent EP1174518.			
ACCESSION	AX353323			
VERSION	AX353323.1	GI:18618405		
				PAT 06-FEB-2002

REFERENCE	AUTHORS	TITLE	JOURNAL
1	Loukachov, V. V., Van Gemen, B. and Goudamit, J	Collection of binding molecules Patient: EP 1174518-A-529 23-0AN-2002; Amsterdam Support Diagnostics B. V. (NL)	
FEATURES			
source	location/qualifiers		
	1..18		
	/organism="synthetic construct"		
	/mol_type="unassigned DNA"		
	/db_xref="taxon:32630"		
	/note="position 219"		

Qy	836	ACCAGACAGGTACATC	852
Db	2	ACCAGACAGGAACATC	18

RESULT 200	AX353332	LOCUS	AX353332	18 bp	DNA	1linear	PAT 06-FEB-2002
DEFINITION	Sequence 538 from Patent EP1174518.						
ACCESSION	AX353332						
VERSION	AX353332.1						GI:18618414

SOURCE ORGANISM	REFERENCE
synthetic construct	1
synthetic construct	Loukachev, V.V., van G
artificial sequences.	

TITLE Collection of binding molecules
JOURNAL Patent: EP 1174518-A 538 23-JAN-2002;
Amsterdam Support Diagnostics B.V. (NL)
FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="position 219"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 836 ACCGACGAGTAACATC 852
Db 2 ACCGACGAGAAACATC 18
|||||
|

RESULT 201
AX363168 18 bp DNA linear PAT 15-FEB-2002
LOCUS Sequence 529 from Patent WO0208463.
DEFINITION AX363168
ACCESSION AX363168
VERSION AX363168.1 GI:18695308
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Loukachov,V.V., Goudamit,J. and van Gemen,B.
TITLE Collection of binding molecules
JOURNAL Patent: WO 0208463-A 529 31-JAN-2002;
Amsterdam Support Diagnostics B.V. (NL)
FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="position 219"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 836 ACCGACGAGTAACATC 852
Db 2 ACCGACGAGAAACATC 18
|||||
|

RESULT 202
AX363177 18 bp DNA linear PAT 15-FEB-2002
LOCUS Sequence 538 from Patent WO0208463.
DEFINITION AX363177
ACCESSION AX363177
VERSION AX363177.1 GI:18695317
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Loukachov,V.V., Goudamit,J. and van Gemen,B.
TITLE Collection of binding molecules
JOURNAL Patent: WO 0208463-A 538 31-JAN-2002;
Amsterdam Support Diagnostics B.V. (NL)
FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="position 219"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 836 ACCGACGAGTAACATC 852
Db 2 ACCGACGAGAAACATC 18
|||||
|

Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 836 ACCGACGAGTAACATC 852
Db 2 ACCGACGAGAAACATC 18
|||||
|

RESULT 203
AX419744/c 18 bp DNA linear PAT 18-JUN-2002
LOCUS Sequence 81 from Patent WO0198537.
DEFINITION AX419744
ACCESSION AX419744
VERSION AX419744.1 GI:21524111
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Lyamichev,V., Allawi,H., Dong,F., Neri,B.P. and Vener,I.T.
TITLE Nucleic acid accessible hybridization sites
JOURNAL Patent: WO 0198537-A 81 27-DEC-2001;
THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 483 GGTGCCCCGGCGTCAGG 499
Db 17 GGGGCCCGCGGCTCTCG 1
|||||
|

RESULT 204
AX428594 18 bp DNA linear PAT 20-JUN-2002
LOCUS Sequence 1 from Patent WO0217899.
DEFINITION AX428594
ACCESSION AX428594
VERSION AX428594.1 GI:21538505
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Hla,T., Lee,M.J., Claffey,K.P., Ancellin,N. and Thangada,S.
TITLE Method for regulating angiogenesis
JOURNAL Patent: WO 0217899-A 1 07-MAR-2002;
The University of Connecticut (US)
FEATURES
source
1..18
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1602 GGGCGTGTGGGACCCA 1618
Db 1 GAGCGTGTGGGCCCCA 17
|||||
|

RESULT 205
AX428596/c 18 bp DNA linear PAT 20-JUN-2002
LOCUS Sequence 3 from Patent WO0217899.

```

ACCESSION  AX428596
VERSION     AX428596.1  GI:21538507
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
  AUTHORS   Hla,T., Lee,M.J., Claffey,K.P., Ancillin,N. and Thangada,S.
  TITLE     Method for regulating angiogenesis
  JOURNAL   Patent: WO 021789-A 3 07-MAR-2002;
            The University of Connecticut (US)
FEATURES
  source
    1..18
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1602 GCGCGTGTGGACCCA 1618
Db      18 GACGCTGTGGGCCCCA 2

RESULT 206
LOCUS     AX663784                18 bp  DNA
DEFINITION Sequence 159 from Patent WO02097127.
ACCESSION AX663784
VERSION   AX663784.1  GI:29163964
KEYWORDS
SOURCE     synthetic construct
           synthetic construct
           artificial sequences.
ORGANISM
REFERENCE   1
  AUTHORS   Oellers,N., Gehrmann,M., Kallabis,H., Hall,R., Schulze,T. and
            Kroegel,C.
  TITLE     Genes and proteins for prevention, prediction, diagnosis, prognosis
            and treatment of chronic lung disease
  JOURNAL   Patent: WO 02097127-A 159 05-DEC-2002;
            Bayer Aktiengesellschaft (DE)
FEATURES
  source
    1..18
    /organism="synthetic construct"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32630"
    /note="M36820 forward sequence"

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      564 GCTGCTCTGCTCTGG 580
Db      2 GCTGCTCTGCTCTGG 18

RESULT 207
LOCUS     BD085006/c              18 bp  DNA
DEFINITION Target-dependent reactions using structure-bridging
            oligonucleotides.
ACCESSION BD085006
VERSION   BD085006.1  GI:22630616
KEYWORDS
SOURCE     unidentified
           unidentified
           unidentified.
           1 (bases 1 to 18)
REFERENCE   1 (bases 1 to 18)
  AUTHORS   Dong,F., Lyamichev,V.I., Prudent,J.R., Fors,L., Nerl,B.P.,

```

```

TITLE      Brow,M.A.D., Anderson,T.A. and Dahlberg,J.E.
            Target-dependent reactions using structure-bridging
            oligonucleotides
JOURNAL    Patent: JP 2001523111-A 81 20-NOV-2001;
            THIRD WAVE TECHNOLOGIES INC
COMMENT    OS Unidentified
            PN JP 2001523111-A/81
            PD 20-NOV-2001
            PR 05-MAY-1998 JP 1998548047
            PR 05-MAY-1997 US 08/851588,19-SEP-1997 US 08/934097 PR
            PI FANG DONG,VICTOR I LYAMICHEV,JAMES R PRUDENT,LANCE FORS,BRUCE
            PI P NERI,
            PI MARY ANN D BROW,TODD A ANDERSON,JAMES E DAHLBERG PC
            CO7H21/04,CO7H21/02,C12O1/68
            CC Strandedness: Single;
            CC Topology: Linear;
            CC /desc = 'DNA'
            FT Key
            FT source
            FT Location/Qualifiers
              1..18
              /organism="Unidentified".
              Location/Qualifiers

FEATURES
  source
    1..18
    /organism="unidentified"
    /mol_type="genomic DNA"
    /db_xref="taxon:32644"

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      483 GGTGCGCGGCGGTGACG 499
Db      17 GGGGCCCGCGGCTGTGG 1

RESULT 208
LOCUS     BD097068                18 bp  DNA
DEFINITION Therapeutic agents.
ACCESSION BD097068
VERSION   BD097068.1  GI:22642656
KEYWORDS
SOURCE     synthetic construct
           synthetic construct
           artificial sequences.
ORGANISM
REFERENCE   1 (bases 1 to 18)
  AUTHORS   Enoki,T., Yamaehita,S., Nishimura,K., Sagawa,H. and Kato,I.
  TITLE     Therapeutic agents
  JOURNAL   Patent: WO 0151480-A 27 19-JUL-2001;
            TAKARA SHUZO CO LTD,TATSUJI ENOKI,SHUSAKU YAMASHITA,KAKORI
            NISHIMURA,HIROAKI SAGAWA,IKUNOSHIN KATO
            OS Artificial Sequence
            PN WO 0151480-A/27
            PD 19-JUL-2001
            PR 11-JAN-2001 WO 2001JP000082
            PR 13-JAN-2000 JP 00P 4989,03-OCT-2000 JP 00P 303711 PI
            TATSUJI ENOKI,SHUSAKU YAMASHITA,KAKORI NISHIMURA,HIROAKI SAGAWA,
            PI IKUNOSHIN KATO
            PC C07D309/32,C07D493/08,A61K31/351,A61K31/357,A61P43/00,A61P43/
            PC 111,A61P1/16,
            PC A61P29/00
            CC Designed primer based on nucleotide sequence of human CC
            CC macrophage
            CC inflammatory protein-2-alpha mRNA.
            FH Key
            FH source
            FH Location/Qualifiers
              1..18
              /organism="Artificial Sequence".
              Location/Qualifiers
                1..18
                /organism="synthetic construct"
                /mol_type="genomic DNA"
                /db_xref="taxon:32630"

```

QY	564	GCTGTTCTGTCGTCG 580	0.6%; Score 13.8; DB 1; Length 18;
Db	2	GCTGTCCTCTGCTCTCG 18	88.2%; Pred. No.2.9e+02; Indels 0; Gaps 0;
Query Match			
Best Local Similarity			
Matches	15;	Conservative 0;	Mismatches 2;
RESULT 209			
BD132439		18 bp DNA linear	PAT 18-SEP-2002
LOCUS	BD132439/c		
DEFINITION	A basal cell carcinoma tumor suppressor gene.		
ACCESSION	BD132439		
VERSION	BD132439.1 GI:23227384		
KEYWORDS	JP 2002504805-A/51.		
SOURCE	synthetic construct		
ORGANISM	synthetic construct		
REFERENCE	artificial sequences.		
AUTHORS	1 (bases 1 to 18)		
	Dean,W.F., Hahn,H., Wicking,C., Christiansen,J., Zaphiropoulos,P.G., Gallani,M.R., Shanley,S., Chidambaram,A., Vorechovsky,I., Holmberg,E., Unden,A.B., Gillies,S., Negus,K., Smyth,I., Pressman,C., Leffell,D.J., Gerrard,B., Goldstein,A., Wainwright,B., Toftgard,R., Trench,G.C. and Bale,A.E.		
	A basal cell carcinoma tumor suppressor gene		
	Patent: JP 2002504805-A 51 12-FEB-2002;		
	THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES		
TITLE	PN JP 2002504805-A/51		
JOURNAL	PD 12-FEB-2002		
	PF 16-MAY-1997 JP 1997541164		
	PR 17-MAY-1996 US 60/017906,21-MAY-1996 AU PO 0011 PR		
	07-JUN-1996 AU PO 0363,14-JUN-1996 US 60/019765 PI		
	MICHAEL FREDERICK DEAN, HEIDI HAHN, CAROL WICKING, JEFFREY PI		
	CHRISTIANSEN,		
	PI PETER G. ZAPHIROPOULOS, MAE R GAILANI, SUSAN SHANLEY, ABIRAMI PI		
	CHIDAMBARAM		
	PI IGOR VORECHOVSKY, ERIKA HOLMBERG, ANNE BIRGITTE UNDEN, SUSAN PI		
	GILLIES,		
	PI KYLIE NEGUS, IAN SMYTH, CAROL PRESSMAN, DAVID J LEFFELL, BERNARD		
	PI GERRARD,		
	PI ALISA GOLDSTEIN, BRANDON WAINWRIGHT, RUNE TOFTGARD, GEORGIA PI		
	CHENEVIX TRENCH,		
	PI ALLEN E BALE		
	PC C12N15/12, C07K14/47, C12N5/10, C12Q1/68, G01N33/50, A61K48/00, PC		
	A61K39/395,		
	PC A61K38/17		
	CC Strandedness: Single;		
	CC Topology: linear;		
	CC /note= 'PTCR25 primer'		
	FN key		
FEATURES			
source			
	1..18		
	/organism="synthetic construct"		
	/mol_type="genomic DNA"		
	/db_xref="taxon:32630"		
QY	1461	CTGCCACCCAGTGTC 1477	0.6%; Score 13.8; DB 1; Length 18;
Db	17	CTGCCACCCAGTGATC 1	88.2%; Pred. No. 2.9e+02; Indels 0; Gaps 0;
Query Match			
Best Local Similarity			
Matches	15;	Conservative 0;	Mismatches 2;
RESULT 210			
LOCUS	AX095593/c		
DEFINITION	Sequence 771 from Patent WO0118250.		
ACCESSION	AX095593		

VERSION	AX095593.1	GI:13511796
KEYWORDS	.	Homo sapiens (human)
SOURCE	.	Homo sapiens
ORGANISM	.	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE	1	Lander, E.S., Gargill, M., Ireland, J.S., Bolk, S., Daley, G.O. and McCarthy, J.J. Single nucleotide polymorphisms in genes Patent: WO 018250-A 711 15-MAR-2001; WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)
TITLE	Journal	Pharmaceuticals, Inc. (US)
JOURNAL	Journal	Pharmaceuticals, Inc. (US)
FEATURES	Location/Qualifiers	
source	. .21	/organism="Homo sapiens"
		/mol_type="unassigned DNA"
		/db_xref="taxon:9606"
Query Match	0.6%; Score 13.8;	DB 1; Length 21;
Best Local Similarity	78.9%; Pred. No. 3.2e+02;	Matches 15; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
OY	864 AACAGAGGACCGTCACC 882	
Db	20 AAGAGAGGASAGACACC 2	
RESULT 211		
LOCUS	AX513808/c	41 bp DNA linear PAT 05-OCT-2002
DEFINITION	Sequence 6 from Patent W002052044.	
ACCESSION	AX513808	
VERSION	AX513808.1 GI:23559990	
KEYWORDS	.	Homo sapiens (human)
SOURCE	.	Homo sapiens
ORGANISM	.	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE	1	Nakamura, Y., Sekine, A., Iida, A. and Satto, S. Detection of genetic polymorphisms Patent: WO 02052044-A 6 04-JUL-2002; Riken (JP)
AUTHORS		
TITLE		
JOURNAL		
FEATURES	Location/Qualifiers	
source	. .41	/organism="Homo sapiens"
		/mol_type="unassigned DNA"
		/db_xref="taxon:9606"
Query Match	0.6%; Score 13.6;	DB 1; Length 41;
Best Local Similarity	67.9%; Pred. No. 3.9e+02;	Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;
OY	2105 ACCTCAGCGTGTGGAGCAGGCTGACCA 2132	
Db	37 AGCAGAGGCAGGCTGAYCACGGTGACCA 10	
RESULT 212		
LOCUS	AX518978	41 bp DNA linear PAT 05-OCT-2002
DEFINITION	Sequence 5176 from Patent W002052044.	
ACCESSION	AX518978	
VERSION	AX518978.1 GI:23568986	
KEYWORDS	.	Homo sapiens (human)
SOURCE	.	Homo sapiens
ORGANISM	.	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE	1	Nakamura, Y., Sekine, A., Iida, A. and Satto, S. Detection of genetic polymorphisms
AUTHORS		
TITLE		

JOURNAL Patent: WO 02052044-A 5176 04-JUL-2002;
Riken (JP)
FEATURES
source
1. .41
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.64; Score 13.6; DB 1; Length 41;
Best Local Similarity 67.94; Pred. No. 3.9e+02;
Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 2105 ACCTCAGCTGTGTGAGCAGGCTGACCA 2132
Db 37 AGCAGAGCAGCAGGCTGATCAGGCTACCA 10

RESULT 213
AX521440 41 bp DNA linear PAT 05-OCT-2002
LOCUS Sequence 7638 from Patent WO02052044.
ACCESSION AX521440
VERSION AX521440.1 GI:23572410
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Nakamura, Y., Sekine, A., Iida, A. and Saito, S.
TITLE Detection of genetic polymorphisms
JOURNAL Patent: WO 02052044-A 7638 04-JUL-2002;
Riken (JP)
FEATURES
source
1. .41
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.64; Score 13.6; DB 1; Length 41;
Best Local Similarity 67.94; Pred. No. 3.9e+02;
Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 2105 ACCTCAGCTGTGTGAGCAGGCTGACCA 2132
Db 37 AGCAGAGCAGCAGGCTGATCAGGCTACCA 10

RESULT 214
AR048008 15 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 12 from patent US 5820871.
ACCESSION AR048008
VERSION AR048008.1 GI:5970351
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Palese, P. and Garcia-Sastre, A.
TITLE Recombinant negative strand RNA virus expression systems and vaccines
JOURNAL Patent: US 5820871-A 12 13-OCT-1998;
FEATURES
source
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.64; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.34; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 999 CACCCTGCTCTGCT 1013

Db 1 CACCCTGCTCTGCT 15

RESULT 215
AR056189 15 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 393 from patent US 5837542.
ACCESSION AR056189
VERSION AR056189.1 GI:5981766
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 393 17-NOV-1998;
FEATURES
source
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.64; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.34; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2102 AGCAGCTCAGCCTGG 2116
Db 1 AGGACCTCAGCCTGG 15

RESULT 216
AR056452 15 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 656 from patent US 5837542.
ACCESSION AR056452
VERSION AR056452.1 GI:5982029
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 656 17-NOV-1998;
FEATURES
source
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.64; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.34; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2102 AGCAGCTCAGCCTGG 2116
Db 1 AGGACCTCAGCCTGG 15

RESULT 217
AR059760 15 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 10 from patent US 5840520.
ACCESSION AR059760
VERSION AR059760.1 GI:5986210
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)

AUTHORS Clarke,D.Kirkwood, and Palese,P.M.
TITLE Recombinant negative strand RNA virus expression systems
JOURNAL Patent: US 5840520-A 10 24-NOV-1998;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred.No.2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 999 CACCCTGCTCTGCT 1013
|||||
Db 1 CACCCTGCTCTGCT 15

RESULT 218
LOCUS AR068636 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 12 from patent US 5854037.
ACCESSION AR068636
VERSION AR068636.1 GI:6000843
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Palese,P. and Garcia-Sastre,A.
TITLE Recombinant negative strand RNA virus expression systems and
JOURNAL Patent: US 5854037-A 12 29-DEC-1998;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred.No.2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 999 CACCCTGCTCTGCT 1013
|||||
Db 1 CACCCTGCTCTGCT 15

RESULT 219
LOCUS AR076280 15 bp DNA linear PAT 30-AUG-2000
DEFINITION Sequence 6 from patent US 5958769.
ACCESSION AR076280
VERSION AR076280.1 GI:10003026
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Roberts,J.M., Coats,S.R. and Fero,M.L.
TITLE Compositions and methods for mediating cell cycle progression
JOURNAL Patent: US 5958769-A 6 28-SEP-1999;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred.No.2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 799 GCTGTCTCGCGCCAG 813
|||||
Db 15 GCTCTCTCGCCAG 1

RESULT 220
LOCUS AR094244 15 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 12 from patent US 6001634.
ACCESSION AR094244
VERSION AR094244.1 GI:10020989
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Palese,P. and Garcia-Sastre,A.
TITLE Recombinant negative strand RNA viruses
JOURNAL Patent: US 6001634-A 12 14-DEC-1999;
FEATURES Location/Qualifiers
SOURCE 1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred.No.2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 999 CACCCTGCTCTGCT 1013
|||||
Db 1 CACCCTGCTCTGCT 15

RESULT 221
LOCUS AR113947 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 393 from patent US 6132967.
ACCESSION AR113947
VERSION AR113947.1 GI:14094269
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
TITLE Ribozyme treatment of diseases or conditions related to levels of
JOURNAL intercellular adhesion molecule-1 (ICAM-1)
FEATURES Patent: US 6132967-A 393 17-OCT-2000;
SOURCE Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred.No.2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2102 AGCACTCAGCCTGG 2116
|||||
Db 1 AGCACTCAGCCTGG 15

RESULT 222
LOCUS AR114210 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 656 from patent US 6132967.
ACCESSION AR114210
VERSION AR114210.1 GI:14094532
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
TITLE Ribozyme treatment of diseases or conditions related to levels of

Intercellular adhesion molecule-1 (ICAM-1)
Patent: US 6132967-A 656 17-OCT-2000;
Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2102 AGCAGCTCAGCCTGG 2116
1 AGGAGCTCAGCCTGG 15
|||||

RESULT 223
AR131738/c 15 bp DNA linear PAT 16-MAY-2001
LOCUS AR131738
DEFINITION Sequence 163 from patent US 6194150.
ACCESSION AR131738
VERSION AR131738.1 GI:14120641
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 163 27-FEB-2001;
FEATURES Location/Qualifiers
1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 502 GGCTCTGGAAACCT 516
15 GGCTCTGGAAACCT 1
|||||

RESULT 224
AX322707 15 bp DNA linear PAT 07-JAN-2002
LOCUS AX322707
DEFINITION Sequence 1 from Patent EP1162278.
ACCESSION AX322707
VERSION AX322707.1 GI:18093699
KEYWORDS
SOURCE Synthetic construct
ORGANISM Synthetic construct
REFERENCE 1
AUTHORS Wang,X.B.
TITLE Isomeric primer extension method and kit for detection and
JOURNAL quantification of specific nucleic acid
PATENT: EP 1162278-A 1 12-DEC-2001;
FEATURES Wang, Xiao Bing (US); Morisawa, Shinkatsu (JP)
source Location/Qualifiers
1. .15
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="synthetic oligonucleotide"

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1322 GTGGAACTGTGA 1336
|||||

1 GTGGAACTGTGA 15
|||||

RESULT 225
AX633248 15 bp RNA linear PAT 21-FEB-2003
LOCUS AX633248
DEFINITION Sequence 387 from Patent EP1260586.
ACCESSION AX633248
VERSION AX633248.1 GI:28468862
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,
Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
JOURNAL Genes
PATENT: EP 1260586-A 387 27-NOV-2002;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)
source Location/Qualifiers
1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2102 AGCAGCTCAGCCTGG 2116
1 AGGAGCTCAGCCTGG 15
|||||

RESULT 226
AX633407 15 bp RNA linear PAT 21-FEB-2003
LOCUS AX633407
DEFINITION Sequence 546 from Patent EP1260586.
ACCESSION AX633407
VERSION AX633407.1 GI:28469021
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,
Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
JOURNAL genes
PATENT: EP 1260586-A 546 27-NOV-2002;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)
source Location/Qualifiers
1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2102 AGCAGCTCAGCCTGG 2116
1 AGGAGCTCAGCCTGG 15
|||||

```
RESULT 227
BD131298          15 bp  DNA      linear  PAT 18-SEP-2002
LOCUS             Isometric primer extension method and kit for detecting and
DEFINITION        quantitating specific nucleic acids.
ACCESSION         BD131298
VERSION           BD131298.1 GI:23226243
KEYWORDS          JP 2002027993-A/1.
SOURCE            synthetic construct
ORGANISM          synthetic construct
                  artificial sequences.
REFERENCE         1 (bases 1 to 15)
AUTHORS          Wang,X.
TITLE            Isometric primer extension method and kit for detecting and
                  quantitating specific nucleic acids
JOURNAL          Patent: JP 2002027993-A 1 29-JAN-2002;
COMMENT          XIROBING WANG,SHINKATSU MORISAWA
OS              Artificial Sequence
PN              JP 2002027993-A/1
PD              29-JAN-2002
PF              01-JUN-2001 JP 2001166477
PR              08-JUN-2000 US 60/209987,23-MAY-2001 US 09/862417 PT
XINROBING WANG
CC              C12N15/09,C12Q1/68,C12N15/00
CQ              Description of Artificial Sequence:synthetic oligonucleotide
FH              Location/Qualifiers
FT              1..15
                  /organism='Artificial Sequence'.
FEATURES
source          1..15
                  location/Qualifiers
                  /organism="synthetic construct"
                  /mol_type="genomic DNA"
                  /db_xref="taxon:32630"
Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No.2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy              1322 GTGGGACCTGTGCA 1336
Db              1 GTGGGACCTGTGCA 15
RESULT 228
BD208457          15 bp  RNA      linear  PAT 17-JUL-2003
LOCUS             Enzymatic nucleic acid treatment of diseases or conditions related
DEFINITION        to hepatitis C virus infection.
ACCESSION         BD208457
VERSION           BD208457.1 GI:33018227
KEYWORDS          JP 2002512791-A/2047.
SOURCE            unidentified
ORGANISM          unidentified
                  unclassified.
REFERENCE         1 (bases 1 to 15)
AUTHORS          Blatt,L., McSwiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE            Enzymatic nucleic acid treatment of diseases or conditions related
                  to hepatitis C virus infection
JOURNAL          Patent: JP 2002512791-A 2047 08-MAY-2002;
COMMENT          RIBOZYME PHARMACEUTICALS INC
OS              Hepatitis virus (hepatitis C virus)
PN              JP 2002512791-A/2047
PD              08-MAY-2002
PF              26-APR-1999 JP 20060545991
PR              27-APR-1998 US 60/083217,18-SEP-1998 US 60/100842 PR
                23-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PT
LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A PT
PAVCO,
PI              DENNIS MACEJAK
PC              C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
                A61K37/66,
                C12N15/00
CC              Enzymatic nucleic acid treatment of diseases or conditions CC
```

```
related to
CC      hepatitis C virus infection.
FH      Key      Location/Qualifiers
FT      source   1..15
                  /organism='Hepatitis virus (hepatitis C FT
                  virus)',
                  Location/Qualifiers
FEATURES
source          1..15
                  /organism="unidentified"
                  /mol_type="genomic RNA"
                  /db_xref="taxon:32644"
Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No.2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy              1010 TGCTTTCCTTCGTC 1024
Db              1 TGCTTTCCTTCGTC 15
RESULT 229
AR329677          16 bp  RNA      linear  PAT 17-AUG-2003
LOCUS             Sequence 7079 from patent US 6566127.
DEFINITION        AR329677
ACCESSION         AR329677
VERSION           AR329677.1 GI:33715485
KEYWORDS          Unknown.
SOURCE            Unknown.
ORGANISM          Unknown.
REFERENCE         1 (bases 1 to 16)
AUTHORS          Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE            Method and reagent for the treatment of diseases or conditions
                  related to levels of vascular endothelial growth factor receptor
JOURNAL          Patent: US 6566127-A 7079 20-MAY-2003;
COMMENT          Location/Qualifiers
FEATRES          1..16
                  /organism="unknown"
                  /mol_type="unassigned RNA"
Query Match          0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No.3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy              770 ACAGCACCCTGCAGG 784
Db              1 ACAGCACCCTGCAGG 15
RESULT 230
AR391399/c        16 bp  DNA      linear  PAT 18-DEC-2003
LOCUS             Sequence 11 from patent US 6613520.
DEFINITION        AR391399
ACCESSION         AR391399
VERSION           AR391399.1 GI:40114888
KEYWORDS          Unknown.
SOURCE            Unknown.
ORGANISM          Unknown.
REFERENCE         1 (bases 1 to 16)
AUTHORS          Ashby,M.
TITLE            Methods for the survey and genetic analysis of populations
JOURNAL          Patent: US 6613520-A 11 02-SEP-2003;
COMMENT          Location/Qualifiers
FEATRES          1..16
                  /organism="genomic DNA"
                  /mol_type="genomic DNA"
Query Match          0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No.3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```


QY 297 AGCTGCGGCACTGGG 311
| | | | | | | | | |
Db 16 AGCTGCGGCACTGGG 2

RESULT 231
AR391401/c 16 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 13 from patent US 6613520.
ACCESSION AR391401
VERSION AR391401.1 GI:40114892
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Ashby, M.
TITLE Methods for the survey and genetic analysis of populations
JOURNAL Patent: US 6613520-A 13 02-SEP-2003;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTGCGGCACTGGG 311
| | | | | | | | | |
Db 16 AGCTGCGGCACTGGG 2

RESULT 232
AR391465/c 16 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 77 from patent US 6613520.
ACCESSION AR391465
VERSION AR391465.1 GI:40114958
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Ashby, M.
TITLE Methods for the survey and genetic analysis of populations
JOURNAL Patent: US 6613520-A 77 02-SEP-2003;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTGCGGCACTGGG 311
| | | | | | | | | |
Db 16 AGCTGCGGCACTGGG 2

RESULT 233
AX281879/c 16 bp DNA linear PAT 02-NOV-2001
DEFINITION Sequence 11 from Patent WO0177392.
ACCESSION AX281879
VERSION AX281879.1 GI:16609130
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Ashby, M.

TITLE Methods for the survey and genetic analysis of populations
JOURNAL Patent: WO 0177392-A 11 18-OCT-2001;
AUTHORS Ashby, Matthew (US)
FEATURES Location/Qualifiers
source 1..16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/note="unidentified soil organism"

Query Match 0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTGCGGCACTGGG 311
| | | | | | | | | |
Db 16 AGCTGCGGCACTGGG 2

RESULT 234
AX281881/c 16 bp DNA linear PAT 02-NOV-2001
DEFINITION Sequence 13 from Patent WO0177392.
ACCESSION AX281881
VERSION AX281881.1 GI:16609132
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Ashby, M.
TITLE Methods for the survey and genetic analysis of populations
JOURNAL Patent: WO 0177392-A 13 18-OCT-2001;
FEATURES Location/Qualifiers
source 1..16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/note="unidentified soil organism"

Query Match 0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTGCGGCACTGGG 311
| | | | | | | | | |
Db 16 AGCTGCGGCACTGGG 2

RESULT 235
AX281945/c 16 bp DNA linear PAT 02-NOV-2001
DEFINITION Sequence 77 from Patent WO0177392.
ACCESSION AX281945
VERSION AX281945.1 GI:16609196
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Ashby, M.
TITLE Methods for the survey and genetic analysis of populations
JOURNAL Patent: WO 0177392-A 77 18-OCT-2001;
FEATURES Location/Qualifiers
source 1..16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/note="unidentified soil organism"

Query Match 0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTGCGGCACTGGG 311
| | | | | | | | | |
Db 16 AGCTGCGGCACTGGG 2

Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTGCGGCACTGG 311
|||
16 AGCTGCGGCACTGG 2

RESULT 236
LOCUS A03835 17 bp DNA linear PAT 09-JUL-1993
DEFINITION Artificial sequence (plasmid pMP31) for ENDO II.
ACCESSION A03835
VERSION A03835.1 GI:412356
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE artificial sequences.
1 (bases 1 to 17)
AUTHORS
TITLE YEAST STRAINS PRODUCING CELLULOXYLIC ENZYMES AND METHODS AND MEANS
FOR CONSTRUCTING THEM
JOURNAL Patent: WO 8504672-A 26 24-OCT-1985;
FEATURES location/Qualifiers
source 1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 965 GGGATCAGTGTCCC 979
|||
1 GGGATCAGTGTCCC 15

RESULT 237
LOCUS AR057440 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1644 from patent US 5837542.
ACCESSION AR057440
VERSION AR057440.1 GI:5983017
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1644 17-NOV-1998;
FEATURES location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGTCCTGTGG 583
|||
2 TCCTGTCCTGTGG 16

RESULT 238
LOCUS AR057496 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1700 from patent US 5837542.
ACCESSION AR057496
VERSION AR057496.1 GI:5983073

KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1700 17-NOV-1998;
FEATURES location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGTCCTGTGG 583
|||
2 TCCTGTCCTGTGG 16

RESULT 239
LOCUS AR057503 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1707 from patent US 5837542.
ACCESSION AR057503
VERSION AR057503.1 GI:5983080
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1707 17-NOV-1998;
FEATURES location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGTCCTGTGG 583
|||
2 TCCTGTCCTGTGG 16

RESULT 240
LOCUS AR057539 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1743 from patent US 5837542.
ACCESSION AR057539
VERSION AR057539.1 GI:5983116
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1743 17-NOV-1998;
FEATURES location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCTGCTGG 583
|||||
Db 2 TCCTGCTCTGCTGG 16

RESULT 241

LOCUS AR057592 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1796 from patent US 5837542.
ACCESSION AR057592
VERSION AR057592.1 GI:5983169
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1796 17-NOV-1998;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCTGCTGG 583
|||||
Db 2 TCCTGCTCTGCTGG 16

RESULT 242
LOCUS AR057669 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1873 from patent US 5837542.
ACCESSION AR057669
VERSION AR057669.1 GI:5983246
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1873 17-NOV-1998;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCTGCTGG 583
|||||
Db 2 TCCTGCTCTGCTGG 16

RESULT 243
LOCUS AR057730 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1934 from patent US 5837542.
ACCESSION AR057730
VERSION AR057730.1 GI:5983307
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1934 17-NOV-1998;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCTGCTGG 583
|||||
Db 2 TCCTGCTCTGCTGG 16

RESULT 244
LOCUS AR115198 17 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1644 from patent US 6132967.
ACCESSION AR115198
VERSION AR115198.1 GI:14095520
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of
intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 1644 17-OCT-2000;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCTGCTGG 583
|||||
Db 2 TCCTGCTCTGCTGG 16

RESULT 245
LOCUS AR115254 17 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1700 from patent US 6132967.
ACCESSION AR115254
VERSION AR115254.1 GI:14095576
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of
intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 1700 17-OCT-2000;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCTGCTGG 583
|||||
Db 2 TCCTGCTCTGCTGG 16

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      569 TCCTGCTCTCGTGG 583
      2 TCCTGCTCTCGTGG 16

RESULT 246
LOCUS   AR115261
DEFINITION Sequence 1707 from patent US 6132967.
ACCESSION AR115261
VERSION  AR115261.1 GI:14095583
KEYWORDS
SOURCE   .
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS  1 (bases 1 to 17)
          Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
          Draper,K.G.
TITLE    Ribozyme treatment of diseases or conditions related to levels of
JOURNALS intercellular adhesion molecule-1 (ICAM-1)
FEATURES Location/Qualifiers
          1..17
          /organism="unknown"
          /mol_type="unassigned DNA"

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      569 TCCTGCTCTCGTGG 583
      2 TCCTGCTCTCGTGG 16

RESULT 247
LOCUS   AR115297
DEFINITION Sequence 1743 from patent US 6132967.
ACCESSION AR115297
VERSION  AR115297.1 GI:14095619
KEYWORDS
SOURCE   .
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS  1 (bases 1 to 17)
          Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
          Draper,K.G.
TITLE    Ribozyme treatment of diseases or conditions related to levels of
JOURNALS intercellular adhesion molecule-1 (ICAM-1)
FEATURES Location/Qualifiers
          1..17
          /organism="unknown"
          /mol_type="unassigned DNA"

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      569 TCCTGCTCTCGTGG 583
      2 TCCTGCTCTCGTGG 16

RESULT 248
LOCUS   AR115350
DEFINITION Sequence 1796 from patent US 6132967.
          17 bp DNA linear PAT 16-MAY-2001
```

```
ACCESSION AR115350
VERSION   AR115350.1 GI:14095672
KEYWORDS
SOURCE   .
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS  1 (bases 1 to 17)
          Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
          Draper,K.G.
TITLE    Ribozyme treatment of diseases or conditions related to levels of
JOURNALS intercellular adhesion molecule-1 (ICAM-1)
FEATURES Location/Qualifiers
          1..17
          /organism="unknown"
          /mol_type="unassigned DNA"

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      569 TCCTGCTCTCGTGG 583
      2 TCCTGCTCTCGTGG 16

RESULT 249
LOCUS   AR115427
DEFINITION Sequence 1873 from patent US 6132967.
ACCESSION AR115427
VERSION  AR115427.1 GI:14095749
KEYWORDS
SOURCE   .
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS  1 (bases 1 to 17)
          Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
          Draper,K.G.
TITLE    Ribozyme treatment of diseases or conditions related to levels of
JOURNALS intercellular adhesion molecule-1 (ICAM-1)
FEATURES Location/Qualifiers
          1..17
          /organism="unknown"
          /mol_type="unassigned DNA"

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      569 TCCTGCTCTCGTGG 583
      2 TCCTGCTCTCGTGG 16

RESULT 250
LOCUS   AR115488
DEFINITION Sequence 1934 from patent US 6132967.
ACCESSION AR115488
VERSION  AR115488.1 GI:14095810
KEYWORDS
SOURCE   .
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS  1 (bases 1 to 17)
          Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
          Draper,K.G.
TITLE    Ribozyme treatment of diseases or conditions related to levels of
JOURNALS intercellular adhesion molecule-1 (ICAM-1)
FEATURES Location/Qualifiers
          1..17
          /organism="unknown"
          /mol_type="unassigned DNA"
```

```
source
1.17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 569 TCCGTGCTCGGTG 563
Db 2 TCCGTGCTCGGTG 16

RESULT 251
BD254305/c 17 bp DNA linear PAT 17-JUL-2003
LOCUS BD254305
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254305
VERSION BD254305.1 GI:33064075
KEYWORDS JP 2002541795-A/2098.
SOURCE unidentified
ORGANISM unidentified
unclassified.

REFERENCE
1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2098 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/2098
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1.17
ORGANISM 'Eukaryote'.
FEATURES
source
1.17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1784 TTCAGAAATATTG 1798
Db 17 TTCAGAAATATTG 3

RESULT 252
BD254306/c 17 bp DNA linear PAT 17-JUL-2003
LOCUS BD254306
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254306
VERSION BD254306.1 GI:33064076
KEYWORDS JP 2002541795-A/2099.
SOURCE unidentified
ORGANISM unidentified
unclassified.

REFERENCE
1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2099 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/2100
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1.17
ORGANISM 'Eukaryote'.
FEATURES
source
1.17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
```

```
TITLE
JOURNAL
RIBOZYME PHARMACEUTICALS INC
COMMENT
OS Eukaryote
PN JP 2002541795-A/2099
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1.17
ORGANISM 'Eukaryote'.
FEATURES
source
1.17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1784 TTCAGAAATATTG 1798
Db 16 TTCAGAAATATTG 2

RESULT 253
BD254307/c 17 bp DNA linear PAT 17-JUL-2003
LOCUS BD254307
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254307
VERSION BD254307.1 GI:33064077
KEYWORDS JP 2002541795-A/2100.
SOURCE unidentified
ORGANISM unidentified
unclassified.

REFERENCE
1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2100 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/2100
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1.17
ORGANISM 'Eukaryote'.
FEATURES
source
1.17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
```

/db_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1784 TTCAAGAAATATG 1798
|||||
15 TTCAAGAAATGTTG 1

Db

RESULT 254

BD254406 17 bp DNA linear PAT 17-JUL-2003

DEFINITION Regulation of repressor genes using nucleic acid molecules.

ACCESSION BD254406

VERSION BD254406.1 GI:33064176

KEYWORDS JP 2002541795-A/2199.

SOURCE unidentified

ORGANISM unidentified

REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcawiggen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2199 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC

COMMENT OS Eukaryote
PN JP 2002541795-A/2199
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,

PC C12P21/02,C12P21/02//A61K31/711, (C12N5/10,C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91), (C12P21/02,C12R1:91), C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
location/Qualifiers
1..17
/organism='Eukaryote',
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1384 CTCCTCATCTACCC 1398
|||||
1 CTCCTCGCTACCCC 15

Db

RESULT 255

BD259619 17 bp DNA linear PAT 17-JUL-2003

DEFINITION Regulation of repressor genes using nucleic acid molecules.

ACCESSION BD259619

VERSION BD259619.1 GI:33069389

KEYWORDS JP 2002541795-A/7412.

SOURCE unidentified

ORGANISM unidentified

REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcawiggen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 7412 10-DEC-2002;

COMMENT OS Eukaryote
PN JP 2002541795-A/7412
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,

PC C12P21/02,C12P21/02//A61K31/711, (C12N5/10,C12R1:91), (C12P21/02, PC
C12R1:91)
PC (C12P21/02,C12R1:91), (C12P21/02,C12R1:91), C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
location/Qualifiers
1..17
/organism='Eukaryote',
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref="taxon:32644"

FEATURES source
1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 666 TACCTTCACTCGAA 680
|||||

RESULT 256

E59892 17 bp DNA linear PAT 31-JAN-2002

DEFINITION Rhizomania-resisting plant.

ACCESSION E59892

VERSION E59892.1 GI:18622728

KEYWORDS JP 2000312540-A/4.

SOURCE synthetic construct

ORGANISM synthetic construct

REFERENCE 1 (bases 1 to 17)
AUTHORS Nomura, S., Kamitani, G., Saito, M., Kiguchi, T., Kusui, S. and Soma, C.
TITLE Rhizomania-resisting plant
JOURNAL Patent: JP 2000312540-A 4 14-NOV-2000;
GENICHI KAMITANI, SHADANHOJIN HOKKAIDO TENSAI KYOKAI
OS Artificial Sequence
PN JP 2000312540-A/4
PD 14-NOV-2000
PF 28-APR-1999 JP 1999122628
PR SHINGI NOMURA, GENICHI KAMITANI, MINAKO SAITO, TADAHIKO KIGUCHI,
PI SHUNZO KUSUME,
PI CHIHIRO SOMA
PC A01H5/00,C12N5/10,C12N15/09,C12N5/00,C12N15/00 CC
FH key location/Qualifiers
FT source 1..17
location/Qualifiers
1..17
/organism='Artificial Sequence',
/organism='synthetic construct'

Db 2 TACCTCAGTCGACA 16

RESULT 257

LOCUS AR326795 17 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 4197 from patent US 6566127.

ACCESSION AR326795

VERSION AR326795.1 GI:33712603

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 4197 20-MAY-2003;

FEATURES

source

/organism="unknown"

/mol_type="unassigned RNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 3.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 977 CCCTCACCACGTCGA 991

Db 2 CGCTCACCGATGTCGA 16

RESULT 258

LOCUS AR327103 17 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 4505 from patent US 6566127.

ACCESSION AR327103

VERSION AR327103.1 GI:33712911

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 4505 20-MAY-2003;

FEATURES

source

/organism="unknown"

/mol_type="unassigned RNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 3.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1991 TTATCCGATGATGANG 2005

Db 3 TTATCCGATGATGCTG 17

RESULT 259

LOCUS AR327353 17 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 4755 from patent US 6566127.

ACCESSION AR327353

VERSION AR327353.1 GI:33713161

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 4755 20-MAY-2003;

FEATURES

source

/organism="unknown"

/mol_type="unassigned RNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 3.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2214 CATGTGTCAGGCTCC 2228

Db 17 CTGTGTCAGGCTCC 3

RESULT 260

LOCUS AR329223 17 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 6625 from patent US 6566127.

ACCESSION AR329223

VERSION AR329223.1 GI:33715031

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 6625 20-MAY-2003;

FEATURES

source

/organism="unknown"

/mol_type="unassigned RNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 3.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 770 ACAGCCACTTGACAG 784

Db 1 ACAGCAACTTGACAG 15

RESULT 261

LOCUS AR434048 17 bp DNA linear PAT 18-DEC-2003

DEFINITION Sequence 471 from patent US 6656700.

ACCESSION AR434048

VERSION AR434048.1 GI:40196891

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Gu, Y. and Shannon, M. E.

TITLE Isoforms of human pregnancy-associated protein-E

JOURNAL Patent: US 6656700-A 471 02-DEC-2003;

FEATURES

source

/organism="unknown"

/mol_type="genomic DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 3.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1027 AAGAGGTGGGAAA 1041

Db 3 AAGAGGGGGGAAA 17

```
RESULT 262
AR434049          17 bp  DNA      linear  PAT 18-DEC-2003
LOCUS              Sequence 472 from patent US 6656700.
DEFINITION         AR434049
ACCESSION          AR434049
VERSION            AR434049.1  GI:40196892
KEYWORDS
SOURCE
ORGANISM            Unknown.
REFERENCE            Unclassified.
AUTHORS             1 (bases 1 to 17)
TITLE               Gu, Y. and Shannon, M.E.
JOURNAL             Isoforms of human pregnancy-associated protein-E
FEATURES             Patent: US 6656700-A 472 02-DEC-2003;
                     Location/Qualifiers
                     1..17
                     /organism="Unknown"
                     /mol_type="genomic DNA"

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1027 AAGAAAGTGGGAAA 1041
Db      2 AAGAAAGGCGGAAA 16

RESULT 263
AR434050          17 bp  DNA      linear  PAT 18-DEC-2003
LOCUS              Sequence 473 from patent US 6656700.
DEFINITION         AR434050
ACCESSION          AR434050
VERSION            AR434050.1  GI:40196893
KEYWORDS
SOURCE
ORGANISM            Unknown.
REFERENCE            Unclassified.
AUTHORS             1 (bases 1 to 17)
TITLE               Gu, Y. and Shannon, M.E.
JOURNAL             Isoforms of human pregnancy-associated protein-E
FEATURES             Patent: US 6656700-A 473 02-DEC-2003;
                     Location/Qualifiers
                     1..17
                     /organism="Unknown"
                     /mol_type="genomic DNA"

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1027 AAGAAAGTGGGAAA 1041
Db      1 AAGAAAGGCGGAAA 15

RESULT 264
AX215470          17 bp  RNA      linear  PAT 07-SEP-2001
LOCUS              Sequence 912 from Patent WO0159103.
DEFINITION         AX215470
ACCESSION          AX215470
VERSION            AX215470.1  GI:15525513
KEYWORDS
SOURCE
ORGANISM            synthetic construct
                     synthetic construct
                     artificial sequences.
REFERENCE            1
AUTHORS             Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE               Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL             nogo gene expression
FEATURES             Patent: WO 0159103-A 912 16-AUG-2001;
                     RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
```

```
FEATURES
source
location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      201 GCTCTGCTGGGGGC 215
Db      17 GCTCTGCTGGGGGC 3

RESULT 265
AX216969          17 bp  RNA      linear  PAT 08-SEP-2001
LOCUS              Sequence 2411 from Patent WO0159103.
DEFINITION         AX216969
ACCESSION          AX216969
VERSION            AX216969.1  GI:15527030
KEYWORDS
SOURCE
ORGANISM            synthetic construct
                     synthetic construct
                     artificial sequences.
REFERENCE            1
AUTHORS             Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE               Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL             nogo gene expression
FEATURES             Patent: WO 0159103-A 2411 16-AUG-2001;
                     RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
                     McSwiggen, James (US) ; Chowrira, Bharat M. (US)
                     Location/Qualifiers
                     1..17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      201 GCTCTGCTGGGGGC 215
Db      16 GCTCTGCTGGGGGC 2

RESULT 266
AX327094          17 bp  DNA      linear  PAT 07-JAN-2002
LOCUS              Sequence 290 from Patent WO0178894.
DEFINITION         AX327094
ACCESSION          AX327094
VERSION            AX327094.1  GI:18097805
KEYWORDS
SOURCE
ORGANISM            synthetic construct
                     synthetic construct
                     artificial sequences.
REFERENCE            1
AUTHORS             Keith, T.
TITLE               Novel human gene relating to respiratory diseases, obesity, and
JOURNAL             inflammatory bowel disease
FEATURES             Patent: WO 0178894-A 290 25-OCT-2001;
                     Genome Therapeutics Corp. (US)
                     Location/Qualifiers
                     1..17
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"
```


Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 588 CTCCTCTCTTGGGGA 602
|||||
Db 2 CTCCTCTCTTGGCGA 16

RESULT 267
AX423543/c 17 bp RNA linear PAT 18-JUN-2002
LOCUS
DEFINITION Sequence 1879 from Patent WO0188124.
ACCESSION AX423543
VERSION AX423543.1 GI:21526925
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Jarvis, T., von Carlwiltz, I., Mcawiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1879 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 345 GCTGATCTCATGGG 359
|||||
Db 15 GCTGATCTCTGGG 1

RESULT 268
AX475178 17 bp DNA linear PAT 12-AUG-2002
LOCUS
DEFINITION Sequence 399 from Patent WO0224750.
ACCESSION AX475178
VERSION AX475178.1 GI:22214463
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 399 28-MAR-2002;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 566 TGTTCCTGCTCTGG 580
|||||
Db 3 TGTTCCTGCTCTGG 17

RESULT 269

AX475179 17 bp DNA linear PAT 12-AUG-2002
LOCUS
DEFINITION Sequence 400 from Patent WO0224750.
ACCESSION AX475179
VERSION AX475179.1 GI:22214464
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 400 28-MAR-2002;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 566 TGTTCCTGCTCTGG 580
|||||
Db 2 TGTTCCTGCTCTGG 16

RESULT 270
AX475180 17 bp DNA linear PAT 12-AUG-2002
LOCUS
DEFINITION Sequence 401 from Patent WO0224750.
ACCESSION AX475180
VERSION AX475180.1 GI:22214465
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 401 28-MAR-2002;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 566 TGTTCCTGCTCTGG 580
|||||
Db 1 TGTTCCTGCTCTGG 15

RESULT 271
AX531763 17 bp DNA linear PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 1272 from Patent EP1239051.
ACCESSION AX531763
VERSION AX531763.1 GI:25255305
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1

AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1272 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2182 CAGCTCATGAGAAA 2196
|||||
3 CAGCCCATGAGAAA 17
Db
RESULT 272
AX531764 17 bp DNA linear PAT 22-NOV-2002
LOCUS Sequence 1273 from Patent EP1239051.
DEFINITION AX531764
ACCESSION AX531764
VERSION AX531764.1 GI:25255307
KEYWORDS
SOURCE
Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1273 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2182 CAGCTCATGAGAAA 2196
|||||
2 CAGCCCATGAGAAA 16
Db
RESULT 273
AX531765 17 bp DNA linear PAT 22-NOV-2002
LOCUS Sequence 1274 from Patent EP1239051.
DEFINITION AX531765
ACCESSION AX531765
VERSION AX531765.1 GI:25255309
KEYWORDS
SOURCE
Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1274 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2182 CAGCTCATGAGAAA 2196
|||||
1 CAGCCCATGAGAAA 15
Db
RESULT 274
AX544971/c 17 bp DNA linear PAT 26-NOV-2002
LOCUS Sequence 484 from Patent EP1243660.
DEFINITION AX544971
ACCESSION AX544971
VERSION AX544971.1 GI:25810182
KEYWORDS
SOURCE
Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
AUTHORS Zhang,J., Gu,Y. and Nguyen,C.T.
TITLE Human udb-galnac:polypeptide n-acetylglucosaminyltransferase 10
JOURNAL Patent: EP 1243660-A 484 25-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1487 CCTTACACTTGAGG 1501
|||||
15 CCTTACACTTGCTGG 1
Db
RESULT 275
AX579026/c 17 bp RNA linear PAT 10-JAN-2003
LOCUS Sequence 864 from Patent WO0211674.
DEFINITION AX579026
ACCESSION AX579026
VERSION AX579026.1 GI:27648228
KEYWORDS
SOURCE
Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
AUTHORS Thompson,J., Mcswiggen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (Clca-1)
JOURNAL Patent: WO 0211674-A 864 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1997 TGGATGATGCCACCA 2011
|||||
16 TGGATGATGCCACCA 2
Db

```

RESULT 276
AX579182/c
LOCUS      AX579182
DEFINITION Sequence 1020 from Patent WO0211674.
ACCESSION  AX579182
VERSION     AX579182.1 GI:27648384
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Thompson,J., Mcswigen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.
TITLE       Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL     Patent: WO 0211674-A 1020 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      0.64; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1887 TCAGGGCTATGCAC 1901
Db      16 TCAGGGCTGTGCAC 2

RESULT 277
AX579727/c
LOCUS      AX579727
DEFINITION Sequence 1565 from Patent WO0211674.
ACCESSION  AX579727
VERSION     AX579727.1 GI:27648929
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Thompson,J., Mcswigen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.
TITLE       Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL     Patent: WO 0211674-A 1565 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      0.64; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1887 TCAGGGCTATGCAC 1901
Db      15 TCAGGGCTGTGCAC 1

RESULT 278
AX615975/c
LOCUS      AX615975
DEFINITION Sequence 782 from Patent EP1262488.
ACCESSION  AX615975

```

```

VERSION     AX615975.1 GI:28447021
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu,Y. and Nguyen,C.T.
TITLE       Human lcl-domain containing protein
JOURNAL     Patent: EP 1262488-A 782 04-DEC-2002;
Aeomica, Inc. (US)
FEATURES
source      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.64; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      918 TCTGTGCTACCTGCT 932
Db      16 TCTGTGCTACCTGCT 2

RESULT 279
AX615976/c
LOCUS      AX615976
DEFINITION Sequence 783 from Patent EP1262488.
ACCESSION  AX615976
VERSION     AX615976.1 GI:28447022
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu,Y. and Nguyen,C.T.
TITLE       Human lcl-domain containing protein
JOURNAL     Patent: EP 1262488-A 783 04-DEC-2002;
Aeomica, Inc. (US)
FEATURES
source      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.64; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      918 TCTGTGCTACCTGCT 932
Db      15 TCTGTGCTACCTGCT 1

RESULT 280
AX634510
LOCUS      AX634510
DEFINITION Sequence 1649 from Patent EP1260586.
ACCESSION  AX634510
VERSION     AX634510.1 GI:28470124
KEYWORDS
SOURCE      unidentified
ORGANISM    unidentified
REFERENCE   1
AUTHORS     Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A.,
Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
Mcswigen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.

```

TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 1694 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGTCCTGTCG 583
|||||
2 TCCTGTCCTGTCG 16

Db

RESULT 281
AX634541 17 bp RNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 1680 from Patent EP1260586.
ACCESSION AX634541
VERSION AX634541.1 GI:28470155
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE unclassified.
AUTHORS 1
Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Belgelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
Method and reagent for inhibiting the expression of disease related genes
Patent: EP 1260586-A 1680 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 1680 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGTCCTGTCG 583
|||||
2 TCCTGTCCTGTCG 16

Db

RESULT 282
AX634555 17 bp RNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 1694 from Patent EP1260586.
ACCESSION AX634555
VERSION AX634555.1 GI:28470169
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE unclassified.
AUTHORS 1
Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Belgelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
Method and reagent for inhibiting the expression of disease related genes
Patent: EP 1260586-A 1694 27-NOV-2002;

FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)
SOURCE Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGTCCTGTCG 583
|||||
2 TCCTGTCCTGTCG 16

Db

RESULT 283
AX634626 17 bp RNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 1765 from Patent EP1260586.
ACCESSION AX634626
VERSION AX634626.1 GI:28470240
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE unclassified.
AUTHORS 1
Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Belgelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
Method and reagent for inhibiting the expression of disease related genes
Patent: EP 1260586-A 1765 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 1765 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGTCCTGTCG 583
|||||
2 TCCTGTCCTGTCG 16

Db

RESULT 284
AX634635 17 bp RNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 1774 from Patent EP1260586.
ACCESSION AX634635
VERSION AX634635.1 GI:28470249
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE unclassified.
AUTHORS 1
Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Belgelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
Method and reagent for inhibiting the expression of disease related genes
Patent: EP 1260586-A 1774 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 569 TCCTGCTCTCTGCTG 583
|||||
2 TCCTGCTCTCTGCTG 16

RESULT 285
AX634691 17 bp RNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 1830 from Patent EPI260586.
ACCESSION AX634691
VERSION AX634691.1 GI:28470305
KEYWORDS
SOURCE
ORGANISM
unidentified
unclassified.

REFERENCE
AUTHORS
1 Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,
Karpeisky,A., Draper,K.G., Kleich,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Mincott,F.E. and
Woolf,T.

TITLE
JOURNAL
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1. .17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 569 TCCTGCTCTCTGCTG 583
|||||
2 TCCTGCTCTCTGCTG 16

RESULT 286
AX634812 17 bp RNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 1951 from Patent EPI260586.
ACCESSION AX634812
VERSION AX634812.1 GI:28470426
KEYWORDS
SOURCE
ORGANISM
unidentified
unclassified.

REFERENCE
AUTHORS
1 Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,
Karpeisky,A., Draper,K.G., Kleich,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Mincott,F.E. and
Woolf,T.

TITLE
JOURNAL
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1. .17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 569 TCCTGCTCTCTGCTG 583
|||||
2 TCCTGCTCTCTGCTG 16

RESULT 287
AX722446 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 133 from Patent WO03025176.
ACCESSION AX722446
VERSION AX722446.1 GI:30422947
KEYWORDS
SOURCE
ORGANISM
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
AUTHORS
1 Telemann,A., Amson,R. and Tuijnder,M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025176-A 133 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 337 TTCCTGAGCTGATC 351
|||||
15 TTCCTGAGCTGATC 1

RESULT 288
AX725610 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 3297 from Patent WO03025176.
ACCESSION AX725610
VERSION AX725610.1 GI:30504953
KEYWORDS
SOURCE
ORGANISM
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
AUTHORS
1 Telemann,A., Amson,R. and Tuijnder,M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025176-A 3297 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 976 TCCTCAGCATGCTC 990
|||||

Db 3 TCCTCACCCTGTC 17

RESULT 289
LOCUS AX732419 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4053 from Patent WO03025175.
ACCESSION AX732419
VERSION AX732419.1 GI:30511762
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Telerman,A., Amson,R. and Tuijnder,M.
Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines
Patent: WO 03025175-A 4053 27-MAR-2003;
JOURNAL Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1523 TCTCCTTGCTACC 1537
Db 3 TCTCCTTGCTACC 17

RESULT 290
LOCUS AX734744 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 334 from Patent WO03025177.
ACCESSION AX734744
VERSION AX734744.1 GI:30514021
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Telerman,A., Amson,R. and Tuijnder,M.
Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
Patent: WO 03025177-A 334 27-MAR-2003;
JOURNAL Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2221 CAGGCTCCTGCAGAT 2235
Db 16 CATGCTCCTGCAGAT 2

RESULT 291
LOCUS AX737134 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2724 from Patent WO03025177.

ACCESSION AX737134
VERSION AX737134.1 GI:30516422
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Telerman,A., Amson,R. and Tuijnder,M.
Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
Patent: WO 03025177-A 2724 27-MAR-2003;
JOURNAL Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1334 TCACATTTGTTCTCT 1348
Db 3 TCACATCTGTTCTCT 17

RESULT 292
LOCUS AX745329 17 bp DNA linear PAT 14-MAY-2003
DEFINITION Sequence 1294 from Patent WO03031621.
ACCESSION AX745329
VERSION AX745329.1 GI:30723996
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Zhang,J.
A human G protein coupled receptor
Patent: WO 03031621-A 1294 17-APR-2003;
JOURNAL Amerisham Biosciences (SV) Corp. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 861 GGTAAAGAGGACAC 875
Db 17 GGTAAAGAGGAAAC 3

RESULT 293
LOCUS AX745330 17 bp DNA linear PAT 14-MAY-2003
DEFINITION Sequence 1295 from Patent WO03031621.
ACCESSION AX745330
VERSION AX745330.1 GI:30723997
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Zhang,J.

TITLE A human G protein coupled receptor
JOURNAL Patent: WO 03031621-A 1295 17-APR-2003;
Amersham Biosciences (SV) Corp. (US)

FEATURES
SOURCE
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.64; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 861 GGTACAGAGACAC 875
16 GGTACAGAGAAC 2

RESULT 294
AX760054/c 17 bp DNA linear PAT 25-JUN-2003
LOCUS
DEFINITION Sequence 3375 from Patent WO03040369.
ACCESSION AX760054
VERSION AX760054.1 GI:32254670
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)

REFERENCE
AUTHORS
TITLE

1 Telerman, A., Amson, R. and Tuijnder, M.
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

Sequences involved in tumoral suppression, tumor reversal, apoptosis and/or viral resistance phenomena and their use as medicines

JOURNAL Patent: WO 03040369-A 3375 15-MAY-2003;
Molecular Engines Laboratories (FR)

FEATURES
SOURCE
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.64; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1181 TGCAGAAATTAACA 1195
17 TGAAGAAATTAACA 3

RESULT 295
AX783930 17 bp DNA linear PAT 17-JUN-2003
LOCUS
DEFINITION Sequence 2261 from Patent WO03050284.
ACCESSION AX783930
VERSION AX783930.1 GI:32951779
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)

REFERENCE
AUTHORS
TITLE

1 Homo sapiens
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

Human prostate cancer candidate protein 1
Patent: WO 03050284-A 2261 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)

FEATURES
SOURCE
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.64; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1631 AGAGCACAGTGTCTG 1645
3 AGAGCACAGTGTCTG 17

RESULT 296
BD198659 17 bp RNA linear PAT 17-JUN-2003
LOCUS
DEFINITION Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response.
ACCESSION BD198659
VERSION BD198659.1 GI:33008429
KEYWORDS JP 2002509721-A/1685.
SOURCE
ORGANISM Homo sapiens (human)

REFERENCE
AUTHORS
TITLE

1 (bases 1 to 17)
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

Pavco, P.A., Roberts, E., Jarvis, T., Coeshott, C. and Mcswigen, J.A.
Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response

JOURNAL Patent: JP 2002509721-A 1685 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC

COMMENT
OS Homo sapiens (human)
PN JP 2002509721-A/1685
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT,
PI JAMES A MCSWIGEN

PC C12N15/09, A61K31/7088, A61K31/7125, A61K48/00, A61P3/10, A61P17/06, PC
A61P29/00,
PC A61P35/00, A61P43/00, C12N5/10, C12N9/00//A61K35/76, C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response

PH Key
FT source
FT Location/Qualifiers
1. .17
/organism="Homo sapiens (human)".

FEATURES
SOURCE
1. .17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match 0.64; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 909 GAGCTATTCTGTG 923
3 GAGCTATTCTGTG 17

RESULT 297
BD198660 17 bp RNA linear PAT 17-JUN-2003
LOCUS
DEFINITION Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response.
ACCESSION BD198660
VERSION BD198660.1 GI:33008430
KEYWORDS JP 2002509721-A/1686.
SOURCE
ORGANISM Homo sapiens (human)

REFERENCE
AUTHORS
TITLE

1 Homo sapiens
Eukaryota; Metazoa; Chordata; Cranialia; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

1 (bases 1 to 17)

FEATURES	FT	/organism="Homo sapiens (human)".
Source	1. .17	Location/Qualifiers
		/organism="Homo sapiens"
		/mol_type="genomic RNA"
		/db_xref="taxon:9606"
Query Match	0.6%; Score 13.4; DB 1; Length 17;	
Best Local Similarity	93.3%; Pred. No. 3.2e+02;	
Matches	14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
Qy	675	TCGAACCTTACTCT 689
Db	17	TCGAACCTGAACCTCT 3
RESULT 299		
AR092454/C		
LOCUS	AR092454	15 bp DNA linear PAT 08-SEP-2000
DEFINITION	Sequence 10 from patent US 5998166.	
ACCESSION	AR092454	
VERSION	AR092454.1	GI:10019208
KEYWORDS	.	
SOURCE	Unknown.	
ORGANISM	Unknown.	
REFERENCE	1	Unclassified.
AUTHORS	Luo,S.	1 (bases 1 to 15)
TITLE	CD16-II variants	
JOURNAL	Patent: US 5998166-A 10 07-DEC-1999;	
FEATURES	Location/Qualifiers	
source	1. .15	
	/organism="unknown"	
	/mol_type="unassigned DNA"	
Query Match	0.6%; Score 13; DB 1; Length 15;	
Best Local Similarity	100.0%; Pred. No. 3.3e+02;	
Matches	13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	153	GCTGCACACTGCTC 165
Db	13	GCTGCACACTGCTC 1
RESULT 300		
AR092463		
LOCUS	AR092463	15 bp DNA linear PAT 08-SEP-2000
DEFINITION	Sequence 21 from patent US 5998166.	
ACCESSION	AR092463	
VERSION	AR092463.1	GI:10019217
KEYWORDS	.	
SOURCE	Unknown.	
ORGANISM	Unknown.	
REFERENCE	1	Unclassified.
AUTHORS	Luo,S.	1 (bases 1 to 15)
TITLE	CD16-II variants	
JOURNAL	Patent: US 5998166-A 21 07-DEC-1999;	
FEATURES	Location/Qualifiers	
source	1. .15	
	/organism="unknown"	
	/mol_type="unassigned DNA"	
Query Match	0.6%; Score 13; DB 1; Length 15;	
Best Local Similarity	100.0%; Pred. No. 3.3e+02;	
Matches	13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	153	GCTGCACACTGCTC 165
Db	3	GCTGCACACTGCTC 15
RESULT 301		

BD266376/c
 LOCUS BD266376 15 bp DNA linear PAT 17-JUL-2003
 DEFINITION Universal arrays.
 ACCESSION BD266376
 VERSION BD266376.1 GI:33076144
 KEYWORDS JP 2002539849-A/376.
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S., Lockhart,D.J., Ryder,T. and Sklar,P.
 TITLE Universal arrays
 JOURNAL Patent: JP 2002539849-A 376 26-NOV-2002;
 COMMENT WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, AFFYMETRIX INC
 OS Artificial Sequence
 PN JP 2002539849-A/376
 PD 26-NOV-2002
 PR 27-MAR-2000 JP 2000608794
 PZ 26-MAR-1999 US 60/126473, 23-JUN-1999 US 60/140359 PI
 JIAN BING PAN, JOEL N HIRSCHHORN, XIAOHUA HUANG, PAUL KAPLAN, ERIC PI S LANDER,
 PI DAVID J LOCKHART, THOMAS RYDER, PAMELA SKLAR
 PC C1201/68, C12M1/00, C12N15/09, C12N15/09, C12N15/09, G01N33/53, PC
 G01N33/566,
 PC G01N37/00, C12N15/00, C12N15/00, C12N15/00
 CC Primer
 FM Key
 FT source
 FT 1.15
 Location/Qualifiers
 /organism='Artificial Sequence',
 1.15
 /organism='synthetic construct'
 /mol_type='genomic DNA'
 /db_xref='taxon:32630'

Query Match 0.6%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 3.3e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 805 CTGGCCAGAGAGA 817
 DB 15 CTGGCCAGAGAGA 3

RESULT 302
 AR226464 15 bp mRNA linear PAT 20-DEC-2002
 LOCUS AR226464
 DEFINITION Sequence 10 from patent US 6444789.
 ACCESSION AR226464
 VERSION AR226464.1 GI:27265001
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Luo,S.
 TITLE CD16-II variants
 JOURNAL Patent: US 6444789-A 10 03-SEP-2002;
 FEATURES Location/Qualifiers
 1.15
 /organism='unknown'
 /mol_type='mRNA'

Query Match 0.6%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 3.3e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 153 GCTGCCACTGCTC 165
 DB 13 GCTGCCACTGCTC 1

RESULT 303
 AR226473 15 bp mRNA linear PAT 20-DEC-2002
 LOCUS AR226473
 DEFINITION Sequence 21 from patent US 6444789.
 ACCESSION AR226473
 VERSION AR226473.1 GI:27265010
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Luo,S.
 TITLE CD16-II variants
 JOURNAL Patent: US 6444789-A 21 03-SEP-2002;
 FEATURES Location/Qualifiers
 1.15
 /organism='unknown'
 /mol_type='mRNA'

Query Match 0.6%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 3.3e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 153 GCTGCCACTGCTC 165
 DB 3 GCTGCCACTGCTC 15

RESULT 304
 AX362574 15 bp DNA linear PAT 15-FEB-2002
 LOCUS AX362574
 DEFINITION Sequence 8 from Patent WO0208425.
 ACCESSION AX362574
 VERSION AX362574.1 GI:18694718
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 REFERENCE 1
 AUTHORS Finkel,K. and Koshy,B.
 TITLE Haplotypes of the adrb3 gene
 JOURNAL Patent: WO 0208425-A 8 31-JAN-2002;
 Genaisance Pharmaceuticals, Inc. (US)
 FEATURES Location/Qualifiers
 1.15
 /organism='Homo sapiens'
 /mol_type='unassigned DNA'
 /db_xref='taxon:9606'

Query Match 0.6%; Score 13; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 3.3e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 507 TCGAACCCTGTGCG 521
 DB 1 TCGAACCCTGTGCG 15

RESULT 305
 AX377251 15 bp DNA linear PAT 18-MAR-2002
 LOCUS AX377251
 DEFINITION Sequence 13 from Patent WO0212562.
 ACCESSION AX377251
 VERSION AX377251.1 GI:19573539
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 REFERENCE 1
 AUTHORS Kazemi,A., Klien,S.E. and Koshy,B.

TITLE Haplotypes of the pla2g1b gene
JOURNAL Patent: WO 0212562-A 13 14-FEB-2002;
Genaisance Pharmaceuticals, Inc. (US)
FEATURES
source 1..15
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 3.3e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 198 CGTGTCTGCTGGG 212
Db 15 CRTGCTGTGCTCGG 1

RESULT 306
BD005833/c 15 bp DNA linear PAT 31-JAN-2002
LOCUS Novel probes for the detection of Mycobacteria.
ACCESSION BD005833
VERSION BD005833.1 GI:18634204
KEYWORDS JP 2001501825-A/44.
SOURCE unidentified
ORGANISM unidentified
unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Stender,H., Lund,K. and Mollerup,T.A.
TITLE Novel probes for the detection of Mycobacteria
JOURNAL Patent: JP 2001501825-A 44 13-FEB-2001;
DAKO AS
COMMENT OS Unidentified
PN JP 2001501825-A/44
PD 13-FEB-2001
PR 03-OCT-1997 JP 1998517095
PR 04-OCT-1996 DK 1096/96,18-OCT-1996 DK 1156/96 PR
OS-MAY-1997 DK 0512/97
PI HENRIK STENDER,KAARE LUND,TINA ANDRESEN MOLLERUP PC
C12Q1/68,C07K14/00
CC Strandedness: Single;
CC Topology: linear;
FH Key Location/Qualifiers
FT source 1..15
FEATURES location/Qualifiers
source 1..15
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1962 CCGAGCATTTGATC 1974
Db 13 CCGAGCATTTGATC 1

RESULT 307
BD208455 15 bp RNA linear PAT 17-JUN-2003
LOCUS Enzymatic nucleic acid treatment of diseases or conditions related
DEFINITION to hepatitis C virus infection.
ACCESSION BD208455
VERSION BD208455.1 GI:33018225
KEYWORDS JP 2002512791-A/2045.
SOURCE unidentified
ORGANISM unidentified
unclassified.

REFERENCE 1 (bases 1 to 15)

AUTHORS Blatt,L., Mcswigen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
JOURNAL Patent: JP 2002512791-A 2045 08-MAY-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Hepatitis virus (hepatitis C virus)
PN JP 2002512791-A/2045
PD 08-MAY-2002
PR 26-APR-1999 JP 2000545991
PR 27-APR-1998 US 60/083217,18-SEP-1998 US 60/100842 PR
25-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI
LAWRENCE BLATT,JAMES A MCSWIGEN,ELISABETH ROBERTS,PAMELA A PI
PAVCO
PI DENNIS MACEJAK
PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions
CC related to
CC hepatitis C virus infection.
FH key location/Qualifiers
FT source 1..15

FEATURES location/Qualifiers
source 1..15
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Qy 1010 TGCTTTCTCTTCT 1022
Db 3 TGCTTTCTCTTCT 15

RESULT 308
BD208456 15 bp RNA linear PAT 17-JUN-2003
LOCUS Enzymatic nucleic acid treatment of diseases or conditions related
DEFINITION to hepatitis C virus infection.
ACCESSION BD208456
VERSION BD208456.1 GI:33018226
KEYWORDS JP 2002512791-A/2046.
SOURCE unidentified
ORGANISM unidentified
unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Blatt,L., Mcswigen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
JOURNAL Patent: JP 2002512791-A 2046 08-MAY-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Hepatitis virus (hepatitis C virus)
PN JP 2002512791-A/2046
PD 08-MAY-2002
PR 26-APR-1999 JP 2000545991
PR 27-APR-1998 US 60/083217,18-SEP-1998 US 60/100842 PR
25-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI
LAWRENCE BLATT,JAMES A MCSWIGEN,ELISABETH ROBERTS,PAMELA A PI
PAVCO
PI DENNIS MACEJAK
PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions
CC related to
CC hepatitis C virus infection.
FH key location/Qualifiers
FT source 1..15

```

FT      /organism='Hepatitis virus (hepatitis C FT
FEATURES
SOURCE      Location/Qualifiers
              1. .15
              /organism="unidentified"
              /mol_type="genomic RNA"
              /db_xref="taxon:32644"

Query Match      0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1010 TGCCTTTCCTCT 1022
Db      2 TGCCTTTCCTCT 14

RESULT 309
AR328425/c      16 bp      RNA      linear      PAT 17-AUG-2003
LOCUS      AR328425
DEFINITION      Sequence 5827 from patent US 6566127.
ACCESSION      AR328425
VERSION      AR328425.1 GI:33714233
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 16)
AUTHORS      Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE      Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6566127-A 5827 20-MAY-2003;
FEATURES      Location/Qualifiers
              1. .16
              /organism="unknown"
              /mol_type="unassigned RNA"

Query Match      0.6%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2216 TGGTGACGGCTCC 2228
Db      16 TGGTGACGGCTCC 4

RESULT 310
AR046237      17 bp      DNA      linear      PAT 29-SEP-1999
LOCUS      AR046237
DEFINITION      Sequence 1030 from patent US 5817796.
ACCESSION      AR046237
VERSION      AR046237.1 GI:5967702
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE      C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL      Patent: US 5817796-A 1030 06-OCT-1998;
FEATURES      Location/Qualifiers
              1. .17
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1242 CACTAGATTTC 1254
Db      5 CACTAGATTTC 17

```

```

RESULT 311
AR046239      17 bp      DNA      linear      PAT 29-SEP-1999
LOCUS      AR046239
DEFINITION      Sequence 1032 from patent US 5817796.
ACCESSION      AR046239
VERSION      AR046239.1 GI:5967704
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE      C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL      Patent: US 5817796-A 1032 06-OCT-1998;
FEATURES      Location/Qualifiers
              1. .17
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1243 ACTAGATTTCAG 1255
Db      1 ACTAGATTTCAG 13

RESULT 312
AR046724/c      17 bp      DNA      linear      PAT 29-SEP-1999
LOCUS      AR046724
DEFINITION      Sequence 1517 from patent US 5817796.
ACCESSION      AR046724
VERSION      AR046724.1 GI:5968189
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE      C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL      Patent: US 5817796-A 1517 06-OCT-1998;
FEATURES      Location/Qualifiers
              1. .17
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1050 GTTGCTGGAAGTG 1062
Db      17 GTTGCTGGAAGTG 5

RESULT 313
AR046726/c      17 bp      DNA      linear      PAT 29-SEP-1999
LOCUS      AR046726
DEFINITION      Sequence 1519 from patent US 5817796.
ACCESSION      AR046726
VERSION      AR046726.1 GI:5968191
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE      C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL      Patent: US 5817796-A 1519 06-OCT-1998;
FEATURES      Location/Qualifiers
              1. .17

```

Query Match	0.6%;	Score 13;	DB 1;	Length 17;	
Best Local Similarity	100.0%;	Pred. No. 3.66+02;			
Matches 13;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;	
OY	1050	GTTCGTCGAGTG	1062		
Db	16	GTTCGTCGAGTG	4		
RESULT 314					
LOCUS	AR075049	17 bp	DNA	linear	PAT 28-AUG-2000
DEFINITION	Sequence 9 from patent US 5955306.				
ACCESSION	AR075049				
VERSION	AR075049.1	GI:10001801			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 17)				
AUTHORS	Gimeno,C.J. and Errada,P.R.				
TITLE	Genes encoding proteins that interact with the tub protein				
JOURNAL	Patent: US 5955306-A 9 21-SEP-1999;				
FEATURES	Location/Qualifiers				
source	1..17				
	/organism="unknown"				
	/mol_type="unassigned DNA"				
Query Match	0.6%;	Score 13;	DB 1;	Length 17;	
Best Local Similarity	100.0%;	Pred. No. 3.66+02;			
Matches 13;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;	
OY	1009	CTGCTTTTCCTTC	1021		
Db	16	CTGCTTTTCCTTC	4		
RESULT 315					
LOCUS	AR141867	17 bp	DNA	linear	PAT 08-AUG-2001
DEFINITION	Sequence 9 from patent US 6147192.				
ACCESSION	AR141867				
VERSION	AR141867.1	GI:15101383			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 17)				
AUTHORS	Gimeno,C.J. and Errada,P.R.				
TITLE	Tub interactor (TI) polypeptides and uses therefor				
JOURNAL	Patent: US 6147192-A 9 14-NOV-2000;				
FEATURES	Location/Qualifiers				
source	1..17				
	/organism="unknown"				
	/mol_type="unassigned DNA"				
Query Match	0.6%;	Score 13;	DB 1;	Length 17;	
Best Local Similarity	100.0%;	Pred. No. 3.66+02;			
Matches 13;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;	
OY	1009	CTGCTTTTCCTTC	1021		
Db	16	CTGCTTTTCCTTC	4		
RESULT 316					
LOCUS	BD254342	17 bp	DNA	linear	PAT 17-JUL-2003
DEFINITION	Regulation of repressor genes using nucleic acid molecules.				
ACCESSION	BD254342				

VERSION	BD254342.1	GI:33064112
KEYWORDS	JP 2002541795-A/2135.	
SOURCE	unidentified	
ORGANISM	unclassified.	
REFERENCE	1 (bases 1 to 17)	
AUTHORS	Blatt, L., Zwick, M., Payco, P. and Mcswiggen, J.	
TITLE	Regulation of repressor genes using nucleic acid molecules	
JOURNAL	Patent: JP 2002541795-A 2135 10-DEC-2002;	
COMMENT	RIBOZYME PHARMACEUTICALS INC	
OS	Eukaryote	
PN	JP 2002541795-A/2135	
PD	10-DEC-2002	
PF	11-APR-2000 JP 2000611654	
PR	12-APR-1999 US 60/129390	
PI	LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAYCO, JAMES MCSWIGGEN	
PC	PC	
C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC		
C12P21/02,		
PC		
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC		
C12R1:91),		
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N5/00, C12N5/00,		
PC A61K37/02,		
PC (C12N5/00, C12R1:91)		
CC	Regulation of repressor genes using nucleic acid molecules	
Key	Location/Qualifiers	
FT	1..17	
FT	source	
FEATURES	location/Qualifiers	
source	1..17	
	/organism="Eukaryote".	
	1..17	
	/organism="unidentified"	
	/mol_type="genomic DNA"	
	/db_xref="taxon:32644"	
Query Match	0.6%; Score 13; DB 1; Length 17;	
Best local Similarity	100.0%; Pred. NO. 3.6e+02;	
Matches	13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
OY	1847 CAGTAAAGTCTGG 1859	
DB	14 CAGTAAAGTCTGG 2	
RESULT 317		
BD259547	17 bp DNA linear PAR 17-JUL-2003	
LOCUS	BD259547	
DEFINITION	Regulation of repressor genes using nucleic acid molecules.	
ACCESSION	BD259547	
VERSION	BD259547.1 GI:33069317	
KEYWORDS	JP 2002541795-A/7340.	
SOURCE	unidentified	
ORGANISM	unclassified	
REFERENCE	1 (bases 1 to 17)	
AUTHORS	Blatt, L., Zwick, M., Payco, P. and Mcswiggen, J.	
TITLE	Regulation of repressor genes using nucleic acid molecules	
JOURNAL	Patent: JP 2002541795-A 7340 10-DEC-2002;	
COMMENT	RIBOZYME PHARMACEUTICALS INC	
OS	Eukaryote	
PN	JP 2002541795-A/7340	
PD	10-DEC-2002	
PF	11-APR-2000 JP 2000611654	
PR	12-APR-1999 US 60/129390	
PI	LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAYCO, JAMES MCSWIGGEN	
PC	PC	
C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC		
C12P21/02,		
PC		
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC		
C12R1:91),		
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N5/00, C12N5/00,		
PC A61K37/02,		
PC (C12N5/00, C12R1:91)		
CC	Regulation of repressor genes using nucleic acid molecules	

```

Key          Location/Qualifiers
FT          source          1..17
            /organism="Eukaryote".
FEATURES
    source          1..17
                    /organism="unidentified"
                    /mol_type="genomic DNA"
                    /db_xref="taxon:32644"

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          307 CTGGGCTTGCC 319
            |||||
            2 CTGGGCTTGCC 14

RESULT 318
LOCUS          153289          17 bp          DNA          linear          PAT 07-OCT-1997
DEFINITION          Sequence 1030 from patent US 5646042.
ACCESSION          153289
VERSION          153289.1 GI:2474492
KEYWORDS
SOURCE          .
ORGANISM          Unknown.
REFERENCE          1 (bases 1 to 17)
AUTHORS          Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE          C-myb targeted ribozymes
JOURNAL          Patent: US 5646042-A 1032 08-JUL-1997;
FEATURES
    source          1..17
                    /organism="unknown"
                    /mol_type="unassigned DNA"

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1242 CACTAGTATTCA 1254
            |||||
            5 CACTAGTATTCA 17

RESULT 319
LOCUS          153291          17 bp          DNA          linear          PAT 07-OCT-1997
DEFINITION          Sequence 1032 from patent US 5646042.
ACCESSION          153291
VERSION          153291.1 GI:2474494
KEYWORDS
SOURCE          .
ORGANISM          Unknown.
REFERENCE          1 (bases 1 to 17)
AUTHORS          Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE          C-myb targeted ribozymes
JOURNAL          Patent: US 5646042-A 1032 08-JUL-1997;
FEATURES
    source          1..17
                    /organism="unknown"
                    /mol_type="unassigned DNA"

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1243 ACTAGTATTTCAG 1255
            |||||
            1 ACTAGTATTTCAG 13

```

```

RESULT 320
LOCUS          153776          17 bp          DNA          linear          PAT 07-OCT-1997
DEFINITION          Sequence 1517 from patent US 5646042.
ACCESSION          153776
VERSION          153776.1 GI:2474979
KEYWORDS
SOURCE          .
ORGANISM          Unknown.
REFERENCE          1 (bases 1 to 17)
AUTHORS          Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE          C-myb targeted ribozymes
JOURNAL          Patent: US 5646042-A 1517 08-JUL-1997;
FEATURES
    source          1..17
                    /organism="unknown"
                    /mol_type="unassigned DNA"

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1050 GTTGCTGGAAGTG 1062
            |||||
            17 GTTGCTGGAAGTG 5

RESULT 321
LOCUS          153778          17 bp          DNA          linear          PAT 07-OCT-1997
DEFINITION          Sequence 1519 from patent US 5646042.
ACCESSION          153778
VERSION          153778.1 GI:2474981
KEYWORDS
SOURCE          .
ORGANISM          Unknown.
REFERENCE          1 (bases 1 to 17)
AUTHORS          Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE          C-myb targeted ribozymes
JOURNAL          Patent: US 5646042-A 1519 08-JUL-1997;
FEATURES
    source          1..17
                    /organism="unknown"
                    /mol_type="unassigned DNA"

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1050 GTTGCTGGAAGTG 1062
            |||||
            16 GTTGCTGGAAGTG 4

RESULT 322
LOCUS          ARI86780          17 bp          DNA          linear          PAT 20-APR-2002
DEFINITION          Sequence 2268 from patent US 6346398.
ACCESSION          ARI86780
VERSION          ARI86780.1 GI:20232745
KEYWORDS
SOURCE          .
ORGANISM          Unknown.
REFERENCE          1 (bases 1 to 17)
AUTHORS          Payco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE          Method and reagent for the treatment of diseases or conditions
JOURNAL          Patent: US 6346398-A 2268 12-FEB-2002;
FEATURES
    Location/Qualifiers

```

```
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 691 ATGTCCATTCTCA 703
|||||
5 ATGTCCATTCTCA 17

RESULT 323
AR186781 17 bp DNA linear PAT 20-APR-2002
LOCUS Sequence 2269 from patent US 6346398.
DEFINITION AR186781
ACCESSION AR186781.1 GI:20232746
VERSION
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 2269 12-FEB-2002;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 691 ATGTCCATTCTCA 703
|||||
1 ATGTCCATTCTCA 13

RESULT 324
AR323411 17 bp RNA linear PAT 17-AUG-2003
LOCUS AR323411
DEFINITION Sequence 813 from patent US 6566127.
ACCESSION AR323411
VERSION AR323411.1 GI:33709219
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 813 20-MAY-2003;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 691 ATGTCCATTCTCA 703
|||||
5 ATGTCCATTCTCA 17

RESULT 325
AR323412 17 bp RNA linear PAT 17-AUG-2003
LOCUS AR323412
DEFINITION Sequence 814 from patent US 6566127.
ACCESSION AR323412
VERSION AR323412.1 GI:33709220
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 814 20-MAY-2003;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 691 ATGTCCATTCTCA 703
|||||
1 ATGTCCATTCTCA 13

RESULT 326
AR327352 17 bp RNA linear PAT 17-AUG-2003
LOCUS AR327352
DEFINITION Sequence 4754 from patent US 6566127.
ACCESSION AR327352
VERSION AR327352.1 GI:33713160
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4754 20-MAY-2003;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 691 ATGTCCATTCTCA 703
|||||
1 ATGTCCATTCTCA 13

RESULT 327
AR327387 17 bp RNA linear PAT 17-AUG-2003
LOCUS AR327387
DEFINITION Sequence 4789 from patent US 6566127.
ACCESSION AR327387
VERSION AR327387.1 GI:33713195
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4789 20-MAY-2003;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2216 TGGTGACAGCTCC 2228
|||||
16 TGGTGACAGCTCC 4
```

```
LOCUS AR323412 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 814 from patent US 6566127.
ACCESSION AR323412
VERSION AR323412.1 GI:33709220
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 814 20-MAY-2003;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 691 ATGTCCATTCTCA 703
|||||
1 ATGTCCATTCTCA 13

RESULT 326
AR327352 17 bp RNA linear PAT 17-AUG-2003
LOCUS AR327352
DEFINITION Sequence 4754 from patent US 6566127.
ACCESSION AR327352
VERSION AR327352.1 GI:33713160
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4754 20-MAY-2003;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2216 TGGTGACAGCTCC 2228
|||||
16 TGGTGACAGCTCC 4

RESULT 327
AR327387 17 bp RNA linear PAT 17-AUG-2003
LOCUS AR327387
DEFINITION Sequence 4789 from patent US 6566127.
ACCESSION AR327387
VERSION AR327387.1 GI:33713195
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4789 20-MAY-2003;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2216 TGGTGACAGCTCC 2228
|||||
16 TGGTGACAGCTCC 4
```

```

/organism="unknown"
/mol_type="unassigned RNA"

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      328  CTTCGCTTGTTCC 340
      |||||
Db      16  CTTCGCTTGTTCC 4

RESULT 328
AR327651      AR327651      17 bp      RNA      linear      PAT 17-AUG-2003
LOCUS      Sequence 5053 from patent US 6566127.
DEFINITION  AR327651
ACCESSION   AR327651
VERSION     AR327651.1 GI:33713459
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS     Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE       Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
JOURNAL     Patent: US 6566127-A 5053 20-MAY-2003;
FEATURES
SOURCE      Location/Qualifiers
            1..17
            /organism="unknown"
            /mol_type="unassigned RNA"

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1917 TGGGAGCCAGCTG 1929
      |||||
Db      2   TGGGAGCCAGCTG 14

RESULT 329
AR327652      AR327652      17 bp      RNA      linear      PAT 17-AUG-2003
LOCUS      Sequence 5054 from patent US 6566127.
DEFINITION  AR327652
ACCESSION   AR327652
VERSION     AR327652.1 GI:33713460
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS     Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE       Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
JOURNAL     Patent: US 6566127-A 5054 20-MAY-2003;
FEATURES
SOURCE      Location/Qualifiers
            1..17
            /organism="unknown"
            /mol_type="unassigned RNA"

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1917 TGGGAGCCAGCTG 1929
      |||||
Db      1   TGGGAGCCAGCTG 13

RESULT 330
AR327792      AR327792      17 bp      RNA      linear      PAT 17-AUG-2003
LOCUS

```

```

DEFINITION  Sequence 5194 from patent US 6566127.
ACCESSION   AR327792
VERSION     AR327792.1 GI:33713600
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS     Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE       Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
JOURNAL     Patent: US 6566127-A 5194 20-MAY-2003;
FEATURES
SOURCE      Location/Qualifiers
            1..17
            /organism="unknown"
            /mol_type="unassigned RNA"

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      691  ATGTCCATTCTCA 703
      |||||
Db      4   ATGTCCATTCTCA 16

RESULT 331
AR327793      AR327793      17 bp      RNA      linear      PAT 17-AUG-2003
LOCUS      Sequence 5195 from patent US 6566127.
DEFINITION  AR327793
ACCESSION   AR327793
VERSION     AR327793.1 GI:33713601
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS     Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE       Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
JOURNAL     Patent: US 6566127-A 5195 20-MAY-2003;
FEATURES
SOURCE      Location/Qualifiers
            1..17
            /organism="unknown"
            /mol_type="unassigned RNA"

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      691  ATGTCCATTCTCA 703
      |||||
Db      3   ATGTCCATTCTCA 15

RESULT 332
AX672226/c    AX672226/c    17 bp      DNA      linear      PAT 27-MAR-2003
LOCUS      Sequence 671 from Patent WO03004526.
DEFINITION  AX672226
ACCESSION   AX672226
VERSION     AX672226.1 GI:29330574
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE    1
AUTHORS     Telerman,A., Amson,R. and Tufinder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
JOURNAL     Patent: WO 03004526-A 671 16-JAN-2003;
            Molecular Engines Laboratories (FR)

```

```
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  Best Local Similarity 100.0%; Pred. No. 3.6e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2147 AAGAGGCGCTAT 2159
Db 17 AAGAGGCGCTAT 5

RESULT 333
AX722951 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 638 from Patent WO03025176.
ACCESSION AX722951
VERSION AX722951.1 GI:30423452
KEYWORDS
SOURCE
  Mus musculus (house mouse)
ORGANISM
  Mus musculus
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
  1
  Telerman,A., Amson,R. and Tuijnder,M.
  Sequences involved in phenomena of tumour suppression, tumour
  reversion, apoptosis and/or virus resistance and their use as
  medicines
  Patent: WO 03025176-A 638 27-MAR-2003;
  Molecular Engines Laboratories (FR)
JOURNAL
  Location/Qualifiers
    1..17
      /organism="Mus musculus"
      /mol_type="unassigned DNA"
      /db_xref="taxon:10090"
FEATURES
  source

Query Match
  Best Local Similarity 100.0%; Pred. No. 3.6e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 959 TGCTCTGGGGATC 971
Db 13 TGCTCTGGGGATC 1

RESULT 334
AX730455 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 2089 from Patent WO03025175.
ACCESSION AX730455
VERSION AX730455.1 GI:30509798
KEYWORDS
SOURCE
  Homo sapiens (human)
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Telerman,A., Amson,R. and Tuijnder,M.
  Sequences involved in phenomena of tumour suppression, tumour
  reversion, apoptosis and/or virus resistance and their use as
  medicines
  Patent: WO 03025175-A 2089 27-MAR-2003;
  Molecular Engines Laboratories (FR)
JOURNAL
  Location/Qualifiers
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"
FEATURES
  source

Query Match
  Best Local Similarity 100.0%; Pred. No. 3.6e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2138 TCTTTCTGAAGG 2150
Db 3 TCTTTCTGAAGG 15
```

```
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 829 CAACGAACGAGA 841
Db 15 CAACGAACGAGA 3

RESULT 335
AX732634 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 4268 from Patent WO03025175.
ACCESSION AX732634
VERSION AX732634.1 GI:30511977
KEYWORDS
SOURCE
  Homo sapiens (human)
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Telerman,A., Amson,R. and Tuijnder,M.
  Sequences involved in phenomena of tumour suppression, tumour
  reversion, apoptosis and/or virus resistance and their use as
  medicines
  Patent: WO 03025175-A 4268 27-MAR-2003;
  Molecular Engines Laboratories (FR)
JOURNAL
  Location/Qualifiers
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"
FEATURES
  source

Query Match
  Best Local Similarity 100.0%; Pred. No. 3.6e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1364 CCCAGGCTGTGGA 1376
Db 15 CCCAGGCTGTGGA 3

RESULT 336
AX735420 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 1010 from Patent WO03025177.
ACCESSION AX735420
VERSION AX735420.1 GI:30514697
KEYWORDS
SOURCE
  Homo sapiens (human)
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
  Telerman,A., Amson,R. and Tuijnder,M.
  Sequences involved in phenomena of tumour suppression, tumour
  reversion, apoptosis and/or resistance to viruses and the use
  thereof as medicaments
  Patent: WO 03025177-A 1010 27-MAR-2003;
  Molecular Engines Laboratories (FR)
JOURNAL
  Location/Qualifiers
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"
FEATURES
  source

Query Match
  Best Local Similarity 100.0%; Pred. No. 3.6e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2138 TCTTTCTGAAGG 2150
Db 3 TCTTTCTGAAGG 15
```



```

RESULT 337
AX735658
LOCUS AX735658 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1248 from Patent WO03025177.
ACCESSION AX735658
VERSION AX735658.1 GI:30514935
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
JOURNAL
FEATURES
source
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2027 ACAGCCAGTTACA 2039
Db 5 ACAGCCAGTTACA 17
|||||
|||||

RESULT 338
AX802040/c
LOCUS AX802040 17 bp DNA linear PAT 24-NOV-2003
DEFINITION Sequence 179 from Patent WO03057913.
ACCESSION AX802040
VERSION AX802040.1 GI:38500964
KEYWORDS
SOURCE
ORGANISM Bos taurus (cow)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
JOURNAL Bovidae; Bovinae; Bos.
BIO MERIEUX (FR)
FEATURES
source
1.17
/organism="Bos taurus"
/mol_type="unassigned DNA"
/db_xref="taxon:9913"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 860 GCGTAAACAGAGA 872
Db 13 GCGTAAACAGAGA 1
|||||
|||||

RESULT 339
BD198661
LOCUS BD198661 17 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
ACCESSION molecule participating in vasculogenic response.
BD198661

```

```

VERSION BD198661.1 GI:33008431
KEYWORDS JP 2002509721-A/1687.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
JOURNAL 1 (bases 1 to 17)
COMMENT Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A.
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
Patent: JP 2002509721-A 1687 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/1687
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00/A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1.17
/organism="Homo sapiens (human)"
1.17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 911 GCTTATTCTGTG 923
Db 2 GCTTATTCTGTG 14
|||||
|||||

RESULT 340
BD198662
LOCUS BD198662 17 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
ACCESSION molecule participating in vasculogenic response.
BD198662
VERSION BD198662.1 GI:33008432
ACCESSION JP 2002509721-A/1688.
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
JOURNAL 1 (bases 1 to 17)
COMMENT Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A.
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
Patent: JP 2002509721-A 1688 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/1688
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,

```

```

PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
CC concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
FT /organism='Homo sapiens (human)'
FEATURES
source
1..17
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 911 GCTTATTTCGTGTG 923
Db 1 GCTTATTTCGTGTG 13

RESULT 341
A31053/c 16 bp DNA linear PAT 21-AUG-1995
LOCUS A31053
DEFINITION primer DNA lpa-7 from patent WO9203550.
ACCESSION A31053
VERSION A31053.1 GI:1249289
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
artificial sequences.
1 (bases 1 to 16)
REFERENCE
AUTHORS RYEGRASS, POLLEN, ALLERGEN
TITLE Patent: WO 9203550-A 11 05-MAR-1992;
JOURNAL Location/Qualifiers
FEATURES
source
1..16
/organism='synthetic construct'
/mol_type='unassigned DNA'
/db_xref='taxon:32630'

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1439 AGTACCTTGACCGAC 1454
Db 16 AGTACCGGACGAC 1

RESULT 342
AR028650 16 bp DNA linear PAT 29-SEP-1999
LOCUS AR028650
DEFINITION Sequence 18 from patent US 5858740.
ACCESSION AR028650
VERSION AR028650.1 GI:5940623
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
1 (bases 1 to 16)
REFERENCE
AUTHORS Finer,M.H., Roberts,M.R., Dull,T.J., Zsebo,K.M., Qin,L. and
Farrson,D.A.
TITLE Method for production of high titer virus and high efficiency
retroviral mediated transduction of mammalian cells
JOURNAL Patent: US 5858740-A 18 12-JAN-1999;
FEATURES
source
1..16
/organism='unknown'
/mol_type='unassigned DNA'

```

```

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1499 AGGGCCTTGCCAGTT 1514
Db 1 AGGGCATTGCCAGCT 16

RESULT 343
AR053743 16 bp DNA linear PAT 29-SEP-1999
LOCUS AR053743
DEFINITION Sequence 18 from patent US 5834256.
ACCESSION AR053743
VERSION AR053743.1 GI:5978605
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
1 (bases 1 to 16)
REFERENCE
AUTHORS Finer,M.H., Roberts,M.R., Dull,T.J., Zsebo,K.M., Qin,L. and
Farrson,D.A.
TITLE Method for production of high titer virus and high efficiency
retroviral mediated transduction of mammalian cells
JOURNAL Patent: US 5834256-A 18 10-NOV-1998;
FEATURES
source
1..16
/organism='unknown'
/mol_type='unassigned DNA'

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1499 AGGGCCTTGCCAGTT 1514
Db 1 AGGGCATTGCCAGCT 16

RESULT 344
AR069284/c 16 bp DNA linear PAT 18-FEB-2000
LOCUS AR069284
DEFINITION Sequence 23 from patent US 5891631.
ACCESSION AR069284
VERSION AR069284.1 GI:7220172
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
1 (bases 1 to 16)
REFERENCE
AUTHORS Goldstein,J.L., Brown,M.S., Briggs,M.R. and Wang,X.
TITLE Methods relating tosterol regulatory element binding proteins
JOURNAL Patent: US 5891631-A 23 06-APR-1999;
FEATURES
source
1..16
/organism='unknown'
/mol_type='unassigned DNA'

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 780 GCAGGAGAGAGTGTTT 795
Db 16 GCAGGGGAGAGAGTGT 1

RESULT 345
AR126826/c 16 bp DNA linear PAT 16-MAY-2001
LOCUS AR126826
DEFINITION Sequence 16 from patent US 6180368.
ACCESSION AR126826
VERSION AR126826.1 GI:14113419

```

KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE
AUTHORS 1 (bases 1 to 16)
TITLE Singh,M.Bir., Knox,R.Bruce., Smith,P., Avjiloglu,A.,
Theerakulpitue,P. and Hough,T.
JOURNAL Ryegrass pollen allergen
Patent: US 6180368-A 16 30-JAN-2001;
FEATURES Location/Qualifiers
1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1439 AGTACTGGACCGCAC 1454
Db 16 AGTACCGGACGCGCAC 1

RESULT 346
LOCUS AR137189 16 bp DNA linear PAT 16-JUN-2001
DEFINITION Sequence 16 from patent US 6197313.
ACCESSION AR137189
VERSION AR137189.1 GI:14478698
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE
AUTHORS 1 (bases 1 to 16)
TITLE Singh,M.Bir., Knox,R.Bruce., Smith,P., Avjiloglu,A.,
Theerakulpitue,P. and Hough,T.
JOURNAL Ryegrass pollen allergen
Patent: US 6197313-A 16 06-MAR-2001;
FEATURES Location/Qualifiers
1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1439 AGTACTGGACCGCAC 1454
Db 16 AGTACCGGACGCGCAC 1

RESULT 347
LOCUS AR146243 16 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 18 from patent US 6218187.
ACCESSION AR146243
VERSION AR146243.1 GI:15109432
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE
AUTHORS 1 (bases 1 to 16)
TITLE Finer,M.H., Dull,T.J., Zeebo,K.M., Cooke,K. and Parnon,D.A.
Method for production of high titer virus and high efficiency
retroviral mediated transduction of mammalian cells
JOURNAL Patent: US 6218187-A 18 17-APR-2001;
FEATURES Location/Qualifiers
1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1499 AGGCGCTTGTCCAGTT 1514
Db 1 AGGCGCATGTCCAGCT 16

RESULT 348
LOCUS AR156010 16 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 16 from patent US 6239269.
ACCESSION AR156010
VERSION AR156010.1 GI:15124063
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE
AUTHORS 1 (bases 1 to 16)
TITLE Singh,M.Bir., Knox,R.Bruce., Smith,P., Avjiloglu,A.,
Theerakulpitue,P. and Hough,T.
JOURNAL Ryegrass pollen allergen
Patent: US 6239269-A 16 29-MAY-2001;
FEATURES Location/Qualifiers
1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1439 AGTACTGGACCGCAC 1454
Db 16 AGTACCGGACGCGCAC 1

RESULT 349
LOCUS AR178197 16 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 16 from patent US 6319494.
ACCESSION AR178197
VERSION AR178197.1 GI:20219335
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE
AUTHORS 1 (bases 1 to 16)
TITLE Capon,D.J., Welles,A., Irving,B.A., Roberts,M.R. and Zeebo,K.
Chimeric chains for receptor-associated signal transduction
JOURNAL Patent: US 6319494-A 16 20-NOV-2001;
FEATURES Location/Qualifiers
1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1499 AGGCGCTTGTCCAGTT 1514
Db 1 AGGCGCATGTCCAGCT 16

RESULT 350
LOCUS I18842 16 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 23 from patent US 5498696.
ACCESSION I18842
VERSION I18842.1 GI:1599197
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 16)
TITLE Briggs,M.R., Brown,M.S., Goldstein,J.L. and Wang,X.
JOURNAL Sterol regulatory element binding proteins and their use in
screening assays
FEATURES Patent: US 5498696-A 23 12-MAR-1996;
Location/Qualifiers
1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 780 GCAGGAGAGGCTTT 795
Db 16 GCAGGGGAGGAGCTT 1

RESULT 351
LOCUS 122296/c 16 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 23 from patent US 5527690.
ACCESSION 122296
VERSION 122296.1 GI:1602650
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Goldstein,J.L., Brown,M.S., Briggs,M.R. and Wang,X.
TITLE Methods and compositions relating to sterol regulatory element
binding proteins
JOURNAL Patent: US 5527690-A 23 18-JUN-1996;
FEATURES Location/Qualifiers
1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 780 GCAGGAGAGGCTTT 795
Db 16 GCAGGGGAGGAGCTT 1

RESULT 352
LOCUS 173322 16 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 18 from patent US 5686279.
ACCESSION 173322
VERSION 173322.1 GI:3009461
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 16)
TITLE Fliner,M.H., Roberts,M.R., Dull,T.J., Zeebo,K.M., Qin,L. and
Parson,D.A.
JOURNAL Method for production of high titer virus and high efficiency
retroviral mediated transduction of mammalian cells
FEATURES Patent: US 5686279-A 18 11-NOV-1997;
Location/Qualifiers
1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1499 AGGCGCTGTCCAGTT 1514
Db 1 AGGCGCATGTCCAGCT 16

RESULT 353
LOCUS AR214479 16 bp mRNA linear PAT 25-SEP-2002
DEFINITION Sequence 16 from patent US 6407221.
ACCESSION AR214479
VERSION AR214479.1 GI:23312304
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 16)
TITLE Capon,D.J., Weiss,A., Irving,B.A., Roberts,M.R. and Zeebo,K.
JOURNAL Chimeric chains for receptor-associated signal transduction
pathways
FEATURES Patent: US 6407221-A 16 18-JUN-2002;
Location/Qualifiers
1..16
/organism="unknown"
/mol_type="mRNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1499 AGGCGCTGTCCAGTT 1514
Db 1 AGGCGCATGTCCAGCT 16

RESULT 354
LOCUS AR217686 16 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 26 from patent US 6416984.
ACCESSION AR217686
VERSION AR217686.1 GI:23317557
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 16)
TITLE Haseltine,W.A., Ruben,S.M., Wei,Y.-F., Adams,M.D.,
Fleischmann,R.D., Fraser,C.M., Fuldner,R.A., Kirkness,E.F. and
Rosen,C.A.
JOURNAL Human DNA mismatch repair proteins
FEATURES Patent: US 6416984-A 26 09-JUL-2002;
Location/Qualifiers
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2089 CTTCTCATCACCCAGC 2104
Db 1 CTTCTCAACACCAAGC 16

RESULT 355
LOCUS AR229701/c 16 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 16 from patent US 6451324.
ACCESSION AR229701
VERSION AR229701.1 GI:27269418

```

KEYWORDS      .
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 16)
AUTHORS        Singh,M.B., Knox,R.B., Smith,P., Avjoglou,A., Theerakulpisut,P. and
               Hough,T.
TITLE          Ryegrass pollen allergen
JOURNAL        Patent: US 6451324-A 16 17-SEP-2002;
FEATURES       Location/Qualifiers
               1..16
               /organism="unknown"
               /mol_type="genomic DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1439 AGTACTGACACCGCAC 1454
Db      16 AGTACCCGACGCGCAC 1

RESULT 356
AR234410
LOCUS          AR234410          16 bp      DNA          linear      PAT 20-DEC-2002
DEFINITION     Sequence 64 from patent US 6458567.
ACCESSION      AR234410
VERSION        AR234410.1  GI:27277098
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 16)
AUTHORS        Barber,J.R., Welch,P.J., Tritz,R., Yei,S. and Yu,M.
TITLE          Hepatitis C Virus ribozymes
JOURNAL        Patent: US 6458567-A 64 01-OCT-2002;
FEATURES       Location/Qualifiers
               1..16
               /organism="unknown"
               /mol_type="genomic DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      713 GTGCAGTCTGAGCTT 728
Db      1 GTGCAGTCTGAGCT 16

RESULT 357
AR255710
LOCUS          AR255710          16 bp      DNA          linear      PAT 20-DEC-2002
DEFINITION     Sequence 24 from patent US 6482606.
ACCESSION      AR255710
VERSION        AR255710.1  GI:27304807
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 16)
AUTHORS        Adame,M.D., Flaischmann,R.D., Fraser,C.M., Fuldner,R.A.,
               Kirkness,E.F., Haseilaine,W.A., Rosen,C.A., Ruden,S. and Wei,Y.-F.
TITLE          Human DNA mismatch repair polynucleotides
JOURNAL        Patent: US 6482606-A 24 19-NOV-2002;
FEATURES       Location/Qualifiers
               1..16
               /organism="unknown"
               /mol_type="genomic DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;

```

```

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2089 CTTCTCATCACCAGC 2104
Db      1 CTTCTCATCACCAGC 16

RESULT 358
AR274833
LOCUS          AR274833          16 bp      DNA          linear      PAT 10-APR-2003
DEFINITION     Sequence 18 from patent US 6506604.
ACCESSION      AR274833
VERSION        AR274833.1  GI:29707382
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 16)
AUTHORS        Finer,M.H., Dull,T.J., Zeebo,K.M., Cooke,K. and Parson,D.A.
TITLE          Method for production of high titer virus and high efficiency
               retroviral mediated transduction of mammalian cells
JOURNAL        Patent: US 6506604-A 18 14-JAN-2003;
FEATURES       Location/Qualifiers
               1..16
               /organism="unknown"
               /mol_type="genomic DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1499 AGGCGCTGTCCAGTT 1514
Db      1 AGGCGCTGTCCAGCT 16

RESULT 359
AR328356
LOCUS          AR328356          16 bp      RNA          linear      PAT 17-AUG-2003
DEFINITION     Sequence 5758 from patent US 6566127.
ACCESSION      AR328356
VERSION        AR328356.1  GI:33714164
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 16)
AUTHORS        Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE          Method and reagent for the treatment of diseases or conditions
               related to levels of vascular endothelial growth factor receptor
JOURNAL        Patent: US 6566127-A 5758 20-MAY-2003;
FEATURES       Location/Qualifiers
               1..16
               /organism="unknown"
               /mol_type="unassigned RNA"

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1992 TATCTGATGATGCC 2007
Db      1 TATCTGATGATGAC 16

RESULT 360
AR328357
LOCUS          AR328357          16 bp      RNA          linear      PAT 17-AUG-2003
DEFINITION     Sequence 5759 from patent US 6566127.
ACCESSION      AR328357
VERSION        AR328357.1  GI:33714165
KEYWORDS
SOURCE         Unknown.

```

```

ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 16)
AUTHORS      Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE      Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6566127-A 5759 20-MAY-2003;
FEATURES      Location/Qualifiers
              1..16
              /organism="unknown"
              /mol_type="unassigned RNA"

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      2016 CCTGATGCACAAACGC 2031
Db      1 CCTGATGCTGACAC 16

RESULT 361
LOCUS      AR329600 16 bp RNA linear PAT 17-AUG-2003
DEFINITION      Sequence 7002 from patent US 6566127.
ACCESSION      AR329600
VERSION      AR329600.1 GI:33715408
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 16)
AUTHORS      Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE      Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6566127-A 7002 20-MAY-2003;
FEATURES      Location/Qualifiers
              1..16
              /organism="unknown"
              /mol_type="unassigned RNA"

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1469 CCAGTGTGTGTGTGAC 1484
Db      1 CCAGTGGGCTGATGAC 16

RESULT 362
LOCUS      AR364124 16 bp DNA linear PAT 03-SEP-2003
DEFINITION      Sequence 4 from patent US 5256545.
ACCESSION      AR364124
VERSION      AR364124.1 GI:34426450
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 16)
AUTHORS      Brown, M.S., Goldstein, J.L., Russell, D.W. and Sudhof, T.C.
TITLE      Sterol Regulatory Elements
JOURNAL      Patent: US 5256545-A 4 26-OCT-1993;
FEATURES      Location/Qualifiers
              1..16
              /organism="unknown"
              /mol_type="genomic DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Oy      780 GCAGGGAGAGGTGTT 795
Db      16 GCAGGGGAGGAGGTTT 1

RESULT 363
LOCUS      AR364150 16 bp DNA linear PAT 03-SEP-2003
DEFINITION      Sequence 33 from patent US 5256545.
ACCESSION      AR364150
VERSION      AR364150.1 GI:34426476
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 16)
AUTHORS      Brown, M.S., Goldstein, J.L., Russell, D.W. and Sudhof, T.C.
TITLE      Sterol Regulatory Elements
JOURNAL      Patent: US 5256545-A 33 26-OCT-1993;
FEATURES      Location/Qualifiers
              1..16
              /organism="unknown"
              /mol_type="genomic DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      780 GCAGGGAGAGGTGTT 795
Db      1 GCAGGGGAGGAGGTTT 16

RESULT 364
LOCUS      AR382044 16 bp DNA linear PAT 18-DEC-2003
DEFINITION      Sequence 26 from patent US 6610477.
ACCESSION      AR382044
VERSION      AR382044.1 GI:40090449
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 16)
AUTHORS      Haseltine, W.A., Ruben, S.M., Wei, Y.-F., Adams, M.D.,
              Fleischmann, R.D., Fraser, C.M., Fuldner, R.A., Kirnesh, E.F.,
              Rosen, C.A., Vogelstein, B., Kinzler, K.W., Nicolaides, N.C. and
              Papadopoulos, N.
TITLE      Human DNA mismatch repair proteins
JOURNAL      Patent: US 6610477-A 26 26-AUG-2003;
FEATURES      Location/Qualifiers
              1..16
              /organism="unknown"
              /mol_type="genomic DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      2089 CTTCTCATCACCCAGC 2104
Db      1 CTTCTCAACACCAAGC 16

RESULT 365
LOCUS      AR391495 16 bp DNA linear PAT 18-DEC-2003
DEFINITION      Sequence 107 from patent US 6613520.
ACCESSION      AR391495
VERSION      AR391495.1 GI:40114993
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.

```

```

REFERENCE      Unclassified.
AUTHORS        1 (bases 1 to 16)
TITLE          Methods for the survey and genetic analysis of populations
JOURNAL        Patent: US 6613520-A 107 02-SEP-2003;
FEATURES       Location/Qualifiers
SOURCE         1. .16
               /organism="unknown"
               /mol_type="genomic DNA"

Query Match    0.64; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY             39 CTGCGTCCCGGAGCT 54
Db             1 CTGCGCGCGCGAGCT 16

RESULT 366
LOCUS          AR399532                16 bp    DNA
DEFINITION     Sequence 24 from patent US 6620619.
ACCESSION      AR399532
VERSION        AR399532.1 GI:40141634
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 16)
AUTHORS        Haseltine, W.A., Ruben, S., Wei, Y.-F., Adams, M.D., Fleischmann, R.D.,
               Fraser, C.M., Rosen, C.A., Fuldner, R.A. and Kirkness, E.F.
TITLE          Human DNA mismatch repair protein
JOURNAL        Patent: US 6620619-A 24 16-SEP-2003;
FEATURES       Location/Qualifiers
SOURCE         1. .16
               /organism="unknown"
               /mol_type="genomic DNA"

Query Match    0.64; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY             2089 CTTCTCATCACCCAGC 2104
Db             1 CTTCTCAACACCAAGC 16

RESULT 367
LOCUS          AR436078                16 bp    RNA
DEFINITION     Sequence 337 from patent US 6656731.
ACCESSION      AR436078
VERSION        AR436078.1 GI:40199162
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 16)
AUTHORS        Eksstein, F., Ludwig, J. and Beigelman, L.
TITLE          Nucleic acid catalysts with endonuclease activity
JOURNAL        Patent: US 6656731-A 337 02-DEC-2003;
FEATURES       Location/Qualifiers
SOURCE         1. .16
               /organism="unknown"
               /mol_type="unassigned RNA"

Query Match    0.64; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY             604 ATGGCCATTCATTCT 619
               |||||

```

```

Db             16 ATGGCCATTCATTCT 1

RESULT 368
LOCUS          AX281975                16 bp    DNA
DEFINITION     Sequence 107 from Patent WO0177392.
ACCESSION      AX281975
VERSION        AX281975.1 GI:16609226
KEYWORDS
SOURCE         unidentified
ORGANISM       unidentified
REFERENCE      1
AUTHORS        Aabhy, M.
TITLE          Methods for the survey and genetic analysis of populations
JOURNAL        Patent: WO 0177392-A 107 18-OCT-2001;
FEATURES       Location/Qualifiers
SOURCE         1. .16
               /organism="unidentified"
               /mol_type="unassigned DNA"
               /db_xref="taxon:32644"
               /note="unidentified soil organism"

Query Match    0.64; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY             39 CTGCGTCCCGGAGCT 54
Db             1 CTGCGCGCGCGAGCT 16

RESULT 369
LOCUS          AX708805                16 bp    DNA
DEFINITION     Sequence 21 from Patent WO02095071.
ACCESSION      AX708805
VERSION        AX708805.1 GI:29564532
KEYWORDS
SOURCE         synthetic construct
ORGANISM       synthetic construct
REFERENCE      1
AUTHORS        Plassterk, R.H.
TITLE          Means and methods for identifying genes and proteins involved in
               the prevention and/or repair of a replication error
JOURNAL        Patent: WO 02095071-A 21 28-NOV-2002;
FEATURES       Koninklijke Nederlandse Akademie van Wetenschappen (NLI)
SOURCE         Location/Qualifiers
               1. .16
               /organism="synthetic construct"
               /mol_type="unassigned DNA"
               /db_xref="taxon:32630"
               /note="Unc-93 (el500) mutation in C. elegans msh-6"

Query Match    0.64; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY             1161 CCAGAGTTTAGGAA 1176
Db             16 CCCGAGATTAGGAA 1

RESULT 370
LOCUS          AX802066                16 bp    DNA
DEFINITION     Sequence 205 from Patent WO03057913.
ACCESSION      AX802066
VERSION        AX802066.1 GI:38500990
KEYWORDS

```

SOURCE Saimo salar (Atlantic salmon)
ORGANISM Saimo salar
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Euteleostei;
Protacanthopterygii; Salmoniformes; Salmonidae; Saimo.
REFERENCE 1
AUTHORS Mahlat,C., Desvarene,S., Babola,O., Lacroix,B. and bello Pigem,N.
TITLE Method for the detection and/or identification of the original
JOURNAL animal species in animal matter contained in a sample
BIO MERIEUX (FR)
Patent: WO 03057913-A 205 17-JUL-2003;
FEATURES
source Location/Qualifiers
1..16
/organism="Saimo salar"
/mol_type="unassigned DNA"
/db_xref="taxon:8030"
Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 77 TACTGCTACTCTCGC 92
Db 1 TACTTCTACTCTCAGC 16
RESULT 371
BD166014/C 16 bp DNA linear PAT 17-JAN-2003
LOCUS Ryegrass pollen allergen.
DEFINITION BD166014
ACCESSION BD166014 GI:27871826
VERSION JP 2002159298-A/13.
KEYWORDS Lolium perenne
SOURCE Lolium perenne
ORGANISM Lolium perenne
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Pooidae; Poae; Lolium.
REFERENCE 1 (bases 1 to 16)
AUTHORS Singh,M.B., Hough,T., Knox,R.B., Theerakulpisut,P., Smith,P. and
AVTIOGLU,A.
TITLE Ryegrass pollen allergen
JOURNAL Patent: JP 2002159298-A 13 04-JUN-2002;
COMMENT THE UNIVERSITY OF MELBOURNE
OS Lolium perenne (perennial ryegrass)
PN JP 2002159298-A/13
PD 04-JUN-2002
PF 05-SEP-2001 JP 2001269054
PR 17-AUG-1990 AU PK1823
PI MOHAN BIR SINGH, TERRYN HOUGH, ROBERT BRUCE KNOX, PIYADA PI
THEERAKULPISUT,
PC PENNELOPE SMITH,ASIL AVTIOGLU
PC C12N15/09,A61K38/00,A61K39/36,A61P27/14,A61P37/08,C07K14/415,
PC C12N1/15,
PC C12N1/19,C12N1/21,C12N5/10,G01N33/53,C12N15/00,C12N5/00,A61K37/PC
02
CC Ryegrass pollen allergen
FH Key Location/Qualifiers
FT source 1..16
/organism="Lolium perenne (perennial FT
ryegrass)"
Location/Qualifiers
1..16
/organism="Lolium perenne"
/mol_type="genomic DNA"
/db_xref="taxon:4522"
Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1439 AGTACCTGACCGCAGC 1454

Db 16 AGTACCGGACCGCAGC 1
RESULT 372
BD167992 16 bp DNA linear PAT 17-JAN-2003
LOCUS Method of constructing mutation DNA library and utilization
DEFINITION thereof.
ACCESSION BD167992
VERSION BD167992.1 GI:27873804
KEYWORDS WO 0226964-A/39
SOURCE WO 0226964-A/39
ORGANISM synthetic construct
synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 16)
AUTHORS Tsuji,T. and Yanagawa,H.
TITLE Method of constructing mutation DNA library and utilization thereof
JOURNAL Patent: WO 0226964-A 39 04-APR-2002;
COMMENT MITSUBISHI CHEMICAL CORP.,TORU TSUJI,HIROSHI YANAGAWA
OS Artificial Sequence
PN WO 0226964-A/39
PD 04-APR-2002
PF 26-SEP-2001 WO 2001JP08387
PR 27-SEP-2000 JP 00P 293692,06-FEB-2001 JP 01P 029138 PI
TORU TSUJI,HIROSHI YANAGAWA
PC C12N15/09,C12P21/02
CC Description of Artificial Sequence:Synthesized FH Key
FT source 1..16
Location/Qualifiers
/organism="Artificial Sequence".
1..16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1804 GGCTGACCGCAGAGC 1819
Db 1 GGCTGACCTGCGAC 16
RESULT 373
BD181119 16 bp DNA linear PAT 15-MAY-2003
LOCUS Human DNA mismatch repair proteins.
DEFINITION BD181119
ACCESSION BD181119.1 GI:30792037
VERSION JP 2002325588-A/23.
KEYWORDS synthetic construct
synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 16)
AUTHORS Haseltine,W.A., Ruben,S.M., Wei,Y.F., Adams,M.D., Fleischmann,R.D.,
Fraser,C.M., Fuldner,R.A., Kirkness,E.F. and Rosen,C.A.
TITLE Human DNA mismatch repair proteins
JOURNAL Patent: JP 2002325588-A 23 12-NOV-2002;
COMMENT HUMAN GENOME SCIENCES INC
OS Artificial Sequence
PN JP 2002325588-A/23
PD 12-NOV-2002
PF 25-JAN-2002 JP 2002016830
PR 27-JAN-1994 US 08/187757,16-MAR-1994 US 08/210143 PR
23-AUG-1994 US 08/294312
PI WILIAM A HASELTINE,STEVEN M RUBEN,YING FEI WEI,MARK D ADAMS,
PI ROBERT D FLEISCHMANN,CLAIRE M FRASER,REBECCA A FULDNER, EWEN F
PI KIRKNESS,
PI CRAIG A ROSEN
PC C12N15/09,C07K14/47,C12P21/02,C1201/68//C12P21/02,C12R1:19),


```

PC C12N15/00
CC hMLH1 sense primer
FH Key Location/Qualifiers
FT source 1..16 /organism='Artificial Sequence'
FEATURES
    source
        Location/Qualifiers
            1..16 /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2089 CTTCTCATCACCCGCG 2104
Db 1 CTTCTCAACACGACG 16

RESULT 374
LOCUS AR028970 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 9 from patent US 5858981.
ACCESSION AR028970
VERSION AR028970.1 GI:5940943
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Schreiber,A.D. and Park,J.-G.
TITLE Method of inhibiting phagocytosis
JOURNAL Patent: US 5858981-A 9 12-JAN-1999;
FEATURES
    source
        Location/Qualifiers
            1..17 /organism="unknown"
            /mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1109 CTCTGTGGCCATGCC 1124
Db 1 CGCTGTCAACCATGCC 16

RESULT 375
LOCUS AR046049 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 842 from patent US 5817796.
ACCESSION AR046049
VERSION AR046049.1 GI:5967514
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwigen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
JOURNAL Patent: US 5817796-A 842 06-OCT-1998;
FEATURES
    source
        Location/Qualifiers
            1..17 /organism="unknown"
            /mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1430 AAATATTGAGTACT 1445
Db 1 AAATATTGAGTACT 1445

```

```

Db 17 AAATACTGAGTACT 2

RESULT 376
LOCUS AR057432 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1636 from patent US 5837542.
ACCESSION AR057432
VERSION AR057432.1 GI:5983009
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwigen,J., Sullivan,S. and
Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1636 17-NOV-1998;
FEATURES
    source
        Location/Qualifiers
            1..17 /organism="unknown"
            /mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTCTCTGTCTCT 578
Db 2 CTCTGTCTCTGTCTCT 17

RESULT 377
LOCUS AR057439 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1643 from patent US 5837542.
ACCESSION AR057439
VERSION AR057439.1 GI:5983016
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwigen,J., Sullivan,S. and
Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1643 17-NOV-1998;
FEATURES
    source
        Location/Qualifiers
            1..17 /organism="unknown"
            /mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTCTCTGTCTCT 578
Db 2 CTCTGTCTCTGTCTCT 17

RESULT 378
LOCUS AR057596 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1800 from patent US 5837542.
ACCESSION AR057596
VERSION AR057596.1 GI:5983173
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwigen,J., Sullivan,S. and

```

Draper,K.G.
Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1800 17-NOV-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTCCTGGTCCT 578
Db 2 CTCTGCTCTGGTCCT 17

RESULT 379
LOCUS AR104994 17 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 28 from patent US 6096501.
ACCESSION AR104994
VERSION AR104994.1 GI:12818591
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Foxall,P.A. and Berger,D.M.
TITLE Assay for Chlamydia trachomatis by amplification and detection of
JOURNAL Chlamydia trachomatis cryptic plasmid
FEATURES Patent: US 6096501-A 28 01-AUG-2000;
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1679 GACAGCTGCTGTGA 1694
Db 1 GACAGCTTGTGATGA 16

RESULT 380
LOCUS AR115190 17 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1636 from patent US 6132967.
ACCESSION AR115190
VERSION AR115190.1 GI:14095512
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
TITLE Ribozyme treatment of diseases or conditions related to levels of
JOURNAL intercellular adhesion molecule-1 (ICAM-1)
FEATURES Patent: US 6132967-A 1636 17-OCT-2000;
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTCCTGGTCCT 578
Db 1 ||||| ||||| |||||

Db 2 CTCTGCTCTGGTCCT 17

RESULT 381
LOCUS AR115197 17 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1643 from patent US 6132967.
ACCESSION AR115197
VERSION AR115197.1 GI:14095519
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
TITLE Ribozyme treatment of diseases or conditions related to levels of
JOURNAL intercellular adhesion molecule-1 (ICAM-1)
FEATURES Patent: US 6132967-A 1643 17-OCT-2000;
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTCCTGGTCCT 578
Db 2 CTCTGCTCTGGTCCT 17

RESULT 382
LOCUS AR115354 17 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1800 from patent US 6132967.
ACCESSION AR115354
VERSION AR115354.1 GI:14095676
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
TITLE Ribozyme treatment of diseases or conditions related to levels of
JOURNAL intercellular adhesion molecule-1 (ICAM-1)
FEATURES Patent: US 6132967-A 1800 17-OCT-2000;
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTCCTGGTCCT 578
Db 2 CTCTGCTCTGGTCCT 17

RESULT 383
LOCUS AR145857 17 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 28 from patent US 6218125.
ACCESSION AR145857
VERSION AR145857.1 GI:15109046
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
TITLE Ribozyme treatment of diseases or conditions related to levels of
JOURNAL intercellular adhesion molecule-1 (ICAM-1)
FEATURES Patent: US 6218125-A 28 01-AUG-2000;
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTCCTGGTCCT 578
Db 2 CTCTGCTCTGGTCCT 17

```

REFERENCE 1 (bases 1 to 17)
AUTHORS Foxall,P.A. and Berger,D.M.
TITLE Assay for Chlamydia trachomatis by amplification and detection of
JOURNAL Chlamydia trachomatis cryptic plasmid
FEATURES
    source
        1. .17
            /organism="unknown"
            /mol_type="unassigned DNA"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1679 GACAGCTGCTGTGA 1694
Db 1 GACAGCTTGTGATGA 16

RESULT 384
LOCUS ARI56852 17 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 9 from patent US 6242427.
ACCESSION ARI56852
VERSION ARI56852.1 GI:15125556
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Schreiber,A.D. and Park,J.-G.
TITLE Methode of inhibiting phagocytosis
JOURNAL Patent: US 6242427-A 9 05-JUN-2001;
FEATURES
    source
        1. .17
            /location/Qualifiers
            /organism="unknown"
            /mol_type="unassigned DNA"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1109 CTCGTGCGCCATGCC 1124
Db 1 CGCTGTGAGCATGCC 16

RESULT 385
LOCUS BD241028 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Process for enzymatically modifying pectin.
ACCESSION BD241028
VERSION BD241028.1 GI:33050798
KEYWORDS JP 2002525071-A/6.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS Christensen,T.M.T.E., Pedersen,A.A., Brunstedt,J. and
Mikkelsen,J.D.
TITLE Process for enzymatically modifying pectin
JOURNAL Patent: JP 2002525071-A 6 13-AUG-2002;
COMMENT
    OS Artificial Sequence
    PN JP 2002525071-A/6
    PD 13-AUG-2002
    PR 15-SEP-1999 JP 2000570357
    PR 16-SEP-1998 GB 9820195.7
    PI TOVE MARTEL IDA ELSE CHRISTENSEN,ANETTE
    AMSTRUP PEDERSEN,JANNE
    FT BRUNSTEDT,
    JOERN DALGAARD MIKKELSEN
    PC C12P19/04,A23I1/05//C12N9/18,C12N15/09,C12N15/09,A23I1/04, PC

```

```

C12N15/00,
PC C12N15/00
CC Description of Artificial Sequence: Primer
FH Key Location/Qualifiers
FT source
    1. .17
        /organism="Artificial Sequence".
FEATURES
    source
        1. .17
            /location/Qualifiers
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 129 ATTCTCCCTGCTGCTG 144
Db 2 ATTATCCATGCTGCTG 17

RESULT 386
LOCUS BD241330/c 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Methods and products related to genotyping and DNA analysis.
ACCESSION BD241330
VERSION BD241330.1 GI:33051100
KEYWORDS JP 2002525127-A/277.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 17)
AUTHORS Landers,J.E., Jordan,B., Houseman,D.E. and Charest,A.
TITLE Methods and products related to genotyping and DNA analysis
JOURNAL Patent: JP 2002525127-A 277 13-AUG-2002;
COMMENT
    OS Homo sapiens (human)
    PN JP 2002525127-A/277
    PD 13-AUG-2002 JP 2000572407
    PF 24-SEP-1999 JP 2000572407
    PR 25-SEP-1998 US 60/101757
    PI JOHN E LANDERS, BARBARA JORDAN, DAVID E HOUSEMAN, ALAIN CHAREST
    C12N15/09, C12Q1/68, G01N33/53, G01N33/566, G01N33/58, G01N37/00, PC
    G01N37/00
    CC Methods and products related to genotyping and DNA analysis FH
    Key Location/Qualifiers
    FT source
        1. .17
            /location/Qualifiers
            /organism="Homo sapiens (human)".
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 267 CCAGGCTGCTGACT 282
Db 16 CCAGAGCTGCTGACT 1

RESULT 387
LOCUS BD254112 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254112
VERSION BD254112.1 GI:33063882
KEYWORDS JP 2002541795-A/1905.
SOURCE unidentified

```

ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 1905 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/1905
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC C12P21/02,C12P21/02//A61K31/71.1,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
FEATURES
source Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1700 AGCCCTTCCCATTA 1715
|||
2 AGCCCTTCCCATTA 17
Db 2 AGCCCTTCCCATTA 17
RESULT 388
BD254113 17 bp DNA linear PAT 17-JUN-2003
LOCUS BD254113
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254113.1 GI:33063883
VERSION JP 2002541795-A/1906.
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unidentified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 1906 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/1906
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC C12P21/02,C12P21/02//A61K31/71.1,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
FEATURES
source Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

FEATURES
source Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1700 AGCCCTTCCCATTA 1715
|||
1 AGCCCTTCCCATTA 16
Db 1 AGCCCTTCCCATTA 16
RESULT 389
BD254344/c
LOCUS BD254344 17 bp DNA linear PAT 17-JUN-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254344
VERSION BD254344.1 GI:33064114
KEYWORDS JP 2002541795-A/2137.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2137 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT OS Eukaryote
PN JP 2002541795-A/2137
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC C12P21/02,C12P21/02//A61K31/71.1,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
FEATURES
source Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1843 GCTCAGTAAAGTCTG 1858
|||
16 GCCACAGTAAAGTCTG 1
Db 16 GCCACAGTAAAGTCTG 1
RESULT 390
BD254398
LOCUS BD254398 17 bp DNA linear PAT 17-JUN-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254398
VERSION BD254398.1 GI:33064168
KEYWORDS JP 2002541795-A/2191.
SOURCE unidentified
ORGANISM unidentified
unclassified.

REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2192 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC

COMMENT OS Eukaryote
PN JP 2002541795-A/2191
PD 10-DEC-2002
PR 11-APR-2000 JP 2000611654
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N5/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

FEATURES
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1700 AGCCCTTCCTCCAGATA 1715
|||||
2 AGCCCTTCCTCCAGATA 17

Db

RESULT 391
BD254399 17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254399
VERSION BD254399.1 GI:33064169
KEYWORDS JP 2002541795-A/2192.
SOURCE unidentified
ORGANISM unidentified
unclassified.

REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2192 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC

COMMENT OS Eukaryote
PN JP 2002541795-A/2192
PD 10-DEC-2002
PR 11-APR-2000 JP 2000611654
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09, A61K38/00, A61P43/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N5/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

FEATURES
source

/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1700 AGCCCTTCCTCCAGATA 1715
|||||
1 AGCCCTTCCTCCAGATA 16

Db

RESULT 392
BD254560 17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254560
VERSION BD254560.1 GI:33064330
KEYWORDS JP 2002541795-A/2353.
SOURCE unidentified
ORGANISM unidentified
unclassified.

REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2353 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC

COMMENT OS Eukaryote
PN JP 2002541795-A/2353
PD 10-DEC-2002
PR 11-APR-2000 JP 2000611654
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09, A61K38/00, A61P43/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N5/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

FEATURES
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1161 CCAAGAGTTTAAAGGAA 1176
|||||
1 CCAAGAGTTTAAAGGAA 16

Db

RESULT 393
BD254561 17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254561
VERSION BD254561.1 GI:33064331
KEYWORDS JP 2002541795-A/2354.
SOURCE unidentified
ORGANISM unidentified
unclassified.

REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.

```

TITLE      Regulation of repressor genes using nucleic acid molecules
JOURNAL    Patent: JP 2002541795-A 2354 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS Eukaryote
            PN JP 2002541795-A/2354
            PD 10-DEC-2002
            PF 11-APR-2000 JP 2000611654
            PR 12-APR-1999 US 60/129390
            PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
            C12R1:91),
            PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC A61K37/02,
            PC (C12N5/00,C12R1:91)
            CC Regulation of repressor genes using nucleic acid molecules FH
            Key Location/Qualifiers
            FT source 1..17
            /organism='Eukaryote'.

FEATURES
source
1..17 location/Qualifiers
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1163 AGAAGTTTAAAGGAAAA 1178
|||||
2 AGAAGTTTAAAGGAAATA 17

Db
2 AGAAGTTTAAAGGAAATA 17

RESULT 394
BD254562 17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254562
VERSION BD254562.1 GI:33064332
KEYWORDS JP 2002541795-A/2355.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2355 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS Eukaryote
            PN JP 2002541795-A/2355
            PD 10-DEC-2002
            PF 11-APR-2000 JP 2000611654
            PR 12-APR-1999 US 60/129390
            PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
            C12R1:91),
            PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC A61K37/02,
            PC (C12N5/00,C12R1:91)
            CC Regulation of repressor genes using nucleic acid molecules FH
            Key Location/Qualifiers
            FT source 1..17
            /organism='Eukaryote'.

FEATURES
source
1..17 location/Qualifiers
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1163 AGAAGTTTAAAGGAAAA 1178
|||||
2 AGAAGTTTAAAGGAAATA 17

Db
2 AGAAGTTTAAAGGAAATA 17

RESULT 395
BD255504 17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD255504
VERSION BD255504.1 GI:33065274
KEYWORDS JP 2002541795-A/3297.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 3297 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS Eukaryote
            PN JP 2002541795-A/3297
            PD 10-DEC-2002
            PF 11-APR-2000 JP 2000611654
            PR 12-APR-1999 US 60/129390
            PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
            C12R1:91),
            PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC A61K37/02,
            PC (C12N5/00,C12R1:91)
            CC Regulation of repressor genes using nucleic acid molecules FH
            Key Location/Qualifiers
            FT source 1..17
            /organism='Eukaryote'.

FEATURES
source
1..17 location/Qualifiers
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1376 AGTACTGCTCTCCAT 1391
|||||
2 AGTACTACTCTCCAT 17

Db
2 AGTACTACTCTCCAT 17

RESULT 396
BD259177 17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD259177
VERSION BD259177.1 GI:33068947
KEYWORDS JP 2002541795-A/6970.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 6970 10-DEC-2002;

```

```

/db_xref="taxon:32644"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1163 AGAAGTTTAAAGGAAAA 1178
|||||
1 AGAAGTTTAAAGGAAATA 16

Db
1 AGAAGTTTAAAGGAAATA 16

RESULT 395
BD255504 17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD255504
VERSION BD255504.1 GI:33065274
KEYWORDS JP 2002541795-A/3297.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 3297 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS Eukaryote
            PN JP 2002541795-A/3297
            PD 10-DEC-2002
            PF 11-APR-2000 JP 2000611654
            PR 12-APR-1999 US 60/129390
            PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
            C12R1:91),
            PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC A61K37/02,
            PC (C12N5/00,C12R1:91)
            CC Regulation of repressor genes using nucleic acid molecules FH
            Key Location/Qualifiers
            FT source 1..17
            /organism='Eukaryote'.

FEATURES
source
1..17 location/Qualifiers
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1376 AGTACTGCTCTCCAT 1391
|||||
2 AGTACTACTCTCCAT 17

Db
2 AGTACTACTCTCCAT 17

RESULT 396
BD259177 17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD259177
VERSION BD259177.1 GI:33068947
KEYWORDS JP 2002541795-A/6970.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 6970 10-DEC-2002;

```

```

COMMENT      RIBOZYME PHARMACEUTICALS INC
OS           Eukaryote
PN           JP 2002541795-A/6970
PD           10-DEC-2002
PR           11-APR-2000 JP 2000611654
PI           LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N5/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key          Location/Qualifiers
FT source    1..17
              /organism='Eukaryote',
              location/Qualifiers
              1..17
              /organism='unidentified'
              /mol_type='genomic DNA'
              /db_xref='taxon:32644'

FEATURES
source
Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1162 CAGAAAGTTTGGGAAA 1177
Db      1 CAGAACTTAGCGAAA 16

RESULT 397
BD259430/c      17 bp      DNA      linear      PAT 17-JUL-2003
LOCUS           Regulation of repressor genes using nucleic acid molecules.
DEFINITION      BD259430
ACCESSION      BD259430.1 GI:33069200
VERSION        BD259430.1
KEYWORDS       UP 2002541795-A/7223.
SOURCE         unidentified
ORGANISM       unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS       Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE         Regulation of repressor genes using nucleic acid molecules
JOURNAL       Patent: JP 2002541795-A 7223 10-DEC-2002;
              RIBOZYME PHARMACEUTICALS INC
COMMENT      OS Eukaryote
PN JP 2002541795-A/7223
PD 10-DEC-2002
PR 11-APR-2000 JP 2000611654
PI 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N5/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key          Location/Qualifiers
FT source    1..17
              /organism='Eukaryote',
              location/Qualifiers
              1..17
              /organism='unidentified'
              /mol_type='genomic DNA'
              /db_xref='taxon:32644'

FEATURES
source
Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      43 CTCGCCGAGCTTCTC 58
Db      16 CTCGCCGAGATTCTC 1

RESULT 399
BD270691
LOCUS           BD270691      17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION      Selection system.
ACCESSION      BD270691
VERSION        BD270691.1 GI:33080459
KEYWORDS       UP 2002514413-A/18.
SOURCE         synthetic construct
ORGANISM       artificial sequence.
REFERENCE      1 (bases 1 to 17)
AUTHORS       Riechmann,L., Kristensen,P., Jeslin,J.L. and Winter,G.P.
TITLE         Selection System
JOURNAL       Patent: JP 2002514413-A 18 21-MAY-2002;
              DIVERSYS LTD
COMMENT      OS Artificial Sequence

```

```

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      44 TCCCGGAGCTTCTCT 59
Db      17 TCCCGGAGATTCTCT 2

RESULT 398
BD259431/c      17 bp      DNA      linear      PAT 17-JUL-2003
LOCUS           BD259431
DEFINITION      Regulation of repressor genes using nucleic acid molecules.
ACCESSION      BD259431
VERSION        BD259431.1 GI:33069201
KEYWORDS       UP 2002541795-A/7224.
SOURCE         unidentified
ORGANISM       unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS       Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE         Regulation of repressor genes using nucleic acid molecules
JOURNAL       Patent: JP 2002541795-A 7224 10-DEC-2002;
              RIBOZYME PHARMACEUTICALS INC
COMMENT      OS Eukaryote
PN JP 2002541795-A/7224
PD 10-DEC-2002
PR 11-APR-2000 JP 2000611654
PI 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N5/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key          Location/Qualifiers
FT source    1..17
              /organism='Eukaryote',
              location/Qualifiers
              1..17
              /organism='unidentified'
              /mol_type='genomic DNA'
              /db_xref='taxon:32644'

FEATURES
source
Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      43 CTCGCCGAGCTTCTC 58
Db      16 CTCGCCGAGATTCTC 1

RESULT 399
BD270691
LOCUS           BD270691      17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION      Selection system.
ACCESSION      BD270691
VERSION        BD270691.1 GI:33080459
KEYWORDS       UP 2002514413-A/18.
SOURCE         synthetic construct
ORGANISM       artificial sequence.
REFERENCE      1 (bases 1 to 17)
AUTHORS       Riechmann,L., Kristensen,P., Jeslin,J.L. and Winter,G.P.
TITLE         Selection System
JOURNAL       Patent: JP 2002514413-A 18 21-MAY-2002;
              DIVERSYS LTD
COMMENT      OS Artificial Sequence

```

```

PN      JP 2002514413-A/18
PD      21-MAY-2002
PR      13-MAY-1999 JP 2000548446
PR      13-MAY-1998 GB 9810222.9,13-MAY-1998 GB 9810228.8 PI
LUTZ RIECHMANN,PETER KRISTENSEN,JEAN LUC JESTIN,GREGORY PAUL PI
WINTER
PC      C12N15/00,C12N7/02,C12N15/00
CC      Description of Artificial Sequence:PRIMER/POLYPEPTIDE FH Key
TITLE   Location/Qualifiers
FT      source 1..17
        /organism='Artificial Sequence'.
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      2203 TGCTACTGGCCGATGG 2218
Db      2 TGCACCTGGCCATGG 17

RESULT 400
BD270691/c
LOCUS   BD270691
DEFINITION Selection system.
ACCESSION BD270691.1 GI:33080459
VERSION   JP 2002514413-A/18.
KEYWORDS  synthetic construct
SOURCE    synthetic construct
ORGANISM  artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS   Riechmann,L., Kristensen,P., Jestin,J.L. and Winter,G.P.
TITLE     Selection system
JOURNAL   Patent: JP 2002514413-A 18 21-MAY-2002;
DIVERSYS LTD
OS      Artificial Sequence
PN      JP 2002514413-A/18
PD      21-MAY-2002
PR      13-MAY-1999 JP 2000548446
PR      13-MAY-1998 GB 9810222.9,13-MAY-1998 GB 9810228.8 PI
LUTZ RIECHMANN,PETER KRISTENSEN,JEAN LUC JESTIN,GREGORY PAUL PI
WINTER
PC      C12N15/00,C12N7/02,C12N15/00
CC      Description of Artificial Sequence:PRIMER/POLYPEPTIDE FH Key
TITLE   Location/Qualifiers
FT      source 1..17
        /organism='Artificial Sequence'.
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      755 CCATGGCCGACGTGCA 770
Db      17 CCATGGCCGACGTGCA 2

RESULT 401
E35301
LOCUS   E35301
DEFINITION Assay of Chlamydia trachomatis by amplifying and detecting
Chlamydia trachomatis-latent plasmid.

```

```

ACCESSION E35301
VERSION   E35301.1 GI:13019028
KEYWORDS  JP 1999221088-A/28.
SOURCE    unidentified
ORGANISM  unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS   Paul,A.F. and Dororesu,M.B.
TITLE     Assay of Chlamydia trachomatis by amplifying and detecting
Chlamydia trachomatis-latent plasmid
JOURNAL   Patent: JP 1999221088-A 28 17-AUG-1999;
BECTON DICKINSON & CO
OS      Unidentified
PN      JP 1999221088-A/28
PD      17-AUG-1999
PR      04-NOV-1998 JP 1998312798
PR      04-NOV-1997 US 08/963927
PI      PAUL A FOKUSOUL,DORORESU M BAGA
PC      C12N15/09,C12Q1/04,C12Q1/68,G01N33/569,G01N33/571,C12N15/00 CC
CC      Strandedness: Single;
        Topology: Linear;
        Key Key
        FT source 1..17
        /organism='Unidentified'.
FEATURES
source
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1679 GACAGCTGCTGTGGA 1694
Db      1 GACAGCTTGTGATGGA 16

RESULT 402
146652
LOCUS   146652
DEFINITION Sequence 631 from patent US 5639612.
ACCESSION 146652
VERSION   146652.1 GI:2470617
KEYWORDS
SOURCE    Unknown.
ORGANISM  Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS   Mitsuhashi,M. and Cooper,A.
TITLE     Method for detecting polynucleotides with immobilized
polynucleotide probes identified based on T.sub.m
JOURNAL   Patent: US 5639612-A 631 17-JUN-1997;
        Location/Qualifiers
FEATURES
source
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred.No.3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      550 ACGGCGCCCTCTGCG 565
Db      2 ACGGCGCCCTCTGCG 17

RESULT 403
153101/c
LOCUS   153101
DEFINITION Sequence 842 from patent US 5646042.
ACCESSION 153101

```


VERSION 153101.1 GI:2474304
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwigen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 842 08-JUL-1997;
FEATURES
LOCATION/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1430 AAATATTGACTACT 1445
DB 17 AAATCTGACTACT 2

RESULT 404
LOCUS 184477/c 17 bp DNA linear PAT 04-APR-1998
DEFINITION Sequence 1 from patent US 5635940.
ACCESSION 184477
VERSION 184477.1 GI:3021997
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Dymnac,R.T. and Crkvenjakov,R.B.
TITLE Method of sequencing by hybridization of oligonucleotide probes
JOURNAL Patent: US 5695940-A 1 09-DEC-1997;
FEATURES
LOCATION/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1666 CAGCCACCGGGGAC 1681
DB 17 CAGCCACCGAGGAC 2

RESULT 405
LOCUS 184484 17 bp DNA linear PAT 04-APR-1998
DEFINITION Sequence 8 from patent US 5695940.
ACCESSION 184484
VERSION 184484.1 GI:3022004
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Dymnac,R.T. and Crkvenjakov,R.B.
TITLE Method of sequencing by hybridization of oligonucleotide probes
JOURNAL Patent: US 5695940-A 8 09-DEC-1997;
FEATURES
LOCATION/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1666 CAGCCACCGGGGAC 1681
DB 17 CAGCCACCGAGGAC 2

RESULT 406
LOCUS ARI86248/c 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 1736 from patent US 6346398.
ACCESSION ARI86248
VERSION ARI86248.1 GI:20232213
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwigen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 1736 12-FEB-2002;
FEATURES
LOCATION/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 881 CCCGAGTGATCTCT 896
DB 17 CGCTGAGTGATCTCT 2

RESULT 407
LOCUS ARI86747 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 2235 from patent US 6346398.
ACCESSION ARI86747
VERSION ARI86747.1 GI:20232712
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwigen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 2235 12-FEB-2002;
FEATURES
LOCATION/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1637 CAGTGCTGCCCTGCT 1652
DB 1 CAGTGCTTCCAGCT 16

RESULT 408
LOCUS ARI88407 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 3895 from patent US 6346398.
ACCESSION ARI88407
VERSION ARI88407.1 GI:20234372
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

```

REFERENCE      Unclassified.
AUTHORS        1 (bases 1 to 17)
TITLE          Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
JOURNAL        Method and reagent for the treatment of diseases or conditions
FEATURES       related to levels of vascular endothelial growth factor receptor
SOURCE         Patent: US 6346398-A 3895 12-FEB-2002;
               Location/Qualifiers
               1..17
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1430 AAATATTTGAGTACCT 1445
        |||||
        2 AAATTTTGAGCACCCT 17

RESULT 409
LOCUS      AR188415      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 3903 from patent US 6346398.
ACCESSION  AR188415
VERSION     AR188415.1 GI:20234380
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    Unclassified.
AUTHORS      1 (bases 1 to 17)
TITLE        Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
JOURNAL      Method and reagent for the treatment of diseases or conditions
FEATURES     related to levels of vascular endothelial growth factor receptor
SOURCE       Patent: US 6346398-A 3903 12-FEB-2002;
               Location/Qualifiers
               1..17
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      91 GCCGACTGGTGCTGC 106
        |||||
        17 GCCCAGCTGATGCTGC 2

RESULT 410
LOCUS      AR188667/c      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 4155 from patent US 6346398.
ACCESSION  AR188667
VERSION     AR188667.1 GI:20234632
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    Unclassified.
AUTHORS      1 (bases 1 to 17)
TITLE        Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
JOURNAL      Method and reagent for the treatment of diseases or conditions
FEATURES     related to levels of vascular endothelial growth factor receptor
SOURCE       Patent: US 6346398-A 4155 12-FEB-2002;
               Location/Qualifiers
               1..17
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      685 ACTCATGTCATTC 700
        |||||
        2 ACTCTCTTTCATTC 17

```

```

Qy      2120 AGCAGGCTGACACAT 2135
        |||||
        17 AGAGGTTTGACACAT 2

RESULT 411
LOCUS      AR190412      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 5900 from patent US 6346398.
ACCESSION  AR190412
VERSION     AR190412.1 GI:20236377
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    Unclassified.
AUTHORS      1 (bases 1 to 17)
TITLE        Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
JOURNAL      Method and reagent for the treatment of diseases or conditions
FEATURES     related to levels of vascular endothelial growth factor receptor
SOURCE       Patent: US 6346398-A 5900 12-FEB-2002;
               Location/Qualifiers
               1..17
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1207 AAGGAGGCTGTGGCCT 1222
        |||||
        2 AGGAGGTCTGTGGCCT 17

RESULT 412
LOCUS      AR190474      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 5962 from patent US 6346398.
ACCESSION  AR190474
VERSION     AR190474.1 GI:20236439
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    Unclassified.
AUTHORS      1 (bases 1 to 17)
TITLE        Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
JOURNAL      Method and reagent for the treatment of diseases or conditions
FEATURES     related to levels of vascular endothelial growth factor receptor
SOURCE       Patent: US 6346398-A 5962 12-FEB-2002;
               Location/Qualifiers
               1..17
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      685 ACTCATGTCATTC 700
        |||||
        2 ACTCTCTTTCATTC 17

RESULT 413
LOCUS      AR190475      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 5963 from patent US 6346398.
ACCESSION  AR190475
VERSION     AR190475.1 GI:20236440
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    Unclassified.

```

```

REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5963 12-FEB-2002;
FEATURES
SOURCE Location/Qualifiers
1.17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 685 ACTCTCATGTCATTC 700
1 ACTCTCTTTCATTC 16

RESULT 414
LOCUS AR286467 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 839 from patent US 6528640.
ACCESSION AR286467
VERSION AR286467.1 GI:29724063
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
Metulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 839 04-MAR-2003;
FEATURES
SOURCE Location/Qualifiers
1.17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 1206 GAAGAGGCTGTGGCC 1221
17 GAAGGGGCTGGGCC 2

RESULT 415
LOCUS AR322879 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 281 from patent US 6566127.
ACCESSION AR322879
VERSION AR322879.1 GI:33708687
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 281 20-MAY-2003;
FEATURES
SOURCE Location/Qualifiers
1.17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 881 CCTGAGTATTCCT 896

```

```

Db 17 CGCTGAGTATTCCT 2
17 CGCTGAGTATTCCT 2

RESULT 416
LOCUS AR323378 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 780 from patent US 6566127.
ACCESSION AR323378
VERSION AR323378.1 GI:33709186
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 780 20-MAY-2003;
FEATURES
SOURCE Location/Qualifiers
1.17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 1637 CAGTGCTGCCCTGCT 1652
1 CAGTGCTGCCAGCT 16

RESULT 417
LOCUS AR324260 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1662 from patent US 6566127.
ACCESSION AR324260
VERSION AR324260.1 GI:33710068
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 1662 20-MAY-2003;
FEATURES
SOURCE Location/Qualifiers
1.17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 2 AAATTTTGAGCACCCT 17
17 AAATTTTGAGTACT 1445

RESULT 418
LOCUS AR324268 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1670 from patent US 6566127.
ACCESSION AR324268
VERSION AR324268.1 GI:33710076
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)

```

AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.
 TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
 JOURNAL Patent: US 6566127-A 1670 20-MAY-2003;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 91 GCCGACTGGTGCTGC 106
 Db 17 GCCCAGTGGATGCTGC 2

RESULT 419
 AR324520/c 17 bp RNA linear PAT 17-AUG-2003
 LOCUS AR324520
 DEFINITION Sequence 1922 from patent US 6566127.
 ACCESSION AR324520
 VERSION AR324520.1 GI:33710328
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 1 (bases 1 to 17)
 REFERENCE Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.
 AUTHORS Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
 JOURNAL Patent: US 6566127-A 1922 20-MAY-2003;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2120 AGCAGGCTGACCACAT 2135
 Db 17 AGAAGTTGACCACAT 2

RESULT 420
 AR325337 17 bp RNA linear PAT 17-AUG-2003
 LOCUS AR325337
 DEFINITION Sequence 2739 from patent US 6566127.
 ACCESSION AR325337
 VERSION AR325337.1 GI:33711145
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 1 (bases 1 to 17)
 REFERENCE Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.
 AUTHORS Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
 JOURNAL Patent: US 6566127-A 2739 20-MAY-2003;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1207 AAGGAGCTGTGGCCT 1222
 Db 17 AAGGAGCTGTGGCCT 1222

Db 2 AGGAGTCTGTGGCCT 17

RESULT 421
 AR325397 17 bp RNA linear PAT 17-AUG-2003
 LOCUS AR325397
 DEFINITION Sequence 2799 from patent US 6566127.
 ACCESSION AR325397
 VERSION AR325397.1 GI:33711205
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 1 (bases 1 to 17)
 REFERENCE Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.
 AUTHORS Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
 JOURNAL Patent: US 6566127-A 2799 20-MAY-2003;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 685 ACTCTCATGTCATTC 700
 Db 2 ACTCTCTTTCATTC 17

RESULT 422
 AR325398 17 bp RNA linear PAT 17-AUG-2003
 LOCUS AR325398
 DEFINITION Sequence 2800 from patent US 6566127.
 ACCESSION AR325398
 VERSION AR325398.1 GI:33711206
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 1 (bases 1 to 17)
 REFERENCE Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.
 AUTHORS Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
 JOURNAL Patent: US 6566127-A 2800 20-MAY-2003;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 685 ACTCTCATGTCATTC 700
 Db 1 ACTCTCTTTCATTC 16

RESULT 423
 AR326829 17 bp RNA linear PAT 17-AUG-2003
 LOCUS AR326829/c
 DEFINITION Sequence 4231 from patent US 6566127.
 ACCESSION AR326829
 VERSION AR326829.1 GI:33712637
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 1 (bases 1 to 17)
 REFERENCE Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.

TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4231 20-MAY-2003;
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1637 CAGTGGCTGCCCTGCT 1652
Db 17 CAGTGTCTGGCTGCT 2

RESULT 424
AR326830/c 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 4232 from patent US 6566127.
ACCESSION AR326830
VERSION AR326830.1 GI:33712638
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4232 20-MAY-2003;
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1637 CAGTGGCTGCCCTGCT 1652
Db 16 CAGTGTCTGGCTGCT 1

RESULT 425
AR327109/c 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 4511 from patent US 6566127.
ACCESSION AR327109
VERSION AR327109.1 GI:33712917
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4511 20-MAY-2003;
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 883 CTGAGTATTCCTGA 898
Db 17 CTGAGTATTCCTCA 2

RESULT 426
AR327110/c 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 4512 from patent US 6566127.
ACCESSION AR327110
VERSION AR327110.1 GI:33712918
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4512 20-MAY-2003;
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 881 CCTGAGTATTCCT 896
Db 16 CGTGTGATGCTCT 1

RESULT 427
AR327761 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 5163 from patent US 6566127.
ACCESSION AR327761
VERSION AR327761.1 GI:33713569
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 5163 20-MAY-2003;
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1637 CAGTGGCTGCCCTGCT 1652
Db 2 CAGTGGCTGCCCTGCT 17

RESULT 428
AR328881/c 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 6283 from patent US 6566127.
ACCESSION AR328881
VERSION AR328881.1 GI:33714689
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions

related to levels of vascular endothelial growth factor receptor
Patent: US 6566127-A 6283 20-MAY-2003;

JOURNAL
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 91 GCCGACTGGTGGTGC 106
Db 16 GCCCACTGATGCTGC 1

RESULT 429
LOCUS AR329248 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6650 from patent US 6566127.
ACCESSION AR329248
VERSION AR329248.1 GI:33715056
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwigen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6650 20-MAY-2003;
FEATURES Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2120 AGCAGGCTGACCACAT 2135
Db 16 AGAGGTTGACCACT 1

RESULT 430
LOCUS AR398457 17 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 838 from patent US 6617438.
ACCESSION AR398457
VERSION AR398457.1 GI:40136287
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman, L., Burgh, A.B., Beaudry, A., Karpelsky, A., Matulich-Adamic, J., Sweedler, D. and Zinnen, S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 838 09-SEP-2003;
FEATURES Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1206 GAAGAGGCTGTGGCC 1221
Db 17 GAAGGGGCTGTGGCC 2

RESULT 431
LOCUS AR402394 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 734 from patent US 6623962.
ACCESSION AR402394
VERSION AR402394.1 GI:40149844
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 17)

AUTHORS Akhtar, S., Fell, P. and McSwigen, J.A.
TITLE Enzymatic nucleic acid treatment of diseases of conditions related to levels of epidermal growth factor receptors
JOURNAL Patent: US 6623962-A 734 23-SEP-2003;
FEATURES Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1425 AGAGAAATATTGAG 1440
Db 17 AGAGAAATATTGAG 2

RESULT 432
LOCUS AR403935 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 8 from patent US 6627429.
ACCESSION AR403935
VERSION AR403935.1 GI:40151859
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Christensen, T.M.I.E., Pedersen, A.A., Brunstedt, J. and Mikkeisen, J.D.
TITLE Process for enzymatically modifying pectin
JOURNAL Patent: US 6627429-A 8 30-SEP-2003;
FEATURES Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 129 ATTCTCCCTGCTGTG 144
Db 2 ATTATCATGCTGTG 17

RESULT 433
LOCUS AR412050 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 9 from patent US 6638764.
ACCESSION AR412050
VERSION AR412050.1 GI:40164599
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Schreiber, A.D. and Park, J.-G.
TITLE Methods of inhibiting phagocytosis
JOURNAL Patent: US 6638764-A 9 28-OCT-2003;

FEATURES
source

Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1109 CTCGTGCGCCATGCC 1124
DB 1 CGCTGTCAGCCATGCC 16

RESULT 434
AR434370/c

LOCUS AR434370 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 793 from patent US 6656700.
ACCESSION AR434370
VERSION AR434370.1 GI:40197213
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y. and Shannon,M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 793 02-DEC-2003;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1809 GACCCAGAGCCACT 1824
DB 17 GACCCAGAGTCACACT 2

RESULT 435
AR434371/c

LOCUS AR434371 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 794 from patent US 6656700.
ACCESSION AR434371
VERSION AR434371.1 GI:40197214
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y. and Shannon,M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 794 02-DEC-2003;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1809 GACCCAGAGCCACT 1824
DB 16 GACCCAGAGTCACACT 1

RESULT 436
AR434378/c
LOCUS AR434378 17 bp DNA linear PAT 18-DEC-2003

DEFINITION Sequence 801 from patent US 6656700.
ACCESSION AR434378
VERSION AR434378.1 GI:40197221
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y. and Shannon,M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 801 02-DEC-2003;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 TTCCACAGAACGAGA 841
DB 17 TTCTACAGAACGAGA 2

RESULT 437
AR434379/c

LOCUS AR434379 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 802 from patent US 6656700.
ACCESSION AR434379
VERSION AR434379.1 GI:40197222
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y. and Shannon,M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 802 02-DEC-2003;
FEATURES Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 TTCCACAGAACGAGA 841
DB 16 TTCTACAGAACGAGA 1

RESULT 438
AX010677

LOCUS AX010677 17 bp DNA linear PAT 06-SEP-2000
DEFINITION Sequence 19 from Patent WO9958655.
ACCESSION AX010677
VERSION AX010677.1 GI:9997476
KEYWORDS
SOURCE synthetic construct
ORGANISM artificial sequences.

REFERENCE 1
AUTHORS Kristensen,P., Jeslin,J.L., Winter,G.P. and Riechmann,L.
TITLE Selection system
JOURNAL Patent: WO 9958655-A 19 18-NOV-1999;
KRISTENSEN PETER (DK); JESTIN JEAN LUC (FR); MEDICAL RES COUNCIL (GB); WINTER GREGORY PAUL (GB); RIECHMANN LUTZ (GB)
FEATURES Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"

/db_xref="taxon:32630"
/note="PRIMER"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No.3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2203 TGCTACTGGCCATGG 2218
||| ||||| |||||
Db 2 TGCACCTGGCCATGG 17

RESULT 439
LOCUS AX010677/c 17 bp DNA linear PAT 06-SEP-2000
DEFINITION Sequence 19 from Patent WO958655.
ACCESSION AX010677
VERSION AX010677.1 GI:9997476
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
1 Kristensen, P., Jestin, J.L., Winter, G.P. and Riechmann, L.
AUTHORS Selection system
TITLE Patent: WO 958655-A 19 18-NOV-1999;
JOURNAL KRISTENSEN PETER (DK); JESTIN JEAN LUC (FR); MEDICAL RES COUNCIL
(GB); WINTER GREGORY PAUL (GB); RIECHMANN LUTZ (GB)
FEATURES
source Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PRIMER"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No.3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 755 CCATGGCCACGTGCA 770
||| ||||| |||||
Db 17 CCATGGCCACGTGCA 2

RESULT 440
LOCUS AX055664 17 bp DNA linear PAT 13-JAN-2001
DEFINITION Sequence 22 from Patent WO0073499.
ACCESSION AX055664
VERSION AX055664.1 GI:12228804
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 Emricella nidulans (anamorph: Aspergillus nidulans)
AUTHORS Emricella nidulans
TITLE Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
Eurotiales; Trichocomaceae; Emricella.
Smith, T., Maher, M., Martin, C., Janne, G., Rossau, R. and van der
Weide, M.
TITLE Nucleic acid probes and methods for detecting clinically important
JOURNAL fungal pathogens
PATENT: WO 0073499-A 22 07-DEC-2000;
INNOGENETICS N.V. (BE); Enterprise Ireland (trading as Bioresarch
Ireland) (IE)
FEATURES
source Location/Qualifiers
1..17
/organism="Emricella nidulans"
/mol_type="unassigned DNA"
/db_xref="taxon:162425"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No.3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 30 CGGTGCGCGTGCCTC 45
||| ||||| |||||
Db 2 CGAGTGGCGGTGCCTC 17

RESULT 441
LOCUS AX167488/c 17 bp DNA linear PAT 03-JUL-2001
DEFINITION Sequence 4 from Patent WO0142439.
ACCESSION AX167488
VERSION AX167488.1 GI:14596891
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
1

Perham, R.N. and Domingo, G.J.
AUTHORS Molecular display on multimeric protein scaffolds derived from the
TITLE e2 component of the alpha-ketoadid dehydrogenase
JOURNAL Patent: WO 0142439-A 4 14-JUN-2001;
CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB)
FEATURES
source Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No.3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 476 GCCTCTGGGTGCCCG 491
||| ||||| |||||
Db 16 GCCTCTGGGTGCCCG 1

RESULT 442
LOCUS AX214663 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 105 from Patent WO0159103.
ACCESSION AX214663
VERSION AX214663.1 GI:15524706
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Blact, L., Mcswigen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 105 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blact, Lawrence (US);
Mcswigen, James (US); Chowrira, Bharat M. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No.3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1778 GAAGCTTCAAGAAA 1793
||| ||||| |||||
Db 2 GAACACTTCAAGAAA 17

RESULT 443
LOCUS AX215471/c 17 bp RNA linear PAT 07-SEP-2001

FEATURES
source
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2001 TGATGCACGAGTCC 2016
Db 17 TTATTCACGAGTCC 2

RESULT 448
AX216891 17 bp RNA linear PAT 07-SEP-2001
LOCUS
DEFINITION Sequence 2333 from Patent W00159103.
ACCESSION AX216891
VERSION AX216891.1 GI:15526952
KEYWORDS
SOURCE
ORGANISM
synthetic construct
artificial sequences.
REFERENCE
1 Blatt, L., McSwiggen, J. and Chowrira, B.M.
AUTHORS Method and reagent for the modulation and diagnosis of cd20 and
TITLE nogo gene expression
JOURNAL Patent: WO 0159103-A 2333 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 541 GGCTCGAGACGCGC 556
Db 1 GGCTCGAGACGCGC 16

RESULT 449
AX217378 17 bp RNA linear PAT 07-SEP-2001
LOCUS
DEFINITION Sequence 2820 from Patent W00159103.
ACCESSION AX217378
VERSION AX217378.1 GI:15527439
KEYWORDS
SOURCE
ORGANISM
synthetic construct
artificial sequences.
REFERENCE
1 Blatt, L., McSwiggen, J. and Chowrira, B.M.
AUTHORS Method and reagent for the modulation and diagnosis of cd20 and
TITLE nogo gene expression
JOURNAL Patent: WO 0159103-A 2820 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1384 CTCGCATCTACCCCA 1399
Db 1 CTCGCATCTACCCCA 16

RESULT 450
AX217540/c 17 bp RNA linear PAT 07-SEP-2001
LOCUS
DEFINITION Sequence 2982 from Patent W00159103.
ACCESSION AX217540
VERSION AX217540.1 GI:15527601
KEYWORDS
SOURCE
ORGANISM
synthetic construct
artificial sequences.
REFERENCE
1 Blatt, L., McSwiggen, J. and Chowrira, B.M.
AUTHORS Method and reagent for the modulation and diagnosis of cd20 and
TITLE nogo gene expression
JOURNAL Patent: WO 0159103-A 2982 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2184 GCTCATGAGAAAAAG 2199
Db 16 GCTCATGAGAAAAATG 1

RESULT 451
AX217882/c 17 bp RNA linear PAT 07-SEP-2001
LOCUS
DEFINITION Sequence 3324 from Patent W00159103.
ACCESSION AX217882
VERSION AX217882.1 GI:15527943
KEYWORDS
SOURCE
ORGANISM
synthetic construct
artificial sequences.
REFERENCE
1 Blatt, L., McSwiggen, J. and Chowrira, B.M.
AUTHORS Method and reagent for the modulation and diagnosis of cd20 and
TITLE nogo gene expression
JOURNAL Patent: WO 0159103-A 3324 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
Location/Qualifiers
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2184 GCTCATGAGAAAAAG 2199
Db 17 GCTCATGAGAAAAATG 2

```

RESULT 452
AX218127/c
LOCUS AX218127
DEFINITION Sequence 3569 from Patent WO0159103.
ACCESSION AX218127
VERSION AX218127.1 GI:15528188
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Blact, L., Mcswiggen, J. and Chowitra, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 3569 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blact, Lawrence (US) ;
Mcswiggen, James (US) ; Chowitra, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1965 AGCATGATCCGANA 1980
17 AGGAGTATCCGANA 2

Db 17

RESULT 453
AX218281/c
LOCUS AX218281
DEFINITION Sequence 3723 from Patent WO0159103.
ACCESSION AX218281
VERSION AX218281.1 GI:15528342
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Blact, L., Mcswiggen, J. and Chowitra, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 3723 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blact, Lawrence (US) ;
Mcswiggen, James (US) ; Chowitra, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1045 TACCAATTGCTGGAAG 1060
17 TACCAATTGCTGGAAG 2

Db 17

RESULT 454
AX226997
LOCUS AX226997
DEFINITION Sequence 369 from Patent WO0157206.
ACCESSION AX226997

```

```

VERSION AX226997.1 GI:15556138
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Fattaey, A.R., Jarvis, T., Mcswiggen, J., Bocher, R.N. and Holman, P.S.
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk
JOURNAL 1) enzyme
PATENT: WO 0157206-A 369 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2207 ACTGGGCCATGTCGA 2222
1 ACTGGGACTGTGTGCA 16

Db 16

RESULT 455
AX227311/c
LOCUS AX227311
DEFINITION Sequence 683 from Patent WO0157206.
ACCESSION AX227311
VERSION AX227311.1 GI:15556452
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Fattaey, A.R., Jarvis, T., Mcswiggen, J., Bocher, R.N. and Holman, P.S.
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk
JOURNAL 1) enzyme
PATENT: WO 0157206-A 683 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2097 CACCCAGACCTCAGC 2112
16 CACCGAGCACCTCGGC 1

Db 16

RESULT 456
AX263388
LOCUS AX263388
DEFINITION Sequence 779 from Patent WO0173002.
ACCESSION AX263388
VERSION AX263388.1 GI:16512187
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Kniiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL Patent: WO 0173002-A 779 04-OCT-2001;

```

UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

FEATURES
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 917 TTCTGTGGTACCTGCT 932
||| |||||
1 TTCTGTGGTACCTGCT 16

Db

RESULT 457
AX263389/c 17 bp DNA linear PAT 26-OCT-2001
LOCUS
DEFINITION Sequence 780 from Patent W00173002.
ACCESSION AX263389
VERSION AX263389.1 GI:16512188
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Kniec,E.B., Gamper,H.B. and Rice,M.C.
JOURNAL Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 780 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

FEATURES
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 917 TTCTGTGGTACCTGCT 932
||| |||||
1 TTCTGTGGTACCTGCT 2

Db

RESULT 458
AX265515 17 bp DNA linear PAT 26-OCT-2001
LOCUS
DEFINITION Sequence 2906 from Patent W00173002.
ACCESSION AX265515
VERSION AX265515.1 GI:16514314
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Kniec,E.B., Gamper,H.B. and Rice,M.C.
JOURNAL Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 2906 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

FEATURES
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;

Best Local Similarity 87.5%; Pred. No. 3.8e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 143 TGCCACCGCGCTGCC 158
||||| |||||
2 TGCCACCGCGCTGCTC 17

Db

RESULT 459
AX265516/c 17 bp DNA linear PAT 26-OCT-2001
LOCUS
DEFINITION Sequence 2907 from Patent W00173002.
ACCESSION AX265516
VERSION AX265516.1 GI:16514315
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Kniec,E.B., Gamper,H.B. and Rice,M.C.
JOURNAL Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 2907 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

FEATURES
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 143 TGCCACCGCGCTGCC 158
||||| |||||
16 TGCCACCGCGCTGCTC 1

Db

RESULT 460
AX265711 17 bp DNA linear PAT 26-OCT-2001
LOCUS
DEFINITION Sequence 3102 from Patent W00173002.
ACCESSION AX265711
VERSION AX265711.1 GI:16514510
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Kniec,E.B., Gamper,H.B. and Rice,M.C.
JOURNAL Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
Patent: WO 0173002-A 3102 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

FEATURES
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2179 CAGCAGCTCATGAGCA 2194
||||| |||||
2 CAGCAGCAGCATGAGCA 17

Db

RESULT 461
AX265712/c

```

LOCUS       AX265712                17 bp    DNA             linear    PAT 26-OCT-2001
DEFINITION  Sequence 3103 from Patent WO0173002.
ACCESSION   AX265712
VERSION     AX265712.1  GI:16514511
KEYWORDS
SOURCE      Homo sapiens (human)
            Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE   1
AUTHORS    Kulec,E.B., Gamper,H.B. and Rice,M.C.
TITLE      Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
JOURNAL    Patent: WO 0173002-A 3103 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES
SOURCE      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2179 CAGCAGCTCATCGAGA 2194
Db      16 CAGCAGCAGCATCGAGA 1

RESULT 462
LOCUS       AX272955                17 bp    RNA             linear    PAT 29-OCT-2001
DEFINITION  Sequence 524 from Patent WO0162911.
ACCESSION   AX272955
VERSION     AX272955.1  GI:16545692
KEYWORDS
SOURCE      Homo sapiens (human)
            Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE   1
AUTHORS    Jarvis,T., von Carlwiltz,I., Mcswiggen,J.A., Hamblin,P.A. and
            Ellis,J.H.
TITLE      Method and reagent for the inhibition of grid
JOURNAL    Patent: WO 0162911-A 524 30-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
SOURCE      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2223 GGCTCTGCGAGATGCT 2238
Db      17 GGCTGCTGCGACTGCT 2

RESULT 463
LOCUS       AX421665                17 bp    RNA             linear    PAT 18-JUN-2002
DEFINITION  Sequence 1 from Patent WO0188124.
ACCESSION   AX421665
VERSION     AX421665.1  GI:21525047
KEYWORDS
SOURCE      Homo sapiens (human)
            Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

LOCUS       AX422048                17 bp    RNA             linear    PAT 18-JUN-2002
DEFINITION  Sequence 384 from Patent WO0188124.
ACCESSION   AX422048
VERSION     AX422048.1  GI:21525430
KEYWORDS
SOURCE      Homo sapiens (human)
            Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE   1
AUTHORS    Jarvis,T., von Carlwiltz,I., Mcswiggen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE      Method and reagent for the inhibition of erg
JOURNAL    Patent: WO 0188124-A 384 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
SOURCE      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      540 GGCTCGAGACGCGC 555
Db      16 GGCGCGCAGACGCGC 1

RESULT 464
LOCUS       AX422048                17 bp    RNA             linear    PAT 18-JUN-2002
DEFINITION  Sequence 384 from Patent WO0188124.
ACCESSION   AX422048
VERSION     AX422048.1  GI:21525430
KEYWORDS
SOURCE      Homo sapiens (human)
            Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE   1
AUTHORS    Jarvis,T., von Carlwiltz,I., Mcswiggen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE      Method and reagent for the inhibition of erg
JOURNAL    Patent: WO 0188124-A 384 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
SOURCE      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1531 GCCTACCCAAACGCGC 1546
Db      17 GCCTACCCAAATGCC 2

RESULT 465
LOCUS       AX422379                17 bp    RNA             linear    PAT 18-JUN-2002
DEFINITION  Sequence 715 from Patent WO0188124.
ACCESSION   AX422379
VERSION     AX422379.1  GI:21525761
KEYWORDS
SOURCE      Homo sapiens (human)
            Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE   1
AUTHORS    Jarvis,T., von Carlwiltz,I., Mcswiggen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE      Method and reagent for the inhibition of erg
JOURNAL    Patent: WO 0188124-A 715 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
SOURCE      1..17
            /organism="Homo sapiens"

```

```
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      347 TGATCTCATGGGAGC 362
          |||||
          17 TGATCTCCTGGGGGC 2

Db

RESULT 466
LOCUS      AX422704      17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 1040 from Patent WO0188124.
ACCESSION  AX422704
VERSION     AX422704.1 GI:21526086
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Jarvis,T., von Carlwiltz,I., Mcswigen,J.A., McLaughlin,F.G. and
             Randi,A.M.
TITLE       Method and reagent for the inhibition of erg
JOURNAL     Patent: WO 0188124-A 1040 22-NOV-2001;
RIBOZYME   PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
SOURCE      location/Qualifiers
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned RNA"
             /db_xref="taxon:9606"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1906 GTAGACGAGGCTGGGA 1921
          |||||
          2 GGAGACCGAGGCTGGGA 17

Db

RESULT 467
LOCUS      AX423493      17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 1829 from Patent WO0188124.
ACCESSION  AX423493
VERSION     AX423493.1 GI:21526875
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Jarvis,T., von Carlwiltz,I., Mcswigen,J.A., McLaughlin,F.G. and
             Randi,A.M.
TITLE       Method and reagent for the inhibition of erg
JOURNAL     Patent: WO 0188124-A 1829 22-NOV-2001;
RIBOZYME   PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
SOURCE      location/Qualifiers
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned RNA"
             /db_xref="taxon:9606"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1030 AAGGTGGGAATGCT 1045
          |||||
          11 |||||

Db

RESULT 468
LOCUS      AX423710      17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 2046 from Patent WO0188124.
ACCESSION  AX423710
VERSION     AX423710.1 GI:21527092
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Jarvis,T., von Carlwiltz,I., Mcswigen,J.A., McLaughlin,F.G. and
             Randi,A.M.
TITLE       Method and reagent for the inhibition of erg
JOURNAL     Patent: WO 0188124-A 2046 22-NOV-2001;
RIBOZYME   PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
SOURCE      location/Qualifiers
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned RNA"
             /db_xref="taxon:9606"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1906 GTAGACGAGGCTGGGA 1921
          |||||
          1 GGAGACCGAGGCTGGGA 16

Db

RESULT 469
LOCUS      AX423761/c      17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 2097 from Patent WO0188124.
ACCESSION  AX423761
VERSION     AX423761.1 GI:21527143
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
             Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Jarvis,T., von Carlwiltz,I., Mcswigen,J.A., McLaughlin,F.G. and
             Randi,A.M.
TITLE       Method and reagent for the inhibition of erg
JOURNAL     Patent: WO 0188124-A 2097 22-NOV-2001;
RIBOZYME   PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
SOURCE      location/Qualifiers
             1..17
             /organism="Homo sapiens"
             /mol_type="unassigned RNA"
             /db_xref="taxon:9606"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1531 GCCTACCCAAACCGCC 1546
          |||||
          16 GCCTACCCAAATGCC 1

Db

RESULT 470
LOCUS      AX475792      17 bp      DNA      linear      PAT 12-AUG-2002
DEFINITION Sequence 1013 from Patent WO0224750.
ACCESSION  AX475792
VERSION     AX475792.1 GI:22215077
```

KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
TITLE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 1013 28-MAR-2002;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 147 CACCGCGTCCACTG 162
Db 2 CACCGAGAGCCACTG 17

RESULT 471
AX475794 17 bp DNA linear PAT 12-AUG-2002
LOCUS
DEFINITION Sequence 1015 from Patent WO0224750.
ACCESSION AX475794
VERSION AX475794.1 GI:22215079
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE 1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 1015 28-MAR-2002;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 148 ACCGCGTCCACTGC 163
Db 1 ACCGAGAGCCACTGC 16

RESULT 472
AX494762 17 bp DNA linear PAT 26-SEP-2002
LOCUS
DEFINITION Sequence 527 from Patent WO02059256.
ACCESSION AX494762
VERSION AX494762.1 GI:23340372
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
TITLE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Tuijnder, M., Teijerman, A., Amsen, R. and Suijini, L.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 02059256-A 527 01-AUG-2002;

MOLECULAR ENGINES LAB (FR)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1139 TTGCCAAGAGAGCGG 1154
Db 1 TTTCACAGAGAGAGCG 16

RESULT 473
AX498756 17 bp DNA linear PAT 27-SEP-2002
LOCUS
DEFINITION Sequence 63 from Patent EP1229046.
ACCESSION AX498756
VERSION AX498756.1 GI:23381038
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 63 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1009 CTGCTTCTCTCTGC 1024
Db 2 CTGCTTCTCTCTCTGC 17

RESULT 474
AX498757 17 bp DNA linear PAT 27-SEP-2002
LOCUS
DEFINITION Sequence 64 from Patent EP1229046.
ACCESSION AX498757
VERSION AX498757.1 GI:23381039
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
TITLE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 64 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1009 CTGCTTTCTCTGCG 1024
Db 1 CTGCTGTTCTCTGCG 16

RESULT 475
LOCUS AX499211 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 518 from Patent EP1229046.
ACCESSION AX499211
VERSION AX499211.1 GI:23381504
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 518 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 131 TCTCCTGCTGCTGCG 146
Db 2 TCTCCTGCTGCTGCG 17

RESULT 476
LOCUS AX499213 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 520 from Patent EP1229046.
ACCESSION AX499213
VERSION AX499213.1 GI:23381506
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 520 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 132 CTCCTGCTGCTGCG 147
Db 1 CTCCTGCTGCTGCG 16

RESULT 477
LOCUS AX499242 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 549 from Patent EP1229046.
ACCESSION AX499242
VERSION AX499242.1 GI:23381535

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 549 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 138 GCTGTGCCACCGCG 153
Db 17 GCCGTGCCACCGCG 2

RESULT 478
LOCUS AX499243 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 550 from Patent EP1229046.
ACCESSION AX499243
VERSION AX499243.1 GI:23381536
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 550 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 138 GCTGTGCCACCGCG 153
Db 16 GCCGTGCCACCGCG 1

RESULT 479
LOCUS AX499259 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 566 from Patent EP1229046.
ACCESSION AX499259
VERSION AX499259.1 GI:23381552
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 566 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers


```

source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1525 TCCTTGCTTACCCCA 1540
|||||
2 TCCTGTACTACCCCA 17

RESULT 480
AX499260 17 bp DNA linear PAT 29-SEP-2002
LOCUS
DEFINITION Sequence 567 from Patent EP1229046.
ACCESSION AX499260
VERSION AX499260.1 GI:23381553
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS
1 Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 567 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1525 TCCTTGCTTACCCCA 1540
|||||
1 TCCTGTACTACCCCA 16

RESULT 481
AX530926 17 bp DNA linear PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 435 from Patent EP1239051.
ACCESSION AX530926
VERSION AX530926.1 GI:25253643
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS
1 Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 435 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1101 CATTGAGCTCTGTCG 1116
|||||

```

```

Db 2 CATTGAGCGCTGCGC 17

RESULT 482
AX530931 17 bp DNA linear PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 440 from Patent EP1239051.
ACCESSION AX530931
VERSION AX530931.1 GI:25253653
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS
1 Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 440 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1105 GAGGCTCTGTGCGCA 1120
|||||
1 GAGGCGCTGCGCGCA 16

RESULT 483
AX531054 17 bp DNA linear PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 563 from Patent EP1239051.
ACCESSION AX531054
VERSION AX531054.1 GI:25253890
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS
1 Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 563 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 307 CTGGGCTTGCCCTGC 322
|||||
17 CTGGGCTTGCTCTGC 2

RESULT 484
AX531055 17 bp DNA linear PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 564 from Patent EP1239051.
ACCESSION AX531055
VERSION AX531055.1 GI:25253892
KEYWORDS
SOURCE
Homo sapiens (human)

```

```
ORGANISM      Homo sapiens
REFERENCE      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS        Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE          1
JOURNAL        Shannon, M.
                Human posh-like protein 1
                Patent: EP 1239051-A 564 11-SEP-2002;
                Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
source         1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match    0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      307 CTGGGCTTGCCCTGC 322
Db      16 CTGGGCTTGCTGCCTGC 1

RESULT 485
AX531704/c    17 bp  DNA  linear  PAT 22-NOV-2002
LOCUS         AX531704
DEFINITION    Sequence 1213 from Patent EP1239051.
ACCESSION     AX531704
VERSION       AX531704.1 GI:25255192
KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE      1
AUTHORS        Shannon, M.
TITLE          Human posh-like protein 1
JOURNAL        Patent: EP 1239051-A 1213 11-SEP-2002;
                Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
source         1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match    0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1341 TGTTCCTACCAATG 1356
Db      17 TGATCTCTACCATATG 2

RESULT 486
AX531705/c    17 bp  DNA  linear  PAT 22-NOV-2002
LOCUS         AX531705
DEFINITION    Sequence 1214 from Patent EP1239051.
ACCESSION     AX531705
VERSION       AX531705.1 GI:25255194
KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE      1
AUTHORS        Shannon, M.
TITLE          Human posh-like protein 1
JOURNAL        Patent: EP 1239051-A 1214 11-SEP-2002;
                Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
source         1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match    0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      2092 CTCATCACCCGAGACC 2107
Db      2 CTTATCACCCGAGACC 17

RESULT 488
AX531818      17 bp  DNA  linear  PAT 22-NOV-2002
LOCUS         AX531818
DEFINITION    Sequence 1327 from Patent EP1239051.
ACCESSION     AX531818
VERSION       AX531818.1 GI:25255412
KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE      1
AUTHORS        Shannon, M.
TITLE          Human posh-like protein 1
JOURNAL        Patent: EP 1239051-A 1327 11-SEP-2002;
                Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
source         1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match    0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      2093 TCATCACCCGACCT 2108
Db      1 TTATCACCCGACCT 16
```

RESULT 489
AX544923 17 bp DNA linear PAT 26-NOV-2002
LOCUS
DEFINITION Sequence 436 from Patent EP1243660.
ACCESSION AX544923
VERSION AX544923.1 GI:25810134
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
AUTHORS Zhang, J., Gu, Y. and Nguyen, C.T.
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10
JOURNAL Patent: EP 1243660-A 436 25-SEP-2002;
Aeomica, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1421 CCTCAGGAAATTT 1436
|||||
2 CCTCAGTGAATAATTT 17

RESULT 490
AX544925 17 bp DNA linear PAT 26-NOV-2002
LOCUS
DEFINITION Sequence 438 from Patent EP1243660.
ACCESSION AX544925
VERSION AX544925.1 GI:25810136
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
AUTHORS Zhang, J., Gu, Y. and Nguyen, C.T.
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10
JOURNAL Patent: EP 1243660-A 438 25-SEP-2002;
Aeomica, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1422 CTCGAGGAAATATTT 1437
|||||
1 CTCAGTGAATAATTT 16

RESULT 491
AX544967 17 bp DNA linear PAT 26-NOV-2002
LOCUS
DEFINITION Sequence 480 from Patent EP1243660.
ACCESSION AX544967
VERSION AX544967.1 GI:25810178
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE
AUTHORS Zhang, J., Gu, Y. and Nguyen, C.T.
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10
JOURNAL Patent: EP 1243660-A 480 25-SEP-2002;
Aeomica, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1489 TTACACTTGGAGGCC 1504
|||||
17 TTACACTTGGTGGGAC 2

RESULT 492
AX545279 17 bp DNA linear PAT 26-NOV-2002
LOCUS
DEFINITION Sequence 792 from Patent EP1243660.
ACCESSION AX545279
VERSION AX545279.1 GI:25810490
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
AUTHORS Zhang, J., Gu, Y. and Nguyen, C.T.
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10
JOURNAL Patent: EP 1243660-A 792 25-SEP-2002;
Aeomica, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 277 CTGCTGCTTTGAAGC 292
|||||
2 CTGCTTCTTTGATGC 17

RESULT 493
AX545281 17 bp DNA linear PAT 26-NOV-2002
LOCUS
DEFINITION Sequence 794 from Patent EP1243660.
ACCESSION AX545281
VERSION AX545281.1 GI:25810492
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE
AUTHORS Zhang, J., Gu, Y. and Nguyen, C.T.
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10
JOURNAL Patent: EP 1243660-A 794 25-SEP-2002;
Aeomica, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 278 TGGCTGCTTGAAGCC 293
|||||
Db 1 TGGCTTCTTGATGCC 16

RESULT 494
AX578253 17 bp RNA linear PAT 10-JAN-2003
LOCUS Sequence 91 from Patent WO0211674.
ACCESSION AX578253
VERSION AX578253.1 GI:27647455
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1
TITLE Thompson, J., Mcswigen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
METHOD and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL Patent: WO 0211674-A 238 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 881 CCTGAGTATTCCT 896
|||||
Db 1 CCTGAGTATTCCT 16

RESULT 495
AX578400 17 bp RNA linear PAT 10-JAN-2003
LOCUS Sequence 238 from Patent WO0211674.
ACCESSION AX578400
VERSION AX578400.1 GI:27647602
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1
TITLE Thompson, J., Mcswigen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
METHOD and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL Patent: WO 0211674-A 238 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

QY 1009 CTGCTTTTCCCTTCGC 1024
|||||
Db 2 CAGCTTTTCCCTGC 17

RESULT 496
AX578401 17 bp RNA linear PAT 10-JAN-2003
LOCUS Sequence 239 from Patent WO0211674.
ACCESSION AX578401
VERSION AX578401.1 GI:27647603
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1
TITLE Thompson, J., Mcswigen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
METHOD and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL Patent: WO 0211674-A 239 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1481 TGACTCCCTTACACTT 1496
|||||
Db 17 TGCTCCCTGACACTT 2

QY 1009 CTGCTTTTCCCTTCGC 1024
|||||
Db 1 CAGCTTTTCCCTGC 16

RESULT 497
AX578890 17 bp RNA linear PAT 10-JAN-2003
LOCUS Sequence 728 from Patent WO0211674.
ACCESSION AX578890
VERSION AX578890.1 GI:27648092
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1
TITLE Thompson, J., Mcswigen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
METHOD and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL Patent: WO 0211674-A 728 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

RESULT 498
AX579181/c
LOCUS AX579181
DEFINITION Sequence 1019 from Patent WO0211674.
ACCESSION AX579181
VERSION AX579181.1 GI:27648383
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1
TITLE Thompson, J., Mcawiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
JOURNAL Method and reagent for the inhibition of calcium activated chloride
channel-1 (cica-1)
PATENT: WO 0211674-A 1019 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
SOURCE location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1683 GCTGCTGTGATGCG 1698
Db 2 GCTGCTGACGATGCG 17

RESULT 500
AX580127/c
LOCUS AX580127
DEFINITION Sequence 1965 from Patent WO0211674.
ACCESSION AX580127

```

```

VERSION AX580127.1 GI:27649329
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1
TITLE Thompson, J., Mcawiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
JOURNAL Method and reagent for the inhibition of calcium activated chloride
channel-1 (cica-1)
PATENT: WO 0211674-A 1965 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
SOURCE location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1481 TGACTCCCTTACACTT 1496
Db 16 TGCTTCCTGACACTT 1

RESULT 501
AX615494/c
LOCUS AX615494
DEFINITION Sequence 301 from Patent EP1262488.
ACCESSION AX615494
VERSION AX615494.1 GI:28446540
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1
TITLE Gu, Y. and Nguyen, C.T.
JOURNAL Human lcc1-domain containing protein
PATENT: EP 1262488-A 301 04-DEC-2002;
Aeomica, Inc. (US)
FEATURES
SOURCE location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1009 CTGCTTTCCTTCGC 1024
Db 17 CTTCCTTCCTTC 2

RESULT 502
AX615495/c
LOCUS AX615495
DEFINITION Sequence 302 from Patent EP1262488.
ACCESSION AX615495
VERSION AX615495.1 GI:28446541
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1
TITLE Gu, Y. and Nguyen, C.T.

```

TITLE Human lcc1-domain containing protein
JOURNML Patent: EP 1262488-A 302 04-DEC-2002;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1009 CTGCTTTTCTCTGTC 1024
Db 16 CTCTCTTCTCTCTTC 1

RESULT 503
AX615973/c 17 bp DNA linear PAT 20-FEB-2003
LOCUS Sequence 780 from Patent EP1262488.
DEFINITION AX615973
ACCESSION AX615973.1 GI:28447019
VERSION
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE 1
AUTHORS Gu, Y. and Nguyen, C. T.
TITLE Human lcc1-domain containing protein
JOURNML Patent: EP 1262488-A 780 04-DEC-2002;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 919 CTGTGTACTGTGTGC 934
Db 17 CTGTGGACCTGTGTAC 2

RESULT 504
AX634494 17 bp RNA linear PAT 21-FEB-2003
LOCUS Sequence 1633 from Patent EP1260586.
DEFINITION AX634494
ACCESSION AX634494.1 GI:28470108
VERSION
KEYWORDS
SOURCE
ORGANISM unidentified
REFERENCE unidentified
AUTHORS unclassified.

TITLE Stinchcomb, D. T., Dudycz, L. W., Chowrira, B., Grimm, S., Dizenzo, A.,
Karpelsky, A., Draper, K. G., Kisich, K., Matulic-Adamic, J.,
Mcswiggen, J. A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S. M.,
Sweedler, D., Thompson, J. D., Tracz, D., Usman, N., Wincott, F. E. and
Wolf, T.
Method and reagent for inhibiting the expression of disease related
genes
JOURNML Patent: EP 1260586-A 1633 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unidentified"
/mol_type="unassigned RNA"

/db_xref="taxon:32644"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTTCTGTGTCCT 578
Db 2 CTCTGCTCTGTGTCCT 17

RESULT 505
AX634508 17 bp RNA linear PAT 21-FEB-2003
LOCUS Sequence 1647 from Patent EP1260586.
DEFINITION AX634508
ACCESSION AX634508.1 GI:28470122
VERSION
KEYWORDS
SOURCE
ORGANISM unidentified
REFERENCE unidentified
AUTHORS unclassified.

TITLE Stinchcomb, D. T., Dudycz, L. W., Chowrira, B., Grimm, S., Dizenzo, A.,
Karpelsky, A., Draper, K. G., Kisich, K., Matulic-Adamic, J.,
Mcswiggen, J. A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S. M.,
Sweedler, D., Thompson, J. D., Tracz, D., Usman, N., Wincott, F. E. and
Wolf, T.
Method and reagent for inhibiting the expression of disease related
genes
JOURNML Patent: EP 1260586-A 1647 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTTCTGTGTCCT 578
Db 2 CTCTGCTCTGTGTCCT 17

RESULT 506
AX634643 17 bp RNA linear PAT 21-FEB-2003
LOCUS Sequence 1782 from Patent EP1260586.
DEFINITION AX634643
ACCESSION AX634643.1 GI:28470257
VERSION
KEYWORDS
SOURCE
ORGANISM unidentified
REFERENCE unidentified
AUTHORS unclassified.

TITLE Stinchcomb, D. T., Dudycz, L. W., Chowrira, B., Grimm, S., Dizenzo, A.,
Karpelsky, A., Draper, K. G., Kisich, K., Matulic-Adamic, J.,
Mcswiggen, J. A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S. M.,
Sweedler, D., Thompson, J. D., Tracz, D., Usman, N., Wincott, F. E. and
Wolf, T.
Method and reagent for inhibiting the expression of disease related
genes
JOURNML Patent: EP 1260586-A 1782 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES Location/Qualifiers
SOURCE 1..17
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTCCTGCTCCT 578
Db 2 CTCTGCTCTGCTCCT 17

RESULT 507

AX671610/c 17 bp DNA linear PAT 27-MAR-2003
Sequence 55 from Patent WO03004526.

DEFINITION AX671610
ACCESSION AX671610 GI:29323958
VERSION
KEYWORDS
SOURCE
ORGANISM

Homo sapiens (human)

REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

Telerman, A., Amson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines

Patent: WO 03004526-A 55 16-JAN-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers

FEATURES

1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1330 CTGTGCACATTGTTTC 1345
Db 16 CTGTGCACGTTTGATC 1

RESULT 508

AX672330 17 bp DNA linear PAT 27-MAR-2003
Sequence 775 from Patent WO03004526.

DEFINITION AX672330
ACCESSION AX672330 GI:29330678
VERSION
KEYWORDS
SOURCE
ORGANISM

Homo sapiens (human)

REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

Telerman, A., Amson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines

Patent: WO 03004526-A 775 16-JAN-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers

FEATURES

1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 382 ACCAGCTACTGCACT 397
Db 2 ATCTGCTACTGCACT 17

RESULT 509

AX673085/c 17 bp DNA linear PAT 27-MAR-2003
Sequence 1530 from Patent WO03004526.

DEFINITION AX673085
ACCESSION AX673085 GI:29331433
VERSION
KEYWORDS
SOURCE
ORGANISM

Homo sapiens (human)

REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

Telerman, A., Amson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines

Patent: WO 03004526-A 1530 16-JAN-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers

FEATURES

1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1263 GCTGAAGTCGGAATC 1278
Db 16 GCTGAAGTCGGAATC 1

RESULT 510

AX674220 17 bp DNA linear PAT 27-MAR-2003
Sequence 2665 from Patent WO03004526.

DEFINITION AX674220
ACCESSION AX674220 GI:29332568
VERSION
KEYWORDS
SOURCE
ORGANISM

Homo sapiens (human)

REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

Telerman, A., Amson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines

Patent: WO 03004526-A 2665 16-JAN-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers

FEATURES

1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 905 ATCTGAGCTTATTCT 920
Db 2 ATCTGAGCTTATTCT 17

RESULT 511

AX687554/c 17 bp DNA linear PAT 31-MAR-2003
Sequence 286 from Patent EP1281758.

DEFINITION AX687554
ACCESSION AX687554 GI:29410250
VERSION

KEYWORDS										
SOURCE										
ORGANISM	Homo sapiens (human)									
REFERENCE	Homo sapiens									
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.									
TITLE	1									
JOURNAL	Shannon, M., Gu, Y. and Nguyen, C.T.									
FEATURES	Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12									
source	Patent: EP 1281758-A 286 05-FEB-2003;									
	Aeomica, Inc. (US)									
	Location/Qualifiers									
	1..17									
	/organism="Homo sapiens"									
	/mol_type="unassigned DNA"									
	/db_xref="taxon:9606"									
Query Match	0.6%;	Score 12.8;	DB 1;	Length 17;						
Best Local Similarity	87.5%;	Pred. No. 3.8e+02;								
Matches	14;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;	
QY	31 GGGTCCCGCTGCTCC 46									
Db	17 GGGTCACGCTGCTCC 2									
RESULT 512										
AX687555/c	17 bp DNA linear PAT 31-MAR-2003									
LOCUS	AX687555									
DEFINITION	Sequence 287 from Patent EP1281758.									
ACCESSION	AX687555									
VERSION	AX687555.1 GI:29410251									
KEYWORDS										
SOURCE	Homo sapiens (human)									
ORGANISM	Homo sapiens									
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.									
AUTHORS	1									
TITLE	Shannon, M., Gu, Y. and Nguyen, C.T.									
JOURNAL	Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12									
FEATURES	Patent: EP 1281758-A 287 05-FEB-2003;									
source	Aeomica, Inc. (US)									
	Location/Qualifiers									
	1..17									
	/organism="Homo sapiens"									
	/mol_type="unassigned DNA"									
	/db_xref="taxon:9606"									
Query Match	0.6%;	Score 12.8;	DB 1;	Length 17;						
Best Local Similarity	87.5%;	Pred. No. 3.8e+02;								
Matches	14;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;	
QY	31 GGGTCCCGCTGCTCC 46									
Db	16 GGGTCACGCTGCTCC 1									
RESULT 513										
AX687643/c	17 bp DNA linear PAT 31-MAR-2003									
LOCUS	AX687643									
DEFINITION	Sequence 375 from Patent EP1281758.									
ACCESSION	AX687643									
VERSION	AX687643.1 GI:29410339									
KEYWORDS										
SOURCE	Homo sapiens (human)									
ORGANISM	Homo sapiens									
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.									
AUTHORS	1									
TITLE	Shannon, M., Gu, Y. and Nguyen, C.T.									
JOURNAL	Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12									

JOURNAL	Patent: EP 1281758-A 375 05-FEB-2003;
FEATURES	Neomica, Inc. (US)
source	Location/Qualifiers
	1..17
	/organism="Homo sapiens"
	/mol_type="unassigned DNA"
	/db_xref="taxon:9606"
Query Match	0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity	87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	2177 ACCGAGCGCTCATGGA 2192
Db	
	17 ACCGAGCGCTCCAGGA 2
RESULT 514	
AX687645/c	
LOCUS	AX687645 17 bp DNA linear PAT 31-MAR-2003
DEFINITION	Sequence 377 from Patent EP1281758.
ACCESSION	AX687645
VERSION	AX687645.1 GI:29410341
KEYWORDS	
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS	1 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
TITLE	Shannon,M., Gu,Y. and Nguyen,C.T.
JOURNAL	Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
FEATURES	mdz12
source	Patent: EP 1281758-A 377 05-FEB-2003;
	Neomica, Inc. (US)
	Location/Qualifiers
	1..17
	/organism="Homo sapiens"
	/mol_type="unassigned DNA"
	/db_xref="taxon:9606"
Query Match	0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity	87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	2176 CACCAGCAGCTCATGG 2191
Db	
	16 CACCAGCAGCTCCAGG 1
RESULT 515	
AX687796	
LOCUS	AX687796 17 bp DNA linear PAT 31-MAR-2003
DEFINITION	Sequence 528 from Patent EP1281758.
ACCESSION	AX687796
VERSION	AX687796.1 GI:29410492
KEYWORDS	
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS	1 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
TITLE	Shannon,M., Gu,Y. and Nguyen,C.T.
JOURNAL	Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
FEATURES	mdz12
source	Patent: EP 1281758-A 528 05-FEB-2003;
	Neomica, Inc. (US)
	Location/Qualifiers
	1..17
	/organism="Homo sapiens"
	/mol_type="unassigned DNA"
	/db_xref="taxon:9606"
Query Match	0.6%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 773 GCCACTTCGACGGAGA 788
|||||
Db 2 GCCACAGCAGGAGA 17

RESULT 516

LOCUS AX687798 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 530 from Patent EP1281758.
ACCESSION AX687798
VERSION AX687798.1 GI:29410494
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
JOURNAL Patent: EP 1281758-A 530 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 774 CCACTTCGACGGAG 789
|||||
Db 1 CCAACAGCAGGAGA 16

RESULT 517
LOCUS AX687801/c 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 533 from Patent EP1281758.
ACCESSION AX687801
VERSION AX687801.1 GI:29410497
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
JOURNAL Patent: EP 1281758-A 533 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 993 CCGATCACCCTGCT 1008
|||||
Db 17 CCGCTCTCCTGCT 2

RESULT 518

AX687802/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS AX687802
DEFINITION Sequence 534 from Patent EP1281758.
ACCESSION AX687802
VERSION AX687802.1 GI:29410498
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
JOURNAL Patent: EP 1281758-A 534 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 993 CCGATCACCCTGCT 1008
|||||
Db 16 CCGCTCTCCTGCT 1

RESULT 519
LOCUS AX688332/c 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 1064 from Patent EP1281758.
ACCESSION AX688332
VERSION AX688332.1 GI:29411032
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
JOURNAL Patent: EP 1281758-A 1064 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 381 CACCAGGCTACTGCAC 396
|||||
Db 17 CACCAGGCTCCTGCTC 2

RESULT 520
LOCUS AX688333/c 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 1065 from Patent EP1281758.
ACCESSION AX688333
VERSION AX688333.1 GI:29411033
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
REFERENCE
1 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
AUTHORS
1 Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL
Patent: EP 1281758-A 1065 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY
381 CACGAGGCTACTGCAC 396
16 CACGAGGCTCCTCCTC 1
Db

RESULT 521
AX688366/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS
Sequence 1098 from Patent EPI281758.
ACCESSION
AX688366
VERSION
AX688366.1 GI:29411066
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE
1 Shannon,M., Gu,Y. and Nguyen,C.T.
AUTHORS
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL
Patent: EP 1281758-A 1098 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY
1149 GAGAGGCGAGGCCAG 1164
17 GAGAGGAGGAGGCCAG 2
Db

RESULT 522
AX688367/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS
Sequence 1099 from Patent EPI281758.
ACCESSION
AX688367
VERSION
AX688367.1 GI:29411067
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE
1 Shannon,M., Gu,Y. and Nguyen,C.T.
AUTHORS
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL
Patent: EP 1281758-A 1099 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1..17
Location/Qualifiers
```

```
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY
1149 GAGAGGCGAGGCCAG 1164
16 GAGAGGAGGAGGCCAG 1
Db

RESULT 523
AX688660/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS
Sequence 1392 from Patent EPI281758.
ACCESSION
AX688660
VERSION
AX688660.1 GI:29411362
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE
1 Shannon,M., Gu,Y. and Nguyen,C.T.
AUTHORS
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL
Patent: EP 1281758-A 1392 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY
1640 TGGCTGCCCTGCTGCA 1655
17 TGGCTGCCCTGCTGCA 2
Db

RESULT 524
AX688662/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS
Sequence 1394 from Patent EPI281758.
ACCESSION
AX688662
VERSION
AX688662.1 GI:29411364
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE
1 Shannon,M., Gu,Y. and Nguyen,C.T.
AUTHORS
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL
Patent: EP 1281758-A 1394 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY
1639 GTGGCTGCCCTGCTGC 1654
```

Db 16 GTGAGCTGCGCTGCTGC 1

RESULT 525
AX690650/c
LOCUS AX690650 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 3382 from Patent EP1281758.
ACCESSION AX690650
VERSION AX690650.1 GI:29413531
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y., and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
PATENT: EP 1281758-A 3382 05-FEB-2003;
Aecomica, Inc. (US)
LOCATION/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

FEATURES
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2176 CACCAGACGCTCAGG 2191

Db 16 CACCAGACGCTCAGG 1

RESULT 527
AX690666
LOCUS AX690666 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 3398 from Patent EP1281758.
ACCESSION AX690666

VERSION AX690666.1 GI:29413547
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y., and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
PATENT: EP 1281758-A 3398 05-FEB-2003;
Aecomica, Inc. (US)
LOCATION/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

FEATURES
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2040 GTGAGACGCTCCTG 2055

Db 2 GCTGAGACGCTCCTG 17

RESULT 528
AX690667
LOCUS AX690667 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 3399 from Patent EP1281758.
ACCESSION AX690667
VERSION AX690667.1 GI:29413548
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y., and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
PATENT: EP 1281758-A 3399 05-FEB-2003;
Aecomica, Inc. (US)
LOCATION/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

FEATURES
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2040 GGTGAGACGCTCCTG 2055

Db 1 GCTGAGACGCTCCTG 16

RESULT 529
AX691878
LOCUS AX691878 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 4610 from Patent EP1281758.
ACCESSION AX691878
VERSION AX691878.1 GI:29414819
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Shannon, M., Gu, Y., and Nguyen, C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and

JOURNAL mdz12
Patent: EP 1281758-A 4610 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2125 GCTGACCAATCTCT 2140
Db 2 GCTGCCACAGCCTCT 17

RESULT 530
AX691879 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 4611 from Patent EP1281758.
ACCESSION AX691879
VERSION AX691879.1 GI:29414820
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS
TITLE Shannon,M., Gu,Y. and Nguyen,C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
Patent: EP 1281758-A 4611 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2125 GCTGACCAATCTCT 2140
Db 1 GCTGCCACAGCCTCT 16

RESULT 531
AX691881/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 4613 from Patent EP1281758.
ACCESSION AX691881
VERSION AX691881.1 GI:29414822
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS
TITLE Shannon,M., Gu,Y. and Nguyen,C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
Patent: EP 1281758-A 4613 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1206 GAAGAGGCTGTGGCC 1221
Db 17 GAGAGAGCTGTGGCC 2

RESULT 532
AX691882/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 4614 from Patent EP1281758.
ACCESSION AX691882
VERSION AX691882.1 GI:29414823
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS
TITLE Shannon,M., Gu,Y. and Nguyen,C.T.
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
Patent: EP 1281758-A 4614 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1206 GAAGAGGCTGTGGCC 1221
Db 16 GAGAGAGCTGTGGCC 1

RESULT 533
AX701413/c 17 bp DNA linear PAT 03-APR-2003
LOCUS
DEFINITION Sequence 17 from Patent WO0209095.
ACCESSION AX701413
VERSION AX701413.1 GI:29537062
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
artificial sequences.
REFERENCE
AUTHORS
TITLE Barry,A., Bretzel,W., Huemelin,M., Lopez-Ulbarri,R., Mayer,A.F.
JOURNAL Improved isoprenoid production
Patent: WO 0209095-A 17 12-DEC-2002;
Roche Vitamins AG (CH)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1308 TGGGCTGTAGCAGT 1323
Db 17 TGGGCTGTAGCAGT 2

RESULT 534
AX710060 17 bp DNA linear PAT 10-APR-2003
LOCUS
DEFINITION Sequence 12 from Patent EP1288314.
ACCESSION AX710060
VERSION AX710060.1 GI:29786663
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 Eyre,D.J., Rasmussen,R.P., Caplin,B.E., Stevenson,W.R. and Desilva,D.M.
TITLE Real-time gene quantification with internal standards
JOURNAL Patent: EP 1288314-A 12 05-MAR-2003;
The University of Utah Research Foundation (US) ; Idaho Technology, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1936 GGTGACGCGACGACG 1951
|||||
1 GGTGACGCGCGACGACG 16

RESULT 535
AX723750 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 1437 from Patent WO03025176.
ACCESSION AX723750
VERSION AX723750.1 GI:30503093
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 1437 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 582 GGTCTCTCTCTCTT 597
|||||
1 GATCTCTCTCTCTT 16

RESULT 536
AX723821 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 1508 from Patent WO03025176.
ACCESSION AX723821
VERSION AX723821.1 GI:30503164
KEYWORDS

SOURCE Mus musculus (house mouse)
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 1508 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2184 GCTCATGAGAGAAAAG 2199
|||||
1 GATCATGAGAGAAAAG 16

RESULT 537
AX724325 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 2012 from Patent WO03025176.
ACCESSION AX724325
VERSION AX724325.1 GI:30503668
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025176-A 2012 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 431 ATCGAGCGGCACTGCC 446
|||||
2 ATCGAGCGGCACTGCC 17

RESULT 538
AX724370 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 2057 from Patent WO03025176.
ACCESSION AX724370
VERSION AX724370.1 GI:30503713
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour

reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025176-A 2057 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1731 GCACAGCGCAGTGCT 1746
17 GCACAGCGCAGTGAT 2

RESULT 539
AX724543/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 2230 from Patent WO03025176.
ACCESSION AX724543
VERSION AX724543.1 GI:30503886
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 2230 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 729 CGTGGTGACGGGATC 744
16 CGTAGGTGACGATC 1

RESULT 540
AX724787 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 2474 from Patent WO03025176.
ACCESSION AX724787
VERSION AX724787.1 GI:30504130
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 2474 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2184 GCTCATGAGAGAAAAG 2199
1 GATCATGAGAGAAAAG 16

RESULT 541
AX725087/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 2774 from Patent WO03025176.
ACCESSION AX725087
VERSION AX725087.1 GI:30504430
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 2774 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 956 TCATGCTGTGGGATC 971
16 TCATGCCCTGGAGATC 1

RESULT 542
AX725274/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 2961 from Patent WO03025176.
ACCESSION AX725274
VERSION AX725274.1 GI:30504617
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 2961 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 174 GGCGGTGGCCTGAGC 189
|||
Db 16 GGCTGTGGCCTGATC 1

RESULT 543

LOCUS AX725956 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3643 from Patent WO03025176.
ACCESSION AX725956
VERSION AX725956.1 GI:30505299
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 3643 27-MAR-2003;
Molecular Engines Laboratories (FR)

FEATURES
SOURCE 1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 996 GATCACCTGCTCTG 1011
|||
Db 1 GATCTGCTGCTCTG 16

RESULT 544

LOCUS AX727191 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4878 from Patent WO03025176.
ACCESSION AX727191
VERSION AX727191.1 GI:30506534
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 4878 27-MAR-2003;
Molecular Engines Laboratories (FR)

FEATURES
SOURCE 1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 996 GATCACCTGCTCTG 1011
|||
Db 1 GATCTCTGCTCTG 16

RESULT 545

AX727575

LOCUS AX727575 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5262 from Patent WO03025176.
ACCESSION AX727575
VERSION AX727575.1 GI:30506918
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 5262 27-MAR-2003;
Molecular Engines Laboratories (FR)

FEATURES
SOURCE 1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 503 GCTCTGGAACCTGT 518
|||
Db 1 GATCTGGAACACTGT 16

RESULT 546
LOCUS AX728137 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5824 from Patent WO03025176.
ACCESSION AX728137
VERSION AX728137.1 GI:30507480
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 5824 27-MAR-2003;
Molecular Engines Laboratories (FR)

FEATURES
SOURCE 1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 996 GATCACCTGCTCTG 1011
|||
Db 1 GATCACCTGCTCTG 16

RESULT 547
LOCUS AX728606/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 240 from Patent WO03025175.
ACCESSION AX728606
VERSION AX728606.1 GI:30507949
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens

REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS 1 Telerman, A., Amson, R. and Tuijinder, M.

TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025175-A 240 27-MAR-2003;

FEATURES Molecular Engines Laboratories (FR)

source Location/Qualifiers

1. .17

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.8e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1680 ACAGCTGCTGTGGAT 1695

Db 17 ACAGCTCCTGTGGAT 2

RESULT 548

AX728864/c 17 bp DNA linear PAT 08-MAY-2003

LOCUS Sequence 498 from Patent WO03025175.

DEFINITION AX728864

ACCESSION AX728864

VERSION AX728864.1 GI:30508207

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS 1 Telerman, A., Amson, R. and Tuijinder, M.

TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025175-A 498 27-MAR-2003;

FEATURES Molecular Engines Laboratories (FR)

source Location/Qualifiers

1. .17

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.8e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 984 CATGTCACCTGATC 999

Db 16 CAAAGTTACCTGATC 1

RESULT 549

AX728907/c 17 bp DNA linear PAT 08-MAY-2003

LOCUS Sequence 541 from Patent WO03025175.

DEFINITION AX728907

ACCESSION AX728907

VERSION AX728907.1 GI:30508250

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS 1 Telerman, A., Amson, R. and Tuijinder, M.

TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025175-A 541 27-MAR-2003;

FEATURES Molecular Engines Laboratories (FR)

source Location/Qualifiers

1. .17

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.8e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 822 GTTTTCCACACAGAC 837

Db 16 GTTTTCCACCTGATC 1

RESULT 550

AX731757/c 17 bp DNA linear PAT 08-MAY-2003

LOCUS Sequence 3391 from Patent WO03025175.

DEFINITION AX731757

ACCESSION AX731757

VERSION AX731757.1 GI:30511100

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS 1 Telerman, A., Amson, R. and Tuijinder, M.

TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025175-A 3391 27-MAR-2003;

FEATURES Molecular Engines Laboratories (FR)

source Location/Qualifiers

1. .17

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.8e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1406 AGAAGCTGTGGCTC 1421

Db 16 AGAAGCTTGGATC 1

RESULT 551

AX732158/c 17 bp DNA linear PAT 08-MAY-2003

LOCUS Sequence 3792 from Patent WO03025175.

DEFINITION AX732158

ACCESSION AX732158

VERSION AX732158.1 GI:30511501

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS 1 Telerman, A., Amson, R. and Tuijinder, M.

TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025175-A 3792 27-MAR-2003;

FEATURES Molecular Engines Laboratories (FR)

source Location/Qualifiers

1. .17

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1989 ACTTATCTCGATGAT 2004
|||
17 ACATATCTCGAATGAT 2

RESULT 552
AX732941 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 4575 from Patent WO03025175.
ACCESSION AX732941
VERSION AX732941.1 GI:30512284
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 4575 27-MAR-2003;
FEATURES
source Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

QY 382 ACCAGGCTACTGCACT 397
|||
2 ATCAGCGTACTGCACT 17

RESULT 553
AX733047 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 4681 from Patent WO03025175.
ACCESSION AX733047
VERSION AX733047.1 GI:30512390
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 4681 27-MAR-2003;
FEATURES
source Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2095 ATCACCAGCACCTCA 2110
|||
|||

DB 2 ATCACCCTCCACCTCA 17

RESULT 554
AX733291 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 4925 from Patent WO03025175.
ACCESSION AX733291
VERSION AX733291.1 GI:30512634
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 4925 27-MAR-2003;
FEATURES
source Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

QY 382 ACCAGGCTACTGCACT 397
|||
2 ATCAGGCGCTACTGCACT 17

RESULT 555
AX733627 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 5261 from Patent WO03025175.
ACCESSION AX733627
VERSION AX733627.1 GI:30512970
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 5261 27-MAR-2003;
FEATURES
source Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2002 GATGCCACGATGCC 2017
|||
1 GATCCCATCATGATGCC 16

RESULT 556
AX734653 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 243 from Patent WO03025177.

ACCESSION AX734653
VERSION AX734653.1 GI:30513930
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 243 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1178 AGCTGCAGGAATATA 1193
DB 2 ATCTGAAGAATAATA 17
RESULT 557
AX734659 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX734659
DEFINITION Sequence 249 from Patent WO03025177.
ACCESSION AX734659
VERSION AX734659.1 GI:30513936
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 249 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 905 ATCTGAGCTATTCT 920
DB 2 ATCTGAGCTATTCTT 17
RESULT 558
AX736797 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX736797
DEFINITION Sequence 2387 from Patent WO03025177.
ACCESSION AX736797
VERSION AX736797.1 GI:30516085
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 2387 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 850 ATCATGCTCGGGTAA 865
DB 2 ATCCTGCTCGGGGAA 17
RESULT 559
AX739468/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX739468
DEFINITION Sequence 5058 from Patent WO03025177.
ACCESSION AX739468
VERSION AX739468.1 GI:30518765
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 5058 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1680 ACAAGCTGCTGTGGAT 1695
DB 17 ACAAGCTGCTGTGGAT 2
RESULT 560
AX739703 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX739703
DEFINITION Sequence 5293 from Patent WO03025177.
ACCESSION AX739703
VERSION AX739703.1 GI:30519000
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 5293 27-MAR-2003;
Molecular Engines Laboratories (FR)

FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 GCTCTGCAGATGCTC 2239
|||||
1 GATCCTCAGCTGCTC 16

RESULT 561
AX744302 17 bp DNA linear PAT 14-MAY-2003
LOCUS
DEFINITION Sequence 267 from Patent WO03031621.
ACCESSION AX744302
VERSION AX744302.1 GI:30722969
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Zhang, J.
TITLE A human G protein coupled receptor
JOURNAL Patent: WO 03031621-A 267 17-APR-2003;
Ameresham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1623 GTCGTGGAAGACACA 1638
|||||
2 GTCGTGGAAGATACA 17

RESULT 562
AX744303 17 bp DNA linear PAT 14-MAY-2003
LOCUS
DEFINITION Sequence 268 from Patent WO03031621.
ACCESSION AX744303
VERSION AX744303.1 GI:30722970
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Zhang, J.
TITLE A human G protein coupled receptor
JOURNAL Patent: WO 03031621-A 268 17-APR-2003;
Ameresham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1623 GTCGTGGAAGACACA 1638

Db
|||||
1 GTCGTGGAAGATACA 16

RESULT 563
AX745332/c 17 bp DNA linear PAT 14-MAY-2003
LOCUS
DEFINITION Sequence 1297 from Patent WO03031621.
ACCESSION AX745332
VERSION AX745332.1 GI:30723999
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Zhang, J.
TITLE A human G protein coupled receptor
JOURNAL Patent: WO 03031621-A 1297 17-APR-2003;
Ameresham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 859 CCGGTACAGAGACA 874
|||||
16 CAGGTACAGAGAAA 1

RESULT 564
AX753782 17 bp DNA linear PAT 23-JUN-2003
LOCUS
DEFINITION Sequence 129 from Patent WO03037931.
ACCESSION AX753782
VERSION AX753782.1 GI:32166479
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Shannon, M. and Phan, T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 129 08-MAY-2003;
Ameresham Biosciences SV Corp. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 ACGAGAGGCGAAGC 1160
|||||
2 ACGAGAGGCCAAGC 17

RESULT 565
AX753783 17 bp DNA linear PAT 23-JUN-2003
LOCUS
DEFINITION Sequence 130 from Patent WO03037931.
ACCESSION AX753783
VERSION AX753783.1 GI:32166480
KEYWORDS

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Shannon,M. and Phan,T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 130 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1145 ACGAGAGGCGCAAGC 1160
Db 1 ACGAGAGGCGCAAGC 16
|||||
|

RESULT 566
AX756714/c 17 bp DNA linear PAT 25-JUN-2003
LOCUS
DEFINITION Sequence 35 from Patent WO03040369.
ACCESSION AX756714
VERSION AX756714.1 GI:32251268
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 35 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 651 AGATGCTCAGCCGAT 666
Db 17 AGAAGCACACCCGAT 2
|||||
|

RESULT 567
AX757942 17 bp DNA linear PAT 25-JUN-2003
LOCUS
DEFINITION Sequence 1263 from Patent WO03040369.
ACCESSION AX757942
VERSION AX757942.1 GI:32252558
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines

JOURNAL Patent: WO 03040369-A 1263 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 703 ACCATAGCCAGTGCAG 718
Db 2 ATCATACAGTGCAG 17
|||||
|

RESULT 568
AX758903/c 17 bp DNA linear PAT 25-JUN-2003
LOCUS
DEFINITION Sequence 2224 from Patent WO03040369.
ACCESSION AX758903
VERSION AX758903.1 GI:32253519
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 2224 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2188 ATGGAAGAAAAAGGGT 2203
Db 17 ATGTAAGAAAAAGGAT 2
|||||
|

RESULT 569
AX759607/c 17 bp DNA linear PAT 25-JUN-2003
LOCUS
DEFINITION Sequence 2928 from Patent WO03040369.
ACCESSION AX759607
VERSION AX759607.1 GI:32254223
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 2928 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

[illegible]

Db	16	ATATCCTTGGGGATC	1
RESULT 572			
LOCUS	AX761670	17 bp	DNA
DEFINITION	Sequence 4991 from Patent WO03040369.	linear	PAT 25-JUN-2003
ACCESSION	AX761670		
VERSION	AX761670.1		
KEYWORDS	GI:32256286		
SOURCE			
ORGANISM	Homo sapiens (human)		
REFERENCE	Homo sapiens		
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
TITLE	Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.		
JOURNAL	1		
FEATURES	Teleman,A., Amson,R. and Tuijinder,M.		
source	Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines		
	Patent: WO 03040369-A 4991 15-MAY-2003;		
	Molecular Engines Laboratories (FR)		
	Location/Qualifiers		
	1..17		
	/organism="Homo sapiens"		
	/mol_type="unassigned DNA"		
	/db_xref="taxon:9606"		
Query Match	0.6%; Score 12.8; DB 1;	Length 17;	
Best Local Similarity	87.5%; Pred. No. 3.8e+02;		
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
Qy	850 ATCATGTCTCGGGTAA 865		
Db	2 ATCATGTCTCGGCATA 17		
RESULT 573			
LOCUS	AX761804	17 bp	DNA
DEFINITION	Sequence 5125 from Patent WO03040369.	linear	PAT 25-JUN-2003
ACCESSION	AX761804		
VERSION	AX761804.1		
KEYWORDS	GI:32256420		
SOURCE			
ORGANISM	Homo sapiens (human)		
REFERENCE	Homo sapiens		
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
TITLE	Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.		
JOURNAL	1		
FEATURES	Teleman,A., Amson,R. and Tuijinder,M.		
source	Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines		
	Patent: WO 03040369-A 5125 15-MAY-2003;		
	Molecular Engines Laboratories (FR)		
	Location/Qualifiers		
	1..17		
	/organism="Homo sapiens"		
	/mol_type="unassigned DNA"		
	/db_xref="taxon:9606"		
Query Match	0.6%; Score 12.8; DB 1;	Length 17;	
Best Local Similarity	87.5%; Pred. No. 3.8e+02;		
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
Qy	642 GATCTCAAGATGCG 657		
Db	1 GATCTCAAGCTGCG 16		
RESULT 574			
LOCUS	AX761929	17 bp	DNA
DEFINITION	Sequence 5250 from Patent WO03040369.	linear	PAT 25-JUN-2003

ACCESSION AX761929
VERSION AX761929.1 GI:32256545
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in tumoral suppression, apoptosis and/or viral resistance phenomena and their use as medicines
JOURNAL Patent: WO 03040369-A 5250 15-MAY-2003;
FEATURES Molecular Engines Laboratories (FR)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 382 ACCAGGCTACTGCCT 397
Db 2 ATCAGGCCACTGCCT 17
|||||
|

RESULT 575
AX781766/c 17 bp DNA linear PAT 17-JUL-2003
LOCUS AX781766
DEFINITION Sequence 97 from Patent WO03050284.
ACCESSION AX781766
VERSION AX781766.1 GI:32949600
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Guo, J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 97 19-JUN-2003;
FEATURES Amerisham Biosciences (SV) Corp. (US)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 298 GCTGCGGCACTGGCT 313
Db 17 GCTGCGGCACTGGCT 2
|||||
|

RESULT 576
AX781767/c 17 bp DNA linear PAT 17-JUL-2003
LOCUS AX781767
DEFINITION Sequence 98 from Patent WO03050284.
ACCESSION AX781767
VERSION AX781767.1 GI:32949601
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Guo, J.

TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 98 19-JUN-2003;
FEATURES Amerisham Biosciences (SV) Corp. (US)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 298 GCTGCGGCACTGGCT 313
Db 16 GCTGCGGCACTGGCT 1
|||||
|

RESULT 577
AX782300/c 17 bp DNA linear PAT 17-JUL-2003
LOCUS AX782300
DEFINITION Sequence 631 from Patent WO03050284.
ACCESSION AX782300
VERSION AX782300.1 GI:32950149
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Guo, J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 631 19-JUN-2003;
FEATURES Amerisham Biosciences (SV) Corp. (US)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1605 GCTGCGGCACTGGCT 1620
Db 17 GCTGCGGCACTGGCT 2
|||||
|

RESULT 578
AX782301/c 17 bp DNA linear PAT 17-JUL-2003
LOCUS AX782301
DEFINITION Sequence 632 from Patent WO03050284.
ACCESSION AX782301
VERSION AX782301.1 GI:32950150
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Guo, J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 632 19-JUN-2003;
FEATURES Amerisham Biosciences (SV) Corp. (US)
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;

	Matches	14;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
Qy	1605	GCTGTGGGAGCCCAAT	1620							
Db	16	GCTGATGGAGCCCAATT	1							
	RESULT 579									
LOCUS	AX783936									
DEFINITION	Sequence 2267 from Patent WO03050284.									
ACCESSION	AX783936									
VERSION	AX783936.1									
KEYWORDS	GI:32951785									
SOURCE	Homo sapiens (human)									
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.									
REFERENCE	1									
AUTHORS	Guo,J.									
TITLE	Human prostate cancer candidate protein 1									
JOURNAL	Patent: WO 03050284-A 2267 19-JUN-2003; Amersham Biosciences (SV) Corp. (US)									
FEATURES	location/Qualifiers									
source	1..17 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"									
Query Match	0.6%; Score 12.8;									
Best Local Similarity	87.5%; Pred. No. 3.8e+02;									
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
Qy	1635	CACAGTGCGTGCCTG	1650							
Db	1	CACAGTGTCTGCCCG	16							
	RESULT 580									
LOCUS	AX816806									
DEFINITION	Sequence 97 from Patent WO03014390.									
ACCESSION	AX816806									
VERSION	AX816806.1									
KEYWORDS	GI:39647135									
SOURCE	Homo sapiens (human)									
ORGANISM	Homo sapiens									
REFERENCE	1									
AUTHORS	Sampson,J.R. and Cheadle,J.P.									
TITLE	Screening methods and sequences relating thereto									
JOURNAL	Patent: WO 03014390-A 97 20-FEB-2003; University of Wales College of Medicine (GB)									
FEATURES	location/Qualifiers									
source	1..17 /organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"									
Query Match	0.6%; Score 12.8;									
Best Local Similarity	87.5%; Pred. No. 3.8e+02;									
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
Qy	1704	CCTTCCCCAATATGAG	1719							
Db	1	CCCTCCCCAACATGAG	16							
	RESULT 581									
LOCUS	BD067894/c									
DEFINITION	Enzymatic nucleic acid treatment of diseases or conditions related									

ACCESSION	VERSION	KEYWORDS	SOURCE	ORGANISM
B067894	BD067894.1	GI:22613497	JP 2001511003-A/734.	unclassified
JOURNAL	TITLE	REFERENCE	AUTHORS	COMMENT
1 (bases 1 to 17)	1 (bases 1 to 17)	Akhatar,S., Felle,P. and Mcswigen,J.A.	Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors	RIBOZYME PHARMACEUTICALS INC,ASTON UNIV OS Unidentified PN JP 2001511003-A/734 PD 07-AUG-2001 PF 14-JAN-1998 JP 1998532913 PR 31-JAN-1997 US 60/036476, 04-DEC-1997 US 08/985162 PI SAKHIR AKHTAR, PATRICIA FELL, JAMES A MCSWIGGEN PC C12N9/00, C07K14/71 CC Strandedness: Single; CC Topology: Linear; CC Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
FEATURES	source			
CC Levels of epidermal growth factor receptors	Location/Qualifiers			
FH Key	1..17			
FT source	/organism='Unidentified'. location/Qualifiers 1..17 /organism="unidentified" /mol_type="genomic RNA" /db_xref="taxon:32644"			
Query Match	0.6%; Score 12.8; DB 1; Length 17;			
Best Local Similarity	87.5%; Pred. No. 3.8e+02;			
Matches 14; Conservative	0; Mismatches 2; Indels 0; Gaps 0;			
Cy 1425 AGAGAAATATTGTGAG 1440				
Db 17 AGAGAAATATTGTGAG 2				
RESULT 582				
BD104823	17 bp DNA linear PAT 27-AUG-2002			
LOCUS	BD104823			
DEFINITION	Kit and method for determining HLA type.			
ACCESSION	BD104823			
VERSION	BD104823.1 GI:22650397			
KEYWORDS	WO 0192572-A/927.			
SOURCE	synthetic construct			
ORGANISM	artificial sequence.			
REFERENCE	1 (bases 1 to 17)			
AUTHORS	Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and Nishida,M.			
TITLE	Kit and method for determining HLA type			
JOURNAL	Patent: WO 0192572-A-927 06-DEC-2001; NISHINO INDUSTRIES INC, SYSTEM RESEARCH INC, HIDETOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIOYUKI MATSUMURA, SHOGO MORIYA, MICHIO NISHIDA			
COMMENT	OS			
Artificial Sequence	PN WO 0192572-A/927			
PD 06-DEC-2001	PF 01-JUN-2001 WO 2001JP004662			
PR 01-JUN-2000 JP 00P 164798	PI HIDETOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIOYUKI MATSUMURA,			
MATSUMURA,	PI SHOGO MORIYA, MICHIO NISHIDA			
PC C12Q1/68, C12M1/00, C12N15/09, G01N33/53	CC Description of Artificial Sequence: capture			
FH Key	Location/Qualifiers			
1..17	source			

FEATURES	source	Location/Qualifiers	/organism='Artificial Sequence'.
1..17			
Query Match		0.6%; Score 12.8; DB 1;	Length 17;
Best Local Similarity		87.5%; Pred. No. 3.8e+02;	
Matches 14;		Conservative 0;	Mismatches 2; Indels 0; Gaps 0;
Oy	1911	CGAGGCTCGAGCCGAG	1926
Db	1	CGACGCCGAGGCCAG	16
RESULT 583			
BD105166			
LOCUS	BD105166	17 bp	DNA linear PAT 27-AUG-2002
DEFINITION	Kit and method for determining HLA type.		
ACCESSION	BD105166	1	GI:22650740
VERSION	WO 0192572-A/1270.		
KEYWORDS	WO 0192572-A/1270.		
SOURCE	synthetic construct		
ORGANISM	artificial construct		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and Nishida,M.		
TITLE	Kit and method for determining HLA type		
JOURNAL	Patent: WO 0192572-A 1270 06-DEC-2001;		
	NISHISHINO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO NISHIDA		
COMMENT	OS Artificial Sequence		
	PN	WO 0192572-A/1270	
	PD	06-DEC-2001	
	PF	01-JUN-2001	WO 2001JP004662
	PR	01-JUN-2000	JP 00P 164798
	PI	HIDETOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA,	
		MATSUMURA,	
	PI	SHOGO MORIYA, MICHIO NISHIDA	
	PC	C12Q1/68, C12M1/00, C12N15/09, G01N33/53	
	CC	Description of Artificial Sequence:capture	
	FH	Key	Location/Qualifiers
	FT	source	1..17
			/organism='Artificial Sequence'.
FEATURES			
source		Location/Qualifiers	
	1..17		
		/organism="synthetic construct"	
		/mol_type="genomic DNA"	
		/db_xref="taxon:32630"	
Query Match		0.6%; Score 12.8; DB 1;	Length 17;
Best Local Similarity		87.5%; Pred. No. 3.8e+02;	
Matches 14;		Conservative 0;	Mismatches 2; Indels 0; Gaps 0;
Oy	491	GCGGTCAGGGCGGCTC	506
Db	2	GCGGACAGGCGGCTC	17
RESULT 584			
BD202752/c			
LOCUS	BD202752	17 bp	RNA linear PAT 17-JUN-2003
DEFINITION	Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.		
ACCESSION	BD202752		
VERSION	BD202752.1	GI:33012522	
KEYWORDS	JP 2002509721-A/5778.		
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		

REFERENCE AUTHORS TITLE JOURNAL	COMMENT
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo. 1 (bases 1 to 17) Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A. Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response Patent: JP 2002509721-A 5778 02-APR-2002; RIBOZYME PHARMACEUTICALS INC	OS Homo sapiens (human) PN JP 2002509721-A/5778 PD 02-APR-2002 PF 24-MAR-1999 JP 2000541291 PR 27-MAR-1998 US 60/079678 PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT, PI JAMES A MCSWIGGEN
FEATURES source	CC Method and reagent for treating diseases or conditions CC concerning molecule CC participating in vasculogenic response FH Key Location/Qualifiers FT source 1..17 FT Location/Qualifiers 1..17 /organism="Homo sapiens (human)". /organism="Homo sapiens" /mol_type="genomic RNA" /db_xref="taxon:9606"
Query Match 0.6%; Score 12.8; DB 1; Length 17; Best Local Similarity 87.5%; Pred. No. 3.8e+02; Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
OR 541 GGCTCGAGAGCGGCC 556	
Db 17 GGCTCGAGAGCGGCC 2	
RESULT 585 BD0202753/c	
LOCUS BD0202753 17 bp RNA linear PAT 17-JUL-2003	
DEFINITION Method and reagent for treating diseases or conditions concerning	
ACCSSION BD0202753	
VERSION BD0202753.1 GI:33012523	
KEYWORDS JP 2002509721-A/5779.	
SOURCE Homo sapiens (human)	
ORGANISM Homo sapiens	
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo. 1 (bases 1 to 17) Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A. Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response Patent: JP 2002509721-A 5779 02-APR-2002; RIBOZYME PHARMACEUTICALS INC	
OS Homo sapiens (human) PN JP 2002509721-A/5779 PD 02-APR-2002 PF 24-MAR-1999 JP 2000541291 PR 27-MAR-1998 US 60/079678 PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT, PI JAMES A MCSWIGGEN	
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00, PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00	
CC Method and reagent for treating diseases or conditions CC concerning molecule CC participating in vasculogenic response	


```

FEATURES
  source
    FH Key
    FT source
    FT Location/Qualifiers
      1..17
      /organism="Homo sapiens (human)".
      Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="genomic RNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 540 GGGCTCGAGACGCC 555
Db 16 GGGCTCAGACATGCC 1

RESULT 586
BD202918
LOCUS
DEFINITION
  BD202918 17 bp RNA linear PAT 17-JUL-2003
  Method and reagent for treating diseases or conditions concerning
  molecule participating in vasculogenic response.
ACCESSION
  BD202918.1 GI:33012688
VERSION
  BD202918
KEYWORDS
  JP 2002509721-A/5944.
SOURCE
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
  1 (bases 1 to 17)
REFERENCE
  Pavco,P.A., Robert,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  Method and reagent for treating diseases or conditions concerning
  molecule participating in vasculogenic response
  Patent: JP 2002509721-A 5944 02-APR-2002;
JOURNAL
  RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/5944
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N5/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06,PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00,PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key
FT source
FT Location/Qualifiers
  1..17
  /organism="Homo sapiens (human)".
  Location/Qualifiers
  1..17
  /organism="Homo sapiens"
  /mol_type="genomic RNA"
  /db_xref="taxon:9606"

FEATURES
  source
    FH Key
    FT source
    FT Location/Qualifiers
      1..17
      /organism="Homo sapiens (human)".
      Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="genomic RNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1108 GCTCTGTCGCCATGC 1123
Db 2 GCTCTGTCGCCAGGC 17

RESULT 587
BD203057
LOCUS
DEFINITION
  BD203057 17 bp RNA linear PAT 17-JUL-2003
  Method and reagent for treating diseases or conditions concerning

```

```

ACCESSION
  BD203057
VERSION
  BD203057.1 GI:33012827
KEYWORDS
  JP 2002509721-A/6083.
SOURCE
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
  1 (bases 1 to 17)
REFERENCE
  Pavco,P.A., Robert,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  Method and reagent for treating diseases or conditions concerning
  molecule participating in vasculogenic response
  Patent: JP 2002509721-A 6083 02-APR-2002;
JOURNAL
  RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/6083
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N5/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06,PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00,PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key
FT source
FT Location/Qualifiers
  1..17
  /organism="Homo sapiens (human)".
  Location/Qualifiers
  1..17
  /organism="Homo sapiens"
  /mol_type="genomic RNA"
  /db_xref="taxon:9606"

FEATURES
  source
    FH Key
    FT source
    FT Location/Qualifiers
      1..17
      /organism="Homo sapiens (human)".
      Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="genomic RNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 992 CCTGATCACCCTGCC 1007
Db 2 CCTGATCAGCTGCC 17

RESULT 588
BD226467
LOCUS
DEFINITION
  BD226467 17 bp DNA linear PAT 17-JUL-2003
  Method and probes for the detection of chromosome aberrations.
ACCESSION
  BD226467.1 GI:33036237
VERSION
  BD226467
KEYWORDS
  JP 2002513587-A/13.
SOURCE
  synthetic construct
  artificial sequences.
ORGANISM
  artificial sequences.
  1 (bases 1 to 17)
REFERENCE
  Dongen,J.J.M.V., Pluzek,K.J., Nielsen,K.V. and Adelhorst,K.
  Method and probes for the detection of chromosome aberrations
  Patent: JP 2002513587-A 13 14-MAY-2002;
JOURNAL
  DAKO AS
OS Artificial Sequence
PN JP 2002513587-A/13
PD 14-MAY-2002
PF 04-MAY-1999 JP 2000547260
PR 04-MAY-1998 DK 0615/98
PI JACOBS JOHANNES MARIA VAN DONEN,KARL JOHAN PLUZEK,KIRSTEN PI
PI VANG NIELSEN
PI KIM ADELHORST
PC
C12N15/09,C07H21/00,C12Q1/68,G01N33/53,G01N33/566,C12N15/00,CC
Description of Artificial Sequence:PNA probe, mbr, exon CC 4,
position 589-573

```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 30, 2004, 08:41:08 ; Search time 10 Seconds
(without alignments)
2.874 Million cell updates/sec

Title: US-10-024-369-3
Perfect score: 2247
Sequence: 1 atgcagctcctcagctgctcc.....ctgcagatgctccagatga 2247

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 374 seqs, 6395 residues

Total number of hits satisfying chosen parameters: 748

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 377 summaries

Database : rml3.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	27	1.2	27	1	US-08-700-035A-4 Sequence 4, Appli
C 2	27	1.2	27	1	US-08-700-035A-5 Sequence 5, Appli
C 3	27	1.2	27	1	PCT-US96-13457-4 Sequence 4, Appli
C 4	27	1.2	27	1	PCT-US96-13457-5 Sequence 5, Appli
C 5	24	1.1	24	1	US-09-061-764A-20 Sequence 20, Appli
C 6	17.2	0.8	22	1	US-08-276-567A-1 Sequence 1, Appli
C 7	17.2	0.8	22	1	PCT-US95-09011-1 Sequence 1, Appli
C 8	16.8	0.7	20	1	US-09-517-467B-55 Sequence 55, Appli
C 9	16.2	0.7	21	1	US-08-596-319-12 Sequence 12, Appli
C 10	15.8	0.7	19	1	US-08-299-074A-40 Sequence 40, Appli
C 11	15.8	0.7	19	1	US-09-399-773-40 Sequence 40, Appli
C 12	15.8	0.7	20	1	US-08-276-567A-2 Sequence 2, Appli
C 13	15.8	0.7	20	1	US-09-657-452A-33 Sequence 33, Appli
C 14	15.8	0.7	20	1	US-09-679-299A-159 Sequence 159, Appli
C 15	15.8	0.7	20	1	US-09-596-248D-36 Sequence 36, Appli
C 16	15.8	0.7	20	1	US-09-596-248D-37 Sequence 37, Appli
C 17	15.8	0.7	20	1	PCT-US95-09011-2 Sequence 2, Appli
C 18	15.4	0.7	17	1	US-09-866-108A-891 Sequence 891, Appli
C 19	15.4	0.7	17	1	US-09-866-108A-892 Sequence 892, Appli
C 20	15.4	0.7	17	1	US-09-866-108A-893 Sequence 893, Appli
C 21	15.4	0.7	18	1	US-08-800-751-23 Sequence 23, Appli
C 22	15.4	0.7	18	1	US-08-990-818-33 Sequence 33, Appli
C 23	15.4	0.7	18	1	US-08-679-645-609 Sequence 609, Appli
C 24	15.4	0.7	18	1	US-09-503-654-1 Sequence 1, Appli
C 25	15.2	0.7	20	1	US-08-388-381-22 Sequence 22, Appli
C 26	15.2	0.7	20	1	US-08-276-567A-3 Sequence 3, Appli
C 27	15.2	0.7	20	1	US-08-276-567A-4 Sequence 4, Appli
C 28	15.2	0.7	20	1	US-08-910-629A-57 Sequence 57, Appli
C 29	15.2	0.7	20	1	US-08-469-461-17 Sequence 17, Appli
C 30	15.2	0.7	20	1	US-07-890-609-17 Sequence 17, Appli
C 31	15.2	0.7	20	1	US-08-765-626-22 Sequence 22, Appli
C 32	15.2	0.7	20	1	US-09-287-796-57 Sequence 57, Appli
C 33	15.2	0.7	20	1	US-09-280-805-8 Sequence 8, Appli
C 34	15.2	0.7	20	1	US-09-130-616-57 Sequence 57, Appli
C 35	15.2	0.7	20	1	US-09-048-810-8 Sequence 8, Appli
C 36	15.2	0.7	20	1	US-09-851-062-32 Sequence 32, Appli
C 37	15.2	0.7	20	1	US-09-706-197-47 Sequence 47, Appli
C 38	15.2	0.7	20	1	US-09-422-978-8790 Sequence 8790, Appli
C 39	15.2	0.7	20	1	US-09-422-978-8838 Sequence 8838, Appli
C 40	15.2	0.7	20	1	US-09-198-452A-3216 Sequence 3216, Appli
C 41	15.2	0.7	20	1	US-09-198-452A-3350 Sequence 3350, Appli
C 42	15.2	0.7	20	1	US-09-198-452A-4873 Sequence 4873, Appli
C 43	15.2	0.7	20	1	US-09-572-891-8 Sequence 8, Appli
C 44	15.2	0.7	20	1	PCT-US95-08605-22 Sequence 22, Appli
C 45	15.2	0.7	20	1	PCT-US95-09011-3 Sequence 3, Appli
C 46	15.2	0.7	20	1	PCT-US95-09011-4 Sequence 4, Appli
C 47	15	0.7	20	1	US-09-488-671-108 Sequence 108, Appli
C 48	14.8	0.7	18	1	US-09-513-783A-39 Sequence 39, Appli
C 49	14.8	0.7	19	1	US-08-860-882A-52 Sequence 52, Appli
C 50	14.8	0.7	19	1	US-09-111-945-110 Sequence 110, Appli
C 51	14.8	0.7	19	1	US-09-011-769A-34 Sequence 34, Appli
C 52	14.8	0.7	19	1	US-09-548-797B-94 Sequence 94, Appli
C 53	14.4	0.6	16	1	5164485-15 Patent No. 5164485
C 54	14.4	0.6	17	1	US-07-977-630-6 Sequence 6, Appli
C 55	14.4	0.6	17	1	US-08-109-391A-10 Sequence 10, Appli
C 56	14.4	0.6	17	1	US-08-459-019A-10 Sequence 10, Appli
C 57	14.4	0.6	17	1	US-08-460-428A-10 Sequence 10, Appli
C 58	14.4	0.6	17	1	US-08-458-860A-10 Sequence 10, Appli
C 59	14.4	0.6	17	1	US-08-679-645-139 Sequence 139, Appli
C 60	14.4	0.6	17	1	US-09-866-108A-890 Sequence 890, Appli
C 61	14.4	0.6	17	1	US-09-866-108A-894 Sequence 894, Appli
C 62	14.4	0.6	17	1	US-09-866-108A-8005 Sequence 8005, Appli
C 63	14.4	0.6	17	1	US-09-866-108A-8006 Sequence 8006, Appli
C 64	14.4	0.6	19	1	US-09-565-808-17 Sequence 17, Appli
C 65	14	0.6	14	1	US-08-862-337-12 Sequence 12, Appli
C 66	14	0.6	16	1	US-09-829-855-101 Sequence 101, Appli
C 67	14	0.6	17	1	US-08-152-313-113 Sequence 113, Appli
C 68	14	0.6	17	1	US-08-579-223-113 Sequence 113, Appli
C 69	14	0.6	17	1	US-09-866-108A-895 Sequence 895, Appli
C 70	14	0.6	17	1	US-09-866-108A-896 Sequence 896, Appli
C 71	14	0.6	17	1	PCT-US94-12947A-113 Sequence 113, Appli
C 72	14	0.6	18	1	US-09-156-424-42 Sequence 42, Appli
C 73	14	0.6	18	1	US-09-638-509C-5 Sequence 5, Appli
C 74	14	0.6	18	1	US-09-387-341-56 Sequence 56, Appli
C 75	14	0.6	17	1	US-09-474-432B-730 Sequence 730, Appli
C 76	13.8	0.6	17	1	US-09-474-432B-720 Sequence 720, Appli
C 77	13.8	0.6	17	1	US-09-371-772B-4198 Sequence 4198, Appli
C 78	13.8	0.6	17	1	US-09-476-387-629 Sequence 629, Appli
C 79	13.8	0.6	17	1	US-09-476-387-719 Sequence 719, Appli
C 80	13.8	0.6	17	1	US-09-866-108A-515 Sequence 515, Appli
C 81	13.8	0.6	17	1	US-09-866-108A-665 Sequence 665, Appli
C 82	13.8	0.6	17	1	US-09-866-108A-1530 Sequence 1530, Appli
C 83	13.8	0.6	17	1	US-09-866-108A-1572 Sequence 1572, Appli
C 84	13.8	0.6	17	1	US-09-866-108A-1572 Sequence 1572, Appli
C 85	13.8	0.6	17	1	US-09-866-108A-1572 Sequence 1572, Appli
C 86	13.8	0.6	17	1	US-09-866-108A-2739 Sequence 2739, Appli
C 87	13.8	0.6	17	1	US-09-866-108A-6521 Sequence 6521, Appli
C 88	13.8	0.6	17	1	US-09-866-108A-6522 Sequence 6522, Appli
C 89	13.8	0.6	17	1	US-09-866-108A-6525 Sequence 6525, Appli
C 90	13.8	0.6	17	1	US-09-866-108A-6526 Sequence 6526, Appli
C 91	13.8	0.6	17	1	US-09-866-108A-6526 Sequence 6526, Appli
C 92	13.8	0.6	17	1	US-09-866-108A-6758 Sequence 6758, Appli
C 93	13.8	0.6	17	1	US-09-866-108A-8057 Sequence 8057, Appli
C 94	13.8	0.6	17	1	US-09-866-108A-9583 Sequence 9583, Appli
C 95	13.8	0.6	18	1	US-08-483-122-7 Sequence 7, Appli
C 96	13.8	0.6	18	1	US-08-483-122-7 Sequence 7, Appli
C 97	13.8	0.6	18	1	US-08-486-648-7 Sequence 7, Appli
C 98	13.8	0.6	18	1	US-08-486-648-8 Sequence 8, Appli
C 99	13.8	0.6	18	1	US-08-627-254C-9 Sequence 9, Appli
C 100	13.8	0.6	18	1	US-08-442-809A-57 Sequence 57, Appli
C 101	13.8	0.6	18	1	US-08-442-809A-59 Sequence 59, Appli
C 102	13.8	0.6	18	1	US-08-486-307-7 Sequence 7, Appli
C 103	13.8	0.6	18	1	US-08-486-307-8 Sequence 8, Appli
C 104	13.8	0.6	18	1	US-08-857-946-23 Sequence 23, Appli
C 105	13.8	0.6	18	1	US-09-205-921-35 Sequence 35, Appli
C 106	13.8	0.6	18	1	US-08-970-740-23 Sequence 23, Appli

C 107	13.8	0.6	18	1	US-08-479-795-7	Sequence 7, Appli	C 180	13	0.6	17	1	US-08-435-628-1517	Sequence 1517, Ap
C 108	13.8	0.6	18	1	US-08-479-795-8	Sequence 8, Appli	C 181	13	0.6	17	1	US-08-435-628-1519	Sequence 1519, Ap
C 109	13.8	0.6	18	1	US-09-344-521-25	Sequence 25, Appli	C 182	13	0.6	17	1	US-08-897-340-9	Sequence 9, Appli
C 110	13.8	0.6	18	1	US-08-847-844A-135	Sequence 135, App	C 183	13	0.6	17	1	US-09-252-329-9	Sequence 9, Appli
C 111	13.8	0.6	18	1	US-09-474-922A-84	Sequence 84, Appli	C 184	13	0.6	17	1	US-08-584-040-2268	Sequence 2268, Ap
C 112	13.8	0.6	18	1	US-08-484-406-7	Sequence 7, Appli	C 185	13	0.6	17	1	US-08-584-040-2269	Sequence 2269, Ap
C 113	13.8	0.6	18	1	US-08-484-406-8	Sequence 8, Appli	C 186	13	0.6	17	1	US-09-371-772B-813	Sequence 813, App
C 114	13.8	0.6	18	1	US-08-484-203-7	Sequence 7, Appli	C 187	13	0.6	17	1	US-09-371-772B-814	Sequence 814, App
C 115	13.8	0.6	18	1	US-08-484-203-8	Sequence 8, Appli	C 188	13	0.6	17	1	US-09-371-772B-4754	Sequence 4754, Ap
C 116	13.8	0.6	18	1	US-08-486-313-7	Sequence 7, Appli	C 189	13	0.6	17	1	US-09-371-772B-5053	Sequence 4789, Ap
C 117	13.8	0.6	18	1	US-08-486-313-8	Sequence 8, Appli	C 190	13	0.6	17	1	US-09-371-772B-5054	Sequence 5053, Ap
C 118	13.8	0.6	18	1	US-09-422-978-8459	Sequence 8459, Ap	C 191	13	0.6	17	1	US-09-371-772B-5194	Sequence 5194, Ap
C 119	13.8	0.6	18	1	US-08-857-636-51	Sequence 51, Appli	C 192	13	0.6	17	1	US-09-371-772B-5195	Sequence 5195, Ap
C 120	13.4	0.6	15	1	US-07-664-989B-121	Sequence 121, App	C 193	13	0.6	17	1	US-09-371-772B-813	Sequence 813, App
C 121	13.4	0.6	15	1	US-08-323-192D-13	Sequence 13, Appli	C 194	13	0.6	17	1	US-09-866-108A-897	Sequence 897, App
C 122	13.4	0.6	15	1	US-08-470-887A-12	Sequence 12, Appli	C 195	13	0.6	17	1	US-09-866-108A-9584	Sequence 9584, Ap
C 123	13.4	0.6	15	1	US-08-292-620A-193	Sequence 193, App	C 196	13	0.6	17	1	US-09-866-108A-9585	Sequence 9585, Ap
C 124	13.4	0.6	15	1	US-08-292-620A-656	Sequence 656, App	C 197	13	0.6	17	1	US-09-866-108A-9586	Sequence 9586, Ap
C 125	13.4	0.6	15	1	US-08-316-439A-10	Sequence 10, Appli	C 198	13	0.6	17	1	US-09-866-108A-9587	Sequence 9587, Ap
C 126	13.4	0.6	15	1	US-08-252-508B-12	Sequence 12, Appli	C 199	13	0.6	17	1	US-07-988-194A-16	Sequence 16, Appli
C 127	13.4	0.6	15	1	US-08-585-684B-163	Sequence 163, App	C 200	12.8	0.6	16	1	US-08-061-697-23	Sequence 23, Appli
C 128	13.4	0.6	15	1	US-08-588-595-6	Sequence 6, Appli	C 201	12.8	0.6	16	1	US-08-131-365B-23	Sequence 23, Appli
C 129	13.4	0.6	15	1	US-09-106-377-12	Sequence 12, Appli	C 202	12.8	0.6	16	1	US-08-258-152-18	Sequence 18, Appli
C 130	13.4	0.6	15	1	US-09-071-845-383	Sequence 383, App	C 203	12.8	0.6	16	1	US-08-076-289A-18	Sequence 18, Appli
C 131	13.4	0.6	15	1	US-09-071-845-656	Sequence 656, App	C 204	12.8	0.6	16	1	US-08-438-582-18	Sequence 18, Appli
C 132	13.4	0.6	15	1	US-09-038-073-163	Sequence 163, App	C 205	12.8	0.6	16	1	US-08-668-123-23	Sequence 23, Appli
C 133	13.4	0.6	15	1	US-09-038-073-163	Sequence 163, App	C 206	12.8	0.6	16	1	US-08-954-210-64	Sequence 64, Appli
C 134	13.4	0.6	16	1	US-09-371-772B-7079	Sequence 7079, Ap	C 207	12.8	0.6	16	1	US-08-413-974-16	Sequence 16, Appli
C 135	13.4	0.6	16	1	US-09-829-855-11	Sequence 11, Appli	C 208	12.8	0.6	16	1	US-08-434-418-16	Sequence 16, Appli
C 136	13.4	0.6	16	1	US-09-829-855-13	Sequence 13, Appli	C 209	12.8	0.6	16	1	US-09-256-556-18	Sequence 18, Appli
C 137	13.4	0.6	16	1	US-09-829-855-77	Sequence 77, Appli	C 210	12.8	0.6	16	1	US-08-433-288-16	Sequence 16, Appli
C 138	13.4	0.6	17	1	US-08-292-620A-1644	Sequence 1644, Ap	C 211	12.8	0.6	16	1	US-08-174-739A-16	Sequence 16, Appli
C 139	13.4	0.6	17	1	US-08-292-620A-1700	Sequence 1700, Ap	C 212	12.8	0.6	16	1	US-08-479-737-16	Sequence 16, Appli
C 140	13.4	0.6	17	1	US-08-292-620A-1707	Sequence 1707, Ap	C 213	12.8	0.6	16	1	US-08-294-312B-26	Sequence 26, Appli
C 141	13.4	0.6	17	1	US-08-292-620A-1743	Sequence 1743, Ap	C 214	12.8	0.6	16	1	US-08-475-442A-16	Sequence 16, Appli
C 142	13.4	0.6	17	1	US-08-292-620A-1796	Sequence 1796, Ap	C 215	12.8	0.6	16	1	US-08-468-024B-26	Sequence 26, Appli
C 143	13.4	0.6	17	1	US-08-292-620A-1873	Sequence 1873, Ap	C 216	12.8	0.6	16	1	US-08-434-256-16	Sequence 16, Appli
C 144	13.4	0.6	17	1	US-08-292-620A-1934	Sequence 1934, Ap	C 217	12.8	0.6	16	1	US-09-431-419A-64	Sequence 64, Appli
C 145	13.4	0.6	17	1	US-09-071-845-1644	Sequence 1644, Ap	C 218	12.8	0.6	16	1	US-08-187-757D-24	Sequence 24, Appli
C 146	13.4	0.6	17	1	US-09-071-845-1700	Sequence 1700, Ap	C 219	12.8	0.6	16	1	US-09-944-411-18	Sequence 18, Appli
C 147	13.4	0.6	17	1	US-09-071-845-1707	Sequence 1707, Ap	C 220	12.8	0.6	16	1	US-09-371-772B-5758	Sequence 5758, Ap
C 148	13.4	0.6	17	1	US-09-071-845-1743	Sequence 1743, Ap	C 221	12.8	0.6	16	1	US-09-371-772B-5759	Sequence 5759, Ap
C 149	13.4	0.6	17	1	US-09-071-845-1796	Sequence 1796, Ap	C 222	12.8	0.6	16	1	US-09-371-772B-7002	Sequence 7002, Ap
C 150	13.4	0.6	17	1	US-09-071-845-1873	Sequence 1873, Ap	C 223	12.8	0.6	16	1	US-08-465-679-26	Sequence 26, Appli
C 151	13.4	0.6	17	1	US-09-071-845-1934	Sequence 1934, Ap	C 224	12.8	0.6	16	1	US-09-829-855-107	Sequence 107, App
C 152	13.4	0.6	17	1	US-09-371-772B-4197	Sequence 4197, Ap	C 225	12.8	0.6	16	1	US-08-210-143C-24	Sequence 24, Appli
C 153	13.4	0.6	17	1	US-09-371-772B-4505	Sequence 4505, Ap	C 226	12.8	0.6	16	1	US-09-479-005A-337	Sequence 337, App
C 154	13.4	0.6	17	1	US-09-371-772B-4755	Sequence 4755, Ap	C 227	12.8	0.6	16	1	5256545-4	Sequence 337, App
C 155	13.4	0.6	17	1	US-09-371-772B-6625	Sequence 6625, Ap	C 228	12.8	0.6	16	1	5256545-33	Patent No. 5256545
C 156	13.4	0.6	17	1	US-09-827-998-471	Sequence 471, App	C 229	12.8	0.6	17	1	US-08-379-078-631	Sequence 631, App
C 157	13.4	0.6	17	1	US-09-827-998-472	Sequence 472, App	C 230	12.8	0.6	17	1	US-08-373-124A-842	Sequence 842, App
C 158	13.4	0.6	17	1	US-09-827-998-473	Sequence 473, App	C 231	12.8	0.6	17	1	US-08-460-853-1	Sequence 1, Appli
C 159	13.4	0.6	17	1	US-09-866-108A-889	Sequence 889, App	C 232	12.8	0.6	17	1	US-08-460-853-8	Sequence 8, Appli
C 160	13.4	0.6	17	1	US-09-866-108A-6756	Sequence 6756, App	C 233	12.8	0.6	17	1	US-08-435-628-842	Sequence 842, App
C 161	13.4	0.6	17	1	US-09-866-108A-6757	Sequence 6757, App	C 234	12.8	0.6	17	1	US-08-292-620A-1636	Sequence 1636, App
C 162	13.4	0.6	17	1	US-09-866-108A-6950	Sequence 6950, App	C 235	12.8	0.6	17	1	US-08-292-620A-1643	Sequence 1643, App
C 163	13.4	0.6	17	1	US-09-866-108A-6951	Sequence 6951, App	C 236	12.8	0.6	17	1	US-08-292-620A-1800	Sequence 1800, App
C 164	13.4	0.6	17	1	US-09-866-108A-6952	Sequence 6952, App	C 237	12.8	0.6	17	1	US-08-657-884-9	Sequence 9, Appli
C 165	13.4	0.6	17	1	US-09-866-108A-8004	Sequence 8004, App	C 238	12.8	0.6	17	1	US-08-985-162-734	Sequence 734, App
C 166	13.4	0.6	17	1	US-09-866-108A-8007	Sequence 8007, App	C 239	12.8	0.6	17	1	US-08-963-927-28	Sequence 28, Appli
C 167	13.4	0.6	17	1	US-09-866-108A-8054	Sequence 8054, App	C 240	12.8	0.6	17	1	US-08-998-099-119	Sequence 119, App
C 168	13.4	0.6	17	1	US-09-866-108A-8055	Sequence 8055, App	C 241	12.8	0.6	17	1	US-09-071-845-1636	Sequence 1636, App
C 169	13	0.6	15	1	US-08-667-939A-10	Sequence 10, Appli	C 242	12.8	0.6	17	1	US-09-071-845-1643	Sequence 1643, App
C 170	13	0.6	15	1	US-08-667-939A-21	Sequence 21, Appli	C 243	12.8	0.6	17	1	US-09-071-845-1800	Sequence 1800, App
C 171	13	0.6	15	1	US-08-433-123-10	Sequence 21, Appli	C 244	12.8	0.6	17	1	US-09-481-810-28	Sequence 28, Appli
C 172	13	0.6	15	1	US-08-433-123-21	Sequence 21, Appli	C 245	12.8	0.6	17	1	US-09-158-960-5	Sequence 9, Appli
C 173	13	0.6	16	1	US-09-371-772B-5827	Sequence 5827, App	C 246	12.8	0.6	17	1	US-07-974-409C-631	Sequence 631, App
C 174	13	0.6	17	1	US-08-373-124A-1030	Sequence 1030, App	C 247	12.8	0.6	17	1	US-08-584-040-1736	Sequence 1736, App
C 175	13	0.6	17	1	US-08-373-124A-1032	Sequence 1032, App	C 248	12.8	0.6	17	1	US-08-584-040-2235	Sequence 2235, App
C 176	13	0.6	17	1	US-08-373-124A-1517	Sequence 1517, App	C 249	12.8	0.6	17	1	US-08-584-040-2895	Sequence 2895, App
C 177	13	0.6	17	1	US-08-373-124A-1519	Sequence 1519, App	C 250	12.8	0.6	17	1	US-08-584-040-2903	Sequence 2903, App
C 178	13	0.6	17	1	US-08-435-628-1030	Sequence 1030, App	C 251	12.8	0.6	17	1	US-08-584-040-4155	Sequence 4155, App
C 179	13	0.6	17	1	US-08-435-628-1032	Sequence 1032, App	C 252	12.8	0.6	17	1	US-08-584-040-5900	Sequence 5900, App

253	12.8	0.6	17	1	US-08-584-040-5962	Sequence 5962, Ap	326	12.4	0.6	14	1	US-08-303-004-19	Sequence 19, Appl
254	12.8	0.6	17	1	US-08-584-040-5963	Sequence 5963, Ap	C 327	12.4	0.6	14	1	US-08-985-162-1761	Sequence 1761, Ap
C 255	12.8	0.6	17	1	US-09-474-432B-839	Sequence 839, App	C 328	12.4	0.6	14	1	US-08-998-099-355	Sequence 355, App
C 256	12.8	0.6	17	1	US-09-371-772B-281	Sequence 281, App	C 329	12.4	0.6	14	1	US-09-401-063-1761	Sequence 1761, Ap
257	12.8	0.6	17	1	US-09-371-772B-780	Sequence 780, App	C 330	12.4	0.6	15	1	US-08-093-383-19	Sequence 19, Appl
258	12.8	0.6	17	1	US-09-371-772B-1662	Sequence 1662, App	C 331	12.4	0.6	15	1	US-08-259-148A-32	Sequence 32, Appl
C 259	12.8	0.6	17	1	US-09-371-772B-1670	Sequence 1670, Ap	C 332	12.4	0.6	15	1	US-08-292-620A-426	Sequence 426, App
C 260	12.8	0.6	17	1	US-09-371-772B-1922	Sequence 1922, Ap	C 333	12.4	0.6	15	1	US-08-657-884A-25	Sequence 25, Appl
261	12.8	0.6	17	1	US-09-371-772B-2739	Sequence 2739, Ap	C 334	12.4	0.6	15	1	US-08-585-684B-1267	Sequence 29, Appl
262	12.8	0.6	17	1	US-09-371-772B-2799	Sequence 2799, Ap	C 335	12.4	0.6	15	1	US-08-585-684B-1262	Sequence 162, App
263	12.8	0.6	17	1	US-09-371-772B-2800	Sequence 2800, Ap	C 336	12.4	0.6	15	1	US-08-585-684B-1341	Sequence 1341, Ap
C 264	12.8	0.6	17	1	US-09-371-772B-4231	Sequence 4231, Ap	C 337	12.4	0.6	15	1	US-08-585-684B-2049	Sequence 2049, Ap
C 265	12.8	0.6	17	1	US-09-371-772B-4232	Sequence 4232, Ap	C 338	12.4	0.6	15	1	US-08-585-684B-2267	Sequence 2267, Ap
C 266	12.8	0.6	17	1	US-09-371-772B-4511	Sequence 4511, Ap	C 339	12.4	0.6	15	1	US-07-876-941A-48	Sequence 2, Appl
C 267	12.8	0.6	17	1	US-09-371-772B-4512	Sequence 4512, Ap	C 340	12.4	0.6	15	1	US-08-318-826A-2	Sequence 2, Appl
268	12.8	0.6	17	1	US-09-371-772B-5163	Sequence 5163, Ap	C 341	12.4	0.6	15	1	US-08-588-595-1	Sequence 1, Appl
C 269	12.8	0.6	17	1	US-09-371-772B-6283	Sequence 6283, Ap	C 342	12.4	0.6	15	1	US-08-850-347-5	Sequence 5, Appl
C 270	12.8	0.6	17	1	US-09-371-772B-6650	Sequence 6650, Ap	C 343	12.4	0.6	15	1	US-09-071-845-426	Sequence 426, App
C 271	12.8	0.6	17	1	US-09-476-387-838	Sequence 838, App	C 344	12.4	0.6	15	1	US-09-038-073-1361	Sequence 162, App
C 272	12.8	0.6	17	1	US-09-401-063-734	Sequence 734, App	C 345	12.4	0.6	15	1	US-09-038-073-1341	Sequence 1341, Ap
C 273	12.8	0.6	17	1	US-09-787-069-8	Sequence 8, Appl	C 346	12.4	0.6	15	1	US-09-038-073-2049	Sequence 2049, Ap
274	12.8	0.6	17	1	US-09-811-492-9	Sequence 9, Appl	C 347	12.4	0.6	15	1	US-09-038-073-2267	Sequence 2267, Ap
C 275	12.8	0.6	17	1	US-09-827-998-793	Sequence 793, App	C 348	12.4	0.6	15	1	US-09-158-980-25	Sequence 25, Appl
C 276	12.8	0.6	17	1	US-09-827-998-794	Sequence 794, App	C 349	12.4	0.6	15	1	US-09-158-980-29	Sequence 29, Appl
C 277	12.8	0.6	17	1	US-09-827-998-801	Sequence 801, App	C 350	12.4	0.6	15	1	US-09-042-353-38	Sequence 38, Appl
C 278	12.8	0.6	17	1	US-09-827-998-802	Sequence 802, App	C 351	12.4	0.6	15	1	US-08-758-417A-303	Sequence 303, Appl
C 279	12.8	0.6	17	1	US-09-866-108A-514	Sequence 514, App	C 352	12.4	0.6	15	1	US-09-081-646-417	Sequence 417, App
C 280	12.8	0.6	17	1	US-09-866-108A-516	Sequence 516, App	C 353	12.4	0.6	15	1	US-09-081-646-506	Sequence 506, App
C 281	12.8	0.6	17	1	US-09-866-108A-664	Sequence 664, App	C 354	12.4	0.6	15	1	US-09-811-492-25	Sequence 25, Appl
C 282	12.8	0.6	17	1	US-09-866-108A-666	Sequence 666, App	C 355	12.4	0.6	15	1	US-09-811-492-29	Sequence 29, Appl
C 283	12.8	0.6	17	1	US-09-866-108A-1134	Sequence 1134, App	C 356	12.4	0.6	16	1	US-07-988-194A-22	Sequence 22, Appl
C 284	12.8	0.6	17	1	US-09-866-108A-1135	Sequence 1135, App	C 357	12.4	0.6	16	1	US-08-311-760A-392	Sequence 392, Appl
285	12.8	0.6	17	1	US-09-866-108A-1456	Sequence 1456, App	C 358	12.4	0.6	16	1	US-08-258-152-24	Sequence 24, Appl
286	12.8	0.6	17	1	US-09-866-108A-1457	Sequence 1457, App	C 359	12.4	0.6	16	1	US-08-076-299A-24	Sequence 24, Appl
287	12.8	0.6	17	1	US-09-866-108A-1529	Sequence 1529, App	C 360	12.4	0.6	16	1	US-08-292-620A-1615	Sequence 1615, App
288	12.8	0.6	17	1	US-09-866-108A-1531	Sequence 1531, App	C 361	12.4	0.6	16	1	US-08-438-582-24	Sequence 24, Appl
C 289	12.8	0.6	17	1	US-09-866-108A-1564	Sequence 1564, App	C 362	12.4	0.6	16	1	US-08-173-489C-168	Sequence 168, App
C 290	12.8	0.6	17	1	US-09-866-108A-1565	Sequence 1565, App	C 363	12.4	0.6	16	1	US-08-774-310-392	Sequence 392, Appl
C 291	12.8	0.6	17	1	US-09-866-108A-1571	Sequence 1571, App	C 364	12.4	0.6	16	1	US-09-071-845-1615	Sequence 1615, App
C 292	12.8	0.6	17	1	US-09-866-108A-1573	Sequence 1573, App	C 365	12.4	0.6	16	1	US-09-266-596-24	Sequence 24, Appl
293	12.8	0.6	17	1	US-09-866-108A-1959	Sequence 1959, App	C 366	12.4	0.6	16	1	US-08-479-737-22	Sequence 22, Appl
294	12.8	0.6	17	1	US-09-866-108A-1961	Sequence 1961, App	C 367	12.4	0.6	16	1	US-08-475-442A-22	Sequence 22, Appl
295	12.8	0.6	17	1	US-09-866-108A-2445	Sequence 2445, App	C 368	12.4	0.6	16	1	US-09-944-411-24	Sequence 24, Appl
296	12.8	0.6	17	1	US-09-866-108A-2446	Sequence 2446, App	C 369	12.4	0.6	16	1	US-09-829-855-25	Sequence 25, Appl
C 297	12.8	0.6	17	1	US-09-866-108A-2716	Sequence 2716, App	C 370	12.4	0.6	16	1	US-09-829-855-30	Sequence 30, Appl
C 298	12.8	0.6	17	1	US-09-866-108A-2717	Sequence 2717, App	C 371	12.4	0.6	16	1	US-09-829-855-32	Sequence 32, Appl
299	12.8	0.6	17	1	US-09-866-108A-2738	Sequence 2738, App	C 372	12.4	0.6	16	1	US-09-829-855-34	Sequence 34, Appl
300	12.8	0.6	17	1	US-09-866-108A-2740	Sequence 2740, App	C 373	12.4	0.6	16	1	US-09-829-855-91	Sequence 91, Appl
301	12.8	0.6	17	1	US-09-866-108A-6520	Sequence 6520, App	C 374	12.4	0.6	16	1	US-09-829-855-92	Sequence 92, Appl
302	12.8	0.6	17	1	US-09-866-108A-6523	Sequence 6523, App	C 375	12.4	0.6	16	1	US-09-829-855-103	Sequence 103, App
303	12.8	0.6	17	1	US-09-866-108A-6524	Sequence 6524, App	C 376	12.4	0.6	16	1	US-09-829-855-105	Sequence 105, App
304	12.8	0.6	17	1	US-09-866-108A-6527	Sequence 6527, App	C 377	12.4	0.6	16	1	US-09-829-855-106	Sequence 106, App
305	12.8	0.6	17	1	US-09-866-108A-6759	Sequence 6759, App							
306	12.8	0.6	17	1	US-09-866-108A-7938	Sequence 7938, App							
307	12.8	0.6	17	1	US-09-866-108A-7939	Sequence 7939, App							
308	12.8	0.6	17	1	US-09-866-108A-8058	Sequence 8058, App							
309	12.8	0.6	17	1	US-09-866-108A-8136	Sequence 8136, App							
310	12.8	0.6	17	1	US-09-866-108A-8137	Sequence 8137, App							
311	12.8	0.6	17	1	US-09-866-108A-8379	Sequence 8379, App							
312	12.8	0.6	17	1	US-09-866-108A-8380	Sequence 8380, App							
313	12.8	0.6	17	1	US-09-866-108A-8619	Sequence 8619, App							
314	12.8	0.6	17	1	US-09-866-108A-8620	Sequence 8620, App							
315	12.8	0.6	17	1	US-09-866-108A-9582	Sequence 9582, App							
C 316	12.8	0.6	17	1	US-09-866-108A-10081	Sequence 10081, App							
C 317	12.8	0.6	17	1	US-09-866-108A-10082	Sequence 10082, App							
318	12.8	0.6	17	1	US-09-866-108A-10318	Sequence 10318, A							
319	12.8	0.6	17	1	US-09-866-108A-10319	Sequence 10319, A							
320	12.8	0.6	17	1	US-09-866-108A-10320	Sequence 10320, A							
321	12.8	0.6	17	1	US-09-866-108A-10321	Sequence 10321, A							
322	12.8	0.6	17	1	PCT-US93-00877-631	Sequence 631, App							
323	12.8	0.6	18	1	US-09-513-783A-39	Sequence 39, Appl							
324	12.8	0.6	27	1	US-08-700-035A-4	Sequence 4, Appl							
325	12.8	0.6	27	1	PCT-US96-13457-4	Sequence 4, Appl							

ALIGNMENTS

RESULT 1
 US-08-700-035A-4/C
 / Sequence 4, Application US/08700035A
 / Patent No. 5831068
 / GENERAL INFORMATION:
 / APPLICANT: Natr, et al., Smith K.
 / TITLE OF INVENTION: A METHOD TO INCREASE THE DENSITY OF
 / NUMBER OF SEQUENCES: 16
 / CORRESPONDENCE ADDRESS:
 / ADDRESSEE: Fish & Richardson P.C.
 / STREET: 225 Franklin Street
 / CITY: Boston
 / STATE: MA
 / COUNTRY: USA
 / ZIP: 02110-2804

```
COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/700,035A
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/517,373
; FILING DATE: 21-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 06765/009001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-700-035A-4
```

```
Query Match 1.2%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.3;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1192 AAGACTCAACAGAGAGGCTGTG 1218
Db 27 AAGACTCAACAGAGAGGAGGCTGTG 1
```

```
RESULT 2
US-08-700-035A-5/c
; Sequence 5, Application US/08700035A
; Patent No. 5831068
; GENERAL INFORMATION:
; APPLICANT: Nait, et al., Smita K.
; TITLE OF INVENTION: A METHOD TO INCREASE THE DENSITY OF
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/700,035A
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/517,373
; FILING DATE: 21-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 06765/009001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
```

```
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-700-035A-5
```

```
Query Match 1.2%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.3;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1978 AACCGTGCTACTATCTCGATGAT 2004
Db 27 AACCGTGCTACTATCTCGATGAT 1
```

```
RESULT 3
PCT-US96-13457-4/c
; Sequence 4, Application PC/TUS9613457
; GENERAL INFORMATION:
; APPLICANT: Duke University
; TITLE OF INVENTION: A METHOD TO INCREASE THE DENSITY OF
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/13457
; FILING DATE: 20-AUG-1996
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/517,373
; FILING DATE: 21-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 06765/009001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; PCT-US96-13457-4
```

```
Query Match 1.2%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.3;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1192 AAGACTCAACAGAGAGGCTGTG 1218
Db 27 AAGACTCAACAGAGAGGAGGCTGTG 1
```

```
RESULT 4
PCT-US96-13457-5/c
; Sequence 5, Application PC/TUS9613457
; GENERAL INFORMATION:
```

APPLICANT: Duke University
TITLE OF INVENTION: A METHOD TO INCREASE THE DENSITY OF
TITLE OF INVENTION: ANTIGEN ON ANTIGEN PRESENTING CELLS
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/13457
FILING DATE: 20-AUG-1996
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/517,373
FILING DATE: 21-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: Clark, Paul T.
REGISTRATION NUMBER: 30,162
REFERENCE/DOCKET NUMBER: 06765/009W01
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
PCT-US96-13457-5

Query Match 1.2%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.3;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1978 AAACCGTGTACTTATCTGGATGAT 2004
Db 27 AAACCGTGTACTTATCTGGATGAT 1

RESULT 5
US-09-061-764A-20
Sequence 20, Application US/09061764A
Patent No. 6284879
GENERAL INFORMATION:
APPLICANT: Fautschman, Denise L
TITLE OF INVENTION: TRANSPORT ASSOCIATED PROTEIN SPLICING VARIANTS
TITLE OF INVENTION: AND MODEL FOR IMMUNE DIVERSITY
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Yankwich & Associates
STREET: 130 Bishop Allen Drive
CITY: Cambridge
STATE: Massachusetts
COUNTRY: United States of America
ZIP: 02139
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44MB storage
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Microsoft Word 97 SR-1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/061.764A
FILING DATE: April 16, 1998
CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Yankwich, Leon R
REGISTRATION NUMBER: 30,237
REFERENCE/DOCKET NUMBER: MGH-002.0 US/MGH-1247.0
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-491-4343
TELEFAX: 617-491-8801
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: synthetic DNA fragment
US-09-061-764A-20

Query Match 1.1%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1866 TAGTTTCATCTCTGACTCCCTCA 1889
Db 1 TAGTTTCATCTCTGACTCCCTCA 24

RESULT 6
US-08-276-567A-1/c
Sequence 1, Application US/08276567A
Patent No. 5866699
GENERAL INFORMATION:
APPLICANT: Adrienne Smyth
TITLE OF INVENTION: Oligonucleotides Having Anti-MDR-1 Gene Activity
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Lappin & Kusner
STREET: 200 State Street
CITY: Boston
STATE: Massachusetts
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/276.567A
FILING DATE:
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Kerner, Ann-Louise
REGISTRATION NUMBER: 33,523
REFERENCE/DOCKET NUMBER: HYZ-022
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-330-1300
TELEFAX: 617-330-1311
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHEetical: NO
ANTI-SENSE: YES
US-08-276-567A-1

Query Match 0.8%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 30;

Matches	19;	Conservative	0;	Mismatches	3;	Indels	0;	Gaps	0;
Qy	1617	CAATGGCTCTGGGAAGACACA	1638						
Db	22	CAGTGGCTGTGGGAAGACACA	1						

```

1      RESULT 7
2      PCT-US95-09011-1/c
3      Sequence 1, Application PC/TUS9509011
4      GENERAL INFORMATION:
5      APPLICANT: Hybridon, Inc.
6      TITLE OF INVENTION: Oligonucleotides Having Anti-MDR-1
7      FILE OF INVENTION: Gene Activity
8      NUMBER OF SEQUENCES: 9
9      CORRESPONDENCE ADDRESS:
10     ADDRESSEE: Lappin & Kusmer
11     STREET: 200 State Street
12     CITY: Boston
13     STATE: Massachusetts
14     COUNTRY: USA
15     ZIP: 02109
16
17     COMPUTER READABLE FORM:
18     MEDIUM TYPE: Floppy disk
19     COMPUTER: IBM PC compatible
20     OPERATING SYSTEM: PC-DOS/MS-DOS
21     SOFTWARE: Patentin Release #1.0, Version #1.25
22     CURRENT APPLICATION DATA:
23     APPLICATION NUMBER: PCT/US95/09011
24     FILING DATE:
25     CLASSIFICATION:
26     ATTORNEY/AGENT INFORMATION:
27     NAME: Kerner, Ann-Louise
28     REGISTRATION NUMBER: 33,523
29     REFERENCE/DOCKET NUMBER: HYZ-022PCT
30     TELECOMMUNICATION INFORMATION:
31     TELEPHONE: 617-330-1300
32     TELEFAX: 617-330-1311
33     INFORMATION FOR SEQ ID NO: 1:
34     SEQUENCE CHARACTERISTICS:
35     LENGTH: 22 base pairs
36     TYPE: nucleic acid
37     STRANDEDNESS: single
38     TOPOLOGY: linear
39     MOLECULE TYPE: cDNA
40     HYPOTHETICAL: NO
41     ANTI-SENSE: YES
42
43     PCT-US95-09011-1

```

```

Query Match          0.8%; Score 17.2; DB 1; Length 22;
Best Local Similarity      86.4%; Pred. No. 30;
Matches    19; Conservative   0; Mismatches     3; Indels       0; Gaps     0;

OY              1617 CAATGGGTCTGTGGGAAGACGACA 1638
                ||||| | | | | | | | | | | | | | |
Db              22 CAGTGGCTGTGTGGGAAGACGACA 1

RESULT 8
US-09-517-467B--55/C
; Sequence 55, Application US/09517467B
; Patent No. 6451602
; GENERAL INFORMATION:
; APPLICANT: Ian Popoff
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PARP EXPRESSION
; FILE REFERENCE: RTS-0150
; CURRENT APPLICATION NUMBER: US/09/517,467B
; CURRENT FILING DATE: 2001-03-02
; PRIOR APPLICATION NUMBER: 09/517,467
; PRIOR FILING DATE: 2000-03-02
; NUMBER OF SEQ ID NOS: 345
; SEQ ID NO 55
```

```

; LENGTH: 20
;
; TYPE: DNA
;
; ORGANISM: Artificial Sequence
;
; FEATURE:
;
; OTHER INFORMATION: Antisense Oligonucleotide
US-03-517-467B-55

```

Query Match	0.74;	Score 16.8;	DB 1;	Length 20;
Best Local Similarity	90.0%;	Pred. No. 33;		
Matches	18;	Conservative	0;	Mismatches
			2;	Indels
				Gaps 0;
QY	1193	AGACATCTAACGAGAGG	1212	
Db	20	AGACATCTAACGAGAGG	1	

```

RESULT 9
US-08-596-319-12
Sequence 12, Application US/08596319
Patent No. 5981262
GENERAL INFORMATION:
APPLICANT: Brugge, Joan
APPLICANT: Morgenstern, Jay
APPLICANT: Shue, Lily
APPLICANT: Zydowsky, Lynne
APPLICANT: Zoller, Mark
APPLICANT: Pawaon, Anthony
TITLE OF INVENTION: HUMAN syk
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESSES:
ADDRESSEE: ARIAD Pharmaceuticals, Inc.
STREET: 26 Landsdowne Street
CITY: Cambridge
STATE: MA
COUNTRY: USA
ZIP: 02139
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/0596,319
FILING DATE: 31-OAN-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: WO US94/04540
FILING DATE: 25-APR-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/052,560
FILING DATE: 23-APR-1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: BERSTEIN, David L.
REGISTRATION NUMBER: 31,235
REFERENCE/DOCKET NUMBER: ARIAD305A-PCT/US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 494-0400
TELEFAX: (617) 494-0208
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-596-319-12
Query Match 0.7%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 46;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0.

```



```

; REFERENCE/DOCKET NUMBER: HYZ-022
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-330-1300
; TELEFAX: 617-330-1311
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHEICAL: NO
; ANTI-SENSE: YES
; US-08-276-567A-2

Query Match          0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 53;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1620 TGGGCTGGGAAGACACA 1638
Db      19   TGGCTGTGGAAAGACACA 1

RESULT 13
US-09-657-452A-33/c
; Sequence 33, Application US/09657452A
; Patent No. 6426188
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHORYLASE KINASE ALPHA 1 EXPRESSION
; FILE REFERENCE: RTS-0125
; CURRENT APPLICATION NUMBER: US/09/657,452A
; CURRENT FILING DATE: 2000-09-07
; NUMBER OF SEQ ID NOS: 178
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-657-452A-33

Query Match          0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 53;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1676 GGGGACAGCTGCTGTGGA 1694
Db      19   GGGGACACCTGCACTTGA 1

RESULT 14
US-09-679-299A-159/c
; Sequence 159, Application US/09679299A
; Patent No. 6566135
; GENERAL INFORMATION:
; APPLICANT: Vickie L. Brown-Driver
; APPLICANT: Hong Zhang
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 6 EXPRESSION
; FILE REFERENCE: RTS-0187
; CURRENT APPLICATION NUMBER: US/09/679,299A
; CURRENT FILING DATE: 2000-10-04
; NUMBER OF SEQ ID NOS: 164
; SEQ ID NO 159
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-679-299A-159
```

```

Query Match          0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 53;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1885 CCTGAGGCTATGACACAG 1903
Db      20   CCTGAGGCTTAGACACCG 2

RESULT 15
US-09-596-248D-36
; Sequence 36, Application US/09596248D
; Patent No. 6599727
; GENERAL INFORMATION:
; APPLICANT: Christenson, Erik
; APPLICANT: Demaggio, Anthony J
; APPLICANT: Goldman, Phyllis S
; APPLICANT: McElligott, David L
; TITLE OF INVENTION: Human Poly(ADP-Ribose) Polymerase 2 Materials and
; FILE REFERENCE: 27866/36544
; CURRENT APPLICATION NUMBER: US/09/596,248D
; CURRENT FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/139,543
; PRIOR FILING DATE: 1999-06-16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
; US-09-596-248D-36

Query Match          0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 53;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1193 AGACACTCAGCCAGAGGA 1211
Db      2   AGACACCCAGCCGAGGAGA 20

RESULT 16
US-09-596-248D-37/c
; Sequence 37, Application US/09596248D
; Patent No. 6599727
; GENERAL INFORMATION:
; APPLICANT: Christenson, Erik
; APPLICANT: Demaggio, Anthony J
; APPLICANT: Goldman, Phyllis S
; APPLICANT: McElligott, David L
; TITLE OF INVENTION: Human Poly(ADP-Ribose) Polymerase 2 Materials and
; FILE REFERENCE: 27866/36544
; CURRENT APPLICATION NUMBER: US/09/596,248D
; CURRENT FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/139,543
; PRIOR FILING DATE: 1999-06-16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
; US-09-596-248D-37

Query Match          0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 53;
```

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1193 AGACACTCAACGAGAGGA 1211
Db 19 AGACACCAACGAGAGGA 1

RESULT 17
PCT-US95-09011-2/c
Sequence 2, Application PC/TUS9509011
GENERAL INFORMATION:
APPLICANT: Hybridon, Inc.
TITLE OF INVENTION: Oligonucleotides Having Anti-MDR-1
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lappin & Kuemer
STREET: 200 State Street
CITY: Boston
STATE: Massachusetts
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/09011
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Kerner, Ann-Louise
REGISTRATION NUMBER: 33,523
REFERENCE/DOCKET NUMBER: HYZ-022PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-330-1300
TELEFAX: 617-330-1311
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
HYPOTHEICAL: NO
ANTI-SENSE: YES
PCT-US95-09011-2

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 53;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1620 TGGGCTGGGAGAGACACA 1638
Db 19 TGGCTGTGGAGAGACACA 1

RESULT 18
US-09-866-108A-891/c
Sequence 891, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: A60MCA-7
CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263, 6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 1575
SOFTWARE: A60MCA Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 891
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-891

Query Match 0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 55;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1701 GCCCCTTCCCAATATG 1717
Db 17 GCCCCTTCCCAATATG 1

RESULT 19
US-09-866-108A-892/c
Sequence 892, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: A60MCA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263, 6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 892
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-892

Query Match      0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 55;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1700 AGCCCTTCCCATAT 1716
Db      17 AGCCCTTCCCATAT 1

RESULT 20
US-09-866-108A-893/c
; Sequence 893, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 893
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-893

Query Match      0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 55;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1699 AAGCCCTTCCCATATA 1715
```

```

Db      17 AAGCCCTTCCCATCTA 1

RESULT 21
US-08-800-751-23/c
; Sequence 23, Application US/08800751
; Patent No. 5807730
; GENERAL INFORMATION:
; APPLICANT: ITO, Kiyoshi
; APPLICANT: YAMAKI, Toshifumi
; APPLICANT: ARII, Teruo
; APPLICANT: TSURUOKA, Miyuki
; APPLICANT: NAKAMURA, Takeshi
; TITLE OF INVENTION: NOVEL NITRILE HYDRATASE
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/800,751
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 8-027004
; FILING DATE: 14-FEB-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Teekin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 028022-007
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-2021
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "synthetic DNA"
US-08-800-751-23

Query Match      0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 58;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2068 GAGCGTACTCCGCTC 2084
Db      17 GAGCGTACTCCGCTC 1

RESULT 22
US-08-990-818-23/c
; Sequence 23, Application US/08990818
; Patent No. 5910432
; GENERAL INFORMATION:
; APPLICANT: ITO, Kiyoshi
; APPLICANT: YAMAKI, Toshifumi
; APPLICANT: ARII, Teruo
; APPLICANT: TSURUOKA, Miyuki
; APPLICANT: NAKAMURA, Takeshi
; TITLE OF INVENTION: NOVEL NITRILE HYDRATASE
; NUMBER OF SEQUENCES: 42
```

;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
;; STREET: P.O. Box 1404
;; CITY: Alexandria
;; STATE: Virginia
;; COUNTRY: United States
;; ZIP: 22313-1404
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; OPERATING SYSTEM: IBM PC compatible
;; SOFTWARE: Patentin Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/990,818
;; FILING DATE:
;; CLASSIFICATION: 435
;; PRIORITY APPLICATION DATA:
;; APPLICATION NUMBER: 08/800,751
;; FILING DATE:
;; APPLICATION NUMBER: JP 8-027004
;; FILING DATE: 14-FEB-1996
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Teskin, Robin L.
;; REGISTRATION NUMBER: 35,030
;; REFERENCE/DOCKET NUMBER: 028022-007
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (703) 836-6620
;; TELEFAX: (703) 836-2021
;; INFORMATION FOR SEQ ID NO: 23:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: other nucleic acid
;; DESCRIPTION: /desc = "synthetic DNA"
;; US-08-990-818-23

Query Match 0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 58;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2068 GAGCGTACTCCGCTC 2084
Db 17 GAGCGTACTCCGCTC 1

RESULT 23
US-08-679-645-609
; Sequence 609, Application US/08679645
; Patent No. 6150934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent B.
; APPLICANT: McSwiggan, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; TITLE OF INVENTION: IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/679,645
;; FILING DATE: July 12, 1996
;; CLASSIFICATION: 800
;; PRIORITY APPLICATION DATA:
;; APPLICATION NUMBER: 60/001,135
;; FILING DATE: July 13, 1995
;; APPLICATION NUMBER: 08/300,726
;; FILING DATE: September 2, 1994
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 219/247
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 609:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-679-645-609

Query Match 0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 58;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2178 CCAGAGCTCATGAGA 2194
Db 2 CCGGACGCUCAUGAGA 18

RESULT 24
US-09-509-654-1
; Sequence 1, Application US/09509654
; Patent No. 6537805
; GENERAL INFORMATION:
; APPLICANT: VON MELCHNER, HARALD
; APPLICANT: ANDREU, THOMAS
; APPLICANT: EBENSPERGER, CHRISTOPHE
; TITLE OF INVENTION: SELF-DELETING VECTORS FOR CANCER THERAPY
; FILE REFERENCE: 07089,0009U1
; CURRENT APPLICATION NUMBER: US/09/509,654
; CURRENT FILING DATE: 2000-03-30
; PRIOR APPLICATION NUMBER: PCT/EP99/03607
; PRIOR FILING DATE: 1999-05-25
; PRIOR APPLICATION NUMBER: Germany 198 34 430.9
; PRIOR FILING DATE: 1998-07-30
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of artificial sequence:/note=synthetic
; OTHER INFORMATION: construct
; US-09-509-654-1

Query Match 0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 58;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 318 CCGCGGAGACTGCT 314
||||| |||||||

Db 1 CCTGCTGTGGACTTGCT 17

RESULT 25
US-08-388-381-22
; Sequence 22, Application US/08388381
; Patent No. 5552283
; GENERAL INFORMATION:
; APPLICANT: Diamandis, Eleftherios
; APPLICANT: Dunn, James M.
; APPLICANT: Stevens, John K.
; TITLE OF INVENTION: Method, Reagents and Kit for Diagnosis
; TITLE OF INVENTION: and Targeted Screening for p53 Mutations
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oppedahl & Larson
; STREET: 1992 Commerce Street, Suite 309
; CITY: Yorktown Heights
; STATE: NY
; COUNTRY: USA
; ZIP: 10598-4412
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS 5.0
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,381
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/271,946
; FILING DATE: 08-JUL-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Marina T. Larson
; REGISTRATION NUMBER: 32,038
; REFERENCE/DOCKET NUMBER: VSEN-P-003-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (914) 245-3252
; TELEFAX: (914) 962-4330
; TELEX:
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; HYPOTHETICAL: no
; ANTI-SENSE: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: human
; FEATURE:
; NAME/KEY: primer for exon 7 of human p53 gene
; US-08-388-381-22

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1935 GGGTCAGCGACAGCAGTGG 1954
|||
1 GGGTCAGCGCGACAGCAGAGG 20

RESULT 26
US-08-276-567A-3/c
; Sequence 3, Application US/08276567A
; Patent No. 5866699
; GENERAL INFORMATION:
; APPLICANT: Adrienne Smyth
; TITLE OF INVENTION: Oligonucleotides Having Anti-MDR-1 Gene Activity

NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lappin & Kusmer
; STREET: 200 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/276,567A
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Kerner, Ann-Louise
; REGISTRATION NUMBER: 33,523
; REFERENCE/DOCKET NUMBER: HYZ-022
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-330-1300
; TELEFAX: 617-330-1311
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-08-276-567A-3

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1618 AATGGTCTGTGGAGAGCAC 1637
|||
20 AGTGGCTGTGGAGAGCAC 1

Db 20 AGTGGCTGTGGAGAGCAC 1

RESULT 27
US-08-276-567A-4/c
; Sequence 4, Application US/08276567A
; Patent No. 5866699
; GENERAL INFORMATION:
; APPLICANT: Adrienne Smyth
; TITLE OF INVENTION: Oligonucleotides Having Anti-MDR-1 Gene Activity
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lappin & Kusmer
; STREET: 200 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/276,567A
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Kerner, Ann-Louise
; REGISTRATION NUMBER: 33,523
; REFERENCE/DOCKET NUMBER: HYZ-022
; TELECOMMUNICATION INFORMATION:

TELEPHONE: 617-330-1300
TELEFAX: 617-330-1311
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHEICAL: NO
ANTI-SENSE: YES
US-08-276-567A-4

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1617 CAATGGCTCTGGAGAGCA 1636
|||
DB 20 CAGTGGCTGTGGAGAGCA 1

RESULT 28
US-08-910-629A-57
Sequence 57, Application US/08910629A
Patent No. 5877309
GENERAL INFORMATION:

APPLICANT: Robert A. McKay
APPLICANT: Nicholas M. Dean
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK
NUMBER OF SEQUENCES: 86
CORRESPONDENCE ADDRESS:

ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: USA
ZIP: 08053

COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB
MEDIUM TYPE: STORAGE
COMPUTER: PENTIUM
OPERATING SYSTEM: WINDOWS 95
SOFTWARE: WORDPERFECT 6.1

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/910,629A
FILING DATE: August 13, 1997
CLASSIFICATION: 514

PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:

ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata

REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0215
TELECOMMUNICATION INFORMATION:

TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 57:
SEQUENCE CHARACTERISTICS:

LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: YES
US-08-910-629A-57

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 167 GGGTCTGGCGGTGGCCTG 186
|||||
DB 1 GGGTCTGGCGGTGGACATG 20

RESULT 29
US-08-469-461-17/c
Sequence 17, Application US/08469461B
Patent No. 5981178

GENERAL INFORMATION:
APPLICANT: Tsui, Lap-Chee
APPLICANT: Rommins, Johanna M.
APPLICANT: Kerem, Bat-Sheva

TITLE OF INVENTION: Introns and Exons of the Cystic Fibrosis Gene and
TITLE OF INVENTION: Mutations at Various Positions of the Gene
FILE REFERENCE: 3477-61, 033477/139840
CURRENT APPLICATION NUMBER: US/08/469,461B

CURRENT FILING DATE: 1995-06-06
NUMBER OF SEQ ID NOS: 33
SOFTWARE: PatentIn Ver. 2.0

SEQ ID NO 17
LENGTH: 20
TYPE: DNA

ORGANISM: Homo sapiens
US-08-469-461-17

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1988 TACTATCTCGATGATGCC 2007
|||
DB 20 TAGTTTCTCGATGATGCC 1

RESULT 30
US-07-890-609-17/c
Sequence 17, Application US/07890609C
Patent No. 6001588

GENERAL INFORMATION:
APPLICANT: Tsui, Lap-Chee
APPLICANT: Rommins, Johanna M.

TITLE OF INVENTION: Introns and Exons of the Cystic Fibrosis Gene and
TITLE OF INVENTION: Mutations at Various Positions of the Gene
FILE REFERENCE: 3477-61, 033477/139840
CURRENT APPLICATION NUMBER: US/07/890,609C

CURRENT FILING DATE: 1992-07-13
NUMBER OF SEQ ID NOS: 33
SOFTWARE: PatentIn Ver. 2.0

SEQ ID NO 17
LENGTH: 20
TYPE: DNA

ORGANISM: Homo sapiens
US-07-890-609-17

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1988 TACTATCTCGATGATGCC 2007
|||
DB 20 TAGTTTCTCGATGATGCC 1

RESULT 31
US-08-765-626-22
Sequence 22, Application US/08765626
Patent No. 6071726

GENERAL INFORMATION:
APPLICANT: Visible Genetics Inc.
APPLICANT: Diamandis, Eleftherios

```
; APPLICANT: Dunn, James M.
; APPLICANT: Stevens, John K.
; TITLE OF INVENTION: Method, Reagents and Kit for Diagnosis
; TITLE OF INVENTION: and Targeted Screening for p53 Mutations
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oppedahl & Larson
; STREET: 1992 Commerce Street, Suite 309
; CITY: Yorktown Heights
; STATE: NY
; COUNTRY: USA
; ZIP: 10598-4412
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 1.44 MB
; OPERATING SYSTEM: DOS 5.0
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/765,626
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/08605
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/388,381
; FILING DATE: 14-FEB-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Marina T. Larson
; REGISTRATION NUMBER: 32,038
; REFERENCE/DOCKET NUMBER: VGEN-P-003-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (914) 245-3252
; TELEFAX: (914) 962-4330
; TELEX:
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; HYBOTHEICAL: no
; ANTI-SENSE: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: human
; FEATURE:
; NAME/KEY: primer for exon 7 of human p53 gene
; US-08-765-626-22

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1935 GGGTCAGCGACGACGACTGG 1954
Db 1 GGGTCAGCGACGACGACGAGG 20

RESULT 32
US-09-287-796-57
; Sequence 57, Application US/09287796A
; Patent No. 6133246
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monta, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS
; FILE REFERENCE: ISPH-0350
```

```
; CURRENT APPLICATION NUMBER: US/09/287,796A
; CURRENT FILING DATE: 1999-04-07
; EARLIER APPLICATION NUMBER: 09/130,616
; EARLIER FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
; US-09-287-796-57

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 167 GGGTCGCGCGGTGGGCGCTG 186
Db 1 GGGTCGTCGCGTGGACATG 20
```

```
RESULT 33
US-09-280-805-8/c
; Sequence 8, Application US/09280805
; Patent No. 6184212
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
; APPLICANT: Graham, Brett P. Monta
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PC
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/280,805
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/048,810
; FILING DATE: March 26, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Licata, Jane Massey
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0346
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-810-1515
; TELEFAX: 609-810-1454
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: linear
; ANTI-SENSE: Yes
; US-09-280-805-8

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```


OY 243 CTCGAGCGGAGGAGGAG 262
|||
Db 20 CTCGAGCGGAGGAGGAGGAG 1

RESULT 34
US-09-130-616-57
Sequence 57, Application US/09130616C
Patent No. 6221850
GENERAL INFORMATION:
APPLICANT: Mckay, Robert A.
APPLICANT: Dean, Nicholas M.
APPLICANT: Monia, Brett
APPLICANT: Nero, Pam
APPLICANT: Gaarde, William A.
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
FILE REFERENCE: ISPH-0318
CURRENT APPLICATION NUMBER: US/09/130,616C
CURRENT FILING DATE: 1998-08-07
EARLIER APPLICATION NUMBER: 08/910,629
EARLIER FILING DATE: 1997-08-03
NUMBER OF SEQ ID NOS: 178
SEQ ID NO 57
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
US-09-130-616-57

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 167 GGGTCTGGCGGCTGGCGCTG 186
|||
Db 1 GGGTCTGGCGGCTGGCGCATG 20

RESULT 35
US-09-048-810-8/c
Sequence 8, Application US/09048810
Patent No. 6238921
GENERAL INFORMATION:
APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
APPLICANT: Graham, Brett P. Monia
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE
TITLE OF INVENTION: MODULATION OF HUMAN MDM2 EXPRESSION
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: U.S.A.
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM 486
OPERATING SYSTEM: WINDOWS FOR WORKGROUPS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/048,810
FILING DATE: herewith
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Licata, Jane Massey
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0302
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-779-2400
TELEFAX: 609-810-1454

INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-09-048-810-8

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 243 CTCGAGCGGAGGAGGAG 262
|||
Db 20 CTCGAGCGGAGGAGGAGGAG 1

RESULT 36
US-09-851-062-32/c
Sequence 32, Application US/09851062
Patent No. 6448081
GENERAL INFORMATION:
APPLICANT: Brenda F. Baker
APPLICANT: Susan M. Freiler
TITLE OF INVENTION: ANTISENSE MODULATION OF INTERLEUKIN 12 P40 SUBUNIT EXPRESSION
FILE REFERENCE: RTS-0247
CURRENT APPLICATION NUMBER: US/09/851,062
CURRENT FILING DATE: 2001-05-07
NUMBER OF SEQ ID NOS: 87
SEQ ID NO 32
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
US-09-851-062-32

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1633 AGCAGTGGCTGCTGCTGCT 1652
|||
Db 20 AGCAGTGGCTGCTGCTGCT 1

RESULT 37
US-09-706-197-47/c
Sequence 47, Application US/09706197
Patent No. 6475797
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: David Spector
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF SR-CYP EXPRESSION
FILE REFERENCE: RTS-0145
CURRENT APPLICATION NUMBER: US/09/706,197
CURRENT FILING DATE: 2000-11-03
NUMBER OF SEQ ID NOS: 87
SEQ ID NO 47
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-706-197-47

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1269 AGTGAATCCTCTACATTG 1288


```
; CURRENT APPLICATION NUMBER: US/09/198.452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4873
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-4873

Query Match          0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1696 GGAAGCCCTTCCCAATA 1715
      ||||| ||||| |||||
Db      1 GGAAGGCCCTTCCCTAATA 20

RESULT 43
US-09-572-891-8
; Sequence 8, Application US/09572891
; Patent No. 6566064
; GENERAL INFORMATION:
; APPLICANT: SHIRAKI, MASATAKA
; APPLICANT: OUCHI, YASUYOSHI
; APPLICANT: HOSOI, TAKAYUKI
; APPLICANT: KUSABA, NOBUTAKA
; APPLICANT: BABA, TOSHIKAKI
; APPLICANT: YOSHIDA, HIROSHI
; TITLE OF INVENTION: METHOD FOR ANTICIPATING SENSITIVITY TO MEDICINE FOR
; FILE REFERENCE: NISS-051
; CURRENT APPLICATION NUMBER: US/09/572,891
; CURRENT FILING DATE: 2000-05-18
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Located on the 6th chromosome; a part of the base sequence
US-09-572-891-8

Query Match          0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1647 CCTGCTGAGAAATCTGTACC 1666
      ||||| ||||| |||||
Db      1 CCTGACACGAAATATGTACC 20

RESULT 44
PCT-US95-08605-22
; Sequence 22, Application PC/TUS9508605
; GENERAL INFORMATION:
; APPLICANT: Visible Genetics Inc.
; APPLICANT: Diamandis, Eleftherios
; APPLICANT: Dunn, James M.
; APPLICANT: Stevens, John K.
; TITLE OF INVENTION: Method, Reagents and Kit for Diagnosis
; TITLE OF INVENTION: and Targeted Screening for p53 Mutations
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oppe Dahl & Larson
; STREET: 1992 Commerce Street, Suite 309
; CITY: Yorktown Heights
; STATE: NY
; COUNTRY: USA
; ZIP: 10596-4412
; COMPUTER READABLE FORM:
```

```
; MEDIUM TYPE: Diskette, 3.5 inch, 1.44 MB
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS 5.0
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/08605
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/271,946
; FILING DATE: 08-JUL-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/388,381
; FILING DATE: 14-FEB-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Marina T. Larson
; REGISTRATION NUMBER: 32,038
; REFERENCE/DOCKET NUMBER: VGEN.P-003-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (914) 245-3252
; TELEFAX: (914) 962-4330
; TELEX:
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; HYPOTHEetical: no
; ANTI-SENSE: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: human
; FEATURE:
; NAME/KEY: primer for exon 7 of human p53 gene
PCT-US95-08605-22

Query Match          0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1935 GGGTCAGCGACGAGCAGTGG 1954
      ||||| ||||| |||||
Db      1 GGGTCAGCGGCAAGCAGAGG 20

RESULT 45
PCT-US95-09011-3/C
; Sequence 3, Application PC/TUS9509011
; GENERAL INFORMATION:
; APPLICANT: Hybridon, Inc.
; TITLE OF INVENTION: Oligonucleotides Having Anti-MDR-1
; TITLE OF INVENTION: Gene Activity
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lappin & Kuemer
; STREET: 200 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/09011
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kerner, Ann-Louise
```

REGISTRATION NUMBER: 33,523
REFERENCE/DOCKET NUMBER: HYZ-022PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-330-1300
TELEFAX: 617-330-1311
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: YES
PCT-US95-09011-3

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1618 AATGGCTGTGGAGAGCAC 1637
Db 20 AGTGGCTGTGGAGAGCAC 1

RESULT 46
PCT-US95-09011-4/c
Sequence 4, Application PC/TUS9509011
GENERAL INFORMATION:
APPLICANT: Hybridon, Inc.
TITLE OF INVENTION: Oligonucleotides Having Anti-MDR-1
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lappin & Kusmer
STREET: 200 State Street
CITY: Boston
STATE: Massachusetts
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/09011
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Keiner, Ann-Louise
REGISTRATION NUMBER: 33,523
REFERENCE/DOCKET NUMBER: HYZ-022PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-330-1300
TELEFAX: 617-330-1311
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: YES
PCT-US95-09011-4

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1617 CAATGGCTGTGGAGAGCA 1636
Db 20 AATGGCTGTGGAGAGCAC 1637

Db 20 CAGTGGCTGTGGAGAGCA 1

RESULT 47
US-09-488-671-108
Sequence 108, Application US/09488671A
Patent No. 6187545
GENERAL INFORMATION:
APPLICANT: Robert McKay
APPLICANT: Madeline M. Butler
APPLICANT: Jacqueline Wyatt
APPLICANT: Lex M. Cowest
TITLE OF INVENTION: ANTISENSE MODULATION OF PEPCK-CYTOSOLIC EXPRESSION
FILE REFERENCE: RTS-0123
CURRENT APPLICATION NUMBER: US/09/488,671A
CURRENT FILING DATE: 2000-01-21
NUMBER OF SEQ ID NOS: 177
SEQ ID NO 108
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-488-671-108

Query Match 0.7%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 830 AACGAAACGACG 844
Db 3 AACGAAACGACG 17

RESULT 48
US-09-513-783A-39/c
Sequence 39, Application US/09513783A
Patent No. 6416959
GENERAL INFORMATION:
APPLICANT: Giuliano, Kenneth A.
APPLICANT: Kapur, Ravi
TITLE OF INVENTION: A System for Cell Based Screening
FILE REFERENCE: 97-022-11
CURRENT APPLICATION NUMBER: US/09/513,783A
CURRENT FILING DATE: 2000-02-25
NUMBER OF SEQ ID NOS: 180
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 39
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: KT3 epitope
US-09-513-783A-39

Query Match 0.7%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 77;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 566 TGTTCTGTCTCTGTGG 583
Db 18 TGTTCTGTCTCTGTGG 1

RESULT 49
US-08-860-882A-52
Sequence 52, Application US/08860882A
Patent No. 5985281
GENERAL INFORMATION:
APPLICANT: TAYLORSON, CHRISTOPHER JOHN
APPLICANT: EGGEITE, HENDRIKUS JOHANNES
APPLICANT: TARRAGONA-FIOU, ANTONIO
APPLICANT: RABIN, BRIAN ROBERT

APPLICANT: BOYLE, FRANCIS THOMAS
APPLICANT: HENNAM, JOHN FREDERICK
APPLICANT: BLAKLEY, DAVID CHARLES
APPLICANT: MARSHAM, PETER ROBERT
APPLICANT: HEATON, DAVID WILLIAM
APPLICANT: DAVIES, DAVID HUIW
TITLE OF INVENTION: CHEMICAL COMPOUNDS
NUMBER OF SEQUENCES: 77
CORRESPONDENCE ADDRESS:
ADDRESSEE: PILLSBURY, MADISON & SUTRO
STREET: 1100 NEW YORK AVENUE, N.W.
CITY: WASHINGTON
STATE: D.C.
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/860,882A
FILING DATE: JUNE 23, 1997
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: DONALD J. BIRD
REGISTRATION NUMBER: 25,323
REFERENCE/DOCKET NUMBER: 9901/238653
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 861-3027
TELEFAX: (202) 822-0944
TELEX: 6174627 CUSH
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-860-882A-52

Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 81;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCCCTGCTGCAGATCTG 1662
DB 2 GACCTGCTGCAGACTCTG 19

RESULT 50
US-09-171-945-110
Sequence 110, Application US/09171945
Patent No. 6277599
GENERAL INFORMATION:
APPLICANT: Emery, Stephen
APPLICANT: Copley, Clive Graham
APPLICANT: Edge, Michael Derek
TITLE OF INVENTION: Monoclonal Antibody to CEA, Conjugates Comprising Said
FILE REFERENCE: Monoclonal Antibody to CEA
CURRENT APPLICATION NUMBER: US/09/171,945
CURRENT FILING DATE: 1998-10-29
PRIOR APPLICATION NUMBER: GB9703103.3
PRIOR FILING DATE: 1997-02-14
PRIOR APPLICATION NUMBER: GB9609405.7
PRIOR FILING DATE: 1996-05-04
PRIOR APPLICATION NUMBER: PCT/GB97/01165
PRIOR FILING DATE: 1997-04-29
NUMBER OF SEQ ID NOS: 131
SOFTWARE: Patent Ver. 2.1
SEQ ID NO 110
LENGTH: 19
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: humanized
US-09-171-945-110

Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 81;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCCCTGCTGCAGATCTG 1662
DB 2 GACCTGCTGCAGACTCTG 19

RESULT 51
US-09-011-769A-34
Sequence 34, Application US/09011769A
Patent No. 6436691
GENERAL INFORMATION:
APPLICANT: SLATER, Anthony M.
BLAKLEY, David C.
DAVIES, David H.
HENNAM, John F.
HENNEQUIN, Laurent F.A.
MARSHAM, Peter R.
DOWELL, Robert I.
TITLE OF INVENTION: Chemical Compounds
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pillsbury Madison & Suto, LLP
STREET: 1100 New York Ave., N.W.
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: 1.44 Mb disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MS Word
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/011,769A
FILING DATE: 13-Feb-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB96/01975
FILING DATE: 13-AUG-1996
APPLICATION NUMBER: GB 9612295.7
FILING DATE: 12-JUN-1996
APPLICATION NUMBER: GB 9611019.2
FILING DATE: 25-MAY-1996
APPLICATION NUMBER: GB 9516810.0
FILING DATE: 16-AUG-1995
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-09-011-769A-34

Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 81;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCCCTGCTGCAGATCTG 1662
DB 2 GACCTGCTGCAGACTCTG 19

RESULT 52

US-09-548-797B-94/C
; Sequence 94, Application US/09548797B
; Patent No. 6683165
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES AND
; FILE REFERENCE: 2976-4039
; CURRENT APPLICATION NUMBER: US/09/548,797B
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: 60/129,391
; PRIOR FILING DATE: 1999-04-13
; NUMBER OF SEQ ID NOS: 170
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 94
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-548-797B-94

Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 81;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 867 AGAGACACGTCACCCCT 884
Db 19 AGAGACACGACGACCCCT 2

RESULT 53
5164485-15/C
; Patent No. 5164485
; APPLICANT: FUJISAWA, YUKIO; ITOH, YASUAKI; NISHIMURA, OSAMU
; FUJII TOMOKO
; TITLE OF INVENTION: MODIFIED HEPATITIS B VIRUS SURFACE
; ANTIGEN P31 AND PRODUCTION THEREOF
; NUMBER OF SEQUENCES: 22
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/547,948
; FILING DATE: 03-JUL-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 898,425
; FILING DATE: 20-AUG-1986
; SEQ ID NO:15
; LENGTH: 16
5164485-15

Query Match 0.6%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 82;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 85 CTTCTCCGCGACTGGG 100
Db 16 CTTCTCGCAGACTGGG 1

RESULT 54
US-07-977-630-6
; Sequence 6, Application US/07977630
; Patent No. 5583038
; GENERAL INFORMATION:
; APPLICANT: Stover, Charles K.
; TITLE OF INVENTION: BACTERIAL EXPRESSION VECTORS CONTAINING
; TITLE OF INVENTION: DNA ENCODING SECRETION SIGNALS OF LIPOPROTEINS
; NUMBER OF SEQUENCES: 84
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Carella, Byrne, Bain, Gilfillan, Cecchi,
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey

COUNTRY: USA
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/977,630
; FILING DATE: No. 5583038ember 17, 1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Heron, Charles J.
; REGISTRATION NUMBER: 28,019
; REFERENCE/DOCKET NUMBER: 469201-174
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-994-1700
; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: nucleic acid
US-07-977-630-6

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1690 TTGATGGGAAGCCCC 1705
Db 2 TTGATGGGAAGCCCC 17

RESULT 55
US-08-109-391A-10/C
; Sequence 10, Application US/08109391A
; Patent No. 5639876
; GENERAL INFORMATION:
; APPLICANT: Tripp, Cynthia A.
; APPLICANT: Frank, Glenn R.
; APPLICANT: Griev, Robert B.
; TITLE OF INVENTION: NUCLEIC ACID MOLECULES ENCODING NOVEL
; TITLE OF INVENTION: PARASITIC HELMINTH PROTEINS
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheridan Ross & McIntosh
; STREET: 1700 Lincoln St., Suite 3500
; CITY: Denver
; STATE: CO
; COUNTRY: U.S.A.
; ZIP: 80203
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/109,391A
; FILING DATE: 19-AUG-1993
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Connell, Gary J.
; REGISTRATION NUMBER: 32,020
; REFERENCE/DOCKET NUMBER: 2618-13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 303/863-0223
; TELEFAX: 303/863-0223
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..17
OTHER INFORMATION: /label= PRIMER
US-08-109-391A-10

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GGTCAGAGCTCTGCA 2232
|||
Db 16 GGTCAGAGCTCTGCA 1

RESULT 56
US-08-459-019A-10/C
Sequence 10, Application US/08459019A
Patent No. 5686080
GENERAL INFORMATION:
APPLICANT: Tripp, Cynthia A.
APPLICANT: Frank, Glenn R.
APPLICANT: Griev, Robert B.
TITLE OF INVENTION: NOVEL PARASITIC HELMINTH P4 PROTEINS
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Sheridan Ross & McIntosh
STREET: 1700 Lincoln Street, #3500
CITY: Denver
STATE: CO
COUNTRY: U.S.A.
ZIP: 80203
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/459, 019A
FILING DATE: 06-JUN-1995
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Connell, Gary J.
REGISTRATION NUMBER: 33,020
REFERENCE/DOCKET NUMBER: 2618-13-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303) 863-9700
TELEFAX: (303) 863-0223
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "primer"
US-08-459-019A-10

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GGTCAGAGCTCTGCA 2232
|||
Db 16 GGTCAGAGCTCTGCA 1

RESULT 57
US-08-460-428A-10/C

Sequence 10, Application US/08460428A
Patent No. 5912337
GENERAL INFORMATION:
APPLICANT: Tripp, Cynthia A.
APPLICANT: Frank, Glenn R.
APPLICANT: Griev, Robert B.
TITLE OF INVENTION: NOVEL PARASITIC HELMINTH
P22U PROTEINS
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Sheridan Ross P.C.
STREET: 1700 Lincoln St., Suite 3500
CITY: Denver
STATE: CO
COUNTRY: U.S.A.
ZIP: 80203
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/460, 428A
FILING DATE: 02-JUN-1995
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Connell, Gary J.
REGISTRATION NUMBER: 32,020
REFERENCE/DOCKET NUMBER: 2618-13-3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 303/863-9700
TELEFAX: 303/863-0223
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..17
OTHER INFORMATION: /label= PRIMER
US-08-460-428A-10

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GGTCAGAGCTCTGCA 2232
|||
Db 16 GGTCAGAGCTCTGCA 1

RESULT 58
US-08-458-860A-10/C
Sequence 10, Application US/08458860A
Patent No. 6100390
GENERAL INFORMATION:
APPLICANT: Frank, Glenn R.
APPLICANT: Tripp, Cynthia A.
APPLICANT: Griev, Robert B.
TITLE OF INVENTION: NOVEL PARASITIC HELMINTH
P22U NUCLEIC ACID MOLECULES
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Sheridan Ross P.C.
STREET: 1700 Lincoln St., Suite 3500
CITY: Denver
STATE: CO
COUNTRY: U.S.A.
ZIP: 80203
COMPUTER READABLE FORM:

```

MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
  APPLICATION NUMBER: US/08/458,860A
  FILING DATE: 02-JUN-1995
  CLASSIFICATION: 536
  ATTORNEY/AGENT INFORMATION:
    NAME: Connell, Gary J.
    REGISTRATION NUMBER: 32,020
    REFERENCE/DOCKET NUMBER: 2618-13-2
  TELECOMMUNICATION INFORMATION:
    TELEPHONE: 303/863-9700
    TELEFAX: 303/863-0223
  INFORMATION FOR SEQ ID NO: 10:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 17 base pairs
      TYPE: nucleic acid
      STRANDEDNESS: single
      TOPOLOGY: linear
  MOLECULE TYPE: DNA (genomic)
  FEATURE:
    NAME/KEY: misc feature
    LOCATION: 1..17
    OTHER INFORMATION: /label= PRIMER
US-08-458-860A-10

Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2217 GGTGAGGCTCTCTGCA 2232
Db      16 GGTGAGGATCTCTCA 1

RESULT 59
US-08-679-645-139
Sequence 139, Application US/08679645
Patent No. 6350934
GENERAL INFORMATION:
  APPLICANT: Zwick, Michael G.
  APPLICANT: Edington, Brent B.
  APPLICANT: McSwiggen, James A.
  APPLICANT: Merlo, Patricia Ann Owens
  APPLICANT: Guo, Lining
  APPLICANT: Skokut, Thomas A.
  APPLICANT: Young, Scott A.
  APPLICANT: Folckerts, Otto
  APPLICANT: Merlo, Donald J.
  TITLE OF INVENTION: COMPOSITION AND METHODS FOR
  TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
  TITLE OF INVENTION: IN PLANTS
  NUMBER OF SEQUENCES: 1263
  CORRESPONDENCE ADDRESS:
    ADDRESSEE: Lyon & Lyon
    STREET: 633 West Fifth Street
    STREET: Suite 4700
    CITY: Los Angeles
    STATE: California
    COUNTRY: U.S.A.
    ZIP: 90071-2066
  COMPUTER READABLE FORM:
    MEDIUM TYPE: 3.5" Diskette, 1.44 MB
  MEDIUM TYPE: storage
  COMPUTER: IBM Compatible
  OPERATING SYSTEM: IBM P.C. DOS 5.0
  SOFTWARE: Word Perfect 5.1
  CURRENT APPLICATION DATA:
    APPLICATION NUMBER: US/08/679,645
    FILING DATE: July 12, 1996
    CLASSIFICATION: 800
```

```

PRIOR APPLICATION DATA:
  APPLICATION NUMBER: 60/001,135
  FILING DATE: July 13, 1995
  APPLICATION NUMBER: 08/300,726
  FILING DATE: September 2, 1994
  ATTORNEY/AGENT INFORMATION:
    NAME: Waidburg, Richard J.
    REGISTRATION NUMBER: 32,327
    REFERENCE/DOCKET NUMBER: 219/247
  TELECOMMUNICATION INFORMATION:
    TELEPHONE: (213) 489-1600
    TELEFAX: (213) 955-0440
    TELEX: 67-3510
  INFORMATION FOR SEQ ID NO: 139:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 17 base pairs
      TYPE: nucleic acid
      STRANDEDNESS: single
      TOPOLOGY: linear
US-08-679-645-139

Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 87;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      2179 CAGCAGCTCATGAGA 2194
Db      1 CCGCAGCCTCAVAGAGA 16

RESULT 60
US-09-866-108A-890/c
Sequence 890, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
  APPLICANT: GU, Yizhong
  APPLICANT: JI, Yonggang
  APPLICANT: PENN, Sharron G.
  APPLICANT: HANZEL, David K.
  APPLICANT: RANK, David R.
  APPLICANT: CHEN, Wensheng
  APPLICANT: SHANNON, Mark
  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
  FILE REFERENCE: AEOMICA-7
  CURRENT APPLICATION NUMBER: US/09/866,108A
  CURRENT FILING DATE: 2001-05-25
  PRIOR APPLICATION NUMBER: US 60/207,456
  PRIOR FILING DATE: 2000-05-26
  PRIOR APPLICATION NUMBER: GB 24263.6
  PRIOR FILING DATE: 2000-10-04
  PRIOR APPLICATION NUMBER: US 60/236,359
  PRIOR FILING DATE: 2000-09-27
  PRIOR APPLICATION NUMBER: PCT/US01/00666
  PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: PCT/US01/00667
  PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: PCT/US01/00664
  PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: PCT/US01/00669
  PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: PCT/US01/00665
  PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: PCT/US01/00668
  PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: PCT/US01/00663
  PRIOR FILING DATE: 2001-01-30
  Remaining Prior Application data removed - See File Wrapper or PALM.
  SOFTWARE: Aeomica Sequence Listing Engine
  Patent No. 6686188
  SEQ ID NO 890
  LENGTH: 17
  TYPE: DNA
```



```
! ORGANISM: Homo sapiens
US-09-866-108A-890

Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1702 CCCCTCCCAATG 1717
      |||||
Db      17 CCCCTCCCACTATG 2

RESULT 61
US-09-866-108A-894/c
; Sequence 894, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 894
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-894

Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1699 AAGCCCTCCCAAT 1714
      |||||
Db      16 AAGCCCTCCCACT 1

RESULT 62
US-09-866-108A-8005
; Sequence 8005, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
```

```
! APPLICANT: JI, Yonggang
! APPLICANT: PENN, Sharon G.
! APPLICANT: HANZEL, David K.
! APPLICANT: RANK, David R.
! APPLICANT: CHEN, Wensheng
! APPLICANT: SHANNON, Mark
! TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
! FILE REFERENCE: AEOMICA-7
! CURRENT APPLICATION NUMBER: US/09/866,108A
! CURRENT FILING DATE: 2001-05-25
! PRIOR APPLICATION NUMBER: US 60/207,456
! PRIOR FILING DATE: 2000-05-26
! PRIOR APPLICATION NUMBER: GB 24263.6
! PRIOR FILING DATE: 2000-10-04
! PRIOR APPLICATION NUMBER: US 60/236,359
! PRIOR FILING DATE: 2000-09-27
! PRIOR APPLICATION NUMBER: PCT/US01/00666
! PRIOR FILING DATE: 2001-01-30
! PRIOR APPLICATION NUMBER: PCT/US01/00667
! PRIOR FILING DATE: 2001-01-30
! PRIOR APPLICATION NUMBER: PCT/US01/00664
! PRIOR FILING DATE: 2001-01-30
! PRIOR APPLICATION NUMBER: PCT/US01/00669
! PRIOR FILING DATE: 2001-01-30
! PRIOR APPLICATION NUMBER: PCT/US01/00665
! PRIOR FILING DATE: 2001-01-30
! PRIOR APPLICATION NUMBER: PCT/US01/00668
! PRIOR FILING DATE: 2001-01-30
! PRIOR APPLICATION NUMBER: PCT/US01/00663
! PRIOR FILING DATE: 2001-01-30
! Remaining Prior Application data removed - See File Wrapper or PALM.
! NUMBER OF SEQ ID NOS: 15755
! SOFTWARE: Aeomica Sequence Listing Engine
! Patent No. 6686188
! SEQ ID NO 8005
! LENGTH: 17
! TYPE: DNA
! ORGANISM: Homo sapiens
US-09-866-108A-8005

Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2038 CAGCTGAGCAGCTCC 2053
      |||||
Db      2 CAGCTGAGCAGCTCC 17

RESULT 63
US-09-866-108A-8006
; Sequence 8006, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8006
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8006
```

```

Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY 2038 CAGGTGAGCAGCTCC 2053

Db 1 CAGCTGGAGCAGCTCC 16

```

RESULT 64
US-09-565-808-17/c
; Sequence 17, Application US/09565808
; Patent No. 6432674
; GENERAL INFORMATION:
; APPLICANT: Hirata, Yuichi
; TITLE OF INVENTION: STEROID HORMONE BINDING PROTEIN
; FILE REFERENCE: 06501-059001
; CURRENT FILING DATE: 2000-05-05
; PRIOR APPLICATION NUMBER: US/09/565,808
; PRIOR FILING DATE: 1998-11-06
; PRIOR APPLICATION NUMBER: WO/JP98/05010
; PRIOR FILING DATE: 1997-11-07
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificially synthesized primer sequence
US-09-565-808-17
```

```

Query Match      0.6%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY 1258 ATGCTGCTGAAGTGG 1273

Db 16 ATGCTGCTGAAGTGG 1

```

RESULT 65
US-08-862-337-12
; Sequence 12, Application US/08862337
; Patent No. 6582902
; GENERAL INFORMATION:
; APPLICANT: Keene, Jack D.
; APPLICANT: Kenan, Daniel J.
; APPLICANT: Tsai, Donald E.
; TITLE OF INVENTION: Nucleic Acid Epitopes and Methods of
```

```

; TITLE OF INVENTION: Making and Using the Same
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenneth D. Sibley, Bell, Seltzer, Park and
; ADDRESSEE: Gibson
; STREET: Post Office Drawer 34009
; CITY: Charlotte
; STATE: No. 6582902th Carolina
; COUNTRY: U.S.A.
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/862,337
; FILING DATE: 23-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/447,196
; FILING DATE:
; APPLICATION NUMBER: US/07/956,693
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5405-69
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: rRNA
US-08-862-337-12
```

```

Query Match      0.6%; Score 14; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 87;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

QY 2112 CCTGTGAGCAGCAG 2125

Db 1 CTUGUGAGCAGCAG 14

```

RESULT 66
US-09-829-855-101/c
; Sequence 101, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY-1
; CURRENT FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US/09/829,855
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 101
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-101
```

Query Match 0.6%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 297 AGCTGCGGCACTGG 310
Db 16 AGCTGCGGCACTGG 3

RESULT 67
US-08-152-313-113/c
Sequence 113, Application US/08152313
Patent No. 5561041
GENERAL INFORMATION:
APPLICANT: Sidransky, David
TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION BY
TITLE OF INVENTION: ANALYSIS OF SPUTUM
NUMBER OF SEQUENCES: 128
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Spensley Horn Jubas & Lubitz
STREET: 1880 Century Park East, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90067
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/152,313
FILING DATE: 12-NOV-1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Wetherell, Jr., Ph.D., John R.,
REGISTRATION NUMBER: 31,678
REFERENCE/DOCKET NUMBER: PD-2912
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 455-5100
TELEFAX: (619) 455-5110
INFORMATION FOR SEQ ID NO: 113:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: CDS
LOCATION: 1..17
US-08-152-313-113

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 11e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1729 CTGCACAGCAGGT 1742
Db 16 CTGCACAGCAGGT 3

RESULT 68
US-08-579-223-113/c
Sequence 113, Application US/08579223
Patent No. 5726019
GENERAL INFORMATION:
APPLICANT: Sidransky, David
TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION BY
TITLE OF INVENTION: ANALYSIS OF SPUTUM
NUMBER OF SEQUENCES: 128
CORRESPONDENCE ADDRESSES:

ADDRESSEE: Spensley Horn Jubas & Lubitz
STREET: 1880 Century Park East, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90067

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/579,223
FILING DATE: 28-DEC-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Wetherell, Jr., Ph.D., John R.,
REGISTRATION NUMBER: 31,678
REFERENCE/DOCKET NUMBER: PD-2912
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 455-5100
TELEFAX: (619) 455-5110
INFORMATION FOR SEQ ID NO: 113:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: CDS
LOCATION: 1..17
US-08-579-223-113

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 11e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1729 CTGCACAGCAGGT 1742
Db 16 CTGCACAGCAGGT 3

RESULT 69
US-09-866-108A-895/c
Sequence 895, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664

```
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aecomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO: 895
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-895
```

```
Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy      1699 AAGCCCTTCCCA 1712
          |||||||
Db       15 AAGCCCTTCCCA 2
```

```
RESULT 70
US-09-866-108A-896/c
;; Sequence 896, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AECOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108A
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aecomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO: 896
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-896
```

```
Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy      1699 AAGCCCTTCCCA 1712
          |||||||
Db       14 AAGCCCTTCCCA 1
```

```
RESULT 71
PCT-US94-12947A-113/c
;; Sequence 113, Application PC/TUS9412947A
;; GENERAL INFORMATION:
;; APPLICANT: The Johns Hopkins University School of Medicine
;; TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION BY
;; NUMBER OF SEQUENCES: 128
;; CORRESPONDENCE ADDRESSES:
;; ADDRESSEE: Spensley Horn Jubas & Lubitz
;; STREET: 1880 Century Park East, Suite 500
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: USA
;; ZIP: 90067
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: PCT/US94/12947A
;; FILING DATE: 10-NOV-1994
;; CLASSIFICATION:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Haile, Ph.D., Lisa A.
;; REGISTRATION NUMBER: P-38,347
;; REFERENCE/DOCKET NUMBER: FD-2912
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (619) 455-5100
;; TELEFAX: (619) 455-5110
;; INFORMATION FOR SEQ ID NOS: 113:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; FEATURE:
;; NAME/KEY: CDS
;; LOCATION: 1..17
PCT-US94-12947A-113

Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy      1729 CTGCACAGCAGGT 1742
          |||||||
Db       16 CTGCACAGCAGGT 3
```

```
RESULT 72
US-09-156-424-42/c
;; Sequence 42, Application US/09156424
;; Patent No. 5945290
;; GENERAL INFORMATION:
;; APPLICANT: Cowsett, Lex M.
;; TITLE OF INVENTION: ANTISENSE MODULATION OF RHOA EXPRESSION
;; FILE REFERENCE: RTS-0012
;; CURRENT APPLICATION NUMBER: US/09/156,424
;; CURRENT FILING DATE: 1998-03-18
;; NUMBER OF SEQ ID NOS: 47
```

```
; SEQ ID NO 42
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-09-156-424-42
```

```
Query Match          0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1814 AGAGCCCACTATG 1827
Db      15 AGAGCCCACTATG 2
```

```
RESULT 73
US-09-638-509C-5
; Sequence 5, Application US/09638509C
; Patent No. 6372435
; GENERAL INFORMATION:
; APPLICANT: Tang, Jiaming
; APPLICANT: Kaslow, Richard A.
; TITLE OF INVENTION: Methods of Surveying For CC (Beta) Chemokine
; TITLE OF INVENTION: Receptor Variants and Their Association With HIV-1
; TITLE OF INVENTION: Transmission and/or Disease Progression
; FILE REFERENCE: D6217
; CURRENT APPLICATION NUMBER: US/09/638,509C
; CURRENT FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/148,530
; PRIOR FILING DATE: 1999-08-12
; NUMBER OF SEQ ID NOS: 35
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: primer bind
; OTHER INFORMATION: CCR5-5/1S, primer used for typing major
; OTHER INFORMATION: polymorphism in CCR2b, CCR5 and the CCR5 downstream
; OTHER INFORMATION: promoter region
US-09-638-509C-5
```

```
Query Match          0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      2189 TGGAGAAAAGGGG 2202
Db      4 TGGAGAAAAGGGG 17
```

```
RESULT 74
US-09-638-509C-6
; Sequence 6, Application US/09638509C
; Patent No. 6372435
; GENERAL INFORMATION:
; APPLICANT: Tang, Jiaming
; APPLICANT: Kaslow, Richard A.
; TITLE OF INVENTION: Methods of Surveying For CC (Beta) Chemokine
; TITLE OF INVENTION: Receptor Variants and Their Association With HIV-1
; TITLE OF INVENTION: Transmission and/or Disease Progression
; FILE REFERENCE: D6217
; CURRENT APPLICATION NUMBER: US/09/638,509C
; CURRENT FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/148,530
; PRIOR FILING DATE: 1999-08-12
; NUMBER OF SEQ ID NOS: 35
; SEQ ID NO 6
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; NAME/KEY: primer bind
; OTHER INFORMATION: CCR5-5/2S, primer used for typing major
; OTHER INFORMATION: polymorphism in CCR2b, CCR5 and the CCR5 downstream
; OTHER INFORMATION: promoter region
US-09-638-509C-6
```

```
Query Match          0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      2189 TGGAGAAAAGGGG 2202
Db      4 TGGAGAAAAGGGG 17
```

```
RESULT 75
US-09-387-341-56/c
; Sequence 56, Application US/09387341
; Patent No. 6410323
; GENERAL INFORMATION:
; APPLICANT: Roberts, M. Luisa
; APPLICANT: Cowsett, Lex M.
; TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
; TITLE OF INVENTION: Expression
; FILE REFERENCE: ISPH-0404
; CURRENT APPLICATION NUMBER: US/09/387,341
; CURRENT FILING DATE: 1999-08-31
; EARLIER APPLICATION NUMBER: 09/156,424
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,979
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,807
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/161,015
; EARLIER FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 233
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 56
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-387-341-56
```

```
Query Match          0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1814 AGAGCCCACTATG 1827
Db      15 AGAGCCCACTATG 2
```

```
RESULT 76
US-09-474-432B-630/c
; Sequence 630, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MBH800-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
```

```

; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 630
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-630

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      259 GCAGGTGCCAGGCGCTG 275
Db      17 GTAGGTGACCGAGGCTG 1

RESULT 77
US-09-474-432B-720/c
; Sequence 720, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 720
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-720

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      269 AGGCGTGGCTGCTGCT 285
Db      17 AGGCGTGGCTGCTGCT 1

RESULT 78
US-09-371-772B-4198
; Sequence 4198, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
```

```

; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4198
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4198

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.2e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      977 CCTCACCATGCTCACC 993
Db      1 CGCUCACCAUGGUCAGC 17

RESULT 79
US-09-476-387-629/c
; Sequence 629, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their incorporation into Oligonucleot
; FILE REFERENCE: MBH00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 629
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-629

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      259 GCAGGTGCCAGGCGCTG 275
Db      17 GTAGGTGACCGAGGCGCTG 1

RESULT 80
```

```
US-09-476-387-719/c
; Sequence 719, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Belgelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adams, Jasenka Matulic
; APPLICANT: Swedler, Dave
; APPLICANT: Zimen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MHB00-831-C (129/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 719
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-719

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      269 AGGCGTGGCTGGTGGT 285
Db      17 AGGCGTGGCTGGTGGT 1

RESULT 81
US-09-866-108A-515/c
; Sequence 515, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 515
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-515

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      160 CTGCTCGGCTGGGC 176
Db      17 CTGCTCGGCTGGGC 1

RESULT 82
US-09-866-108A-665/c
; Sequence 665, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 665
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-665

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      53  CTCTCTGCATGGCTG  69
          |||||
          17  CTCTCTGGCTTGGCTG  1
          |||||

RESULT 83
US-09-866-108A-1530
; Sequence 1530, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1530
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1530

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1595 AGGTGACGCGCGCTGCTG  1611
          |||||
          1  AGGTGATGGCGCTGCTG  17
          |||||

RESULT 84
US-09-866-108A-1572/c
; Sequence 1572, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
```

```
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1572
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1572

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      267  CCAGGCGCTGCGCTGCTG  283
          |||||
          17  CCAGGCGCGCTGCTGCTG  1
          |||||

RESULT 85
US-09-866-108A-1960
; Sequence 1960, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
```



```

; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1960
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1960

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1832 AAATCAGAGCTGCTGCA 1848
Db      1 AAAGCTCAGCTGCTGCA 17

RESULT 86
US-09-866-108A-2739
; Sequence 2739, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AROMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2739
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2739

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      297 AGCTGGGCACTGGGCT 313
Db      1 AGCTGAGCCCTGGGCT 17

RESULT 87
US-09-866-108A-6521
; Sequence 6521, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AROMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6521
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6521

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2100 CCAGCACTCAGCCTGG 2116
Db      1 CCAGCACCAGCAGCCTGG 17

RESULT 88
US-09-866-108A-6522
; Sequence 6522, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
```

```

; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6522
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6522

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      2101 CAGCAGCTGAGCTGGT 2117
Db      1 CACCGCAGCTGCTGT 17

RESULT 89
US-09-866-108A-6525
; Sequence 6525, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6526
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6526

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6525
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6525

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      2104 CACCTCAGCTGAGTGA 2120
Db      1 CACCGCAGCTGCTGTA 17

RESULT 90
US-09-866-108A-6526
; Sequence 6526, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6526
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6526

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2105 ACCTGACCTGCTGAG 2121

Db 1 ACCGACCTGCTGAG 17

RESULT 91

US-09-866-108A-6758
Sequence 6758, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 6758
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-6758

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2041 GTGAGAGCTCTGTA 2057

Db 1 GTGAGAGCTCTGTA 17

RESULT 92

US-09-866-108A-8056
Sequence 8056, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 8056
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-8056

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2230 GCAGATCCTCAGATG 2246

Db 1 GCAGATCCTCAGATG 17

RESULT 93

US-09-866-108A-8057
Sequence 8057, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30

;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aecomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 8057
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-8057

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2231 CAGATGCTCAGATGA 2247

Db 1 CAGATGCACGAGAGA 17

RESULT 94

US-09-866-108A-9583
;; Sequence 9583, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yizhong
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AECOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108A
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aecomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 9583
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-9583

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1167 GTTAGGGAAGGCTGC 1183

Db 1 GTCGAGGGAAGGCTGC 17

RESULT 95

US-08-483-122-7/c
;; Sequence 7, Application US/08483122
;; Patent No. 5750376
;; GENERAL INFORMATION:
;; APPLICANT: Weiss, Samuel
;; APPLICANT: Reynolds, Brent A.
;; APPLICANT: Hammang, Joseph P.
;; APPLICANT: Baetge, Edward E.
;; TITLE OF INVENTION: In Vitro and In Vivo
;; TITLE OF INVENTION: Proliferation and Use of Multipotent
;; TITLE OF INVENTION: Neural Stem Cells and their Progeny
;; NUMBER OF SEQUENCES: 8
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Flehr, Hobbach, Test, Albritton
;; ADDRESSEE: & Heibert
;; STREET: Four Embarcadero Center, Suite 3400
;; CITY: San Francisco
;; STATE: California
;; COUNTRY: United States
;; ZIP: 94111-4187
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patentin Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/483,122
;; FILING DATE: 07-JUN-1995
;; CLASSIFICATION: 424
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Brunelle, Jan P.
;; REGISTRATION NUMBER: 35,081
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (415) 781-1989
;; TELEFAX: (415) 398-3249
;; TELEX: 910 277299
;; INFORMATION FOR SEQ ID NO: 7:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: unknown
;; TOPOLOGY: unknown
;; MOLECULE TYPE: cDNA
US-08-483-122-7

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1593 CGAGTGACGGCGCTGG 1609

Db 18 CGAGTGATGCGCGCTGG 2

RESULT 96

US-08-483-122-8
;; Sequence 8, Application US/08483122
;; Patent No. 5750376
;; GENERAL INFORMATION:
;; APPLICANT: Weiss, Samuel
;; APPLICANT: Reynolds, Brent A.
;; APPLICANT: Hammang, Joseph P.


```
; MOLECULE TYPE: cDNA
US-08-486-648-8
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGGTGACGCGCTGG 1609
      ||||| |||||
      1 CGAGGTGATGCCGCTGG 17

RESULT 99
US-08-627-254C-9/c
; Sequence 9, Application US/08627254C
; Patent No. 5859229
; GENERAL INFORMATION:
; APPLICANT: Kniss, Douglas A.
; TITLE OF INVENTION: Eicosanoid Formation
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Calfee, Halter & Griwold LLP
; STREET: 800 Superior Avenue
; CITY: Cleveland
; STATE: Ohio
; COUNTRY: USA
; ZIP: 44114
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/627,254C
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Gollick, Mary E
; REGISTRATION NUMBER: 34,829
; REFERENCE/DOCKET NUMBER: 18525/00107
; TELEPHONE: (216) 622-8200
; TELEFAX: (216) 241-0816
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to mRNA
; ANTI-SENSE: YES
US-08-627-254C-9

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 807 GCGCCAGAGACGAGT 823
      ||||| |||||
      18 GCGCCATGAGCCGAGT 2

Db 18 GCGCCATGAGCCGAGT 2

RESULT 100
US-08-442-809A-57
; Sequence 57, Application US/08442809A
; Patent No. 5976873
; GENERAL INFORMATION:
; APPLICANT: Bohinski, Robert J.,
; APPLICANT: Whitsett, Jeffrey A.
; TITLE OF INVENTION: Nucleic Acid Sequences
; TITLE OF INVENTION: Controlling Lung Cell -
; TITLE OF INVENTION: Specific Gene Expression
; NUMBER OF SEQUENCES: 76
```

```
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Carella, Byrne, Bain, Gilfillan,
; ADDRESSEE: Cecchi, Stewart & Olstein
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/442,809A
; FILING DATE: 17-MAY-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,356
; FILING DATE: 18-MAY-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Olstein, Elliot M.
; REGISTRATION NUMBER: 24,025
; REFERENCE/DOCKET NUMBER: 271010-360
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-994-1700
; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
US-08-442-809A-57

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1416 GGGCTCTTCAGAGAAA 1432
      ||||| |||||
      1 GGGCTCTTCAGAGCAA 17

Db 1 GGGCTCTTCAGAGCAA 17

RESULT 101
US-08-442-809A-59
; Sequence 59, Application US/08442809A
; Patent No. 5976873
; GENERAL INFORMATION:
; APPLICANT: Bohinski, Robert J.,
; APPLICANT: Whitsett, Jeffrey A.
; TITLE OF INVENTION: Nucleic Acid Sequences
; TITLE OF INVENTION: Controlling Lung Cell -
; TITLE OF INVENTION: Specific Gene Expression
; NUMBER OF SEQUENCES: 76
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Carella, Byrne, Bain, Gilfillan,
; ADDRESSEE: Cecchi, Stewart & Olstein
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/442,809A
; FILING DATE: 17-MAY-1995
; CLASSIFICATION: 536
```

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,356
FILING DATE: 18-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: Olstein, Elliot M.
REGISTRATION NUMBER: 24,025
REFERENCE/DOCKET NUMBER: 271010-360
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201-994-1700
TELEFAX: 201-994-1744
INFORMATION FOR SEQ ID NO: 59:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: oligonucleotide
US-08-442-809A-59

Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.24; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1416 GGCGCTCTCAGAGAAA 1432
1 GGCGCTCTCAGAGCAA 17

Db 1 GGCGCTCTCAGAGCAA 17

RESULT 102
US-08-486-307-7/c
Sequence 7, Application US/08486307
Patent No. 5980885
GENERAL INFORMATION:
APPLICANT: Weis, Samuel
APPLICANT: Reynolds, Brent A.
APPLICANT: Hamman, Joseph P.
APPLICANT: Baetge, Edward E.
TITLE OF INVENTION: In Vitro and In Vivo
TITLE OF INVENTION: Proliferation and Use of Multipotent
TITLE OF INVENTION: Neural Stem Cells and their
NUMBER OF INVENTIONS: 8
CURRENT APPLICATION DATA:
CORRESPONDENCE ADDRESS:
ADDRESSEE: Flehr, Hohbach, Teet, Albritton
ADDRESSEE: E Herbert
STREET: Four Embarcadero Center, Suite 3400
CITY: San Francisco
STATE: California
COUNTRY: United States
ZIP: 94111-4187
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/486,307
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Brunelle, Jan P.
REGISTRATION NUMBER: 35,081
REFERENCE/DOCKET NUMBER: A-61105-3/DJB/JPB
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 781-1989
TELEFAX: (415) 398-3249
TELEX: 910 277239
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown

MOLECULE TYPE: CDNA
US-08-486-307-7

Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.24; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGTGACGCGCTGG 1609
18 CGAGTGATGCGCTGG 2

Db 18 CGAGTGATGCGCTGG 2

RESULT 103
US-08-486-307-8
Sequence 8, Application US/08486307
Patent No. 5980885
GENERAL INFORMATION:
APPLICANT: Weis, Samuel
APPLICANT: Reynolds, Brent A.
APPLICANT: Hamman, Joseph P.
APPLICANT: Baetge, Edward E.
TITLE OF INVENTION: In Vitro and In Vivo
TITLE OF INVENTION: Proliferation and Use of Multipotent
TITLE OF INVENTION: Neural Stem Cells and their
NUMBER OF INVENTIONS: 8
CURRENT APPLICATION DATA:
CORRESPONDENCE ADDRESS:
ADDRESSEE: Flehr, Hohbach, Teet, Albritton
ADDRESSEE: E Herbert
STREET: Four Embarcadero Center, Suite 3400
CITY: San Francisco
STATE: California
COUNTRY: United States
ZIP: 94111-4187
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/486,307
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Brunelle, Jan P.
REGISTRATION NUMBER: 35,081
REFERENCE/DOCKET NUMBER: A-61105-3/DJB/JPB
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 781-1989
TELEFAX: (415) 398-3249
TELEX: 910 277239
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: CDNA
US-08-486-307-8

Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.24; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGTGACGCGCTGG 1609
1 CGAGTGATGCGCTGG 17

Db 1 CGAGTGATGCGCTGG 17

RESULT 104
US-08-857-946-23/c
Sequence 23, Application US/08857946
Patent No. 5994075

```

; GENERAL INFORMATION:
; APPLICANT: Goodfellow, P.N.
; TITLE OF INVENTION: METHODS FOR IDENTIFYING A MUTATION IN A
; TITLE OF INVENTION: GENE OF INTEREST
; NUMBER OF SEQUENCES: 162
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Inc.
; STREET: 75 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1807
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/857,946
; FILING DATE: 16-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION NUMBER: US/60/017,824
; FILING DATE: 17-MAY-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kathleen M. Williams
; REGISTRATION NUMBER: 34,380
; REFERENCE/DOCKET NUMBER: 3529/05573
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-345-9100
; TELEFAX: 617-345-9111
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
;
US-08-857-946-23
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2200 GGGTGCTACTGGCCAT 2216
Db 18 GGGTTCTCTCGGCCAT 2

RESULT 105
US-09-205-921-35
; Sequence 35, Application US/09205921A
; Patent No. 6008048
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: ex M. Cowseart
; TITLE OF INVENTION: ANTISENSE MODULATION OF EGR-1 EXPRESSION
; FILE REFERENCE: RTS-0028
; CURRENT APPLICATION NUMBER: US/09/205,921A
; CURRENT FILING DATE: 1998-12-04
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 35
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURES:
; OTHER INFORMATION: Antisense oligonucleotide
;
US-09-205-921-35
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY 2054 TGTCGAAGCCCTGAG 2070
Db 2 TGTCGAAGCCCTGTG 18

RESULT 106
US-08-970-740-23/C
; Sequence 23, Application US/08970740
; Patent No. 6015670
; GENERAL INFORMATION:
; APPLICANT: Goodfellow, P.N.
; TITLE OF INVENTION: METHODS FOR IDENTIFYING A MUTATION IN A
; TITLE OF INVENTION: GENE OF INTEREST
; NUMBER OF SEQUENCES: 162
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Inc.
; STREET: 28 State Street, 28th Floor
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/970,740
; FILING DATE: 14-NOV-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/857,946
; FILING DATE: 16-MAY-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/017,824
; FILING DATE: 17-MAY-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kathleen M. Williams
; REGISTRATION NUMBER: 34,380
; REFERENCE/DOCKET NUMBER: 3529/59829
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-227-7111
; TELEFAX: 617-227-4399
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
;
US-08-970-740-23
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2200 GGGTGCTACTGGCCAT 2216
Db 18 GGGTTCTCTCGGCCAT 2

RESULT 107
US-08-479-795-7/C
; Sequence 7, Application US/08479795
; Patent No. 6071889
; GENERAL INFORMATION:
; APPLICANT: Weis, Samuel
; APPLICANT: Reynolds, Brent A.
; APPLICANT: Hamman, Joseph P.
; APPLICANT: Baerger, Edward E.
; TITLE OF INVENTION: In Vitro and In Vivo
; TITLE OF INVENTION: Proliferation and Use of Multipotent
; TITLE OF INVENTION: Neural Stem Cells and their Progeny
; NUMBER OF SEQUENCES: 8
```


;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Flehr, Hohbach, Teet, Albritton
;; ADDRESSEE: & Herbert
;; STREET: Four Embarcadero Center, Suite 3400
;; CITY: San Francisco
;; STATE: California
;; COUNTRY: United States
;; ZIP: 94111-4187
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patentin Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/479,795
;; FILING DATE: 07-JUN-1995
;; CLASSIFICATION: 435
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Brunelle, Jan P.
;; REGISTRATION NUMBER: 35,081
;; REFERENCE/DOCKET NUMBER: A-61105-6/DJB/JPB
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (415) 781-1989
;; TELEFAX: (415) 398-3249
;; TELE: 910 277299
;; INFORMATION FOR SEQ ID NO: 7:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: unknown
;; TOPOLOGY: unknown
;; MOLECULE TYPE: cDNA
;; US-08-479-795-7

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGGTGACGGCGCTGG 1609
DB 18 CGAGGTGATGCCGCTGG 2

;; RESULT 108
;; US-08-479-795-8
;; Sequence 8, Application US/08479795
;; Patent No. 6071889
;; GENERAL INFORMATION:
;; APPLICANT: Weis, Samuel
;; APPLICANT: Reynolds, Brent A.
;; APPLICANT: Hamman, Joseph P.
;; APPLICANT: Baetge, Edward E.
;; TITLE OF INVENTION: In Vitro and In Vivo
;; TITLE OF INVENTION: Proliferation and Use of Multipotent
;; TITLE OF INVENTION: Neural Stem Cells and their Progeny
;; NUMBER OF SEQUENCES: 8
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Flehr, Hohbach, Teet, Albritton
;; ADDRESSEE: & Herbert
;; STREET: Four Embarcadero Center, Suite 3400
;; CITY: San Francisco
;; STATE: California
;; COUNTRY: United States
;; ZIP: 94111-4187
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patentin Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/479,795
;; FILING DATE: 07-JUN-1995
;; CLASSIFICATION: 435

;; ATTORNEY/AGENT INFORMATION:
;; NAME: Brunelle, Jan P.
;; REGISTRATION NUMBER: 35,081
;; REFERENCE/DOCKET NUMBER: A-61105-6/DJB/JPB
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (415) 781-1989
;; TELEFAX: (415) 398-3249
;; TELE: 910 277299
;; INFORMATION FOR SEQ ID NO: 8:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: unknown
;; TOPOLOGY: unknown
;; MOLECULE TYPE: cDNA
;; US-08-479-795-8

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGGTGACGGCGCTGG 1609
DB 1 CGAGGTGATGCCGCTGG 17

;; RESULT 109
;; US-09-344-521-25/c
;; Sequence 25, Application US/09344521
;; Patent No. 6100090
;; GENERAL INFORMATION:
;; APPLICANT: Brett P. Monia
;; APPLICANT: Lex M. Cowsett
;; TITLE OF INVENTION: ANTISENSE MODULATION OF PI3K P85 EXPRESSION
;; FILE REFERENCE: RTS-0062
;; CURRENT APPLICATION NUMBER: US/09/344,521
;; CURRENT FILING DATE: 1999-06-25
;; NUMBER OF SEQ ID NOS: 47
;; SEQ ID NO 25
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Antisense Oligonucleotide
;; US-09-344-521-25

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1772 TTGAGAGAGCTTCAA 1788
DB 17 TTGAGAGAGACTTGAA 1

;; RESULT 110
;; US-08-847-844A-135
;; Sequence 135, Application US/08847844A
;; Patent No. 6150160
;; GENERAL INFORMATION:
;; APPLICANT: KAZAZIAN JR., HAIG H.
;; APPLICANT: BOEKE, JBF D.
;; APPLICANT: MORAN, JOHN V.
;; APPLICANT: DOMBOSKI, BETH A.
;; TITLE OF INVENTION: COMPOSITIONS AND METHODS OF USE OF
;; TITLE OF INVENTION: MAMMALIAN RETROTRANSPOSONS
;; NUMBER OF SEQUENCES: 137
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: PANITCH SCHWARZE JACOBS & NADEL, P.C.
;; STREET: ONE COMMERCE SQUARE, 2005 MARKET STREET, 22ND FL.
;; CITY: PHILADELPHIA
;; STATE: PA
;; COUNTRY: U.S.A.

ZIP: 19103-7086
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/847,844A
FILING DATE: 28-APR-1997
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/749,805
FILING DATE: 16-NOV-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/006,831
FILING DATE: 16-NOV-1995
ATTORNEY/AGENT INFORMATION:
NAME: DOYLE LEARY Ph.D., KATHRYN
REGISTRATION NUMBER: 36,317
REFERENCE/DOCKET NUMBER: 9596-2302
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-567-2991
TELEFAX: 215-567-2020
INFORMATION FOR SEQ ID NO: 135:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-847-844A-135

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1817 AGCCACTATGAGGAA 1833
DB 2 AGGCAACTATGATGAA 18

RESULT 111
US-09-474-922A-84/C
Sequence 84, Application US/09474922A
Patent No. 6187586
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: Lex M. Cowser
APPLICANT: Richard A. Roth
TITLE OF INVENTION: ANTISENSE MODULATION OF Akt-3 EXPRESSION
FILE REFERENCE: RTS-0036
CURRENT APPLICATION NUMBER: US/09/474,922A
CURRENT FILING DATE: 1999-12-29
NUMBER OF SEQ ID NOS: 89
SEQ ID NO 84
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-474-922A-84

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1867 AGTTTCATCTCGACT 1883
DB 18 AGTTCTTCTCTGAGT 2

RESULT 112
US-08-484-406-7/C

Sequence 7, Application US/08484406
Patent No. 6294346
GENERAL INFORMATION:
APPLICANT: Weiss, Samuel
APPLICANT: Reynolds, Brent A.
APPLICANT: Hamman, Joseph P.
APPLICANT: Baetge, Edward E.
TITLE OF INVENTION: In Vitro and In Vivo Proliferation and
NUMBER OF INVENTION: Use of Multipotent Neural Stem Cells and their Progeny
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSER: Flehr, Hobbach, Test, Albritton
ADDRESSER: & Herbert
STREET: Four Embarcadero Center, Suite 3400
CITY: San Francisco
STATE: California
COUNTRY: United States
ZIP: 94111-4187
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,406
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Brunelle, Jan P.
REGISTRATION NUMBER: 35,081
REFERENCE/DOCKET NUMBER: A-61105-5/DJB/JPB
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 781-1989
TELEFAX: (415) 398-3249
TELEX: 910 277239
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: cDNA
US-08-484-406-7

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGTGACGCGCTGG 1609
DB 18 CGAGTGATGCCGCTGG 2

RESULT 113
US-08-484-406-8
Sequence 8, Application US/08484406
Patent No. 6294346
GENERAL INFORMATION:
APPLICANT: Weiss, Samuel
APPLICANT: Reynolds, Brent A.
APPLICANT: Hamman, Joseph P.
APPLICANT: Baetge, Edward E.
TITLE OF INVENTION: In Vitro and In Vivo Proliferation and
NUMBER OF INVENTION: Use of Multipotent Neural Stem Cells and their Progeny
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSER: Flehr, Hobbach, Test, Albritton
ADDRESSER: & Herbert
STREET: Four Embarcadero Center, Suite 3400
CITY: San Francisco
STATE: California
COUNTRY: United States
ZIP: 94111-4187


```
US-08-486-313-7/c
; Sequence 7, Application US/08486313
; Patent No. 6497872
; GENERAL INFORMATION:
; APPLICANT: Weiss, Samuel
; APPLICANT: Reynolds, Brent A.
; APPLICANT: Hammang, Joseph P.
; APPLICANT: Baetge, Edward E.
; TITLE OF INVENTION: In Vitro and In Vivo Proliferation
; TITLE OF INVENTION: and Use of Multipotent Neural Stem Cells and their
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Flehr, Hohbach, Test, Albritton
; ADDRESSEE: & Herbert
; STREET: Four Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: United States
; ZIP: 94111-4187
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,313
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Brunelle, Jan P.
; REGISTRATION NUMBER: 35,081
; REFERENCE/DOCKET NUMBER: A-61105-11/DJB/JPB
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 781-1989
; TELEFAX: (415) 398-3249
; TELEX: 910 277299
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: cDNA
US-08-486-313-7

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1593 CGAGGTGACGCGCTGG 1609
Db      18 CGAGGTATGCGCGCTGG 2

RESULT 117
US-08-486-313-8
; Sequence 8, Application US/08486313
; Patent No. 6497872
; GENERAL INFORMATION:
; APPLICANT: Weiss, Samuel
; APPLICANT: Reynolds, Brent A.
; APPLICANT: Hammang, Joseph P.
; APPLICANT: Baetge, Edward E.
; TITLE OF INVENTION: In Vitro and In Vivo Proliferation
; TITLE OF INVENTION: and Use of Multipotent Neural Stem Cells and their
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Flehr, Hohbach, Test, Albritton
; ADDRESSEE: & Herbert
; STREET: Four Embarcadero Center, Suite 3400
; CITY: San Francisco
```

```
STATE: California
COUNTRY: United States
ZIP: 94111-4187
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/486,313
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Brunelle, Jan P.
REGISTRATION NUMBER: 35,081
REFERENCE/DOCKET NUMBER: A-61105-11/DJB/JPB
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 781-1989
TELEFAX: (415) 398-3249
TELEX: 910 277299
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: cDNA
US-08-486-313-8

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1593 CGAGGTGACGCGCTGG 1609
Db      1 CGAGGTATGCGCGCTGG 17

RESULT 118
US-09-422-978-8459
; Sequence 8459, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSER.020C91
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8459
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-15599 for SEQ 594, in complete
US-09-422-978-8459

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      77 TACTGTACTTTCGCC 93
Db      1 TACTGTACTTTCGCC 93
```

Db 2 TACTGCTACTCTCC 18

RESULT 119
US-08-857-636-51/c
Sequence 51, Application US/08857636
Patent No. 6552181
GENERAL INFORMATION:
APPLICANT: Dean, Michael Carlton
APPLICANT: Hahn, Heidi Eve
APPLICANT: Wicking, Carol
APPLICANT: Christensen, Jeffrey
APPLICANT: Zaphiropoulos, Peter G.
APPLICANT: Gailani, Mae R.
APPLICANT: Shanley, Susan Mary
APPLICANT: Chidambaram, Abirami
APPLICANT: Vorechovsky, Igor
APPLICANT: Holmberg-Lindstrom, Erika
APPLICANT: Unden, Anne Birgitte
APPLICANT: Gillies, Susan Alana
APPLICANT: Negus, Kylie
APPLICANT: Smyth, Ian McLeod
APPLICANT: Preseman, Carol Leah
APPLICANT: Lefkell, David J.
APPLICANT: Gerrard, Bernard
APPLICANT: Goldstein, Alisa Miriam
APPLICANT: Mainwright, Brandon
APPLICANT: Totfgard, Rune Carl-Magnus
APPLICANT: Chenevix-Trench, Georgia
APPLICANT: Bale, Allen E.
TITLE OF INVENTION: A Basal Cell Carcinoma Tumor Suppressor Gene
NUMBER OF SEQUENCES: 83
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/857,636
FILING DATE: 16-MAY-1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/017,906
FILING DATE: 17-MAY-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: AU P00011
FILING DATE: 21-MAY-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: AU P00363
FILING DATE: 07-JUN-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/019,765
FILING DATE: 14-JUN-1996
ATTORNEY/AGENT INFORMATION:
NAME: Hunter, Tom
REGISTRATION NUMBER: 38,498
REFERENCE/DOCKET NUMBER: 015280-278200US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 51:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: DNA
FEATURE:
NAME/KEY: -
LOCATION: 1..18
OTHER INFORMATION: /note= "PTCR25 primer"
US-08-857-636-51

Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.24; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1461 CTGCCACCCAGTGTGTC 1477
Db 17 CTGCCACCAAGTGATC 1

RESULT 120
US-07-664-989B-121/c
Sequence 121, Application US/07664989B
Patent No. 5223409
GENERAL INFORMATION:
APPLICANT: Ladner, Robert Charles
APPLICANT: Guterman, Sonia Kosow
APPLICANT: Roberts, Bruce Lindsey
APPLICANT: Markland, William
APPLICANT: Ley, Arthur Charles
TITLE OF INVENTION: Directed Evolution of No. 5223409e1
NUMBER OF SEQUENCES: 121
CORRESPONDENCE ADDRESS:
ADDRESSEE: Broadway and Nelmark
STREET: 419 Seventh Street, N.W.
CITY: Washington,
STATE: DC
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WORDPERFECT 4.2
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/664,989B
FILING DATE: 19910301
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US89/03731
FILING DATE: 01-SEP-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/487,063
FILING DATE: 02-MAR-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/240,160
FILING DATE: 02-SEP-1988
ATTORNEY/AGENT INFORMATION:
NAME: Cooper, Iver P.
REGISTRATION NUMBER: 28005
REFERENCE/DOCKET NUMBER: LADNER 7
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-628-5197
TELEFAX: 202-737-3528
INFORMATION FOR SEQ ID NO: 121:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: double
TOPOLOGY: circular
MOLECULE TYPE: genomic DNA
US-07-664-989B-121

Query Match 0.64; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 597 TGGGAGATGSCCAT 611
Db 15 TGGGAGATGACCAT 1

RESULT 121

US-08-323-192D-13
; Sequence 13, Application US/08323192D
; Patent No. 5786199
; GENERAL INFORMATION:
; APPLICANT: Palasee, Peter
; TITLE OF INVENTION: RECOMBINANT NEGATIVE STRAND RNA VIRUS
; TITLE OF INVENTION: EXPRESSION SYSTEMS AND VACCINES
; NUMBER OF SEQUENCES: 70
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036-2711

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/323,192D
; FILING DATE: 14-OCT-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A.
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 7682-035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 790-9090
; TELEFAX: (212)869-9741/8864
; TELEX: 66141 PENNIE

INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: RNA
; US-08-323-192D-13

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

OY 999 CACCTGCTCTGCT 1013
Db 1 CACCTGCTCTGCT 15

RESULT 122

US-08-470-887A-12
; Sequence 12, Application US/08470887A
; Patent No. 5820871
; GENERAL INFORMATION:
; APPLICANT: Palasee, Peter

APPLICANT: Garcia-Sastre, Adolfo
; TITLE OF INVENTION: RECOMBINANT NEGATIVE STRAND RNA VIRUS
; TITLE OF INVENTION: EXPRESSION SYSTEMS AND VACCINES
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York

STATE: New York
; COUNTRY: USA
; ZIP: 10036-2711

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/470,887A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A.
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 7682-036
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 790-9090
; TELEFAX: (212) 869-9741/8864
; TELEX: 66141 PENNIE

INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: unknown
; MOLECULE TYPE: RNA
; US-08-470-887A-12

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

OY 999 CACCTGCTCTGCT 1013
Db 1 CACCTGCTCTGCT 15

RESULT 123

US-08-292-620A-393
; Sequence 393, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm

APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper

TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

ZIP: 90071-2066
COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:

PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 393:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-393

Query Match 0.64; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2102 AGGACCTCAGCCTGG 2116
DB 1 AGGACCTCAGCCTGG 15

RESULT 124
US-08-292-620A-656
Sequence 656, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435.
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 656:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-656

Query Match 0.64; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2102 AGGACCTCAGCCTGG 2116
DB 1 AGGACCTCAGCCTGG 15

RESULT 125
US-08-316-439A-10
Sequence 10, Application US/08316439A
Patent No. 5840520
GENERAL INFORMATION:
APPLICANT: CLARKE, DAVID KIRKWOOD
APPLICANT: PALSEE, PETER M
TITLE OF INVENTION: RECOMBINANT NEGATIVE STRAND RNA VIRUS EXPRESSION
TITLE OF INVENTION: SYSTEMS
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSEE: COOLEY GODWARD CASTRO HUDDLESON & TATUM
STREET: FIVE PALO ALTO SQUARE
CITY: PALO ALTO
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/316,439A
FILING DATE: September 30, 1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/190,678
FILING DATE: February 1, 1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/925,061
FILING DATE: August 4, 1992
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/527,237
FILING DATE: May 22, 1990
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/440,053
FILING DATE: No. 5840520 December 21, 1989
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/399,728
FILING DATE: August 28, 1989
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: CSERR, LUANN
REGISTRATION NUMBER: 31,822

```

: REFERENCE/DOCKET NUMBER: AVIR-010/00US
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (415) 843-5165
: TELEFAX: (415) 857-0663
: TELEX: 380816 COOLEY PA
: INFORMATION FOR SEQ ID NO: 10:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 15 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: SYNTHETIC RNA
US-08-316-439A-10

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 999 CACCTGCTCTGCT 1013
Db 1 CACCCGCUUCGCU 15

RESULT 126
US-08-252-508B-12
: Sequence 12, Application US/08252508B
: Patent No. 5854037
: GENERAL INFORMATION:
: APPLICANT: Palese, Peter
: APPLICANT: Garcia-Sastre, Adolfo
: TITLE OF INVENTION: RECOMBINANT NEGATIVE STRAND RNA VIRUS
: TITLE OF INVENTION: EXPRESSION SYSTEMS AND VACCINES
: NUMBER OF SEQUENCES: 60
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Pennie & Edmonds
: STREET: 1155 Avenue of the Americas
: CITY: New York
: STATE: New York
: COUNTRY: USA
: ZIP: 10036-2711
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: PatentIn Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/252,508B
: FILING DATE: 01-JUN-1994
: CLASSIFICATION:
: ATTORNEY/AGENT INFORMATION:
: NAME: Coruzzi, Laura A.
: REGISTRATION NUMBER: 30,742
: REFERENCE/DOCKET NUMBER: 7682-034
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (212) 790-9090
: TELEFAX: (212) 869-9741/8664
: TELEX: 66141 PENNIE
: INFORMATION FOR SEQ ID NO: 12:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 15 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: unknown
: MOLECULE TYPE: RNA
US-08-252-508B-12

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 999 CACCTGCTCTGCT 1013
Db 1 CACCCGCUUCGCU 15
```

```

RESULT 127
US-08-585-684B-163/C
: Sequence 163, Application US/08585684B
: Patent No. 5877021
: GENERAL INFORMATION:
: APPLICANT: Stinchcomb, Daniel T.
: APPLICANT: Jarvis, Thale
: APPLICANT: McSwiggan, James
: TITLE OF INVENTION: METHOD AND REAGENT FOR THE
: TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
: TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
: NUMBER OF SEQUENCES: 2751
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Lyon & Lyon
: STREET: 633 West Fifth Street
: STREET: Suite 4700
: CITY: Los Angeles
: STATE: California
: COUNTRY: U.S.A.
: ZIP: 90071
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
: MEDIUM TYPE: storage
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: IBM P.C. DOS 5.0
: SOFTWARE: FastSeq Version 1.5
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/585,684B
: FILING DATE: January 16, 1996
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 60/000,951
: FILING DATE: July 7, 1995
: ATTORNEY/AGENT INFORMATION:
: NAME: Warburg, Richard
: REGISTRATION NUMBER: 32,327
: REFERENCE/DOCKET NUMBER: 218/078
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (213) 489-1600
: TELEFAX: (213) 955-0440
: TELEX: 67-3510
: INFORMATION FOR SEQ ID NO: 163:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 15 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
US-08-585-684B-163

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 502 GGCTCTGGAACCT 516
Db 15 GGCTCTGGAACCT 1

RESULT 128
US-08-588-595-6/C
: Sequence 6, Application US/08588595
: Patent No. 5958769
: GENERAL INFORMATION:
: APPLICANT: Robert, James M.
: APPLICANT: Coats, Steven R.
: APPLICANT: Fero, Matthew L.
: TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR MEDIATING
: TITLE OF INVENTION: CELL CYCLE PROGRESSION
: NUMBER OF SEQUENCES: 13
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Townsend and Crew
: STREET: One Market Plaza, Stewart Street Tower
```


RESULT 129
 US-09-106-377-12
 Sequence 12, Application US/09106377
 Patent No. 6001634
 GENERAL INFORMATION:
 APPLICANT: Palese, Peter
 APPLICANT: Garcis-Sastre, Adolfo
 TITLE OF INVENTION: RECOMBINANT NEGATIVE STRAND RNA VIRUS
 TITLE OF INVENTION: EXPRESSION SYSTEMS AND VACCINES
 NUMBER OF SEQUENCES: 60
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Pennie & Edmonds
 STREET: 1155 Avenue of the Americas
 CITY: New York
 STATE: New York
 COUNTRY: USA
 ZIP: 10036-2711
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/106,377
 FILING DATE:
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/252,508
 FILING DATE: 01-JUN-1994
 ATTORNEY/AGENT INFORMATION:
 NAME: Coruzzi, Laura A.
 REGISTRATION NUMBER: 30,742
 REFERENCE/DOCKET NUMBER: 7682-034
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 790-9090

Sequence 393, Application US/09071845
 Patent No. 6132967
 GENERAL INFORMATION:
 APPLICANT: Susan Grimm
 APPLICANT: Dan T. Stinchcomb
 APPLICANT: James McSwiggen
 APPLICANT: Sean Sullivan
 APPLICANT: Kenneth G. Draper
 TITLE OF INVENTION: RIBOZYME TREATMENT OF
 DISEASES OR CONDITIONS
 TITLE OF INVENTION: RELATED TO LEVELS OF
 INTRACELLULAR ADHESION
 TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
 NUMBER OF SEQUENCES: 2390
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street
 STREET: Suite 4700
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071-2066
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: Word Perfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/071,845
 FILING DATE:
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/08/292,620
 FILING DATE: August 17, 1994
 APPLICATION NUMBER: 08/008,895
 FILING DATE: January 19, 1993
 APPLICATION NUMBER: 07/989,849
 FILING DATE: December 7, 1992
 ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard J.
 REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 208/149
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEEX: 67-3510
 INFORMATION FOR SEQ ID NO: 393:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 15 base pairs
 TYPE: nucleic acid

```
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-393

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      2102 AGCAGCTCAGCCTGG 2116
      |||:|||||:|
Db      1 AGGACCTCAGCCTGG 15

RESULT 131
US-09-071-845-656
; Sequence 656, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Diaper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 656:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-656

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      2102 AGCAGCTCAGCCTGG 2116
      |||:|||||:|
Db      1 AGGACCTCAGCCTGG 15

RESULT 132
US-09-038-073-163/c
; Sequence 163, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 163:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-038-073-163

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      502 GGCTGTGGAACCT 516
      |||:|||||:|
Db      15 GGCTGTGGAACCT 1

RESULT 133
US-09-038-073-163/c
; Patent No. 5166057
; APPLICANT: PALASE, PETER; PARVIN, JEFFREY D.; KRYSTAL, MARK
; TITLE OF INVENTION: RECOMBINANT NEGATIVE STRAND RNA VIRUS
; EXPRESSION-SYSTEMS
; NUMBER OF SEQUENCES: 43
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/527,237
; FILING DATE: 22-MAY-1990
```


Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGTCGGCGGCGACTGG 311
|||||
Db 16 AGTCGGCGGCGGCGG 2

RESULT 138
US-08-292-620A-1644
Sequence 1644, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Waiburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1644:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1644

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGATCCTGCTGGTG 583
:|:|:|:|:|:|:|:|:|
Db 2 UCCUGGUCUGGUCUGG 16

RESULT 139
US-08-292-620A-1700
Sequence 1700, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Waiburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1700:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1700

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGATCCTGCTGGTG 583
:|:|:|:|:|:|:|:|:|
Db 2 UCCUGGUCUGGUCUGG 16

RESULT 140
US-08-292-620A-1707
Sequence 1707, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb

```

/ APPLICANT: James McSwigen
/ APPLICANT: Sean Sullivan
/ APPLICANT: Kenneth G. Draper
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF
/ TITLE OF INVENTION: DISEASES OR CONDITIONS
/ TITLE OF INVENTION: RELATED TO LEVELS OF
/ TITLE OF INVENTION: INTRACELLULAR ADHESION
/ TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
/ NUMBER OF SEQUENCES: 2390
/ CORRESPONDENCE ADDRESS:
/ ADDRESSER: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: Word Perfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/292,620A
/ FILING DATE: August 17, 1994
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ PRIOR APPLICATION DATA: including application
/ PRIOR APPLICATION DATA: described below:
/ APPLICATION NUMBER: 08/008,895
/ FILING DATE: January 19, 1993
/ APPLICATION NUMBER: 07/989,849
/ FILING DATE: December 7, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Wardburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/149
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 1707:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-292-620A-1707

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY      569 TCCTGTCTCTGTGG 583
Db      2 UCCUGGUCUGUG 16

RESULT 141
US-08-292-620A-1743
/ Sequence 1743, Application US/08292620A
/ Patent No. 5837542
/ GENERAL INFORMATION:
/ APPLICANT: Susan Grimm
/ APPLICANT: Dan T. Stinchcomb
/ APPLICANT: James McSwigen
/ APPLICANT: Sean Sullivan
/ APPLICANT: Kenneth G. Draper
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF
/ TITLE OF INVENTION: DISEASES OR CONDITIONS
/ TITLE OF INVENTION: RELATED TO LEVELS OF
/ TITLE OF INVENTION: INTRACELLULAR ADHESION
/ TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
/ NUMBER OF SEQUENCES: 2390
/ CORRESPONDENCE ADDRESS:
/ ADDRESSER: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
```

```

/ TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
/ NUMBER OF SEQUENCES: 2390
/ CORRESPONDENCE ADDRESS:
/ ADDRESSER: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: Word Perfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/292,620A
/ FILING DATE: August 17, 1994
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ PRIOR APPLICATION DATA: including application
/ PRIOR APPLICATION DATA: described below:
/ APPLICATION NUMBER: 08/008,895
/ FILING DATE: January 19, 1993
/ APPLICATION NUMBER: 07/989,849
/ FILING DATE: December 7, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Wardburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/149
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 1743:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-292-620A-1743

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY      569 TCCTGTCTCTGTGG 583
Db      2 UCCUGGUCUGUG 16

RESULT 142
US-08-292-620A-1796
/ Sequence 1796, Application US/08292620A
/ Patent No. 5837542
/ GENERAL INFORMATION:
/ APPLICANT: Susan Grimm
/ APPLICANT: Dan T. Stinchcomb
/ APPLICANT: James McSwigen
/ APPLICANT: Sean Sullivan
/ APPLICANT: Kenneth G. Draper
/ TITLE OF INVENTION: RIBOZYME TREATMENT OF
/ TITLE OF INVENTION: DISEASES OR CONDITIONS
/ TITLE OF INVENTION: RELATED TO LEVELS OF
/ TITLE OF INVENTION: INTRACELLULAR ADHESION
/ TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
/ NUMBER OF SEQUENCES: 2390
/ CORRESPONDENCE ADDRESS:
/ ADDRESSER: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
```

```
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1796:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1796

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy      569 TCCTGCTCCTGCTG 583
Db      2 UCCUGGUCUGGUCG 16

RESULT 143
US-08-292-620A-1873
Sequence 1873, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
```

```
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1873:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1873

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy      569 TCCTGCTCCTGCTG 583
Db      2 UCCUGGUCUGGUCG 16

RESULT 144
US-08-292-620A-1934
Sequence 1934, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
```

PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below: two
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1934:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1934

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGCTCTGCTGCTG 583
Db 2 UCCUGGUCUGGUCG 16

RESULT 145
US-09-071-845-1644
Sequence 1644, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE: December 7, 1992
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1644:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-1644

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGCTCTGCTGCTG 583
Db 2 UCCUGGUCUGGUCG 16

RESULT 146
US-09-071-845-1700
Sequence 1700, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE: December 7, 1992
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510


```

; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1934:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-1934
;
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
QY 569 TCGTGTCTGTGTG 583
Db 2 UCCUGUCUGUG 16
;
RESULT 152
US-09-371-772B-4197
; Sequence 4197, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-U (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
;

```

```

; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 1425
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4197
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-4197
;
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.4e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 977 CCTCACCAGTGCA 991
Db 2 CGCUCACCAUGUCA 16
;
RESULT 153
US-09-371-772B-4505
; Sequence 4505, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-U (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 1425
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4505
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-4505
;
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 1.4e+02;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
QY 1991 TTATCTGATGATG 2005
Db 3 UUAUCCUGAUGCUG 17
;
RESULT 154
US-09-371-772B-4755/c
; Sequence 4755, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-U (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
;

```

NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 4755
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-4755

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2214 CATGATGCAGGCTCC 2228
Db 17 CTGTGTCAGGCTCC 3

RESULT 155
US-09-371-772B-6625
Sequence 6625, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 6625
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-6625

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 770 ACAGCACTTGACAG 784
Db 1 ACAGCACTTGACAG 15

RESULT 156
US-09-827-998-471
Sequence 471, Application US/09827998
Patent No. 6656700
GENERAL INFORMATION:
APPLICANT: Gu, Yizhong
APPLICANT: Shannon, Mark
TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
FILE REFERENCE: MDH0RF-8
CURRENT APPLICATION NUMBER: US/09/827,998
CURRENT FILING DATE: 2001-04-06
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
NUMBER OF SEQ ID NOS: 1881
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6656700
SEQ ID NO 471
LENGTH: 17

TYPE: DNA
ORGANISM: Homo sapiens
US-09-827-998-471

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1027 AAGAAGTGGGAAA 1041
Db 3 AAGAAGGCGGAAA 17

RESULT 157
US-09-827-998-472
Sequence 472, Application US/09827998
Patent No. 6656700
GENERAL INFORMATION:
APPLICANT: Gu, Yizhong
APPLICANT: Shannon, Mark
TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
FILE REFERENCE: MDH0RF-8
CURRENT APPLICATION NUMBER: US/09/827,998
CURRENT FILING DATE: 2001-04-06
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
NUMBER OF SEQ ID NOS: 1881
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6656700
SEQ ID NO 472
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-827-998-472

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1027 AAGAAGTGGGAAA 1041
Db 2 AAGAAGGCGGAAA 16

RESULT 158
US-09-827-998-473
Sequence 473, Application US/09827998
Patent No. 6656700
GENERAL INFORMATION:
APPLICANT: Gu, Yizhong
APPLICANT: Shannon, Mark
TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
FILE REFERENCE: MDH0RF-8
CURRENT APPLICATION NUMBER: US/09/827,998
CURRENT FILING DATE: 2001-04-06
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
NUMBER OF SEQ ID NOS: 1881
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6656700
SEQ ID NO 473
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-827-998-473

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy      1027 AAGAAGTGGGAAAA 1041
      |||||
Db      1 AAGAAGGGGGGAAAA 15

RESULT 159
US-09-866-108A-889/c
; Sequence 889, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 889
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-889

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6756
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6756

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      2041 GTGAGCAGCTCTCG 2055
      |||||
Db      3 GTGAGAGCTCTCG 17

RESULT 161
US-09-866-108A-6757
; Sequence 6757, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
```

;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aeomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 6757
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-6757

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2041 GTGAGCAGCTCTG 2055
Db 2 GTGAGCAGCTCTG 16

RESULT 162
US-09-866-108A-6950

;; Sequence 6950, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108A
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263, 6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aeomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 6950
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-6950

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 89 TCGCCGACTGGTGC 103
Db 3 TCGCCGACTGGTGC 17

RESULT 163
US-09-866-108A-6951

;; Sequence 6951, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: AEOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108A
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263, 6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 15755
;; SOFTWARE: Aeomica Sequence Listing Engine
;; Patent No. 6686188
;; SEQ ID NO 6951
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108A-6951

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 89 TCGCCGACTGGTGC 103
Db 2 TCGCCGACTGGTGC 16

RESULT 164
US-09-866-108A-6952

;; Sequence 6952, Application US/09866108A
;; Patent No. 6686188
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharon G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wensheng

```
APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: AeoMica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6952
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6952
```

```
Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Oy      89 TCGCCGACTGGGCTC 103
Db      1 TCGCCGACTGGCTGC 15
```

```
RESULT 165
US-09-866-108A-8004
; Sequence 8004, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: AeoMica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8004
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8004
```

```
Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Oy      2038 CAGGTGAGCAGCTC 2052
Db      3 CAGCTGAGCAGCTC 17
```

```
RESULT 166
US-09-866-108A-8007
; Sequence 8007, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: AeoMica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8007
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8007
```

```
Query Match      0.6%; Score 13.4; DB 1; Length 17;
```

Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2039 AGCTGAGCAGCTCC 2053

Db 1 AGCTGAGCAGCTCC 15

RESULT 167

US-09-866-108A-8054

Sequence 8054, Application US/09866108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharon G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: A60MICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aeomica Sequence Listing Engine

Patent No. 6686188

SEQ ID NO 8054

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-8054

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2230 GCAGATGCTCCAGAA 2244

Db 3 GCAGATGCTCCAGAA 17

RESULT 168

US-09-866-108A-8055

Sequence 8055, Application US/09866108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharon G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: A60MICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aeomica Sequence Listing Engine

Patent No. 6686188

SEQ ID NO 8055

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-8055

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2230 GCAGATGCTCCAGAA 2244

Db 2 GCAGATGCTCCAGAA 16

RESULT 169

US-08-667-939A-10/c

Sequence 10, Application US/08667939A

Patent No. 5998166

GENERAL INFORMATION:

APPLICANT: LUC, Shun

TITLE OF INVENTION: CD16-II VARIANTS

NUMBER OF SEQUENCES: 25

CORRESPONDENCE ADDRESSES:

ADDRESSEE: BROWDY AND NEIMARK

STREET: 419 Seventh Street, N.W., Suite 300

CITY: Washington

STATE: D.C.

COUNTRY: USA

ZIP: 20004

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent in Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/667,939A

FILING DATE: 24-JUN-1996

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/433,123

FILING DATE: 03-MAY-1995

ATTORNEY/AGENT INFORMATION:

NAME: BROWDY, Roger L.

REGISTRATION NUMBER: 25,618
REFERENCE/DOCKET NUMBER: LWO-2A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-628-5197
TELEFAX: 202-737-3528
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-667-939A-10

Query Match 0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 153 GCTGCCACTGCTC 165
|||||
Db 13 GCTGCCACTGCTC 1

RESULT 170
US-08-667-939A-21
Sequence 21, Application US/08667939A
Patent No. 5998166
GENERAL INFORMATION:
APPLICANT: LWO, Shun
TITLE OF INVENTION: CD16-II VARIANTS
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESSES:
ADDRESSEE: BROWDY AND NEIMARK
STREET: 419 Seventh Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/667,939A
FILING DATE: 24-JUN-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/433,123
FILING DATE: 03-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: BROWDY, Roger L.
REGISTRATION NUMBER: 25,618
REFERENCE/DOCKET NUMBER: LWO-2A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-628-5197
TELEFAX: 202-737-3528
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-667-939A-21

Query Match 0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 153 GCTGCCACTGCTC 165
|||||
Db 3 GCTGCCACTGCTC 15

RESULT 171
US-08-433-123-10/c
Sequence 10, Application US/08433123
Patent No. 6444789
GENERAL INFORMATION:
APPLICANT: LWO, Shun
TITLE OF INVENTION: CD16-II VARIANTS
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESSES:
ADDRESSEE: BROWDY AND NEIMARK
STREET: 419 Seventh Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/433,123
FILING DATE:
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: BROWDY, Roger L.
REGISTRATION NUMBER: 25,618
REFERENCE/DOCKET NUMBER: LWO-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-628-5197
TELEFAX: 202-737-3528
TELEX: 248633
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-433-123-10

Query Match 0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 153 GCTGCCACTGCTC 165
|||||
Db 13 GCTGCCACTGCTC 1

RESULT 172
US-08-433-123-21
Sequence 21, Application US/08433123
Patent No. 6444789
GENERAL INFORMATION:
APPLICANT: LWO, Shun
TITLE OF INVENTION: CD16-II VARIANTS
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESSES:
ADDRESSEE: BROWDY AND NEIMARK
STREET: 419 Seventh Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/433,123


```

; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: BROWDY, Roger L.
; REGISTRATION NUMBER: 25,618
; REFERENCE/DOCKET NUMBER: LEO=2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; TELEX: 248633
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-433-123-21

Query Match          0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      153 GCTGCCACTGCTC 165
      |||||
Db      3 GCTGCCACTGCTC 15

RESULT 173
US-09-371-772B-5827/c
; Sequence 5827, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-U (237/198)
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5827
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-5827

Query Match          0.6%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2216 TGGTGACGAGCTCC 2228
      |||||
Db      16 TGGTGACGAGCTCC 4

RESULT 174
US-08-373-124A-1030
; Sequence 1030, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
```

```

; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Marburg, Richard
; REGISTRATION NUMBER: 32,337
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1030:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-373-124A-1030

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.6e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1242 CACTAGATTTC 1254
      |||||
Db      5 CACTAGATUUUCA 17

RESULT 175
US-08-373-124A-1032
; Sequence 1032, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
```

STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373.124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245.466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192.943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987.132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936.422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32.327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1032:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-1032

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.6e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1243 ACTAGTATTCAG 1255
Db 1 ACUAGUAVUUCAG 13

RESULT 176
US-08-373-124A-1517/c
Sequence 1517, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
APPLICATION NUMBER: 07/987.132

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373.124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245.466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192.943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987.132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936.422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32.327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1517:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-1517

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1050 GTTGCTGGAAGTG 1062
Db 17 GTTGCTGGAAGTG 5

RESULT 177
US-08-373-124A-1519/c
Sequence 1519, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373.124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245.466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192.943
FILING DATE: February 7, 1992
APPLICATION NUMBER: 07/987.132

;; FILING DATE: December 7, 1992
;; APPLICATION NUMBER: 07/936,422
;; FILING DATE: August 26, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Wardburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/035
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1519:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-373-124A-1519

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1050 GTTCTGGAAGTG 1062
Db 16 GTTCTGGAAGTG 4

RESULT 178
US-08-435-628-1030
; Sequence 1030, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard
; REGISTRATION NUMBER: 32,327

;; REFERENCE/DOCKET NUMBER: 209/035
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1030:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-435-628-1030

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.6e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1242 CACTAGTATTTC 1254
Db 5 CACTAGTATTTC 17

RESULT 179
US-08-435-628-1032
; Sequence 1032, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1032:

```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-1032

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.6e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Oy      1243 ACTAGTATTCAG 1255
Db      1 ACUGAUAUUCAG 13

RESULT 180
US-08-435-628-1517/C
; Sequence 1517, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwigen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1517:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-1517
```

```

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      1050 GTTGCTGGAAGTG 1062
Db      17 GTTGCTGGAAGTG 5

RESULT 181
US-08-435-628-1519/C
; Sequence 1519, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwigen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1519:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-1519

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      1050 GTTGCTGGAAGTG 1062
```

Db 16 GTGCTGCAAGTG 4

RESULT 182

US-08-897-340-9/c

Sequence 9, Application US/08897340

Patent No. 5955306

GENERAL INFORMATION:

APPLICANT: Gimeno, Carlos J. and Errada, Patrick. R.

TITLE OF INVENTION: Weight Control Pathway Genes and Uses

TITLE OF INVENTION: Therefor

NUMBER OF SEQUENCES: 36

CORRESPONDENCE ADDRESS:

ADDRESSEE: LAHIVE & COCKFIELD, LLP

STREET: 28 State Street

CITY: Boston

STATE: Massachusetts

COUNTRY: USA

ZIP: 02109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/897,340

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/715,032

FILING DATE: 17-SEP-1996

ATTORNEY/AGENT INFORMATION:

NAME: Silverl, Jean M.

REGISTRATION NUMBER: 39,030

REFERENCE/DOCKET NUMBER: NMI-005CP

TELECOMMUNICATION INFORMATION:

TELEPHONE: (617)227-7400

TELEFAX: (617)227-5941

INFORMATION FOR SEQ ID NO: 9:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: CDNA

US-08-897-340-9

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1009 CTGCTTTCTTC 1021

Db 16 CTGCTTTCTTC 4

RESULT 183

US-09-252-329-9/c

Sequence 9, Application US/09252329

Patent No. 6147192

GENERAL INFORMATION:

APPLICANT: Gimeno, Carlos J. and Errada, Patrick. R.

TITLE OF INVENTION: Weight Control Pathway Genes and Uses

TITLE OF INVENTION: Therefor

NUMBER OF SEQUENCES: 36

CORRESPONDENCE ADDRESS:

ADDRESSEE: LAHIVE & COCKFIELD, LLP

STREET: 28 State Street

CITY: Boston

STATE: Massachusetts

COUNTRY: USA

ZIP: 02109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/252,329

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/897,340

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Silverl, Jean M.

REGISTRATION NUMBER: 39,030

REFERENCE/DOCKET NUMBER: NMI-005CP

TELECOMMUNICATION INFORMATION:

TELEPHONE: (617)227-7400

TELEFAX: (617)227-5941

INFORMATION FOR SEQ ID NO: 9:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: CDNA

US-09-252-329-9

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1009 CTGCTTTCTTC 1021

Db 16 CTGCTTTCTTC 4

RESULT 184

US-08-584-040-2268

Sequence 2268, Application US/08584040

Patent No. 6346398

GENERAL INFORMATION:

APPLICANT: Pavco, Pamela

APPLICANT: McSwigen, James

APPLICANT: Stinchcomb, Dan T.

TITLE OF INVENTION: METHOD AND REAGENT FOR THE

TITLE OF INVENTION: TREATMENT OF DISEASES OR

TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS

TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL

TITLE OF INVENTION: GROWTH FACTOR

NUMBER OF SEQUENCES: 8502

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Suite 4700

STATE: Los Angeles

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/584,040

FILING DATE: January 11, 1996

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/005,974

FILING DATE: October 26, 1995

```

; ATTORNEY/AGENT INFORMATION:
; NAME: Waiburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
;
; INFORMATION FOR SEQ ID NO: 2268:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-584-040-2268

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.6e+02;
Matches      8; Conservative      5; Mismatches      0; Indels      0; Gaps      0;

Qy      691 ATGTCATTCTCA 703
Db      5 AUGGCCAUCUCA 17

RESULT 185
US-08-584-040-2269
; Sequence 2269, Application US/08584040
; Patent No. 6346398
;
GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
;
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Filth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
;
COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584, 040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
;
ATTORNEY/AGENT INFORMATION:
; NAME: Waiburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
;
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2269:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
;
Qy      691 ATGTCATTCTCA 703
Db      5 AUGGCCAUCUCA 17

STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-584-040-2269

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.6e+02;
Matches      8; Conservative      5; Mismatches      0; Indels      0; Gaps      0;

Qy      691 ATGTCATTCTCA 703
Db      1 AUGGCCAUCUCA 13

RESULT 186
US-09-371-772B-813
; Sequence 813, Application US/09371772B
; Patent No. 6566127
;
GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
;
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MEHBO0,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 813
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
;
US-09-371-772B-813

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.6e+02;
Matches      8; Conservative      5; Mismatches      0; Indels      0; Gaps      0;

Qy      691 ATGTCATTCTCA 703
Db      5 AUGGCCAUCUCA 17

RESULT 187
US-09-371-772B-814
; Sequence 814, Application US/09371772B
; Patent No. 6566127
;
GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
;
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MEHBO0,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 814
; LENGTH: 17
; TYPE: RNA
;
Qy      691 ATGTCATTCTCA 703
Db      5 AUGGCCAUCUCA 17
```

ORGANISM: Homo sapiens
US-09-371-772B-814

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.6e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 691 ATGTCATTCTCA 703
DB 1 AUGUCAUUCUCA 13

RESULT 188

US-09-371-772B-4754/C
Sequence 4754, Application US/09371772B

Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim

APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MHB00, 876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B

PRIOR FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974

PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040

PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225

SOFTWARE: Patentin version 3.0
SEQ ID NO 4754

LENGTH: 17
TYPE: RNA

ORGANISM: Homo sapiens
US-09-371-772B-4754

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2216 TGGTCAGGCTCC 2228
DB 16 TGGTCAGGCTCC 4

RESULT 189
US-09-371-772B-4789/C
Sequence 4789, Application US/09371772B

Patent No. 6566127
GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam

APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

FILE REFERENCE: MHB00, 876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B

PRIOR FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974

PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040

PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225

SOFTWARE: Patentin version 3.0
SEQ ID NO 4789

LENGTH: 17
TYPE: RNA

ORGANISM: Homo sapiens
US-09-371-772B-4789

US-09-371-772B-4789

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 328 CTTGCTTGTTC 340
DB 16 CTTGCTTGTTC 4

RESULT 190

US-09-371-772B-5053
Sequence 5053, Application US/09371772B

Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim

APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MHB00, 876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B

PRIOR FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974

PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040

PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225

SOFTWARE: Patentin version 3.0
SEQ ID NO 5053

LENGTH: 17
TYPE: RNA

ORGANISM: Homo sapiens
US-09-371-772B-5053

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1917 TGGAGCCAGCTG 1929
DB 2 UGGAGCCAGCTG 14

RESULT 191

US-09-371-772B-5054
Sequence 5054, Application US/09371772B

Patent No. 6566127
GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam

APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

FILE REFERENCE: MHB00, 876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B

PRIOR FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974

PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040

PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225

SOFTWARE: Patentin version 3.0
SEQ ID NO 5054

LENGTH: 17
TYPE: RNA

ORGANISM: Homo sapiens
US-09-371-772B-5054

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 1917 TGGGAGCCAGCTG 1929
Db 1 UGGGAGCCAGCTG 13

RESULT 192
US-09-371-772B-5194
; Sequence 5194, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 5194
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5194

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.6e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
Qy 691 ATGTCCTTCGA 703
Db 4 AUGGCCAUTCUCA 16

RESULT 193
US-09-371-772B-5195
; Sequence 5195, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 5195
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5195

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.6e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
Qy 691 ATGTCCTTCGA 703
Db 3 AUGGCCAUTCUCA 15

RESULT 194
US-09-866-108A-897/C
; Sequence 897, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 897
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-897

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1699 AAGCCCTTCGCC 1711
Db 13 AAGCCCTTCGCC 1

RESULT 195
US-09-866-108A-9584
; Sequence 9584, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.


```

; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9584
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-9584

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1171 AGGGAAGAAGCTGC 1183
Db      4 AGGGAAGAAGCTGC 16

RESULT 196
; US-09-866-108A-9585
; Sequence 9585, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9584
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-9584
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9585
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-9585

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1171 AGGGAAGAAGCTGC 1183
Db      3 AGGGAAGAAGCTGC 15

RESULT 197
; US-09-866-108A-9586
; Sequence 9586, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9586
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-9586
```

```
Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1171 AGGGAAGCTGC 1183
      |||||
Db      2 AGGGAAGCTGC 14

RESULT 198
US-09-866-108A-9587
; Sequence 9587, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MCA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9587
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9587

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1171 AGGGAAGCTGC 1183
      |||||
Db      1 AGGGAAGCTGC 13

RESULT 199
US-07-988-194A-16
; Sequence 16, Application US/07988194A
; Patent No. 5359046
; GENERAL INFORMATION:
; APPLICANT: Capon, Daniel J.
; APPLICANT: Weiss, Arthur
; APPLICANT: Irving, Brian A.
```

```
APPLICANT: Roberts, Margo R.
APPLICANT: Zsebo, Krisztina
TITLE OF INVENTION: Chimeric Chains for Receptor
TITLE OF INVENTION: Associated Signal Transduction Pathways
NUMBER OF SEQUENCES: 49
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fleht, Hohbach, Teet, Albritton &
ADDRESS: Herbert
STREET: 4 Embarcadero Center, Suite 3400
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94111-4187
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/988,194A
FILING DATE: December 9, 1992
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Rowland, Berttram I.
REGISTRATION NUMBER: 20015
REFERENCE/DOCKET NUMBER: A-55107-1 CELL-0051
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-781-1989
TELEFAX: 415-398-3249
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-07-988-194A-16

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1499 AGGCGCTTGTCACATT 1514
      |||||
Db      1 AGGCGCATGTCACACT 16

RESULT 200
US-08-061-697-23/C
; Sequence 23, Application US/08061697
; Patent No. 5498696
; GENERAL INFORMATION:
; APPLICANT: Brown, Michael S.; Briggs, Michael R.; Wang,
; APPLICANT: Xiaodong, Goldstein, Joseph L.
; TITLE OF INVENTION: Sterol Regulatory Element Binding Proteins
; TITLE OF INVENTION: and Their Use in Screening Assays
; NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P. O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/061,697
FILING DATE: Concurrently Herewith
CLASSIFICATION: 435
```

ATTORNEY/AGENT INFORMATION:
NAME: Parker, David L.
REGISTRATION NUMBER: 32,165
REFERENCE/DOCKET NUMBER: UTSD:347/PAR
TELECOMMUNICATION INFORMATION:
TELEPHONE: (512) 320-7200
TELEFAX: (512) 474-7577
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-061-697-23

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 780 GCAGGGAGAGTGT 795
Db 16 GCAGGGAGAGTGT 1

RESULT 201

US-08-131-365B-23/C
Sequence 23, Application US/08131365B
Patent No. 5527690

GENERAL INFORMATION:
APPLICANT: Brown, Michael S.
APPLICANT: Briggs, Michael R.
APPLICANT: Wang, Xiaodong
APPLICANT: Goldstein, Joseph L.
TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING
TO STEROID REGULATORY ELEMENT BINDING
TITLE OF INVENTION: PROTEINS
NUMBER OF SEQUENCES: 64
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77210

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/131,365B
FILING DATE: 01-OCT-1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Parker, David L.

REGISTRATION NUMBER: 32,165
REFERENCE/DOCKET NUMBER: UTSD:372/PAR
TELECOMMUNICATION INFORMATION:
TELEPHONE: (512) 418-3000
TELEFAX: (512) 474-7577
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "DNA"

US-08-131-365B-23

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 780 GCAGGGAGAGTGT 795
Db 16 GCAGGGAGAGTGT 1

RESULT 202

US-08-258-152-18
Sequence 18, Application US/08258152
Patent No. 5686279

GENERAL INFORMATION:
APPLICANT: FINER, MITCHELL H.
APPLICANT: ROBERTS, MARGO R.
APPLICANT: DULL, THOMAS J.
APPLICANT: ZSEBO, KRISZTINA M.

APPLICANT: QIN, LU
TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION
TITLE OF INVENTION: OF MAMMALIAN CELLS
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: CELL GENESYS, INC.
STREET: 322 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94404

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/258,152
FILING DATE: 10-JUN-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/076,299
FILING DATE: 11-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: KRUPEN, KAREN I.

REGISTRATION NUMBER: 34,647
REFERENCE/DOCKET NUMBER: CELL 13.1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-358-9600 X131
TELEFAX: 415-349-7392

INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-258-152-18

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1499 AGGGCTGTCCAGTT 1514
Db 1 AGGGCTGTCCAGTT 16

RESULT 203

US-08-076-299A-18
Sequence 18, Application US/08076299A
Patent No. 5834256

GENERAL INFORMATION:
APPLICANT: FINER, MITCHELL H.
APPLICANT: ROBERTS, MARGO R.
APPLICANT: DULL, THOMAS J.

```

; APPLICANT: ZSEBO, KRISZTINA M.
; APPLICANT: QIN, LU
; TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
; TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION
; TITLE OF INVENTION: OF MAMMALIAN CELLS
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: CELL GENESYS, INC.
; STREET: 322 LAKESIDE DRIVE
; CITY: FOSTER CITY
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94404
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/076,299A
; FILING DATE: 11-JUN-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: KRUPEN, KAREN I.
; REGISTRATION NUMBER: 34,647
; REFERENCE/DOCKET NUMBER: CELL 13.0
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-358-9600 X131
; TELEFAX: 415-349-7392
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-076-299A-18

Query Match          0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1499 AGGCGCTGTCCAGTT 1514
Db      1 AGGCGCATGTCACACT 16

RESULT 204
US-08-438-582-18
; Sequence 18, Application US/08438582
; Patent No. 5858740
; GENERAL INFORMATION:
; APPLICANT: FINER, MITCHELL H.
; APPLICANT: ROBERTS, MARGO R.
; APPLICANT: DULL, THOMAS J.
; APPLICANT: ZSEBO, KRISZTINA M.
; APPLICANT: QIN, LU
; TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
; TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: CELL GENESYS, INC.
; STREET: 322 LAKESIDE DRIVE
; CITY: FOSTER CITY
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
```

```

; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/438,582
; FILING DATE: 10-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/258,152
; FILING DATE: 10-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/076,299
; FILING DATE: 11-JUN-93
; ATTORNEY/AGENT INFORMATION:
; NAME: KRUPEN, KAREN I.
; REGISTRATION NUMBER: 34,647
; REFERENCE/DOCKET NUMBER: CELL 13.2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-358-9600 X131
; TELEFAX: 415-349-7392
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-438-582-18

Query Match          0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1499 AGGCGCTGTCCAGTT 1514
Db      1 AGGCGCATGTCACACT 16

RESULT 205
US-08-668-123-23/c
; Sequence 23, Application US/08668123
; Patent No. 5891631
; GENERAL INFORMATION:
; APPLICANT: Brown, Michael S.
; APPLICANT: Briggs, Michael R.
; APPLICANT: Wang, Xiaodong
; APPLICANT: Goldstein, Joseph L.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING
; TITLE OF INVENTION: TO STEROL REGULATORY ELEMENT BINDING
; NUMBER OF SEQUENCES: 64
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/668,123
; FILING DATE: 14-JUN-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/131,365
; FILING DATE: 01-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, David L.
; REGISTRATION NUMBER: 32,165
```

```

?
?
? TELECOMMUNICATION INFORMATION:
?
? TELEPHONE: (512) 418-3000
?
? TELEFAX: (512) 474-7577
?
? INFORMATION FOR SEQ ID NO: 23:
?
? SEQUENCE CHARACTERISTICS:
?
? LENGTH: 16 base pairs
?
? TYPE: nucleic acid
?
? STRANDEDNESS: single
?
? TOPOLOGY: linear
?
? MOLECULE TYPE: other nucleic acid
?
? DESCRIPTION: /desc = "DNA"
US-08-668-123-23

```

Query Match	0.6%	Score 12.8;	DB 1;	Length 16;
Best Local Similarity	87.5%;	Pred. No. 1.7e+02;		
Matches 14;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;

Qy	780	GCAGGAGAGCTGTT	795
Db	16	GCAGGGGAGAGTT	1

RESULT 206
 US-08-954-210-64
 Sequence 64, Application US/08954210
 Patent No. 6043077
 GENERAL INFORMATION:
 APPLICANT: Barber, Jack R.
 APPLICANT: Welch, Peter J.
 APPLICANT: Triltz, Richard
 APPLICANT: Yel, Scoopun
 APPLICANT: Yu, Mang
 TITLE OF INVENTION: HEPATITIS C VIRUS RIBOZYMES
 NUMBER OF SEQUENCES: 73
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: SEED AND BERRY LLP
 STREET: 6300 Columbia Center, 701 Fifth Avenue
 City: Seattle
 STATE: Washington
 COUNTRY: USA
 ZIP: 98104-7092
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/954,210
 FILING DATE: 20-OCT-1997
 CLASSIFICATION: 514
 ATTORNEY/AGENT INFORMATION:
 NAME: McMaisters, David D.
 REGISTRATION NUMBER: 33,963
 REFERENCE/DOCKET NUMBER: 480124.403C1
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (206) 622-6030
 TELEFAX: (206) 682-6031
 INFORMATION FOR SEQ ID NO: 64:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 16 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-954-210-64

	Query Match	Score	DB 1	Length
	Best Local Similarity	62.5%	Pred. No. 1.7e+02	
Matches	10; Conservative	4; Mismatches	2; Indels	0; Gaps
QY	713 GTGCAGTCTGTGAGTT	728		
nb	1 GUGCAGUCCUGAGCU	16		

RESULT 207
US-08-413-974-16/c
Sequence 16, Application US/08413974
Patent No. 6180368
GENERAL INFORMATION:
APPLICANT: Singh, Mohan B/r
APPLICANT: Knox, Robert B.
APPLICANT: Smith, Penelope
APPLICANT: Ayiloglu, Atil
APPLICANT: Theerakijpibut, Piyada
APPLICANT: Hough, Terry
TITLE OF INVENTION: Ryegrass Pollen Allergen
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6180368r18
STREET: 1 Liberty Place 4eth Floor

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/413,974
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/202,861
FILING DATE:
APPLICATION NUMBER: US/07/746,703
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Hohenschultz, Liza D.
REGISTRATION NUMBER: 33,712
REFERENCE/DOCKET NUMBER: IMPH-0003
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3949
INFORMATION FOR SEQ. ID NO.: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-413-974-16

Query Match	0.6%	Score 12.8	DB 1	Length 16
Best Local Similarity	87.5%	Pred. NO. 1.7e+02		
Matches 14; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

```

QY      1439 AGTACTGACCGCAC 1454
          |||||
Db      16 AGTACCGGACGGCAC 1

```

RESULT 208
 US-08-434-418--16/c
 Sequence 16, Application US/08434418
 Patent No. 6197313
 GENERAL INFORMATION:
 APPLICANT: Singh, Mohan B et al.
 TITLE OR INVENTION: RYEGRASS POLLEN ALLERGEN
 FILE REFERENCE: IMT-0510ND2
 CURRENT APPLICATION NUMBER: US/08/434,418
 CURRENT FILING DATE: 1995-05-03
 PRIOR APPLICATION NUMBER: 08/202,861
 PRIOR FILING DATE: 1994-25-02
 NUMBER OF SEQ ID NOS: 25

SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 16
LENGTH: 16
TYPE: DNA
ORGANISM: Lolium perenne
US-08-434-418-16

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1439 AGTACCTGACCGCAGC 1454
Db 16 AGTACCGGACGCGCAGC 1

RESULT 209
US-09-266-596-18
Sequence 18, Application US/09266596
Patent No. 6218187
GENERAL INFORMATION:
APPLICANT: FINER, MITCHELL H.
APPLICANT: DULL, THOMAS J.
APPLICANT: ZSEBO, KRISZTINA M.
APPLICANT: COOKE, KEEGAN
APPLICANT: FARSON, DEBORAH A.
TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESSES:
ADDRESSEE: CELL GENESYS, INC.
STREET: 322 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94404
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/266,596
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/517,488
FILING DATE: 21-AUG-1995
APPLICATION NUMBER: US 08/258,152
FILING DATE: 10-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/076,299
FILING DATE: 11-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: KRUPEN, KAREN I.
REGISTRATION NUMBER: 34,647
REFERENCE/DOCKET NUMBER: CELL 13.3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-358-9600 X131
TELEFAX: 415-349-7392
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-266-596-18
Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1499 AGGGCCTGTTCAGTT 1514
Db 1 AGGGCCTGTTCAGTT 16

RESULT 210
US-08-433-288-16/c
Sequence 16, Application US/08433288
Patent No. 6239269
GENERAL INFORMATION:
APPLICANT: Singh, Mohan Bir et al
TITLE OF INVENTION: RYEGRASS POLLEN ALLERGEN
FILE REFERENCE: IMI-051CND1
CURRENT APPLICATION NUMBER: US/08/433,288
CURRENT FILING DATE: 1995-05-03
PRIOR APPLICATION NUMBER: 08/413,947
PRIOR FILING DATE: 1995-03-30
PRIOR APPLICATION NUMBER: 08/202,861
PRIOR FILING DATE: 1994-02-25
PRIOR APPLICATION NUMBER: 07/746,703
PRIOR FILING DATE: 1991-08-16
PRIOR APPLICATION NUMBER: 07/585,086
PRIOR FILING DATE: 1990-10-26
NUMBER OF SEQ ID NOS: 25
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 16
LENGTH: 16
TYPE: DNA
ORGANISM: Lolium perenne
US-08-433-288-16

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1439 AGTACCTGACCGCAGC 1454
Db 16 AGTACCGGACGCGCAGC 1

RESULT 211
US-08-174-739A-16/c
Sequence 16, Application US/08174739A
Patent No. 6265566
GENERAL INFORMATION:
APPLICANT: Singh, Mohan Bir
APPLICANT: Knox, Robert B.
APPLICANT: Smith, Penelope
APPLICANT: Aviloglu, Asil
APPLICANT: Theerakulpisit, Piyada
APPLICANT: Hough, Terry
TITLE OF INVENTION: Ryegrass Pollen Allergen
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Iahive & Cockfield, LLP
STREET: 60 State Street, Suite 510
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/174,739A
FILING DATE: 29-DEC-1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Maniragoutam, Amy E.
REGISTRATION NUMBER: 36,207

```

; REFERENCE/DOCKET NUMBER: IMI-051DV
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 227-7400
; TELEFAX: (617) 227-5941
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-174-739A-16

Query Match          0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1439 AGTACCTGACCGCAGC 1454
Db 16 AGTACCGGACGCGCAC 1

RESULT 212
US-08-479-737-16
; Sequence 16, Application US/08479737
; Patent No. 6319494
; GENERAL INFORMATION:
; APPLICANT: Capon, Daniel J
; WEISS, ARTHUR
; IRVING, BRIAN A
; ROBERTS, MARGO R
; ZSEBO, KRISTINA
; TITLE OF INVENTION: CHIMERIC CHAINS FOR RECEPTOR ASSOCIATED
; SIGNAL TRANSDUCTION PATHWAYS
; NUMBER OF SEQUENCES: 51
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CELL GENESYS, INC.
; STREET: 322 Lakeside Drive
; CITY: Foster City
; STATE: California
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/479,737
; FILING DATE: 07-Jun-1995
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/238,405
; FILING DATE: 05-MAY-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Mandel, Saralynn
; REGISTRATION NUMBER: 31,853
; REFERENCE/DOCKET NUMBER: Cell 5.3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 358-9600
; TELEFAX: (415) 358-0803
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
;
US-08-479-737-16

Query Match          0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY 1499 AGGGCCTTGTCCAGTT 1514
Db 1 AGGGCAGTTCAGCT 16

RESULT 213
US-08-294-312B-26
; Sequence 26, Application US/08294312B
; Patent No. 6380369
; GENERAL INFORMATION:
; APPLICANT: Adams et al.
; TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
; FILE REFERENCE: P106P2
; CURRENT APPLICATION NUMBER: US/08/294,312B
; CURRENT FILING DATE: 1994-08-23
; PRIOR APPLICATION NUMBER: 08/210,143
; PRIOR FILING DATE: 1994-03-16
; PRIOR APPLICATION NUMBER: 08/187,757
; PRIOR FILING DATE: 1994-01-27
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: Patentin Version 3.0
; SEQ ID NO 26
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hMLH1 sense primer
;
US-08-294-312B-26

Query Match          0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2089 CTTCTCATCACCGCAGC 2104
Db 1 CTTCTCATCACCGCAGC 16

RESULT 214
US-08-475-442A-16
; Sequence 16, Application US/08475442A
; Patent No. 6407221
; GENERAL INFORMATION:
; APPLICANT: CAPON, DANIEL J
; WEISS, ARTHUR
; IRVING, BRIAN A
; ROBERTS, MARGO R
; ZSEBO, KRISTINA
; TITLE OF INVENTION: CHIMERIC CHAINS FOR
; RECEPTOR-ASSOCIATED SIGNAL TRANSDUCTION PATHWAYS
; NUMBER OF SEQUENCES: 51
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CELL GENESYS, INC.
; STREET: 322 LAKESIDE DRIVE
; CITY: FOSTER CITY
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/475,442A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/238,405
; FILING DATE: 05-MAY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/988,194
```

```
; FILING DATE: 09-DEC-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/627,643
; FILING DATE: 14-DEC-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/09431
; FILING DATE: 12-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: KRUPEN, KAREN I
; REGISTRATION NUMBER: 34,647
; REFERENCE/DOCKET NUMBER: CELLS-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415)358-9600x131
; TELEFAX: (415)349-7392
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; US-08-475-442A-16
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 1499 AGGCGCTTGCCAGTT 1514
Db 1 AGGCGCATGTCACACT 16
```

```
RESULT 215
US-08-468-024B-26
; Sequence 26, Application US/08468024B
; Patent No. 6416984
; GENERAL INFORMATION:
; APPLICANT: Haseltine et al.
; TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
; FILE REFERENCE: PF106P3
; CURRENT APPLICATION NUMBER: US/08/468,024B
; CURRENT FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: 08/294,312
; PRIOR FILING DATE: 1994-08-23
; PRIOR APPLICATION NUMBER: 08/210,143
; PRIOR FILING DATE: 1994-03-16
; PRIOR APPLICATION NUMBER: 08/187,757
; PRIOR FILING DATE: 1994-01-27
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 26
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hmlh1 sense primer
; US-08-468-024B-26
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 2089 CTTCTCATCACCAGC 2104
Db 1 CTTCTCAACACCAAGC 16
```

```
RESULT 216
US-08-434-256-16/c
; Sequence 16, Application US/08434256
; Patent No. 6451324
; GENERAL INFORMATION:
; APPLICANT: Singh, Mohan Bir, Knox, Robert B., Smith, Penelope,
```

```
; APPLICANT: Avtioglu, Asil, Theerakulpisut, Piyada, Hough, Terryn
; TITLE OF INVENTION: Ryegrass Pollen Allergen
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6451324ris
; STREET: 1 Liberty Place, 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/434,256
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Hohenschutz, Liza D.
; REGISTRATION NUMBER: 33,712
; REFERENCE/DOCKET NUMBER: IMPH-0003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215)568-3100
; TELEFAX: (215)568-3949
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-434-256-16
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 1439 AGTACTGTGACCGCAGC 1454
Db 16 AGTACCCGACGCGCAC 1
```

```
RESULT 217
US-09-431-419A-64
; Sequence 64, Application US/09431419A
; Patent No. 6458567
; GENERAL INFORMATION:
; APPLICANT: Barber, Jack R.
; APPLICANT: Welch, Peter J.
; APPLICANT: Tiltz, Richard
; APPLICANT: Yel, Soomin
; APPLICANT: Yu, Mang
; TITLE OF INVENTION: HEPATITIS C VIRUS RIBOZYMES
; FILE REFERENCE: 480124.403C3
; CURRENT APPLICATION NUMBER: US/09/431,419A
; CURRENT FILING DATE: 1999-11-01
; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 64
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Hepatitis C Virus
; US-09-431-419A-64
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 1.7e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 713 GTGCAGTGTGAGATT 728
Db 1 GUGCAGUCUCUGAGACU 16
```


RESULT 218
US-08-187-757D-24
Sequence 24, Application US/0818757D
Patent No. 6482606
GENERAL INFORMATION:
APPLICANT: Adams et al.
TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
FILE REFERENCE: P1106
CURRENT APPLICATION NUMBER: US/08/187,757D
CURRENT FILING DATE: 1994-01-27
NUMBER OF SEQ ID NOS: 33
SOFTWARE: PatentIn version 3.0
SEQ ID NO 24
LENGTH: 16
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: hMLH1 sense primer
US-08-187-757D-24

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2089 CTTCTCATCACCACG 2104
DB 1 CTTCTCATCACCACG 16

RESULT 219
US-09-944-411-18
Sequence 18, Application US/09944411
Patent No. 6506604
GENERAL INFORMATION:
APPLICANT: FINER, MITCHELL H.
DULL, THOMAS J.
ZSEBO, KRISZTINA M.
COOKE, KEEGAN
PARSON, DEBORAH A.
TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
OF MAMMALIAN CELLS
VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: CELL GENESYS, INC.
STREET: 322 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/944,411
FILING DATE: 04-Sep-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/914,893
FILING DATE: <Unknown>
APPLICATION NUMBER: US 08/258,152
FILING DATE: 10-JUN-1994
APPLICATION NUMBER: US 08/076,299
FILING DATE: 11-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: KRUPEN, KAREN I.
REGISTRATION NUMBER: 34,647
REFERENCE/DOCKET NUMBER: CELL 13.3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-358-9600 X131

TELEFAX: 415-349-7392
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-944-411-18

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1499 AGGCGCTGTCCAGT 1514
DB 1 AGGCGCTGTCCAGT 16

RESULT 220
US-09-371-772B-5758
Sequence 5758, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: MCSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MBH00.876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 5758
LENGTH: 16
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-5758

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 56.2%; Pred. No. 1.7e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1992 TATCTGATGATGCC 2007
DB 1 TATCTGATGATGCC 16

RESULT 221
US-09-371-772B-5759
Sequence 5759, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: MCSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MBH00.876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26

```
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5759
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-5759

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 16;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2016 CTTGGATGCAACAGC 2031
Db 1 CCUGAUGCUGACAGC 16

RESULT 222
US-09-371-772B-7002
; Sequence 7002, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-U (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7002
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-7002

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 16;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1469 CCACTGCTCTGTTGAC 1484
Db 1 CCAGUGGCGCUGAC 16

RESULT 223
US-08-465-679-26
; Sequence 26, Application US/08465679
; Patent No. 6610477
; GENERAL INFORMATION:
; APPLICANT: Haseeltine et al.
; TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
; FILE REFERENCE: PF106P4
; CURRENT APPLICATION NUMBER: US/08/465,679
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: 08/294,312
; PRIOR FILING DATE: 1994-08-23
; PRIOR APPLICATION NUMBER: 08/210,143
; PRIOR FILING DATE: 1994-03-16
; PRIOR APPLICATION NUMBER: 08/187,757
; PRIOR FILING DATE: 1994-01-27
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 26
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hMLH1 sense primer
; US-08-465-679-26

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2089 CTTCTCATCACCAGC 2104
Db 1 CTTCTCAACACCAAGC 16

RESULT 224
US-09-829-855-107
; Sequence 107, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY-1
; CURRENT APPLICATION NUMBER: US/09/829,855
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 107
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
; US-09-829-855-107

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 39 CTGCGCTCCCGAGCT 54
Db 1 CTGCGCGCGCGAGCT 16

RESULT 225
US-08-210-143C-24
; Sequence 24, Application US/08210143C
; Patent No. 6620619
; GENERAL INFORMATION:
; APPLICANT: Haseeltine et al.
; TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
; FILE REFERENCE: PF106P1
; CURRENT APPLICATION NUMBER: US/08/210,143C
; PRIOR FILING DATE: 1994-03-16
; PRIOR APPLICATION NUMBER: 08/187,757
; PRIOR FILING DATE: 1994-01-27
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 24
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hMLH1 sense primer
; US-08-210-143C-24

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 16;
```

Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2089 CTTCTCATCACCAGC 2104

Db 1 CTTCTCAACACCAAGC 16

RESULT 226

US-09-479-005A-337/C
Sequence 337, Application US/09479005A

Patent No. 6656731

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity

FILE REFERENCE: MEH800-884-C

CURRENT APPLICATION NUMBER: US/09/479,005A

PRIOR FILING DATE: 2000-01-07

PRIOR APPLICATION NUMBER: US 09/444,209

PRIOR FILING DATE: 1999-11-19

PRIOR APPLICATION NUMBER: US 09/159,274

PRIOR FILING DATE: 1998-09-22

PRIOR APPLICATION NUMBER: US 60/059,473

PRIOR FILING DATE: 1997-09-22

NUMBER OF SEQ ID NOS: 1208

SOFTWARE: PatentIn version 3.0

SEQ ID NO 337

LENGTH: 16

TYPE: RNA

ORGANISM: Homo sapiens

US-09-479-005A-337

Query Match

Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 604 ATGCCATTCATCT 619

Db 16 ATGCCATTCATCT 1

RESULT 227

5256545-4/C

Patent No. 5256545

APPLICANT: BROWN, MICHAEL S.; GOLDSTEIN, JOSEPH L.; RUSSELL,

DAVID W.; SUDHOF, THOMAS C.

TITLE OF INVENTION: STEROL REGULATORY ELEMENTS

NUMBER OF SEQUENCES: 42

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/07/425,852

FILING DATE: 20-OCT-1989

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 33,330

FILING DATE: 30-MAR-1987

APPLICATION NUMBER: 33,081

FILING DATE: 30-MAR-1987

SEQ ID NO:4

LENGTH: 16

5256545-4

Query Match

Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 780 GCAGGAGAGGTGTT 795

Db 16 GCAGGAGAGGTGTT 1

RESULT 228

5256545-33

Patent No. 5256545

APPLICANT: BROWN, MICHAEL S.; GOLDSTEIN, JOSEPH L.; RUSSELL,

DAVID W.; SUDHOF, THOMAS C.
TITLE OF INVENTION: STEROL REGULATORY ELEMENTS

NUMBER OF SEQUENCES: 42

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/07/425,852

FILING DATE: 20-OCT-1989

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 33,330

FILING DATE: 30-MAR-1987

APPLICATION NUMBER: 33,081

FILING DATE: 30-MAR-1987

SEQ ID NO:33

LENGTH: 16

5256545-33

Query Match

Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 780 GCAGGAGAGGTGTT 795

Db 1 GCAGGAGAGGTGTT 16

RESULT 229

US-08-379-078-631

Sequence 631, Application US/08379078

Patent No. 5639612

GENERAL INFORMATION:

APPLICANT: Mitsuhashi, Masato

APPLICANT: Cooper, Allan

TITLE OF INVENTION: Gene Detection System

NUMBER OF SEQUENCES: 726

CORRESPONDENCE ADDRESS:

ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR

STREET: 620 Newport Center Drive 16th Floor

CITY: Newport Beach

STATE: CA

COUNTRY: USA

ZIP: 92660

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/379,078

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/974,406

FILING DATE: 12-NOV-1992

ATTORNEY/AGENT INFORMATION:

NAME: Altman, Daniel E.

REGISTRATION NUMBER: 34,115

REFERENCE/DOCKET NUMBER: HITACHI 011CP2

TELECOMMUNICATION INFORMATION:

TELEPHONE: 714-760-0404

TELEFAX: 714-760-9502

INFORMATION FOR SEQ ID NO: 631:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: double

TOPOLOGY: linear

MOLECULE TYPE: cDNA to mRNA

HYPOTHETICAL: NO

ANTI-SENSE: NO

US-08-379-078-631

Query Match

Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 550 ACGCGCGCCTCTCGC 565
| | | | | | | | | |
Db 2 ACGCGCGCCTCTCGC 17

RESULT 230
US-08-373-124A-842/C
Sequence 842, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: MCSwigen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08373.124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 842:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-842

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1430 AATATTGAGTACT 1445
| | | | | | | | | |
Db 17 AATATTGAGTACT 2

RESULT 231
US-08-460-853-1/C
Sequence 1, Application US/08460853

Patent No. 5695940
GENERAL INFORMATION:
APPLICANT: Drmanac, Radoje T.
APPLICANT: Crkvenjakov, Radomir B.
TITLE OF INVENTION: Method of sequencing by Hybridization of
TITLE OF INVENTION: Oligonucleotide Probes
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/460,853
FILING DATE: 06-MAY-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/203,502 CON
FILING DATE: 28-FEB-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/048,152 FWC
FILING DATE: 15-APR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Meyers, Thomas C.
REGISTRATION NUMBER: 36,989
REFERENCE/DOCKET NUMBER: 28110/32735
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-460-853-1

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1666 CAGCCACCGGAGAC 1681
| | | | | | | | | |
Db 17 CAGCCACCGGAGAC 2

RESULT 232
US-08-460-853-8/C
Sequence 8, Application US/08460853
Patent No. 5695940
GENERAL INFORMATION:
APPLICANT: Drmanac, Radoje T.
APPLICANT: Crkvenjakov, Radomir B.
TITLE OF INVENTION: Method of sequencing by Hybridization of
TITLE OF INVENTION: Oligonucleotide Probes
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:

MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/460,853
FILING DATE: 06-MAY-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/203,502 CON
FILING DATE: 28-FEB-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/048,152 FWC
FILING DATE: 15-APR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Meyers, Thomas C
REGISTRATION NUMBER: 36,989
REFERENCE/DOCKET NUMBER: 28110/32735
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-460-853-8

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1666 CAGCCACCGGGGAC 1681
Db 17 CAGCCACCGGAGAC 2

RESULT 233
US-08-435-628-842/c
Sequence 842, Application US/08435628
Patent No. 5817796
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: MCSw19gen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124

FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Walburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 842:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-842

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1430 AAATATTGAGTACT 1445
Db 17 AAATACTGAGTACT 2

RESULT 234
US-08-292-620A-1636
Sequence 1636, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James MCSw19gen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993

```

; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELETYPE: 67-3510
; INFORMATION FOR SEQ ID NO: 1636:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-1636

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      563 CGCTGTCCTGCTCT 578
Db      2 CUCUGCUCUGGUCU 17

RESULT 235
US-08-292-620A-1643
; Sequence 1643, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELETYPE: 67-3510
; INFORMATION FOR SEQ ID NO: 1636:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-1643

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      563 CGCTGTCCTGCTCT 578
Db      2 CUCUGCUCUGGUCU 17

RESULT 236
US-08-292-620A-1800
; Sequence 1800, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELETYPE: 67-3510
; INFORMATION FOR SEQ ID NO: 1800:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-1800
```

```

; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELETYPE: 67-3510
; INFORMATION FOR SEQ ID NO: 1643:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-1643

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      563 CGCTGTCCTGCTCT 578
Db      2 CUCUGCUCUGGUCU 17

RESULT 236
US-08-292-620A-1800
; Sequence 1800, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELETYPE: 67-3510
; INFORMATION FOR SEQ ID NO: 1800:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-1800
```

STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1800

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCGTTCCTGGCT 578
DB 2 CUCGUCUCGUCUCCU 17

RESULT 237
US-08-657-884-9
Sequence 9, Application US/08657884
Patent No. 5858981
GENERAL INFORMATION:
APPLICANT: SCHREIBER, ALAN D.
APPLICANT: PARK, JONG-GU
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESSES:
ADDRESSEE: NIXON & VANDERHAYE P.C.
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/657,884
FILING DATE: 07-JUN-1996
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: WILSON, MARY J.
REGISTRATION NUMBER: 32,955
REFERENCE/DOCKET NUMBER: 555-46
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4000
TELEFAX: (703) 816-4100
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-657-884-9

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1109 CTCTGTGGCCATGCC 1124
DB 1 CGCTGCAGCCATGCC 16

RESULT 238
US-08-985-162-734/C
Sequence 734, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwigen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED

TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,337
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 734:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-734

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1425 AGAGAAATTTTGAG 1440
DB 17 AGAGAAATTTTGTAG 2

RESULT 239
US-08-963-927-28
Sequence 28, Application US/08963927
Patent No. 6096501
GENERAL INFORMATION:
APPLICANT: Berger, Dolores M.
APPLICANT: Foxall, Paul A.
TITLE OF INVENTION: Assay for Chlamydia Trachomatis by
TITLE OF INVENTION: Amplification and Detection of Chlamydia Trachomatis
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Richard J. Rodrick - Becton, Dickinson and
ADDRESSEE: Company
STREET: 1 Becton Drive
CITY: Franklin Lakes
STATE: NJ
COUNTRY: USA
ZIP: 07417
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/963,927
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Highet, David W.
; REGISTRATION NUMBER: 30,265
; REFERENCE/DOCKET NUMBER: P-3889
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (201) 847-5317
; TELEFAX: (201) 848-9228
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-963-927-28
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1679 GACAGCTGCTGTGGA 1694
Db 1 GACAGCTTGTGATGCA 16
```

```

RESULT 240
US-08-998-099-119/c
; Sequence 119, Application US/08998099A
; Patent No. 6103890
; GENERAL INFORMATION:
; APPLICANT: JARVIS, THALE
; APPLICANT: MCSWIGGEN, JAMES A.
; APPLICANT: STINCHCOMB, DAN T.
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES
; FILE REFERENCE: 231/175
; CURRENT APPLICATION NUMBER: US/08/998,099A
; CURRENT FILING DATE: 1997-12-24
; EARLIER APPLICATION NUMBER: 60/037,658
; EARLIER FILING DATE: 1997-01-23
; EARLIER APPLICATION NUMBER: 08/373,124
; EARLIER FILING DATE: 1995-01-13
; EARLIER APPLICATION NUMBER: 08/245,466
; EARLIER FILING DATE: 1994-05-18
; NUMBER OF SEQ ID NOS: 375
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 119
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-08-998-099-119
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1053 GCTGAAGTCGAGGTG 1068
Db 17 GCTGGAGTACAGGTG 2
```

```

RESULT 241
US-09-071-845-1636
; Sequence 1636, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
```

```

; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1636:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-1636
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 563 CGCTGTCTCGTGTCT 578
Db 2 CUCUGCUCUGGUCU 17
```

```

RESULT 242
US-09-071-845-1643
; Sequence 1643, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
```


;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; STREET: Suite 4700
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;;
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/071,845
;; FILING DATE:
;; CLASSIFICATION:
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/08/292,620
;; FILING DATE: August 17, 1994
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/149
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;;
;; INFORMATION FOR SEQ ID NO: 1643:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;;
;; US-09-071-845-1643
;;
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
Qy 563 CGCTGTCCTGCTCT 578
Db 2 CUCUGCUCUGGUCU 17
;;
RESULT 243
US-09-071-845-1800
; Sequence 1800, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (1-CM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

;; ZIP: 90071-2066
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;;
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/071,845
;; FILING DATE:
;; CLASSIFICATION:
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/08/292,620
;; FILING DATE: August 17, 1994
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/149
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;;
;; INFORMATION FOR SEQ ID NO: 1800:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;;
;; US-09-071-845-1800
;;
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
Qy 563 CGCTGTCCTGCTCT 578
Db 2 CUCUGCUCUGGUCU 17
;;
RESULT 244
US-09-481-810-28
; Sequence 28, Application US/09481810
; Patent No. 6218125
; GENERAL INFORMATION:
; APPLICANT: Berger, Dolores M.
; APPLICANT: Foxall, Paul A.
; TITLE OF INVENTION: Assay for Chlamydia Trachomatis by
; TITLE OF INVENTION: Amplification and Detection of Chlamydia Trachomatis
; TITLE OF INVENTION: Cyclic Plasmid
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richard J. Rodrick - Becton, Dickinson and
; ADDRESSEE: Company
; STREET: 1 Becton Drive
; CITY: Franklin Lakes
; STATE: NJ
; COUNTRY: USA
; ZIP: 07417
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/481,810
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Hignet, David W.

```

:
:   REGISTRATION NUMBER: 30,265
:   REFERENCE/DOCKET NUMBER: P-3889
:   TELECOMMUNICATION INFORMATION:
:   TELEPHONE: (201) 847-5317
:   TELEFAX: (201) 848-9228
:   INFORMATION FOR SEQ ID NO: 28:
:   SEQUENCE CHARACTERISTICS:
:   LENGTH: 17 base pairs
:   TYPE: nucleic acid
:   STRANDEDNESS: single
:   TOPOLOGY: linear
US-09-481-810-28

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1679 GACAGCTGCTGTGA 1694
Db      1 GACAGCTTGATGGA 16

RESULT 245
US-09-158-980-9
: Sequence 9, Application US/09158980
: Patent No. 6242427
: GENERAL INFORMATION:
: APPLICANT: SCHREIBER, ALAN D.
: APPLICANT: PARK, JONG-GU
: TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
: NUMBER OF SEQUENCES: 31
: CORRESPONDENCE ADDRESS:
:   ADDRESSEE: NIXON & VANDERHAYE P.C.
:   STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
:   CITY: ARLINGTON
:   STATE: VIRGINIA
:   COUNTRY: U.S.A.
:   ZIP: 22201-4714
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patentin Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/09/158,980
: FILING DATE:
: CLASSIFICATION:
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 08/657,884
: FILING DATE:
: ATTORNEY/AGENT INFORMATION:
: NAME: WILSON, MARY J.
: REGISTRATION NUMBER: 32,955
: REFERENCE/DOCKET NUMBER: 555-46
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (703) 816-4000
: TELEFAX: (703) 816-4100
: INFORMATION FOR SEQ ID NO: 9:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 17 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: DNA (genomic)
US-09-158-980-9

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1109 CTCTGCGGCGCC 1124
Db      1 CGCTGTGCGCATGCG 16
```

```

:
:   REGISTRATION NUMBER: 34,115
:   REFERENCE/DOCKET NUMBER: HITACHI.006CP2
:   TELECOMMUNICATION INFORMATION:
:   TELEPHONE: 714-760-0404
:   TELEFAX: 714-760-9502
:   INFORMATION FOR SEQ ID NO: 631:
:   SEQUENCE CHARACTERISTICS:
:   LENGTH: 17
:   TYPE: nucleic acid
:   STRANDEDNESS: double
:   TOPOLOGY: linear
:   MOLECULE TYPE: cDNA to mRNA
:   HYPOTHETICAL: NO
:   ANTI-SENSE: NO
US-07-974-409C-631

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      550 ACGGCGGCGCTTCGC 565
Db      2 ACGGCGGCGCCTTCGC 17

RESULT 247
US-08-584-040-1736/c
: Sequence 1736, Application US/08584040
: Patent No. 6346398
: GENERAL INFORMATION:
: APPLICANT: Pavco, Pamela
: APPLICANT: McSwiggen, James
: APPLICANT: Stinchcomb, Dan T.
: APPLICANT: Escobedo, Jaime
: TITLE OF INVENTION: METHOD AND REAGENT FOR THE
: TITLE OF INVENTION: TREATMENT OF DISEASES OR
: TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
: TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
: TITLE OF INVENTION: GROWTH FACTOR
: NUMBER OF SEQUENCES: 8502
: CORRESPONDENCE ADDRESS:
:   ADDRESSEE: Lyon & Lyon
```

STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1736:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-1736

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 881 CCCTGAGTATCTCTCT 896
Db 17 CGCTGAGTATCTCTCT 2

RESULT 248
US-08-584-040-2235
Sequence 2235, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2235:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-2235

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1637 CAGTGGCTGCCCTCTCT 1652
Db 1 CAGTGGCTGCCCTCTCT 16

RESULT 249
US-08-584-040-3895
Sequence 3895, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 3895:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-3895

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1430 AAATATTGAGTACT 1445
||:|||||:
Db 2 AAUUUUUGAGCACCU 17

RESULT 250
US-08-584-040-3903/c
; Sequence 3903, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3903:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-3903

Query Match 0.6%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 91 GCCGACTGGGTGCTGC 106
|||||
Db 17 GCCCAGTGGATGCTGC 2

RESULT 251
US-08-584-040-4155/c
; Sequence 4155, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 4155:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-4155

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2120 AGCAGGCTGACCAT 2135
|||||
Db 17 AGAAGTTGACCAT 2

RESULT 252
US-08-584-040-5900
; Sequence 5900, Application US/08584040
; Patent No. 6346398

```

: GENERAL INFORMATION:
: APPLICANT: Pavco, Pamela
: APPLICANT: McSwiggen, James
: APPLICANT: Stinchcomb, Dan T.
: APPLICANT: Escobedo, Jaime
: TITLE OF INVENTION: METHOD AND REAGENT FOR THE
: TITLE OF INVENTION: TREATMENT OF DISEASES OR
: TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
: TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
: TITLE OF INVENTION: GROWTH FACTOR
: NUMBER OF SEQUENCES: 8502
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Lyon & Lyon
: STREET: 633 West Fifth Street
: CITY: Los Angeles
: STATE: California
: COUNTRY: U.S.A.
: ZIP: 90071-2066
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: IBM P.C. DOS 5.0
: SOFTWARE: Word Perfect 5.1
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/584,040
: FILING DATE: January 11, 1996
: CLASSIFICATION: 514
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 60/005,974
: FILING DATE: October 26, 1995
: ATTORNEY/AGENT INFORMATION:
: NAME: Warburg, Richard J.
: REGISTRATION NUMBER: 32,327
: REFERENCE/DOCKET NUMBER: 218/064
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (213) 489-1600
: TELEFAX: (213) 955-0440
: TELEX: 67-3510
: INFORMATION FOR SEQ ID NO: 5900:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 17 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: US-08-584-040-5900

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      1207 AAGGAGCTGTGCT 1222
Db      2 AAGGAGCTGTGCT 17

RESULT 253
US-08-584-040-5962
: Sequence 5962, Application US/08584040
: Patent No. 6346398
: GENERAL INFORMATION:
: APPLICANT: Pavco, Pamela
: APPLICANT: McSwiggen, James
: APPLICANT: Stinchcomb, Dan T.
: APPLICANT: Escobedo, Jaime
: TITLE OF INVENTION: METHOD AND REAGENT FOR THE
: TITLE OF INVENTION: TREATMENT OF DISEASES OR
: TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
: TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
: TITLE OF INVENTION: GROWTH FACTOR
: NUMBER OF SEQUENCES: 8502
: CORRESPONDENCE ADDRESS:

```

```

: ADDRESSEE: Lyon & Lyon
: STREET: 633 West Fifth Street
: CITY: Los Angeles
: STATE: California
: COUNTRY: U.S.A.
: ZIP: 90071-2066
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: IBM P.C. DOS 5.0
: SOFTWARE: Word Perfect 5.1
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/584,040
: FILING DATE: January 11, 1996
: CLASSIFICATION: 514
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 60/005,974
: FILING DATE: October 26, 1995
: ATTORNEY/AGENT INFORMATION:
: NAME: Warburg, Richard J.
: REGISTRATION NUMBER: 32,327
: REFERENCE/DOCKET NUMBER: 218/064
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (213) 489-1600
: TELEFAX: (213) 955-0440
: TELEX: 67-3510
: INFORMATION FOR SEQ ID NO: 5962:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 17 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: US-08-584-040-5962

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.8e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY      685 ACTCTATGTCATTC 700
Db      2 ACUCUCUUCUUCUUC 17

RESULT 254
US-08-584-040-5963
: Sequence 5963, Application US/08584040
: Patent No. 6346398
: GENERAL INFORMATION:
: APPLICANT: Pavco, Pamela
: APPLICANT: McSwiggen, James
: APPLICANT: Stinchcomb, Dan T.
: APPLICANT: Escobedo, Jaime
: TITLE OF INVENTION: METHOD AND REAGENT FOR THE
: TITLE OF INVENTION: TREATMENT OF DISEASES OR
: TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
: TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
: TITLE OF INVENTION: GROWTH FACTOR
: NUMBER OF SEQUENCES: 8502
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Lyon & Lyon
: STREET: 633 West Fifth Street
: CITY: Los Angeles
: STATE: California
: COUNTRY: U.S.A.
: ZIP: 90071-2066
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: IBM P.C. DOS 5.0

```

```
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5963:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-5963
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.8e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

Oy 685 ACCTCATGTCATTC 700

Db 1 ACUCUCUUCCAUUC 16

```
RESULT 255
US-09-474-432B-839/C
Sequence 839, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpelesky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
FILE REFERENCE: MHB00-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
CURRENT FILING DATE: 1999-12-19
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/084,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511
PRIOR FILING DATE: 1999-04-28
NUMBER OF SEQ ID NOS: 1526
SOFTWARE: PatentIn version 3.0
SEQ ID NO 839
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-474-432B-839
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Oy 1206 GAAGAGGCTGTGCC 1221

Db 17 GAAGGAGGCTGTGCC 2

```
RESULT 256
US-09-371-772B-281/C
Sequence 281, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MHB00,876-D (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 1425
SOFTWARE: PatentIn version 3.0
SEQ ID NO 281
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-281
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Oy 881 CCCTGAGTGTCTCT 896

Db 17 CCCTGAGTGTCTCT 2

```
RESULT 257
US-09-371-772B-780
Sequence 780, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MHB00,876-D (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 1425
SOFTWARE: PatentIn version 3.0
SEQ ID NO 780
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-780
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

Oy 1637 CAGTGCTGCCCTGCT 1652

Db 1 CAGUGGCUCCACGU 16

RESULT 258

US-09-371-772B-1662
Sequence 1662, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1662
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-1662

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Cy 1430 AAATATTGACTACT 1445

Db 2 AAUUUUUGAGCACC 17

RESULT 259

US-09-371-772B-1670/C
Sequence 1670, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1670
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-1670

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 91 GCCGACTGGCTGCTGC 106

Db 17 GCCCAGTGGATGCTGC 2

RESULT 260

US-09-371-772B-1922/C
Sequence 1922, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1922
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-1922

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 2120 AGCAGGCTGACCAT 2135

Db 17 AGAGGTTGACCAT 2

RESULT 261

US-09-371-772B-2739
Sequence 2739, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2739
LENGTH: 17
TYPE: RNA
ORGANISM: Mus sp.
US-09-371-772B-2739

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Cy 1207 AAGGAGCTGGCTT 1222

Db 2 AGGAGUCUGGCGCU 17

RESULT 262

US-09-371-772B-2799
; Sequence 2799, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2799
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2799

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.8e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

OY 685 ACTGCTGTCATTC 700
||:|:|:|:|:|:|
Db 2 ACUCUCUUCACUUC 17

RESULT 263
US-09-371-772B-2800
; Sequence 2800, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2800
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2800

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.8e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

OY 685 ACTGCTGTCATTC 700
||:|:|:|:|:|:|
Db 1 ACUCUCUUCACUUC 16

RESULT 264
US-09-371-772B-4231/c

; Sequence 4231, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4231
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4231

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1637 CAGTGTGCTGCTGCT 1652
|||||
Db 17 CAGTGTGCTGCTGCT 2

RESULT 265
US-09-371-772B-4232/c
; Sequence 4232, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4232
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4232

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1637 CAGTGTGCTGCTGCT 1652
|||||
Db 16 CAGTGTGCTGCTGCT 1

RESULT 266
US-09-371-772B-4511/c
; Sequence 4511, Application US/09371772B


```
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Payco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005, 974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584, 040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4511
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4511
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      883 CTGAGTATCTCTGA 898
Db       17 CTGAGTATCTCTCA 2
```

```
RESULT 267
US-09-371-772B-4512/c
; Sequence 4512, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Payco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005, 974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584, 040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4512
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4512
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      881 CCTGAGTATCTCT 896
Db       16 CGCTGAGTATCTCT 1
```

```
RESULT 268
US-09-371-772B-5163
; Sequence 5163, Application US/09371772B
; Patent No. 6566127
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Payco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005, 974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584, 040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5163
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5163
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      1637 CAGTGCTGCCCTGCT 1652
Db       2 CAGUGGCUCCAGCU 17
```

```
RESULT 269
US-09-371-772B-6283/c
; Sequence 6283, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Payco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005, 974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584, 040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6283
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6283
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      91 GCCGACTGGGTGCTGC 106
Db       16 GCCCAGTGGATGCTGC 1
```

```
RESULT 270
US-09-371-772B-6650/c
; Sequence 6650, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
```

```

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6650
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6650
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy          2120 AGCAGCTGACCACAT 2135
Db          16 AGAGGTTGACCACAT 1
```

```

RESULT 271
US-09-476-387-838/C
; Sequence 838, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelesky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MHB00-831-C (249/073)
; CURRENT FILING DATE: 2001-04-04
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 838
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-838
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy          1206 GAAGAGGCTGTGGCC 1221
Db          17 GAAGGGGCTGGGCC 2
```

```

RESULT 272
US-09-401-063-734/C
; Sequence 734, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LESIONS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 734:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-401-063-734
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy          1425 AGAGAAATATTGAG 1440
Db          17 AGAGAAATATTGAG 2
```

```

RESULT 273
US-09-787-069-8
; Sequence 8, Application US/09787069
; Patent No. 6627429
; GENERAL INFORMATION:
; APPLICANT: Danisco A/S
; APPLICANT: Christensen, Tove MIE
; APPLICANT: Pedersen, Anette A
; APPLICANT: Brunstedt, Jøne
; APPLICANT: Mikkelson, Jørn D
; TITLE OF INVENTION: Process
```

FILE REFERENCE: P005380WO CTH
CURRENT APPLICATION NUMBER: US/09/787,069
CURRENT FILING DATE: 2001-07-16
PRIOR APPLICATION NUMBER: GB 9820195.7
PRIOR FILING DATE: 1998-09-16
NUMBER OF SEQ ID NOS: 21
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 8
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-787-069-8

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 129 ATTCTCCCTGCTGCTG 144
Db 2 ATTATCCATGCTGCTG 17

RESULT 274
US-09-811-492-9
Sequence 9, Application US/09811492
Patent No. 6638764
GENERAL INFORMATION:
APPLICANT: SCHREIBER, ALAN D.
PARK, JONG-GU
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHAYE P.C.
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/811,492
FILING DATE: 19-Jul-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/657,884
FILING DATE: 07-JUN-1996
ATTORNEY/AGENT INFORMATION:
NAME: WILSON, MARY J.
REGISTRATION NUMBER: 32,955
REFERENCE/DOCKET NUMBER: 555-46
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4100
FAX: (703) 816-4100
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-811-492-9

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1109 CTCGTGCGCCATGCC 1124
Db 1 CGCTGTGAGCATGCC 16

RESULT 275
US-09-827-998-793/c
Sequence 793, Application US/09827998
Patent No. 6656700
GENERAL INFORMATION:
APPLICANT: Gu, Yizhong
TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
FILE REFERENCE: MDHMF-8
CURRENT APPLICATION NUMBER: US/09/827,998
CURRENT FILING DATE: 2001-04-06
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
NUMBER OF SEQ ID NOS: 1881
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 793
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-827-998-793

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1809 GACCCAGAGCACT 1824
Db 17 GAACGAGAGCACT 2

RESULT 276
US-09-827-998-794/c
Sequence 794, Application US/09827998
Patent No. 6656700
GENERAL INFORMATION:
APPLICANT: Gu, Yizhong
TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
FILE REFERENCE: MDHMF-8
CURRENT APPLICATION NUMBER: US/09/827,998
CURRENT FILING DATE: 2001-04-06
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
NUMBER OF SEQ ID NOS: 1881
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 794
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-827-998-794

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1809 GACCCAGAGCACT 1824
Db 16 GAACGAGAGCACT 1

RESULT 277
US-09-827-998-801/c

; Sequence 801, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDIMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 801
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-801

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 826 TTCCAAGACAGACAGA 841
Db 17 TTCTACAGACACAGA 2

RESULT 278
US-09-827-998-802/c
; Sequence 802, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDIMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 802
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-802

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 826 TTCCAAGACAGACAGA 841
Db 16 TTCTACAGACACAGA 1

RESULT 279
US-09-866-108A-514/c
; Sequence 514, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 514
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-514

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 161 TGCTCGGGTCTGGGC 176
Db 17 TGCTCAGGTCGGGC 2

RESULT 280
US-09-866-108A-516/c
; Sequence 516, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 516
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-516

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy          160 CTGCTCCGGGTCTGGG 175
Db          16 CTGCTCAGGCTGGGG 1

RESULT 281
US-09-866-108A-664/C
; Sequence 664, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 664
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-664
```

```

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy          54 TTCTCTGCATGGCTG 69
Db          17 TTCTCTGCTTGGCTG 2

RESULT 282
US-09-866-108A-666/C
; Sequence 666, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 666
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-666

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy          53 CTCTCTGCATGGCT 68
Db          16 CTCTCTGCTTGGCT 1

RESULT 283
US-09-866-108A-1134/C
; Sequence 1134, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
```

```

; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1134
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1134

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1016 TCCTTCTGCCCAAGAA 1031
          ||||| ||||| |||
Db      17  TCCTTCTGCCAGAA 2

RESULT 284
US-09-866-108A-1135/C
; Sequence 1135, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1135
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1135

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1016 TCCTTCTGCCCAAGAA 1031
          ||||| ||||| |||
Db      16  TCCTTCTGCCAGAA 1

RESULT 285
US-09-866-108A-1456
; Sequence 1456, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1456
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
```

US-09-866-108A-1456

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2176 CACCAGAGCTCATGG 2191
Db 2 CGCCAGCAGCTCCTGG 17

RESULT 286

US-09-866-108A-1457
; Sequence 1457, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1457
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1457

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2176 CACCAGAGCTCATGG 2191
Db 1 CGCCAGCAGCTCCTGG 16

RESULT 287

US-09-866-108A-1529
; Sequence 1529, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1529
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1529

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1595 AGGTGACGGCGCTGGT 1610
Db 2 AGGTGATGGCGCTGGT 17

RESULT 288

US-09-866-108A-1531
; Sequence 1531, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1531
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1531

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1596 GGTGACGCGCTGCTG 1611
Db      1 GGTGATGGGCTGCTG 16

RESULT 289
US-09-866-108A-1564/c
; Sequence 1564, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: UT, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OR INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1564
; LENGTH: 17
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
US-09-866-108A-1564

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      271 GGCTGCTGCTGCTGCTT 286
Db      17 GGCTGGCTGGCTGCTT 2

RESULT 290
US-09-866-108A-1565/c
; Sequence 1565, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: UT, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OR INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1565
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1565

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      271 GGCTGCTGCTGCTGCTT 286
Db      16 GGCTGGCTGGCTGCTT 1

RESULT 291
US-09-866-108A-1571/c
; Sequence 1571, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
```



```
/ APPLICANT: JI, Yongsang
/ APPLICANT: PENN, Sharon G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: A60MICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: A60MICA Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 1571
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-09-866-108A-1571

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CY 268 CAGGCGTGGCTGGCTG 283
DB 17 CAGAGCAGGCTGGCTG 2

RESULT 292
US-09-866-108A-1573/C
/ Sequence 1573, Application US/09866108A
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yongsang
/ APPLICANT: PENN, Sharon G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: A60MICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
```

```
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: A60MICA Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 1573
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-09-866-108A-1573

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CY 267 CAGGCGTGGCTGGCT 282
DB 16 CAGAGCAGGCTGGCT 1

RESULT 293
US-09-866-108A-1959
/ Sequence 1959, Application US/09866108A
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yongsang
/ APPLICANT: PENN, Sharon G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: A60MICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: A60MICA Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 1959
/ LENGTH: 17
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1959

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1832 AATCAGCTGCTGC 1847
      ||| |||||
Db      2 AAGCTCAGCTGCTGC 17

RESULT 294
US-09-866-108A-1961
; Sequence 1961, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1575
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1961
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1961

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1833 AATCAGCTGCTGCA 1848
      ||| |||||
Db      1 AAGCTCAGCTGCTGCA 16

RESULT 295
US-09-866-108A-2445
; Sequence 2445, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
```

```
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1575
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2445
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2445

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1342 GTTCTACCGATGC 1357
      ||| |||||
Db      2 GTTTCCTCCGATGC 17

RESULT 296
US-09-866-108A-2446
; Sequence 2446, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2446
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2446

Query Match
Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1342 GTTCTACCAAGATC 1357
Db 1 GTTCTCCAGATC 16

RESULT 297
US-09-866-108A-2716/c
; Sequence 2716, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2716
```

```

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2716

Query Match
Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1528 TTGGCTACCAACC 1543
Db 1 TTGGCCACTCAACC 2

RESULT 298
US-09-866-108A-2717/c
; Sequence 2717, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2717
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2717

Query Match
Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1528 TTGGCTACCAACC 1543
Db 1 TTGGCCACTCAACC 1

RESULT 299
US-09-866-108A-2738
; Sequence 2738, Application US/09866108A
; Patent No. 6686188
```

```
;; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2738
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2738

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      297 AGTCGGCACTGGGC 312
Db      2 AGCTGAGGCTTGGGC 17

RESULT 300
US-09-866-108A-2740
; Sequence 2740, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
```

```
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
US-09-866-108A-2740

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      298 GCTGGCACTGGGC 313
Db      1 GCTGAGGCTTGGGC 16

RESULT 301
US-09-866-108A-6520
; Sequence 6520, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
```

SEQ ID NO 6520
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-6520

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2100 CCAGCAGCTGAGCTGT 2115
DB 2 CACCGACCGAGCTGT 17

RESULT 302
US-09-866-108A-6523
Sequence 6523, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 6523
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-6523

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2102 AGCAGCTGAGCTGT 2117
DB 1 ACCAGCGAGCTGT 16

RESULT 303
US-09-866-108A-6524
Sequence 6524, Application US/09866108A

Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 6524
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-6524

QY 2104 CACCTGAGCTGTGT 2119
DB 2 CACCGAGCTGTGT 17

RESULT 304
US-09-866-108A-6527
Sequence 6527, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359

```
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6527
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6527

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2106 CCTCAGCCTGCTGAG 2121
Db      1 CCGCAGCCTGCTGAG 16

RESULT 305
US-09-866-108A-6759
; Sequence 6759, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
```

```
; Patent No. 6686188
; SEQ ID NO 6759
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6759

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2042 TGGAGCAGCTCCCTGA 2057
Db      1 TGGAGCAGCTCCCTGA 16

RESULT 306
US-09-866-108A-7938
; Sequence 7938, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7938
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7938

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1264 CTGAAGTGGGAATCC 1279
Db      2 CTGAAGTGGGAATCC 17

RESULT 307
US-09-866-108A-7939
```

```
; Sequence 7939, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7939
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-7939

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      1264 CTGAAGTGGATCC 1279
Db      1 CTGAAGTGGATCC 16

RESULT 308
; US-09-866-108A-8058
; Sequence 8058, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
```

```
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755

; US-09-866-108A-8058
; Patent No. 6686188
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8058
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8058

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      2232 AGATGCTCAGATGA 2247
Db      1 AGATGACACGAGAGA 16

RESULT 309
; US-09-866-108A-8136
; Sequence 8136, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
```

```
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8136
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8136

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1053 GCTGGAAGTGCAGCTG 1068
Db      2 GCTGGAATGCAGCTG 17

RESULT 310
US-09-866-108A-8137
; Sequence 8137, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8137
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8137

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1053 GCTGGAAGTGCAGCTG 1068
Db      1 GCTGGAATGCAGCTG 16

RESULT 311
```

```
US-09-866-108A-8379
; Sequence 8379, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8379
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8379

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2109 CAGCTGTGTCAGCAG 2124
Db      2 CAGCCAGCTGCAGCAG 17

RESULT 312
US-09-866-108A-8380
; Sequence 8380, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
```



```

; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8380
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8380
```

```

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

OY 2109 CAGCTGTGAGGAG 2124

Db 1 CAGCTGTGAGGAG 16

```

RESULT 313
US-09-866-108A-8619
; Sequence 8619, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
```

```

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8619
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8619
```

```

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

OY 1259 TGCTGTGAGGAG 1274

Db 2 TGCTGTGAGGAG 17

```

RESULT 314
US-09-866-108A-8620
; Sequence 8620, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8620
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8620
```

```

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

OY 1259 TGCTGTGAGGAG 1274

Db 1 TGCTGTGAGGAG 16

```
RESULT 315
US-09-866-108A-9582
; Sequence 9582, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9582
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9582

Query Match          0.6%: Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%: Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1167 GTTAGGGAAGCTG 1182
Db      2  GTGAGGGAAGCTG 17

RESULT 316
US-09-866-108A-10081/c
; Sequence 10081, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
```

```
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10081
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10081

Query Match          0.6%: Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%: Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      499 GCGGCTCTGGAAC 514
Db      17  GCGGCTCTGGAAC 2

RESULT 317
US-09-866-108A-10082/c
; Sequence 10082, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
```

```

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10082
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10082

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      499 GGGCGCTCTGGAACC 514
Db      16 GGGCGCTCTGGAACC 1
```

```

RESULT 318
US-09-866-108A-10318
; Sequence 10318, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10318
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10318
```

```

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      943 TGTCTCTGGGATCA 958
Db      2 TTCTCTCGGGATCA 17
```

```

RESULT 319
US-09-866-108A-10319
; Sequence 10319, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10319
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10319

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      943 TGTCTCTGGGATCA 958
Db      1 TTCTCTCGGGATCA 16

RESULT 320
US-09-866-108A-10320
; Sequence 10320, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
```

```
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263. 6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10320
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10320
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY          945 TCTCTGGGATCATG 960
              |||||
Db          2 TCTCTGGGATCAAG 17
```

```
RESULT 321
US-09-866-108A-10321
; Sequence 10321, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263. 6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10321
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10321
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY          945 TCTCTGGGATCATG 960
              |||||
Db          1 TCTCTGGGATCAAG 16
```

```
RESULT 322
PCT-US93-00977-631
; Sequence 631, Application PC/TUS9300977
; GENERAL INFORMATION:
; TITLE OF INVENTION: METHOD AND REAGENT FOR MEASURING MESSENGER RNA
; NUMBER OF SEQUENCES: 711
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Knobe, Martens, Olson, and Bear
; STREET: 620 Newport Center Dr. Sixteenth Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/00977
; FILING DATE: 19930129
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Altman, Daniel E.
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.006H
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 631:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17
; TYPE: NUCLEIC ACID
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to mRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
PCT-US93-00977-631
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY          550 ACGGCGGCGCTTCGC 565
              |||||
Db          2 ACGGCGGCGCTTCGC 17
```

```
RESULT 323
US-09-513-783A-39
; Sequence 39, Application US/09513783A
; Patent No. 6416959
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Guilliano, Kenneth A.
/ APPLICANT: Kapur, Ravi
/ TITLE OF INVENTION: A System for Cell Based Screening
/ FILE REFERENCE: 97-022-11
/ CURRENT APPLICATION NUMBER: US/09/513,783A
/ NUMBER OF SEQ ID NOS: 180
/ SOFTWARE: Patentin Ver. 2.0
/ SEQ ID NO 39
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: K73 epitope
US-09-513-783A-39

Query Match      0.6%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      828 CCAACAGACCAACA 843
Db      1 CCACGAGACCAAGAA 16

RESULT 324
US-08-700-035A-4
/ Sequence 4, Application US/08700035A
/ Patent No. 5831068
/ GENERAL INFORMATION:
/ APPLICANT: Nair, et al., Smita K.
/ TITLE OF INVENTION: A METHOD TO INCREASE THE DENSITY OF
/ TITLE OF INVENTION: ANTIGEN ON ANTIGEN PRESENTING CELLS
/ NUMBER OF SEQUENCES: 16
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Fish & Richardson P.C.
/ STREET: 225 Franklin Street
/ CITY: Boston
/ STATE: MA
/ COUNTRY: USA
/ ZIP: 02110-2804
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/700,035A
/ FILING DATE:
/ CLASSIFICATION: 424
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/517,373
/ FILING DATE: 21-AUG-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Clark, Paul T.
/ REGISTRATION NUMBER: 30,162
/ REFERENCE/DOCKET NUMBER: 06765/009001
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 617/542-5070
/ TELEFAX: 617/542-8906
/ TELEX: 200154
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 27 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-700-035A-4

Query Match      0.6%; Score 12.8; DB 1; Length 27;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      2131 CACATCCTCTTCTGG 2146
Db      1 CACAGCCTCTTCTGG 16

RESULT 325
PCT-US96-13457-4
/ Sequence 4, Application PC/RUS9613457
/ GENERAL INFORMATION:
/ APPLICANT: Duke University
/ TITLE OF INVENTION: A METHOD TO INCREASE THE DENSITY OF
/ TITLE OF INVENTION: ANTIGEN ON ANTIGEN PRESENTING CELLS
/ NUMBER OF SEQUENCES: 16
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Fish & Richardson P.C.
/ STREET: 225 Franklin Street
/ CITY: Boston
/ STATE: MA
/ COUNTRY: USA
/ ZIP: 02110-2804
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US96/13457
/ FILING DATE: 20-AUG-1996
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/517,373
/ FILING DATE: 21-AUG-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Clark, Paul T.
/ REGISTRATION NUMBER: 30,162
/ REFERENCE/DOCKET NUMBER: 06765/009001
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 617/542-5070
/ TELEFAX: 617/542-8906
/ TELEX: 200154
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 27 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
PCT-US96-13457-4

Query Match      0.6%; Score 12.8; DB 1; Length 27;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2131 CACATCCTCTTCTGG 2146
Db      1 CACAGCCTCTTCTGG 16

RESULT 326
US-08-303-004-19
/ Sequence 19, Application US/08303004
/ Patent No. 5556955
/ GENERAL INFORMATION:
/ APPLICANT: Vergnaud, Gilles
/ TITLE OF INVENTION: Process for Detection of New Polymor-
/ TITLE OF INVENTION: phic LocI in an ADN Sequence, Nucleotide Sequences Forming
/ TITLE OF INVENTION: Hybridisation Probes and Their Biological Applications
/ NUMBER OF SEQUENCES: 38
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Oliff & Berridge
/ STREET: P.O. Box 19928
/ CITY: Alexandria
/ STATE: Virginia
```

```
COUNTRY: U.S.A
ZIP: 22320
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent'n Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/303,004
FILING DATE:
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/931,311B
FILING DATE: 19920818
ATTORNEY/AGENT INFORMATION:
NAME: Berridge, William P.
REGISTRATION NUMBER: 30,024
REFERENCE/DOCKET NUMBER: WPB 28264
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 836-6400
TELEFAX: (703) 836-2787
TELEX: 90-1799 PTO ALEX
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHEICAL: NO
ANTI-SENSE: NO
US-08-303-004-19

Query Match          0.6%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      822 GTTTTCCACAGA 835
Db      1 GTTCTCCACAGA 14

RESULT 327
US-08-985-162-1761/c
; Sequence 1761, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
```

```
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1761:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-1761

Query Match          0.6%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      168 GGTCTGGCGCGTGG 181
Db      14 GGTCTGGCGCGCGG 1

RESULT 328
US-08-998-099-355
; Sequence 355, Application US/08998099A
; Patent No. 6103890
; GENERAL INFORMATION:
; APPLICANT: JARVIS, THALE
; APPLICANT: MCSWIGGEN, JAMES A.
; APPLICANT: STINCHCOMB, DAN T.
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF C-FOS
; FILE REFERENCE: 231/175
; CURRENT APPLICATION NUMBER: US/08/998,099A
; CURRENT FILING DATE: 1997-12-24
; EARLIER APPLICATION NUMBER: 60/037,658
; EARLIER FILING DATE: 1997-01-23
; EARLIER APPLICATION NUMBER: 08/373,124
; EARLIER FILING DATE: 1995-01-13
; EARLIER APPLICATION NUMBER: 08/245,466
; EARLIER FILING DATE: 1994-05-18
; NUMBER OF SEQ ID NOS: 375
; SOFTWARE: FASTSEQ for Windows Version 3.0
; SEQ ID NO 355
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Homo sapiens
US-08-998-099-355

Query Match          0.6%; Score 12.4; DB 1; Length 14;
Best Local Similarity 64.3%; Pred. No. 1.8e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      1000 ACCCTGCTCTGCT 1013
Db      1 ACCCTGCTCTGCT 14

RESULT 329
US-09-401-063-1761/c
; Sequence 1761, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
```

```

; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1761:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-401-063-1761

Query Match 0.6%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 168 GGTCTGGCGCGTGG 181
DB 14 GGTCTGGCGCGCGG 1

RESULT 330
US-08-093-383-19/c
; Sequence 19, Application US/08093383
; Patent No. 5489529
; GENERAL INFORMATION:
; APPLICANT: DeBoer, Herman A.
; APPLICANT: Heyneker, Herbert L.
; APPLICANT: Seeburg, Peter H.
; TITLE OF INVENTION: DNA for Expression of Bovine Growth Hormone
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
```

```

; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/093,383
; FILING DATE: 14-JUL-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/619827
; FILING DATE: 28-NOV-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/198824
; FILING DATE: 05-APR-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 06/632361
; FILING DATE: 19-JUL-1984
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 06/303687
; FILING DATE: 18-SEP-1981
; ATTORNEY/AGENT INFORMATION:
; NAME: Johnston, Sean A.
; REGISTRATION NUMBER: P35,910
; REFERENCE/DOCKET NUMBER: 46C4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-3562
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-093-383-19

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 62 CATGGCTGGGACCA 75
DB 15 CATGGCTGGACCA 2

RESULT 331
US-08-259-148A-32/c
; Sequence 32, Application US/08259148A
; Patent No. 5741490
; GENERAL INFORMATION:
; APPLICANT: Reyes, Gregory R.
; APPLICANT: Bradley, Daniel W.
; APPLICANT: Twu, Jr-Shin
; APPLICANT: Purdy, Michael A.
; APPLICANT: Tam, Albert W.
; APPLICANT: Krawczynski, Krzysztof Z.
; APPLICANT: Yarbough, Patrice D.
; TITLE OF INVENTION: Hepatitis E Virus Vaccine and Method
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dehlinger & Associates
; STREET: 350 Cambridge Avenue, Suite 250
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/259,148A
; FILING DATE: 13-JUN-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
```

```

; APPLICATION NUMBER: US 822,335
; FILING DATE: 17-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 505,888
; FILING DATE: 05-APR-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 420,921
; FILING DATE: 13-OCT-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 367,486
; FILING DATE: 16-JUN-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 336,672
; FILING DATE: 11-APR-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 208,997
; FILING DATE: 17-JUN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Sholtz, Charles K.
; REGISTRATION NUMBER: 38,615
; REFERENCE/DOCKET NUMBER: 4600-0093.20
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 324-0880
; TELEFAX: (415) 324-0960
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: DNA sequence, Fig. 7
; US-08-259-148A-32

Query Match      0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      173 GGGGCTGGGCTG 186
DB      14 GGGGCTGGGCTG 1

RESULT 332
; US-08-292-620A-426
; Sequence 426, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwigen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
```

```

; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 426:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-426

Query Match      0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      538 CTGGGCTGGAGAC 551
DB      1 CUGGCTUGGAGAC 14

RESULT 333
; US-08-657-884-25
; Sequence 25, Application US/08657884
; Patent No. 5858981
; GENERAL INFORMATION:
; APPLICANT: SCHREIBER, ALAN D.
; APPLICANT: PARK, JONG-GU
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/657,884
; FILING DATE: 07-JUN-1996
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 555-46
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
```


LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-657-884-25

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1111 CTGTGCGCATGCC 1124
Db 1 CTGTGCGCATGCC 14

RESULT 334
US-08-657-884-29
Sequence 29, Application US/08657884
Patent No. 5858981
GENERAL INFORMATION:
APPLICANT: SCHREIBER, ALAN D.
APPLICANT: PARK, JONG-GU
TITLE OF INVENTION: METHODS OF INHIBITTING PHAGOCYTOSIS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHAYE P.C.
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/657,884
FILING DATE: 07-JUN-1996
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: WILSON, MARY J.
REGISTRATION NUMBER: 32,955
REFERENCE/DOCKET NUMBER: 555-46
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4000
TELEFAX: (703) 816-4100
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-657-884-29

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1111 CTGTGCGCATGCC 1124
Db 1 CTGTGCGCATGCC 14

RESULT 335
US-08-585-684B-162/c
Sequence 162, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale

APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 162:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-162

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 503 GCTCTGGAACCT 516
Db 15 GCTCTGGAACCT 2

RESULT 336
US-08-585-684B-1341/c
Sequence 1341, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.

APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1341:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-1341

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1397 CCAGATACAGAG 1410
DB 14 CCAGATACAGAG 1

RESULT 337
US-08-585-684B-2049/c
Sequence 2049, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440

TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2049:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-2049

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1587 CCTGCGCAGGTGA 1600
DB 15 CCATGCCAGGTGA 2

RESULT 338
US-08-585-684B-2267/c
Sequence 2267, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2267:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-2267

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1372 GTGGAGTACTGCT 1385
DB 15 GTGGAGTACTGTT 2

RESULT 339
US-07-876-941A-48/C
Sequence 48, Application US/07876941A
Patent No. 5885768
GENERAL INFORMATION:
APPLICANT: Reyes, Gregory R.
APPLICANT: Bradley, Daniel W.
APPLICANT: Tam, Albert W.
APPLICANT: Mitchell, Carl
TITLE OF INVENTION: Hepatitis E Virus Peptide Antigen and
TITLE OF INVENTION: Antibodies
NUMBER OF SEQUENCES: 76
CORRESPONDENCE ADDRESS:
ADDRESSEE: Delinger & Associates
STREET: 350 Cambridge Avenue, Suite 250
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/876,941A
FILING DATE: 01-MAY-1992
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 822,335
FILING DATE: 17-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 505,888
FILING DATE: 05-APRIL-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 420,921
FILING DATE: 13-OCTOBER-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 367,486
FILING DATE: 16-JUNE-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 336,672
FILING DATE: 11-APRIL-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 208,997
FILING DATE: 17-JUNE-1988
ATTORNEY/AGENT INFORMATION:
NAME: Sholtz, Charles K.
REGISTRATION NUMBER: 38,615
REFERENCE/DOCKET NUMBER: 4600-0093.33
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 48:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: DNA sequence, Fig. 7
US-07-876-941A-48

Query Match 0.64; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 173 GGGCGTGGGCTG 186

Db 14 GGGCGTGGGCTG 1
|||||
RESULT 340
US-08-318-826A-2
Sequence 2, Application US/08318826A
Patent No. 5891725
GENERAL INFORMATION:
APPLICANT: Soreq, Hermona
APPLICANT: Zakut, Haim
APPLICANT: Eckstein, Fritz
TITLE OF INVENTION: Synthetic Antisense
TITLE OF INVENTION: Oligodeoxynucleotides and Pharmaceutical Compositions
TITLE OF INVENTION: Containing Them
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kohn & Associates
STREET: 30500 No. 5891725thwestern Hwy., Suite 410
CITY: Farmington Hills
STATE: Michigan
COUNTRY: US
ZIP: 48334
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/318,826A
FILING DATE:
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Kohn, Kenneth I.
REGISTRATION NUMBER: 30,955
REFERENCE/DOCKET NUMBER: 2391.00001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (248) 539-5050
TELEFAX: (248) 539-5055
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
ANTI-SENSE: YES
US-08-318-826A-2

Query Match 0.64; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 216 CTGCGGGTGCCTCA 229
Db 1 CTGCGGGGCTCA 14
|||||
RESULT 341
US-08-588-595-1
Sequence 1, Application US/08588595
Patent No. 5958769
GENERAL INFORMATION:
APPLICANT: Roberts, James M.
APPLICANT: Coats, Steven R.
APPLICANT: Fero, Matthew L.
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR MEDIATING
TITLE OF INVENTION: CELL CYCLE PROGRESSION
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew
STREET: One Market Plaza, Stewart Street Tower
CITY: San Francisco

STATE: California
COUNTRY: USA
ZIP: 94105-1492
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentln Release #1.0, Version #1.25
CURRENT APPLICATION NUMBER: US/08/588,595
APPLICATION NUMBER DATA:
FILING DATE: 18-JAN-1996
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W.
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 14538A-19
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleotide
US-08-588-595-1

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 1.9e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 798 GGCTGCTCGGCC 811
|||:|||||
Db 2 GGCTGCTCGGCC 15

RESULT 342
US-08-850-347-5
Sequence 5, Application US/08850347
Patent No. 6110742
GENERAL INFORMATION:
APPLICANT: Soreq, Hermona
APPLICANT: Seidman, Shlomo
APPLICANT: Eckstein, Fritz
TITLE OF INVENTION: SYNTHETIC ANTISENSE
TITLE OF INVENTION: OLIGODEOXYNUCLEOTIDES AND PHARMACEUTICAL COMPOSITIONS
NUMBER OF INVENTION: CONTAINING THEM
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kohn & Associates
STREET: 30500 No. 6110742thwestern Hwy.
CITY: Farmington Hills
STATE: Michigan
COUNTRY: US
ZIP: 48334
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentln Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/850,347
FILING DATE:
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Kohn, Kenneth I.
REGISTRATION NUMBER: 30,955
REFERENCE/DOCKET NUMBER: 2391,00057
TELECOMMUNICATION INFORMATION:
TELEPHONE: (248) 539-5050
TELEFAX: (248) 539-5055
INFORMATION FOR SEQ ID NO: 5:

SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
ANTI-SENSE: YES
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-08-850-347-5

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 216 CTGCGGGGCTCTCA 229
|||||
Db 1 CTGCGGGGCTCTCA 14

RESULT 343
US-09-071-845-426
Sequence 426, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 426:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

TOPOLOGY: linear
US-09-071-845-426

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 538 CTGGCTCGAGAC 551
1 CUGGCTUGAGAC 14

Db 1 CUGGCTUGAGAC 14

RESULT 344
US-09-038-073-162/C
Sequence 162, Application US/09038073
Patent No. 6194150

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 162:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-162

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 503 GCTCTGGAACCT 516
15 GCTCTGGAACCT 2

Db 15 GCTCTGGAACCT 2

RESULT 345
US-09-038-073-1341/C
Sequence 1341, Application US/09038073
Patent No. 6194150

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1341:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1341

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1397 CCAGATACAGAG 1410
14 CCAGATACAGAG 1

Db 14 CCAGATACAGAG 1

RESULT 346
US-09-038-073-2049/C
Sequence 2049, Application US/09038073
Patent No. 6194150

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2049:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-2049

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1587 CCCTGGCGAGGTGA 1600
Db 15 CCATGGCGAGGTGA 2

RESULT 347
US-09-038-073-2267/C
; Sequence 2267, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
```

```

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2267:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-2267

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1372 GTGGAGGTACTGCT 1385
Db 15 GTGGAGGTACTGTT 2

RESULT 348
US-09-158-980-25
; Sequence 25, Application US/09158980
; Patent No. 6242427
; GENERAL INFORMATION:
; APPLICANT: SCHREIBER, ALAN D.
; APPLICANT: PARK, JONG-GU
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/158,980
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/657,884
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 555-46
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-09-158-980-25

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1111 CTGTGGCGCATGCC 1124
Db 1 CTGTGACCATGCC 14
```

RESULT 349
US-09-158-980-29
Sequence 29, Application US/09158980
Patent No. 6242427
GENERAL INFORMATION:
APPLICANT: SCHREIBER, ALAN D.
APPLICANT: PARK, JONG-GU
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESSES:
ADDRESSEE: NIXON & VANDERHAYE P.C.
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/158,980
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/657,884
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: WILSON, MARY J.
REGISTRATION NUMBER: 32,955
REFERENCE/DOCKET NUMBER: 555-46
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4000
TELEFAX: (703) 816-4100
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-158-980-29
Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 1111 CTGTCGCGCATGCC 1124
Db 1 CTGTCGCGCATGCC 14
RESULT 350
US-09-042-353-38
Sequence 38, Application US/09042353
Patent No. 6255458
GENERAL INFORMATION:
APPLICANT: Lomborg, Nils
APPLICANT: Kay, Robert M.
TITLE OF INVENTION: Transgenic No. 6255458-Human Animals for
Producing Heterologous Antibodies
NUMBER OF SEQUENCES: 421
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/042,353
FILING DATE: 13-MAR-1998
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/810,279
FILING DATE: 17-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/853,408
FILING DATE: 18-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/904,068
FILING DATE: 23-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/990,860
FILING DATE: 16-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/053,131
FILING DATE: 26-APR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/096,762
FILING DATE: 22-JUL-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/155,301
FILING DATE: 18-NOV-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/161,739
FILING DATE: 03-DEC-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/165,699
FILING DATE: 10-DEC-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/209,741
FILING DATE: 09-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/352,322
FILING DATE: 07-DEC-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/544,404
FILING DATE: 10-OCT-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/728,463
FILING DATE: 10-OCT-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: WO PCT/US96/16433
FILING DATE: 10-OCT-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/758,417
FILING DATE: 02-DEC-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: WO PCT/US97/21803
FILING DATE: 01-DEC-1997
ATTORNEY/AGENT INFORMATION:
NAME: Apple, Randolph T.
REGISTRATION NUMBER: 36,429
REFERENCE/DOCKET NUMBER: 014643-009040US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 38:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-09-042-353-38
Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;

```
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1135 AGCTTGGCAACGA 1148
Db 1 AGCTTGGCAACTA 14

RESULT 351
US-08-758-417A-303
; Sequence 303, Application US/08758417A
; Patent No. 6300129
; GENERAL INFORMATION:
; APPLICANT: Lomborg, Nils
; Kay, Robert M.
; TITLE OF INVENTION: Transgenic No. 6300129-Human Animals for
; Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 417
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,417A
; FILING DATE: 02-Dec-1996
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/728,463
; FILING DATE: 10-OCT-1996
; APPLICATION NUMBER: US 08/544,404
; FILING DATE: 10-OCT-1995
; APPLICATION NUMBER: US 08/352,322
; FILING DATE: 07-DEC-1994
; APPLICATION NUMBER: US 08/209,741
; FILING DATE: 09-MAR-1994
; APPLICATION NUMBER: US 08/165,699
; FILING DATE: 10-DEC-1993
; APPLICATION NUMBER: US 08/161,739
; FILING DATE: 03-DEC-1993
; APPLICATION NUMBER: US 08/155,301
; FILING DATE: 18-NOV-1993
; APPLICATION NUMBER: US 08/096,762
; FILING DATE: 22-JUL-1993
; APPLICATION NUMBER: US 08/053,131
; FILING DATE: 26-APR-1993
; APPLICATION NUMBER: US 07/990,860
; FILING DATE: 16-DEC-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Serafini, Andrew T.
; REGISTRATION NUMBER: 41,303
; REFERENCE/DOCKET NUMBER: 014643-009030US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 303:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 303:
US-08-758-417A-303

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1135 AGCTTGGCAACGA 1148
Db 1 AGCTTGGCAACTA 14

RESULT 352
US-09-081-646-417/c
; Sequence 417, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 417
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-417

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2204 GCTACTGGGCATG 2217
Db 14 GCCACTGGGCATG 1

RESULT 353
US-09-081-646-506/c
; Sequence 506, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 506
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-506

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 188 GCCGCTGGGCGTG 201
Db 14 GCCGCTGGGCGATG 1
```


RESULT 354
US-09-811-492-25
Sequence 25, Application US/09811492
Patent No. 6638764
GENERAL INFORMATION:
APPLICANT: SCHREIBER, ALAN D.
PARK, JONG-GU
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESSES:
ADDRESSEE: NIXON & VANDERHAYE P.C.
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/811,492
FILING DATE: 19-Jul-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/657,884
FILING DATE: 07-JUN-1996
ATTORNEY/AGENT INFORMATION:
NAME: WILSON, MARY J.
REGISTRATION NUMBER: 32,955
REFERENCE/DOCKET NUMBER: 555-46
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4100
TELEFAX: (703) 816-4100
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 25:
US-09-811-492-25
Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1111 CTGTGCGCCATGCC 1124
Db 1 CTGTGCGCCATGCC 14
RESULT 355
US-09-811-492-29
Sequence 29, Application US/09811492
Patent No. 6638764
GENERAL INFORMATION:
APPLICANT: SCHREIBER, ALAN D.
PARK, JONG-GU
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESSES:
ADDRESSEE: NIXON & VANDERHAYE P.C.
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/811,492
FILING DATE: 19-Jul-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/657,884
FILING DATE: 07-JUN-1996
ATTORNEY/AGENT INFORMATION:
NAME: WILSON, MARY J.
REGISTRATION NUMBER: 32,955
REFERENCE/DOCKET NUMBER: 555-46
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4100
TELEFAX: (703) 816-4100
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 29:
US-09-811-492-29

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/811,492
FILING DATE: 19-Jul-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/657,884
FILING DATE: 07-JUN-1996
ATTORNEY/AGENT INFORMATION:
NAME: WILSON, MARY J.
REGISTRATION NUMBER: 32,955
REFERENCE/DOCKET NUMBER: 555-46
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4100
TELEFAX: (703) 816-4100
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 29:
US-09-811-492-29
Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1111 CTGTGCGCCATGCC 1124
Db 1 CTGTGCGCCATGCC 14
RESULT 356
US-07-988-194A-22/c
Sequence 22, Application US/07988194A
Patent No. 5359046
GENERAL INFORMATION:
APPLICANT: Capon, Daniel J.
APPLICANT: Weiss, Arthur
APPLICANT: Irving, Brian A.
APPLICANT: Roberts, Margo R.
APPLICANT: Zaebo, Krisztina
TITLE OF INVENTION: Chimeric Chains for Receptor
NUMBER OF SEQUENCES: 49
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Flehr, Hobbach, Teet, Albritton &
ADDRESSEE: Herbert
STREET: 4 Embardadero Center, Suite 3400
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94111-4187
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/988,194A
FILING DATE: December 9, 1992
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Rowland, Berttram I.
REGISTRATION NUMBER: 20015
REFERENCE/DOCKET NUMBER: A-55107-1 CELL-0051
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-781-1989
TELEFAX: 415-398-3249
SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-07-988-194A-22/c

SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-07-988-194A-22

Query Match 0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1419 CTCCTCAGAGAAA 1432
15 CTCCTCAGACAAA 2

RESULT 357
US-08-311-760A-392/C
Sequence 392, Application US/08311760A
Patent No. 5599706
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Newton, Roger S.
APPLICANT: Ramnarack, Randy
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
TITLE OF INVENTION: INHIBITING APOLOPROTEIN
NUMBER OF SEQUENCES: 392
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311.760A
FILING DATE: September 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/155
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 392:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-760A-392

Query Match 0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 64 TGGCTGGGACAGT 77

Db 16 TAGCTGGGACAGT 3

RESULT 358
US-08-258-152-24/C
Sequence 24, Application US/08258152
Patent No. 5686279
GENERAL INFORMATION:
APPLICANT: FINER, MITCHELL H.
APPLICANT: ROBERTS, MARGO R.
APPLICANT: DULL, THOMAS J.
APPLICANT: ZSEBO, KRISZTINA M.
APPLICANT: QIN, LU
TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION
TITLE OF INVENTION: OF MAMMALIAN CELLS
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: CELL GENESYS, INC.
STREET: 322 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/258.152
FILING DATE: 10-JUN-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/076.299
FILING DATE: 11-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: KRUPEN, KAREN I.
REGISTRATION NUMBER: 34,647
REFERENCE/DOCKET NUMBER: CELL 13.1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-358-9600 X131
TELEFAX: 415-349-7392
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-258-152-24

Query Match 0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1419 CTCCTCAGAGAAA 1432
15 CTCCTCAGACAAA 2

RESULT 359
US-08-076-299A-24/C
Sequence 24, Application US/08076299A
Patent No. 5834256
GENERAL INFORMATION:
APPLICANT: FINER, MITCHELL H.
APPLICANT: ROBERTS, MARGO R.
APPLICANT: DULL, THOMAS J.
APPLICANT: ZSEBO, KRISZTINA M.
APPLICANT: QIN, LU
TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER

```

; TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CELL GENESIS, INC.
; STREET: 322 LAKESIDE DRIVE
; CITY: FOSTER CITY
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/076,299A
; FILING DATE: 11-JUN-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: KRUPEN, KAREN I.
; REGISTRATION NUMBER: 34,647
; REFERENCE/DOCKET NUMBER: CELL 13.0
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-358-9600 X131
; TELEFAX: 415-349-7392
; INFORMATION FOR SEQ ID NO: 24:
; LENGTH: 16 base pairs
; SEQUENCE CHARACTERISTICS:
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-076-299A-24

Query Match 0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1;

Qy 1419 CTCCTCAGACAAA 1432
Db 15 CTCCTCAGACAAA 2

RESULT 360
US-08-292-620A-1615
; Sequence 1615, Application US/08292620A
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McGswigen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
```

```

; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1615:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-1615

Query Match 0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 71.4%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 10; Conservative 3; Mismatches 1;

Qy 153 GCTGCGACTGCTCC 166
Db 3 GCTGCGCTGCTGCC 16

RESULT 361
US-08-438-582-24/c
; Sequence 24, Application US/08438582
; Patent No. 5858740
; GENERAL INFORMATION:
; APPLICANT: FINER, MITCHELL H.
; APPLICANT: ROBERTS, MARGO R.
; APPLICANT: DULL, THOMAS J.
; APPLICANT: ZSEBO, KRISZTINA M.
; APPLICANT: QIN, LU
; TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
; TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CELL GENESIS, INC.
; STREET: 322 LAKESIDE DRIVE
; CITY: FOSTER CITY
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/438,582
; FILING DATE: 10-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/258,152
; FILING DATE: 10-JUN-1994
```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/076,299
; FILING DATE: 11-JUN-93
; ATTORNEY/AGENT INFORMATION:
; NAME: KRUPEN, KAREN I.
; REGISTRATION NUMBER: 34,647
; REFERENCE/DOCKET NUMBER: CELL 13.2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-358-9600 X131
; TELEFAX: 415-349-7392
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-438-582-24

Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1419 CTCTCAGAGAAA 1432
Db      15  CTCTCAGACAAA 2

RESULT 362
; US-08-173-489C-168
; Sequence 168, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect Version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 168:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 bases
; TYPE: nucleic acid
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: third strand derived from Hepatitis B
; DESCRIPTION: isolate a1w sequence region in Seq ID No. 5861244167
```

```

; HYPOTHETICAL: yes
; ANTI-SENSE: no
; PUBLICATION INFORMATION:
; RELEVANT RESIDUES IN SEQ ID NO: 168 :FROM 1 TO 16
; US-08-173-489C-168

Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1009 CTGCTTCTCTCT 1022
Db      3  CTGCTTCTCTCTT 16

RESULT 363
; US-08-774-310-392/C
; Sequence 392, Application US/08774310
; Patent No. 5877022
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: McSwiggen, James
; APPLICANT: Newton, Roger S.
; APPLICANT: Ramharack, Randy
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF
; TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY
; TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN
; NUMBER OF SEQUENCES: 392
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,310
; FILING DATE: December 23, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/311,760
; FILING DATE: September 23, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/229
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; INFO: 67-3510
; INFORMATION FOR SEQ ID NO: 392:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-310-392

Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      64  TGGCTGGGACAGT 77
Db      16  TAGCTGGGACAGT 3
```

RESULT 364
US-09-071-845-1615
Sequence 1615, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Diaper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1615:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-1615

Query Match 0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 71.4%; Pred. No. 2e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 153 GCTGCCACTGCTCC 166
||:|||||:|||||
Db 3 GCTGCCCTCCTCC 16

RESULT 365
US-09-266-596-24/C
Sequence 24, Application US/09266596
Patent No. 6218187
GENERAL INFORMATION:

APPLICANT: FINER, MITCHELL H.
APPLICANT: DULL, THOMAS J.
APPLICANT: ZSEBO, KRISZTINA M.
APPLICANT: COOKE, KERGAN
APPLICANT: FARSON, DEBORAH A.
TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION
TITLE OF INVENTION: OF MAMMALIAN CELLS
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: CELL GENESYS, INC.
STREET: 322 LAKEVIEW DRIVE
CITY: FOSTER CITY
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/266,596
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/517,488
FILING DATE: 21-AUG-1995
APPLICATION NUMBER: US 08/258,152
FILING DATE: 10-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/076,299
FILING DATE: 11-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: KRUPEN, KAREN I.
REGISTRATION NUMBER: 34,647
REFERENCE/DOCKET NUMBER: CELL 13.3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-358-9600 X131
TELEFAX: 415-349-7392
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-266-596-24

Query Match 0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1419 CTCCTCAGAGAAA 1432
|||:|||||:|||||
Db 15 CTCCTCAGACAAA 2

RESULT 366
US-08-479-737-22/C
Sequence 22, Application US/08479737
Patent No. 6319494
GENERAL INFORMATION:
APPLICANT: Capon, Daniel J
APPLICANT: Weiss, Arthur
APPLICANT: Irving, Brian A
APPLICANT: Roberts, Margo R
APPLICANT: Zsebo, Krisztina
TITLE OF INVENTION: CHIMERIC CHAINS FOR RECEPTOR ASSOCIATED
SIGNAL TRANSDUCTION PATHWAYS
NUMBER OF SEQUENCES: 51
CORRESPONDENCE ADDRESS:
ADDRESSEE: CELL GENESYS, INC.

STREET: 322 Lakeside Drive
CITY: Foster City
STATE: California
COUNTRY: USA
ZIP: 94404

COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/479,737
FILING DATE: 07-Jun-1995
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/238,405
FILING DATE: 05-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: Mandel, SaraLynn
REGISTRATION NUMBER: 31,853
REFERENCE/DOCKET NUMBER: Cell 5.3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 358-9600
TELEFAX: (415) 358-0803
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-08-479-737-22

Query Match 0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1419 CTCCTCAGAGAAA 1432
Db 15 CTCCTCAGAGAAA 2

RESULT 367
US-08-475-442A-22/c
Sequence 22, Application US/08475442A
Patent No. 6407221

GENERAL INFORMATION:
APPLICANT: CAPON, DANIEL J
APPLICANT: WEISS, ARTHUR
APPLICANT: IRVING, BRIAN A
APPLICANT: ROBERTS, MARGO R
APPLICANT: ZSEBO, KRISTINA
TITLE OF INVENTION: CHIMERIC CHAINS FOR
NUMBER OF SEQUENCES: 51
CORRESPONDENCE ADDRESS:
ADDRESSEE: CELL GENESYS, INC.
STREET: 322 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94404

COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/475,442A
FILING DATE: 06-JUN-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/238,405
FILING DATE: 05-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/988,194
FILING DATE: 09-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/627,643
FILING DATE: 14-DEC-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/09431
FILING DATE: 12-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: KRUPEN, KAREN I
REGISTRATION NUMBER: 34,647
REFERENCE/DOCKET NUMBER: CELLS.5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 358-9600x131
TELEFAX: (415) 349-7392
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-475-442A-22

Query Match 0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1419 CTCCTCAGAGAAA 1432
Db 15 CTCCTCAGAGAAA 2

RESULT 368
US-09-944-411-24/c
Sequence 24, Application US/09944411
Patent No. 6506604

GENERAL INFORMATION:
APPLICANT: FINER, MITCHELL H.
DULL, THOMAS J.
ZSEBO, KRISTINA M.
COOKE, KEEGAN
FARSON, DEBORAH A.
TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION
OF MAMMALIAN CELLS
NUMBER OF SEQUENCES: 48
CORRESPONDENCE ADDRESS:
ADDRESSEE: CELL GENESYS, INC.
STREET: 322 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94404

COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/944,411
FILING DATE: 04-Sep-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/914,893
FILING DATE: <Unknown>
APPLICATION NUMBER: US 08/258,152
FILING DATE: 10-JUN-1994
APPLICATION NUMBER: US 08/076,299
FILING DATE: 11-JUN-1993

```
ATTORNEY/AGENT INFORMATION:
NAME: KRUPEN, KAREN I.
REGISTRATION NUMBER: 34,647
REFERENCE/DOCKET NUMBER: CELL 13.3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-358-9600 X131
TELEFAX: 415-349-7392
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 24:
US-09-944-411-24

Query Match
Best Local Similarity 92.9%; Score 12.4; DB 1; Length 16;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1419 CTCTCAGACAAA 1432
DB 15 CTCTCAGACAAA 2

RESULT 369
US-09-829-855-25/c
Sequence 25, Application US/09829855
Patent No. 6613520
GENERAL INFORMATION:
APPLICANT: Matthew, Ashby N.
TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
FILE REFERENCE: ASHBY-1
CURRENT APPLICATION NUMBER: US/09/829,855
CURRENT FILING DATE: 2001-04-10
PRIOR APPLICATION NUMBER: US 60/196063
PRIOR FILING DATE: 2000-04-10
PRIOR APPLICATION NUMBER: US 60/196258
PRIOR FILING DATE: 2000-04-11
NUMBER OF SEQ ID NOS: 244
SOFTWARE: PatentIn version 3.1
SEQ ID NO 25
LENGTH: 16
TYPE: DNA
ORGANISM: unknown
FEATURE:
OTHER INFORMATION: unidentified soil organism
US-09-829-855-25

Query Match
Best Local Similarity 92.9%; Score 12.4; DB 1; Length 16;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGTCGCGCACTGG 310
DB 16 AGTCGCGCACTGG 3

RESULT 370
US-09-829-855-30/c
Sequence 30, Application US/09829855
Patent No. 6613520
GENERAL INFORMATION:
APPLICANT: Matthew, Ashby N.
TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
FILE REFERENCE: ASHBY-1
CURRENT APPLICATION NUMBER: US/09/829,855
CURRENT FILING DATE: 2001-04-10
PRIOR APPLICATION NUMBER: US 60/196063
PRIOR FILING DATE: 2000-04-10
PRIOR APPLICATION NUMBER: US 60/196258
PRIOR FILING DATE: 2000-04-11
```

```
NUMBER OF SEQ ID NOS: 244
SOFTWARE: PatentIn version 3.1
SEQ ID NO 30
LENGTH: 16
TYPE: DNA
ORGANISM: unknown
FEATURE:
OTHER INFORMATION: unidentified soil organism
US-09-829-855-30

Query Match
Best Local Similarity 92.9%; Score 12.4; DB 1; Length 16;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGTCGCGCACTGG 310
DB 16 AGTCGCGCACTGG 3

RESULT 371
US-09-829-855-32/c
Sequence 32, Application US/09829855
Patent No. 6613520
GENERAL INFORMATION:
APPLICANT: Matthew, Ashby N.
TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
FILE REFERENCE: ASHBY-1
CURRENT APPLICATION NUMBER: US/09/829,855
CURRENT FILING DATE: 2001-04-10
PRIOR APPLICATION NUMBER: US 60/196063
PRIOR FILING DATE: 2000-04-10
PRIOR APPLICATION NUMBER: US 60/196258
PRIOR FILING DATE: 2000-04-11
NUMBER OF SEQ ID NOS: 244
SOFTWARE: PatentIn version 3.1
SEQ ID NO 32
LENGTH: 16
TYPE: DNA
ORGANISM: unknown
FEATURE:
OTHER INFORMATION: unidentified soil organism
US-09-829-855-32

Query Match
Best Local Similarity 92.9%; Score 12.4; DB 1; Length 16;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGTCGCGCACTGG 310
DB 16 AGTCGCGCACTGG 3

RESULT 372
US-09-829-855-34/c
Sequence 34, Application US/09829855
Patent No. 6613520
GENERAL INFORMATION:
APPLICANT: Matthew, Ashby N.
TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
FILE REFERENCE: ASHBY-1
CURRENT APPLICATION NUMBER: US/09/829,855
CURRENT FILING DATE: 2001-04-10
PRIOR APPLICATION NUMBER: US 60/196063
PRIOR FILING DATE: 2000-04-10
PRIOR APPLICATION NUMBER: US 60/196258
PRIOR FILING DATE: 2000-04-11
NUMBER OF SEQ ID NOS: 244
SOFTWARE: PatentIn version 3.1
SEQ ID NO 34
LENGTH: 16
TYPE: DNA
ORGANISM: unknown
FEATURE:
```

```
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-34

Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      297 AGCTGCGGCACTGG 310
Db      16 AGCTGCGGCACAGG 3

RESULT 373
US-09-829-855-91/c
; Sequence 91, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; FILE REFERENCE: ASHBY-1
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; CURRENT APPLICATION NUMBER: US/09/829,855
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 91
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-91

Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      297 AGCTGCGGCACTGG 310
Db      16 AGCTTGGGCACTGG 3

RESULT 374
US-09-829-855-92/c
; Sequence 92, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; FILE REFERENCE: ASHBY-1
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; CURRENT APPLICATION NUMBER: US/09/829,855
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 92
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-92

Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      297 AGCTGCGGCACTGG 310
Db      16 AGCTGCGGCACCGG 3

RESULT 375
US-09-829-855-103/c
; Sequence 103, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; FILE REFERENCE: ASHBY-1
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; CURRENT APPLICATION NUMBER: US/09/829,855
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 103
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-103

Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      297 AGCTGCGGCACTGG 310
Db      16 AGCTGCGGCACGGG 3

RESULT 376
US-09-829-855-105/c
; Sequence 105, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; FILE REFERENCE: ASHBY-1
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; CURRENT APPLICATION NUMBER: US/09/829,855
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 105
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-105

Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      297 AGCTGCGGCACTGG 310
Db      16 AGCTGCGGCACCGG 3

RESULT 377
US-09-829-855-106/c
```



```
; Sequence 106, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Leahy N.
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY-1
; CURRENT APPLICATION NUMBER: US/09/829,855
; CURRENT FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 106
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-106.
```

```
Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      297 AGCTGCGGCACTGG 310
        |||||
Db       16 AGCTGCGGCACTGG 3
```

Search completed: June 30, 2004, 08:41:20
Job time : 12 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 30, 2004, 08:50:09 ; Search time 0.001 Seconds
(without alignments)
525.798 Million cell updates/sec

Title: US-10-024-369-3
Perfect score: 2247
Sequence: 1 atgcctagctcctagctgc.....ctgcagatgctccagaatga 2247

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 0.5

Searched: 7 seqs, 117 residues

Total number of hits satisfying chosen parameters: 14

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 7 summaries

Database: ref3.seq.*
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES			
Result No.	Score	Query Match Length DB ID	Description
1	15.2	0.7	20 1 AZ369092 ACCESSION:AZ369092
2	14.8	0.7	19 1 AZ598508 ACCESSION:AZ598508
3	14.4	0.6	19 1 AZ865832 ACCESSION:AZ865832
4	12.8	0.6	16 1 BO592176 ACCESSION:BO592176
5	12	0.5	16 1 AI094839 ACCESSION:AI094839
6	11	0.5	13 1 BM395292 ACCESSION:BM395292
7	10.8	0.5	14 1 CA798290 ACCESSION:CA798290

ALIGNMENTS

RESULT 1
AZ369092 20 bp DNA linear GSS 02-OCT-2000
LOCUS 1M0119E01R Mouse 10kb plasmid UGCM library Mus musculus genomic
DEFINITION clone UGCM0119E01 R, genomic survey sequence.

ACCESSION AZ369092
VERSION AZ369092.1 GI:10482792
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus

REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 20)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D., Weiss, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss

University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert length: 10000 Std Error: 0.00
Plate: 0119 row: E column: 01
Seq primer: CACACAGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 20.
Location/Qualifiers

FEATURES

1. 20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UGCM0119E01"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_1ib="Mouse 10kb plasmid UGCM library"
/note="Vector: PWD42nv, Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (GI:4732114|JB|AF12972.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match
Best local similarity 85.0%; Pred. No. 0.61;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 632 TCACTGACTGATTCACAA 651
DB 1 TCACAACTGATTCACAA 20

RESULT 2
AZ598508 19 bp DNA linear GSS 13-DEC-2000
LOCUS 1M0413B24F Mouse 10kb plasmid UGCM library Mus musculus genomic
DEFINITION clone UGCM0413B24 F, genomic survey sequence.

ACCESSION AZ598508
VERSION AZ598508.1 GI:11720698
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus

REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 19)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D., Weiss, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center

University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0413 row: B column: 24
Seq primer: CGTTGTAAACGACGCGCAGT
Class: plasmid ends
High quality sequence stop: 19.

FEATURES

source

1. 19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUCGCM0413B24"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_1lb="Mouse 10kb plasmid UUCGCM library"
/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMW42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 0.78;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1111 CTGTGCGCATGCTTACA 1128
Db 2 CTCTTGCCATGCTTACA 19

RESULT 3
AZ865832/c 19 bp DNA linear GSS 21-FEB-2001
LOCUS 2M0176D09F Mouse 10kb plasmid UUCGCM library Mus musculus genomic
DEFINITION clone UUCGCM0176D09 F, genomic survey sequence.
ACCESSION AZ865832
VERSION AZ865832.1 GI:13066534
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 19)
Dunn, D., Aoyagi, A., Barber, M., Beacom, T., Duval, B., Hamil, C.,
Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von
Niederhausern, A. and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
Plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0176 row: D column: 09
Seq primer: CGTTGTAAACGACGCGCAGT
Class: plasmid ends
High quality sequence stop: 19.

FEATURES

source

1. 19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUCGCM0176D09"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_1lb="Mouse 10kb plasmid UUCGCM library"
/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMW42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.6%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 0.93;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1896 TGACACACAGGTAGAC 1911
Db 17 TGACACACAGGTAGAC 2

RESULT 4
B0592176 16 bp mRNA linear EST 06-DEC-2002
LOCUS B012696-024-021-004-SP6 MP1Z-ADIS-024-developing root Beta vulgaris
DEFINITION CDNA clone 024-021-004 5-PRIME, mRNA sequence.
ACCESSION B0592176
VERSION B0592176.1 GI:26121759
KEYWORDS EST.
SOURCE Beta vulgaris
ORGANISM Beta vulgaris
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Caryophyllales; Amaranthaceae; Beta.
1 (bases 1 to 16)
Herwig, R., Schulz, B., Weishaar, B., Hemmig, S., Steinfath, M.,
and Radelof, U.
Construction of a 'unigene' cDNA clone set by oligonucleotide
fingerprinting allows access to 25 000 potential sugar beet genes
Journal Plant J. 32 (5), 845-857 (2002)
22362189
12472698
PUBMED
Contact: Weishaar B
ADIS DNA core facility at MP1Z


```

RESULT 7
CA798290 14 bp mRNA linear EST 05-DEC-2002
LOCUS Cac_Bl_611 Cac_Bl (Bean and leaf from Amelonardo type Cacao)
DEFINITION Theobroma cacao cDNA clone Cac_Bl_611 5', mRNA sequence.
ACCESSION CA798290
VERSION CA798290.1 GI:26055376
KEYWORDS EST.
SOURCE Theobroma cacao (cacao)
ORGANISM Theobroma cacao
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Malvales; Malvaceae; Byttnerioideae;
Theobroma.
1 (bases 1 to 14)
Jones, P.G., Allaway, D., Gilmour, D.M., Harris, C., Rankin, D.,
Retzel, E.R. and Jones, C.A.
Gene discovery and microarray analysis of cacao (Theobroma cacao
L.) varieties
Planta 216 (2), 255-264 (2002)
JOURNAL MEDLINE 2237596
PUBMED 1247539
COMMENT Contact: Jones, Paul
Masterfoods
3d Dundee Road, Slough, Berkshire, UK, SL1 4LG
Tel: +44 1664 416644
Email: Paul.Jones@eu.efem.com
Seq primer: T3.
location/Qualifiers
1..14
/organism="Theobroma cacao"
/mol_type="mRNA"
/strain="Amelonado type"
/db_xref="taxon:3641"
/clone="Cac Bl 611"
/tissue_type="Mature leaf and mature bean"
/dev_stage="maturity"
/lab_host="XL-1 Blue MRF"
/clone_1b="Cac_Bl (Bean and leaf from Amelonardo type
Cacao)"
/note="Vector: PBK-CMV; Bean and leaf tissue from an
Amelonado type Cacao tree."
FEATURES
source

```

```

Query Match 0.5%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 6;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 657 CTCAGCGATACCT 670
DB 1 CTCGGCTATACCT 14

```

```

Search completed: June 30, 2004, 08:50:10
Job time : 1 secs

```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 30, 2004, 08:43:33 ; Search time 11 Seconds
(without alignments)
3.377 Million cell updates/sec

Title: US-10-024-369-3

Perfect score: 2247

Sequence: 1 atgcgcagctcagctagctcc.....ctgcagatgctccagatga 2247

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 459 seqs, 8265 residues

Total number of hits satisfying chosen parameters: 918

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 462 summaries

Database : rnmp3.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	40.6	1.8	41	1	US-10-035-833A-6
2	40.6	1.8	41	1	US-10-035-833A-5176
3	40.6	1.8	41	1	US-10-035-833A-7638
4	30.6	1.4	31	1	US-09-801-274-1336
5	23	1.0	23	1	US-10-024-369-4
6	21	0.9	21	1	US-10-010-920-66
7	21	0.9	21	1	US-10-008-721-66
8	20	0.9	20	1	US-10-024-369-5
9	20	0.9	20	1	US-10-024-369-6
10	20	0.9	20	1	US-10-024-369-10
11	20	0.9	20	1	US-10-024-369-11
12	20	0.9	20	1	US-10-024-369-12
13	20	0.9	20	1	US-10-024-369-13
14	20	0.9	20	1	US-10-024-369-14
15	20	0.9	20	1	US-10-024-369-15
16	20	0.9	20	1	US-10-024-369-16
17	20	0.9	20	1	US-10-024-369-17
18	20	0.9	20	1	US-10-024-369-18
19	20	0.9	20	1	US-10-024-369-19
20	20	0.9	20	1	US-10-024-369-20
21	20	0.9	20	1	US-10-024-369-21
22	20	0.9	20	1	US-10-024-369-22
23	20	0.9	20	1	US-10-024-369-23
24	20	0.9	20	1	US-10-024-369-24
25	20	0.9	20	1	US-10-024-369-25
26	20	0.9	20	1	US-10-024-369-26
27	20	0.9	20	1	US-10-024-369-27
28	20	0.9	20	1	US-10-024-369-28
29	20	0.9	20	1	US-10-024-369-29
30	20	0.9	20	1	US-10-024-369-30
31	20	0.9	20	1	US-10-024-369-31
32	20	0.9	20	1	US-10-024-369-32
33	20	0.9	20	1	US-10-024-369-33

C 34	20	0.9	20	1	US-10-024-369-34	Sequence 34, Appl
C 35	20	0.9	20	1	US-10-024-369-35	Sequence 35, Appl
C 36	20	0.9	20	1	US-10-024-369-36	Sequence 36, Appl
C 37	20	0.9	20	1	US-10-024-369-37	Sequence 37, Appl
C 38	20	0.9	20	1	US-10-024-369-38	Sequence 38, Appl
C 39	20	0.9	20	1	US-10-024-369-39	Sequence 39, Appl
C 40	20	0.9	20	1	US-10-024-369-40	Sequence 40, Appl
C 41	20	0.9	20	1	US-10-024-369-41	Sequence 41, Appl
C 42	20	0.9	20	1	US-10-024-369-42	Sequence 42, Appl
C 43	20	0.9	20	1	US-10-024-369-43	Sequence 43, Appl
C 44	20	0.9	20	1	US-10-024-369-44	Sequence 44, Appl
C 45	20	0.9	20	1	US-10-024-369-45	Sequence 45, Appl
C 46	20	0.9	20	1	US-10-024-369-46	Sequence 46, Appl
C 47	20	0.9	20	1	US-10-024-369-47	Sequence 47, Appl
C 48	20	0.9	20	1	US-10-024-369-48	Sequence 48, Appl
C 49	20	0.9	20	1	US-10-024-369-49	Sequence 49, Appl
C 50	20	0.9	20	1	US-10-024-369-50	Sequence 50, Appl
C 51	20	0.9	20	1	US-10-024-369-51	Sequence 51, Appl
C 52	20	0.9	20	1	US-10-024-369-52	Sequence 52, Appl
C 53	20	0.9	20	1	US-10-024-369-53	Sequence 53, Appl
C 54	20	0.9	20	1	US-10-024-369-54	Sequence 54, Appl
C 55	20	0.9	20	1	US-10-024-369-55	Sequence 55, Appl
C 56	20	0.9	20	1	US-10-024-369-56	Sequence 56, Appl
C 57	20	0.9	20	1	US-10-024-369-57	Sequence 57, Appl
C 58	20	0.9	20	1	US-10-024-369-58	Sequence 58, Appl
C 59	20	0.9	20	1	US-10-024-369-59	Sequence 59, Appl
C 60	20	0.9	20	1	US-10-024-369-60	Sequence 60, Appl
C 61	20	0.9	20	1	US-10-024-369-61	Sequence 61, Appl
C 62	20	0.9	20	1	US-10-024-369-62	Sequence 62, Appl
C 63	20	0.9	20	1	US-10-024-369-63	Sequence 63, Appl
C 64	20	0.9	20	1	US-10-024-369-64	Sequence 64, Appl
C 65	20	0.9	20	1	US-10-024-369-65	Sequence 65, Appl
C 66	20	0.9	20	1	US-10-024-369-66	Sequence 66, Appl
C 67	20	0.9	20	1	US-10-024-369-67	Sequence 67, Appl
C 68	20	0.9	20	1	US-10-024-369-68	Sequence 68, Appl
C 69	20	0.9	20	1	US-10-024-369-69	Sequence 69, Appl
C 70	20	0.9	20	1	US-10-024-369-70	Sequence 70, Appl
C 71	20	0.9	20	1	US-10-024-369-71	Sequence 71, Appl
C 72	20	0.9	20	1	US-10-024-369-72	Sequence 72, Appl
C 73	20	0.9	20	1	US-10-024-369-73	Sequence 73, Appl
C 74	20	0.9	20	1	US-10-024-369-74	Sequence 74, Appl
C 75	20	0.9	20	1	US-10-024-369-75	Sequence 75, Appl
C 76	20	0.9	20	1	US-10-024-369-76	Sequence 76, Appl
C 77	20	0.9	20	1	US-10-024-369-77	Sequence 77, Appl
C 78	20	0.9	20	1	US-10-024-369-78	Sequence 78, Appl
C 79	20	0.9	20	1	US-10-024-369-79	Sequence 79, Appl
C 80	20	0.9	20	1	US-10-024-369-80	Sequence 80, Appl
C 81	20	0.9	20	1	US-10-024-369-81	Sequence 81, Appl
C 82	20	0.9	20	1	US-10-024-369-82	Sequence 82, Appl
C 83	20	0.9	20	1	US-10-024-369-83	Sequence 83, Appl
C 84	20	0.9	20	1	US-10-024-369-84	Sequence 84, Appl
C 85	20	0.9	20	1	US-10-024-369-85	Sequence 85, Appl
C 86	20	0.9	20	1	US-10-024-369-86	Sequence 86, Appl
C 87	20	0.9	20	1	US-10-024-369-87	Sequence 87, Appl
C 88	19	0.8	19	1	US-10-010-920-65	Sequence 88, Appl
C 89	19	0.8	19	1	US-10-008-721-65	Sequence 89, Appl
C 90	19	0.8	19	1	US-10-383-664-74	Sequence 90, Appl
C 91	18	0.8	18	1	US-09-938-689-59	Sequence 91, Appl
C 92	18	0.8	18	1	US-10-333-664-83	Sequence 92, Appl
C 93	16	0.7	20	1	US-10-092-9004-550	Sequence 93, Appl
C 94	16	0.7	21	1	US-10-136-942-2	Sequence 94, Appl
C 95	15.8	0.7	19	1	US-09-813-824A-40	Sequence 95, Appl
C 96	15.8	0.7	19	1	US-10-648-512-60	Sequence 96, Appl
C 97	15.8	0.7	20	1	US-10-369-378-36	Sequence 97, Appl
C 98	15.8	0.7	20	1	US-10-369-378-37	Sequence 98, Appl
C 99	15.8	0.7	20	1	US-10-199-937-171	Sequence 99, Appl
C 100	15.8	0.7	20	1	US-10-199-937-172	Sequence 100, Appl
C 101	15.8	0.7	21	1	US-09-817-014-68	Sequence 101, Appl
C 102	15.8	0.7	21	1	US-10-074-246-21	Sequence 102, Appl
C 103	15.8	0.7	21	1	US-10-184-085A-855	Sequence 103, Appl
C 104	15.8	0.7	21	1	US-10-056-229-68	Sequence 104, Appl
C 105	15.4	0.7	17	1	US-09-866-108-891	Sequence 105, Appl
C 106	15.4	0.7	17	1	US-09-866-108-892	Sequence 106, Appl

C 107	15.4	0.7	17	1	US-09-866-108-693	Sequence 893, App	C 180	14.4	0.6	19	1	US-10-205-309-17	Sequence 17, App1
108	15.4	0.7	17	1	US-10-156-306-7105	Sequence 7105, Ap	181	14.4	0.6	19	1	US-10-205-309-142	Sequence 342, App
109	15.4	0.7	18	1	US-09-969-373-4010	Sequence 4010, Ap	182	14	0.6	14	1	US-09-998-780-12	Sequence 12, App1
110	15.4	0.7	18	1	US-09-961-077-609	Sequence 609, App	183	14	0.6	14	1	US-10-417-393-12	Sequence 12, App1
C 111	15.2	0.7	20	1	US-09-752-983-8	Sequence 8, App1	C 184	14	0.6	16	1	US-09-829-855-101	Sequence 101, App
C 112	15.2	0.7	20	1	US-09-851-771A-8	Sequence 8, App1	C 185	14	0.6	16	1	US-10-607-077A-101	Sequence 101, App
C 113	15.2	0.7	20	1	US-09-774-809-57	Sequence 57, App1	C 186	14	0.6	17	1	US-09-866-108-895	Sequence 895, App
C 114	15.2	0.7	20	1	US-09-917-963-36	Sequence 36, App1	C 187	14	0.6	17	1	US-09-866-108-896	Sequence 896, App
C 115	15.2	0.7	20	1	US-10-345-444B-57	Sequence 57, App1	C 188	14	0.6	17	1	US-09-930-423-1483	Sequence 1483, App
C 116	15.2	0.7	20	1	US-10-642-802-42	Sequence 42, App1	C 189	14	0.6	17	1	US-09-930-423-1484	Sequence 1484, Ap
C 117	15.2	0.7	20	1	US-09-759-999B-7	Sequence 7, App1	C 190	14	0.6	17	1	US-09-740-332-2411	Sequence 2411, Ap
C 118	15.2	0.7	20	1	US-10-159-256-20	Sequence 20, App1	C 191	14	0.6	17	1	US-09-745-237A-1483	Sequence 1483, Ap
C 119	15.2	0.7	20	1	US-10-159-266-56	Sequence 96, App1	C 192	14	0.6	17	1	US-09-745-237A-1484	Sequence 1484, Ap
C 120	15.2	0.7	20	1	US-10-161-996-127	Sequence 127, App	C 193	14	0.6	17	1	US-09-817-879-2411	Sequence 2411, Ap
C 121	15.2	0.7	20	1	US-10-161-996-250	Sequence 250, App	C 194	14	0.6	17	1	US-10-156-306-6313	Sequence 6313, Ap
C 122	15.2	0.7	20	1	US-10-001-076-42	Sequence 42, App1	C 195	14	0.6	17	1	US-10-240-046A-64	Sequence 64, App1
C 123	15.2	0.7	20	1	US-10-145-493B-35	Sequence 35, App1	C 196	14	0.6	17	1	US-10-230-006-6189	Sequence 2189, Ap
C 124	15.2	0.7	20	1	US-10-006-191-72	Sequence 72, App1	C 197	14	0.6	17	1	US-10-138-674-9170	Sequence 9170, Ap
C 125	15.2	0.7	20	1	US-10-005-344-8	Sequence 8, App1	C 198	14	0.6	17	1	US-10-287-949A-9170	Sequence 9170, Ap
C 126	15.2	0.7	20	1	US-10-349-143-8790	Sequence 8790, Ap	C 199	14	0.6	18	1	US-10-178-325-56	Sequence 56, App1
C 127	15.2	0.7	20	1	US-10-349-143-8838	Sequence 8838, Ap	C 200	13.8	0.6	17	1	US-09-866-108-515	Sequence 515, App
C 128	15.2	0.7	20	1	US-10-289-762-3216	Sequence 3216, Ap	C 201	13.8	0.6	17	1	US-09-866-108-665	Sequence 665, App
C 129	15.2	0.7	20	1	US-10-289-762-3350	Sequence 3350, Ap	C 202	13.8	0.6	17	1	US-09-866-108-1532	Sequence 1530, Ap
C 130	15.2	0.7	20	1	US-10-289-762-4873	Sequence 4873, Ap	C 203	13.8	0.6	17	1	US-09-866-108-1572	Sequence 1572, Ap
C 131	15.2	0.7	20	1	US-10-210-833-65	Sequence 65, App1	C 204	13.8	0.6	17	1	US-09-866-108-1960	Sequence 1960, Ap
C 132	15.2	0.7	20	1	US-10-444-206-438	Sequence 438, App	C 205	13.8	0.6	17	1	US-09-866-108-7739	Sequence 2739, App
C 133	15.2	0.7	20	1	US-10-293-998-32	Sequence 32, App1	C 206	13.8	0.6	17	1	US-09-866-108-6521	Sequence 6521, Ap
C 134	15.2	0.7	20	1	US-10-293-998-68	Sequence 68, App1	C 207	13.8	0.6	17	1	US-09-866-108-6522	Sequence 6522, Ap
C 135	15.2	0.7	20	1	US-10-296-716-15	Sequence 15, App1	C 208	13.8	0.6	17	1	US-09-866-108-6525	Sequence 6525, Ap
C 136	15.2	0.7	20	1	US-10-316-667-39	Sequence 39, App1	C 209	13.8	0.6	17	1	US-09-866-108-6526	Sequence 6526, Ap
C 137	15.2	0.7	20	1	US-10-316-667-63	Sequence 63, App1	C 210	13.8	0.6	17	1	US-09-866-108-6758	Sequence 6758, Ap
C 138	15	0.7	17	1	US-10-156-306-7106	Sequence 7106, Ap	C 211	13.8	0.6	17	1	US-09-866-108-8056	Sequence 8056, Ap
C 139	15	0.7	17	1	US-10-156-306-7107	Sequence 7107, Ap	C 212	13.8	0.6	17	1	US-09-866-108-8057	Sequence 8057, Ap
C 140	15	0.7	17	1	US-10-230-006-741	Sequence 741, App	C 213	13.8	0.6	17	1	US-09-866-108-9583	Sequence 9583, Ap
C 141	15	0.7	17	1	US-10-230-006-1390	Sequence 1390, Ap	C 214	13.8	0.6	17	1	US-09-895-040A-77	Sequence 77, App1
C 142	14.8	0.7	18	1	US-10-100-957A-39	Sequence 39, App1	C 215	13.8	0.6	17	1	US-09-864-785-577	Sequence 577, App
C 143	14.8	0.7	18	1	US-10-211-088-293	Sequence 293, App	C 216	13.8	0.6	17	1	US-09-864-785-2690	Sequence 2690, App
C 144	14.8	0.7	18	1	US-10-265-689-39	Sequence 39, App1	C 217	13.8	0.6	17	1	US-09-864-785-2870	Sequence 2870, Ap
C 145	14.8	0.7	19	1	US-09-910-059-110	Sequence 110, App	C 218	13.8	0.6	17	1	US-09-864-785-2871	Sequence 2871, Ap
C 146	14.8	0.7	19	1	US-10-099-352-22	Sequence 22, App1	C 219	13.8	0.6	17	1	US-09-825-805-629	Sequence 629, App
C 147	14.8	0.7	19	1	US-10-224-005-84	Sequence 84, App1	C 220	13.8	0.6	17	1	US-09-825-805-719	Sequence 719, App
C 148	14.8	0.7	19	1	US-10-224-005-245	Sequence 245, App	C 221	13.8	0.6	17	1	US-09-730-289B-541	Sequence 541, App
C 149	14.8	0.7	19	1	US-10-277-216-121	Sequence 121, App	C 222	13.8	0.6	17	1	US-09-533A-106	Sequence 106, App
C 150	14.8	0.7	19	1	US-10-126-022-121	Sequence 121, App	C 223	13.8	0.6	17	1	US-09-780-533A-1837	Sequence 1837, App
C 151	14.8	0.7	19	1	US-10-670-184-94	Sequence 94, App1	C 224	13.8	0.6	17	1	US-09-780-533A-2015	Sequence 2015, App
C 152	14.4	0.6	17	1	US-09-866-108-890	Sequence 894, App	C 225	13.8	0.6	17	1	US-09-877-478-699	Sequence 699, App
C 153	14.4	0.6	17	1	US-09-866-108-894	Sequence 894, App	C 226	13.8	0.6	17	1	US-09-877-478-1441	Sequence 1441, App
C 154	14.4	0.6	17	1	US-09-866-108-8005	Sequence 8005, App	C 227	13.8	0.6	17	1	US-09-930-423-583	Sequence 383, App
C 155	14.4	0.6	17	1	US-09-866-108-8006	Sequence 8006, App	C 228	13.8	0.6	17	1	US-09-930-423-1041	Sequence 1041, App
C 156	14.4	0.6	17	1	US-09-961-077-139	Sequence 139, App	C 229	13.8	0.6	17	1	US-09-930-423-1485	Sequence 1485, App
C 157	14.4	0.6	17	1	US-09-818-875-603	Sequence 603, App	C 230	13.8	0.6	17	1	US-09-930-423-1557	Sequence 1557, App
C 158	14.4	0.6	17	1	US-09-818-875-604	Sequence 604, App	C 231	13.8	0.6	17	1	US-09-930-423-1558	Sequence 1558, App
C 159	14.4	0.6	17	1	US-09-930-423-384	Sequence 384, App	C 232	13.8	0.6	17	1	US-09-864-636A-1682	Sequence 1682, App
C 160	14.4	0.6	17	1	US-09-930-423-385	Sequence 385, App	C 233	13.8	0.6	17	1	US-09-827-395A-35	Sequence 35, App1
C 161	14.4	0.6	17	1	US-09-740-332-2144	Sequence 2144, App	C 234	13.8	0.6	17	1	US-09-827-395A-36	Sequence 36, App1
C 162	14.4	0.6	17	1	US-09-745-237A-384	Sequence 384, App	C 235	13.8	0.6	17	1	US-09-827-395A-79	Sequence 79, App1
C 163	14.4	0.6	17	1	US-09-745-237A-385	Sequence 385, App	C 236	13.8	0.6	17	1	US-09-827-395A-270	Sequence 270, App
C 164	14.4	0.6	17	1	US-09-817-879-2144	Sequence 2144, App	C 237	13.8	0.6	17	1	US-09-827-395A-742	Sequence 742, App
C 165	14.4	0.6	17	1	US-10-081-810-33	Sequence 33, App1	C 238	13.8	0.6	17	1	US-09-740-332-338	Sequence 338, App
C 166	14.4	0.6	17	1	US-10-060-895A-482	Sequence 482, App	C 239	13.8	0.6	17	1	US-09-740-332-3694	Sequence 1694, App
C 167	14.4	0.6	17	1	US-10-060-895A-483	Sequence 483, App	C 240	13.8	0.6	17	1	US-09-740-332-3272	Sequence 3272, App
C 168	14.4	0.6	17	1	US-10-156-306-4759	Sequence 4759, App	C 241	13.8	0.6	17	1	US-09-740-332-4243	Sequence 4243, App
C 169	14.4	0.6	17	1	US-10-156-306-4760	Sequence 4760, App	C 242	13.8	0.6	17	1	US-09-740-332-4247	Sequence 4247, App
C 170	14.4	0.6	17	1	US-10-156-306-7104	Sequence 7104, App	C 243	13.8	0.6	17	1	US-09-745-237A-383	Sequence 383, App
C 171	14.4	0.6	17	1	US-10-209-787-603	Sequence 603, App	C 244	13.8	0.6	17	1	US-09-745-237A-1041	Sequence 1041, App
C 172	14.4	0.6	17	1	US-10-209-787-604	Sequence 604, App	C 245	13.8	0.6	17	1	US-09-745-237A-1485	Sequence 1485, App
C 173	14.4	0.6	17	1	US-10-261-185-603	Sequence 604, App	C 246	13.8	0.6	17	1	US-09-745-237A-1557	Sequence 1557, App
C 174	14.4	0.6	17	1	US-10-261-185-604	Sequence 604, App	C 247	13.8	0.6	17	1	US-09-745-237A-1558	Sequence 1558, App
C 175	14.4	0.6	18	1	US-10-230-335-5	Sequence 5, App1	C 248	13.8	0.6	17	1	US-09-817-879-338	Sequence 338, App
C 176	14.4	0.6	18	1	US-10-005-956-1222	Sequence 1222, App	C 249	13.8	0.6	17	1	US-09-817-879-1694	Sequence 1694, App
C 177	14.4	0.6	19	1	US-10-427-432-11	Sequence 11, App1	C 250	13.8	0.6	17	1	US-09-817-879-3272	Sequence 3272, App
C 178	14.4	0.6	19	1	US-10-164-871-17	Sequence 17, App1	C 251	13.8	0.6	17	1	US-09-817-879-3439	Sequence 3439, App
C 179	14.4	0.6	19	1	US-10-238-042-16	Sequence 16, App1	C 252	13.8	0.6	17	1	US-09-817-879-4247	Sequence 4247, App

253	13.8	0.6	17	1	US-09-864-426A-1682	Sequence 1682, Ap	C 326	13.4	0.6	15	1	US-09-896-095-121	Sequence 121, App
C 254	13.8	0.6	17	1	US-10-342-902-659	Sequence 659, App	C 327	13.4	0.6	15	1	US-10-408-157-6	Sequence 6, App1
C 255	13.8	0.6	17	1	US-10-342-902-1441	Sequence 1441, Ap	C 328	13.4	0.6	15	1	US-10-146-505-71	Sequence 71, App1
C 256	13.8	0.6	17	1	US-09-927-046-863	Sequence 863, App	C 329	13.4	0.6	15	1	US-10-440-850-231	Sequence 231, App
C 257	13.8	0.6	17	1	US-10-430-882-35	Sequence 35, App1	C 330	13.4	0.6	15	1	US-10-126-685-121	Sequence 121, App
C 258	13.8	0.6	17	1	US-10-430-882-56	Sequence 56, App1	C 331	13.4	0.6	15	1	US-10-127-028-121	Sequence 121, App
C 259	13.8	0.6	17	1	US-10-430-882-79	Sequence 79, App1	C 332	13.4	0.6	15	1	US-10-126-544-121	Sequence 121, App
C 260	13.8	0.6	17	1	US-10-430-882-770	Sequence 270, App	C 333	13.4	0.6	16	1	US-09-829-855-11	Sequence 11, App1
C 261	13.8	0.6	17	1	US-10-430-882-742	Sequence 742, App	C 334	13.4	0.6	16	1	US-09-829-855-13	Sequence 13, App1
C 262	13.8	0.6	17	1	US-10-060-830-781	Sequence 781, App	C 335	13.4	0.6	16	1	US-09-829-855-77	Sequence 77, App1
C 263	13.8	0.6	17	1	US-10-060-756A-519	Sequence 519, App	C 336	13.4	0.6	16	1	US-10-182-230-68	Sequence 68, App1
C 264	13.8	0.6	17	1	US-10-287-919-1890	Sequence 1890, App	C 337	13.4	0.6	16	1	US-10-138-674-7079	Sequence 7079, Ap
C 265	13.8	0.6	17	1	US-10-060-895A-437	Sequence 437, App	C 338	13.4	0.6	16	1	US-10-287-949A-7079	Sequence 7079, Ap
C 266	13.8	0.6	17	1	US-10-060-895A-481	Sequence 481, App	C 339	13.4	0.6	16	1	US-10-607-077A-11	Sequence 11, App1
C 267	13.8	0.6	17	1	US-10-060-895A-793	Sequence 793, App	C 340	13.4	0.6	16	1	US-10-607-077A-13	Sequence 13, App1
C 268	13.8	0.6	17	1	US-10-163-552-328	Sequence 328, App	C 341	13.4	0.6	16	1	US-10-607-077A-77	Sequence 77, App1
C 269	13.8	0.6	17	1	US-10-163-552-497	Sequence 497, App	C 342	13.4	0.6	17	1	US-09-866-108-889	Sequence 889, App
C 270	13.8	0.6	17	1	US-10-156-306-969	Sequence 969, App	C 343	13.4	0.6	17	1	US-09-866-108-6756	Sequence 6756, App
C 271	13.8	0.6	17	1	US-10-156-306-5001	Sequence 5001, Ap	C 344	13.4	0.6	17	1	US-09-866-108-6757	Sequence 6757, Ap
C 272	13.8	0.6	17	1	US-10-238-700-2992	Sequence 2992, Ap	C 345	13.4	0.6	17	1	US-09-866-108-6950	Sequence 6950, Ap
C 273	13.8	0.6	17	1	US-10-238-700-2993	Sequence 2993, Ap	C 346	13.4	0.6	17	1	US-09-866-108-6951	Sequence 6951, Ap
C 274	13.8	0.6	17	1	US-10-238-700-3609	Sequence 3609, Ap	C 347	13.4	0.6	17	1	US-09-866-108-6952	Sequence 6952, Ap
C 275	13.8	0.6	17	1	US-10-238-700-3610	Sequence 3610, Ap	C 348	13.4	0.6	17	1	US-09-866-108-8004	Sequence 8004, Ap
C 276	13.8	0.6	17	1	US-10-061-201-436	Sequence 436, App	C 349	13.4	0.6	17	1	US-09-866-108-8007	Sequence 8007, Ap
C 277	13.8	0.6	17	1	US-10-061-201-437	Sequence 437, App	C 350	13.4	0.6	17	1	US-09-866-108-8054	Sequence 8054, Ap
C 278	13.8	0.6	17	1	US-10-061-201-438	Sequence 438, App	C 351	13.4	0.6	17	1	US-09-866-108-8055	Sequence 8055, Ap
C 279	13.8	0.6	17	1	US-10-061-201-439	Sequence 439, App	C 352	13.4	0.6	17	1	US-09-827-998-471	Sequence 471, App
C 280	13.8	0.6	17	1	US-10-061-201-1326	Sequence 1326, Ap	C 353	13.4	0.6	17	1	US-09-827-998-472	Sequence 472, App
C 281	13.8	0.6	17	1	US-10-084-839-1682	Sequence 1682, Ap	C 354	13.4	0.6	17	1	US-09-827-998-473	Sequence 473, App
C 282	13.8	0.6	17	1	US-10-084-839-3475	Sequence 3475, Ap	C 355	13.4	0.6	17	1	US-09-969-373-7716	Sequence 3716, Ap
C 283	13.8	0.6	17	1	US-10-230-006-820	Sequence 820, App	C 356	13.4	0.6	17	1	US-09-864-785-55	Sequence 55, App1
C 284	13.8	0.6	17	1	US-10-297-068-1041	Sequence 1041, Ap	C 357	13.4	0.6	17	1	US-09-864-785-55	Sequence 56, App1
C 285	13.8	0.6	17	1	US-10-297-068-1259	Sequence 1259, Ap	C 358	13.4	0.6	17	1	US-09-864-785-1585	Sequence 1585, Ap
C 286	13.8	0.6	17	1	US-10-138-674-4198	Sequence 4198, Ap	C 359	13.4	0.6	17	1	US-09-864-785-1621	Sequence 1621, Ap
C 287	13.8	0.6	17	1	US-10-138-674-7439	Sequence 7439, Ap	C 360	13.4	0.6	17	1	US-09-864-785-1828	Sequence 1828, Ap
C 288	13.8	0.6	17	1	US-10-138-674-8640	Sequence 8640, Ap	C 361	13.4	0.6	17	1	US-09-780-533A-2411	Sequence 912, App
C 289	13.8	0.6	17	1	US-10-287-949A-4198	Sequence 4198, Ap	C 362	13.4	0.6	17	1	US-09-877-478-1387	Sequence 1387, Ap
C 290	13.8	0.6	17	1	US-10-287-949A-7439	Sequence 7439, Ap	C 363	13.4	0.6	17	1	US-09-877-478-1388	Sequence 1388, Ap
C 291	13.8	0.6	17	1	US-10-287-949A-8640	Sequence 8640, Ap	C 364	13.4	0.6	17	1	US-09-877-478-1388	Sequence 1388, Ap
C 292	13.8	0.6	17	1	US-10-712-672-830	Sequence 830, App	C 365	13.4	0.6	17	1	US-09-827-998-2180	Sequence 2180, Ap
C 293	13.8	0.6	18	1	US-09-320-337-57	Sequence 57, App1	C 366	13.4	0.6	17	1	US-09-827-998-2271	Sequence 2271, App
C 294	13.8	0.6	18	1	US-09-320-337-59	Sequence 59, App1	C 367	13.4	0.6	17	1	US-09-740-332-308	Sequence 308, App
C 295	13.8	0.6	18	1	US-09-925-911-7	Sequence 7, App1	C 368	13.4	0.6	17	1	US-09-817-879-308	Sequence 308, App
C 296	13.8	0.6	18	1	US-09-925-911-8	Sequence 8, App1	C 369	13.4	0.6	17	1	US-10-342-902-1387	Sequence 1387, Ap
C 297	13.8	0.6	18	1	US-09-882-945A-81	Sequence 81, App1	C 370	13.4	0.6	17	1	US-10-342-902-1388	Sequence 1388, Ap
C 298	13.8	0.6	18	1	US-09-306-333A-17	Sequence 9, App1	C 371	13.4	0.6	17	1	US-10-342-902-2180	Sequence 2180, Ap
C 299	13.8	0.6	18	1	US-09-838-028-9	Sequence 9, App1	C 372	13.4	0.6	17	1	US-10-675-685-471	Sequence 471, App
C 300	13.8	0.6	18	1	US-10-308-264-685	Sequence 685, App	C 373	13.4	0.6	17	1	US-10-675-685-473	Sequence 472, App
C 301	13.8	0.6	18	1	US-09-945-353-1	Sequence 1, App1	C 374	13.4	0.6	17	1	US-09-927-046-1020	Sequence 1020, Ap
C 302	13.8	0.6	18	1	US-09-945-353-3	Sequence 3, App1	C 375	13.4	0.6	17	1	US-09-927-046-864	Sequence 864, App
C 303	13.8	0.6	18	1	US-10-156-995-131	Sequence 131, App	C 376	13.4	0.6	17	1	US-09-927-046-5005	Sequence 5005, Ap
C 304	13.8	0.6	18	1	US-10-156-995-132	Sequence 132, App	C 377	13.4	0.6	17	1	US-09-927-046-5093	Sequence 5093, Ap
C 305	13.8	0.6	18	1	US-10-037-616-10	Sequence 10, App1	C 378	13.4	0.6	17	1	US-09-958-163A-23	Sequence 23, App1
C 306	13.8	0.6	18	1	US-10-199-830-7	Sequence 7, App1	C 379	13.4	0.6	17	1	US-10-430-882-371	Sequence 271, App
C 307	13.8	0.6	18	1	US-10-199-830-8	Sequence 8, App1	C 380	13.4	0.6	17	1	US-10-060-830-782	Sequence 782, App
C 308	13.8	0.6	18	1	US-10-216-122-135	Sequence 135, App	C 381	13.4	0.6	17	1	US-10-060-830-783	Sequence 783, App
C 309	13.8	0.6	18	1	US-10-169-983-27	Sequence 84, App1	C 382	13.4	0.6	17	1	US-10-060-895A-464	Sequence 84, App
C 310	13.8	0.6	18	1	US-10-169-983-27	Sequence 27, App1	C 383	13.4	0.6	17	1	US-10-163-552-84	Sequence 84, App1
C 311	13.8	0.6	18	1	US-10-302-279-51	Sequence 0, App1	C 384	13.4	0.6	17	1	US-10-156-306-4761	Sequence 4761, App
C 312	13.8	0.6	18	1	US-10-168-445-205	Sequence 205, App	C 385	13.4	0.6	17	1	US-10-156-306-5005	Sequence 5005, Ap
C 313	13.8	0.6	18	1	US-10-349-143-8459	Sequence 8459, Ap	C 386	13.4	0.6	17	1	US-10-156-306-5013	Sequence 5013, Ap
C 314	13.8	0.6	18	1	US-10-703-864-25	Sequence 25, App1	C 387	13.4	0.6	17	1	US-10-156-306-5092	Sequence 5092, Ap
C 315	13.8	0.6	18	1	US-10-628-109-64	Sequence 64, App1	C 388	13.4	0.6	17	1	US-10-156-306-5093	Sequence 5093, Ap
C 316	13.6	0.6	15	1	US-10-160-358-57	Sequence 67, App1	C 389	13.4	0.6	17	1	US-10-156-306-5184	Sequence 5184, Ap
C 317	13.6	0.6	41	1	US-10-035-833A-6	Sequence 6, App1	C 390	13.4	0.6	17	1	US-10-156-306-5885	Sequence 5889, App
C 318	13.6	0.6	41	1	US-10-035-833A-5176	Sequence 5176, Ap	C 391	13.4	0.6	17	1	US-10-156-306-5925	Sequence 5925, Ap
C 319	13.6	0.6	41	1	US-10-035-833A-7638	Sequence 7638, Ap	C 392	13.4	0.6	17	1	US-10-156-306-6931	Sequence 6931, Ap
C 320	13.4	0.6	15	1	US-09-504-231A-714	Sequence 714, App	C 393	13.4	0.6	17	1	US-10-156-306-6960	Sequence 6960, Ap
C 321	13.4	0.6	15	1	US-09-274-553D-714	Sequence 714, App	C 394	13.4	0.6	17	1	US-10-238-700-1261	Sequence 1261, Ap
C 322	13.4	0.6	15	1	US-09-781-988-121	Sequence 121, App	C 395	13.4	0.6	17	1	US-10-061-201-1272	Sequence 1272, Ap
C 323	13.4	0.6	15	1	US-09-879-813-71	Sequence 71, App1	C 396	13.4	0.6	17	1	US-10-061-201-1273	Sequence 1273, Ap
C 324	13.4	0.6	15	1	US-09-893-878-121	Sequence 121, App	C 397	13.4	0.6	17	1	US-10-061-201-1274	Sequence 1274, Ap
C 325	13.4	0.6	15	1	US-09-862-417A-1	Sequence 1, App1	C 398	13.4	0.6	17	1	US-10-230-006-1429	Sequence 1429, Ap

```
399 13.4 0.6 17 1 US-10-277-216-290
400 13.4 0.6 17 1 US-10-126-022-290
401 13.4 0.6 17 1 US-10-138-674-4197
402 13.4 0.6 17 1 US-10-138-674-4505
403 13.4 0.6 17 1 US-10-138-674-4755
404 13.4 0.6 17 1 US-10-138-674-6625
405 13.4 0.6 17 1 US-10-138-674-7633
406 13.4 0.6 17 1 US-10-138-674-8874
407 13.4 0.6 17 1 US-10-287-949A-4197
408 13.4 0.6 17 1 US-10-287-949A-4505
409 13.4 0.6 17 1 US-10-287-949A-4755
410 13.4 0.6 17 1 US-10-287-949A-6625
411 13.4 0.6 17 1 US-10-287-949A-7633
412 13.4 0.6 17 1 US-10-287-949A-8874
413 13.4 0.6 17 1 US-10-712-672-1280
414 13.4 0.6 17 1 US-10-712-672-1917
415 13.4 0.6 17 1 US-10-712-672-1977
416 13 0.6 15 1 US-09-504-231A-712
417 13 0.6 15 1 US-09-504-231A-713
418 13 0.6 15 1 US-09-274-553D-712
419 13 0.6 15 1 US-09-274-553D-713
420 13 0.6 15 1 US-09-748-739A-28
421 13 0.6 15 1 US-10-347-510A-44
422 13 0.6 15 1 US-09-544-934B-44
423 13 0.6 16 1 US-10-138-674-5827
424 13 0.6 16 1 US-10-287-949A-5827
425 13 0.6 17 1 US-09-866-108-897
426 13 0.6 17 1 US-09-866-108-8584
427 13 0.6 17 1 US-09-866-108-9585
428 13 0.6 17 1 US-09-866-108-9586
429 13 0.6 17 1 US-09-866-108-9587
430 13 0.6 17 1 US-09-740-332-641
431 13 0.6 17 1 US-09-740-332-642
432 13 0.6 17 1 US-09-740-332-3913
433 13 0.6 17 1 US-09-740-332-3914
434 13 0.6 17 1 US-09-817-879-641
435 13 0.6 17 1 US-09-817-879-642
436 13 0.6 17 1 US-09-817-879-3913
437 13 0.6 17 1 US-09-817-879-3914
438 13 0.6 17 1 US-10-156-306-5930
439 13 0.6 17 1 US-10-156-306-5802
440 13 0.6 17 1 US-10-230-006-742
441 13 0.6 17 1 US-10-138-674-813
442 13 0.6 17 1 US-10-138-674-814
443 13 0.6 17 1 US-10-138-674-4754
444 13 0.6 17 1 US-10-138-674-4789
445 13 0.6 17 1 US-10-138-674-5053
446 13 0.6 17 1 US-10-138-674-5054
447 13 0.6 17 1 US-10-138-674-5194
448 13 0.6 17 1 US-10-138-674-5195
449 13 0.6 17 1 US-10-138-674-7658
450 13 0.6 17 1 US-10-138-674-7657
451 13 0.6 17 1 US-10-138-674-9169
452 13 0.6 17 1 US-10-287-949A-813
453 13 0.6 17 1 US-10-287-949A-814
454 13 0.6 17 1 US-10-287-949A-4754
455 13 0.6 17 1 US-10-287-949A-4789
456 13 0.6 17 1 US-10-287-949A-5053
457 13 0.6 17 1 US-10-287-949A-5054
458 13 0.6 17 1 US-10-287-949A-5194
459 13 0.6 17 1 US-10-287-949A-5195
460 13 0.6 17 1 US-10-287-949A-7658
461 13 0.6 17 1 US-10-287-949A-7657
462 13 0.6 17 1 US-10-287-949A-9169
```

```
Sequence 290, App
Sequence 290, App
Sequence 4197, App
Sequence 4505, App
Sequence 4755, App
Sequence 6625, App
Sequence 7633, App
Sequence 8874, App
Sequence 4197, App
Sequence 4505, App
Sequence 4755, App
Sequence 6625, App
Sequence 7633, App
Sequence 8874, App
Sequence 1280, App
Sequence 1917, App
Sequence 1977, App
Sequence 712, App
Sequence 713, App
Sequence 712, App
Sequence 713, App
Sequence 28, App
Sequence 44, App
Sequence 44, App
Sequence 5827, App
Sequence 5827, App
Sequence 897, App
Sequence 9584, App
Sequence 9585, App
Sequence 9586, App
Sequence 9587, App
Sequence 641, App
Sequence 641, App
Sequence 3913, App
Sequence 3914, App
Sequence 641, App
Sequence 642, App
Sequence 3914, App
Sequence 3914, App
Sequence 5930, App
Sequence 6802, App
Sequence 742, App
Sequence 813, App
Sequence 814, App
Sequence 4754, App
Sequence 4789, App
Sequence 5053, App
Sequence 5054, App
Sequence 5194, App
Sequence 5195, App
Sequence 7658, App
Sequence 7657, App
Sequence 9169, App
Sequence 813, App
Sequence 814, App
Sequence 814, App
Sequence 4754, App
Sequence 4789, App
Sequence 5053, App
Sequence 5054, App
Sequence 5194, App
Sequence 5195, App
Sequence 7658, App
Sequence 7657, App
Sequence 9169, App
```

ALIGNMENTS

```
RESULT 1
US-10-035-833A-6
; Sequence 6, Application US/10035833A
; Publication No. US20040072156A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Nakamura, Yuho
; APPLICANT: Sekine, Akihiro
; APPLICANT: Iida, Aritoshi
; APPLICANT: Saito, Osamu
; TITLE OF INVENTION: Detection of Genetic Polymorphisms
; FILE REFERENCE: FORS-06904
; CURRENT APPLICATION NUMBER: US/10/035, 833A
; CURRENT FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 7669
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 41
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-035-833A-6

Query Match 1.8%; Score 40.6; DB 1; Length 41;
Best Local Similarity 97.6%; Pred. No. 0.00058;
Matches 40; Conservative 1; Mismatches 0; Gaps 0;

Oy 977 CCTCACCATGATGATCACCCTGATCACCCTGCTGCTTTTC 1017
Db 1 CCTCACCATGATGATCACCCTGATCACCCTGCTGCTTTTC 41

RESULT 2
US-10-035-833A-5176
; Sequence 5176, Application US/10035833A
; Publication No. US20040072156A1
; GENERAL INFORMATION:
; APPLICANT: Nakamura, Yuho
; APPLICANT: Sekine, Akihiro
; APPLICANT: Iida, Aritoshi
; APPLICANT: Saito, Osamu
; TITLE OF INVENTION: Detection of Genetic Polymorphisms
; FILE REFERENCE: FORS-06904
; CURRENT APPLICATION NUMBER: US/10/035, 833A
; CURRENT FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 7669
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5176
; LENGTH: 41
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-035-833A-5176

Query Match 1.8%; Score 40.6; DB 1; Length 41;
Best Local Similarity 97.6%; Pred. No. 0.00058;
Matches 40; Conservative 1; Mismatches 0; Gaps 0;

Oy 977 CCTCACCATGATGATCACCCTGATCACCCTGCTGCTTTTC 1017
Db 1 CCTCACCATGATGATCACCCTGATCACCCTGCTGCTTTTC 41

RESULT 3
US-10-035-833A-7638
; Sequence 7638, Application US/10035833A
; Publication No. US20040072156A1
; GENERAL INFORMATION:
; APPLICANT: Nakamura, Yuho
; APPLICANT: Sekine, Akihiro
; APPLICANT: Iida, Aritoshi
; APPLICANT: Saito, Osamu
; TITLE OF INVENTION: Detection of Genetic Polymorphisms
; FILE REFERENCE: FORS-06904
; CURRENT APPLICATION NUMBER: US/10/035, 833A
; CURRENT FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 7669
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7638
; LENGTH: 41
```



```

; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-024-369-5

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      778 TTGCAGGAGAGGTGTTGG 797
Db      20 TTGCAGGAGAGGTGTTGG 1

RESULT 9
US-10-024-369-6
; Sequence 6, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-10-024-369-6

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      756 CATGGCCACGCTGCACAGCC 775
Db      1 CATGGCCACGCTGCACAGCC 20

RESULT 10
US-10-024-369-10/c
; Sequence 10, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-10
```

```

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ATGGCTAGCTCTAGTGTCC 20
Db      20 ATGGCTAGCTCTAGTGTCC 1

RESULT 11
US-10-024-369-11/c
; Sequence 11, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-11

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      49 GGAGCTTCTCTCGCATGGCT 68
Db      20 GGAGCTTCTCTCGCATGGCT 1

RESULT 12
US-10-024-369-12/c
; Sequence 12, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-12

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      90 CGCCGACTGGGTGCTGCTCC 109
Db      20 CGCCGACTGGGTGCTGCTCC 1

RESULT 13
US-10-024-369-13/c
; Sequence 13, Application US/10024369
```

```
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-13

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      137 TGCTGTGCCCGCCGCGCTG 156
Db      20 TGCTGTGCCCGCCGCGCTG 1

RESULT 14
US-10-024-369-14/c
; Sequence 14, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-14

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      219 CGGGGTCCTCAGGCGCAACG 238
Db      20 CGGGGTCCTCAGGCGCAACG 1

RESULT 15
US-10-024-369-15/c
; Sequence 15, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-15

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      225 CCTCAGGCGCAACGGTTGGCT 244
Db      20 CCTCAGGCGCAACGGTTGGCT 1

RESULT 16
US-10-024-369-16/c
; Sequence 16, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-16

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      255 AAACGACGGTGCCCGAGGCT 274
Db      20 AAACGACGGTGCCCGAGGCT 1

RESULT 17
US-10-024-369-17/c
; Sequence 17, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-17

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      270 GGGCTGGCTGGCTGCTTTGA 289
Db      20 GGGCTGGCTGGCTGCTTTGA 1
```

```
RESULT 18
US-10-024-369-18/c
; Sequence 18, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-18
```

```
Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      294 ATTAGCTGGCGGCACTGGGCT 313
      |||||
Db      20 ATTAGCTGGCGGCACTGGGCT 1
```

```
RESULT 19
US-10-024-369-19/c
; Sequence 19, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-19
```

```
Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      300 TGGCGCACTGGGCTTGGCCC 319
      |||||
Db      20 TGGCGCACTGGGCTTGGCCC 1
```

```
RESULT 20
US-10-024-369-20/c
; Sequence 20, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
```

```
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-20
```

```
Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      304 GCACTGGGCTTGGCCCTGCC 323
      |||||
Db      20 GCACTGGGCTTGGCCCTGCC 1
```

```
RESULT 21
US-10-024-369-21/c
; Sequence 21, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-21
```

```
Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      334 TTGTTCCGAGAGCTGATCTC 353
      |||||
Db      20 TTGTTCCGAGAGCTGATCTC 1
```

```
RESULT 22
US-10-024-369-22/c
; Sequence 22, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-22
```

```
Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 391 CTGCACTGGGAAAGTCACCC 410
| | | | |
Db 20 CTGCACTGGGAAAGTCACCC 1

RESULT 23

US-10-024-369-23/c
; Sequence 23, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-23

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 425 TCAGTATGCGCGGCACTG 444
| | | | |
Db 20 TCAGTATGCGCGGCACTG 1

RESULT 24

US-10-024-369-24/c
; Sequence 24, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-24

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 436 GCGGCACTGCGCGGCAAGC 455
| | | | |
Db 20 GCGGCACTGCGCGGCAAGC 1

RESULT 25

US-10-024-369-25/c
; Sequence 25, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler

; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-25

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 459 GTGGCAACAACTCGGAGCC 478
| | | | |
Db 20 GTGGCAACAACTCGGAGCC 1

RESULT 26
US-10-024-369-26/c
; Sequence 26, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler

; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-26

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 AGCCTGTGGGTGCCCGCG 494
| | | | |
Db 20 AGCCTGTGGGTGCCCGCG 1

RESULT 27

US-10-024-369-27/c
; Sequence 27, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-27

```
Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      620 TTACGGCGCCCTCACTGAC 639
      |||
      20 TTACGGCGCCCTCACTGAC 1

RESULT 28
US-10-024-369-28/c
; Sequence 28, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-28

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      644 TTCTACAGATGCTCAGCC 663
      |||
      20 TTCTACAGATGCTCAGCC 1

RESULT 29
US-10-024-369-29/c
; Sequence 29, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-29

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      649 CAAGATGCTCAGCCGATAC 668
      |||
      20 CAAGATGCTCAGCCGATAC 1

RESULT 30
US-10-024-369-30/c
; Sequence 30, Application US/10024369
; Publication No. US20030134809A1

; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-30

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      672 CACTCGAACTTAACCTCA 691
      |||
      20 CACTCGAACTTAACCTCA 1

RESULT 31
US-10-024-369-31/c
; Sequence 31, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-31

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      714 TGCAGTGTGAGTTGCTGG 733
      |||
      20 TGCAGTGTGAGTTGCTGG 1

RESULT 32
US-10-024-369-32/c
; Sequence 32, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```


FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-32

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 740 GGATCTATACACACCCTG 759
DB 20 GGATCTATACACACCCTG 1

RESULT 33
US-10-024-369-33/c
Sequence 33, Application US/10024369
Publication No. US20030134809A1
GENERAL INFORMATION:
APPLICANT: Alexander H. Borchers
APPLICANT: Donna T. Ward
APPLICANT: Susan M. Freier
TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
FILE REFERENCE: RTS-0353
CURRENT APPLICATION NUMBER: US/10/024,369
CURRENT FILING DATE: 2001-12-17
NUMBER OF SEQ ID NOS: 91
SEQ ID NO 33
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-33

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 776 ACTTGACGGAGAGGTGTTT 795
DB 20 ACTTGACGGAGAGGTGTTT 1

RESULT 34
US-10-024-369-34/c
Sequence 34, Application US/10024369
Publication No. US20030134809A1
GENERAL INFORMATION:
APPLICANT: Alexander H. Borchers
APPLICANT: Donna T. Ward
APPLICANT: Susan M. Freier
TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
FILE REFERENCE: RTS-0353
CURRENT APPLICATION NUMBER: US/10/024,369
CURRENT FILING DATE: 2001-12-17
NUMBER OF SEQ ID NOS: 91
SEQ ID NO 34
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-34

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 839 AGACAGGAACATCATGTCCT 858
DB 20 AGACAGGAACATCATGTCCT 1

RESULT 35
US-10-024-369-35/c
Sequence 35, Application US/10024369
Publication No. US20030134809A1
GENERAL INFORMATION:
APPLICANT: Alexander H. Borchers
APPLICANT: Donna T. Ward
APPLICANT: Susan M. Freier
TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
FILE REFERENCE: RTS-0353
CURRENT APPLICATION NUMBER: US/10/024,369
CURRENT FILING DATE: 2001-12-17
NUMBER OF SEQ ID NOS: 91
SEQ ID NO 35
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-35

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 847 AACATCATGTCGCGGTAC 866
DB 20 AACATCATGTCGCGGTAC 1

RESULT 36
US-10-024-369-36/c
Sequence 36, Application US/10024369
Publication No. US20030134809A1
GENERAL INFORMATION:
APPLICANT: Alexander H. Borchers
APPLICANT: Donna T. Ward
APPLICANT: Susan M. Freier
TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
FILE REFERENCE: RTS-0353
CURRENT APPLICATION NUMBER: US/10/024,369
CURRENT FILING DATE: 2001-12-17
NUMBER OF SEQ ID NOS: 91
SEQ ID NO 36
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-36

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 866 CAGAGACAGTCACCCCTG 885
DB 20 CAGAGACAGTCACCCCTG 1

RESULT 37
US-10-024-369-37/c
Sequence 37, Application US/10024369
Publication No. US20030134809A1
GENERAL INFORMATION:
APPLICANT: Alexander H. Borchers
APPLICANT: Donna T. Ward
APPLICANT: Susan M. Freier
TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
FILE REFERENCE: RTS-0353
CURRENT APPLICATION NUMBER: US/10/024,369
CURRENT FILING DATE: 2001-12-17
NUMBER OF SEQ ID NOS: 91

```
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-37

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      871 GACACGTCACCCCTGAGTGA 890
Db      20 GACACGTCACCCCTGAGTGA 1

RESULT 38
US-10-024-369-38/C
; Sequence 38, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-38

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      899 GTGAGATCTGAGCTTATT 918
Db      20 GTGAGATCTGAGCTTATT 1

RESULT 39
US-10-024-369-39/C
; Sequence 39, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-39

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      915 ATTTCTGTGTAAGCTGTGC 934
```

```
Db      20 ATTTCTGTGTAAGCTGTGC 1

RESULT 40
US-10-024-369-40/C
; Sequence 40, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-40

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      920 TGTGTACTGTCGCGAGGC 939
Db      20 TGTGTACTGTCGCGAGGC 1

RESULT 41
US-10-024-369-41/C
; Sequence 41, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-41

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      936 AGGCTATGTCCTCTGGGGA 955
Db      20 AGGCTATGTCCTCTGGGGA 1

RESULT 42
US-10-024-369-42/C
; Sequence 42, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
```

FILE REFERENCE: RTS-0353
CURRENT APPLICATION NUMBER: US/10/024,369
CURRENT FILING DATE: 2001-12-17
NUMBER OF SEQ ID NOS: 91
SEQ ID NO 42
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-42

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 953 GGATCATGCTCTGGGGATCA 972
DB 20 GGATCATGCTCTGGGGATCA 1

RESULT 43
US-10-024-369-43/c
Sequence 43, Application US/10024369
Publication No. US20030134809A1
GENERAL INFORMATION:
APPLICANT: Alexander H. Borchers
APPLICANT: Donna T. Ward
TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
FILE REFERENCE: RTS-0353
CURRENT APPLICATION NUMBER: US/10/024,369
CURRENT FILING DATE: 2001-12-17
NUMBER OF SEQ ID NOS: 91
SEQ ID NO 43
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-43

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 962 TCTGGGATCAGTGTCCCTC 981
DB 20 TCTGGGATCAGTGTCCCTC 1

RESULT 44
US-10-024-369-44/c
Sequence 44, Application US/10024369
Publication No. US20030134809A1
GENERAL INFORMATION:
APPLICANT: Alexander H. Borchers
APPLICANT: Donna T. Ward
TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
FILE REFERENCE: RTS-0353
CURRENT APPLICATION NUMBER: US/10/024,369
CURRENT FILING DATE: 2001-12-17
NUMBER OF SEQ ID NOS: 91
SEQ ID NO 44
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-44

Query Match 0.9%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 969 ATCAGTGTCCCTCACCATTGG 988
DB 20 ATCAGTGTCCCTCACCATTGG 1

RESULT 45
US-10-024-369-45/c
Sequence 45, Application US/10024369
Publication No. US20030134809A1
GENERAL INFORMATION:
APPLICANT: Alexander H. Borchers
APPLICANT: Donna T. Ward
TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
FILE REFERENCE: RTS-0353
CURRENT APPLICATION NUMBER: US/10/024,369
CURRENT FILING DATE: 2001-12-17
NUMBER OF SEQ ID NOS: 91
SEQ ID NO 45
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-45

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 979 CTCACCATGTGTACCCCTGAT 998
DB 20 CTCACCATGTGTACCCCTGAT 1

RESULT 46
US-10-024-369-46/c
Sequence 46, Application US/10024369
Publication No. US20030134809A1
GENERAL INFORMATION:
APPLICANT: Alexander H. Borchers
APPLICANT: Donna T. Ward
TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
FILE REFERENCE: RTS-0353
CURRENT APPLICATION NUMBER: US/10/024,369
CURRENT FILING DATE: 2001-12-17
NUMBER OF SEQ ID NOS: 91
SEQ ID NO 46
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-46

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 995 TGATCACCTGTGCTTGCTT 1014
DB 20 TGATCACCTGTGCTTGCTT 1

RESULT 47
US-10-024-369-47/c
Sequence 47, Application US/10024369
Publication No. US20030134809A1
GENERAL INFORMATION:

```
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-47

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1018 CTTCTGCCCAAGAGTGG 1037
Db 20 CTTCTGCCCAAGAGTGG 1

RESULT 48
US-10-024-369-48/c
; Sequence 48, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-48

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1028 AGAAGGTGGAAATGTGATC 1047
Db 20 AGAAGGTGGAAATGTGATC 1

RESULT 49
US-10-024-369-49/c
; Sequence 49, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-49

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1033 GTGGGAAATGTGACAGTT 1052
Db 20 GTGGGAAATGTGACAGTT 1

RESULT 50
US-10-024-369-50/c
; Sequence 50, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-50

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 ATGGTACCACTGTGTGAAG 1060
Db 20 ATGGTACCACTGTGTGAAG 1

RESULT 51
US-10-024-369-51/c
; Sequence 51, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-51

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1045 TACCAGTTGCTGGAAGTGA 1064
Db 20 TACCAGTTGCTGGAAGTGA 1

RESULT 52
```

```
US-10-024-369-52/c
; Sequence 52, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-52

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1078 CTGCGAAGTCCAGCAGT 1097
DB      20 CTGCGAAGTCCAGCAGT 1

RESULT 53
US-10-024-369-53/c
; Sequence 53, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-53

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1086 GTCCAGCAGTGGCATTG 1105
DB      20 GTCCAGCAGTGGCATTG 1

RESULT 54
US-10-024-369-54/c
; Sequence 54, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 54

US-10-024-369-55/c
; Sequence 55, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-55

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1101 CATTGAGCTCTGTGCGCCA 1120
DB      20 CATTGAGCTCTGTGCGCCA 1

RESULT 55
US-10-024-369-55/c
; Sequence 55, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-55

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1109 CTGTGTGGCCATGCTTACA 1128
DB      20 CTGTGTGGCCATGCTTACA 1

RESULT 56
US-10-024-369-56/c
; Sequence 56, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-56

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1123 CTTACAGTTGGAAGCTTTGC 1142
DB      20 CTTACAGTTGGAAGCTTTGC 1142
```

```
Db      20 CCTACAGTTGCAAGCTTTGC 1

RESULT 57
US-10-024-369-57/c
; Sequence 57, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RRS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-57

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1131 TCGAAGCTTGGCCAAACGAGG 1150
Db      20 TCGAAGCTTGGCCAAACGAGG 1

RESULT 58
US-10-024-369-58/c
; Sequence 58, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RRS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-58

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1157 AAGCCGAGAGTTAGGGA 1176
Db      20 AAGCCGAGAGTTAGGGA 1

RESULT 59
US-10-024-369-59/c
; Sequence 59, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RRS-0353

Db      20 GGCCTATGACGTCACTCT 1

OY      1218 GGCCTATGACGTCACTCT 1237
Db      20 GGCCTATGACGTCACTCT 1

RESULT 60
US-10-024-369-60/c
; Sequence 60, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RRS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-60

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1274 GAATCCTCTACATTGTGGG 1293
Db      20 GAATCCTCTACATTGTGGG 1

RESULT 61
US-10-024-369-61/c
; Sequence 61, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RRS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-61

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
```

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1345 CTCACGAGTGCAGTTCAC 1364
|||||
Db 20 CTCACGAGTGCAGTTCAC 1

RESULT 62
US-10-024-369-62/C
; Sequence 62, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Susan M. Freier
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-62

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1378 GTACTGCTCCCACTACCC 1397
|||||
Db 20 GTACTGCTCCCACTACCC 1

RESULT 63
US-10-024-369-63/C
; Sequence 63, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Susan M. Freier
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-63

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1424 CAGAGAAATTTGAGTAC 1443
|||||
Db 20 CAGAGAAATTTGAGTAC 1

RESULT 64
US-10-024-369-64/C
; Sequence 64, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers

APPLICANT: Donna T. Ward
APPLICANT: Susan M. Freier
TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
FILE REFERENCE: RTS-0353
CURRENT APPLICATION NUMBER: US/10/024,369
CURRENT FILING DATE: 2001-12-17
NUMBER OF SEQ ID NOS: 91
SEQ ID NO 64
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-64

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1431 AATATTGAGTACCTGACC 1450
|||||
Db 20 AATATTGAGTACCTGACC 1

RESULT 65
US-10-024-369-65/C
; Sequence 65, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Susan M. Freier
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-65

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1473 TGGTCTGTGACCTCCCTTAC 1492
|||||
Db 20 TGGTCTGTGACCTCCCTTAC 1

RESULT 66
US-10-024-369-66/C
; Sequence 66, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Susan M. Freier
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide

US-10-024-369-66

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1481 TGACTCCCTTACCTTGAG 1500

Db 20 TGACTCCCTTACCTTGAG 1

RESULT 67

US-10-024-369-67/c

; Sequence 67, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-67

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1506 TGTCAGTTCAGATGTCT 1525

Db 20 TGTCAGTTCAGATGTCT 1

RESULT 68

US-10-024-369-68/c

; Sequence 68, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-68

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1521 TGTCCTTTGCGCTACCCAA 1540

Db 20 TGTCCTTTGCGCTACCCAA 1

RESULT 69

US-10-024-369-69/c

; Sequence 69, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-69

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1537 CCAACCGCCGATGTCTT 1556

Db 20 CCAACCGCCGATGTCTT 1

RESULT 70

US-10-024-369-70/c

; Sequence 70, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-70

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1743 GGCTGAGTGGGCAAGAGC 1762

Db 20 GGCTGAGTGGGCAAGAGC 1

RESULT 71

US-10-024-369-71/c

; Sequence 71, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 71
; LENGTH: 20


```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-71
```

```
Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1756 CAAGAGCCACAGGTATTGG 1775
      |||
Db       20 CAAGAGCCACAGGTATTGG 1
```

```
RESULT 72
US-10-024-369-72/C
; Sequence 72, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-72
```

```
Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1773 TGGAGAAGTCTTCAGAAA 1792
      |||
Db       20 TGGAGAAGTCTTCAGAAA 1
```

```
RESULT 73
US-10-024-369-73/C
; Sequence 73, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 73
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-73
```

```
Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1810 ACCCAGAAGCCAACTATGGA 1829
      |||
Db       20 ACCCAGAAGCCAACTATGGA 1
```

```
RESULT 74
US-10-024-369-74/C
; Sequence 74, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-74
```

```
Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1824 TATGAGAAATCAGACTG 1843
      |||
Db       20 TATGAGAAATCAGACTG 1
```

```
RESULT 75
US-10-024-369-75/C
; Sequence 75, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-75
```

```
Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1842 TGCTGAGTAAGTCTGGGG 1861
      |||
Db       20 TGCTGAGTAAGTCTGGGG 1
```

```
RESULT 76
US-10-024-369-76/C
; Sequence 76, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
```

```
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-76

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1871 TCATCTCTGAGACTCCCTCAG 1890
Db      20 TCATCTCTGAGACTCCCTCAG 1

RESULT 77
US-10-024-369-77/c
; Sequence 77, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-77

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1879 GGACTCCCTCAGGGCTATGA 1898
Db      20 GGACTCCCTCAGGGCTATGA 1

RESULT 78
US-10-024-369-78/c
; Sequence 78, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-78

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1885 CCTCAGGGCTATGACACAGA 1904
Db      20 CCTCAGGGCTATGACACAGA 1

RESULT 79
US-10-024-369-79/c
; Sequence 79, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 79
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-79

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1978 AAACCGTGTGTACTTATCT 1997
Db      20 AAACCGTGTGTACTTATCT 1

RESULT 80
US-10-024-369-80/c
; Sequence 80, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-80

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1988 TACTTATCTGATGATGCC 2007
Db      20 TACTTATCTGATGATGCC 1

RESULT 81
US-10-024-369-81/c
; Sequence 81, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
```

```

; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 81
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-81

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2003 ATGCCACGAGTCCCTGGAT 2022
Db      20 ATGCCACGAGTCCCTGGAT 1

RESULT 82
US-10-024-369-82/c
; Sequence 82, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 82
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-82

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2020 GATGCAACAGCCGTTACA 2039
Db      20 GATGCAACAGCCGTTACA 1

RESULT 83
US-10-024-369-83/c
; Sequence 83, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-83
```

```

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2041 GTGAGCAGCTCCTGTACGA 2060
Db      20 GTGAGCAGCTCCTGTACGA 1

RESULT 84
US-10-024-369-84/c
; Sequence 84, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-84

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2059 GAAAGCCTGAGCGTACTC 2078
Db      20 GAAAGCCTGAGCGTACTC 1

RESULT 85
US-10-024-369-85/c
; Sequence 85, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 85
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-85

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2073 GTACTCCGCTCAGTGTTC 2092
Db      20 GTACTCCGCTCAGTGTTC 1

RESULT 86
US-10-024-369-86/c
; Sequence 86, Application US/10024369
```

```
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 86
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-86

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2106 CCTCAGCCTGTGTGAGCAGG 2125
Db      20 CCTCAGCCTGTGTGAGCAGG 1

RESULT 87
US-10-024-369-87/c
; Sequence 87, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 87
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-87

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2228 CTGCAGATGCTCCGAGATGA 2247
Db      20 CTGCAGATGCTCCGAGATGA 1

RESULT 88
US-10-010-920-65
; Sequence 65, Application US/10010920
; Publication No. US20030027165A1
; GENERAL INFORMATION:
; APPLICANT: Saus, Juan
; TITLE OF INVENTION: Alternatively spliced polk nucleotide and amino acid sequences
; FILE REFERENCE: 98,723-E3
; CURRENT APPLICATION NUMBER: US/10/010,920
; CURRENT FILING DATE: 2001-12-07
; PRIOR APPLICATION NUMBER: 60/254,649
; PRIOR FILING DATE: 2000-12-08
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 65
```

```
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer ON-TAP1-F2
US-10-010-920-65

Query Match      0.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      626 GCCGCTCACTGACTGAT 644
Db      1 GCCGCTCACTGACTGAT 19

RESULT 89
US-10-008-721-65
; Sequence 65, Application US/10008721
; Publication No. US20030082745A1
; GENERAL INFORMATION:
; APPLICANT: Saus, Juan
; TITLE OF INVENTION: TNF-Inducible Promoters and Methods for Using
; FILE REFERENCE: 98,723-E1
; CURRENT APPLICATION NUMBER: US/10/008,721
; CURRENT FILING DATE: 2001-12-07
; PRIOR APPLICATION NUMBER: 60/254,649
; PRIOR FILING DATE: 2000-12-08
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 65
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer ON-TAP1-F2
US-10-008-721-65

Query Match      0.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      626 GCCGCTCACTGACTGAT 644
Db      1 GCCGCTCACTGACTGAT 19

RESULT 90
US-10-383-864-24/c
; Sequence 24, Application US/10383864
; Publication No. US20040081976A1
; GENERAL INFORMATION:
; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
; APPLICANT: SIDRANSKY, David
; TITLE OF INVENTION: GENOMIC SCREEN FOR EPIGENETICALLY SILENCED TUMOR SUPPRESSOR GENES
; FILE REFERENCE: JHU1860-1
; CURRENT APPLICATION NUMBER: US/10/383,864
; CURRENT FILING DATE: 2003-07-25
; PRIOR APPLICATION NUMBER: US 60/362,577
; PRIOR FILING DATE: 2002-03-07
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 24
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-383-864-24

Query Match      0.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 2016 CCGATGCAACAGCCAG 2034
Db 19 CCGATGCAACAGCCAG 1

RESULT 91
US-09-938-689-59
; Sequence 59. Application US/09938689
; Publication No. US20030028911A1
; GENERAL INFORMATION:
; APPLICANT: Huang, Manley
; APPLICANT: Harding, Fiona
; TITLE OF INVENTION: TRANSGENIC MAMMAL CAPABLE OF FACILITATING PRODUCTION OF
; TITLE OF INVENTION: DONOR-SPECIFIC FUNCTIONAL IMMUNITY
; FILE REFERENCE: 9342-028
; CURRENT APPLICATION NUMBER: US/09/938,689
; CURRENT FILING DATE: 2001-08-23
; PRIOR APPLICATION NUMBER: 09/651,361
; PRIOR FILING DATE: 2000-08-30
; PRIOR APPLICATION NUMBER: 60/151,688
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 59
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: PCR primer
US-09-938-689-59

Query Match 0.8%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 879 CACCCTGAGTGTCTCT 896
Db 1 CACCCTGAGTGTCTCT 18

RESULT 92
US-10-383-864-23
; Sequence 23. Application US/10383864
; Publication No. US20040081976A1
; GENERAL INFORMATION:
; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
; APPLICANT: SIDRANSKY, David
; TITLE OF INVENTION: GENOMIC SCREEN FOR EPIGENETICALLY SILENCED TUMOR SUPPRESSOR GENES
; FILE REFERENCE: JHU1860-1
; CURRENT APPLICATION NUMBER: US/10/383,864
; CURRENT FILING DATE: 2003-07-25
; PRIOR APPLICATION NUMBER: US 60/362,577
; PRIOR FILING DATE: 2002-03-07
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 23
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-383-864-23

Query Match 0.8%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 CAGATCTGTACCGCC 1671
Db 1 CAGATCTGTACCGCC 18

RESULT 93
US-10-092-900A-550
; Sequence 550. Application US/10092900A
; Publication No. US20040043382A1
; GENERAL INFORMATION:
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Spytek, Kimberly A.
; APPLICANT: Shenoy, Suresh G.
; APPLICANT: Taupier Jr., Raymond J.
; APPLICANT: Pena, Carol E.A.
; APPLICANT: Li, Li
; APPLICANT: Zernhusen, Bryan D.
; APPLICANT: Gusev, Vladimir Y.
; APPLICANT: Ji, Weizhen
; APPLICANT: Gorman, Linda
; APPLICANT: Miller, Charles E.
; APPLICANT: Kekuda, Ramesh
; APPLICANT: Patturajan, Meera
; APPLICANT: Gangolli, Baha A.
; APPLICANT: Verneet, Corine A.M.
; APPLICANT: Guo, Xiaojia Saeha
; APPLICANT: Tchernev, Vellizar T.
; APPLICANT: Fernandes, Elma R.
; APPLICANT: Casman, Stacie J.
; APPLICANT: Malyankar, Uriel M.
; APPLICANT: Gerlach, Valerie
; APPLICANT: Liu, Yi
; APPLICANT: Anderson, David W.
; APPLICANT: Spaderne, Steven K.
; APPLICANT: Catterton, Elina
; APPLICANT: Leite, Mario W.
; APPLICANT: Zhong, Haihong
; APPLICANT: Alsobrook, John P.
; APPLICANT: Lepley, Denise M.
; APPLICANT: Rieger, Daniel K.
; APPLICANT: Burgess, Catherine E.
; TITLE OF INVENTION: No. US20040043382A1el Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-290C
; CURRENT APPLICATION NUMBER: US/10/092,900A
; CURRENT FILING DATE: 2002-03-07
; PRIOR APPLICATION NUMBER: USN 60/274,322
; PRIOR FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: USN 60/283,675
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: USN 60/338,092
; PRIOR FILING DATE: 2001-12-03
; PRIOR APPLICATION NUMBER: USN 60/274,281
; PRIOR FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: USN 60/274,191
; PRIOR FILING DATE: 2001-03-08
; PRIOR APPLICATION NUMBER: USN 60/325,681
; PRIOR FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: USN 60/304,354
; PRIOR FILING DATE: 2001-07-10
; PRIOR APPLICATION NUMBER: USN 60/279,995
; PRIOR FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: USN 60/294,899
; PRIOR FILING DATE: 2001-05-31
; PRIOR APPLICATION NUMBER: USN 60/287,424
; PRIOR FILING DATE: 2001-04-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 768
; SEQ ID NO 550
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Forward Primer
US-10-092-900A-550

Query Match 0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 42;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY	1259	TGCTGTGAAGTGGGAATC	1278
Dd	1	TGTCCTGAAGTGAATC	20

```

RESULT/ 94
US-10-136-942-2/c
; Sequence 2, Application us/10136942
; Publication No. US20030049656A1
; GENERAL INFORMATION:
; APPLICANT: Avogenics, Inc
; TITLE OF INVENTION: High Throughput Screening Assay for Detecting a DNA Sequence
; FILE REFERENCE: A181 1020
; CURRENT APPLICATION NUMBER: us/10/136,942
; CURRENT FILING DATE: 2002-05-02
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer chGAPDH-2
; US-10-136-942-2

```

Query Match	0.7%;	Score 16;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 64;		
Matches 16;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

Qy	1075	TCTCTGGCAAAGTCCA	1090
Db	21	TCTCTGGCAAAGTCCA	6

```

RESULT 95
US-09-813-824A-40
Sequence 40, Application US/09813824A
Patent No. US20020164599A1
GENERAL INFORMATION:
APPLICANT: Vogelstein, Bert
Kinzler, Kenneth
Sherman, Michael
TITLE OF INVENTION: SEQUENCE SPECIFIC DNA BINDING
BY P53
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Banner & Witcoff
STREET: 1001 G Street, NW
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20001
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/813.824A
FILING DATE: 22-Mar-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/860,758
FILING DATE: 31-MAR-1992
APPLICATION NUMBER: 07/715,182
FILING DATE: 14-JUN-1991
ATTORNEY/AGENT INFORMATION:
NAME: Kagan, Sarah A
REGISTRATION NUMBER: 32141
REFERENCE/DOCKET NUMBER: 01107.47071
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-508-9100

```

```

? TELEFAX: Unknown> 9299
? TELEX: <Unknown>
? INFORMATION FOR SEQ ID NO: 40:
?     SEQUENCE CHARACTERISTICS:
?         LENGTH: 19 base pairs
?         TYPE: nucleic acid
?         STRANDEDNESS: single
?         TOPOLOGY: linear
?     SEQUENCE DESCRIPTION: SEQ ID NO: 40:
? US-09-813-624A-40

```

Query Match	0.7%	Score 15.8;	DB 1;	Length 19;
Best Local Similarity	89.5%;	Pred. No. 65;		
Matches 17; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

QY 318 CCTGCCGGACTTGCCTTG 336
 |||||
Db 1 CTGCGTGGACTTGCCTGG 19

```

RESULT 96
US-10-648-512-60
; Sequence 60, Application US/10648512
; Publication NO. US20040096922A1
; GENERAL INFORMATION:
; APPLICANT: Hildebrandt, Friedhelm
; APPLICANT: Otto, Edgar
; APPLICANT: Hoeftle, Julia
; APPLICANT:
; APPLICANT: Ruf, Rainer
; APPLICANT: Mueller, Adelheid M.
; APPLICANT: Hiller, Karl S.
; APPLICANT: Wolf, Matthias T.F.
; APPLICANT: Schuermann, Maria J.
; APPLICANT: Becker, Achim
; TITLE OF INVENTION: NPHX Nucleic Acids and Proteins
; FILE REFERENCE: WO-0833
; CURRENT APPLICATION NUMBER: US/10/648,512
; CURRENT FILING DATE: 2003-08-26
; NUMBER OF SEQ. ID NOS: 102
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 60
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
; US-10-648-512-60

```

Query Match	0.7%	Score 15.8;	DB 1;	Length 19;
Best Local Similarity	89.5%	Pred. No. 65;		
Matches 17; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

Qy 1635 CACAGTGGCTGCCCTGCTG 1653
|||||
Db 1 CACAGTGGCTTTCCTGCTG 19

```

RESULT 97
US-10-369-378-36
; Sequence 36, Application US/10369378
; Publication No. US20030170859A1
; GENERAL INFORMATION:
; APPLICANT: Christenson, Erik
; APPLICANT: Demaggio, Anthony J
; APPLICANT: Goldman, Phyllis S
; APPLICANT: McElligott, David L
; TITLE OF INVENTION: Human Poly (ADP-Ribose) Polymerase 2 Materials and
; TITLE OF INVENTION: Methods
; FILE REFERENCE: 27866/36544
; CURRENT APPLICATION NUMBER: US/10/369,378
; CURRENT FILING DATE: 2003-02-19
; PRIOR APPLICATION NUMBER: US/09/596,248D
; PRIOR FILING DATE: 2000-06-16

```

```
; PRIOR APPLICATION NUMBER: 60/139,543
; PRIOR FILING DATE: 1999-06-16
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: Patentn Ver. 2.1
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-369-378-36

Query Match          0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 68;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1193 AGACACTCAACCGAGAGA 1211
Db      2 AGACACCCCAACCGAGAGA 20

RESULT 98
US-10-369-378-37/c
; Sequence 37, Application US/10369378
; Publication No. US20030170859A1
; GENERAL INFORMATION:
; APPLICANT: Christenson, Erik
; APPLICANT: Demaggio, Anthony J
; APPLICANT: Goldman, Phyllis S
; APPLICANT: McElligott, David L
; TITLE OF INVENTION: Human Poly(ADP-Ribose) Polymerase 2 Materials and
; FILE REFERENCE: 27866/36544
; CURRENT APPLICATION NUMBER: US/10/369,378
; CURRENT FILING DATE: 2003-02-19
; PRIOR APPLICATION NUMBER: US/09/596,248D
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/139,543
; PRIOR FILING DATE: 1999-06-16
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: Patentn Ver. 2.1
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-369-378-37

Query Match          0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 68;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1193 AGACACTCAACCGAGAGA 1211
Db      19 AGACACCCCAACCGAGAGA 1

RESULT 99
US-10-199-937-171
; Sequence 171, Application US/10199937
; Publication No. US20030190739A1
; GENERAL INFORMATION:
; APPLICANT: Christenson, Erik
; APPLICANT: Demaggio, Anthony J
; APPLICANT: Goldman, Phyllis S
; APPLICANT: McElligott, David L
; TITLE OF INVENTION: TANKYRASE2 MATERIALS AND METHODS
; FILE REFERENCE: 27866/36559
; CURRENT APPLICATION NUMBER: US/10/199,937
; CURRENT FILING DATE: 2002-07-22
; PRIOR APPLICATION NUMBER: US/09/606,035
; PRIOR FILING DATE: 2000-06-28
```

```
; PRIOR APPLICATION NUMBER: 60/141,582
; PRIOR FILING DATE: 1999-06-29
; NUMBER OF SEQ ID NOS: 178
; SOFTWARE: Patentn Ver. 2.0
; SEQ ID NO 171
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-199-937-171

Query Match          0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 68;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1193 AGACACTCAACCGAGAGA 1211
Db      2 AGACACCCCAACCGAGAGA 20

RESULT 100
US-10-199-937-172/c
; Sequence 172, Application US/10199937
; Publication No. US20030190739A1
; GENERAL INFORMATION:
; APPLICANT: Christenson, Erik
; APPLICANT: Demaggio, Anthony J
; APPLICANT: Goldman, Phyllis S
; APPLICANT: McElligott, David L
; TITLE OF INVENTION: TANKYRASE2 MATERIALS AND METHODS
; FILE REFERENCE: 27866/36559
; CURRENT APPLICATION NUMBER: US/10/199,937
; CURRENT FILING DATE: 2002-07-22
; PRIOR APPLICATION NUMBER: US/09/606,035
; PRIOR FILING DATE: 2000-06-28
; PRIOR APPLICATION NUMBER: 60/141,582
; PRIOR FILING DATE: 1999-06-29
; NUMBER OF SEQ ID NOS: 178
; SOFTWARE: Patentn Ver. 2.0
; SEQ ID NO 172
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-199-937-172

Query Match          0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 68;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1193 AGACACTCAACCGAGAGA 1211
Db      19 AGACACCCCAACCGAGAGA 1

RESULT 101
US-09-817-014-68
; Sequence 68, Application US/09817014
; Patent No. US20020106646A1
; GENERAL INFORMATION:
; APPLICANT: Remacle, Jose
; APPLICANT: Hamels, Sandrine
; APPLICANT: Zammatteo, Nathalie
; APPLICANT: Lockman, Laurence
; APPLICANT: Dufour, Sophie
; APPLICANT: Alexandre, Isabelle
; APPLICANT: De Longueville, Francoise
; TITLE OF INVENTION: IDENTIFICATION OF BIOLOGICAL
; TITLE OF INVENTION: (MICRO)ORGANISMS BY DETECTION OF THEIR HOMOLOGOUS NUCLEOTIDE
; FILE REFERENCE: VANM213.001AUS
```

```

; CURRENT APPLICATION NUMBER: US/09/817,014
; CURRENT FILING DATE: 2001-03-23
; PRIOR APPLICATION NUMBER: EP 00870055.1
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: EP 00870204.5
; PRIOR FILING DATE: 2000-09-15
; NUMBER OF SEQ ID NOS: 192
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 68
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Mycobacterium marinum capture probe
; US-09-817-014-68

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1594 GAGGTGACGGCGCTGCTG 1612
Db      3 GAGGTGATGGCGCTGCTG 21

RESULT 102
US-10-074-246-21
; Sequence 21, Application US/10074246
; Publication No. US20030027174A1
; GENERAL INFORMATION:
; APPLICANT: Universit  Catholique de Louvain
; TITLE OF INVENTION: Identification of nucleotide sequences specific for mycobacterial
; TITLE OF INVENTION: pseudomonas species, development of differential diagnosis strat
; FILE REFERENCE: UCL-021-US
; CURRENT APPLICATION NUMBER: US/10/074,246
; CURRENT FILING DATE: 2002-02-14
; PRIOR APPLICATION NUMBER: US 60/269,848
; PRIOR FILING DATE: 2001-02-21
; PRIOR APPLICATION NUMBER: US 60/292,509
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: EP 01870030.2
; PRIOR FILING DATE: 2001-02-19
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 21
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Mycobacterium marinum
; US-10-074-246-21

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1594 GAGGTGACGGCGCTGCTG 1612
Db      3 GAGGTGATGGCGCTGCTG 21

RESULT 103
US-10-184-085A-855/c
; Sequence 855, Application US/10184085A
; Publication No. US20030152950A1
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Minna, John D.
; APPLICANT: Luebke, Kevin, J.
; APPLICANT: Balogh, Robert P.
; TITLE OF INVENTION: Identification of Chemically Modified Polymers
; FILE REFERENCE: 119929-1035
; CURRENT APPLICATION NUMBER: US/10/184,085A
; CURRENT FILING DATE: 2002-10-01
```

```

; PRIOR APPLICATION NUMBER: US 60/301,370
; PRIOR FILING DATE: 2001-06-27
; NUMBER OF SEQ ID NOS: 1291
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 855
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-184-085A-855

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      783 GGGAGAGGTGTTGGGGCT 801
Db      19 GGGAGAGGTGTTGGCGGCT 1

RESULT 104
US-10-056-229-68
; Sequence 68, Application US/10056229
; Publication No. US20030198943A1
; GENERAL INFORMATION:
; APPLICANT: Remacle, Jose
; APPLICANT: Hamels, Sandrine
; APPLICANT: Zammateo, Nathalie
; APPLICANT: Lockman, Laurence
; APPLICANT: Dufour, Sophie
; APPLICANT: Alexandre, Isabelle
; APPLICANT: De Longueville, Francoise
; TITLE OF INVENTION: IDENTIFICATION OF A LARGE NUMBER OF
; TITLE OF INVENTION: BIOLOGICAL (MICRO)ORGANISMS GROUPS AT DIFFERENT
; FILE REFERENCE: VANM213.001CPI
; CURRENT APPLICATION NUMBER: US/10/056,229
; CURRENT FILING DATE: 2002-01-23
; PRIOR APPLICATION NUMBER: EP 00870055.1
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: EP 00870204.5
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: US 09/817,014
; PRIOR FILING DATE: 2001-03-23
; NUMBER OF SEQ ID NOS: 321
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 68
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Mycobacterium marinum capture probe
; US-10-056-229-68

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1594 GAGGTGACGGCGCTGCTG 1612
Db      3 GAGGTGATGGCGCTGCTG 21

RESULT 105
US-09-866-108-891/c
; Sequence 891, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
```



```

; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 891
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-891.

Query Match          0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 70;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1701 GCCCCTTCCCAATATG 1717
Db      17 GCCCCTTCCCACTATG 1

RESULT 106
US-09-866-108-892/c
; Sequence 892, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
```

```

; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 892
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-892

Query Match          0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 70;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1700 AGCCCTTCCCAATAT 1716
Db      17 AGCCCTTCCCACTAT 1

RESULT 107
US-09-866-108-893/c
; Sequence 893, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 893
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-893
```

```
Query Match 0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 70;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1699 AAGCCCTTCCCAATA 1715
Db 17 AAGCCCTTCCCACTA 1
```

```
RESULT 108
US-10-156-306-7105
; Sequence 7105, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7105
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7105
```

```
Query Match 0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 70;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 391 CTGCACCTGGGGAAGTCA 407
Db 1 CGGCACUGGGGAAGUCA 17
```

```
RESULT 109
US-09-969-373-4010
; Sequence 4010, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Efiertz, Roger J.
; APPLICANT: Hauege, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
```

```
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 4010
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-4010
```

```
Query Match 0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2219 TGCAAGCTCCTGCAGAT 2235
Db 2 TGCAAGCTCCTGCAGAT 18
```

```
RESULT 110
US-09-961-077-609
; Sequence 609, Application US/09961077
; Publication No. US20030014775A1
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; MODULATION OF GENE EXPRESSION
; IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/961,077
; FILING DATE: 21-Sep-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/679,645
; FILING DATE: July 12, 1996
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEEX: 67-3510
; INFORMATION FOR SEQ ID NO: 609:
```

SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 609:
US-09-961-077-609

Query Match 0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 74;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2178 CCAGACGCTCATGAGA 2194
Db 2 CCGCAGCUCACUGAGA 18

RESULT 111
US-09-752-983-8/c
Sequence 8, Application US/09752983
Patent No. US20010016575A1
GENERAL INFORMATION:
APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
APPLICANT: Graham, Brett P. Monia
TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
TITLE OF INVENTION: EXPRESSION
NUMBER OF SEQUENCES: 271
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: U.S.A.
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PC
OPERATING SYSTEM: WINDOWS 95
SOFTWARE: WORDPERFECT 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/752,983
FILING DATE: 02-Jan-2001
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/280,805
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Licata, Jane Massey
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0346
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-810-1515
TELEFAX: 609-810-1454
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-09-752-983-8

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 243 CTCGAAGCGGAAGCAG 262
Db 20 CTCGAAGCGGAAGCAG 1

RESULT 112
US-09-851-771A-8/c

Sequence 8, Application US/09851771A
Patent No. US200201511A1
GENERAL INFORMATION:

APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.

APPLICANT: Graham, Brett P. Monia

TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE
MODULATION OF HUMAN MDM2 EXPRESSION

NUMBER OF SEQUENCES: 32

CORRESPONDENCE ADDRESS:

ADDRESSEE: Law Offices of Jane Massey Licata

STREET: 66 East Main Street

CITY: Marlton

STATE: NJ

COUNTRY: U.S.A.

ZIP: 08053

COMPUTER READABLE FORM:

MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE

COMPUTER: IBM 486

OPERATING SYSTEM: WINDOWS FOR WORKGROUPS

SOFTWARE: WORDPERFECT 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/851,771A

FILING DATE: 09-May-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 09/048,810

FILING DATE: 1998-03-26

ATTORNEY/AGENT INFORMATION:

NAME: Licata, Jane Massey

REGISTRATION NUMBER: 32,257

REFERENCE/DOCKET NUMBER: ISPH-0302

TELECOMMUNICATION INFORMATION:

TELEPHONE: 609-779-2400

TELEFAX: 609-810-1454

INFORMATION FOR SEQ ID NO: 8:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs

TYPE: Nucleic Acid

STRANDEDNESS: Single

TOPOLOGY: Linear

ANTI-SENSE: Yes

SEQUENCE DESCRIPTION: SEQ ID NO: 8:

US-09-851-771A-8

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 243 CTCGAAGCGGAAGCAG 262
Db 20 CTCGAAGCGGAAGCAG 1

RESULT 113

US-09-774-809-57

Sequence 57, Application US/09774809

Publication No. US20030004120A1

GENERAL INFORMATION:

APPLICANT: McKay, Robert A.

APPLICANT: Dean, Nicholas M.

APPLICANT: Monia, Brett

APPLICANT: Nero, Pam

APPLICANT: Garde, William A.

TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS

TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS

FILE REFERENCE: ISPH-0412

CURRENT APPLICATION NUMBER: US/09/774,809

PRIOR FILING DATE: 2001-01-31

PRIOR APPLICATION NUMBER: 09/396,902

PRIOR FILING DATE: 1999-09-15

PRIOR APPLICATION NUMBER: 09/130,616

PRIOR FILING DATE: 1998-08-07

PRIOR APPLICATION NUMBER: 08/910,629

```
; PRIOR FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-774-809-57
```

```
Query Match          0.7%: Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy      167 GGGTCTGGCGCGTGGCGCTG 186
           ||||| ||||| ||||| |||||
Db      1 GGGTCTGGTGGTGGTGGACATG 20
```

```
RESULT 114
US-09-917-963-36/c
; Sequence 36, Application US/09917963
; Publication No. US20030086912A1
; GENERAL INFORMATION:
; APPLICANT: Rosanne M. Crooke
; APPLICANT: Mark J. Graham
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN
; FILE REFERENCE: ISPH-0591
; CURRENT APPLICATION NUMBER: US/09/917,963
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 137
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-917-963-36
```

```
Query Match          0.7%: Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy      146 CCACCGCGCTGCCACTGCTC 165
           ||||| ||||| ||||| |||||
Db      20 CCACCTGGCTACCACTGCTC 1
```

```
RESULT 115
US-10-345-444B-57
; Sequence 57, Application US/10345444B
; Publication No. US20040029823A1
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULA
; TITLE OF INVENTION: OF JNK PROTEINS
; FILE REFERENCE: ISPH-0726
; CURRENT APPLICATION NUMBER: US/10/345,444B
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/774,809
; PRIOR FILING DATE: 2001-01-31
; PRIOR APPLICATION NUMBER: US 09/396,902
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: US 09/287,796
; PRIOR FILING DATE: 1999-04-07
; PRIOR APPLICATION NUMBER: US 09/130,616
; PRIOR FILING DATE: 1998-08-07
; PRIOR APPLICATION NUMBER: US 08/910,629
```

```
; PRIOR FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 168
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-345-444B-57
```

```
Query Match          0.7%: Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy      167 GGGTCTGGCGCGTGGCGCTG 186
           ||||| ||||| ||||| |||||
Db      1 GGGTCTGGTGGTGGTGGACATG 20
```

```
RESULT 116
US-10-642-802-42/c
; Sequence 42, Application US/10642802
; Publication No. US20040043956A1
; GENERAL INFORMATION:
; APPLICANT: Mark J. Graham
; APPLICANT: Andrew T. Walt
; TITLE OF INVENTION: ANTISENSE MODULATION OF COMPLEMENT COMPONENT C3 EXPRESSION
; FILE REFERENCE: RFS-0329
; CURRENT APPLICATION NUMBER: US/10/642,802
; CURRENT FILING DATE: 2003-08-18
; PRIOR APPLICATION NUMBER: US/10/001,076
; PRIOR FILING DATE: 2001-10-23
; NUMBER OF SEQ ID NOS: 179
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-642-802-42
```

```
Query Match          0.7%: Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy      1348 TACCAGATGCAGTTCACCCA 1367
           ||||| ||||| ||||| |||||
Db      20 TACCAGATCCACTTCACCA 1
```

```
RESULT 117
US-09-759-999B-7
; Sequence 7, Application US/09759999B
; Publication No. US20020086838A1
; GENERAL INFORMATION:
; APPLICANT: OH, Chad
; APPLICANT: CHO, Seong
; APPLICANT: DEMISSIR-SANDERS, Sossiena
; APPLICANT: THOMAS, David
; APPLICANT: TAN, Sun
; TITLE OF INVENTION: Use of Antagonists of Plasminogen Activator Inhibitor-1 (PAI-1) Fr
; TITLE OF INVENTION: Treatment of Asthma and Chronic Obstructive Pulmonary Disease
; FILE REFERENCE: 65329.0107
; CURRENT APPLICATION NUMBER: US/09/759,999B
; CURRENT FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: US 60/176,211
; PRIOR FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: PAI reverse primer
US-09-759-999B-7

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      1460 GCTGCCACCCAGTGTCTG 1479
Db      1 GCTGTCCACCCGCTGCTCTG 20

RESULT 118
US-10-159-266-20/c
; Sequence 20, Application US/10159266
; Publication No. US20030224511A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CATHEPSIN Z EXPRESSION
; FILE REFERENCE: RTS-0398
; CURRENT APPLICATION NUMBER: US/10/159,266
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 158
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-159-266-20

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      66 GCTGGGACAGTACTGCTAC 85
Db      20 GCCGGGACAGACTGCTAC 1

RESULT 119
US-10-159-266-96
; Sequence 96, Application US/10159266
; Publication No. US20030224511A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CATHEPSIN Z EXPRESSION
; FILE REFERENCE: RTS-0398
; CURRENT APPLICATION NUMBER: US/10/159,266
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 158
; SEQ ID NO 96
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-159-266-96

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      66 GCTGGGACAGTACTGCTAC 85
Db      1 GCCGGGACAGACTGCTAC 20

RESULT 120
US-10-161-996-127/c
; Sequence 127, Application US/10161996
; Publication No. US20030224511A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Brenda F. Baker
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN
; FILE REFERENCE: RTS-0395
; CURRENT APPLICATION NUMBER: US/10/161,996
; CURRENT FILING DATE: 2002-06-04
; NUMBER OF SEQ ID NOS: 273
; SEQ ID NO 127
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-161-996-127

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      1875 CTCTGACTCCCTCAGGGCT 1894
Db      20 CTCTGACTCCTTCAGGGCT 1

RESULT 121
US-10-161-996-250
; Sequence 250, Application US/10161996
; Publication No. US20030224511A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Brenda F. Baker
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN
; FILE REFERENCE: RTS-0395
; CURRENT APPLICATION NUMBER: US/10/161,996
; CURRENT FILING DATE: 2002-06-04
; NUMBER OF SEQ ID NOS: 273
; SEQ ID NO 250
; LENGTH: 20
; TYPE: DNA
; ORGANISM: M. musculus
; FEATURE:
US-10-161-996-250

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      1875 CTCTGACTCCCTCAGGGCT 1894
Db      1 CTCTGACTCCTTCAGGGCT 20

RESULT 122
US-10-001-076-42/c
; Sequence 42, Application US/10001076
; Publication No. US20030096775A1
; GENERAL INFORMATION:
; APPLICANT: Mark J. Graham
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF COMPLEMENT COMPONENT C3 EXPRESSION
; FILE REFERENCE: RTS-0329
; CURRENT APPLICATION NUMBER: US/10/001,076
; CURRENT FILING DATE: 2001-10-23
; NUMBER OF SEQ ID NOS: 179
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-001-076-42

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      1348 TACCAGATGCAGTTCACCCA 1367
Db      20 TACCAGATCCACTTCACCCA 1

RESULT 123
US-10-145-493B-35/c
; Sequence 35, Application US/10145493B
; Publication No. US20030096777A1
; GENERAL INFORMATION:
; APPLICANT: Besterman, Jeffrey
; APPLICANT: MacLeod, Robert
; APPLICANT: Siders, William
; TITLE OF INVENTION: Modulation of Gene Expression by Combination Therapy
; FILE REFERENCE: MET-015DV
; CURRENT APPLICATION NUMBER: US/10/145,493B
; PRIOR FILING DATE: 2002-05-14
; PRIOR APPLICATION NUMBER: 09/420,692
; PRIOR FILING DATE: 1999-10-19
; PRIOR APPLICATION NUMBER: US 60/104,804
; PRIOR FILING DATE: 1998-10-19
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-145-493B-35

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      26 CCCGCGGTGCGCGCTGCTC 45
Db      20 CCCGCTGTGCTGCTGCTC 1

RESULT 124
US-10-006-191-72
; Sequence 72, Application US/10006191
; Publication No. US20030144223A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION
; FILE REFERENCE: RFS-0274
; CURRENT APPLICATION NUMBER: US/10/006,191
; CURRENT FILING DATE: 2001-12-10
; NUMBER OF SEQ ID NOS: 153
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-006-191-72

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      763 CACGTGCACAGCCACTTGCA 782
Db      1 CACGTGCAGTGTACTTGCA 20
```

```
Db      1 CACGTGCAGTGTACTTGCA 20

RESULT 125
US-10-005-344-8/c
; Sequence 8, Application US/10005344
; Publication No. US20030203862A1
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia
; APPLICANT: Pamela Nero
; APPLICANT: Mark J. Graham
; APPLICANT: Brett P. Montia
; APPLICANT: Erich Koller
; APPLICANT: Mingsi Chiang
; APPLICANT: Mano Manoharan
; TITLE OF INVENTION: Antisense Modulation of mdm2 expression.
; FILE REFERENCE: ISPH-0622
; CURRENT APPLICATION NUMBER: US/10/005,344
; CURRENT FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: US 09/048,810
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/280,805
; PRIOR FILING DATE: 1999-03-26
; NUMBER OF SEQ ID NOS: 379
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-005-344-8

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      243 CTCGAGAGCGGAAACGAG 262
Db      20 CTCGAGCGCGGAAACCCCG 1

RESULT 126
US-10-349-143-8790
; Sequence 8790, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumentfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8790
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer bind
; LOCATION: 1..20
; OTHER INFORMATION: downstream amplification primer 99-18258 for SEQ 925, in compleme
US-10-349-143-8790
```

```
Query Match          0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1025 CCAAGAGGTGGGAAATGG 1044
Db      1 CAAAGTAGTGGGAAATATGG 20

RESULT 127
US-10-349-143-8838/c
; Sequence 8838, Application US/10349143
; Publication No. US200400055841
; GENERAL INFORMATION:
; APPLICANT: Blumenfeld, Marla
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8838
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: downstream amplification primer 99-18602 for SEQ 973, in compleme
US-10-349-143-8838

Query Match          0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      688 CTGATGTCATCTCCACCAT 707
Db      20 CTCTCTCCATCTCCACCAT 1

RESULT 128
US-10-289-762-3216
; Sequence 3216, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Grifffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, preve
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 3216
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-3216

Query Match          0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1762 CCACAGGTATTGGAGAG 1781
Db      1762 CCACAGGTATTGGAGAG 1781
```

```
Query Match          0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      939 CCTATGCTCTTGGGATCA 958
Db      1 CCTATGATCTTGGGACCA 20

RESULT 129
US-10-289-762-3350
; Sequence 3350, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Grifffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, preve
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 3350
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-3350

Query Match          0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1696 GGAAGGCCCTTCCCATATA 1715
Db      1 GGAAGGCCCTTCCCATATA 20

RESULT 130
US-10-289-762-4873
; Sequence 4873, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Grifffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, preve
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4873
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-4873

Query Match          0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1696 GGAAGGCCCTTCCCATATA 1715
Db      1 GGAAGGCCCTTCCCATATA 20

RESULT 131
US-10-210-833-65
; Sequence 65, Application US/10210833
; Publication No. US20040023383A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF RESISTIN EXPRESSION
; FILE REFERENCE: RTS-0396
; CURRENT APPLICATION NUMBER: US/10/210,833
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 65
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-833-65

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1158 AGCCGAGAGTTTGGGAAA 1177
Db      1 AGCCGAGAGTTTCAAGGACA 20

RESULT 132
US-10-444-206-438
; Sequence 438, Application US/10444206
; Publication No. US20040023917A1
; GENERAL INFORMATION:
; APPLICANT: Bennett, Clarence Frank
; APPLICANT: Vickers, Timothy A.
; APPLICANT: Karris, James G.
; TITLE OF INVENTION: Oligonucleotide Compositions and Methods for the
; TITLE OF INVENTION: Modulation of the Expression of B7 Protein
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/444,206
; CURRENT FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: 09/851,871
; PRIOR FILING DATE: 2001-05-09
; PRIOR APPLICATION NUMBER: PCT/US00/14471
; PRIOR FILING DATE: 2000-05-25
; PRIOR APPLICATION NUMBER: 09/326,186
; PRIOR FILING DATE: 1999-06-04
; PRIOR APPLICATION NUMBER: 08/777,266
; PRIOR FILING DATE: 1996-12-31
; NUMBER OF SEQ ID NOS: 444
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 438
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-444-206-438

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1473 TGGTCTGTTGACTCCCTTAC 1492
Db      1 TGGTCTGTTCACTCTCTCC 20

RESULT 133
US-10-293-998-32
; Sequence 32, Application US/10293998
; Publication No. US20040091871A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF G PROTEIN-COUPLED RECEPTOR RE2 EXPRESSION
; FILE REFERENCE: HTS-0026
; CURRENT APPLICATION NUMBER: US/10/293,998
; CURRENT FILING DATE: 2002-11-11
; NUMBER OF SEQ ID NOS: 82
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-293-998-32

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      816 GACGAGCTTTTCCACACGA 835
Db      1 GACGAGCTTTTCCCCCAGA 20

RESULT 134
US-10-293-998-68/c
; Sequence 68, Application US/10293998
; Publication No. US20040091871A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF G PROTEIN-COUPLED RECEPTOR RE2 EXPRESSION
; FILE REFERENCE: HTS-0026
; CURRENT APPLICATION NUMBER: US/10/293,998
; CURRENT FILING DATE: 2002-11-11
; NUMBER OF SEQ ID NOS: 82
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-293-998-68

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      816 GACGAGCTTTTCCACACGA 835
Db      20 GACGAGCTTTTCCCCCAGA 1

RESULT 135
US-10-296-716-15
; Sequence 15, Application US/10296716
; Publication No. US20040091456A1
; GENERAL INFORMATION:
; APPLICANT: NAKAI, MICHIO
; APPLICANT: KOMIYA, KAZUO
; APPLICANT: MURATA, MASASHI
; APPLICANT: TOHDOH, NAKI
; APPLICANT: SAITO, IZUMU
; TITLE OF INVENTION: NOVEL RECOMBINANT ADENOVIRUS VECTOR HAVING A PROPERTY
; TITLE OF INVENTION: OF REDUCED ADVERSE EFFECT
; FILE REFERENCE: 072860
; CURRENT APPLICATION NUMBER: US/10/296,716
; CURRENT FILING DATE: 2003-07-08
; PRIOR APPLICATION NUMBER: PCT/JP01/04360
; PRIOR FILING DATE: 2001-05-24
; PRIOR APPLICATION NUMBER: JP 2000-155603
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: JP 2000-373850
; PRIOR FILING DATE: 2000-12-08
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-296-716-15

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
```



```
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 28 CGCGGGTGCCGCTGC 42
   |||||
Db 15 CGCGGGTGCCGCTGC 1

RESULT 141
US-10-230-006-1390/c
; Sequence 1390, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: MCSwigen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1390
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1390

Query Match 0.7%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 28 CGCGGGTGCCGCTGC 42
   |||||
Db 17 CGCGGGTGCCGCTGC 3

RESULT 142
US-10-100-957A-39/c
; Sequence 39, Application US/10100957A
; Publication No. US20030096322A1
; GENERAL INFORMATION:
; APPLICANT: Giuliano, Kenneth A.
; APPLICANT: Kapur, Ravi
; TITLE OF INVENTION: A System for Cell Based Screening
; FILE REFERENCE: 97-022-11A
; CURRENT APPLICATION NUMBER: US/10/100,957A
; CURRENT FILING DATE: 2002-03-19
; NUMBER OF SEQ ID NOS: 180
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 39
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: K13 epitope
US-10-100-957A-39

Query Match 0.7%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 99;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 566 TGTTCCTGTCCTGCTGG 583
   |||||
Db 18 TGTTCCTGTCCTGCTGG 1

RESULT 143
US-10-211-088-293/c
; Sequence 293, Application US/10211088
; Publication No. US20030104479A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Bright, Gary R.
; APPLICANT: Premkumar, D. David
; TITLE OF INVENTION: No. US20030104479A1el Fusion Proteins And Assays For Molecular Bir
; FILE REFERENCE: 01-1022-US
; CURRENT APPLICATION NUMBER: US/10/211,088
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/309,395
; PRIOR FILING DATE: 2001-08-01
; PRIOR APPLICATION NUMBER: 60/341,589
; PRIOR FILING DATE: 2001-12-13
; NUMBER OF SEQ ID NOS: 366
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 293
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence encoding detection domain
US-10-211-088-293

Query Match 0.7%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 99;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 566 TGTTCCTGTCCTGCTGG 583
   |||||
Db 18 TGTTCCTGTCCTGCTGG 1

RESULT 144
US-10-265-689-39/c
; Sequence 39, Application US/10265689
; Publication No. US20030119775A1
; GENERAL INFORMATION:
; APPLICANT: SURMIT, RICHARD S.
; APPLICANT: COLLINS, SHELIA A.
; APPLICANT: WARDEN, CRAIG H.
; APPLICANT: SELDIN, MICHAEL F.
; APPLICANT: RICOUIER, DANIEL
; APPLICANT: BOUILLAUD, FREDERIC
; TITLE OF INVENTION: RESPIRATION UNCOUPLING PROTEIN
; FILE REFERENCE: 1579-376
; CURRENT APPLICATION NUMBER: US/10/265,689
; CURRENT FILING DATE: 2002-10-08
; PRIOR APPLICATION NUMBER: US/09/353,645
; PRIOR FILING DATE: 1999-07-15
; PRIOR APPLICATION NUMBER: PCT/US97/06864
; PRIOR FILING DATE: 1997-04-22
; PRIOR APPLICATION NUMBER: 60/034,960
; PRIOR FILING DATE: 1997-01-15
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 39
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Oligonucleotide
US-10-265-689-39

Query Match 0.7%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 99;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1903 GAGGTAGACGAGCTGGG 1920
   |||||
Db 18 GAGGTAGACGAGCTGGG 1

RESULT 145
US-09-910-059-110
```

```
/ Sequence 110, Application US/09910059
/ Patent No. US20020142359A1
/ GENERAL INFORMATION:
/ APPLICANT: Copley, Clive G
/ APPLICANT: Edge, Michael Derek
/ APPLICANT: Emery, Stephen Charles
/ TITLE OF INVENTION: Monoclonal Antibody to CEA, Conjugates Comprising Said Antibody,
/ TITLE OF INVENTION: Their Therapeutic use in an Adept System
/ FILE REFERENCE: 1991-209
/ CURRENT APPLICATION NUMBER: US/09/910,059
/ CURRENT FILING DATE: 2001-07-23
/ PRIOR APPLICATION NUMBER: US 09/171,945
/ PRIOR FILING DATE: 1998-10-29
/ PRIOR APPLICATION NUMBER: PCT/GB97/01165
/ PRIOR FILING DATE: 1997-04-29
/ PRIOR APPLICATION NUMBER: GB 9703103.3
/ PRIOR FILING DATE: 1997-02-14
/ PRIOR APPLICATION NUMBER: GB9609405.7
/ PRIOR FILING DATE: 1996-05-04
/ NUMBER OF SEQ ID NOS: 131
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 110
/ LENGTH: 19
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: PCR primer for preprohCBP
US-09-910-059-110
```

```
Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1645 GCCTGCTGCAGACTCTG 1662
DB 2 GACCTGCTGCAGACTCTG 19
```

```
RESULT 146
US-10-099-352-22/c
/ Sequence 22, Application US/10099352
/ Publication No. US20030082569A1
/ GENERAL INFORMATION:
/ APPLICANT: Johnson, Clayvon H.
/ APPLICANT: McEwen, Joan E.
/ APPLICANT: York, J. Lyndal
/ TITLE OF INVENTION: Histoplasma Capsulation Catalase Sequences and Their Use in the
/ TITLE OF INVENTION: of Histoplasma Capsulation and Histoplasmosis
/ FILE REFERENCE: 40715-255988
/ CURRENT APPLICATION NUMBER: US/10/099,352
/ CURRENT FILING DATE: 2002-03-13
/ PRIOR APPLICATION NUMBER: US 60/275,353
/ PRIOR FILING DATE: 2001-03-13
/ NUMBER OF SEQ ID NOS: 48
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 22
/ LENGTH: 19
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic primer
US-10-099-352-22
```

```
Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 290 AGCATAGCTGCGGCAC 307
DB 18 AACCATCAGCTGCGGCAC 1
```

RESULT 147

```
US-10-224-005-84
/ Sequence 84, Application US/10224005
/ Publication No. US20030143732A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Fossnaugh, Kathy
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Adenosine A1 Receptor (AD
/ TITLE OF INVENTION: Gene Expression Using Short Interfering RNA
/ FILE REFERENCE: 900/041 (MBHB01-1110-A)
/ CURRENT APPLICATION NUMBER: US/10/224,005
/ CURRENT FILING DATE: 2002-08-20
/ PRIOR APPLICATION NUMBER: US 60/315,315
/ PRIOR FILING DATE: 2001-08-28
/ NUMBER OF SEQ ID NOS: 347
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 84
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-224-005-84
```

```
Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 1e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 205 TGGCTGGGGGCTGCGGG 222
DB 1 UGCUGGGGCGCAUGCGGG 18
```

```
RESULT 148
US-10-224-005-245/c
/ Sequence 245, Application US/10224005
/ Publication No. US20030143732A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Fossnaugh, Kathy
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Adenosine A1 Receptor (AD
/ TITLE OF INVENTION: Gene Expression Using Short Interfering RNA
/ FILE REFERENCE: 900/041 (MBHB01-1110-A)
/ CURRENT APPLICATION NUMBER: US/10/224,005
/ CURRENT FILING DATE: 2002-08-20
/ PRIOR APPLICATION NUMBER: US 60/315,315
/ PRIOR FILING DATE: 2001-08-28
/ NUMBER OF SEQ ID NOS: 347
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 245
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-224-005-245
```

```
Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 205 TGGCTGGGGGCTGCGGG 222
DB 19 TGGCTGGGGGCTGCGGG 2
```

```
RESULT 149
US-10-277-216-121/c
/ Sequence 121, Application US/10277216
/ Publication No. US20040002470A1
/ GENERAL INFORMATION:
/ APPLICANT: KEITH, TIM
```

```
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
; FILE REFERENCE: 2976-4051
; CURRENT APPLICATION NUMBER: US/10/277,216
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 10/126,022
; PRIOR FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 121
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-277-216-121
```

```
Query Match          0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      867 AGAGGACACGTCACCT 884
Db       19 AGAGGACACGACGACCT 2
```

```
RESULT 150
US-10-126-022-121/c
; Sequence 121, Application US/10126022
; Publication No. US20040023215A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
; FILE REFERENCE: 2976-4039US2
; CURRENT APPLICATION NUMBER: US/10/126,022
; PRIOR FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 121
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-126-022-121
```

```
Query Match          0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      867 AGAGGACACGTCACCT 884
Db       19 AGAGGACACGACGACCT 2
```

```
RESULT 151
US-10-670-184-94/c
; Sequence 94, Application US/10670184
; Publication No. US20040077011A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES AND
; FILE REFERENCE: 2976-4039
```

```
; CURRENT APPLICATION NUMBER: US/10/670,184
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: 60/129,391
; PRIOR FILING DATE: 1999-04-13
; NUMBER OF SEQ ID NOS: 170
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 94
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-670-184-94
```

```
Query Match          0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      867 AGAGGACACGTCACCT 884
Db       19 AGAGGACACGACGACCT 2
```

```
RESULT 152
US-09-866-108-890/c
; Sequence 890, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOGLIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 890
; LENGTH: 17
```

TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-890

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1702 CCCCTCCCAATG 1717
Db 17 CCCCTCCCAATG 2

RESULT 153

US-09-866-108-894/C
Sequence 894, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 894
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-894

Db 16 AAGCCCTTCCCACT 1

RESULT 154

US-09-866-108-8005
Sequence 8005, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 8005
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-8005

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2038 CAGGTGAGCAGCTCC 2053
Db 2 CAGGTGAGCAGCTCC 17

RESULT 155

US-09-866-108-8006
Sequence 8006, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang

US-09-866-108-894

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1699 AAGCCCTTCCCACT 1714
Db 16 AAGCCCTTCCCACT 1

```

; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AROMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8006
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-8006

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2038 CAGGTGAGCAGCTCC 2053
Db      1 CAGCTGAGCAGCTCC 16

RESULT 156
; Sequence 961-077-139
; Publication No. US20030014775A1
; GENERAL INFORMATION:
; APPLICANT: ZWICK, Michael G.
; Edington, Brent E.
; MCSWIGGEN, James A.
; Merlo, Patricia Ann Owens
; Guo, Lining
; Skokut, Thomas A.
; Young, Scott A.
; Folkerts, Otto
; Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; MODULATION OF GENE EXPRESSION
; IN PLANTS
```

```

; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LYON & LYON
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/961,077
; FILING DATE: 21-Sep-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/679,645
; FILING DATE: July 12, 1996
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 139:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 139:
; US-09-961-077-139

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      2179 CAGCAGCTCAGGAGA 2194
Db      1 CCGCAGCUCAGGAGA 16

RESULT 157
; Sequence 603-875-603
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
```

```
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 603
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-603

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1806 CCGAGCCCGAGAGCCA 1821
Db      2   CCAGACCCAGAGGCCA 17

RESULT 158
US-09-818-875-604/c
; Sequence 604, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 604
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-604

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1806 CCGAGCCCGAGAGCCA 1821
Db      16  CCAGACCCAGAGGCCA 1

RESULT 159
US-09-930-423-384/c
; Sequence 384, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 384
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens

US-09-930-423-384
Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      360 AGCCCCCGGTCGCG 375
Db      17  AGCCCCCGGTCGCG 2

RESULT 160
US-09-930-423-385/c
; Sequence 385, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 385
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-385

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      360 AGCCCCCGGTCGCG 375
Db      16  AGCCCCCGGTCGCG 1

RESULT 161
US-09-740-332-2144
; Sequence 2144, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2144
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-2144

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.1e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      1224 TGCAGTCACTCCTGG 1239
Db      1   UCCAGUCACUCCUGG 16

RESULT 162
```

```

US-09-745-237A-384/c
; Sequence 384, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MEH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 384
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-384

```

```

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      360 AGCCCCCGGTCCGCG 375
      |||||
Db      17 AGCCCCCGGTCCGCG 2

```

```

RESULT 163
US-09-745-237A-385/c
; Sequence 385, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MEH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 385
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-385

```

```

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      360 AGCCCCCGGTCCGCG 375
      |||||
Db      16 AGCCCCCGGTCCGCG 1

```

```

RESULT 164
US-09-817-879-2144
; Sequence 2144, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MEH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2144
; LENGTH: 17
; TYPE: RNA

```

```

; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2144

```

```

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.1e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      1224 TGCAGTCACTCTCG 1239
      :|||:|||||:|
Db      1 UCCAGUCACUCCUG 16

```

```

RESULT 165
US-10-081-810-33/c
; Sequence 33, Application US/10081810
; Publication No. US20030064438A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: G-PROTEIN COUPLED RECEPTOR NUCLEIC ACIDS, POLYPEPTIDES, ANTIBODIES
; TITLE OF INVENTION: US28 THEREOF
; FILE REFERENCE: D0132 NP
; CURRENT APPLICATION NUMBER: US/10/081,810
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: US 60/270,793
; PRIOR FILING DATE: 2001-02-23
; PRIOR APPLICATION NUMBER: US 60/270,792
; PRIOR FILING DATE: 2001-02-23
; PRIOR APPLICATION NUMBER: US 60/296,427
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 33
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-081-810-33

```

```

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      113 CCGCGTGTCCCGCAT 128
      |||||
Db      17 CCGCGTGTCCCGCAT 2

```

```

RESULT 166
US-10-060-895A-482/c
; Sequence 482, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN UDP-GALNA4:POLYPEPTIDE N-ACETYLGLACTOSAMINYLTRANSFERASE
; FILE REFERENCE: PB0158
; CURRENT APPLICATION NUMBER: US/10/060,895A
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668

```


;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 09/864,761
;; PRIOR FILING DATE: 2001-05-23
;; PRIOR APPLICATION NUMBER: US 60/315,984
;; PRIOR FILING DATE: 2001-08-30
;; NUMBER OF SEQ ID NOS: 1682
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 482
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-060-895A-482

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1487 CCTTACCTTGAGCG 1502
DB 17 CCTTACCTTGAGCG 2

RESULT 167
US-10-060-895A-483/C
;; Sequence 483, Application US/10060895A
;; Publication No. US20030104403A1
;; GENERAL INFORMATION:
;; APPLICANT: Zhang, Jian
;; APPLICANT: Gu, Yizhong
;; APPLICANT: Nguyen, Chung-Tuong
;; TITLE OF INVENTION: HUMAN UDP-GALNA4:POLYPEPTIDE N-ACETYLGLACTOSAMINYLTRANSFERASE 10
;; FILE REFERENCE: PB0158
;; CURRENT APPLICATION NUMBER: US/10/060, 895A
;; CURRENT FILING DATE: 2002-06-10
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 09/864,761
;; PRIOR FILING DATE: 2001-05-23
;; PRIOR APPLICATION NUMBER: US 60/315,984
;; PRIOR FILING DATE: 2001-08-30
;; NUMBER OF SEQ ID NOS: 1682
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 483
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-060-895A-483

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1487 CCTTACCTTGAGCG 1502
DB 16 CCTTACCTTGAGCG 1

RESULT 168
US-10-156-306-4759/C
;; Sequence 4759, Application US/10156306
;; Publication No. US20030119017A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyne Pharmaceuticals, Inc.
;; APPLICANT: McSwiggen, James
;; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
;; FILE REFERENCE: MBH01-664-A (400/050)
;; CURRENT APPLICATION NUMBER: US/10/156,306
;; CURRENT FILING DATE: 2002-05-28
;; NUMBER OF SEQ ID NOS: 8013
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 4759
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-10-156-306-4759

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 214 GCCTGCGGGGTCTCA 229
DB 17 GCTGCGGGGTCTCA 2

RESULT 169
US-10-156-306-4760/C
;; Sequence 4760, Application US/10156306
;; Publication No. US20030119017A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyne Pharmaceuticals, Inc.
;; APPLICANT: McSwiggen, James
;; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
;; FILE REFERENCE: MBH01-664-A (400/050)
;; CURRENT APPLICATION NUMBER: US/10/156,306
;; CURRENT FILING DATE: 2002-05-28
;; NUMBER OF SEQ ID NOS: 8013
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 4760
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-10-156-306-4760

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 214 GCCTGCGGGGTCTCA 229
DB 16 GCTGCGGGGTCTCA 1

RESULT 170
US-10-156-306-7104
;; Sequence 7104, Application US/10156306
;; Publication No. US20030119017A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyne Pharmaceuticals, Inc.
;; APPLICANT: McSwiggen, James
;; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
;; FILE REFERENCE: MBH01-664-A (400/050)
;; CURRENT APPLICATION NUMBER: US/10/156,306
;; CURRENT FILING DATE: 2002-05-28
;; NUMBER OF SEQ ID NOS: 8013

```
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 7104
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7104

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      391 CTGCACTGGGGAAGTC 406
Db      2  CGGCACTGGGGAAGTC 17

RESULT 171
US-10-209-787-603
; Sequence 603, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 603
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-603

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1806 CCGAGCCCGAGAAGCCA 1821
Db      2  CCAGACCCCGAGAAGCCA 17

RESULT 172
US-10-209-787-604/C
; Sequence 604, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
```

```
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 604
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-604

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1806 CCGAGCCCGAGAAGCCA 1821
Db      16  CCAGACCCCGAGAAGCCA 1

RESULT 173
US-10-261-185-603
; Sequence 603, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 603
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-603

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1806 CCGAGCCCGAGAAGCCA 1821
Db      2  CCAGACCCCGAGAAGCCA 17

RESULT 174
US-10-261-185-604/C
; Sequence 604, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
```

```

; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 604
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-604

Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1806 CCTGACCCAGAGCCA 1821
DB      16 CCAGACCCAGAGCCA 1

RESULT 175
US-10-230-335-5/c
; Sequence 5, Application US/10230335
; Publication No. US20030109016A1
; GENERAL INFORMATION:
; APPLICANT: MURAKAMI, Yoshihori
; TITLE OF INVENTION: TSL1 GENE
; FILE REFERENCE: 071665
; CURRENT APPLICATION NUMBER: US/10/230,335
; CURRENT FILING DATE: 2002-11-22
; PRIOR APPLICATION NUMBER: JP 2001-313966
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Gene Amplification Primer
US-10-230-335-5

Query Match      0.6%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      264 TGCCAGGCGCTGCTG 279
DB      17 TGTCAGGCGCTGCTG 2

RESULT 176
US-10-005-956-1222
; Sequence 1222, Application US/10005956
; Publication No. US20030113726A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: D0053NP
; CURRENT APPLICATION NUMBER: US/10/005,956
; CURRENT FILING DATE: 2001-12-03
; PRIOR APPLICATION NUMBER: 60/251,015
; PRIOR FILING DATE: 2000-12-04
```

```

; PRIOR APPLICATION NUMBER: 60/263,678
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: 60/273,037
; PRIOR FILING DATE: 2001-03-02
; NUMBER OF SEQ ID NOS: 1579
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1222
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-005-956-1222

Query Match      0.6%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2190 GGAGAAAAGGGCTGC 2205
DB      2 GGAGAAAAGGGCTGC 17

RESULT 177
US-10-427-432-11
; Sequence 11, Application US/10427432
; Publication No. US20030225260A1
; GENERAL INFORMATION:
; APPLICANT: Snyder, Richard O.
; TITLE OF INVENTION: PRODUCTION OF RECOMBINANT AAV VIRIONS
; FILE REFERENCE: 5853-240
; CURRENT APPLICATION NUMBER: US/10/427,432
; CURRENT FILING DATE: 2003-04-30
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotides
US-10-427-432-11

Query Match      0.6%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1941 GCGACGCGAGTGGCG 1956
DB      3 GCTACAGCGAGTGGCG 18

RESULT 178
US-10-164-871-17/c
; Sequence 17, Application US/10164871
; Publication No. US2002017194A1
; GENERAL INFORMATION:
; APPLICANT: Hirata, Yuichi
; TITLE OF INVENTION: STEROID HORMONE BINDING PROTEIN
; FILE REFERENCE: 06501-059001
; CURRENT APPLICATION NUMBER: US/10/164,871
; CURRENT FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US/09/565,808
; PRIOR FILING DATE: 2000-05-05
; PRIOR APPLICATION NUMBER: WO/99/05010
; PRIOR FILING DATE: 1998-11-06
; PRIOR APPLICATION NUMBER: JP/9/322376
; PRIOR FILING DATE: 1997-11-07
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PasteSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
; OTHER INFORMATION: Artificially synthesized primer sequence
US-10-164-871-17

Query Match
Best Local Similarity 93.8%; Score 14.4; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1258 ATGCTGCTGAAGTGG 1273
|||||
Db 16 ATGCTGCTGAACGTGG 1

RESULT 179
US-10-238-042-16
; Sequence 16, Application US/10238042
; Publication No. US20030115618A1
; GENERAL INFORMATION:
; APPLICANT: Murray, James D.
; APPLICANT: Maga, Elizabeth A.
; APPLICANT: Anderson, Gary B.
; APPLICANT: Oppenheim, Stefanie M.
; TITLE OF INVENTION: METHOD OF GENERATING A TRANSGENIC
; FILE REFERENCE: UCAL-245
; CURRENT APPLICATION NUMBER: US/10/238,042
; CURRENT FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: 60/317,925
; PRIOR FILING DATE: 2001-09-07
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Goat
US-10-238-042-16

Query Match
Best Local Similarity 93.8%; Score 14.4; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 268 CAGGGCTGGCTGGCTG 283
|||||
Db 1 CCGGGCTGGCTGGCTG 16

RESULT 180
US-10-205-309-17/c
; Sequence 17, Application US/10205309
; Publication No. US20030190635A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA interference Mediated Inhibition of Alzheimer's Disease Using
; FILE REFERENCE: 900/033
; CURRENT APPLICATION NUMBER: US/10/205,309
; CURRENT FILING DATE: 2002-10-25
; NUMBER OF SEQ ID NOS: 674
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 17
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense
US-10-205-309-17

Query Match
Best Local Similarity 93.8%; Score 14.4; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 360 AGCCCCGGGCTCCGGC 375
|||||
```

```
Db 19 AGCCCCGGGCTCCGGC 4

RESULT 181
US-10-205-309-342
; Sequence 342, Application US/10205309
; Publication No. US20030190635A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA interference Mediated Inhibition of Alzheimer's Disease Using
; FILE REFERENCE: 900/033
; CURRENT APPLICATION NUMBER: US/10/205,309
; CURRENT FILING DATE: 2002-10-25
; NUMBER OF SEQ ID NOS: 674
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 342
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-205-309-342

Query Match
Best Local Similarity 87.5%; Score 14.4; DB 1; Length 19;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 360 AGCCCCGGGCTCCGGC 375
|||||
Db 1 AGCCCCGGGCTCCGGC 16

RESULT 182
US-09-998-780-12
; Sequence 12, Application US/09998780
; Publication No. US20030229211A1
; GENERAL INFORMATION:
; APPLICANT: Keene, Jack D.
; APPLICANT: Keene, Daniel J.
; APPLICANT: Teal, Donald E.
; TITLE OF INVENTION: Nucleic Acid Epitopes and Methods of
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenneth D. Sibley; Bell, Seltzer, Park and
; Gibson
; STREET: Post Office Drawer 34009
; CITY: Charlotte
; STATE: No. US20030229211A1th Carolina
; COUNTRY: U.S.A.
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/998,780
; FILING DATE: 03-Dec-2001
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/944,208
; FILING DATE: 19920911
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5405-69
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
```

```

; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 14 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
; MOLECULE TYPE: rRNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-998-780-12

Query Match      0.6%; Score 14; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      2112 CCTGCTGAGCAGG 2125
Db      1 CCUGUGGAGCAGG 14

RESULT 183
US-10-417-393-12
; Sequence 12, Application US/10417393
; Publication No. US20030225024A1
; GENERAL INFORMATION:
;   APPLICANT: Keene, Jack D.
;               Kenan, Daniel J.
;               Tsai, Donald E.
; TITLE OF INVENTION: Nucleic Acid Epitopes and Methods of
;                   Making and Using the Same
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Kenneth D. Sibley; Bell, Seltzer, Park and
;               Gibson
;               STREET: Post Office Drawer 34009
;               CITY: Charlotte
;               STATE: North Carolina
;               COUNTRY: U.S.A.
;               ZIP: 28234
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: Floppy disk
;   COMPUTER: IBM PC compatible
;   OPERATING SYSTEM: PC-DOS/MS-DOS
;   SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/10/417,393
;   FILING DATE: 16-Apr-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: US/07/944,208
;   FILING DATE: 1992-09-11
; ATTORNEY/AGENT INFORMATION:
;   NAME: Sibley, Kenneth D.
;   REGISTRATION NUMBER: 31,665
;   REFERENCE/DOCKET NUMBER: 5405-69
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: 919-881-3140
;   TELEFAX: 919-881-3175
;   TELEX: 575102
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 14 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
; MOLECULE TYPE: rRNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-10-417-393-12

Query Match      0.6%; Score 14; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      2112 CCTGCTGAGCAGG 2125
```

```

Db      1 CCUGUGGAGCAGG 14

RESULT 184
US-09-829-855-101/c
; Sequence 101, Application US/09829855
; Patent No. US20020065609A1
; GENERAL INFORMATION:
;   APPLICANT: Matthew, Ashby N.
;   TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
;   FILE REFERENCE: ASHBY-1
;   CURRENT APPLICATION NUMBER: US/09/829,855
;   CURRENT FILING DATE: 2001-04-10
;   PRIOR APPLICATION NUMBER: US 60/196063
;   PRIOR FILING DATE: 2000-04-10
;   PRIOR APPLICATION NUMBER: US 60/196258
;   PRIOR FILING DATE: 2000-04-11
;   SOFTWARE: Patentin version 3.1
; SEQ ID NO 101
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: ribosomal DNA sequence tag isolated from
;                   microbes in soil sample collected
; OTHER INFORMATION: in Wyoming, USA
US-10-607-077A-101

Query Match      0.6%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      297 AGCTGGCGCACTGG 310
Db      16 AGCTGGCGCACTGG 3

RESULT 185
US-10-607-077A-101/c
; Sequence 101, Application US/10607077A
; Publication No. US20040110183A1
; GENERAL INFORMATION:
;   APPLICANT: Ashby, Matthew
;   TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
;   FILE REFERENCE: ASHBY/1 DIV
;   CURRENT APPLICATION NUMBER: US/10/607,077A
;   CURRENT FILING DATE: 2003-06-25
;   PRIOR APPLICATION NUMBER: US 09/829855
;   PRIOR FILING DATE: 2001-04-10
;   PRIOR APPLICATION NUMBER: PCT/US01/11609
;   PRIOR FILING DATE: 2001-04-10
;   PRIOR APPLICATION NUMBER: US 60/196063
;   PRIOR FILING DATE: 2000-04-10
;   PRIOR APPLICATION NUMBER: US 60/196258
;   PRIOR FILING DATE: 2000-04-11
;   NUMBER OF SEQ ID NOS: 244
;   SOFTWARE: Patentin version 3.1
; SEQ ID NO 101
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: ribosomal DNA sequence tag isolated from
;                   microbes in soil sample collected
; OTHER INFORMATION: in Wyoming, USA
US-10-607-077A-101

Query Match      0.6%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      297 AGCTGGCGCACTGG 310
Db      16 AGCTGGCGCACTGG 3
```

Db 16 AGCTGGCGCACTGG 3

RESULT 186
US-09-866-108-895/c
; Sequence 895, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 895
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-895

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1699 AAGCCCTTCCCA 1712
|||
15 AAGCCCTTCCCA 2

RESULT 187
US-09-866-108-896/c
; Sequence 896, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 896
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-896

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1699 AAGCCCTTCCCA 1712
|||
14 AAGCCCTTCCCA 1

RESULT 188
US-09-930-423-1483/c
; Sequence 1483, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00.918-A-400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; PRIOR FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1483
; LENGTH: 17
; TYPE: RNA

ORGANISM: Homo Sapiens
US-09-930-423-1483

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 360 AGCCCCCGGTCG 373
Db 15 AGCCCCCGGTCG 2

RESULT 189

US-09-930-423-1484/c
; Sequence 1484, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1484
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-1484

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 360 AGCCCCCGGTCG 373
Db 14 AGCCCCCGGTCG 1

RESULT 190
US-09-740-332-2411/c
; Sequence 2411, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2411
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-2411

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1226 CAGTCACTCCTGG 1239
Db 16 CAGTCACTCCTGG 3

RESULT 191

US-09-745-237A-1483/c
; Sequence 1483, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1483
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1483

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 360 AGCCCCCGGTCG 373
Db 15 AGCCCCCGGTCG 2

RESULT 192
US-09-745-237A-1484/c
; Sequence 1484, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1484
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1484

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 360 AGCCCCCGGTCG 373
Db 14 AGCCCCCGGTCG 1

RESULT 193
US-09-817-879-2411/c
; Sequence 2411, Application US/09817879
; Publication No. US2003017311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2411
; LENGTH: 17

```
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2411
```

```
Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1226 CAGTCACTCTCTGG 1239
           |||||
Db       16 CAGTCACTCTCTGG 3
```

```
RESULT 194
US-10-156-306-6313/C
; Sequence 6313, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6313
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6313
```

```
Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      216 CTGGGGGTCTCTCA 229
           |||||
Db       17 CTGGGGGTCTCTCA 4
```

```
RESULT 195
US-10-240-046A-64/C
; Sequence 64, Application US/10240046A
; Publication No. US20030190639A1
; GENERAL INFORMATION:
; APPLICANT: HUGOT, JEAN-PIERRE
; APPLICANT: THOMAS, GILLES
; APPLICANT: ZOUALI, MOHAMED
; APPLICANT: LESAGE, SUZANNE
; APPLICANT: CHAMAILLARD, MATHIAS
; TITLE OF INVENTION: GENES INVOLVED IN INTESTINAL INFLAMMATORY DISEASES AND USE
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: 37991-0009
; CURRENT APPLICATION NUMBER: US/10/240,046A
; CURRENT FILING DATE: 2003-04-02
; PRIOR APPLICATION NUMBER: PCT/FR 01/00935
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: FR 00/03832
; PRIOR FILING DATE: 2000-03-27
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 64
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-240-046A-64
```

```
Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      595 CTTGGGAGATGGC 608
           |||||
Db       14 CTTGGGAGATGGC 1
```

```
RESULT 196
US-10-230-006-2189/C
; Sequence 2189, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Fossnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
; FILE REFERENCE: 400/056 (MBHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2189
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-2189
```

```
Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      29 GCGGGTCCGCTGC 42
           |||||
Db       17 GCGGGTCCGCTGC 4
```

```
RESULT 197
US-10-138-674-9170/C
; Sequence 9170, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9170
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-9170
```

```
Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      76 GTACTGCTACTTCT 89
           |||||
Db       15 GTACTGCTACTTCT 2
```

```
RESULT 198
```


US-10-287-949A-9170/c
 ; Sequence 9170, Application US/10287949A
 ; Publication No. US20040102389A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MEH00-876-N (400/049)
 ; CURRENT FILING DATE: 2003-04-11
 ; NUMBER OF SEQ ID NOS: 20822
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 9170
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-287-949A-9170

Query Match 0.6%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 76 |||||
 DB 15 GTACTGCTACTTCT 2

RESULT 199
 US-10-178-325-56/c
 ; Sequence 56, Application US/10178325
 ; Publication No. US20030199467A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Roberts, M. Luisa
 ; APPLICANT: Cowsett, Lex M.
 ; TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
 ; TITLE OF INVENTION: Expression
 ; FILE REFERENCE: ISPH-0404
 ; CURRENT APPLICATION NUMBER: US/10/178,325
 ; CURRENT FILING DATE: 2002-06-21
 ; PRIOR APPLICATION NUMBER: US/09/387,341
 ; PRIOR FILING DATE: 1999-08-31
 ; PRIOR APPLICATION NUMBER: 09/156,424
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 09/156,979
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 09/156,807
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 09/161,015
 ; PRIOR FILING DATE: 1998-09-25
 ; NUMBER OF SEQ ID NOS: 233
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 56
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 US-10-178-325-56

Query Match 0.6%; Score 14; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1814 AGAGCCACTATG 1827
 DB 15 AGAGCCACTATG 2

RESULT 200

US-09-866-108-515/c
 ; Sequence 515, Application US/09866108
 ; Patent No. US20020048800A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: Ji, Yonggang
 ; APPLICANT: PENN, Sharon G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
 ; FILE REFERENCE: AEOMICA-7
 ; CURRENT APPLICATION NUMBER: US/09/866,108
 ; CURRENT FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00662
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00661
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00670
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: US 60/234,687
 ; PRIOR FILING DATE: 2000-09-21
 ; PRIOR APPLICATION NUMBER: US 60/266,860
 ; PRIOR FILING DATE: 2001-02-05
 ; NUMBER OF SEQ ID NOS: 15752
 ; SOFTWARE: Aeomica Sequence Listing Engine
 ; SEQ ID NO 515
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-866-108-515

Query Match 0.6%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 160 CTGCTCCGGCTCGGCGC 176
 DB 17 CTGCTCAGGCTCGGCGC 1

RESULT 201
 US-09-866-108-665/c
 ; Sequence 665, Application US/09866108
 ; Patent No. US20020048800A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: Ji, Yonggang
 ; APPLICANT: PENN, Sharon G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng

```

; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 665
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-665

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      53 CTTCTCGCATGGCTG 69
Db      17 CTTCTCGCATGGCTG 1

RESULT 202
US-09-866-108-1530
; Sequence 1530, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
```

```

; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1530
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1530

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1595 AGGTGACGCGCTGGTG 1611
Db      1 AGGTGATGGCGCTGGTG 17

RESULT 203
US-09-866-108-1572/c
; Sequence 1572, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1572
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1572

```

```

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      267 CCAGGCTGCTGCTGCTG 283
Db      17 CCAGAGCAGCTGCTGCTG 1

```

RESULT 204

```

US-09-866-108-1960
; Sequence 1960, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670

```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1960
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1960

```

```

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      1832 AAATCACGCTGCTGCA 1848
Db      1 AAAGCTCAGCTGCTGCA 17

```

RESULT 205

```

US-09-866-108-2739
; Sequence 2739, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2739
; LENGTH: 17
; TYPE: DNA

```

```
; ORGANISM: Homo sapiens
US-09-866-108-2739

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      297 AGCTGCGCAGCTGGGCT 313
Db      1 AGCTGAGGCCCTGGGCT 17

RESULT 206
US-09-866-108-6521
; Sequence 6521, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6521
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6521

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2100 CCAGCAGCTCAGCCTGG 2116
Db      1 CCACACCGCAGCCTGG 17
```

```
RESULT 207
US-09-866-108-6522
; Sequence 6522, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6522
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6522

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2101 CAGCAGCTCAGCCTGGT 2117
Db      1 CACCACCGCAGCCTGGT 17

RESULT 208
US-09-866-108-6525
; Sequence 6525, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
```

```

; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6525
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6525

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2104 CACCTGAGCCTGTGTGGA 2120
Db      1 CACCGACGCTGTGTGGA 17

RESULT 209
US-09-866-108-6526
; Sequence 6526, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
```

```

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6526
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6526

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2105 ACCTGAGCCTGTGTGAG 2121
Db      1 ACCGACGCTGTGTGAG 17

RESULT 210
US-09-866-108-6758
; Sequence 6758, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6758
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6758
```

```

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      2041 GTGAGCAGCTCCTGTGA 2057
```

```
Db      1 GTGAGAGAGCTCCTGGA 17
```

```

RESULT 211
US-09-866-108-8056
; Sequence 8056, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8056
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8056
```

```

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      2230 GCAGATGCTCCAGATG 2246
```

```
Db      1 GCAGATGCACAGAGG 17
```

```

RESULT 212
US-09-866-108-8057
; Sequence 8057, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
```

SEQ ID NO 8057
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-8057

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2231 CAGATGCTCCAGATGA 2247
Db 1 CAGATGACCCAGAGGA 17

RESULT 213
US-09-866-108-9583
Sequence 9583, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:

APPLICANT: GU, Yizhong
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00660
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 9583
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-9583

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1167 GTTAGGAAAAGCTGC 1183
Db 1 GTGAGGGAAGAGCTGC 17

RESULT 214
US-09-895-040A-77/c
Sequence 77, Application US/09895040A
Patent No. US20020123474A1
GENERAL INFORMATION:

APPLICANT: Shannon, Mark
APPLICANT: JI, Yonggang
TITLE OF INVENTION: HUMAN GTP-RHO BINDING PROTEIN 2
FILE REFERENCE: AEOMICA-11
CURRENT APPLICATION NUMBER: US/09/895,040A
CURRENT FILING DATE: 2001-06-29
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
NUMBER OF SEQ ID NOS: 180
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 77
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-895-040A-77

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 206 GGCTGGGGGCTGCGGG 222
Db 17 GGCTGGGGGCGCGCGG 1

RESULT 215
US-09-864-785-577/c
Sequence 577, Application US/09864785
Patent No. US20020177568A1
GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Stinchcomb, Dan
APPLICANT: Draper, Ken
APPLICANT: MSWISGEN, Jim
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
FILE REFERENCE: 400/022 (MBH00-812-D)
CURRENT APPLICATION NUMBER: US/09/864,785
CURRENT FILING DATE: 2001-05-23
NUMBER OF SEQ ID NOS: 3929
SOFTWARE: PatentIn version 3.0
SEQ ID NO 577
LENGTH: 17
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid

US-09-864-785-577

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2162 GGGAGGGGGGAAACCAC 2178

DB 17 GGGATGGGGGAGCCAC 1

RESULT 216

US-09-864-785-2690/c
; Sequence 2690, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2690
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2690

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTCCTGCTCCTG 579

DB 17 CACTGTCTCTGCTCTG 1

RESULT 217

US-09-864-785-2870/c
; Sequence 2870, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2870
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2870

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 356 GGGAGCCCCCGGCTCC 372

DB 17 GGGAGCCCCCGGCCCC 1

RESULT 218

US-09-864-785-2871/c
; Sequence 2871, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MBH00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2871
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2871

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 355 TGGGAGCCCCCGGCTC 371

DB 17 TGGGAGCCCCCGGGGCC 1

RESULT 219

US-09-825-805-629/c
; Sequence 629, Application US/09825805
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelesky, Alex
; APPLICANT: Adams, Jasenka Matulic
; APPLICANT: Suedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBH00-831-P (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 629
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

US-09-825-805-629

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 259 GCAGTGTCCCGAGGCTG 275

Db 17 GTAGTGTACCAAGGCTG 1

RESULT 220

US-09-825-805-719/c

; Sequence 719, Application US/09825805
; Publication No. US2003004122A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Beigelman, Leo

; APPLICANT: Beaudry, Amber

; APPLICANT: Karpelesky, Alex

; APPLICANT: Adamic, Jasenka Matulic

; APPLICANT: Sweedler, Dave

; APPLICANT: Zinnen, Shawn

; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot

; FILE REFERENCE: MBH00-831-F (400/009)

; CURRENT APPLICATION NUMBER: US/09/825,805

; PRIOR FILING DATE: 2001-09-27

; PRIOR APPLICATION NUMBER: 09/578,223

; PRIOR FILING DATE: 2000-05-23

; PRIOR APPLICATION NUMBER: 09/476,387

; PRIOR FILING DATE: 1999-12-30

; PRIOR APPLICATION NUMBER: 09/474,432

; PRIOR FILING DATE: 1999-12-29

; PRIOR APPLICATION NUMBER: 09/301,511

; PRIOR FILING DATE: 1999-04-28

; PRIOR APPLICATION NUMBER: 09/186,675

; PRIOR FILING DATE: 1998-11-04

; PRIOR APPLICATION NUMBER: 60/083,727

; PRIOR FILING DATE: 1998-04-29

; PRIOR APPLICATION NUMBER: 60/064,866

; PRIOR FILING DATE: 1997-11-05

; NUMBER OF SEQ ID NOS: 1558

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 719

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-825-805-719

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 269 AGGCGTGGCTGCTGCT 285

Db 17 AGGCGTGGCTGCTGCT 1

RESULT 221

US-09-730-289B-541/c

; Sequence 541, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Blatt, Larry

; APPLICANT: McSwiggen, Jim

; TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease

; FILE REFERENCE: MBH00-864-A (400/006)

; CURRENT APPLICATION NUMBER: US/09/730,289B

; PRIOR FILING DATE: 2000-12-05

; PRIOR APPLICATION NUMBER: US 60/169,100

; PRIOR FILING DATE: 1999-12-06

; NUMBER OF SEQ ID NOS: 3897

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 541

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-730-289B-541

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1465 CCACCCAGTGTGTT 1481

Db 17 CTAAGTGTGTT 1

RESULT 222

US-09-780-533A-106

; Sequence 106, Application US/09780533A
; Publication No. US2003006061A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Blatt, Larry

; APPLICANT: McSwiggen, Jim

; APPLICANT: Chowitra, Bharat

; APPLICANT: Haebertli, Pete

; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene

; FILE REFERENCE: MBH00,878-A (400/011)

; CURRENT APPLICATION NUMBER: US/09/780,533A

; PRIOR FILING DATE: 2001-02-09

; PRIOR APPLICATION NUMBER: US 60/181,797

; PRIOR FILING DATE: 2000-02-11

; NUMBER OF SEQ ID NOS: 6679

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 106

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-780-533A-106

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.5e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1778 GAAGCTTCAGAAAT 1794

Db 1 GAACACUCAAAGAAAU 17

RESULT 223

US-09-780-533A-1837/c

; Sequence 1837, Application US/09780533A
; Publication No. US2003006061A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Blatt, Larry

; APPLICANT: McSwiggen, Jim

; APPLICANT: Chowitra, Bharat

; APPLICANT: Haebertli, Pete

; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene

; FILE REFERENCE: MBH00,878-A (400/011)

; CURRENT APPLICATION NUMBER: US/09/780,533A

; PRIOR FILING DATE: 2001-02-09

; PRIOR APPLICATION NUMBER: US 60/181,797

; PRIOR FILING DATE: 2000-02-11

; NUMBER OF SEQ ID NOS: 6679

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1837

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-780-533A-1837

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
ORGANISM: Hepatitis B virus
US-09-877-478-699

Db 17 GGAGCTGCTGGGGGC 1

RESULT 224
US-09-780-533A-2015
; Sequence 2015, Application US/09780533A
; Publication No. US2003006011A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwigen, Jim
; APPLICANT: Chowrita, Bharat
; APPLICANT: Haebertl, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2015
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2015

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.5e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 784 GGAGGAGTTTGGGCGC 800
Db 1 GGAGUGUGUUGUGGC 17

RESULT 225
US-09-877-478-699/C
; Sequence 699, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 699
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-699

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 963 CTGGGATCAGTGTCCC 979
Db 17 CTGAGATGAGTGTCCC 1

RESULT 226
US-09-877-478-1441/C
; Sequence 1441, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1441
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1441

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 964 TGGGATCAGTGTCCC 980
Db 17 TGAGATGAGTGTCCC 1

RESULT 227
US-09-930-423-383/C
; Sequence 383, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MHB00,918-A 400/027

;; CURRENT APPLICATION NUMBER: US/09/930,423
;; CURRENT FILING DATE: 2001-08-15
;; NUMBER OF SEQ ID NOS: 4553
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 383
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo Sapiens
US-09-930-423-383

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 165 CCGGCTCGGGCGGTGG 181
DB 17 CCGGCTCGGGCTGTGG 1

RESULT 228
US-09-930-423-1041/c
; Sequence 1041, Application US/09930423
; Publication No. US2003092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1041
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-1041

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2101 CAGCACTCAGCCGTGT 2117
DB 17 CAGCACTCAGACTGTGT 1

RESULT 229
US-09-930-423-1485/c
; Sequence 1485, Application US/09930423
; Publication No. US2003092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1485
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-1485

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 356 GGGAGCCCCCGGCTCC 372

DB 17 GGCACAGCCCCGGGTCC 1

RESULT 230
US-09-930-423-1557/c
; Sequence 1557, Application US/09930423
; Publication No. US2003092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1557
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-1557

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 317 CCTGCGCGGACTTGCC 333
DB 17 CCTGCGCGGACTTGCC 1

RESULT 231
US-09-930-423-1558/c
; Sequence 1558, Application US/09930423
; Publication No. US2003092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1558
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-1558

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 316 GCCCTGCGGACTTGC 332
DB 17 GCCCTGCGGACTTGC 1

RESULT 232
US-09-864-636A-1682
; Sequence 1682, Application US/09864636A
; Publication No. US20030104378A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allwail, Hatim
; APPLICANT: Bartholomay, Christian
; APPLICANT: Chehak, Luanne
; TITLE OF INVENTION: Detection of RNA Sequences
; FILE REFERENCE: FORS-04944

```
; CURRENT APPLICATION NUMBER: US/09/864,636A
; CURRENT FILING DATE: 2002-10-15
; NUMBER OF SEQ ID NOS: 2640
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1682
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-864-636A-1682

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1586 GCCCTGGCGAGGTGACG 1602
Db      1   GCCCTGCCGAGAGACG 17

RESULT 233
US-09-827-395A-35/C
; Sequence 35, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 35
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-35

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      779 TGCAGGAGAGGTGTTT 795
Db      17 TGCAGGAAGAGGTGTGT 1

RESULT 234
US-09-827-395A-36/C
; Sequence 36, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 36
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-36

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      777 CTGCGAGGAGAGGTGT 793
Db      17 CTGCGAGGAAGAGGTGT 1

RESULT 235
US-09-827-395A-79/C
; Sequence 79, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 79
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-79

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      178 GTGGGCTGAGCCGCTG 194
Db      17 GTGGGCCAGAGCCGTTG 1

RESULT 236
US-09-827-395A-270/C
; Sequence 270, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 270
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

US-09-827-395A-270

Query Match

Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 780 GCAGGAGAGGTGTTG 796

Db 17 GCAGGAGAGGTGCTG 1

RESULT 237

US-09-827-395A-742/C

; Sequence 742, Application US/09827395A

; Publication No. US20030113891A1

; GENERAL INFORMATION: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Lawrence Blatt

; APPLICANT: James McSwiggen

; APPLICANT: Bharat Chowitra

; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor C

; FILE REFERENCE: MHB00-878-C (400/017)

; CURRENT FILING DATE: 2001-04-05

; PRIOR APPLICATION NUMBER: US/09/827,395A

; PRIOR FILING DATE: 2001-02-09

; PRIOR APPLICATION NUMBER: 60/181,797

; PRIOR FILING DATE: 2000-02-11

; NUMBER OF SEQ ID NOS: 2617

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 742

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-827-395A-742

Query Match

Best Local Similarity 88.2%; Score 13.8; DB 1; Length 17;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 175 GCGGTGGGCTGACCG 191

Db 17 GCGGTGGGCTGACCG 1

RESULT 238

US-09-740-332-338

; Sequence 338, Application US/09740332

; Publication No. US20030125270A1

; GENERAL INFORMATION: Ribozyme Pharmaceuticals Inc.

; APPLICANT: Ribozyme Pharmaceuticals Inc.

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: RPI 400/003

; CURRENT APPLICATION NUMBER: US/09/740,332

; CURRENT FILING DATE: 2001-03-26

; NUMBER OF SEQ ID NOS: 9704

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 338

; LENGTH: 17

; TYPE: RNA

; ORGANISM: artificial sequence

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION:

; OTHER INFORMATION: oligonucleotide substrate

US-09-740-332-338

Query Match

Best Local Similarity 64.7%; Score 13.8; DB 1; Length 17;

Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 318 CTTGCCGAGCTTGCTT 334

Db 1 CCUGGCGGCGCCUCCU 17

RESULT 239

US-09-740-332-1694

; Sequence 1694, Application US/09740332

; Publication No. US20030125270A1

; GENERAL INFORMATION: Ribozyme Pharmaceuticals Inc.

; APPLICANT: Ribozyme Pharmaceuticals Inc.

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: RPI 400/003

; CURRENT APPLICATION NUMBER: US/09/740,332

; CURRENT FILING DATE: 2001-03-26

; NUMBER OF SEQ ID NOS: 9704

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1694

; LENGTH: 17

; TYPE: RNA

; ORGANISM: artificial sequence

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION:

; OTHER INFORMATION: oligonucleotide substrate

US-09-740-332-1694

Query Match

Best Local Similarity 64.7%; Score 13.8; DB 1; Length 17;

Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 689 TCATGTCATTCTCACC 705

Db 1 UCACGUCACGUCACAC 17

RESULT 240

US-09-740-332-3272

; Sequence 3272, Application US/09740332

; Publication No. US20030125270A1

; GENERAL INFORMATION: Ribozyme Pharmaceuticals Inc.

; APPLICANT: Ribozyme Pharmaceuticals Inc.

; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related

; FILE REFERENCE: RPI 400/003

; CURRENT APPLICATION NUMBER: US/09/740,332

; CURRENT FILING DATE: 2001-03-26

; NUMBER OF SEQ ID NOS: 9704

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 3272

; LENGTH: 17

; TYPE: RNA

; ORGANISM: artificial sequence

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION:

; OTHER INFORMATION: oligonucleotide substrate

US-09-740-332-3272

Query Match

Best Local Similarity 76.5%; Score 13.8; DB 1; Length 17;

Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1948 GCAGTGGCGTGGCCCG 1964

Db 1 GCAGGCGGUGGCGCG 17

RESULT 241

US-09-740-332-3439

; Sequence 3439, Application US/09740332

; Publication No. US20030125270A1

; GENERAL INFORMATION:

```

; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3439
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3439

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

OY 1330 CTGTGCACATTGTCT 1346
Db 1 CUCGUCACAUUUCUUCU 17

RESULT 242
US-09-740-332-4247/C
; Sequence 4247, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; NUMBER OF SEQ ID NOS: 2001-03-26
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4247
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-4247

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 59 TCGCATGCGTGGGACA 75
Db 17 TCGCATGCGTGGGATA 1

RESULT 243
US-09-745-237A-383/C
; Sequence 383, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
```

```

; SEQ ID NO 383
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-383

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 165 CCGGCTCGGCGGTGG 181
Db 17 CCGGCTCGGCGGTGG 1

RESULT 244
US-09-745-237A-1041/C
; Sequence 1041, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1041
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1041

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2101 CAGCAGCTCAGCTGT 2117
Db 17 CAGCAGCTCAGCTGT 1

RESULT 245
US-09-745-237A-1485/C
; Sequence 1485, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1485
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1485

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 356 GGGAGCCCGCGGTCC 372
Db 17 GGGAGCCCGCGGTCC 1
```

```
RESULT 246
US-09-745-237A-1557/c
; Sequence 1557, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1557
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1557

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 317 CCCTGCCGCGACTTGCC 333
Db 17 CCCTGCCGCGACTTGCC 1

RESULT 247
US-09-745-237A-1558/c
; Sequence 1558, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Biact, Larry
; APPLICANT: MCSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1558
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1558

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 316 GCCCTGCCGCGACTTGC 332
Db 17 GCCCTGCCGCGACTTGC 1

RESULT 248
US-09-817-879-338
; Sequence 338, Application US/09817879
; Publication No. US2003017311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 338
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-338

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 318 CCTGCCGCGACTTGCT 334
Db 1 CCTGCCGCGACTTGCT 17

RESULT 249
US-09-817-879-1694
; Sequence 1694, Application US/09817879
; Publication No. US2003017311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; APPLICANT: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1694
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1694

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 689 TCATGCCATTCTCACC 705
Db 1 UCACGUCCAUGCUCACC 17

RESULT 250
US-09-817-879-3272
; Sequence 3272, Application US/09817879
; Publication No. US2003017311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3272
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3272

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```



```
Db      17 CTGAGATGAGTCTCCC 1
RESULT 255
US-10-342-902-1441/C
; Sequence 1441, Application US/10342902
; Publication No. US20040054156a1
; GENERAL INFORMATION:
; APPLICANT: Sirona Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-1)
; CURRENT APPLICATION NUMBER: US/0/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1441
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1441

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      964 TGGGATCAGTCTCCT 980
Db      17 TGAGATGAGTCTCCT 1

RESULT 256
US-09-927-046-863/C
; Sequence 863, Application US/09927046
; Publication No. US20030064946a1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloro
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 863
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-863

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      779 TGCAGGAGAGGCTTT 795
Db      17 TGCAGGAAGAGCTCTGT 1

RESULT 257
US-10-430-882-35/C
; Sequence 35, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blact
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; APPLICANT: Peter Haebertl
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 35
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-35

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      779 TGCAGGAGAGGCTTT 795
Db      17 TGCAGGAAGAGCTCTGT 1

RESULT 258
US-10-430-882-36/C
; Sequence 36, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blact
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; APPLICANT: Peter Haebertl
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
```

; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 36
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-36

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 777 CTTGACGAGAGAGGTGT 793
Db 17 CGTCAGAGAGAGGTGT 1

RESULT 259
US-10-430-882-79/c
; Sequence 79, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haederli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MHB00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; FILE REFERENCE: MHB00-878-H (400/112)
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 79
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-79

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 178 GTGGGCTGAGCCGCTG 194
Db 17 GTGGGCTGAGCCGCTG 1

RESULT 260
US-10-430-882-270/c
; Sequence 270, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haederli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MHB00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06

; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 270
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-270

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 780 GCAGGAGAGGTGTTG 796
Db 17 GCAGGAGAGGTGTTG 1

RESULT 261
US-10-430-882-742/c
; Sequence 742, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haederli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MHB00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 742
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-742

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 175 GCGGTGGCTGAGCCG 191
Db 17 GCGGTGGCTGAGCCG 1

RESULT 262
US-10-060-830-781/c
; Sequence 781, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:

```

; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCLL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0159
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 781
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-781

```

```

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      918 TCTGTGCTGCTGTGCTC 934
Db      17 TCTGTGCTGCTGTGCTC 1

```

```

RESULT 263
US-10-060-756A-519
; Sequence 519, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 519
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-519

```

```

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      131 TCTCCTGCTGTGCTCC 147
Db      1 TCTTCCTGCTGTGCTCC 17

```

```

RESULT 264
US-10-287-919-1890/c
; Sequence 1890, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Methanococcus jannaschii complete genome.
; FILE REFERENCE: Jim Zeiger Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/287,919
; CURRENT FILING DATE: 2002-11-05
; NUMBER OF SEQ ID NOS: 2706
; SOFTWARE: Proprietary
; SEQ ID NO 1890
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Methanococcus jannaschii complete genome.
; FEATURE:
; LOCATION: (115631)..(115647)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectorObjectNumber = 2404
US-10-287-919-1890

```

```

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      570 CCTGTGCTGTGCTGCTC 586
Db      17 CCAGTTCCTGTGCTGCTC 1

```

```

RESULT 265
US-10-060-895A-437
; Sequence 437, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN UDP-GALNA4:POLYPEPTIDE N-ACETYLGLACTOSAMINYLTRANSFERASE 10
; FILE REFERENCE: PB0158
; CURRENT APPLICATION NUMBER: US/10/060,895A
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/315,984
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 1682
; SOFTWARE: Aeomica Sequence Listing Engine

```

```
; SEQ ID NO 437
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-895A-437
```

```
Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      1421 CCTCAGAGAAATATTT 1437
Db      1 CCTCAGTGAATAATTT 17
```

```
RESULT 266
US-10-060-895A-481/C
; Sequence 481, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; APPLICANT: Nguyen, Cung-Thuong
; TITLE OF INVENTION: HUMAN UDP-GALNAc:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 10
```

```
; FILE REFERENCE: PR0158
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/315,984
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 1682
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 481
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-895A-481
```

```
Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      1488 CTTACACTTGAGGGCC 1504
Db      17 CTTACACTTGAGGGAC 1
```

```
RESULT 267
US-10-060-895A-793
; Sequence 793, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Thuong
; TITLE OF INVENTION: HUMAN UDP-GALNAc:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 10
```

```
; FILE REFERENCE: PR0158
; CURRENT APPLICATION NUMBER: US/10/060, 895A
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/315,984
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 1682
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 793
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-895A-793
```

```
Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      277 CTGGCTGCTTGAAACC 293
Db      1 CTGGCTGCTTGAGGCC 17
```

```
RESULT 268
US-10-163-552-228/C
; Sequence 228, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level.
; FILE REFERENCE: MEB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 228
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-228
```

```
Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      259 GCAGTGCCAGGGCTG 275
Db      17 GTAGTGACCAAGGCTG 1
```

```
RESULT 269
US-10-163-552-497/C
; Sequence 497, Application US/10163552
; Publication No. US20030105051A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 497
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-497

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      269 AGGCGCTGGCTGCT 285
Db      17 AGGCGCTGCTGCT 1

RESULT 270
US-10-156-306-4969/C
; Sequence 4969, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4969
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4969

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2106 CCTCAGCTGCTGAGC 2122
Db      17 CCTCGCCTGCTGAGC 1

RESULT 271
US-10-156-306-5001/C
; Sequence 5001, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5001
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5001

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2224 GCTCTGACAGATGCTCC 2240
Db      17 GCTCCTGACAGATGCTCC 1

RESULT 272
US-10-238-700-2992
; Sequence 2992, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2992
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2992

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.5e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      443 TGCCCGCAGCAGCCCTG 459
Db      1 UGCCAGCAGCUGCCCTG 17

RESULT 273
US-10-238-700-2993
; Sequence 2993, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2993
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2993

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.5e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      446 CCGCAGCAGCCCTGTG 462
Db      1 CAGCAGCUGCCCTG 17

US-10-156-306-5001
```

```
RESULT 274
US-10-238-700-3609/c
; Sequence 3609, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: US/10/238,700
; PRIOR FILING DATE: 2002-05-28
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 3609
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3609
```

```
Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Oy 2127 TGACCACTCCTCTTC 2143

Db 17 TGACCACTCTGCTTC 1

```
RESULT 275
US-10-238-700-3610/c
; Sequence 3610, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: US/10/238,700
; PRIOR FILING DATE: 2002-05-28
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 3610
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3610
```

```
Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Oy 2125 GCTGACCACTCCTT 2141

Db 17 GCTGACCACTCTGCTT 1

```
RESULT 276
US-10-061-201-436
; Sequence 436, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
```

```
;; CURRENT APPLICATION NUMBER: US/10/061,201
;; PRIOR FILING DATE: 2002-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 09/864,761
;; PRIOR FILING DATE: 2001-05-23
;; PRIOR APPLICATION NUMBER: US 60/328,205
;; PRIOR FILING DATE: 2001-10-10
;; NUMBER OF SEQ ID NOS: 4162
;; SOFTWARE: Aeomica Sequence Listing Engine
;; SEQ ID NO 436
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-10-061-201-436
```

```
Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Oy 1101 CATGAGCTCTGTCG 1117

Db 1 CATGAGCGCTGCCG 17

```
RESULT 277
US-10-061-201-437
; Sequence 437, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 437
; LENGTH: 17
```

TYPE: DNA
ORGANISM: Homo sapiens
US-10-061-201-437

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1102 TTGAGGCTGTGCGCC 1118
Db 1 TTGAGGCGCTGCGGCC 17

RESULT 278
US-10-061-201-438

Sequence 438, Application US/10061201
Publication No. US20030166229A1
GENERAL INFORMATION:
APPLICANT: Shannon, Mark
TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
FILE REFERENCE: PB0178
CURRENT APPLICATION NUMBER: US/10/061,201
PRIOR FILING DATE: 2002-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/328,205
PRIOR FILING DATE: 2001-10-10
NUMBER OF SEQ ID NOS: 4162
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 438
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-061-201-438

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1103 TTGAGGCTGTGCGCC 1119
Db 1 TTGAGGCGCTGCGGCC 17

RESULT 279
US-10-061-201-439

Sequence 439, Application US/10061201
Publication No. US20030166229A1
GENERAL INFORMATION:
APPLICANT: Shannon, Mark
TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
FILE REFERENCE: PB0178
CURRENT APPLICATION NUMBER: US/10/061,201
PRIOR FILING DATE: 2002-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/328,205
PRIOR FILING DATE: 2001-10-10
NUMBER OF SEQ ID NOS: 4162
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 439
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-061-201-439

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1104 TGAGGCTGTGCGCCA 1120
Db 1 TGAGGCGCTGCGGCCA 17

RESULT 280
US-10-061-201-1326

Sequence 1326, Application US/10061201
Publication No. US20030166229A1
GENERAL INFORMATION:
APPLICANT: Shannon, Mark
TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
FILE REFERENCE: PB0178
CURRENT APPLICATION NUMBER: US/10/061,201
CURRENT FILING DATE: 2002-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/328,205
PRIOR FILING DATE: 2001-10-10
NUMBER OF SEQ ID NOS: 4162
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 1326
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-061-201-1326

Query Match 0.6%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2092 CTCATCACCCGACACT 2108
Db 1 CTTATCACCCGACACT 17

RESULT 281

US-10-084-839-1682
; Sequence 1682, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: IP, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichiev, Victor
; APPLICANT: Lyamichieva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah P.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tsetska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084, 839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1682
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-1682

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1586 GCCCTGGCGAGCTACG 1602
Db 1 GCCCTGGCGAGAGACG 17

RESULT 282

US-10-084-839-3475/C
; Sequence 3475, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.

; APPLICANT: IP, Hon S.

; APPLICANT: Ji, Lin

; APPLICANT: Kaiser, Michael

; APPLICANT: Kwiatkowski, Jr., Robert W.

; APPLICANT: Lukowiak, Andrew A.

; APPLICANT: Lyamichiev, Victor

; APPLICANT: Lyamichieva, Natalie E.

; APPLICANT: Ma, WuPo

; APPLICANT: Neri, Bruce P.

; APPLICANT: Olson, Sarah P.

; APPLICANT: Olson-Munoz, Marilyn C.

; APPLICANT: Schaefer, James J.

; APPLICANT: Skrzypczynski, Zbigniew

; APPLICANT: Takova, Tsetska Y.

; APPLICANT: Thompson, Lisa C.

; APPLICANT: Vedvik, Kevin L.

; TITLE OF INVENTION: RNA Detection Assays

; FILE REFERENCE: FORS-06666

; CURRENT APPLICATION NUMBER: US/10/084, 839

; CURRENT FILING DATE: 2002-02-26

; NUMBER OF SEQ ID NOS: 4004

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 3475

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic

US-10-084-839-3475

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 756 CATGGCCAGCTGCACA 772
Db 17 CATGGCCAGCTGCACA 1

RESULT 283

US-10-230-006-820/C
; Sequence 820, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC COND
; FILE REFERENCE: 400/056 (MEHBO1-1110)
; CURRENT APPLICATION NUMBER: US/10/230, 006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 820
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-820

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 632 TCACTGACTGATTCTA 648
Db 17 TCACTGACTGATTCTA 1

RESULT 284

US-10-297-068-1041
; Sequence 1041, Application US/10297068


```
; Publication No. US20030228585A1
; GENERAL INFORMATION:
; APPLICANT: INOKO, Hidetoshi
; APPLICANT: KAGIYA, Taeko
; APPLICANT: ICHIHARA, Tatsuo
; APPLICANT: Matsumura, Yoshiyuki
; APPLICANT: MORIYA, Shogo
; APPLICANT: NISHIDA, Michio
; TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
; FILE REFERENCE: 13140B1174
; CURRENT APPLICATION NUMBER: US/10/297,068
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: JP 2000-164798
; PRIOR FILING DATE: 2000-06-01
; NUMBER OF SEQ ID NOS: 1298
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1041
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-1041
```

```
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 490 GCGGCTCAGCGCGCTC 506
Db 1 GCGCGACAGCGCGCTC 17
```

```
RESULT 285
US-10-297-068-1259
; Sequence 1259, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
; APPLICANT: INOKO, Hidetoshi
; APPLICANT: KAGIYA, Taeko
; APPLICANT: ICHIHARA, Tatsuo
; APPLICANT: Matsumura, Yoshiyuki
; APPLICANT: MORIYA, Shogo
; APPLICANT: NISHIDA, Michio
; TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
; FILE REFERENCE: 13140B1174
; CURRENT APPLICATION NUMBER: US/10/297,068
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: JP 2000-164798
; PRIOR FILING DATE: 2000-06-01
; NUMBER OF SEQ ID NOS: 1298
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1259
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-1259
```

```
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 370 TCCGCGATACGACCAG 386
Db 1 TCCGCGGATACGACCAG 17
```

```
RESULT 286
US-10-138-674-4198
; Sequence 4198, Application US/10138674
; Publication No. US20040077565A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4198
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4198
```

```
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.5e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 977 CCTCACCATGTCACC 993
Db 1 CGCUCACCAUGCUCAGC 17
```

```
RESULT 287
US-10-138-674-7439
; Sequence 7439, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7439
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7439
```

```
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.5e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 1992 TATCCTGATGATGCCA 2008
Db 1 UAUCCUGAUGCUGACA 17
```

```
RESULT 288
US-10-138-674-8640/c
; Sequence 8640, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
```

; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 8640
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8640

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1004 TGCCCTGCTTTTCCTT 1020
Db 17 TGGCTCTGCTTCTCCTT 1

RESULT 289
US-10-287-949A-4198
; Sequence 4198, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Payco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 4198
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4198

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.5e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 977 CCCACACCATGTCACC 993
Db 1 CGCUCACCAUGGUCAGC 17

RESULT 290
US-10-287-949A-7439
; Sequence 7439, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Payco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 7439
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7439

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.5e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1992 TATCCTGGATGATGCCA 2008
Db 1 UAUCCUGAUGCUGACA 17

RESULT 291
US-10-287-949A-8640/C
; Sequence 8640, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Payco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 8640
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8640

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1004 TGCCCTGCTTTTCCTT 1020
Db 17 TGGCTCTGCTTCTCCTT 1

RESULT 292
US-10-712-672-830
; Sequence 830, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowitra, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 830
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-830

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.5e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 300 TGGCGCAGCTGGCTTGG 316
:|||||:|||||
Db 1 UGCGGAGACUCGCGCTUGG 17

RESULT 293
US-09-320-337-57
Sequence 57, Application US/09320337
Patent No. US20010016352A1
GENERAL INFORMATION:
APPLICANT: Bohinski, Robert J.,
APPLICANT: Whitsett, Jeffrey A.
TITLE OF INVENTION: Nucleic Acid Sequences Controlling
TITLE OF INVENTION: Lung Cell - Specific Gene Expression
NUMBER OF SEQUENCES: 76
CORRESPONDENCE ADDRESS:
ADDRESSEE: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein
STREET: 6 Becker Farm Road
CITY: Roseland
STATE: New Jersey
COUNTRY: USA
ZIP: 07068
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch diskette
COMPUTER: IBM P160
OPERATING SYSTEM: WINDOWS 95
SOFTWARE: MS WORD 97
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/320,337
FILING DATE: 26-MAY-1999
CLASSIFICATION:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/442,809
FILING DATE: 17-MAY-1995
APPLICATION NUMBER: 08/245,356
FILING DATE: 18-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: Olstein, Elliot M.
REGISTRATION NUMBER: 24,025
REFERENCE/DOCKET NUMBER: 271010-447
TELECOMMUNICATION INFORMATION:
TELEPHONE: 973-994-1700
TELEFAX: 973-994-1744
INFORMATION FOR SEQ ID NO: 157:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: oligonucleotide
US-09-320-337-57
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1416 GGGCTCTCAGAGAAA 1432
:|||||:|||||
Db 1 GGGCTCTCAGAGCAA 17

RESULT 294
US-09-320-337-59
Sequence 59, Application US/09320337
Patent No. US20010016352A1
GENERAL INFORMATION:
APPLICANT: Bohinski, Robert J.,
APPLICANT: Whitsett, Jeffrey A.
TITLE OF INVENTION: Nucleic Acid Sequences Controlling
TITLE OF INVENTION: Lung Cell - Specific Gene Expression
NUMBER OF SEQUENCES: 76
CORRESPONDENCE ADDRESS:
ADDRESSEE: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

STREET: 6 Becker Farm Road
CITY: Roseland
STATE: New Jersey
COUNTRY: USA
ZIP: 07068
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch diskette
COMPUTER: IBM P160
OPERATING SYSTEM: WINDOWS 95
SOFTWARE: MS WORD 97
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/320,337
FILING DATE: 26-MAY-1999
CLASSIFICATION:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/442,809
FILING DATE: 17-MAY-1995
APPLICATION NUMBER: 08/245,356
FILING DATE: 18-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: Olstein, Elliot M.
REGISTRATION NUMBER: 24,025
REFERENCE/DOCKET NUMBER: 271010-447
TELECOMMUNICATION INFORMATION:
TELEPHONE: 973-994-1700
TELEFAX: 973-994-1744
INFORMATION FOR SEQ ID NO: 59:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: oligonucleotide
US-09-320-337-59
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1416 GGGCTCTCAGAGAAA 1432
:|||||:|||||
Db 1 GGGCTCTCAGAGCAA 17

RESULT 295
US-09-925-911-7/C
Sequence 7, Application US/09925911
Publication No. US20030049837A1
GENERAL INFORMATION:
APPLICANT: Weiss et al.
TITLE OF INVENTION: In Vitro and In Vivo Proliferation and Use of
TITLE OF INVENTION: Multipotent Neural Stem Cells and Their Progeny
FILE REFERENCE: 17810-705 (CTI-N5 DIVALCON)
CURRENT APPLICATION NUMBER: US/09/925,911
CURRENT FILING DATE: 2001-08-09
PRIORITY APPLICATION NUMBER: 08/484,203
PRIORITY FILING DATE: 2001-06-07
PRIORITY APPLICATION NUMBER: 08/270,412
PRIORITY FILING DATE: 1994-07-05
PRIORITY APPLICATION NUMBER: 07/726,812
PRIORITY FILING DATE: 1991-07-08
PRIORITY APPLICATION NUMBER: 08/385,404
PRIORITY FILING DATE: 1995-02-07
PRIORITY APPLICATION NUMBER: 07/961,813
PRIORITY FILING DATE: 1992-10-16
PRIORITY APPLICATION NUMBER: 08/359,945
PRIORITY FILING DATE: 1994-12-20
PRIORITY APPLICATION NUMBER: 08/221,655
PRIORITY FILING DATE: 1994-04-01
PRIORITY APPLICATION NUMBER: 07/967,622
PRIORITY FILING DATE: 1992-10-28
PRIORITY APPLICATION NUMBER: 08/376,062
PRIORITY FILING DATE: 1995-01-20

```
; PRIOR APPLICATION NUMBER: 08/010,829
; PRIOR FILING DATE: 1993-01-29
; PRIOR APPLICATION NUMBER: 08/149,508
; PRIOR FILING DATE: 1993-11-09
; PRIOR APPLICATION NUMBER: 08/311,099
; PRIOR FILING DATE: 1994-09-23
; PRIOR APPLICATION NUMBER: 08/338,730
; PRIOR FILING DATE: 1994-11-14
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:chemically
; US-09-925-911-7

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGTGACGCGCTGG 1609
Db 18 CGAGTGATGCGCTGG 2

RESULT 296
US-09-925-911-8
; Sequence 8, Application US/09925911
; Publication No. US20030049837A1
; GENERAL INFORMATION:
; APPLICANT: Weis et al.
; TITLE OF INVENTION: In Vitro and In Vivo Proliferation and Use of
; FILE REFERENCE: 17810-705 (CTI-N5 DIVILCON)
; CURRENT APPLICATION NUMBER: US/09/925,911
; PRIOR FILING DATE: 2001-08-09
; PRIOR APPLICATION NUMBER: 08/484,203
; PRIOR FILING DATE: 2001-06-07
; PRIOR APPLICATION NUMBER: 08/270,412
; PRIOR FILING DATE: 1994-07-05
; PRIOR APPLICATION NUMBER: 07/726,812
; PRIOR FILING DATE: 1991-07-08
; PRIOR APPLICATION NUMBER: 08/385,404
; PRIOR FILING DATE: 1995-02-07
; PRIOR APPLICATION NUMBER: 07/961,813
; PRIOR FILING DATE: 1992-10-16
; PRIOR APPLICATION NUMBER: 08/359,945
; PRIOR FILING DATE: 1994-12-20
; PRIOR APPLICATION NUMBER: 08/221,655
; PRIOR FILING DATE: 1994-04-01
; PRIOR APPLICATION NUMBER: 07/967,622
; PRIOR FILING DATE: 1992-10-28
; PRIOR APPLICATION NUMBER: 08/376,062
; PRIOR FILING DATE: 1995-01-20
; PRIOR APPLICATION NUMBER: 08/010,829
; PRIOR FILING DATE: 1993-01-29
; PRIOR APPLICATION NUMBER: 08/149,508
; PRIOR FILING DATE: 1993-11-09
; PRIOR APPLICATION NUMBER: 08/311,099
; PRIOR FILING DATE: 1994-09-23
; PRIOR APPLICATION NUMBER: 08/338,730
; PRIOR FILING DATE: 1994-11-14
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:chemically
```

```
; OTHER INFORMATION: synthesized
; US-09-925-911-8

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGTGACGCGCTGG 1609
Db 1 CGAGTGATGCGCTGG 17

RESULT 297
US-09-882-945A-81/c
; Sequence 81, Application US/09882945A
; Publication No. US20030143535A1
; GENERAL INFORMATION:
; APPLICANT: Lyanichev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neri, Bruce
; APPLICANT: Vener, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: FORS-04586
; CURRENT APPLICATION NUMBER: US/09/882,945A
; CURRENT FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 81
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
; US-09-882-945A-81

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 483 GGTGCCCCGGCGTCAGG 499
Db 17 GGGGCCCGCGCTCTGG 1

RESULT 298
US-09-306-333A-17/c
; Sequence 17, Application US/09306333A
; Publication No. US20030152918A1
; GENERAL INFORMATION:
; APPLICANT: Academy of Applied Science
; TITLE OF INVENTION: BRCA1 and hMLH1 Gene Primer Sequences and Method for
; FILE REFERENCE: BRCA1
; CURRENT APPLICATION NUMBER: US/09/306,333A
; CURRENT FILING DATE: 1999-05-06
; PRIOR APPLICATION NUMBER: PCT/IB00/01607
; PRIOR FILING DATE: 2000-11-06
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-306-333A-17

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1166 AGTTAGGAAGAGCTG 1182
Db 17 ACTTAGGAAGAGCTG 1
```

```
RESULT 299
US-09-838-028-9
; Sequence 9, Application US/09838028
; Publication No. US20030175857A1
; GENERAL INFORMATION:
; APPLICANT: Lind, Peter
; APPLICANT: Berthold, Malin
; TITLE OF INVENTION: No. US20030175857A1e1 G Protein-Coupled Receptor
; FILE REFERENCE: 001250S2
; CURRENT APPLICATION NUMBER: US/09/838,028
; CURRENT FILING DATE: 2001-04-19
; PRIOR APPLICATION NUMBER: 60/198,600
; PRIOR FILING DATE: 2000-04-19
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Primer
US-09-838-028-9

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      557 GCCTCTGCTGTTCTG 573
Db      1 GCCTCTACTGTTCTG 17

RESULT 300
US-10-308-264-685/c
; Sequence 685, Application US/10308264
; Publication No. US20040029133A1
; GENERAL INFORMATION:
; APPLICANT: Hermetz, Corinna
; TITLE OF INVENTION: MITOCHONDRIAL DNA POLYMORPHISM
; FILE REFERENCE: 660088.461
; CURRENT APPLICATION NUMBER: US/10/308,264
; CURRENT FILING DATE: 2002-11-25
; NUMBER OF SEQ ID NOS: 697
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 685
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-308-264-685

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      658 TCAGCCGATACCTTCAC 674
Db      18 TCATCCGCTACTTCAC 2

RESULT 301
US-09-945-353-1
; Sequence 1, Application US/09945353
; Publication No. US20020142982A1
; GENERAL INFORMATION:
; APPLICANT: University of Connecticut Health Center
; APPLICANT: Hla, Timothy
; APPLICANT: Lee, Meng-Jer
; APPLICANT: Clafey, Kevin P
```

```
; APPLICANT: Ancellin, Nicholas
; APPLICANT: Thangada, Shobha
; TITLE OF INVENTION: Method for regulating Angiogenesis
; FILE REFERENCE: UCT-0012
; CURRENT APPLICATION NUMBER: US/09/945,353
; CURRENT FILING DATE: 2001-08-31
; PRIOR APPLICATION NUMBER: US 60/152,266
; PRIOR FILING DATE: 1999-09-02
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; APPLICANT: M.J. Lee, S. Thangada, K.P. Clafey, N. Ancellin, C.H. Liu, M.
; AUTHORS: Kluk, W. Volip, R. Sha-fi and T. Hla
; TITLE: Vacuolar endothelial cell adherens junction assembly and
; TITLE: morphogenesis induced by sphingosine-1-phosphate-
; JOURNAL: Cell
; VOLUME: 99
; ISSUE: 3
; PAGES: 301-312
; DATE: 1999-10-29
; RELEVANT RESIDUES: (1)..(18)
US-09-945-353-1

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1602 GCGCGTGTGGGACCCA 1618
Db      1 GACGCTGTGGGCCCCA 17

RESULT 302
US-09-945-353-3/c
; Sequence 3, Application US/09945353
; Publication No. US20020142982A1
; GENERAL INFORMATION:
; APPLICANT: University of Connecticut Health Center
; APPLICANT: Hla, Timothy
; APPLICANT: Lee, Meng-Jer
; APPLICANT: Clafey, Kevin P
; APPLICANT: Ancellin, Nicholas
; APPLICANT: Thangada, Shobha
; TITLE OF INVENTION: Method for regulating Angiogenesis
; FILE REFERENCE: UCT-0012
; CURRENT APPLICATION NUMBER: US/09/945,353
; CURRENT FILING DATE: 2001-08-31
; PRIOR APPLICATION NUMBER: US 60/152,266
; PRIOR FILING DATE: 1999-09-02
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; APPLICANT: Homo sapiens
US-09-945-353-3

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1602 GCGCGTGTGGGACCCA 1618
Db      18 GACGCTGTGGGCCCCA 2

RESULT 303
US-10-156-995-131/c
; Sequence 131, Application US/10156995
```

```
; Publication No. US20030211486A1
; GENERAL INFORMATION:
; APPLICANT: DNA Print Genomics, Inc.
; APPLICANT: FRUDAKIS, Tony N.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DETECTING POLYMORPHISMS ASSOCIATED W
; TITLE OF INVENTION: PIGMENTATION
; FILE REFERENCE: DNA1140-7
; CURRENT APPLICATION NUMBER: US/10/156,995
; CURRENT FILING DATE: 2002-05-28
; PRIOR APPLICATION NUMBER: US 60/346,303
; PRIOR FILING DATE: 2002-01-02
; PRIOR APPLICATION NUMBER: US 60/334,674
; PRIOR FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: US 60/344,418
; PRIOR FILING DATE: 2001-10-26
; PRIOR APPLICATION NUMBER: US 60/323,662
; PRIOR FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: US 60/310,781
; PRIOR FILING DATE: 2001-08-07
; PRIOR APPLICATION NUMBER: US 60/300,187
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: US 60/293,560
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 224
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 131
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-156-995-131

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1077 TCTGGCAAGTCCAGCC 1093
          |||||||
Db       17 TCCGCGAAAGTCCAGGC 1

RESULT 304
US-10-156-995-132/c
; Sequence 132, Application US/10156995
; Publication No. US20030211486A1
; GENERAL INFORMATION:
; APPLICANT: DNA Print Genomics, Inc.
; APPLICANT: FRUDAKIS, Tony N.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DETECTING POLYMORPHISMS ASSOCIATED W
; FILE REFERENCE: DNA1140-7
; CURRENT APPLICATION NUMBER: US/10/156,995
; CURRENT FILING DATE: 2002-05-28
; PRIOR APPLICATION NUMBER: US 60/346,303
; PRIOR FILING DATE: 2002-01-02
; PRIOR APPLICATION NUMBER: US 60/334,674
; PRIOR FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: US 60/344,418
; PRIOR FILING DATE: 2001-10-26
; PRIOR APPLICATION NUMBER: US 60/323,662
; PRIOR FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: US 60/310,781
; PRIOR FILING DATE: 2001-08-07
; PRIOR APPLICATION NUMBER: US 60/300,187
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: US 60/293,560
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 224
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 132
; LENGTH: 18
; TYPE: DNA
```

```
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-156-995-132

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1077 TCTGGCAAGTCCAGCC 1093
          |||||||
Db       17 TCCGCGAAAGTCCAGGC 1

RESULT 305
US-10-037-616-10
; Sequence 10, Application US/10037616
; Publication No. US20020123148A1
; GENERAL INFORMATION:
; APPLICANT: English, Denis
; APPLICANT: Kovacs, Richard J.
; APPLICANT: Rizzo, Maria T.
; APPLICANT: Silva, Daniel T.
; TITLE OF INVENTION: Sphingolipid Compositions and Methods for Their Therapeutic Use
; FILE REFERENCE: 7042-119
; CURRENT APPLICATION NUMBER: US/10/037,616
; CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: US 60/243,887
; PRIOR FILING DATE: 2000-10-27
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-10-037-616-10

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1602 GCGCGTGTGGGACCCA 1618
          |||||||
Db       1 GACGCTGTGTGGGCCCA 17

RESULT 306
US-10-199-830-7/c
; Sequence 7, Application US/10199830
; Publication No. US20030109008A1
; GENERAL INFORMATION:
; APPLICANT: Weles, Samuel
; APPLICANT: Reynolds, Brent
; APPLICANT: Hammang, Joseph P
; APPLICANT: Baetge, E. B.
; TITLE OF INVENTION: Methods of Making cDNA Libraries
; FILE REFERENCE: 17810-705 DIV2CON2
; CURRENT APPLICATION NUMBER: US/10/199,830
; CURRENT FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: 08/486,313
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/270,412
; PRIOR FILING DATE: 1994-07-05
; PRIOR APPLICATION NUMBER: 07/726,812
; PRIOR FILING DATE: 1991-07-08
; PRIOR APPLICATION NUMBER: 08/385,404
; PRIOR FILING DATE: 1995-02-07
; PRIOR APPLICATION NUMBER: 07/961,813
; PRIOR FILING DATE: 1992-10-16
; PRIOR APPLICATION NUMBER: 08/359,945
; PRIOR FILING DATE: 1994-12-20
```

PRIOR APPLICATION NUMBER: 08/221,655
PRIOR FILING DATE: 1994-04-01
PRIOR APPLICATION NUMBER: 07/967,622
PRIOR FILING DATE: 1992-10-28
PRIOR APPLICATION NUMBER: 08/376,062
PRIOR FILING DATE: 1995-01-20
PRIOR APPLICATION NUMBER: 08/010,829
PRIOR FILING DATE: 1993-01-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 8
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO: 7
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: FGF sense
US-10-199-830-7

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1593 CGAGGTGACGCGCTGG 1609
DB 18 CGAGGTGATGCCCTGG 2

RESULT 307
US-10-199-830-8
Sequence 8, Application US/10199830
Publication No. US20030109008A1
GENERAL INFORMATION:
APPLICANT: Weises, Samuel
APPLICANT: Reynolds, Brent
APPLICANT: Hamman, Joseph P
APPLICANT: Baetge, E. E
TITLE OF INVENTION: Methods of Making cDNA Libraries
FILE REFERENCE: 17810-705 DIV12CON2
CURRENT APPLICATION NUMBER: US/10/199,830
PRIOR FILING DATE: 2002-07-19
PRIOR APPLICATION NUMBER: 08/486,313
PRIOR FILING DATE: 1995-06-07
PRIOR APPLICATION NUMBER: 08/270,412
PRIOR FILING DATE: 1994-07-05
PRIOR APPLICATION NUMBER: 07/726,812
PRIOR FILING DATE: 1991-07-08
PRIOR APPLICATION NUMBER: 08/385,404
PRIOR FILING DATE: 1995-02-07
PRIOR APPLICATION NUMBER: 07/961,813
PRIOR FILING DATE: 1992-10-16
PRIOR APPLICATION NUMBER: 08/359,945
PRIOR FILING DATE: 1994-12-20
PRIOR APPLICATION NUMBER: 08/221,655
PRIOR FILING DATE: 1994-04-01
PRIOR APPLICATION NUMBER: 07/967,622
PRIOR FILING DATE: 1992-10-28
PRIOR APPLICATION NUMBER: 08/376,062
PRIOR FILING DATE: 1995-01-20
PRIOR APPLICATION NUMBER: 08/010,829
PRIOR FILING DATE: 1993-01-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 8
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO: 8
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: FGF anti-sense
US-10-199-830-8

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1593 CGAGGTGACGCGCTGG 1609
DB 1 CGAGGTGATGCCCTGG 17

RESULT 308
US-10-216-122-135
Sequence 135, Application US/10216122
Publication No. US20030121063A1
GENERAL INFORMATION:
APPLICANT: Kazarian, Haig H.
APPLICANT: Oseletag, Eric
APPLICANT: Deberardinis, Ralph
TITLE OF INVENTION: COMPOSITIONS AND METHODS OF USE OF MAMMALIAN RETROTRANSPOSONS
FILE REFERENCE: 053893-5006-03
CURRENT APPLICATION NUMBER: US/10/216,122
CURRENT FILING DATE: 2002-08-09
PRIOR APPLICATION NUMBER: US 09/653,812
PRIOR FILING DATE: 2000-09-01
PRIOR APPLICATION NUMBER: US 08/847,844
PRIOR FILING DATE: 1997-04-28
PRIOR APPLICATION NUMBER: US 08/749,805
PRIOR FILING DATE: 1996-11-15
PRIOR APPLICATION NUMBER: US 60/006,831
PRIOR FILING DATE: 1995-11-16
NUMBER OF SEQ ID NOS: 154
SOFTWARE: PatentIn version 3.1
SEQ ID NO 135
LENGTH: 18
TYPE: DNA
ORGANISM: Homo sapiens
US-10-216-122-135

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1817 AGCCACTATGAGGAA 1833
DB 2 AGCCACTATGATGAA 18

RESULT 309
US-10-168-771-84/C
Sequence 84, Application US/10168771
Publication No. US20030148974A1
GENERAL INFORMATION:
APPLICANT: Bretl P. Monia
APPLICANT: Lex M. Cowser
APPLICANT: Richard A. Roth
APPLICANT: Isis Pharmaceuticals, Inc.
TITLE OF INVENTION: ANTISENSE MODULATION OF Akt-3 EXPRESSION
FILE REFERENCE: RTSP-0322
CURRENT APPLICATION NUMBER: US/10/168,771
CURRENT FILING DATE: 2002-06-21
PRIOR APPLICATION NUMBER: 09/474,922
PRIOR FILING DATE: 1999-12-29
NUMBER OF SEQ ID NOS: 89
SEQ ID NO 84
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-168-771-84

Query Match 0.6%; Score 13.8; DB 1; Length 18;

```
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1867 AGTTTCATCTGAGCT 1883
    ||||| |||||
Db 18 AGTTTCCTCTGAGCT 2

RESULT 310
US-10-169-983-27
; Sequence 27, Application US/10169983
; Publication No. US20030158250A1
; GENERAL INFORMATION:
; APPLICANT: Takara Shuzo Co., Ltd.
; TITLE OF INVENTION: Therapeutic agents
; FILE REFERENCE: 01-011-PCT
; CURRENT APPLICATION NUMBER: US/10/169,983
; CURRENT FILING DATE: 2002-07-14
; PRIOR APPLICATION NUMBER: JP 2000-4989
; PRIOR FILING DATE: 2000-01-13
; PRIOR APPLICATION NUMBER: JP 2000-303711
; PRIOR FILING DATE: 2000-10-03
; NUMBER OF SEQ ID NOS: 61
; SEQ ID NO 27
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Designed primer based on nucleotide sequence of
; OTHER INFORMATION: human macrophage inflammatory protein-2-alpha mRNA.
US-10-169-983-27

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 564 GCTGTTCTGCTGCTGG 580
    ||||| |||||
Db 2 GCTGCTCTGCTGCTGG 18

RESULT 311
US-10-302-279-51/c
; Sequence 0, Application US/10302279
; Publication No. US20030171566A1
; GENERAL INFORMATION:
; APPLICANT: Dean, Michael Carlton
; Hahn, Heidi Eve
; Wickling, Carol
; Christiansen, Jeffrey
; Zaphiropoulos, Peter G.
; Galiani, Mae R.
; Shanley, Susan Mary
; Chidambaram, Abhirami
; Vorechovsky, Igor
; Holmberg-Lindstrom, Erika
; TITLE OF INVENTION: A Basal Cell Carcinoma Tumor Suppressor Gene
; NUMBER OF SEQUENCES: 84
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/302,279
; FILING DATE: 22-No. US20030171566A1-2002
```

```
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/857,636
; FILING DATE: 16-MAY-1997
; APPLICATION NUMBER: US 60/017,906
; FILING DATE: 17-MAY-1996
; APPLICATION NUMBER: AU P00011
; FILING DATE: 21-MAY-1996
; APPLICATION NUMBER: AU P00363
; FILING DATE: 07-JUN-1996
; APPLICATION NUMBER: US 60/019,765
; FILING DATE: 14-JUN-1996
ATTORNEY/AGENT INFORMATION:
; NAME: Hyman, Laurence J.
; REGISTRATION NUMBER: 35, 551
; REFERENCE/DOCKET NUMBER: 015280-278200US
TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: /note= "PTCR25 primer"
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: -
; LOCATION: 1..18
; SEQUENCE DESCRIPTION: SEQ ID NO: 51:
US-10-302-279-51

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1461 CTGCCACCAAGTGTC 1477
    ||||| |||||
Db 17 CTGCCACCAAGTGATC 1

RESULT 312
US-10-168-445-205
; Sequence 205, Application US/10168445
; Publication No. US20030177518A1
; GENERAL INFORMATION:
; APPLICANT: Osbourn, Anne E
; APPLICANT: Haralampidis, Kosmas
; APPLICANT: Bryan, Gregory T
; TITLE OF INVENTION: Plant Gene
; FILE REFERENCE: 0380-P02892US0
; CURRENT APPLICATION NUMBER: US/10/168,445
; CURRENT FILING DATE: 2002-10-30
; PRIOR APPLICATION NUMBER: PCT/GB00/04908
; PRIOR FILING DATE: 2000-12-20
; PRIOR APPLICATION NUMBER: GB 9930394.3
; PRIOR FILING DATE: 1999-12-22
; PRIOR APPLICATION NUMBER: GB 0020217.6
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 219
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 205
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Primer
US-10-168-445-205

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```


QY 941 TATGCTCTTGGGATC 957
|||
Db 1 TATGGCTCTTGGGGAC 17

RESULT 313

US-10-349-143-8459
; Sequence 8459, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marla
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8459
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-15599 for SEQ 594, in compleme
US-10-349-143-8459

Query Match 0.6%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 77 TACTGCTACTTCTGCCC 93
|||
Db 2 TACTGCTACTACTCTCC 18

RESULT 314

US-10-703-864-25/c
; Sequence 25, Application US/10703864
; Publication No. US20040077580A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowsett
; APPLICANT: Susan Murray
; APPLICANT: Madeline M. Butler
; APPLICANT: Nicholas M. Dean
; TITLE OF INVENTION: ANTISENSE MODULATION OF PI3K P85 EXPRESSION
; FILE REFERENCE: ISIS0057-102 (ISPH-0519)
; CURRENT APPLICATION NUMBER: US/10/703,864
; CURRENT FILING DATE: 2003-11-10
; PRIOR APPLICATION NUMBER: US/09/715,983
; PRIOR FILING DATE: 2000-11-20
; NUMBER OF SEQ ID NOS: 73
; SEQ ID NO 25
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-703-864-25

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1772 TTGGAGAGAGCTTCAA 1788
|||
Db 17 TTGGAGAGAGCTTGAA 1

RESULT 315

US-10-628-109-64/c
; Sequence 64, Application US/10628109
; Publication No. US20040101866A1
; GENERAL INFORMATION:
; APPLICANT: Bowdlen, Katherine S.
; APPLICANT: Frederickson, Shana
; APPLICANT: Lin, Ying-Chi
; APPLICANT: McWhirter, John
; APPLICANT: Maruyama, Yoshiaki
; TITLE OF INVENTION: NESTED OLIGONUCLEOTIDES CONTAINING A HAIRPIN FOR NUCLEIC ACID
; FILE REFERENCE: 1087-35 DIV
; CURRENT APPLICATION NUMBER: US/10/628,109
; CURRENT FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US 60/254,669
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 60/323,400
; PRIOR FILING DATE: 2001-09-19
; PRIOR APPLICATION NUMBER: US 10/014,012
; PRIOR FILING DATE: 2001-12-10
; NUMBER OF SEQ ID NOS: 231
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 64
; LENGTH: 18
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-628-109-64

Query Match 0.6%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1757 AAGAGCCACAGGTATTT 1773
|||
Db 17 AAGAGCCACAGGTGTTT 1

RESULT 316

US-10-160-358-67
; Sequence 67, Application US/10160358
; Publication No. US20030198969A1
; GENERAL INFORMATION:
; APPLICANT: Genesense Pharmaceuticals, Inc.
; APPLICANT: Bieganski, Karyn
; APPLICANT: Cappola, Gina-Marie
; APPLICANT: Koshy, Beena
; APPLICANT: Monroe, Glen
; TITLE OF INVENTION: HAPLOTYPES OF THE TACR2 GENE
; FILE REFERENCE: TACR2 MMH-0225US
; CURRENT APPLICATION NUMBER: US/10/160,358
; CURRENT FILING DATE: 2002-05-30
; PRIOR APPLICATION NUMBER: PCT/US01/47394
; PRIOR FILING DATE: 2001-11-09
; PRIOR APPLICATION NUMBER: 60/247,649
; PRIOR FILING DATE: 2000-11-09
; NUMBER OF SEQ ID NOS: 139
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 67
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-160-358-67

Query Match 0.6%; Score 13.6; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1.5e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 62 CATGCTGGGACA 75
Db 1 CATGCTGGGACR 14

RESULT 317
US-10-035-833A-6/c
; Sequence 6, Application US/10035833A
; Publication No. US20040072156A1
; GENERAL INFORMATION:
; APPLICANT: Nakamura, Yuho
; APPLICANT: Sekine, Akihiro
; APPLICANT: Iida, Aritoshi
; APPLICANT: Saito, Osamu
; TITLE OF INVENTION: Detection of Genetic Polymorphisms
; FILE REFERENCE: FORS-06904
; CURRENT APPLICATION NUMBER: US/10/035, 833A
; CURRENT FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 7669
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 41
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-035-833A-6

Query Match 0.6%; Score 13.6; DB 1; Length 41;
Best Local Similarity 67.9%; Pred. No. 2.7e+02;
Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 2105 ACCTCAGCCTGTGAGACGAGCTGACCA 2132
Db 37 AGCAGAGCAGGCTGATCAGGCTGACCA 10

RESULT 318
US-10-035-833A-5176/c
; Sequence 5176, Application US/10035833A
; Publication No. US20040072156A1
; GENERAL INFORMATION:
; APPLICANT: Nakamura, Yuho
; APPLICANT: Sekine, Akihiro
; APPLICANT: Iida, Aritoshi
; APPLICANT: Saito, Osamu
; TITLE OF INVENTION: Detection of Genetic Polymorphisms
; FILE REFERENCE: FORS-06904
; CURRENT APPLICATION NUMBER: US/10/035, 833A
; CURRENT FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 7669
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5176
; LENGTH: 41
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-035-833A-5176

Query Match 0.6%; Score 13.6; DB 1; Length 41;
Best Local Similarity 67.9%; Pred. No. 2.7e+02;
Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 2105 ACCTCAGCCTGTGAGACGAGCTGACCA 2132
Db 37 AGCAGAGCAGGCTGATCAGGCTGACCA 10

RESULT 319
US-10-035-833A-7638/c
; Sequence 7638, Application US/10035833A
; Publication No. US20040072156A1
; GENERAL INFORMATION:

; APPLICANT: Nakamura, Yuho
; APPLICANT: Sekine, Akihiro
; APPLICANT: Iida, Aritoshi
; APPLICANT: Saito, Osamu
; TITLE OF INVENTION: Detection of Genetic Polymorphisms
; FILE REFERENCE: FORS-06904
; CURRENT APPLICATION NUMBER: US/10/035, 833A
; CURRENT FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 7669
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7638
; LENGTH: 41
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-035-833A-7638

Query Match 0.6%; Score 13.6; DB 1; Length 41;
Best Local Similarity 67.9%; Pred. No. 2.7e+02;
Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 2105 ACCTCAGCCTGTGAGACGAGCTGACCA 2132
Db 37 AGCAGAGCAGGCTGATCAGGCTGACCA 10

RESULT 320
US-09-504-231A-714
; Sequence 714, Application US/09504231A
; Patent No. US20020013458A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence
; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; FILE REFERENCE: IP1 247/282
; CURRENT APPLICATION NUMBER: US/09/504, 231A
; CURRENT FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: 09/274, 553
; PRIOR FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257, 608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100, 842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083, 217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3242
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 714
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-504-231A-714

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 40.0%; Pred. No. 1.6e+02;
Matches 6; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

Qy 1010 TGCTTTCCTCTGTC 1024
Db 1 TGCCTTTCCTCTGTC 15

RESULT 321
US-09-274-553D-714
; Sequence 714, Application US/09274553D
; Patent No. US20020082225A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Lawrence

```

; APPLICANT: McSwiggen, James
; APPLICANT: Roberts, Beth
; APPLICANT: Pavco, Pamela
; APPLICANT: Macejak, Dennis
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
; FILE REFERENCE: rpi 247/282
; CURRENT APPLICATION NUMBER: US/09/274,553D
; CURRENT FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3148
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 714
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-274-553D-714

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 40.0%; Pred. No. 1.6e+02;
Matches 6; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY      1010 TGCTTTCCTCTCTGC 1024
Db      1 UGCUUUUCCUUC 15

RESULT 322
US-09-781-988-121/c
; Sequence 121, Application US/09781988
; Patent No. US20020150881A1
; GENERAL INFORMATION:
; APPLICANT: Ladner, Robert Charles
; Guterman, Sonia Kosow
; Roberts, Bruce Lindsey
; Markland, William
; Ley, Arthur Charles
; Kent, Rachel Baribault
; TITLE OF INVENTION: Directed Evolution of No. US20020150881A1
; Binding Proteins
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Broadway and Neimark
; STREET: 419 Seventh Street, N.W.
; Suite 300
; CITY: Washington,
; STATE: DC
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 4.2
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/781,988
; FILING DATE: 14-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/664,989
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/487,063
; FILING DATE: 02-MAR-1990
; APPLICATION NUMBER: 07/240,160
; FILING DATE: 02-SEP-1988
; ATTORNEY/AGENT INFORMATION:
```

```

; NAME: Cooper, Iver P.
; REGISTRATION NUMBER: 28005
; REFERENCE/DOCKET NUMBER: LADNER 7
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 121:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: circular
; MOLECULE TYPE: genomic DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 121:
US-09-781-988-121

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      597 TGGGAGATGGCCAT 611
Db      15 TGGGAGATAGCCAT 1

RESULT 323
US-09-879-813-71/c
; Sequence 71, Application US/09879813
; Patent No. US2002015453A1
; GENERAL INFORMATION:
; APPLICANT: Sale, Julian E.
; APPLICANT: Neuberger, Michael S.
; APPLICANT: Cumbers, Sarah J.
; TITLE OF INVENTION: Method of Generating Diversity
; FILE REFERENCE: 18396/2005
; CURRENT APPLICATION NUMBER: US/09/879,813
; CURRENT FILING DATE: 2001-06-11
; PRIOR APPLICATION NUMBER: 09/828,717
; PRIOR FILING DATE: 2001-06-04
; PRIOR APPLICATION NUMBER: PCT/GB99/03358
; PRIOR FILING DATE: 1999-10-08
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 71
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (7)-(9)
; OTHER INFORMATION: F242
; OTHER INFORMATION: The sequence GCA replaces the sequence ACACGCTGTGTTACTGT
US-09-879-813-71

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      18 TCCCGCTCCCGCGG 32
Db      15 TCTCGCTCCCGCGG 1

RESULT 324
US-09-893-878-121/c
; Sequence 121, Application US/09893878
; Publication No. US2003013717A1
; GENERAL INFORMATION:
; APPLICANT: Ladner, Robert Charles
; Guterman, Sonia Kosow
; Roberts, Bruce Lindsey
; Markland, William
; Ley, Arthur Charles
```

```

;
; TITLE OF INVENTION: Directed Evolution of No. US20030113717A1e1
; ORGANISM: Binding Proteins
; FEATURE: 121
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Browdy and Neimark
; STREET: 419 Seventh Street, N.W.
; Suite 300
; CITY: Washington,
; STATE: DC
; COUNTRY: USA
; ZIP: 20004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/893,878
; FILING DATE: 29-Jun-2001
; CLASSIFICATION: <Unknown>
; PRIORITY INFORMATION:
; APPLICATION NUMBER: 08/009,319
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/664,989
; FILING DATE: 01-MAR-1991
; APPLICATION NUMBER: PCT/US89/03731
; FILING DATE: 01-SEP-1989
; APPLICATION NUMBER: 07/487,063
; FILING DATE: 02-MAR-1990
; APPLICATION NUMBER: 07/240,160
; FILING DATE: 02-SEP-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Cooper, Iver P.
; REGISTRATION NUMBER: 28605
; REFERENCE/DOCKET NUMBER: LADNER 7
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
;
; INFORMATION FOR SEQ ID NO: 121:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: circular
; MOLECULE TYPE: genomic DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 121:
US-09-893-878-121

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      597 TGGGAGATGGCCAT 611
DB      15 TGGGAGATAGCCAT 1

RESULT 325
US-09-862-417A-1
; Sequence 1, Application US/09862417A
; Publication No. US20030148525A1
; GENERAL INFORMATION:
; APPLICANT: Wang, Xiao
; TITLE OF INVENTION: of Specific Primer Extension Method and Kit for Detection and Quant
; FILE REFERENCE: 55861.00007
; CURRENT APPLICATION NUMBER: US/09/862,417A
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 15
```

```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic oligonucleotide
US-09-862-417A-1

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1322 GTGGGACCTTGCA 1336
DB      1 GTGGGACCTGTCA 15

RESULT 326
US-09-896-095-121/c
; Sequence 121, Application US/09896095
; Publication No. US20030219886A1
; GENERAL INFORMATION:
; APPLICANT: LADNER, Charles C.
; APPLICANT: GUTERMAN, Sonia K.
; APPLICANT: ROBERTS, Bruce L.
; APPLICANT: MARKLAND, William
; APPLICANT: LEY, Arthur C.
; TITLE OF INVENTION: DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS
; FILE REFERENCE: LADNER=7L
; CURRENT APPLICATION NUMBER: US/09/896,095
; FILING DATE: 2001-06-29
; PRIOR APPLICATION NUMBER: 08/415,922
; PRIOR FILING DATE: 1995-03-04
; PRIOR APPLICATION NUMBER: 08/009,319
; PRIOR FILING DATE: 1993-01-26
; PRIOR APPLICATION NUMBER: 07/664,989
; PRIOR FILING DATE: 1991-03-01
; PRIOR APPLICATION NUMBER: 08/993,776
; PRIOR FILING DATE: 1997-12-18
; NUMBER OF SEQ ID NOS: 274
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 121
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic, Epic20 (15-19) DNA
US-09-896-095-121

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      597 TGGGAGATGGCCAT 611
DB      15 TGGGAGATAGCCAT 1

RESULT 327
US-10-408-157-6/c
; Sequence 6, Application US/10408157
; Publication No. US20040034878A1
; GENERAL INFORMATION:
; APPLICANT: Roberts, James M.
; APPLICANT: Coats, Steven R.
; APPLICANT: Fero, Matthew L.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR MEDIATING
; FILE REFERENCE: CELL CYCLE PROGRESSION
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew
; STREET: One Market Plaza, Stuart Street Tower
; CITY: San Francisco
; STATE: California
```

```

; COUNTRY: USA
; ZIP: 94105-1492
; LOCATION: (7)-(9)
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/408,157
; FILING DATE: 03-Apr-2003
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/656,562
; FILING DATE: 31-MAY-31
; APPLICATION NUMBER: US/08/588,595
; FILING DATE: 18-JAN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W.
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 14538A-19
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleotide
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-10-408-157-6

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      799 GCTGCTCGCGCCAG 813
Db      15 GCTCTCTCGCGCCAG 1

RESULT 328
US-10-146-505-71/C
; Sequence 71, Application US/10146505
; Publication No. US2003010889A1
; GENERAL INFORMATION:
; APPLICANT: Neuberger, Michael S.
; APPLICANT: Cumbers, Sarah J.
; TITLE OF INVENTION: Method of Generating Diversity
; FILE REFERENCE: 18396/2005B
; CURRENT APPLICATION NUMBER: US/10/146,505
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: 09/828,717
; PRIOR FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: 09/879,813
; PRIOR FILING DATE: 2001-06-11
; PRIOR APPLICATION NUMBER: PCT/GB99/03358
; PRIOR FILING DATE: 1999-10-08
; PRIOR APPLICATION NUMBER: GB 9822104.7
; PRIOR FILING DATE: 1998-10-09
; PRIOR APPLICATION NUMBER: GB 9901141.3
; PRIOR FILING DATE: 1999-01-19
; PRIOR APPLICATION NUMBER: GB 9913435.5
; PRIOR FILING DATE: 1999-06-09
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 71
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
```

```

; NAME/KEY: misc feature
; LOCATION: (7)-(9)
; OTHER INFORMATION: F242
; OTHER INFORMATION: The sequence GGA replaces the sequence ACACGCTGTATTACTGT
US-10-146-505-71

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      18 TCCCGCTCCCGCGG 32
Db      15 TCTCGCTCCCGCGG 1

RESULT 329
US-10-440-850-231/C
; Sequence 231, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Reverse
; FILE REFERENCE: 250/130 (MEH800-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 231
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-440-850-231

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      502 GGCTCTGGAACCT 516
Db      15 GGCTCTGGAACCT 1

RESULT 330
US-10-126-685-121/C
; Sequence 121, Application US/10126685
; Publication No. US20030219722A1
; GENERAL INFORMATION:
; APPLICANT: Ladner, Robert Charles
; APPLICANT: Guetman, Sonia Kosow
; APPLICANT: Roberts, Bruce Lindsey
; APPLICANT: Markland, William
; APPLICANT: Ley, Arthur Charles
; APPLICANT: Kent, Rachel Baribault
; TITLE OF INVENTION: Directed Evolution of No. US20030219722A1
; BINDING PROTEINS
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Browdy and Neimark
; STREET: 419 Seventh Street, N.W.
; SUITE: Suite 300
; CITY: Washington,
```

```

; STATE: DC
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/126,685
; FILING DATE: 22-Apr-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/009,319
; FILING DATE: 1993-01-26
; APPLICATION NUMBER: 07/664,989
; FILING DATE: 01-MAR-1991
; APPLICATION NUMBER: PCT/US89/03731
; FILING DATE: 01-SEP-1989
; APPLICATION NUMBER: 07/487,063
; FILING DATE: 02-MAR-1990
; APPLICATION NUMBER: 07/240,160
; FILING DATE: 02-SEP-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Cooper, Iver P.
; REGISTRATION NUMBER: 28005
; REFERENCE/DOCKET NUMBER: LADNER 7
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 121:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: circular
; MOLECULE TYPE: genomic DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 121:
US-10-126-685-121

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      597 TGGGAGATGGCCAT 611
Db      15 TGGGAGATAGCCAT 1

RESULT 331
US-10-127-028-121/c
; Sequence 121, Application US/10127028
; Publication No. US20040005539A1
; GENERAL INFORMATION:
; APPLICANT: Ladner, Robert Charles
; Guterman, Sonia Kosow
; Roberts, Bruce Lindsey
; Markland, William
; Ley, Arthur Charles
; Kent, Rachel Barbault
; TITLE OF INVENTION: Directed Evolution of No. US20040005539A1e1
; Binding Proteins
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Browdy and Neimark
; STREET: 419 Seventh Street, N.W.
; Suite 300
; CITY: Washington,
; STATE: DC
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
```

```

; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/127,028
; FILING DATE: 22-Apr-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/009,319
; FILING DATE: 1993-01-26
; APPLICATION NUMBER: 07/664,989
; FILING DATE: 01-MAR-1991
; APPLICATION NUMBER: PCT/US89/03731
; FILING DATE: 01-SEP-1989
; APPLICATION NUMBER: 07/487,063
; FILING DATE: 02-MAR-1990
; APPLICATION NUMBER: 07/240,160
; FILING DATE: 02-SEP-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Cooper, Iver P.
; REGISTRATION NUMBER: 28005
; REFERENCE/DOCKET NUMBER: LADNER 7
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 121:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: circular
; MOLECULE TYPE: genomic DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 121:
US-10-127-028-121

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      597 TGGGAGATGGCCAT 611
Db      15 TGGGAGATAGCCAT 1

RESULT 332
US-10-126-544-121/c
; Sequence 121, Application US/10126544
; Publication No. US20040023205A1
; GENERAL INFORMATION:
; APPLICANT: Ladner, Robert Charles
; Guterman, Sonia Kosow
; Roberts, Bruce Lindsey
; Markland, William
; Ley, Arthur Charles
; Kent, Rachel Barbault
; TITLE OF INVENTION: Directed Evolution of No. US20040023205A1e1
; Binding Proteins
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Browdy and Neimark
; STREET: 419 Seventh Street, N.W.
; Suite 300
; CITY: Washington,
; STATE: DC
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/126,544
```

```

; FILING DATE: 22-Apr-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/009,319
; FILING DATE: 1993-01-26
; APPLICATION NUMBER: 07/664,989
; FILING DATE: 01-MAR-1991
; APPLICATION NUMBER: PCT/US89/03731
; FILING DATE: 01-SEP-1989
; APPLICATION NUMBER: 07/487,063
; FILING DATE: 02-MAR-1990
; APPLICATION NUMBER: 07/240,160
; FILING DATE: 02-SEP-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Cooper, Iver P.
; REGISTRATION NUMBER: 28005
; REFERENCE/DOCKET NUMBER: LADNER 7
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 121:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: circular
; MOLECULE TYPE: genomic DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 121:
US-10-126-544-121
```

```

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      597 TGGGAGATGCCCAT 611
Db      15 TGGGAGATGCCCAT 1
```

```

RESULT 333
US-09-829-855-11/c
; Sequence 11, Application US/09829855
; Patent No. US20020065609A1
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY-1
; CURRENT APPLICATION NUMBER: US/09/829,855
; CURRENT FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-11
```

```

Query Match          0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      297 AGCTGGCGCACTGGG 311
Db      16 AGCTGGCGCACTGGG 2
```

RESULT 334

```

US-09-829-855-13/c
; Sequence 13, Application US/09829855
; Patent No. US20020065609A1
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY-1
; CURRENT APPLICATION NUMBER: US/09/829,855
; CURRENT FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-13
```

```

Query Match          0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      297 AGCTGGCGCACTGGG 311
Db      16 AGCTGGCGCACTGGG 2
```

```

RESULT 335
US-09-829-855-77/c
; Sequence 77, Application US/09829855
; Patent No. US20020065609A1
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY-1
; CURRENT APPLICATION NUMBER: US/09/829,855
; CURRENT FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 77
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-77
```

```

Query Match          0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      297 AGCTGGCGCACTGGG 311
Db      16 AGCTGGCGCACTGGG 2
```

```

RESULT 336
US-10-182-230-68/c
; Sequence 68, Application US/10182230
; Publication No. US20030215817A1
; GENERAL INFORMATION:
; APPLICANT: Leonardi, Amedeo
; APPLICANT: Sartani, Abraham
; APPLICANT: Glass, James R.
```

```
; APPLICANT: Sutcliffe, J. Gregor
; APPLICANT: Hasel, Karl W.
; TITLE OF INVENTION: Modulation of Gene Expression in Formation of Fatty Atherosclerosis
; TITLE OF INVENTION: Lesions
; FILE REFERENCE: 216019-143
; CURRENT APPLICATION NUMBER: US/10/182,230
; CURRENT FILING DATE: 2003-02-03
; PRIOR APPLICATION NUMBER: 60/177,963
; PRIOR FILING DATE: 2000-01-25
; NUMBER OF SEQ ID NOS: 197
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 68
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: 5' PCR Primer with parsing base
; OTHER INFORMATION: see CTGA
US-10-182-230-68
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      658 TCAGCCGATACCTTC 672
Db      16 TCAGCCGATACCGTC 2
```

```
RESULT 337
US-10-138-674-7079
; Sequence 7079, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7079
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7079
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 80.0%; Pred. No. 3.7e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      770 ACAGCCACTTCGAG 784
Db      1 ACAGCACTUCGACG 15
```

```
RESULT 338
US-10-287-949A-7079
; Sequence 7079, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
```

```
; FILE REFERENCE: MEB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7079
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7079
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 80.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      770 ACAGCCACTTCGAG 784
Db      1 ACAGCACTUCGACG 15
```

```
RESULT 339
US-10-607-077A-11/c
; Sequence 11, Application US/10607077A
; Publication No. US20040110183A1
; GENERAL INFORMATION:
; APPLICANT: Ashby, Matthew
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY/1 DIV
; CURRENT APPLICATION NUMBER: US/10/607,077A
; CURRENT FILING DATE: 2003-06-25
; PRIOR APPLICATION NUMBER: US 09/829855
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: PCT/US01/11609
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: ribosomal DNA sequence tag isolated from
; OTHER INFORMATION: microbes in soil sample collected
; OTHER INFORMATION: in Wyoming, USA
US-10-607-077A-11
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      297 AGCTGCGGCACTGGG 311
Db      16 AGCTGCGGCACTGGG 2
```

```
RESULT 340
US-10-607-077A-13/c
; Sequence 13, Application US/10607077A
; Publication No. US20040110183A1
; GENERAL INFORMATION:
; APPLICANT: Ashby, Matthew
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY/1 DIV
; CURRENT APPLICATION NUMBER: US/10/607,077A
; CURRENT FILING DATE: 2003-06-25
; PRIOR APPLICATION NUMBER: US 09/829855
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: PCT/US01/11609
; PRIOR FILING DATE: 2001-04-10
```



```
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: ribosomal DNA sequence tag isolated from
; OTHER INFORMATION: microbes in soil sample collected
; OTHER INFORMATION: in Wyoming, USA
US-10-607-077A-13
```

```
Query Match      0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      297 AGCTGCGGCACTGGG 311
Db      16 AGCTGCGGCACTGGG 2
```

```
RESULT 341
US-10-607-077A-77/C
; Sequence 77, Application US/10607077A
; Publication No. US2004011083A1
; GENERAL INFORMATION:
; APPLICANT: Ashby, Matthew
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY/1 Div
; CURRENT APPLICATION NUMBER: US/10/607,077A
; PRIOR FILING DATE: 2003-06-25
; PRIOR APPLICATION NUMBER: US 09/829855
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: PCT/US01/11609
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 77
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: ribosomal DNA sequence tag isolated from
; OTHER INFORMATION: microbes in soil sample collected
; OTHER INFORMATION: in Wyoming, USA
US-10-607-077A-77
```

```
Query Match      0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      297 AGCTGCGGCACTGGG 311
Db      16 AGCTGCGGCACTGGG 2
```

```
RESULT 342
US-09-866-108-889/C
; Sequence 889, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
```

```
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 889
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-889

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1703 CCCTCCCAATATG 1717
Db      17 CCCTCCCACTATG 3
```

```
RESULT 343
US-09-866-108-6756
; Sequence 6756, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
```

```

; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6756
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6756
```

```

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```

Qy      2041 GTGAGCAGCTCTG 2055
Db      3 GTGAGCAGCTCTG 17
```

```

RESULT 344
US-09-866-108-6757
; Sequence 6757, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6757
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6757
```

```

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```

Qy      2041 GTGAGCAGCTCTG 2055
Db      2 GTGAGCAGCTCTG 16
```

```

RESULT 345
US-09-866-108-6950
; Sequence 6950, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6950
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6950

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      89 TCGCCGACTGGGTGC 103
Db      3 TCGCCGACTGGGTGC 17

RESULT 346
US-09-866-108-6951
; Sequence 6951, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6951
```

```

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6951

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      89 TCGCCGACTGGGTGC 103
Db      2 TCGCCGACTGGGTGC 16

RESULT 347
US-09-866-108-6952
; Sequence 6952, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6952
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6952

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      89 TCGCCGACTGGGTGC 103
```

```
Db      1  TCCGCGAGCTGCTC 15

RESULT 349
US-09-866-108-8004
; Sequence 8004, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8004
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8004

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2038 CAGGTGAGCAGCTC 2052
Db      3  CAGCTGAGCAGCTC 17

RESULT 349
US-09-866-108-8007
; Sequence 8007, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25

APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25

APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25

QY      2039 AGGTGAGCAGCTCC 2053
Db      1  AGCTGAGCAGCTCC 15

RESULT 350
US-09-866-108-8054
; Sequence 8054, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
```

PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 8054
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-8054

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2230 GCAGATGCTCCAGAA 2244
DB 3 GCAGATGCTCCAGAA 17

RESULT 351
US-09-866-108-8055
Sequence 8055, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wenheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 8055
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-8055

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2230 GCAGATGCTCCAGAA 2244
DB 2 GCAGATGCTCCAGAA 16

RESULT 352
US-09-827-998-471
Sequence 471, Application US/09827998
Patent No. US20020102252A1
GENERAL INFORMATION:
APPLICANT: Gu, Yizhong
APPLICANT: Shannon, Mark
TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
FILE REFERENCE: MDIMORF-8
CURRENT APPLICATION NUMBER: US/09/827,998
CURRENT FILING DATE: 2001-04-06
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
NUMBER OF SEQ ID NOS: 1881
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 471
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-827-998-471

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1027 AAGAAGTGGGAAA 1041
DB 3 AAGAAGTGGGAAA 17

RESULT 353
US-09-827-998-472
Sequence 472, Application US/09827998
Patent No. US20020102252A1

```
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MIMMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 472
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-472
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      1027 AAGAAAGGTGGGAAA 1041
Db       2 AAGAAAGGTGGGAAA 16
```

```
RESULT 354
US-09-827-998-473
; Sequence 473, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MIMMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 473
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-473
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      1027 AAGAAAGGTGGGAAA 1041
Db       1 AAGAAAGGTGGGAAA 15
```

```
RESULT 355
US-09-969-373-3716/c
; Sequence 3716, Application US/09969373
; Patent No. US2002013852A1
; GENERAL INFORMATION:
; APPLICANT: Efferetz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
```

```
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 3716
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-3716
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      1835 TCACAGCTGCTGAG 1849
Db       15 TCACAGCTGCTGAG 1
```

```
RESULT 356
US-09-864-785-55/c
; Sequence 55, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 55
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-55
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      565 CTGTTCTGTGCTCTG 579
Db       17 CTGTTCTGTGCTCTG 3
```

```
RESULT 357
US-09-864-785-56/c
; Sequence 56, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 56
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
```

```
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-56

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      565 CTGTCCTGCTGCTG 579
DB      16 CTGTCCTGCTGCTG 2

RESULT 358
US-09-864-785-1585
/ Sequence 1585, Application US/09864785
/ Patent No. US2002017568A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Draper, Ken
/ APPLICANT: McSwiggen, Jim
/ TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
/ FILE REFERENCE: 400/022 (MBH00-812-D)
/ CURRENT APPLICATION NUMBER: US/09/864,785
/ CURRENT FILING DATE: 2001-05-23
/ NUMBER OF SEQ ID NOS: 3929
/ SOFTWARE: Patentin version 3.0
/ SEQ ID NO 1585
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1585

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.8e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      1362 CACCCAGGCTGTGGA 1376
DB      2 CACCCAGGCTGTGGA 16

RESULT 359
US-09-864-785-1621/C
/ Sequence 1621, Application US/09864785
/ Patent No. US2002017568A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Draper, Ken
/ APPLICANT: McSwiggen, Jim
/ TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
/ FILE REFERENCE: 400/022 (MBH00-812-D)
/ CURRENT APPLICATION NUMBER: US/09/864,785
/ CURRENT FILING DATE: 2001-05-23
/ NUMBER OF SEQ ID NOS: 3929
/ SOFTWARE: Patentin version 3.0
/ SEQ ID NO 1621
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1621

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      355 TGGGAGCCCCCGGG 369
DB      16 TGGGAGCCCCCGGG 2

RESULT 360
US-09-864-785-2828
/ Sequence 2828, Application US/09864785
/ Patent No. US2002017568A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Draper, Ken
/ APPLICANT: McSwiggen, Jim
/ TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
/ FILE REFERENCE: 400/022 (MBH00-812-D)
/ CURRENT APPLICATION NUMBER: US/09/864,785
/ CURRENT FILING DATE: 2001-05-23
/ NUMBER OF SEQ ID NOS: 3929
/ SOFTWARE: Patentin version 3.0
/ SEQ ID NO 2828
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2828

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.8e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      1362 CACCCAGGCTGTGGA 1376
DB      3 CACCCAGGCTGTGGA 17

RESULT 361
US-09-780-533A-912/C
/ Sequence 912, Application US/09780533A
/ Publication No. US2003006011A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Blatt, Larry
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Chowrira, Bharat
/ APPLICANT: Haeblerli, Pete
/ TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
/ FILE REFERENCE: MBH00, 878-A (400/011)
/ CURRENT APPLICATION NUMBER: US/09/780,533A
/ CURRENT FILING DATE: 2001-02-09
/ PRIOR FILING DATE: 2000-02-11
/ NUMBER OF SEQ ID NOS: 6679
/ SOFTWARE: Patentin version 3.0
/ SEQ ID NO 912
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-09-780-533A-912

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      201 GCTGTGCTGGGGGC 215
DB      17 GCTGTGCTGGGGGC 3

RESULT 362
```

```
US-09-780-533A-2411/c
; Sequence 2411, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrita, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NCO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2411
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2411
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      201 GCTCTGGCTGGGGGC 215
Db      16 GCTCTGGCTGGGGGC 2
```

```
RESULT 363
US-09-877-478-1387/c
; Sequence 1387, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1387
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1387
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      2162 GGGAGGGGGGAACCC 2176
Db      17 GGGAGGGGTGAACCC 3
```

```
RESULT 364
US-09-877-478-1388/c
; Sequence 1388, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1388
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1388
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      2162 GGGAGGGGGGAACCC 2176
Db      15 GGGAGGGGTGAACCC 1
```

```
RESULT 365
US-09-877-478-2180/c
; Sequence 2180, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
```


;; PRIOR APPLICATION NUMBER: US 09/696,347
;; PRIOR FILING DATE: 2000-10-24
;; PRIOR APPLICATION NUMBER: US 08/193,627
;; PRIOR FILING DATE: 1994-02-07
;; PRIOR APPLICATION NUMBER: US 08/433,993
;; PRIOR FILING DATE: 1995-05-04
;; PRIOR APPLICATION NUMBER: US 08/434,504
;; PRIOR FILING DATE: 1995-05-04
;; PRIOR APPLICATION NUMBER: US 09/436,430
;; PRIOR FILING DATE: 1999-11-08
;; NUMBER OF SEQ ID NOS: 6586
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO: 2180
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Hepatitis B virus
US-09-877-478-2180

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2162 GGGAGGGGGGAGCC 2176
DB 17 GGGAGGGGGTGAACC 3

RESULT 366
US-09-827-395A-271/c
;; Sequence 271, Application US/09827395A
;; Publication No. US20030113891A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyme Pharmaceuticals, Inc.
;; APPLICANT: Lawrence Blatt
;; APPLICANT: James McSwigen
;; APPLICANT: Bharat Chowitra
;; TITLE OF INVENTION: Method and Reagent for the Inhibition of NCOG and NCOG Receptor G
;; FILE REFERENCE: MHB00-878-C (400/017)
;; CURRENT APPLICATION NUMBER: US/09/827,395A
;; CURRENT FILING DATE: 2001-04-05
;; PRIOR APPLICATION NUMBER: 09/780,533
;; PRIOR FILING DATE: 2001-02-09
;; PRIOR APPLICATION NUMBER: 60/181,797
;; PRIOR FILING DATE: 2000-02-11
;; NUMBER OF SEQ ID NOS: 2617
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO: 271
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-09-827-395A-271

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 779 TGCAGGAGAGCTGT 793
DB 16 TGCAGGAGAGCTGT 2

RESULT 367
US-09-740-332-308
;; Sequence 308, Application US/09740332
;; Publication No. US20030125270A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyme Pharmaceuticals Inc.
;; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
;; FILE REFERENCE: RPI 400/003
;; CURRENT APPLICATION NUMBER: US/09/740,332
;; CURRENT FILING DATE: 2001-03-26
;; NUMBER OF SEQ ID NOS: 9704

;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO: 308
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: artificial sequence
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION:
;; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-308

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 59 TCGCATGCTGGGGA 73
DB 2 UCGCAUGGCTUGGGA 16

RESULT 368
US-09-817-879-308
;; Sequence 308, Application US/09817879
;; Publication No. US2003017311A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyme Pharmaceuticals Inc.
;; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
;; FILE REFERENCE: MHB00-801-F
;; CURRENT APPLICATION NUMBER: US/09/817,879
;; CURRENT FILING DATE: 2001-03-26
;; NUMBER OF SEQ ID NOS: 9703
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO: 308
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: artificial sequence
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION:
;; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-308

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 59 TCGCATGCTGGGGA 73
DB 2 UCGCAUGGCTUGGGA 16

RESULT 369
US-10-342-902-1387/c
;; Sequence 1387, Application US/10342902
;; Publication No. US20040054156A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; APPLICANT: Draper, Kenneth
;; APPLICANT: Blatt, Larry
;; APPLICANT: McSwigen, Jim
;; APPLICANT: Morrissey, Dave
;; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;; FILE REFERENCE: 400/075 (MHB00-845-1)
;; CURRENT APPLICATION NUMBER: US/10/342,902
;; CURRENT FILING DATE: 2003-01-15
;; PRIOR APPLICATION NUMBER: US 09/877,478
;; PRIOR FILING DATE: 2001-06-08
;; PRIOR APPLICATION NUMBER: US 09/531,025
;; PRIOR FILING DATE: 2000-03-20
;; PRIOR APPLICATION NUMBER: US 09/636,385
;; PRIOR FILING DATE: 2000-08-09
;; PRIOR APPLICATION NUMBER: US 09/696,347

```
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1387
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1387

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2162 GGGAGGGGGGAACCC 2176
Db      17 GGGAGGGGTGAACCC 3

RESULT 370
US-10-342-902-1388/c
; Sequence 1388, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1388
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1388

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2162 GGGAGGGGGGAACCC 2176
Db      15 GGGAGGGGTGAACCC 1

RESULT 371
US-10-342-902-2180/c
; Sequence 2180, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2180
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-2180

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2162 GGGAGGGGGGAACCC 2176
Db      17 GGGAGGGGTGAACCC 3

RESULT 372
US-10-675-685-471
; Sequence 471, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 471
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-471

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1027 AAGAGGTGGGAAA 1041
Db      3 AAGAGGGGGGAAA 17
```

```
RESULT 373
US-10-675-685-472
; Sequence 472, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 472
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-472

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1027 AAGAGGTGGGAAA 1041
Db      2 AAGAGGGGGGAAA 16

RESULT 374
US-10-675-685-473
; Sequence 473, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 473
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-473

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1027 AAGAGGTGGGAAA 1041
Db      1 AAGAGGGGGGAAA 15

RESULT 375
US-09-927-046-864/C
; Sequence 864, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc
; APPLICANT: MCSwigen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzle, Tim
```

```
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 864
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-864

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1997 TGGATGATGCCACCA 2011
Db      16 TGGATGATGCCACCA 2

RESULT 376
US-09-927-046-1020/C
; Sequence 1020, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc
; APPLICANT: Thompson, Jim
; APPLICANT: MCSwigen, Jim
; APPLICANT: McKenzle, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1020
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1020

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1887 TCAGGGCTATGACAC 1901
Db      16 TCAGGGCTGTGACAC 2

RESULT 377
US-09-927-046-1565/C
; Sequence 1565, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc
; APPLICANT: MCSwigen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzle, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1565
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1565
```

```

; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1565
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1565

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1887 TCAGGGCTATGACAC 1901
Db      15   TCAGGGCTGTGACAC 1

RESULT 378
US-09-958-163A-23/C
; Sequence 23, Application US/09958163A
; Publication No. US20030104389A1
; GENERAL INFORMATION:
; APPLICANT: Sergeev, Pavel
; TITLE OF INVENTION: Synthesis of biologically active compounds in cells
; FILE REFERENCE: sergeev
; CURRENT APPLICATION NUMBER: US/09/958,163A
; CURRENT FILING DATE: 2001-10-03
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURES:
; OTHER INFORMATION: antisense to the human tissue plasminogen activator mRNA
; PUBLICATION INFORMATION:
; AUTHORS: Degen,S.J., Rajput,B. and Reich,E.
; TITLE: The human tissue plasminogen activator gene
; JOURNAL: Journal of Biological Chemistry
; VOLUME: 261
; ISSUE: 15
; PAGES: 6972-85
; DATE: 1986-05-25
; DATABASE ACCESSION NUMBER: K03021
; DATABASE ENTRY DATE: 1986-04-08
US-09-958-163A-23

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      101 TGTGCTCCGACCG 115
Db      17   TGTGCTCCGACCG 3

RESULT 379
US-10-430-882-271/C
; Sequence 271, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwigen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haeblerli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
```

```

; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 271
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-271

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      779 TGCAGGAGAGGTGT 793
Db      16   TGCAGGAGAGGTGT 2

RESULT 380
US-10-060-830-782/C
; Sequence 782, Application US/10060830
; Publication No. US2003032154A1
; GENERAL INFORMATION:
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 782
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-782

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      918 TCTGTGTAACCTGCT 932
Db      16   TCTGTGCACTGTGT 2

RESULT 381
US-10-060-830-793/C
```

```
; Sequence 783, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 783
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-060-830-783
```

```
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 918 TCTGTGTACTGCT 932
DB 15 TCTGTGTACTGCT 1
```

```
RESULT 382
; US-10-060-895A-484/C
; Sequence 484, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN UDP-GALNA4:POLYPEPTIDE N-ACETYLGLACTOSAMINYLTRANSFERASE 10
; FILE REFERENCE: PB0158
; CURRENT APPLICATION NUMBER: US/10/060,895A
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/315,984
```

```
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 1682
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 484
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-060-895A-484
```

```
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1487 CCTTACTGTGAGG 1501
DB 15 CCTTACTGTGAGG 1
```

```
RESULT 383
; US-10-163-552-84/C
; Sequence 84, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: MBH01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 84
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-163-552-84
```

```
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1284 CATTGTGGGACGT 1298
DB 15 CATTGTGGGACGT 1
```

```
RESULT 384
; US-10-156-306-4761/C
; Sequence 4761, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4761
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-156-306-4761
```

```
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 214 GCCTGCGGGTCTC 228
DB 15 GCCTGCGGGTCTC 1
```

Db 15 GTCTGGGGGTCTC 1

RESULT 385
US-10-156-306-5005/c
; Sequence 5005, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5005
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5005

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 CTGCAGCTGCTCCAG 2242
Db 16 CTGCAGCTGCTCCAG 2

RESULT 386
US-10-156-306-5013
; Sequence 5013, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5013
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5013

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1922 GCCAGCTGTGAGGG 1936
Db 3 GCCAGCTGTGAGAG 17

RESULT 387
US-10-156-306-5092/c
; Sequence 5092, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5092
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5092

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1945 CAGGCACTGGCGCTTG 1959
Db 17 CAGGCACTGGCGCTTG 3

RESULT 388
US-10-156-306-5093/c
; Sequence 5093, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5093
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5093

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1945 CAGGCACTGGCGCTTG 1959
Db 16 CAGGCACTGGCGCTTG 2

RESULT 389
US-10-156-306-5184
; Sequence 5184, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5184
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5184

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 391 CTGCACCTGGGGAAGT 405
Db 3 CGGCACTGGGGAAGU 17

```
RESULT 390
US-10-156-306-5889/C
; Sequence 5889, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5889
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5889

Query Match
Best Local Similarity 93.3%; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 143 TGCCACCGCGCTGC 157
DB 15 TGCCACCGCGCTGC 1

RESULT 391
US-10-156-306-5925/C
; Sequence 5925, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5925
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5925

Query Match
Best Local Similarity 93.3%; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 CTGCAGTGTCTCCAG 2242
DB 15 CTGCAGTGTCTCCAG 1

RESULT 392
US-10-156-306-5931
; Sequence 5931, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5931
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5931

Query Match
Best Local Similarity 80.0%; DB 1; Length 17;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1922 GCCAGCTGTCCAGG 1936
DB 2 GCCAGCTGTCCAGG 16

RESULT 393
US-10-156-306-6960/C
; Sequence 6960, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6960
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6960

Query Match
Best Local Similarity 93.3%; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 143 TGCCACCGCGCTGC 157
DB 16 TGCCACCGCGCTGC 2

RESULT 394
US-10-238-700-3261
; Sequence 3261, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3261
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3261

Query Match
Best Local Similarity 73.3%; DB 1; Length 17;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 167 GGGTCTGGCGGTGC 181
```

```
Db      1  GGAGUCGAGGUCUGG  15

||||:|||||:|
RESULT 395
US-10-061-201-1272
; Sequence 1272, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1272
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1272

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2182 CAGCTCATGAGAGAA 2196
Db      3  CAGCCCATGAGAGAA 17

|||||
RESULT 396
US-10-061-201-1273
; Sequence 1273, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1273
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1273

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2182 CAGCTCATGAGAGAA 2196
Db      2  CAGCCCATGAGAGAA 16

|||||
RESULT 397
US-10-061-201-1274
; Sequence 1274, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1274
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1274

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2182 CAGCTCATGAGAGAA 2196
Db      1  CAGCCCATGAGAGAA 15

|||||
RESULT 398
```



```
US-10-230-006-1429/c
; Sequence 1429, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fossnaugh, Kathy
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
; FILE REFERENCE: 400/056 (MBH01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1429
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1429

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 632 TCACGACTGATTC 646
Db 16 TCACGACTGATTC 2

RESULT 399
US-10-277-216-290
; Sequence 290, Application US/10277216
; Publication No. US20040002470A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
; FILE REFERENCE: 2976-4051
; CURRENT APPLICATION NUMBER: US/10/277,216
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 10/126,022
; PRIOR FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 290
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-277-216-290

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 588 CTCCTCTCTGGGA 602
Db 2 CTCCTCTCTGGGA 16

RESULT 400
US-10-126-022-290
; Sequence 290, Application US/10126022
; Publication No. US2004002215A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
```

```
; TITLE OF INVENTION: OBESITY, AND INFLAMMATORY BOWEL DISEASE
; FILE REFERENCE: 2976-403US2
; CURRENT APPLICATION NUMBER: US/10/126,022
; CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 290
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-126-022-290

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 588 CTCCTCTCTGGGA 602
Db 2 CTCCTCTCTGGGA 16

RESULT 401
US-10-138-674-4197
; Sequence 4197, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4197
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4197

Query Match
Best Local Similarity 73.3%; Score 13.4; DB 1; Length 17;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 977 CCTCACCACGTCA 991
Db 2 CCTCACCACGTCA 16

RESULT 402
US-10-138-674-4505
; Sequence 4505, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
```

```
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4505
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4505
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 1.8e+02;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1991 TTATCTGATGATG 2005
       3 UUAUCCUGAUGCG 17
```

```
RESULT 403
US-10-138-674-4755/C
; Sequence 4755, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4755
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4755
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      2214 CATGTCAGGCTCC 2228
       17 CTTGTCAGGCTCC 3
```

```
RESULT 404
US-10-138-674-6625
; Sequence 6625, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6625
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6625
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      770 ACAGCCACTTGACAG 784
       1 ACAGCAACUUGCAG 15
```

```
RESULT 405
US-10-138-674-7633/C
; Sequence 7633, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7633
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7633
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      2214 CATGTCAGGCTCC 2228
       16 CTTGTCAGGCTCC 2
```

```
RESULT 406
US-10-138-674-8874
; Sequence 8874, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8874
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8874
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      770 ACAGCCACTTGACAG 784
       3 ACAGCAACUUGCAG 17
```

```
RESULT 407
US-10-287-949A-4197
; Sequence 4197, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4197
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4197

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      977 CCTCACCATTGCTCA 991
Db      2 CGCVCACCAUGGCUCA 16

RESULT 408
US-10-287-949A-4505
; Sequence 4505, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4505
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4505

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 1.8e+02;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY      1991 TTATCTGATGATG 2005
Db      3 UUAUCCUGAUGGUCG 17

RESULT 409
US-10-287-949A-4755/C
; Sequence 4755, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan

US-10-287-949A-6625
; Sequence 6625, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6625
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6625

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      770 ACAGCCACTTGACG 784
Db      1 ACAGCAACUUGCAGG 15

RESULT 410
US-10-287-949A-6625
; Sequence 6625, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6625
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6625

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2214 CATGTGACGCTCC 2228
Db      17 CTGTGTCAGGCTCC 3

RESULT 411
US-10-287-949A-7633/C
; Sequence 7633, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7633
```

LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-287-949A-7633

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2214 CATGTGCAGGCTCC 2228
DB 16 CTGTGTCAGGCTCC 2

RESULT 412
US-10-287-949A-8874
Sequence 8874, Application US/10287949A
Publication No. US20040102389A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MHB00-876-N (400/049)
CURRENT APPLICATION NUMBER: US/10/287,949A
CURRENT FILING DATE: 2003-04-11
NUMBER OF SEQ ID NOS: 20822
SOFTWARE: PatentIn version 3.0
SEQ ID NO 8874
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-287-949A-8874

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 770 ACAGCCACTGCAGC 784
DB 3 ACAGCAACUUGCAGC 17

RESULT 413
US-10-712-672-1280
Sequence 1280, Application US/10712672
Publication No. US20040102413A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Chowitra, Bharat
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
FILE REFERENCE: MHB00-882-C (400/019)
CURRENT APPLICATION NUMBER: US/10/712,672
CURRENT FILING DATE: 2003-11-13
PRIOR APPLICATION NUMBER: US/09/653,225
PRIOR FILING DATE: 2000-08-31
PRIOR APPLICATION NUMBER: 60/197,769
PRIOR FILING DATE: 2000-04-14
PRIOR APPLICATION NUMBER: 60/150,713
PRIOR FILING DATE: 1999-08-31
NUMBER OF SEQ ID NOS: 5586
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1280
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-712-672-1280

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.8e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 437 CGGCGCCGCCGCGC 451
DB 3 CGGCGCCGCCGCGC 17

RESULT 414
US-10-712-672-1917/C
Sequence 1917, Application US/10712672
Publication No. US20040102413A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Chowitra, Bharat
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
FILE REFERENCE: MHB00-882-C (400/019)
CURRENT APPLICATION NUMBER: US/10/712,672
CURRENT FILING DATE: 2003-11-13
PRIOR APPLICATION NUMBER: US/09/653,225
PRIOR FILING DATE: 2000-08-31
PRIOR APPLICATION NUMBER: 60/197,769
PRIOR FILING DATE: 2000-04-14
PRIOR APPLICATION NUMBER: 60/150,713
PRIOR FILING DATE: 1999-08-31
NUMBER OF SEQ ID NOS: 5586
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1917
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-712-672-1917

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 551 CGGCGCCGCTCGC 565
DB 17 CGGCGCCGCTCGC 3

RESULT 415
US-10-712-672-1977/C
Sequence 1977, Application US/10712672
Publication No. US20040102413A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Chowitra, Bharat
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
FILE REFERENCE: MHB00-882-C (400/019)
CURRENT APPLICATION NUMBER: US/10/712,672
CURRENT FILING DATE: 2003-11-13
PRIOR APPLICATION NUMBER: US/09/653,225
PRIOR FILING DATE: 2000-08-31
PRIOR APPLICATION NUMBER: 60/197,769
PRIOR FILING DATE: 2000-04-14
PRIOR APPLICATION NUMBER: 60/150,713
PRIOR FILING DATE: 1999-08-31
NUMBER OF SEQ ID NOS: 5586
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1977
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-712-672-1977

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2169 GGGAGCCACACGCA 2183
Db 15 GGGAGCCACACGCA 1

RESULT 416

US-09-504-231A-712

Sequence 712, Application US/09504231A
Patent No. US20020013458A1

GENERAL INFORMATION:

APPLICANT: Blatt, Lawrence

APPLICANT: McSwigen, James

APPLICANT: Roberts, Beth

APPLICANT: Pavco, Pamela

APPLICANT: Macejak, Dennis

TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE

FILE REFERENCE: IP1 247/282

CURRENT APPLICATION NUMBER: US/09/504,231A

CURRENT FILING DATE: 2000-02-15

PRIOR APPLICATION NUMBER: 09/274,553

PRIOR FILING DATE: 1999-03-23

PRIOR APPLICATION NUMBER: 09/257,608

PRIOR FILING DATE: 1999-02-24

PRIOR APPLICATION NUMBER: 60/100,842

PRIOR FILING DATE: 1998-09-18

PRIOR APPLICATION NUMBER: 60/083,217

PRIOR FILING DATE: 1998-04-27

NUMBER OF SEQ ID NOS: 3242

SOFTWARE: PatentIn version 3.0

SEQ ID NO 712

LENGTH: 15

TYPE: RNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target

US-09-504-231A-712

Query Match 0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 38.5%; Pred. No. 1.9e+02;
Matches 5; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1010 TGCTTTCCTTCT 1022

Db 3 UGCUUUCUUCU 15

RESULT 417

US-09-504-231A-713

Sequence 713, Application US/09504231A

Patent No. US20020013458A1

GENERAL INFORMATION:

APPLICANT: Blatt, Lawrence

APPLICANT: McSwigen, James

APPLICANT: Roberts, Beth

APPLICANT: Pavco, Pamela

APPLICANT: Macejak, Dennis

TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE

FILE REFERENCE: IP1 247/282

CURRENT APPLICATION NUMBER: US/09/504,231A

CURRENT FILING DATE: 2000-02-15

PRIOR APPLICATION NUMBER: 09/274,553

PRIOR FILING DATE: 1999-03-23

PRIOR APPLICATION NUMBER: 09/257,608

PRIOR FILING DATE: 1999-02-24

PRIOR APPLICATION NUMBER: 60/100,842

PRIOR FILING DATE: 1998-09-18

PRIOR APPLICATION NUMBER: 60/083,217

PRIOR FILING DATE: 1998-04-27

NUMBER OF SEQ ID NOS: 3242
SOFTWARE: PatentIn version 3.0
SEQ ID NO 713

LENGTH: 15

TYPE: RNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target

US-09-504-231A-713

Query Match 0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 38.5%; Pred. No. 1.9e+02;
Matches 5; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1010 TGCTTTCCTTCT 1022

Db 2 UGCUUUCUUCU 14

RESULT 418

US-09-274-553D-712

Sequence 712, Application US/09274553D

Patent No. US2002008225A1

GENERAL INFORMATION:

APPLICANT: Blatt, Lawrence

APPLICANT: McSwigen, James

APPLICANT: Roberts, Beth

APPLICANT: Pavco, Pamela

APPLICANT: Macejak, Dennis

TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE

FILE REFERENCE: IP1 247/282

CURRENT APPLICATION NUMBER: US/09/274,553D

CURRENT FILING DATE: 1999-03-23

PRIOR APPLICATION NUMBER: 09/257,608

PRIOR FILING DATE: 1999-02-24

PRIOR APPLICATION NUMBER: 60/100,842

PRIOR FILING DATE: 1998-09-18

PRIOR APPLICATION NUMBER: 60/083,217

PRIOR FILING DATE: 1998-04-27

NUMBER OF SEQ ID NOS: 3148

SOFTWARE: PatentIn version 3.0

SEQ ID NO 712

LENGTH: 15

TYPE: RNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target

US-09-274-553D-712

Query Match 0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 38.5%; Pred. No. 1.9e+02;
Matches 5; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1010 TGCTTTCCTTCT 1022

Db 3 UGCUUUCUUCU 15

RESULT 419

US-09-274-553D-713

Sequence 713, Application US/09274553D

Patent No. US2002008225A1

GENERAL INFORMATION:

APPLICANT: Blatt, Lawrence

APPLICANT: McSwigen, James

APPLICANT: Roberts, Beth

APPLICANT: Pavco, Pamela

APPLICANT: Macejak, Dennis

TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE

FILE REFERENCE: IP1 247/282

CURRENT APPLICATION NUMBER: US/09/274,553D

```

; CURRENT FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3148
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 713
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-274-553D-713

Query Match          0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 38.5%; Pred.No.1.9e+02;
Matches 5; Conservative 8; Mismatches 0; Gaps 0; Indels 0;

Qy      1010 TGCTTTCCTCTCT 1022
Db      2 UGCUUUCUUCU 14

RESULT 420
US-09-748-739A-28
; Sequence 28, Application US/09748739A
; Patent No. US20020119489A1
; GENERAL INFORMATION:
; APPLICANT: Lockridge, Oksana
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Butyrylcholinesterase Variants and
; TITLE OF INVENTION: Methods of Use
; FILE REFERENCE: P-IX 4143
; CURRENT APPLICATION NUMBER: US/09/748,739A
; CURRENT FILING DATE: 2000-12-06
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 28
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: human butyrylcholinesterase variant
US-09-748-739A-28

Query Match          0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred.No.1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      417 CTTGCTGTGAGT 429
Db      2 CTTGCTGTGAGT 14

RESULT 421
US-10-347-510A-44/C
; Sequence 44, Application US/10347510A
; Publication No. US20040063110A1
; GENERAL INFORMATION:
; APPLICANT: Henrik Stender
; APPLICANT: Kaare Lund
; APPLICANT: Tina Anderson Hollerup
; TITLE OF INVENTION: No. US20040063110A1el Process For The Detection of Mycobact
; NUMBER OF SEQUENCES: 123
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER
; STREET: 1300 I ST. NW
; CITY: Washington
; STATE: District of Columbia
; COUNTRY: USA
```

```

; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk 3.5 inch
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: ASCXI
; SOFTWARE: Microsoft Word
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/347,510A
; FILING DATE: 21-Jan-2003
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/028,392
; FILING DATE: 15-Oct-96
; APPLICATION NUMBER: 60/029,595
; FILING DATE: 23-Oct-96
; APPLICATION NUMBER: 60/045,962
; FILING DATE: 08-May-97
; APPLICATION NUMBER: 08/943,777
; FILING DATE: 3-Oct-97
; ATTORNEY/AGENT INFORMATION:
; NAME: Anthony C. Tridico
; REGISTRATION NUMBER: 45,958
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4173
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 44:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 basepairs
; TYPE: nucleic acid basepairs
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 44:
US-10-347-510A-44

Query Match          0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred.No.1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1962 CCGAGCATGTGATC 1974
Db      13 CCGAGCATGTGATC 1

RESULT 422
US-09-544-934B-44/C
; Sequence 44, Application US/09544934B
; Publication No. US20020137035A1
; GENERAL INFORMATION:
; APPLICANT: Henrik Stender
; APPLICANT: Kaare Lund
; APPLICANT: Tina Anderson Hollerup
; TITLE OF INVENTION: Novel Process For The Detection of Mycobacteria
; NUMBER OF SEQUENCES: 123
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER
; STREET: 1300 I ST. NW
; CITY: Washington
; STATE: District of Columbia
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk 3.5 inch
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: ASCXI
; SOFTWARE: Microsoft Word
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/544,934B
; FILING DATE: 07-Apr-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/028,392
; FILING DATE: 15-Oct-96
; APPLICATION NUMBER: 60/029,595
; FILING DATE: 23-Oct-96
; APPLICATION NUMBER: 60/045,962
```

```

; FILING DATE: 08-May-97
; APPLICATION NUMBER: 08/943,777
; FILING DATE: 3-Oct-97
; ATTORNEY/AGENT INFORMATION:
; NAME: Anthony C. Tridico
; REGISTRATION NUMBER: 45,958
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4173
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 44:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 basepairs
; TYPE: nucleic acid basepairs
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-544-934B-44
; SEQUENCE DESCRIPTION: SEQ ID NO: 44:

Query Match          0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1962 CCGAGCATGATC 1974
DB      13 CCGAGCATGATC 1

RESULT 423
US-10-138-674-5827/C
; Sequence 5827, Application US/10138674
; Publication No. US2004007565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: MCSwiggan, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5827
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-138-674-5827

Query Match          0.6%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      2216 TGGTGAGGCTCC 2228
DB      16 TGGTGAGGCTCC 4

RESULT 424
US-10-287-949A-5827/C
; Sequence 5827, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: MCSwiggan, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
```

```

; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5827
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-287-949A-5827

Query Match          0.6%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      2216 TGGTGAGGCTCC 2228
DB      16 TGGTGAGGCTCC 4

RESULT 425
US-09-866-108-897/C
; Sequence 897, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MCA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: A60MCA Sequence Listing Engine
; SEQ ID NO 897
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-897

Query Match          0.6%; Score 13; DB 1; Length 17;
```

Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1699 AGGCCCCCTCCCC 1711
|||
Db 13 AGCCCCCTCCCC 1

RESULT 426
US-09-866-108-9584
; Sequence 9584, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9584
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9584

Query March 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1171 AGGGAAGCTGC 1183
|||
Db 4 AGGGAAGCTGC 16

RESULT 427
US-09-866-108-9585

; Sequence 9585, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9585
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9585

Query March 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1171 AGGGAAGCTGC 1183
|||
Db 3 AGGGAAGCTGC 15

RESULT 428
US-09-866-108-9586
; Sequence 9586, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

RESULT 427
US-09-866-108-9585


```

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9586
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-9586

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1171 AGGGAAGAGCTGC 1183
Db      2 AGGGAAGAGCTGC 14

RESULT 429
US-09-866-108-9587
; Sequence 9587, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9587
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-9587

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1171 AGGGAAGAGCTGC 1183
Db      1 AGGGAAGAGCTGC 13

RESULT 430
US-09-740-332-641
; Sequence 641, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 641
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-09-740-332-641

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 2.2e+02;
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      576 CCGGCGGCGGCGGCTC 588
Db      5 CCGGCGGCGGCGGCTC 17
```

```
RESULT 431
US-09-740-332-642
; Sequence 642, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 642
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-642
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 2.2e+02;
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      576 CCTGGTGTCTCTC 588
Db      2 CCUGUGGUCUCC 14
||:|:|:|:|:|:|:|
```

```
RESULT 432
US-09-740-332-3913/c
; Sequence 3913, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3913
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3913
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      576 CCTGGTGTCTCTC 588
Db      17 CCTGGTGTCTCTC 5
```

```
RESULT 433
US-09-740-332-3914/c
; Sequence 3914, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
```

```
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3914
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3914
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      576 CCTGGTGTCTCTC 588
Db      14 CCTGGTGTCTCTC 2
||:|:|:|:|:|:|:|
```

```
RESULT 434
US-09-817-879-641
; Sequence 641, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 641
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-641
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 2.2e+02;
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      576 CCTGGTGTCTCTC 588
Db      5 CCUGUGGUCUCC 17
||:|:|:|:|:|:|:|
```

```
RESULT 435
US-09-817-879-642
; Sequence 642, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 642
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
```

NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-642

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 2.2e+02;
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 576 CCTGGTGTCTC 588
DB 2 CCGUGGUGUCC 14

RESULT 436
US-09-817-879-3913/C
Sequence 3913, Application US/09817879
Publication No. US2003017311A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
FILE REFERENCE: MHB00-801-F
CURRENT APPLICATION NUMBER: US/09/817,879
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9703
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3913
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3913

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 576 CCTGGTGTCTC 588
DB 17 CCTGGTGTCTC 5

RESULT 437
US-09-817-879-3914/C
Sequence 3914, Application US/09817879
Publication No. US2003017311A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
FILE REFERENCE: MHB00-801-F
CURRENT APPLICATION NUMBER: US/09/817,879
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9703
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3914
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3914

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 576 CCTGGTGTCTC 588
DB 14 CCTGGTGTCTC 2

RESULT 438
US-10-156-306-5930
Sequence 5930, Application US/10156306
Publication No. US20030119017A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: MCSwigen, James
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
FILE REFERENCE: MHB01-664-A (400/050)
CURRENT APPLICATION NUMBER: US/10/156,306
CURRENT FILING DATE: 2002-05-28
NUMBER OF SEQ ID NOS: 8013
SOFTWARE: PatentIn version 3.0
SEQ ID NO 5930
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-156-306-5930

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 2.2e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1922 GCCAGCTGTGAG 1934
DB 5 GCCAGCTGTGAG 17

RESULT 439
US-10-156-306-6802/C
Sequence 6802, Application US/10156306
Publication No. US20030119017A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: MCSwigen, James
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
FILE REFERENCE: MHB01-664-A (400/050)
CURRENT APPLICATION NUMBER: US/10/156,306
CURRENT FILING DATE: 2002-05-28
NUMBER OF SEQ ID NOS: 8013
SOFTWARE: PatentIn version 3.0
SEQ ID NO 6802
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-156-306-6802

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 217 TGGCGGGTCTCA 229
DB 17 TGGCGGGTCTCA 5

RESULT 440
US-10-230-006-742/C
Sequence 742, Application US/10230006
Publication No. US20030191077A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Fosnaugh, Kathy
TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
FILE REFERENCE: 400/056 (MHB01-1110)

```

; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 742
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-742

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      28 CGCGGATGCGCGCT 40
Db      13 CGCGGATGCGCGCT 1

RESULT 441
US-10-138-674-813
; Sequence 813, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 813
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-813

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.2e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      691 ATGTCAATCTCTCA 703
Db      5 AUGGCCAUCUCUCA 17

RESULT 442
US-10-138-674-814
; Sequence 814, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 814
; LENGTH: 17
; TYPE: RNA
```

```

; ORGANISM: Homo sapiens
US-10-138-674-814

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.2e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      691 ATGTCAATCTCTCA 703
Db      1 AUGGCCAUCUCUCA 13

RESULT 443
US-10-138-674-4754/c
; Sequence 4754, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4754
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4754

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2216 TGGTGACAGCTCC 2228
Db      16 TGGTGACAGCTCC 4

RESULT 444
US-10-138-674-4789/c
; Sequence 4789, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4789
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4789

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      328 CTGCGCTTGTTCC 340
Db      16 CTGCGCTTGTTCC 340
```

```
Db      16  CTGCTGTTC 4

RESULT 445
US-10-138-674-5053
; Sequence 5053, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5053
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5053

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 2.2e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1917 TGGGAGCCAGCTG 1929
        :|||||:
Db      2  UGGAGCCAGCTG 14

RESULT 446
US-10-138-674-5054
; Sequence 5054, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5054
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5054

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 2.2e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1917 TGGGAGCCAGCTG 1929
        :|||||:
Db      1  UGGAGCCAGCTG 13

RESULT 447
US-10-138-674-5194
; Sequence 5194, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.

Db      691  ATGTCTCTCTCA 703
        :|:|:|:|:|:|
Db      4  AUGUCCAUUCUCA 16

RESULT 448
US-10-138-674-5195
; Sequence 5195, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5195
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5195

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.2e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      691  ATGTCTCTCTCA 703
        :|:|:|:|:|:|
Db      3  AUGUCCAUUCUCA 15

RESULT 449
US-10-138-674-7658/c
; Sequence 7658, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
```

```
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 7658
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7658
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      328 CTTGCTTTGTTCC 340
      |||||
Db      13 CTTGCTTTGTTCC 1
```

```
RESULT 450
US-10-138-674-7857
; Sequence 7857, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 7857
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7857
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 2.2e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1917 TGGAGCCAGCTG 1929
      :|||||
Db      4 UGGAGCCAGCTG 16
```

```
RESULT 451
US-10-138-674-9169/C
; Sequence 9169, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 9169
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-9169
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
```

```
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      77 TACTGCTACTTCT 89
      |||||
Db      17 TACTGCTACTTCT 5
```

```
RESULT 452
US-10-287-949A-813
; Sequence 813, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 813
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-813
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.2e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      691 ATGTCAATTCTCA 703
      ||:||||:|
Db      5 AUGGCCAUTCUCA 17
```

```
RESULT 453
US-10-287-949A-814
; Sequence 814, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 814
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-814
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.2e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      691 ATGTCAATTCTCA 703
      ||:||||:|
Db      1 AUGGCCAUTCUCA 13
```

```
RESULT 454
```

```
US-10-287-949A-4754/c
; Sequence 4754, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4754
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4754

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2216 TGGTCAGGCTCC 2228
DB      16  TGGTCAGGCTCC 4

RESULT 455
US-10-287-949A-4789/c
; Sequence 4789, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4789
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4789

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      328 CTGCGCTTGTTC 340
DB      16  CTGCGCTTGTTC 4

RESULT 456
US-10-287-949A-5053
; Sequence 5053, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
```

```
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5053
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5053

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 2.2e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1917 TGGGAGCCAGCTG 1929
DB      2  UGGGAGCCAGCTG 14

RESULT 457
US-10-287-949A-5054
; Sequence 5054, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5054
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5054

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 2.2e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1917 TGGGAGCCAGCTG 1929
DB      1  UGGGAGCCAGCTG 13

RESULT 458
US-10-287-949A-5194
; Sequence 5194, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5194
; LENGTH: 17
```

; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5194

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.2e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 691 ATGTCCATTCTCA 703
|:|:|:|:|:|:|:|
Db 4 AUGGCCAUVUCCA 16

RESULT 459
US-10-287-949A-5195
; Sequence 5195, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5195
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5195

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.2e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 691 ATGTCCATTCTCA 703
|:|:|:|:|:|:|:|
Db 3 AUGGCCAUVUCCA 15

RESULT 460
US-10-287-949A-7658/c
; Sequence 7658, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7658
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7658

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 328 CTGCTTGTTCC 340

Db 13 CTGCTTGTTCC 1
|||||

RESULT 461
US-10-287-949A-7857
; Sequence 7857, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7857
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7857

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 2.2e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1917 TGGGAGCCAGCTG 1929
:|||||
Db 4 UGGGAGCCAGCTG 16

RESULT 462
US-10-287-949A-9169/c
; Sequence 9169, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9169
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-9169

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 77 TACTGCTACTTCT 89
|||||
Db 17 TACTGCTACTTCT 5

Search completed: June 30, 2004, 08:43:46
Job time : 13 secs